OX	ATC code7X	~W	NX	W	ħO	@	qΥΪk	`Nƶ1	ѰOAĮɸӫH	ĥiް_Ƨ@ΦǡApGoͤFӫH/pBz	ī~Ӧps	Dn	Ĳz	ĲzW	ñвM榨	Ag	Tүg	Ƨ@	hMIʯż	Ŧw	Ϊkζq	qվ	ľq	`Nƶ	xs覡	ʨ	{ɥγ~()	Ƨ@()	ī~ĵy()	Lī()	rϤ	Ƹ˹Ϥ	˹Ϥ	
OX	ATC code7X	~W	NX	W	ħO	@	qΥΪk	`Nƶ1	ѰOAĮɸӫH	ĥiް_Ƨ@ΦǡApGoͤFӫH/pBz	ī~Ӧps	Dn	Ĳz	ĲzW	ñвM榨	Ag	Tүg	Ƨ@	hMIʯż	Ŧw	Ϊkζq	qվ	ľq	`Nƶ	xs覡	ʨ	{ɥγ~()	Ƨ@()	ī~ĵy()	Lī()	rϤ	Ƹ˹Ϥ	˹Ϥ	
AC467331G0	A10BD02	Jެ 5/500 @J	OGLUCM	ĵGlucometƤ議}5/500mg(Glibenclam		"GlibenclamideOĤGNsulfonylureaAbI~󤤵GEŦخqAyʦ}CCӧ@ε]ӭMsbөwC
Metformin@θg3G(1)}sͩMxޤѦӴ֨xŦ}ͦC(2)٦ײ´خqӷPʡBﵽg´︲}MQΡC(3)wzD︲}lC"	"C@T, C@, C̤jqiW4  GlucoMet 500mg/5mg"	ŶsBCTw˴}C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Glyburide/Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}f	"1.糧~ҧt@άO@ؽξLӪ̡C
2.}fgP଻ĤrAYxεǷlˡAߦٱAŦIܡAs뤤rC"	LBfݨBȮBGhBæRB魫BŻĤrBC}	C	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OGLUCM-A	OGLUCM-B	OGLUCM-c	110.6.16
KC01063209	L04AC13	0	ITALT	fTaltz inj. 80mg/1ml/(N)		Ixekizumab @ؤHIgG4 AiܩʪPӭMEկ17A (IL-17A)XAçPIL-17 骺椬@ΡCIL-17A @ئ۵MΦӭMEA|ѻP@몺oPK̤CIxekizumab iPoӭMEPͤƯC	"1. ʰ~
H֤U`g覡TALTZCĳq0 g160 mg (⾯80 mg `g)A۩2B4B6B8B10 P12 g뤩80 mgAC4 g뤩80 mgC
2. ~`
ĳq0 gH֤U`g覡160 mg (⾯80 mg `g)AHC4 g뤩80mgCPɱwצܭ״ʰ~~`fHAĥδʰ~ĳqC"	̱``gPkhC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Né2XC10XC (]ץxs)	Ixekizumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	"1. ʰ~
vAXʪvܭ״ʰ~Hw̡C
2. ~`
AΩvwʩʰ~`HfHC"	TALTZ oϥΩ󴿹ixekizumab ΥξoYLӤ(pʹLөʤ)fwC	̱``gPkhC	D 	SmҦwADnקKϥΡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6000637?cesid=79EgXBueGio&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DIxekizumab%26t%3Dname%26acs%3Dfalse%26acq%3DIxekizumab#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-29 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6.1._20250601.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6._20250601.pdf"">OI` 8.2.4.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.6.1.</a>         "	"OI` 8.2.4.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.6.,8.2.4.6.1."	0	OIs 20251124	ITALT-a	ITALT-b	10C01063-2	111.8.19
AC460741G0	A10BB12	ަw2@J	OAMAR	ĵGlusafe 2mg/tab(Glimepiride)		"1. ~O@ݩsulfonylurea}AXb]ӭMAEGlut4ʨӭMAB}ӭMAӴɩP´insulinӷPסAW[P串}C
2. ~̥ͲzpU]ӭMͯخqAӥBCŸخqȧYiF즳Ī}C
3. ~㰪Ĳv}A@ѥuݵĤ@YC"	}lɨCѪA1mg glimepirideApf}nAiq~vC̾ڦ}ΧP_AYvpzQɡAhqACj1-2gAvBW[qܨC2A34mg glimepirideCȦSfҡAϥΨC龯qWL4mg glimepirideA~oΤvĪGCGlimepirideC̰ĳq8mgC	"1.FzQ}ATBWߥBBʡBHδ魫(Yn)APɪAΥ~OP˭nC}C(}){ɼx]AGpKWvW[BפfBfBΥֽC
2.vAoͧC}MIʥi|ɰASOpߺʱCpGX{C}MI]lAiභnվ㾯qνվӪv覡C
3.bS檬pUA}i|cơABiॲȮɧίخqC
4.H~vAwˬd}ȻP}ȡA~Aˬd}ƦC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Glimepiride	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	Dخq̿૬(ĤG)}f	"1.~AΩvخq̿૬(1)}f(Ҧpv଻Ĥrfv}f)B}f଻ĤrBο}fgC
2.iΩglimepirideBLsulfonylureasBLsulfonamidesBΥξLӤw(o͹LӤMI)C
3.Yxεǥ\l`fwAίخqA~FzQN±C"	̱`}CBtwBIzBYhߡC	C	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H5 [2]_H5 [ws]_w62-02 [s]_361 [®]_361 [E]_E5-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OAMAR-a	OAMAR-b	OAMAR-c	110.6.16
AC196431G0	H02AB02	oߥͿ 4 @J	ODORI	Dorison 4mg/tab(Dexamethasone)		"ĬXīTJA@μsxAiध@λPҦʤǤWֽଡ]ۦcTJApiQ-cortisol^ۦPC{ΩܵoΧܹLӡASulΤdʧCAGsΡC
"	"H쾯qC4mgAQDAH̷ӯfuWqܨC8mgCpĪ쾯qC2mgAQDC
"	"1.CʷPVgAϥήɽЦPɨ֥ξAƾkΧܥͯī~HvPVefC
2.ƺ޻êApGzűw̡AȽЯSO`NC
3.]DnƧ@άް_B~BWɡAץHŦewΰw`NC
4.}fw̨ϥήɡAЪ`NW[Insulin ζqC
5.󦳺믫f]̦h[`NC
6.AΥХRɥRJսC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~30J^ץB򳬮eJsC	Dexamethasone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	ƵǥֽYgBʭ`BީʮݡBfBʹLӯfBֽf	믫fBƺ޼šBܥͪ褣૵ĤnNPVʯewCŦ޻ٮ`BŦणB}fBRߪBPfBj˩ʯewB֡C	`fAܦhhAΤjqAΫhiX{zGAB|ϯB~AYX{zGDgAݥߧYivC	קKϥΰDvn/קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_97 [®]_97 [ws]_w02-08 [E]_A2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ODORI-a	ODORI-b	ODORI-c	110.6.16
BC27289100	L04AA37	R4@J	OOLUM	fOlumiant F.C Tablets 4mg(Baricitinib)		"BaricitinibܩʩMifJanusE?(JAK) 1JAK2CbtߪïRAbaricitinibFJAK1BJAK2BTiĿE?2JAK3ʡAIC50ƭȤO5.9B5.7B53> 400 nMC
JanusE?(JAKs)OѻPy@ΡBoΧK̥\धƺزӭMEΥͪ]lӭMΨӶǻӭMT@ػïCbӭMTǻ~|AJAK|PϰTǾɻPƦ]l(STATs)CĤƤάơASTATh|ƲӭM]{CBaricitinibzLJAK1JAK2ïʴSTATCĤƤάơAiӨӽո`Tǻ~|C "	"1. Olumiantĳq4 mgAC@CC@2 mgqAΩp~? 75fHA]iAΩ㦳Cʩδ_oPVfvfHCĥΨC@4 mgqFefíwABAXqխfHA]iHҼ{ĥΨC@2 mgqC 
2. Oڲyp(ALC)֩0.5 x 109ӭM/ɡBݤʲyp(ANC)֩1 x 109ӭM/ɡAΦƭȤ֩8 g/dLfHAo}li榹vCpGUƭȴɦܫezȥHWAhi}livC Ŧ\ण 
ٻMv3060 @/fHAĳq2 mgAC@CٻMv< 30 @/fHAĳϥOlumiantCxŦ\ण
שΤרx\णfHݭnվ㾯qC󭫫רx\णfHAĳϥOlumiantC
ϥΤ覡 
fAϥΡC
OlumiantC@AH\ΪŸAiɶAΡC 
OlumiantibAAΡC "	ٻMv< 30@/fHAĳϥOlumiantChTOlumiantCbvMvܤ1gA㦳ͨ|OkʥϥΦĪץICpGfHbAOlumianthAifHĪL઺bIC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 		L04A	Ķ IMMUNOSUPPRESSANTS	0	Xmethotrexate ΨLǲΫefwѫܭĪ (DMARDs)AΩvwר쭫׬ʩ`Bܤ֤@دefwѫܭĪ(DMARDs)Lk;AvεLk@HfwFboǱw̤AYfwLk@ΤAX~Pmethotrexate ΨLǲΫefwѫܭĪ(DMARDs)AiOlumiant WvC	"1. ﬡʪΥ椤ҦCξLӤ̡C
2. h"	LDLxTJɰBWIlDPVMߡBa?lC 			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.13._20240101.pdf"">OI` 8.2.4.13.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.2.</a>             "	"OI` 8.2.4.13.,8.2.4.2."		OIs 20251124	OOLUM-a	OOLUM-b	OOLUM-c	
BC24002212	N05CM18	Qw`g	IPREC	Precedex 200mcg/2ml/vial Dexmedetomidine 		Dexmedetomidineܩʣ\2ǤW@ξ (agonist)AR@ΡCʪo{AHCtR߿`PCqܤq]10-300 mcg/kg^dexmedetomidinei[ܩʪ\2@ΡFӥHCtR߿`q]1000mcg/kg^ΧֳtR߿`hi[\1P\2ҦʡC	"ICU sedation
 Adult: initial 0.5-1mcg/kg IV over 10min; followed by 0.2-0.7mcg/kg/hr continuous IVF for a max of 24hr
Procedural sedation
 Adult: initial 0.5-1mcg/kg IV over 10min; followed by 0.2-1mcg/kg/hr continuous IVF for a max of 24hr"	"1.xs15-30JC}~}xs2-8JAŶWL24pɡC
2.x\णfwҼ{CqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs󱱨UǷ25JAi15- 30JC 	Dexmedetomidine	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	ޤΤHuIl@fHR@	TΩwDexmedetomidine LӤfHC	"Hypotension, Nausea, Xerostomia, Bradycardia"	ĤC 	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668812?cesid=0Xe9oopoV2L&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDexmedetomidine%26t%3Dname%26acs%3Dfalse%26acq%3DDexmedetomidine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.07	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.5._20190301_000.pdf"">OI` 1.4.5.</a>              "	OI` 1.4.5.	0	OIs 20251124	DC	DC	DC	114.07.07
AC59232100	J02AC03	𽤦200@J	OVFEN1	Vaway 200mg/F.C.tab (Voriconazole)		triazole߾Aǥѧߪ׾JͦAӹFߪͪ@ΡD	"fAe1pɩζ@pɪAΡA
ҦAg}lvɬLoading dose: (1)IV:6mg/Kg Q12H (e24hr) (2)魫40kg:400mg Q12HF魫40kg:200mg Q12H
qG(1)IV:4mg/Kg Q12H (e24hr) (2)魫40kg:200mg Q12HF魫40kg:100mg Q12H
ǥ\णվ㾯q
"	"vĤ@ӤCPʴx\A`NxfHWO_x,xĲJn"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Voriconazole 200mg	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	@BvIǩT߯g(invasive aspergillosis)CGBvYIǩʩ]߷PV(Serious invasive Candida infections)CTBvK(Scedosporium spp.)MIM(Fusarium spp.)Y߷PVC|BwMIw̵oͫIJ߷PVA]AyFӭM(HSCT)w̡C	VoriconazoleLӸT	ıêAx\ˬdG`AoNAXlAߡAæRAmAhAP~AYhD	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-12 j	Ts111.11.4		OI` 	0	OIs 20251124	OVFEN1-a	OVFEN1-b	OVFEN1-c	111.11.4
AC60236500	A06AB02	"""""־ɫK꾯10@J"	EDULC1	"Cathartinol Suppository 10mg supp (Bisacodyl) ""Kojar"" (꾯) "		~|Q餺lAȻPz߽ĲAEz߽PıAӤް_gϮgAϵzįʦYW[AӦ۵MƫKC~pzS@ΡAGܤ֤ް_hPKC	"꾯wpݧYɱƫKɥiϥΧCbNeAXˬdeAιׯfw̡A@KĤzNΫ~C
HGq`ζq10gm꾯@ӡCubSUݭnGӡCb30Yiް_ƫKC
pGϥ5mgpή꾯C"	"1. wmvYzXAYhAθz\MܮɡAnWqvC
2.SԸvpUAnϥνwmWL12gAӥBnקK~LĮɡAզۼW[qA|oͽwm̿ʩιqѽ褣šC
3.jըnΩMʭ~AH֫KoͩMYKCzQ]Aѥ]AM\AͪMA尮AMCAG(610M/)P˦anC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Bisacodyl	A06A	m DRUGS FOR CONSTIPATION	0	nK	æʸhBj˩ʫKAgwKw̡B꾯GzHBũʲ֡C	hALӡAzEPC	B	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-03 [UDx]_U01-36 [E]_C3-09 j	Ts112.02.16		OI` 	0	OIs 20251124	EDULC1-a	EDULC1-b	EDULC1-c	112.02.16
AA38330277	B05XA03	״ƶu`gG3H(Y.F)	INAC31	ĵSodium Chloride Inj. 3% 500ml/Bt(Y.F)		R`~Uؿ@סAiGMqѽӡAi@G`JޡAiGzC 	q魫ίfݭnӽվ	"1.IwCRߪ`g
2.`tפŶWL 100ml/hr
3.ʴJ@XvΦ夤qѽ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU 	"
sodium chloride  30@J"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	uδlɥR]Guδl@פ^w}ͤMHο}fʩg	RʤŦIܡAYǷlˡAζudҤް_~	LqP|ɭPugAxC	קKϥΰDvn	ثeõL{ɬsPhkϥΥ~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.02.16		OI` 	0	OIs 20251124	INAC31-a	INAC31-b	INAC31-c	112.02.16
AC47771100	G04CA01	0	OXATR	Lafuzo XL PR 10mg/tab		Alfuzosin OܩʪĲ\-l-ǤWܾCAlfuzosin bH֡B?DΫe?T٤W\-l 㦳ܩʡC\_igѪe??٤@ΦӽwѻH֤U?A?CH֦?(detrusor pressure)AöiӼW[??Ҳͱj??Cִ??CoǮĪG]ﵽ(?Eʪ)αƪ(?ʪ)g?C	"@뾯?:@ѡ@A߶?YAΡC
Ĭʾо]AC"	"1.S`Nƶ
YǱw̡ASOOA?w̡AAΥī?pɷ|oͫ
թʧCHΨSg?(?tB«B?)C
ĳpߡASOO??HC
oǧ@άOȮɪAoͦb}lAĮɡAq`?|zZʪv?C
iw̦إioͤ?pC
a?ʯߥ\?w̡A?WBAlfuzosinCi?
a?ʯߥ\?v?C?ߵhg??oΥ[AAlfuzosinC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHU	Alfuzosin	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	}ʫeCΤj	"(1)Alfuzosin LӡC
(2)թʧCC
(3)x\?C
(4)Yǥ\?(ٻM?p30ml/min)C
(5)z?(ѩɳªosb)C
q`?ĳĻP?ҫ-_֥"	bƨtΤ譱]A:ߡBGhBmC?tBYPBzP(malaise)CYh	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 [ws]_w15-01 [UDx]_U02-05 [E]_B1-08 j	Ts110.6.16		OI` 	0	OIs 20251124	OXATR--a	OXATR--b	OXATR-	110.6.16
AC21959209	H02AB01	0	IRIND	Betamethasone 4mg/ml/amp		BetamethasonesXƵǥֽXA㦳@Ƶǥֽ辯jOvĪGABƧ@Τoͥ֡AbCqUYioġAܪgBܭBܹLӮĪGjAPrednisolonej8~10ABDexamethasonjO	"1.RߤΦ٦ת`gAC412mgAC12 C
2.IwRߪ`gA@12 A1 420mgAHͲzQε}}G}`gC
3.`Ĥ`g0.44mg סAH`jp׶qC
4.ĤίݵĤ`gACg13 AC14mgAguqϥΤC
5.ĭvϥΡC"	"1. CʷPVgAϥήɽЦPɨ֥ξAƾkΧܥͯī~HvPVefC
2. ƺ޻êpGGzűw̰ȽЯSO`NC
3. ]DnƧ@άް_B~BWɡAץHŦewΰw`NC
4. }fw̨ϥήɡAЪ`NW[Insulin ζqC
5. 󦳺믫f]̦h[`NC
6. AΥХRɥRJսC
7. α¨ŰSOVθTϥΡC
8.mɩwὤ~`g(epidural administration)ֽTJoͨuYgtΤ}A]AOॢBBȡB`AhƭӮ׵oͩaBνwֽTJ`gī~C
9.~tGAHպޤ(intracanal)εwὤ~(epidural)`gġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץJsC	Betamethasone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	fBǪʯgԸsBLөʥֽewBgPVgC	"1.糧ĦLӯfw̡D
2.PVg`ĤAƲGnAxTAθxPD
3.ww``ĤD
"	ɷ|X{oPVgAoʰƸֽणA}fAgաAƩʼšA믫êA٦׵h`hA`wwơAӡAAB~	קKϥΰDvn/קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-03 [E]_G1-06 j	Ts110.6.16		OI` 	0	OIs 20251124	IRIND-a	01C27718-1	01C27718-2	110.6.16
AC324951G0	P02CA01	0	OVERM	Cowbalin 100mg/tab(Mebendazole)		MebendazoleXΧ@ξǫY_PVHΤ}lӧYӺɨͬOAiӤͦs`CMebendazoleb餺ȷLֳѭGzDlATѤѧHNªέ쫬ƥX~C	HPpĤζqۦPC PX@ΡBΤΐuΤΤΧZɡAC1AC馭ߦU@A sAΤTѧYĪGCXΥunAΤ@(1)NġCpGAΤ@v{TPLᤴXpɮɩyAAΤ@v{AHTwHΤΧZXCAĮɤݸTβMzqKC	 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Mebendazole	P02C	ܽuλs ANTINEMATODAL AGENTS	0	ΡBΡB_ΡB@ΡBlΡBTεҤް_PV	mebendazoleLӪ̸T	pjqPVMXήɡA|uȪhMUggo͡C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-18 j	Ts110.6.16		OI` 	0	OIs 20251124	OVERM-a	OVERM-b	OVERM-c	110.6.16
AC32282429	S01AA01	⵷߯ĤDH	PCHLO	CHLORAMPHENICOL OPHTHALMIC SOLUTION 0.25(N)		ĬO׷ʥiXqLӵ߲ӭMAMӵֿ߮}(Ribosome)50S쵲XAiġAΦ`G]iରpeptidyl transferaseʳQ^]`GMJս誺XӹFӵߤĪGC	C1-4p1AC1wC	"ĶsN,ץקKsN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsC	Chloramphenicol	S01A	ܷPV ANTIINFECTIVES	0	FByߡByߡBͪyߡBjzߵҤް_ew	糧ĦνξLӪ̸T	`BEPC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6576375?cesid=1DYbAAyUEmA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DChloramphenicol%26t%3Dname%26acs%3Dfalse%26acq%3DChloramphenicol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.08.20		OI` 	0	OIs 20251124	DC	DC	DC	114.08.20
AC24696216	M01AB05	0	IVORE1	Diclofenac inj 25mg/amp		"1. DiclofenacDTJĨ㦳hθѼ@ΡC@ξରe CXCbΦoBkhPoNL{AeCtۥDn C
2.j ѨxŦN¡AAHNªѵŦƥXCbʹ 2 pɡC
3.ʪgMȫʪgް_B~Bתn~Φת޸~ܱj@ΡAP indomethacin, prednisolone ǼġAӤphenylbutazone ĮıjC
4.g뤩AtlAF夤̰@סAoѼhܪĪGB ɶC"	H@ 75 mgA@@A~v٦ײ`wC`gAɱ`ﴫkv`gC	"1.NSAIDsī~|W[oYߦޮƥ󤧭IA]AߦٱMABiରPRCIioͦbϥθī~ABϥī~ɶVAIVjC
2.iaʯ¶DN(Coronary artery bypass graft, CABG)14ѤTΥġC
3.GzD@ w GzšBXάդMI
DTJĥ]A diclofenac b iް_GBpzΤjz oBXBŤάյYӥiPGzD}C
4.Ŧ@:뤩DT JĥiɭPǨYaΨLŦlˡC oͳoMIڸs ~̡Bǥ\lB߰IܡBx\णΨϥΧQP ACE fH ԷV뤩C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m HU 25 סAץxs	Diclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	LkfApUAuϥΩwѵoΦ]oް_khC	"1. diclofenac LӤw̡C
2.ʮƩʼšBXάձw̡F NSAIDs zGDXάկfv̡Fеo@ƩʼũΥXfv̡C
3.YX Vw̡C
4.YxIܡC
5.YǰIܡC
6.A aspirin ΨLDTJĤᴿoͮݡBC¯lΨLLӤ̡CfHY ּƬP LӤ (anaphylactic like reaction) oͤiC
7.iaʯ¶DN (Coronary artery bypass graft,  14 ѤTΥġC
8.hĤTkTΥġC"	vfH`}GzDvTA]AhB KBmBƤ}BȮBjX աBߨ`PBߡBGzD G QGzPæRCL]Aǥ\ಧ`BhBYwBxïɰBYhB XɶBkoBlΦջC	"1.α¨ŰH뤩G便α¨ŰHwʩ|إߡC󥥰Υihkα¨ŤHAP_vįqWLMIʮɡA褩PC
2.h̫3Ӥ몺kϥΥ~SO`N(]iylcYLO/έLʯ߳L)C
3.FDA Pregnancy Category (hįż)GC"	"1.α¨ŰH뤩G便α¨ŰHwʩ|إߡC󥥰Υihkα¨ŤHAP_vįqWLMIʮɡA褩PC
2.h̫3Ӥ몺kϥΥ~SO`N(]iylcYLO/έLʯ߳L)C
3.FDA Pregnancy Category (hįż)GC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.7.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a>              "	OI` 1.1.2.	0	OIs 20251124	IVORE1-a	IVORE1-b	IVORE1-c	112.7.22
BC209712CX	J01CR05	Fᴹ`g	ITAZO	Tazocin 2.25gm/vial		"Piperacillin sodium i{ߤOOaӵߤjΦHβӭMXC
Tazobactam sodium ֦ͩʤLͪĤOADѩCXJդXvƧCtGARichmond-SykesĤT(Bush Class 2b & 2b')C?YUl?beta-lactamaseCĤGβĥ|(2a & 4)C?OhUtC"	"H X 
IV @PVG 4.5g Q6H-Q8H.
@ |PVG 4.5g Q6H ĳtX Aminoglycoside(ĳHY-site)
                          4.5g+150ml }G (NSAD5W)
                          2.25g+50ml }G (NSAD5W)
                          aminoglycoside conc. (amikin:0.75-1.5mg/ml)(gentamycin:0.7-3.32mg/ml)
ǥ\णG
@PV            
 CrCl(ml/min)20-40G2.25g Q6H
 CrCl(ml/min)20G 2.25g Q8H
 GzRG2.25g  Q12H
ൣ:
>9ӤA魫<40kgG100mg  piperacillin/12.5mg Tazobactam/kg  Q8H
>2ӤA<9Ӥ: 80mg piperacillin/10mg Tazobactam/kg  Q8H
>40kgHq"	"1.`NLӤ}AStecen-Johnson SyndromeɡD
2.~ǰIܯfHϥήɡAiW[X孷IAϥ˴yD
3.RߵqɡAioͯg٦פĩεjˡD
4.ﭫgfHϥtapimycinOǰIܪWߦ]lAPVancomycin֥ΥiPʵŦl˪oͲvD
5.~utq54mg/g piperacillinAݭQ`N.ϥΧQι[tqCfHʴ[D
6.v߬mAi]A׸mvzD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUJsD 
tmǷŢ׹FpɩΧNùFpD"	Piperacillin/Tazobactam	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	piperacillin㦳PʡAHιpiperacillinĩʦpiperacillin/tazobactamPʤ]-lactamase͵߮Ҥް_Y{׷PVC	" penicillins, beta-lactamase inhibitors,ΨLξLӤfH,TΥ."	"m,,æR,l,Yh,vD"	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667973?cesid=6TN2ymP2lJo&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTAZOCIN%26t%3Dname%26acs%3Dfalse%26acq%3DTAZOCIN"">LexidrugľǸƮw</a>"	"CClr>40      4.5g q6-q8h
CClr 20-40  2.25g q6h
CClr<20       2.25g q8h
IHD              2.25g q8h
CAPD           2.25g q8h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tsǷxs24hr, Nxs48 hr
2.}Ƿxs24hrFNxs7day 
tsGG1g Piperacillin+ 5ml WFIBNSBD5W
ĳ}@סG50-150ml /dose
ۮe}GG50ml WFIB50-150ml NSBD5W
ĳĳ~|tvG30min
`NƶG1.ŻPaminoglycosideܥͯVX"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ITAZO-a	ITAZO-b	ITAZO-c	110.6.16
۶O		CD34ͧޮɥ	OCD341	CD34ͧޮɥ 15/		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts		OI` 	0	OIs 20251124	OCD341-a	OCD341-b	OCD341-c	
۶O		Ӯa	OROYA1	Ӯa(饻˶if)  250/		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU    					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts		OI` 	0	OIs 20251124	OROYA1-a	OROYA1-b	OROYA1-c	
۶O		Biobran NK PLUS߰(Hp)	OBIOB1	Biobran NK PLUS߰(Hp)		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts112.11.08		OI` 	0	OIs 20251124	OBIOB1-a	OBIOB1-b	OBIOB1-c	112.11.08
۶O		yYft25	OBIXI1	OBixine  25mg/tab (Pyridoxine) (Vit.B6)		(~) ɥRͯB6	ftΪCZΡA@ŶWL3D		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts112.6.23		OI` 	0	OIs 20251124	OBIXI1-a	OBIXI1-b	OBIXI1-c	112.6.23
۶O		wtMon	OFISH1	wtMon 60/		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iɥR  					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts		OI` 	0	OIs 20251124	OFISH1-a	OFISH1-b	OFISH1-c	
۶O		ZC׻ïq͵	OLETH1	"Lethicin/Probiotics 60]//ZC׻ïq͵
"		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		OI` 	0	OIs 20251124	OLETH1-a	OLETH1-b	OLETH1-c	
۶O		uQT/60/	OULG1	uQT/60/		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts		OI` 	0	OIs 20251124	OULG1-a	OULG1-b	OULG1-c	
۶O		Od?E޽n	OWELM1	WellmuneåE(yeast?-1.3/1.6 glucan) 300mg/ 60cap box		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts		OI` 	0	OIs 20251124	OWELM1-a	OWELM1-b	OWELM1-c	
KC011162B5	L01FD01	P	IHERZ	fĵHerzuma  440mg/vial (Trastuzumab )		Trastuzumab|PIVlc(HER2ӭM~c쪺񽤰ϰ)@˩MOBSʪXCTrastuzumabiHER2Lת{{HH~FӭMW͡C15%-20%oʨHER2Lת{{HAtrastuzumabi]Lת{HER2H~FӭMW͡C	"Cg{G
_lq:4mg/kg IVD 90minAMD:2mg/kg IVD 30min QWD
CTg@{G
_lq:8mg/kg IVD 90minAMD:6mg/kg IVD 90min Q3W
Duratiom:
fHv1~AΪef_oΥX{HrʬAHo̬ͪǡCĳ
vWL@~
ಾʨಾʭGfHHHerzumavefc(disease progression)ΥX{HrʬC"	"oͻשΤ׿`ɡAC`tvF
fHoͩIlx{ɤW㤧C{HɡA_`F
oYΨͩR¯٩ʿ`ɡAϥHerzumaC
vw߫ǮgXv(LVEF)LVEFMveۤﭰCT?16%FLVEFȧC󤽭q`dBMveۤﭰCT?10%F Yb4-8gALVEF_ܥ`dBMveۤﭰCT?15%ɡAiiHsϥHerzumaFLVEFC(>8g)Φ]ߦٯfܦӼȰϥHerzumaWL3HWɡAä[HerzumaC
{ʤ߰I(ìŦǷ|ŤII-IV)O@ئbtrastuzumabv`}BiɭP`C
trastuzumabvfH[Ŧ\णxAҦpGIlxBݧIl(orthopnea)By¥[@
Bͤ~BĤT߭b(S3 gallop)B߫ǮgXvU"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʪp~sBc(2XC - 8XC)A4~C
440 mg HerzumaHҪߪ`gΤVXᤧtmGs2XC - 8XCU(ŧNts᪺G)Ai28Ѫ
íwCts᪺GtGAҥHAXhϥΡAWL28ѫAѾlϥΪtsGӥCH0.9%ƶu`G}ᤧHerzumaRߪ`gGAYsbEAmBAmλEm`UAbWL30XCūפUiOzMƾíw24pɡC"	Trastuzumab 440mg/vial	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	(@)ϥΩUCHER2 Lת{HER2 ]amplification BಾʨfHC 1. (EBC) (1) g~NBƾk (NeγN) UkC (2) HdoxorubicinPcyclophosphamide vAAXpaclitaxel docetaxel UkC (3) P docetaxelcarboplatin ֥ΤUkC (4) NePƾk֥ΩMNᤧUkϥΩvߴ(]Ag)θ~F(|>2 )C 2. ಾʨ(MBC) (1) WϥΩ󴿱L@ (t) HWƾkಾʨFDfHAXϥanthracyclinetaxaneA_heƾǪvܤ֥]AanthracyclinetaxaneCϥΩXkѤX鶧ʤfHADfHAβXkC (2) Ppaclitaxeldocetaxel֥Ω󥼴LƾkಾʨC (3) Pڭ?֥ΩX鶧ʤಾʨC (G) ಾʭG (mGC) Xcapecitabine (5-fluorouracil)  cisplatin AΩ󥼴LƾǪvHER2Lת{ಾʭG (έGDXB) vC	TϥΩw|trastuzumabβ~󦨤LӤfHC	"HŸBoBIlxBCBݡB޵jˡB߸L֡B񹡩MפUBIl~B֯lB
ߡBæRYhAoʶݤʥզy֯gBզy֯gBhBpO֯gζݤʥզy֯g`"	DA便뤩trastuzumab|Lyˮ`C	ثeäTtrastuzumabO_|ciJHťġAҼ{HerzumaưbIΦĪ˪nʡAMMwO_nũάOΦġC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-09 j	Ts111.11.28	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.18._20250501.pdf"">OI` 9.18.</a>              "	OI` 9.18.	0	OIs 20251124	IHERZ-a	IHERZ-b	IHERZ-c	111.11.28
AC60826100	M04AA03	hw80@J	OFEBU1	Fetrin FC tablets 80mg(Febuxostat)		febuxostatO@ضIƞJAiCMĹFv@ΡCbv@׮ɤ|ѻPbIBG䪺XPN¹L{Lï@ΡC	"1.vhw̪ĦgAFeburicĳqO40mg80mgCѤ@Cĳ_lqO40mgCѤ@Cϥ40mgGgMĿ@(sUA)C6mg/dLw̡AĳϥFeburic 80mgC
2.~FѯgԸsGFEBURICĳqO80mgCѤ@C
FEBURICbӭMrĪv}leGѶ}lġAåB~ĳ̤7ѡFMӮھڤ{ɧP_Avi9ѡC
AFeburicLU{ΨľϥΡC
hGYǥ\णfH(Clcr 15-29mL/min) Feburic q 40 mg CѤ@ "	"}lϥ Febuxostat Ag`[ho@W[AoOѩMĿ@׭CAQq´InಾҭPC
Fho@Aĳ}lϥ Feburic ɡAPɵDTJܵo(NSAID)άPwʪv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Febuxostat	M04A	ܵhs ANTIGOUT PREPARATIONS		vCʵhfHĦgCĳΩLgĦg̡C Ω]G~FAo͸~Fѯgs(Tumor Lysis Syndrome)צܰ׭I~fHAHwMvĦgC  	FebuxostatΥ~ξLӪ̸TΡC	x\ಧ`B֯lBߡB`h	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w31-09 [UDx]_U03-04 [E]_B3-27 j	Ts112.7.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.11.1._20191201.pdf"">OI` 2.11.1.</a>              "	OI` 2.11.1.	0	OIs 20251124	OFEBU1-a	OFEBU1-b	OFEBU1-c	112.7.24
AB38075351	A07EA02	"""w""izGDA]ֽJ^"	ECORT	Cortema enema 100mg/60ml(Hydrocortisone)		ҧt㦳ܦn@ΪHydrocortisoneAigѤjzlA@Ω󧽳ΥCΩvũʵzμũʪzCھ{ɹ絲GܡAgѤjzzġA30-50%Hydrocortisone|QlAä`Ƨ@ΡCխYġAhi޵oPfAĤ@˪ʤ}C	Cѱ߶ϥΤ@AgѨzpJAΧYCĳfwbϥήɡAVסAC30½@A̦nԦ@pɥHWAƥXCq`@ӧ㪺{21ѡAϥ3-5ѫAfYiowѡCYfݭn21ѥHW{ɡAhϥ21ѫAv֥ζqAHj鵹2-3gyC	"?tTJAϥΥpߡC
?frʷPVw̥pߨϥΥAHf[C
?ī~ϥΫeХRnáC
?sΤϥΧֽTJī~|ɭPvX{ϼuʵo@]TJ_^CYϼuʵo@diWXlvAgiH֪񦳱jPoBhM`PASOϥΩyMsϰ쵥bֽɧeo͡CpGbv\ƤѦܼƶgAX{WzgAhåiରϼuʵo@CtpݭsϥΧֽTJī~AԷV{ɮįqPIAΦҼ{HLv״NC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Hydrocortisone	A07E	zDܪ INTESTINAL ANTIINFLAMMATORY AGENTS	0	ũʵzUvC	"AΩUCfwG
?߷PVC
?jzyfNw̡C
"	"?DtHydrocortisoneAuϥΤ֨}AϥήɡAi|ް_ʰƧ@ΡApzZGιqѽ誺šB٦׵LOBGŤΥ~ˤ¡X@TJ`Ƨ@ΡC
?ֽM֤U´ef-_(Wv)GֽoBi|WXlvϰB`ΨhPBkoBֽhBwC
"	קKϥΰDvn	¨ŴkgvJӵiϥΡCSmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-05 j	Ts112.5.15		OI` 	0	OIs 20251124	ECORT-a	ECORT-b	ECORT-c	112.5.15
KC00990288	S01LA04	0	ILUCE1	f Lucentis Syringe 10mg/ml;0.17ml/		"AΩv޷sͫ()~֬ʶhƯf (age-related macular degeneration, AMD)C"	0.5 mg (0.05 mL) by INTRAVITREAL injection once a month (approximately 28 days); give adequate anesthesia and a broad-spectrum microbicide prior to injection.	ϥΥī~30кʴB@g[LogC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Nī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC 	Ranibizumab	S01L	ޯfgվ OCULAR VASCULAR DISORDER AGENTS	0	"AΩv޷sͫ()~֬ʶhƯf (age-related macular degeneration, AMD)C"	ĸTΩ󦹦褧զLӤfH	"Conjunctival hemorrhage, cataract, Foreign body sensation in the eyes, Raised intraocular pressure, Iridocyclitis, etc."	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.2._20250501.pdf"">OI` 14.9.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.7._20250501.pdf"">OI` 14.9.7.</a>             "	"OI` 14.9.2.,14.9.7."	0	OIs 20251124	ILUCE1-a	ILUCE1-b	ILUCE1-c	110.6.16
KC01054266	A10AE06	կثO կS	ITRES	()ĵTresiba FlexTouch 100U/mlA3ml/pen (insulin degludec)		"خq(]ATresiba?)Dnʬո`}N¡CخqΨ|EP串}l(רOf٤ίת)ΧxŦ}ͦӭC}Cخq]|תդѩMJսѡAëPiJսXCTresiba?`g֤U´|ΦhEA֤ͥUinsulin degludecΡC

Tresiba?[ɶ@ίSʡADnOѩinsulin degludecq֤U´liJ`ɶA֤@Oѩinsulin degludec|P`ճJյXC
"	"?󦨤HfHAC1Ab@ѤNɶ`gTresiba?֤UC
1}ffHAĳTresiba?_lqCخq`q1/31/2C
bخqv1}ffHAiϥΨC魫0.20.4خqӭplvCخq`q
2}fGbخqv2}ffHAĳTresiba?_lq10C1
?ൣfHAC1Ab@ѤP@ɶ`gTresiba?֤UC
?ھگfHӤHN»ݨDB}ʴGΦ}ؼг]pýվTresiba?qC
?ĳCW[qj34ѡC
ܯfHTO⦸Tresiba?s`gjܤ8pɡC
ΩwخqvfH_lq:1}fP2}fHfHG
HMī(long-acting)Τī(intermediate-acting)خqC`qۦPqƶ}lTresiba?vC
1}fP2}fൣfH(@HW)G
HMīΤīخqC`q80%qƶ}lTresiba?vAH֧C}I
bC}IfHιC}gNѸzfHAĳ}ʴWvC

"	"?P@ϰ줺Cy`g󤣦PAHCתեN»ê(lipodystrophy)MֽIng(cutaneous amyloidosis)ICФŪ`gܯתեN»êΧֽIngC?
ФťHRߪ`gB٦ת`g覡θ˩خq`뤩Tresiba?C
?Фŵ}Tresiba?AαNPLخqī~ηGVXC
?ФűNTresiba?qTresiba?`gwi
fHخqkiܧɡAбKʷüW[}ʴWvCYfHNخqƪ`gܯתեN»ê(lipodystrophy)ΧֽIng(cutaneous amyloidosis)AЫĳfHܪ`g (`gbvT)AñKʴO_oͧC}C2}ffHAiݭnվ֥ΪfAܿ}fvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"DϥΤ(})N2XC8XC즳Ĵ
DϥΤ(})ǷŤU56(8g)
}(ϥΤ)ǷŤU56(8g)
}(ϥΤ)N2XC8XC56(8g)





"	"insulin degludec 100IU/ml;300IU/3ml/syr
"	A10A	خqΨPt INSULINS AND ANALOGUES	0	"AΩv@HW}fw̡AHﵽ}C

ϥέ
?ĳΩv}f଻ĤrC
?ĳΩݭnTresiba?p5ӳ쪺ൣfH
"	"?Tresiba?Ψ@ؽξLӪfH,Tresiba?TΩinsulin degludecΥ@ؽξo͹LӤfH
?C}o@"	"C},ĥ~ް_C},C[g,?LӻPLӤ,ϥίخq(]ATresiba?)iɭPخqЪ`goͯתեN»êCתեN»ê]AתռW(תղ´Wp)ίתյY(תղ´)AåivTخql,魫W[,iɭPudΤ~CP~C"	gįqjIUAhiҼ{ϥTresiba?vC	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-05 [N]_B03-20 [E]_K-16 j	Ts112.5.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	ITRES-a	ITRES-b	ITRES-c	112.5.15
AC40096162	A12AX	"""͹F"" uŶtž"	LALLC	All-right Ca. susp.ƤtG180ml/bot.		"tricalcium phosphateGզft褧DnA
vitamine AGUΦAֽHdD
Vitamine D3GUtClD"	"H10-15ml /d
ൣ10-15/d
ť2.5ml/d"	`Ntg	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25JHU^	"Tricalcium phosphate 103mg
Vitamine A 1600IU
Vitamine D3 160IU "	A12A	t CALCIUM	0	tκͯϡBүʥFgvC 	"tricalcium phosphate,vitamine A,Vitamine D3LӪ"	`Ntg	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-02 [ws]_w73-01 [E]_I4-08 j	Ts111.11.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.4._20000201_000.pdf"">OI` 3.3.4.</a>              "	OI` 3.3.4.	0	OIs 20251124	LALLC-a	LALLC-b	LALLC-c	111.11.4
	G04BE08	έ5@J	OVETA1	Vetawon F.C. tab 5mg(Tadalafil)		"ʨEL{yk_AO]ʯ߻P饭Ʀ٩PyyW[COǥѯgPֲӭM
X@ƴ(NO)AEƦٲӭMXcGMPCCyclic GMP|ϥƦ٩PAüW[yyJCPDE5ɷ|y
cGMP@׼W[ӼWjk_\CTadalafilPDE5@ΡC@ƴᥲǥѩʨE~yXAYLʨEA
hTadalafilSPDE5@ΡC"	"TadalafilibAAΡC
1.vk_\êG
󴿸gϥΦbݭnɪA10@J20@JTadalafilġABg`ATadalafil]@gܤ֪AΨ⦸^fHAvM
~P_MfHN@AiҼ{CѤ@̧CqTadalafilv覡CCѰ_lq2.5@J@Ѥ@AþqbCѪP@ɶAġAPʦ欰oͮɶLAiھگfHĤP@ʼW5@J@Ѥ@C
wCѵPĪvAʡC
ٻMv<30 mL/minλݭnGzR̡GĳCATadalafil
2.}@Τj
CѰ_lq2.5@J@Ѥ@AþqbCѪP@ɶAġAiھگfwĤP@ʼW5@J@Ѥ@C
HTadalafilPfinasteride֥ΨӶ}l}@ΤjvAĳqTadalafil 5@J@Ѥ@ACѦbjۦPɶAĹF26gC
ٻMv30-50 mL/minGĳ_lq2.5@JAiھگfHW5@JC
ٻMv<30 mL/minλݭnGzR̡GĳCATadalafil
YxŦ\ण(Child Pugh Class C)GĳϥTadalafil
}@ΤjФĳATadalafilfH֥alpha_Ӫv}@Τj"	"vfVfHߦުpA]ʦ欰ŦYص{תICYfH]bߦުpӤĳʦ欰A礣
ik_\êvA]APTadalafilC
PfHQ׷L̪ATadalafilAYoͶϥεvƥ̪ovߵhɡAӦpABzCiyͩRM
`AnitratesĪB쥻ATadalafilfHAATadalafilܤ48pɫAAҼ{ϥnitratesĪiv
C
pPLPDE5ATadalafil㦳ץʦXiĪGAi|yȮɩʪCC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC	Tadalafil 5mg	G04B	c UROLOGICALS	0	"1. vk_\êC
2. }@]eC^ΤjgҦHUcDgC
"	"TadalafilTΩWߩζAΥΦnitratesĪfHC
TadalafilTΩwTadalafilYLӤfHC
UCߦޯeffHϥTadalafilTҡG
Цb̪90Ѥߦٱ몺fHA
ЦíwߵhδbʥɵoͤߵhfHA
Цb̪6Ӥw̯ìŦ|ŬĤGũΥHWŦIܪfHA
ЯfH߫ߤBC]<90/50@̨EW^AΥA
г̪6Ӥ릳fH
]Dʯߩʫeʦʵgf(NAION)Ӥ@fHTϥTadalafil"	YhAƤ}AIhA׵hAA]]AyΨLC^A|ϯkhD	"TadalafilAΩkʡCثeSTadalafilM/ΨNªiJHťġBधvTBιťĤcvTTC
קKϥ/SmҦw"	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-03 j	Ts112.5.15		OI` 	0	OIs 20251124	OVETA1-a	OVETA1-b	OVETA1-c	112.5.15
	C05CA53	FPԽ 1000 @J	ODAFL1	Daflon  film-coated tablets 1000 mg		MPFF ( micronised purified  flavonoid fraction )  q a        flavonoidsAq 1000 mg/tabA䤤]t 90%  diosmin P 10% hesperidin VXA⦨ҨĲzʡC@ΩR߻PpRߡAiW[iOP[jLުOﵽCRߥ\णgPʲHo@gA(kh BXBko)AUˤf¡XDﵽCRߥ\णg]LkhP~^BﵽʲHgC	"ĥΩRߤfHĳq1 tab QDFʲHfHLD(C):1 tab TID*4dayse| then 1 tab BID*3daysT;MDq:1 tab QD
ĶȾAΩ 18 HWHFxBǥ\णfHLqվĳAԷVϥ"	"ĿnjAYfHH@]`Aĳb⦸]AC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷūOs]30XCHU^AקKs󰪷ũμBC	ѬaӪѨflavonoids (ƦX) - micronized purified flavonoid fraction (MPFF) 1000 mgA۷Ĳzʦ Diosmin 900 mg + Hesperidin 100 mgC	C05C	LޫO@ CAPILLARY STABILIZING AGENTS	0	"1. ﵽCRߥ\णgC 2. ﵽʲHo@gC 
"		"Ƥ}B߹æRBmzGDg ( 1-10% )A
uƧ@άz ( 0.1-1% )Bgtίg( YwBYhB«F0.01-0.1% )Bֽg ( koBlBC¯lF0.01-0.1% )C
"	hPŰkwʩ|T	hPŰkwʩ|T	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-01 [E]_B3-06 j	Ts111.11.22		OI` 	0	OIs 20251124	ODAFL1-a	ODAFL1-b	ODAFL1-c	111.11.22
AB198751G0	C07AA05	"""a"" ߱dֿ]߹^"	OINDE1	Cardolol 40mg/tab (Propranolol) 		~C߸tvM߸YOAǯXHΧqF޹Bʤ϶ǥXPgަYMŦ[t@ΪİʡC	"1. ܤ߫ߤ㾯G1030mg@34Aiݭnέ@ĽվC 
2. ܤߵh:fAA10-20mgA@3-4AnɨC3-7ѳvW[@320mgC 
3. wYh:fAA쾯q20mgA@4AHW@160-240mgƦϥΡAݭnvW[q@240mgC
4. ܰ:fAq`CѺq120-240mgAnɵݭnP@ĩʳvW[qiΨ640mgC
5. ܥҪr:fAA10-40mgA@3-4AݭnP@ʦӽվ㾯qC
6. ˻̲ӭMF:fAANeA20mgA@3ɤTѡAP\_@ΡC"	ޮݩΤjˤw̽ФŨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUץ	Propranolol 40mg	C07A	]_ BETA BLOCKING AGENTS	0	U߯gBߡ]W߫ǩʤߡB߫ǩʤ߷iLt^BoʤεǩʰBYhBoʾ_ABJ{ʤ߷iLtBҪrgUB˻̲ӭMF	"Hypersensitivity to propranolol or any component of the formulation; cardiogenic shock; severe sinus bradycardia or heart block, severe hyperactive airway disease (athma or COPD)"	twBYwBCӱʡC	hĵ: C	ֶqcťġAŽƨϥΡANϥΦMIPįq[HҼ{	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w47-03 [E]_B5-20 j	Ts111.11.4		OI` 	0	OIs 20251124	OINDE1-a	OINDE1-b	OINDE1-c	111.11.4
BC25005100	C09CA08	߽ 40 @J 	OOLME4	Olmetec 40mg/tab (Olmesartan)		Olmesartanܩʦa_ު@IIPޥƦAT1XAiӪ_ު@IIަY@ΡC	"ĳ}lq20@JACѤ@Cv2gAݶi@BCfHA
Olmetec?qiW[40@JCWL40@Jq|㪺ĪGC"	"1.Olmetec?ĳΩ~֤p1HUC
2.ǯ-ު@tγQƪfHAҦpn-/Q֪fH(ҦpHqQvfH)A@}lHOlmetec?vi|X{ʧCgC
3.ǥ\Pǯ-ު@-ǩTନtάʦfH(ҦpY{ʤ߰IܪfH)AYHު@ഫ?Φު@ܾvA|X{֯g/ζiʴg(u)ʵǰIܤ/Φ`C
4.iܦbϥolmesartanƤܼƦ~fHWAoYCʸmH魫ABq`ibfHz´Wo{Y{HC
5.Olmetec?fHʴ[C ǯ-ު@tΪĪiް_[gC
6.PYQ֥ήɡAݺʱfHYQ@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Olmesartan 40mg	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0		"1. 糧~LӪ̡ATϥΡC
2. hk
3. X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C"	LOAީʤ~ALӤAæRA[gACʸmzfA夤ٻ@׼W[AʵǰIܡArYAkoAC¯lD	oıhߧYOlmetecD@Ωrenin-AngiotesintΪĪA|ˮ`o|LƦܳy`D	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w41-05 [UDx]_U03-42 [E]_B4-31 j	Ts111.11.4		OI` 	0	OIs 20251124	OOLME4-a	OOLME4-b	OOLME4-c	111.11.4
	D08AJ	qγnI	EENTO1	ENT Nasal ointment 5gm/tube		קKCʻ󪢡BHӵ߷PVC	"iAqĻI٩󤺡Fpϥδ֪ΡAоiणnĲĻIfC
"	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25JHUJs	":
Tyrothricin 0.25mg
Cetylpyridinium Chloride 0.25mg"	D08A	r ANTISEPTICS AND DISINFECTANTS	0	Cʻ󪢡BHӵ߷PVC 	ʫCBRʫCBB2HUĵTΡC	ӦLӲ{HͦD`֨C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.11.4		OI` 	0	OIs 20251124	EENTO-a	EENTO-b	EENTO-c	111.11.4
	G03GA09	ի`gG 150 LJ/0.5 @	IELON1	Elonva 150mcg/0.5ml (Corifollitropin alfa)		Cortfollltropln alfaO]p@@owEDĮįSʩM]rec)FSHۦPʧ[C]ĤO໤oúhywo|@gA澯ĳqElonva֤U`gHNCOS{eCC]rec)FSH`gC	"魫Φ~֫ĳEloavaϥξqC
~֦b36]t^HUB魫60HU]6Okg)kʫĳϥξq100ug
~֦b36]t^HWB魫50HW]6Okg)kʫĳϥξq150ug
魫60kgHWAĳq150ugD

bE{Ĥ@`gE l o n v a(FSH)CѤA UZ_E(Controlled Dvadan stimulation, COS)kiݭn~IHC`g]]ա^owE]]rec^FSH)ܹF커oZЭMз3ow>17mm)CbE{ĤΤHNǶWi˴wBʱZ_AC(rec) FSHϥξqݵZ_өwD`̨Cĳϥζq150ڳ(IU)(rec) FSHC[3ow>17@̮ɡAYiѩβĤGѪ`g@5,00010,000 IUhCG ?ǥHo̲קZӭMC"	"b}l Elonva ve  Thp C
Elonva H榸֤U`gCP@ v  g`g WL@
ϥ Elonva ܨE{ĤKeA  PLt FSH ~
Elonva P ʸE E GnRH agonist) X ϥ  ƾ Q C]A 
ĳ Elonva P GnRH   (GnRH X ϥ
Fʱ OHSS IAbve{wHWiy owo|PB˴MۿE@פ]i঳UCbI ART  A 18  ΥHW ow |j 11mm ɡAIo OHSS C
Elonva v  Ai|W[oͦ IC]惡kʧPʸE A]A Elonva vɡAJvůfHQqPICtݪ`NOAhN|W[ΦIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJsBc(2XC-8XC)	corifollitropin alfa 150ug	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	kHuUʹާ޳NpɡAPGnRH antagonist?ΡAϥΩ󱱨UEZ_AHɦhowo|C 	"DΨLξLӪ 
 Z_B ũ BlcB U ΤU C ~F fH C
 ] D` Dg XC
 oʧZ_I C
 Z_n~θ~jC
 AXhlc ٽFC
 AXhʹ޾xΡC
 Z_LרEgԸs OHSS I]l
o Z_LרEgԸs OHSS fv C
o beCOSgA̾ڶWiˬdGAWL30owd11@̡C
o ¦Z_ow (antral Ƥj 20  fH C
o hnʧZ_gԸs(PCOS)C"	YhB ߡB hҡB OHSSB ֯kh B ֤A B ũ h	"ElonvaiϥΩhk C Ybhp߱Ĳ Elonva ɡA{{ɸƨäH
ưo h }GiʡCbʪs[X{ʹ tάrʪ{H"	bŴAXϥElonva C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-45 j	Ts111.11.15		OI` 	0	OIs 20251124	IELON1-a	IELON1-b	IELON1-c	111.11.15
	LO1XY01	P֤U`g	IPHE11	ĵPhesgo 1200/600mg (Pertuzumab 1200mg+trastuzumab 600mg)				"PHESGOi|ɭPL{ɯgP{ɯgŦIܡC
PHESGO֥Χtanthracyclineƾkv(anthracycline-containing chemotherapy regimens)fHAoͲvPY{׳̰C
bHPHESGOvePvŦ\CbX{{ɤW߫ǥ\ۭCpUAUvfHPHESGOvAಾʨfHhȰPHESGOv
PHESGOĥiɭPYBPRͳrʡC]oͥʹLӡBީʤ~BʪͯfΫʩIl~gԸsӰPHESGOvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1 (EBC)PƾǪvĪX֨ϥΩG
? NeUkAΩHER2ʡAߴBoʩΦ(~F|j2 cmβOڵ)fHA@vB褧@C
? NỲUvAΩ HER2 ʥB㦳_oIfHC
2 ಾʨ(MBC)Pdocetaxel֥Ωvಾ᥼H HER2 Τƾkv HER2 ಾʨfH
"					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.5.15		OI` 	0	OIs 20251124	IPHE11-a	IPHE11-b	IPHE11-c	112.5.15
	LO1XY01	P֤U`g	IPHE21	ĵPhesgo 600/600mg (Pertuzumab 600mg+trastuzumab 600mg)				"PHESGOi|ɭPL{ɯgP{ɯgŦIܡC
PHESGO֥Χtanthracyclineƾkv(anthracycline-containing chemotherapy regimens)fHAoͲvPY{׳̰C
bHPHESGOvePvŦ\CbX{{ɤW߫ǥ\ۭCpUAUvfHPHESGOvAಾʨfHhȰPHESGOv
PHESGOĥiɭPYBPRͳrʡC]oͥʹLӡBީʤ~BʪͯfΫʩIl~gԸsӰPHESGOvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1 (EBC)PƾǪvĪX֨ϥΩG
? NeUkAΩHER2ʡAߴBoʩΦ(~F|j2 cmβOڵ)fHA@vB褧@C
? NỲUvAΩ HER2 ʥB㦳_oIfHC
2 ಾʨ(MBC)Pdocetaxel֥Ωvಾ᥼H HER2 Τƾkv HER2 ಾʨfH
"					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.5.15		OI` 	0	OIs 20251124	IPHE21-a	IPHE21-b	IPHE21-c	112.5.15
BC27796263	J02AC05	XQ200@J`g 	ICRES	Cresemba 200 mg/ vial		IsavuconazoleigѧNlanosterolƬergosterollanosterol 14-alpha-demethylase (ӭMP-450̿ʻï)AiӪ_ergosterol (߲ӭMnզ)XAܨߧ@ΡCp|ɭPӭMҰƩTJeXֿnPergosterolʥFAiӴz߲ӭMcM\C	"ȾAΩ󦨤HC
_lq: 200mg q8h *48hr
q:200mg QD(۳̫@_lq1224pɰ_}lq)
ϥΤծ|0.2 gm1.2 gm޸o(in-line filter)`է뤩CAñN޸oKȶK`UWC"	"R߿`isavuconazoleɴqoͿ`A]A
CBIlxBYwBPı`BߡBMYhCYoͳoǤA`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sBc(2XC-8XC)C
հt᷻GibsƯfH`Gexs25XCHUҦܦh1pɡC
`Gb}ߧYN(2XC8XC)ABb24pɤ`C"	Isavuconazole 200 mg(۷372.6 mg isavuconazonium sulfate)	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	"(1) IǩT߯g(invasive aspergillosis)
(2) ϥΩ󤣾AXamphotericin BfHv߯f(mucormycosis)"	CRESEMBATΩwisavuconazoleΥ~ξLӪ	"xŦƾ˴ƭȤɰ(7.9%)B(7.4%)BæR(5.5%)BIlx(3.2%)Bh(2.7%)Bm(2.7%)B`g(2.2%)BYh(2.0%)BC[(1.7%)M֯l(1.7%)C
ɭPä[CRESEMBAv̱`}NѲVc(0.7%)B夤xɰ(0.5%)Bjp(0.5%)BIlx(0.5%)Bw(0.5%)BIlI(0.5%)MæR(0.5%)C"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-59 j	Ts111.11.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.11._20210607.pdf"">OI` 10.6.11.</a>              "	OI` 10.6.11.	0	OIs 20251124	ICRES-a	ICRES-b	ICRES-c	111.11.4
	J07CA09	HEXAXIMhPX@̭]	IHEXA	Hexaxim (X@̭]) 0.5ml/dose		hPX@̭](DTaP-IPV-HB-Hib) AΩX6gHWΥ઺¦ةMl[ءAHwճB}˭BʤyBBxBp·bݦ(Hib) ҾɭPIŧʯefC	"¦ج3(⾯ܤֶj4g)C
YXͮɦ1Bx̭]AhhPX@̭]iq6gְ_Bx̭]ɥRqCYbg֫eNز2Bx̭]AhBx̭]C 
3hPX@̭]¦ثAl[ءC
l[P̫1¦ئܤֶj6ӤC
YXͮɦBx̭]Ahb3X@̭]¦ثAĳ15-18Ӥl[اtճrB}˭rBƤp·̭]Pbݦߤ̭]CiϥΤX@̭](DTaP-IPV/Hib)A]iҼ{ϥΫhPX@̭]C"	שέ׵oNgηPVᱵءC׷PV/λ׵oṊ]ءC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsBc]2J-8J^C̭]bWL25JpUiíwF72pɡCoqɡAhPX@̭]wϥΩΤHC	"ճr֩ 20 IU2
}˭r֩ 40 IU2
ʤy(Bordetella pertussis)ܭ
ʤyr25 gg
y(Filamentous haemagglutinin) 25 gg
p·fr(h)3
1(Mahoney) 40ܭ4
2(MEF-1) 8ܭ4
3(Saukett) 32ܭ4
Bxܭ5 10 gg
bݦ(Haemophilus influenzae)h12gg
(CĦhֿ}ֿ}J(Polyribosylribitol Phosphate))
X}˭J22-36 gg"	J07C	"ӵ̭߬]Mfr̭]Ƥ BACTERIAL AND VIRAL VACCINES, COMBINED"		AΩX6gHWΥ઺¦ةMl[ءAHwճB}˭BʤyBBxBp·bݦ(Hib) ҾɭPIŧʯefC	eثhPX@̭]ᴿo͹LөʥJ(anaphylactic reaction)C		DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-11 j	Ts111.11.08		OI` 	0	OIs 20251124	IHEXA-a	IHEXA-b	IHEXA-c	111.11.08
BC27532277	L01BA04	TR߭ᴹ`g	IALIM1	ĵPemetrexed 500mg/vial		īܾĪAǥѪ_ӭMƻsĨ̿ʥN¹L{AHFܸ~F@ΡC~pemetrexed ithymidylate synthase (TS)dihydrofolate reductase (DHFR)glycinamide ribonucleotide formyltransferase (GARFT)AoǻïҬfolate-dependent ïAѻPthymidine purine nucleotides ͦXCPemetrexed ǥ٭츭ĸ(reduced folate carrier)PӭMĵXJնǿtΡAiJӭMCiJӭMApemetrexed folylpolyglutamate synthase ï@ഫpolyglutamate CPolyglutamate idsӭMATS PGARFT CPolyglutamation L{PɶBĪ@צAioͩ~FӭMAֵoͩ󥿱`´CPolyglutamated N²ӭMbIA]iī~~FӭM@ΡC	"Pemetrexed ĳq500 mg/m2A21Ѷg1ѡAHR߿`覡P10Acisplatinĳq75 mg/m2AAlimta`30AHR߿`覡P2pɡCcisplatinPe/ΧPAfwɥRAqCcisplatinhơAаѾ\ī~C
2.ϥγ@ĪDpӭM
Pemetrexed ĳq500 mg/m2A21Ѷg1ѡAHR߿`覡P10HWC"	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG100ml
ĳĳ~|tvGIVF 10min
ī~}~[GL
L`NƶG
PremedicationsG
Dexamethasone 4 mg bid for 3 consecutive days.
Folic acid 400 to 1000 mcg orally daily and continuing for 21 days after the last pemetrexed dose.
Vitamin B12 1 mg IM beginning 1 week prior to pemetrexed and then given every 3 cycles(thereafter,may give on the same day as the pemetrexed infusion).Do not substitute oral vitamin B12 for IM."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Pemetrexed 500mg	L01B	ܥN ANTIMETABOLITES	0	"1.PemetrexedA֥cisplatinOvߴಾʫDpӭM(쪬ӭM´~)Ĥ@uġC
2.Pemetrexed@ĪOߴಾʫDpӭM(쪬ӭM´~)fH4Ӷgt`ĪĤ@uefåcƤkC
3.Pemetrexed@ĪOvߴಾʫDpӭM(쪬ӭM´~)ĤGuvġC
4.PemetrexedPcisplatin֥ΩvcʦؽӭMFC"	PemetrexedTΩwpemetrexedΨξYLӤfv̡C	hҡBߡBæRBʥFBݤʥզy֯gΫK	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-02 j	Ts111.11.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.26._20251001.pdf"">OI` 9.26.</a>              "	OI` 9.26.	0	OIs 20251124	IALIM1-a	IALIM1-b	IALIM1-c	111.11.4
	N02BE05	ίk`g	IACET1	ACETAMOL INJ 1G( Propacetamol )		h@(Analgesic effect)-bϧcyclooxygenase@ΡAeC(prostaglandin)ͦAbg䦳p_kh߽Ī͡Aް_khƾǪ誺ͦC 	"ĵ: 30mg/kg q6h (Max:120mg propacetamol/kg/dayY60mg paracetamol(Acetaminophen)/kg/day)
H:1-2g q4hA(Max:<6g)Sp<8g
tm覡G(tM)
ĵG
}G:D5W ANS
`tv:1-2ml/kgA>15min
HGRߪ`g>2min  P125ml NStsA15min`"	"nΩ󦨤HM|(17kg)HWൣ
Yǯfw̡AĥHe߰v
Lӱw̥iണLӵo"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	t1g   propacetamol(۷  0.5g   paracetamol)	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS	0	bLkϥΤfAĤ覡ɡAΩkhεoNgvC	"wpropacetamolLӤw
x\ê
h3Ӥ뤣ĳϥΥ~"	YwدtA߹æRAxŦïͤƭȧܡApOUAֽ_lLӤ	he3Ӥ뤣ĳϥ	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-25 [w]_w03-01 [E]_G1-02 j	Ts112.5.15		OI` 	0	OIs 20251124	IACET1-a	IACET1-b	IACET1-c	112.5.15
AC59663100	L04AX04	bn15@J	OLEAV	ĵfLeavdo Capsules 15mg (Lenalidomide)		Lenalidomide @ξAݶi@BMA㦳ܸ~Fs͡BK̽ո`Mܦ޷sͪSCLenalidomide PGֲycPioӭMEAüW[ܵoӭMEcCLenalidomide YǲӭMWޡAj(IC50s) h@A]ҦӭMCbչLӭM褤Ao{lenalidomide ঳ħNamalwa ӭM]@ؤHB ӭMOӭMA֤@Ӳ5 V^ͪAMӡAKG-1 ӭM]HFӭMA]֤@Ӳ5 V^MLS5 VʥӭMAͪĪGĤOC Lenalidomide ໤ɲӭMgP`Aqӧѱw̨WohoʰFӭMͪA]MM.1 S ӭM]@ؤHhoʰFӭM^ͪC~o{Alenalidomide 2 X?(COX-2) ʡAäCOX-1C	ĳLenalidomide _lqC25 @JAHeAAb28 ѥĶg1 21 ѡACA1 25 @JnC	"1.Ķȯ}ߵw̡AӥBYϨLHۦgA]iLHAΡC2.ĥsൣiΤBAYTѵihkC
3.AΥĴAw̤oC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCC	Lenalidomide 15mg	L04A	Ķ IMMUNOSUPPRESSANTS	0	"RevlimidPdexamethasoneX֨ϥΥivewܤ֤@تvѤhoʰF(multiple myeloma, MM)w̡C"	YwTw̹REVLIMID (lenalidomide) Ψ䦨LӡAhTϥΡC	hBP~BKBmB⵬C	X 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-06 j	Ts111.11.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.43._20251001.pdf"">OI` 9.43.</a>              "	OI` 9.43.	0	OIs 20251124	OLEAV-a	OLEAV-b	OLEAV-c	111.11.4
KC01138210	N02CD03	[`gG	IAJOV	fAjovy inj. 225mg/1.5ml/syringe (Fremanezumab)		FremanezumabHƳA|Pt]t`?XA_P骺X@ΡC	"225mgC@A675mgC3Ӥ@(Cu@)C
󴫾qܮɡAUwwĤ뤩Ĥ@s{qCY|@AJOVYA֧ġAAH̫@ĤӱƩwAJOVY򪺧ĮɶC
AJOVYȨѥ֤U`gC
OƼfWdA}(112.3)BiPbotox֥"	Yo͹LӤAҼ{AJOVYñĨAkChƤצܤסAyĩΥֽTJvChƤīƤpɦܤ@Ӥ뤺qC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ץNxs2XC8XC
?pGnAAJOVYiml]˲AxsǷų̰30XC(77XF)̦h7ѡCۦBcXAJOVYA7ѤϥΧΥC~xsǷūAФũ^BcC"	Fremanezumab 225mg/syr	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	wHYh	fremanezumabΥξYLӪfHTϥAJOVYA]ALӤMީʤ~C	`gkhBwP	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-26 j	Ts112.5.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.5._20220301.pdf"">OI` 1.6.5.</a>              "	OI` 1.6.5.	0	OIs 20251124	IAJOV-a	IAJOV-b	IAJOV-c	112.5.15
AC559241G0	N03AE01	i 2 @J	ORIVO2	()Rivopam 2mg/tab (Clonazepam)[ޥ|]		"Clonazepam 㦳benzodiazepines `??SʡA]Aܵj(w)@ΡBR@ΡB٦P@ΤεJ
{wѧ@ΡCM䥦benzodiazepines @ˡAoǧ@ΥDnO۬ĲGABA ҴC@ΡA]
ʪs?ܡAClonazepamt~٥iMͧ@ΡCʪs?ڤΤH?qϬsGܡA
Clonazepam ith?}oʬʡA]Aʵo@(po@)ƺCiB}ƪiBxoʴƪiB
?Ψ䥦mƪiBH?WhƪiMCiC
Clonazepam xoʻPwiಣͦ?@ΡAM?`ۤAxoʤEEG ?`
?`Clonazepam C"	"wAӫĵ0.5 mg C?Hb}lv?ɡAAθCC龯?A]0.5 mg C
קK}lv???AHC?}lClonazepam v?CACCW[C龯?AܾAXU
fH?CfA@?Clonazepam b30-60 }lo@ΡAĵi6-8 pɦġAHh8-12 p
ġC
M10 HUĵ(魫30 kg HU)_l?C0.01-0.03 mg/kgA2 3 ġAᤧ?
W[C3 ?oWL0.25-0.5 mgAC?Fj0.1 mg/kg 魫AΥiwAΦ]??
ӱư?i@B?W[CĵC̤j??iWL0.2 mg/kg 魫C
ھ10 HUĵ(?Wq)PH(?Uq)T??A10-16 ĵĳ?pUG_l?
C1-1.5 mgA2-3 ġAᤧ?W[C3 0.25-0.5 mgAܹFUӯfH?(q`
C3-6 mg)C
H_l??iWLC1.5 mgA3 ġCᤧ?W[?3 0.5 mgAwQA
AΦ]??ӱư?i@B?W[A?C@fHAq`C
?3-6 mg YCH̤jv??C20 mgAB?iWLC
C龯?3 A??QtA䤤̤j?bΫeC?̦nbv?1-3
PFC@F?{?AC龯?iߤW榸뤩C
[JClonazepam @wsbw?{eAҼ{ϥΦhاܵjĥiɭPƧ@ΪW[C
ǯfw̨?վ㾯?C"	"ΥϥClonazepam i|ɭPGΤޤ?ͦ?W[C]SO`NIlD
qZ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Clonazepam 2mg	N03A	w ANTIEPILEPTICS	0	"wC
b嫬ʵo@(po@petit mal)MD嫬ʵo@(Lennox-Gastaut gԸs)A٩Do@(myoclonic
seizures)Υi?ʵo@(atonic seizures, drop syndrome)AClonazepam iĤ@uġC
bधIYj(infantile spasms, West-Syndrome)AClonazepam iĤGuġC
boʩ~oʱjа}˩ʵjˡAνʵo@(complex partial seizures)AClonazepam iĤTu
ġC"	~TΩwClonazepam Ψξ(plactose)LӡAΦYIl?fHC	"Gh¡BΡBh(lassitude)Bٱi?LCB٦׵L?BYBY?BBʥաB
wCoǧ@γq`OuȪABbv?L{?C?UAjh|۵MCb}lv?ɺCC
aW[?AiקKoǱpC"	"bhAuݭnϥClonazepam ɡA~iCbh̫TӤΤYɵ?
ClonazepamAiyXͨ઺߸?WhAsͨ઺ŹLCBٱi?LCB?IlMxC
~A?OhMM?̬ҥi[wfC"	i?Īv?ˤ?ӱ¨šCpGnϥClonazepamAh¨šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M03-04 []_E6 []_w78-15 j	Ts111.11.4		OI` 	0	OIs 20251124	ORIVO2-a	ORIVO2-b	ORIVO2-c	111.11.4
	R06AX27	Q	OLABI1	Labixten 20mg/tab]Bilastine^		"bilastineO@ثDRBī´iܾAPH1ܩʤܾAAQxP]muscarinicreceptor^hL@ΡC
Aγ@qbilastineA´i޵oֽClMF24pɡC
"	"HMC֦~]QG]t^HW^
C@20mg bilastine wѹLөʻ󪢡]u`ʩM`~ʡ^MC¯lgC
Ѧ~HMǥ\णfHAbilastineݭnվ㾯qC
"	שέ׵Ŧl˪fHקKX֨ϥbilastineMP-gp(ҦpketoconazoleBerythromycinBcyclosporineBritonavir  diltiazem)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHU	bilastine 20mg	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wѦH12]t^HWൣLөʻ󪢤κCC¯lg	TΩDΥξLӪfH	YhBݺΡBYwMh	קKϥ/SmҦw	קKϥ/SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.5.15		OI` 	0	OIs 20251124	DC	DC	DC	112.5.15
AC60307100	N04BA02	0	ONUMI	Numient ER(Levodopa 48.75mg / Carbidopa 195mg)		"carbidopa O@ةPڭiĥhn?Aਾlevodopa bP`N?hiAHTOҪĪ
qyJAhiboêv\ġC
"	"T骺lqbɨCAΤT;۪v4_AC@@ɪAΤTC
"	"Levodopar /Carbidopae xǥ\णvTpAwԷVIYxǥ\णw̡C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25JHU^	"Levodopar,Carbidopa"	N04B 	hi DOPAMINERGIC AGENTS	0	"ˤgBᤧˤxԸsBgʩˤxԸs(@ƺҩοr)C
"		", æR,m"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w05-03 [s]_240 j	Ts111.5.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	OI` 1.3.4.	0	OIs 20251124	ONUMI-a	ONUMI-b	ONUMI-c	111.5.06
AC585611G0	N05BA06	0	OANXI	()Anxicam 2mg/tab (Lorazepam)[ޥ|]		"1. ~benzodiazepineܵJ{A12HUĵnϥΡAqӧOwFvW[qӴ֤}C
2. ~ѩΰIzfHA}lqC12mgC
3. ѩSʥNªͦA]LlͪASnWMIʡC"	"Anxiety disorders2-6 mg/day in 2-3 divided doses; MAX. 10 mg/day.
Insomnia2-4 mg HS.
@fw쾯qC1~3mgi2~3AYOvvhibNe@龯q2~4mgC
2HWൣvMwqϥΡC
Ѧ~HΨIzw̡A쾯qĳĨC1mg2mgAΡAi̷ӱpݭnίfH@{פHվAקKƧ@CCW[qAqߤW}lնqA@NeĪkAĳNe]ΤNe@BGpɵ2mg4mgC"	bALorazepam AsMLϯgt@ʱN|CAҥHקKܰsΨLϯgtC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷxsABAЩmൣΤ쪺aC	Lorazepam 2mg	N05B	ܵJ{ ANXIOLYTICS	0	J{A	Lorazepam iΩwbenzodiazepine ĪLӪ̡C	}po͡Ahq`ObvA ~AΩδqAYwѩήCBenzodiazepine Ī̱`ް_}ΡBtwBzαíC	Ĥ C	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_E6 []_w78-01 []_86-4Lj	Ts111.11.4		OI` 	0	OIs 20251124	OANXI-a	OANXI-b	OANXI-c	111.11.4
	R05CB15	n 300 @J	OECTR1	Ectrin Capsules 300mg		"~PNªҨ𪺬ʡAǥѴJ򪺧@ΡA}GHG
JջPLJսlBl䵲cAiӭCG
uʩMHסFPɧﵽ֤򪺶ǿOAϱoGeyXC"	"HΤj 15 HWĵG 300mg (1 ) Q12H
~ACʪʪͯe(COPD)_ofHΦѦ~HäݭnվvqC
"	"1. Yfwe{LӪgAߧYϥΡC
2. ǥ\णw̵ Erdosteine | CmaxH AUCA
ӹYǥ\lˮɡAĶjC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"25JHUxsBൣBC
"	Erdosteine 300mg	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	C	"HUpĳϥΥī~
1. 靈Ħνξ@αaʲJ
(SH-group)ĪLӤw̡C
2. xŦ\ಧ`(pGserum alkaline phosphateBtransaminase
W[)w̡C
3. Ŧ\ण(ٻMv<25ml/min)w̡C
4. iħg(homocystinuria)w̡C
5. p 15 ĵC
"	"1. oͲv 13%GGhBߡBYhC
2. oͲvb 0.51%GKBUgBfBwt
(vertigo)BA(general malaise)C"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.11.08		OI` 	0	OIs 20251124	OECTR1-a	OECTR1-b	OECTR1-c	111.11.08
	G02CX01	O@Y`G	ITRAC1	Tractocile 7.5mg/ml;5ml/vial(Atosiban)wL		"TRACTOCILE? atosibanAO@ئX`?Catosiban O@vʶʲܾCatosiban P
鵲XA֦YWvHΤlcټhiOAӧFlcYCatosiban ]|Pޥ[鵲XA]ޥ[@ΡCAtosiban AlcP}l@ήɶܧ֡AlcYb10 i۪֡AӹF12 píwlcR]? 4 Y/ pɡ^C"	RߵTRACTOCILE? TӶqG lHTRACTOCILE? 7.5 mg/ml `gR߱`6.75 @JqFHߧY3 pɫ򪺤jq`TRACTOCILE? 7.5 mg/ml `ο@YG( tqw`300 LJ/ )FHpq`TRACTOCILE? 7.5 mg/ml @Y`G]򾯶qw`100LJ/ ^A̪45 pɡCvɶWL48 pɡA{TRACTOCILE? `q̦nnWL330 @J]Hatosiban p^CpGbTRACTOCILE? vAlcYAҼ{LNkC	"Atosiban ϥΦbL줣fHC
Atosiban ϥΩhLWάOhgƤ24 27 gk{
gD`
WᴿIltΤ}ƥ󪺳ipIlxMͤ~ASOOPɨ
ΨLlcYī~ptlܾM beta-mimetics M/ ΦhL
WɡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsb2 8JҡA@}ҡAߧY}C
R߿`G}b24 pɤϥΡC"	Atosiban 7.5mg/ml	G02C	L OTHER GYNECOLOGICALS	0	"𧳮W??
G
TRACTOCILE? Ω󩵿HUWkG
- W߮cYܤ֫30 AWvj󵥩C30 4 
- cVXi1-3 ( g0-3 ) McVij󵥩50%
- ~֤j󵥩18 
- ֦b24-33 P
- L߲v`"	"bHUpUnϥTRACTOCILE?G
- hgƤ24 gζWL33 g
- }BhgƤj30 g
- co|wέL߲v`
- YelcXݭnߧYY
- lwYlwݭnY
- Lc`
- hîcPV
- emLL
- LL
- ~򧳮W˩ML঳`p
- ĪΥ@ؽξL"	"ߡA}ɰAYhBYwA߸LtACAB`g
"	Atosiban uΩhgƦb24-33 gWkC	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-13 j	Ts112.1.10		OI` 	0	OIs 20251124	ITRAC1-a	ITRAC1-b	ITRAC1-c	112.1.10
BC27795100	J02AC05	XQ100@Jn	OCRE	Cresemba 100 mg/cap (Isavuconazole)		"IsavuconazoleigѧNlanosterolƬergosterollanosterol 14-alpha-demethylase
(ӭMP-450̿ʻï)AiӪ_ergosterol (߲ӭMnզ)XA
ߧ@"	"_lq: 2 Cap Q8H,@6(48p)D۳̫@_lq1224pɰ_}lq
q:1 Cap QD
iCRESEMBAR߿`PfAഫA]wҩ۵ʡA
ഫɤݵP_lqCfAɶ]AnCZHBBѩΥ}nC"	"Azole߾vqoYֽ}AҦpvj(Stevens-Johnson)
gԸsCYfHoYֽ}ACRESEMBAC
xŦiCɰΨx
{ɸ礤qoͨxŦiCɰ
CRESEMBA|bרx\णfH(Child-PughC)isCĳϥΩ
fHADi઺QqIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsl]ˤHקKC
xs30?CHU"	Isavuconazonium sulfate 	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	"(1)IǩT߯g(invasive aspergillosis)
(2)ϥΩ󤣾AXamphotericin BfHv߯f(mucormycosis) 
"	"CRESEMBATΩwisavuconazoleΥ~ξLӪ
TCRESEMBAPjCYP3A4֥ΡApketoconazole
TCRESEMBAPjCYP3A4ɾ֥"	"̱`v}xŦƾ˴ƭȤɰ(7.9%)B(7.4%)BæR(5.5%)B
Ilx(3.2%)Bh(2.7%)Bm(2.7%)B`g(2.2%)BYh(2.0%)BC[
(1.7%)M֯l(1.7%)C
ɭPä[CRESEMBAv̱`}NѲVc(0.7%)B夤xɰ
(0.5%)Bjp(0.5%)BIlx(0.5%)Bw(0.5%)BIlI(0.5%)MæR(0.5%)C"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_8-01 j	Ts112.02.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.11._20210607.pdf"">OI` 10.6.11.</a>              "	OI` 10.6.11.	0	OIs 20251124	OCRE-a	OCRE-b	OCRE-c	112.02.16
X000250100	A06AD02	250 @J	OMGO2	(M)Magnesium Oxide 250mg/tab		"@Bľ:ĨävTGĤcAӬOǥѤƾǩʪPMwĹLhG
GBhqm@ΡATKYܬ}AƪnƼW[C"	"HG@34C
12HWGAΦHqC
612GAΦHq1/2C
36GAΦHq1/4C
3HUAЬvC"	ŶWLĳqAYN~ΰƧ@β͡AߧYĴNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Magnesium oxide	A02A	ܻ ANTACIDS	0	wѭGAΨ`PAθgE_GΤQGzšBGBDҦHGĹLhC	TΩGzDBhBߡBæRw̡C	m	B	i/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.01.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	DC	DC	DC	114.01.23
AC19462100	A02AX	έG	OSTRO1	STOLINE Ƥ		"1.¾K@
2.Gc@ΡGfAPoxethazaine|acetylcholineEժް_GcC
3.GĤc@ΡGfAPoxethazaine]|pentagastrinһoάOEް_GĤc@ΡC
4.GzDBʧ@ΡGfAP|GBʡFbGPQGzAoxethazaine]|ƾXһoj˩ʦY@ΡC"	q`HC3-8A3~4fAϥΡCqi̱w̪~֤ίgӽվC	"1.קKsAΡC
2.AΡA`NnrHάOCZAHקKݯdfӲͳ¤PC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"oxethazaine 5 mg, polymigel 244mg"	A02X	vPGĤcef䥦Ī OTHER DRUGS FOR ACID RELATED DISORDERS	0	GBzBDҦHGhBGĹLhBGAΨ`P	糧~󦨤Lӯfvw̡C	", f,ߡBKBYhBΡAol{HC"	DnAקKϥΡC	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w09-01 [s]_252 [®]_252 [E]_C4-02 [Ew]_EX094 [Ew]_Z-13w9 [Ew]_Z-16w3 j	Ts111.12.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OSTRO1-a	OSTRO1-b	OSTRO1-c	111.12.15
AC32892500	A03FA03	L꾯@J	EDOMP1	Molin SUPPOSITORY 10MG		"1. [t\᪺GƪšA]iWiNA٪iOAëPiժA٩\᪺įXi{סC
2. Domperidone@hiܾAi_D1D2A@ΩPΫḣپ~ƾ鱵E(CTZ)AGPiGzDƦ٬ʤΤR@ΡC"	"1.uHvΡu12HW魫j35kgC֦~vG110-30mgAC̦h2C
2.u12HUൣvΡu12HW魫p35kgC֦~vG110mgAC̦h3C"	pX{߫ߤ㤧xίgAϥdomperidone	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Domperidone	A03F	GzʤO PROPULSIVES	0	LkfApUAΩߡBæRgvA}fް_Gzįʲ`	"1. צYx\ê̡C
2. wsbŦǾɶjASOOQTcA۹qѽ貧`έ즳Ŧef]p{ʤ߰Iܡ^̡C
3. ֥Υiް_QTī~C
4. ֥αjOCYP3A4]ެO_QT@Ρ^C"	fBfBȮɩʥ֯lηkoBYhBzGABmBݺεCucſE@פɰBkʤkůgC	"SmҦw
DnAקKϥΡC"	MO_sͨ঳`C]AbϥDomperidoneĳ˦ۭšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-11 [E]_I2-10 j	Ts111.12.15		OI` 	0	OIs 20251124	EDOMP1-a	EDOMP1-b	EDOMP1-c	111.12.15
KC01080216	A10AE54	nعF`g100+50LJ	ISOLI	ĵSoliqua solution for injection 100 units+50ug		"insulin glargineAO@ذ¦خq (DnwŸ})AlixisenatideAO@ɿ}`?-1(GLP-1)Pľ(Dnw\})CInsulin glargine
خq(]Ainsulin glargine)Dn@άո`}N¡CخqΨiǥѨEP´︲}^ASOOf٩Mתղ´AåBxŦͦ}ӹF쭰}@ΡCخqiHתդѤγJսѡAüW[Jս誺XC
Lixisenatide
LixisenatideO@ɿ}`?-1(GLP-1)PľCGLP-1鬰۵MͦGLP-1@μЪAGLP-1@ؤͩʸzcXAPiŦ]-ӭMc}̿ʯخqåB\-ӭMcɿ}C
Lixisenatide b}Wɮɷ|EخqcA}`ɫh|A]CFC}ICPɡA]|ɿ}cCbC}pUAOdFɿ}cϾC\`glixisenatide|wGƪšA]qX}QlöiJ`tv|CC"	"Soliqua}līeΰ¦خq?lixisenatideΨLɿ}`?-1 (GLP-1)PľCsoliqua_lĳqoWL20Ӿq(20 units/10 gg)
evϥιLخq(fA}ĩGLP-1 Pľ^:Soliqua_lq10 Ӿq(10 units/5 gg)
evInsulin glargine(100 units/ml)**<20 units:Soliqua_lq10 Ӿq(10 units/5 gg)
evInsulin glargine (100 units/ml)**?20 ~ <30 units:20 Ӿq(20 units/10 gg)*
Y¦خqC鵹2ΨϥΨC@insulin glargine (300 units/mL) AheĪC`qU20%H@Soliqua _lqC
C̰qinsulin glargine 40 units[Wlixisenatide 20 ggAo۷40 ӾqC
Soliqua̰qiվ40ӾqC
צܤ׵ǥ\णfHϥSoliquaɡAiWcʴ}ýվ㾯qC
Yǥ\णΥǯffHĳϥSoliquaA]lixisenatideboǯfHWvg礣C"	"SoliquaiϥΩĤ@}ffHΥΩv}f଻ĤrC
YfH㦳C}PʪI]lAhHYKʴBiݽվ㾯qC
oǭI]l]AG
- 󴫪`g
- خqӷPoﵽ (ҦpAO]Ѱ)
- M`aW[Ωଡ
- Pɦsbfg (ҦpæRBm)
- 
- ~\
- s
- YǫDNvʪcef (ҦpAҪ\CUθUeεǤWֽ\ण)
- PYǯSwLĪ֥Ϊv
Lixisenatide/insulin֥sulfonylurea|W[C}IC]SoliquaĳPsulfonylureaX֨ϥΡC
ϥɿ}`?-1(GLP-1)PľQ{PoͫʯŦICYhõoͯŦASoliquaFYTwʯŦAlixisenatideisġCŦfvfHϥήpߡC
~ĳϥΩYǥ\णΥǯffH"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}xsBc (2XC - 8XC)C
}ʫxs<30׫Os14ѡAOs<25׫Os28ѡD"	insulin glargine 100 unitslixisenatide 50 ggC	A10A	خqΨPt INSULINS AND ANALOGUES	0	1. AΩmetforminX֨ϥΥt@ؤfA}ĩmetforminX֨ϥΰ¦خq(C龯q֩60)vɦ}ΪĤG}fHfHAbPBʥ~Aﵽ}UvC 2. AΩmetforminX֨ϥɿ}`?-1 (GLP1)Pľmetformin Mt@ؤfA}X֨ϥɿ}`?-1 (GLP1)Pľvɦ}ΪĤG}fHfHAbPBʥ~Aﵽ}UvC 3. AΩ¦خq(C龯q֩60)lixisenatidevɦ}ΪĤG}fHfHAbPBʥ~Aﵽ}UvC	ﬡʦΥξLӪ̡C	C}έGzD}]ߡBmBæR^Yw	"insulin glarginehõLSw}@
ثe|Lhkϥlixisenatide"	"SmҦw/DnקKϥ
Insulin glarginelixisenatideO_|qHťĤcoӪC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.12.28	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3.3._20210701.pdf"">OI` 5.1.3.3.</a>              "	OI` 5.1.3.3.	0	OIs 20251124	ISOLI-a	ISOLI-b	ISOLI-c	111.12.28
AC49204100	A10BF01	0	OGLUB1	ĵLitacarbose 100mg/tab		\-glucosidase inhibitorAiPpzW\-glucosidase@ifʪvAHwbpzѡA]AilAHקKᰪ}Ȫ{HAӹFí}C	C3AC50-100 mgA\eAΡC	"1.ĳ\eAΡC
2.AΥ~Aν}Χt}ɡAiް_ABmC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Acarbose	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ݩĤG}ffHfA}Ī	"1. 糧ĪoĪLӪw̡C
2. ĵΫC֦~ĮĤέ@ʪƤMA~iϥΩ~֤p18̡C 
3. CʸzDAAHơBlê̡C 
4. ~iϥΩYǥ\णfw(CrCl<25ml/min)C"	i|GzȮBBӸmBh	B	"קK
ư acarbose gѥŹध@ΡAhWĳvB Acarbose ŰkC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668825?cesid=0NtFW6txgRM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcarbose%26t%3Dname%26acs%3Dfalse%26acq%3DAcarbose"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.1._20091201_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.1.</a>             "	"OI` 5.1.,5.1.1."	0	OIs 20251124	DC	DC	DC	114.06.06
AB57225100	A10BX02	X޿1@J	OREPA	ĵRepaglinide 1mg/tab (Repaglinide)		"Repaglinide uĪPiخqc(insulin secretagogue)CRepaglinide oHֳtC}ADgѨEخq\ध ] ӭMc خqӨӡCRepaglinide P ] ӭM@γXAq ] ӭMW ATP-̦sʹ[lqD(ATP-dependent potassium channels)AP ] ӭMhơA}ҶtlqD (calcium channels)AW[tlyJ(calcium influx)A ] ӭMXخqC
"	" 2 }fwAH\fA repaglinide  30 ioPخqcĪGAæb\ɫF쭰}ĪGC夤repaglinide @רtaCAA 4 pɫA 2 }fw̪夤Ī@׫ܧCC2}fw̨ϥ 0.5  4 mgrepaglinide ɡAqP}CC {ɹ絲GܡArepaglinide b\e 15 AΡAO]iHbYN\ɪAΩάO\e 30 AΡC
ĳlq0.5mg}lCYfHϥΨLfA}Aĳlq1mg}lC
榸Ḭ̄ĳqe4mgAC̰qoWL16mgC"	"1.~\eAΡAihݪAġAקKC}
2.קKPɨϥ Gemfibrozil P RepaglinideCMӡAnX֦ĪɡApߺʴ}A] Repaglinide qiݭnվC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Repaglinide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	2}f]NIDDM^LkgѶBΥ[jBʵkAF}n	"1.w糧ī~DRepaglinideΨLLӪ
2.خq̿૬}f(Type1}f)
3.}f଻Ĥr
4.~p12pġC"	C}BߡBæRBƤ}C	C 	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w63-05 [s]_372 [®]_372 [E]_E4-12 j	Ts112.5.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OREPA-a	OREPA-b	OREPA-c	112.5.15
	B01AD04	귻60000ڳ`g	IUROKX	ĵUrokinase 60000I.U 60KIU/~(Urokinase)B		~NplasminogenƦplasmin(fibrinolysin)AMiNֺJժѡC	R߮g:Ĥ@60000-240000IUAấ־qAsϥ7ѥkC	"1.PLfHioͥXʸC
2.ϥΥ~n`NY۵oʥXAg`@GˬdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Urokinase	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʪͮAʫaʯ߮AMR߾ɺ	"1.ī~󦨤LӯfvfwC
2.XBI~NB72pɤLw´BCYx\êBCֺJխpΩX̧ҥΡCHypersensitivity to "	`-`gˤfBXκyF-LӡBYhBBoNBR?BߡBooB۵oʥXC	B	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.4.4		OI` 	0	OIs 20251124	IUROKX-a	IUROKX-b	IUROKX-c	112.4.4
BC24260277	B05AA07	qR߿`G	IVOLU	Voluven 6% 500ml/bag(Tetrastarch) q		~ߥNΫ~Aണѽ麯zAb`gbޤA|ܧX´PAӹFֳtBʪGenɥRĪGCEBNGyαѦgBN˯fHGyfHAíwGenXRĪGC 	CѨC魫20mlA@C500@ɦ1000@ɡC 	ѩiಣ͹LӤA̪쪺10-20@wC`JòӤ[fHA`NѩֳtΤjq`JͪL`WtMIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Hydroxyethylstarch	B05A	Gάī~ BLOOD AND RELATED PRODUCTS	0	Wϥδ`GLkvʥXɭPCenfHA~LkNyΦߤ]lC	YʦBYRʤߤOIܡB񦳤֧BLǰIܡC 	LөʥJB`êB޵jˡBIlMŦC	D   קKϥΰDvn	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w11-10 [E]_F2-09 j	Ts		OI` 	0	OIs 20251124	IVOLU-a	IVOLU-b	IVOLU-c	
NC02789209	B02BA01	0	IVK1	Katimin-1(Vit.1)10mg/ml/amp		PixŦX]l]IIAVIIAIXAX^F MӡAoبET|MC MenadiolOͯKʧΦF phytonadionemenadione㦳֡A[@ΡF menadiol sodium diphosphate (K4)ĤOOmenadione (K3)@bC	"1.@ΤNɥXw
   H嬰تɡAjH@Ѧ٦ת`g2~20mgQNɥXwتɡAjHq`Ne1~2ѨCѦ٦ת`g20~50mgC
2.sͨXΥXʶɦVwΪv
   vɡAsͨͤU`g0.5~2mgBnɨC1~2pɤЪ`g̰qiF10mgQwɡAbYe1~2PCѦ٦ת`g10mgB
   nɦbYe2pɪ`g10~20mgC
3.gfܾ徯Īܾ
   ̾T{פίgΨMwζqAq`jH^`g0.5mg~10mgBnɼW[25mgCbXɤ@^`g10~50mg"	"ĳq`٦ת`gAYݭn]iRߤΥ֤U`gC٦ת`gP@a`g20mgHUQRߪ`gɨ`gtרC10mgHUλPͲzQVitagen Inj VM}}`gC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Phytonadione	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	lcĳXBȤlcXB`lcXBgLhBxŦέGzêǬVʯefҭPXΥXɦVefBsͨXʯΥXgভB`YBHui઺XʶɦVBsͨNɪXBĪҤް_C夸gX嵥	糧LӯfvfH	Rߪ`goY]AIlxAݵh^Að`AiOѩŤƾް_F `gLӡC	C	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-29 [w]_w03-04 [w]_w03-10 [E]_G3-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	IVK1---	IVK1-b	IVK1-c	110.6.16
AC19573100	G03GB02	֥50@J	OCLOM1	"Clomiphene 50mg/tab (clomiphene) ""PEILI"""		~W[FSHLHq鸢ʳXӡCPiZλoƧZCQĪܻۿEʧ@Φb鸢ʳ(adenohypophysis)AhۿEotjXAXʸE(gonadotropin)A]iHW[Z_XͦX	"Ĥ@vGۤgӼĤѶ}lAġACѤ@ AsAѡC 
ĤGvGeAΫ᥼FƧZتAUgӼĤѦAתAġACѤGAsAѡC 
ĤTvGgGvAFƧZ̡ADL~E_ίfHu AiAiĤTvAΪkBζqPĤGvۦPC"	AΫAiಣ͵OҽkAФp߾rpξާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Clomiphene	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	ƧZêް_goƧZ	"(1) 糧~LӪ̡ATϥΡC
(2) D]Z_~FΦhnʧZ_gԸsҤް_Z_~jC(i|]Z_LרEӨϱoZ_[~j)
 (3) xl`Φxef̡C
(4) hkC"	ߡBæRBUhBYhBıҽkC	PL	hα¨ŴϥΥ~	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667979?cesid=4oM0NoSCuFb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCLOMIPHENE%26t%3Dname%26acs%3Dfalse%26acq%3DCLOMIPHENE#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts112.4.4		OI` 	0	OIs 20251124	OCLOM1-a	OCLOM1-b	OCLOM1-c	112.4.4
AC39703100	C07AG01	"""""@J]ԨL֡^"	OLABE	Labtal 200mg/tab( LABETALOL)		Labetalol @غ٬u]_vġC @ΩŦAϤ߸tvNŦGXqCC åBSඡaϦ޵αiPAGbޤ󶶺ZayqA]ӯF쭰تC ĦPɯ୰CŦu@qNŦһݭn𪺮ӡA]iΨӹwŦʮɭPӭMaΤߵho͡C	"G
lq@CѨ⦸  C100@J
qШCѨ⦸AC200-400 @J.
̰q800@J/ѡAHA⦸

YxTʰ
2400 @J/ (GΥ|)

W
lq@CѨ⦸  C100@J; 
YʰhiH@TĤ覡A@ѳ̰qiWG2400@J
"	"1.YzݯfvAЧiv
 2.viX{YhBh¡AvAoǲ{H|vzήC
3.BC}MҪrgx"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Js30JHUxs	Labetalo HCl 200@J	C07A	]_ BETA BLOCKING AGENTS	0		"1.TҨϥΩĤGβĤTŦǾɪ_BŦJHΨLYΫCwY߰ʮ}wpw̡C
2.TҨϥΩw糧LӤ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D3 [2]_D3 [ws]_w36-07 [E]_B4-14 j	Ts111.12.15		OI` 	0	OIs 20251124	OLABE-a	OLABE-b	OLABE-c	111.12.15
A020892343	D02AE01	""""" ƨŻI"	EUREA2	Sinpharderm cream(urea)		ĥDUrea㦳跻@	"@2-3AAqw

"	~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 @2-3AAqw	Urea 100 mg	D02A	ĩM@ EMOLLIENTS AND PROTECTIVES	0	h	"1.ϥΦĤް_L
2.ˤfά~
3.ywμ
4.ˤfm{H"	"olBoBooBEPB

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-05 [E]_H3-25 j	Ts111.10.20		OI` 	0	OIs 20251124	EUREA2-a	EUREA2-b	EUREA2-c	111.10.20
AC41990321	D07AC03	0	EESPE	Uson cream(group2)		ϥαjħܵoǤWֽTJsA㦳B ܹLӡBܺXBܼW͡BHΧܷko@	11~2AAq٩wB	iΩ󲴷	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Щ󳱲DB	 Desoximetasone 2.5 mg	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	ïlB~BNˡBδBΫr˵ֽPVg	0				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P01-01 j	Ts110.6.16		OI` 	0	OIs 20251124	EESPE-a	EESPE-b	EESPE-c	110.6.16
AC48181100	G03CA03	0	OINDI	VeninaƤ		Estradiol valerateOѵMۿEestradiol୤ƪAĲzĪGDgѥؼв´SwۿEoͧ@ΡCTJPƦXPӭMDNAXAèESwJս誺XCMedrosyprogesterone acetateOѵMlͪ17-alpha-hydroxy-6-methylprogesteroneAmedroxyprogesterone acetateMM@鵲Xç@ΩlcHϤlcѼWͪAରcAC	"CѤfA@AϥεLݶ_AĳCѩTwɶAΡCĳϥΥ 1@J/2.5@J_lqC
Medroxyprogesterone acetate (MPA) 2.5mg q`wHwXAYoͥX屡pBAbưlc`iʡAqiW[ 5mgC
pG 1mg  estradiol valerate (E2V) HwۿEʥFgAqiW[ 2mgCvϥγ̧CľqCLgBϥβXɥRkΤeϥΨLʽƦXXɥRskAi@Ѷ}lAΥ~eϥζqʲXɥRsk󧹦gA@g}lAΥġC
ۿE󰩽Kת@ΩMqA]A 1mg E2V ĪGiCA 2mgC"	"q`ʱEbSLˬdpUA]AˬdAϥζWL@~C}lϥΪeXӤAioͥXIXAq`oǲ{HOuȪAMӡApGXIXAΦbv~}lX{AΪvᤣ[X{AinE_ʪ´ˬdΨNAHưlc~Fi
ϥλ۩ʿELqi|ߡBYhBDXC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOs25JHUΨൣ⤣ΤBC	Estradiol/Medroxyproesterone	G03C	ۿE ESTROGENS	0	gkۿEҤް_ѯgC	"1. whäwh̡C
2. ¨ŰC
3. wAhéδww̡C
4. whñwʱE̿૬~F(p Endometrial cancer) C
5. ]ɭPDX̡C
6. Lh~wRߦ̡AҦp`RߦΪͮC
7. _oRߦfvΦefө|ܾĪvC
8. Cʨxfw̩δwxfABx\ॼ_`C
9. 惡ĪҧtLӪ̡C"	̱`Ƨ@άũеȷPAϥ 1mg E2V ɸ֨AviX{lcXAvq`|ήAYg~Y}lvAlcX屡θ`C	ĦbP¨ŰT	ĦbP¨ŰT	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-11 j	Ts110.6.16		OI` 	0	OIs 20251124	OINDI.a	OINDI.b	01C48181-2	110.6.16
AC57842100	J01FA10	Y250@J	OZITH1	Zirocin 250mg tablets		Azithromycin |P 50S ֿ}馸椸23S rRNA۵XAJսXL{?/ (transpeptidation/translocation) Aç 50S 馸椸ոˡAqӪ_JսXC	"Azithromycin HCѨϥΤ@C
iP֪AC
H
Ⲵܦ߳yʶǬVLֵogDPlcVG1g@qfAC
Ⲵܦ߳yPⲴGCg@1gA̦hϥΤTgC
vϷPVʪͪɡAbRߪ`gkGCѤ@500mgA{710ѡC
jʵ֤K߽ƦX]MAC^efwGiWCgAΣ1200mgAάO֥ΫĳqrifabutinC
PediatricX 5- 12 mg/kg QD; MAX 500 mg/day or 30 mg/kg as as a single dose; MAX: 1500 mg
ҦLAg]]A]ͪyߩάyʷP_ݦߦӿwϷPVʪͪBw}lfAvEfw^GN1.5g`qbĤ@ѪA500mgAM2ܲ5ѨCѪA250mgAis3ѨCѪA500mgC
"	" 1. pPΨLܥͯ@ˡA~ܤ֦YLӤpޤ~BLӳQiCǦ]~ɭP_ogA@[PvC
2. ׵ǥ\ण} (creatinine clearance>40ml/min)fHϥξqAݧ@վAYǥ\ण}fHϥΥ~qثeMAofHϥΥ~pߡC
3. 󻴫ר줤רx\ण}fHA~MİʾǯSʻPx\ॿ`̵LCfHgѧGư~W[AiOxMvCո`ʸv@ΡC]ר줤רx\ण}fHϥΥ~ݭnվ㾯qCѩxŦO~Dnƪn~|A]Yxefw̨ϥΥ~ɤpߡC
4. fHlͪvɡAY֥άYǥܥͯoͳrCMثeõLܳM~椬@ΡAbzפWoͳriʡA]~iMl֥ͪΡC
5. pPLsħܥͯAϥΥ~|DPLͪ(]Ax)зPV(superinfection){Ho͡C
6. ϥΩHα¨Űw譱Ʃ|إߡA]DOLܡA~˨ϥΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Azithromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	󶧩ʡBʤιߤް_UIlDPV]]AުΪͪ^ֽγn´PVBժBWIlDPVMʶǬVf	TΩ糧~ΥܥͯLӥvΨxlfw	"mBnKBA(h/j)BߡBæRB
"	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669551?cesid=74aB80LMvc0&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAZITHROMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DAZITHROMYCIN"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_I4 [2]_I4 []_01-02 [E]_B1-20 j	Ts114.02.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	OZITH1-a	OZITH1-b	OZITH1-c	114.02.13
			IAUGM2	Anbicyn 1.2gm/Vial 		~O@ؼsĩʧܥͯ]amoxycillin^Σ]-QiJ]clavulanic acid^sƦӦƦXsCSwߺصoͧ@ΡC	"~tamoxycillin1000mgMclavulanate 200mg (Curam 1.2g)
IV , H12HWൣX1.2 g IV Q6H-Q8H. 
3Ӥ~12ൣX 30 mg/kg/dose Q6H-Q8H.
0~3ӤX30 mg/kg/dose Q12H-Q8H
ǥ\णG
CrCl(ml/min)10-30G Loading Dose: 1.2g, maintenance 600mg Q12H
CrCl(ml/min)10G  Loading Dose:  1.2g, maintenance 600mg Q24H"	curamvfwx\iX{ܤơAǥ\णwվζq.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ѱts20ϥΡC}Ƿťis4pɡANåi8pɡC	Amoxycillin +Clavulanic acid	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	s@LӪ̸TΩpenicillinn/x\ॢ`fvC	mBߡBæRBC¯lBlC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.12.28		OI` 	0	OIs 20251124	IAUGM2-a	IAUGM2-b	IAUGM2-c	111.12.28
AC60520100	L02BB03	ڦʰ50@J	OABIC	ĵAbicalutamide F.C. Tablets 50mg (bicalutamide)		1. ~O@ثDTJܶʯALLcE@ΡC~|Xandrogen receptorsAӤư]{A]iʯEAǥѦ@Φӳy@~FhC	~klA]AѤHG@Ѥ@(50)C~PLHRHΤNhkPɶ}lϥΡC	"1. ~sxѨxŦN¡CܡAYx\l˪fH󥻫~ưiCAo|ɭPֶq~b餺ֿnC]A󤤫שέרx\ॢժfHAΥ~ԷVC
2. ~TΩkʡAӥBiΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Bicalutamide	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	PLHRHkΤNhk֥Ωii@C	TΩkʤΨൣιĹLӥfH	BkoBmBߡBæRBֽ	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2R-01 j	Ts112.6.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.40._20120701_000.pdf"">OI` 5.2.4.</a><a href="""">OI` 9.40.</a>             "	"OI` 5.2.4.,9.40."	0	OIs 20251124	OABIC-a	OABIC-b	OABIC-c	112.6.23
AC59078209	J01DH03	̥Ln`g1J	IERTA	"Ertapenem for injection ""SLC"" 1g"		b~礤Aertapenem sxܦhح?󶧩ʩM?󳱩ʻݮߩMߡCErtapenem ?ߧ@ξOӭMXAo઺oOǥertapenem Ppenicillin XJ(penicillin binding proteins; PBPs) XӦ	"INVANZ 13 HWfHA@ϥξ?OCѤ@AC1 JC3 Ӥ
j12 f@ϥξ?15 @J/@?(̦h?WL@1 J)C
INVANZ iHĨR߿`Φ٦ת`gCĨRߧPɡA`INVANZ ɶ
WLTQC
YǷPVpGAΦ٦ת`gv?ɡAiHΦ٦ת`gINVANZ NR߿
`CӪv?uOѥD
vvھگfHPVMY{?ίfH?@MwC
INVANZ @몺v?O3 14 ѡA̷PVAMfߦӦ?P"	"ϥvalproic acid divalproex sodium ?nwfHAv?PVɡAҼ{ϥΰ?carbapenems~ܵ?CpGnϥINVANZ ɡAҼ{ɥR֪v?
XGҦܥͯ(]Aertapenem)?ް_ʵz(pseudomembranous
colitis)AY{?qLܨͩR¯٩ʪCӪ`NfHbܥͯv?AO_X{mΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ᴹxs?iWL25XC(77XF)C
ѫᤧī~GHtn`G:
Ƿš]25XC^6 pɤϥΡA]i?á]5XC^ܦh24 pɡA?èXᶷ
4 pɤϥ"	Ertapenem	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	"INVANZ AΩv?fwѨPʤLͪҤް_?ܭ?PVAӥBA
U?PVb|ŲwXfߤeg窺v?B?(empiric therapy)G
? ĤPV
? ֽMֽ´PV
? PVʪͪ(Community Acquired Pneumonia)
? ?DPVA]AǪǪ
? ʰַPVA]Alc٪BѦ?MNPV"	"w糧~@LөιLP?ĪLөι]-lactams LӤ
fHTΥġC
ѩϥlidocaine HCl @}AwQi(amide)?¾KLӪfH
wYJΤŦ?fHATĥθgѦ٦ת`g覡PINVANZ"	m(4.3%)BR߿`쪺ֵog(3.9%)B(2.9%)MYh(2.1%)C	ثe|Lh?Aγ]p?nӸCȦbέL઺b?BjMIʮɡA~ibhϥINVANZC	ثe Ertapenem |?ܤH?ťĤ(???ǡAG)C¨Ű?INVANZ v?ɡAԷVpߡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U09-15 [w]_w05-05 [E]_G5-09 [Ew]_F5-09 j	Ts112.6.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.2._20071201_000.pdf"">OI` 10.5.2.</a>             "	"OI` 10.1.,10.5.2."	0	OIs 20251124	IERTA-a	IERTA-b	IERTA-c	112.6.23
BC27375100	J05AF07	0	OVIRE	TENO F 300mg/tab(Tenoforvir D.F.)		"Tenofovir disoproxil fumarate O@اܯfrġC
Tenofovir disoproxil fumarate O?CQL?CQG?CTenofovir disoproxil fumarate ݭnlG୤ѡAϨƬtenofovirAMǥѲӭMïCĤ Gilead Sciences 21Φ tenofovir diphosphateAoO@رMפlCTenofovir diphosphate ǥѻPѵM?-TCQvX DNA AMǥ DNA פ@? HIV-1 ?ïʡCTenofovir diphosphate OŰʪ DNA hEï \B] M? DNA hEï ^ zC"	v? HIV-1 κC B xGVIREAD 300mgACѤfA@A?|iɶC 	KPɨ֪AVIREADMvTǥ\धĪC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Tenoforvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"1. VireadAΩPLܤfrĪX֨ϥΩ󦨤HHIV-1PVvC 
2. Ωv㦳frƻsάʩʨxŦoҾڪHCBxw̡C "	糧~LӪ	ߡBæRBmBYhBYwC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.3._20250601.pdf"">OI` 10.7.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.4._20220901.pdf"">OI` 10.7.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>            "	"OI` 10.7.3.,10.7.4.,10.9."	0	OIs 20251124	OVIRE-a	OVIRE-b	OVIRE-c	110.6.16
AB449971G0	M01AB05	ݥiA罤25	OCATA1	Volna-K 25mg/tab (Diclofenac )		"diclofenacO@ثDTJAܵoBhBΰhNSʡC
wҹ򥻧@ξରeCͦXCbΦoBkhBPoNL{AeCtۥDnC
~礤APH餺ۦP@ת diclofenac potassiumAä|nJզh (proteoglycan) ͦXC"	HC100150mgA14HWpĨC75100mgA23AΡC	"1.voͭGX嵥ġC
2.Ѧ~w̤SOp魫Lϥγ̧CľqC
3.iɭPx\ïȤɰGϥΪ̶ʴx\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Diclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	UCewίghBGC`Bܼ½贵ܧΩ`gBܧΩʯկgByhgBLgB鯫gfܡByնXgC	"1.GzšC
2.w糧~ʦΥξLӪ̡C
3.PLDTJܵoĪ (NSAIDs) @ˡADiclofenac]TΩwUCefw̡GݡAC¯lAHΥѤAQĩΨLeCXïʤĪҤް_ʻ󪢡C"	GzgAŸhAtwAolAֵo̡ͪGǥ\ಧ`AGzXAxALӡC	C/D (30 weeks gestation)	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I4 [2]_I4 [ws]_w25-05 []_01-15 [s]_354 [®]_354 [UDx]_U02-36 [E]_B2-25 [Ew]_EX027 j	Ts112.5.15		OI` 	0	OIs 20251124	OCATA1-a	OCATA1-b	OCATA1-c	112.5.15
																																		
AC47788100	L02AB02	0	OFARL	ĵ MEPRO 500mg/tab(Medroxyprogesterone		"Medroxyprogesterone acetate]MPA^O progesterone lͦӨӡA@XTJAfAġAcPѵM progesterone ۦAPBb \-6 m Methyl group P 17 m acetoxy
groupCMedroxyprogesterone acetate 㦳ପ@λPܨDʻPܦVʸʡCbAqAMedroxyprogesterone acetate vTctλPӭMʡC "	"Ciq100~1,000mg ]qɥiC2~3AΡ^A@CqΩlcAqΩ󥽴ಾʨCMedroxyprogesterone acetateiP䥦ؽFvApƾkΩgukX֪vC
񦳴cf誺gGC1,000mgAi@AΩάOC2AΡC "	hĳϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUAץJsC	Medroxyprogesterone	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	"Nδ_oʩಾʤlcUkAgkA@Φ񦳴cf
褧gC"	RߪAʮ몺աAYx\lˡALyA]XAĪLӪ̥ioͰtC 	P䥦ۦPAiް_ũĲhBŷBD`XBgy`BgB~B魫ܡBlcVSAβ`cBxĺdxAΨSogB믫{C 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-03 j	Ts111.8.19		OI` 	0	OIs 20251124	OFARL.a	OFARL.b	OFARL-c	111.8.19
AC58256100	N06AB05	ʼ֦潤20@J	OPAROX	Paroxin 20mg/tab (Paroxetine)		vHG{gAWgAgegA߯gA(J{g)C	"Major depressive disorder (MDD):
Initial: 20 mg QD, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day
Generalized anxiety disorder (GAD):
Initial: 20 mg QD, preferably in the morning (if dose is increased, adjust in increments of 10 mg/day at 1-week intervals); doses of 20-50 mg/day were used in clinical trials, however, no greater benefit was seen with doses > 20 mg.
Obsessive-compulsive disorder (OCD):
Initial: 20 mg QD, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 20-60 mg/day; maximum dose: 60 mg/day.
Panic disorder:
Initial: 10 mg QD, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 10-60 mg/day; maximum dose: 60 mg/day.
Post-traumatic stress disorder (PTSD):
Initial: 20 mg QD, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; range: 20-50 mg. Limited data suggest doses of 40 mg/day were not more efficacious than 20 mg/day.
Social anxiety disorder:
Initial: 20 mg QD, preferably in the morning; recommended dose: 20 mg/day; range: 20-60 mg/day; doses > 20 mg may not have additional benefit."	"1.P֪AAФũCZC
2. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25J^ҤU C	Paroxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	U{g{gHJ{ggvιw_oBjggvBWggvιw_oB߯g(J{g)vBxJ{ggvιw_o(GAD)Bж˫OgԸsv(PTSD)C	w paroxetine LӪ̡Cparoxetine Pi? ( åΡAΦbMAOīgϥΡC	ߡBxTJWɡBCBίvêBwtBıҽkBʥ\êBXBLOB魫W[C	"1.bheTӤ˨ϥΧܼ~{hGiXAparoxetine|W[ѩʷΪIASOOߦޤ譱(p߫ǻPߩйjʳ)C
2. hάOpehkAvҼ{NvܤסAubbQqjbIɤ~ϥΡC"	ֶqParoxetine|cťġCĳbŴϥParoxetineCDҩbˤݧQqWL઺bIC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 [ws]_w49-02 [E]_B5-11 j	Ts112.4.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	OI` 1.2.1.	0	OIs 20251124	OPAROX-a	OPAROX-b	OPAROX-c	112.4.4
AC49958100	N06AX16	dwn 37.5 @J	OVENL	(^)Calmdown SR Capsules 37.5mg (VenlafaxineHCL)		"@{ Venlafaxine bH餤ܼ~{󤤼ϯgtΡAP[jg誺ʦC{ɫesܡAVenlafaxine P䬡ʥNª O-desmethylvenlafaxine (ODV)A|[jgʦM(serotonin)ΥǤW(norepinephrine)Al@ΡA dopamine Al@θzCVenlafaxineMODVb~礤muscarinic cholinergicBH1-histaminergicΣ\1-ǤWLۿ˩MOC@AoǨĲzʥiML믫ĩ[쪺UاxP(anticholinergic)BR(sedative)Τߦ޵@ΦCVenlafaxineMODV㦳iƻï(monoamine oxidase, MAO)ʡC"	"Depression (inpatients)75 mg/day (2-3 divided doses); may increase dosage by 75 mg/day increments every 4 days to MAX 375 mg/day (3 divided doses).
Depression, Generalized anxiety disorder, Social Anxiety Disorder (extended release capsule)37.5-75 mg/day (single dose); may increase dosage by 75 mg/day increments every 4 days to MAX 225 mg/day.
1._lqC@75mgAGܤTAΡC{ɻݭnAC龯qiW[150mgA`NqWL75mg/dayɡAվɶoC|ѡC
2.̰qiW[ܨC375mgC
3.M@_]AHGEC"	Ĥγiƻï(MAOI)PɨϥΡAΦܤ֦bMAOIQ|ѫA~iϥΥġC̾ڥĪbIAϥMAOeAĦܤΤCѡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Venlafaxine	N06A	ܧ{ ANTIDEPRESSANTS	0	AΩv~{g]depression^A]A{g]melancholia^C	"1.w|Venlafaxine͹LӪfwC
2.PɪAγiƻï]MAOIs^fwC"	ߡBYhBݺΡBfBKBwtBvBgiBsC	קKϥΰDvn/SmҦw/|qLť		аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w55-03 j	Ts112.5.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	OI` 1.2.1.	0	OIs 20251124	OVENL-a	OVENL-b	OVENL-c	112.5.15
AC434601G0	N05CF01	dovD@J	OIMOV1	(^) GENCLONE 7.5MG F.C.T. (Zopiclone)[ޥ|]		"MM@ʫܤGABA macromolecul-ar complex receptor , iձCL Channel }ҡA㦳wvARܵJ{B٦PΧܵj˵@; iYuJήɶA֩]MơAWίvɶCĴֺίvĤ@BW[ĤGBΩδ(ĤTB|)"	3.75-7.5 mg ΫeA; prolonged use (longer than 28 days) should be avoided	1.ŶsC2.AīAФp߶}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Zopiclone	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vg	"HUpŨϥΥ~--- 
1BZopicloneΥĤ@LӡC 
2BgٵLO]Cʶiʦܡ^C 
3BIlIܡC 
4BYίvIlȰg]ίvIlȰ^C 
5BYx\णC"	RBΡB`NOxBfBfW	ĤC 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M05-03 []_E6 []_w78-11 j	Ts112.4.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.3._20131101_000.pdf"">OI` 1.2.3.</a>              "	OI` 1.2.3.	0	OIs 20251124	OIMOV1-a	OIMOV1-b	OIMOV1-c	112.4.4
	N01BB02	Qd]`gG 2%	ILIDOC	ĵLidocaine 2% 20ml/vial (lidocaine Hcl) 		"pP󧽳¾K@ˡAlidocaineiǥѨulVgVʡAӥifagİʪuۯgֺǾɡCQi(amide)¾KQ{OPgul޹D@ΡC
¾Ki󸣳Τߦ٤E(excitable membrane)ۦ@ΡC"	"`gSOpߡAHKVRߤAӤް_ʬrʤCĳb`geΪ`gɱ`ԷVa˩@UCnjqɡApw~_ɡAĳHtǤW lidocaine 3-5 @ɥկfHCYVRߤAiǨϤ߸ȮɩʼW[ӹıC
DnqHC 100  200 @JtvwC`gAΦbW[qɡAPfH͡CYoͬrʤAߧY`gC@ӨAn_jgҦgyɡAݭnϥθ@סFӷ_һݤj׸pɡ]pYkhѰ^AhϥθC@קYiCĪϥΤen|vT¾KGdC
ϥΧtǤWGAiW[@Τɶ]Ѿ\q^C
b楽ݤqACX`Τ¾K޳N@릨HĳqAHѰѦҡCbpݨDqɡAvgίfH骬pTA۷nCɶϥΪ_¾KɡApĥέеĤ覡AҶqĪbߤ@רFr@סAξɭPgˮ`MIʡC"	"ϰΧ¾K{ǡAbA]ƤΤHҹIAϤκʵһݤĪγ]ơAƧBiߧYϥΡCIj_¾KɡAb`g¾KeARߦsdɺ޲աCvnI椧{ǡAwAίSwVmABƧ@ΤE_ΥʬrʡAΨLֵogv۷xC

lidocaine bpH Ȥj6.5 HWɡA䷻ѫפjCFGn[JPʷG]pGһQ^ɭnSOҼ{IA_h|oͨHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" Xylocaine]tǤW^hqĲ~FJs󤣰25JBAiNC
hqĲ~b}~WL3 ѤAiAϥΡC"	Lidocaine	N01B	"¾K ANESTHETICS, LOCAL"	0	¾KC	"wQi(amide)¾KAηGL]ptǤWGmethylpar ahydroxybenzoatesodium metabisulphin)|o͹LӤ̡C
wҰΤmfһୡ]methyl-/propyl paraben^AιNªifһġ]PABA^LӪ̡C¾KΨNªPABALӤfwקKϥΧtmfһ୤lidocainet"	"pGOĪLqλ~JޤA¾Kܤ֤ް_}C
YhBVáBݺΡB wtBߡBæR"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669686"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.11.4		OI` 	0	OIs 20251124	ILIDOC-a	ILIDOC-b	ILIDOC-c	111.11.4
BC248703B9	N02AB03	"""""hֶ߬K 12 LJ/p"	EFEN1	ĵDurogesic Transdermal Patch 12gg/h [ޤG]		ĬֶKAണѫ72p(ī)AĪFentanylO@رjĪ~hAgֽlFhĪG¾Kī~ADnΨӱCʯkhC	" DUROGESIC?q̷ӯfwӧOpөwAæbϥΫwɶiC
 pe24pɩһݤh(]AfAMIV)ζqC
eϥιL~hĪĳqtĪmorphine,tramadol,codeine}lA24pɤһݪhľq⦨KD
60-134mg/day morphine(PO)ĳഫ25ug/hr Fentanyl K
135-224mg/day morphine(PO)ĳഫ50ug/hr Fentanyl K
225-314mg/day morphine(PO)ĳ|75ug/hr Fentanyl K
HAYIM morphine10mgi۷fA30mg morphine
ԲӽаѦҥΰ|khv
DUROGESIC?isK72pɡCKAsKnKbPe@PmCP@쪺ֽ۹jƤ~iAKW@sKC
ϥιLDUROGESIC?HJ]˯ȳUAú^(|)ħPCpϥΤKhٵ(|)ħC"	"`N[fHIlt
]uɶϥεLk@AqվAӥBi|ɭPYΦMΥͩR𤣨AGʩγNkhŨϥDUROGESIC?CoYƧ@ΪfwAbDUROGESIC?Aܤ[24pɡA] fentanyl夤@׫YvUA17pɫ(13-22p)~|ܭӪ 50%C
YfHoNiW[fentanyliJ餺qD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	J25JHU	Fentanyl	N02A	P OPIOIDS	0	ݭnϥ~sCʯkhMxTʯkh	" wfentanylζKHKLӤfwTϥDUROGESIC?C
"	LӡAߡBæRBKBmBƤ}BfIlBݤξj`BIl	קKϥΰDvn/SmҦw/|qLť	קKϥΰDvn/SmҦw/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669815?cesid=0kLVRFf5PqH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFENTANYL%26t%3Dname%26acs%3Dfalse%26acq%3DFENTANYL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts112.1.10		OI` 	0	OIs 20251124	EFEN1-a	EFEN1-b	EFEN1-c	112.1.10
	N01AX03	0	IKETA1	ĵKetamine-hameln 50mg/ml; 10ml/vial[ޤT]		~͸A@بt@Ϊ¾KAiͲ`תh@ΡAۥ`fٱiOM諸ϮgAMUؤŦޤΩIlE@ΡC@{@άObͷPı~|M@ʪeAB_pQ~|C 	ɾqw14.5mg/kgAb60IV`g6.513mg/kgIM`gCqwpGnܡAiWܥɾq1.5AHfHݭnAվC 	"1. s뤤rBBG@fHAHΥbϥΥ~yp
2. ~nwCIV`gP(WL1)AקKyLתIlMAnIV`g@׬100mg/mlA]iHSߪBͲzQθ}G}̡C
3. nNketaminePϥιLbarbiturates`gVXA]|yƾǩʪtXTҡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Ketamine	N01A	"¾K ANESTHETICS, GENERAL"	0	¾KC 	W@B㦳MIʪfHAAʯ߽FAҪiA{ʤ߰IܡAU߯gM믫fwC 	W@A߸L֡AIlEC 	Ħbwʩ|TߡAĳϥ	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.1.10		OI` 	0	OIs 20251124	IKETA1-a	IKETA1-b	IKETA1-c	112.1.10
AC495931G0	N02BE71	Qq	OTALL	TALLSEA TAB(Acetaminophen450mg+ Mephenoxalone200mg)		"~hθѼPfPƤ覨
Mephenoxalone@Φbֽ誺AƨtΩΦۥDgtεLS@ΡAͰf٤PFAcetaminophen㦳Ѽh@"	"H15HWĵ:C1-2,C2-4 6-15C1/3-1,@Ѩ⦸"	AΥī~ФŶs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Acetaminophen/Mephenoxalone	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS	0	UCѯΦ٦׵jˤް_kh㦳wѧ@ΡGVB٩ʭhB٦׻wBVĵhBٵhByhB`B`BiB٦׵jˤް_٦׵hBʯkh⵬jˡC	1.Hypersensitivity2.wG6PDfHФŨϥ	ݺ.GzA.Yw.f.ֽko	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I4 [2]_I4 [ws]_w53-01 [s]_298 [®]_298 [UDx]_U03-51 [E]_C2-01 [Ew]_EX062 j	Ts111.10.20		OI` 	0	OIs 20251124	OTALL-a	OTALL-b	OTALL-c	111.10.20
A009038100	R05CB02	Ϋy@J	OBROM	Bisco 8mg/tab (Bromhexine)		(1)~㦳HGMPi߲GcACޤcHYסAѰy¡C (2)~W[ܥͯbf_@סAġC (3)~޲´IgA@סAW[ުܤOC	"1.HB10HWൣGC@ACT
2.510pGC1/2C|
3.5HUGC1/2CG"	sBjqPA|MTransaminaseȡWɪΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Bromhexine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	׶]ޯewҾɭPط]g^	wbromhexineλsLLӪ̡C	fHAĤA߲GQѡAqW[Ay¥i|yL[@CmBߡBæRΨLLGzƧ@γiC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-05 []_01-05 [s]_25 [®]_25 [E]_A1-06 j	Ts112.5.15		OI` 	0	OIs 20251124	OBROM-a	OBROM-b	OBROM-c	112.5.15
AC24474100	N05AN01	ߩw@J	OLITH	Lidin 300mg/Cap (Lithium)		~gļS@ξ|MCoĪܯgݪuBAҥHAܯgӭMqͲzʽAPig^norepinephrineMserotoninA]Ay󨳳tƧ@ΡA~]norepinephrineXMicyclic AMPΦC	"Mania(Acute)1800 mg/day in 2-3 divided doses; desired serum lithium level ranging between 1-1.5 mEq/L;
Mania(maintenance)  900-1200 mg/day in 2-3 divided doses; desired serum lithium levels ranging between 0.6-1.2 mEq/L
ļ{gw̡G`ΤAqCAΥ~600mg(),CTCؾqq`i;YĿ@1.0-1.5mEq/L C kGCAΥ~300mg(1 ),CTΥ|.(夤Y@Ob0.6-1.2mEq/l C"	6. pPLܺ믫fĪ@Awo@fvΪ̥i୰Cwo@֭Ȥef]pqg^fHAϥquetiapinevpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lithium	N05A	ܺ믫f ANTIPSYCHOTICS	0	ļfBwļ{f	"Hypersensitivity to lithium, or any component of the formulation; sever cardiovascular or renal disease, or debilitation, dehydration,or sodium depletion; pregnancy"	TAߡAoݡAYh C	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-06 [s]_161 [®]_161 j	Ts111.12.28		OI` 	0	OIs 20251124	OLITH-a	OLITH-b	OLITH-c	111.12.28
AC390071G0	N05BB01	0	OVIST	Arax 25mg/tab(Hydroxyzine)		ܹLөʺ믫gwwCܹæRBܲ´i@	1.믫igѰAHι󾹩xefAް_wUġGC4AC50100@JC 2.CC¯lAαĲʥֽM´iް_koGHC34AC25@JC	Ŷs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Hydroxyzine	N05B	ܵJ{ ANXIOLYTICS	0	J{ABæRBLӯew	Arax䦨νξLӪ̸T	ΡBfBYhB魫W[BHG߸Y	ĤC 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w33-04 [UDx]_U03-20 [E]_B3-30 j	Ts110.6.16		OI` 	0	OIs 20251124	OVIST--A	OVIST-B	01C39007-2	110.6.16
AC43824100	N02AX02	"""h""Shn@J"	OTRA2	"ĵTramed
50mg/cap(Tramadol)[ޥ|]
"		"TramadolO@ا@Ω󤤼ϯgtΪ~hCO@Ωg, _Mk~Dܩʯ­PľAg˩MOCLyh@ΪgAlǤWAHΫPiMC"	"fAi25~100mg Q6H ,Max:400mg/day
ĳϥΩ12HUൣ"	"1. ¾KɡALIMADOLϥζqYWLĳqƦhAhưIliʡC
2. YϬOӫܵġAi|vTfHOAҦp:rpTPާ@񤧯OAרOPs@_֥ήɡC
3. ]ϥΥi|ͨ̿ʡAGvMwvɶuHάO_nȮɰġC
4. LIMADOLiPӶWLvһݡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XC HUxsC	Tramadol	N02A	P OPIOIDS	0	צYʪCʯkh	PsBwvġBhΨLϯgtΧ@Ī֥ήɷ|yʤrC	oBtwBߡBæRBfHίhҡC	קKϥΰDvn	bŴĳϥ tramadolCΪ̡Ab tramadol vTšCb榸P tramadol Aq`ݭn_šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M05-02 []_E6 []_w78-12 j	Ts111.10.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.3._19980401_000.pdf"">OI` 1.1.3.</a>              "	OI` 1.1.3.	0	OIs 20251124	OTRA2-a	OTRA2-b	OTRA2-c	111.10.20
AC525321G0	R06AE07	ӽ 10 @J	OCETI1	Cetirizine F.C. Tablets 10mg		"CetirizineAnti-H1ܹLӪvABL㪺Anti-CholinergicAnti-Serotonin@ΡCbľqCetirizine|qL޻پA襤ϯgS@ΡA|ͦwvΦ欰`{HC@Υ]AG
1. t~ͩʲ´iC
2. 鷺ͩʲ´iX@(p48/80´i)C
3. VIP(Vasoactive Intenstinal Polypetide)MSubstance PҤް_LӤC
4. ۪Cݱw̪޹´iLפC
5. CѯSLӭް_LӤCoǧ@ΡAѤߴQuantified EEGoA襤ϯg|ͥ@ΡC"	6HWGC10@JA@Ѥ@Cǥ\णw̪AΥĮɡA侯qbCǥ\( Ccr (ml/min)  30qվ5mg qD )C	b.gGϰקK`gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Cetirizine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	u`ʻ󪢡BXBLөʻ󪢡BC¯lBLөʷkoLӲ{H	糧Ĥ󦨤LӪ̡C	fBYhBݺΡBhҡBLOB󪢡B|甆BhBYh	קKϥ	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w24-01 []_01-09 [UDx]_U02-30 [E]_B2-10 j	Ts112.5.15		OI` 	0	OIs 20251124	OCETI1-a	OCETI1-b	OCETI1-c	112.5.15
AC49453100	N06AX16	0	OVENF	(^)Easyfor S.R 75mg/cap		MǤW^]SNRI^	C馭WαߤWP@ɶH\ϥγ@q	"?ī~iɭPAp venlafaxine CA
?j 150 mgAΦfv̡AʴC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	venlafaxine hydrochloride	N06A	ܧ{ ANTIDEPRESSANTS	0	{gBǵJ{gBJ{gBWgC	"ϥγi?(MAOI)Ӷ}lϥ Venlafaxine SRAܤֻݭnj 14
ѡC~Aϥ Venlafaxine SR Ӷ}lϥγi?(MAOI)Aܤֻݭn
j 7 ѡC"	"ߡB
Y?BvBRB?B?C"	hį? CAקKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w55-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	OI` 1.2.1.	0	OIs 20251124	OVENF-a	OVENF-b	OVENF-c	110.6.16
BC26193100	N06BA09	wOwn25@J	OATOM	Apo-atomoxetine 25mg/cap		ܩʥǤW(norepinephrine^AlAiܩʪ_ĲeǤWAlǿAW[ĲǤW@	"Children6 years, and < 70 kg : Initial, 0.5 mg/kg/day (at least for 3 days), then increased to 1.2 mg/kg/day. MAX1.4 mg/kg /day or 100 mg/day. Children6 years, and > 70 kg and adult: Initial, 40 mg/day (at least for 3 days),then increased to 80 mg/day. MAX 100 mg/day"	"1.AtomoxetineﲴE,Gi}n.
2.yi"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Atomoxetine	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	`NOʷl/Lʯg(ADHD)	"1. iPMAOIX֪A, MAOIg~i}lϥ(i|W[Ŧr)
2. ĳΩUʫCfw"	Ƥ}BߡBæRBh¡BCBwtBKBfBGd	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 j	Ts111.12.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	OI` 1.3.5.	0	OIs 20251124	OATOM-a	OATOM-b	OATOM-c	111.12.15
AC60231297	J01CR02	wǦhRߪ`g	IAUGM3	AmonadowƤ1.2gm/vial (Amoxicillin 1000mg/ Clavulanate 200mg)		~O@ؼsĩʧܥͯ]amoxycillin^Σ]-QiJ]clavulanic acid^sƦӦƦXsCSwߺصoͧ@ΡC	"~tamoxycillin1000mgMclavulanate 200mg (Curam 1.2g)
IV , H12HWൣX1.2 g IV Q6H-Q8H. 
3Ӥ~12ൣX 30 mg/kg/dose Q6H-Q8H.
0~3ӤX30 mg/kg/dose Q12H-Q8H
ǥ\णG
CrCl(ml/min)10-30G Loading Dose: 1.2g, maintenance 600mg Q12H
CrCl(ml/min)10G  Loading Dose:  1.2g, maintenance 600mg Q24H"	curamvfwx\iX{ܤơAǥ\णwվζq.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Amoxycillin +Clavulanic acid	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC  	s@LӪ̸TΩpenicillinn/x\ॢ`fvC	mBߡBæRBC¯lBlC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U08-04 [w]_w04-12 [w]_w04-24 [E]_G4-10 [Ew]_F5-07 j	Ts112.7.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.2.1._20210608.pdf"">OI` 10.2.1.</a>             "	"OI` 10.1.,10.2.1."	0	OIs 20251124	IAUGM3-a	IAUGM3-b	IAUGM3-c	112.7.22
AC150781G0	N07CA	"""͹F""Ī⥧}"	OCEPH1	Diphenidol 25mg/tab		]ջêް_tw]]A޻êYV~˫gtw^Bg	q`HC12A@TfAϥΡA̦~֡BgiAyW C	iPts뤧ƨ֥ΡFAīiݺΡAp߶^ˡF	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Diphenidol	N07C	ܯtw ANTIVERTIGO PREPARATIONS	0	]ջêް_tw]]A޻êYV~˫gtw^Bg	ĪLӤfHεǾ঳׻ٮ`̤yϥΡC	wtPBıҽkBΡC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 [ws]_w28-04 [s]_84 [UDx]_U02-43 [E]_B2-22 [Ew]_EX023 j	Ts112.02.02		OI` 	0	OIs 20251124	OCEPH1-a	OCEPH1-b	OCEPH1-c	112.02.02
X000226351	P03AC04	0	EPERM	Permethrin cream 5H 60G/Tube (Lindane^-BHC)		νHBBYΨΧZPV	NwBHŤ~bAAH~AqwAg8-12pɫi~hCȻݨϥΣAYiġC	iXAƨϥΩάOLindane ϥήɶA|ywo@Φ`	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Permethrin cream 5%	P03A	"~ξ ECTOPARASITICIDES, INCL. SCABICIDES"	0	νHBBYΨΧZPV	"Hypersensitivity, premature infants, seizure"	ֽEC	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669229?cesid=4LxT0Rh97er&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPermethrin%26t%3Dname%26acs%3Dfalse%26acq%3DPermethrin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.11.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.15._20241201.pdf"">OI` 13.15.</a>              "	OI` 13.15.	0	OIs 20251124	EPERM-a	EPERM-b	EPERM-c	111.11.22
AB43735112	R03AC03	0	EBRIC1	BUTANYL INHALATION SOLN 2.5MG/ML  (Bricanyl)		TerbutalineO@ؿܩʵǤWbeta 2PEA@ήɰwަ٦סAbeta 2EνwޥƦ١AiwHGBeAPɥiiH֤򪺲MΦPt٦תwѡC	"InhalationGbody weight20kg5 mg is inhaled up to 4 times in a 24 hour period; body weight20kg2.5 mg is inhaled up to 4 times in a 24 hour period.
C@@q 5mg/2mlA@ϥΥ|AY@澯qβAisQJsѡA24pɤwwiϥΡC"	PgiLӪԷVϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Terbutaline	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	ޮݡBުΪͮ~ҦH޵jˤw	߷iLtH߫ߤC	ŸBjˡB߱	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-32 [UDx]_U01-39 [UDx]_U09-18 [w]_w03-18 [E]_C3-02 j	Ts111.9.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	OI` 6.1.	0	OIs 20251124	EBRIC1-a	EBRIC1-b	EBRIC1-c	111.9.29
AC289451G0	R03DA05	"""u}""iDL@J(T/)"	OAMINO	()Aminophylline 100mg/tab		"LPOvʧPhosphodiesteraseAïiHCyclic 3',5'-adenosine monophosphate(Cyclic AMP)C 
1. ܵj˧@ΡAminophylline ѦTheophylline |PxDƦ١AѰxhC
2. Xi@ΡTheophylline P޻PͦުƦ١AѰ޵j˨åBW[ytPͬqC
3. Ŧħ@ΡAminophylline ߦ٦Wj٦צYOĪGABuеW[YvĪGCŦ@ΤȬObPhosphodiesterase PӭMCyclic AMP qW[ӥB٥]AӭMtbC 
4. Q@ΡAminophylline ͧQ@ΤDOѩ󥦹ŦGʤOǻPǤpުAl@ΡAiW[ŦGXAåBXiǥXPǤJŦǤpʯߡAɭPǤpyLotv(GFR)PŦyqW[C]ulPlb񰼵ǤpުAlC"	"@릨HqG
XiкCʪvGfAA쾯qGC魫۷LAminophylline 18.7mgAΨC467mg(ξqC)A4 AΡFY@AiCj2~3 ѼW[q25%AiFCѨC魫15.2mg ΨC1.1g(ξqC)̤jqŶ˴M@סC
@ൣqG
XiЦP@릨HqGY@iCj2~3 ѼW[q25%AŶ˴M@סAiFCѳ̤jqpUG 9 HUC魫28.2mgA9 ~12 C魫23.5mgA12 ~16 C魫21.2mgC16 HWC魫15.2mgAΨC1.1g(ξqC)C"	"1. UCfHfʵSOnGުή~fHbϥΥīeθgL@qvɶͥ\˴HMwO_~ġCʪ[jvλݭnvqɡAMTheophylline @˴HTwAqC
2. Aοɳ̦nŸ(e30 1 pɩζ2 p)AUH[tlAib\ζߨAΡAH֭GzDEC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	x󳱲D(15~30J)ץBĵoBҡC	Aminophylline	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	ݤΤ޵j/ߦ]ʤޮݤΤ޵j	"Hypersensitivity to theophylline, ethylenediamine, or to any product component"	֯lBC¯lBYhBߡC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 [ws]_w16-02 [E]_B1-02 j	Ts112.02.03		OI` 	0	OIs 20251124	OAMINO-a	OAMINO-b	OAMINO-c	112.02.03
A034503429	S01XA20	wIG	PARTI	"ARTIFICIAL TEAR ""WU-FU""10ml/bot"		1.Ĥi@]\GcթHդް_gC	@3-4A@12wAݭnɨϥΡC	"קKg
}30ѫ,Ф~ϥ
ϥΫe,~b
زĤj5
PĻIj10"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30CHU	hydroxypropyl Methyl cellulose 5mg	S01X	L OTHER OPHTHALMOLOGICALS	0	ȮɽwѦ]ߩҤް_`PPEPC	]tBenzalkonium ChlorideAGnβɽФŨϥΡC	LC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-05 [E]_H1-03 j	Ts112.7.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.5._20240701.pdf"">OI` 14.5.</a>              "	OI` 14.5.	0	OIs 20251124	PARTI-a	PARTI-b	PARTI-c	112.7.24
AC58202100	R05DB01	yvonn100@J	OZCOU	Zcough Soft Capsules 100mg(Benzonatate)yvonn100@J		Ѱy¯g	"HCTAC1ɡAC̤jq600mg.
(1) HGC3AC100-200 mgC
(2) ൣG[>10] C3AC100-200 mgC"	о]AAiCZAHKͧ¾KӦPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Benzonatate	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	Ѱy¯g	"Hypersensitivity, children"	ߡBzGABKBYhBwtC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-04 [s]_48 [®]_48 [E]_A1-04 j	Ts111.10.03		OI` 	0	OIs 20251124	OZCOU-a	OZCOU-b	OZCOU-c	111.10.03
AC27598100	R05FA02	hy罦n	OMEDA2	Fucou cap. (Ƥ)		"Dextromethorphan HBr@ΩHy¤ϡAy¤ϮgӲy@ΡC
Potassium Cresolsulfonate}ޤ߸YסAeC
Lysozyme ChlorideHYAeC"	H(15HW)G@3AC1ɡC	AΥAi঳ݺΤΡAФžrpξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Detromethorphan	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	"1.oĪLӯg̡C
2.bϥMAOIvw̡C"	olBoBߡBæRBBtw	קKϥΰDvn/SmҦw	Safe	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-06 []_01-21 [s]_146 [®]_146 [E]_C4-04 [Ew]_EX082 [Ew]_Z-10w9 [Ew]_Z-17w3 j	Ts111.12.28		OI` 	0	OIs 20251124	OMEDA2-a	OMEDA2-a	OMEDA2-a	111.12.28
A043361157	R05FA02	0	LDINC	DincoƤ}120ml/~(Codeine 0.48mg/ml)		yB׶	ĳ@3AHC10ccA12-15C6cc	"UCΪ̡AФŨϥΡG
(1) ]Ħް_LӪHC
(2) 㦳CYP2D6WŧֳtĪN»ïH(ultra-rapid metabolizers)C
(3) ŰC
(4) 12C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Codeine/Methylephedrine/Chlorpheniramine	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	"ħtܲ´iA`NUCƶ:
(1) AΥīAiް_ݺβ{HArξާ@MIɭnpߡCnXֶΧts뤧ơA礣nAΦwvġBRī~C
(2) DvĮvľͫܡAUCfwФŪAΥġGCBͮ~BIlPBΩIlxBΦ]eC~jް_ƧxC"	ݺΡBfBwt	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-03 [E]_I4-06 j	Ts110.6.16		OI` 	0	OIs 20251124	LDINC--a	01043361-1	01043361-2	110.6.16
AC262891G0	R05X	0	OPPC	P.P.CcapƤP_(Acetaminophen 120mg		P_gw	q`H(15HW)C1ɡA814C1/2ɡA@A3A󶺫30HAΤC	wCBͮ~BIlPΧxBeC~jް_ƧxfHAvܤUϥΡAФŦۦA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Acetaminophen	R05X	LP_s Other cold preparations	0	P_gw	"fଧw, acetaminophenLӪ̸T,Cʪʪͯf.C.ͮ~̤ŦۦAΡC"	ݺΡBfB«PBıҽkBáBpKxB߸[t	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w45-02 [E]_B5-10 j	Ts110.6.16		OI` 	0	OIs 20251124	OPPC.a	OPPC.b	01C02101-2	110.6.16
BC27156100	J01XX08	ߧA	OZYVO1	Linetero (Linezolid Tablets 600mg)		"1. LinezolidOs@HuXܥͯAݩoxazolidinoneA{ɥγ~DnAΩvݭnʤ󶧩ʵߩҳyPVC~linezolid@ǭ󳱩ʵߩMߦ@ΡCLinezolidǥѤ@ةMLܥͯP@ξӧӵ߳Jս誺XC]linezolidMLܥͯioͥ椬ĩ(cross-resistance)CLinezolid|Pӵ50Sֿ}p(subunit)W23Sֿ}RNAXM\ʪ70S_l_X骺ΦC_XOӵĶ(translation)L{nCھڮɶ-(time-kill)sܡAzy(enterococci)My(staphylococci)ӨAlinezolidO߾(bacteriostatic)Cy(straptococci)jhƪߺئӨAlinezolidO߾(bactericidal)
2. UCߺخĪG΢wݮʩMݩ(Aerobic and facutative)󶧩ʵߡGEnterococcus facium(ȭvancomycinĩʪߺ)A⸲yStaphylococcus aureus(]Amethicillinͧĩʪߺ)AʨyStreptococcus agalactiaeAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AwyStreptococcus pyogenesC
3. ݮʩMݩʭ󶧩ʵߡGTyEnterococcus faecalis(ȭvancomycinĩʪߺ)AEnterococcus facium(ȭvancomycinĩʪߺ)AָyStaphylococcus epidermidis(]Amethicillinͧĩʪߺ)AStreptococcus harmolyticusAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AViridans group streptococciC
4. ݮʩMݩʭ󳱩ʵߡGPasteurella multocidamC"	"~sĳϥζqC侯qOHC12pɧP@覡PC
1. Vancomycin-ĩʪEnterococcus faeciumPVA]AֵoߦgfҡG600mgRߪ`gAΤfAC12pɤ@As1428ѡC
2. |PVͪBֽMֽ´PVBϷPVͪA]AֵoߦߪfҡG600mgRߪ`gAΤfAC12pɤ@As1014ѡC
3. DֽMֽ´PVG400mgRߪ`gAΤfAC12pɤ@As1014ѡC
4. ~]iNC龯q}ӪA(pGWAĤ@AߤWAĤ@)C"	"1. ϥΧܥͯ|PϫDPʲӵߪLץͪCvL{pGX{ƷPV(superinfection)ɡAӱĨAIC
2. linezolidw̴oͦpO֯giC󦳥XʦMIfwBepO֯gfwBPɨ֥η|֦pOƥةΥ\धĪfwΨlinezolidvݶWL2PfwAʴpOƥءC
3. ~iPΪŸɪAΡC
4. pGfwfvAivC
5. AΥ~ɡAקKΤjqttyraminetqζơCC\tyraminetqC100mgCttyraminetq]AǥѦѤơBoáBMηtHW[DkҲͪܩʳJսC
6. pGAΧtpsudoephedrine HCLphenylpropanolamine HCLī~pP_ĩΥh몺ĪɡAiDvC
7. pGAserotonin re-uptakeΨLܼ~{ɡAiDvC
8. xsG1530JUץOsA`gnUwBCĳbϥΫen}`gnU~]ˡF`gGieAHxsɶW[C|[`AvTĻC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Linezolid	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	uvѤUCPʵ߮PVw̡GVancomycinĩʪEnterococcus faeciumPVA]AֵoߦgfҡC|PVͪAStaphylococcus aureus]methicillinPʩMmethicillinĩʪ߮^Streptococcus pneumoniae]penicillinPʪ߮^Ҥް_CʥֽMֽcyPVA]A}fPVALֵo誢AStaphylococcus aureus]methicillinPʩMmethicillinĩʪ߮^BStreptococcus pyogenesStreptococcus agalactiaeҤް_CDʥֽMֽcyPVAStaphylococcus aureus]ȭmethicillinPʪ߮^Streptococcus pyogenesҤް_CϷPVͪAStreptococcus pneumoniae]ȭpenicillinPʪ߮^A]AֵoߦgfҡAStaphylococcus aureus]ȭmethicillinPʪ߮^Ҥް_vC     	linezolidβ~LLӪ̸TΡC	`2%̡GmBYhBߡBæRBvBKB֯lBYBoNF̡G]߯fBBƤ}BhBkoMYܦC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-13 j	Ts112.7.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.3._20210607.pdf"">OI` 10.8.3.</a>             "	"OI` 10.1.,10.8.3."	0	OIs 20251124	OZYVO1-a	OZYVO1-b	OZYVO1-c	112.7.24
AC225571G0	V03AX	߲n]Yï^	OLYSO	Reason tablets 50mg(Lysozyme)		"1.UسNN(p@~BBΥ~Bޤ)XB~ȡA
Mж˭Pi¡XC
2.ջ줧UHʪgefGCʰƻĪBLөʻ󪢡ByʷP_B
yB󤺸~ȵC
3.طإXxAfMw|vC"	q`H@60?270mg(O) TAΡAè̦~֯guqWϥΡC	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷšBBץBC	Lysozyme 50mg	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	CʰƻĪBIlewBطإXxBpNɤNNX]Bc^	Yï󬡩ʩΫDʦLӡC	"ֽX{άlAmAzGAA
"	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w35-03 [s]_269 [UDx]_U03-17 [E]_C4-12 j	Ts112.7.24		OI` 	0	OIs 20251124	OLYSO-a	OLYSO-b	OLYSO-c	112.7.24
AC46257421	S01FA01	0	PATR03	()0.3%Atropine eye drop. 5ml/bot		"atropine |iA٪xE@ΩMtdո`٧@ΡC
|թjGC
iϷٽո`\·Gٳ·C"	q`@12wA@24AguWC	"1. 靈CΦɭPUʫCɦVw̸TϥΥ~C
2. קKsϥΡACʫCw̨ϥΫᶷ@lˬdC
3. eCw̨ϥέn`NC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. }ʫA1Ӥ뤺ϥΧC
2. ФxsWL30JC
3. m]ˤץxsC"	Atropine	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	Bٳ·C	靈CΦɭPUʫCɦVw̸TϥΥ~C	@ʹLqɡGVBoNBhB߸[֡ByBKB~j̷|믫鱫BC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5767295?cesid=1fNsQ3jfmTb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAtropine%26t%3Dname%26acs%3Dfalse%26acq%3DAtropine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-04 j	Ts110.6.16		OI` 	0	OIs 20251124	PATRO3-b	PATR03-b	PATR03-c	110.6.16
AC21893209	G02AB01	YīGĥҰsP`gG	IMETH1	Methylergonovine injection  0.2mg/ml F1ml/amp		MetherginO@ؤѵMͪsP(ergometrine)bXlͪAO@رjOBM@ʪlcYC@ΩlcƦ١AüW[`ߩʦY򩳱iOBWvαjסCҰsPjOBܩʪ@ΡAOѩM@ʪ@μҦAҰsPOMBhialpha-ǤW骺@ξΫܾC	"1. fAw0.2mgC34A̦hu൹1ӬPC
2. IMAIVwbeӥXӫALLƥXβAP0.2mgCpGݭnܡAb۹j24pɡAiƤ@C"	"1. ~iҦIV`gAӥBnYKʵfHC
2. ѦgAʦޯefAMxŦ\ॢ`AAΥ~ypߡC
3. pG~GCܡAiϥΡA~nJæbNtBAӥBPץ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC	Methylergometrine	G02A	lcY UTEROTONICS		lcX	AhrgC	ߡBæRBBtwBջBoB߱BݵhBIlPC	hTϥΡA㦳jOlcY@ΡC	iyťĤc֡AĳŴϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-21 [E]_G2-13 j	Ts112.7.22		OI` 	0	OIs 20251124	IMETH1-a	IMETH1-b	IMETH1-c	112.7.22
A008355100	A03AX13	[Կ	OGASC1	Gaslan tablets 40mg(Dimethicone)		ĩGzǥѭCwiOAӨϭӮIGzHWw]iOܡAiӯ}AéHЩαƮ覡NƥX~C	"1.134AλݭnɪAΡC 
2.HC1A 3HW (t)AAΦHqC 
3.3HUAЬvEvAyۦϥΡC"	1.קKκһĶơBήeyȪ2.X{ߵ{H	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dimethylpolysiloxane	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS		ѰȮBwѮȬg 	糧Ĳ͹LӤw̸TΥġC	nKBGַPBUgBhBæRBîBGPέ{HC	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w13-01 []_01-11 [s]_105 [®]_105 [E]_C4-08 [Ew]_EX083 [Ew]_Z-04w9 j	Ts112.7.27		OI` 	0	OIs 20251124	OGASC1-a	OGASC1-b	OGASC1-c	112.7.27
NC05351277	B05BA03	0	IG101	10% Glucose Injection (500ML)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	θ}ɥR					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		OI` 	0	OIs 20251124				
AC39429345	M02AA07	hmh	ETORI	"Toricam  GEL 10MG/G,40gm/tube (Piroxicam)"		PiroxicamO@ب㦳hAܪMѼSʪDrܪġCX?]COX-1MCOX-2^|CeC͡AoQ{OhM@Ϊ]C	C@ܼƦAuqũwûJC	ФŶ٩󲴷HBˤf	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Piroxicam 10mg/g	M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	`B`]`hBhƩ`^BʯժBʦ٦װfl˩MʵhB٦׵hB~˫ᤧ~Ȥίkh 	糧~LӪ̡ATϥΡC	`BEPC	B/D(ĤT)	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N06-04 [E]_I3-11 j	Ts112.7.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.1._20200201.pdf"">OI` 1.1.1.</a>              "	OI` 1.1.1.	0	OIs 20251124	ETORI-a	ETORI-b	ETORI-c	112.7.22
AC011541G0	M01AB01	Fqn	OINDO1	Indoy capsule		hPLNSAID@ˡA㦳ܪAѼMh@ΡC [?]COX-1MCOX-2^iɭPeCX֡C	"HC1ɡ]25mg^C2-3
Aζi\ɦPɪAΡC"	"1.ĥiӵ߷PVfxAb{ɳiRAeTൣϥΡC
2.ĥiް_զy֯gBpO֯gBɩʥզyʥFgBGzXΧgApw̥īo͵ıD[`NC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUJs	Indomethacin 25mg	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	٦װftΤgBkhBNᤧ~ 	"1.TΩ󬡰ʩʭGŪ̡FLhwGŤw̡A]pߨϥΡC
2.]AAspirinLӾɭPݱw̸TΡC
3.TΩQ|HUpġF麟WέŴw̡AԷVϥΡC
4.ZwBˤfκ믫fw̡A]`NϥΡC
5.iaʯ¶DN (Coronary artery bypass graft, CABG) 14ѤTΥġC"	ϥΡAɥioYwYhAp}lAθCqvAYi֦ذƧ@Τo	B/D(ĤT)	iwA|X{bŤ(RID:8.6%)(RID<10%i)	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.8.11		OI` 	0	OIs 20251124	DC	DC	DC	112.8.11
AA49344100	B01AC04	Ty 75 @J	OPLAV1	Carvetone F.C. Tablets 75 mg (Clopidogrel)		"ClopidogrelAΩ󵰪ʯ߮ƥ󪺦ŹwUCfw:
- CoͤBߦٱΩPʯߦޯefʯߵwƯfHʯ߮ƥ(pGߦٱB
ΨL]ޯfܤް_`)o͡C
- Paspirin֥έCDSTqWɤʫa߯g(íwʤߵhMDQiߦٱ)fH]]Ag֫aʯߤJ
vm[w̡^ʯ߮ƥC
- Paspirin֥ΥiΩHvSTqWɤʤߦٱfHC
- AXVitamin K antagonistsߩֺŸʱw̡A֦ܤ֤@ӵoͦިƥMI]lABݩXMI
C̡AiPaspirin֥ΥHwʯ߮ΦƥA]AC"	"ClopidogrelĳqC75mgA@Ѥ@AiMPɪAΩΤ}AΡC
ʫa߯gw(ACS)G
NSTEMI(íwʤߵhΫDQiߦٱ):LD:Clopidogrel 300mg+ Aspirin 325mg; MD: Clopidogrel 75mg QD+Aspirin 100mg QDA̤jĪGbĤTӤX{A{ɸƾڥiϥΦ12ӤD
STqWɤʤߦٱG
׬O_ϥΦ귻ѾAclopidogrelC@q75mgA}lɥiΤwq(loading dose)AP
ɨ֥aspirinCWL75fw}lvɡAwqCgoͫ}lXkBϥΦ
֥|ӬPC֥clopidogrelPaspirinWL|ӬPįq|T
wߩֺŸʪw̡AclopidogrelC@q75mgAaspirin]龯q75-100 mg^PɵĨûPclopidogrel
֥Ϊv"	"DClopidogrel @Pro-drugA餺gCYP2C19 CN¦ʥNªHFw媺@ΡCӲBl(Proton pump inhibitorsAPPIs)OΩvƩʼŻPGDfyʯefĪAo@Īi|CYP2C19 CʡAӴclopidogrelഫʥNªAiӼvT
DMLܦpOs@ˡAclopidogrel pߨϥΩi঳XMIfHAҦpGжˡBNBLfzpαaspirinBxBglycoprotein IIb/IIIa BDTJܪh(NSAID)]ACox-2 BοܩʦMAl(SSRIs)CfHpߪ`Ni઺XxA]AΩʪXASOObv}lĤ@gΤNΫIJʤŦˬdCѩi|W[X媺MIAclopidogrel ĳPfAܾ徯֥
DYfHܤNvåBƱbNܦpO@ΡANie7 ѰϥclopidogrelC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Clopidogrel 75mg	B01A	ܦ ANTITHROMBOTIC AGENTS	0	CoͤBߦٱΩPʯߦޯefʯߵwƯfHʯ߮ƥ(pGߦٱBΨL]ޯfܤް_`)o͡CPASPIRIN֥έCDSTqWɤʫa߯g(íwʤߵhMDQiߦٱ)fH(]Ag֫aʯߤJʪvm[w)ʯ߮ƥCPASPIRIN֥ΥiΩHvSTqWɤʤߦٱfHC	"ī~DΨLDʦLӪ̡C
Yx\ण}w̡C
bX媺w̦pƩʼũ`X媺w̡C"	ˡByB姿BGzDX]`^A`X]`^AX]`^	ѩƤAhĳϥclopidogrelC	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K5 [2]_K5 [ws]_w22-02 [ws]_w65(2) [s]_71 [®]_71 [UDx]_U02-31 [E]_B2-18 j	Ts112.8.11	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.6._20121201_000.pdf"">OI` 2.1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.8._20121201_000.pdf"">OI` 2.1.1.8.</a><a href="""">OI` 2.1.7.</a>            "	"OI` 2.1.1.6.,2.1.1.8.,2.1.7."	0	OIs 20251124	OPLAV1-a	OPLAV1-b	OPLAV1-c	112.8.11
AC03286100	J01FA01	n@J	OILOS1	Hylomycin 250mg/cap(Erythromycin)		"ͤƾǴܡAerythromycinifߺسJս誺XAӤ|vTֻĪXCwerythromycinMclindamycinBlincomycin chloramphenicol|ܧ@ΡC
ErythromycinǥѻPPӵߪ50Sֿ}馸쵲XAΧJս誺Xӵo@ΡC|vTֻĪXC
@Ωmotilin receptorPizGDįʡC"	"HGfA250-500 mgC6-8pɤ@F MAX 4 g/day.ൣGfA30-50 mg/kg/ѨC6pɤ@C MAX 2 g/day
PiGįʡGPO:250mg-500mg TIDAC;IV:3mg/kg Q8H
"	"1.gv\BYıonBФŦۦ氱ġC
2.ϥΩx\ण}fwC 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC		J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	gBw~gB̤ڡBOfBrC	"ZErythromycinLӪ̸TΡC
Erythromycin?oPterfenadineBastemizoleBcisapridepimozide֥"	ABߩιæR	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w06-04 [s]_104 [E]_A2-06 j	Ts112.8.11	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	OILOS1-a	OILOS1-b	OILOS1-c	112.8.11
A035676338	M02AA15	h羮H]ݧJᨺ^	EVORG1	Painstop gel 1% 20gm/(Diclofenac)		"1.ĬDTJBDLthA㦳uqhBܪ@ΡCbDTJAĤLPĪbBh譱ġCifaCOX-1MCOX-2?AqӴ֫eCe骺ΦF 㦳ѼAhMܪSʡC
2.Ĭ~ΤܵoΤhsAtD1%ADiclofenac SodiumAPɥīYHS򾯡AiUʦήɵoĮġABϥηPMDoC
3.ħϥήɡADitzJֽAäG֤U´ӯ঳ĦaܫʤκCʤoAGĥiۦawѦ]`ιBʶˮ`ҳy~ȵoίkh{HC
"	khjpөwAXAqwBAϥήɽлJC	ֽ~ΤoAAΨϥΩ󲴷A礣oI󲴷|gH	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC		M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	uϥΥHwѦ]oް_khC	w糧~ʦΥξLӪ̡C	ֽksB`PBoιLөʥֽ	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N06-01 [E]_I3-12 j	Ts112.8.11	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.1._20200201.pdf"">OI` 1.1.1.</a>              "	OI` 1.1.1.	0	OIs 20251124	EVORG1-a	EVORG1-b	EVORG1-c	112.8.11
	V03AB14	0	IPROT3	(3)Protamine Sulphate 10mg/ml;5ml/amp					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS		MLq֢ӢޢϢעܡC     					аѦҾqPΪk	  		  	ixiij	Ts		OI` 		OIs 20251124	IPROT3-a	IPROT3-b	IPROT3-c	
X000265212	C01EB10	0	IADEN1	MĵADENOCOR INJECTION 3MG/ML		v}oʤW߫Ǥ߷iLtBUE_QRSiܼeܯʤW߫Ǥ߷iLt	"쾯qGֳtRߪ`g 3mg(WL 2 )C
ĤGqGp쾯qLkb 1-2 ưW߫Ǥ߷iLtAhAֳtRߪ`g 6mgC
ĤTqGpĤGqLkb 1-2 ưW߫Ǥ߷iLtAhAֳtRߪ`g 12mgC
W[Ϊ`g󰪪qhĳC"	 1.C~ 2ml  0.9% w/v Lߪ`gΥͲzQ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ĤnNáC	Adenosine  6mg 	C01E	䥦vŦf OTHER CARDIAC PREPARATIONS	0	v}oʤW߫Ǥ߷iLtBUE_QRSiܼeܯʤW߫Ǥ߷iLt	"fuеxԸsBĤGβĤTũЫǶǾɪ_(DfwHu`߾㦳\)C
E Cʪʪͯf (ҦpGݱw)C
E QT gԸsC
E YCF߰IܥNvqC
E  Adenosine LӪ̡C"	"Chest pain or pressure, dyspnea, headache, lightheadedness, flushing, neck, throat or jaw discomfort"	"ѩʥF adenosine |vTL઺ҾڡAD
沈nA_hhkiϥ Adenocor"	"ʥF¨Ŵϥ adenocor {ɸgAD
nA_h¨Ŵiϥ adenocor"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.7.27		OI` 	0	OIs 20251124	IADEN1-a	IADEN1-b	IADEN1-c	112.7.27
		ëHg_n75@J	OERAF	eާOEraflu 75mg/cap (Oseltamivir )		"1. ~gi?Ai@ΨyʷP_frC
2. gi(neuraminidase)OyʷP_fr@ӭnJսAPϷsΦfrqJDӭMXAӥBUfrLIlDHӭMC
3. frgiĝ@ΥiHsΦfrqPVӭMXACyPfrC"	"vΡG
1.H@2AC1n(75mg)AsAΤѡFCrC1 1030mL/ minGCqܨC1nAs5ѡC
2.1HWൣĳqG15AC30mgAC2F>15-23AC45mgAC2F>23-40AC60mgAC2F>40AC75mgAC2C
3. UAΡAĪGUnCFϥ~ĵo̤ܳjAfHbgoͫ48pɤAΦġC"	"1. ~iUfH23Ѧ^_`ʤOAܦhiYufHgɶ60%C
2. ~BġAgvBץiAΡAAΫ24pɥi[dvĪGC
3. yʷP_goͫ24pɤAΥĪ̡A40pɤAΪ̮ĪGnAgɶOi2Ѥ1.3ѡC
4. MFDA֭㥻ĥΩyʷP_vPwANѦ~HΦMIڸsC~Tw̭]ءC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 		J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	HMൣ(]tsͨ)yʷP_vCHM1ΥHWൣyʷP_wC	oseltamivir phosphateβ~@LӪ̡C 	`G(SæR)BæRBmFGުBhBwtBYhBy¡BvBtwBh¡C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiE2j	Ts112.8.11		OI` 	0	OIs 20251124	OTAMI1-a	OTAMI1-b	OTAMI1-c	112.8.11
AC46759100	N06CA02	ñd	OMOCA	Mocalm F.C. tab( Flupentixol+ Melitracen)		"1.flupentixolO㦳gw믫ww,pq,iܧ{ѵJ{
2.MelitracenO@بⷥʺ믫ww,Cq,믫ᬡ@"	C2C@AMȪAΡApfᾯqiW2ɡC	Aī~קKܰs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Flupentixol/Melitracen	N06C	wwĩM믫ĪƤ PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0	J{gB~{gC  	"1.ʰsARAhĩpsychopharmaceuticalr
2.ĸk
3.C
4.eCF
5.y\ê"	vBuҽkBƧxBf	קKϥΰDvn/קKϥ/SmҦw/|qLť	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D4 [2]_D4 [ws]_w39-02 [E]_B3-02 j	Ts112.8.11		OI` 	0	OIs 20251124	OMOCA-a	OMOCA-b	OMOCA-c	112.8.11
		0	OEZEE2	Qb  4]/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		OI` 		OIs 20251124	OEZEE2-a	OEZEE2-b	OEZEE2-c	
۶O		0	LBIOG1	BioGaia D-PLUS (_ĨD-PLUSw)		"(~) 1. PLUStCĶt(Tribasic calcium phosphate)κͯD3 (Cholecalciferol)A ঳ĴѳyһݤtBCqAΫPitBClͯD3C
2.  PLUS]DTribasic calcium phosphateA|ͤGƺҮAӨLһĶtsbGħ@ΤUCO2ӾɭPȮ𤧰Ƨ@ΡC"	C@A@5wAhLqD	  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os覡GϥΧ~ɡA~\AקKPG鱵ĲC}~3Ӥ뤺ΧAëOs󳱲DB25ץHUBC	ùŻı(Limosilactobacillus reuteri DSM1793 +Vit D(400IU)	0000	~iɥR~	0	iU	糧~LӪ̸TΤC	ĹLqɰtgAǵۤfҵo͡C	ihέŴA	  ihέŴA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		OI` 	0	OIs 20251124	LBIOG-1			44322.49692
۶O		0	OHOLY1	HolyCon (Odn) 60/ (Artichoke)		(~) D B xfrIŧҭCCb@몺ĳqUA夤|X{io anti-HBs qA	"CѤ@,C@"	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	AѨBlѨBï]ѨBVIT B1BB2BB6BB12BġBxBL-iġBL-iġBL-QiġBD	0000	~iɥR~	0	iU	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts110.6.16		OI` 	0	OIs 20251124	OHOLL-1		0	110.6.16
۶O		0	OSIDE1	"Sideral Forte ?
vitamin C 70 mg
Sucrosomial Iron 30 mg
/iBͧުѥq"		"(~) Sucrosomial Iron]sucrestorޯ׽]СAO@KbGĤQ}a(iקK3K)AiקKKbzGDް_E@Ρ]߷QR^A2KpzQlAU󥿱`yΦή𪺿ePQ
"	"C@,t"	"ζqWLΤkĳq(C30mgK)
NhBiŤ\,礣N}nͬA
ĳ2Ӥb~˴Hb"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30CHU곱DBxs	"Vitamine C 70mg
Sucrosomial Iron(element Fe) 30mg"	0000	~iɥR~	0	iU	ƥ\௿áALөʥ֯lAֽo - ߧYϥθӸɥRAÿԸ͡I	",«K"	iH̫ĳq	iH̫ĳq	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	"ixiiM,Ej"	Ts110.6.16		OI` 	0	OIs 20251124	OSIDE1-a	OSIDE1-b	OSIDE1-c	110.6.16
۶O		0	ODENS1	Density amorphous calcium carbonate		(~) 	1 tab BID AC or PCA@ŶWL4AhLqD		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		amorphous calcium carbonate	0000	~iɥR~							аѦҾqPΪk	  		  	ixiiMϡj	Ts110/9/24		OI` 	0	OIs 20251124	ODENS1-a	ODENS1-b	ODENS1-c	110/9/24
۶O		WyAG	LCHEM1	MICRSOY oral soln 4ml/~;45~/		(~) ﵽƾĪvgfwhҤέ	C8 c.c.AGAOHŶ}100 c.c.}ŸAΡC	-------	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Soy bean	0000	~iɥR~	0	iU	-------	"Diarrhea, constipation"	/	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M07-01 j	Ts113.12.2		OI` 	0	OIs 20251124	LCHEM1-a	LCHEM1-b	LCHEM1-c	113.12.2
۶O		0	OETHA	Ethanwell[o432gm/~		(~) ~Fw̱MΤi~AABMI19BiALk{~Fw̡C	1ζq:[o5(72g)+[o1(2.5g)ACĳ3~5C	pfH]qΤX{mpAb̪ϥ[oeTѡANwnǷRm10~15AϻïѫAΡCAδYX{miW[ïK[qCήɥiK[Bª۳¡BGվffPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"[ѵMJڽ,ƻï,q͵,L-Qi,L-i,D,ͯE,ïQ10,ֺ,MQִå,o(TG form),z:450mOsm/Kg H2OC"	0000	~iɥR~	0	iU	0	0	/	/	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OETHA-a	OETHA-b	OETHA-c	110.6.16
۶O		0	OETHA1	Ethanwell[oզX](6~+1~[o)		(~) ~Fw̱MΤi~AABMI19BiALk{~Fw̡C	1ζq:[o5(72g)+[o1(2.5g)ACĳ3~5C	pfH]qΤX{mpAb̪ϥ[oeTѡANwnǷRm10~15AϻïѫAΡCAδYX{miW[ïK[qCήɥiK[Bª۳¡BGվffPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"[ѵMJڽ,ƻï,q͵,L-Qi,L-i,D,ͯE,ïQ10,ֺ,MQִå,o(TG form),z:450mOsm/Kg H2OC"	0000	~iɥR~	0	iU	0	0	/	/	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii|U10j	Ts110.6.16		OI` 	0	OIs 20251124	OETHA-a	OETHA-b	OETHA-c	110.6.16
		0	EAC	Rvݮݧlxs()p		0	0	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC		0		0	0	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	EAC-a	EAC-b	EAC-c	110.6.16
		0	ESAVA2	SAVAGEL herbal intimate cleanser 250ml/b		0	0	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC		0		0	0	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-02 j	Ts110.6.16		OI` 	0	OIs 20251124	ESAVA2-a	ESAVA2-b	ESAVA2-c	110.6.16
۶O		0	LVITA1	Vitamins (_qƤLR)50ml/~		(~) ո`ͲzPsN¤`A WjO;Pi୹	C@1C.C.AΧlީfAβK[}GĤ	"1.~g}ʫQŮơAC|[AΧХߧY\W\lAé}2Ӥ뤺tϥΧ
2.~AhLq"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"LRA
LRB1B2B3B6B12
LRC
LRD3
LRE

]Jڵԯ

DHA
¤
}
ܤl"	0000	~iɥR~	0	iU	~	~	~	~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	LVITA1-a	LVITA1-b	LVITA1-c	110.6.16
۶O		0	ODLPC	CױdDLPC(hMCxPPPC)		(~) ո`Ͳzध~C	ĳ@2AC馭ߦU@C	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Polyenylphosphatidylcholine	0000	~iɥR~	0	iU	0	LӪ̽ФŪAΡC	PLʡATϥ	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts110.6.16		OI` 	0	OIs 20251124	ODLPC-a	ODLPC-b	ODLPC-c	110.6.16
۶O		0	OEASE1	Ease TummyPlusƤq͵ 320(6]/)		(~) دq͵ߡ]C]320)A[W}AhخƻïAitAܲӵOͺAAϱƫKZAUơAPiAPisN	C@]ATHUĵiuqbAΫeΪŸΡAλPGġAAΡAŶWL40	"1.pGAΧܥͯAjТpɦAAΥ~D
2.oסAAE]@ؿ@^֭"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	"Lactobacillus acidophilus,Lactobacillus reuteri,Streptococcus thermophillus,Lacrobacillus platarum,Bifidobacterium breve,Bifidobacterium bifidum,Bifidobacterium lactis,Lactobacillus paracasei,Lactobacillus rhamnosus,Bifidobacterium longum,Lactobacillus casei,Bifidobacterium longum"	0000	~iɥR~	0	iU	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiMϡj	Ts110.6.16		OI` 	0	OIs 20251124	OEASE1-a	OEASE1-b	OEASE1-c	110.6.16
		0	PBOS4	ʪl		Uwβ誺t	0	"iΩnβ
Фũmb(Ҧp:Dǵ)
Цsq
ĳw󴫷s~AHֲӵ߷PVI
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC		0		0	0	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.6.16		OI` 	0	OIs 20251124	PBOS4-a	PBOS4-b	PBOS4-c	110.6.16
A031170363	A01AB03	0	EPARM	PARMASON GARGLE		ChlorhexidineO@ؼsħܵ߾AOwߴWLͪo@ΨåBiJ_AĦa G(+) G(-)ӵߪͪAרOyߡAhfC	C 10-20ml( 1-2 ~\)AfĤ~ðdTQܤQRXAi󦭱ߩλݭnɨϥΡCФŧ]ACAġCߩλݭnɨϥΡC	i](f)A	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Chlorhexidine Gluconate	A01A	fįfĪ STOMATOLOGICAL PREPARATIONS	0	fĤߡBrBMBhfC	糧ĹLӪ̸T	ۦBEP	C	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-01 [E]_I2-13 j	Ts110.6.16		OI` 	0	OIs 20251124	EPARM-a	EPARM-b	EPARM-c	110.6.16
AC21981423	A01AC01	0	ENINC	Nincort oral gel 6gm/tube(Triamcinolone)(Group4)		Triamcinolone acetonideTJXA㦳ܪg@ΡA[JfıMΰ򾯡AتbHüж˭Aľ঳Īv˳BAtSIuߵ۩ʡAbfĤGyXAGfĤUتgαwotvĪGC	q`@@A̦nNɨϥΡAgYɡA@2-3նq٩wBAϥΫȮקKC	"1.YoͤwʤPVɡAаϥΡC
2.Ywo͵֩ʡBoLʩΨLwʷPVɡAФŨϥΡC
3.Z֯fBGũο}fw̡ADgvܤoϥΡC
4.ϥΥ7ѫwBYLۧﵽAANˬdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Triamcinolone	A01A	fįfĪ STOMATOLOGICAL PREPARATIONS	0	סBf߽BޡBũʤfBfCʪgvBw|B EewC	糧ĹLӪ̸T	X{īeS`PBkoB_wBֵC	C	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O04-03 [UDx]_U01-62 [E]_H3-23 j	Ts110.6.16		OI` 	0	OIs 20251124	ENINC-a	ENINC-b	ENINC-c	110.6.16
AC503401G0	A02AH	0	ONAHC1	Sodium bicarbonate  600mg/tab		"1.vN©ʻĤrA~ϦߤһĲBڿ@פɰAMBlAqӪȥĤrC
2.PƧGAΥ~ɡAѩ󧿤һĲBڿ@פɰAGpHɰAϧġBDiĤΦJյbΦλEC
3.ġAfAਲ਼tMνwĭGġAӤvTGĤcC]ӭGpHtɰAwѰGĤް_gC"	1~5g֤URߪ`g	"1.x\णBǥ\णBŦefBhέQw̡BѦ~HקKϥΡC
2.ɥRu|WAyGdΪͤ~IAGLPƷ|cƯfC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium bicarbonate	A02A	ܻ ANTACIDS	0	N©ʻĤrPƾC	"1.BŦfBǯewBB~w̸TϥΥC
2.Ъ`Nī~tT"	GzȮ	C	ư઺IC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669504?cesid=66ox1kr8jQY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSodium%2Bbicarbonate%26t%3Dname%26acs%3Dfalse%26acq%3DSodium%2Bbicarbonate"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.12	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.7._20071201_000.pdf"">OI` 3.3.7.</a>              "	OI` 3.3.7.	0	OIs 20251124	DC	DC	DC	114.04.12
AC49763100	A02AG	0	ONOLI	NolidinƤ(Butinolin 2mg+Al.200mg		"Ĩ㦳1.xPΧܵj˧@ΡCGzDBxnj˯khġC
2.ħ@ΡAiMLhGġC
3.iΦмŪAHO@ƾx"	H@ѤTAC@	ǰIܯfwAΧtTGĥiɭPΥ[zRvް_zRʳngBzRʸfܤΧCCgAԷVpߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"Butinolin phosphate 2mg
Aluminum hydroxide gel 200mg
Calcium carbonate 300mg"	A02A	ܻ ANTACIDS	0	GĹLhBGBQGzBGΤQGzũҤް_jˤίkhC	糧ĹLӪ̸T	mBK	C	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w11-01 [s]_207 [s]_208 [®]_207 [®]_208 [E]_C4-10 [Ew]_EX091 [Ew]_Z-12w9 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	ONOLI-a	ONOLI-b	ONOLI-c	110.6.16
AC15543100	A02AX	0	OPEIC	Peichia tab(Ƥ)		"1.PiLަAͱjƦިçﵽwG`G\
2.Ma´ΨcPisAת޲´WޫPiŭ¡X
3.Pepsin@ΧPepsinƺ޹D
4.MG"	q`HC2A@T󶺫AΩΨ̦~־AyWC	1.~fCZrH]AC2.~tڲξAfଧg̤yϥΡC3.ǰIܯfwAΧtTGĥiɭPΥ[zRvް_zRʰnƯgBzRʸfܤΧCCgAԷVpߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"Dihydroxyaluminium allantoinate 50 mg
Aluminum magnesium silicate 450mg"	A02A	ܻ ANTACIDS	0	GĹLhBGšBQGzšBBCʭG	fଧgyϥ	"K,GַP,"	iw	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.6.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OPEIC-a	OPEIC-b	OPEIC-c	111.6.29
AC236061G0	A02AG	0	OPEPT	Peptidin Ƥ 400mg/tab(Mag.Alum.Hydroxi		"1.HomoatropinePgAzGtΦܩʪĪGPAtropineĮĬۦPrʸC C
2.SulfateɭʾAGHW|ΦO@HwMGĪE C
3.Aluminum Magnesium Hydrate ĦiMGġC
4.tGlycyrrhizin㦳HO@@ΤΧܹLӧ@ΡC"	13AC12AbeζAΡC	ǰIܯfwAΧtTGĥiɭPΥ[zRvް_zRʰnƯgBzRʸfܤΧCCgAԷVpߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"Homatropine Methylbromide 2mg, 
Polymagal 400mg, 
Magnesium Trisilicate 300mg, 
Sodium Carboxymethyl Cellulose 22.5mg, 
Sodium Lauryl Sulfate 10mg
"	A02A	ܻ ANTACIDS	0	GBGΤQGzšBGhBGjˡBGĹLh	糧ĹLӪ̸T	0	SmҦw	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OPEPT-a	OPEPT-b	OPEPT-c	110.6.16
		0	OULCE1	Aluminum hydroxide 324mg/tab		ľAΩvGĹLhgApGhAGABGİfyέGĩʮƤ}C BƾT٥iHΨӭCŦfw餺CQFBƾT]iH@DB誺vġC	" 1 pɤκΫeλݭnɪAΡCZH]AC
~   q:
H 12 HW 1  2 A1 ѪA 3~4 
6 HW 12  1  1 A1 ѪA 3~4 
3 HW 6  1  1/2 A1 ѪA 3~4 
3 HU ЬvEvAyۦϥ
"	"@BUCΪ̡AФŨϥΡG
1.]Ħް_LӪHC
2. 3 Ӥ뤧C
GBUCΪ̡AϥΫeЬvEvG
1.ƹDŪHC
2.ݭQHC
3.BŦfBǯeBB~HC
4.CʭGhHC
5.ǰIܯfw(AΧtTGĥiɭPΥ[zRvް_zRʰnƯgBz
RʸfܤΧCCgAԷVpߨϥΡC)
TBUCΪ̡AϥΫeХԸvĮvľ͡G
1.BihkέŰC
2.PLĪ֥ήɡC
3.ΨŻs~@קCHC
|BLϥΤW`NƶG
1.ൣ~ЧOޡC
2.קKgC
3.ŶWLĳϥζqC
4.@ѤiAζWL@̤jϥζqA]isAΤ@̤jϥζqgHWC
5.ľZH]AC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aluminum Hydroxide Gel	A02A	ܻ ANTACIDS	0	wѭGAΨ`PBθgE_GΤQGzšBGBDҦHGĹLhC	"1.]Ħް_LӪHC
2. 3 Ӥ뤧C"	KBߡBæR0	RsҾ	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-01 [s]_1 [®]_1 j	Ts110.6.16		OI` 	0	OIs 20251124	OULCE1-a	OULCE1-b	OULCE1-c	110.6.16
	A02BX13	0	LALGI1	Alginos oral suspension(50mg/ml)		AΫPGGĤAΦ@ػP״XGʪƯBHA঳ĪGGfyA]iwѦ]Gĩxİfy쭹DҾɭPgApƤ}BfyʭDBϭGBWίݰkh	"1.12HWACA10-20@
2.6-12AC5-10@
3.2-6AC5-10@ɡAϥΫeЬvEv"	"1.YPt֥ΡAiް_tBǰIܡBPrBߡBæRBYhBNѤM
2.ϥΫeзn"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Osb 25JHUAõLN	"
sodium alginate 50 @J
sodium bicarbonate 26.7@J
calcium carbonate 16@J"	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	wѭGĤxĤϬyJDҲͤkh	"1.2 HUൣ
2.]Īް_LӪH"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-01 [ws]_w73-02 [E]_J2-04 j	Ts110.6.16		OI` 	0	OIs 20251124	LALGI1-d	01050033-1	01050033-2	110.6.16
AC58196245	A02BC05	0	INEXI	Esomelone inj. 40mg/vial		Esomeprazole@zPA|bGӭMcpޤ׻ĩҤUAƦʫAiGH+-K+-ATPïA]¦GĤcΦ]EͤGĤcAĪGC	"󤣯౵fAĪw̡Ai`g 20-40mg CѤ@[HvCfyʭDw̡Aӥ 40mg CѤ@[HvCwfyʯefgvhH 20mg C1[HvC NSAIDvGŪvG@뾯q 20mg C1Cq`Rߪ`gvܵuAӾtאּfAvC
wGŻPQGzŦAX
ΪvʤBmʥXʭGũΤQGzŤAHֳtR߿`覡 80mgA`ɶ30AHH 8mg/pɪtvsRIw` 3  (72p)C(40 mg in 50 mL D5W, LR, or NSA2 vial/ 100 mlArun 10 ml/hrAt@]Oi run 10pɡC([x12hr))Dg`vfAGħvC"	"1. ĵܩʯgX{( Ҧp魫LGa۴BйæRB]`xBRζT )AHηhéΤwsbGŮɡAưcʸ~FiʡA]Hesomeprazolev|gAө~E_C
2. PPI ī~ϥΩ㦳貨PIw̮ɡAyʱfw説pAþAɥRVitamin DPCalciumC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"հtᤧx[b25JHUAƾǤΪzWwwʤwQҩ12pɤSDAqLͪ[IӬݡAհtī~ߨϥΡC
xsɯSO`Nƶ
FץAЦs]ˤCY~ApĲ~Sb@ǤuU̦hixs24pɡCxsŶWL25JC"	Esomeprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	"Ω󤣾AXϥΤfAvɤNvG
1. GDfyʯefA󭹹D/ΦYfygfwC 2. NSAIDvGŪvC
vʤBmʥXʭGũΤQGzŤwAXC"	"1. w䬡ʦesomeprazoleBLbenzimidazoleNī~ξLӤw̡C
2. EsomeprazoleiPnelfinavir֥ΡC"	YhBhBKBmBȡB/æRBĳC	C	ثeäD esomeprazole O_|ѤHťĤƥXF祼ŤkisC]AbŴϥ NexiumC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	INEXI--a	INEXI-b	INEXI-c	110.6.16
AC57794245	A02BC02	0	IPANT	Panole inj. 40mg/vial		X֤GؾAܷLͪsvPժ۱߬ƩʼšBGšBQGzšBפYfyʭDBZollinger-Ellison SyndromeC	"GšBQGzšBפYfyʭDJRߪ`gPĳqOC@p~CZolinger-Ellison Syndrome)fHvJ_lqC80mgA ̭GĤcpվһݾqCĤkJC@p~`J10ml`gΥͲzQѡCts᪺Gi`gPΥH100ml`gΥͲzQ5%}`gGVXw`Cts᪺G12pɤϥΡC
PPI Pump:_lqĳ:80mg(2 vail)q:200mg Panole(5 vial)tm500ml NSD5W(Y0.4mg/ml) run 20ml/hr Y8mg/hrArun 72hr"	"1. PantazolAΩ󻴫׭GzefpgʮƤ}C
2. ϥpantoprazolevGŤeATwfHS󪺴cʭGũδcʭDefA]pantoprazolev|cʯefgө~E_C
3. E_fyʭD@ˬdTwC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pantoprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	X֤GؾAܷLͪsvPժ۱߬ƩʼšBGšBQGzšBפYfyʭDBZollinger-Ellison SyndromeC	ϥΩw䦨LӤw̡C	mBYh	B	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-25 [w]_w03-07 [w]_w03-23 [E]_G3-11 [Ew]_D1-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	IPANT-a	IPANT-b	IPANT-c	110.6.16
AC58521243	A02BC03	0	IWESF	Wesfor inj.30mg/vial(Lansoprazole)		1. @ξ୺iJGHӭMsİϡAMzLĪƤܦƫACo|PsİϤ@lW  B򵲦XAïʥHGĤcCLansoprazoleiGPȡAӴɾpOE\AçGGʡAF媺ĪGCLansoprazole]iGĤcAGPȡAPϦbĩҤlH״_iC2. GXAlansoprazoleiXʥJɭPGXC3. GHl:iǪLndomethacinɭPG߽lC	ϥΩ󦨦~w̡Aq`N~PͲzQ5%}`gGVXAAHC@ܤGRߺw`覡ġCR߿`ɶ30HW	"~uH`gΥͲzQ5%}`gGVXѡAѫߧYϥΤisC(PS:HͲzQ8pɤ`g,H5%}`gG4pɤϥΧ) "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lansoprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	GšBQGzšBGDfyʯef-SʰfyʭDvBZOLLINGER-ELLISONgJsAX֧ܥͯvPժ۱(HELICOBACTER PYLORI)ƩʼšC	"1.糧~LӪ̡C
2.ثeatazanavir sulfatevw"	" LӯgGolBkog KBUgBfBȵg, YhBݺεg"	B	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	IWESF-a	IWESF-b	IWESF-c	110.6.16
AC33436212	A02BA01	0	ICIME	"wCIMETIDINE INJECTION 200mg/amp ""ASTAR"""		򥻤GĤcAæħUبEҤް_GĤcAδCGJսcqCvʪ´ib´iH2 骺@ΡAݩ´iH2 ܾCFĤc@Τ]O@H@ΡA]iĦaGHêqtC	"H`gPAigѦ٦ת`gARߪ`g覡ġC
 ٦ת`gqq`O 300@JACj 6-8 pɦ٦ת`g@A`g촿ȮɩʯkhiC
Rߪ`giϥζRIwA 300@J}b 100mL D5W(ΨLAXRߪ`gG)ARIw 15-20 HWACj 6-8 pɡA RIw@C"	Gűw̨ϥΥvɡAhcʼŤiA]|cʭGůgApi|~E_vɾC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Cimetidine	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	|fHHfzʭGĤcLgxTʡ]v^QGzũΤfAfHƩʼŤuNkC	ثe|o{TҡC	ּƯfw׼ȮɩʪUgBh¡BwtBolBּƨkʤkůgAgi]ĦӮC	B	"1.i|cšC
2.઺IܤpC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669111?cesid=56EAqyfkRYv&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCIMETIDINE%26t%3Dname%26acs%3Dfalse%26acq%3DCIMETIDINE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.01.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	DC	DC	DC	114.01.22
AC43945129	A02BX02	0	LSCRA	Scrat susp. 100mg/ml;10ml/pk		Sucralfate uֶqigGzDlAѭGzDl Sucralfate OgѧGưCȺ Sucralfate v¡GMQGzŪ@ξ|MAiҩ@Ω󧽳ӫDC{Ĳzso{ASucralfateMų쪺JպXΦ@ƦXlųBApiҹSucralfate ܼŧ@άOΦƦXܩʦalŪ߽AåBO@߽ӭMBܭGġBGJ?MxQI`CSucralfate uֳ\GĤM@ΡAGܼŧ@ΨëDѩGĪMC	"~SAੵlʡA]@ήɶACѪAΤGYiC
@ϥζq@ѤGAC@UAŸB\e@pɦWMΫeUAΤ@C 
k:qbAY@ѪAΤ@A@@UAΫeAΡC"	"CʵǰIܤγzRfw|W[Tb餺WnIӴrʡCG\ण}fHAקKϥΡCSucralfate sɷ|SDAAΥ~ߧYΤάyYiDC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sucralfate	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	GšBQGzšBDšBfyʭD	"1.糧ĹLӪ̸TΡC
2.AΥ|ܥͯAnA SucralfateAHKΦƦXQӥhܥͯ@ΡAקKܨLĪiβvAĳĪAγ̦n۹j 2 pɡC"	ϥΦɷ|yKAGzABfB֯lBooBtwBvuC	SmҦwDnAקKϥΡC	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H2 [2]_I2 [E]_I1-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	LSCRA-a	LSCRA-b	LSCRA-c	110.6.16
BC20674100	A02BB01	0	OCYTO	Cytotec 200mcg/tab(Misoprostol)		~@ئXeCE1AGĤcASEGMQGzHGcAO@GzӭMC	"1. QGzšBGšG@Ѿq800mcgAGΥ|\/ΨC@D\eHκΫeAΡAsv48PC
2. wNSAIDsҾɭPƩʼšGC200mcgA@Ѩ⦸A@ѤTΤ@ѥ|CݭnivCϥξq̭ӧOfH{ɪpөwC"	ikbAΥ~AǽTץC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Misoprostol	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	GΤQGz	eCLӪ̡BBAĴ̶Tҥ~AHקKyC	mBߡBYhBAC	X	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 [E]_B4-17 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OCYTO-a	OCYTO-b	OCYTO-c	110.6.16
BC25887100	A02BC06	0	ODEXI	Dexilant 60mg/cap		DexlansoprazoleO@اܤ?ƦXAiǥѱMGӭM]B?lA[?l^?TC??GĪ?C]o?Q{OGӭMGġ]l^ADexlansoprazolei_GĻsy̫@ӨBJݲB?lC	"1.vSʭD(EE)GĳqG60 mgAC飸Aϥ 8 g 
2.SʭD(EE)wv¡᪺ġGĳqG30 mgAC飸Aϥ 6 Ӥ 
3.DSʭGDfyef(GERD)gvGĳqG30 mgAC飸Aϥ 4 g"	nHq]AAiCZοiAiH\ΪŸAΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dexlansoprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	vSʰfyDBSʰfyDwv¡᪺ġBvSʭGDfyefgv	"1.糧~LӪ̡ATϥΡC
2.PLPPI(]Alansoprazole)ʶʵǪ(AIN)ɡAYAINAĳġD
3.PPIiW[x߬mI
4.q(@Ѧh)Ϊ(>@~)PPIiണ貨Pΰ魷I
5.Cvit B12ʥFӦҶqPPIvT
"	hBmBߡBæRBεȮ𪺱	B	SmҦw/iण|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I5 [2]_I5 [ws]_w28-01 [ws]_w65(2) [s]_88 [®]_88 [UDx]_U02-45 [E]_B3-08 [Ew]_EX041 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	ODEXI-a	ODEXI-b	ODEXI-c	110.6.16
AC413521G0	A02BA03	0	OGASTD	Ulstop F.C.20mg/tab(Famotidine)		gѹGHӭMH2 骺_@ΡAGĤcA{GBQGzšBGv¡ĪGC	q`H1 Famotidine 20mgA1  2 ]\B\κıe)gfPCΪ1 40mgA1 1 ]ıe^gfPiC	vAR[Aè̯fϥΪvһݪ̤pmGϥΥYĪGɡAЧΨLkC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Famotidine	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	GšBQGzšBkXšBWƺޥX(ƩʼšBstressšBXʭGӤް_)BfyʭDBZollinger-EllisongԸsC	糧ΨLH2 ܾLӥv̸T	KAmC	B	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w33-02 [s]_349 [®]_349 [UDx]_U03-12 [E]_C4-14 [Ew]_EX073 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OGASTD-a	OGASTD-b	OGASTD-c	110.6.16
AC49055100	A02BC01	0	OLOSE	Omeprazole 20mg/cap		Omeprazole@zPA|bGӭMӭMpޡAƦʫAi:H+-K+-ATPïC㾯q̿ʡAB¦GĤcΨEUGĤc(LצبE)AjPĪGC	"GšGĳqOmeprazole 20mgACѤ@CgitwѡABjhƱw̷|b4g¡C
QGzšGwʩʤQGzŤfHĳqOmeprazole 20mgA CѤ@C
fyʭDGĳqOmeprazole 20mgACѤ@AgitwѡABjhƱw̷|b4g¡C
Zollinger-EllisongԸsGvZollinger-EllisongԸsqݨ̭ӤHӽվABun{ɤWݭnANvUhCĳqCOmeprazole 60mgC"	ϥΩ㦳貨PIw̮ɡAAɥR vitamin D P CalciumC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Omeprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	QGzšBGšBfyʭDBZollinger-EllisongԸs	wOmeprazole|o͹LӤ	YhBGzDAC	C	ư઺IC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669537?cesid=7KVIxvO2yl1&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOMEPRAZOLE%26t%3Dname%26acs%3Dfalse%26acq%3DOMEPRAZOLE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OLOSE-a	OLOSE-b	OLOSE-c	110.6.16
BC23221100	A02BC05	0	ONEXI	Nexium 40mg/TAB		Esomeprazole @zPA|bGӭMӭMpޡA׻ĩҤUAƦʫAilC¦GĤcΨEUGĤcAĪGC	"@BGfyʭDef(GERD)
1.SʰfyʭDvG40 mg C 1 A 4 gCﭹD|¡Ω|gw̡Aĳt~A 4 g{C
2.GDfyʯefgvGﭹDow 20 mg C 1 FY 4 gᤴgɡAhi@Bˬdw̡C@gowѫAiHC 1  20 mg kӰ򪺯gCNHӨApݭnɡAiH 20 mg C 1 kCϥΫDTJܵo(NSAID)vӦoGũMQGzŦMIfwAĳHݭnɤ~AĪ覡@򪺯gC
H
GBPAܵ߾k֥ΡAHڰժ۱ߡAHΪvѫժ۱ߤ޵oQGzšG20 mg Nexium + 1 g Amoxicillin + 500 mg ClarithromycinFC 2 A@p 7 ѡC
TBwƩʼŦAX大vA40 mg C 1 A 4 gC
|BݭnϥΫDTJܵo(NSAID)fw:NSAID vGŪvG@뾯q 20 mg C 1 A 4-8 gC
BZollinger Ellison Syndrome (ZES)v
ĳ_lqA Nexium 40mg C 2 AMA̭ӧOpվ㾯qAõ{ɪxMwO_~vCھ{ɸ絲GҥܡACA 80  160mg esomeprazoleAjfHfioCpCAξqF 80mg HWAݤC 2 ġC
12 HUĵ
1  11 ĵΪkζqаѾ\u@AaBɾvC
[qվ]
x\ण}
x\໴פΤפ}w̡Aäվ㾯qCx\Y}fHANexium ̰ϥξq
WL 20 mgC"	"1. ĵܩʯgX{( Ҧp魫LGa۴BйæRB]`xBRζT )AHηhéΤwsbGŮɡAưcʸ~FiʡA]Hesomeprazolev|gAө~E_C
2. PPI ī~ϥΩ㦳貨PIw̮ɡAyʱfw説pAþAɥRVitamin DPCalciumC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Esomeprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	"GDfyʯef
SʰfyʭDvC
GDfyʯefgvC
PAܵ߾k֥ΡAHڰժ۱ߡAΪvѫժ۱ߤ޵oQGzšC
ݭnϥΫDTJܵo(NSAID)fw
NSAID vGŪv
wƩʼŦAX大vC
Zollinger Ellison Syndrome (ZES)vC"	"1.w esomeprazoleBbenzimidazole Nΰt褤LLӤw̡C
2.Esomeprazole iP nelfinavir ֥"	YhBhBKBmBȡB/æR	C	"ثeäD esomeprazole O_|ѤHťĤƥXF祼ŤkisC]Ab
Ŵϥ NexiumC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w29-03 [s]_249 [®]_249 [UDx]_U03-09 [E]_B3-13 [Ew]_EX035 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	ONEXI-a	ONEXI-b	ONEXI-c	110.6.16
AC44261100	A02BC03	0	ORICH	Rich 30mg/cap (Lansoprazole )		sDnOǵۧsbGHWӭMl(Protopump)AY(H+K+)-ATPaseʡAGjOBaGĤcC	"H. pylori ް_QGzŤX֪vG30 mg C⦸\eAΪv 10-14ѡCGDfy (GERD)G15-30 mg C@\eAΪv8-16 PC
ൣq: 1-11 30kg 15mg QD ϥιF8PAĳWL12PF>30kg 30mg QD ϥιF8PAĳWL12P"	"1.ī~AXΩ󥿦bŤkApowݪAĮɡAקKšC
2.GAХ}nAΡAſiHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lansoprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	GšBQGzšBGDfyʯef-SʰfyʭDvBZOLLINGER-ELLISONgJsAX֧ܥͯvPժ۱߬ƩʼšC	糧~LӪ̡C	ݵhBKBmBߡBYhC	B	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I5 [2]_I5 [ws]_w37-04 [s]_257 [®]_257 [UDx]_U03-18 [E]_B4-11 [Ew]_EX046 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	ORICH-A	ORICH-b	ORICH-B	110.6.16
A031800100	A02BX13	0	OTOPAA	AlgitabƤchewable tab (Alginic acid)		Algitab@ξSADnQΦĦ(sodium alginate)PsLqľҧtl@ΡAPGıĲΦʪCKתwjŽh(raft)ӥʦaO@GPDHCraft|}BGGeWAΦzʫ̻(physical barrier)AiĭCfyo͡AëD@ľȧ@MGĤΡC~AYfyo͡AAlgitabٷ|mɨGeWAê۩GDHWAHGĪEPˮ`	CѤTAC12 A\CZAΡAΫeAήĪGΡC	C@tul9.2mgAulHNҼ{pC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Alginic acid	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	fyʭD(Gastro-oesophageal reflux)Bջ(Hiatal hernia)BG`(Pyrosis)BGΤQGzšBGĹLh	糧ĹLӪ̸T	"GzA, mΫK"	SmҦw	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w17-04 [UDx]_U02-01 [E]_B1-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OTOPAA-a	OTOPAA-b	OTOPAA-c	110.6.16
BC17407100	A03AX04	0	ODELI	Dicetel 50mg/tab(Pinaverium Bromide)		PinaveriumO@ؿܩʧ@ΩGzDܵj˾CO@ضtlܾAitlyJzDƦٲӭMC	"HG ĳq 3  4 C bSpUAqiHW[C 6 C
ൣڸsGDicetel wʻPĩ|ൣRإߥBϥθg禳C]ADicetel ĳϥΩൣڸs"	"pGfwUC@uǰDGbſ}@gBLapp ſ}JʥFgθ}- bſ}l}ANiϥΥ
׮ɩδNeФŪAαoίS"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pinaverium bromide	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	"G, QGz, Lөʵz, z, x޹Bʧx"	Dicetel ʦΥ@ξLӡAФŨϥΡC	hBmBߡBæRC	SmҦw	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I5 [2]_I5 [ws]_w43-01 [s]_85 [®]_85 [UDx]_U03-37 [E]_B5-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	ODELI-a	ODELI-b	ODELI-c	110.6.16
AC354771G0	A03AA04	0	ODUSP	Padalin 100mg/tab(Mebeverine)		O@ئV٩ʸѵjAi@ΩzGDƦٸѰj˦Ӥ|vT`zDįʡA]ëDǥѦۥDgtΨӧ@άG|@뤧xPʰƧ@ΥX{AAΩ@Τjw̤ΫCw̡C	C|A߶eAΨC	Cw̻ԷVϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mebeverine	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	GzjˡBkhwѡBʸzBLөʤjzBGBGšBQGzšBxnBʵLOgC	"惡s~LӪ?yϥ 
"	twBߡBYhBKBC	DnAקKϥΡC	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.02.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	DC	DC	DC	114.02.25
AC399281G0	A03AX91	0	OKOWE	Kowell 2mg/tab(Azulene water soluble)		CʭGBG	H@A@@ѤTAeTQ]Aηѩϥ	1.֪̭YͲzण}qC2.ǰIܯfwAΧtTGĥiɭPΥ[zRvް_zRʰnƯgBzRʸfܤΧCCgAԷVpߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Azulene/Magnesium aluminum	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	CʭGBG	-------	UgBKBȷPBhBߡBæRC	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	DC	DC	DC	110.6.16
AC438671G0	A03AX08	0	OSPAL	Alverine 60mg/cap		~ߤ@XD¾KʡBLߺDʪѵjġApzMlcƦ٦M@ʡAvTIlΤߦިtΡC	60-120 mg QD-TIDA12HUĵAΡC	"1.Yzpe]w^hBšAΪ̬OxBǡBŦefAizͤĮvC
2.QGHUൣAĳϥΡC
3.Ī|YhwtgAwקKqƻݺ믫u@AAΥĪvAФpߦʡAHקKoͶ^˷N~yMIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Alverine	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	LөʸzxԸs	糧~ΨξLӪ̸T	zBYBYhBLӵol	קKϥ	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [s]_11 [ws]_w17-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OSPAL-a	OSPAL-b	OSPAL-c	110.6.16
AC50008100	A03AB20	0	OURAC	Uracare 10mg/tab		ݥ|iƦXxPĪAz帣̾Ӳͻ{êADn@ΦbgM1 MM3 receptorC	"HֹLʯg:10-20 mg bid e 1 p
Lef:10-20 mg bid-tid e 1 p
ǥ\ण CrCl < 30 mL/min w Ϋe20mg
"	vTlAЪŸA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Trospium	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	Ʀٵj˽wѤh	"1.糧~LӪ̡ATϥΡC
2.C̡C
3.]eCΤjް_Ƨê̡C
4.YŦef̡C
5.·ileus̡C"	KBfBYhC	C	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w54-02 [s]_339 [®]_339 [E]_C2-10 j	Ts110.6.16		OI` 	0	OIs 20251124	OURAC-a	OURAC-b	OURAC-c	110.6.16
AC04951209	A03BA01	0	IATRO	ATROPINE 1MG/ML/AMP		zGj˩ʯkhBxޡBޤhBj˩ʫKB]gBƩʼŤɧUkBЫǶǾɻêBggʮ}ߡB¾KeġBCξBƥPgľrBuw	"@릨Hq
ܿrPG٦סBRߩΥ֤U`gA400600mcgAC46pɤ@C
ܤ߫ߤ㾯GRߪ`gA400mcg(0.4mg)~1.0mgAݭnC12pɤ@Anɥiq̤ܳjq2.0mgC
GzDCiʩguӬۡG٦ת`gA1.0mgC
¾KeġG٦ת`gA200600mcg(0.2~0.6mg)ANe1/21pɵġC
Ѭr]Cξ^G٦שRߪ`gA1.02.0mgAC2030еĪoiA~ĪTﵽAɻ2ѩΧ[C
Ѭr]rrP^G٦שRߪ`gC1.02.0mgACpɤ@AIl͡C"	 AΦĦ]|ϤHΤεOҽkAw̻קKqƻݺ믫εOӾUu@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Atropine	A03B	"AXΨlͪ BELLADONNA AND DERIVATIVES, PLAIN"	0	zGj˩ʯkhBxޡBޤhBj˩ʫKB]gBƩʼŤɧUkBЫǶǾɻêBggʮ}ߡB¾KeġBCξBƥPgľrBuw	CB@ΤjҭPƧxBY߯ewAʫժUHγ·ʸzw̸TΡC	OҽkBKBfC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-01 [E]_G1-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	IATRO-a	IATRO-b	IATRO-c	110.6.16
	A03BB01	0	IBUSC	Escopan 20mg/ml/amp inj(Butylscopolamine		GšBQGzšBGBQGzBNjˡBDjˡBj˩ʫKBxޤjˤιBʻêBjˡC	"HP12HWC֦~
C1-2wAwCaHRߡB٦שΥ֤U`gACƦCC̤jqiWL100mgC
Ψൣ
bYרҡACHC魫0.3-0.6mgqAwCaHRߡB٦שΥ֤U`gACƦCC̤jqiWLC魫1.5mgC"	gE_ΪvʫCfw뤩xĪApEscopanA䲴i|WɡCY`gEscopanAkhBoBOॢAߧYбвvC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Butylscopolamine	A03B	"AXΨlͪ BELLADONNA AND DERIVATIVES, PLAIN"	0	GšBQGzšBGBQGzBNjˡBDjˡBj˩ʫKBxޤjˤιBʻêBjˡC	"TΩ
1. Hyoscine-N-butylbromideβ~@o͹LӤfwC
2. vʫCC
3. eCΤj񦳧dC
4. GzDʪC
5. ߸LtC
6. zgC
7. gٵLOC

H٦ת`g覡ɡAEscopan`gGTΡC"	fB߸L֡BGdC	C	|qLť/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-14 [w]_w02-14 [E]_C5-05 [Ew]_C1-07 j	Ts110.6.16		OI` 	0	OIs 20251124	IBUSC-a	IBUSC-b	IBUSC-c	110.6.16
AC501791G0	A03BA03	0	OBUWE	Spasmotin 0.125mg/tab(Hyoscyamine)		"ĥiM@ʧAQxP󯫸g`xʯgΩ󥭷Ʀ٤@ΡCӥyxʱhss󥭷Ʀ١Bߦ١BuеBЫuΥ~cAbvqUAĨä@ΩۥDgWC
HyoscyamineGzDBʩʨíCGĤc@ΡCt~Aĥ౱|BޤΤޤLפc@ΡC"	"H12HWൣ:@12AC4pɩλݭnɤ@AC餣WL12C
2~12ൣ:@1/2~1AC4pɩλݭnɤ@AC餣WL6"	UCwԷVġGۥDgew̡AҪमiBa߯fB{ʤ߰IܡB߫ߤBεŦefw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Hyoscyamine	A03B	"AXΨlͪ BELLADONNA AND DERIVATIVES, PLAIN"	0	UCewjˤιBʾमiBGšBGĤcLhBŦjˡBj˩ʵzBH֪BժjˡBWæRBǵmhBxmhBhg	CBʧgB.GzDgB·ʸzBѦ~HΰIzw̤pziOʥFBʥX大íwʤߦުABYũʵzBrʥzgֵoũʵzέgٵLOw̸TΥġC	PLxP/ܵj˾ۦAUzgiX{ּƱw̡A]AfBGdBƵB߸LtB߱Bթj'Bٳ·BıiOW[BıॢBYhBgBݺΡBzBtwBvBߡBæRBBťĴ֡BKBȮBS褧LӤBC¯lBBʥաBίvxBVéοĤδֱƦC	C	|qLť/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w34-02 []_01-26 [s]_293 [®]_293 [UDx]_U03-21 [E]_B3-29 [Ew]_EX036 j	Ts111.5.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OBUWE-a	01C50179-1	OBUWE-c	111.5.24
AB03552212	A03FA01	0	IPRIM	PROMERAN 10MG/2ML/AMP		iEWƹDBʡA[tGΤQGzƪšAçæRϡAwæRgC	"H: `g 1 ampAnɥiƵ
ൣ: 
14 HWA@q 10 mgF
6-14 ൣA@q 2.5  5 mgF
1-6 ൣA@qC魫 0.1 mg (0.1mg/kg/dose)F
1 HUA@qC魫 0.1 mg (0.1mg/kg/dose)A̦hCѤGCĳq 0.1mg/kg/doseA ̦hC 3 C̤jq@qC魫 0.2 mg(0.2mg/kg/dose)CC`qiWLC魫 0.5 mgC
٦שRߪ`gARߪ`gwCA`gɶܤ 3HWC"	"1.Rߪ`g뤩ɡA`gtwCB`gɶܤ 3 HWC
2.ĪĳϥΩww̡]|W[wo@Wvαjס^C
3.ǩΨxणw̡AĳCϥξqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Metoclopramide	A03F	GzʤO PROPULSIVES	0	wæRBfyʮƩʭDA}fް_Gzįʲ`	"1. metoclopramide ĪLLӪ̡C
2.YEzGDįʡAw̷|MI̡GҦpGzDXBʪέGzDժ̡C
3.eAκ믫wwĩ metoclopramide ɡAX{oʹBʻêw̡C
4.whæݻ̲ӭMFw̡]Eoժ̰^FofwϥΥ]AY benzamide bhiܾoYiC
5.P levodopa ΦhiPi֥Φ]䤬ܾC
6.ˤgC
7.wϥ metoclopramide X{Lܩʦg NADH-ӭM b5 ٭?ʥFfvC"	ϥΧtMetoclopramide ī~iyoʹBʻêAX{yBYΥ|ϫDۥDBʻêA㦳bifʻPYʡCoʹBʻêoͤIPϥΥ~vP`ֿnqʡABR~ϥΫAA20HfHϥζWL12gAGĳ(WL12g)ϥΥ~vADӮ׬OgLAvįqotardive dyskinesia I̡C	B	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-33 [UDx]_U01-19 [w]_w02-22 [w]_w02-27 [E]_C5-06 [Ew]_C1-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	IPRIM-a	IPRIM-b	IPRIM-c	110.6.16
AB46242151	A03FA03	0	LWEMP	Wempty suspension 1mg/ml;60ml/bot(Domper		"1. [t\᪺GƪšA]iWiNA٪iOAëPiժA٩\᪺įXi{סC
2. Domperidone@hiܾAi_D1D2A@ΩPΫḣپ~ƾ鱵E(CTZ)AGPiGzDƦ٬ʤΤR@ΡC"	"pݪAΦġAĳeκΫe15-30AΦġC
HΫC֦~]j12B魫WL35^G@3-4A@10mgC
12HUൣ12HW魫p35礧C֦~:10.25@J/,C̦h3C

"	" 1. ŴϥΡШϥγ̰ĳ?ɡAw|ƪnHťĪ domperidone `?C?WL 7ggC?MosͨO_`C]AbA domperidone ?ĳšC
2. ϥΩШu?gǰƧ@ΡCѩͲĤ@Ӥ뤺N¤Φ帣پ\|o|AoͯgǰƧ@ΪMIʸC]AĳnTaMwsͨBΨൣϥξ?AY?CL?i|ൣygǰƧ@ΡA䥦]綷ǤJ?C
3. ϥΩx\?`w̡Хѩ domperidone DnѨxŦN¡AxŦlfHϥ domperidone pߡCpGx?ơAX{nH ASP]GOT^BALT]GPT^B^-GTP ȤWɡARi?[AҼ{ĨðABmC
4. ϥΩǥ\?`w̡Yǥ\?(夤ٻ> 6mg/100ml,Y>0.6m mol/l)Adomperidone ưbI 7.4 pɴ 20.8 pɡA夤Ī@?dժ̧CCѩgѵŦƪn쫬ķ֡Aǥ\?w̩|?ݽվ榸ʧP?CMӡAеĮŦlY{?NAĦ??CCѤ@ܤGA?u??CC?fH?v?wˬdC 5. AΫeХáC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Domperidone	A03F	GzʤO PROPULSIVES	0	"ߡBæRgvA}fް_Gzįʲ`C

"	"UCθTϥdomperidoneG
1.wdomperidoneΥ~䥦@ؽξLӪ̡C
2.w|XcſEU~F(prolactinoma)fHC 3.֥ketoconazolefAī~C
4.EGįʥiyMIɡATϥdomperidoneApX{zGDXBʪάաC"	Ĥ}ܤ֡AfBfBȮɩʥ֯lηkoBYhBzGABmBݺεCucſE@פɰBkʤkůgC	"SmҦw
DnAקKϥΡC"	MO_sͨ঳`C]AbϥDomperidoneĳ˦ۭšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668235?cesid=1cGTy27Dok5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDomperidone%26t%3Dname%26acs%3Dfalse%26acq%3DDomperidone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_07-02 [E]_J2-08 j	Ts114.3.12		OI` 	0	OIs 20251124	LWEMP-a	LWEMP-b	LWEMP-c	114.3.12
AC476561G0	A03FA09	0	OMOSA	Mopride 5mg/tab(Mosapride citrate)		ĬOܩʪserotonin 5-HT4PiA|EsbƹDgO5-HT4AǥѼW[AcetylcholineA]ܥXPiƹDįʤέGƥX@εC	@릨H@15mgAT󶺫eζfAϥΡC	ī~PŦ`Ī֥ή`Nʴ߹qϡAp߫ߤ㤧εoͮɡA֨ϥξqΰġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mosapride citrate	A03F	GzʤO PROPULSIVES	0	ƾxįʾಧ`ް_AgA]Aߺۨ`BߡBæR	"1.惡o͹LӪw
2.zGXw "	DnƧ@άUgBnK(1.8H)Bf(0.5H)B«P(0.3H)C	B	¨űwקKϥ;YnϥΥ~ĳ¨	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w38-03 []_01-16 [s]_219 [®]_219 [UDx]_U03-29 [E]_B4-12 [Ew]_EX044 j	Ts110.6.16		OI` 	0	OIs 20251124	OMOSA-a	OMOSA-b	OMOSA-c	110.6.16
AB339471G0	A03FA03	0	OMOTI	Emetrol 10mg/tab(Domperidone)		"1. [t\᪺GƪšA]iWiNA٪iOAëPiժA٩\᪺įXi{סC
2. Domperidone@hiܾAi_D1D2A@ΩPΫḣپ~ƾ鱵E(CTZ)AGPiGzDƦ٬ʤΤR@ΡC"	"(1)HG
C3AC10 mg (̤jqG30 mg/day)C
(2)ൣG
[<12A<35kg] C3AC0.25 mg/kgF
[>12A>35kg] C3AC10 mg (̤jqG30 mg/day)C"	"1. ǥ\l̡GYǥ\l̡AdomperidoneưbIiੵChĮɡA䵹W̵ǥ\l{״֦ܨC12AiݭCľqC
 2.Ŧާ@ΡG
(1)DomperidonewQҹP߹qQTjpCWg礤AAdomperidonefHּƮרҵoQTtorsades de pointesCoǭӮצPɦLMI]lBqѽ貧`Ψ֥ΨLvAiW[}oͪIC
(2)yfǬsܡAdomperidonePY߫Ǥ߫ߤάoʤߦ]ʦ`IW[pC䤤~֤j60BC龯qWL30mgHΥbAη|QTī~CYP3A4fHAQo{IC
(3)󦨤HΫĵAdomperidoneϥγ̧CľqvCTҥΩwŦǾɰDASOOQTcA۹qѽ貧`]C[B[BC^AΤ߷i}wAΦŦefAp{ʤ߰Iܪ̡Ai|W[߫Ǥ߫ߤ㪺IC
(4)qѽ貧`]C[B[BC^Τ߷i}wAw|W[߫ߤ㤧ICpX{߫ߤ㤧xίgAϥdomperidoneAæVBvԸߡCHifHpX{ŦAgߧYC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Domperidone	A03F	GzʤO PROPULSIVES	0	ߡBæRgvA}fް_Gzįʲ`	"1. צYx\ê̡C 
2. wsbŦǾɶjASOOQTcA۹qѽ貧`έ즳Ŧef]p{ʤ߰Iܡ^̡C
3. ֥Υiް_QTī~C
4. ֥αjOCYP3A4]ެO_QT@Ρ^C"	fBfBȮɩʥ֯lηkoBYhBzGABmBݺεCucſE@פɰBkʤkůgC	"SmҦw
DnAקKϥΡC"	MO_sͨ঳`C]AbϥDomperidoneĳ˦ۭšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w27-06 []_01-12 [s]_114 [®]_114 [UDx]_U02-42 [E]_B2-28 [Ew]_EX031 j	Ts110.6.16		OI` 	0	OIs 20251124	OMOTI-a	OMOTI-b	OMOTI-c	110.6.16
AC02101100	A03FA01	0	OPRIM	Perone S.C 5mg/tab		iEWƹDBʡA[tGΤQGzƪšAçæRϡAwæRgC	q`H110~30mgA2-3󶺫eAΡAi̦~֡BgAyWC	AĴݺΡBwt{H	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Metoclopramide	A03F	GzʤO PROPULSIVES	0	wæRBfyʮƩʭDA}fް_Gzįʲ`	æݻ̲ӭMFw̸TΥ~]ް_ؤWɤ^C	@~gԸsBhBYhBwtC	B	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-03 []_01-24 [s]_255 [®]_255 [E]_A3-07 [Ew]_Z-07w9 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	OI` 7.1.	0	OIs 20251124	OPRIM-a	01C02101-1	OPRIM-c	110.6.16
BC25522261	A04AD12	0	IEMEN1	Emend I.V. 150mg/vial(Aprepitant)		Fosaprepitant aprepitant eXġA]R@ΫYk]aprepitant @ΡCAprepitant 㦳WS@μҦFHsubstance P neurokinin 1 (NK1)A㦳ܩʻP׿˦XOܾC	EMEND IV 150 mg b1 ѤƾǪvie30 AH20-30 R߿`覡ϥΡC	EMEND IV iP pimozide Bterfenadine Bastemizole  cisapride PɨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aprepitant	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	PLRľ֥ΡAiHѰPRʤΤPRʤĪb즸έƨϥήɩҤް_ʩΩ߻PæRC	"1. EMENDiΩ惡~|LӪfHC
2. EMENDiPpimozideBterfenadineBastemizolecisapridePɨϥΡCAprepitantcytochrome P450 isoenzyme 3A4(CYP3A4)@ΡA|ɭPoĪ夤@פɰAi|޵oYΦMΥͩRC"	СBzLO«BxALTɰBKBYhMC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.2._20130801_000.pdf"">OI` 7.2.2.</a>              "	OI` 7.2.2.	0	OIs 20251124	IEMEN1-a	IEMEN1-b	IEMEN1-c	111.8.19
BC27233100	A04AA55	0	OAKYN	Akynzeo Ƥ(Netupitant 300mg +Palonos		AKYNZEOAΩw_lΤgƾk]ȭ󰪭PRʤƾk^ް_ʤΩߩMæRCAKYNZEOO@اtpalonosetronPnetupitantfATwƤĪApalonosetroniwgƾk᪺ʴ߻PæRAnetupitantiwʴP߻PæRC	"PRʤƾkA]AtCisplatinƾkG
HĳqbĤ@ѤƾǪvgie1pɵ@AKYNZEOnAévie30fA뤩dexamethasone 12mgAb2Ѧܲ4ѨCfA@8mg dexamethasoneC"	ϥ5HT3ܾoͦMgԸs]Serotonin Syndrome^iAjhƪiP֥ΦM@ξC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Netupitant/Palonosetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	AKYNZEOAΩw_lΤgƾk]ȭ󰪭PRʤƾk^ް_ʤΩߩMæRC	-------	Ƥ}BhΡBKBYhC	C	Ҽ{Ī˪nʮɡAݨMwũΰA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.3._20250801.pdf"">OI` 7.2.3.</a>              "	OI` 7.2.3.	0	OIs 20251124	OAKYN-a	OAKYN	02C27233-2	110.6.16
AC60319221	A04AA05	0	IALOX1	Stothu (Palonosetron 0.25mg/5ml/vial)		㰪׿˦Xʪ5-HT3ܾA5-HT3bϤƾǱP(CTZ)ߤΰggWCƾkĪ|PϤpzzݻ̩ʲӭMMAXӪM۬ƦbggǤJg5-HT3AҰʹæRϮgAӳyߤιæRC	"HGb}lƾǪv30eARߪ`gWL30A뤩@q0.25@JC
ൣΫC֦~Gb}lƾǪv30e뤩@q20ug/kg(̦h1500ug)AR߿`ɶݶWL15C"	wQiMgԸsIASOO~PLM@Ī֥ή C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUץxs	Palonosetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS		wƾkް_ߩMæR	ҥΩw惡ĪΨ󦨤LӪfw	YhBKBmBwt	B	PalosetronO_|sbťĤAĳšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-26 j	Ts111.8.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	OI` 7.2.1.	0	OIs 20251124	ISTOT-a	ISTOT-b	ISTOT-c	111.8.25
BC23985100	A04AD12	0	OEMEN	Emend 80mg/cap(Aprepitant)		"1. Aprepitant㦳WS@μҦAHsubstance P neurokinin1(NK1)A㦳ܩʻP׿˦XOܾC
2. AprepitantiHziJAæڸNK1C{ɫesܡAaprepitant襤ϨtΪ@ήɶܪAiHcisplatinް_ʴPæRAåiWjR@Ϊ5-HT3-ܾondansetronPֽTJdexamethasonecisplatinҤް_æR@ΡC"	"1. EMENDoĥΤTѵĪ覡A֤J]A@إֽTJM@5-HT3ܾv{@_ϥΡC
2. EMENDĳqĤ@ѦbƾǪvie@pɤfA125mgAbĤGѩMĤTѦCѪAΤ@80mgC"	ϥEMENDɥi୰CfAץĪ\ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aprepitant	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	PLRľ֥ΡAiHѷް_æRgĪ(]AqCISPLATIN)b즸έШϥήɩҤް_ʩΩ߻PæRC	"1. EMENDiΩ惡~|LӪfHC
2. EMENDiPpimozideBterfenadineBastemizolecisapridePɨϥΡCAprepitantcytochrome P450 isoenzyme 3A4(CYP3A4)@ΡA|ɭPoĪ夤@פɰAi|޵oYΦMΥͩRC"	СBzLO«BxALTɰBKBYhMC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668672?cesid=7YFxReCGEzV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAprepitant%26t%3Dname%26acs%3Dfalse%26acq%3DAprepitant#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.2._20130801_000.pdf"">OI` 7.2.2.</a>              "	OI` 7.2.2.	0	OIs 20251124	OEMEN-a	OEMEN-b	02-2	111.8.19
BC23986100	A04AD12	0	OEMEN1	Emend 125mg/cap(Aprepitant)		"1. Aprepitant㦳WS@μҦAHsubstance P neurokinin1(NK1)A㦳ܩʻP׿˦XOܾC
2. AprepitantiHziJAæڸNK1C{ɫesܡAaprepitant襤ϨtΪ@ήɶܪAiHcisplatinް_ʴPæRAåiWjR@Ϊ5-HT3-ܾondansetronPֽTJdexamethasonecisplatinҤް_æR@ΡC"	"1. EMENDoĥΤTѵĪ覡A֤J]A@إֽTJM@5-HT3ܾv{@_ϥΡC
2. EMENDĳqĤ@ѦbƾǪvie@pɤfA125mgAbĤGѩMĤTѦCѪAΤ@80mgC"	ϥEMENDɥi୰CfAץĪ\ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aprepitant	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	PLRľ֥ΡAiHѷް_æRgĪ(]AqCISPLATIN)b즸έШϥήɩҤް_ʩΩ߻PæRC	"1. EMENDiΩ惡~|LӪfHC
2. EMENDiPpimozideBterfenadineBastemizolecisapridePɨϥΡCAprepitantcytochrome P450 isoenzyme 3A4(CYP3A4)@ΡA|ɭPoĪ夤@פɰAi|޵oYΦMΥͩRC"	̱`PĪ}]AGСBzLO«BxALTɰBKBYhMC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668672?cesid=7YFxReCGEzV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAprepitant%26t%3Dname%26acs%3Dfalse%26acq%3DAprepitant#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.2._20130801_000.pdf"">OI` 7.2.2.</a>              "	OI` 7.2.2.	0	OIs 20251124	OEMEN1-a	OEMEN1-b	02-2	111.8.19
AC48809209	A04AA02	0	IGRAN1	Kytron 1mg/ml/amp(Granisetron)		wΪvܸ~Fƾkް_ߡBæRΪvܸ~Fgukް_ߡBæRCwʤΥbʧܸ~Fgukް_ߡBæRCvNް_ߡBæR	"H
w:Grenisetron@q13J(10~40?g/kg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}20~50ml`GHR߿`覡`ɶݤj󤭤C
v:Grenisetron@q13J(10~40?g/kg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}20?50ml`GHR߿`覡`ɶݤj󤭤CYl[vqPe@qjܤ֤QHW~iAGrenisetron̰q24pɤWL9mgC
ൣ
w:Grenisetron@q魫C10~40?g/kg(̦h3mg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}10?30ml`GHR߿`覡`ɶݤj󤭤CYݭn24pɥHi@l[qAl[qP_lqj10HW~iC
"	1.KytriliVXLī~ϥΡC 2.wʧPb}lƾkeγ¾KieC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Granisetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	wΪvܸ~Fƾkް_ߡBæRΪvܸ~Fgukް_ߡBæRCwʤΥbʧܸ~Fgukް_ߡBæRCvNް_ߡBæR	惡ΨL selective 5-HT3 antagonists o͹LӪw	LYhBCzįʡC	B	MO_sͨ঳`C]bϥΥ~vQqjधbMIɤ~iϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	OI` 7.2.1.	0	OIs 20251124	IGRAN1-a	IGRAN1-b	IGRAN1-c	110.6.16
BC21236219	A04AA01	0	IZOFR	ZOFRAN 8mg/4ml/Amp(2mg/ml)		"Ondansetron O@ĤOBܩʪ 5-HT3 ܾA䱱ߡBæRT@ΤCƾkvΩgukiް_pzX 5HTAg 5HT3 鬡ưggAӤ޵oæRϮgCOndansetron i_@Ϯg@Ϊo͡Cggƫ]iް_ĥ|ǩḣ 5HTAgѤϾӫPϵo͹æRC]AondansetronӭMrʤƾkΩgukҤް_ߤιæR@ΧYiY]諒ΤϯgtΤgW5HT3 㦳ܧ@ΩҭPCثeNް_ߡBæR@ξऴAOܥiMӭMrʤް_ߡBæR@ξOۦP@γ~|CgѯgBʴҹ ondansetron |l`g`A]|ް_R@ΡC
"	"@B
HG
1.wPRʤƾǪvҤް_ߤιæRG
ZOFRANHfAĳq24 mgAYi}鰪PRʤƾǪv]]tq ? 50 mg/m2cisplatin^30eA뤩 3  8 mg ĿCLhwhB榸뤩 24 mg qisC
2.wPRʤƾǪvҤް_ߤιæRG
HfAĳq@ѵ⦸BCU@8 mgZOFRANĿC1i}PRʤƾǪv30e뤩AA 1  8 pɫᵹ 2 CƾǪvACѨ⦸]C 12 pɤ@^BC@ 8 mg  ZOFRAN ĿA뤩 1  2 ѡC
3.wgv]gvAι︡i檺榸qgvΨCgv^Ҥް_ߤιæRG
fAĳq@ѤTBC@ 8 mg ZOFRAN ĿC
4.wgvACѬICөgvO]fraction^ 1  2 pɫeA뤩@ 8 mg ZOFRAN ĿC
5.w︡i檺榸qgvAgv 1  2 pɫe뤩@ 8 mg ZOFRAN ĿABbĤ@C8 pɧ뤩@Agv᪺ 1  2 ѬC
6.w︡i檺CgvAgv 1  2 pɫe뤩@ 8 mg ZOFRAN ĿABbĤ@C8 pɧ뤩@ ( bIgvC@ )C
ĵPC֦~ (6 Ӥj 17 ^G
1.ƾkҭPߤιæR :
Ω󱱨ƾkҭPߤιæRqi̾n]body surface areaA² BSA^魫pCbwൣi檺{ɬsAZOFRAN YH 25  50 ml ͲzQΨLۮe`G}AHR߿`覡ġA`ɶiu 15 C
n
ZOFRAN YNieRߪ`g澯 5 @J /m2ARߪ`gqiWL 8 @JCfAĥi 12 pɫ}l
iA̦hi 5 ѡCiWLHqC
Ѧ~fHG
Ω 65 HWѦ~HA@ʨ}nA]ݧܾqBĦƩΧP~|C
x\l`̡G
󤤫שέרx\l`̡AMv|㭰CAӥBMbI|㩵AofHCRߪ`gΤfAqiWL 8 mgC
 (Sparteine)/Debrisoquine N¤}fHG
k debrisoquine N¤}fHϥήɡAondansetron MbI|ܡC]AofHƥĮɩҲͪĪSqAP@ڸsõLtCݭnܨC龯qεWvC
GBNް_ߡBæR (PONV)
HG
1.wNᤧߡBæRAb¾Ke 1 pɧPfA 16 mgA]iH 4 mg @qwCRߪ`gΩ¾KɴC
2.woͪNް_ߡBæRAĳΪ`g뤩覡vC
ĵPC֦~ (1 Ӥj 17 ^G
1.ثe|LwpİwΪvNް_ߡBæRBϥΤfAĤ{ɸCĳϥνwCRߪ`g뤩 ( ɶ֩ 30  )C
Ѧ~fHG
1.Ω 65 Ѧ~HA@ʨ}nA]ݧܾqBĦƩΧP~|C
2.x\l`̡G
󤤫שέרx\l`̡AMv|㭰CAӥBMbI|㩵AofHCRߪ`gΤfAqiWL 8 mgC
3. (Sparteine)/Debrisoquine N¤}fHG
k debrisoquine N¤}fHϥήɡAondansetron MbI|ܡC]AofHƥĮɩҲͪĪSqAP@ڸsõLtCݭnܨC龯qεWvC"	"1.Lܩ 5HT3 骺ܾ|LӪfH惡Ĥ]|X{LӤC
2.קKbѩ QT gԸsfHϥΥ~C
3.ϥ ondansetron ԷVABʴ߹qϡC
4.fHQʴO_oͦMgԸsASOO֥ Zofran ΨLM@ĪɡCYoͦMgsgAߧYĨõʪvCfHQiMgԸsIASOO Zofran PLM@Ī֥ήɡC
5.w|W[jzeɶAfHbϥĪʱO_X{ȫʸz몺xHC
6.bϥ ondansetron eAȥBC[gPCgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ondansetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	ӭMrʤƾkΩgukҭPߤιæRAHΤNް_ߡBæRC	"1. ondansetron P apomorphine hydrochloride֥ήɡAX{YCΥhNѪiA~TPapomorphineX֨ϥΡC
2.s󦨤LӪ̸T"	̱`Ƨ@άONҳyeBN쪺ˤfDBߤ/ιæRBQ/RBJ{/믫EʡBMYhC	B	MO_sͨ঳`C]AbϥΥ~ĳ˦ۭšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	OI` 7.2.1.	0	OIs 20251124	IZOFR-a	IZOFR-b	IZOFR-c	110.6.16
AC55953100	A04AA02	0	OSETR	Setron F.C. 1mg/tab (Granisetron)		"5-HT3MggݤΫ|nϰ쪺ƾǱPϤߡCbƾkް_æRAHz˻̲ӭM񪺦MA|E5-HT3Co|EggǾA]AæRC
Granisetron HClOĤRΰܩʫ5-HT3CѩgʰtX鵲XsGranisetron HClLA]A5-HTΦhiD2Xm˩MOOiC"	"ܸ~Fƾ?kް_ߤιæR
H
wGƾkvA1@J@ѤG2@J@Ѥ@CĤ@Ļݦbve@pɤC

ܸ~Fgukް_ߤιæR
H
fA:Hܸۧ~FgukA@A2@JA@Ѥ@A̦hܤ@gCGranisetron HClĤ@ľqܸ~Fguk}le@pɤC"	Granisetron HCli|CzįʩʡAGȫʸzgfwAϥGranisetron HClYKʴC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Granisetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	wΪvܸ~FƾkPܸ~Fgukް_ߡBæRC	~TΩGranisetron HClSetronξLӪfwC	YhBKC	B	MO_sͨ঳`C]bϥΥ~vQqjधbMIɤ~iϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-02 [E]_B3-28 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	OI` 7.2.1.	0	OIs 20251124	OSETR-a	OSETR-b	OSETR-c	110.6.16
AC37720100	A05AA02	0	OURSO2	Ursolic 100mg/tab(Ursodeoxy-cholicacid)		~i㦳Qx@ΡAxƪnPi@ΡAVit B1AB2lP୤ƫPi@ΡAVit CbŦJüW[@ΡAxʪ]Glycogen^ͦW[@ΡAPiƻïPƲGcAt㦳xyW[@ΡAתդlPi@ΡAxĤChloesterolM@ΡC	HCѾq13-15mg/kgA|AΡC	AĴw^E;Yoͦ姿οBBƧxЦ^EN	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ursodeoxycholic acid	A05A	xfv BILE THERAPY	0	"xTJtxۤѡBoxDxwơ]primary biliary cirrhosis, PBC^x\ﵽ"	Ursodeoxycholic acidLӪ̸T	GA..æR.nK.ol	B	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-08 [s]_348 [®]_348 [E]_A4-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.1._20250601.pdf"">OI` 3.3.1.</a>              "	OI` 3.3.1.	0	OIs 20251124	OURSO2-a	OURSO2-b	OURSO2-c	110.6.16
AC419521G0	A05BA03	0	OSILY	"Bao-gan capsules 150mg ""Chen Ta""(Silymar"		~iíwxӭMA_lxӭMAϥѭBfrBĪrʪl`xӭM_d`xC	HC1~2ɤ@ѤTA̯gyuqWC	"3.3.1.x@G(85/1/1B88/3/1B94/7/1B108/11/1)
1.xwơBxw̡AUCΤ@̡Aov̨x\MvˬdίfzˬdTE_AfݭnB褧C(94/7/1)
(1)HBV (+) HCV (+) fwBGOTBGPTȤj(ε)`ȤW1HWC
(2)]Ҥް_xwƥBGOTBGPTȤj(ε)`ȤW1HWC
(3)HBV (-) HCV (-) fwAGOTBGPTȤj(ε)`ȤW2HWC
2.x@ϥΡAEHfA@جhFϥΩ󰪦g(hyperammonemia) x@˪򤧲`iC
3.ϥΨx@˪x\iAӳiĴTܤӤAOAƬdC(108/11/1)
4.x\ˬdpˬdG`AġAbˬdoGeAҥĪH@gyC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Silymarin	A05B	"xfv LIVER THERAPY, LIPOTROPICS"	0	CʨxfBxwܡBίתըxġC	L	L	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I5 [2]_I5 [ws]_w42-01 [s]_45 [®]_45 [UDx]_U03-63 [E]_B5-25 [Ew]_EX052 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.1._20250601.pdf"">OI` 3.3.1.</a>              "	OI` 3.3.1.	0	OIs 20251124	OSILY-c	OSILY-e	01C41952-2	110.6.16
		0	OBOWK1	Bowklean  powderƤMz		"Picosulfate sodium gѸzDӵߤѧΦʥNªG
bis-(p-hydroxy-phenyl)-pyridyl-2-methane( BHPM)ABHPM|@ΩjzHèEjzįʡC
Pfcķ|bGӧΦfcAfc⬰zľAPϤdGzDC"	C]H`ŧN150@ɪwsAͩզܤ5 Cjzˬde@ѱߤWAΡAAīΫeɥR250@ɼMy趼~ܤ5Ab5pɤܧCijzˬde5pɥkAβĤGAAīɥR250@ɼMy趼~ܤ3Abjzˬd2pɫeܧC	"i]A, HK`˭D"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Picosulfate sodium/Magnesium oxide/Citric acid anhydrous	A06A	m DRUGS FOR CONSTIPATION	0	HjzˬdeMz	ǥ\YUw̡]Clcr< 30 mL/min^BGzDθzBzաBrʤjzΤrʥzgBGd(Gastric retention)	ߡBYhBæRBYwPh/h	B	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H2 [2]_H2 [ws]_w70-01 [E]_C3-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OBOWK1-a	OBOWK1-b	OBOWK1-c	110.6.16
		0	OGIKP1	"GI Klean Powder?
(Sodium bicarbonate 1.685 g
Potassium chloride 0.7425g
Sodium chloride 1.465g
Sodium sulfate anhydrous 5.685g
Polyethylene glycol 3350 59g )
/iBͧަq"		?εzjlqѽGiMzAҥHī~XG?ˮ`zGDH]?|y餺qѽP?P?šC]A?ī~󦳺CʵŦfA߰IܡAxwƵ?AXlj?ΨLe?yqѽ?ŪCʯeffHAOAX@زMz	tsGHfA뤩Cīe2pɤniAˬdΤNG1.ˬdΤNe@ѳıߤ@AΡGC]H1000 mLN}wsGAͩզܯѡCܱƥXGMΪA΢]qAݦb4-6pɤAΧC2.⦸AΡGC]UH1000 mLN}wsGA2](2)ˬdΤNe@ѳıߪAΡAѾl]ˬdΤNѦAΡDĳ̫@MGܤ֦biˬde@pɳܧAHTOƲb.	"(1)pGzGDBšBzBzgAΥbšBwghAаȥiDvC(2)pGŦefBŦIܡBλݭnulAаȥivC
(1)ĶvBϥΡC(2)ϥΫApGX{zXμ@PhAаġAçivC(3)AβMzˬdeoqɶAкɥihܤAHֲ{HC(4)hƫKeyzΪAAĳbƫKΤR~zAnνåͯC(5)ϥθzb3]3]HWAbA2ӤpɫApGSƫKAмȰϥΡAƫKA~ϥΡC
ϥΫeΪvᶷ`Nqѽ説AD
PLfAĩܤ1pɪAΡD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	(1)25JUAJsC(2)tsGNåB24pɤϥΧC(3)ѾlΤΤGݥC	"Polyethylene Glycol 3350 59g
Sodium Sulfate Anhydrous 5.6850 g
Sodium Bicarbonate 1.6850 g
Sodium Chloride 1.4650 g
Potassium Chloride 0.7425 g"	A06A	m DRUGS FOR CONSTIPATION	0	zDˬdBNebzC	"糧ĦνξL
RʤŦI(NYHA Grade IIIAIV)
YŦ\ण
GzDBաBzBGdBʭGzŵC
魫C20kg"	ߡFȡBhBæRBzEP]֨^	DnקKϥ/SmҦw	DnקKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.11		OI` 	0	OIs 20251124	DC	DC	DC	114.04.11
		0	LCAST	Castor oil 30ml/bot (Oleum ricini)		"~AΫ26pɤġA]EpzAӧemġC~FpzɡAPpzPʤ
G_@ΡAɳªoӴɳªoġAE@ΡAӼW[pzįʡAPɥ~禳
ƸzġATKJjzA~bjzKįʡAêlAϱƪnn
KC~Ω`߫KArCYeXzE_eΤC"	".H12HWG@1560mlBYONMzݦbNe16pɨϥ
2HW12G@515mlF@@C
2HUGЬvEvAyۦϥΡC
AΤkGĳŸϥΡAftq}CYıfPΡAi֪AGĩκһĶơC"	"1 YΫeϥΡAwdƫKɶC
2.. isϥΤ@gHWC
3. ʸzB B TΡC
4. ~קKPDroperidolBLevomethadylBLicorice åΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Oleum ricini	A06A	m DRUGS FOR CONSTIPATION	0	ȮɽwѫK	糧~LӪ̽ФŨϥΡC	"1. ioͤWhBߡBæRƧ@ΡC
2. @ΩpzAȮɪêpzƧlAӼvTiAAyקKsϥΡC"	C	 ĥΩ¨Űwʩ|TߡA]¨ŰbϥΤeAyvŪvnʤlPC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-44 [E]_I4-03 j	Ts110.6.16		OI` 	0	OIs 20251124	LCAST-d	LCAST-b	LCAST-c	110.6.16
		0	LFLEE1	SlipFeel oral saline laxative 45ml/~(		wm	"1.wm
H:24pɳ̤jq45ml
10~11:24pɳ̤jq15ml
5~9:24pɳ̤jq7.5ml
2.{ǫeMz:
H12HW:ϥΨ⦸30-45ml⦸j10~12p
12HUp:ثeL"	"1.uΨLpwԸ߹Lviϥ
2.ϥΥ~ЦhɥR"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"monobasic souidm phosphate,dilbasc souidm phosphat"	A06A	m DRUGS FOR CONSTIPATION	0	wѰoʫKA{ǫeMz	5HUĵ	qѽ襢šBCQǯfBlBko	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.23		OI` 	0	OIs 20251124	DC	DC	DC	114.06.23
A034255356	A06AD17	0	EFLEE	EVAC ENEMA		~t(Monosodium Phosphate)(Disodium Phosphate)Awm@ΡAiHæwb215MjzeA|ް_hεjˡAϤƥX~AAΩKwѡAjzˬdezDeƪšANewUC	HCl~A212ൣbqϥΡAϥήɽзũMýwCaNzݶJzAýwCaVeܨz~fAMAHNĲG۲~VeAĲGJC	wǥ\णBŦfA餺qѽ褣šAΥbACalcium Channel BlockersBQAݤpߨϥΥC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Disodium phosphate and Monosodium phosphate	A06A	m DRUGS FOR CONSTIPATION	0	KwѡAjzˬdezDeƪšANewU	"1.wѩʥzgBLzgBRʤŦfiϥΥC
2.ĳϥΩⷳHUൣC"	g`ϥΥi|yߺD̿C	C	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U07-01 [E]_J3-05 j	Ts110.6.16		OI` 	0	OIs 20251124	EFLEE-a	EFLEE-b	EFLEE-c	110.6.16
		0	EGLYB	ATOMIC ENEMA (GLYCERIN BALL)		ƶuOMqѽ誺ӷC uOӭM~GDnlAOӭM~GDnlC utqq`MwӭM~GnAåBbzAPũMӭMq쪺ո`ܭn	"1.HGC1~20 mLAYĪGɥiA`J1~A@ѳ̦hiϥ2~AϥήɽзũMýwCaNzݶJzAýwCaVeܨz~fAMAHNĲG۲~VeAĲGJC
2.ൣG[3-6] C1/2~10 mLF[>6] C1~20 mLC"	~λsAФŧ]AAĳsϥζWL1g	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium Chloride	A06A	m DRUGS FOR CONSTIPATION	0	wѫK	(1) 糧~LӪ̡ATϥΡC(2) GzDBhBæRBߪ̡C	mBh	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-46 [UDx]_U07-02 [E]_I2-07 j	Ts110.6.16		OI` 	0	OIs 20251124	EGLYB-a	EGLYB-b	EGLYB-c	110.6.16
AB39701151	A06AD11	0	LLACT1	Lactul syrup 60ml/~		"Lactulose bUbzDQѦġCoǦľɭPzDP( pH )CABzLd@ΡATKnW[Coǧ@ΨEzįʡAèTKwץ`ơA_z`Ͳz`ߤθѰKCtxf(PSE, portal systemic encephalopathy) ΨxgeA@άOӦ۩ǥѼW[ݻĩʲӵ (pݨŻıLactobacillus) ӧJսѲӵߡAHlAAHzDCPפκz@ΡAMýո`ӵߩʴ᪺N¡C"	"1. KG쾯qpUGHw15ml CGA510ൣ 15ml C2A5HUൣ 5ml C2Aw2.5mlCGC
2. xʸfܡ]tfܡ^AxgΪvC쾯q30ml50mlCTAqվ㬰ϱw̨C馳23nKC
"	"1. w}fh¨ŪfHAAΥ~ypߡC
2. FC夤@סA~iϯfH@ѱƫK2~3C
3. YfHsmέGzAWL2ӬPAϥΥ~yԷVC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lactulose	A06A	m DRUGS FOR CONSTIPATION	0	wfCʫKBtxfܡBxgeBxg	 AzA]hɤiAΡBt~AεLgalactosefH礣iΡAbſ}gC	AΤjqɥio͸hAߡAUmAC	B	"SmҦw
ϥLactuloseiyCuβg"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G5 [2]_G5 [ws]_w73-04 [UDx]_U01-45 [E]_I1-04 j	Ts110.6.16		OI` 	0	OIs 20251124	LLACT1-a	LLACT1-b	LLACT1-c	110.6.16
AC323721G0	A06AB20	0	OCONS	Conslife Ƥwm		1.Dioctyl Sodium Sulfosuccinate@ؤʾA@ίݪzʯAϺdjzwTo쨬zȳnơA۵MQƥX2.Sennosidegzӵߧ@ΫͦN²Rhein anthroneAEzӫPijzįʡA~㦳ƫKBwU@ΡC]䵲zħ@ΨM@ʡA|vTWqGzD`įʡC3.Bisacodyl@رĲʽwUgѺIzHg餧Ϯg@ΦӲͮĪG	q`H@㢲A@Ѥ@ΫeAΡC즸ϥγֶ̤qAb@qKpWqC	קKϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dioctyl 20mg+Bisacodyl 2mg+Sennoside 10mg0	A06A	m DRUGS FOR CONSTIPATION	0	KνwMKҦͤUCѯgG꺡Bz`oáB	ʸgw̡Bj˩ʫK@w̡Bg``w̨zЩμũʵi֤w	h߹æR	"SmҦw
DnAקKϥΡC
קKjqϥ"	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w23-03 [s]_49 [UDx]_U02-28 [E]_B2-11 j	Ts110.6.16		OI` 	0	OIs 20251124	OCONS-a	OCONS-b	01C32372-2	110.6.16
NC00261100	A06AB02	0	ODULC	Johnlax 5mg/tab(Bisacodyl)		Bisacodyl@ĲmA]㦳ܤlɤ@ΡCdulcolaxbjzѫAEzįʡAëPiPqѽ躢d󵲸zĤA]ӾɭPEƫKAYuƫKɶAèTKnơC	"H10HWൣ:1-2(5-10mg)
4-10ൣ:1(5mg)
4HUൣ:ĳϥ1/2꾯(5mg)
ĳbߤWAθzAݱYiƫKABPAqG]AC
ΩE_L{ΤNeǳơG
H:ĳqbˬde]ΫeA2-4z}AˬdѦAϥΤ@Ӯ꾯C
44HWൣ:ĳbߤWAΤ@z}AݱAϥΥbӮ꾯C"	"1. ݾɧ]AiruCľpSod bicarbonateMLPʪ赥]iѿ}AGiPɪAΡC
2. khɪAĪwʩ|TߡA]󥥰Υi঳h̡AYP_vWqөMIʮɡAlokġC
3. ]olcYӦyBMIʡAҥHΥiwhkAojqġC
4. wmvYzXAYhAθz\MܮɡAnWqvC
5. SԸvpUAnϥνwmWL12gAӥBnקK~LĮɡAզۼW[qA|oͽwm̿ʩιqѽ褣šC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Bisacodyl	A06A	m DRUGS FOR CONSTIPATION	0	"~AΫ26pɤġA]EpzAӧemġC~FpzɡAPpzPʤ
G_@ΡAɳªoӴɳªoġAE@ΡAӼW[pzįʡAPɥ~禳
ƸzġATKJjzA~bjzKįʡAêlAϱƪnn
KC~Ω`߫KArCYeXzE_eΤC"	"TΩ󦳸zȡBpzP檬p]AzBʵoʸzgAΦHߡBæRYhC

TΩYfHAΤwbisacodylβ~@LӪ̡C"	i|o͸AA]AzhPh(iHߤ/ιæR)Co͸mC	B	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w20-05 [s]_173 [®]_173 [UDx]_U02-14 [E]_B1-28 j	Ts110.6.16		OI` 	0	OIs 20251124	ODULC-a	ODULC-b	ODULC-c	110.6.16
AC60991123	A06AC01	0	OKONS	Kocel 6gm/pk(Psyllium)		~O@ئĪBLEʪ¤ѵMֺAiUƫK`C]KonsyliΧ@nKC¤ѵMKonsylC@qutq֩4@JABK[LvĪCKonsylOPlantogo ovataبel~߰׺sӦAbWQ{㦳ո`ƫK`\C	"1. HGC@p]ACѪA1-3AeBκΫeBΥvܨϥΡC
2. 6kHq@bΥvܪAΡC"	".ϥΤkG(1). @p]6J@M8oz]240cc^G餤]GġB״Τ^ANGiUVXC(2). VXAHGľBʤf~νզXϧýզXC(3). VXߨܤUAðl[@MN}W[ĮġC
.Normacol plusPī~Ũ֥
3. mϥΡA@ƫK`AYġCDvĮvľͫܡAosϥΤ@PHWA
qHtֺARιBʨӧﵽKC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Psyllium	A06A	m DRUGS FOR CONSTIPATION	0	nK	"1. DvĮv ͫܡA o֥ΨLm C(~ରѵMֺAgȨEƫKA̫K]վϥΡ^
2. DvĮvľͫܡAg]Īް_Lӯg̤oϥΡC
3. AsϥδAYߡBæRBYhεolLӯgɡAϥΨýбvĮvľ͡C
4. YKΦ۵oʸzDX媬pAߧYĴNC
5. ϥΤ@PLĪ̡AߧYĴNC
6. ϥδ|mo͡AYm򤣤Υ[@pUAϥΨýбvĮvľ͡C
7. DvĮvľͫܡA 3 णoϥΡC
8. TΩGzDBhBæRBߡBzDšBUHw̡C
9.  12 pɦܤTѤ~|oͧ@ΡC
10. AΩ󶷭w̡C
11. ϥήɶ̫ܥ[qAΡA_hް_ݵhBæRBfLhBe쵥D뤧gμxԡA
ϥΨýбvĮvľ͡C"	i|߹æRBmƧ@	B	 ĥΩ¨Űwʩ|TߡA]¨ŰbϥΤeAyvŪvnʤlPC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G2 [2]_I2 [ws]_w66-01 [E]_C3-06 [Ew]_EX103 j	Ts111.6.27		OI` 	0	OIs 20251124	OKONS-a	OKONS-b	OKONS-c	111.6.27
B017218124	A06AC53	0	ONORM	Normacol plusƤ 7gm/pk		Sterculia O@ȾAǥѼW[ƪnnPizįʡAiӭCzAzOCFrangula O anthraquinone lͪA@mAiW[zįʡBHGcθzDdC	"HG@ 1 ~ 2 AC 1 ~ 2 ]C\AΡCൣ(6 ~ 12 )GvMwһݨϥδCqC
NɪJfAũCZHοiAtXRΧN]AC"	"1.ũNeAΩΪAΧߧYe׫աASOOѦ~HC 
2.i]myιqѽ誺ӡC
3.Pq֪AHקKDC
4.AqC
5.ιLרϥΨEmiy̿μvT`zD\C
6.ũʵz̶pߨϥΡC
7.YϥΥ~ 4 ѤƫKAаϥΡC
8.KonsylPī~ФŨ֥"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sterculla	A06A	m DRUGS FOR CONSTIPATION	0	wѫKC	"1.zC
2.TKOθzDLiOC
3.糧~LӪ̡C
4.hέŰkC"	"K̨tίewGLӤC
GzewGDBzBȡBȮBmBߡBhεzܡC"	D	|qLťġAkŴTϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ONORM-a	ONORM-b	02017218-2	110.6.16
A037697100	A06AB06	0	OTHRO	Through 12mg/tab(Sennoside A+B)		P~AGΤpzålAӬOH쫬Fjz@γAgzӵߧ@ΫͦN²Rhein anthroneAEzӫPijzįʡA~㦳ƫKBwU@ΡC]䵲zħ@ΨM@ʡA|vTWqGzD`įʡC	"@@AΫe(ΪŪA)AΡC
H@1~2A
12HWOΦHqF
6HW12A@1/2~1;
3HW6A@1/4~1/2;
3AЬvEvAyۦϥΡC
쾯qϥγ̤pqAAqKpWζqC"	mϥΡA@ƫK`AYġCDvĮvܡAosAΤ@PHWCqHtֺARιBʨӧﵽKC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sennoside	A06A	m DRUGS FOR CONSTIPATION	0	wѫK	"1.THUhTΡC 
2.TΩGzDBhBæRBߤw̡C"	LzGABmByιqѽC	C	 ĥΩ¨Űwʩ|TߡA]¨ŰbϥΤeAyvŪvnʤlPC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w11-02 [s]_302 [®]_302 [E]_A4-07 j	Ts110.6.16		OI` 	0	OIs 20251124	OTHRO-a	OTHRO-b	OTHRO-c	110.6.16
AC18895100	A07AA02	0	ONYST	Nystatin 500000U/cap(Nystatin)		PolyeneܥͯAiP߲ӭMTJ(Sterols)۵Xӧܨ亯zʡAϨӭMeX]Ӧ`AGRoWS@ΡC	"q`C12ɡA@ѤT|AΤC
({ɯgᤴ~A48pɥHWAH_o^C"	AΤ覡G (1) fAGeζ᧡iC (2) faBGGC@ɥH 10 25 @ɪN}wsCϥΫeХnáAN ĲGtfUAqRaf(3-5 )AMЧ]UΦRX (̷v)C (3) wsnaBGGN(2-8XC)OsA̦hiOsCѡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Nystatin	A07A	zDܷPV INTESTINAL ANTIINFECTIVES	0	zD]߷PVgwPvBsĩʧܥͯTJkɨ֥ά]߹L׼WޤwkC	糧YolBkoPLӯgoͤfATϥΡC	fAjqɷ|{mέGzêC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ONYST-a	ONYST-b	ONYST-c	110.6.16
B0215491CC	A07BA01	0	LCARB	CARBOMIX GRANULES FOR SUSP 50GM/BTL		~U٬ʺҡAbGzlYĪAHwlӹFѬrġC	"ifAαqGJ30120gհtGAbJrᾨiધɶϥΡFb~GiAƤ@C
~˻\ٷɾA[J]HҤWu]50J~ˬ[400^náCòVXaBGAiΥHlް_fArD`sxUجrʪC

"	"\ٷɾq`|CfAľĪGApB`vCPɪAץĮɡAбvC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Activated Charcoal	A07B	zDl INTESTINAL ADSORBENTS	0	vĪΤƾǫ~rfH	"1.糧~LӪ̡ATϥΡC
2.w̥ϥΤfAľΤfASѬrɡAiϥάʺҡC"	uּƱw̥i|KMm{HApoͫKiHLiquid ParaffinA LactuloseΨLwmvC	Sm	Sm	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[E]_I1-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=11.1.1._19950301_000.pdf"">OI` 11.1.1.</a>              "	OI` 11.1.1.	0	OIs 20251124	LCARB-a	LCARB-b	LCARB-c	110.6.16
BC23349116	A07BC05	0	OSMEC	Smecta oral.powder 3g/pk		ѩθF(Smecta)cM߶ʡA㦳ܱjGz߽л\OAzLP߲G޳Jլۤ@ΡAθFWj߲G誺ܤOFgѹGz߽̻٪@ΤΨ䰪XOAθF㦳O@Gz߽@ΡCθFvTXˬdAθFܤjKCA`WqUA|vT`zDƪŮɶC	"ൣG
2HWGC3U
C龯q3AΡACUī~iP50mlVéλPbypG״BGġBdB୹~VëAΡC
HG 
C3UA3APbMVëAΡC
bʸmvA}lɪζqi[ϥΡC

AĮɶG
DfH\AΡClfHy\AΡC"	"1.ⷳHUൣקKϥΥ
2.iP50mlVéΥbypG״BGġBdB୹~VëAΡCC龯q3AΡC
3.īe1pקKϥΨLĪC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dioctahedral	A07B	zDl INTESTINAL ADSORBENTS	0	v2(t)HWൣ(֥ΤfAɥRG)ΦHʸmC gʪvHCʥ\ʸmC	diosmectite ΩҧtξLӪ̡C	ּƯfҥX{KA־qAi~ivC	SmҦw/ĳϥ	SmҦw/ĳϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I1 01[1]_I2 [2]_I1 [2]_I2 []_03-05 [UDx]_U01-54 [E]_C3-10 [Ew]_EX132 j	Ts110.6.16		OI` 	0	OIs 20251124	OSMEC-D	OSMEC-E	OSMEC-F	110.6.16
		0	OKREM2	Kremezin () (ʺҤfA)		"lzZGzDӵߩʬrAƩʬrΨLʼogC
"	"1. H12HWൣGʤrɡA֨ϥ50-100JʺҡCYrɡAAΪ쾯qAC46pAA20JʺҡAsƤѡA̤jq12gC 2. 12HUൣGʺҥΦbpĤ˾qOC魫1JʺҡCʤrɡA̤pĤ魫Mr{׵10-50JʺҡF쾯q10-20JʺҡAƤھvܡAiƵġFjpīhqjq30-50JʺҡC
"	"1.b?~lpUA?PɦX֨ϥΨ
   LfAĪC
2.wƹDe(Transit disorder)fHA~i|zZƪnC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25JHU^	"Spherical Absorptive Carbon
"	"A07BA01
"			"lzZGzDӵߩʬrAƩʬrΨLʼogC
"	"1.b?~lpUA?PɦX֨ϥΨ
   LfAĪC
2.wƹDe(Transit disorder)fHA~i|zZƪnC
"	"wƹDe(Transit disorder)fHA~i|zZƪnC
"	DnקKϥ/iw	DnקKϥ/iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-02 j	Ts111.5.03		OI` 	0	OIs 20251124	OKREM21-a	OKREM21-b	OKREM21-c	111.5.03
AC28218100	A07DA03	0	OIMOD	Lopela 2mg/cap(Loperamide)		wzDBʩʡAê@ΩzDa٥H٦ӧzDiįʡC	H즸A2ɡAHCƫKPnA[A1ɡAC̰qoWL8ɡAĵ즸A1ɡAHCƫKPnA[A1ɡA@̰oWL4~6ɡA̦~־AyWqC	YݪġAbC`WʪEɡAˬdfO_iiC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Loperamide	A07D	ܭGzʤO ANTIPROPULSIVES	0	ʫDSʸmθzHCʸm	"1. 糧~LӪ̡ATϥΡC
2.YzįʬTұw̡AФŨϥΥC"	hBߡC	B	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-05 [s]_193 [®]_193 [E]_A3-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OIMOD-a	OIMOD-b	OIMOD-c	110.6.16
AC45696355	A07EC02	0	ECOLA	Colasa enema 20mg/ml;100ml/~		Mesalazineb~M餺Ĳz@ΦզyƾͤƧ@ΡBCӭMMդTmͤβMۥѰCثeb{ɤW@ӬOmesalazineDn@ξC	"(1) HGC1AC2-4 g (1-2~)AΫeϥΡC
(2) ൣGwʤΦĩʩ|TߡC 
ϥΤ覡G
(1) ϥΫeAFzmŤ10Ϩ䱵ŷūסC
(2) JFzeAХnáC
(3) }~\ANҪ޴b~fWC
(4) ϥήɥΤֳ\ZhL٦bFzޤWC
(5) İ׫(סA}Ak}s)AaNFz޶izAñiܲ~\fCNĲGCCaiz(ܤ1)C
(6) TwĲGJANĲ~OpUޥXAós~C
(7) TOFzຢd餺AۦP5-10AMH`պıAɶqhjKĤGѦWC"	TOFzຢd餺Aк׫5-10C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mesalazine	A07E	zDܪ INTESTINAL ANTIINFLAMMATORY AGENTS	0	ũʵzAר줤פzΪzAzC	"1.SalicylatesLӪ
2.YǰIܱw̡]eGFR20ml/min^
3. 2HUൣ"	hBߡBmFLYhC	B	"iwC
pfHbvX{มmgAߧYšC
"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.3.1._20050501_000.pdf"">OI` 7.3.1.</a>              "	OI` 7.3.1.	0	OIs 20251124	ECOLA-a	ECOLA-b	01C45696-2	110.6.16
BC25351100	A07EC02	0	OMEZA	Mezavant XL 1200mg/tab(Mesalazine)		Mesalazine O@iġA@ξ|MAMﵲzWֲӭM㦳ܵo@ΡCoʸzDefH̨Hsyͥ|mĥNªWhAsyL{gïP׮ïس~|AmesalazineigѪ_ïçjzeCsyӴֵo{HCMesalazineiHNFeBơA]ӧDnPoӭME͡C̪s{PPAR-^ ֨骺liPũʵzCPPAR-^PľܹũʵzĥBҲֿnҾmesalazine@ξiOg PPAR-^ӧ@ΡC	"C@fA뤩CĿݻP֥ΡAirHΩCZC
]tѦ~H(>65 )b~H G
ɽwѡGC@AC2.4 mg 4.8mg (24) CYfHθpqmesalazineLAiΦ̰ܳĳq4.8mgC
C4.8mgΪkζqu8g{ɸAWL8gwʤĩ|TߡC
wѡGC@C2.4mg(2)C"	"q`@Ѥ@H\AΡFɧ]AAibοiC
`NO_Y}(steven johnson syndrome)TEN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
Щm]ˤHKC"	Mesalazine	A07E	zDܪ INTESTINAL ANTIINFLAMMATORY AGENTS	0	ɻܤ׬ʩʼũʵzwѤκwѧ@	"1.AQġAL(]t mesalazineb )ι wAZ S󦨤LӤfHC
2.YǤ (Clcr <30 ml/min/1.73 m2n)/Ψx lfHC"	hBKBmBߡBæRB`hBLOBYhg	B	"SmҦwADnקKϥΡC
pfHbvX{มmgAߧYšC
"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w39-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.3.1._20050501_000.pdf"">OI` 7.3.1.</a>              "	OI` 7.3.1.	0	OIs 20251124	OMEZA-a	OMEZA-b	OMEZA-c	110.6.16
AB43929100	A07EC01	0	OSALA	Salazine E.C 500mg/tab		Sulfasalazine YϥΩoʸzDef(Inflammatory Bowl Disease)`(Rheumatoid Arthritis)AϥθzDiָzGDoͰƧ@ΤҡC`ȥiϥθzCSulfasalazine 󵲸zQzDӭMѦSulfapyrine 5-aminosalicylic acid CSulfasalazine ΨNª㦳ܵoAĶΧܵߧ@ΡC	"q̯fHξAΦӽվA󥼴ϥιLĤfwĳHCq}lAMCCW[qAzūrHC
oʸzDef(Inflammatory Bowl Disease)G
o@: H:Yo@-C24 AC34 AiPTJ֥ΡC
׵o@--C2 AC34 Cp:CѨC魫4060mgA36 AΡC
w_o: H:`C2 AC23 AYcƫhW[C34 C
p: CѨC魫2030mgA36 AΡC
`(Rheumatoid Arthritis)G
g{ɮĪGiϥΤ@ܤGӤX{Aϥήɫĳ֥TJhĮĥX{CSulfasalazine ϥΦĥBԩʨ}nCH:C2 AC2 AY@2gApϥΥĪvGӤLܫhiW[qܨC3gC"	"1.ǤΨx\ण}fwpߨϥΡABwˬdGΨx\C
2.YYrʩιLӤɡAߧYΡC
3.G6PDʥFwK`NLʳh(Hemolytic anemia)o͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sulfasalazine	A07E	zDܪ INTESTINAL ANTIINFLAMMATORY AGENTS	0	ũʵzBJgB`	"1. DiΤAQĪLӪ̡C
2. ʶmIۯgC"	ߡBBŤW@BBoBYhC	B	"iwC
`NO_G6PDʥFgw̡C"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-05 [s]_295 [®]_295 [E]_A4-08 j	Ts110.6.16		OI` 	0	OIs 20251124	OSALA-a	OSALA-b	OSALA-c	110.6.16
		0	LLIQU1	LiquiD P&B  (Vit D3 400IU/drop)		ͯD3ɥR	"C@AC1w(400IU/drop)
ͯDɥRĳG
貨P:800IU-1000IU/day
wͯDʥF:400IU/dayl;ʥFĵC֦~:600IU/day
vͯʥF:
Infants: Oral: 2,000 units (50 mcg) daily for 6 weeks to achieve a serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 400 to 1,000 units (10 to 25 mcg) daily.  
Children and Adolescents: Oral: 2,000 units (50 mcg) daily for 6 to 8 weeks to achieve serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 600 to 1,000 units (15 to 25 mcg) daily.
Note: For patients at high risk of fractures a serum 25(OH)D level >30 ng/mL has been suggested
CKD (stages 2 to 5)fHͯDʥF(serum 25(OH)D level <30 ng/mL)ĳ:


1.Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: Oral: 2,000 units (50 mcg) daily for 3 months or 50,000 units (1,250 mcg) every month for 3 months.

2.Serum 25(OH)D level 5 to 15 ng/mL: Infants, Children, and Adolescents: Oral: 4,000 units (100 mcg) daily for 12 weeks or 50,000 units (1,250 mcg) every other week for 12 weeks.

3.Serum 25(OH)D level <5 ng/mL: Infants, Children, and Adolescents: Oral: 8,000 units (200 mcg) daily for 4 weeks then 4,000 units (100 mcg) daily for 2 months for total therapy of 3 months or 50,000 units (1,250 mcg) weekly for 4 weeks followed by 50,000 units (1,250 mcg) 2 times/month for a total therapy of 3 months.

Maintenance dose [once repletion accomplished; serum 25(OH)D level >30 ng/mL]: Infants, Children, and Adolescents: Oral: 200 to 1,000 units (5 to 25 mcg) daily.
"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Vitamin D3	A07F	mLͪ ANTIDIARRHEAL MICROORGANISMS		ͯD3ɥR					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.28		OI` 	0	OIs 20251124	LLIQU1-a	LLIQU1-b	LLIQU1-c	111.4.28
		0	OANTI	Antibiophilus 250mg/CAP		ĬŻıݤNᰮ굲AΩv׸mΥŸzDӵߡCŻıߦbUحGzD]GI^fzħ@Ϊi]AΨŻıߴNGIDfAoK̤ACTKpHȥHΤzZfߪO ߪz߽ӭMC	"H@28C
12HWAAΦHqC
6HW12AAΦHq1/2C
3HW6AAΦHq1/4C
3HUAЬĮvBvܡC"	Yz惡ġBΨſ}LӡAЧiz()vC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lactobacillus casei	A07F	mLͪ ANTIDIARRHEAL MICROORGANISMS	0	Ȯɽwѻ׸mBhΫKBz(վƫK)BnK	"1.惡LӪH
2.šBſ}@ʧCH"	LzGA	Sm	Sm	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L2 [2]_L2 []_01-17 [UDx]_U01-49 [E]_A2-15 j	Ts110.6.16		OI` 	0	OIs 20251124	OANTI-a	OANTI-b	OANTI-c	110.6.16
		0	OMIYA1	MiyarisanQ		OHz-cJߡ]Clostridium butyricum MIYAIRI^DzCClostridium Butyricum MIYAIRI (CBMAcJ)O@دq͵ߡAݬʻszf ߡBGѵߪWޤΫPiwߡBŻĵߤo|AվzOšAﵽzDefA䬡ʤGļvTCt~A]ܥͯvTAiPܥ֥ͯΡC	"@ѤTAλݭnɪAΡC
HC1g(1])C12HWAAΦHqC
6HW12AC1/2g(1/2])C
3HW6C1/4g(1/4])C
3HUAЬvEvAyۦϥΡC"	WLĳqAYAp͡AߧYĴN	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Clostridium Butyricum Miyairi	A07F	mLͪ ANTIDIARRHEAL MICROORGANISMS	0	wѻ׸mBhΫKBz]վƫK^BnK	TΩũΨŻs~@קC̡C	Ȯ	iwC	iwC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L2 [2]_L2 []_01-22 [UDx]_U01-57 [E]_C3-05 [Ew]_EX130j	Ts110.6.16		OI` 	0	OIs 20251124	OMIYA1-a	OMIYA1-b	OMIYA1-c	110.6.16
		0	IMAGH	STRONGER NEO-MINOPHAGEN C 40MG/20ML/AMP		"1.ܪg@
(1)ܹLӧ@ΡG㦳ܹLӡCtbcortisone@Τ譱A㦳[jiAHΤMܦתާ@ΤίݸY@ΡCOAvTܮX@ΡC
(2)Phospholipase A2ʧ@ΡGGlycyrrhizin@׶WL10-30mcgɡA]PcAMP-dependent protein kinasekinase PXAӲͧ phospholipase A2ʪ@ΡCD]cAMP-dependent protein kinasekinase P|Clipocortin IAlipocortin Iphospholipase A2]lCYglycyrrhizin۩lYarachidonic acidN¨tN²@ΡC
2.K̽ո`@
Glycyrrhizinwҹ㦳(1)TӭMƩʽո`@ΡA(2)r-interferono@ΡA(3)NKӭMʤƧ@ΡA(4)ݽu~TOڲyƼWj@εC
3.xӭMl`@:glycyrrhizin]|ƺҩҦܨxӭMl`C
4.frWȤΤƧ@:Herpes virus㦳WޤΤʤơCAminoacetic acidL-cysteine hydrochlorideδ]jqϥglycyrrhizinAҤް_qѽN²`pseudo-aldosteronismgC"	"q`H 1  1 A5-20 mlRߪ`gCζqi̦~֡AgAaWC
Cʨxew 1  1  40-60 mlRߪ`gAIwRߪ`gAζqi~֡BgAaWCWqɡA1 H100 mlC"	"1.`gtv:[w̱pABHwCtvRߪ`gC
2.pGåΧt̯sA]tglycyrrhizinA`NŭƨϥΡC
3.fA뤩tglycyrrhizinΥ̯so;ٷѤiC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	"GLYCINE,CYSTEINE,GLYCYRRHIZINATE MONOAMMONIUM"	A09A	"ġAtï DIGESTIVES, INCL. ENZYMES"	0	@xŦ`\BĪLӯgBLӡC	"1.󥻾Lӥgw̡C
2.Aldosteronismgw̡BMyopathyw̡BC[gw(|ް_C[gBgc)C"	qѽN¡GWqΪϥΡAȷ|X{pseudo-aldosteronismApYC[gAεoͧC[gWvW[AWɡAuGdBB~A魫W[AG`N[fwC	DnAקKϥΡC	Sm	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-22 [w]_w03-25 [E]_F2-07 j	Ts110.6.16		OI` 	0	OIs 20251124	IMAGH-a	IMAGH-b	IMAGH-c	110.6.16
AC384651G0	A09AA02	0	ODIAL	DialiconƤ(Vit.Bs+Diastase60mg+Pa		FѵH`һݤi~AåijƭGƾϡAϦۭioHRåBtalCAΥioiɵAiGTzӼWiHTOH餧dC	@AΤT| HC23 ൣC12	1.~tڲAfଧgw̤yϥ2.~lʡAЦܩҥHKѡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Vit.Bs+Diastase60mg+Pancreatin30mg	A09A	"ġAtï DIGESTIVES, INCL. ENZYMES"	0	BƤ}BHιwLRЯʥFgC	糧ĤΨξLӪ̡C	ߡBæRC	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w26-03 [UDx]_U02-37 [E]_B3-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIAL-a	ODIAL-b	01C38465-2	110.6.16
AC46067100	A09AA02	0	OPROT	Protease 280mg/cap(Pancrelipase)		uƸzLɽnҧtزGўJYѸz]qAGiGį}aӥġCزGўJiNתդѦglycerolfatty acidsANJսѦproteosesΨlͪANѦdextrinsεu쪺}C	H6HWൣ:_lqC\1ɡAP֪AC6HUൣJ{ɸgP_ڪqC	ݾɧ]A.iCZH.HKyfHE	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pancrelipase	A09A	"ġAtï DIGESTIVES, INCL. ENZYMES"	0	n~ֺƯefBCʯŦBŦBGzDNΦ]~F޵oغަxު뵥efҾɭPزGcC	1.ʯŦT 2.糧ĦLӪ̸TΡC	ߡBæRBȮBhBKΤUgC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiG6(2) [1]_E4 [2]_E4 [ws]_w43-03 [E]_B5-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.3.6._20210101.pdf"">OI` 7.3.6.</a>              "	OI` 7.3.6.	0	OIs 20251124	OPROT-a	OPROT-b	OPROT-c	110.6.16
KC00898266	A10AD04	0	IHUMA	ĵHumalog Mix 25 300IU/3ml/(N)		"Insulin lispro Dn@άո`}N¡C
~Aخq٩餺hB´㦳PƤΧܲƧ@ΡC٦ײ´AخqW[xޡBתջġB̪oγJս誺ͦXiĪlCt@譱ACxޤѧ@ΡB}sͧ@ΡBΦ@ΡB׽ѧ@ΡBJսѧ@ΤiĪXC Insulin lispro ֳt_l@(j15 )A]i۸`Wخq(\e30-45 )󱵪\ɶ(\ɦ15 )ϥΡCb֤U`gucֵ-VX50 Ai[Insulin lispro ֳt_lΦF̰@ΪSʡCInsulin lispro protamine aGh㦳P¦خq(NPH)۷j15 Ӥpɪ@ίSʡC

"	"v|ww̪ݨDHMwqCخq@ήɶi|]PΦP@餺Ӧ۷tC

"	}lϥΫis30JHU28	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
}lϥΫis30JHU28
bĤ@}ʨϥΫάOa@ƥήɡGݧN
ϥΤ[sbC30XCUO6ӬPC
"	Insulin-Lispro	A10A	خqΨPt INSULINS AND ANALOGUES	0	"}f

"	"1.TΩinsulin lispro γB褤@᫬ӷPw̡C
2.TΩC}gC
"	C}O}fw̨ϥίخq̱`Ƨ@ΡC	B	iwAԷVϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-03 [N]_B03-17 [E]_K-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	IHUMA-a	IHUMA-b	IHUMA-c	110.6.16
KC00899266	A10AD04	0	IHUMA1	ĵHumalog Mix 50 300IU/3ml/(Insulinl(N)		"Insulin lispro Dn@άո`}N¡C~Aخq٩餺hB´㦳PƤΧܲƧ@ΡC٦ײ´AخqW[xޡBתջġB̪oγJս誺ͦXiĪlCt@譱ACxޤѧ@ΡB}sͧ@ΡBΦ@ΡB׽ѧ@ΡBJսѧ@ΤiĪXC Insulin lispro ֳt_l@(j15 )A]i۸`Wخq(\e30-45 )󱵪\ɶ(\ɦ15 )ϥΡCb֤U`gucֵ-VX50 Ai[Insulin lispro ֳt_lΦF̰@ΪSʡCInsulin lispro protamine aGh㦳P¦خq(NPH)۷j15 Ӥpɪ@ίSʡC

"	"v|ww̪ݨDHMwqCخq@ήɶi|]PΦP@餺Ӧ۷tC

"	"}lϥΫis30JHU28
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
}lϥΫis30JHU28
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
ϥΤ[sbC30XCUO6ӬPC
"	Insulin-Lispro	A10A	خqΨPt INSULINS AND ANALOGUES	0	"}f

"	"1.TΩinsulin lispro γB褤@᫬ӷPw̡C
2.TΩC}gC
"	C}O}fw̨ϥίخq̱`Ƨ@ΡC	B	iwAԷVϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-06 [N]_B03-19 [E]_K-17 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	IHUMA1-a	10C00899-1	10C00899-2	110.6.16
K000760299	A10AC01	0	IINSU	ĵInsulatard HM 100IU/ml		خqOǥѻP٦ײӭMίתղӭMWخqXHPi}iJӭMAåBxŦ}XAӹF쭰}ĪGC	qOӭӧOpPw̪ݭnӨMwCCӤHݨDqq`0.31.0 IU /kg/dayC	"hPɰϮȦeAwMDvĳA]oiܱw̻ݭn󤣦PɶIIخqPiC
 "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
}ʫ[sbC30XCUO6ӬPC
"	Human Monocomponent isophane insulin	A10A	خqΨPt INSULINS AND ANALOGUES	0	"}f
"	"1.TΩDγB褤@᫬ӷPw̡C
2.TΩC}gC
"	 C}Bתկf	B	"SmҦw
ԷVϥΡC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	IINSU-a	IINSU-b	IINSU-c	110.6.16
KC00810266	A10AE05	0	ILEVE	ĵ Levemir Flexpen 300IU/3ml/pen(N)		}fC	q֥ΤfAܿ}fĪliraglutideɡAĳCѪ`g@Levemir?A_lq10 U  0.1V0.2 U/kgCLevemir?q̷ӨCw̪ݨDHվCYϥLevemir?¦-\eخqv@A̾ڱw̻ݨDALevemir?iHCѪ`g@ΤGCLevemir?qӧOվCݭnCѧ뤩GHFzQ}w̡AߤWqibߤWκΫe`gCYw̬ʶqW[BߺDܡAΦLefAqiݭnվC	bVɰϮȦeAwvɡA]w̥i]ȦӥbPɶIϥίخqΥ\C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
sb30XCHUҡCϥΤ[sO6gC"	Insulin detemir	A10A	خqΨPt INSULINS AND ANALOGUES	0	}fC	DLӤw	`g줣ABC}BYhBLӤ	B	"SmҦw
insulin detemir O_|ѤHťĤcCHŭ|sͨbťīAw|N¤WvTC
oO]insulin detemirpeptideAbHGzD|Ʀamino acidsC¨ŰkiݭnվخqqC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	ILEVE-a	ILEVE-b	ILEVE-c	110.6.16
KC00820266	A10AD05	0	IMIXP	ĵNovomix 30FlexPen 100U/mlF300U/(N)		"qLW[P򸲵}çxŦ}ͦӽո`}N

"	"Ĥ@}fq`lqGA0.5-1 IU/KG/DAYF i\e5-10֤U`gC
ĤG}flqG6U BID12U QN
ѨL۫خqഫGHۦPqPΪk}lD
pW[qFѨCѤ@WL30UHWɡA|ĳtߦU@;ѨC⦸W[C3ɡAWiWMȡAoܦCѤTD
qOӭӧOpPw̪ݭnӨMwAĳi}ʱνվخqqC
pվ㾯qĢīeTѳ̧C\e}Ȩӽվ㾯qAiHCg@վ㾯qA}ƦFЬ.(ϥδYoͧC}{HAhӼW[q^YfHW[ଡʡAܤ`ΨæsLefAiݭnվ㾯qD
\e}ȡG<80mg/dL -2U;80-110mg/dL+0U;111-140mg/dL+2U;141-180mg/dL+4U;>180mg/dL+6U
ĤG}fwHbA1c<8%APGLP-1Pľ֥ήɡANovomix 30qĳC20%FĤG}fwHbA1c>8%APGLP-1Pľ֥ήɡANovomix 30Ҽ{խq"	"hPɰϮȦeAwMDvĳA]oiܱw̻ݭn󤣦PɶIIخqPiC
 "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
}ʫ[sbC30XCUO6ӬPC
"	Insulin aspart 30%A insulin protamine 70%	A10A	خqΨPt INSULINS AND ANALOGUES	0	"}f

"	"C}g, ﲣ~βK[LӪ"	C}	B	"SmҦw
ԷVϥΡC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	IMIXP-a	IMIXP-b	IMIXP-c	110.6.16
KC00823266	A10AB05	0	INOVO	ĵNovoRapid FlexPen 100U/mlF300U/(N)		̾ڥ\4pɪAP@iʤHخqۤANovoRapid?_l@θ֡AB}@׸CC۸iʤHخqANovoRapid?֤U`g@ήɶuCNovoRapid? ֤U`g@ήɶb`g10-20}lC`g1-3pɹF̤j@ΡC@Υi3-5pɡCۦPռƪinsulin aspartPiʤHخq۵ĤOC	NovoRapid?O@سtīخqCNovoRapid?qOӭӧOpPw̪ݭnӨMwC`PīΪīخq֥ΪvAܤ֤@Ѥ@Cĳi}ʱPخqqվHF̨Ϊ}Cھڱw̭ӧOݭnAHPĵخqݨDqq`0.51.0 IU /kg/dayCݨDq50%70%ibasal-boluskNovoRapid?ѡAlqiѤīΪīخqѡC	"hPɰϮȦeAwMDvĳA]oiܱw̻ݭn󤣦PɶIIخqPiC
 "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
}lϥΫis30JHU28ѡC
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
ϥΤ[sbC30XCUO6ӬPC
"	Insulin aspart	A10A	خqΨPt INSULINS AND ANALOGUES	0	}f	"1.TΩDγB褤@᫬ӷPw̡C
2.TΩC}gC
"	C}Bתկf	C	iwAԷVϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-07 [N]_B03-22 [E]_K-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	INOVO-a	INOVO-b	INOVO-c	110.6.16
K000739299	A10AB01	0	IRI	ĵACTRAPID(N)		خqOǥѻP٦ײӭMίתղӭMWخqXHPi}iJӭMAåBxŦ}XAӹF쭰}ĪGC	1.qOӭӧOpPw̪ݭnӨMwCCӤHخqݨDqq`O0.3 M 1.0 IU/kg/dayAخqCݨDqb㦳خq(ҦpGbCKΪέD)w̸AӦb餺ͩʯخqcw̫hCC`g30\ΪAΧtҤƦXIߡC2.վ㾯q:֦sLدefAרOPVεoNAg`|W[w̯خqݨDqCbŦBxŦμvTǤWBάOҪ譱֦sefAi|ݭnվخqqCpGw̧ܤ`ߺDάOଡʡFάOwഫPخqɡA]iݭṉpվ㾯qC	"w̥i]C}Ӫ`NOLkΤ
CAbpUqƷݪ`NOPO
ɡA(ҦpGrξާ@)i|IC
wQiĨwIHקKrɵoͧC
}C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbBc (2XC-8XC)CiӾaNwCiNC
bĤ@}ʨϥΫάOa@ƥήɡGݧNáC
ϥΤ[sbC30XCUO6ӬPC
"	Insulin	A10A	خqΨPt INSULINS AND ANALOGUES	0	}f	DΨ䤤᫬LӪ̡C	 C}Bתկf	B	iwAԷVϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-01 [E]_K-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	IRI-a	IRI-b	IRI-c	110.6.16
KC01011272	A10AE04	0	ITOUJ	ĵToujeo450IU/1.5ml/pen(Insulin glarine) (N)		"Insulin glargine OQ DNA է޳NAqjz(Escherichia coli)K12 һsyHخqC 
خqPinsulin glargineDn@γOո`}N¡CخqΨǥѨEg´}^ASOOf٩ίתյ´AHΧxŦͦ}ӹF쭰}@ΡCخq|תդѤγJսѡAüW[Jս誺XC"	"H֤U`g覡ġA`g쬰BjLΤWuT١Ai@ѤY@ɶ`gATwCѦP@ɶ`g@C
خqvfw_lq
1}fG
خqv1}fw̡AToujeo_lĳqjخqC`q1/3~1/2C@뻡ӡALخqv1}fw̡AخqC_l`qp覡C魫خq0.2-0.4C
2}fG
خqv2}fw̡AToujeo_lĳqC魫0.2AC鵹Ĥ@C
wخqv1β2}fw̪_lq
FϧC}I̧ܳCAfwq@Ѥ@īΤīخqﴫToujeoɡAToujeo_lqP@Ѥ@īخqqۦPC"	"1. ifwAToujeo SoloStar߱󦡹w`gqfܪƦrToujeo`gCLݦA⾯qC 
2. оɯfwAwYiHШϥΡCC`geWswYCwYШϥη|W[wY몺IA]ӾɭPqξqLqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʪToujeo SoloStar߱󦡹w`gxsBcA 2XC -8XCC
}(ϥΤ)WL42ѪToujeo SoloStar߱󦡹w`gHC"	Insulin glargine	A10A	خqΨPt INSULINS AND ANALOGUES	0	H6HWൣΫC֦~}f	ToujeoTΩC}o@CAXΩv}f଻ĤrfHC	C}A~AתեN»êALӯgC	C	"SmҦw
ԷVϥΡC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-04 [N]_B03-18 [E]_K-14 j	Ts110.6.16		OI` 	0	OIs 20251124	ITOUJ-a	ITOUJ-b	ITOUJ-c	110.6.16
BC24839100	A10BD05	Re 15/850 @J	OACTM	ĵActosmet 15/850mg		"@PioglitazoneAthiazolidinedione ĪخqWĪADn@άW[g串}QΡC
t@metforminAbiquanide ĪCDn@Ω󭰧CͩʨxŦ}ͦC"	"C`q 13C@ΨCGfAC
ھڦĩʩM@ʡAbWLC̤jĳq(pioglitazone O45mgAmetformin O3000mg)pUA̭ӤHpqwqMΪkC"	"1.oΩĤ@}fw̡AΪv}f଻ĤrC
2.C}GApioglitazoneX֯خqΤfA}Īw̡Ai঳C}MIAiݭnC֥ĪqC
3.ߦޡGּƦŦefvw̨֥p i o g l i t a z o n eMخqo{ʤŦIܡC
4.~G~w̨ϥACTOSMETԷVCThiazolidinediones]tACOTSA|yGdAӥ[ξɭP{ʤ߰IܡC]AACTOSMETpߨϥΦb߰IܭIfHC[fHO_߰I(]AL׫t魫W[AIlx/Τ~)gμxHC
5.魫W[Gpioglitazone@kM֥ΨL}Īo{q魫W[(3)C魫W[णAiPd[WתհnC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pioglitazone/Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	H@ĪkLkFAĤG}f	Rʤ߰IܡBǥ\ण̡BN©ʻĤrT	YhB~BhBߡBæR	C	קKϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668448?cesid=9KEnc8uzY1W&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dactosmet%26t%3Dname%26acs%3Dfalse%26acq%3Dactosmet"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	DC	DC	DC	110.6.16
BC26950100	A10BK02	0	OCANA	ĵCanaglu 100mg/tab		Canagliflozin  SGLT2 ܩʧ@ΡA|Ŧ}Al@ΡAǦN夤Lh}ƪnܧGAoC}@ΡC	HC@A\eΦ\fACanagliflozin 100 mgC	"1. ϥΥī~ɡAVfHԲӻC}gγBz覡C
2. ī~Q@ΥiɭPhWΡC
3. ϥΥī~vw˴}ApHī~v3ӤĤAҼ{אּLvkC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Canagliflozin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}fC	"1.糧ī~LӯfvfHC
2.ଯf(ketosis)B}fʩgΩgefH[]`خqHtBv}AGAX뤩ī~C]
3.׷PVBNeBY~˪fH[ĳHخq`g}AGAX뤩ī~C]
4.ʵǷl˯fHBESRDγzRfHC"	LgC}BC}BWB夤W[BKC	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w58-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.5.</a>              "	OI` 5.1.5.	0	OIs 20251124	OCANA-a	OCANA-b	OCANA-c	110.6.16
AC480891G0	A10BB09	0	ODIAM	ĵDiamin MR 30mg/tab (Gliclazide)		~sulphonylureafA}ĪAPLPĪtO~bcW㦳NVheterocyclicPendocyclicCGliclazide}@ΥDnOEŦ ] ӭMXخqC	CѦ\ɪA1-4AYC30120mgA@AΡC	ĳʴglycated haemoglobin}Ʀȡ]ΪŸ}ȡ^	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Gliclazide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	g魫LkFzQĪGHDخq̿૬}f(TYPE II)	"1. GliclazideΥ~LAsulphonylureas sulphonamidesĪLӪ̡C
2. Ĥ@}fwC 
3. ଻ĤrB}fgeΩgC
4. YʵŦΨxŦ\ಧ`GfHҼ{PخqC
5. ¨ŰkC"	C}B魫W[BYwBYhBzGAC	קKϥ/SmҦw	"קKϥ
L Gliclazide ΨNª|cܨťĤCקKsͨoͧC}gAvi¨šC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H5 [2]_H5 [s]_369 [®]_369 [E]_E5-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	ODIAM-a	ODIAM-b	ODIAM-c	110.6.16
AC028631G0	A10BB01	0	OEUGL	ĵGliben 5mg/tab		Glibenclamide ﵽ]-cell \AӾAqaXخq(Insulin)HL}C	"Hq`}lqCb(2.5mg)A35ѫᥲnɥiW[bC
C`qWL3Aé\ɪAΡFpWL2ɡAWLq\ɪAΡC"	"1.]~}@άƱjAG\ɩκ\ߧYA
2.PDiBܵ֯f(pEthionamides)APhenylbutazone Coumarinlͪ@PPɶ`N]}LCiް_MIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Glibenclamide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	}f	"1.惡LӪ
2.}଻Ĥr"	C}]_NB߱BYhBjˡBá^AoNBVhAֽlAngC	C	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	DC	DC	DC	110.6.16
BC25481100	A10BD08	0	OGALVM	ĵGalvus Met 50/850mg		"Galvus Met X֨ئbĪ@ξW㤬ɩʪܰ}ĪAiﵽĤG}fw̪}C
Vildagliptin ݩخqWjAmetformin hydrochloricde ݩ biguanide ĪC Vildagliptin ݩخqWjAO@jĥBܩʪDPP-4 C
Metformin Dn@άCͩʨx}qC"	"̱w̥ثeϥΪmetformin qAGalvus Met _lqiରCѨ⦸50 @J/500 @JB50 @J/850 @J50 @J/1000 @JAO󦭱P߶AΡCCĳq100 @Jvildagliptin [W2000 @JmetforminC
Pɨϥvildagliptin Pmetformin ӧOw̡AiഫܨϥΧtۦPqGalvus MetC Vildagliptin C`qWL100 @JC"	] Galvus Met t metformin ApݥH¾KiDݩʤNAb 48 pɫev	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Vildagliptin/Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	AΩ󦨦~HtXMBʡAHﵽUCĤG}fw̪}Gwvildagliptin M metformin X֪v̡AγWϥmetforminvildagliptinA}Ϊ̡CιBʥ[WsulphonylureametforminkLkѾA}ɡA~iPsulphonylurea֥ΡCιBʥ[WíwqخqmetforminLkѾA}ɡA~AXPخqX֨ϥ	"1. w糧~Υ~ҧtξ󦨤LӪ̡C 
2. }f଻Ħgο}fʪgeAC 
3. ǰIܩεǥ\ಧ`AwqClcr<60 ml/minC
4. i|vTǥ\઺ʯfgAҦpGBYPVBJBgު`gtKvC 
5. i|ɭP´ʮ񪺫ʩκCʯefAҦpGŦIܩΩIlIܡBwߦٱBJC
6. x\णC 
7. ʰs뤤rBsC 
8. šC"	C}BYwBzGAC	SmҦw/DnAקKϥΡC	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G4 [2]_G4 [ws]_w59-01 [®]_266 [E]_E4-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a><a href="""">OI` 5.1.4.</a>             "	"OI` 5.1.,5.1.4."	0	OIs 20251124	OGALVM-a	OGALVM-b	OGALVM-c	110.6.16
AB58071100	A10BD02	0	OGLIM	ĵGlimet2/500mg/tab(Glimepiride+Glucomin		"1. ~O@ݩsulfonylurea}AXb]ӭM65K Da ProteinAEGlut4ʨӭMAB}ӭMAӴɩP´insulinӷPסAW[P串}C
2. ~̥ͲzpU]ӭMͯخqAӥBCŸخqȧYiF즳Ī}C
3. Metformin hydrochloride@}ġAﵽĤG}fw̪}@ʡAC¦ζ夤}CĲz@ξणPLfA}ĪCMetformin֨xŦ}ͦACpz︲}lAüW[g串}lMQΡC"	"1CѪAľqΪk@@Ψ⦸\eH\AΡCĳlqGlimepiride/metformin 2/500mg @@Cmetformin MAX 3g/dayBGlimepiride MAX 8mg/day
2.eGFR<45qϥ"	"Ѧ~HקKϥ,oYC}C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Glimepiride+metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	vHglimepiridemetformin@ĪkLkFA}ĤG}fw̡A@MBʤ~UCAX@Ĥ@uvC	"1. خq̿૬}ffH]Ĥ@^]ҦpAଦgfv}ffH^BʥN©ʻĤr]pŻĩʻĤrA}fଯgĤrA}feg^C
2. w糧ĪDΥξBsulfonylureasBsulfonamidesbiguanideLӪ̡C
3. ĩ|L?Yx\णΦGzRfHgCYxŦεŦ\effHA?خqAHϦ}oAC
4. hkB|ִkBb|ŪˡC
5. eoͨŻĩʻĤrfHBŻĩʻĤrfv̡BŦefYǰIܡ]ǵyLov]GFR^p30 ml/min/1.73m2^A]iӦ۩ߦ޵]J^BʤߦٱαѦgC
6. YfHKƪvRߪ`gAhȰġA]oǪi|ɭPǥ\઺ܤơC
7. YPVBNeBY~ˡC
8. i}BȾjBΰIzfHBθUεǤW\ण̡C
9. x\णBYͥ\णBΨLppLCBsLqBB]AmιæRbzGDAC
10. Īv{ʤŦIܡC"	}LCBYhBȾjBߡBæRC	C	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H5 [2]_H5 [ws]_w62-01 [E]_E5-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OGLIM.a	OGLIM.b	01B58071-2	110.6.16
AB340961G0	A10BA02	0	OGLU5	ĵGlucomine F.C 500mg/tab(Metformin)		MetforminiCxŦ}ͦ@ΡBCpz}l@ΡBåiP´︲}lPQΡAqӧﵽw̪خqӷPʡC	"HGC2AC500-1000 mg (̤jqG2250 mg/day)AH\\AΡC
ൣG[10-16] C2AC500-1000 mg (̤jqG2000 mg/day)F
            [>17] C2AC500-1000 mg (̤jqG2250 mg/day)AH\\AΡC"	"1.Rߪ`gveAΥ~AݽT{Nǥ\_`A~A}lϥΡC
2.ws|jƥĪſ}N®ĪGA]fHAĴAyLqs"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	}f	"1.糧~LӪ̡ATϥΡC
2.ŦfΦ]ߦްIܡAߦٱαѦgް_ǥ\ण}gC
3.b`ggKvL{AȮɰAΥġA]|ɭPǥ\ܡC
4.CʥN»ĤrA]tgP_}f଻ĤrC
5.ǵyLov(eGFR)<30mL/min/1.73m2C"	ߡBæRBmBGzABYhBfݨC	B	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G5 [2]_G5 [ws]_w64-01 [s]_360 [®]_360 [E]_E4-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OGLU5-a	OGLU5-b	OGLU5-c	110.6.16
BC27073100	A10BD19	0	OGLYX	Glyxambi 25/5mg/tab		"Empagliflozin
u-}@PBeJ 2 (SGLT2) OtdAlѵǵyLo^`}DnBqDCEmpagliflozin O@ SGLT2 Cǥѧ SGLT2Aempagliflozin iֵŦwLo}
Al@ΡACŦ}HȡAiӼW[}ƪnqC

Linagliptin
Linagliptin O@ DPP-4 A DPP-4 OѸzcXɿ}` 1 (GLP-1) M}̿૬Pخqh (GIP) ïC]Alinagliptin iϬʸzcX@׼WAb}̿ʪAEخqXAíC`ɿ}@סCoظzcXѻPF餺ŪͲzո`@ΡCɧY򥻿@תCqzcXcA@ץi\ߧYWɡCb}@ץ`PɰɡAGLP-1 P GIP ҥiW[خqͦXHαqŦ ] ӭMcC~AGLP-1 iCŦ \ ӭMɿ}cAӨϨxŦ}XqCC"	"1.ĳqC馭W@BC 10mg empagliflozin/5 mg linagliptinAiP@_AΡAiŸAΡC
2.qiW[ܨC@ 25 mg empagliflozin/5mg linagliptinC"	ĳΩĤ@}fHΥΩv}f଻Ĥr	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Empagliflozin/Linagliptin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}f	ǵyLovp (eGFR) C 30 mL/min/1.73m2 fHAϥ GLYXAMBIC	i঳`hBIhBYh	B	"קK
iﱵŪyY}(]AempagliflozinivTX᪺ͫŦo|)AifHAĳbŴϥΥ~C"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G5 [2]_G5 [ws]_w58-05 [E]_E4-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.6._20200501_000.pdf"">OI` 5.1.6.</a>              "	OI` 5.1.6.	0	OIs 20251124	OGLYX_a	OGLYX_b	OGLYX.c	110.6.16
BC25043100	A10BD07	0	OJANUM	ĵJanumet 50/500mg Film-Coated		"~YѨا@ξबɪܰ}ĪզXӦAiΥHﵽĤG}fw̪}G䤤sitagliptin phosphate ODPP-4Ametformin hydrochloride hݩgĪC 
Sitagliptin phosphateG YݩDPP-4fAܰ}ĪAiʸzc@סAqӧﵽĤG}w̪}C
MetforminGO@إiﵽĤG}fw̤}@ʡAåiC¦}Ȥ\}Ȫܰ}ĪCĲz@ξäP䥦fAܰ}ĪCMetforminiCxŦ}ͦ@ΡBCpz}l@ΡBåiP´︲}lPQΡAqӧﵽw̪خqӷPʡC  "	@G JANUMET ܰ}vq̾ڱw̥ثeұvBĩʤέ@ʤHӤHơAWLsitagliptin ̰Cĳq100 @JHmetformin 2000 @JCHC⦸P֪A覡뤩CiaqAǥHCmetformin GzD(GI)Ƨ@ΡC	JANUMETiΩĤ@}fw̩ΥΩv}f଻ĦgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sitagliptin/Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	AΩtXMBʡAHﵽUCĤG}fw̪}Gwb SitagliptinMmetforminX֪v̡AζȾASitagliptinmetforminΪ̡C	"1.ǯfεǥ\êApX{SCr1.5mg/dL[k]BSCr1.4mg/dL[k]BClcr`{HC
2.wSitagliptinBMetforminΥ~LLӡC 
3.֦Υ֦g{HʩκCʥN©ʻĤrA]A}f଻ĦgC"	mBߡBæRBYhBFOgC	B	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G4 [2]_G4 [ws]_w59-03 [s]_367 [®]_367 [E]_E4-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OJANUM-a	OJANUM-b	OJANUM-c	110.6.16
BC26405100	A10BK03	0	OJARD	ĵJardiance 25mg/F.C.tab(Empagliflozin)		Empagliflozin Y@ SGLT2 Cǥѧ SGLT2Aempagliflozin iֵŦwLo}Al@ΡAíCŦ︲}Al֭ȡAǦW[}ƪnqC	"JARDIANCEiWϥΥiPmetforminBmetformin֥sulfonylureaBpioglitazone(֥ΩΤ֥metformin)Bخq(֥ΩΤ֥metformin/sulfonylurea)X֨ϥΡA@[󶼭ιBʤ~vĪAǥHﵽĤG}ffH}ĪGCJARDIANCEĳqC馭W@BC10 mgAiP@_AΡAiŸAΡC@ʨ}nAqiɦ25 mgwGeq֪fHAĳb}lAJARDIANCEeBv@p
[qվ]
}lϥJARDIANCEeĳǥ\Aé󤧫wC
ǵyLov<30 mL/min/1.73 m2:ĳAJARDIANCEC
ǵyLov>30mL/min/1.73 m2:Lվ㾯qC"	"1.JARDIANCEĳΩĤ@}ffHΥΩv}f଻ĤrC
2.Jardiancei޵oޤeq֡Dǥ\णfHAѦ~HAYCfHAHΥbϥΧQfHWD
jardiancevfHpGץN©ʻĤrALצ}hAhìO_଻ĤrAv଻ĤrɡAiݭnخqAøɥRҤƦXD
3.ʵŦIܪ](QAACEIAARBANSAIDs)ANPOAGyACʵǥ\णéwʴǥ\.
4.i|W[cDPVI"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Empagliflozin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	1BĤG}fG (1)}GĤG}fC (2)wߦިƥ:ΩĤG}fBwߦޯefHfHɡAiCߦޭ]`IC 2BŦIܡGΩìŦǷ|(NYHA)ĤGŦܲĥ|ŪŦIܦ~fHAiG Cߦަ`MŦIܦ|IC wwǵyLov(eGFR)UC 3BCʵŦfGAΩwCʵŦfHfHAHCHUIG (1)Ŧefcơ]wǵyLov (eGFR) 򭰧CBŦefεŦ`^Τߦަ`C (2)]ʦ|C	"1.  JARDIANCE YLӤC 
2. w׵ǥ\णBǯfΥzRC"	CBʵŦlˤεǥ\णC	C 	"קK
ĳbŴϥΡC(ivTLŦ)"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5280392?cesid=6aoePQvBUvO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEmpagliflozin%26t%3Dname%26acs%3Dfalse%26acq%3DEmpagliflozin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.5.</a>             "	"OI` 5.1.,5.1.5."	0	OIs 20251124	OJARD-a	OJARD-1-b	OJARD-1-c	111.8.23
BC25221100	A10BH03	0	OONGL	ĵOnglyza 5mg/tab(Saxagliptin)		SaxagliptinDPP-4 ADPP-4incretinXGLP-1PGIPïF]ALinagliptiniϬincretinX@׼WAb}̿ʪAEخqXAíC`ɿ}@סCoظzcXѻPF}餺ŪͲzո`@ΡCɧY򥻿@תCqzcXcA@ץi\ߧYWɡCb}@ץ`PɰɡAGLP-1PGIPҥiW[خqͦXHαqŦ]ӭMcC~AGLP-1iCŦ\ӭMɿ}cAӾɭPxŦ}XqCC	"C@2.5@J5@JAiWϥΥiPmetforminBsulfonylureaBPPAR@ξ] pthiazolidinedione^X֨ϥΡA[󶼭ιBʤ~vĪAǥHﵽĤG}fw}ĪGCiP֪AΪŸAΡC
[qվ]
CrCl >50 mL/min:ĳվ ONGLYZA qC
CrCl<50 mL/min:ONGLYZAqC@2.5@JC
ONGLYZA bGzRᵹ(ONGLYZA w︡zRw̶isC)
ѩǥ\णw̪ ONGLYZAq̰2.5@JA]ĳ}l ONGLYZA veǥ\AwiCǥ\઺iQ Cockcroft-Gault εŦefեѦMٻ@צXӡC"	1.֥ΤwiyC}ĪخqcEpD?(sulfonylurea)A|yC}C]P ONGLYZA ֥ήɡAخqcEqiݭnCAH֧C}IC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Saxagliptin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}f	"1.ǥ\णAo]iOѤŦ޵(cardiovascular collapse) (J) BʤߦٱMѦgpyC
2.󥻫~󦨤LӪ̸TΡC"	YhBuBhBGzBæRC	B	"SmҦwADnקKϥΡC
ثe|M saxagliptin O_|cHťġC]\hĪ|cHťĤAҥH¨Űkϥ ONGLYZA ԷVC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	DC	DC	DC	110.6.16
BC26683100	A10BD09	0	OOSEN	ĵOseniƤ 25/30mg		"alogliptinDPP-4AwzcEhʡAG@סAçQθ}̿ʡACĤG}fw̪ŸM\᪺}@סC
pioglitazone֯خqܩʡAϦ夤خq@μWjA]ʥFʯخqʪA}|CC"	OseniĳC@AH\ΪŸAΡC]A	NYHAIIIũβIVŤŦIܪw̤AXAΦī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
eOKAקKC"	Alogliptin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}f	"OsenialogliptinpioglitazoneYLӤfvApʹLӡBޤ~Yֽ}C
iΩ NYHAIIIũβIVŤŦIܪw̡C"	|BIhBWIlDPVBC}C	C	"SmҦwADnקKϥΡC
OseniiಣY??A]?Ī ˪nʡAAMw¨ũΰĪC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w63-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OOSEN-a	OOSEN-b	02C26683-2	110.6.16
AA49116100	A10BG03	0	OPIOT	ĵPiotas 30mg/tab(Pioglitazone HCL)		peroxisome proliferators-activated receptor-gamma (PPAR^)vT}ί׽褧]ӼWjP´خqӷPʨçxŦ}s(gluconeogenesis)FPPAR\AFibrateĪק@ΡC	CѤ@AC15mg30mgAC̰q45mgC	"1.Ŷs 
2.wʴŸ}HbA1c 
3.w^Eç@x\ˬd"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pioglitazone	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}fw̡]Dخq̿૬}f^	"1.糧ĪoĪLӪw̡C
2.ĳϥΩ󦳤ŦIܯgfH,ŦIܪAĤTũβĥ|ŪfHTϥΥī~C"	OҽkBh¡B_NBߡBIlGBYhB٦׻ĵhB魫W[B~BnC	C 	"SmҦwADnקKϥΡC
ݿŶqŹo|ΰdqBP˹pioglitazone{ɻݨDAHpioglitazoneΥefp ઺b}C"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w63-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OPIOT-a	OPIOT-b	OPIOT-c	110.6.16
BC27463100	A10BD24	0	OSTEG	"Steglujan ? 5/100 mg F. C. tab
( Ertugliflozin 5 mg
Sitagliptin 100 mg )
/qFFļtѥq"		"Ertugliflozin
SGLT2 DOtdNǵyLoG}Al^`DnBJաC
Ertugliflozin O@SGLT2 CzLSGLT2 @ΡAertugliflozin iC
ŦLoᤧ}Al@ΡAåiCŦ}HȡA]|ɰ
G}ƪnqC
Sitagliptin
Sitagliptin O@DPP-4 AĪiCzc(incretin)Xh
ƳtסAqӹĤG}ffHͧ@ΡC"	C@steglujanAᶡAΡAiP֪AAiP֪ACiW[q15mg Ertugliflozin /100mg Sitagliptin	"1.靈eqy(volume depletion){HfHAb}lϥSTEGLUJAN eB{H
2.STEGLUJAN TΩeGFR C30 mL/min/1.73 m2 fH
3.b}lϥ
STEGLUJAN eAeqAAõpHBC}lvʵO_X{CxίgC
4.ϥSTEGLUJAN vfHpGX{PץN©ʻĤr۲ŦXxMgAצ}ȬAO_o଻ĤrA]STEGLUJAN Ҥް_଻ĤrYϦb}ȧC250 mg/dL pU]i|X{CpGhõo଻ĤrASTEGLUJANAfHiAåߧYIvC଻Ĥrvi]A뤩خqBɥRGPҤƦXC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ŦsWL30XC ҡCиml]ˤOs	ertugliflozin / sitagliptin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"AΩtXιBʡAHﵽUCĤG}fHfH}Gϥ
metformin Xertugliflozin sitagliptin FA}̡FΤwbϥ
ertugliflozin sitagliptin X֪v̡C"	"1.׵ǥ\णBǯf(ESRD)αzRv
2.sitagliptin YLӤApʹLӤ(anaphylaxis)Φީʤ~
3.ertugliflozin YLӤC"	ʹ޾]߯gBʹ޾߷PV AcDPVAWBƧqW[BHΩ]CWIlDPVB|BYhBhBߡBmC	"STEGLUJANĳĤGPĤTϥΡC
ثehϥertugliflozin Psitagliptin ƨäHT{O_s|y}o|vTĪICh}f}|˩MLyM`"	"bŴĳϥ
STEGLUJANC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.8._20210716.pdf"">OI` 5.1.8.</a>              "	OI` 5.1.8.	0	OIs 20251124	OSTEG-a	OSTEG-b	OSTEG-c	110.6.16
BC25537100	A10BH05	0	OTRAJ	ĵTrajenta 5mg/tab(Linagliptin)		LinagliptinDPP-4ADPP-4incretinXGLP-1PGIPïF]ALinagliptiniϬincretinX@׼WAb}̿ʪAEخqXAíC`ɿ}@סCoظzcXѻPF}餺ŪͲzո`@ΡCɧY򥻿@תCqzcXcA@ץi\ߧYWɡCb}@ץ`PɰɡAGLP-1PGIPҥiW[خqͦXHαqŦ]ӭMcC~AGLP-1iCŦ\ӭMɿ}cAӾɭPxŦ}XqCC	"1. TRAJENTA ĳq 5mgAHCѤ@C
2. iWϥΥiP metforminBsulfonylureaBPPAR^ @ξ(p thiazolidinediones) X֨ϥΡA@ιBʪU?kAHﵽ}C
3. TRAJENTA iP@_AΡAiŸAΡC"	"1.oͧC}ΡC
2.YL@ĪAФũU@ɪAqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Linagliptin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}f	TΩ󴿹 linagliptin X{LӤfwC]ҦpGʹLӡBީʤ~B渨ʥֽeBC¯lΤ޹LӡC^	i঳`hBIhBYhBC}λ|ΡC	B	"SmҦwADnקKϥΡC
ثe|M Linagliptin O_|cHťġC]\hĪ|cHťĤAҥH¨Űkϥ Trajenta ԷVC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w63-01 [s]_375 [®]_375 [E]_E4-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	OI` 5.1.	0	OIs 20251124	OTRAJ-a	OTRAJ-b	OTRAJ-c	110.6.16
BC27117100	A10BD15	0	OXIGD	ĵXigduo XR 10/1000mg/tab		"XIGDUO XR XFا@ξɪ}ġAﵽĤG}fw̪}G@ dapagliflozinAO@ضu-}PBJ 2 (SGLT2)At@ metformin hydrochlorideAO@ biguanide ĪC
Dapagliflozin
bݵǤpު{u-}PBJ 2(SGLT2)AtdAljbHǤp޵ĤQLo}CDapagliflozin O SGLT2 CqL SGLT2Adapagliflozin ֤wLo}AlMC}HȡA]W[}ƪnC
Metformin hydrochloride
ﵽĤG}fw̪}@ʡAC¦}ȩM}ȡCMetformin ֨xŦ}ͦBָzD}lAǥѼW[P串}MQΡAqӧﵽخqӷPʡC"	"1. vھڱw̥ثevӧOqwXIGDUO XR_lqC 2. XIGDUO XRӨCѪAΤ@A󦭱P֪AAĺi覡հqAHmetforminް_GzƧ@ΡC
3. XIGDUO XRɧ]AAſiHBΩZHC
4. XIGDUO XRLʪɷ|HXntqTKƥXAΪC
5. qiھڦĩʩM@ʽվAiWLdapagliflozin 10 mgMmetformin HCl 2000 mgC̤jĳqC
6. bߤWA metformin XR w̡AL̫@qAA}lA XIGDUO XRC
7. Ωeq]Volume depletion^ w̡Aĳ}lXIGDUO XReBoرpC"	"1. ĳb}l~veæbϥδwǥ\C
2. x\णBs뤤rΤ߰Iܯfvw̡Aέpeʯߪ`gtKvw̡Abiޤ`gtKvgˬdɩˬdenȰXIGDUO XRvAˬd 48 pɭseGFRATwǥ\íwAis}lAġC
3. XIGDUO XRĳΩx\णw̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dapagliflozin 10mg+Metformin 1000mg	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	AΩtXMBʡAHﵽHUĤG}fHw̪}Gwb dapagliflozin M metforminX֪v̡AΨϥmetforminΪ̡C	"XIGDUO XRTΩHUw̡G
1. צܭ׵ǥ\ण]eGFRp60 mL/min/1.73 m2^Aǯfά~Ǫw̡C
2. dapagliflozin oYLӤιmetformin hydrochloride LӡC
3. ʩκCʥN©ʻĤrA]A}f଻ĤrAεLHgC}f଻ĤrӥίخqvC"	CBǥ\ಧ`BcDʹިt߷PVBC}C	C	"SmҦwADnקKϥΡC
ĪSiHŦo|IC]\hĪ|cHťĤAS]dapagliflozin iYyY}AGҼ{Ī˪nʡAӨMwO_ũΰ XIGDUO XRC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G4 [2]_G4 [ws]_w64-03 [E]_E4-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.5.</a>             "	"OI` 5.1.,5.1.5."	0	OIs 20251124	OXIGD-a	OXIGD-b	OXIGD-c	110.6.16
		0	ICACA1	Cacare 1mcg/ml/amp		"CalcitriolLRD3ʧΦCbH餤۵MΤbͩʲͪvitamin D3DnO̿൵~uഫvitamin D3ӨӡC@ΩؼЫeAbxŦεŦgLN¬ơC̪쪺ͤഫOgѨxŦvitamin D3-25-hydroxylaseïӶʤơAӦ25-]OH^D3(calcifediol)AMbŦ´ɽu餺AǥѵŦihydroxylationAHvitamin D3ʧΦAY1,25-(OH)2D3(calcitriol)C
@γ쬰xBYBŦΰƥҪCbYAcalcitriolbƥҪP@ΤUAEtblFӦbŦAcalcitriolW[tbǤpުAl@ΡCb~餺wܡAcalcitriolઽPTHcΦXC]rgfwŦLkNXAaഫʤƦXAҥHi|Vitamin Dܩʪ{HC"	~@ĳ_lqA̾ڧCtM/ΦoʰƥҪमiA1?g]0.02?g/kg^2?gACPPTAjOCj@ѧP@C쾯q̤pq 0.5 ?gA̤jq 4 ?gACPP3C~iHֳtRߪ`g覡PCYObͤƫФίefp{ɪ{W[캡NAibC24PjW[0.51?gqC	"1. ~Lq|ytgABbYǱp|ɭPtg;]Abվ㾯qqACӬPܤʴ⦸夤tC@סApGoͰtgɡAߧYġC
2. ϥDigitalisfwpߵ~A]ofwtgi|o߫ߤ㪺{HC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Calcitriol	A11C	"ͯAMͯDAt̪Ƥ VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO"	0	BzǳzRfHCtpC	~TΩ󦳰tgΦvitamin DrfwC	zBYhBݺΡBߡBæRBfBKB٦ׯkhC	C /D	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.25		OI` 	0	OIs 20251124	DC	DC	DC	114.06.25
AC40864100	A11CC04	0	OROCA	U-CAnn0.25ug/ cap(Calcitriol)		"CalcitriolLRD3ʧΦCbH餤۵MΤbͩʲͪvitamin D3DnO̿൵~uഫvitamin D3ӨӡC@ΩؼЫeAbxŦεŦgLN¬ơC̪쪺ͤഫOgѨxŦvitamin D3-25-hydroxylaseïӶʤơAӦ25-]OH^D3(calcifediol)AMbŦ´ɽu餺AǥѵŦihydroxylationAHvitamin D3ʧΦAY1,25-(OH)2D3(calcitriol)C
@γ쬰xBYBŦΰƥҪCbYAcalcitriolbƥҪP@ΤUAEtblFӦbŦAcalcitriolW[tbǤpުAl@ΡCb~餺wܡAcalcitriolઽPTHcΦXC]rgfwŦLkNXAaഫʤƦXAҥHi|Vitamin Dܩʪ{HC"	"}l10.25mcgAnɥiCj24gCѪqW[0.25mcgAoNC
@몺q0.5mcg1mcg/ѡC"	"1.fAЪ]AoZH 
2.~AΧtܻĨνwmAHKް_"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Calcitriol	A11C	"ͯAMͯDAt̪Ƥ VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO"	0	LRDʥFg; PitCl; ng; Fܼg;LөʯewC	tg	i|æRBzB٦שΰfkhBtgC	C /D	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w24-02 [E]_B2-02 [Ew]_EX026 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2.2._20211201.pdf"">OI` 3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.2.</a>             "	"OI` 3.2.,3.2.2."	0	OIs 20251124	OROCA-a	OROCA-b	OROCA-c	110.6.16
	A11EX	0	IINFU	Lyo-povigent inj.Ƥ5ml/vial(N)		LROH餺iʤ֤Aq`gfACʮөʯefΪgfXALRݨDqhq~ɥRC@tH饲 13 غLRĄ䷻ѩʽAϤⳡAVial(PART)t 9ؤʺLRAᵲsAAmp(PART)t 4 د׷ʺLRAʪ`gGAϥήɱN Amp.(PART)`J Vial(PART)ѲVXçYiC 	"N PART[J PARTVXѫA[JqRiGAHRIw`C
Hq`@Ѥ@Ai̦~֡Ag[HAWC"	"1.OK[󰪼qRiGϥΡAYw̥iHgfBgziɥRɡA֧θgfP覡C
2.קKWPAΥRߤPC
3.UCw̡AVPG
(1)]t Vitamin D3G󰪶tgw̡AYGBGˬdAo{`{HɡAϥΡC
(2)ǥ\êw̡C
(3)HΤBS̩jfݡBolBC¯lL̡C
(4)ĪLӤw̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~N(2~8J)AץJsC	Multivitamin	A11E	"ƦXͯBAtƤ VITAMIN B-COMPLEX, INCL. COMBINATIONS"	0	ΤRgfBgzDɵiӻݨ̿RiɤLRɵC	"1.g糧ΥtXo͹LӪ
2.ͯfw(]t Panthenol)"	JBLӡBBxŦƤWɡBӷ|ް_tg	"SmҦw
קK Vitamin D3LѡAGVPC "	"SmҦw
קK Vitamin D3LѡAGVPC "	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-30 j	Ts110.6.16		OI` 	0	OIs 20251124	IINFU-a	IINFU-b	IINFU-c	110.6.16
NC049281G0	A11EA	0	OVBC	DailyCare ActibestƤ		ͯB1BB6BB12ʥFҤް_ghB٦׵hByhBӻHĵhB}fFhҮɡBW¨ŴBffᵥiɵC	q`HC13AΡC	AήɡAɧeADVit. B2sbҭPAФű{C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Vitamin B	A11E	"ƦXͯBAtƤ VITAMIN B-COMPLEX, INCL. COMBINATIONS"	0	ͯB1BB6BB12ʥFҤް_ghB٦׵hByhBӻHĵhB}fFhҮɡBW¨ŴBffᵥiɵC	糧~ĦνξLӪ̡C	"vqU,LƧ@"	A	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w55-01 [s]_89 [®]_89 [UDx]_U03-50 [E]_C2-18 [Ew]_EX061 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	OVBC-a	OVBC-b	01C14025-2	110.6.16
AC09346212	A11HA06	0	IPYRI	Pyridoxal Phosphate(Vit.B6) 20mg/2ml/amp		"1.BsͯOݤʺͯAΩwΪvͯBʥFCدʥF|ѩ󤣾AiέGzDl}Ҥް_AӧOBsͯ©iO֨A]APOyhغͯCͯB6wQΩYSideroblastic ancmiasvWC 
2.Pyridoxineb餺QܦPyridoxal phosphatePyridoxamine phosphateC̬OUإN¥\઺J|vTJսBҤƦXί׽誺N¡CbiܦүĪഫWAPyridoxine]ѻP䤤C"	"1.@5-30 mg ֤U`gB٦ת`gBRߪ`gҥiAq~ֻC
2.ĥiGzRҲCzRfHPyridoxineݭnqW[C"	"1.ĤyPlevodopa֥ΡA]|levodopaantiparkinsonism@βͰfApNcarbidopaPlevodopa֦XϥΡAhPo͡C
2.LSjqpyridoxinelc|ɭPpyridoxine̿gC
3.ħΩC饿`ݭnqŰwʩ|إߡC
4.ѰOAΤߡA]ĤN»ݮɫܪAqOӫܮɶAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pyridoxal phosphate	A11H	䥦ͯs OTHER PLAIN VITAMIN PREPARATIONS	0	BClBC¯lBֽkogBfBfBBުBLRЯʥFg	L	Pı`AݺΡAMĭC	"A
LSjqpyridoxinelc|ɭPpyridoxine̿gC"	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	IPYRI-a	IPYRI-b	IPYRI-c	110.6.16
AC27940100	A11HA02	0	OBEE6	Beesix(Vit.B6) 50mg/tab(Pyridoxine)		"1.BsͯOݤʺͯAΩwΪvͯBʥFCدʥF|ѩ󤣾AiέGzDl}Ҥް_AӧOBsͯ©iO֨A]APOyhغͯCͯB6wQΩYSideroblastic ancmiasvWC 
2.Pyridoxineb餺QܦPyridoxal phosphatePyridoxamine phosphateC̬OUإN¥\઺J|vTJսBҤƦXί׽誺N¡CbiܦүĪഫWAPyridoxine]ѻP䤤C"	"@릨HqG 
1.Pyridoxine̿gG
쾯q-fAAC30600mgCq-fAAC50mgAרAΡC
2.ĪͩPyridoxineʥFgG
wGC10~50 mg (penicillamine) ΨC100~300 mg (cycloserineBhydralazineisoniazide)C
vGC50~200 mgA3gAHݭnC25~100 mgC
s뤤rGC50 mgA2~4gAݭnLC
ǩKLhhGC200~600 mgA1~2ӤCY~HC30~50 mgAרAΡC
3.ĥiGzRҲCzRfHPyridoxineݭnqW[C"	"1.ĤyPlevodopa֥ΡA]CfA5 mgN|levodopaantiparkinsonism@βͰfApNcarbidopaPlevodopa֦XϥΡAhPo͡C
2.LSjqpyridoxinelc|ɭPpyridoxine̿gC
3.ħΩC饿`ݭnqŰwʩ|إߡC
4.ѰOAΤߡA]ĤN»ݮɫܪAqOӫܮɶAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pyridoxine	A11H	䥦ͯs OTHER PLAIN VITAMIN PREPARATIONS	0	Wް_ߡBæRBֽBLRТʥFg	L	Pı`AݺΡAMĭC	"A
LSjqpyridoxinelc|ɭPpyridoxine̿gC"	"SmҦw
ߧYA> 600 mg /Ѫqi|c"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_19 [®]_19 [ws]_w06-01 [E]_A4-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	OBEE6-a	OBEE6-b	OBEE6-c	110.6.16
AC237931G0	B03BA51	0	OLIVE	"LIVERALL ""z""?"		"1.Cysteine HClinositol㦳Ѭr@ΤΧQx@
2.Choline bitartrate O@X׾
Aq`hΩO@xӭMνո`׽褧sN¹L{
"	"H@1-2 A@3 C
"	"ϥθT:
Choline bitartrate:xʩΪ
        fH
2. Cysteine:iĥN¤}
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25CHUxsD	"Cysteine HCl 20 mg
Choline bitartrate 100 mg
Inositol (Vit. B8) 25 mg
Cyanocobalamin (Vit. B12) 1.5 mcg
"	A11J 	"ƦXͯBAtƤ VITAMIN B-COMPLEX, INCL. COMBINATIONS"		iɥR			"C 
"	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D3 [2]_D3 [ws]_w35-02 [E]_B4-13 j	Ts111.5.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.1._20250601.pdf"">OI` 3.3.1.</a>              "	OI` 3.3.1.	0	OIs 20251124	OLIVE-a	OLIVE-b	OLIVE-c	111.5.06
AC58006229	A12AA03	0	ICALG	ĵCalglon IV inj.100mg/ml;10ml/amp		"1.qLʧ@qHȽո`ӽո`gM٦ת{C
2.bHFSA}ĶtѤFtlӷAiHXtlèέCrʡC ٦Uȥtƪް_CtgC"	"@.Ctg(Rߪ`g)G
1.ס]tl@סG45mg/dL[11.2mmol/ml]^G12JA2pɡFLgw̥iHfA覡t
2.ר쭫ס]Lwo@Τ⨬zFtl@סG<4 mg / dL [<1 mmol / L]^G4JA4p
3.Yg]ҦpwA⨬z^G1012JFC60Ƥ@MAg
!!`NGī610ӤpɡAƶiltqCˬdO_sbCgApGsbAЧ󥿡CpG򪺷lܥiɭPCtg_oAЦҼ{`C
!!s`G520 mg / kg /hrFҪǸ\CUw̡Abi檺pUɧֶ}lfAtMʺͯD]Ycalcitriol^AtΤtergocalciferol cholecalciferol C
G.ŦJΤŦr([gACtgΰgsb)G25Rߪ`g1.53 g
!!q
Calcium gluconate inj. 10%, 10ml/Amp :Ca=0.465mEq/mL, 9.3mg/mL).Note: 1mEq Calcium = 20mg.



"	"1.Cal. Gluconateݰ_pĪARߪ`gpקK|CiH IM  SC  ġC
PUCī~ۮeGAmphotericin B, Ceftriaxone, Diazepam, Foscarnet, Lansoprazole, Methylprednisolone, oxacillin sodiumBphenytoin sodium, NaHCO3BPotassium phosphate, Co-trimoxazol.
2.] Ceftriaxone inj]Rocephin^|PtXͨInAY̦PɨϥΡA䤤@صīᥲNR߿`޸RbAAt@ءC
3.~PsVX|RXIAG`gpϥΰsrɡASs봧oϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Calcium gluconate	A12A	t CALCIUM	0	ΦBXBMfBޤݵj˩ʦ]Bֽew	"1.tg
2.bsͨ(<28)PɨϥRߪ`g}ĶttMceftriaxone
3.߫ŸʡC"	Y`gɺ|Rߥ~Aް_gBB`BajƧ@	C 	SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669353?cesid=4HJ6QKBmDeY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCALCIUM%2BGLUCONATE%26t%3Dname%26acs%3Dfalse%26acq%3DCALCIUM%2BGLUCONATE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[w]_w06-04 [w]_w08-06 [E]_D2-07 j	Ts114.08.11		OI` 	0	OIs 20251124	ICALG-a	ICALG-b	ICALG-c	114.08.11
		0	OBIOC1	BIO-CAL PLUSCZ		"1. PLUStCĶt(Tribasic calcium phosphate)κͯD3 (Cholecalciferol)A ঳ĴѳyһݤtBCqAΫPitBClͯD3C
2.  PLUS]DTribasic calcium phosphateA|ͤGƺҮAӨLһĶtsbGħ@ΤUCO2ӾɭPȮ𤧰Ƨ@ΡC"	C23AϥΡAZHAΡC	"1.pPLtQAiް_KC
2.tQiWjvaxŦ@ΡC
3.tQP|PɪAήɥizZ|lC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Tricalcium phosphate 1203mg+Vit D3 330IU	A12A	t CALCIUM	0	wtPͯDʥFgAp貨PgC	糧ĦLӪ̸TΤC	ĹLqɰtgAǵۤfҵo͡C	"iwC
ϥΫeХԸv"	"iwC
ϥΫeХԸv"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A5 [2]_A5 j	Ts110.6.16		OI` 	0	OIs 20251124	OBIOC1-a	OBIOC1-b	OBIOC1-c	110.6.16
		0	OCALC	Calcium carbonate 500mg/tab		tOfiίʪզA٥iHո`gM٦ץ\Aè㦳`Ŧ\C]iqLPCQXΦCĶtAqӱNƪnbTKAqӥΩvCʵŦfw̪CQgCtQ@ܻľiMGġAɭPGMQGzpHɰCpHȼW[> 4Aٷ|GJ?JդѬʡAüW[CDAٱiOwѭGAΨ`PBGĹLhBƤ}	"HGC3AC1000 mg (̤jqG8000 mg/day)C
ൣG
[3-6] C3AC250 mgF
[6-12] C3AC500 mgF
[>12] C3AC1000 mg (̤jqG8000 mg/day)C"	"1.~fCZrH]AC
2.~i@ľBtɥRBCQXϥΡC
3. 3HUAϥΫeпԸvAyۦϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Calcium carbonate	A12A	t CALCIUM	0	wѭGAΨ`PBθgE_GΤQGzšBGBDҦHGĹLhC	"digitalis glycosidesw̡AΦ߫Ÿʩΰtgw̡F
rgoͮɡACĶtͲ60-70|P~´tƦAקKϥΡC"	ߡBGzABСBKBmC	"C 
1.tLLLC
2.LͪݭntChzDlMtƥXqW[CFL઺tqM󲣰ͲzܤơAӲͲzܤƳq`θɥRvTC
3.MDtݨDqۦPFĳhRDA|W[C
4.ܤƩMͬ覡ܤɡA`W˾qϥκһĶtivG`έGޤϬyC
5.קKqһĶtCbhϥΰqһĶt@ܻľAiɭPsͨtMwo@AΪ̥˥X{YtgA{PXxC"	"iw
1.t|qŤƥXAbcŴ|jqyCVP]IOM 2011^C
2.ͲݭntCŤttqOíAո`A|]tJӧܡCbŴPɶAkʤHΦP@kʤڤttqUۦP]IOM 2011F Prentice 2000^C
3.ŴMDŴkʪtݨDqۦPFų޾ikĳ|W[]IOM 2011^CH˾qϥήɡAܻľQ{iΩų޾ikʡ]Th?lin2020^C
4.ϥΰqһĶt@ܻľi|ɭPYtgA{˪PXg]Caplan 2004F Murphy 2016^C"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w23-01 [E]_B2-09 [Ew]_EX111 j	Ts110.6.16		OI` 	0	OIs 20251124	OCALC-a	OCALC-b	OCALC-c	110.6.16
AC20573229	A12BA51	0	IKCL	ĵKCL 15% 10ML/AMP		[lӭMGDnlAӭM~zBqѽ襭šBPšAHΥͲzOiίʪC~󯫸gġBߦ١BƦ١Bf٦YBGĤcBǥ\BҲBƦXN³KYC[lDnѵŦƪnC	"1.wC[gGC20 mEq
2.[ӺܡGPR߿`40-100mEq /ѡ]MK> 2.5mEq / L^iH10-20mEq / hr`F ̰@פWL40 mEq / L
3.RߤRߪ`g]MK <2.5mEq / L^iHH30-60 mEq / hrt׿`F ̰@פWL80 mEq / L
!!q: 2 mEq of K/ml"	"1. uRߺw`(IVD)ϥΡC
2. n}jnGϥΡA_hߧY`MIC
3. @뾯qCRIwG[J40mEq potassium chlorideC̰@׬80mEq/LC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Potassium chloride	A12B	[ POTASSIUM	0	[qӤް_C[gBgPrgB[l׷lɤ[lɵ	糧ĦLӪ̸TΤC	mAzGȡAߡAæR	B/C	"iw
Ťsb[CHŤ[`tq13 mEq / LCɥR]|ް_鰪[g^|vT`@סC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-12 [w]_w08-01 [w]_w09-02 [E]_F3-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IKCL-a	IKCL-b	IKCL-c	110.6.16
AC58956135	A12BA05	0	LKGLU	K-Glu Oral Solution(Potassium Gluconate) 		"~[ltq ]K:20mEq/amp^fAKC
t[QAzGHEC "	C34AC15mP}ΪGĲVXAΡAAΡCAΦܹ[ʥFgoBC~fAsAoΩ`gC	"1.~fAsAoΩ`gC
2.P}ΪGĲVXAΡAA
3.ĤoP|d[lQ֥ΡC
4.ĤĳϥΩ󥥰α¨ŰC()
5.Addisons disease(w}ͤf)w̡AIHAw}ͤfkC
6.ѩoA1dosteronism(ǩTହLhg)ް_C[gAлPǩTଫܾ֥ΡC
7.ǥ\Bǥ\CUβӧޡB駿ޯfܱw̽ԷVAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUC
mĵĲ줧BC"	Potassium Gluconate(20mEq)	A12B	[ POTASSIUM	0	[ʥFgC	"UCefw̤oϥΥġG
- Potassium Gluconate ΥĨLLӪ̡C
- wYŦeffHC
- wǤWef(Addison g)fHC
- Aη|d[lQfH"	ߡBæRBBUgBhBݴeBKBΰ[(`夤[l@׹L(SO`oͩŦeffH)Ah|NѲVáBCB߫ߤ㵥ΡC)	DnקKϥ/LƦҦw	DnקKϥ/LƦҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-43 [E]_C4-01 j	Ts110.6.16		OI` 	0	OIs 20251124	LKGLU-a	LKGLU-b	LKGLU-c	110.6.16
AC60560100	A12BA01	Const-K ER(10mEq) θɹ[ĮĿ750@J	OCONK	Const-K ER(10mEq) θɹ[ĮĿ750@J		[lӭMGDnlAӭM~zBqѽ襭šBPšAHΥͲzOiίʪC~󯫸gġBߦ١BƦ١Bf٦YBGĤcBǥ\BҲBƦXN³KYC 	"C[ĳqC40 100 mEqA
wC[hC20mEqC
C龯qYWL40meqӤA."	"vʴ[A[@קC2.5meq/LHRߪ`gNfAɹ[D
ϥΧQAivT[AAYCPɮեCAקKvT[^_
񾯫AקKHACZAlm
wŦefAŦefλĤrfHAvC[ɡASO`NĸѥšA߶qA[AAuAACQAtbqѽA߹qϡAίfH{ɪpD
񦳥N©ʻĤrH AyHƹ[vD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25CHUxsD	Potassium chloride 750mg(۷10meq K)	A12B	[ POTASSIUM		ʹ[A	"~TΩwiyĿqLzGDɦdοweffHD
ҦΦ[g
YǰI"	"ߡAæRAzGȮAkhAAPmD(禳zGDA,X,յi)"	DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-02 [s]_264 [®]_264 [E]_A4-06 j	Ts114.07.02		OI` 	0	OIs 20251124	OCONK-a	OCONK-b	OCONK-c	114.07.02
		0	LLICU1	Licure susp 20gm/pk;14pk/		iĤiɵC	@Ѥ@B@@](20g)C	ѩʥN¯ʳHiϥΡASOOiĥN²`AҦp }gBĦgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Amino acids	A16A	LƹDMNĪ OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	0	iĤiɵC	ѩʥN¯ʳHiϥΡASOOiĥN²`AҦp }gBĦgC	N»ê(W[)Bxǥ\l`	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M07-02 j	Ts110.6.16		OI` 	0	OIs 20251124	LLICU1-a	LLICU-1-d	18027063-2	110.6.16
XCOVID0001		0	OPAXL	Paxlovid 2+1 (PF-07321332+ ritonavir)		"PF-07321332 O@ SARS-CoV-2 DnJ? (Mpro) ?A]٬ 3C-like J? (3CLpro) 
nsp5 J?CSARS-CoV-2 Mpro ϨLkBzhJիeXAiקKfrƻs
RitonavirO@ HIV-1 J?A SARS-CoV-2 Mpro LʡCRitonavirgCYP3Aո`
PF-07321332 N¡A PF-07321332 ߿@׼W[C
PF-07321332 Pritonavir֥ΡCॿTaPritonavir֥ΥiɭPߤ PF-07321332 @פHFwvĪGC"	"bE_ COVID-19 Hίgo@ 5 Ѥֶ}l PAXLOVID  5 {C
PAXLOVID q 300 mg PF-07321332]2  150 mg ^M 100 mg ritonavir]1  100 mg ^A3 @PAΡAC⦸A 5 ѡC
㪺 5 {Mj̤jצaMfrM̤jצa SARS-CoV-2 ǼD`nC
׵ǥ\ण]eGFR ? 60  < 90 mL/min^fHLݽվ㾯qCb׵ǥ\ण]eGFR ? 30  < 60 mL/min^fHAPAXLOVID q 150 mg PF-07321332 M 100 mg ritonavirAC⦸A 5 ѡC"	"ݾ]AAoCZB}HC
ī~o᪺֭æ}qQnCoiUʴī~įq/IšCM~@H̾YSǬVʪͪy̱߳WwAqæ}Ap妸/帹Ф@ִѡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25oCHUC	PF-07321332 Mritonavir	ATC code not yet assigned.			"AΩof5ѤB㦳gI]lHPൣfH(12HWB魫ܤ40)צܤ׷safref(COVID-19AYSǬVʪͪ)TE
PAXLOVID |Q֭Ω]gΦM COVID-19 ӻݭn|fHv
PAXLOVID |Q֭Ω COVID-19 SeμS᪺wvC
PAXLOVID Q֭sϥζWL 5 ѡC"	"ﬡʦ]PF-07321332 ritonavir^β~L{۹LӤv
T PAXLOVID Pר̿ CYP3A MĪX֨ϥΡA@פɰPYM/ΦMΥͩR"	PAXLOVID ա]? 1%^oWv]? 5 Ҩժ̮t^wժ}ƥ]ҦšAҼ{]GY^Oıê]O 6% M < 1%^Bm]3% M 2%^B]1% M < 1%^M٦׵h]1% M < 1%^C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	"eGFR 30-60ml/min:150 mg nirmatrelvir]@ 150mg ^M 100 mg ritonavir]@ 100 mg ^AC⦸A 5 ѡC
eGFR<30ml/min: Day1-300 mg nirmatrelvir]G 150mg ^M 100 mg ritonavir]@ 100 mg ^AAΤ@;Day2-5-150 mg nirmatrelvir]@ 150mg ^M 100 mg ritonavir]@ 100 mg ^AC@C"	ѦҡuqΥΪkv	  	ixiiE2j	Ts114.10.28		OI` 	0	OIs 20251124	OPAXL-a	OPAXL-b	OPAXL-c	114.10.28
BC25126206	B01AX05	0	IARIX	ĵArixtra 2.5mg/0.5ml/syringe		Fondaparinux O@ؤHuXﬡƲ X ]l]Xa ]l^ܩʤCFondaparinux ܦꬡʤDOܾۧ? III]ATIII^ҴCܩ Xa ]l@ΡCFondaparinux |ܩʦaM ATIII XAqӨ ATIII TXa ]lM@Χ󬰼Wj] 300 ^CXa ]lQMAsK|zZA?ΦPꪺoͤ]|PɨC	"1.DnUϤNθNfHG
ARIXTRA ĳqNC@֤U`g 2. 5 @JC
Ĥ@ĮɶbN 6 pɡAåBTww大~iICvRߦ몺IwCAq`OvNܤ 5~9 ѡAfHiHʪpC
2.víwߵhΫD ST qɰߦٱ(UA/NSTEMI)G
ARIXTRA ĳqC@֤U`g 2. 5 @JCTwE_ֶ}lvAëvF 8 ѩΨX|(̦hv 8 )C
pGϥ Fondaparinux fHǳƶiD( >120 )g֫aʯߤN(PCI)APCI N뤩qx(unfractionated heparinFUFH)FҼ{fHX孷IA]A뤩̫@ Fondaparinux NɶjC
3.v ST qɰߦٱ(STEMI):
ARIXTRA ĳqC@ 2.5 @JCĤ@ Fondaparinux HRߪ`g覡ġA򪺾qhH֤U`
g覡ġCTwE_ֶ}lvAëvF 8 ѩΨX|(̦hv 8 )C
4.vʲ`hRߦ]DVT^Mʪͮ]PE^ ARIXTRA ĳq(Ĥ覡)pUACѤ@֤U`gG
- 魫p 50 ̡A 5 @J
- 魫 50  100 ̡A 7.5 @J
- 魫j 100 ̡A 10 @J
b 72 pɤt}l֥ warfarin sodiumCH ARIXTRA vܤ 5 ѡAfAܾsĪGT߮(INR: 2?3^CARIXTRA q`Ĵ 59 ѡC
"	"1.ARIXTRA iH٦ת`g覡?ġC
2.ϥ ARIXTRA fHnwŦ\A@vo{׵ǥ\णߧYġC
3.xoʦpO֯g(HIT)G HIT fvfHAԷVϥ ARIXTRAC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Fondaparinux	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1.Rߦƥ(VTE)
2.vwíwߵhΫDSTqɰߦٱ(UA/NSTEMI)
3.vSTqɰߦٱ(STEMI)ʫagJs
4.Pwarfarin sodium֥ΥHvʲ`hRߦ(DVT)Ϋʪͮ(PE)"	"1.w糧~Υ~@᫬LӡC
2.ARIXTRAiΩٻMvCp20@ɤfH"	X(~B姿ByBiX)	B	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w06-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.1._20220301.pdf"">OI` 2.1.4.1.</a><a href="""">OI` 2.1.9.</a>             "	"OI` 2.1.4.1.,2.1.9."	0	OIs 20251124	IARIX-a	IARIX-b	02C25126-2	110.6.16
BC27361100	B01AC22	0	OEFIE	Efient F.C. 3.75mg/tab		Prasugrel hydrochloride @ثeXĪ(prodrug)Abഫ䬡ʥNªAzLܩʥBifXܦpOP2Y12 ADPApO@ΡC	"Efient_lq榸ϥ20mgfAq, HqC@3.75mgfAq"	(1) ЯdN_lqMaspirin֥ήɡAi|W[X媺IC (2) EfientҤ޵opO@ΡAi|nNfwyDAĳ{vbNeܤ14ѰϥEfientC(3)㦳XɦVΥX(`Xfv)iyXD(4)㦳μȮɩʸʦ媺fH(TIA)ϥefient60mg(LD)+10mg(MD)QDX孷IW[D(5)򰾰fHD(6)clopidogrelLӪfHiX{LӡD(6)魫CfH(50kg)X孷IiW[D(7)ǥ\णi|W[X孷ID(8)רx\णiW[X孷ID	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Prasugrel	B01A	ܦ ANTITHROMBOTIC AGENTS	0	EfientAΩݭnaʯߤJʪv(PCI)ʫaʯ߯gԸs	"1. Xgfw(ͯfB`XBƹDXBDXByBX嵥)C
2. ī~󦨤LӯfvfwC"	DnĪ}]t֤UXByB姿Bެ볡~HΥ֤U~C	C 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668756?cesid=6lTNcc5zzlY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPrasugrel%26t%3Dname%26acs%3Dfalse%26acq%3DPrasugrel"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w49-04 [E]_B5-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.10._20181101_000.pdf"">OI` 2.1.1.10.</a>              "	OI` 2.1.1.10.	0	OIs 20251124	OEFIE-a	OEFIE-b	OEFIE-c	110.6.16
BC22606248	B01AC17	0	IAGGRA	ĵAggrastat 12.5mg/50ml/bt		Aggrastat֥HeparinAiΩwíwߵhfHΫDߪiߦٱfHoͯʦʤŦfo@AΥΩwwaʯ߯ʦgӶaʯߦγNΫaʯߵwƤfHoͪvaʯ߬MɩҳyʦʤŦֵogC	AGGRASTATRߪ`gAûPheparin֥ΡA_l`tv0.4 microgram/kg/minA`30C_l`AA~H0.1 microgram/kg/min`tv`C	̪@~XAwfܡApO`ΦpOʥFgfvFpOƥؤp150000ӭMƢAߤ@̡C̪@~ޯef̡A̪@Ӥ뤺jNY~ˡCDʯ߭fvFY}Fʤߥ]FXʵfܡFgʯߩmʯߥ~TFYǥ\णC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Tirofiban	B01A	ܦ ANTITHROMBOTIC AGENTS	0	Aggrastat֥HeparinAiΩwíwߵhfHΫDߪiߦٱfHoͯʦʤŦfo@AΥΩwwaʯ߯ʦgӶaʯߦγNΫaʯߵwƤfHoͪvaʯ߬MɩҳyʦʤŦֵogC	"1.糧Ĥ@LӤfwTaggrastatC
2.UC{ɯgTΡGiʥXF`XB`~FBRߦ޷Ωΰʯ߽F̡Fe`gaggrastatӤ޵opO֯g̡C"	X媺MIʡFߡBoNAYhC	B	קK	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)Gunstable anginaΫDQiߦٱ0.4ug/k/min(`30min)FaʯߦγN/aʯߵwƤ-10ug/kg(>3min)
q(MD)G12.5mg(1Vial)+250mltm50ug/mlDunstable anginaΫDQiߦٱ0.1ug/kg/min(ܤ48hr)FaʯߦγN/aʯߵwƤ-0.15mg/kg/min(36hr)
}GGNS,D5W
}@סG50ug/ml
ĳĳtvGPW
wwʡGǷ20~25Jim24
pɡC
CVP
ʴءGXAPLTAPheparin֥ʴaPTTAeGFR<30ml/minCq"	ixii[w]_w09-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.3._20110701_000.pdf"">OI` 2.1.1.3.</a><a href="""">OI` 2.1.3.</a>             "	"OI` 2.1.1.3.,2.1.3."	0	OIs 20251124	IAGGRA-a	IAGGRA-b	IAGGRA-c	110.6.16
KC00743248	B01AD02	0	ITPA	ĵACTILYSE 50MG/50ML/VIAL		ʫaʯ߮뤧귻ѡBʤjͮBʯʦʤ귻	"**ACTILYSE bgX{AֵġC
1.ߦٱ
a) gX{b 6 pɤߦٱw̡AA 90 ][t^qkG
̪ARߪ`g (IV bolus) 15 mgFۡA50 mgR߿` 30 FHA35 mgR߿` 60 A`qF 100 mgC
fH魫C 65 ̡A`q魫վpUG
̪ARߪ`g 15 mgFۡA0.75 mg/kgAR߿` 30 ]̰q 50 mg^FH; 0.5 mg/kgAR߿` 60 ]̰q 35 mg^C
b) gX{b 6  12 pɤߦٱw̡AA 3 pɤqkG
̪ARߪ`g 10 mgFۡAbĤ@ӤpR߿` 50 mgFHAAH 30 ` 10 mgA 3 pɿ``qF 100 mgC
fH魫C 65 ̡A`qŶWL1.5mg/kgC
ACTILYSE vʤߦٱ몺̤jq 100 mgC
2.ͮ
`q 100 mgP 2 pɡCjhϥΤUCqkG
̪AH 1-2 Rߪ`g 10 mgCۡA90 mgR߿` 2 pɡC
魫C 65 礧w̡A`qiWLC 1.5 mgC
3.ʯʦʤ
vʯʦʤ`qŶWL 90 mgC
ĳq0.9 mg/kg]̤jq 90 mg^`60 C`q10%_lqAHRߪ`g (IV  bolus) P 1 CbgX{᪺ 3 pɤAt}lvC"	"@B@`Nƶ
1.X:H ACTILYSE vɡA̱`X֯gOXC֥ heparin ܾ徯iɭPXCpoYXAרOXɡAֺJշѾM heparinC
2.vʤߦٱΪͮɡAACTILYSE qŶWL 100 AvʯʦʤqŶWL 90 A]WLezqoͼW[`X媺MIʡC
3.ACTILYSE ϥΩൣg۷C
4.̪񴿦٤`gγ̪񦳤p~ˡAҦpˬdBDnެBŦ_dC
5.bTүg|W[XMIpC
GBvʤߦٱΪͮ:Y160mmHg 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Alteplase (Human tissue-type plasminogen activator)	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʫaʯ߮뤧귻ѡBʤjͮBʯʦʤ귻	"1.ī~󦨤LӯfvfwC
2.wXɦVfҡA̪YX媺w̡AXA̪(6Ѥ)jNAYBHAӵߩʤߤAʯŦC"	`g컴LXC	C	SmҦwADnקKϥΡC	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)Gߦٱ(6pɤ)-15mg;ߦٱ(6-12p)-50mg(1st hr);ͮ-10mg(push 1-2min);ʯʦʤ(3hr)-10%`q(1min)
q(MD)Gߦٱ(6pɤ)-50mg(0.75mg/kg) 30min+35mg(0.5mg/kg) 60min(`qF100mg)ߦٱ(6-12p)-10mg/30min3pɹF`q 100mg;ͮ-90mg run 2hr;ʯʦʤ(3hr)-0.9mg/kg run 1 hr(Max:90mg)
}GGNS
}@סG0.2mg alteplase / mlC
ĳĳtvGPW
wwʡGGYNéBc̦his 24 pɡAbWL 30JuiJ 8 pɡC
ʴءGX(`X,GzDX)"	ixii[E]_E7-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.2.1._20181101_000.pdf"">OI` 2.1.2.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.2.2._20231001.pdf"">OI` 2.1.2.2.</a><a href="""">OI` 2.5.1.</a><a href="""">OI` 2.5.2.</a>           "	"OI` 2.1.2.1.,2.1.2.2.,2.5.1.,2.5.2."	0	OIs 20251124	ITPA-a	ITPA-b	ITPA-c	110.6.16
BC22354280	B01AB05	0	ICLEX	ĵClexane 6000IU/vial(enoxaparin)		"1.Enoxaparin@اClqxA㦳зǨxܦΧܾ嬡ʡCS⬰anti-Xaʰanti-IIaΧܾ?ʡCenoxaparinӨAoجʪȬ3.6C
2.oǧܾ嬡ʬOgѧܾ?III]ATIII^@ΦӦbH餺FܦꬡʡCEnoxaparinF-Xa/IIaʥ~AbD{ɼҦUҹﰷdHίfwܦΧܵoĪGCo]AFenoxaparinL]l]pVIIa]l^ܾ?III]ATIII^̿ʪ@ΡBoͩʲ´]l|]TFPI^XAHδvon Willebrand]l]vWF^qޤܦG`CoǦ]lenoxaparinܦ@άҦҰ^mC
3.EnoxaparinbwʾqUAﬡƳ?ɶ]aPTT^õL۪vTC
4EnoxaparinbvqUA̰ʮɡAƳ?ɶ]aPTT^i|1.5-2.2CƳ?ɶXݯdܾïʡC"	"1.v`Rߦg(DVT)G
H12pɬjACѪ`gGCC`gq100 anti-Xa IU/kgCHClqxv{WL10ѡA]APͯKܾFíwɩһݪɶ]`NƶGpOʴ^ADfwLkΤfAܾ徯A_hΤfAܦ徯C
2.Paspirin֥ΥHvíwʯU߯gΫDQiߦٱG
PAspirin]ĳqĢCʪ쾯q160mgAAfA75325mg^Pɨ֥ΡAC֤U`gEnoxaparin 2100 anti-Xa IU/kg]H12pɬj^Cĳ{28ѡAw̱píwC"	"1.Enoxaparin sodium: 1 mg= 100 IU
2.ĪiH٦ת`gġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Enoxaparin	B01A	ܦ ANTITHROMBOTIC AGENTS	0	v`RߦBPaspirin֥ΥHvíwU߯gΫDQiʤߦٱCAΩ~75HUAǥ\]Ccr^j60 ml/minAST-iqɰʤߦٱ몺fwAױwHO_aʯߦަγNAҥiP귻Ѿ֥	"1.enoxaparinLӡF
2.㦳]ǲΨx]unfractionated heparin^ΧClqx޵oYĢx޵op֯g(HIT)fv̡F
3.XgΤêɦV]pPϥΨxLɡAiधҥ~άOGʦޤ^F
4.xfܡAeXF
5.`XF
6.HClqx@vAiiwҥ~ίպޤ¾KC"	XBߡBhBpO֡BoNΩP~BkhB~BXάC	B	bŤ˴ֶqLMWHFEnoxaparin ~ҤĳΩŴkC OAܦnXAbŴkiH~ϥLMWHC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-06 [w]_w09-03 [E]_D2-11 j	Ts110.6.16		OI` 	0	OIs 20251124	ICLEX-a	ICLEX-b	ICLEX-c	110.6.16
BC19378229	B01AB04	0	IFRAG	ĵFragmin 2500IU/ml;4ml/vial		Dalteparinܦ@άO][jXa]lξï@ΩҭPC	"  igѦ٦ת`gġC
@BwGzRPGRG
 1.GzRPGLoWL4pɡGHRߤjq`g30~40IU/kg`魫AۨCp10~15IU/kg魫AΪ̤@Rߤjq`g5000 IUC
 2.GzRPGLoWL4pɡGHRߤjq`g30~40IU/kg`魫AۨCp10~15IU/kg魫C
3.ʵǰIܩΦץXMIw̡GHRߤjq`g5~10IU/kg`魫AۨCp4~5IU/kg魫C
GBHѦΤNvAXʲ`RߦPͮvG
  1.CѧĤ@GCѤ@AC֤U`g200 IU/kg`魫A̰18000IUC
  2.CѧĤGGiCѧĤGAC֤U`g100 IU/kg`魫C"	"i֤URߪ`gCigѦ٦ת`gġC
 1mgJ(protamine)iHMDalteparin100 IU@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Dalteparin sodium	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʮgΨwBܾC	" 1.wҹhæK̤ӳyx޵opO֤fvC
 2.{۪XFYêFѦʤߤC 
3.ϯgtΤNC"	pO֡AȮɩʨxŦiï@פɰA`g~AֽaArvALөʤC	" hӨϥ dalteparinCYbhϥ dalteparinALyˮ`iʷpGMӦ] ưˮ`iʡAubۻݭnɤiϥΡC
"	 DvnAקKϥΡD| dalteparin sodium O_|cܨťĤA¨ŰpߨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts44322.4969212963		OI` 	0	OIs 20251124	IFRAG-a	IFRAG-b	02C19378-2	44322.49692
AC44805240	B01AB01	0	IHEPA	ĵHepac 5000IU/ml;25KIU/vial		"1. Heparin Sodium餺̥Dn۵Mܾ徯A Lצb餺ά~AGT㦳ۦP@ΡAb`qUA XɶBleeding Time@LvTAu|TɶClotting TimeӤwA GGlKKXõLMIC 
2. ܾïT hrombin@ Heparin SodiumPHeparin Co-Factor@PsbUAﾮïϷѩֺJխFibrinogenܬֺJFibrinAG]T@ΡA঳ĩΥIC 
3. ïΦ Heparin Sodium ﾮïProthrombin ܬïL{Ҷ]( pE ThromboplastinMĤ]l)㦳۷j@ΡC 
4. EͫwHHeparin SodiumEBQBQ@]lΦΧ@ΦҤzZAPɴCpOEAϨLkXpO]lA ]AEͦ۵MN"	"ܾvDvtWwA ζq{ɱpδ`tΧܾï@צөwA bvɶҼ{Heparin SodiumUطPʤΤήeԩʡCp`ľRߪ`g40000 i.u.~ĶWL 24pɡA hCpɥĶq1700 i.u.AHeparin SodiumRߪ`gɡA ӨC4pɪ`g@A]bIܵuC֤U`gHeparin SodiumvhζqbAèCj12pɥ@Cq`vWnH侮ïɶAWLӪƭ2~3vѦҨ̾ڡC
1.`RߦΦMͮ몺vGRߪ`gA̪쬰10,000 IUAMᬰ4-6pɡAC5000-10,000 IUC
2.sR߿`г̪H5000 IU`qAMb24pɤ`20,000-40,000 IUC 
3.`SC`g5000 IU IVAMSC`g10,000 IU 8pɩ15,000 IU 12pɡC 
4.GzR7500-12,500 IUC 
5.~NwSCANe2pɪ`g5000 IUAMC8-12pɶi7ѩΪw̯@C
6.wWSCAC12p7500-10,000"	ϥHeparin ~pߡAiW[X大ɦVCϥHeparin vAӳWw`@Ap禳LשΥX{Ho͡AY谱PC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Heparin Sodium	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʮgΨwA ܾA Ψ䥦{ɥγ~	ĸTΩUCpw̡GͯfBGzDXʼšBNvդް_YgBϯgtΥ~NWBæXgBʤߤBҪNBæcʸ~FӦXMI̡BHeparin SodiumLӪ̡C 2.ܾ徯vɡG bYxŦBŦMŦefHκ檺pɡA O_iHϥ Heparin SodiumAHӮ{ɵӨMwC	XALӤ(NŸBC¯lBoNB󪢡Bݼ˪)AʥifʦpOL֯gArYA}PfBǥ\lASCMIM`g짽EC	C 	wAHeparin|bŤƪnC	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G5000U(1mLG)
q(MD)G25,000 units(1 vial)tm250 mL(100U/mL)
}GGD5W, NS, HS
}@סG100 units/mL
ĳĳtvG500-1500 units/hr(5-15mL)
wwʡG24hr (RT)
SݨDiH`h֤U`gC
ʴءGʴPLT, aPTTC"	ixii[UDx]_U06-08 [w]_w06-11 [w]_w08-05 [E]_D3-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IHEPA-a	IHEPA-b	IHEPA-c	110.6.16
BC26599100	B01AF03	0	OLIXI	ĵLixiana F.C. 60mg/tab		LixianaO@ب㦳׿ܩʡBBifXa]l(Factor Xa)FXa]l(Factor Xa)s̲צ@P|(final common pathway)iĳJ՞JCLixianaiAXa]l(Factor Xa)AHξJJ(prothrombinase)ʡCsXa]l(Factor Xa)YAi־J(thrombin)ͦBɶAíCΦIC	"ĳqCLixiana 60mg QDC
[qվ]
ǯf(ESRD)(CrCl)<15 mL/min:קKϥΡC
שέ׵ǥ\ण(CrCl) 15-50mL/min:ĳqC30mg QD
׵ǥ\ण(CrCl) >50-80mL/min:C60mg QD"	pGzpN(]AN)AΫIJˬdeAШƥizvAzAΧܾ徯C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Edoxaban	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1.wDäʤߩֺŸ
2.LixianaiΩvR߮CR߮]A`hR߮ΪͮC"	"1. ﬡʦλsҧt@ξLӡC
2. {ɤWjʩʥXC
3. xŦefX־\êB㦳{ɬX孷IC
4. wg{wiaӬ۷{פjX孷If_ίfgC
5. ΤYC
6. PɱLܾ徯vApǲΨx(UFH)BClqx(enoxaparinBdalteparin)Bxlͪ (fondaparinux)BfAܾ徯(warfarinBdabigatran etexilateBrivaroxabanBapixaban)ApHUpbGഫfAܾ徯vAΨϥζǲΨx(UFH)qȥHRߩΰʯ߾ɺ޺ZqһݤqC
7.׵ǥ\णw(CrCl<15 mL/min)C"	̱`}]Aֽn´XPyB姿AhAzGDXAʹުcDXC	C	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5488128?cesid=3qnGAevn3Vx&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEdoxaban%26t%3Dname%26acs%3Dfalse%26acq%3DEdoxaban"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w57-03 [E]_E5-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.4._20220201.pdf"">OI` 2.1.4.4.</a>              "	OI` 2.1.4.4.	0	OIs 20251124	OLIXI-a	OLIXI-b	OLIXI-c	110.6.16
BC25648100	B01AF01	0	OXARE	ĵXarelto 15mg/tab(Rivaroxaban)		Rivaroxaban fAiβvܩʪ]lXa C]lX gѤͩʩM~ͩʸ|Ʀ]lXa]FXa ^AåBbGr@ΤtnC	"1. ΩDäʤߩŸʯfwAwΥʮ
Xarelto 15 mgA20 mgH\AΡFXarelto 10 mgi\e\AΡC
2. v`RߦPͮιwAoʲ`RߦPͮ
Xarelto 15 mgA20 mgH\AΡFXarelto 10 mgi\e\AΡC
ʲ`RߦPͮ몺_lvĳqObeTgC⦸15mgAۨC@20mgA@ʪvHιwAoʲ`RߦPͮCѭjuȦMI]l(Y̪񦳭jNγж)Ҥް_DVTPEfwAҼ{uv(ܤ֤TӤ)CDo]DVTλPjuȦMI]lLPEBΤ]DVTPEBΦ_ofvDVTPEfwAҼ{vC
bܤ6ӤDVTPEvAĳ̾ڦ_oDVTPEI۹X孷IӧOAXarelto 10 mgCѤ@Xarelto 20 mgCѤ@C
[qվ]
ٻMv(CrCl)<15 mL/min:קKϥΡC
ٻMv(CrCl) > 50 mL/min:C115mg20mg@C
ٻMv(CrCl) 15-50 mL/min:ĳqC110mg15mgA䤤CrCl1530 mL/minwԷVϥΡC"	"1. רx\ಧ`(Child-Pugh B or C)Φ\ಧ`קKϥΡC
2.qwarfarinഫRivaroxabanʴINRAINR< 3.
3.pGܾvHCNΨLvBmX媺IAhӪvܤ24pɫeXARELTOCpݨMwYvBmO_oAγ̫@秴24pɫAiɡAbX媺IɰHΤJv止ʤ쥭ICNΨLvBmATww̨㦳A\ᾨts}l秴vCpGw̩NJLkfAĪAiҼ{뤩`gܾ徯"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Rivaroxaban	B01A	ܦ ANTITHROMBOTIC AGENTS	0	1.ΩDäʤߩŸ(non-valvular atrial fibrillation) BUCܤ֤@MI]l̦HfwAwΥʮ(systemicembolism)CMI]lҦpG߰IܡAA~֤j󵥩75A}fAo͸εuȩʸʦo@(transient ischemic attack)C 2. vͮPʦgݲ`RߦιwAoʲ`RߦPͮ	"1. rivaroxabanĿξLӪfwATϥΥ~C
2. {ɤWYiʥX媺fw]Ҧp`XBzGDX^C
3. P岧`|ɭP{ɬX孷Ixfw̡C
4.׵ǥ\णw(CrCl<15 mL/min)C"	~|W[X孷IӥBiyYέPRXAfVfwXg/xAlܦˬdAiʯfzXΥ~C	X	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w56-02 [E]_E5-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.2._20230301.pdf"">OI` 2.1.4.2.</a>              "	OI` 2.1.4.2.	0	OIs 20251124	OXARE-a	OXARE-b	OXARE-c	110.6.16
	B01AB01	0	IHEPAC	Hepac Lock flush 100IU/ml;10ml/syringe		xiGMΦֺJվCxi@Φb`L{\hBJA?xMxU]l-ܾ?(antithrombin III)XAǥѥhƤwƪ Factor XAiӧ?(prothrombin)ܬ?(thrombin)?ΦC	" ?ĳsͨMϥ 100 USP /@ɲ~C
?bJR߾ɺޫᲣͦAq`g?`g?LGxR~GAӾɺޥRLGxR~GCCϥΤR߾ɺ޸˸mɡA?xR~GCbI󷻲GܤR߾ɺ޸˸meA^⤤R߾ɺ޸˸mAT{R߾ɺ޸˸mqZʡAHΰwYξɺަyݪmCϥΤkШ̾ڦUR߾ɺޤĳϥΡC"	"x?iΩ٦ת`gC
xw̴XGb骺󳡦쳣ioͥXCX{]?yen?C(hematocrit)B?CBΥL?]g?AԷVҼ{ioͥXC
ھڤmiAxw̨pOCUo? 0~30%CpGpO??C 100,000/mm3 Φ?oΦAϥΨxC
X{X媺?ɯg?ӻݭnfx@ήɡAiwCa` 1% protamine sulfate GHMxuFb뤩 1% protamine sulfate GɡAHwCt?`Ab@10 ??iWL 50 @JC  "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 20~25JҡC	Heparin	B01A	ܦ ANTITHROMBOTIC AGENTS	0	Ω󤤥R߾ɺޫʺޡAHɺ޳qZC	"xu?iΦb㦳HU?pw:YpOCUBLki?ʥX?A Aʦޤ (Disseminated intravascular@coagulation, DIC)ҳy̰~C   "	"XOϥΨxiyDnֵog,?E,i|oͷkoM`hPAѨO}C"	C šAubT꦳nɡA~ih?IxuC	x?|?H?ťĤC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts44322.4969212963		OI` 	0	OIs 20251124	IHEPAC-a	IHEPAC-b	IHEPAC-c	44322.49692
BC25691100	B01AC24	0	OBRIL	Brilinta 90mg/tab		Ticagrelor ΨDnNªPpOP2Y12 ADP- iifaۤ@ΡAHTǾɩMpOơCTicagrelor Ψ䬡ʥNªjġC	"ʫa߯gAʯʦʸμȮɩʸʦ(TIA)G
Brilinta vӱq@wq]loading dose^180 mg]90 mg ^}lAMC90 mgAC2 C
 Aspirin wq]q`O325 mg^APBrilinta ֥ήɡAAspirin qC75-100 mgC
clopidogrel wqʫa߯gw̡AiH̫@LܦpOĪ24pɫ}lϥBrilintaC 
 Brilinta iP֪AΪŸAΡC"	iNΩޤeAivAΦġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ticagrelor	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"BrilintaPAspirin֥ΡAi֫ʫa߯g(]AíwߵhBDSTqWɫߦٱSTqWɫߦٱ)w̤ʤߦިƥ󪺵oͲvCPClopidogrelۤABrilintaiHCߦަ`BߦٱoͲvC󤤭ƥWĄõLtC󱵨g֫aʯߤJv̡ABrilintai֤[몺o͡CBrilintaPAspirin֥ήɡAAspirinqקKCѶWL100 mg
BrilintaPAspirin֥ΡAAΩ󭰧Cʯʦʸ(NIHSSơ5)ΰIȮɩʯʦ(TIA)fHI"	"1. `Xfv:`Xfv]ICH^w̸TBrilintaA]ڸs_oICHIC
2. ʩʥX:ʩʯfzʥX]ҦpƩʼũ`X^w̸TBrilintaC 
3. Yx\ण:Yx\णw̸TBrilintaA]iW[SqAӥB|boǱw̤isCYx\ण|W[X媺IA]JզX֡C
4. LӤ:Brilinta TΩwticagrelor Υ~󦨤Lӡ]ҦpGީʤ~^fHC"	YhBYwBy¡BmBIhBM`XBIlxC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w54-05 [s]_23 [®]_23 [UDx]_U03-54 [E]_C2-12 [Ew]_C2-12w j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.9._20130701_000.pdf"">OI` 2.1.1.9.</a>              "	OI` 2.1.1.9.	0	OIs 20251124	OBRIL-a	OBRIL-b	OBRIL-c	110.6.16
BC26133100	B01AF02	0	OELIQ	ĵEliquis 5mg/tab(Apixaban)		ApixabanO@FXaܩʧCäɧUܾIIIӲͧܦꬡʡCApixabaniλPGXFXaAHξïʡCApixabanpOä|ͪvTA|aѾҤ޵opOCzLFXa @ΡAapixabaniCͦ@ΤΦΦ@ΡC	"1.bDäʤߩֺŸʯfHwMʮ
jfHӨAELIQUISĳqC⦸CfA5@JC
֦ܤ֨ؤUCSʪfHAELIQUISĳq2.5@JC⦸G
E ~֤jε80
E 魫Cε60
E Mٻ@װε1.5mg/dL 
2.v`RߦPͮ 
ELIQUISĳqC⦸CfA10@Jv̪쪺7ѡA7Ѥ᪺ĳqhC⦸CfA5@JC
3.w`RߦPͮ_o
gLܤ6Ӥ몺`RߦΪͮvAELIQUISĳqC⦸CfA2.5@JC
[qվ]
ǯf(ESRD)(CrCl)<15 mL/min:קKϥΡC
שέ׵ǥ\ण(CrCl) 15-30 mL/min:ĳqC2.5mg BIDAԷVϥΡC
׵ǥ\ण(CrCl) > 30 mL/min:C5mg BID
"	"1.bwƥNBBmΤBmeAHζ}lϥΥsĪeA@wniDvPvL̥bϥΥ
2.qwarfarinഫELIQUISGϥwarfarinAڼзǾɶ(INR)C2ɡA}lϥELIQUISC
3.Lk]AfHAiN5@J2.5@JELIQUISHaBB5% i}G (D5W) BīGĤBλPīGVXAMߧYHfA覡ϥΡC~AiNELIQUISHaB60 mL5%i}G (D5W)AMߧYgѻG(NGT)뤩CHELIQUISbBi}G(D5W)BīGĤBHīG椤iíw̦h4ӤpɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Apixaban	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"Ω󦨤HDäʤߩֺŸʯfwBHUܤ֤@MI]l̹woͤPʮC
MI]l]AG(1)o͸εuȩʸʦo@(transient ishemic attack)A(2)~֤jε75A(3)A(4)}fA(5)g߰I (NYHA Class II)"	"1.ʩʯfzʥX
2.ELIQUIS|YLӤ(pLөʤAanaphylatic reactions)C
3.֦岧`{ɬX孷IxfC
4.׵ǥ\णw(CrCl<15 mL/min)C"	bϥELIQUISq̬Y}XC	B	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w57-01 [E]_E5-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.3._20220201.pdf"">OI` 2.1.4.3.</a>              "	OI` 2.1.4.3.	0	OIs 20251124	OELIQ-a	OELIQ-b	OELIQ-c	110.6.16
AC285921G0	B01AC07	0	OPEYS	Parotin S.C  75mg/tab(Dipyridamole)		DipyridamoleyBpOΤֲӭM︢(adenosine)Abv?@?(0.5 - 2 mcg/ml)ɡA̤jĪGiF 80%A@ε{?P?Cا@Ψϱo@ΩpO A2 (platelet A2 -receptor )(adenosine)@?W[A?EpO?(platelet adenylate cyclase)AɭPpO?ֳC(plateletcAMP)@?W[C]ipOP]l(PAF)B(collagen)B֤GC(ADP)Ҥް_pO@(platelet aggregation)CpO֯?CpOӡAϤ^?쥿`@?C~A(adenosine)㦳Xi@ΡA笰 dipyridamole ͦXi@Ϊ@	"1. yŸ(e@pɩζp)@jM(240m1)AΡCl֡C֭GzfEAi󶺤ζAΡC 
2. ζqGCʯU߯gw̤@25mgA@TC"	"1.ɦVCfHAĤϥpߡC
2.ĵLkʤߵho@hAUo@δ֡C
3.ĥΩߵhwWAFR?ĥiݮ 2-3 ӤC
4.ĨäʯU߯go@C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. mp⤣γBC
2. Ƿ25XCHUAקKӮgC"	Dipyridamole	B01A	ܦ ANTITHROMBOTIC AGENTS	0	CʯU߯gvi঳	糧ĦLӪ̸T	bvqUAİƧ@γq`OȮɥBLC[쪺Ƨ@Υ]AæRBmΤUCgptwBߡBYhB٦׵hCHdipyridamolevɡAoǰƧ@γq`|C	B	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w27-03 [E]_B2-23 j	Ts110.6.16		OI` 	0	OIs 20251124	OPEYS-A	OPEYS-b	OPEYS-c	110.6.16
AB44124100	B01AC23	0	OPLET1	Pletaal 100mg/tab(cilostazol)		"Pletaal󶡷ʶ_gĪ@ξ|AC
PletaalΨƺإNªOcyclic AMP]cAMP^phosphodiesterase III]PDE III^AiphosphodiesteraseʩMêcAMPN¡APϦbpOMޤcAMP@׼W[AiӦܦpOMXi@ΡC
Uؾɦ]pGthrombin, ADP, collagen, arachidonic acid, epinephrineM_O]shear stress^Ҥް_pOifʪ@ΡC"	"ĳqPletaal@100 mgA@ѤGFb\B\ܤ֥bpɫe2pɫAΡC
ĻPCYP3A4BCYP2C9֥ήɡAĸCq50mgA@Ѩ⦸C"	"1.~beܤ֥bpɩζ2pɪAΡC
2.~ﶡʶ_gﵽLkߧYġC
3.PΦbYbʤŦeffHɥiyߦޤ譱MIAO`Nƶ
4.קKϥθc"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Cilostazol	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ϥΩL𮧮ɯkhΩP´aʶ_fH]Pʯ߯efFontaine stage II^AΩW[̤jεLh樫ZθgͬҦܡ]]tٵҤιBʭpe^ΨLvALkRﵽʶ_gfHGuvC	"1. ߫ǩʤ߷iLtB߫ŸʩΦh_ʤ߫ǩʤ߫ߤ̡AL׬O_RvAΦQTcjfv̡C 
2. YWߩʤ߫ߤfv̡C 
3. 2ة2إHWܦpOΧܾ徯(pGacetylsalicylic acid, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban apixaban)v̡C 
4. íwߵhA̪6Ӥ뤺ߦٱAιLh6Ӥ뤺aʯߤJv̡C"	XBpO֡Bզy֡BƤ}BmBYhBtwC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 [ws]_w24-04 [s]_237 [®]_237 [UDx]_U02-34 [E]_B2-14 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.5._20160501_000.pdf"">OI` 2.1.1.5.</a><a href="""">OI` 2.1.6.</a>             "	"OI` 2.1.1.5.,2.1.6."	0	OIs 20251124	OPLET1-a	OPLET1-b	OPLET1-c	110.6.16
BC25459100	B01AE07	0	OPRAD	ĵPradaxa 110mg/cap(Dabigatran)		Dabigatran Pacyl glucuronides N²vʾJC]󾮦tCL{Aserine proteaseNֺJխ]fibrinogen^ܬֺJա]fibrin^A]Yiwo͡CAMPXBHξJһopOEA|oǬʦҧC	"wDäʤߩֺŸʯfwoͤPʮG
ĳϥξqCfA110~150mgA@Ѩ⦸AŸζAΧiAfHӤH{ɪpϥΤC@150mgniΨ75mgnNCXʭI̩yϥξqCfA110mgA@Ѩ⦸AҦpG~֤j󵥩75BCHADS 2> 3B魫<50kgBeGzXB׵ǥ\l]ٻMv30-50mL/min^fwC
[qվ]
Yǥ\ण]CrCL< 30 mL/min^fwT Pradaxa vC
׵ǥ\ण]CrCL30-50 mL/min^ĳqCA150 mg]75 mgn^A@Ѥ@C


ʲ`hRߦ(DVT) ΡΪͮ (PE) v:
H
ĳ`gܾ徯vܤ֤ѤAϥΤ@300 mgqPRADAXA]CfA@150 mgnA@Ѩ⦸^Av6ӤC"	"1.pN(]AN)AΫIJˬdeAШƥivAbAΧܾ徯C
2.ЧifwNn]AA˯}BCZΨXnĲɧiɭPĪSqW[C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dabigatran	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1. ΩRߦ갪MIsfwAHw󱵨UϭjNᤧRߦg (VTE)C
2. wDäʤߩֺŸʯfwoͤPʮC
3. ʲ`hRߦ (DVT) /Ϊͮ (PE) vC"	"1.wdabigatrandabigatran etexilateΥ~@᫬LӡC
2.Yǥ\l]ٻMv< 30 ml/min^
3.Xg{BsbX]BΦ۵oʩĪʤ\lfwC
4.sb{YX孷IʯfܡA]ALh6Ӥ뤺oͪXʤC
5.Pɱketoconazole, cyclosporine, itraconazolevC
6.HuämC"	XBhBߡC	SmҦw	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w56-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.5._20230301.pdf"">OI` 2.1.5.</a><a href="""">OI` 2.1.5.1.</a>             "	"OI` 2.1.5.,2.1.5.1."	0	OIs 20251124	OPRAD-	OPRAD-b	OPRAD-c	110.6.16
AC436641G0	B01AC06	0	OTAPA	Espin 100mg/cap(Acetylsalicylate)		"1. ĥigѫPiJ(Cyclo-oxygenase)AQƦӦħ`pOThromboxaneͦAöiӽwѦޤjYΨpOC 
2. ĤܦpOAiwέCʮefoͤδcơC
3. ĥiThromboxaneߴ`ͦABgѨtΫeN¡]xN¡^jhΦpOvTʤNªSalicylateC]AiJ`Acetyl Salicylic Acid@׷CAGp|ProstacyclinΦAӤzZĮĪoC
 4. ĤtHAcetyl Salicylic AcidDzLɡAiĪGYӳyGzAAåiǥѷLɤíwĪGAϱwowB󦳮ĪvGC"	"1. Ci|oͫʤߦٱfH`vGCѪA100-200@JΨCj@ѪA300@JC
2. CgoͤߦٱfHAoͲvΦ`vGCѪA100-300@JC
3. wAGCѪA100-300@JC
4. Cuȯʦʵo@fHAo͵uȯʦʵo@ΤGCѪA100-300@JC
5. CíwΤíwߵhfHoͲvΦ`vGCѪA100-300@JC
6. wbޥ~NΫIJʪvҤް_ʮgAҦpGg֫aަγNBaʯߤyӳNBVʯߤNBR߾ɺޡGCѪA100-300@JC
7. wʩҲͪ`R߮ΪͮAҦpGbjNGCѪA100-200@JΨCj@ѪA 300@JC
8. CߦަMI]lfHoͲĤ@ߦٱ몺MIAҦpG}fBׯgBBέDBϡBѦ~HGCѪA100@JΨCj@ѪA300@JC"	ĻPLܾ徯֥ήɩyԷVʴGΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. mp⤣γBC
2. Ƿ25XCHUAקKӮgC"	Acetylsalicylate(Aspirin)	B01A	ܦ ANTITHROMBOTIC AGENTS	0	kʵuȩʯʦʵo@BwߦٱBwʮg	"1. wAspirin(Acetyl Salicylic Acid)BLsalicylatesΥ~LLӪ̡C
2. ]salicylatesάۦ@ΪApDTJġAҤް_ݯfvC 
3. YxBǯewBͯfΨLXʯewBSʭGήƩʼűw̸TΤC
4. h 3kGoϥΡC 
5. ֥ξqCP15@JΧ󰪾qmethotrexateCW[methotrexateGrʡ]ܵoĴM|C methotrexateǲMsalicylates|NmethotrexateP߳JյX ) C"	GzABߡBæRBG߽lBŤoʦGy{H	"C/D
1.bhTӤϥΥiyBʯ߾ɺ޹LBlcYBW[PLX孷IvTC
2.ͲeqAspirin|W[`X媺IAרOsͨC"	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K5 [2]_K5 [ws]_w16-03 [s]_103 [®]_103 [UDx]_U02-06 [E]_B1-04 [Ew]_B1-04w j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.1._20110701_000.pdf"">OI` 2.1.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1._20110701_000.pdf"">OI` 2.1.1.1.</a>             "	"OI` 2.1.1.,2.1.1.1."	0	OIs 20251124	OTAPA-a	OTAPA-d	OTAPA-c	110.6.16
AC33675100	B01AC05	0	OTICL	Declot 100mg/tab(Ticlopidine)		adenyl cyclaseACAMP@סAӫpO@ΡC	"`ξq:CѤfA200500mgA2~3AΡC
w:250 mg BIDC
aʯߤ[mJN:250 mg BID 30ѡC"	"1.ϥΦĪwNe7-14ѰΦġC
2.UCw̷VϥΡG gw̡BXɦVw̡BbAΧܾĩΦpOw̡Bwxfδدfw̡B㦳զy֯gfw̡BwwnINw̡B̡֪C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ticlopidine	B01A	ܦ ANTITHROMBOTIC AGENTS	0	AΩ󴿵oͧʮ뫬]completed thromobotic stroke^Φe]stroke precursors^ABAϥaspirinw	XʯfHAYxêAզyL֡A糧~LӪ̡AC	Gf}BGhBԨ{lBߡBæRBYwCɷ|ް_XΦpO֯gA]R[H[Ao{{HɡAAΡC	B	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.2._20110701_000.pdf"">OI` 2.1.1.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.2._20110701_000.pdf"">OI` 2.1.2.</a>             "	"OI` 2.1.1.2.,2.1.2."	0	OIs 20251124	DC	DC	DC	110.6.16
AC50095100	B01AA03	0	OWARF	ĵMafarin 5mg/tab(Coumadin)		"~MLcoumarinܾ徯YgѧͯK̿૬]lXӦܾ@ΡAӵ]l]A]lIIAVIIAIXMXHΧܾJսCMSA]lbIpU:]lII--60pɡAVII--4-6pɡDIX--24pɡAX--48-72pɡDJսC--8pɡAJսS--30pɡCb餺ӵ]lǨ̦VIIAJսC (Protein C)A]lIXAJսS (Protein S)A]lXMIICͯKOͯK̿૬]lֿ}XDnU]lAͯKiPiJս褺r-carboxyglutamic acid(ͪʬn)ݰ򪺥XA۫HwarfarinYgѧͯK1ƪAͦӤzZ]lXAӧ{׫YPľqAvqwarfarini֨xŦsyUجʧΦͯK̿૬]l`qF30%-50%C
ܾĪGq`ī24pɤ͡A̰ܾĪGiੵ7296pɡA뤩澯q~۩warfarin@Υi25ACq|[WhɡA~ĪGܱoۡCܾ徯wgͪlõLĪGA]Lkfʦ´´ˮ`A@ΦlAܾ徯vؼЬOwgΦi@BAHιw~oֵogAӵ~oֵogiɭPYBƦܥiPRgC"	"1. 쾯qG쾯qѨC 2mg  5mg }lϥΡAè PT/INR qȽվ㾯qC
2. qGhƯfHHC 2mg  10mg qҥioNĪGAiǿ貪bӼuʽվ㾯qAӧOfHqPɶj̾ïMwC
3. vɶGvɶṷӧOfHվA@ӨAܾvܦPoͪMIC"	"1.T{zҦvΤvDzbϥΥġAYniNάOYˬdiݭnμƤѡC
2.kʩAĴץC
3.YWX{ֽCBūܤƩηC{HкɧֻPHpC
4.CTwLRKqAHKvTġC
5.ĻPhī~椬@ΡAϥηsīeԸvĮvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	warfarin	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1.w/ΪvR߮gΨefAHΪͮC
2.wΪv]ߩֺŸʤ/Χ󴫤Ŧäް_ʮgC"	"1.糧~LӪ̡ATϥΡC
2.XɦVΦGcf(blood dyscrasias)C
3.YNέpeϯgtΤNBNAζ}j֤~ˤNC
4.XɦVC
5.ʬyBlwgMlwegC"	YhB٦ש`khBzGABߡBæRBmBXC	X	"SmҦwADnקKϥΡC
تkL|JšAiHŪˡC OƾڪAYi|X{PTC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w57-05 [E]_E5-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OWARF-a	01050095-1	OWARF-c	110.6.16
AC52559100	B01AA03	0	OWARF1	ĵMafarin 1mg/tab(Warfarin)		gѧͯK̿૬]lXӦܾ@ΡAӵ]l]A]lIIAVIIAIXMXHΧܾJսCMSA]lbIpU:]lII--60pɡAVII--4-6pɡDIX--24pɡAX--48-72pɡDJսC--8pɡAJսS--30pɡCb餺ӵ]lǨ̦VIIAJսC (Protein C)A]lIXAJսS (Protein S)A]lXMIICͯKOͯK̿૬]lֿ}XDnU]lAͯKiPiJս褺r-carboxyglutamic acid(ͪʬn)ݰ򪺥XA۫HwarfarinYgѧͯK1ƪAͦӤzZ]lXAӧ{׫YPľqAvqwarfarini֨xŦsyUجʧΦͯK̿૬]l`qF30%-50%C	"1. 쾯qG쾯qѨC 2mg  5mg }lϥΡAè PT/INR qȽվ㾯qC
2. qGhƯfHHC 2mg  10mg qҥioNĪGAiǿ貪bӼuʽվ㾯qAӧOfHqPɶj̾ïMwC
3. vɶGvɶṷӧOfHվA@ӨAܾvܦPoͪMIC"	"1.T{zҦvΤvDzbϥΥġAYniNάOYˬdiݭnμƤѡC
2.kʩAĴץC
3.YWX{ֽCBūܤƩηC{HкɧֻPHpC
4.CTwLRKqAHKvTġC
5.ĻPhī~椬@ΡAϥηsīeԸvĮvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	warfarin	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1.w/ΪvR߮gΨefAHΪͮC
2.wΪv]ߩֺŸʤ/Χ󴫤Ŧäް_ʮgC"	"1.糧~LӪ̡ATϥΡC
2.XɦVΦGcf(blood dyscrasias)C
3.YNέpeϯgtΤNBNAζ}j֤~ˤNC
4.XɦVC
5.ʬyBlwgMlwegC"	YhB٦ש`khBzGABߡBæRBmBXC	X	"SmҦwADnקKϥΡC
تkL|JšAiHŪˡC OƾڪAYi|X{PTC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w57-04 [E]_E5-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OWARF1-a	OWARF1-b	OWARF1-c	110.6.16
BC27750100	B01AF01	0	OXARE2	2.5mg xarelto (Rivaroxaban 2.5mg)秴		"Rivaroxaban fAiβvܩʪ]lXa C
]lX gѤͩʩM~ͩʸ|Ʀ]lXa (FXa)AåBbGr@ΤtnC"	"CAD PAD fHwĳq@2.5 @J Xarelto ACѨ⦸A֥ΩC龯q100 @JASA (acetylsalicylic acid)C
oͫʦƥαޤNBݭnܦpOĪvfHAXarelto 2.5 @JC⦸AX֥ΩܦpOĪvCCrCl < 15 mL/min fHTϥΥ~C"	"~LܦĪ@ˡAbUCX孷IW[fHԷVϥΡJ
? ѩʩΫѩʪXʯef
? Yʯ߰
? ʴũʭGzDef
? s񪺭GzD
? ޯf
? s`θX
? թ`޲`
? jBթβN
? XiΪͥXfv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsūפiWL30JC	rivaroxaban2.5mg	B01A	ܦ ANTITHROMBOTIC AGENTS	0	PAQ( FFASA) ֥ΡAiΩoͯʦƥ󰪦MIsaʯ߯ef(CAD) ίgʩPʯ߯ef(PAD) fHAHwʯߵwƦΦƥ(atherothrombotic events)C	1. rivaroxabanĿξLӪfwATϥΥ~C 2. {ɤWYiʥX媺fw]Ҧp`XBzGDX^ATϥΥ~C 3. P岧`|ɭP{ɬX孷Ixfw̡ATϥΥ~C 4. LϥΥ~wʻPĩʸƥiѰѦҡCʪܥ~iLLLپA]bhTϥΥ~C 5. L¨ŰkϥΥ~wʻPĩʸƥiѰѦҡCʪܥ~icܥŤA]ū~iHϥΥ~C 6. CrCl: < 15 mL/min fwTϥΡC|	~|W[X孷IӥBiyYέPRXAfVfwXg/xAlܦˬdAiʯfzXΥ~C	hkTϥΥ~	ȯb_ϥΥ~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [ws]_w56-03 [E]_E5-04 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.2._20230301.pdf"">OI` 2.1.4.2.</a>              "	OI` 2.1.4.2.	0	OIs 20251124	OXARE2-a	OXARE2-b	OXARE2-c	111.8.19
BC18669255	B02AB91	0	IFOY	FOY 100mg/amp (Gabexate mesilate)		~_trypsinAkallikreinPɹOddiA٦w@ΡAJդѻïXҦͤŦewgwѦuĪGCSGTtΦ_ĪGAbAntithrombin IIIsbUA_thrombinάʫX]lBBpOAxoʦޤGTgT{ġC	"ʯظG즸ϥ1~3~(500~1500 ml D5W})Apb24pɤiAl[1~3~s` 
xoʦޤGTg(DIC)G20-39 mg / kg /ѡAs`24p(D5W})C"	"1.iŻPľVXϥΡC 
2.קKjqϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Gabexate mesilate	B02A	ֺJշ? ANTIFIBRINOLYTICS	0	ʯŦB񦳳Jդѻïh椧ŦewgwѡBxoʦޤGTg	糧LӯfvfH	LӤB`ghBoBզy֡BpO֡B[	iwCקKjqϥΡC	iwCקKjqϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-10 [E]_G2-05 j	Ts110.6.16		OI` 	0	OIs 20251124	IFOY-a	IFOY-b	IFOY-c	110.6.16
AC45154221	B02AA02	0	ITRAN	ĵTRANSAMINE 250MG/5ML/AMP		ΧXΥXʯefFfBզfB͵֤ئBBNɤ`XBǥX	@릨HHTransamin`gG@250-500mgA1-2RߩΦ٦ת`gCNBNAnɥiH1500-1000mgRߪ`gA500-2500mgRIw`gC	"UCw̽ԷVϥ
1.ꪺw̤Υiް_ꪺw̡C
2.өʦGTêw̡C
3.糧LӪw̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Tranexamic acid	B02A	ֺJշ? ANTIFIBRINOLYTICS	0	ΧXΥXʯefFfBզfB͵֤ئBBNɤ`XBǥX	"1.惡L
2.ʩʦʯefF ΦΦvA]ARߩεʯߪF ΦΦ몺bI
3. PɨϥοEץ"	ߡBæR{HCֳt`gɰoͧCC	B	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U05-01 [w]_w10-01 [w]_w10-02 [w]_w10-03 [w]_w10-04 [E]_E7-02 [Ew]_D1-05 j	Ts110.6.16		OI` 	0	OIs 20251124	ITRAN-a	ITRAN-b	ITRAN-c	110.6.16
NC15392100	B02AA02	0	OTRAN	Transamin  250mg/cap(Tranexamic acid)		"1. ֺJշ?@
Tranexamic acidYPֺJշ?ֺJ?(Plasminogen)ֺJտ˩M줧(Lysine)X(LBS)jPXAiֺJշ?ֺJ?PֺJյXC]AijPֺJշ?ֺJդѧ@ΡCA̡Ab\2-macroglobulineߤֺJշ?sbpUANi@BjTranexamic acidַ@ΡC
2. @
`iֺJշ?AN޵opOêBξT]lѵAY϶ȬתiAN޵oSʪֺJդѡC]A@XɡATranexamic acidiêWzֺJդѡAHFتC"	H1750?2000mg3?4gfPC̷Ӧ~֡BgAWζqC	"HUڸsԷVϥ
1.ꪺw(BߦٱBRߪ)ΥiX{gw(ww)
2.өʾTêw(PHeparin֥) (ww)
3.NקɪAUw̤α屹Iw(]BeRߦꪺAAI~wwCiܴX{]UɡBѰAӾɭPͮgo@fҡC)
4.ǰIܪw(i|ɭP夤@פW@)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Tranexamic acid	B02A	ֺJշ? ANTIFIBRINOLYTICS	0	ΧXΥXʯefFfBզfB͵֤ئBBNɤ`XBǥX	"1.w糧~Υ~@᫬LӡC
2.(Thrombin)Īw̡C"	ߡBæRBBݵhBkoPBolC	B	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w12-02 [s]_306 [s]_307 [®]_306 [®]_307 [E]_A4-14 j	Ts110.6.16		OI` 	0	OIs 20251124	OTRAN	OTRAN-b	OTRAN-c	110.6.16
KC00608299	B02BD04	0	IBENE	BeneFix (Gama-Fix) 500IU/vial(N)		ȮɨNĤҥݦSʥFĤE]lC	"plq
ϥΤU?p⻫A BeneFIX? lqG
کһݲĤE]l?= 魫 xW[ĤE]l?]`Ȫ%IU/dL^x[^???]IU/dL/IU/kg)
̾گfH?ɤվ뤩qC
?wʪv
A BeneFIX? i@wʪvA? B ͯfH̤wXC@wʪvXAĳϥξq 100 IU/kg Cg@CPC?MHۤA]ൣ(<12 )bIuBM? (ھڨC魫pұo)AGbൣ^??CC̾گfH?ɤվ㵹Ĥ覡 (qW?)C"	"1.LӤi
2.?ֵogiA󻫾A BeneFIX? HR߫ʿ`wʻPĸ?|Q?C
3.ǯfgԸsi
4.Mʧ():bwgͲĤE]l骺fHWAYs뤩ĤE]lA|W[oYLӤΫʹLөʤ (anaphylaxis)MI2C
5.A BeneFIX? ?AΩU?UدgԪvG
a. L]lʥFg]?pĤGBĤCBĤKMĤQ]l^
b. ;ĤK]l]inhibitors^ A ͯf
c. ] coumarin ޵oܾ@
d. ]xŦ̿ʾ]l@??Ӥް_X{H"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"NA BeneFIX? ī~xsǷũ?áAb 2  30 ?AקK?AHK˵}Ĳ~laC
վtsGհt᪺A BeneFIX? ī~]?tGAҥHtsᥲb 3 pɥHϥΡC"	GAMMA-FIX[Coagulation Factor IX (Recombinant)]	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	"1.Pw B ͯf]ѩʲĤE]lʥFgAκٸtϸ`g^XA]A~NɪX山PwXC
2.`Wwʪv B ͯffw(ѩʲĤE]lʥFg) XC"	"A BeneFIX? TΩ󴿹糧~Ψզ(]AܹJ)ͨͩR¯٩ʤ?Y
LӤ(]ALӯg)fHC"	"ʹLӤ(]A޵jˤ()CPLӯg)BoNBy¡BYhBwtBߡB`gB`gkhΥֽLӤ(p֯lBC¯l)C
"	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IBENE-a	IBENE-b	IBENE-c	110.6.16
KC00430299		0	IKOAT2	HAEMATE P(KOATE-DVI) 250IU/vial(N)		"1.ŭB]lvon Willebrand factor
Haemate P@Τ覡󤺥ͩʪVWFCF@ĤK]lO@JաAŭB]lո`pO۩ި˳쪺H۩ʨæbpOtDnCPVWFiHBfwѩVWFʥF(VWD)X{岧`{HApU2hG
- VWFAإߦpOۨި˳쪺ޤUֲӭM(LP䵲ޤUֲӭMΦpOӭMW)Aѳ̪쪺{HH
YuXɶܡCoĪGOߧYoͪAӥBwjOjqlqVWFhEX(multimers) C
- VWFyFVIII ʥFBw{HCRߧPɡAVWFXͩʪFVIII (`ѯfwsy)AåBǥíwoӦ]lAקKֳt
ѡCŲ󦹡APªVWF (VWF~ȦC@תFVIII)NFVIII:C夤@שԦ^쥿`ȪĪGAbR߿`ɷ|@ǩwC
bR߿`ɡAPtVWFFVIII:C|ߨNFVIII:C夤@שԦ^쥿`ȡC
2.ĤK]l(FVIII)
Haemate P@Τ覡󤺥ͩʪFVIIICĤK]l/von Willebrand factorEX]AӤl(ĤK]lvonWillebrand factor)㦳PͲz\CQ`iJͯfw餺ɡAĤK]l|Pfw`tΤvonWillebrand factorXC
ƪĤK]lANƪĤE]l]lA[tܲĤQ]lƪĤQ]lCƪĤQ]l|N?(prothrombin)ܦ?(thrombin)C?|NֺܦֺAçΦGCAͯfOѩʬV骺ǩʦGTաAFVIIIqCAѩ۵o͡BN~AΥ~NGAӾɭPjqX庯J`B٦סBΤxCǥѴNkAϲĤK]l߿@׼W[AȮɭץ]lABX媺ɦVC"	"1.ŭBefG
@ӨAC@魫I1 IUVWF:RCoiH餺C@ɦGVWF:Rco@0.02 IU (Y0.02 IU/mL; 2%)C C@ɦGVWF:Rcotqnj0.6 IU (Y0.6 IU/mL; 60%)FVIII:Cj0.4 IU (Y0.4 IU/mL; 40%)tqCq`C1魫(BW)ݦ40-80 IUŭB]l(VWF:Rco)20-40 IUFVIII:C@פi\ClqiݭnC80 IUŭB]l(VWF)AרO3ŭBfwAA夤@סAiݭnϥΤLŭBfwjqC
2.NY~ˮɡAjqX媺wG
bNL{ɩάONoͤjqX{HAbNe1~2pɬIī~CC12~24pɡAݦA뤩AqCvqΨϥδݨ̯fw{ɪpBefΥXYʡA٦VWF:RCoMFVIII:Cؿ@צөwCϥΧtĤK]l(FVIII)ŭB]l(VWF)~ɡADvvAavɡAiɭPFVIII:CLCgL24-48pɪvAFקKFVIII:CLaWɡAҼ{Cq/ΩĶjC"	Haemate PC1000 IU FVIII / 2400 IU VWFt70 mguCϥΦbufHҼ{C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	FACTOR VIII	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	"1.ѤΫѯʥFĤK]lgC
2.ŭBefVon Willebrand Disease (VWD)
3.Aͯf(ѲĤK]lʥF)"	w糧~Υ~@᫬LӡC	"ioͫʹLӤCYLӤgo͡AߧY`g~ûPvpôC
ifwLӤxA]AC¯lBC¯lBݴeBݡBCAιLөʥJC
YoͥJpA`ثeзǡAiJvC
"	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiB05-05j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.4._20140401_000.pdf"">OI` 4.2.4.</a>             "	"OI` 4.2.3.,4.2.4."	0	OIs 20251124	IKOAT2-a	IKOAT2-b	IKOAT2-c	110.6.16
KC01027299	B02BD02	0	IELOC2	Eloctate inj. 500IU/vial		"ELOCTATEO@]տĦXJեiȮɨNľһݪĤK]lCELOCTATEtHK̲yJG1(IgG1) FcݡAûPsͨFc(FcRn)XCFcRnO@ѵM~|AiϧK̲yJկdb`ө?魰ѡAéߥbIC
"	"1.`Ww
ĳ_lqC4ѵ50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡC
p6ൣĳ_lqCP2AC50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡCiݭnWcΧ󰪪q(̰80 IU/)C
2.w餺ĤK]lpȼW[OϥΥHUӭpAHIU/dL (Υ`%)ܡG
wĤK]lW[IU/dL(Υ`%) = [`q(IU)/魫(kg)] x 2 (IU/dLCIU/kg)
3.nFw餺ĤK]lpȼW[iϥΥHUӭpG
ݧ뤩q(IU) = 魫(kg) x wĤK]lW[(IU/dLΥ`%)q x 0.5 (IU/kgCIU/dL)
4.PfHĪʤO(pbIB餺^v)M{ɤiणPCШ̾ڭ{ɤվELOCTATEľqMWvC
5.p6ൣfHiݭnվ㾯qC6HWfHAq`ݽվ㾯qC
"	"1.LӤ
2.Mʧ:YELOCTATEGĤK]ltqSpwW[άOXSAhç(Mʧ)ͨöiAC
3.ʴ:ʴO_ͲĤK]lCYߤwĤK]l@׵LkFAάOĳELOCTATEqLkɡABethesda աCϥBethesda(BU)ӳitqC
4.ELOCTATEAΩvŭBf(von Willebrand disease)
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"NöJs2XC8XC (36XF  46XF)ΫǷ(ŶWL30XC (86XF))A̦h6ӤCקKuC
"	"Antihemophilic Factor(Recombinant),Fc Fusion Prote"	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	vPwAͯfw(ѩʲĤK]lʥFg)XC	w糧~Υ~@᫬LӡC	"`hBLOBٵhBYhΥ֯lC
"	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IELOC2-a	IELOC2-b	IELOC2-c	110.6.16
KC01029299	B02BD02	0	IELOC3	Eloctate inj. 1000IU/vial		"ELOCTATEO@]տĦXJեiȮɨNľһݪĤK]lCELOCTATEtHK̲yJG1(IgG1) FcݡAûPsͨFc(FcRn)XCFcRnO@ѵM~|AiϧK̲yJկdb`ө?魰ѡAéߥbIC
"	"1.`Ww
ĳ_lqC4ѵ50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡC
p6ൣĳ_lqCP2AC50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡCiݭnWcΧ󰪪q(̰80 IU/)C
2.w餺ĤK]lpȼW[OϥΥHUӭpAHIU/dL (Υ`%)ܡG
wĤK]lW[IU/dL(Υ`%) = [`q(IU)/魫(kg)] x 2 (IU/dLCIU/kg)
3.nFw餺ĤK]lpȼW[iϥΥHUӭpG
ݧ뤩q(IU) = 魫(kg) x wĤK]lW[(IU/dLΥ`%)q x 0.5 (IU/kgCIU/dL)
4.PfHĪʤO(pbIB餺^v)M{ɤiणPCШ̾ڭ{ɤվELOCTATEľqMWvC
5.p6ൣfHiݭnվ㾯qC6HWfHAq`ݽվ㾯qC
"	"1.LӤ
2.Mʧ:YELOCTATEGĤK]ltqSpwW[άOXSAhç(Mʧ)ͨöiAC
3.ʴ:ʴO_ͲĤK]lCYߤwĤK]l@׵LkFAάOĳELOCTATEqLkɡABethesda աCϥBethesda(BU)ӳitqC
4.ELOCTATEAΩvŭBf(von Willebrand disease)
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"NöJs2XC8XC (36XF  46XF)ΫǷ(ŶWL30XC (86XF))A̦h6ӤCקKuC
"	"Antihemophilic Factor(Recombinant),Fc Fusion Prote"	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	vPwAͯfw(ѩʲĤK]lʥFg)XC	w糧~Υ~@᫬LӡC	"`hBLOBٵhBYhΥ֯lC
"	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IELOC3-a	IELOC3-b	IELOC3-c	110.6.16
KC01019299	B02BD04	0	IALPR	Alprolix (ĲĤE]l)1000IU(N)		ALPROLIXO@]տĦXJաAiȮɨNľһݪĤE]lCALPROLIXtHIgG1FcݡAûPsͨFc(FcRn)XCFcRnOѵM~|@AiϧK̲yJկdb`ө?魰(lysosomal degradation)AéߥbICBͯfO@XefASxʥF\઺ĤE]l(FIX)AɭPb~嬡?ɶ(aPTT)(@ؤwإߪĤE]lͪʪ~)ɶCALPROLIXvibĵĴYuaPTTC	"utsRߪ`gCbBͯfvg窺HʷU}lALPROLIXvC
P vqMɶMwĤE]lʥFYʡBXmM{סBfHӧOĪʤOǸơBH/ίfH{ɱpC
P fHĪʤO(pbIA餺^_v)M{ɤiणPCھڭ{ɤMwALPROLIXqMWvCp12ൣiݭn󰪪WvξqASOOp6ൣ12HWfHAq`ݭn̦~ֽվ㾯qCӨAC魫1 IUALPROLIXiĤE]lG`@צbH6?HWൣ1% [IU/dL]Abp6ൣ0.6%CϥΥHUӦݭnqάOw餺ĤE]lpȼW[AHIU/dL(Υ`%)G
IU/dL (Υ`%) = [`q(IU)/魫(kg)]  ^_v(IU/dLCIU/kg)

q(IU) = 魫(kg)  wĤE]lW[(IU/dLΥ`%)  ^_v˼(IU/kgCIU/dL)
Ҽ{b`WjNeMwfH餺^_v(IU/dLCIU/kg)ýT{bjNeĤE]l@פwFYX媺ؼЭȡC
`Ww
P H12HWC֦~ĳ_lqCg@50 IU/άOC10Ѥ@100 IU/C
P p12ൣA_lqCg@50-60 IU/C
P ̾ڭӤHӽվ㾯qCp12ൣiݭn󰪪WvξqASOOp6ൣC
ΩN{BmqG(]tLֵogޤ)GݭnĤE]lG`@[IU/dLΥ`%]50-80榸`gYiਬCݭn24-48pɫ᭫Ъ찱XåBˤf¡XCYGݭnĤE]lG`@[IU/dLΥ`%]60-100 (l)
beTѡAҼ{b6-10pɫHΤC24pɭơCѩALPROLIXbIA3ѫiCqíCNᵹWvܨC48pɩΧ[A찱XåBˤf¡XC"	"ioiLөʤgi]Aީʤ~AݴeACAlAߡAæRAPı`AļwAݻMIlxCYX{LӯgAALPROLIXö}lAvC
Yo͹LӪx(]tC¯lBݴeBݡBIlxHy~)MLөʤAfHϥβ~
Y|oͦ/AߧYpHδMD@"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js28XC (36XF to 46XF)CiNCN|}awR}G`gCALPROLIXiJsǷšAiWL30XC (86XF)A~Τp~WХܪĴeA̦h6ӤtsiJsǷšAiWL30XC (86XF)BiWL3pɡCקKugCts3ӤpɤϥΫhC	rFIXFc(Recombinat Coagulant factor IX Fc fusion protein)	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	"ALPROLIXAĤE]l()AFcĦXJաAOѰ]u{һsyĤE]lAΩ󦨤HMൣBͯfw̤G
P MwX
P N{Bm(Perioperative management)
P `Wwδ֥XWv
ALPROLIXAΩ󻤵oBͯffHK̭@ʡC"	"ALPROLIXiϥΩw糧~HΨξ(sucrose, mannitol, sodium chloride, L-histidinepolysorbate 20)|͹Lӥ]tLөʤ(anaphylaxis)fHC"	`}(oͲv?1%)YhBfķPı`MʧefC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALPR-a	IALPR-b	IALPR-c	110.6.16
BC25272100	B02BX05	0	OREVO	Revolade 25mg/F.C.tab (Eltrombopag)		pOͪ]l(TPO)Oո`ֲӭMƻPpOͦDnӭMEA]OpOͪ]l(TPO-R)ͩʰtCEltrombopag|PHTPO-RӭMOXϰ첣ͥ椬@ΡAûoPͩʦpOͪ]l(TPO)ۦPT|Aiӻo۰跽ӭMֲӭMWͻPơC	"Hĳ_lqC@25 mgC
[qվ]
b}lϥEltrombopagAеݭnվ㾯qAϦpOpƺb50,000/gAHCX孷ICC龯qФŶWL50 mgC"	"1.ӿQfACEltrombopagbAΥthl~ܤ4pɤeΤAΡAҦpGľBŻs~(ΨLttl)ΧthlqɥR(ҦpGKBtBBTBִBN)
2.bEltrombopagAwʴ{ɦGǻPx\ˬdAè̦pOp(p1ҥ)վEltrombopag{CbEltrombopagvACgyp(CBC)A]ApOpƻPPG٤AFíwpOp(? 50,000/gl ܤ4g)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Eltrombopag	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	ΩvbŦBLv(Ҧp:TJBK̲yJյ)Ѥ~Cʦ۵o(K̩)pOʥFg(ITP)w̡Aι󤣾AXiŦ~Cʦ۵o(K̩)pOʥFg(ITP)w̤ĤGuvC	w糧~Υ~@᫬LӡC	vBYhBPı`C	"C
ثeϥ 6 ӤHWwƫD`C"	SmҦwAקK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.2.1._20230101.pdf"">OI` 4.3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.2._20200201.pdf"">OI` 4.3.2.1.</a>             "	"OI` 4.3.2.,4.3.2.1."	0	OIs 20251124	OREVO-a	OREVO-b	OREVO-c	110.6.16
KC01031299	B02BD02	0	IELOC4	Eloctate inj. 2000IU/vial		"ELOCTATEO@]տĦXJեiȮɨNľһݪĤK]lCELOCTATEtHK̲yJG1(IgG1) FcݡAûPsͨFc(FcRn)XCFcRnO@ѵM~|AiϧK̲yJկdb`ө?魰ѡAéߥbIC
"	"1.`Ww
ĳ_lqC4ѵ50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡC
p6ൣĳ_lqCP2AC50 IU/窺ELOCTATEC̾ڭӤHӽվ㾯qAqd25-65 IU/Aɶj3-5ѡCiݭnWcΧ󰪪q(̰80 IU/)C
2.w餺ĤK]lpȼW[OϥΥHUӭpAHIU/dL (Υ`%)ܡG
wĤK]lW[IU/dL(Υ`%) = [`q(IU)/魫(kg)] x 2 (IU/dLCIU/kg)
3.nFw餺ĤK]lpȼW[iϥΥHUӭpG
ݧ뤩q(IU) = 魫(kg) x wĤK]lW[(IU/dLΥ`%)q x 0.5 (IU/kgCIU/dL)
4.PfHĪʤO(pbIB餺^v)M{ɤiणPCШ̾ڭ{ɤվELOCTATEľqMWvC
5.p6ൣfHiݭnվ㾯qC6HWfHAq`ݽվ㾯qC
"	"1.LӤ
2.Mʧ:YELOCTATEGĤK]ltqSpwW[άOXSAhç(Mʧ)ͨöiAC
3.ʴ:ʴO_ͲĤK]lCYߤwĤK]l@׵LkFAάOĳELOCTATEqLkɡABethesda աCϥBethesda(BU)ӳitqC
4.ELOCTATEAΩvŭBf(von Willebrand disease)
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"NöJs2XC8XC (36XF  46XF)ΫǷ(ŶWL30XC (86XF))A̦h6ӤCקKuC
"	"Antihemophilic Factor(Recombinant),Fc Fusion Prote"	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	vPwAͯfw(ѩʲĤK]lʥFg)XC	w糧~Υ~@᫬LӡC	"`hBLOBٵhBYhΥ֯lC
"	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IELOC4-a	IELOC4-b	IELOC4-c	110.6.16
KC01016299	B02BD04	0	IALPR3	ALPROLIX 3000IU (ĲĤE]l)(N)		ALPROLIXO@]տĦXJաAiȮɨNľһݪĤE]lCALPROLIXtHIgG1FcݡAûPsͨFc(FcRn)XCFcRnOѵM~|@AiϧK̲yJկdb`ө?魰(lysosomal degradation)AéߥbICBͯfO@XefASxʥF\઺ĤE]l(FIX)AɭPb~嬡?ɶ(aPTT)(@ؤwإߪĤE]lͪʪ~)ɶCALPROLIXvibĵĴYuaPTTC	"utsRߪ`gCbBͯfvg窺HʷU}lALPROLIXvC
P vqMɶMwĤE]lʥFYʡBXmM{סBfHӧOĪʤOǸơBH/ίfH{ɱpC
P fHĪʤO(pbIA餺^_v)M{ɤiणPCھڭ{ɤMwALPROLIXqMWvCp12ൣiݭn󰪪WvξqASOOp6ൣ12HWfHAq`ݭn̦~ֽվ㾯qCӨAC魫1 IUALPROLIXiĤE]lG`@צbH6?HWൣ1% [IU/dL]Abp6ൣ0.6%CϥΥHUӦݭnqάOw餺ĤE]lpȼW[AHIU/dL(Υ`%)G
IU/dL (Υ`%) = [`q(IU)/魫(kg)]  ^_v(IU/dLCIU/kg)

q(IU) = 魫(kg)  wĤE]lW[(IU/dLΥ`%)  ^_v˼(IU/kgCIU/dL)
Ҽ{b`WjNeMwfH餺^_v(IU/dLCIU/kg)ýT{bjNeĤE]l@פwFYX媺ؼЭȡC
`Ww
P H12HWC֦~ĳ_lqCg@50 IU/άOC10Ѥ@100 IU/C
P p12ൣA_lqCg@50-60 IU/C
P ̾ڭӤHӽվ㾯qCp12ൣiݭn󰪪WvξqASOOp6ൣC
ΩN{BmqG(]tLֵogޤ)GݭnĤE]lG`@[IU/dLΥ`%]50-80榸`gYiਬCݭn24-48pɫ᭫Ъ찱XåBˤf¡XCYGݭnĤE]lG`@[IU/dLΥ`%]60-100 (l)
beTѡAҼ{b6-10pɫHΤC24pɭơCѩALPROLIXbIA3ѫiCqíCNᵹWvܨC48pɩΧ[A찱XåBˤf¡XC"	"ioiLөʤgi]Aީʤ~AݴeACAlAߡAæRAPı`AļwAݻMIlxCYX{LӯgAALPROLIXö}lAvC
Yo͹LӪx(]tC¯lBݴeBݡBIlxHy~)MLөʤAfHϥβ~
Y|oͦ/AߧYpHδMD@"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js28XC (36XF to 46XF)CiNCN|}awR}G`gCALPROLIXiJsǷšAiWL30XC (86XF)A~Τp~WХܪĴeA̦h6ӤtsiJsǷšAiWL30XC (86XF)BiWL3pɡCקKugCts3ӤpɤϥΫhC	rFIXFc(Recombinat Coagulant factor IX Fc fusion protein)	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	"ALPROLIXAĤE]l()AFcĦXJաAOѰ]u{һsyĤE]lAΩ󦨤HMൣBͯfw̤G
P MwX
P N{Bm(Perioperative management)
P `Wwδ֥XWv
ALPROLIXAΩ󻤵oBͯffHK̭@ʡC"	"ALPROLIXiϥΩw糧~HΨξ(sucrose, mannitol, sodium chloride, L-histidinepolysorbate 20)|͹Lӥ]tLөʤ(anaphylaxis)fHC"	`}(oͲv?1%)YhBfķPı`MʧefC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALPR3-a	IALPR3-b	IALPR3-c	110.6.16
AC45362221	B03AC	0	IFERR	FE-BACK 20mg/ml;/5ml/vial		h֪BKOPqxŦɽu̪KJդΦƦXӥHKJղVX]nJK^κAJsۡAKbߤP] -yJഫಾKAJսPCӤlJս褤ҧt2ӭlTKlΦ@ӯ⪺VXCಾK誺Dn@άOKz骺a̡AಾΦٲyXm]ಾӭM^AӻsyFtKïCboǤu@ɨFKNªͩRΤϨCಾK]ĤGحn\AΰѻPF騾mHܷPVCMbKϥγ~|KX骺OWߪAHKQfAvȱN|W[֧C	"~i٦ת`gAuRߪ`gRߺw`.אּRߺw`D
~5mlACmlt20mgKA1~Fe-backt100mgKD
IV pushݽwC`g:1ml/min(~1mlt20mg K)
IV dripHNS}A1 vial 5mlĳH100ml}Adrip 15D@̤jq(H)10ml(2)DWL200mgK
wzѡACWL120mgqAHR߿`Ab2pɥHW`C
H1Ѭ2.5@ɡA2Ѭ5@ɡA3Ѭ10@ɡAMO10@ɤ@P⦸ΨMHbC
H@̤jq10@ɡCൣ5-10@̤jq 2.5@ɡCൣ<5@̤jq1.25@
tO:70kg,Hb=8 ݭn`Kq=70kg*(15g/dL-8g/dL)*2.4=1200mgKF1200mg+500mg(nJK)=1700mg(17)
WL@鵹ľqAib@P."	"NS}1-2 mg / ml; 100 mgK(5ml 1) ts100 ml NS> 15F 300 mgK(15ml 3) ts 250 ml NS> 1.5pɡF 400 mgK(20ml 4) ts250 ml> 2.5pɡF 500mgK(25ml 5) ts250@> 3.5pɡC IVP(20mgK)1ml> 5
1.PwaGˬdAЪ`NnPLqC
2.I̽ФŨϥΡC 
3.~קKPLsVXϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ferric-hydroxide-sucrose complex	B03A	Ks IRON PREPARATIONS	0	BCʥBhBNKʥFg	"1.tKqLhKQΨzZfHקKϥΡC 
2.Yxǥ\ê̡AyϥΡC"	LөʤCooΤַP	"A
hkĤ@oͳhhHfAKɥRA~筭ĤGβĤTϥΡC"	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-08 [w]_w02-07 [w]_w02-26 [E]_G2-01 [Ew]_D1-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IFERR-a	IFERR-b	IFERR-c	110.6.16
NC018221G0	B03AE03	0	OFEGB	Ferrous Gluco-B 300mg/tab(Ferrous glucon)		h֪BKOPqxŦɽu̪KJդΦƦXӥHKJղVX]nJK^κAJsۡAKbߤP] -yJഫಾKAJսPCӤlJս褤ҧt2ӭlTKlΦ@ӯ⪺VXCಾK誺Dn@άOKz骺a̡AಾΦٲyXm]ಾӭM^AӻsyFtKïCboǤu@ɨFKNªͩRΤϨCಾK]ĤGحn\AΰѻPF騾mHܷPVCMbKϥγ~|KX骺OWߪAHKQfAvȱN|W[֧C	HC@BCA3Bp~ִq	"yŸA,Aīe30,ŶΩ@"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ferrous gluconate/Vit.B1/Vit.C	B03A	Ks IRON PREPARATIONS	0	KʥFʳhBWehBphB~hC	ƩʼšBũʪzBզHۯfBʳhBxŦa	GzEB«K	A	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w31-08 [UDx]_U03-14 [E]_B3-20 [Ew]_EX032 j	Ts110.6.16		OI` 	0	OIs 20251124	OFEGB-a	OFEGB-b	OFEGB-c	110.6.16
AC47456100	B03AB04	0	OFERR	HOTE chewable 100mg/tab (Ferric hydroxid		h֪BKOPqxŦɽu̪KJդΦƦXӥHKJղVX]nJK^κAJsۡAKbߤP] -yJഫಾKAJսPCӤlJս褤ҧt2ӭlTKlΦ@ӯ⪺VXCಾK誺Dn@άOKz骺a̡AಾΦٲyXm]ಾӭM^AӻsyFtKïCboǤu@ɨFKNªͩRΤϨCಾK]ĤGحn\AΰѻPF騾mHܷPVCMbKϥγ~|KX骺OWߪAHKQfAvȱN|W[֧C	"1QD-BID. (b@ѤɭԩCZλP@ǲG@_]`)
(1) HGC1-2AC1C
(2) ൣGq̦~֡BgAyWϥΡC"	"1.~CZAĳH\\AΡC
2.AΫTKCܶ¡A`{HC
3.׶}@دC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Ferric hydroxide polymaltose complex	B03A	Ks IRON PREPARATIONS	0	wΪvʥFgBKʳhg	"1.糧~LӪ̡ATϥΡC
2.KL׭t(pGIۯfBKI)C
3.KQΥ`(pG]rʳhBKQΤ}ʳhBah)C
4.DKʥFgް_h(pGʳhBͯB12ʥFް_yh)C"	ߡBæRBKBGzABTKCܷtC	A	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w31-07 [UDx]_U03-03 [E]_B3-25 j	Ts110.6.16		OI` 	0	OIs 20251124	OFERR-a	01C47456-1	OFERR-c	110.6.16
B016285209	B03BA05	0	IMECO1	wMethycobal 500mcg/ml/amp		餺?ͯB12@	"H500 mcg BID-TID.
ĵwʩ|إ"	"٦ת`gɬKvT´ίg`NUCƶ:
1.קKbP@Ъ`gAרOĥSO`N
2.׶}gV"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	 Mecobalamin	B03B	ͯB12M VITAMIN B12 AND FOLIC ACID	0	LRТʥFҤް_yʳhΥʯgê	w糧~ʦLӪw̡C	GABBߡBmBol	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-37 [UDx]_U10-06 [UDx]_U10-09 [w]_w02-06 [w]_w02-19 [E]_G3-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2.1._20110801_000.pdf"">OI` 3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.1.</a>             "	"OI` 3.2.,3.2.1."	0	OIs 20251124	IMECO1-a	IMECO1-b	IMECO1-c	110.6.16
AC346701G0	B03BB01	0	OFOLA	Folacin 5mg/tab(Folic acid)		ĬOXDNA RNA ҤiίʪARNA PDNA SӭMҥAb餺|Ʀ|BġAiXDNA MRNAAMAΦֻġC	}lɤ@AΤ@ܤGAHC@ܤGAq@GC	-------	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Folic acid	B03B	ͯB12M VITAMIN B12 AND FOLIC ACID	0	cʳhBʳhBp२jyhΰWͩΰIhް_h	w糧~ʦLӪw̡C	BߡC	A	i/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w31-06 [s]_131 [®]_131 [UDx]_U03-05 [E]_B3-23 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	OFOLA-a	OFOLA-b	OFOLA-c	110.6.16
AC296301G0	B03BA05	0	OYOUC	Methycobal 500mcg/cap(Mecobalamin)		餺?ͯB12@	"H500 mcg BID-TID.
ĵwʩ|إ"	"u|ɭPDtq֡AĳAΫeANnqT]ˤX
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mecobalamin	B03B	ͯB12M VITAMIN B12 AND FOLIC ACID	0	LRB12ʥFҤް_yʳhΥ鯫gê	w糧~ʦLӪw̡C	GABBߡBmBol	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L5 [2]_L5 [ws]_w38-01 [s]_213 [®]_213 [UDx]_U03-30 [E]_B4-22 [Ew]_EX043 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2.1._20110801_000.pdf"">OI` 3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.1.</a>             "	"OI` 3.2.,3.2.1."	0	OIs 20251124	OYOUC-a	OYOUC-b	OYOUC-c	110.6.16
KC00869255	B03XA03	0	IMIRC	Mircera 100mcg/0.3ml/syring (Epoetin ])		Cʵǯfް_gʳhC(|֭v]gƾkް_h)	"_lq
1.ثeϥΥESAvw̡G
ΩvثeϥΥESAHCʵǰIܱw̪gʳhɡAMirceraĳ_lqCg@AHRߩΥ֤U`g覡뤩澯0.6LJ/魫qC
뤩MirceraؼϦȹFú1012 g/dLC@Ⱥboӽd򤺤AMirceraĤ覡i令CI@AϥΨCgI@⭿qAMAݭnվ㾯qC
2.ثebϥESAvw̡G
ثebϥESAvBȤwíww̡Ai令CgΨCI@MirceraCMircera澯RߩΥ֤U`gqĪɭҨϥΤESACg`qөwC"	"1.ͪ12 g/dLΦb2gWɵ{׶WL1 g/dLɡACMirceraqC
2.vwʴGǰѼơC
3.ھڥثeުĳAȪWɲvΥؼЭCw̭ӧOqwCCʵ
fw̡AvؼЬϦȹF1012 g/dLdCKʴw̡ATOMircera̧CľqϥΨHhgC
4.MirceraHRߡ]IV^Υ֤U]SC^`g覡ġC
5.勵biGzRw̡AĳĥR߳~|ġA]R߳~|iް_K̤C
6.ĥΥ֤U`g覡ĮɡANMircera`g󸡳BuΤjLC
7.űNMirceraM`gGVXb@_ϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~ib2-8JUxsCץC	Methoxy Polyethylene Glycol-Epoetin ]	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	Cʵǯfް_gʳhC(|֭v]gƾkް_h)	"1. TΩ֦򱱨w̡C
2. TΩ󴿹糧~͹LӤw̡C"	̱`i}BmB |BYhBHΤWIlDPVC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-23 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.1._20160901_000.pdf"">OI` 4.1.1.</a>              "	OI` 4.1.1.	0	OIs 20251124	IMIRC-a	IMIRC-b	IMIRC-c	110.6.16
KC00955206	B03XA02	0	INESP	NESP inj. 20mcg/0.5ml(~ǫǭpM)(N)		vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"CʵǰIܱw̡J
~ľqRߪ`gΥ֤U`gCg@C
GzRfHAĳHRߪ`gPC
_lq:
vhG
HRߪ`gΥ֤U`gCg@ĳ_lqC魫0.45mcg/kgC
qG
ľqӤHƥHȦb1012g/dLC
qվG
~ľqվCw̪ȯFӥBȦb10g/dL12g/dLC"	1.󦳬YǦGf]ҦpGʳhBIMyʳhBahBg^w̡AåTߥHDarbepoetin alfavwʤΦĩʡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~ib2-8JUxsCץC	Darbepoetin \	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"~TΩG
1.Lkw̡C
2.DARBEPOETIN ALFA ΨLyͦJĪv}l¬yo|(PRCA)C
3.w DARBEPOETIN ALFA YLӤ̡C"	ΧCB~BYhBhBmBߡBæRB٦`khBWIlDPVC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-55 [E]_K-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.1._20160901_000.pdf"">OI` 4.1.1.</a>              "	OI` 4.1.1.	0	OIs 20251124	IARAN1-a	IARAN1-b	IARAN1-c	110.6.16
KC00876212	B03XA01	0	IEPO2	Recormon 2000IU/syringe (Epoetin ])		"yͦO@޳JաAEyͦeXͦyͪ]lCi@
E]lHΤƶPXC

"	"֤U`gG쾯qOCg320 IU/kgAYeW[zQ]CPC0.5 H^AqiHCӬPjACPW[20 IU/kgFCPq]iCPC
Rߪ`gG쾯qOCP340 IU/kgC"	 ̤jqWLCP720 IU/kg	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Nī~m 2 ~ 8 צBcFpoܽιLAiAϥΡC	Epoetin Beta	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	vCʵǰIܥBHgʳhfH	iϥΦb}w̡AάOw糧~ʦLӪw̡C	WɡBB¬yAͤ}C	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-56 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.1._20160901_000.pdf"">OI` 4.1.1.</a>              "	OI` 4.1.1.	0	OIs 20251124	IEPO2-a	IEPO2-b	IEPO2-c	110.6.16
KC00197248	B05AA01	0	IALB25	Albumin 25% 50ml/bot (Normal serum Album		ߥNΫ~M߳J	Rߪ`gGAζqpөwC	"RʤŦIܯfvfHBǥ\णfHíw
CʳhfHSOoʹ`entL
IAv|w惡fH@ϥΥĪ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sbWL30CǷŤUCᵲC}ʫWL4Ӥpɥ	Human albumin	B05A	Gάī~ BLOOD AND RELATED PRODUCTS	0	CJզgBJBN	"1.ճJջsβ~󦨤LӤ
2.׳hΤߤOIܱw
3.RʤߤOIܡAǥ\णCʳhfH
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U04-01 [E]_F2-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.1._20220201.pdf"">OI` 4.2.1.</a>              "	OI` 4.2.1.	0	OIs 20251124	IALB25-a	IALB25-b	IALB25-c	110.6.16
AC12824277	B05AA05	0	IDEXT	DEXTRAN 40 500ML/BTL(LOW MOT)		ߥNΫ~M߳J	"q`H@^ 500mLARߪ`gC̪ 24 pɧPq 20mL/Kg
HUCwΪvgAsPɡAPq 1  10mL/Kg
HUA5 餺C@~`yGAPq 10~20mL/KgA
b 20mL/Kg HUCt~APqBPtר̦~֡B魫Bg
@AyWC
"	קKsϥΡC(iuPA餺ϥΡC)	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"30JHUJsA
~ˮɺɥi覡OsAקK Dextran RX"	Dextran	B05A	Gάī~ BLOOD AND RELATED PRODUCTS	0	Xɤ߼Wq	"1.Ciʲgw
2. Rʤߤw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IDEXT-d	IDEXT-b	IDEXT-c	110.6.16
BC25173277	B05BA01	0	IA10X	Aminoplasmal NEO 10% 500ml		iĿ`G	"R߿`
H
C饭qG10 V 20 ml/魫
C̤jqG20 ml/魫
̤j`tסG1.0 ml/魫/p 
ൣG
3-5ൣC饭qG15 ml/魫
6-14ൣC饭qG10 ml/魫"	"wʴfwMqѽB}ȡBGšBPŤεǥ\(BUN Creatinine)C
MJսΨx\]wʴ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.Jsūפi25XCC
2.VXᤧG2-8XCJsWL24pɡC"	Amino acids	B05B	Rߪ`gG I.V. SOLUTIONS	0	εLkAagfθzDiTҤw̡A@RiĸɥRA@XJս褧CRivɡAPɾAɥRqӷApR߿`ҤƦXC	"ﷻGiĹL
? ѩiĥN»ê
? MΥͩRíw`ApJ
? ʮ
? N©ʻĤr
? xef
? gGzRΦGLovYǥ\ण
? 2HUϥ
VŦy
VʪͰI
VLh"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IA10X-a	02C25173-1	02C25173-2	110.6.16
BC25179209	B05BA10	0	IBFLU	ĵBFluid  inj. Ƥ1000ml/U		uRiɥRΡC	ϥΫeA}~UAUǥH}ǶsBAϤGǷGVXCq`H@^500@ɥѥR߫`CHзǿ`t׬120 `500@ɡCѤHPgww`tסCq̯gB魫B~֧@AyWCC̤jPq2500@ɡC	"1. 500@ɤt15J]2.35J^PDJսq150 kcalCH@ߤ@iӷLkFCqݨDC
2.  NWPAϥδ3~5ѡAֶ}lgfBgzi檺iɥR覡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץA25JHUxsC	WǲGGġBqѽGCUǲGGͯB1B}BqѽG	B05B	Rߪ`gG I.V. SOLUTIONS	0	gfBתCJզgBתiêBNeᵥAɪġBqѽBͯB1ΤiɵC	"1. xʩgΦxʩgw̡C
2. gǻêΰgw̡C
3. Rʤ߰Iܱw̡C
4. YĤr]ŻĦg^w̡C
5. qѽN²`w̡C a. [gw̡]觿BAddisonsg^C b. Cgw̡]ƥҪCU^C c. gw̡]ҪCU^C d. tgw̡C
6. ]Dӧq֪w̡C
7. ĥN²`w̡C
8. ͯB1Lӯgw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w00-04 [E]_F1-08 j	Ts110.6.16		OI` 	0	OIs 20251124	IBFLU-a	IBFLU-b	IBFLU-c	110.6.16
BC251502FN	B05BA10	0	IKABI1	ĵSmofKabiven PI 1448mg/bag		Ri`AAΩLkѤfĶiθgzDiAθTѤfĤθzDi~w	"13HWC֦~ΦH
20~40ml/kg/day (ĳC̤jq40 ml/kg/day)
ൣ(2-11)
̰q 40 @/ 魫/ѡApݨDqܲ~HjAݭnھڻݨDվ㾯q"	"1.jM͵oͥeLӤרҡC
2.ʴM}Bqѽ@שMzGŪpBPpMxŦïˬdC
ɶתծɡAʴ夤yӭMƻP\

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1}ʤOs2~
 2.VXǷūOsĳ24pɡC"	Amino acids Combinations	B05B	Rߪ`gG I.V. SOLUTIONS	0	Ri`AAΩLkѤfĶiθgzDiAθTѤfĤθzDi~w	"ﳽBJBjΪͪJսLөι糧~󦳮ĦνξLӪ̥ѩiĥN²`
Yׯg
רx\ण
רx\ण
YGef
׵ǥ\णABiGLoγzRv
ʥJ
Lk}
ΨⷳHUൣ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w12-06 [E]_F3-07 j	Ts110.6.16		OI` 	0	OIs 20251124	IKABI1-a	IKABI1-b	IKABI1-c	110.6.16
BC252032FC	B05BA10	0	IKABI2	ĵ SMOFKABIVEN ()1477ml/U		Ri`gG	"H13-31ml/kg/day (ĳC̤jq35 ml/kg/day)
ൣ:ھڻݨDվ㾯q(ĳC̤jq35 ml/kg/day)"	"1.jM͵oͥeLӤרҡC
2.ʴM}Bqѽ@שMzGŪpBPpMxŦïˬdC
ɶתծɡAʴ夤yӭMƻP\"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʤOs2~
VXb2~8JOsĳ24pɡC"	iķGB}GBתըž	B05B	Rߪ`gG I.V. SOLUTIONS	0	Ri`AAΩLkѤfĶiθgzDiAθTѤfĤθzDi~w̤2HWൣC	"ﳽBJBjΪͪJսLөι糧~󦳮ĦνξLӪ̥ѩiĥN²`
Yׯg
רx\ण
רx\ण
YGef
׵ǥ\णABiGLoγzRv
ʥJ
Lk}
ΨⷳHUൣ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w11-09 j	Ts110.6.16		OI` 	0	OIs 20251124	IKABI2-a	IKABI2-b	IKABI2-c	110.6.16
BC20975209	B05BA10	0	INUTR	ĵ Nutriflex special Ƥ()1000ml/U		RiGAƦXs	"HĳC̤jq25 ml/kg/day
ൣG
2-8 ĳC̤jq29 ml/kg/day
9-12 ĳC̤jq24ml/kg/day
13-17 ĳC̤jq17ml/kg/day"	"1.X{ߡBæRBΦhgAG
2.Ѧ~HŦ\णεǥ\णeffHpߨϥ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.}ʥis2~
2.}ʫiHsbū2 V 8XC Nîw̦h7ѡAåibǷŤΤDgpUhs2ѡC"	ĩM}G	B05B	Rߪ`gG I.V. SOLUTIONS	0	LkgfA᭹θzDliB\णTүgɡA襤Y @ΪAfHRiѮġB }BqѽMGCYOd uRi`GAΩ󦨤HM 2 17 ൣ	"1.ξLӤ
2. ѩʮĥN²`
3.Cp 6 خqvL}gC
4.  `δպޤX
5.Ĥr
6.Yx\ण
7.Yǥ\णBŦNk"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
	B05BA10	0	INUTR1	ĵ NuTRIflex Lipid(TX@)()625ml/U		RiGAƦXs	HĳC̤jq35 ml/kg/day	ugѤR߿`C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"GVXߧYϥΡAVXG2-8XCHUis4ѡA[WǷ25XCU
48pɡC"	iġBҤƦXBתդιqѽ誺ž	B05B	Rߪ`gG I.V. SOLUTIONS	0	"HbLkϥΡBAyΤRϥΤfABzDiɡA@Riv
qBiġBݯתջġBqѽβG骺ɥRC"	"ViĥN»ê
VתեN»ê
V[gBug
VN¤íwҦpGYgԸsAíw}fpA]
g
VCp6خqvL}g
VĤr
VxxĲJng
VYx\ण
VYǥ\णBŦNk
V㪺Ŧ\ण
VYXɦV
VߦٱΤʴ
Vʦ-Aתծ
VwJBjJաAͪoΨLLӪ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.24		OI` 		OIs 20251124	DC	DC	DC	114.04.24
		0	IOMEG1	Omegaven Emulsion IV.100ml/bot		"ot״Is-3 תջġAMMCT άOOliver oil AnͪʡC?uOɥRiAѯ??A
ܵoSʡA֦\h?ǤWU?CA٦K[ͯE (\-tocopherol)?W[ܮƧ@ΡC"	"1~2@ Omegaven 魫0. 1~ 0. 2 J o 魫70~ 140 @ Omegaven  魫 70 fw
̤j`tv
`tvoWL 0.5 @ Omega ven 魫 p ]۷ 0. 05Jo 魫 p ^C
̤j`tvYʱA _h夤Tĥ̪o @ץi|ؼW[ C~PLתըžPɨϥ CתըCĳJq 1~2 J魫~o Jq  10~20% CgѤߩΩPR߿`C~ϥδoWL|g C"	"`~i|XɶΧpOC
b`~ɡACѺʴ夤Tĥ̪oୡCbתըž`ATĥ̪o WL 3 mmol/l ] 266 mg/dl i
|ͯתչLqxC ߧY `תըž εݭnH ֿ`q"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 25 XC Os 24 p	Highly refined fish oil 0.1g/ml	B05B	Rߪ`gG I.V. SOLUTIONS		Riѱw̪תջ om ega 3 fatty acid ]רOEicosapentaenoic acid  Docosahexaenoic acid ^ɵ C	"1.תեN·l`
2.YXg
3.íw}f
4.YǺΦMΥͩRpApGJPBߦٱBBBgA
5.]ثe{ɨϥθg礣A ~ФťΩYxBǥ\णw
6.]ثe{ɨϥθg礣A ~ФťΩ󦭲Bsͨ
7. i ` @TүgGC[gB 餺LhBC iʲBN¤}BĤr

w  JL ӤfwAФŨϥΥ~C"	h BߡBæRBŤW BoݡBHŸ Bh¡B Tĥ̪o gBYh	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  		  	ixii[w]_w11-05 j	Ts110.8.11		OI` 		OIs 20251124	IOMEG1-a	IOMEG1-b	IOMEG1-c	110.8.11
AC29276277	B05BA01	0	IAH500	AMINOPOLY-H 500ML		iĿ`G	"q`H 1 饻 500ml H 50%} 80ml VX 2  3 pɤw
CIwRߪ`gCLkgfiw̩θgfiXw̡AIHqGkɡAAminopoly-H 1  400~600ml gR߫`J"	 Ъ`NiHPתջĦ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUBJsC	iġBD	B05B	Rߪ`gG I.V. SOLUTIONS	0	xgɮĤɵ	LgAѥͮĥN²`ASOOĥN¯fp Maple Syrup Urine Disease  Isovaleric AcidemiaιĹLӪ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w11-04 j	Ts110.6.16		OI` 	0	OIs 20251124	IAH500-a	IAH500-b	IAH500-c	110.6.16
BC22023255	B05BA01	0	IAMI10	AMINOSTERIL INFANT 10% 100ML/BTL ̭Y		iĿ`G	"R߿`C
̤j`t?G
0.1Jġ魫pɡ 1.0@ɡ魫p
̤j龯?G
1HG1.52.5Jġ魫C
1 G1.5Jġ魫C
24G1.5Jġ魫C
ϥΥ~ɶuAݭnөwC
`NG`t?ӧ֡AigѵŦ?Aӳy?šCݭnӨMwO_K[qѽC"	`NGBΥవz~iɡAw˴U?ءG?APšAqѽ(ionogram)AxïA׽@?(?Pɿ`תըž)AšApݭn˴MĿ@?C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKӮgBǷŧC25?C	amino acids	B05B	Rߪ`gG I.V. SOLUTIONS		BΥधz~i(Partial Parenteral Nutrition)	"ĥN??BĬrgBLhBC[gCǥ\??Ψx\??w̶ӧO?CCuw[`NC
"	`즳ΦBN©ʻĤrBLhC 	DnקKϥ	DnקKϥ	аѦҾqPΪk	  		  	ixii[w]_w11-06 j	Ts110/9/30		OI` 	0	OIs 20251124	IAMI10-a	IAMI10-b	IAMI10-c	110/9/30
AC25550263	B05BA01	0	IAMIY	AMIYU 200ML/BTL		iĿ`G	"1.CʵǤGq`H 1  1 ^ 200ml gR߽wC`A`tצH 200ml 120~180(1  25~15 w)ǡCpġBѤHYw̶SOwC`ASIzRkɳzRפF 90~60 eѳzR^R߰`C
2.ʵǤGq`H 1  200~400ml R߽wC`AqGkqRߤIw`JCq̦~֡BgB魫AyWC"	1. }ʫߧYϥΡAŦAϥδݲGC2.YRXAib 50~60JѫANoťkAϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js 25JHUAçūץHRX		B05B	Rߪ`gG I.V. SOLUTIONS	0	BCʵǤɮĤɵ	xʩΩΨxʩζäw				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U10-11 [E]_F2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IAMIY-a	IAMIY-b	IAMIY-c	110.6.16
BC25179277	B05BA10	0	IBFLU1	ĵBFluid inj.Ƥ 500ml/U		uRiɥRΡC	q`H@^500@ɥѥR߫`CHзǿ`t׬120 `500@ɡCѤHPgww`tסCq̯gB魫B~֧@AyWCC̤jPq2500@ɡC	"1. 500@ɤt15J]2.35J^PDJսq150 kcalCH@ߤ@iӷLkFCqݨDA]uuiɥRΡC
2. gfAӻݥHɥRiw̡Aw̪iݨDMgfqAPC
3. NWPAϥδ3~5ѡAֶ}lgfBgzi檺iɥR覡C
4. 500@ɤtͯB1 0.96@JAͯӷCB~ͯB1ΨLͯɥṞw̪gөwC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץA25JHUxsC	i qѽ LRB2}	B05B	Rߪ`gG I.V. SOLUTIONS	0	gfBתCJզgBתiêBNeᵥAɪġBqѽBͯB1ΤiɵC	"1. xʩgΦxʩgw̡C
2. gǻêΰgw̡C
3. Rʤ߰Iܱw̡C
4. YĤr]ŻĦg^w̡C
5. qѽN²`w̡C a. [gw̡]觿BAddisonsg^C b. Cgw̡]ƥҪCU^C c. gw̡]ҪCU^C d. tgw̡C
6. ]Dӧq֪w̡C
7. ĥN²`w̡C
8. ͯB1Lӯgw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w12-04 [E]_F1-07 j	Ts110.6.16		OI` 	0	OIs 20251124	IBFLU1-a	02C25179-1	02C25179-2	110.6.16
AC24986265	B05BC92	0	IGLYB1	Glycerol inj.Ƥ250ml/bag		~O󰪺zʲ@(@)AHΧQGlycerolqJN¹L{AHPiNªﵽ(@)Ate{`UBB~θyoﵽĪGC	"Rߺw`:C200500ml,C12;500mlw`23pɡCv12g,fHվC"	"1.QhìwUBw~~w̡ABzX巽AýT{SAX媺ü{AiPC(pGƥåT{~sbP_AYJMPA]Y\UiȮɤA|AX)
2.]tQGݭnQw̡APɶ`NC
3.]tG}AGjqBtPɡA`N|ͨŻĻĤrC
4.NA]|ް_NAGƱNeƧC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Glycerin	B05B	Rߪ`gG I.V. SOLUTIONS	0	C`B~C	ǩʪG}@gw̽ФŨϥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w00-03 [E]_F2-04 j	Ts110.6.16		OI` 	0	OIs 20251124	IGLYB1-a	IGLYB1-b	IGLYB1-c	110.6.16
AC09633277	B05BC01	0	IMANN1	Maniton 20%;500ml/bot(Mannitol)		QB	"1.z@ΡGR߿`AC魫 0.5g2gm H1525%GAIw` 3060 C
2.E_Ρ]ǥ\^GR߿`AC魫200mg H1525%G3-5 `J餺C"	1.ѩ󥻾iGAGHNɩRXAХ[Ŧ40~50XCAݷѫAŵ{רϥΡC 2.bY~ˡAY\X大iʮɡAVϥΤC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ǷŤU25JHUxs	Mannitol	B05B	Rߪ`gG I.V. SOLUTIONS	0	QB`B~BPirưBǤpyLotvw]E_Ρ^	LgBYͤ~{ʤ߰IܡB`XBYB12HUൣC				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6063397?cesid=aKmEXt5nrzA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMANNITOL%26t%3Dname%26acs%3Dfalse%26acq%3DMANNITOL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[w]_w00-02 [E]_F2-06 j	Ts110.6.16		OI` 	0	OIs 20251124	IMANN1-a	IMANN1-b	IMANN1-c	110.6.16
BC24519265	B05BA02	0	ISMOF	ĵSMOFlipid 20% Emulsion 250ML/BOT		תըž	"HG
зǾqO1.02.0Jת/ 魫 /ѡ]۷5-10 @/魫 / ^C
ĳ`tvO0.125Jת/ 魫/ pɡ]۷0.63@SMOFlipid/ 魫 / pɡ^AoWL0.15Jת/ 魫/ p(۷0.75@SMOFlipid/ 魫 / p)C

ĵG
ĳC龯qWL2.0Jת/ 魫 /ѡ]۷10@SMOFlipid/ 魫/ ѡ^C
ĲĤ@gWC龯qC
`tvoWL0.15Jת / 魫 / pɡC"	fHYX{LӤxίg]ҦpGoNBŸݡBlΩIlx^AߧYJ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"25JHUxsC
2.VX2-8JҤiWL24p"	"SOYBEAN OIL REFINED, FISH-OIL RICH IN OMEGA-3 ACID"	B05B	Rߪ`gG I.V. SOLUTIONS	0	fwfAθgziiAθTҮɡA@Dgziv覡@	"1.ﳽBJΤjJսLӡAι@جʪν᫬LӡC
2.YׯgC
3.Yx\णC
4.Y岧`C
5.٥GLoγzRYǥ\णC
6.ʥJC
7.`v@TүgGʪͤ~BLhBNvժŦ\णC
8.fíw"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ISMOF-a	ISMOF-b	ISMOF-c	110.6.16
AC42601238	B05BC01	0	IANOL	ANOL inj. 200mg/ml;20ml/amp(Mannitol)		QB	"1.z@ΡGR߿`AC魫 0.5g2gm H1525%GAIw` 3060 C
2.E_Ρ]ǥ\^GR߿`AC魫200mg H1525%G3-5 `J餺C"	1.ѩ󥻾iGAGHNɩRXAХ[Ŧ40~50XCAݷѫAŵ{רϥΡC 2.bY~ˡAY\X大iʮɡAVϥΤC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷŤU25JHUxs	Mannitol	B05B	Rߪ`gG I.V. SOLUTIONS	0	QB`B~BPirưBǤpyLotvw	LgBYͤ~{ʤ߰IܡB`XBYB12HUൣC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U04-02 [UDx]_U05-02 [E]_G3-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IANOL-a	01C42601-1	01C42601-2	110.6.16
NC13141277	B05BA03	0	IG10	VITAGEN 10% 500ML/BT(D10)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		OI` 	0	OIs 20251124	IG10-a			
NC06067238	B05BA03	0	IG50	ĵVITAGEN 50% 20ML/AMP		ҤƦXGC	"1.֤U`gGN`gG`jL֤UΡC
2.Rߤ`gGרOzkΨϥΤjq}ɥHkKC"	iGRߤ`gɭnbid򤺽wCaIAjq`gɱNӲGηŤ[ūϥάyC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Glucose	B05B	Rߪ`gG I.V. SOLUTIONS	0	GBi	󭫯g}fw̡AyקKϥΨϥΥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-14 [w]_w06-09 [E]_F3-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IG50-a	IG50-b	IG50-c	110.6.16
NA04135277	B05BA03	0	IG500	ĵGlucose inj. 50% 500ml/bag		ҤƦXG	qɵݭnAHC20ml~500mlA`tvC0.5/hr/kg	iGRߤ`gɭnbid򤺽wCaIAjq`gɱNӲGηŤ[ūϥάyC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJs	DEXTROSE 	B05B	Rߪ`gG I.V. SOLUTIONS	0	ʶǬVgBBiٮ`BĪ`gɤrwΪvBsBhҡBʰ}hIz	󭫯g}fw̡AyקKϥΨϥΥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IG500-a	IG500-b	IG500-c	110.6.16
BC24270210	B05BA10	0	IOLIC	ĵ Oliclinomel  N7-1000E?()1500ml/U		Ri`gG	"H ,ݨDq 0.16  0.35  g/kg/day(Xi 1  2 J//)CqݨDfwipΤѥNµ{צӦҤPAݨDq 20  40 dd// (C̤jq33ml/kg)
ⷳܤQ@ൣ, 0.16  0.35 (̰ 0.45) J//A۷i 1  2 (̰ 3 J) J//C
12  18 ൣGݨD 0.16  0.35 J//A۷i 1  2 J//C. (ĳC̤jq: 75 mL/kg)"	 igѩPR߿`	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1 xs 25XC HU
2.iNC
3.VX᪺`ŲGAwܦb 2~8XC UíwF 7 Hb
25XC UF 48 pɡC
"	iķGB}GBתըž	B05B	Rߪ`gG I.V. SOLUTIONS	0	AΩ󦨤HΤGHWĵbLkΦ]TүgӤAyiΨϥΤfAzDiɤRi	"B 2 
wJBBͳJսBΥɦ/ɦ̻s~AΥ󥻫~ҧtDΨξLӪ
ѩiĥN²`
 YצgΥDn{Tĥ̪o୦g׽
NY
Y}gfzWuB[BBtM/C߿@"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w11-03j	Ts110.6.16		OI` 	0	OIs 20251124	IOLIC-a	IOLIC-b	IOLIC-c	110.6.16
BC15979209	B05CB10	0	IPLEG	ĵPlegisol 1000ml/bag		[JһĶuPLEGISOLNoM~iJaʯ߫Aް_t߹q񬡰ʤOAܲӭMllAwįʦʻĤrCbCŤίʦɨϥΡA|SxNʦʹ[oRCpiv@ӦwRBPBy媺NϡC  	ϥκһĶu`gGgѵL߾ާ@VXå[JPLEGISOLAվpHF7.8(ǷŤU)A[JwľGb24pɤΧAϥΫe~N4JC	ug}nVmiI}ߤNͤ~iϥΥ~Aaʯߴ`Qj}ʴ`ߪͺINɤ~ϥΥ~ADXAwľ]κһĶu^wg[JA_h`GJaʯߦޡAYPRGQjq`AB\^yߪ;ӤvTkߡAhߤι[@׷|@Cb¶DNAjq]8-10ɡ^G`ä\iJM`ɡA|yYCMN©ʻĤrA]ĳkventingCbϥΫeA~No4CåBbVX24pɤΧC  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	" CaCl2, MgCl2, KCl, NaCl"	B05C	R~G	0	bʦBCŤU}ߤNɻɤ߸C  	S[JһĶu`gGվLpHȪPLEGISOLiϥΡCDRߨϥΡC	NγNi઺M]AߦٱA߹qϲ`Τ߫ߤA]A߫ŸʡC	C 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		OI` 	0	OIs 20251124	IPLEG-a	IPLEG-b	IPLEG-c	44322.49692
		0	IDIPE	Dipeptiven inj. 100ml/bot		@@DgƹDiB~ɥR(glutamine)fH(p:ƹLשηsN¹LפfH)ķGɥR~	"1.5-2 ml/kg/day
(Y0.3-0.4JN(2)-L-alanyl-L-glutamine魫)C
̤jC龯qG2 ml/kg(Y0.4JN(2)-L-alanyl-L-glutamine/魫C

}(ex: Dipeptiven 100ml+400ml}G)g̤j`tv2.5ml/kg/hr"	 Lī~ŦAK[󦹲VXG	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m 15 ~ 25 װB	" 
Alanyl glutamine 20 J
"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	@@DgƹDiB~ɥR(glutamine)fH(p:ƹLשηsN¹LפfH)ķGɥR~	1.Yǥ\ण(creatinineMv<25ml/min) 2.Yx\ण 3.YN©ʻĦg 4.糧~ҧt󦨥LӪ̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U10-10 j	Ts110.6.16		OI` 	0	OIs 20251124	IDIPE-a	IDIPE-b	IDIPE-c	110.6.16
BC26993229	B05XA31	0	IADDA	"Addaven conc.ƤG 10ml/amp (tCr,Cu,Fe,Mn,Mo,Se,Zn,F and I,Na.K)"		PLĪ֥Ϊqѽ	"HGwݺ򥻦ܾAqW[LqݨDHw̡AAddavenCĳq10 ml (@w)C
"	"1.ǳƶ}li`e 1 pɤHLߤ覡[J AddavenC
2.~g}A@b 2 - 8XC ɤoWL 24 p
3.ib}pUAddavenC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Wī~Ĵ
30XC HU 3 ~"	"qP
u
120 gg 5.2 gmol
[
3.9 gg 0.1 gmol"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ϥΩ󱵨RiɥRfHAH򥻷LqݨD	"靈Ħν᫬LӡC
- xDefC
- ºˤg (Wilsons disease), KIۯg(hemochromatosis)
- 15 HUൣ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-01 [w]_w01-06 j	Ts110.6.16		OI` 	0	OIs 20251124	IADDA-a	IADDA-b	IADDA-c	110.6.16
AC58248255	B05XA01	0	IKCL1	ĵ1.49% KCl in water inj. 20meq/100ml/bot		potassium chloride	"ĳgѤR߿`AqP`tv̷ӯfHӧOpөw
"	"1.uRߺw`(IVD)ϥΡC
2.w[JLɥRĪ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	OsbǷŤ( 25J)	KCl	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	AΩLkĥΤfAv[ʥFg	[BǰIܡBΦ[dbfHW				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w10-05 j	Ts110.6.16		OI` 	0	OIs 20251124	IKCL1-a	IKCL1-b	IKCL1-c	110.6.16
	B05XA05	0	IMGSO	ĵMAGNESIUM SULFATE 10% INJ 20 ml/amp		"magnesium sulfate 

"	"1-10 g/day IV/IMq`Cq110g AlwgY@뤩4gACbpRߪ`g5mL]0.5g^C
lwgBlwegBWrgB¾KUG
q`Cq110g I.V.I.M.AlwgY@뤩4gACbpRߪ`g5mL]0.5g^C

餺lʥFɤɥRG
ĨCmLtMg2+G0.81mEqAȭΩRi`GհtϥΡC
"	"1ĭYΩ餺lʥFɤɥR]ӰRi`GհtϥήɡAФųWRߤIw`gC
2..ШϥΪLo˸mGMAɤJwH覡JֶAJ
ŧAHK]wΡ]Coring^͸HC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Ƿ25JHUJsC	"ġG
Magnesium sulfateD7H2O............100mg
۷C@w}20mL~16.23mEq"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	"lwgBlwegBWrgB¾KUF餺lʥFɤɥR

"	"1.糧ĦLӪ
2..ǥ\ٮ`w̡Fgw̡FzHΤpıw̤ΦŦefw̥fVPAHKyMIC
3.ĻPtDiBPʺһQBһĲBQBsۻQBiCQB~QBͤƹ[Bͤƻϵs@_VXϥήɷ|I͡AtXɥ`NC

"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w07-07 [E]_F3-04 j	Ts110.6.16		OI` 	0	OIs 20251124	IMGSO-a	IMGSO-b	IMGSO-c	110.6.16
NC04582238	B05XA02	0	INAHC	"ĵNaHCO3 70mg/ml,20ml/amp(16.6mEq/amp)"		"SOD.BICARBONATE 

"	̾گgACѩΨCj@20~60@Rߪ`g	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ץxs25JHUC	Sodium bicarbonate	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	"ľB@Ĥrʯew

"	"1.ФŻPtQsVXϥΡAHקKͨI
2.~tq70mg/ml,20ml/amp(16.6mEq/amp)
3.iHNSBD5W}AϿ@׬G0.5 mEq/mLAR߿`2p (̤j`tvG1 mEq/kg/hr)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-13 [w]_w08-02 [E]_F3-01 j	Ts110.6.16		OI` 	0	OIs 20251124	INAHC-a	INAHC-b	INAHC-c	110.6.16
AC21343238	B05XA06	0	IPOTA	ĵPOTASSIUM PHOSPHATE 20ML/AMP		"1.餺CʥFAרqtq֩ΨCݨDqW[ɡAiC
RC
2.iCt@סA]it۪ͦC
3.iĦavCQʿ}f(Phosphate Diabetes)C
4.۵oʪtLhgġAåiCQʷlɧUC
5.w̦Lik(Hyperalimentation)ɡA}N©ҥݡC"	"1.CʥFgɡA@뾯qOC8~64mMAϥΡC
2.wtۡAC龯qC32mMAϥΡC
3.Lik(Hyperalimentation)ɡACJ}ݰtXC0.04~0.048mMϥΡC "	"ȨѥRi`GհtϥΡAФŪWyRߤIw`gC
ּƱw̦bϥΥY@BGѦm{HACqYi{HC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU	"G
Monobasic Potassium Phosphate . 224.0 mg
Dibasic Potassium Phosphate .. 236.0 mg
۷G
P. 3.0mM
K+. 4.4mEq"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	餺CʥFΤũҤް_g	"CĹ[g; C[; Ct; C, ǰI"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w09-04 [E]_D3-06 j	Ts110.6.16		OI` 	0	OIs 20251124	ipota-a	IPOTA-b	IPOTA-c	110.6.16
NC00476209	B05XC	0	IVBC	"B-Combeplex inj.Ƥ1ml/amp (tVit B1, Vit B2, PQi nicotinamide, Vit B6)"		"Thiamine-HClG@q٬B1 QQA}f(Beriberi)wΪv\ġABﯫgB
BhҵġCB󭫭nAD@餺sN¤ïɻïsbAGͪA
qഫjUCʥFB1 ɡAhiಣͤUCgGygA|ϷPıIӵLOAƦܲͧ·ιLױӷPAkhεINAHP߷FA}BáAhıA̫ܳḣg]B1 ʥFͰOФMAʮܡAļA~{wAʥF®AHP󯫸gáAYɬƩέPRC
2. Riboflavin-5-PhosphateG@٤Vitamin B2 CQA餺ʥF~ɡA`ͤfAާΦAƩΦXAyjˡA۩gAIAkoAy\AHPCA]i঳YC]Vitamin B2 iv¡ιwWzUدfgC
3. NicotinamideGD@ΩޡAϤXiAץHCơCʥFNicotinamide ɡA֯fA
ֽADAUgtΡAʥֽolA(Erythematous Cutaneouseruptioon)p
NˡCnֽAbUBCf(Stomatitis)AEnteritis (z)Am(Diarrhea)
Y~AHPCGcLצӦ~Ȳ{HCjKtqW[ӱaA`æRA
ƲGʥFg(Achylia)͡Ctw(Dizziness)Avg(Insomina)AOʧCA۷Q(Delusions)Aı
(Hallucinationa)Aig(Dementia)CNicotinamide iΪvWzUgC
4. Pyridoxine-HClG@ҿVitamin B6 QQAʥF~ɡAh`o{gֽͩAgAM
yΦC
(1) ֽgG֯׷XˡAר󲴡BBf(ުBB)C
(2) gtΡG֩ʵo@C
(3) yͦGͲLpyh(Hypochromic Microcytic Anemia)"	"1-2 amp daily SC/IM/IV infusion
q`HCP@ܼƦAC 1mlAൣ̦~ֻA٦שRߪ`gC"	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm 25JHUJsC 	"G
Thiamine HCl  60mg
Riboflavin-5-Phosphate SodiumK.3mg
NicotinamideK..30mg
Pyridoxine HClK3mg"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	"LRиsʥFg
}fvPwBBgBiɵBֽBïlBWc"	L				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-02 [w]_w01-09 [w]_w01-18 [E]_G1-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	OI` 3.2.	0	OIs 20251124	IVBC--a	IVBC-b	IVBC-c	110.6.16
NC03063238	B05XA07	0	IVITA	ĵVitacal inj. Ƥ20ml/amp(glucose+Caclium)		"qѽ
įYXtBXAj@λP}iAjߧQ@ΡA̭ݳơAꬰzQľAWϥθ}Aδƶt󦳨}nį]"	"R߽wC`g, ̾گgACѩΨCj@10~20@Rߪ`g"	LѸ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ץ xs15~30J
קKN"	"
Calcium chloride 2 H2O  20 mg
Glucose H2O  100 mg
۷tCa+2: 0.272 mEq/ml
Ca+2:5.44 meq"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	"CtgvPﵽ
Bi"	LѸ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w10-05 [E]_D2-05 j	Ts110.6.16		OI` 	0	OIs 20251124	IVITA-a	IVITA-b	IVITA-c	110.6.16
AC47126151	C01AA05	0	LDIGO	ĵCARDIACIN ELIXIR 0.05MG/ML as		"]1^Rʤ߰IܡGDigitalis glycoside gѻPӭMWNa+-K+ ATPase XANa+-K+ DʹBAiӬNa+-Ca++DʹBAW[ߦٲӭMtl@סAW[ߦ٦YO]positive inotropic effect^C
]2^ߩФ߫ߤG
Digitalis glycoside t@ӥDn@ξOgѼW[ggʧ@qAϮgʴ֥PgiOAgѩЫǸ`ǾɪөPR intervalACߩмʤΨ䥦߫ǤW]supraventricular arrhythmias^߫ߤAЫǤAiӴuеt"	"@?@3~4 AΡC
?
1 ӤHW:
?2~4ml (0.1~0.2mg)
?1ml (0.05mg)

3 ӤHW:
?4~6ml (0.2~0.3mg)
1.5~2ml (0.075~0.1mg)

12 ӤHW
?6~8ml (0.3~0.4mg)
?2ml (0.1mg)

2 ~ 3 
?:8ml (0.4mg)
?:2~3ml (0.1~0.15mg)

4 ~ 6 
?:10~12ml (0.5~0.6mg)
?:3~4ml (0.15~0.2mg)"	"1. Ѧ~HGDigoxinDnѵŦƪnAѦ~Hǥ\IzA]iݭnֺqC
2. arg]ABߡBæRBmεOáAyp
3.ϥ DigoxinfHi`gt
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"бKʨæb25JU,LN"	"
Digoxin     0.05 mg"	C01A	jGlycoside CARDIAC GLYCOSIDES	0	ŦIܡBߩмʡBߩֺŸʡB}oʤ߫ǩʤ߷iLt	ʩЫǪβĤGũЫǪAL?uʤ߷i}wC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-09 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.15._20210101.pdf"">OI` 2.15.</a>              "	OI` 2.15.	0	OIs 20251124	LDIGO-a	LDIGO-b	LDIGO-c	111.8.19
BC09714212	C01AA05	0	IDIGO	ĵLANOXIN 0.5MG/2ML/AMP		"1.ߦ٦YOqMtתW[-@{,oؼW[OѩߦٲӭMtyJMtlXW[,ϱoŦYֺOWjҭPC
2Ŧ´qͲzǯSʴ,@{,oخOѩuι[lPTCĸ??(Adenosin?| Triphosphatease)XӨ϶uM[lqLߦٲӭMʨҭP,ЫǩMIеǾɳtvC,èϫǿķP׼W[,FѩϮgggةM]AFPgMƥPgt´~,]ѩDigoxinҾɭP"	"tq
`gĭtq:(eGPPj߰t餧hH)`gtqq0.51.0mg,̦~,魫εǥ\өwC
sͨ 10HUൣ
sfHR߭tq̥HU:
p1.5礧sͨ
20ug/kg,24-14 ɤ
1.52.5礧sͨ
30ug/kg,24-14 ɤ
sͨ2ൣ
35 ug/kg,24-14 ɤ
2.5ൣ
35ug/kg/24pɤ
510ൣ
30ug/kg,24pɤ

q
 sͨ
C龯q=24pɭtq20%
sͨ10HUൣ
C龯q=24pɭtq25%"	 }GH`gΤBͲz?B5%}GBlactated Ringer'sG}4A`gɶܤ5HWC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"~]?Ke,x󳱲D(15-30J) BൣoB"	"
Digoxin  250 ug"	C01A	jGlycoside CARDIAC GLYCOSIDES	0	ŦIܡBߩмʡBߩֺŸʡB}oʤ߫ǩʤ߷iLt	"1TΩ󶡷ʧߪ_ΤGũЫǪ_,רO|Stokes-Adamso@fvfHC
2,TΩ]j߰t?餤rް_߫ߤC
3.TΩ񦳰ƩЫǸ|Wǩʤ߫ߤ,Ҧp:Wolf-Park inson-hitegԸs,D|LӰƸ|qͲzSʤ1@,whæsbƸ|ӥWǤ߫ߤfvC
4.TΩΫpʪߦٯf,DbPɦߩֺŸʤΤ߰I,ϥήɶpߨϥΡC
5.TΩDigexinΨ䥦DigitalistLӯfHC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-05 [E]_D2-06 j	Ts110.6.16		OI` 	0	OIs 20251124	IDIGO-a	IDIGO-b	IDIGO-c	110.6.16
BC09554100	C01AA05	0	ODIGO	ĵDigosin 0.25mg/tab(Digoxin)		"]1^Rʤ߰IܡGDigitalis glycoside gѻPӭMWNa+-K+ ATPase XANa+-K+ DʹBAiӬNa+-Ca++DʹBAW[ߦٲӭMtl@סAW[ߦ٦YO]positive inotropic effect^C

]2^ߩФ߫ߤG
Digitalis glycoside t@ӥDn@ξOgѼW[ggʧ@qAϮgʴ֥PgiOAgѩЫǸ`ǾɪөPR intervalACߩмʤΨ䥦߫ǤW]supraventricular arrhythmias^߫ߤAЫǤAiӴuеt"	"1. aۮľqGfAGHGtw}l0.50.75mgAۨC68p1AC0.250.5mgA`q11.5mgAwCwC0.1250.25mgAs7ѡCĵGsͨwC4060mcgF1Ӥ2̨C60mcgC
2. qGfA/R`GHwC0.125-0.5mg(qC0.25mg)CpĢwaۮľq20%-30%C
"	"1. Ѧ~HGDigoxinDnѵŦƪnAѦ~Hǥ\IzA]iݭnֺqC1.ϥdigoxin fw?i`gtC
2.?a?ʯ?Bqѽ?šBŦΨxŦêɡAдC?C
3.ϥΥJ[AýT{H 2 ~ 3 geLAιLaΨ䥦j߰tVMwP?C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	"
Digoxin 0.25@J"	C01A	jGlycoside CARDIAC GLYCOSIDES	0	ŦIܡBߩмʡBߩֺŸʡB}oʤ߫ǩʤ߷iLt	"1. ʧߪ_ΤGũЫǪ_,רOStokes-Adamso@fvw̡C
- ]j߰t餤rް_߫ߤC
2. 񦳰ƩЫǸ|W߫ǩʤ߫ߤ,ҦpWolff-Parkinson-WhitegԸs,DLӰƸ|qͲzSʤdigoxinoSʥiy`@ΡCYwhæsbƸ|ӵLW߫ǩʤ߫ߤfv,Pˤ]TLanoxinC
3 ߫ǩʤ߷iLtΤ߫ǩֺŸʡC
4. Ϋpʪߦٯf,DPɦߩֺŸʤΤ߰I,YϦpYnϥLanoxinnSOpߡC
5.wdigoxinBLDigitalistΨ󦨤LӪw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H4 [2]_H4 [E]_E5-10 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIGO-a	ODIGO-b	ODIGO-c	110.6.16
BC14861216	C01BD01	0	IAMIO	CORDARONE 150MG/3ML/AMP		ĤTܤ߫ߤ	"_lqGC魫5mgpAѩ󸲵}GCYi઺ܡAШϥιqʪ`gAb202pɮɶR߿`ġAiCGQ|pɭƪ`gGܤTC
qG龯q@魫10-20mg/kgp(q`600800mg/24pɡAܦh1.2g/24p)AtH250ml }GA`ƤѡC
̪Rߪ`gq300mg (5mg/kg) H20ml5%}G}ֳt`gC
- Y߫ǩֺŸʫɡAiҼ{ARߧ뤩150mg (2.5mg/kg)C
- ФűNL~[J`gwC"	Amiodarone is intended for use only in patients with life-threatening arrhythmias because of substantial toxicity.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Ƿ(25J)ץxsC	Amiodarone	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	uϥΪvֺ߫ŸʡBWOLFF-PARKINSON-WHITEgԸsBWǩʤΤ߫ǩʤ߷iLtBߩмʤߩֺŸʡCΩqܩʪֺ߫Ÿʬ߸ɩҶi檺ߪ͸dNC	"uʤ߷i}wAuФŦǾɪBϥΤHu`߾w̡C
- uefBϥΤHu`߾w̡C(߸MI)
- שЫǶǾɪBϥΤHu`߾w"				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G5mg/kgA300mg(2A)+ D5W  >30min  150mg(1A)+D5W 100ml(1.5mg/mliP䵹) >10min 2
q(MD)GĤ@تwk(})G900 mg(6A)+432mL D5W(@450mL) (2mg/mL)P䵹 AWL@׫ĳCVPġFĤGتwk(@)G900mg(6A)+90mL D5W(@90mL)(10mg/mL)CVP
}GGD5W
}@סĢC@>0.6mg/mL;>2mg/mlCVP
ĳĳtvGtv :300mg LD 1hr ,then10-50mg/hr 24hr MD,then 100-200mg/dayfA
wwʡG5(RT)ץ
CVP
ʴءGEKGAҪ\AA߲vAĪlCXR(ֺ)Aˬd"	ixii[UDx]_U06-01 [w]_w06-01 [w]_w08-03 [E]_D2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IAMIO-a	IAMIO-b	IAMIO-c	110.6.16
BC25224100	C01BD07	0	OMULT	Multaq 400mg/tab(Dronedarone)		Dronedarone@ξ| i C Dronedarone 㦳Ҧ Vaughan Williams | ܤ߫ߤSʡA	AΤ覡 ߦU@A P \ \  AC	"1.ĳAMULTAQ  fH ܤ֨CӤi ECG ˴AYA MULTAQ  fH oiä[ ߩŸʡAϥ MULTAQC
2.fHQiA Y X{ ߰Iܪgμx ]ҦpA魫W[B̿ʤ~BΩIlP pW[Aϥ MULTAQ
3.}lvMultaq eA i x\   Aé}lv @g ζ}lv  @Ӥ BĤGӤBĤTӤBĥ|ӤBĤӤB ĤӤBĤEӤβĤQGӤix\ʴAé󦹫wʴx\C  "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЦsǷŤU(30JHU)Os	Dronedarone	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	AΩ̪6Ӥ뤺}oʩΫʤߩֺŸ (AF) Τߩм (AFL)ABثeBuʸ`ߡ]sinus rhythm^Aw̡AiCfwoͤߩŸʦӦ|I	"1. ʦ dronedarone Υī~LξLӪ̡C
2. 2 β 3 ũЫǶǾɪ Bʧ_Bݪ_Buи`\êBߩжǾɯʳ A fugԸs
(sick sinus  fH ϥ \ `߾̰~ C
3.߷i}w <50 bpm ̡C
4.ߩŸʫ򤻭ӤHWä[ʤߩŸ fH ΥߩŸ o@ ɶ BvA {i_"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w26-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.10.1._20231201.pdf"">OI` 2.10.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.10._20231201.pdf"">OI` 2.10.1.</a>             "	"OI` 2.10.,2.10.1."	0	OIs 20251124	OMULT-a	OMULT-b	OMULT-c	110.6.16
BC25280221	C01BB01	0	IXYL2V	ĵ Lignocaine 2% 5ml/amp		"1.¾K@ΡGBMǾɪ¾K@ΡAgh~Ӳh¦A{ɸAĪGwQT{C
2(1) ]aʯߵϡB DigitalisBEpinephrine ʨE]Ӳͤ߫ߤAOܦjO@
(2) b¾KqEҰ絲GAFֺ߫ŸʪHȡC 
"	"Rߤ@,q`H@ 50~100 mg]1~2 mg/kgA2%`gG 2.5~5 mL^H 1~2 ɶ
ĪGɡAb 5 ᵹۦPqAt~AݮĪGoHɡAHj 10~20 ɶl[PۦPq
]LA@pɤ̰ǵĶqO 300 mg]2%`gGG15 mL^C
Rߪ`gĪGA@b 10~20 C"	] Lidocaine OQQANĻPһĲBuPʪ`gGVXɷ| Lidocaine RXA]ФűNVXϥΡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Js 25JHUA׶}pıĲC 
"	"
Lidocaine  20 mg"	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	߫ǩʤߤʪv	"1.YEǾɻê]ЫǪ_^w
2. HeL]ĩ Anilide ¾KӤް_Lӯgw"	߳չLCBoNB_ŸBtwC	P_vWqʶWVMIʮɤ~i	P_vWqʶWVMIʮɤ~i	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G50-100mg]1~2 mg/kgA2%`gG 2.5~5 mL^
q(MD)G12A(1200mg)tm100mL(12mg/ml)
}GGD5W, LR, NS, HS, D5NS
}@סG1-12mg/ml
ĳĳtvG60-120mg/hr(1-4mg/min) Max: 300mg/hr
wwʡGǷ24p
CVP
ʴءGEKG"	ixii[w]_w07-03 [E]_D2-13 j	Ts110.6.16		OI` 	0	OIs 20251124	IXYL2V-a	IXYL2V-b	IXYL2V-c	110.6.16
AC46077100	C01BD01	0	OAMIO	Adarone 200mg (Amiodarone)		~iʧ@q(action potential duration)P(refractory period)C	fAGlqC600mgAi\ɪAΡC8~10ѡC̯fHӧOAqC100~400mgC	(1)߷iLC̻PЫǶǾɪê̤yϥΡC(2)KLӪ̡AҪef̥yקKϥΡC(3)AΥ~ɩyקKΤӶC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs 25JHUømpĤΤBC	Amiodarone	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	WOLFF-PARKINSON-WHITEgԸsBWǩʤΤ߫ǩʤ߳չLtBߩоʡBߩֺŸʡBֺ߫Ÿ	YuеdysfanctionA2XM3XϡТ_A߳չLCAް_w֡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w18-01 [s]_8 [®]_8 [UDx]_U02-10 [E]_B1-12 j	Ts110.6.16		OI` 	0	OIs 20251124	OAMIO-a	OAMIO-b	OAMIO-c	110.6.16
AC43632100	C01BB02	0	OMEXI	Meletin 100mg/cap(Mexiletine)		̾Vaughan-Willaiams I AMexiletine HCl ݩIB ܤ߫ߤġA䵲cMlidocaineA㦳¾KʽC	"InitialX 200 mg Q8H; maintenanceX200-300 mg Q8H; MAX 1200 mg/day
AqGpGYݹF̰夤@סAAq400mgC
򾯶qG{ɤөwAĤ@򾯶qbAq2-6pɶAΡAC400-800mgPC"	uеx٪̡AǾɻٮ`A߸LCACΤŦBŦΨxŦIܥiݭnCqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30J HUxsC	Mexiletine	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	߫ǩʤ	"1. ߫ǩʤ߫ߤfwDͩRMIA_hߦٱTӤ뤺Τ߿Xqɡ]߫ǿXvC35H^AiϥΥ~Cߦ]ʥJΤGΤTЫǶǾɪ_fwAYL`߾TΥ~C
2. 糧~Υ@ξΧ¾K]pLidocaine^LӤfwTΡC 
3. 󰪫פŦǾɪ_ӵLHuW˸mfHTҨϥΡC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 [ws]_w39-07 [UDx]_U03-24 [E]_B4-16 j	Ts110.6.16		OI` 	0	OIs 20251124	OMEXI-a	OMEXI-b	OMEXI-c	110.6.16
BC19918100	C01BC03	0	ORYTM	Rytmonorm 150mg/tab(Propafenone)		"@بӭMíw@λPulqD_ʽ(Vaughan Williams,class 1C) ܤ߫ߤ㾯C]㦳Lzs-_ĥ(Vaughan Williams, class II)C
Propafenone hydrochloride |Cʧ@q쪺WɤҡA]|ϽİʶǾɴC(tܾɩʧ@)GbߩСBЫ(AV)uP߫Ǥ(refractory period)|CPropafenone hydrochloride|W-P-W gԸsfwݸ|C"	"魫 70 祪kw̡Aĳ propafenone hydrochloride 쾯qMqOC 450-600 mgAGܤTAΡCɭԡApropafenone hydrochloride qiݭnW[C 900 mgCYw̪魫CAC龯qru֡C


ൣ
bqվMvɴAĵĳqC10-20 mg/kgA3-4 @qC"	OBtwBhһPAʧCi|vTw̪tצӴzӤH}ξާ@񪺯OC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"жJs 25JHUømpĤΤBC
"	Propafenone	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	߫ǩʤ߷iLtBW߫ǩʤ߷iLtBW-P-WgԸs	"1.w糧~DApropafenone hydrochlorideAΩҧtξL
2. wBrugada gԸs
3. 㵲cʤŦefApG I. {ʤŦI(߫ǦGXȧC35%) II. ߦ]ʥJ(]߫ߤҤް_J~)
4. Yg߷i}w 
5. bSHu߽߫վ㾹sbɪuе\णBߩжǾɻêBĤGũΧYЫǪ_ΤǾɧ_Υݪ_
6. YC 
7. qѽ㪺(pG[lN²`) 
8. Yʪͳef
9. ֥ritonavir v"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w48-02 [E]_B5-21 j	Ts110.6.16		OI` 	0	OIs 20251124	ORYTM-a	ORYTM-b	ORYTM-c	110.6.16
		0	ISIMD1	Simdax 2.5mg/ml;5ml/vial(Levosimendan)(N)		"1.ǥѼW[ӭMtlPߦ٪troponin CXӷPצӾɭPŦYA]A|l`߫ǩPC2.Levosimendan }ޥƦ٤WATPӷP[l޹DAǦɥBaʯߤΥRߦުXiC
~ҹ Levosimendanܩʪ phosphodiesterase III AäMbv@פUʡCw߰Iܪw̡A3.LevosimendanߦYOWjΦީP@ΡAiɭPYOW[AåBCetPtAӤ|αi\঳}C
4.bPTCAΦ귻ѤALevosimendan|Ʊw̤ߦ١C"	"1.̯fHӧO{ɪpPӨMwvqPɶC
2.ĮɡA_lq6-12LJ/R߿`WL10AH0.1LJ//qs`C
3.Y{ɧP_TPXi(Vasodilator)αj߾֥ΥnʮɡA}l`ɧYX֨ϥRߪ`
g޵αiαj߾Ψ̬ҨϥΪ̡AĳϥθC_lq6LJ/"	"1.~ĳPXi(Vasodilator)αj߾(Inotropes)֥ΡC
2.vʴpGECGBB߸ByqAʴݫ찱`ܤ3ѩΪfH{ɪ{íwCצܤ׵ǩΨx\णfHĳܤֺʴ5ѡC
3.SimdaxiϥΩൣM18HUC֦~C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsū2-8J	Levosimendan	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	uv]ǲΪv覡LĥBAαj߾vʥNvʺCʤ߰I	"1.LevosimendanΥξLӡC ΥξLӡC
2C(SBP<100 mmHgDBP<60 mmHg)M߸L֡CvT߫ǥRΥ~y vT߫ǥRΥ~yΨ̬ҦʪC ̬ҦʪC
3.׵ǥ\ण(ٻMvp ٻMvp30@/)Mx\णfHC Mx\णfHC
4.Torsades de PointesfvHC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-15 j	Ts111.8.19		OI` 	0	OIs 20251124	ISIMD1-a	ISIMD1-b	ISIMD1-c	111.8.19
BC21128229	C01CE02	0	IPRIMA	ĵPRIMACOR  IV injection 10ml/amp		"PRIMACORO@Wjߦ٦YO(positive inotrope)MXi, vTߦ٦YOMXi@פU,Oߦ٩Mަ٦תpeak III cAMP phosphodiesterase isozyme ܩʧC@ΤDMPCAMPߦٲӭMtlW[Mߦ٦YOW[,HΩMަ٦׻PCAMPߦٲӭMtlW[Mߦ٦YOW[,HΩMަ٦
2.߰IܪfHͻPqM߿@׼W[euyqW[,Dܥī~ʯߦXi@
3.ﵽαi\,iѧﵽ߫ǵαiPܤC"	"_lqX 50 mcg/kgwCĥBĮɶj 10.
q X
̤ `tv0.375 mcg/kg/min  ~̤j`tv 0.75 mcg/kg/min R.
ʴȽվ㾯q"	"1.ϥΩYDʯߪΪäfܥHN몺Nv
2.v,YKʴM߸tv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ?s15~25JAקKN	"C1ml 
Milrinone 1 mg"	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	Rʤ߰Iܪuk	PRIMACORTΩLӪ̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w07-04 [E]_D3-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IPRIMA-a	IPRIMA-b	IPRIMA-c	110.6.16
AC42141238	C01CA07	0	IDOBU	ĵDOBUTAMINE 12.5mg/ml/20ML/BTL		EߦPgҳy	`t׬C2.5-10mcg/kg Cq`ﵽypIHWLC20mcg/kgqC֪pU`t׶WLC40mcg/kgC 뤩tפΪvھگfHӽվ	1.ndobutamine hydrochloride[5% Sodium bicarbonateAInjectionΨLjPGC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU	Dobutamine	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	Wjߦ٦YOӾAΩuvʤŦfBŦ~Nް_ߦ٦YOӾɭPŦNvI	TΩe惡Ĵo͹LӪfH				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G3mL/hr
q(MD)G500mg(2A)w83mL(6mg/mL)
}GGD5W, D10W, D5NS, LR, NS, HS
}@סG6mg/mL
ĳĳtvG2.5~10 gg/kg/minFMax dose: 40 gg/kg/min(H60kgG1.5mL/hr~6mL/hrFMax:24mL/hr)
wwʡG24hr (RT)
CVP
ʴءGEKG,BP,HR,cardiac output, Pulmonary wedge pressure, Eletrolyte(K)"	ixii[w]_w06-05 [E]_D2-10 j	Ts110.6.16		OI` 	0	OIs 20251124	IDOBU-a	IDOBU-b	IDOBU-c	110.6.16
AC55025219	C01CA03	0	ILEVO	ĵNorepinephrine 1mg/ml;4ml/amp		"~@άOP ަYξ \ Pg@ BŦYľΫaʯX
i ] Pg@"	"1.} GG~G[bG~G[b 5% }G 5% }ͲzQGϥ
2.Norepinephrine  4ml(4mg) ~G[J 1000ml 5% }GAC ml }Gt 4 g g Norepinephrine
3.
"	"1.קK 
2.o{ĪXɭntϥPhentolamine"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30XC HUץJsC	Norepinephrine	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	ʧCB߸	~Ωeq֪CfHADbeqɥRveaʯߤθ ʯyC				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G
q(MD)G16 mg(4A)tm250 mL
}GGD5W, D5NS
}@סG60 mcg/mL
ĳĳtvG0.5-30ug/min(0.5-30mL/hr)
wwʡG24hr (RT)ץ
CVP
ʴءGBP,electrolyte,plasma volumn,`gBO_~,`gަN`P"	ixii[UDx]_U06-11 [w]_w07-08 [w]_w07-09 [E]_D3-04 [Ew]_D1-01j	Ts110.6.16		OI` 	0	OIs 20251124	ILEVO-a	ILEVO-b	ILEVO-c	110.6.16
AC32704221	C01CA04	0	IDOPA	ĵDopamin inj.40mg/ml;5ml/amp		"1.Dopamine HCt?`}0.5-2 mcg/kg/min~ɡAiM@@ΦbŦBzôa?ʯߡB`ާɤ Dopamine AӾɭPXi@ΡAɭPŦyBǤpyLotvByMuƪnW[
2.Dopamine H?t?`}2-10 mcg/kg/min~ɡA@Φb beta ǤWAӲͪPħ@ΡAöϥPgJsX ǤWAWjŦYO
3.Dopamine Ht?`}10-20 mcg/kg/min~ @Φb alpha ǤWAͦަY@ΤΦɰ{HCަY@γ̪i?f٪LާɡAH۾?W[禳Ҿ Dopamine |@ΦbŦθzôޡCCǦyΧƥXqCѩ߱ƥXqMPOW[ӨϦYMαiҼW[
"	"InitialXIV, 2 to 5 mcg/kg/min; increase in 5 to 10 mcg/kg/min increments; MAX 50 mcg/kg/min"	"קK Dopamine HCl Rߪ`g
`K?ʴU?-??B߿X?ΦCGt?AbΤw??ffwpߨϥ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s 25JHU	Dopamine	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	JgԸsΤŦI	"1.Dopamine HCl ?iΩݻ̲ӭMFw̡C
2.߸L֡B??Τ߫Ÿʫo[Hv?w?i Dopamine HClC
3.t?GsAwɦ̩Υɦ̻s~LӪ̥iOT"				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G
q(MD)G600mg(3A)w100mL(6mg/mL)
}GGD5W, D5NS, LR, NS, HS
}@סG6mg/mL
ĳĳtvG1.Ct(W[Ŧy)0.5-2 mcg/kg/min(60kg0.5-1mL/hr) 2.t(j)2-10 mcg/kg/min(60kg1-6mL/hr) 3.t()10-20 mcg/kg/min(60kg6-12mL/hr)(Max::50 gg/kg/minF60kg30mL)
wwʡG24hr (RT)ACܩΥX{HФŨϥ
ϥΫe~}A}24pɤΧݥC
CVP
ʴءGEKG,BP,HR,urine output,renal function,CVP,cardiac output,`N`gBO_~
"	ixii[UDx]_U06-04 [w]_w06-06 [E]_D2-09 j	Ts110.6.16		OI` 	0	OIs 20251124	IDOPA-a	IDOPA-b	IDOPA-c	110.6.16
AC00480209	C01CA24	0	IEPIN	ĵEPINEPHRINE(ADRENALIN) 1MG/1ML/AMP		"1.@ا@Ω\-ǤWΣ]-ǤW骺@ΩPgi
2.@Ω]-ǤWAWiFbxΨL´}ѧ@ΡC]@Ω\-ǤWAFŦخqåBָ}Q´]ӼW[夤}@
3.Epinephrine @Ω]2-ǤWϤޥƦPΧ@Ω\-ǤW馬YުpʯߡA]ӸѰ޵jˡBRΤ~üW[eqMͬqC]ѧܭһͤ´iιLөʽwCʪ誺BܥѲ´iͦަYBXiP~C
4.Epinephrine @ΩŦ]1-ǤWAgѥ[tʧ@γqLuеӨϤ߸W[åBgѥ[jߦ٦YO@μW[FŦYOqC
5.Epinephrine @ΩֽHBΤ\-ǤWӲͦަYΤpߺޥX媺@ΡC
Epinephrine ]ѩަY@ΦӴC¾KާltvAϳ¾K@ΧơA@δ]C
6.bCqɡAEpinephrine ͤפߦYɰADnOѤŦĩһͤ߿XqW[CLbCqUA]Pɧ@Ωf٦ިt]2-鲣ͦP@ΦӴCOAHPαiCCbqɡAEpinephrine @Ωf٦ިt\-ǤWyަYӼW[OAɭPYεαiW[C"	"1.Lөʤv
٦שΥ֤U`gA_lq۷Epinephrine0.2 ~0.5mgAݭnC 10~15 еġCnɨC@qiW[ 1mg ̰qC
2.XiХ֤U`gA_lq۷0.2~0.5mgAݭnC 20~4pɭеġC  nɨC@qiW[ 1mg ̰qC
3.ŦľФߤRߪ`gA۷ 0.1mg~1mg nɨC 5 еġC
4.ަYлP¾K@ήɡA۷0.2~0.4mg  [¾KGVXGC
5.P¾K@ήɡA۷ 0.1~0.2 mg @ 1:200,000~1:20,000 GC
6.ޥ[]LөʥJ^Ц٦שΥ֤U`gɡA_l
q۷ 500mcg(0.5mg) EpinephrineAݭnAC5
~15 Rߪ`g 25~50mcg(0.025~0.050 mg)CR
` g  A H    100~250 mcg(0.1~ 0.25 mg) 
Epinephrine wC`gAݭnC 5~15 еġC
@ൣqG
1.LөʤvBXiХ֤U`gAC@
qHC魫۷ 10mcg(0.01mg)nC
褽 300mcg(0.3mg) Epinephrine W[ 500mcg
(0.5mg) ̤jqAC 15 Ĥ@AШ⦸C
ݭnC 4 pɦAġC
2.ŦľФߤRߪ`gA۷C魫 5~
10mcg(0.005~0.01mg) ΨC  褽    n 150~300
mcg(0.15~0.3mg) EpinephrineC

3.ަYЦP@릨HqC
4.ޥ[]LөʥJ^Ц٦שRߪ`gA_l
q۷ 300 mcg(0.3mg) EpinephrineAnɨC 15 
Ĥ@A 3~4 "	" 1.@Ŧ`gRߪ`geN`g 0.5ml δƶu`gG} 10mlC
2.Epinephrine y@ʯߪ`g"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	x󳱲D(15~30J)ץBҨקKN	GEpinephrine 1mg	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	LӤް_JAIlDj˩γY~A߸ϡAީʮ	Hypersensitivity to epinephrine or any component of the formulation; narrow-angle glaucoma; shock; heart failure; coronary insufficiency				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G߸G1mg 3-5@
q(MD)G6 mg(6A)tm100mL15 mg(15A)tm250 mL(60ug/mL)
}GGD5W, NS
}@סG60 ug/mL
ĳĳtvGa.YC:2~10 gg/min(2-10mL/hr) 
wwʡG5(RT)ץACܩΥX{HФŨϥΡC
CVP
ʴءGLӬO_w,WjŦ\,BP,`gBO_~
"	ixii[]_01-31 [UDx]_U06-07 [w]_w06-07 [E]_D2-08 j	Ts110.6.16		OI` 	0	OIs 20251124	IEPIN-a	IEPIN-b	IEPIN-c	110.6.16
AC45334100	C01CA17	0	OGUTR	*Midorine 2.5mg/tab(Midodrine)		~ǵۼW[wPުiOMwGjqdURߨӤɰC	"`աGHΫC~(12HW)GC@A@2(BߦU@)C

TGHG@1-2A@2-3C"	ߦިtΦYܤơA߫ߤAǥ\ण}̡Aݪ`NPqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxs	"
Midodrine 2.5 mg"	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0	ʦLCBߩʴ`tΥΡAfBNβᤧLCC	"UCw̤iP~G
A
ǤWF(ݻ̩ʲӭMF)
ʵǪA
Yǥ\ण
C
wΦݯd@Τj
Ƨʪ
ҪमigC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-04 [s]_223 [®]_223 [E]_A3-09 j	Ts110.6.16		OI` 	0	OIs 20251124	OGUTR-a	OGUTR-b	OGUTR-c	110.6.16
AC49260229	C01DA08	0	IISOK	Isocin Injection 10mg/10ml		XiRߦޡAW[GyqC	"1.̯fHո`qACpɧľq2~7mgCɨ̯fHݨDHqFCp10 mg
"	"1.~]ˬ@ī~Ao
2.īeHA`GApƶuθ}[H}
3.~tIssorbide dinitrate ͲzQGAP@몺`GҬ۷
4.~P`HλEAm`Mձۮe"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsū25JHU	Isosorbide dinitrate 1 mg	C01D	vŦfΦ޵αi VASODILATORS USED IN CARDIAC DISEASES	0	vU߯go@	"1~ivߦ]ʥJ
2.~TΩ`IܤYCfH
3.~wvQĪLӡA"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-15 j	Ts110.6.16		OI` 	0	OIs 20251124	IISOK-a	IISOK-b	IISOK-c	110.6.16
BC18979229	C01DA02	0	INTG	Millisrol 5mg/10ml/AMP(Nitroglycerin)		"NitroglycerinbCqɹRߥƦXi@ΡA
qɹʯߩMRߥƦ٦Xi@
"	"1.NɧC1-5 mcg/kg/minĶq}lġAܥتȫAʱո`wt
2.Nɲ`ϳBm0.5-5 mcg/kg/minĶq}lġAܥتȫAʱո`wt
3.ʤŦI (tʤŦIܪ?c)GH0.05-0.1 mcg/kg/min}lP, æbU5~15vBWq 0.1-0.2 mcg/kg/minTwؼЦGʤOǦAH̨κwtפH"	"1)]˩Ƿץxs
2)ШϥNON-PVC褧eB޸AYnϥιLoݨϥΤ|lnitroglycerinLoC3)iϥNS, D5WLR}ܿ@0.005~0.05%(50~500 mcg/mL)AIV pumpġC
4)}ߧYϥΡAϥήɤSOBC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ץOŤUOs	"C10 mL
Nitroglycerin 5 mg"	C01D	vŦfΦ޵αi VASODILATORS USED IN CARDIAC DISEASES	0	"U߯gvιwBNΨeᰪpBʤߦٱɭP{ʤ߰IܡBvQΪ_ͤU߯gB~NɥΥHC
"	"1.vġBȵv୨tĪL
2.ʫC
3.׳h
4.bPPDE-5 inhibitorĪfH"				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G-
q(MD)G30 mg(6A)tm100 mL
}GGD5W, NS
}@סG300 mcg/mL
ĳĳtvG 5-100mcg/min(1-20mL/hr)AMaxG200ug/min(40mL/hr)
wwʡG48hr(RT)AiϥPVCŨ`C
CVP
ʴءGhypotension and tachycardia"	ixii[w]_w02-24 [w]_w02-30 [E]_F2-05 j	Ts110.6.16		OI` 	0	OIs 20251124	INTG-a	INTG-b	INTG-c	110.6.16
AC311681G0	C01DA14	0	OISMO	Isormol 20mg/tab(Isosorbide)		Isosorbide-5-mononitrate O Isosorbide dinitrate DnNªAO{ɧ@ΪDnӷAIsosorbide-5-mononitrate DnĲz@άOXiޥƦ٦]ӾɭPPʯߩMRߤרO̲XiĥΡARXi|PiP䪺GWs]pooling^δRߦy^yܤŦ]ӴC߫ǥݵαiΪͤӺޫ]wedge pressure^(te)C	_lqGAĪĤ@BGѡACGA۹jCpɡAC1/4-1/2A᪺sѡACGAC@CзǺqGCGAC@C󶺫APjq}]AAirHAnɥibΫeAΤ@Aḙ̀ӧOw̰qվC	"1.PjqA AirH
2.iPts뤧ƨ֥"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.xsū25JHU
2.ЩmൣΤ쪺aABxsC"	Isosorbide mononitrate 20mg/tab	C01D	vŦfΦ޵αi VASODILATORS USED IN CARDIAC DISEASES	0	wU߯go@	"(1). nitrate ͹LөʡC 
(2).㪺C]Yա90mmHg^A`]circulatory collapse^AJΤߥJADOٯۨ׺ݵαiAYǵۼWjߦ٦YʪĪάODʯߤyϦViʥHۦC 
(3).ΫpʤߦٯfܡBUʤߥ]BDʯߤ}PUäUC 
(4).`ɰC 
(5).C߫ǥRߦٱC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D1 [2]_D1 [ws]_w34-01 [s]_154 [®]_154 [UDx]_U03-22 [E]_B3-32 j	Ts110.6.16		OI` 	0	OIs 20251124	OISMO-a	OISMO-b	OISMO-c	110.6.16
BC20802100	C01DA02	0	ONTG	Nitrostat 0.6mg/tab(Nitroglycerin)		NitrglycerinΦ@ƴۥѰ(free radical nitric oxide)AۥѰ|ƳI֥̻ƨC(guanylate cyclase)AӨϱoƦ٩ML´I֥3'5'CQ[guanosine 3'5'monophosphate(cyclic GMP)]W[Co@γ̲׷|ɭPո`Ʀ٦YAٳJղBoͥhM@ΦӤް_޵αiC	"1ʤߵhĤ@xHo@ɡAtN@ɭ@ܩޤUΤfUAϨ䷻ƧlCbgwѫeACjƪAΤ@ɡC2.Yb15A3ɫᤴ¯khhߧYNCNitrostat @wϥήɡAhbqƥiް_ߵho@ʫe5-10AΡC
3.ʤߵho@ɡA̦n𮧨ñĨAΡC"	"1.C5iƪAΧtbޤU1ɡAA3ɫᤴLwѽдN 
2.}ʫе
3.NitroglycerinmeAñN~\\AxsǷҤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ20XC~25XC (68XF~77XF)קK	"
Nitroglycerin 0.6@J"	C01D	vŦfΦ޵αi VASODILATORS USED IN CARDIAC DISEASES	0	U߯gvιwBNΨeᰪpBʤߦٱɭP{ʤ߰IܡBvQΪ_ͤU߯gB~NɥΥHC	"1YhB`ɰBHιnitroglycerinΨ䦨ΨLvQ(nitrates)ΨȵvQ(nitrites)LӤw̡C
2.NitroglycerinTΩ󥿦bϥβĤCĤG୨C(PDE5)psildenafil citrate (Viagra)w̡A]sildenafil
citrate (Viagra)|[jvQ@ΡC
3.AΥiʳI ƨC(GC)E(Ҧp
riociguat)w̡AФŦX֨ϥnitroglycerinAiɭP
CC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w05-04 [UDx]_U03-25 [E]_C2-17 j	Ts110.6.16		OI` 	0	OIs 20251124	ONTG-a	ONTG-b	ONTG-c	110.6.16
BC23661100	C01DX16	0	OSILV	Silvinol 5mg/tab		"1Eguanylate cyclaseiӾɭPޥƦٲӭMcyclic-GMPͼW[Aoخį঳pNitratesNitritess(in vitro)CA̡A
2.iϲӭM͹L׷ơA]ӨϫaަyqW[M㦳a޸ѵjĪGCaަXi@ΡAiϦޥƦPAͤߦ٫O@ĪGC
3iϫaުyqW[,wѫa޵j˪"	q`H@q15mgATAΡALھڪgiAyWC	"1. Uw̥ԷVġG
(1)Yxêw̡F
(2)Cw̡C
[iɭPW@C]
(3) ֱw(]ͲzzX{Ƨ@)AbAΥĮɽбqֶq}lA÷VġC
(4) ]ʥF{ɸƼƾڡA~ԷVϥΩwNYHA IIIIVŦIܯfH
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU(Ƿxs)	Nicorandil  5 mg	C01D	vŦfΦ޵αi VASODILATORS USED IN CARDIAC DISEASES	0	U߯g	"APDE 5 (phosphodiesterase type 5)Hvk_êw(sildenafil citrate Viagra?¦ӿvardenafil hydrochloride
trihydrateLevitra?֫§tadalafil CIALIS?RQh)ΪA
GC (guanylatecyclase)E(riociguat)w̡AФŨ֥
Nicorandils "				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w39-09 [s]_282 [®]_282 [UDx]_U03-27 [E]_B4-27 j	Ts110.6.16		OI` 	0	OIs 20251124	OSILV-a	OSILV-b	OSILV-c	110.6.16
BC26097100	C01EB17	0	OCORA	Coralan F.C. 5mg/tab (Ivabradine)		"Ivabradine Oª߸sAܩʥBM@ʦaŦ`If qyAIf qyiHuе۵oʵαihƩMո`߸tvCŦĪGuwuеWAߩФBЫǶΤ߫ǤǾɮɶAάOߦ٦YB߫ǪAƧ@εS
vTC

Ivabradine ]|@ΩqyIhAIh PŦIf qyۦC]ǥYuuEAѻPıtΪȮɵθѧ@ΡCbĲopU (Yקֳt)AIvabradine Ih @ΡAyw̰|go{HCo{H (ı) Qyzbϰ줺uȪjC"	"q`ĳ_lqC 2 Ivabradine 5 mgC
bv2 gAYRA߸WL60bpmA侯qiHW[C2 7.5 mgC
CfA2 AYߦU@AH\AΡC"	"1.brpξާ@Ҽ{o{HoͪiAרO]rpuj׬Mܮɥio͡C
2.~ĳH\AΡCAĴAФŪAθcBclC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCC	Ivabradine 5 mg/tab	C01E	䥦vŦf OTHER CARDIAC PREPARATIONS	0	"vCʤ߰I
Ivabradine AΩvìŦ| (NYHA) ŲII III šBYʥ\णBuʤ߫ߥBC߸tv ? 75 Cʤ߰Iܱw̡ABϥΩ]-_TүgΤ@ɡC"	"1. 靈ĦΥĥ@ξLӪ̸TΡC
2. veARA߸C 70 bpmC
3. ߦ]ʥJC
4. ʤߦٱC
5. YC (90/50mmHg)C
6. רx\णC
7. fugԸs (sick sinus syndrome) C
8. uЪ_ (Sino-atrial block)C
9. íwΫʤ߰IܡC
10. ϥΤ߽߫վ㾹 (߸Ѥ߽߫վ㾹)C
11. íwU߯g̡C
12.  3 שЫǶǾɪ_ (AV-block) w̡C
13. P cytochrome p450 3A4 j֥ΡApazole ߾ (ketoconazoleBitraconazole)Bmacrolide ܥͯ(clarithromycinBfAerythromycinBjosamycinB telithromycin)BHIV J? (nelfinavirBritonavir) nefazodoneC
14. P verapamil diltiazem ֥ΡAӻs㦳߸S誺cytochrome p450 3A4 קC
15. hkB¨ŰkBHΥϥξAץI|ְk"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w34-06 [E]_B4-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.12._20171001_000.pdf"">OI` 2.12.</a>              "	OI` 2.12.	0	OIs 20251124	OCORA-a	OCORA-b	OCORA-c	110.6.16
BC18720238	C01EA01	0	IPGE1	PROMOSTAN 20UG/AMP		"PGE1㦳wޥƦ٤@ΡAiW[yqApO
 @ΡAT{Cʰʯ߳gBʯfΦAئġC"	" 1.ʯߤġG
(1) 1Vial (Alprostadil 20mcg) 5mlͲzQGѤC
 q`H1 qAlprostadil 10~15mcg (0.1~0.15ng/ kg/min) 
HInfusion Pumpʯߤ`gġC
(2) i̯gb0.05~0.2ng/kg/minAWqC
2. RߤġG
@q`H12~3Vial(Alprostadil 40~60mcg)ѩ500mlG
 AIwR`2pɥHW(5~10ng/kg/min)A11~2i̯g AWqCĳt魫C2pɤWL1.2mcg"	" 1.߰IܡAͤ~ίݽGio͡AЯdNGqäp[`t(pGB޵)AY߱BݴeBIl
 xΤ~gͮɡAХߧYĨõABz
 2.V (UCwV)G
(1) ߰Iܱw (]߰IܴcƤiAJ[`A)
 (2) g}fw (]iUfܤX)C
(3) XɦVw (]iUX)C
(4) X֤δwGŤw (]iUX)C
(5) ϥΧܦpOBܾ徯Φ귻Ѿw 
(6) 񤺻١Biw (ʪ紿Wɤi)C
(7) ǰIܱw (]ǰIܥic)C
@(8) ֪"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ץBǷūOs	"
Alprostadil 20 mcg"	C01E	䥦vŦf OTHER CARDIAC PREPARATIONS	0	"1.ʯߤΤjRߤIw`gGPʯߪefgﵽ

2.RߤPGAسNᤧy"	"1.פ߰IܩΪͤ~w̡C(iϤ߰IܡBͤ~c)
2. Xw(pY\XBXʲeBƹDXBئ嵥A
 ]iUX)C
3. Υiwhk(аѦҥBB¨Ű)C
4. 糧o͹LӤw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-02 [w]_w01-07 [E]_G1-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.4.1._19970901_000.pdf"">OI` 2.4.1.</a>              "	OI` 2.4.1.	0	OIs 20251124	IPGE1-a	IPGE1-b	IPGE1-c	110.6.16
BC25391100	C02AC01	0	OCLON	Catapres  75ug/tab(Clonidine)()		~@ΦbFWŦ޲ΦX(cardovascular integrating centers)AӬƬĲeǤWEʣ\-2AG֥PgʦަYMŦ[tİʡA߷itvM߿߶qyL|CC~]|֦ߤǯ(renin)ʡC	"סBװ : vH0.075mg0.15mgAC2}lC
pGW[qAӦb214ѤվAiFC0.45mgqA
bYAiݭnC^0.3mgqAåiHCѰF3^, MAX dose is 2.4 mg/day.
1. vH0.075mg0.15mgAC2}lCǯfHC1ΫeA0.075mg0.15mgYġCpGW[qAӦb214ѤվAiFC0.45mgqAbYAiݭnC^0.3mgqAåiHCѰF3^(0.9mg)bxTfҡACѾqiW[1.21.8mgAd򤺪qΧ󰪾quϥΩiY@|fHC
ǥ\णw̩yϥθC_lq"	"1. Yt{HANnUifwCܴmAýUӡA]LթʧCiC
2. ĵiAΥ~fHnqƻݭn`NOu@ASOObvA]oͫΪƧ@ά۷MC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Clonidine	C02A	"_ߧ@ΪܵǤW Antiadrenergic agents, centrally acting"	0		"1.ݻ̩ʲӭMFް_ASick-Sinus SydromefHC
2.惡νξL
3.23ũЫǶǾɪ_ yCt߫ߤ㤧fw"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-07 [E]_B2-20 j	Ts110.6.16		OI` 	0	OIs 20251124	OCLON-a	OCLON-b	OCLON-c	110.6.16
BC216411G0	C02CA04	0	ODOX2	Doxaben 2mg/tab (Doxazosin)		~gѿܩʩMvʪ_Ĳ\-1ǤWӲͦXi@ΡAӹF쭰ĪGC	"1.iCѦWαߤWAΡC
2.v:_lq1mgA@Ѥ@(̰q1-16mg/day)
3.}@Τj:1mg,@Ѥ@A̰q8mg/dayC"	Ĥ@AΥ~i|PwtAyܤ1pɡAy}αqƦMIʤu@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	doxazosin mesylate salt ۷doxazosin 2 mgC	C02C	"~P@ΪܵǤW Antiadrenergic agents, peripherally acting"	0	B}ʫeCΤjC	TΩquinazolineBdoxazosinΥ@ثDʦLӪw̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w27-04 [UDx]_U02-44 [E]_B3-01 j	Ts110.6.16		OI` 	0	OIs 20251124	ODOX2-a	ODOX2-b	02C21641-2	110.6.16
BC23711100	C02CA04	0	ODOX4	Doxaben XL 4mg/tab(Doxazosin)		~gѿܩʩMvʪ_Ĳ\-1ǤWӲͦXi@ΡAӹF쭰ĪGC	"1.doxaben xliPPɨ֪AγWAΡC
2.C4mg@A~F̲zQĪGiݭn4g~FC̰ĳqC8mg@C"	"HqG]ACw̤iZHBΩοiHĿC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30XCHUxs	doxazosin mesylate	C02C	"~P@ΪܵǤW Antiadrenergic agents, peripherally acting"	0	B}ʫeCΤjC	TΩquinazolineBdoxazosinΥ@ثDʦLӪw̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w27-01 [UDx]_U02-41 [E]_B2-29 j	Ts110.6.16		OI` 	0	OIs 20251124	ODOX4-c	ODOX4-a	02021642-2	110.6.16
AC42874100	C02CA04	0	OGENZ	Genzosin (Doxazosin) 4mg/tab		~gѿܩʩMvʪ_Ĳ\-1ǤWӲͦXi@ΡAӹF쭰ĪGC	"qG C1  1 6 A _lq@A @Ѥ@A MӯfHA̤jq 1 6 
 @ϥΪqCѢܢC
}ʫeCΤjqG_lq@A@Ѥ@A̤jqC"	"ϥΰդ߿|zw̾rpξާ@OAרOb
ĪC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30XCHUxs	doxazosin mesylate	C02C	"~P@ΪܵǤW Antiadrenergic agents, peripherally acting"	0	B}ʫeCΤjC	TΩq u i n a z o l i n e s LӪfHC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
AC109171G0	C03AA	0	OBEHY	Behyd 4mg/tab(Benzylhydrochlorothiazide)		"1.Q@
󭫺һQAK+ॢ֡AGШϥΤ]Ͷ餺qѽ褧šAӥBݳƤȧQPһĲï@ΡAQƪnĪGhydrochlorothiazidej6CW[C1-ƪnApHhLܤơC
2.U@
YӧޤNa+lAATP-aseʤơAӱjƦ޾ACC"	"H@2A@1-2A~֯gӰuqC

qH@g2~3PC

ݩ]𮧤w̡AקK]ƧAЩȫeϥΡC"	"1.]QĪGۡAqֶq}lAΡAA}}WqC
2.sAήɡAݩwˬdqѽO_աC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Bץ25XCHUxs	"
Benzylhydrochlorthiazide 4 mg"	C03A	"CѪOQ,Thiazide LOW-CEILING DIURETICS, THIAZIDES"	0	QB	"1.LΫʵǤw̡C
2.GuB[ʤ֤w̡C
3.HThiazidetĪƦX(pchlorthalidonesulfonamidelͪ)Lӯgw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.03		OI` 	0	OIs 20251124	DC	DC	DC	114.10.03
BC223871G0	C03BA11	0	ONATR	Natrilix SR 1.5mg/tab(Indapamide)		"@ΦbݵǤpޡ]cortical dilution segment^CIndapamideO@Ө㦳Indole sulfonamidelͪAĲzWP thiazideQGDn@ΨӦۧQΦ޵αi@ΡCQ@ΦbݵǤpޡAuAlAiW[uδlۧGƪnA]CgOAiӭCFާ@ΡADnOCޥƦ٤tl@פμW[ProstacyclinͦXAϦ޵αiACC
bphase IIphase III{ɸ礤AWϥθĪĪGi24pɡC
fH׬OuAΪϥIndapamideHUĪGG --|vT׽N¡GTĥ̪o(TG)BCKׯ׳JxTJ(LDL-C)ΰKׯ׳JxTJ(HDL-C)C --ּvTҤƦXN¡C  
Ag"	CѦfA@AW[qä|[jĪGAOQ@Ϋo|W[	1.姿ĹL]h^̦bϥΥĮɤ֥έľC 2.ФſiC 3.ŶsC 4.Ŷ}ξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30XCHUxs	Indapamide 1.5 mg	C03B	"DThiazideCqQ LOW-CEILING DIURETICS, EXCL. THIAZIDES"	0		sulfonamide LӪfHBYǰIܪfHBYxIܩΨxʸfܪfHBC[gfHC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D1 [2]_D1 [ws]_w34-04 [UDx]_U03-23 [E]_B3-33 j	Ts110.6.16		OI` 	0	OIs 20251124	ONATR-a	ONATR-b	ONATR-c	110.6.16
AB44046157	C03CA01	0	LFUMI	Fumide Oral Solution 10mg/ml		~@ΦbQΫpWqAuM⪺ǤpަAlAB]|@ΦbݩMݪǤpޡAӱƥXuBB[BBlΨLqѽAMjq	"1.Q@
 20~80 mgACѳ̤jq160mg
2.@
   CѨ⦸A@40 mg"	~iಣͧC[gAĳhAt[褧( pGסBaBBfXBᷦBԵBG)	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץ25XCHUxs	Furosemide 10 mg	C03C	ѪOQ HIGH-CEILING DIURETICS	0	Q 	LιDiΥĥ@?Lӯfv̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.9.3._20210630.pdf"">OI` 2.9.3.</a>              "	OI` 2.9.3.	0	OIs 20251124	LFUMI-a	LFUMI-b	LFUMI-c	110.6.16
NC05612212	C03CA01	0	ILASI	Fursemide 10mg/mlF2ml/amp(Furosemide)		~@ΦbQΫpWqAuM⪺ǤpަAlAB]|@ΦbݩMݪǤpޡAӱƥXuBB[BBlΨLqѽAMjq	"1.ܦt: ٦שRߪ`g
 80~100 mgAnɨC1~2pɭƪ`g@AwF쬰
2.ܰG
(1)`ǥ\పMίfH
      Rߪ`g40~80 mg
(2)ͤ~ΫʵǰIܤMίfH  Rߪ`g100~200 mg
3.QG٦שRߪ`g
쾯q:20~40 mgBbj2pɥtW[20 mgAwF쬰
ЩwT{qACѪ`g1~2
3.ʪͤ~(DPM)
@쾯q40 mgARߪ`gAYAb1pɤA`g80mg
@ൣq
1.ܰt:٦שRߪ`g
 20~50 mgAnɨC4pɭƪ`gAwF쬰
2..QG٦שRߪ`g
C魫1 mgBbj2pɥtW[C魫1 mgAwF쬰"	"1.`gPʡAŻP׻ĩʲGVX
2.R߿`tvWL4 mg/min
3.`GiL.R., D5W, N/S"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~30 ץAקKN	Furosemide	C03C	ѪOQ HIGH-CEILING DIURETICS	0	QBBʪͤ~	LιDiΥĥ@?Lӯfv̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-09 [w]_w02-02 [w]_w02-09 [E]_G2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ILASI-a	ILASI-b	ILASI-c	110.6.16
AC010471G0	C03CA01	0	OLASI	Uretropic 40mg/tab(Furosemide)		~@ΦbQΫpWqAuM⪺ǤpަAlAB]|@ΦbݩMݪǤpޡAӱƥXuBB[BBlΨLqѽAMjqCǦyq`|vTA~]|vTcarbonic anhydrasealdosteroneC	"1..ܦt:fA
  @120mg(1Τ2~3)
 2.ܰGfA
  40 mgA@Ѩ⦸AA̱w̾q
3.QGfA
쾯q:20~80 mgB@AΡAbCj6~8pɥtW[20~40 mgAwF쬰
ЩwT{qACѥH澯qΤ2~3qιjѵ
̰q600mg/

@ൣq
.QGfA
C魫2 mgBbj6~8pɥtW[C魫1~2 mgAwF쬰
̰q40mg/

"	jqAήɡAˬd夤qѽ誺@סAHšABݮɮɸɥRRt[C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץ	Furosemide	C03C	ѪOQ HIGH-CEILING DIURETICS	0	QB	Lι糧ĴLӯfv̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C3 [2]_C3 [ws]_w32-03 [s]_345 [®]_345 [UDx]_U03-13 [E]_B3-21 j	Ts110.6.16		OI` 	0	OIs 20251124	OLASI-a	OLASI-b	OLASI-c	110.6.16
BC24306100	C03DA04	0	OINSP	Inspra F.C 50mg/tab		"EplerenoneǩT(aldosterone)XA̬Oǯ-޺i-ǩTନt(RAAS)
nXAoAձPߦޯeffzͲz"	"1.ߦٱᤧ߰I
ĳqO50 mgCѤ@C25 mgCѤ@}lvAfHԨɡA̦nb4g⾯qհ50 mgCѤ@ؼоqAñN[@ׯǤJҶq
(1)[@< 5.0 (mmol/LmEq/L)ABmOqCq25 mg EOD25 mg ODαq 25 mg OD50 mg OD 
(2)5.0<[@< 5.4 (mmol/LmEq/L)ABmܡCվ㾯q
(3)5.5<[@< 5.9 ABmCqC
q50 mg ODC25 mg OD
q25 mg ODC25 mg EOD
q25 mg EODCܰ
(4)[@>6.0
   
2.
ĳ_lq50 mgCѤ@
̰q: 1Ѩ⦸AC50@J"	"1.AeplerenonefHAYxDBvNAnϥι[lɥRBt[lNQθTϥΪī~C
2.ϥeplerenonevAקK֥ξYQ(lithium)BcyclosporinetacrolimusC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHU	eplerenone	C03D	O[ POTASSIUM-SPARING AGENTS	0	ߦٱᤧ߰IܡBNYHAII(C)߰IܡBC	"1.eplerenoneΥ~󦨤LӤfH
2 {ɤW۪[gΦH[fgfH
3_lvɦ[@>5.0 mmol/L (mEq/L)
4׵ǥ\l(ٻMv<30 mL/min)
5 רx\l(Child-Pugh C)
6֥ίd[QαjCYP450 3A4pclarithromycin
7.Pɨ֥ΦޱiOƨC(ACE) ΦޱiO_(ARB)fH
8.LճJէĤG}f
9 Mٻk>2.0 mg/dL (>177 gmol/L)Τk>1.8 mg/dL (>159 gmol/L)
10 ֥ι[lɥR
11 ٻMv<50 mL/min"	[AYwACAy¡Aǥ\lˡABUNW[	DnקKϥ/LƦҦw	DnקKϥ/LƦҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 [ws]_w29-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.9.1._20151201_000.pdf"">OI` 2.9.1.</a>              "	OI` 2.9.1.	0	OIs 20251124	OINSP-a	OINSP-b	OINSP-c	110.6.16
AC229081G0	C03DA01	0	OSPIR	Spironolactone 25mg/tab		Spironolactone O׾J]Aldosterone^vʧCQΧܰĪGA@γbǤpޡA_ul[l洫AɭPulMƪnW[ι[ldC	"1.QͤC[gGfAAC25~100mgA@Τ2~4 AΡC
2.RʤŦIܡAxwƤεǯfʼxԸsɭP~G
_lqGfAAC25~200mgA2~4 AΡAܤֳsA5 ѡC
qGfAAC75~400mgA2~4 AΡC
3.G
_lqGfAAC50~100mgA@Τ2~4 AΡAܤֳsAΤGPAݭnCGPvո`qܤ@ѳ̰q200mg.
qGfAA̯fHһݦӽո`qC
4.o׾JLhgG
qGNeAfAAC100~400mgA2~4 AΡCAXNfwiHpq@qC
@릨HB譭qGq̰iW[ܰ_lq3 Τ@ѳ̰iF400mgC
@ൣqG
~BΦLwG
_lqGfAACC魫1~3mgFΨC褽n30~90mgA@Τ2~4 AΡA5 ѫAվ㾯qA̰iW[ܪ쾯q3 C"	"1. קKιLh[lQNΫ~ΨL[ɥRC
2. CAΤ@̡A̦nbAΡAN]ίvɶѧƴ̧ܳCC 
3. ĥi֦޹Norepinephrine ʡA]AAΥĪfHbI槽Υ¾KɡASO`NC
4.PĮɯfH@HUˬdG
(1)bveΪvw˴姿@פΦߦi@
סC
(2)vfHAר֪AtΩTJĪYxwƪ̡Aw
ɰ߹qˬdA߹qѽw]SOOM[l@פw^C
5. ɶAĲߺDAiPΤ@_AΡAH֭GzEåi
W[iβvA
6. kʨũܤjq`ibƤ뤺_C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~30 װץB	"
Spironolactone  25@J"	C03D	O[ POTASSIUM-SPARING AGENTS	0	QBo׾JLhg	[gw̤iAΥġC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w51-03 [s]_281 [®]_281 [UDx]_U03-52 [E]_B5-28 j	Ts110.6.16		OI` 	0	OIs 20251124	OSPIR-a	OSPIR-b	OSPIR-c	110.6.16
AC41659100	C03EA01	0	OMODU	AnzaƤ(Hydrochlorothiazide50mg+amilo		QB	"P֪A
쾯q@Ѥ@ɡAnɼW[ܤ@Ѩ
̤jq餣WL4C"	"AΥĥiಣYw{HA]ɶqקK}ξާ@MIC
2.?thiazideQ?o?~S?l(uӷPg)רҡCpGo?uӷPgAĳ?vCpGAĬOnA
ĳO@??gnΪC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ15-30CUxsAקKӮg
"	"
Hydrochlorothiazide 50 mg
Amiloride 5 mg"	C03E	QĩMO[ĪƤ DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	0	QB	[gBǥ\ण̡B惡Ĥ󦨤ΨLSulfonamidelͪĪLӪ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [UDx]_U02-09 [E]_B1-07 j	Ts111.7.19		OI` 	0	OIs 20251124	OMODU-a	OMODU-b	OMODU-c	111.7.19
		0	OJINA2	Jinarc 90+30mg/tab(Tolvaptan)(28+28/		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡BBߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
 EALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨC	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m4CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 90 mg  7 Tolvaptan 30 mg A@ 56	ixiij	Ts110.6.16		OI` 		OIs 20251124	OJINA2-a	OJINA2-b	OJINA2-c	110.6.16
BC27341100	C03XA01	0	OJIN15	Jinarc 15mg/tab (Tolvaptan) 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixii[]_03-08 j	Ts111.4.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.2._20210201.pdf"">OI` 2.13.2.</a>              "	OI` 2.13.2.	0	OIs 20251124	OJIN15-a	OJIN15-b	OJIN15-c	111.4.27
BC27342100	C03XA01	0	OJIN30	Jinarc 30mg/tab (Tolvaptan) 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixii[]_03-08 j	Ts111.4.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.2._20210201.pdf"">OI` 2.13.2.</a>              "	OI` 2.13.2.	0	OIs 20251124	OJIN30-a	OJIN30-b	OJIN30-c	111.4.27
BC27343100	C03XA01	0	OJIN45	Jinarc 45mg/tab (Tolvaptan) 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixii[]_03-08 j	Ts111.4.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.2._20210201.pdf"">OI` 2.13.2.</a>              "	OI` 2.13.2.	0	OIs 20251124	OJIN45-a	OJIN45-b	OJIN45-c	111.4.27
BC27345100	C03XA01	0	OJIN90	Jinarc 90mg/tab (Tolvaptan) 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixii[]_03-08 j	Ts111.4.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.2._20210201.pdf"">OI` 2.13.2.</a>              "	OI` 2.13.2.	0	OIs 20251124	OJIN90-a	OJIN90-b	OJIN90-c	111.4.27
BC25296100	C03XA01	0	OSAMS	Samsca 15mg/tab		"olvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.@_lq15@JAC鵹Ĥ@AåBҼ{iɶC
2.iNqW[30@JC@AgLܤ24pɤAɰܻݨDMu@תݭn
3.̰q60@JC@C
4.֨xlˤIAPSAMSCAnWL30"	"1.b|}lέs}lĨúʵMu@
2 ϥΩʦhnʵŦf(ADPKD)
3.bSAMSCAAĳfH_Aʵu@פΦGenAܤơC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨC	tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩvŦIܤΧܧQEcgԸs]SIADH^ް_CugC	"1.ϥΩWXTFDA֭㪺εǱd(JINARC Tablets)I޲zpe(RMP)~ʦhnʵŦf(ADPKD)fH
2 ݭnֳtɰu@
3 fHLkͤfPıεLkf;A
4.CenʧCug
5 PjOCYP 3A֥
6 LgfH
7.TΩī~DtolvaptanΨLDʦLӪ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.1._20200301_000.pdf"">OI` 2.13.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13._20201001.pdf"">OI` 2.13.1.</a>             "	"OI` 2.13.,2.13.1."	0	OIs 20251124	OSAMS-a	OSAMS-b	02C25296-2	110.6.16
AC200371G0	C04AC	0	OEUCL	Songora 50mg/tab(Nicametate)		"XiyޡAW[GyqC
1.´Il@:
2.޵αi@:
3.´i@:
4.gٿħ@
5.ո`߫ߧ@
6.Eʸ
7.ܯhҤΧܰIܧ@
"	C1-2@T	֨ϥήɡA]Ͳz୰CAqϥΤC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	"
Nicametate 50 mg"	C04A	~PXi PERIPHERAL VASODILATORS	0	޴`ê	"1.糧~LӪ̡ATϥΡC 
2YolLӲ{HФPC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w41-01 [s]_288 [®]_288 [UDx]_U03-28 [E]_B4-26 j	Ts110.6.16		OI` 	0	OIs 20251124	OEUCL-a	OEUCL-b	OEUCL-c	110.6.16
AC312601G0	C04AE01	0	OHYDE	Hodrin 1.5mg/tab (Dihydroergotoxine)		ξ?MAiObϴ֦޺iפδ֤߸ê_FP\; ]iOvTgӭMN¡AiӧﵽAΧﵽN¦ӨϧʯgǾɶq`	C3~6 mg A  ̦nbeA	"1.ĥiY߰ʹLwAϥζ`NC
2.CBoʺ믫w̡AAΥ~ŶqMIʻPĤOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUKeץB	"
Dihydroergotoxine 1.5 mg"	C04A	~PXi PERIPHERAL VASODILATORS	0	ѤHbUv	w糧ĹLӪ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w28-03 [s]_150 [®]_150 [UDx]_U02-39 [E]_B2-30 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	OI` 2.8.1.	0	OIs 20251124	OHYDE-a	OHYDE-b	OHYDE-c	110.6.16
AC415351G0	C04AD03	0	OTREN	Pentop 400mg/tab(Pentoxifylline)		Pentoxifylline iPiG`A@νB|AC	C1ɡA@3CYfHX{GzΤϯgƧ@ήɡAh侯qqApGƧ@ΤAhAΡC	ä[ĤĳǫhpUG	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 CHU	"
Pentoxifylline 400 mg"	C04A	~PXi PERIPHERAL VASODILATORS	0	y޴`ê	"1.ʤߦٱBXBsxʵXιPentoxifyllinLӪw̡AyϥΥġC
2.pentoxifyllinemethylxanthines(pcaffineBtheophylline)LӪ̸T"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w47-01 [s]_259 [®]_259 [UDx]_U03-36 [E]_B5-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	OI` 2.8.1.	0	OIs 20251124	OTREN-a	OTREN-b	OTREN-c	110.6.16
AC47029500	C05AD04	0	EPOSU	Posuline supp 2.5mg/supp(cinchocaineHcl)		"HΨzzةM}Ҥް_kh,Xkoεo"	C2~3AC1ӡAƫKJCgAiאּCѤ@Ӯ꾯	"1.`N]ˤWĴC
2.꾯i|ܦHΥ]˥i|}lA|vT~ĩʡC
3.xsɥpߡAൣĲΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	"G
Policresulen 50% 200mg ( eq to Policresulen 100 mg)
 Cinchocaine HCl 2.5mg"	C05A	vHMz~ AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	0	"HΨzzةM}Ҥް_kh,Xkoεo"	CinchocaineLӪ̤iϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-04 [E]_I2-06 j	Ts110.6.16		OI` 	0	OIs 20251124	EPOSU-a	EPOSU-b	EPOSU-c	110.6.16
AC59413335	C05AA05	0	EXYLM	CALMSIT CREAMƤ15gm/(Group 7)		"Betamethasone:MϥΩ~ΡBΤlͪBF㦳ܪgΧܹLӧ@Υ~APɤ]OҦcorticosteroidsߤ@㦳~i֤ĪC
Lidocaine:¾K@ΡAiw~ihΨzkogC
Phenylephrine:㥽ަY@ΥiHiXC"	@2~3ANw~bAHAqwAĥiϥΩ󪽸zC	"1. ĭֽ~ΤoAAoϥΩ󲴷A礣oΩ󲴷|PHC
2. ٥ֽ~īpݰtβA~bAA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUA׶}xsC	"Betamathasone valerate 0.5 mg
Lidocaine 25 mg
Phenylephrine HCl 1 mg"	C05A	vHMz~ AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	0	~֡BXBkhBzP򪢡BzkogBzlBzšBzСC	糧ī~LӪ̤iϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N04-01 [UDx]_U01-59 [E]_I2-09 j	Ts110.6.16		OI` 	0	OIs 20251124	EXYLM-d	EXYLM-b	EXYLM-c	110.6.16
AC51522338	C05BA51	0	EESAR	Esarin gelƤ20gm/(Escin10mg+Heparino		"1.DEscinߺؤlѨA㦳O@ήķL޷L`S
2.HeparinoidʪxAnƲ´Χܾ@
3.DIETHYLAMINE SALICYLATEAWjܵo@ΡAh`khġC"	@hֽ`A@Ѥ@ΦhAĤϺJֽABzŮɡAȾAbũP򪺥ֽWC	ֽŮɡAȾAPֽ(ybˤfW)C.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30ץHU	"Escin10 mg
Heparinoid 10 mg
Dlethylamine Salicylate 50 mg"	C05B	Rߦi ANTIVARICOSE THERAPY	0	CRߥ\णUﵽγж˫ᤧkhw	糧ĪLӪ̤iϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-05 [E]_H2-11 [Ew]_F1-02 j	Ts110.6.16		OI` 	0	OIs 20251124	EESAR-a	EESAR-b	EESAR-c	110.6.16
A023231338	C05BA01	0	ECIVI	Cividoid Gel 250IU/Gm 20gm/tube		ܾή@ΡAvʦB˦~ΦRߪAinƶˬ͡CĦaofgAﵽwBGAlGAvU~ίB~CīAਲ਼twBhMPıAwѸ~ȡAlhXGAPi´_C	"̾ڱwjpACѤGܤTA@ӨAW35ī~YC
2.pϥγ߬HбN߬æa٩wC߬Ω󧹾㪺ֽAקKPHĲC
3.pPҦts릨@AP߬ᤣi]ϡC
4.YΩqlkA߬ѳɤJC
5.ϥγ߬ܯfpwѬCwж˪v10 ѥHWALhRߪhv1-2gCϥγ߬õLiAYvgfLkoﵽAΰīA_oAпԸ߱zvC"	߬Ω󧹾㪺ֽAקKPHĲC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25 JHUOsAЩܩĵĲΪaC	"Heparinoid Natural 3 mg
(Heparin activity 250IU)"	C05B	Rߦi ANTIVARICOSE THERAPY	0	wж˫ᤧ~ALhRߪv	Heparinoid NaturalΨLLӮɡAiϥΥ~C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N04-03 [E]_H2-07 j	Ts110.6.16		OI` 	0	OIs 20251124	ECIVI-a	ECIVI-b	ECIVI-c	110.6.16
AC32350221	C07AG01	0	ITRAD	ĵTRANDATE 5MG/ML/5ML/AMP		Labetalol @غ٬u]_vġC @ΩŦAϤ߸tvNŦGXqCC åBSඡaϦ޵αiPAGbޤ󶶺ZayqA]ӯF쭰تC ĦPɯ୰CŦu@qNŦһݭn𪺮ӡA]iΨӹwŦʮɭPӭMaΤߵho͡C	"H
@q`g(  Bolus injection)Rߪ`g 50@J(`gɶܤ1HW)A,iCj5Ƥ@ozQPC`qoWy200@JC MAX total dose, 300 mg IV.
ϥ?cIw?`:
ϥ1m/mgTRANDATE(C)G
,Y.N8 amp (200mg) ?C}?@200 mlG (t ͲzQD5W)

W
}lIw?`qCp20
mgAPMCj30?[oqܩαoOHNΫبCp160mgqP
n,i
q

?ʤߦٱ몺oʰ 
@}l}Cp15mg, ̦嫬?vW[̤ܳjqCp120 mgC

L]ް_f
@}lI??`?C2 mgoz@ϱګY`g䦳ľq`50-200 mg,?n?iq`"	"1.PUC`gIw`G۰tX
5% Detrose BP
0.18% Sodium Chloride
4% Dextrose BP
0.3% Potassium Chloride
5% Dextrose BP
Compound Sodium Lactate BP
ϥΤVXGts24pɥ

2iPSodium Bicarbonate Injection BP4.2%w/v۰tX"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ~Js30JHUxs	Labetalol HCl 25 @J	C07A	]_ BETA BLOCKING AGENTS	0		"1.TҨϥΩĤGβĤTŦǾɪ_BŦJHΨLYΫCwY߰ʮ}wpw̡C
2.TҨϥΩw糧LӤ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-09 [w]_w07-06 [E]_D3-01 j	Ts110.6.16		OI` 	0	OIs 20251124	ITRAD-a	ITRAD-b	ITRAD-c	110.6.16
AC453481G0	C07AB07	0	OBISOP	Biso(Bisoprolol)5mg/tab		"1. ~@jOAפŦܩʤ]-1ǤW_A㤺]ʥPgE@(ISA)ALww@ΡC
2. pPL]-_@ˡAﰪ@ξ|AFOA~㦳C߳ճtvHΧߵǯ@ΡC
3. U߯gfwA]_ߦ٤]-1Ӵ֤ŦʡAiӭCߦ٤ݭnqA~㦳δU߯ggγ~C"	"1.U߯gΰ
DvSOBA
q`ī~@1 AqiW[ܥī~@ 2 
2.íwCʤצܭפ߰Iܪv]CHF)
Υ~v߰IܡAѧCq}lAvW[qF̨
_lq1.25 mg }lA̤jĳqO 10 mg 1  1 C"	"1.ޮݩκCʪʪͯef̥iް_gPXiHvAӦ]IlDO
W[ް_ݡAiW[ ]2 пľv
2.ǤW~FPheochromocytoma fHAub \ blockade vA~iP bisoprolol C
3bbisoprolol vUҪrg|QBC
4.~viMADwTܡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Js25 JHUΨൣ⤣ΤBC	"??
Bisoprolol Fumarate .... 5 mg."	C07A	]_ BETA BLOCKING AGENTS	0	U߯gBBíwCʤצܭפ߰I	"ʤ߰I Τ߰IܥNv}Aݨϥ
R߱j߾vC
2. ߦ]ʥJC
3. ĤGשβĤTשЫǶǾɻê]ϥθ`
^C
4. uеgԸsC
5. uжǾɪ_C
6. bve۪߸LC]wߧC 60 U
^C
7. C]YC 100 mm Hg C
8. ޮݩΪʪͯefC
9. ߴgʯ߳MpgԸs
( Raynaus phenomenon ^̡C
10. vǤW~F
Pheochromocytoma ^C
11. N©ʻĤr̡C
12. 糧~ΥξLӪ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w21-03 [s]_43 [®]_43 [UDx]_U02-18 [E]_B1-27 j	Ts110.6.16		OI` 	0	OIs 20251124	OBISOP-a	OBISOP.b	OBISOP.c	110.6.16
BC24039100	C07AB07	0	OCONC	Concor 1.25mg/tab (bisoprolol fumarate)		"1. ~@jOAפŦܩʤ]1ǤW_A㤺]ʥPgE@(ISA)ALww@ΡC
2. pPL]-_@ˡAﰪ@ξ|AFOA~㦳C߳ճtvHΧߵǯ@ΡC
3. U߯gfwA]_ߦ٤]-1Ӵ֤ŦʡAiӭCߦ٤ݭnqA~㦳δU߯ggγ~C
4.PޤΦޥƦ٤W]2AλPN½ո`]2骺˦XO۷CC]A@{bisoprolol fumarate|vTIlDOA]|vT]2-ո`N§@"	"fHbLh6gLʤ߰Iܵo͡ABbLh2gLܰ򥻪vAYAqACE inhibitors]ΩACE inhibitorsLkԨUAϥΨLXi^MQBj߰tUAA֥bisoprololCĳvvObv߰Iܤ譱g̡CϥΥ~v߰IܡAѧCq}lAvW[qF̨ġCվ̾ڦpUCBJG
1.25mg11Aϥ1PAfHA}nUW[
2.5mg11AAϥ1PAfHA}nUW[
3.75mg11AAϥ1PAfHA}nUW[
5mg11AAϥ4PAfHA}nUW[
7.5mg11AAϥ4PAfHA}nUW[
10mg11A@ʪvC"	"1. ~ԷVϥΩ󦳤UCpfwGPRǾɶjA߿qΡAHΥ`êpRaynaud{HC
2. wʦʤŦefw̡AJMΥġC
3.ЦHG]AAnZHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHU	Bisoprolol fumarate	C07A	]_ BETA BLOCKING AGENTS	0	íwCʤצܭפ߰I	"? ʤ߰IܡAΥB߰IܳॢNvOӥݭnRߪ`gĪHW[ŦYOɡC
? Ŧ\ê޵oJ]ߦ]ʥJ^C
? SˤWŦ`߾YЫǶǾɻê]?GũβĤTŪЫǪ_^C
? fAugԸsC
? uе_C
? gʤ߷iLwC
? gʧCC
? YޮݡC
? Ygʯߦ޳efRaynaud gԸsC
? ǤW|v~F]ݻ̲ӭMF^C
? N©ʻĤrC
? bisoprolol fumarateνξ󦨤LӪ"				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668521?cesid=aENKtX4CZ1g&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBisoprolol%26t%3Dname%26acs%3Dfalse%26acq%3DBisoprolol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OCONC-a	OCONC-b	OCONC-c	110.6.16
BC22071100	C07AG02	0	ODILAT	Dilatrend 6.25mg/tab(Carvedilol)		Carvedilol 㦳hا@ΪǤW_t\1B]1 M ]2-ǤW_ʽCCarvedilol 㦳O@x@ΡCCarvedilol O@ӱjOܮƾMʮư(reactive oxygen radicals)MDҡCCarvedilol O۩ʡAB R(+)M S(-)蹳cۦP\-ǤW_ʽMܮƾʽCCarvedilol HޥƦٲӭMܼWު@ΡC	"1. vJACarvedilolݪʪvCMvHPjv֪vA֦aŦeffHר䭫nC 
2. AʰJ
}lveѪĳq12.5MGA@Ѥ@CAĳq25MGA@Ѥ@CnɡAۥHܤ֨gjANqW[ܨC̤jĳq50MGA@Ѥ@ΤA(@Ѩ⦸)C
3. gBíwBCʤŦIܡJ
_lvĳq3.125MGA@Ѩ⦸A2gCpGfwiԨqAi۱NqHܤ֨gjW[6.25MGB12.5MGM25MGA@Ѩ⦸CqվfwԨ̤jqC

4.YŦIܪҦfHMצܤפŦIܤ魫C85(187S)fH
̤jĳq25MGA@Ѩ⦸C

5.שΤפŦIܤ魫85窺fH
̤jĳq50MGA@Ѩ⦸C"	޵j˪Cʪʪͯf(COPD) AfAΧlJĪw̡Apߨϥcarvedilol	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCҤUC xs]ˤ(ӷP)	"
Carvedilol 6.25@J"	C07A	]_ BETA BLOCKING AGENTS	0	"6.25mg:{ʤŦI
25mg:B{ʤŦI"	"1. carvedilolΦĪ󦨤L
2íw/NvhŦI
3 { ɤWx\l
4pPL]-_AcarvedilolTΩUCfwG
(1)GũMTŤЫǶǾɪ_(Atrioventricular block, AV block) (Fmä[
ʤ߽߫վ㾹~)
(2) Y߸LC(bradycardia)(<50 bpm)
(3)fAuЯgԸs(]AuжǾɪ_)
(4)YC(Y<85 mmHg)
(5)ߦ]ʥJ
(6)޵j˩ήݯfv"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w25-04 [UDx]_U02-27 [E]_B2-04 j	Ts110.6.16		OI` 	0	OIs 20251124	ODILAT-a	ODILAT-b	ODILAT-c	110.6.16
AB091021G0	C07AA05	0	OINDE	Propranolol 10mg/tab		~C߸tvM߸YOAǯXHΧqF޹Bʤ϶ǥXPgަYMŦ[t@ΪİʡC	"1. ܤ߫ߤ㾯G1030mg@34Aiݭnέ@ĽվC 
2. ܤߵh:fAA10-20mgA@3-4AnɨC3-7ѳvW[@320mgC 
3. wYh:fAA쾯q20mgA@4AHW@160-240mgƦϥΡAݭnvW[q@240mgC
4. ܰ:fAq`CѺq120-240mgAnɵݭnP@ĩʳvW[qiΨ640mgC
5. ܥҪr:fAA10-40mgA@3-4AݭnP@ʦӽվ㾯qC
6. ˻̲ӭMF:fAANeA20mgA@3ɤTѡAP\_@ΡC"	ޮݩΤjˤw̽ФŨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUץ	Propranolol	C07A	]_ BETA BLOCKING AGENTS	0	U߯gBߡ]W߫ǩʤߡB߫ǩʤ߷iLt^BoʤεǩʰBYhBoʾ_ABJ{ʤ߷iLtBҪrgUB˻̲ӭMF	"Hypersensitivity to propranolol or any component of the formulation; cardiogenic shock; severe sinus bradycardia or heart block, severe hyperactive airway disease (athma or COPD)"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w47-02 []_01-28 [s]_260 [®]_260 [UDx]_U03-33 [E]_B5-19 [Ew]_EX054 j	Ts110.6.16		OI` 	0	OIs 20251124	OINDE-A	OINDE-B	OINDE-c	110.6.16
BC26700100	C07AB12	0	ONEBI	Nebilet 5mg/tab(Nebivolol)		"NebivololOSRRR-Nebivolol]d -Nebivolol^MRSSS-Nebivolol]l -Nebivolol^蹳c~۲VXCXFزcĤOGE oO@vʩMܩʪ]-ܾGoخĪGOӦSRRR-蹳c]d -蹳c^E ѩPL-arginine/nitric oxide pathwayۤ@ΡA]㦳צXiSʡC
b`ΰw̤A@Pƾq뤩Nebivolol|Cb𮧩MBʮɪ߸tvMAbv̵MiĪGC
bvqANebivololL \-ǤWܧ@ΡC"	"ĳCTwɶAΤ@@񬥡]5@J^CfAAĥiH\AΡC 
A1~2Pᦳ㪺ĪGCq`A4PF̤jġC 
ǥ\णw 
wǥ\णw̡Aĳ_lqC2.5@JCYݭnAqiվܨC5@JC 
x\णw 
@񬥹x\णΨx\lw̬sƦC]AoǱw̤ĳϥέ@񬥡C"	ϥΣ]-_ֳ¾KM޴޴߫ߤ㪺IAYFN_]-_AbNe24pɰϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Js30JHU	"
Nebivolol   5 mg"	C07A	]_ BETA BLOCKING AGENTS	0	voʰC	"1.x\णΨx\lw
2 Nebivololνξ@LӪ
3 ʤ߰IܡB߷ʥJΥB߰I"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w40-02 [E]_B4-29 j	Ts110.6.16		OI` 	0	OIs 20251124	ONEBI.a	ONEBI.b	02C26700-2	110.6.16
AC46404100	C07AG02	0	OSYNT	Syntrend 25mg/tab(Carvedilol)		Carvedilol 㦳hا@ΪǤW_t\1B]1 M ]2-ǤW_ʽCCarvedilol 㦳O@x@ΡCCarvedilol O@ӱjOܮƾMʮư(reactive oxygen radicals)MDҡCCarvedilol O۩ʡAB R(+)M S(-)蹳cۦP\-ǤW_ʽMܮƾʽCCarvedilol HޥƦٲӭMܼWު@ΡC	"1. vJACarvedilolݪʪvCMvHPjv֪vA֦aŦeffHר䭫nC 
2. AʰJ}lveѪĳq12.5MGA@Ѥ@CAĳq25MGA@Ѥ@CnɡAۥHܤ֨gjANqW[ܨC̤jĳq50MGA@Ѥ@ΤA(@Ѩ⦸)C
3. gBíwBCʤŦIܡJ
_lvĳq3.125MGA@Ѩ⦸A2gCpGfwiԨqAi۱NqHܤ֨gjW[6.25MGB12.5MGM25MGA@Ѩ⦸CqվfwԨ̤jqC
4.YŦIܪҦfHMצܤפŦIܤ魫C85(187S)fH̤jĳq25MGA@Ѩ⦸CשΤפŦIܤ魫85窺fH̤jĳq50MGA@Ѩ⦸C"	޵j˪Cʪʪͯf(COPD) AfAΧlJĪw̡Apߨϥcarvedilo	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~x??25J UΨൣ⤣ΤB??	"
Carvedilol  25@J"	C07A	]_ BETA BLOCKING AGENTS	0	B{ʤŦI	"@BCarvedilol TΩUCfwG
1. carvedilol ΦĪ󦨥L
2. íw/ NvhŦI
3. {ɤWx\l
GBpPL]- _Acarvedilol TΩUCfwG 
1. GũMTŤЫǶǾɪ_(Atrioventricular block, AV block) ( Fmä[ʤ߽߫վ㾹~)
2. Y߸LC(bradycardia)(<50 bpm)
3. fAuЯgԸs( ]AuжǾɪ_)
4. YC( Y<85 mmHg) 
5. ߦ]ʥJ
6. ޵j˩ήݯfv"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w24-05 [s]_301 [®]_301 [UDx]_U02-25 [E]_B2-08 j	Ts110.6.16		OI` 	0	OIs 20251124	OSYNT-a	OSYNT-b	OSYNT-c	110.6.16
BC18843248	C08CA06	0	INIMO	NIMOTOP 0.02% 10MG/50ML		wBv]ʯ߽Fް_j､UXB޵j˩Ҥް_ʦʯgʷlC	"R߿`G
}lvɡACp1@Jnimodipine]Cpɵ5@Nimotop`G^]
15 gg/魫/pɡ^2pɡCYfHiHԨWzqABfHS۪CAbpɫNqհܨCpɵ2@Jnimodipine]Cpɵ10@Nimotop`G^]30 gg/魫/pɡ^C魫pCQΦíwfH_lqCp0.5@Jnimodipine]Cpɵ2.5@Nimotop`G^C"	"1.Nimotop`Gο`HsR߿`gѤɺ(central catheter)`J餺CNimotop`GPUCGH@|ҸgѤTV(three-way stopcock)AoǷG]A5%
}B0.9% ƶuBŻQLG(lactated Ringers solution)Bt⪺ŻQLGBdextran
40 solution HAES?(poly(O-2-hydroxyethyl) starch 6%CӥSJ(mannitol)BHճJ(human
albumin)HΦG]AXPNimotop`GPɵ
2.ѩNimotop`GĦ|QEAm(PVC)ҧlAҥHuϥλEAm(PE)`"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" Ĳ~XȲAקKuӮgC
Nimotop`GbLhϥΡC"	Q@Jnimodipine󤭤Q@ɪts뷻	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	wBv]ʯ߽Fް_j､UXB޵j˩Ҥް_ʦʯgʷlC	"1.Nimotop`GiϥΩnimodipine ΨҧtξLӪ̡C
2.Nimotop`GiϥΩíwߵhw̩Ϋʤߦٱw̵o@@Ӥ뤺C
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U10-01 [E]_F2-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.2.2._20040201_000.pdf"">OI` 2.2.2.</a>              "	OI` 2.2.2.	0	OIs 20251124	INIMO-a	INIMO-b	INIMO-c	110.6.16
AC48882229	C08CA04	0	IPERD	Nicarpine 10mg/10ml/Amp(Nicardipine)		AΩfAviΤAXɡBﰪuBm	"H_lqG
3-5mg/hr `15AqiH0.51mgC15`tvvհA̤jWL15mg/hFqGFvؼЮɡAwCCqAq`H2-4mg/hvĪGC
Ѧ~//x  \   }̡G̾گfH{ɱpA_lq1-5mg/hA`30AڪvĪG
AqiH0.5mg/hvհέCA̤jWL15mg/hC
pG
ĤR߿`ȨϥΩpw̩󭫯g[@ΤNMͩRC
_lqGbM污pUAĳ_lq0.5-5 mcg/kg/minCĳqG1-4 mcg / kg /minC
R߿`ϥΩǥ\ण}pԷVpߡABϥγ̧CqC
Nɲ`BmGīYHͲzQG5%}`gG}nicardipine HCl0.01-0.02%(1 mL۷0.1-0.2 mg)GA@R߿`C_AHCBC魫۷2-10 mcg`tv(2V10 mcg/kg/
min)PAϦUܴȡAMA̦ӽո``tvAYϦtUnɡAhϥΥġAHC魫۷nicardipine hydrochloride 10V30 mcg(10V30 mcg/kg)qA@RߤPC
      g G   Y H ͲzQG5%}`gG}nicardipine hydrochloride0.01-0.02%(1 mL۷
 0.1-0.2 mg)  GA@R߿`CɡAHCBC魫۷0.5V6 mcg`tvPA_AHC
BC魫۷0.5 mcg`tv(0.5 mcg/kg/min)PAϦUܴȡAMA̦ӽո``
"	".1bRIw`gɡA]tXGް_pHȤɰ]Aķ|RXAQ`NC
ħ@t窺GAܤUC`Gi۰tXG
ͲzQGB5%}`gGB10%EL-3BSolita -T Injection No.1BSolita -T Injection No.3B
Physiosol No.3BPhysiosol No.4BPotacol -RBRingers solutio
2.ĹLqPӦCoͮPAݫt_ AiΪ@(norepinephrine)PϥΡC
3ĦbɶPɡA`g즳khεoɡAܧ`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~25 CHUץOsC	"
Nicardipine
1 @J"	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	AΩfAviΤAXɡBﰪuBm	"1.糧ĩΥξLӪw
2.YDʯäUw
3.ʤߦٱfpYBíw"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-23 [w]_w02-29 [E]_F2-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IPERD-a	IPERD-b	IPERD-c	110.6.16
AC24018100	C08CA05	0	OADA10	(^)Nifepin 10mg/cap		NifedipineO@ضtl_A঳ĦaӭM~tlAgѯSSlow calcium channelsiJߦ٩MƦ٪ӭM̡AGXiaʯߩMpʯߡAïaʯߵjpAۧﵽߦ٪AӥB֤ߦٮݭnqAU߯g(ߵh)ΰvܦnĪGC	"q]HӲALq|ް_CC
_lqGC10~20mgA@ѤTCC̰q180mgC"	"1. ϥΥĨ֪AcθcĮɡA`Niಣͪī~ۤ@ΡC 
2. ǾêPͰwVPC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷŤUץBxs	Nifedipine 10mg	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	U߯gB	"1.ĤiΩwnifedipine ΨҧtξLӪfwC
2.ĤiΩߦ]ʥJ(cardiogenic shock)fwC
3.ĤiPrifampicin ֥ΡA]ïɧ@Υi|nifedipine LkF즳Ī夤@סC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w05-05 [s]_239 [®]_239 [UDx]_U01-48 [E]_A3-12 [Ew]_Z-08w1 j	Ts110.6.16		OI` 	0	OIs 20251124	OADA10-a	01C24018-1	OADA10-c	110.6.16
AC57219100	C08CA05	0	OADA30	(^)Nifedipine S.R.F.C 30mg/tab		Nifedipine O@ضtl_(Calcium channel blockers)A঳ĦaӭM~tlAgѯS Slow calcium channels iJߦ٩MƦ٪ӭM̡AGXiaʯߩMpʯߡAïaʯߵjˡAۧﵽߦ٪AӥB֤ߦٮݭnqAU߯g(ߵh)ΰvܦnĪGCfAl}nA|bxŦN¦ӥh(First-pass effect)AҥHiβvC	"1.vaʯߤŦefG
Cʦíw?h(Bʮɤ?h) @Ѥ@AC@

2.vG
@Ѥ@AC@ @ӨAqCѤ@30 @J}lv

3.̯efY{פίfwiW[qܨCѤ@120 @JC
 
4.֥CYP 3A4 
CYP 3A4 oɡAĳվnifedipine  qΤϥnifedipine v"	"1.irZΧ˸HAΡC 
2.ФŻPcĨ֪AC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOsǷ(30JHU)ΤpıĲ줧B	Nifedipine	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	U߯gB	"1.ߦ]ʥJ 
2.nifedipineLӪ̤oϥΡC 
3.iPrifampicin֥ΡA]ïɧ@Υi|nifedipine LkF즳Ī夤@סC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w40-01 [UDx]_U03-26 [E]_B4-28 j	Ts110.6.16		OI` 	0	OIs 20251124	OADA30-a	OADA30-b	OADA30-c	110.6.16
AB44475100	C08CA01	0	OAMPI	Ampin 5mg/tab (Amlodipine)		"1. ~OtlyJ(Slow channel_ζtlܾ)AitliJŦΦޥƦ١C
2. ~@ΪbޥƦ٪P@ΡA~νwߵhT@ξणܲMC"	"1.Mߵh
q`_lq5A@Ѥ@Ai̯fHgW[q̰10C
2.YMthiazideQA]-_ACE֥ήɡAݽվ㾯qC"	"1. ~Lqް_{ɤW㪺CAnDʪŦޤʪvA]AʴŦMIl\Aﰪ|ϡA`N`GnMqC
2. α¨ŤϥΥ~ypߡC
3. ~iyYwBدtAfHbߩΨpߧ߫C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs25CHUAץ?s	"
Amlodipine 5@J"	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	Bߵh	~TΩdihydropyridinesӷPfHC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OAMPI-a	OAMPI-b	OAMPI-c	110.6.16
AC56633100	C08CA15	0	OCONI	(^)Beniel 4mg(Benidipine) 		~|PӭMq̿ʶtqDDHP䵲쵲XAtyJӭMMyaʯ߻PgުXiC	"1.q`A令H 1  1  24 mg q\fAA??pݭnAھڦ~֡BgAyaWALAbĪGΪpɡAW[q 1 1  8 mg

2.YgAfH 1  1  48 mg q\A
"	@η|ް_Yw{HAfwYqưBu@BTrpMIæH񪺾ާ@ɻݭnp	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.ЫOs 25XC HUΨൣ⤣ΤB

2.Ĵ 2 ~"	 benidipine Hydrochlorid 4@J	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0		"1.߷ʥJw
2.Υihk"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w21-01 [s]_56 [®]_56 [UDx]_U02-15 [E]_B1-26 j	Ts110.6.16		OI` 	0	OIs 20251124	OCONI-A	OCONI-B	OCONI-C	110.6.16
BC18842100	C08CA06	0	ONIMO	Nimotop 30mg/tab(Nimodipine)		"Nimodipine 㦳ܸަYΧܯʦ媺ʡC
b~礤AnimodipineiwήUئެʪ(pGMAeCAHβ´i)ΦGΦGѪҤް_ަYCnimodipinePɤ]㦳gĲzǤκ믫ĲzǤ譱SʡC
oͫʸyfܪfHҶi檺so{Animodipineiϸ޵αiëPiy`C@ӻAbӨlΦyqAW[yq|񥿱`nhC
Nimodipine|ۦaCj､UĥXfH]ʦҳygʶˮ`AíCP`vC"	"fANimotopOHNimotopR߿`GvϥΡC
q
DSBA@ĳϥξqpUG
ĳΪkOHNimotopR߿`G`5 - 14ѡAۦAHCѤfABCNimotop(6 x 60 mg nimodipine)C
YfHoͰƧ@ΡAhCqΰvC
PCYP3A4CYP3A4ɾ֥ήɡAiභվ㾯qC
- wʨϥ
R߿`vAĳϥΤfANimotopvA@ѪAΤ60mgNimotopAC|pɪAΤ@ACѡC
- vʨϥ
R߿`vAĳϥΤfANimotopvA@ѪAΤ60mgNimotopAC|pɪAΤ@ACѡC"	"1.AnimodipineקKc/cġC
2.H]AACAĶji֩|p
3.NimotopbLᤣiϥΡC
NĪmൣLkĲΤBC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"NimotopbLᤣiϥΡC
NĪmൣLkĲΤBC"	Nimodipine	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	wBv]ʯ߽Fް_j､UXB޵j˩Ҥް_ʦʯgʷlC	"1.hA@ʸ~A`ۼW[̨ϥνSOpߡC
2.~iϥΩNimotipineΩҧtξLӪ
3.֥nimodipinePrifampicinOT
4.PɤfAnimodipineMwĪphenobarbitalBphenytoinMcarbamazepineOT"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 j	Ts110.6.16		OI` 	0	OIs 20251124	ONIMO-a	ONIMO-b	ONIMO-c	110.6.16
BC21571100	C08CA01	0	ONORV	Norvasc 5mg/tab(Amlodipine)		"1. ~OtlyJ(Slow channel_ζtlܾ)AitliJŦΦޥƦ١C
2. ~@ΪbޥƦ٪P@ΡA~νwߵhT@ξणܲMC"	"1.MߵhAq`_lqC2.5@J5@JAiH̾ڭӧOfHvGNqW[̤ܳj10@JC
2.YMthiazideQA]-_ACE֥ήɡAݽվ㾯qC"	ī~iyYwBدtAfHbߩΨpߧ߫C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs25XCHU	"5@J
Amlodipine"	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	Bߵh	~TΩdihydropyridinesӷPfHC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w18-02 [s]_216 [®]_216 [UDx]_U02-04 [E]_B1-14 j	Ts110.6.16		OI` 	0	OIs 20251124	ONORV-A	ONORV	ONORV-c	110.6.16
BC17488100	C08CA02	0	OPLEN	Plendil ER 5mg/tab(Felodipine)		Felodipine@ءutl_vi@ĪιwߵhϥΡC utl_vĲz@ΡNDnO_tliJŦHΦޥƦٲӭMNϦަYOCöϦީPεαiNϧhGbޤZayqA̫F쭰تC	"
1.?i̭ӤHݭnվC
2.C龯?q5mg @Ѥ@}lC?ݭnA?iAW[Ψ֥ΨL?ġC
3.?q`O5mg 10mg @Ѥ@C
4.??fHҼ{q2.5mg }lv?C
ߵh
?i̭ӤHݭnվC C龯?q5mg @Ѥ@}lCݭnɥiW[ܨC@10mgC"	"1.Ũ֪Asθc,ZH ,Ŧۦ氱 
2.AīAФŶ}ξާ@
3.󦭤WAΡAtH}]AA?ibοiHAΡCiŸɩλ
]?tתթΰҤƦX^A
4.iΤPfHALi~jiC`NfĽåͥiH
Kΰfi~jC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ŶJs 30JHW	"5@J
Felodipine"	C08C	Dn޲ͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0	Bߵh	"1.h
2.w靈Ħ(Felodipine)Ρξ@?ξL
3.Nvʤ߰I
4.ʤߦٱ?
5?íwʤߵh
6.Plendil t?Aǩʥb??@gθ?-b?l??fH?ϥΥ~C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OPLEN-a	OPLEN-b	OPLEN-c	110.6.16
AC27307212	C08DA01	0	IISOP	U-Sodin inj. 2.5mg/ml;2ml/amp		"~`gઽgѤJߦٲӭMqӪN¹L{MgѥyOpӭCߦٮ
(t)A~S୰CޥƦ٪iOAåBwaʯߵjˤέCAS۪ܤ߫ߤ@ΡAרOW߫Ǥ߫ߤA~SੵЫǵ(A-V node)İʤǾɡA]_u߰ʤΥ`߫ǳtv
"	"H@1 Amp.Anɤ@ѥi`2~3AwCRߪ`g

"	"1. YoͤGשΤTפЫǪ_ɡAiϥ AtropineAOrciprenalineAnɥiϥθ`߾C
2. YXiʤߦٯणoͮɡAiϥ DopamineADobutamineACardiac GlycosidζtC
3. YoͦUɡAiϥ DopamineADobutamineA NorepinephrineC
4. TӤASOpߨϥΡC
5. ϥΥī~ɨ֪AcθcĮɡA`Niಣͪī~ۤ@"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~ץJsAHíwĮ	 Verapamil Hydrochloride  2.5 mg	C08D	ŦͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	0	"}oʤWǩʤ߷iLtBߩмʡBߩֺŸʱpɡBֳt߫Ǥ߷iȮɩʱ

"	"1ߦ]ʥJ(F߫ߤް_J)Aʤߦٱް_ֵog(߸LCBCB߰I)C
2.GשMTתЫǪ_(A-V block)
3uʤ߸ígԪ̡C
4Y߰IܯgԪ̡C
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-17 [E]_G3-14 j	Ts110.6.16		OI` 	0	OIs 20251124	IISOP--a	IISOP-b	IISOP-c	110.6.16
AC369661G0	C08DB01	0	OHER3	Cartil 30mg/tab(Diltiazem)		Diltiazem HClO@ضtlܾADn@ΩŦ޲ӭM~tl`JAXiޡAW[ayq]äܦGtl@ס^APɧߦ٤ΦޥƦ٪YAXiaޥޡAC֤ŦtC	"1.U߯g
q`H130mgA1A3??
gɡAiWq160mgA1A3
2.צܤפAʰ
q`H130~60mgA1A3
(Ѧ)[饻ħ11Ҹq: Diltiazem HCl 190mg; 1360mg"	ŦIܡGCߦ٤OA勵`߫ǨõLvT??{ɤWYϥΩ߫Ǩlw̡AhקKϥΡAקKP]-_֥ΡAĨϥΩfwɥקK@PB	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 xsNtBAקKӮg	"Diltiazem HCl
30 mg"	C08D	ŦͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	0	U߯gBצܤפAʰC	"1.uеfܱw
2.ܭשЫǵ_w
3.Y߸}ww
4.Cw̡]YC90mmHg^TҧPC
5.糧Ĳͩ㪺L̡ATҧPC
6.gX-rayҩٱMͥRi̸TҧPC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w27-05 [s]_70 [®]_70 [UDx]_U02-40 [E]_B2-24 j	Ts110.6.16		OI` 	0	OIs 20251124	OHER3-a	OHER3-b	OHER3-c	110.6.16
BC19953100	C08DA01	0	OISOP	Isoptin S.R 240mg/tab(Verapamil)		ܩʶtl_A@ΩŦAphenylalkylaminelͪC	"PPAC@뾯qC120-240mgA󦭤WAΡA̧8pɫ᪺վ㾯qC
ѿഫwɥiϥΦPqC"	"UCpɡApߨϥΡG
1. Ĥ@ũЫǪ_ (First degree AV block)
 2.C
3 ߷i}w 
4רx\णG
5.ǥ\णG
6 wvTg٦׶Ǿɤef"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxsC	verapamil	C08D	ŦͼvTܩʶtqD_ SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	0		"(1) verapamilʪΨLDʦLӡC
(2) ߦ]ʥJC
(3) ĤGβĤTũЫǪ_(Hu߽߫ո`B@fH~) 
(4) fAugԸs(Hu߽߫ո`B@fH~)C (5) ߰I(Ҧp:ŦgXvC 35%AM/ΪͰʯ߷20@̨EWHW) (verapamil vɭP~oʤ߫ǤWW߰~)C 
(6) ߩмʻPߩֺŸʨ֩ЫǰƳ~| (ҦpGWolff-Parkinson-WhitesyndromeLown-Ganong-Levine Syndromes)CofwYϥverapamil hydrochlorideA|B󲣥ͤ߫W (]Aֺ߫Ÿ) IC
(7) Y߫ǥ\ण}C
(8) C (Yp90mmHg)C
(9) ֥ IvabradineC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K5 [2]_K5 [ws]_w54-07 [s]_155 [®]_155 [E]_C2-15 j	Ts110.6.16		OI` 	0	OIs 20251124	OISOP-a	OISOP--	OISOP-c	110.6.16
AC43950100	C09AA16	0	OTANA	Tanatril 5mg/tab(Imidapril)		~SH򪺪Angiotensin converting enzyme(ACE)A䦨Imidapril Hydrochloride@eX(Prodrug)gfPA|ѦʥNªdiacid(Imidaprilat)CImidaprilatǥѧ夤ΤֲӭMACEʡACangiotensin ͦA]Ӧ@ΡC	"q`H11AgfPImidapril Hydrochloride 510mgCo̦~֤ίgAWCgw̡Aĳ2.5mg}l
PC"	"1.Ne24pɤĳP
2.@Φɷ|ɭPYwBڶ\AҥHqƦbMIʡAݶ`NOʡAҦprpTAbBu@ξާ@ASO`
NC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC}ʫ׶}JsC	"
Imidapril 5mg"	C09A	"ޱiOƻï ACE INHIBITORS, PLAIN"	0		"(1) g󥻾o͹LӪw
(2) oͦީʤ~w(]ϥ Angiotensin ഫïoͦީʤ~Bǩʦީʤ~Bѩʤީʤ~B۵oʦީʤ~
(3) ϥdextran sulfate immobilized celluloseBtryptophan immobilized polyvinyl
alcoholpolyethylene terephthalategѧl۾iapheresisw?
_JC?
(4) ϥacrylonitrile sodium methallyl sulfonate(AN69)iGzRw
(5) ΥiwhH
(6) X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw(GFR<60ml/min/1.73m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G6() j	Ts110.6.16		OI` 	0	OIs 20251124	OTANA-a	OTANA-b	OTANA-c	110.6.16
AC45172100	C09AA03	ι	OZEST	Vastril 10mg/tab(Lisinopril)		ZestrilOpeptidyl dipeptidaseAަYഫï (ACE)ʤangiotensin Iഫangiotensin II (@ئަY` [peptide]) @ΡCAngiotensin II]PiǤWֽcaldosteroneCACE|Cangiotensin II@סAqӭC޼W@ΡAôaldosteronecC̤C|ɭP[W[C	"@Ѥ@A lvTC
?G
@ĳ}lq10mgAĺq20mg@Ѥ@; ̰q80mg/
?{ʤ߰I (CHF)G
iΤ@Ѥ@Zestril 2.5mg}lvC@릳ľq5~20mgA@Ѥ@C
?}fǯf
C龯q10 mg @Ѥ@QYݭnAiNqW[20 mg @Ѥ@
?ʤߦٱG
Zestrilbӯgoͪ24pɤ}lAΡAĤ@qfA5mgA24pɫ5mgA48pɫ10mgAᤧq10mg@Ѥ@CfHb}lvα᪺eTѥX{CY (120mmHgΧC)AhݵCqGfA2.5mgCYoͧC(YCε100mmHg)AiCѺq5mgAnɥiȮɭC2.5mgCYyʧC (Y<C90mmHgF1pɥHW)AZestrilC
ZestrilA6PAfHͤ߰IܯgɡA~AZestril 
"	ϥΧQfH}lϥZestrilɡAi|oͯgʧCFpfHwϥΧQhoͦ{HC]i|GM/Q\ܡCb}lϥZestrile2ѩ3ѶΧQC藍ఱΧQfHAZestril}lqq5mg}lAAվ㾯qCpnAQiϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30oCHUC	"
Lisinopril
10 mg"	C09A	"ޱiOƻï ACE INHIBITORS, PLAIN"	0	B{ʤ߰IܡBʤߦٱB}fǯfܡC	"?ZestrilB~󦨤ΨLަYഫï (ACE) LӪ̡C
?]ϥΦަYഫïӵo͹L/LӤΦީʤ~fv̡C
?ǩʩέoʦޤ~̡C
?hĤGMĤT 
?X֨ϥΥ~Χtaliskirenī~}fHεǥ\णfH (GFR < 60 ml/min/1.73 m2)"				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668973?cesid=7iZW391k5f2&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLisinopril%26t%3Dname%26acs%3Dfalse%26acq%3DLisinopril"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.12		OI` 	0	OIs 20251124	DC	DC	DC	114.11.12
AB46742100	C09BB	0	OAMTR	Amtrel tab(Amlodipine/Benazepril)5mg/10m		"ޥƦ٩Mߦ٪YgѯSlqDNӭM~tloǲӭMǰeAamlodipine O@ضtlܾAiHtlqLӭMޥƦ٩Mߦ٪yʡAا㦳ܩʡAޥƦ٪@θߦ٨ӱojF
benazepril@ξରǬ-޺Y-׾J]renin-angiotensin -aldosterone^tΡA]YϬOCǬfHAbenazepril̵MĪGC"	vľq Amlodipine C 2.5-10mgABenazeprilC 10-80mgC	"1.ǥ\णwpߨϥΡC
2.TϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Щ25JHUxsCץOs	Benazepril/Amlodipine 5/10mg/tab	C09B	"ޱiOƻïAƤ ACE INHIBITORS, COMBINATIONS"	0		"TϥΦbbenazeprilamlodipineLӪfHC 
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w19-01 [s]_5 [E]_B1-13 j	Ts110.6.16		OI` 	0	OIs 20251124	OAMTR-a	OAMTR-b	OAMTR-c	110.6.16
BC23655100	C09CA01	0	OCOZA1	Cozaar 100mg/tab(Losartan)		"1. LosartanD(nonpeptide)imidazolelͪADnO_bޤβ´ޥ[IIAT-1(typel angiotensin II receptor)Fbefoͤޥ[II(Angiotensin)tަY(vasoconstriction)ް_WɩMǾJT(aldosterone)XnCثeAޥ[ƞJ(Angiotensin converting enzyme;ACE)sxΨӪvADnO_angiotensin Iangiotensin IIAOangiotensin IIP˦a|ѨLïʤƧΦAä৹Ѧޥ[ƞJ]|_wE(bradykinin)ް_prostaglandinN§ܡF]ޥ[IIܾ(Angiotensin II receptor antogonist)bM@ǿܩʪޥ[ƞJ(ACE)Ae̸৹aǯwޥ[t(renin angiotensin system)C
2. kĦw-D:bWĤGβĤTϥ"	"
_lqκqC50 mgAC@ ; W[ܨC100 mgAC@
vII}fǯf
@_lqC50 mgAC@CUΡAiNqW[ܨC100 mgAC@C"	P~w̥ioͦM[lƧ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	"
Losartan 100 @J"	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0	BvII}fǯf	"1.TΩ糧~զLӪ
2.COZAARPaliskireniX֨ϥΩ}ffHεǥ\णfH (GFR < 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w36-01 [E]_B4-06 j	Ts110.6.16		OI` 	0	OIs 20251124	OCOZA1-a	OCOZA1-b	OCOZA1-c	110.6.16
BC23374100	C09CA03	0	ODIOV1	Diovan 160mg/tab (valsartan)		"~fAıjOM@Angiotensin IIܾBܩʧ@ΩAT1AAT1PwAngiotensinIIҲͪ@ΦCValsartan AT1 A yAngiotensin II bߪ@פWɡA|EQܪAT2 AӹAT1 鲣ͥŧ@ΡCValsartan AT1 餣㦳PĪ@ΡABAT1 骺˩MOAT2 ˩MO 20,000 C"	"~ĳϥξq(CѤ@AC80mg160mg)LkRfHAhiW[qܨC320mgAάOi֥ΧQC
ǥ\णfHAΫDxĩʤεLx{nx\णfHAݭnҼ{վ㾯qC"	"1.wǰʯ߯UfHAAΨL|vTǯBޱiOB׾JͤƨtΪī~Ai|ް_McreatinineȩΦ夤(BUN)W[AGĳ惡fHʴC
2.w߰IܩΤߦٱfHҧ@]Aǥ\˴C
3.X֨ϥACEIsBARBs Χtaliskiren ī~|W[CB[gεǥ\U ( ]AʵǰI) IAGĳX֨ϥACEIsBARBs Χtaliskiren ī~_RAASAYTnϥ_vAKʴfHǥ\BqѽΦCACEIs ARBs X֨ϥΩ}fǯfܯfHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H]xs30JHUBC	Valsartan	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0	B߰I(NYHA G|)Cߦٱᥪ߫ǥ\ಧ`C	"1.w Diovan 󦨥LӪ
2.C
3.X֨ϥΥ~Χtaliskiren ī~}fHεǥ\णfH (GFR < 60 ml/min/1.73 m2 )C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w55-02 [s]_95 [®]_95 [UDx]_U03-49 [E]_C2-13 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIOV1-a	ODIOV1-b	ODIOV1-c	110.6.16
BC25756100	C09CA09	0	OEDAR	Edarbi 40mg/tab(Azilsartan)		"azilsartan medoxomil O@ؤfAĪeXġA|ֳtഫʳ azilsartanAazilsartan |ܩʦa_ަY II Phز´̪ AT1 鵲XAӫܨ@ΡC
ަY II Oǯ  ަYtΤ̥DnA@Υ]tަYBEǩTପXMBEŦAHζubŦAlC
_ AT1 AiަYIIǯct^Xո`@ΡAW[ߵǯʻPަY II 夤@סAõLkazilsartan@ΡC"	"1. ĳ_lqCѤ@AC 20-40 mgC̯fw{ɤվ㾯qA̤jqCѤ@BC 80 mgC 
2. ofAϥΡAiPΪŸAΡC 
3. 2 gɥi㨣챵̤j{תĪGA4gɥiF̤jĪGC"	"1.X֨ϥACEIsBARBsΧtaliskirenī~|W[CB[gεǥ\U(]AʵǰI)IAGĳX֨ϥACEIsBARBsΧtaliskirenī~_RAASCYTnϥ_vAKʴfHǥ\BqѽΦCACEIsARBsX֨ϥΩ}fǯf(diabetic nephropathy)fHC
2.ĳϥΩ󭫫רx\णfHC
3.rpξާ@OAXGSvTCMӦǯfHAīᤴi|Pwtίh¡ApoǱpo͡Arpξާ@󾹨ξC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUCЦs]ˤAHקKӤμC	Azilsartan	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0	v	"1. 䬡ʪΥξLӡC 
2. kC 
3. AliskirenP~iX֨ϥΩ}fw̡C
4. X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w17-01 [s]_121 [®]_121 [E]_B1-16 j	Ts110.6.16		OI` 	0	OIs 20251124	OEDAR-a	OEDAR-d	OEDAR-c	110.6.16
BC24497100	C09CA08	0	OOLME	Olmetec 20mg/tab(Olmesartan)		Olmesartanܩʦa_ު@IIPޥƦAT1XAiӪ_ު@IIަY@ΡC	"ĳ}lq20@JACѤ@Cv2gAݶi@BCfHA
Olmetec?qiW[40@JCWL40@Jq|㪺ĪGC"	"1.Olmetec?ĳΩ~֤p1HUC
2.ǯ-ު@tγQƪfHAҦpn-/Q֪fH(ҦpHqQvfH)A@}lHOlmetec?vi|X{ʧCgC
3.ǥ\Pǯ-ު@-ǩTନtάʦfH(ҦpY{ʤ߰IܪfH)AYHު@ഫ?Φު@ܾvA|X{֯g/ζiʴg(u)ʵǰIܤ/Φ`C
4.iܦbϥolmesartanƤܼƦ~fHWAoYCʸmH魫ABq`ibfHz´Wo{Y{HC
5.Olmetec?fHʴ[C ǯ-ު@tΪĪiް_[gC
6.PYQ֥ήɡAݺʱfHYQ@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Olmesartan 20mg	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0		"1. 糧~LӪ̡ATϥΡC
2. hk
3. X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C"	LOAީʤ~ALӤAæRA[gACʸmzfA夤ٻ@׼W[AʵǰIܡArYAkoAC¯lD	oıhߧYOlmetecD@Ωrenin-AngiotesintΪĪA|ˮ`o|LƦܳy`D	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OOLME-a	OOLME-b	OOLME-c	110.6.16
BC26672100	C09DX04	0	OENTR	Entresto 100mgƤ		"ENTRESTO㦳ʷ?(Neprilysin inhibitor): Sacubitril Τ@ئަY_GvalsartanC
ENTRESTOgѫeXĪ sacubitril ʥNª LBQ657 ʷ?( ?줺?FNEP)Føg valsartan _ĤGަYĤ@(AT1) Cѩ LBQ657 ʷ?AiӼW[ʷ?Ѫ`?(ҦpQu`?)FP valsartan iĤGަY@ΡA] ENTRESTOŦIܱw̪ߦީMŦ|ͧ@ΡCValsartan gѿܩʪ_ AT1 AĤGަY@ΡAçĤGަYǩTC"	"1. ĳ_lqC⦸100@JC̾ڱw̭@p24g[~qAFC⦸200@JؼкqC
2. ثeA ACEI ARB w̡AάOeϥΧCqezĪw̡Aĳ_lqC⦸ 50@JC̾ڱw̭@pAC24g[~qAFC⦸200@JؼкqC
3. ׵ǥ\ण(eGFR<30mL/min/1.73m2) w̤ĳ_lqAC⦸50@JC̾ڱw̭@pAC24g[~qAFC⦸200@JؼкqC
4. שΤ׵ǥ\णw̡Aݭnվ_lqC
5. רx\ण(Child-Pugh B ) w̤ĳ_lqAC⦸50@JC̾ڱw̭@pAC24g[ ~qAFC⦸200@JؼкqC 
6. רx\णw̡Aݭnվ_lqC
7. ĳרx\णw̨ϥΦĪC"	"1. pGo{hAt ENTRESTO?C
2. @Ωǯ - ަYtΪĪ|ˮ`o|LAƦܾɭPL঺`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 30XC HUA`NAxsl]ˤC	"Sacubitril   49 mg
Valsartan 51 mg"	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	CʤŦI	"1. ī~󦨥LӪw̡C
2. Lhϥ ACEI  ARB vީʤ~fvw̡C
3. ֥ ACEIFTbϥ ACEI 36 pɤഫܥĪAΦbϥΥĪ36 pɤഫACEIC
4. Pɨ֥aliskiren }fw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 [ws]_w31-04 [E]_B3-16 j	Ts113.01.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.14._20220501.pdf"">OI` 2.14.</a>              "	OI` 2.14.	0	OIs 20251124	OENTR-a	OENTR-b	OENTR-c	113.01.29
BC26671100	C09DX04	0	OENTR2	Entresto 200mgƤ		"ENTRESTO㦳ʷ?(Neprilysin inhibitor): Sacubitril Τ@ئަY_GvalsartanC
ENTRESTOgѫeXĪ sacubitril ʥNª LBQ657 ʷ?( ?줺?FNEP)Føg valsartan _ĤGަYĤ@(AT1) Cѩ LBQ657 ʷ?AiӼW[ʷ?Ѫ`?(ҦpQu`?)FP valsartan iĤGަY@ΡA] ENTRESTOŦIܱw̪ߦީMŦ|ͧ@ΡCValsartan gѿܩʪ_ AT1 AĤGަY@ΡAçĤGަYǩTC"	"1. ĳ_lqC⦸100@JC̾ڱw̭@p24g[~qAFC⦸200@JؼкqC
2. ثeA ACEI ARB w̡AάOeϥΧCqezĪw̡Aĳ_lqC⦸ 50@JC̾ڱw̭@pAC24g[~qAFC⦸200@JؼкqC
3. ׵ǥ\ण(eGFR<30mL/min/1.73m2) w̤ĳ_lqAC⦸50@JC̾ڱw̭@pAC24g[~qAFC⦸200@JؼкqC
4. שΤ׵ǥ\णw̡Aݭnվ_lqC
5. רx\ण(Child-Pugh B ) w̤ĳ_lqAC⦸50@JC̾ڱw̭@pAC24g[~qAFC⦸200@JؼкqC 
6. רx\णw̡Aݭnվ_lqC
7. ĳרx\णw̨ϥΦĪC"	"1. pGo{hAt ENTRESTO?C
2. @Ωǯ - ަYtΪĪ|ˮ`o|LAƦܾɭPL঺`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 30XC HUA`NAxsl]ˤC	Sacubitril 97mg/Valsartan 103mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	CʤŦI	"1. ī~󦨥LӪw̡C
2. Lhϥ ACEI  ARB vީʤ~fvw̡C
3. ֥ ACEIFTbϥ ACEI 36 pɤഫܥĪAΦbϥΥĪ36 pɤഫACEIC
4. Pɨ֥aliskiren }fw̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.14._20220501.pdf"">OI` 2.14.</a>              "	OI` 2.14.	0	OIs 20251124	OENTR2-a	OENTR2-b	OENTR2-c	110.6.16
BC23109100	C09DA03	0	OCODI	Co-Diovan 80/12.5mg/tab(Ƥ)		"1. ValsartanO@ؤfA㬡ʥBSw@Ωޥ[-II(Ang-II)骺ܾCܩʦa@ΦbAT1ȫAtdwޥ[II@ΡCValsartanbAT1Wä|{X󳡤@ξʡABAT1骺˩MOj(20,000)AT2C
2. ThiazideQ@γDnObŦݪǦpޡCbǥֽ|˩MOOQ@ΤΧƶubݵǦp޹B骺DnXmCThiazide@μҦOzLNa+C1-޹DAiOgvC1-mAiӼvTqѽ誺AlGW[quδlƪnAögѧQ@δ֦ߪenAyߤǯʼW[AǩTତcΧG[lyAHΦߤ[l֡Cǯ-ǩTପsOѦޥ[IIҽո`AҥH@PPޥ[IIܾiPoǧQ[ly{HC"	~ĳq@Ѥ@ɽC24PiF̤jĪGC̤jϥξqValsartan 320mg/Hydrochlorothiazide 25mgC	"1.i|yMqѽܡC
2.ϥΦb氼Ψⰼǰʯ߯Uγ氼ǰʯ߯Uw̡A]i|ް_夤ȩΦMٻȼW[C
3.צܤ׵ǥ\ण(ĲMv>30@/)fwݭnվ㾯qCThiazideī~iyCʵŦefHX{gC
4.Lx{nܤרx\णfwݽվ㾯qC
5.iXthiazideQ]Ahydrochlorothiazide|[tάƥʬʯTHC
6.ThiazideQi|ܸ}@ʨô夤xTJBTĥ̪oסAHΧĿ@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H]˶Js30JHUC	Valsartan 80mg/Hydrochlorothiazide 12.5mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	@kLkAĤGuġC	"1.糧~@LӤC
2.hC
3.Yx\णAxDʨxwƤx{nC
4.LAYǥ\ण(ĲMv<30@/)C
5.LkvC[BCuBtΦgĦgC
6.X֨ϥΥ~Χtaliskirenī~}ffwεǥ\णfw(GFR<60 ml/min/1.73 m2)"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K5 [2]_K5 [ws]_w24-07 [s]_73 [®]_73 [UDx]_U02-32 [E]_B2-16 j	Ts110.6.16		OI` 	0	OIs 20251124	OCODI-a	OCODI-B	OCODI-c	110.6.16
BC25072100	C09DB01	0	OEXFO1	Exforge 5mg/160mg/tab		Exforge XحƦXAoؤƦX㤬ɩʪ@ξӱoʰfHGamlodipine ݩtlqDܾAvalsartan OަY II ܾAX֨ϥγoئ[ʪĪGAi@ܰ@ΡC	C@AC@ɡA֪AΪŸAΧiCYbv 3-4 goɡAqiwCվW[̤ܳj 10/160 mgC	"1.קKϥΥ~C
2.x\ण}wpߡC
3.X֨ϥ ACEIsBARBs Χt aliskiren ī~|W[CB[gεǥ\U ( ]AʵǰI ) IAGĳX֨ϥ ACEIsBARBs Χt aliskiren ī~_ RAASAYTnϥ_vAKʴfHǥ\BqѽΦC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUAץxsC	Amlodipine 5mg/Valsartan 160mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	vAƤī~AXΩ_lvC	"1.TΩӲ~LӪfHC
2.hC
3.X֨ϥΥ~Χt aliskiren ī~}fHεǥ\णfH (GFR< 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K4 [2]_K4 [ws]_w30-02 [s]_112 [®]_112 [UDx]_U03-10 [E]_B3-15 j	Ts110.6.16		OI` 	0	OIs 20251124	OEXF1-a	OEXFO1-b	OEXFO1-c	110.6.16
BC25421100	C09DX01	0	OEXFO3	(TX@)Exforge HCT 10/160/25mg/tab		Exforge HCTʦOwb3ذѻPո`PCӨAamlodipine_tlߦٻPޥƦٲӭMY@ΡFValsartan_ަYIIߦ١BޥƦ١BǤWPŦӭMަYMud@ΡFHydrochlorothiazidePiŦuMlƪnAϦޤen֡C	CĤ@CqibgW[CbܾqgYiF̤jĪGCExforge HCT ̰ĳq10/320/25 @JCExforge HCT iHftΤft@_AΡC	rξާ@Ҽ{Ai|o͵uȪYwίh¡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JAקKAu{Beūץi\15-30JC	Valsartan 160mg/Amlodipine 10mg/hydrochlorothiazide 25mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	"vC~AΩHamlodipineAvalsartanAhydrochlorothiazide䤤ئX֪vALkıw̡C
TwqƤsAäAΩ󰪦lvC"	"ѩExforge HCT t HydrochlorothiazideA] Exforge HCT TΩLgιDilĪLӤfHC
X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w30-01 [UDx]_U03-02 [E]_B3-10 j	Ts110.6.16		OI` 	0	OIs 20251124	OEXFO3-a	OEXFO3-b	OEXFO3-c	110.6.16
BC24643100	C09DA01	0	OHYZA2	Hyzaar 100/12.5mg(Losartan+HCTZ)		"1. LosartanΨDnʥNªǥѿܩʦa_ angiotensin IIP\h´(pޥƦ١AǤW)AT1鵲XAӪ_F angiotensin IIަYΨEadosteronec@ΡC
2. HydrochlorothiazidethiazideQA thiazidesvTǤp޹qѽAlAW[ulδlGqƪnC@άhydrochlorothiazideQ@δ֦߮enAGW[reninʡAW[aldosteronecAW[G[ly AӴ֦M[lC"	C@AC@C	"1.iH@}lNϥΦbޤenfHҦpHqQvfHC
2.~ĳϥΦbYǥ\l(ٻMv30mL/min)Ψx\lfw"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ15-30XCUxsCקKuӮgC	Losartan/Hydrochlorothiazide	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0		"1.糧~󦨤LӤfwC
2.LgfwC
3.LsulfonamidelͪLӤfwC 
X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w33-03 [E]_B3-31 j	Ts110.6.16		OI` 	0	OIs 20251124	OHYZA2-a	OHYZA2-b	OHYZA2-c	110.6.16
BC24929100	C09DB02	0	OSEVI	Sevikar 5/20mg/tab		"SevikarOحĪƤG@جO dihydropyridine tܾ(tlܾκCtqD_) amlodipine besylateAΤ@جOަY_ olmesartan medoxomilC
Sevikar amlodipinetlVӭMiJޥƦ٩Mߦ١A Sevikar olmesartan medoxomilh_ަYަY@ΡC"	_lq5/20mgACѤ@Cv2gAiھڻݭnNqW[10/40mgC̰q10/40mgC	"1.X֨ϥΦު@? (ACEIs)Bޤ_ (ARBs)Χtaliskirenī~A|W[CB[gεǥ\U]AʵǰIܡIC
2. AmlodipineDngѨxŦN¡Aӭרx\णfH߲MbI56pɡA]ofHϥήwCվ㾯qC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Olmesartan 20mg/Amlodipine 5mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	vAƤī~AXΩ_lvC	X֨ϥΥ~Χtaliskirenī~}fwεǥ\णw (GFR < 60 ml/min/1.73 m2)C		"hDC
LrʡAYo{hAߧYΡD
(h2.3ĳϥ)iyϤL֡ALŦ\UAɭPLPŦIܡAo|}ALͳo|AfܧΡACΦ`D"	iɭPŪಣͤ}AҼ{Ī˪nʡAMwO_ũΰĪC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K5 [2]_K5 [ws]_w52-01 [s]_279 [®]_279 [UDx]_U03-61 [E]_B5-29 j	Ts110.6.16		OI` 	0	OIs 20251124	OSEVI-a	OSEVI-b	OSEVI-c	110.6.16
BC25492100	C09DX03	0	OSEVI3	Sevikar HCT(TX@) 20/5/12.5mg/tab		Sevikar HCTո`@ΥDn̨䤣Pʦզi3ؤP@ξCӨAamlodipinetlVӭMiJޥƦ٩MߦٲͤY@ΡFolmesartan medoxomil_ަYIIߦ١BޥƦ١BǤWPǲӭMަYζud@ΡFhydrochlorothiazidehǥѫPiǤuP⪺ƪnACޤGC	"q11C 
iھڻݭnH2PjW[qC~̤jĳq40/10/25mgC"	"1.o{hAоְSevikar HCTC
2.ThiazideQi|ܸ}@ʨô夤xTJBTĥ̪oסAHΧĿ@סC
3.YX{ʪoʶꫬCgAϥΨæ^EC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sū25XCC	Olmesartan 20mg/Amlodipine 5mg/Hydrochlorothiazide 12.5mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	vC~AΩHOlmesartanBAmlodipineBHydrochlorothiazide䤤ئX֪vALkıfwC	"1. ]thydrochlorothiazideALg(anuria)B糧ī~󦨤LөιLDiĪLӪfwoϥSevikar HCTC
2. oPtaliskirenī~X֨ϥΩ}ffwεǥ\णfw(GFR<60 ml/min/1.73 m2)"		LrʡAYo{hAߧYΡC	iɭPŪಣͤ}AvĳšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w52-02 [UDx]_U03-57 [E]_B5-31 j	Ts110.6.16		OI` 	0	OIs 20251124	OSEVI3-a	OSEVI3-b	02025492-2	110.6.16
BC25446100	C09DB04	0	OTWYN	TwynstaƤTablets 80/5mg (Telmisartan/		"Telmisartan 
ަYII YbަY?]ACEAE??[kininase]II^ҶʤƪAѦަY I ƧΦCަYII ǯ-ަYtΪDnA@Υ]AަYB?EǩTପXPBŦ?E@ΡAHεŦuAl@ΡCTelmisartan ib\h´]?pޥ?ٻPǤW^Aܩʦa_ަYII PAT1 骺XAiӪ_ަYII ަYPǩT@ΡC]A@λPަYII X?|LC
Amlodipine
Amlodipine O@dihydropyridine ?t?lqD_Ait?lg?Jޥ?ٻPߦ٪L{C "	"1. @Ѥ@20-80 mg ?telmisartan Ī?kAamlodipine ľ?dh2.5-10mgC?ӧOվAiܤ2 gհCj?ĪGi2 g{Aq`i4 gF̤j?TC 
2. TWYNSTA ̤jĳ?@Ѥ@80/10 mgC 
3.x\l75ΥHWfwAݽwCվ㾯qC
4. TWYNSTA iP@_AΡAiŸAΡC "	ѩϥTWYNSTA ?ܰĪiX{?֡Bt¡B?tίt?Ƨ@ΡA]fwbqƶ}?ξާ@ξʮɡASOԷVC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC 	Telmisartan 80mg/ amlodipine 5mg	C09D	"޺iIIġAƤ ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"	0	v?AƤī~?AΩ_lv?C 	"TWYNSTA TΩwtelmisartanBamlodipineAΥ~LLӡ]?pAʹLӤΦީʤ~^fwC 
}fw̩εǥ\णw (GFR < 60 ml/min/1.73 m2)ФŦPɨåaliskiren TWYNSTAC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K3 [2]_K3 [ws]_w54-04 [E]_C2-08 j	Ts110.6.16		OI` 	0	OIs 20251124	OTWYN-a	OTWYN-b	02C25446-2	110.6.16
AC58639100	C10AA08	0	OZULI	Zulitor F.C. 4mg/tab(Pitavastatin)		HMG-CoA٭?XxTJtvMwïAPitavastatinnivʧ٭?Agѹ骺vʦӯbxŦxTJX@ΡCGLDL-餧{W[ALDLѦGǦܨxŦL{]ӥ[tAiӭC`xTJ@סCxTJbxŦX@ΫAi@BCFCKׯ׳Jժ@סC	"1.HC@fAPitavastatin 1~2mgCC̰Aξq4mgC
2.B׵ǥ\ण(ǵyoLvO30-59 mL/min/1.73m215V29 mL/min/1.73m2)ΥGzRŦfw̡APitavastatin_lqC@1mgA̰qC@2mgC
3.AErythromycinw̡APitavastatinC榸qiWL1mgC
4.ARifampinw̡APitavastatinC榸qiWL2mgC"	"1.VΩ㦳٦ׯfܼb]lfHCYX{]٦ׯkhBĲhBzLOɡAרOHoNΥFO̡AߧYivC
2.ϥΥ~iް_fHxi?ɰAĳҦfH_lvex\˴AçifHv`NO_X{xlˤgA]AhҡBhBkWAB`ζnC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUBpĤoBC	Pitavastatin 4mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	oʰxTJgβVXײ`	"1.w糧~LӪ̡C 
2. ʩʨxfAi]A]xiJWɱΡC
3. ΥihkC 
4. ¨ŰC 
5. ֥cyclosporine ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OZULI.a	OZULI.b	OZULI.c	110.6.16
KC01033209	C10AX13	0	IREPA	Repatha  140mg/ml/pen (Evolocumab )(N)		"Evolocumab iܩʵX PCSK9AG` PCSK9 PbxŦӭMCK
ׯ׳Jը (LDLR) XAiӨ PCSK9 ո` LDLR ѡCxŦӭM LDLR 
ƥؼW[|ɭPM LDL xTJ (LDL-C) ֡C"	"Repatha ĳqCg@ 140 mg ΨCӤ@ 420 mgC
ibBjLΤWuϰi֤U`gC`gg`ܴAi`gĲhBCBoܵwֽWC"	"Repatha iϥRߪ`gΦ٦ת`gġC
C@ 420 mg qAϥΤTwRwb 30 sġC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsbBc (2-8XC)CŧNC
YqBcXARepatha i˦b쥻]˲xsǷ (̦h 25XC)Ab 1 Ӥ뤺ϥΡC"	Evolocumab 140mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	"1.w̰@qstatinACKׯ׳JxTJ (LDL-C) LkFؼЭȤXlaکʰxTJg (HeFH) ΰʯߵwƤߦޯef (clinical ASCVD) Hw̡ARepatha i@~UvC
2. statin @θT statin oʰxTJg (XlaکʤΫDaک) βVXײ`Hw̡ARepatha iWϥΩΨ֥ΨLĪA@~UvC"	ﬡʦΥ@ξLӡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-24 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.4.1._20250901.pdf"">OI` 2.6.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.4.2._20250901.pdf"">OI` 2.6.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.4._20250901.pdf"">OI` 2.6.4.2.</a>            "	"OI` 2.6.4.,2.6.4.1.,2.6.4.2."	0	OIs 20251124	IREPA1-a			111.8.19
AB54967100	C10AA05	0	OATOV	Atover 40mg/F.C.tab(Atorvastatin)		"~O3-hydroxy-3methylglutaryl-coenzyme A(HMG-CoA)٭?ܩʧCo٭?OHMG-CoAܬmevalonatetvMwBJAmelalonateDO]txTJbTJeXC
bʪҫAAtorvastatinǧHMG-CoA٭?xTJbxŦXAǼW[xӭMLDLƥءAPiLDL^ΤѥN¡AӭCxTJί׳Jս誺߿@סC"	qdOatorvastatin 10-80 mgACAΤ@CAĮɶߤAH\ΪŸiC_lqMqھڱwLDL-xTJ¦ȡBvؼлPvĭӧOվC	"1. խYX{]٦ׯkhBhΦ٦׵LOAרHۨ餣AεoN{HɡAߧYiDvC
2.AĴAФŦYcγܧtcĪơC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JUC	Atovastatin 40mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	xTJgATĥ̪o୦gC	"1. ʩʨxfΤ]MಾïWɤw̡C 
2. 糧ĥ󦨤LӤw̡C
3.hP¨šC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OATOV-a	OATOV-d	OATOV-c	110.6.16
BC24131100	C10AA07	0	OCRES	Crestor 10mg/tab(Rosuvastatin)		"CRESTOR OHMG-CoA ٭?ܩvFo٭?O
3-hydroxy-3- methylglutaryl coenzyme A ܬmevalonate tvMwïAmevalonate DOxTJeXCRosuvastatinb譱ͥCתĪGCĤ@AW[xӭMCKׯ׳JըƥءAPiCKׯ׳Jժ^ΤѥN¡CĤGACKׯ׳JզbxŦXAiӴַCKׯ׳JթMCKׯ׳Jղɤl`ơC"	CRESTOR qdO5-20 mg CѤ@AھڪvؼФαw̪AӧOվ㾯qCAĮɶߤAH\ΪŸiC	"1.ٮĿE?(creatinine kinase)@שWɡAΪ̽TwhæٯfɡACRESTOR vCpGX{]٦ׯkhBhΦ٦׵LOAרO񦳥AεoN{HAΪ̦٦׼xԻPgbCRESTOR ᤴMsbANߧYqvC
2.ϥΥ~iް_fHx?ɰAĳҦfH_lvex\˴AçifHv`NO_X{xlˤgA]AhҡBhBkWAB`ζnC
3.VΩjqs/δgwxfw̡C
4.]BʳJէ/Φ姿w̡AӭnҼ{CCRESTOR q"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ml]ˤAxs30JHUC	Rosuvastatin 10mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	xTJgBTĥ̪o୦g	"1.w糧~󦨤LӤw C
2.ʩʨxeffwC
3.hΥihkC
4.¨ŰC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L3 [2]_L3 [ws]_w50-03 [s]_74 [®]_74 [UDx]_U03-45 [E]_B5-23 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OCRES-a	OCRES-b	OCRES-c	110.6.16
BC24058100	C10AX09	0	OEZET	Ezetrol 10mg/tab(Ezetimibe)		EZETROL(ezetimibe)Os@ī~AiHܩʧxTJHάӪTJbzGDlC	"Ezetrolĳq10mgACѪAΤ@AWPλPstatinī~X֧PCEZETROLiHb@ѤɭԪAΡAH\ΪŸiC
@k
ΩŦ\lw̮ɡAݭnվEzetrolqC
֥Simvastatink
bǥ\णfHݭnվEzetrolqC"	"EZETROLPstatinī~X֨ϥήɡAbvx\ˬdAoͮಾïɰ
(ULN`ȤWjTHW)Pɤ]n̷Ӹstatinī~ĳx\ˬdCҦfw
}lAEZETROLɡAQiٯfܪIηoͥ󤣹w٦׵hBĲhBzLOAߧY
^C
YQE_XhæٯfܮɡAߧYΡCٯfܷNoͤWzgΦٻCĦ?
jQ`ȤWC
bשέרx\णfHA]äMezetimibeϥη|
yؼvTAҥHAEZETROLäĳϥΩo@sfHC
EzetimibeMfenofibrate~fibratesX֨ϥΪwʩMĩʩ|
إߡA]AäĳEZETROLMfenofibrate~fibratesX
֨ϥΡC֥EZETROLMfenofibratewhñwxۯgAh@
xnˬdBӦҼ{ܭתv "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsū׬30JHU	Ezetimibe	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	vxTJg	"1. 糧Ī󦨤LӡC 
2. EZETROLX֪AstatinfenofibrateĪɡAаѦҸĪϥΡC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w31-01 [s]_113 [E]_B3-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.2._20050601_000.pdf"">OI` 2.6.2.</a>             "	"OI` 2.6.1.,2.6.2."	0	OIs 20251124	OEZET-a	OEZET-b	OEZET-c	110.6.16
BC23556100	C10AA04	0	OLESC1	Lescol XL 80mg/tab(Fluvastain)		Fluvastatin O@HMG-CoA ٭쪺vʧAxTJͦXAϨxŦӭMxTJCAiӨE LDL - 骺XA]W[ LDL ɪAoǾ̲תGAiCߤxTJ@סC	80 mgC@C	"ϥΥ~iް_fHx ɰAĳҦfH_lvex\˴AçifHv`NO_X{xlˤgA]AhҡBhBkWAB`ζnC
ifwY]٦ׯkhB٬XnΦٵLOݥߧYiAרOHAεoNɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m 15 ~ 25 װBҡFpoܽιLAiAΡC	Fluvastatin 80mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	oʰxTJgέoʲVMײ`Cwa߯ffHAb֦޾γN (PTCA) ᪺jŦޤ}ƥ ( ߦ]ʦ`ADPRʪߦٱΫaʯߦA}qN )C	w fluvastatin λs󦨥LӪ̡AʩʪxefBΤ]MiïWɡAhέ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OLESC1-a	OLESC1-d	OLESC1-c	110.6.16
BC23770100	C10AB05	0	OLIP16	Lipanthyl 160mg/tab(Fenofibrate)		FenofibrateOfibric acidlͪCվתb󬡤ƹLWͬƱ\]PPAR\^CǥѬƹLWͬƱ\AfenofibrateiHƯ׳Jկ׸ѻï]lipoprotein lipase (LPL)^δ֪Jա]apoprotein (apo)^C-IIIͦAϱo夤PʯߵwƪItTĥ̪oɪ׸ѤαƥXAPɻɪJա]apo^A-IBJա]apo^A-IIXW[Cez fenofibrate b׳JդW@ίϱotJա]apo^-BױK׳Jա]VLDL^BCKׯ׳Jա]LDL^֤ΧtJա]apo^A-IBJա]apo^A-IIKׯ׳Jա]HDL^W[C	"ĳq160mg/tabCѤ@APD\֪AC
׺CʵŦefw(ٻMv3060 mL/min)AYCqī~AC@CϥΤ@100 mgn67 mgLɤƽnCYLCqī~AhĳϥfenofibrateC
YCʵŦefw(ٻMv<30 mL/min)AiϥfenofibrateC"	ĳfAܾ徯֥ΡC]|W[fAܾ徯ĮĤμW[X媺ICY֥άOAĳbv1/3ܾ徯qAYݭnAAھڰڼзǤiInternational Normalized Ratio (INR)jʴȶi澯qվC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H˶JsC30JBC	Fenofibrate 160mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	xTJgBTĥ̪oצgBVXׯg(TYPE IIaBIIbBIIIBIVBV )C	"ĵBhα¨ŰkBYx\ण}ApxͤƭȤj󥿱`ȤW3 (]txDʨxwƤΤ]ʨx\ಧ`) BxۡBYCʵŦefBCʩΫʯظ(]YTĥ̪o୦gް_ʯŦ~)BfibratesĪketoprofen vӷPΥrʤw̡Bfenofibrate/Υ~ξLӪw̡C
Lipanthyl? Supra 160mg B赹|UC~LӪfwG͡BͪoBZCୡA]i঳͹LӯgIC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C3 [2]_C3 [ws]_w32-04 [s]_195 [®]_195 [E]_B3-26 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OLIP16-a	OLIP16-b	OLIP16-c	110.6.16
BC22889100	C10AA05	0	OLIPI	Lipitor 40mg/F.C tab		"~O3-hydroxy-3methylglutaryl-coenzyme A(HMG-CoA)٭?ܩʧCo٭?OHMG-CoAܬmevalonatetvMwBJAmelalonateDO]txTJbTJeXC
bʪҫALipitorǧHMG-CoA٭?xTJbxŦXAǼW[xӭMCKׯ׳JըƥءAPiCKׯ׳Jժ^ΤѥN¡AӭCߤxTJί׳Jս誺@סCLipitor]|֧CKׯ׳Jժsyô֧CKׯ׳JղɤlơC"	"qdOatorvastatin 10-80 mgACAΤ@CAĮɶߤAH\ΪŸiC_lqMqھڱwLDL-xTJ¦ȡBvؼлPvĭӧOվC
קKPcyclosporineATiprnavir+ritonavirAglecaprevir+pibrentasvir֥ΡA|ɰoͦ٦ׯf/ٷѤI"	"1.YX{]٦ׯkhBhΦ٦׵LOAרO񦳥AεoN{HAΰLipitorA٦תxԻPgɡAӥߧYqvCCPK@שWɡAΪ̽Twhæ٦ׯfܮɡALipitorvC
2.LipitorVΩjqs/δgwxffHC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm30?CUxsC	Atovastatin 40mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	"xTJgATĥ̪o୦gC
}f(Sa߯f)A@ӦMI]l(Ex:AfܡAճJէAl)AiCߦٱAID
(Sa߯f)ATӦMI]l(Ex:Type 2DMA>55ALJէγJէAlҡA@˦b55(k)60(k)eoͫa߯f)AiCߦٱΤAަAyΤߵhID"	"1. ʩʨxf]AxŦiF]Wɤw̡C 
2. 糧ĥ󦨤LӤw̡C 
3. hC
4. šC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L3 [2]_L3 [ws]_w18-03 [s]_160 [®]_160 [UDx]_U02-12 [E]_B1-19 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OLIPI-a	OLIPI-b	OLIPI-c	110.6.16
BC25350100	C10AA08	0	OLIVA	LIVALO 2mg/tab(Pitavastatin)		HMG-CoA ٭?XxTJtvMwïApitavastatin ivʧ٭?Agѹ骺vʦӯbxŦxTJX@ΡCGLDL-餧{W[ALDL ѦGǦܨxŦL{]ӥ[tAiӭC`xTJ@סCxTJbxŦX@ΫAi@BCFCKׯ׳Jժ@סC	"1. HC1fA LIVALO 1~2mgCC̰Aξq 4mgCb LIVALO {}lγvBվ㾯qɡA 4 g˴׿@רþڥHվ㾯qC
2. 10HWൣaکʰxTJgGC1fALIVALO 1mgCC̰Aξq2mgC
3. B׵ǥ\ण (ǵyoLvO30-59 mL/min/1.73 m215-29 mL/min/1.73 m2) ΥGzRŦffHALIVALO _lqC@ 1mgA̰qC@ 2mgC
4. x\êHAHC1mg}lġA̤jĶqWLC2mgCx\êൣAC鵹1mgC
5. ֥ ErythromycinC榸qiWL 1mgC
2.6 ֥ RifampinC榸qiWL 2mgC"	"1.VΩ㦳٦ׯfܼb]lfHCYX{]٦ׯkhBĲhBzLOɡAרOHoNΥFO̡AߧYivC
2.ϥΥ~iް_fHxi?ɰAĳҦfH_lvex\˴AçifHv`NO_X{xlˤgA]AhҡBhBkWAB`ζnC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os25JA}ʫФũmBC	Pitavastatin 2mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	oʰxTJgβVXײ`BൣaکʰxTJg	"1.w糧~LӪ̡C 
2. ʩʨxfAi]A]xiJWɱΡC
3. ΥihkC 
4. ¨ŰC 
5. ֥cyclosporine ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L3 [2]_L3 [ws]_w48-01 [s]_194 [®]_194 [UDx]_U03-34 [E]_B5-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OLIVA-a	OLIVA-b	OLIVA-c	110.6.16
AC35424127	C10AC01	0	OQUES	Choles powder 9gm/pack		Cholestyramine O@سl洫סAbzDlxīᵲXΦʪƦXAøgTKƥXCpɭPʦaBaNxıqxz`XHAlCxĥTKyqW[|W[xTJƬxġAô֦MxTJΧCKׯ׳J-xTJ@סC	"HG4~8JA@1~2C̤jq24JC
ൣG(魫/*Hq)/70C"	"C]Х[J120ml-180mlN}AΡAŨ֪ALī~C
YϥΨLĪhܤ֦bAΥ~1pɫe4~6pɫ~ϥΨLĪHקKzZoĪlAκɥiɶZ[C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m󳱲DBOs(WL30J)	Cholestyramine Resin 4g	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	oʰxTJgFHxD뤧ogFjzʰjzBggB}fggʯfܩҭPmFguҭPmC	iΩ糧ĦLӪ̡AHxާ몺fHA]xĵLkiJxD~LkͮĪGC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OQUES-a	OQUES-b	OQUES-c	110.6.16
BC27283100	C10BA05	0	OATOZ	Atozet F.C. Tablets 10/20mg(Ezetimibe/at		"1.Ezetimibe-ipzxTJl@ΡAqӭC夤xTJC
2.Atovastatin-iHMG-CoA٭?PxŦxTJX@ΡAåiW[ӭMxŦLDL骺ƶqAPiLDLlPN¡AqӭC夤xTJP׳Jժ@סFatorvastatiniCLDLͦ@ΤLDLɤlƶqC"	ATOZET qd10/10 mg-ezetimibe/atorvastatin 10/20 mgAC@Ci@ѷɶHΤH뤩@qC	"1.Atozetɧ]ACűNHBƩΩCZϥΡC
2.AtorvastatinpPLstatinsĪ@ˡAi޵oٯfܡC
3.w̪ʡBYppQ{iOٯfܡAΦoٷѯg޵oǰIܤMI]l (ҦpYʷPVBCBjNB~ˡAYN©ʡBcʤιqѽ襢աAΥ򱱨w)AhȰϥΩΰATOZETvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsūפiWL30JCקKC	Ezetimibe 10mg/Atorvastatin 20mg	C10B	"׽ո`AƤ LIPID MODIFYING AGENTS, COMBINATIONS"	0	xTJg	"1.ʩʨxfΤ]xŦi?ɰC
2.ATOZET󦨤LӡC
3.wghΥiwghkC
4.¨ťˡC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 [ws]_w19-03 [E]_B1-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.3._20231201.pdf"">OI` 2.6.3.</a>              "	OI` 2.6.3.	0	OIs 20251124	OATOZ-a	OATOZ-b	02C27283-2	110.6.16
BC24392100	C10BX03	0	OCADU2	Caduet? 5mg/20mg tablet		"Amlodipine/atorvastatinXا@ξG
amlodipinedihydropyridine
tlܾ(tlܾκCtqD_)@ΩMatorvastatin
HMG-CoA٭쨻C@ΡCAmlodipine/atorvastatinamlodipine
tlLӭMyJӶiJޥƦ٤Τߦ٤C
Amlodipine/atorvastatinatorvastatinOHMG-CoA٭쨻CܩvCo٭쨻COHMG-CoAܬmevalonatetvMwïAmevalonateDO]AxTJbTJeXC "	"lv 
CADUETĳΩ󦳰ׯgX֦Τߵhw̤_lvC}lϥCADUETɡA侯qӮھamlodipineatorvastatinӧOҶqAӨMwAզXCCADUETamlodipinḛqO10mgCѤ@Aatorvastatin̰qO80mgCѤ@C"	"1.ʫaʯ߯gԸsfvB2.߾ɺޤJvΥ~aʯ߷fNaʯߵwƱw(108/2/1)AWzPĪviæA_lĪv׭ȡGLDL-C70mg/dLAץؼЭȡGLDL-C70mg/dLF
ߦޯefο}fw̡APĪviæA_lĪv׭ȡGTC160mg/dL
LDL-C100mg/dLAץؼЭȡGTC160mg/dLLDL-C100mg/dLF
2ӦMI]lΥHWAīe3-6ӤDĪvA_lĪv׭ȡGTC200mg/dLLDL-C130mg/dL AץؼЭȡGTC200mg/dLLDL-C130mg/dLF
1ӦMI]lAīe3-6ӤDĪvA_lĪv׭ȡGTC240mg/dLLDL-C160mg/dLAץؼЭȡGTC240mg/dLLDL-C160mg/dLF
0ӦMI]lAīe3-6ӤDĪvA_lĪv׭ȡGLDL-C190mg/dLAץؼЭȡGLDL-C190mg/dLF
WzBWwGĤ@~C3-6Ӥˬd@AĤG~Hܤ֨C6-12Ӥˬd@APɽЪ`NƧ@Τͦpx\ಧ`AٷѯgC
ߦޯefwqG
(@) aʯߵwƯfHGߵhfHA߾ɺҹίʮʤ߹qܤƩέtʸ綧ʤ(ˬdi)
(G) ʦ嫬ޯeffH]tG
1.C
2.Ȯɩʸʦw(TIA)C]E_ѯgvTߡ^

MI]lwqG
1.
2.kʡ45Akʡ55ΰg
3.oʫa߯faڥv(kʡ55Akʡ65)
4.HDL-C<40mg/dL
5.l(]lҦӲŦX_BvǫhӮסAYٵҦӭnDĪvAH۶Ov)C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs15-30XCC 	Amlodipine+Atorvastatin	C10B	"׽ո`AƤ LIPID MODIFYING AGENTS, COMBINATIONS"	0	]Mײ`oإiBMI]l֦sAӨϤߦަMIW[w̡FΦ]ߵh{a߯f(CHD)֦iBײ`MI]lAӨϤߦަMIW[w̡C Ca߯fMIsߦިƥoͲv {ɤWSa߯fw̡AOܤ֦TӨLa߯fMI]lA]AĤG}fB~j󵥩55BLճJէγJէBlϡBβĤ@˦b55(k)60(k)egoͫa߯fƥAAΩGCߦٱ몺IBCIBCަAyNPߵhIC	"Amlodipine/atorvastatinTΩUCw̡G
1. dihydropyridineƦXBamlodipineBatorvastatinΥ~󦨤LӤw̡F
2. ʩʨxfΤ]MಾïWɶWL`ȤW(ULN) 3HWw̡F
3. B¨ŰΦͨ|OӥTץkC|ְkߦbihAåBALधbMIpUA~iHA amlodipine/atorvastatinC "	~BmBYhBƤ}C 	Amlodipine/atorvastatintatorvastatinAGTΩ󥥰C	Amlodipine/atorvastatintatorvastatinAGTΩ¨Ű	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L3 [2]_L3 [ws]_w23-02 [E]_B2-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OCADU2-A	OCADU2-B		110.6.16
AC57216100	C10BA01	0	OLINI	Linicor F.C.T 500/20mg		"1. Niacinܦפ@ξ|FѡAioAƺا@ΡA]tתղ´תջġBW[׳J?(@ΥiOW[SɤTĥ̪oױq߲tv)CNiacin|CxŦXVLDL-CMLDL-CtvA|vTתաBTJxıqTKưC
2. LovastatinO3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA)٭?M@ʧA٭?iHʤHMG-CoAܬmevalonateCӱNHMG-CoAܬmevalonateOxTJͦX~|BJCLovastatineXĪAҨ㦳ʫܧCAѬbeta-BīAlovastatin acidAN|X{ʡCLovastatinCLDL@ξiPɥ]tCVLDL-C@פλoLDLAӾɭPLDL-C֤ͦ/μW[LDL-CN¡C"	"ΫeAλPCIߨ֪ACݾAΡA]`ei˯}BHΩCZC
_lqGCѺΫeAΤ@ 500mg/20 mgCC 4 giհWLC 500 mg]ھڽwniacin ^CCѤiWL1000 mg/40 mgC"	"1.fwnBxxefήƩʼůfvAbHwniacin/lovastatinƤvK[Cx\M}˴ɱ`ʱHTO|boǾxtβͤ}C
2.}ffwioͻPqŸ}(FBS)WɡC
3.קKMcĤ@_AΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25XCHUC	Niacin ER 500mg/ Lovastatin 20mg	C10B	"׽ո`AƤ LIPID MODIFYING AGENTS, COMBINATIONS"	0	ׯgABAXPɨϥniacin lovastatin v̡C	"1.TϥΩwniacinBlovastatinΥĪLӡBʩʨxŦefBɰi]transaminases^ӥB]BʩʪƩʼůefΰʯߥX媺fwC
2.֥αjO CYP3A4 ]pAitraconazoleBketoconazoleBposaconazoleBHIV J?BboceprevirBtelaprevirBerythromycinBclarithromycinBtelithromycin P nefazodone^
3.TϥΩhMŰkC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D2 [2]_D2 [ws]_w36-04 [E]_B4-25 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	OI` 2.6.1.	0	OIs 20251124	OLINI-a	OLINI-b	OLINI-c	110.6.16
B021515329	D01AE14	0	EBRUM	Brumixol cream 10mg/gm;10gm/		"sħߧ@ΡF~
Dermatophytes (Trichophytonv~ݡBEpidemophyton~)AMoulds(Aspergillus
ѵݡBTorulopsis 󽤦)AYeasts å(Candida ])A~ CICLOPIROX
OLAMINE ﭲ󶧩ʵ(StreptococcusBStaphylococcusBCorinebacterium)(Wi~
έ Trichomonas V.) ҥHSOAXVXPVCCICLOPIROX OLAMINE Oߤ
~M Imidazole lͪP(p Clotrimazole ) ѩPfʤLͪq
N"	Cϥ1~2AöwC	"1.~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC
2Ъ`Nn~JCU@~JAХߨHηŤR~AåߧYe NC
3ĤŨϥΩjn(HWLϥΪ̪xnѦ)
4.@ߪv 7 ѯg|ﵽA~M~ 2 gA~ 4 gApgL
 ezvɶAgYSﵽХߧYNCpYϭYgﵽīA
 f_oߧYN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js25JHU	 1 J CICLOPIROX OLAMINEC	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	"vֽL߷PVAp~(})B~B
"	]Ħް_L				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.05		OI` 	0	OIs 20251124	DC	DC	DC	114.12.05
AC29790329	D01AC09	0	EEXELS	Exelderm solution (sulconazole)10mg/ml;10		Sulconazole nitrateiPϦ߲ӭMqzʪUتzʽoܤơAëPϻPӭMXATP?ʵoܤơAP߲ӭMqzʾοeoͻêӱߡC	123Aq٩wC	"1.~oΩ󲴬C
2.~ťΩYSꪺC
3.]~EʡAbtPS곡pߨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Sulconazole nitrate	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	UCֽ߯fvG~]}^~B~Bֽ]߯gBᴳ~]^C	糧~LӪ̸TΥ~C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-01 [E]_H3-18 j	Ts110.6.16		OI` 	0	OIs 20251124	EEXELS-a	01C29790-1	01C29790-2	110.6.16
AB56698343	D01AC14	0	EZALA	"Zalain Gel(~ξ,~)2%; 30gm/~"		vY֤׺|ʥֽΦ]߷PVҤް_Y֮h	bY֩YvWپAq~Ag 3 ~ 5 AHMR~A@gϥΨ⦸Asϥ 2 ~ 4 gFpϥ 4 gᤴﵽAݭsҨf]AϥΤ@몺åͱIHPVC	"1. peϥιL֯TJHv׺|ʥֽAаĨgA}lϥΥ~AHקK
X{ֽTJoPӤƧ@ΡC
2. ~AΩv׺|ʥֽC
3. ϥΥ~׶}BfĩγDHC
4. ~iΩ󲴳vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s30XCHUBAקKgAømൣoB	Sertaconazole nitrate 2 g	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	vY֤׺|ʥֽΦ]߷PVҤް_Y֮h	"w糧~Ψ䤤@᫬LӲ{HɡAФŨϥΥ~C} (imidazole)
͹LӤfwԷVϥΡA`Nei"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P01-04 j	Ts110.6.16		OI` 	0	OIs 20251124	EZALA-a	EZALA-b	EZALA-c	110.6.16
AC25567321	D01AC20	0	EECON	ECONALONE CREAM(group4)		ֽ]u߸sBå߸sB`߸sG(+)Ҥް_ֽf	NĦߦU@wABϤJֽAݵogy~ϥΦܧv¡	uΩֽAiΩ󲴷ϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~mǷŤUC	"
Econazole 10 mg
Triamcinolone 1 mg"	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	ֽ]u߸sBå߸sB`߸sҤް_ֽf	"HUpTϥΡG
1.ֽ֡B©lBkBalBصklC
2.糧~Lӯgfw̡C
3.﹪թʪlʥ~չDC
4.š]Behcetf~^AĤGײ`bʥHWˡBˡC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N04-05 []_08-01 [E]_H2-08 j	Ts110.6.16		OI` 	0	OIs 20251124	EECON	EECON-b	EECON-c	110.6.16
AC29789321	D01AC09	0	EEXEL	Exelderm(Sulconazole nitrate)cream		Sulconazole nitrateiPϦ߲ӭMqzʪUتzʽoܤơAëPϻPӭMXATPJʵoܤơAP߲ӭMqzʾοeoͻêӱߡC	C1-3AũwC	oΩ󲴬CťΩYSꪺC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m  25 ץHUץKeOs	"
Sulconazole nitrate 10 mg"	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	UCֽߤvG~]}^~B~Bֽ]߯gBᴳ~]^	糧ĹLӪ̤oϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-04 [E]_H2-10 j	Ts110.6.16		OI` 	0	OIs 20251124	EEXEL-a	EEXEL-b	EEXEL-c	110.6.16
AC35183329	D01AC08	0	EKETO	Ketoconazole cream 20MG/G;10GM/		ֽߩMåߩҤް_ֽBYvBҷPVgC	"@߷PVp߷F~B~B~(})Υֽ]߷PVġCϥήɱNĻIbofֽWAߦU@C
 ``NåͫOAHPVΦAPVC@몺vjpUG
1.v@Ѥ@YiAi_ϥΪgƤ鬰Cv2~3PC
2.å߷PV2~3PC
3.~2~4PC
4.߷F~3~4PC
5.~4~6PC"	1.٫eNαwֽ~bC2.i٩󦳶ˤfֽCi٩󲴷βPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs:25JUxs	Ketoconazole   20 mg	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	ֽߩMåߩҤް_ֽBYvBҷPVgC	糧ĹLӪ̤oϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-05 [E]_H3-19 j	Ts110.6.16		OI` 	0	OIs 20251124	EKETO-a	EKETO-b	EKETO-c	110.6.16
AC44012329	D01AE23	0	EMENTA	Mentax cream 1% 10g/Tube(Butenafine)		"ButenafineSqualene epoxidaseX,]zZ߲ӭMergosterolXC"	"Hֶq(b)٩w{񪺳,ľQhC}B]k^߯fG@ѤGA@PΤ@Ѥ@A|PBBֽKP줧u߷PVG@Ѥ@AGPC"	"1u~
2.pGϥiΨŻIɷ|ް_LӤ,ߧY,õAv
3.AggE_T{,iNֲӭMwsBƹ[G,zLL˩ξAiiC
4.ϥiΨŻIgvB,åBקKĲBlBLڵH´C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"25JUxs,mĵLkoBC"	"
Butenafine 10 mg"	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	]k^߯f]}^B~]~^B~ֽuߤް_ֽPVg	ϥΩ糧~wΥi঳LӪw̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-06 [UDx]_U01-63 [E]_H3-20 j	Ts110.6.16		OI` 	0	OIs 20251124	EMENTA-a	EMENTA-b	EMENTA-c	110.6.16
A025136329	D01AC01	0	EMYCOS	Mycosten cream 10mg/gm; 10g/(Clotrima		 ~ߡBåߤίuߨ㦳ߧ@ΡAQΩv}BҷB]߳BB]tYAĪGVA򾯬ŻIϥΤKABK[ϥDiĮĻUAϨܵߧ@Χ󬰦ġC	@ѤGAwAൣyϥΡC	"1sֽ~ΤoAAoϥΩ󲴷A礣oI󲴷|gHC
2.ϥΫıpﵽΧcơAߧYĨôNC
3.ߪvܤ֤GPAϥΦĶ{{C
4.sŨϥΩjnΥֽ`PV̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKgAyOs󳱲DBC	"
Clotrimazole   10 mg"	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	vֽL߷PVBp~]}^B~B	coltrimazoleLӪ̡CMycostenŻIcetyostearyl alcoholΨLLӪ̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O04-01 [E]_H3-17 j	Ts110.6.16		OI` 	0	OIs 20251124	EMYCOS-a	EMYCOS-b	EMYCOS-c	110.6.16
A023336329	D01AE20	0	EPASC	PASCA GEL(TOLNAFTATE)		~]}^B~B~Bᴳ~]^	MwAC1-ƦũwC	"1.~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC
2Ъ`Nn~JCU@~JAХߨHηŤR~AåߧYe NC
3ĤŨϥΩjn(HWLϥΪ̪xnѦ)
4.@ߪv 7 ѯg|ﵽA~M~ 2 gA~ 4 gApgL
 ezvɶAgYSﵽХߧYNCpYϭYgﵽīA
 f_oߧYN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JUxs	"
Tolnaftate......20mg 
Methylsalicylate.......20mg"	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	~]}^B~B~Bᴳ~]^	糧~LӪ̡ATϥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O04-04 [E]_H3-22 j	Ts110.6.16		OI` 	0	OIs 20251124	EPASC-a	EPASC-b	EPASC-c	110.6.16
AC45950100		0	OFUNG	Fungitech 250mg/tab(Terbinafine)		"1.~OAllylamine lͪAsħߧ@ΡCֽ(Dermatophytes)B(Moulds)PYǦPGΩ(Dimorphie Fungi)AbC@קYߧ@(Fungicidal)Cå(Yeasts)@ΡAh̤PݦӦߩΧߧ@(Fungistatic)C
2. ~izZߧΦw׾JBJAɭPw׾J(Ergosterol)Aߦ`hO]ӭMnEFӦhSqualeneC@ξO~F߲ӭMWSqualene epoxidaseCï(Squalene epioxidase)@λPӭMP450 t(Cytochrome P450 system)LAB
~|vXΨLĪN¡C"	125@JCѤGU@A250@JCѤ@@CvṳPPVP{צӤPCֽPVG@몺vpUG~(kP)w26PF~B~G24PF]ߪַPVG24P{pibߪv¡ƶg~|C	"1. bϥΫXѧYio{ɤWwѡAWhϥΩΤӦķ|ɭPAoCYv2ӬPSoﵽAh˰QO_ץE_C
2. Ѧ~HϥΥ~GbϥξqPioͪƧ@ΤWAѦ~HP~HO@˪CϥοfAvɡAOݩPVsxYPVC
3. Gרxεǥ\ê(ٮMvp50@/ΦMٮj3000L/)AϥθCqCžG~u~ΡAiϥΩ󲴷C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Terbinafine	D01B	tΥΧܯu ANTIFUNGALS FOR SYSTEMIC USE	0	v߷PV	terbinafineΨξLӪ̡C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.4._20090801_000.pdf"">OI` 10.6.4.</a>              "	OI` 10.6.4.	0	OIs 20251124	OFUNG-a	OFUNG-b	OFUNG-c	110.6.16
AC28054100	D01BA01	0	OFUYO	FuYou 125mg/tab(Griseofulvin)		"1.Griseofulvin ֽ]Keratin^SO˦XOAרOfܤ´CQlAYHn_ΦӭMAMsΦccXAӧΦjO@hAߤI\CAHۥֽ誺N¡AO@hvBV~iAt߲´CC渨AOwK¡C
2. Griseofulvin _ߦXֻġ]Nucleic acid^ɡAEX@ΡAӧejO߮įC"	"Adults: 500-1000mg/day as a single or in divided doses Pediatric :125-250 mg/day in divided doses
q`HC龯q500mg 1~4 AΡAൣЫC125~250mg ƦAΡC{uHPV{פγөwA@ݦܤֳsAΥ|PA]k^ҷPViݭnܤ~QGӤ{ɯgA~AΤGPC"	ﵵfgw̡Bxٮ`fwΨϥΥ͹LӤw̡ATΥ~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Griseofulvin	D01B	tΥΧܯu ANTIFUNGALS FOR SYSTEMIC USE	0	~Bv~AAy~ΪvΧ~εLĪֽ߷PV	ﵵfgw̡Bxٮ`fwΨϥΥ͹LӤw̡ATΥ~C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_132 [®]_132 j	Ts110.6.16		OI` 	0	OIs 20251124	OFUYO-a	OFUYO-b	OFUYO-c	110.6.16
A020215357	D02AB	0	ESINB	SINBABY LOTION		"1.O@ֽ@ΡAZinc oxideϥֽġAOCSilicone oilֽΦO@AΥֽƪnEֽC
2.hβMn\ġGolƪnEӵohAӥDibucaine hydrochlorideihACamphorMn\ġC
3.o@ΡGDiphenhydramineO@اܲ´iAlް_ֽko_S\ġC
4.ߧ@αjӦwGBenzalkonium chlorideߤOjLrʡAϥΦwC"	@2-3AAqwAΫeзnáC	"1.~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC
2.ϥΫeзnáC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUBץC	"
 Zinc oxide 100mg
Dibucaine 1.5mg
Diphenhydramine 5mg"	D02A	ĩM@ EMOLLIENTS AND PROTECTIVES	0	wѥֽEΧlBȮɽwѥֽkoBΫr˩ΥֽEҤް_khηkoC	"1.ϥΦĤް_L
2.ˤfά~
3.ywμ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.09.12		OI` 	0	OIs 20251124	DC	DC	DC	114.09.12
A0142383AN	D02AB	0	EZINC	Zin ointment		~ġAO@MG@ΡAŦbˤfμųA㦳OMcĪGC	@2-3AAqw	1~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUBץC	Zinc oxide 100mg	D02A	ĩM@ EMOLLIENTS AND PROTECTIVES	0	wѥֽEΧl	"1.ϥΦĤް_L
2.ˤfά~
3.ywμ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P01-05 []_08-03 [E]_H3-34 j	Ts110.6.16		OI` 	0	OIs 20251124	EZINC-a	EZINC-b	EZINC-c	110.6.16
		0	EFESP1	Fespixon cream 15g/tube(t@ŻI)		"ھڤmsA⭻㦳ܵߡBܵo@ΡFn㦳PiJեͦB޷s͡BܮƵUֲӭMW֤ơA[tˤf¡X@ΡC~gѧoάƯSwͤƦ]lAܺCʶˤfӭMƧ@ΡANˤfťM1ӭMDˤfLҡAƬM2ӭMDˤfLҡCM2ӭMiHzL(1)ձVEGFPi޷s͡AW[GyqF(2)vTTGFɲͲ´AͤFӭMFwAPֺӭMW͡F(3)zLmĦXJաAͭM~InA϶ˤfF짹¡XCWA~@ξରM1ӭMAìM2ӭMAˤfLM1BM2ӭM
šAձˤfoiJWʹAFˤf¡XتC"	wC٨⦸Aл\ˤfCĻIHл\ˤfŰϰAþqOwqAܼŧ¡XC	~ֽ~ΡAoAA礣oϥΩ󲴷B|PHC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JǷťiOs~	"1.25%⭻ѨPA-F4(salvigenin)PnѨS1(asiaticoside)
Plectranthus amboinicus extract - F4 ,CENTELLA ASIATICA EXTRACT"	D03	vжˤμŻs PREPAREATION FORTREATMENT OF WOUNDS AND ULCERS		}fˤf	糧~LӤ̡A]A⭻BnνξLӡC		DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.2.16		OI` 	0	OIs 20251124	EFESP1-a	EFESP1-b	EFESP1-c	111.2.16
		0	EXYLJ	XYLOCAINE JELLY		"ǨulgLgӭMVʡAifʦa_gİʪuۯgֺǼC@{Qi¾K@ΦbgӭMulqDC

"	"1.~֤p12ൣA侯qiWL6 mg/kgC
2.bGQ|pɤAiWL|qC
3.D¾KGHkʡGݭn 20ml(400mg) AH;AתhĪGC
                    ~kʡGpJ5-10mgAHRӧDC
4.ˬdGJ10-20mgAH;Aת¾KĪGAèֶq٦b~AHͼƧ@ΡCpPLlidocaine~ ֥ΡA`qiWL400mgC"	`gȨѳ榸ϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 xsūפiWL 25JAiNC	Lidocaine hydrochloride 20 mg	D04A	"oġAtܲiġB¾Kĵ ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC."	0	¾K	"1.Qi]amide^¾KAξLLӯfv̡C
2.Qi]amide^¾KΨLξLӪ̡C 
3.PABALӪ̡C¾KΨNª PABA LӤfwקKϥΧtmfһ୤ lidocaine tC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P01-03 j	Ts110.6.16		OI` 	0	OIs 20251124	EXYLJ-a	EXYLJ-b	EXYLJ-c	110.6.16
N004550321	D04AB01	0	ECBO	C.B. OINTMENT 5GM/TUBE		"1.Chlorpheniramine MaleatejOoM@ΡC
2.Lidocaine HydrochlorideYjO¾KAਲ਼tѨ˷koҤް_khMogC
3.HexachloropheneO@عֽSEʪjO߾AwʥֽewġAB㦳h䤧@ΡC
4.Methyl SalicylateAMentholACamphorhBoβMD@ΡC"	ݭnɨϥΡAAq/w	" 1.ĭ~ΤoAA礣oI |PH]pfġBġB DBnB~^BBt Y~ˤwC
2ojqϥΡAHקKʧlA PiC
3קKĲI窫B콦~BBݡC
4ijnϥΡAHKް_ ĤrgApIlxBoBŹLB"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ(15-30 CHU)OsAømĵL
kĲΤBC"	"
Chlorpheniramine 10 mg
Lidocaine  30 mg
Diphenydramine 10 mg
dl-Menthol  10 mg
dl-Camphor 5 mg"	D04A	"oġAtܲiġB¾Kĵ ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC."	0	ȮɽwѧlBAΫrˡBֽkoBֽֽewgC	"]Ħް_LӡC
 (G)2HUൣC
 (T)gFΤĦLӷP{
 H̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ECBO-a	ECBO-b	ECBO-c	110.6.16
AC42214335	D04AX91	0	EICHD	ICHDERM CREAM 50MG/GM;15G/TUBE		~ܼ~{ A´i_ĪAjOH1PH2餧_@ΡAb´i骺mvʦa´i餧ͪƧ@ΡC~RBݺήĪGYo׫ܦU	C駽h4Aܤֶj34pɡC_l@ήɶ15AY75%fwFkowѮĪGA@b7ѥiF̨ΤoġC	"1.ʳŮƪĤ覡|WjjhƧslFŻIyϥΦصĪkC
2. ts뤧Ʒ|[jRƧ@ΡC
3.ŻIűĲ
4.vfH`N}ΦMIާ@w"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 xsū 25JHU	Doxepin 50 mg	D04A	"oġAtܲiġB¾Kĵ ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC."	0	Hlʥֽ]pʥֽγ©ʺCʭa~^ҭP׷kiguv	"1. doxepinΨLT{ī~LӪ̡C
2. α¨ŰkBCw̡Bdw̡C
3. ŻIMAOIsĪΫܤֶjP~}lC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-04 [E]_H2-14 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.7._19990601_000.pdf"">OI` 13.7.</a>              "	OI` 13.7.	0	OIs 20251124	EICHD-a	EICHD-b	EICHD-c	110.6.16
AC49320382		0	ELIDO1	Lidopat 700mg/patch(Lidocaine)		~DlidocaineYQi]amide-type^ƦX¾KAǥѧgİʱҰʤζǾɩһݤlyʡAíwgӭMCϥΥ~ALidocainezl˪ֽAͦĪhĪGC	"ϥΩ󥼨lֽWA24pɴ̦hiϥ3AϥΤ@AiWL12pɡC 
ʮM]release liner^eAKiHΰŤMpC"	ϥΫY߱AYwAuȩʵıtΨL߫ߤ㤧gAߧYUAåߨNC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץOsAקKLD	Lidocaine 700mg/patch	D04A	"oġAtܲiġB¾Kĵ ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC."		Ωwѯplᯫgh(Post-herpetic Neuralgia)Cϥγȭ󥼨lֽC 	QiƦXA]Amide-type^¾KLөι糧~䥦զLӪfHC 	v쪺ֽi|oͬB~BBpwBܦBhB`PBkoBΪ̬O`ıCoǤ@뻡ӬOũMBȮɩʪAB|bƤƤpɤ۵MCLʰƧ@ΡC 	B	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N06-03 j	Ts110/10/25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.6._20210501.pdf"">OI` 1.1.6.</a>              "	OI` 1.1.6.	0	OIs 20251124	ELIDO1-a	ELIDO1-b	ELIDO1-c	110/10/25
AC58104343	D05AX52	0	ECALF	Calfine  oint. Ƥ30gm/(Group2)		~LRDlͪACalcipotrioliƻPֽӭM(ӭM)W͡A]iϤ~ֽ`ӭMWͩMƫ_`C	C@٩wB Aĳv|gC Cѳ̤jq15gA Cg̤jqoj100gAvnoWLn30%	"1.iϥΩy
2.ϥΥ~iwΨPֽX{uȩʨEAY{Ho͡AġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m25 ץHU	"
Calcipotriol 0.05g
Betamethasone  0.64g  "	D05A	Ϊv~ ANTIPSORIATICS FOR TOPICAL USE	0	M`~	"1.tկgfHФŨϥ
2.TΩIB渨ʡBwpʤ~
3.TΩYǥ\Ψx\णvfH"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N03-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.2._20101201_000.pdf"">OI` 13.3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.3._20101201_000.pdf"">OI` 13.3.3.</a>             "	"OI` 13.3.2.,13.3.3."	0	OIs 20251124	ECALF-a	01C58104-1	01C58104-2	110.6.16
BC25159343	D05AX52	0	EXAMI	XAMIOL GEL (BETAMETHASONE CALCIPOTRIOL)(Group1)		Calcipotriol O@غͯDlͪC~ƾcalcipotriolɨӭMƤΧW͡CڱAoKOwﰮ~ͧ@Ϊ¦Cbetamethasone dipropionateMLʥֽTJ@ˡA㦳ܵoBoBϦަYMK̥\઺ʽAMӡALkv즳efC\ĸgLX|QWjA]zh{׼W[CƧ@Ϊoͱη|]ӼW[C@ӨATJܵo@ξऴMC 	"1. CѱNXamiol? Gel٩YַPV@Cvɶ2gΫܱwB¡Avi8gC 
2. ҦPVYֳ쳣iHXamiol? GelvCq`C14JqNΥHvY (4J۷@)C 
3. ϥΧt calcipotriol~ɡAC̤jqoWL15JAӨCg̤jqiWL100JCHtcalcipotriol~vɡAiWLn30%C
4. ϥΫeN~ln@nCFǫήĪGAĳbϥXamiol? Gel ᤣnߨ~YvCXamiol? Gel b]Τ鶡ӯdbY֤WC
5.DYֳhCѱNXamiol Gel٩PV@Aĳvɶ4gΫܱw¡Avi8gC "	ѩtcalcipotriolApGWL̤jCgq(100J)ܡAi|ytgCLAvɡAMt@׷|t_`CucalcipotriolĳqAtgIN|O̧CC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	nNáCN~lb~]ˤHקKӡC30JHUxsC 	Betamethasone+Calcipotriol	D05A	Ϊv~ ANTIPSORIATICS FOR TOPICAL USE		"vY֤~C
vDYֳ줧צܤ״M`ʤ~C  "	"DΥξLӪ̡C 
Xamiol? Gel TΩw~B֩ʤ~B鸨ʤ~Mw?~C
Xamiol? GelTΩ󿩱wYǥ\णYx\णw̡C"	ߤ@w`Ƨ@άOkoC	DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.3.14	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.2._20101201_000.pdf"">OI` 13.3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.3._20101201_000.pdf"">OI` 13.3.3.</a>             "	"OI` 13.3.2.,13.3.3."	0	OIs 20251124	EXAMI-a	EXAMI-b	EXAMI-c	111.3.14
BC22118100	D05BB02	0	ONEOT	Neotigason 10mg/cap(Acitretin)		AcitretinONeotigasonʦAiPϪֲӭMW͡BƤΨܩʥ`ơAӰƧ@ΫhOiQԨCNeotigasonvĪGuOºgWﵽ	"̦n@Ѥ@PΤ@_AΡCHUΪkζqi@ѦҡG
H
_lC龯q25 mg (Y@25 mgn)30 mg (Y310 mgn)AbA
2-4PiFOHNġC
qH{ɤWĪGίfw@׬ǡC@ӨAb᪺6-8
PACѪA25-50 mgiFzQ"	PLĪAĤe4ӬPBĴΰv3~TĨץI	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb25JHUūרé]˲s	Acitretin	D05B	tΥΪv~ ANTIPSORIATICS FOR SYSTEMIC USE	0	Yʤ~AֽƯg	"PLĪA]T
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.5._20220301.pdf"">OI` 13.5.</a>              "	OI` 13.5.	0	OIs 20251124	DC	DC	DC	114.10.27
		0	ENEO45	"NEOMYCIN OINTMENT(""ì"" snI)"		neomycing{ɸҩUح󶧩ʵߤέ󳱩ʵߨ㦳α@ΡAĩʦwwAĤO_jArʡAèϱwֽ̥oͱӷPC	CżƦAwBAp~wBֽAīeŮƩΪΨmPM~hAhĪGΡC	Yg@gﵽΧYAХDʧiv	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUB	Neomycin	D06A	Χܥͯ ANTIBIOTICS FOR TOPICAL USE	0	ϡBwδwֽMˡBˡBSˤPVC	惡ĦLӪ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O06-05 j	Ts110.6.16		OI` 	0	OIs 20251124	ENEO45-a	ENEO45-b	ENEO45-c	110.6.16
BC19116335	D06AX01	0	EFUCI1	Fucidin cream 20mg/gm;15gm/tube		"Fusidic acidqLӵߪJսXӲͱߧ@ΡC@ب㦳jħܵߧ@ΪܥͯA
j󶧩ʵߦġAרOyߡA]ALLΨLܥͯĩʪ"	ŻIAqwAC23A@7ѡAi̯fĪɶC	Ŷ٩󲴷β|P	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HU	Fucidic acid	D06A	Χܥͯ ANTIBIOTICS FOR TOPICAL USE	0	󶧩ʵߤθy	糧@LӪ̸TΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-02 [E]_H2-13 j	Ts110.6.16		OI` 	0	OIs 20251124	EFUCI1-a	EFUCI1-b	EFUCI1-c	110.6.16
NC13508345	D06AX04	0	EBIOM	Biomycin ointƤ40gm/		"1.Uح󶧩ʵߤέ󳱩ʵߨ㦳α@ΡAĩʦwwAĤO_jArʡAèϱwֽ̥oͱӷPC 
2. ]tyrothricin^Ĩ夤kwġAiPLsħܥͯBAרΩ󧽳v󬰲zQAﭲ󶧩ʷLͪ_ġA ﭲ󳱩ʷLͪĤOLAĩʦwwrʡAϱw̤oͱӷPC 
3. ~اܥͯXֻsAvd@اܥͯs׬sjAïv]hطLͪҭPX֯gABϥΥ~ ϷLͪβͧħ@ΫeYC"	CżƦAwBAp~wBֽAīeŮƩΪΨmPM~hAhĪGΡC	sĻIYMѧvΡA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUDB	Neomycin and Tyrothricin	D06A	Χܥͯ ANTIBIOTICS FOR TOPICAL USE	0	ϡBwδwֽMˡBˡBSˤPV	Hypersensitivity				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O06-01 [UDx]_U01-58 [E]_I4-09 [Ew]_F1-04 j	Ts110.6.16		OI` 	0	OIs 20251124	EBIOM-a	EBIOM-b	EBIOM-c	110.6.16
AC34124321	D06AX07	0	EGENC1	Gentamycin cream 5mg/tube(Gentamicin)		"~Actinomyces organismӱosĩitA󳱩ʵߪġAwߪPVPcarbenicillinmeglocillinpiperacillin礧eAiMpenicillincephalosporin֥ΨӪvYPVCq`٪`PAѦgAJARʤŦIܡAY`ˡAΦGfw̡AiR`PC`geAnMLĪVXCդPpseudomonasݩҤް_YC.N.SPV(pMiningitis, Ventriculitis)ɥiʧPUkC~ΩvַֽPVAM߽ӭMPVC~Ϋ|o͹ӷPCũֽϰjжˡA|ް_ʪrʡCpߥΩN˩ΤjˤfC"	C3-4Aqw	 ƨϥGentamycinӮg~ufHAiް_ӷP{H	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUB	Gentamicin	D06A	Χܥͯ ANTIBIOTICS FOR TOPICAL USE	0	owʥֽfBPVlBֽB`ˤΨL󳱩ʶʵߤPV	GentamycinLӪקKϥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-03 [E]_H2-15 [Ew]_F1-01 j	Ts110.6.16		OI` 	0	OIs 20251124	EGENC1-a	EGENC1-b	EGENC1-c	110.6.16
		0	EALDA1	Aldara  cream 5%  250gm/pk		AldaraROHK̤ո`]Immune Response ModifierFIRM^@ξAʻoӭMEPK̨tΨӹHPV frAiӹFvتC	"~~ΨŻICgTACbΫe~bö٩ʹ޾~ΨzP򤧱wA 6-10 pɤ(YĤGѦ)AΤʨmMM~ĳ(īe,~)C
CgTAiwbg@BTBζgGB|BΫeΡC"	"1.ϥΨŻIܬЧAsϥζWL 16 gC
2.ķ|COIMΤlcUץ\ġAĳʱĲeŻI~Ap
ݭnAЦbʱĲ~ŻIC
3.٨ŻIAФťH^aΨLŮл\w"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"JsūפiWL25C,礣iND"	Imiquimod	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	ΩvH]18HWw̡^~ʹ޾MzP򪺬ЩMéʦyСBɨ~ΨLC	糧ĦLӪ	wi|ܤת`PBֽƦBhBoBlά	קKϥ/SҾܦw	קKϥ/SҾܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-05 j	Ts110.6.16		OI` 	0	OIs 20251124	EALDA-a	EALDA-b	EALDA-c	110.6.16
AC26128377		0	ESI500	Sulfasil cream 1% 500gm/		"wΪvGšBTſN˪ˤfw

"	`˪v@1~2AMwBAHLߤMGùF2~3MMpF@PVgHAqšAC@ܼƦ	" .ϥΡAҼ{qʤΦMIʤC
2.sͨΦA˨ϥΥC
3.P~λïs֥η|zĮġA֥ή`NC
4.sdBjnϥγXAwwMzC
5.iΩ󲴷C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Silver sulfadiazine	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	"vιwNS˰_PVg

"	DiĹLӡAuLӡAxεǻٮ`wVϥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O06-04 [E]_I1-05 j	Ts110.6.16		OI` 	0	OIs 20251124	ESI500-a	ESI500-b	ESI500-c	110.6.16
AC55546321	D06BB04	0	EWART	Wart Del cream 1.5mg/gm;5gm/		"ѴӪ¤ƵѨXܯfrAħӭMͪAΨ
vʹ޾
"	"C⦸ߦU@AsϥΤTѡAĥ|(@Ӫvg)C
@ӪvgAYOФv¡AЭƤWzvgA̦hϥ
|ӪvgC
"	"1קKNī~٩ͪbH(]ADBzPD)ФWC
2.ī~勵`ֽ㦳ˮ`ʡAקKNĶ٩P򰷱d´WC
3.קKĲβAYĲβߧYHjqMR~AôNC
4.vдĳfHקKʥAHKePVFYʥAϥΫOIM

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Ƿ(15-30J)xsAקKӮg	Podophyllotoxin	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	"ʹ޾ (]A~ʹ޾Ψz񪺬)C

"	"1.}ʶˤfBĵB podophyllotoxin LӪ̡BάOTӤ뤺wϥιL podophyllotoxinLs̡C
2. hα¨Ŵkĳϥ

"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.13._20130901_000.pdf"">OI` 13.13.</a>              "	OI` 13.13.	0	OIs 20251124	EWART-a	EWART-b	EWART-c	110.6.16
AC32571338	D06BA01	0	ESIL20	SILIVERZINE 10MG/20GM		"SiliverzinewwΪvGšBTſN˪ˤfw

"	`˪v@1~2AMwBAHLߤMGùF2~3MMpF@PVgHAqšAC@ܼƦ	"1 .ϥΡAҼ{qʤΦMIʤC
2.sͨΦA˨ϥΥC
3.P~λïs֥η|zĮġA֥ή`NC
4.sdBjnϥγXAwwMzC
5.iΩ󲴷C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Silver sulfadiazine	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	"vιwNS˰_PVg

"	"DiĹLӡAuLӡAxεǻٮ`wVϥΡC
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O06-02 [E]_H3-27 j	Ts110.6.16		OI` 	0	OIs 20251124	ESIL20-a	ESIL20-b	ESIL20-c	110.6.16
AC26128348	D06BA01	0	ESIL50	Sulfasil Cream 1% 50gm/		"wΪvGšBTſN˪ˤfw

"	`˪v@1~2AMwBAHLߤMGùF2~3MMpF@PVgHAqšAC@ܼƦ	" 1.ϥΡAҼ{qʤΦMIʤC
2.sͨΦA˨ϥΥC
3.P~λïs֥η|zĮġA֥ή`NC
4.sdBjnϥγXAwwMzC
5.iΩ󲴷C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Silver sulfadiazine	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	"vιwNS˰_PVg

"	"DiĹLӡAuLӡAxεǻٮ`wVϥΡC
"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O06-03 [E]_H3-28 j	Ts110.6.16		OI` 	0	OIs 20251124	ESIL50-a	ESIL50-b	ESIL50-c	110.6.16
AC35391321	D06BB03	0	EZOVC	Aclovir Cream 50mg/gm;5gm/tube(Acyclovir		ifrDNAƻs@Ϊܯfr	C5ACj4pɡAuqũwAsϥ5Ap¡Aisϥ10	~λsAФŧ]AF}6ӤAΧĽХ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮg	Acyclovir	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	?lް_PVC	糧~LӪ̡ATϥΡC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-02 [E]_H2-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.1.2._20130701_000.pdf"">OI` 10.7.1.2.</a>              "	OI` 10.7.1.2.	0	OIs 20251124	EZOVC-a	EZOVC-b	EZOVC-c	110.6.16
AC29739329	D07AC08	0	ETOPL	TOPSYM LOTION(FLUOCINONIDE)(group2)		"ަY(H)Pﰮ~fH~㦳jĪĲz@

"	"q`113^AqűwC

"	"1.~¥ɡA]iް_@PCAGϥΫenp 
2.PVlΥֽTΥ~AYDΤiɡAϥΩΨ֥ξA
ܵ߾ () Χ߾"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Щ󳱲DB	Fluocinonide	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	"lBֽ]iʫx֯gBkC¥֯gBCʳ­a~BguֽBֽ^ol]C¯l˭a~Ba~BTwC¯l^~Bxw?gBβgBM`ʥմ

"	"1^ֽ֯fB lBkBa lBkC
2^fH糧~LӤC
3^դl˥~ժC
4^Behcet's disease H~šB`huֿN˧YN˻PˡC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-06 [E]_H3-29 j	Ts110.6.16		OI` 	0	OIs 20251124	ETOPL-a	ETOPL-b	ETOPL-c	110.6.16
AC49063340	D07AD01	0	EVIMA	Vimax Foaming Solution  0.5mg/g(group 1)		"~B󥭭a~BLʯTHC

"	"C1~2AwB
"	"1.ť󲴥֮pߡAקKĪiJ
2.o͹LߧY
3.ɥiקKvAvWL|gbƶEAhv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 25 ץHUC	Clobetasol propionate 0.5 mg	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	"~B󥭭a~BLʯTHC

"	"1.糧LӪ̡AФŨϥΡC 

"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P01-02 [E]_H3-33 j	Ts110.6.16		OI` 	0	OIs 20251124	EVIMA-a	EVIMA-b	EVIMA-c	110.6.16
AC19616321	D07AC01	0	EBETAO	Betamethasone oint. 0.5mg/gm;5gm/tube(group2)		~㦳ܪBoΦYޤSʡAGֽTJѺؼxgġC	ťΥ~wBAߦU@C	pֽLPVAPɬIξAΧܵ߻sCpġAhyȰ~	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxs	Betamethasone Dipropionate.........0.64mg	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	ֽBֽLӤΨLֽTJ㦳Ĥֽef	kBkAHαw̹LhTJĪLӤO̤yťΥ~C	pťΥAEʤAYġAäHAvC	קKϥ/SҾܦw	קKϥ/SҾܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N03-02 [E]_H2-05 j	Ts110.6.16		OI` 	0	OIs 20251124	EBETAO-a	EBETAO-b	EBETAO-c	110.6.16
AC36315324	D07AD01	0	ECLOB	Clobetasol cream 0.5mg/gm 7gm/tube(group1)		Clobetasol propionateOӥ~ΦXֽTJCޥֽTJ@ΤλLqֽTJ@ΡCb~Τ譱Aclobetasol㦳ܵoBoΦަY@ΡAަiΩTJUإֽefC	C@ܼƦ^AwC	"1. lBֽHֽPVAhWϥΥ~AϥήҼ{Aܵ߾C
2. jqsxϥήɡAiX{ǥֽPgA]קKC  "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷxsC	Clobetasol propionate	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	~BlB󥭭a~BLʯTHC	"1. ӵߡBuߡBoLʯfrֽPVC
2. 糧LӤw̡C
3. ֽšC  "	X{LӯgɡAħYiC	C 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N04-04 [UDx]_U01-60 [E]_H2-09 j	Ts44322.4969212963		OI` 	0	OIs 20251124	ECLOB-a	ECLOB-b	ECLOB-c	44322.49692
AC44969321		0	EDIP-C	Ciprosone cream 0.5mg/gm 5gm/(group2)		~㦳ܪBoΦYޤSʡAGֽTJѺؼxgġC	ťΥ~wBAߦU@C	iΩ󲴷	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUC	Betamethasone Dipropionate.........0.5mg/g	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	ĲʥֽBʥֽ(Lөʥֽ)BgʥֽBïl	kBkAHαw̹LhTJĪLӤO̤yťΥ~C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N04-02 [E]_H2-06 j	Ts110.6.16		OI` 	0	OIs 20251124	EDIP-C-a	EDIP-C-b	EDIP-C-c	110.6.16
BC20200321	D07AC13	0	EELOM	Elomet cream 0.1% 5gm/tube(group 4)		MometasoneXTJA㦳ܵoBoΦަYSʡCSI{b@αj׼W[ӰƧ@Τ|ҼW[AOثeߤ@oFDA֭iϥΩ2HWൣ~εǤWֽTJC	C@AũwB	pEιLӲ{HoΥī~	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUB	MOMETASONE FUROATE	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	TJ㦳PʤֽfҤް_ʤηkow	"TΩmometasone furoateλs@L
fHC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-03 []_08-06 [UDx]_U01-64 [E]_H2-16 j	Ts110.6.16		OI` 	0	OIs 20251124	EELOM-a	EELOM-b	EELOM-c	110.6.16
AC18063321	D07AC08	0	ETOPS	TOPSYM CREAM 5GM/TUBE(group2)		 ϥαjħܵoǤWֽTJsA㦳B ܹLӡBܺXBܼW͡BHΧܷko@	11~3AAq٩wBC	iHϥΩ󲴷WC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Щ󳱲DB	Fluocinonide	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	lBֽ]iʫx֯gBkC¥֯gBCʳ­a~BguֽBֽ^ol]C¯l˭a~Ba~BTwC¯l^~Bxw?gBβgBM`ʥմ	1.ֽ2.©ʪwlBk3.LlܤƤ~C				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-07 [UDx]_U01-65 [E]_H3-31 j	Ts110.6.16		OI` 	0	OIs 20251124	ETOPS-a	ETOPS-b	ETOPS-c	110.6.16
AC18088321	D07AC08	0	ETOPSO	Topsym ointment 0.5mg/gm (fluocinonide)(group2)		ƥֽX  㦳ܵo@	q`C@~T^AqGwB	iϥΩ󲴬	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Щ󳱲DB	 fluocinonide 0.5@J	D07A	"ֽTJA CORTICOSTEROIDS, PLAIN"	0	lBClBšBplB׺|lBflBĲʥֽBʥֽBM`ʥֽBM`ʰ~BβgBM`ʥմBxw?gBol]C¯l˭a~BɯlΤpClBTwC¯l^	ֽ֡B©ʯplBkεLlܤƤ~fHФŧP				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-04 [UDx]_U01-66 [E]_H3-30 j	Ts110.6.16		OI` 	0	OIs 20251124	ETOPSO-a	01C18088-1	01C18088-2	110.6.16
AC49877321		0	EDIP-G	B-Gencin cream 5gm/tube(group1Ƥ)(group2)		ܪBoHΦަY@	@Ѩ⦸(ߦU@)Ať~ܧл\PVϰ	pGͨEιL  аϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Betamethasone 0.64 mg Gentamicin 1.0mg	D07C	"ֽTJAPܥͯƤ CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS"	0	ĲʥֽBʥֽ(Lөʥֽ)BgʥֽBïl	令LӪ̸TϥΡC2.TJoΩ󵲮ֵߤoLʯfrPVAp GkBkC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N03-04 []_08-04 [E]_H2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	EDIP-G-a	EDIP-G-b	EDIP-G-c	110.6.16
AC21924338	D07CB01	0	EKENB1	Mycomb cream 20gm/(group3Ƥ)(group4)		"(1)nI㦳ܪBoBߩMߤ|ؤPĲz@ΡC
(2) Triamcinolone AcetonideGjOPXA㦳oΧܹLӤįAֽogĮĨtABʪC
(3) NystatinG̦WSʤܩ]ĪAiΨӪvѥզ]ߩMLïߤް_ֽfC
(4) NeomycinGramicidinGاܥͯtX㦳sĩʤߧ@ΡABﲣͭ@FʤӵߥtXܥͯWjOߩʡC"	NŻIwBACѤGܤT	iIΦb	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUC	"
Triacinolone 1.0g
Gramidicin 0.25 mg
Neomycin 2.5 mg 
Nystatin100,000 units"	D07C	"ֽTJAPܥͯƤ CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS"	0	lBLөʩMoʥֽfBoʲӵߩ߷PV]]߷PV^	"1.糧LӪ̡AФŨϥΡC 
2.oΩoLʯfrPVAp GkBkC
3.դlʥ~ժ"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O04-02 []_08-02 [UDx]_U01-61 [E]_H3-21 j	Ts110.6.16		OI` 	0	OIs 20251124	EKENB1-a	01C21924-1	01C21924-2	110.6.16
AC41570335	D07XB01	0	ETOPO	Flusalic ointment 15g/(Ƥ覨)(Group 6)		Salicylic acid㦳֨跻Ѥ@ΡAPiFlumethasone pivalateJֽA]AXIΩYƯfܡAa~Bֽw`CSalicylic acid㦳Squamolytic跻ѡAG@ΡAPɨ㦳Oֽ~ĩʡC~㦳GئVX@ΡA]v~ֽfƨġC 	"fY{סACϥ2-4٩wC 

"	"1.~ŨϥΩ󲴳AˤfAηPVϰC
2.קKjqBϥΥ~AHKͥTJƧ@ΡC 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ǷŶJsAקK	Flumethasone Pivalate and Salicylic acid	D07X	"ֽTJAP䥦ĪƤ CORTICOSTEROIDS, OTHER COMBINATIONS"	0	CʵoֽewBlBgʥ֪B󥭭a~BʯTHB~B~	"1.~ӥΩֽʵ֯fA©?lAkAkC
2.wFlumethasonesalicylacte LӪ̡C"	"ֽ`PAooAEAΤGPVC

"	LΩhk}iAקKjqϥΡC	ϥΦī~AO_iJťġAwzѡAĳŮɨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-06 [E]_H2-12 j	Ts110.6.16		OI` 	0	OIs 20251124	ETOPO-a	ETOPO-b	ETOPO-c	110.6.16
A026636329	D07XA01	0	EULEX	ULEX CREAM(CROTAMITON)		" cortamitionUSPoαHͩ餧vDt[hydrocortisoneϥž㦳UC@:1.oį2.h,Rή@3.֯lﵽ@4.㦳ֽHͩε餧ߧ@,iGPV"	AqwBA@ѼƦC	񦳥ֽPVlBֽpϥΪnɡAnƥϥΩΨ֥ξAܵ߾(A)Χ߾  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU 	"CROTAMITON 100mg/gm+HYDROCORTISONE 2,5mg/gm"	D07X	"ֽTJAP䥦ĪƤ CORTICOSTEROIDS, OTHER COMBINATIONS"	0	lBֽs]]Aiʫx֯gB©ʭa~BguֽBֽBֽkogBˡB~BHͩPVg]νH^ΩΨˡ^C  	"1.ֽ֡B?lBkBa?lC
2.糧Lӯg̡C
3.u߯gC
4.šAĤGײ`bʥHWSˡBˡC  "	ֽPVgBM`ڵHBֽYBBhC  	C	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		OI` 	0	OIs 20251124	EULEX-a	EULEX-b	EULEX-c	44322.49692
A029286329	D08AG02	0	EBIOD	BIODYNE OINT 10GM/TUBE		"~ʼsĩʱ߾AO
LͪľAֽγжˤPVġC~󶧩ʵߤέ󳱩ʵ(]Aܥͯ㦳Ԩʤ߱)AߡAoLʯfrAͰʪλå"	N~ũwCC1~4C	1. mpıĲ줧BC2. קKgAyOs󳱲DBC3. DĮvBľͩvܡAsŨϥΩjnΥֽ`PVC4. DĮvBľͩvܡAϥΥֽ~īФл\AHKW[Ƨ@ΡC5. ٥ֽ~ī~bAAaβC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"mpıĲ줧BAyO
sǷ(30JHU)DBC"	Povidone Iodine 100mg/10g/tube	D08A	r ANTISEPTICS AND DISINFECTANTS	0	ˤfr	"1. KLӪ̤ϥΡC
2. ĪULӪ̤oϥΡC"	ٳBEP	liʡAέŰkMsͨШϥΥiyҪ~ΥҪ\CUC	liʡAέŰkMsͨШϥΥiyҪ~ΥҪ\CUC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N03-03 [E]_H2-04 j	Ts110.6.16		OI` 	0	OIs 20251124	EBIOD-a	EBIOD-b	EBIOD-c	110.6.16
		0	EBIW1	BETTER IODINE AQUEOUS SOLN(Sindine120ml/bot)		Povidone-IodineHyP.V.PPKΦíwƦXAֽΦ߽AKXӡAͱjOߧ@ΡAӵ(]AG(+)AG(-))BߡBåߡBfrBUۮġA㦳߮ĪGC 	HֲygAqѤߦܶPwC	"1. ~ֽ~ΤoAA礣oΩ󲴷|PH(pfġBġB DBnB~)BlBBtY~ˤwC
2. Ъ`Nn~JCU@~JAХߨHηŤR~AåߧYeNC
3. ĤŨϥΩjn(HWLϥΪ̪xnѦ)A`ֽ´PVYﵽδcơAаĨôNvCC 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKgAyOs󳱲DBC	Povidone Iodine	D08A	r ANTISEPTICS AND DISINFECTANTS	0	rˤf	"1.KLӪ̡AϥΡC
2.DĮvvܡAoϥΩjnΥֽ`PVC"	"1. ϥΫЫOٳzAűKʡAHKW[Ƨ@ΡC 
2. |ϥֽΦAVC"	liʡAέŰkMsͨШϥΥiyҪ~ΥҪ\CUC	liʡAέŰkMsͨШϥΥiyҪ~ΥҪ\CUC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-02 [E]_I2-12 j	Ts110.6.16		OI` 	0	OIs 20251124	EBIW1-a	EBIW1-b	EBIW1-c	110.6.16
AC49280335	D10AD03	0	EACUR	Adapalene Gel  0.1% 15gm/ (Adapalene)		"AdapaleneֽiĴ֯뤧o(YClMwM۴)C
(1)~ͯA(Tretinoin)AiXSwͯAĲӭM֨(Retinoic acid nuclear receptors)FMͯA(Tretinoin)POA~|MӭM鵲XJ(Cytosolic receptor binding proteins)۵XC
(2)~iHhή֥զyͤƤΤƾǰʤOǤAPɤ]iͥ|m(Arachidonic Acid)תծ(Lipoxidation)覡AΦoeXCC]NO~iܯ몺ӭMCoAϥΥ~iϤW֤nӭMƥ`C"	"Differin𮧫e(Ϋe)ά~yC@IΩڵHwAIΤ@hAB׶}μLBAīeTwwwC
DifferinYgֽϥΡADnoͯBClwMM`ڵHFAXvBݳέIڵHC"	"1.קKĲ체BLBB߽BˤfBˡBl˩ζ˪ֽ
2.YX{iNӷPYEɡAhġFYE{׼W[ɡAvܯfHWvCAμȮɰġAΧġC
3.ŬIΩ}ֽ(ζˤή)lʥֽA]iΩYڵHfHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25JHUC	Adapalene	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	vM`ڵHC	糧Ī󦨥LӪ̡AAΡC	BȮɩΫʨ`PBkoΰBhC	קKϥΰDvn/SmҦw	|Lwʸ AקKĲLC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-03 j	Ts110.6.16		OI` 	0	OIs 20251124	EACUR-a	EACUR-b	EACUR-c	110.6.16
A034127329	D10AE01	0	EACZO	Aczo gel 50mg/gm		O@طʨťվtAwֽAjO@ΡAຯJֽ´AFߪĪGAӥhpC	C1AwC	"1.ϥΥ~q`4~6PAiڵHgoﵽAOϥδקKΡC 
2.קKtĤ۫~ΨLֽsA?bP@C 
3.vB窫iĲ~AHKQ}ղC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Benzoyl peroxide 	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	M`ڵHBC	iϥΩBenzoyl peroxideΥLLӲ{H̡C	LөʥֽBLתֽB֡BhC	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	|Lwʸ AקKĲLC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-01 j	Ts110.6.16		OI` 	0	OIs 20251124	EACZO-a	EACZO-b	EACZO-c	110.6.16
A024519343	D10AD	0	EADEC	A.D.E. Cream 30mg/tube		"XLRA.D.E.ֽįAAإ[wwΨLSֽiϹֽ㦳SĪGC
SIG
Vitamin AG㦳wPvֽhH´Ʋ{HAiٽtAW[ֽܤOA@A֯׽uOٽAC
Vitamin D3GPiֽdAֽBSC
Vitamin EGiӦުG`APiֽAiɵAB֯׽uAW[ٽuʡAULRAįC
UreaG򾯤wwʡAGVit A.D.E.oĮġAè㦳XnֽįC"	~yB~B{ΫeŨϥΡAy[ĪGΡAChϥΡAoĪGC	"٦ī~׶}PH
ŨϥΩjnAϥΫקKл\HKW[Ƨ@"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JOsAקKg	"
Vitamin A ....  2000I.U.
Vitamin D3....  12.5mcg
Vitamin E ......  2.0mg
Urea..............100mg "	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	ֽ߽gBֽƯgBֽBlBM`ڵHB~ˤΤˤת޷sͫPi	"糧Ī󦨥LӪ̡AAΡC
`´PV"	oALӲ{H	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-04 [E]_H2-01 j	Ts110.6.16		OI` 	0	OIs 20251124	EADEC-a	EADEC-b	EADEC-c	110.6.16
AC38982329	D10AF01	YPIp10@J/J	ECLEO	Royalsense acne Gel(Clindamycin)		ClindamycinwgQҩﭱpBCKkġAb~Clindamycinް_pӵߪPropion bacterium acnes(ı)i䦳Ŀ@׶0.4mcg/mL Aֽ֥תջġC	C2A٩wAĻݥvBϥΡC	o͸mALӲ{HаΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC	Clindamycin(as phosphate)	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	M`ڵHC	糧ĩLinomycinLӪ̡AФŨϥΥC	pϥΫᦳUg͡AаġAýжE_ް_Ug]C	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	|Lwʸ AקKĲLC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669279?cesid=5gOSEmQwRhL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DClindamycin%26t%3Dname%26acs%3Dfalse%26acq%3DClindamycin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.16		OI` 	0	OIs 20251124	DC	DC	DC	114.04.16
AC41753321	D10AX03	0	ESKIN	AZEIC-A(SKINOREN)CREAM		~ڵHĥDnӦۨܵߧ@ΤΪLרƤn@ΪGC	"~CѤG(B)AqbֽwBC
ϥΫeβMMֽAiϥηũMֽM侯C"	CϥΧ~MⳡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs30J ҤUC	Azelaic acid	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	M`ڵHC	糧~ĦνξLӪ̡C	ٱwͨ`PBkoHεo{HC	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	|Lwʸ AקKĲLC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N02-06 j	Ts110.6.16		OI` 	0	OIs 20251124	ESKIN-a	ESKIN-b	ESKIN-c	110.6.16
BC14967100	D10BA01	0	OROAC1	fRoaccutane 10mg/cap(Isotretinoin)		"1. ~ϥֽ西`ơAifʪp֯׸jpAHΧܥ֯תACHʡAϨ䤣PۤnC
2. kĦw:D-ʨϥΡC"	"CѤfAq0.52mg/kgA2AΡAsA1520ӬPC
"	"1. vAʴyAתթMx\A@O4Pw@C
2. J٦ׯkhAtVviC
3. ϥΥ~vAiDfHGβ|L󤣵ΪAC
4. jƧ@γOqWLC1mg/kgAYĩέCqAoǰƧ@γOifC
5. ~ϥΫe@ӤAϥδAϥΫ@ӤAnקKC
6. ϥΥ~oB~AɥRLRAC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@ī~m 15 ~ 25 װBҡANī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAΡC 	Isotretinoin	D10B	tΥΧڵH ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	0	ǲkLĤYڵH	"1. iϥΡA|yΨC
2. ParabenӷP̡ATҨϥΥ~"	"GGMTĥ̪o׿@׼W[50%~70%AhApOWhFϯgGYhA·PFջJXBFxŦGSGOTASGPTAPC୞JW@FֽGBAolAֽAӷPC
"	PL	㰪˯שʡAܥicťĤAĳϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-07 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.4._20220301.pdf"">OI` 13.4.</a>              "	OI` 13.4.	0	OIs 20251124	OROAC1-a	OROAC1-b	OROAC1-c	111.8.19
		0	ESTAQ1	Staquis oint.30G(Crisaborole 2%)		CrisaboroleCĤG?4]PDE-4^APDE-4|ɭPӭMCĸ?]cAMP^tqW[CCrisaborolevʥֽ_v@Ϊ|TTߡC	"C⦸bwBW@hAC
AȨѥ~ΡAAΩ󲴷BfAγDϥΡC
CJ]2%^t20 mg crisaborole"	AvfHo͹LӤ]AĲC¯lCbwBλBoYoB~ȩMɡAhæLӡCpGX{LӼxPgɡAХߧYξAö}lAvC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb25XCHUC	crisaborole	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS		AΩwצܤײʥֽH3ӤjHWfH~ΪvC	w crisaborole ΰt褤󦨤LӪfHTξA	wBkh(N`PΨhP)	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O04-07 j	Ts111.1.27		OI` 	0	OIs 20251124	ESTAQ1-a	ESTAQ1-b	ESTAQ1-c	111.1.27
		0	ESOOL1	Soolantra cream  30gm/		"Ivermectin ݩ avermectin Ī@AoĪǥѧצhޤ޵ooʲӭME
W͡AӨ㦳ܵoĪGCIvermectin ]|zLܩʡB˩MOAPLհʪgH
Φ٦ײӭMWiĹhlqD]glutamate-gated chloride ion channels^XAP
n?Φ`C"	C~Τ@A̦h|ӤCvCѫϥΡAi{CpGϥ 3 Ӥ᳣ﵽAvC	fw了`į?Ϊi|ϰsVguȥ[Aq`bv@P|wgAYoYcƩαjPֽAvD	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb25CHUAŧNxsD	Ivermectin 	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS	0	HsV]Clwp֯l^of_vC	ﬡʪνξL	ֽ`PA۹ֽ֨EBkoBֽC	ثe|LϥΩhkơAҥHĳϥΩhC	ھڰʪs ivermectin |X{ťĤAҥHLkưiyICbMwO__ũΩveAvŭŹ葉Mvkʯfw̤įqC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O05-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ESOOL-a	ESOOL-b	ESOOL-c	110.6.16
		0	ECLEA1	Cleanfleck creamP.LybŻI(group6)		HydroquinonehA|zZ¦XTi-TiQFTretinoinͯAġA跻ѾFFluocinoloneֽTJAܪġC	@Ѥ@AΫeܤ30eϥΡAhܦI۰ϡAéܯf_P򥿱`ֽbTAդѨϥSPF30ξC	iX{EAuȩʥֽoλ׿N`PLġAYX{LӤΤƾǨEɰġC`NΡC׶}BBfC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	N2~8J 	Hydroquinone 40mgBTretinoin 0.5mgBFluocinolone 0.1mg	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS		yצܭרxuvAX֦UαIA]AϥΨξC	LӥvΦ糧t󦨤Lk@fv	B֡B`PBBkoBڵH	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-05 j	Ts111.2.15		OI` 	0	OIs 20251124	ECLEA1-a	ECLEA1-b	ECLEA1-c	111.2.15
BC23645335	D11AH02	0	EELID	Elidel Cream 1% 15gm/(Pimecrolimus)		PimecrolimusO@ܵo@ΪnQi(ascomycin macrolactam)lͪA]iHܩʦaTӭMΪΤjӭMͤXoeX - ӭMΤC	"1.CѨ⦸ϥElidel1%ŻIwWAûa٧áC
2.Elidel1%ŻIiHϥΩ]AYByBVνKBҦֽC"	"~ϥΩwʥֽfrPV
110.12.1OWw:2HWĵ,C֦~ΦHBwn>30%,ײʥֽ,αӷPʥֽ(YV,¥,ի,ʹ޾,ֽsB,ŤU,ѳ)Hwn30-50%,CPWL30gm,wn>50%,CPWL60gm.ĵwn30-50%,CPWL30gm,wn>50%,CPWL30gm.
ӷPʥֽ((YV,¥,ի,ʹ޾,ֽsB,ŤU,ѳ)ʥֽ:HC뤣WL30gm,ĵC뤣WL20gm,BoPĤ}p"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s25JHUAiNC	Pimecrolimus	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS	0	ĤGuϥΩ3ӤHWൣAC֦~ΦHʥֽuζʪvC	糧~@LӪ̸TΡC	"1. `Gϥθ`P(10%)C
2. `Gϥγ(EBkoB)Bֽo(n) (1%ܡ10%)C
3. `GpwlBgcơB©?lֽ(?ll)BǬVʳnСBϥγ첧`(]AlBkhBPı`B֡BB~BֽYOFBK)C(0.1%ܡ1%)C"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N05-02 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.11._20201026.pdf"">OI` 13.11.</a>              "	OI` 13.11.	0	OIs 20251124	EELID-a	EELID-b	EELID-c	111.8.19
BC16229500	G01AX03	wivD꾯	EALBO	ALBOTHYL VAG. SUPPOSITORY		~aίfܲ´㦳ܩʧ@ΡAϯfܲ´өưA`쪬W֫hvTC٥iDUدfLͪAPɫO@Ͳz߸sͪADĩҡAïਲ਼tAgC~A|বĤMPiЭ¡XC	"1. lcVSJϥο@YGCg1-2ANwM~AΪgGlw1-3YiC
2. lcVaUBlcVJHXl~֪yA`lcVDAC1-2ACg1-2C
3. ձaJϥή꾯ACѩιj1As4ASgA2C"	"1.Albothyl|bvL{ͨE@ΡCpGa´ѯfϲ渨AYϬOjqɡAL宣C
2.bvɤiΨEʪΨmM~ΩʥC
3.PLDs@ˡAAlbothylbgӮɤiϥΡC
4.קKĲAlbothylC
5.p´Υ֭PAlbothylĲAbsOά~bC
6.D꾯WIAOѮ꾯򾯲ͪ۵M{HAvTϥΡAĪGέ@ʡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUBҡFpoܽιLAiϥΡC 	Policresulen	G01A	"ܷPVΨGֽ֥TJ ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS"	0	lcVSBձaBDBlcV]tѤwΤΩ]ߤް_̡^C	hФŨϥΡC	bHAlbothyl|bvL{ͨE@ΡAq`tahC 	hФŨϥΥ	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6517063?cesid=2ilm7EhDdD4&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPolicresulen%26t%3Dname%26acs%3Dfalse%26acq%3DPolicresulen"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.11		OI` 	0	OIs 20251124	DC	DC	DC	114.04.11
BC20053500	G01AF12	0	ELOME	Lomexin vaginal 200mg/cap(Fenticonazole)		㦳ߤΧߪĪGA@Ω~ݡAPfåߡAdimorphusεߤWD	C@Ϋeϥ200mgD꾯@	"ϥΩ}ʶˤf,ΦbDīA|ͻLuȪ`PC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiϥΡC 	Fenticonazole	G01A	"ܷPVΨGֽ֥TJ ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS"	0	"߯f(Dermatomycosis):ɦ]߷PVA]Av~(Trichophyton)ApU~(Microsporum)AHΪ~(Epidermophyton)A̷PV줣PiGrv~A~A~A~Atinea manuumAtinea facieiAv~A~D
ֽ]߯fG`zA]ʤfHAy]߯fANapkinA|γn]߯fAʹ޾]߯fGkγDADAgPVAYAY]֪DҧɪΥҷD"	糧~LӪ̤iϥΡD	DĦL`PAܧַ|D	hФŨϥΥ	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M01-04 [E]_I2-02 j	Ts110.6.16		OI` 	0	OIs 20251124	ELOME-a	ELOME-b	ELOME-c	110.6.16
AC27557500	G01AA01	0	ENYST	Statin D100000U/tab(Nystatin)		Ĭ@بߧ@ΤܥͯAhػåߤåߤߦܵߧ@ΡABզ]ߤΨLUة]ߩҤް_DPVA㦳פġC	q`C@AC12(ߦU@)JDA@v13ѤAgܨtAjv12PwA~JA̦n׬10AHĿC	p~ȡBoLӯg͡AϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxsC	Nystatin	G01A	"ܷPVΨGֽ֥TJ ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS"	0	D]߷PVg	ī~ҦLӪ	iLӡAĲʥֽ	hĤ@]eTӤ^Ӭs礤AܸĪLL`ABLܹhTͦMIʡC	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M01-06 [E]_I2-03 [Ew]_F1-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ENYST-a	ENYST-b	ENYST-c	110.6.16
BC18215500	G02AD02	0	EPROS	Prostin.E2 3mg/D(Dinoprostone)		"ElcGYΩw-qG|Elc٦׹{lc@˦YAثe|O_@Φblc٦׼hCLbhƮרҤADYΩw-qGiylc٦ױjPYåBϤlcZƥXC
lcVGYΩw-qG|ɭPlcYXnBXiAHΤlcYޮCWzܤƤ@qhw|۵Mo͡AlcV|ClcVOHۤlc٦תʷ|W[AҥHlceiHQƥXC
LGYΩw-qG]|EH`zDƦ١AҥHϥδYΩw-qG޾ɤlcVɡA|o͹æRθmC"	J@]3@J^ܫKAϥΫ᤻ܤKpɦpLkiͲAiϥβĤGCbGQ|pɤA̰`뤩q6@ JAĳsϥζWLѡC	fHߦޥ\ಧ`AxBǥ\l`AwݡACβɰ̡AΦϽε򽤯}ɡAϥδYΩw-qGD~`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs28JBcC	Dinoprostone	G02A	lcY UTEROTONICS	0	gζ޲	"1 ΩﴶΩwLӪ̡C 
2 󦳤UCpfHTδΩwΨLʲĪG 
(1) hLnWC 
(2) hLv]ΤHWh̡^C 
(3) LY|iJC
(4) ʹLlc̡]YG帡AlcN^C 
(5) LYΥ鰩֤ۺ١C
(6) æνTҩL~ΡC"	mBߡBæRC	קKϥΰDvn	ťĤtqLpAPwյLۮtC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-49 [E]_K-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=15.1._19950301_000.pdf"">OI` 15.1.</a>              "	OI` 15.1.	0	OIs 20251124	EPROS--a	EPROS--b	EPROS-c	110.6.16
NC01749100	G02AB03	0	OERGO	Ergometrine 0.2mg/tab(Ergonovine)		AlkaloidS㦳jOlcY@ΡAGiΩYByᤧlcC	Hq`C@BCAΤTB]q12mg^C	"V뤩:
1.AWrgA߯ewAʦ޻ê̻ԷVPC
2.xǯew
3.Ѧgw."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Ergonovine maleate	G02A	lcY UTEROTONICS	0	ȴXByᤧXBYɤlcwXB`XBYĤT}hLzC	ɬyA۵o٭ʬy(Threatened spontaneous abortion)C	lcjˡBߡBæRC	PL/SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-02 [s]_101 [®]_101 [E]_A2-08 j	Ts110.6.16		OI` 	0	OIs 20251124	OERGO-a	OERGO-b	OERGO-c	110.6.16
		0	OCIMI1	Cimidona߰(۶O) 30/		"߰@Ĳ~AtӦCimicifugaracemosa (Black Cohosh) (_ɳ-ڲ)ѨZe 450C
_ɳ¡]cimicifuga racemosa^ݩ[]ranuncu1aceae^ASٶ¤ɳ¡]black cohsoh^AO@ĥδӪC¤ɳ¦b~QsxϥΩﵽ~Aѩ󦳮ĦADntT?A{ɤW٬OHϥζ¤ɳªѨDACimidona?߰YOtӦ۶¤ɳ®ڲѨC¤ɳ¥izLMtΡAP5-HT7B5-HT1AXA@ξĪGC5-HT7B5-HT1ADnUCAXA㦳ո`ŪĪG"	@ѪAΤ@Aðt]AAirHΩCZCYnAζWL6ӤAzӿԸ߱z͡C	"1. UCΪ̡AФŨϥ:
(1) x\l̡C
(2) 糧Ĩ䤤@ΥRanunculaceae
([ݴӪ)LӪ̡C
(3) BihkέŰC
2. UCΪ̡AϥΫeХԸvĮvľ:
(1) bvvοwLef̡C
(2) HήaڦL̡C
(3) ]Ī͹LӪ̡C
(4) bAΨLĪ (]AfHۤvʶR
) ̡C
3. LϥΤW`Nƶ:
(1) ~ѩثeܥiﵽ]~
ҳy貨P\ġAҥHQ
Ψӧ@貨PgwġC
(2) ൣ~AЧOޡC
(3) קKgC
(4) ŶWLĳϥζqC
(5) YݪϥΡAĳwx\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	}ʫeJsǷ15-25XCC	6.5 mg Native Black cohoshdry extract (_ɳ®ڲѨ)C	G02C	L OTHER GYNECOLOGICALS		AΩ~`fg(BXBίvêBJļHμ~{)C	ӪӷP	"L,xrʳ"	DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-04 j	Ts110/11/16		OI` 	0	OIs 20251124	OCIMI1-a	OCIMI1-b		110/11/16
BC22658100	G02CB03	0	ODOST	Dostinex 0.5mg(Cabergoline)		~@dopaminergic ergolinelͪA㦳jOSħcſE(prolactin)@ΡA@ΦbUlactotrophsD2-dopamineAӧcſE(prolactin)c C	"1. cšGbYĤ@ѤfA@q1mgC
2. _cšGC12pɤfA0.25mgAs2ѡC`q1mgC
3. vcſEg(hyperprolactinemia)Gq`1PfA12A쾯qCqCP0.25mg(ex:0.25mg W1.W4)AMAfվ㾯qAfHwvAHKFѩMfdose range:0.25mg-2mg/week"	"1. }lADostinexeXѡA}Bާ@ΰLưȮɡASOpߡAHKoͦMIC(ݺΡA`)
2. ʴCAרOPL֥ήɡC
3.vwʱfHO_iֺƪ{ESR`ɰ.(ex:ؽֺơAäֺơAֺ)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cabergoline	G02C	L OTHER GYNECOLOGICALS	0	"vkcſEg(hyperprolactinemia)Ψ/c(YfHwgi¨)C
ΧťĤcAΪvūPgް_pC"	DostinexΨLPM`ιLӤfHAiAΡCLαΪfwA礣iϥΡC	twBYwBYhBKB~{BߡBh¡BhBթʧCC	vYhFϥdostinex	YϨťħSoͤĳ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r04-03 [E]_B2-03 j	Ts111.2.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.7._20020601_000.pdf"">OI` 5.4.7.</a>              "	OI` 5.4.7.	0	OIs 20251124	ODOST-a	ODOST-b	ODOST-c	111.2.21
AB37126221	G02CA01	0	IYUTO	Anpo 50MG/5ML/AMP		~ଡƤlcƦ٪]2mA]ӴCYCjqUA]vT]1AGް_߸LtMܡC	"ɶPC̤jfAq120mg/C
}lɡG0.1mg/ARߺw`ACQiW[50mcg/A̤ܳjq350mcg/CYA~w`12pɡCbפw`e30AfAP10mgAMC2p10mgA@24pɡAM46p1020mgAݭnAӪɶPC̤jfAq120mg/C"	"1. Kʵ˯߳ճtפΦAML઺߸tסA[˪ͤ~(ݵhAIlxAX)C
2. `h20geAiġA]ܦhL|`C
3. A}fΤŦl˪fHAnpߨϥΡC
4. YGܦβVBΧtHAhPC
5. fAvYYAoAhǳƶ}lRߺw`C
6. `N˪}GO150mg ritodrine(3w)500mlsodium chloride, 5% dextrose, 10% dextran 40sodium chloride, 10%ƿ}A̫ͪ@׬OCmlt0.3mg ritodrinew`GC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@ī~m 15 ~ 25 װB	Ritodrine	G02C	L OTHER GYNECOLOGICALS	0	wBy	he20gAΥ˩έLb~hpUOMI(pͲeXAL঺`AlwAŦfAͰ)A߫ߤAYީʮݡAݻ̲ӭMFC	(רORߺw`)ܥPL઺߸tפΦAȮɴ@}ίخqAC[A߱AߡA_ŸAYhAC	Ayhe16Pϥ	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-33 [UDx]_U10-03 [E]_C5-02 [Ew]_C1-01 j	Ts110.6.16		OI` 	0	OIs 20251124	IYUTO-a	IYUTO-b	IYUTO-c	110.6.16
AB37196100	G02CA01	0	OANPO	Anpo 10mg/tab(Ritodrine HCl)		~ଡƤlcƦ٪]2mA]ӴCYCjqUA]vT]1AGް_߸LtMܡC	"ɶPC̤jfAq120mg/C
}lɡG0.1mg/ARߺw`ACQiW[50mcg/A̤ܳjq350mcg/CYA~w`12pɡCbפw`e30AfAP10mgAMC2p10mgA@24pɡAM46p1020mgAݭnAӪɶPC̤jfAq120mg/C"	"1. Kʵ˯߳ճtפΦAML઺߸tסA[˪ͤ~(ݵhAIlxAX)C
2. `h20geAiġA]ܦhL|`C
3. A}fΤŦl˪fHAnpߨϥΡC
4. YGܦβVBΧtHAhPC
5. fAvYYAoAhǳƶ}lRߺw`C
6. `N˪}GO150mg ritodrine(3w)500mlsodium chloride, 5% dextrose, 10% dextran 40sodium chloride, 10%ƿ}A̫ͪ@׬OCmlt0.3mg ritodrinew`GC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@ī~m 15 ~ 25 װB	Ritodrine Hydrochloride	G02C	L OTHER GYNECOLOGICALS	0	wBy	he20gAΥ˩έLb~hpUOMI(pͲeXAL঺`AlwAŦfAͰ)A߫ߤAYީʮݡAݻ̲ӭMFC	(רORߺw`)ܥPL઺߸tפΦAȮɴ@}ίخqAC[A߱AߡA_ŸAYhAC	Ayhe16Pϥ	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 [ws]_w50-05 [UDx]_U03-59 [E]_B5-24 [Ew]_EX051 j	Ts110.6.16		OI` 	0	OIs 20251124	OANPO-a	OANPO-d	OANPO-c	110.6.16
BC19879100	G02CB01	0	OPARO1	Syntocriptine 2.5mg/Tab(Bromocriptine)񬥹F		ĥDBromocriptine MesylateO@ب㦳Dopamine receptor agonist activitylͪCigѧEŨt(Prolactin)cӧͲzʪcũΪvfzʨź|gGS]㦳Dopaminergic@ΡAGiΩvڪˤgC	"1.ź|gζʨů_]gAgêΤgG
2.5-5mg BID-TIDA\AΡAcŰΤgg`D
2.]owǲzѡAwΧ᪺ͲzʪcšG
10mg BIDAA14ѡA\AΡD
3.wcšA󲣫άyɦ}lAΡD
ī2-3ѰֶqƨšApHۦPqAΤ@PYio{HD
4.gegG
gg14Ѷ}lA5mg QDAvW[5mgA10mg BIDAgӼ鬰D
5.ʨů_]kʩʸhG
20-40mg QD
6.ʨůcFG
5mg BID-TIDAvW[qܥiHAacſED
7.ϺݪΤjgG
}lq5mg BIDA@ܨPW[ܨC40-80mg A{ɮįqΰƧ@ΦөwAC龯q4AΡD
8.ˤgG
]Ħdopaminergic effectAiﵽX{on-off{HAϥlevodopaSĪˤgAiClevodopaqABﵽˤgfH~{D
C20-40mg AΡD
i1.25mg QD~BIDAC3W[qWL2.5mgAF.ǯfҢТYġD"	"w믫efBYŦޯefBGũθzGX大fHpߦaϥΥC
ź|gζʨſEҤް_gϥΥi_ͨ|OAh̶ĥξAץID
YfHX{AݵhAYAcƩεLkwѪYh(׬O_Hıê)AΤϯgtΤrgߧYĨõfHpD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOs25JHUΨൣ⤣ΤBC	Bromocriptine 2.5mg	G02C	L OTHER GYNECOLOGICALS	0	ťĤcBEůcFBEůޭPgWhBˤgC	"(1) BromocriptineΨLPLӪ
(2) hBYβȴA
(3)aʯ߯efΨLߦޯfv̡AΨ㦳LY믫efgίfv̡D
(4)TΥ~cũΨLDMΥͩRAgD"	äߡBtwBh©ιæRBCC	iw/|qLť	ŴקKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.10.03	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.2._19950301_000.pdf"">OI` 5.4.2.</a>              "	OI` 5.4.2.	0	OIs 20251124	OPARO1-a	OPARO1-b	OPARO1-c	111.10.03
BC225015FR	G03AC03	0	EMIRE	Mirena intrauterine system 52mg/(Lev		"XEC㦳jcPʸE@ΦӧƧZFϮcV߲GܸYAêlzASϤlcYQ󥥧ZۧɡA]Ӱ_ץ@ΡC  
"	~ݸmJlcĤAĪF~Ab餺}lLevonogestrelH20ug/24hrtvXA~᭰C11ug/24hrA~levonogestrelv14ug/24hrCPXɥRvkA~iPtۿEfAsά֧ls֥ΡC	"1.JgաBg`gv̡Bάy|_`g̡BŴ45HWkyϥΡC
2.pX{@}Ai͹gvAnɥiXC
3.peW̡AݦbXӤiC
4.mJ~kw^E[C
5.mJApoͧWAĳHuyפWAèXMIRENAC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ĭvϥ	Levonorgestrel	G03A	ʧ@ζPXץ HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	0	ץBggLhCwۿEɥRvް_lcW͡C 	CʨxfBǪB~FB}fBҪiBYBʯefBIӭMhέ]Dy̡BwAiçW̩MΧܾĪ̸TΡC	`???(10%ϥΪ̵o)]AXκAܤ?ʪ?_n~C䥦٦C?BgBYhBhBߡBڵHBIhBֵįkhBghBD?W[BDBũĲhPkhBlcץ˸mƥXB魫W[C 	hɦ]lcץ˸mΧPX@μvTALkƥXPʡ]SOOkʤơ^ICYN~hĳN~XAN~Χ@lcɥi޵o۰ʬyC	levogestrelwQҹ|cPťĤA~u˸mblcĤSuXLĶqAणӥigѨťĨ쭷IAҸƤADnAקK¨šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.5._20180401_000.pdf"">OI` 5.3.5.</a>              "	OI` 5.3.5.	0	OIs 20251124	EMIRE-a	EMIRE-b	EMIRE-c	110.6.16
		0	OGVEZ1	"Gveza? 24+4 /
( Drospirenone 3 mg
Ethinyl estradiol 0.02 mg )
/ɤƾǻsĪѥq"		"ƦXfAץ(COC)ץ@άOhئ]l椬@ΦӦA䤤̭nO
ZMܤlcVcC"	"C@As21ѡC
ŹL7ѤAġAA}lAΤU@]A7Ѥq`|X{hʥXCXq`bA
@Ī2-3ѥkX{AåiU@]}lAήɡC
qƦXfAץġBץץKﴫRvɳ̦nbAΧefAץĪ
̫@Ŀ(tĦ)ɡA򱵵۶}lϥηRvA̱ߩefAץĪĤ
_εLĿAɶ}lCYeץάOץK̡A̦n󲾰׫
Ѷ}lϥηRvA̱߶쥻wwϥΤU@KeAΡC"	"1.YkWL35 BҡAjPĳϥΨLץ覡C
2.ACHCSAYhoWvY{׼W[(iOޯefe)Ai|OݭnߧYĪ]@C
3.ҦfAץĳiX{WhX(IXάMX)AרO}lϥΪĤ@ӤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s25XCHUC	"Drospirenone, Ethinylestradiol"	G03A	ʧ@ζPXץ HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	0	fAץ	"ϥηRv3@J/0.03 @J:
1.{δߦٱBͮ뵥Rߦ/ʮfvC
2.@YΦh(pGYBY׳Jղ`)RߦꭷI]lC
3.ѩʩΫѩRߩΰʯߦC
4.ggYhC
5.{δwxŦ~FBYxŦefBx\Ƥ^_`ɡC
6.wκæTJvT(:ʹ޾xΨũ)cʸ~FC
7.]DXC
8.wκæhB
8.糧~DΥ@ξLӪ̡C"	"ߡBhAW[魫AYhACB
ܡAݳkhBũ
Ĳh"	hϥΥ~C	fAץĥi|֪cŶqBܥŪӼvT¨šAҥH@뤣ĳ˦b_ūeϥΤfAץġC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 j	Ts110.6.16		OI` 		OIs 20251124	OGVEZ1-A			110.6.16
		0	OPOST	Postinor-2 0.75mg/tab(Levonorgestrel)		levonogestrelO@ضA@ξରZlӤJlcAEZįʤμW[lcVHGHYסDYbggīhiƧZAYbZۧɤᵹġAhץLġD	"ʦ欰72pɤAĤ@AAUĤ@᪺12pɦAAĤGD
YbʥΪAĪjWLpɡAhĩʭCD"	"ĳbP@ӤggƨϥΦī~
~bʥ72pɤϥ
~ȼvTblcۧ,ZާW(lc~)oͪi
n`NwʯfHIVo
hƤHUgp{δAYWLhաD
ϥĪeTwLh"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOs25JHUΨൣ⤣ΤBC	Levonorgestrel	G03A	ʧ@ζPXץ HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	0	LƫeץץI	"wh
令L"	ߡAhAYhAh¡AgܡDmAWhXAIXD	ĳhkϥΡAL઺o|vT	ĳŴϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_1R-07 j	Ts110.6.16		OI` 	0	OIs 20251124	OPOST-a	OPOST-b	OPOST-c	110.6.16
		0	ENATE1	Natesto (Testosterone)ξ4.5% w/w		ͩʶʯ(]AAT଩MGBAT [DHT])\OPikʩʾx`ͪMo|AHκĤGʼxCį]A@BxnBMnͪMFkΦAҦpFyBBݳMŤUFﵲWjBnaܫpB٦תܤơAHίתժCAT଻PDHTĤGʼx`o|ҥݡC	ĳ:C龯qiHq22.0 mg]CզU@QAC⦸^iW[33.0 mg]CզU@QACT^qܤ֬۹j6ӤpɡC	" NATESTO ĳΩUCw
̡G
 󳡯ewfvF
 󳡩λuNfvF
 Lh 6 Ӥ뤺oͻ󳡰ξɭPe󤤹js󳡰骺fvF
 wHoew(p׮gԸs)FH
 wuefC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Testosterone	G03B	ʯ ANDROGENS	0	AXb~kʤ@ATସɥRkAg{ɼxHιT{]ATଯʥFkʥʹ޸\णg(hypogonadism)NvC	NATESTO TΩwΤwκæw@k	yByM󳡤A	PL/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O01-03 j	Ts110.6.16		OI` 	0	OIs 20251124	ENATE1-a	ENATE1-b	ENATE1-c	110.6.16
AC13985209	G03BA03	0	ITESTO	"Testosterone cypionate injection ""TAI YU"		ATସɥRvW[٦׽qBWiYKסBíwçﵽʥ\	C200-400mg IMAQ3-4W	"1.eCAkʨVϥΡC 
2.xಧ`AVϥΡC
3.ŦfAŦfΰgwಾwVĩθTΤC
4.Wso{ATସɥRvi|W[Yߦިƥ󤧭IApߦٱBΤŦIܡAμW[R߮ƥ󤧭IAp`hRߦΦMͮAG}߳BeԷV w̬O_㦳ߦެI]lίfvC 
5.ѩwʼƾڸƤAATସɥRvAPɱKʴioͪYߦިƥC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	15-25JAץJsC 	Testosterone cypionate	G03B	ʯ ANDROGENS	0	ѩʸAYo|A~êAeCΤjgAʸhAg{ɼxHιT{]ATଯʥFkʥʹ޸\णg(hypogonadism)NvC 	"ثeδgeCΨfv̡C
DΥ@ؽξL"	eP@Sܭ(prostate specificantigen) WɡBCKkBoʪٽAPũг쪺hAvTlsy	ĦbP¨ŰT	ĦbP¨ŰT	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-35 j	Ts110.6.16		OI` 	0	OIs 20251124	ITESTO-a	01C13985-1	01C13985-2	110.6.16
		0	OLIVI	Livial 2.5mg/tab(Tibolone)		"1.Livialiíw]Z_ॢ\~UCUtΡADn@ΨӦ۲XXAզXGҦp]tFۿEBηLzʿEʡCoDOǥѤUz@ΡFCѤfA 2.5mg Livial@Ai~kUX@ץBͨ|kƧZC
 2.bۦPqUALivial|E~klcAuּƪfH|ǳ\W͡CbvAWͪ{רä|W[C 
3.LivialﳱDHE@ΡAbۦPqUALiviali~yFgASOO޹BʨtΪAҦpεsgC 
4.ʼα譱]@ΡAۦLTJAtiboloneOgxŦN¦ӥBܬNªѧTKƥXAǥNª٨䦳ĤͤƬʡC"	Livial]˧t28զA̦nbCۦPɶ]ZHAqCѤ@Cg@bƶgoﵽAsvܤ֤TӤ~iP̨ġCb˾qUALivialis򤣶_aϥΧɶCĤ@ХѰ_lϰ졣T]˭I̤W@ơ}lAΡA̶ۨǫɥΧLqAC@Ѥ@AΧC 	"1. Livialѧ@ץΡC
2. Yk`gBOB~eA`NƧZpAggi|QzZC
3. PҦXʤTJۦPAĳfHCb~@@ˬdC
4. pϥθq]˾q^i|yDXCҥHϥΰqɡAĳK[AjCTӤ10ѡC
5. poͦʮ뤧fܡAx\ˬdܬ`ΥX{x{ʶnv
6. YUCpAwlܡG
a. ǰIܡBwBYhΦWzfvA]ϥΨXʤTJiసG麢d{HC
b. xTJgA]LivialvקܪpC
c. ҤƦXN¤`A]Liviali|ָ}@ʦӼW[lnsulinΨL}ĪݨDC
7. bLivialϥδAܾ徯ӷPfHALiviali|W[夤ֺJդѬʡ]CֺJտ@סFWAntithrombin lllAplasminogenֺJդѬʤƭȡ^C
8. LivialfAʬrʷCA]APɪAμƿ|oͤrgAiyGzAAݯSOvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m2 ~ 25 װBҡFpoܽιLAiAΡC 	Tibolone	G03C	ۿE ESTROGENS	0	۵MΤNᰱgް_g]pBoB߱{BʼC^C 	(1)hB(2)wκæXvT~FB(3)ŦθޯewApRߪAʤefL{δLoǱpfv̡B(4)]DXB(5)YxeC	YwAolAkoA׺|ʥֽfAYhAYhAıê]]AOҽk^AzGDAA~{A~A`hΦٵhAx\ƧܡC	hATAΥī~C	ŴATAΥī~C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 j	Ts110.6.16		OI` 	0	OIs 20251124	OLIVI-a	OLIVI-b	OLIVI-c	110.6.16
BC24585309	G03CA03	0	EDIVI	DiviGEL 0.1% 1mg/gm/pk  (Estradiol )		}ξĮĻPLfAۿEۦPADnPbĪʤOǤPA}ξΩ󰱸ggԸs{ɮĪGPfA۷CP medroxyprogesterone ֥ήɡAg֧lۿE|CCKxTJ|ϰKxTJɰC 	"}ξiHʩζgʤ覡Cqi]ӧOݨDPC 0.5J 1.5JA۷C 0. 5@J 1.5@J EstradiolC_lqq`qC 1.0@J Estradiol (Y 1.0 g) }lAbϥ 23ӶgAվ㾯qC
lckAĳϥέ}ξ֥ξAqAҦpCӶgs򵹻P 12 14ѡC
}ξCϥΤ@AϥήɱNbU߷F֩ΥbkjLC٭nx@ܤGC}ξ٩ũСByWθӷPֽWC٤ݼƤܰA@pɤyHMR~CקKN~Ĳ체A٫Y~C "	b}lXkeAӤHfv@@FѡCvC~ܤ@㪺ˬdC{vhAḙ̀ӧO{ɻݭn@ݳΨũvlˬdC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	JsǷ(C 25X C )C 	Estradiol	G03C	ۿE ESTROGENS	0	kʥѩ۵MgΤNް_kʲXʥFgXNk-~ΥͲzABLkckʲXӤް_UؤAC 	"1. ]DXCLh~wRߦ(Ҧp:`RߦΪͮ)C 
2. _oRߦfvΦefө|ܾĪv̡C 
3. Yxefw(]A: Dubin-JohnsonRotors syndrome)C 
4. whäcʸ~FAiTJvT̡ASOO/ΤlcC
5. ӦLӪ̡C "	q`ܻLApũеȵhBWhDXIX嵥C 	iϥΩhα¨Űk	iϥΩhα¨Űk	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M01-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.1.1._20040501_000.pdf"">OI` 5.3.1.1.</a>              "	OI` 5.3.1.1.	0	OIs 20251124	EDIVI-a	EDIVI-b	EDIVI-c	110.6.16
BC19489533	G03CA57	0	EPREM	Premarin Vaginal cream 14g/tube		"ǥѭt^XgonadotropinAFSHALHq.

"	"DΡG0.5-2gm/dayAY{שΥvMwqD
ݶgʵġAҦpGϥΤTPA𮧤@PD
հήwC֥ζq"	 ۿEsW[wlcAߦޯefAAPiʥI	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs20-25JC	Conjugated estrogens	G03C	ۿE ESTROGENS	0	"YʳDΧ~ʥ~Yg

"	"DgE_ʹ޹D`X
Dwhæfv
Dwhÿw|ۿEvTcʸ~F
D`hRߦAͮAef̡]pΤߦٱ^δwoǯef̡D
Dw糧~LӪ
Dx\ಧ`ΨxŦef
Dwh
"	"lc`XA֯khAlcٽFWjAlcW͡AũĲhA`hR߮AͮAߦٱAYh

"	Ĺ麟WkΥihkTҨϥΡC	Ĺ麟WkΥihkTҨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N01-01 [E]_EX12-01 j	Ts110.6.16		OI` 	0	OIs 20251124	EPREM-a	EPREM-b	EPREM-c	110.6.16
AC39304100	G03CA57	0	OESTR	Estromon f.c 0.625mg/tab		~@ξǬGjƦ޾BާɡBNӦ޳zLʧ@ΡBܦ߽@ΡC~bޥ~PiӺީP褧ƦӱjƦާɡAbޥW[ĩߦhӱjƦ޾ΦީPAbޤ@ΩGغئ]lӫPi`GTC	"`ξq
]ʥFۿEӤް_޵YgBYʳDBYʧD - C0.3mg-1.25mgC
貨Pg(y)G
C0.625@JCqOҥݪC
ߦިtΪO@GC0.625mgV1.25mgC
kʻۿEL֡G
C0.3mgV1.25mgCqi̾گg{שMlcӽվCkĥi0.15mgqAPiĤGʼxo|Cqݦ]HӲAHǫήĪGC"	 ۿEsW[wlcAߦޯefAAPiʥI	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Conjugated estrogens	G03C	ۿE ESTROGENS	0	"~êBZ_ʯgBZ_णBʤlcXBĪ
PgީʯgAYʳDA貨PgAkKAkʥʹ޸xणAoʧZ_IܡAPXũxಧ`ʤlcXD"	"DgE_ʹ޹D`X
Dwhæfv
Dwhÿw|ۿEvTcʸ~F
D`hRߦAͮAef̡]pΤߦٱ^δwoǯef̡D
Dw糧~LӪ
Dx\ಧ`ΨxŦef
Dwh
"	"lc`XA֯khAlcٽFWjAlcW͡AũĲhA`hR߮AͮAߦٱAYh

"	Ĺ麟WkΥihkTҨϥΡC	Ĺ麟WkΥihkTҨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J2 [2]_J2 [UDx]_U01-50 [E]_A2-09 j	Ts110.6.16		OI` 	0	OIs 20251124	OESTR-a	01C39304-1	OESTR-c	110.6.16
AC39822100	G03CA03	0	OESTRA	EstrADE 2mg/tab(Estradiol)		Estradiol valerateOѵMۿEestradiol୤ƪAĲzĪGDgѥؼв´SwۿEoͧ@ΡCTJPƦXPӭMDNAXAèESwJս誺XCMedrosyprogesterone acetateOѵMlͪ17-alpha-hydroxy-6-methylprogesteroneAmedroxyprogesterone acetateMM@鵲Xç@ΩlcHϤlcѼWͪAରcAC 	}lvɡAq`H@2mgA2021ѫܤְĤ@PAMNqܤ@1mgC	"ߦޯefpäefA岧`AYx\êԷVPC
gXdXêf]C
Yʯߦޮ뤧A|HۧlϦӥ[C
og񦳫ʨֵogvGYYhAıêAWC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOs25JHUΨൣ⤣ΤBC	Estradiol	G03C	ۿE ESTROGENS	0	~gΰgް_UدfgBZ_w(]efθ~FӱNZ_)C	ũФΤlccʸ~FAhC	ߡBYhB魫W[DũеȵhC	ĦbP¨ŰT	ĦbP¨ŰT	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 [ws]_w31-02 [E]_EX12-04 j	Ts110.6.16		OI` 	0	OIs 20251124	OESTRA-a	OESTRA-b	OESTRA-c	110.6.16
		0	ECRIN	Crinone 90mg/tube (progesterone)		ѵMEAǥѪ۩󳱹DHAiTѥHWAiɤlcRcD	"]ް_gG
bTwƧZΤgg18-21ACϥΤ@.
tXIHuʹ~뤧gvG
Ygҹwh,s뤩30AC@D"	dNefx(RߪAޯefAͮA)	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JC	progesterone	G03D	 PROGESTOGENS	0	tXIHuʹ~뤧gv(㥿`ƧZPA]ZޡA۵oʩΤlcް_g)	"crinoneeLӪ
gE_lcX
whæũЩΥʹ޾x~F
RߪAAʯef
Ly
Acute propria"	"h,|kh,Yh,K,m,,`h,q,ʼC,g,ݺ,ũĲh,ݳkh,ʥx,]"	kibheTӤϥ	ŴɶqקKϥζC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M01-01 j	Ts110.6.16		OI` 	0	OIs 20251124	ECRIN-a	ECRIN-b	ECRIN-c	110.6.16
		0	IPROG2	Progeston-Depot-s 125mg/amp		"@ Progesterone oʾA@jq뤩b餺]ܧֳQƪnh@ΡAGnɶĦ夤@׫ܧxAӶXAgA`vCFتӵoiXбjOʶXsA@`gYieĮġAĮī7-14 AثĮĻP@תsAkʦ]XҤް_gA㦳uVvĪGC
L}Ƨ@ΡAiΩ󥥰AӹlcLL}vTC"	٦ת`gCϥζq250mgAĮĺ7-14 ѡFߺDʬyέʬyAC250-500mgC	"ϥΤW`NG
(1) ͧwiC
(2) ٪`ɽЪ`NUCƶG
׶}g泡
pݳsϥνХk椬`gC
нT[`gϧlɵLGfy{HC
ϥήɭnV`N뤩̡Gw߯ewBǯewΦgJw̡]ΦuGJd{H^зVϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץAЫǷūOs25XC ҡC	Hydroxyprogesterone caproste	G03D	 PROGESTOGENS	0	gxBlcXBߺDʬyBʬyC	"TҨϥΪ̡G
(1) gxٮ`Bxfw̡C
(2) WlJfҪ̡C"	"LӯgGpolLӯgC
x ŦGxಧ`{Ho͡AЪ`N[Ap{HдqϥΩμȮɰġC"	hA]AheXPAϥΥ~äOTҡC	ŴɶqקKϥζC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.10		OI` 	0	OIs 20251124	DC	DC	DC	114.11.10
	G03DA04	0	EENDO1	Endometrin 100mg/vaginal tab (progestero		@藍kʶi滲Uʹާ޳Nv@AΩ\઺ɥR	qZѶ}lA۳D뤩AC100mgACϥ2 3 Aϥ10g(12 ghg)C	35 HW?{?ĩ|LkT?A]?ּh|XAĳqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	PROGESTERONE MICRONIZED	G03D	 PROGESTOGENS	0	@藍kʶi滲Uʹާ޳Nv@AΩ\઺ɥRC	糧~LӪ̡ATϥΡC	YhA~ȡAkhAߡAlcj	Endometrin?DȮ֭ΩhĤ@ɪUʹ(ART)k	wťiC]AŴϥEndometrin?C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	EENDO1-a	EENDO1-b	EENDO1-c	111.8.19
AC60436100	G03DB08	0	OOMOR	Dienogest-Omorose Tablets 2mg/tab		Dienogestlcg@ΨӦ۩֤ʻۤGJA]FۤGJbMlci@ΡCpG뤩dienogestA|yۿECUBLhcҡAϤlc´}lơA۾ɭPlcf_YC	"DienogestqC@A򤣶_A̦nCѦP@ɶAġAõݭnftCi󶺫eζAΡCL׬O_oͳDXAsAġCA@]˪ĪA}lAΤU@ĪAi_C
igg@Ѷ}lAġC
"	"1.󪺲Xץkb}lDienogestveΡCYץݭnAϥΫDXץk(ҦpGjץ)C
2.pG|AĿBæRH/θm(YoͩAī3p - 4pɤ)Ai|CDienogestġCY|AĿAQ_Ӯɾ֪AΤ@Ŀ(ȥiAΤ@)AjѨ̷ӥ`ɶ~AġCpG]æRθmӵLklĿAPˤ]ɪA@ĿC
3.DienogestvʻۿE@׷|תCCثe|LDienogestϥΪ̤K(BMD)P魷IơC
4.YDienogestϥδ_ox{nʶn/ηko(hΥeϥΩTJɭo)ADienogestC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s25XCHUC	dienogest	G03D	 PROGESTOGENS	0	vlcgHֵįkhC	"DienogestϥΩ󦳤UCfg(Ӧ۩LȧtsT)w̡CpGDienogestϥδX{UCfgAߧYġC
1.ثewʯߤΤߦޯefΦfv(ҦpߦٱBBʦʤŦf)
2.X֦ެֵog}f
3.{δwYxŦefBx\઺Uƭȥ^_ܥ`
4.{δxŦ~F (}ʩδc)
5.wκæwʲX̿૬cʸ~F
6.gE_DX
7.糧~DΥ@ξLӪ"	Yh(9.0 %)BũФA(5.4 %)BC(5.1 %)HڵH(5.1 %)Cb̪90ѪDienogestvA100%)GLg(1.7%)B`X(27.2%)Bg`X(13.4%)BWhX(35.2%)BX婵(38.3%)B`X(Yݩez@(19.7%))C	hkʤDienogestvA]hݭnvlcgC	ĳ¨ŴDienogestvCNŹ઺qBΤkʪvįqǤJҶqAAMwO_nũΰDienogestkC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-08 j	Ts110.6.16		OI` 		OIs 20251124	OOMOR-a	OOMOR-b	OOMOR-c	110.6.16
AC02657209	G03DA04	0	IPROG1	Progesterone 25mg/ml/amp(Progesterone)		"1 D㦳PZ_Xۤ@ΦӼW[kʲX઺\ΡC
2 D㦳lcYPicʡA@Lʤlc@ΡAwߺDʬyC
3 D@Φp餺c۵MͲzc{HA㦳zQĪGC"	1. ߺDʬy]khΥX^C1025mgHCg2A@10mg٦ת`gC 2. ~Χ~ʤlcX......C510mg٦ת`gC	h}l|Ӥ뤺ΥihHקKϥΥC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JC	Progesterone	G03D	 PROGESTOGENS	0	LgBʤlcXBʬyBߺDʬyBgxBणҭPgC	椤LSOC	"Yw, ũкh, Yh, h,AC"	hA]AheXPAϥΥ~äOTҡC	ŴɶqקKϥζC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-32 [E]_G3-07 j	Ts110.6.16		OI` 	0	OIs 20251124	IPROG1-a	IPROG1-b	IPROG1-c	110.6.16
AC17382100	G03DC02	0	ONORE	(Norethindrone)Nordron 5mg/tab		"PXs,AΩvݥζXkew"	"णʤlcXG10mg QDAiϻPʷl`LplcXb24-48hrXD~A΢HWA2-4|`g͡D
wणʥX大lcX_oG
pGZ_S_xH]bggb¦ŨSWɡ^hiw|_olcX大gDѤgg19-26 ACAΥ10mgAhiϤgg_`D
gegԸsG
(YhAYhAdA߷iLtA믫êAŸh^Ao͡Ai]AΥӯgѰδAAkgg19-26A5-10mg QD
gAgӹLWcG
wpgӤe3AΥ10mg QDAī2-3g|{ .
lco|(ͰĪG):
W[ۿEζqϤlcPXjAåBiήPlco|gAphgAggáA|gAPXkAN|͵yhhXAokOqgg5}lAĤ@βĤGPAC10mg QDAĤTĤKӬPGC20mgD
ѩy|gG]ggĤG¦ŤWYuΤWh^
gg19-26CA5-10mg AiW[ZۧɪiD
"	LӯgGolLӯgX{ɰϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUAץxsC	Norethindrone	G03D	 PROGESTOGENS	0	णʤlcXBgeѯg]pYhBhB믫êBŸh^LgBgg`Bणް_ |gC	"1.YxêΨxew̡C
2.W׷kogζnJf̡C
3.WΦWiʤw̡C"	BߡBæRBUgBhBlc`XBIXBgqܤơBUkhBũЯkhC	Ĺ麟WkΥihkTҨϥΡC	Ĺ麟WkΥihkTҨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
BC12946100	G03DA02	0	OPRO1	Provera 10mg/tab(Medroxyprogesterone)		qͩʰʱkAAqfAΪ`gɡAlcѼWͩܦܤcʡC	"1.oʰg - C5-10 mgAϥ5~10ѡC޵olcܬcʡA򥻤WϥΤͩΥ~ͻۿEAAΥ̨ΡF̾AqOC10 mgϥ10ѡCboʰgfҡAib@ɶ}lϥΥCAΥ3~7ѤAq`޵o_īXC
2.DʯfܦsbAѩXդް_lc`X - qgg16ѩβ21Ѱ_ACѪAΥ5-10 mgAsA5~10ѡCCѪA10 mgAqgg16Ѷ}lA10ѡANiϤwϥΤͩʩΥ~ͩʻۿE@Ϊ̡Aͤlc̾AcܡCϥΥvA3~7Ѥq`Ͷ_īXC_oʤlc`XfvkAӤggϥΥ|ġC
3.ְgkb0.625@JXۿEvA޵olcW;v -CӤ몺vAs1214ѡACѵP5@J10@JPROVERACĥiCg1ѩβ16Ѷ}lPC"	1.v`NgxH]ޯewAͮε^CYhéεoͥgߨ谱ĪC 2.~iΩhκæhpC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷű20-25XC	Medroxyprogesterone	G03D	 PROGESTOGENS	0	oʰgHΦ]Dʯf(ҦpֺٽFΤlc)Xթҳylc`XC	"PROVERTΩ󦳤UCpkG
1. gE_ʹ޾`XC
2. whÿwAΦfvC
3. whæۿE-ζ-̿ؽFC
4. whåʹ޾xʯfܪfHC
5. RߪBʮfHBfHAΥHeoǯfv
fHC
6. w|PROVERA͹LӤΦީʤ~C
7. wxŦ\l˩ΨxŦefC
8. whhC"	`lcX(WhBWhB)BgyqܡBoʥXBIXBgBlcVMcpܡCũĲhBŸhΨŷCefA]ARߪΪͮCߡBx{ʶnCLӤ(ҦpLӻPLӤAޤ~)BkoʩΫDkoʥ֯l(Lө)B魫(W[δ)BoB~/GdB«B}@ʴCC	hkTPROVERAAPL/SmҦw	¨ŴiϥPROVERA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J2 [2]_J2 [E]_A3-05 j	Ts110.6.16		OI` 	0	OIs 20251124	OPRO1-a	OPRO1-b	OPRO1-c	110.6.16
BC14860100	G03DA02	0	OPRO5	Provera 5mg/tab(Medroxyprocesterone)		qͩʰʱkAAqfAΪ`gɡAlcѼWͩܦܤcʡC	"1.oʰg - C5-10 mgAϥ5~10ѡC޵olcܬcʡA򥻤WϥΤͩΥ~ͻۿEAAΥ̨ΡF̾AqOC10 mgϥ10ѡCboʰgfҡAib@ɶ}lϥΥCAΥ3~7ѤAq`޵o_īXC
2.DʯfܦsbAѩXդް_lc`X - qgg16ѩβ21Ѱ_ACѪAΥ5-10 mgAsA5~10ѡCCѪA10 mgAqgg16Ѷ}lA10ѡANiϤwϥΤͩʩΥ~ͩʻۿE@Ϊ̡Aͤlc̾AcܡCϥΥvA3~7Ѥq`Ͷ_īXC_oʤlc`XfvkAӤggϥΥ|ġC
3.ְgkb0.625@JXۿEvA޵olcW;v -CӤ몺vAs1214ѡACѵP5@J10@JPROVERACĥiCg1ѩβ16Ѷ}lPC"	1.v`NgxH]ޯewAͮε^CYhéεoͥgߨ谱ĪC 2.~iΩhκæhpC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷű20-25XC	Medroxyprogesterone	G03D	 PROGESTOGENS	0	oʰgHΦ]Dʯf(ҦpֺٽFΤlc)Xթҳylc`XC	"PROVERTΩ󦳤UCpkG
1. gE_ʹ޾`XC
2. whÿwAΦfvC
3. whæۿE-ζ-̿ؽFC
4. whåʹ޾xʯfܪfHC
5. RߪBʮfHBfHAΥHeoǯfv
fHC
6. w|PROVERA͹LӤΦީʤ~C
7. wxŦ\l˩ΨxŦefC
8. whhC"	`lcX(WhBWhB)BgyqܡBoʥXBIXBgBlcVMcpܡCũĲhBŸhΨŷCefA]ARߪΪͮCߡBx{ʶnCLӤ(ҦpLӻPLӤAޤ~)BkoʩΫDkoʥ֯l(Lө)B魫(W[δ)BoB~/GdB«B}@ʴCC	hkTPROVERAAPL/SmҦw	¨ŴiϥPROVERA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r04-08 [E]_A3-04 j	Ts110.6.16		OI` 	0	OIs 20251124	OPRO5-a	OPRO5-b	OPRO5-c	110.6.16
AB57107100	G03DA04	0	OPROGE	Promone 100mg/cap(Progesterone)		~㦳ܻۿE@ΡAܶE@ΡAܵǤWֽ@ΥHκ믫ww@ΡA~AӺ޺zʤ]vTC	"fA~|ġG
@зǥζq 200mg  300mgA@GAΡAҦpG]ߴNeA 200mgAnɥibA 100mgC
]gegԸsBgWhBgeB}ʨŸf^GCӥͲz`gܤ֨ϥζ 10 ѡAq`q 17 Ѩ 26 ѨϥΡC
~kGĳWϥλۿECiHbsϥ 3 gۿEk̫ 2 g֥ΡAUӳo@ghҦġFӦbĪo@gi|oͳDXC 
ioͦGھګʮɴ{ɶE_GөwAC 6  8 pɧ]A 400mgAhĺq]ҦpG@ 200mgA@ѤT^h 36 gC
D~|ġG
CnnJD`BC
@Ѵqq 200mgCiϥεľAB߱qD`Ji@ 100mg nCiHھڭӧOfwqC
cê]ƧZxBgWh^G@Ѿq 200mgACӶgϥ 10 ѡAq`qg 17 Ѷ}l 26 ѨϥΡC
LkcҾɭP]Zlء^Glq@ 100mgAqӴ 13 ѻP 14 ѨϥΡA۲ 15 Ѱ_ 25 ѤABߦUϥΤ@ 100mg nCq 26 Ѱ_ApGwghAHgjjgW[ 100mg nAC̤jqiF 600mgATCqܲ 60 ѤC
Huʹާ޳NɥRkGĳqC 600mgABȡBߤTAñqӫѱߤW}lϥΡC
ioͬyιw]cް_ߺDʬyG@Ѿq 200mg  400mgAGAioӾqh 12 gC"	"ī~Ω󨾤hΧ@ץĨϥΡC
pG{}lӦAר䦭 15 ѡAgiYuεoͥXC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Jä覡GХH]˦sAm 30JHUC
лൣuébൣLkBC "	Progesterone	G03D	 PROGESTOGENS	0	"fA~|ġG
G
- yաADnGgegԸsA]`ƧZΰƧZް_gWhA}ʨŸfAgegC
- ~v]ۿEkUī~^C
- êyC
G 
- w]êyߺDʬyC
D~|ġG
- ]êް_ũΦŤ]DnΩGƧZxA@HuΧZlخɪɥR^C
- wêyߺDʬyC"	Yx\êMī~DΨ䥦ξeLӪ̤AXġC	"pGCӤ몺vg}lӦAרOggĤQѫeġAhiygYuΥXC
~YqӰhi|oͩΡBݺΪΡA@CqAhƧ@ΧYA|CġC
"	hA]AheXPAϥΥ~äOTҡC	ŴɶqקKϥζC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.4._20211201.pdf"">OI` 5.3.4.</a>              "	OI` 5.3.4.	0	OIs 20251124	DC	DC	DC	114.06.25
		wXnn100@J	OUTRO1	Utrogestan 100mg/capgM		~㦳ܻۿE@ΡAܶE@ΡAܵǤWֽ@ΥHκ믫ww@ΡA~AӺ޺zʤ]vTC	"fA~|ġG
@зǥζq 200mg  300mgA@GAΡAҦpG]ߴNeA 200mgAnɥibA 100mgC
]gegԸsBgWhBgeB}ʨŸf^GCӥͲz`gܤ֨ϥζ 10 ѡAq`q 17 Ѩ 26 ѨϥΡC
~kGĳWϥλۿECiHbsϥ 3 gۿEk̫ 2 g֥ΡAUӳo@ghҦġFӦbĪo@gi|oͳDXC 
ioͦGھګʮɴ{ɶE_GөwAC 6  8 pɧ]A 400mgAhĺq]ҦpG@ 200mgA@ѤT^h 36 gC
D~|ġG
CnnJD`BC
@Ѵqq 200mgCiϥεľAB߱qD`Ji@ 100mg nCiHھڭӧOfwqC
cê]ƧZxBgWh^G@Ѿq 200mgACӶgϥ 10 ѡAq`qg 17 Ѷ}l 26 ѨϥΡC
LkcҾɭP]Zlء^Glq@ 100mgAqӴ 13 ѻP 14 ѨϥΡA۲ 15 Ѱ_ 25 ѤABߦUϥΤ@ 100mg nCq 26 Ѱ_ApGwghAHgjjgW[ 100mg nAC̤jqiF 600mgATCqܲ 60 ѤC
Huʹާ޳NɥRkGĳqC 600mgABȡBߤTAñqӫѱߤW}lϥΡC
ioͬyιw]cް_ߺDʬyG@Ѿq 200mg  400mgAGAioӾqh 12 gC"	"ī~Ω󨾤hΧ@ץĨϥΡC
pG{}lӦAר䦭 15 ѡAgiYuεoͥXC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Jä覡GХH]˦sAm 30JHUC
лൣuébൣLkBC "	Progesterone	G03D	 PROGESTOGENS	0	"fA~|ġG
G
- yաADnGgegԸsA]`ƧZΰƧZް_gWhA}ʨŸfAgegC
- ~v]ۿEkUī~^C
- êyC
G 
- w]êyߺDʬyC
D~|ġG
- ]êް_ũΦŤ]DnΩGƧZxA@HuΧZlخɪɥR^C
- wêyߺDʬyC"	Yx\êMī~DΨ䥦ξeLӪ̤AXġC	"pGCӤ몺vg}lӦAרOggĤQѫeġAhiygYuΥXC
~YqӰhi|oͩΡBݺΪΡA@CqAhƧ@ΧYA|CġC
"	hA]AheXPAϥΥ~äOTҡC	ŴɶqקKϥζC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669038?cesid=6YuHEY0WM8R&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DProgesterone%26t%3Dname%26acs%3Dfalse%26acq%3DProgesterone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.03.20		OI` 	0	OIs 20251124	DC	DC	DC	114.03.20
AC45181100	G03FB06	0	ODIVI	Synna Ƥ 21/		Estradiol Valerate OѵMʱ୤ƪAMedroxyprogesterone acetate OѵMPX??ͪCҥkʥ`ͲzgPXcAO 11 ѪʱAMO10 Ѫʱ[Aivkʧ~ΤkʶPXʥFҤް_ѯgCھڲ{bzסAʱNӥ]t@_ϥΡAHקKiಣͪlcVC	"զGCt Estradiol Valerate 2 mg
ŦGCt Estradiol Valerate 2 mg
@@@@@@@@ Medroxyprogesterone acetate 10 mg
CѤ@AC@ɡAӥ]˾TWܤǥѥզ}lAΡA11 ѤאּŦAM 7 ѤA}lAβĤG]C
̦nO߶AΡAYOѰOAΡAibĤGѦߦUA@ɡCgHɥi}l@vL{A|g̦bgӼĤѰ_}lAġC"	"1. ĴX{HDYbAŦoͥX{HAߧYAġD
2. UCw̸TAġGhkA޻êAʮfܡATӭMʳhDʩκCʨxŦefAѩhް_xPxêAũЩMlccʸ~FAW?lAhcƤյwơAlcD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~J 25?C Ψൣ⤣ΤBC	Estradiol/Medroxyprogesterone	G03F	MۿEAƤ PROGESTOGENS AND ESTROGENS IN COMBINATION	0	ʱEʥFB~ѯgBPgBLggBgL֡BZ_NᤧvC	kʦpGhBwlcBũЩMlccʸ~FBWlAάO]hް_nx\êALpCʨxŦefA޻êBʮfܵAҸTϥΦī~C	ߡBųȵhPBYhBıêBhҡBʼMܡB`X嵥C	Ĺ麟WkΥihkTҨϥΡC	ŴɶqקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-10 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIVI-a	01C45181-1	01C45181-2	110.6.16
AC44203100	G03FA01	0	OHAVI	Havina F.C.tab Ƥ		bgk~i@Z_ͪʱENC~iְgk]ʱEʥFҲͪgΨϤC~O@XְʱEζEiϥΪsCCѥ[JCqEA໤ɩκlcYA]iקKC@XC	"EstradiolKKKKKKKKKKKKK1mg.
Norethisterone AcetateKKKKKK0.5mg.
CѤfA@AϥεL_A~Olck]psX֫XɥRkC
ĶvBϥΡC"	" YfHUCΡAYKʵCbD`ufҡA~ϥΥi|ϤUCfp_oΥ[C
1. ۿE̿ʸ~FfvC
2. ƦٽFBlcBlcL׼W͡C
3. ũֺFC
4. ʮefvΦsbHUMI]lG
(1) 
(2) }fæޯf
(3) xf(ҦpnBIۯgBx~F)
(4) xۯg
(5) յwƯg
(6) YhYYh
ۿEγ\|yGJdAҥHfHYŦεŦ\ê̶@J[C
ϥΧܰĪvw̡BwBYhB}fBݩΤŦIܪw̡AwʴıΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~J 25?C Ψൣ⤣ΤBC	Estradiol/Norethisterone	G03F	MۿEAƤ PROGESTOGENS AND ESTROGENS IN COMBINATION	0	gWL@~HWkۿEʥFް_gC	"1. wAhéδww̡C
2. whðʱE̿૬~FAplcC
3. Cʨxfw̩δwxfABx\Lk_`̡C
4. `RߦBʯefB޷N~ΥeϥΰʱEAoǯfv̡C
5. f]Ҥް_ʹ޾`X̡C
6. whh̡C
7. صIۯfw̡C
8. ¨šC"	"ũкPYhBYhBDXBUkhBߡBȮBũܤjBlcֺFܤjBֽlMkoBvBqBʮM~C
"	Ĺ麟WkΥihkTҨϥΡC	ŴɶqקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-07 j	Ts110.6.16		OI` 	0	OIs 20251124	OHAVI-a	OHAVI-b	OHAVI-c	110.6.16
AC42536100	G03FB05	0	OSEVIN	Sevina F.C.tab۩ʯƤ		"1.bgk~i@RδNZ_ͪ۩ʿEAiְk]۩ʿEʥFҲͯgΨϤAigkyC
2.@ؤTq۩ʿEζsAbCӴ`{A[JQѪAiO@lcAjfHiް_lcWߪ鸨CbCӴ`{A[JCq۩ʿEAiggAX{AӥB|zZ쥿`XC "	"CѤfA@AϥεLݶ_C
̦Ŧ⽤}lAΡAAAΥզ⽤A̫Aξ⽤C
"	"1. `Xi|X{Aq`bAΧCq۩ʿEAp6ɩΥib̫AΥզX{C
2. ϥΧܰĪvw̡BwBYhB}fBݩΤŦIܪw̡AwʴıΡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	:Estrdiol:Estrdiol+Norethisterone:Estradiol	G03F	MۿEAƤ PROGESTOGENS AND ESTROGENS IN COMBINATION	0	۩ʿEҤް_ѯgMw~kyC	"1. wAhéδww̡C
2. whðʱE̿૬~FAplcC
3. Cʨxfw̩δwxfABx\|_`̡C
4. `RߦBʯefB޷N~ΥeϥΰʱEAoǯfv̡C
5. oǯfv̡C
6. ]Ҥް_ʹ޾`X̡C
7. whh̡C "	ũи~ȡBߡBYhB~BWhXC 	Ĺ麟WkΥihkTҨϥΡC	ŴɶqקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-09 j	Ts110.6.16		OI` 	0	OIs 20251124	OSEVIN-a	OSEVIN-b	OSEVIN-c	110.6.16
		ի`gG 100 LJ/0.5 @	IELON	Elonva solution for inj 100ug/0.5ml		"Corifollitropin alfaO]p @  @   ow E ĮįSʩM rec FSH ۦPʧ[C
]ĤO໤oBh ow o| @  g A澯ĳq Elo n va ֤U`gHN COS {
eC C  rec )FSH `gC FSH Oʪ ]bNH   ʸ  E (
] carboxy terminal peptide [iH F SH ] 줧 C
Corifollitropin alfa ä | { X  ͩ LH hCG ʡC"	"Ωvͨ|~֤kʡAY魫M~֫ĳElonvaϥξqC
- ~֦b36(t)HUB魫60HU(60kg)kʫĳϥξq澯100LJC
- ĳ澯150LJqϥΩUCkʡG
- ~֥B魫60HWC
- ~֤j36B魫50(t)HWC
|w~֤j36B魫50HUkʶisC
WzĳqAثeubE{ĤΤ餧X֨ϥ GnRH (GnRH antagonist){QT"	"b}l Elonva ve  Thp C
Elonva H榸֤U`gCP@ v  g`g WL@
ϥ Elonva ܨE{ĤKeA  PLt FSH ~
Elonva P ʸE E GnRH agonist) X ϥ  ƾ Q C]A 
ĳ Elonva P GnRH   (GnRH X ϥ
Fʱ OHSS IAbve{wHWiy owo|PB˴MۿE@פ]i঳UCbI ART  A 18  ΥHW ow |j 11mm ɡAIo OHSS C
Elonva v  Ai|W[oͦ IC]惡kʧPʸE A]A Elonva vɡAJvůfHQqPICtݪ`NOAhN|W[ΦIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJsBc(2XC-8XC)	corifollitropin alfa 100ug	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	bkHuUʹާ޳NpɡA~PʸEEܾ(GnRH antagonist)֥ΡAϥΩ󱱨UEZ_AHɦhowo|C	"DΨLξLӪ 
 Z_B ũ BlcB U ΤU C ~F fH C
 ] D` Dg XC
 oʧZ_I C
 Z_n~θ~jC
 AXhlc ٽFC
 AXhʹ޾xΡC
 Z_LרEgԸs OHSS I]l
o Z_LרEgԸs OHSS fv C
o beCOSgA̾ڶWiˬdGAWL30owd11@̡C
o ¦Z_ow (antral Ƥj 20  fH C
o hnʧZ_gԸs(PCOS)C"	YhB ߡB hҡB OHSSB ֯kh B ֤A B ũ h	"ElonvaiϥΩhk C Ybhp߱Ĳ Elonva ɡA{{ɸƨäH
ưo h }GiʡCbʪs[X{ʹ tάrʪ{H"	bŴAXϥElonva C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-44 j	Ts110.6.16		OI` 	0	OIs 20251124	IELON-a	IELON-b	IELON-c	110.6.16
		0	IGONA	Gonal-f 450IU/vial(Follitropin alpha)(N)		"Follitropin alfa OQΤܹZ_ӭM]Chinese Hamster Ovary]CHO^Cell^gѰ]u{syӲͪowEECFollitropin alpha O@ݩʸE]Gonadotropins^owEE]Follicle Stimulating Hormone, FSH^AʸE@λPʹީMC̥DnĥάOPiow͡CLkƧZkAGONAL-f ? vؼЬOͳ@Z_ow]Graafian follicle^AMgѧPH򽤩ʸE]hCG^PiƧZC"	"1.LƧZgkʱw̡]]AhnʧZ_gԸs^
󦳤gkʱw̡AbggeCѤ}lvC75 IU 150 IU FSH QDA*7-14ѡApW[37.5 IU 75 IUD
q]A]1^HWiqowjp]2^ʱEcCC̤jqq`WL225 IUC
a.Yw̳sv|PᤴLA󦹤@{C
b.F̨ΤɡAb`g̫@GONAL-f ? 24 48 pɤAIH@`g250 mcg r-hCG 5,000 ~ 10,000 IU hCGCĳw̦b`g򽤩ʸE]hCG^ѤιjѦPСAάOiHuº]IUI^C
c.Y͹LפAhvBo򽤩ʸE]r-hCG^AëĳUvgAխvqC
2.wﱵպΨLʹާ޳Nk
WƧZvp]PϼƭӧZlo|AbI@ؤHuUʹާ޳Ne^ۤggĤGβĤTѶ}lAC
GONAL-f ? 150-225 IUAvowo|]Zw^Aè̱w̪qվA@̰qCѤWL450 IUCoq`ݭnQѡA]iݭn5-20 ѡAiQκʴ夤ۿE@שM/ ζWiˬdӰC
b`g̫@GONAL-f ? 24 48 pɫᵹ250 mcg r-hCG5,000 ~ 10,000 IU hCGAHPi̫owC]Zlܥi^
@`Ϊ{ϥΩʸEE]GnRH agonist^GgAA}lϥGONAL-f ?A̫ϥΡAܲͺNowCҦpGHʸEE]GnRH agonist^svGgAA}l뤩GONAL-f ? 150~225 IUAs`gCѡAM̧Z_ӽվ㾯qC
HثeIVF vgӨAq`be|vhvNOíAhvN|vCC
3.]FSH LH YʥFӾɭPLƧZgk
ʥFFSH LH k]hypogonadotropic hypogonadism^AGONAL-f ? Xlutropin alfa vؼЬOo|X@owAo@w̳q`LgBʱEܧCAvib@ɶ}lC@GONAL-f ? _lq75 IU 150 IUAðtX75 IU lutropin alfa ϥΡCYLվvqAHCCΤQ|ѬqվɬqApW[37.5 IU 75 IUAviO{ɪpܤӬPCF̨ΤɡA b`g̫@G ONA L - f ? Pl u t r o p i n al fa 24 48 pɫAIH@`g250 mcg r -hCG 5,000 ~ 10,000 IU hCGCĳw̦b`g򽤩ʸE]hCG^ѤιjѦPСAάOiHu覡]IUI^NlmJlcĤ"	"knwĪϥGONAL-f ?AζWiwyZ_ΦPɴq夤oestradiol @סC
Z_LרEgԸs]Ovarian Hyperstimulation Syndrome,OHSS^YOHSS gٷ|]AhBȡBYZ_WjB魫W[BIlxΧqֻPzGDg]AߡBæRMmC{ɤWiX{enL֡BG@׼W[Bqѽ褣šBBnBؽĿnΫʪ͵~{HC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ī~xsBcNá]2-8 J^AiNCī~b]˥HץC
@}ϥΡAbLNñΤU]25 JHU^̦hixs28 ѡC"	Follitropin alfa	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	"kʱw
]1^ kgClomiphene Citrate vALkƧZ̡]thnʧZ_gAPCOD^
]2^ IHuʹިU޳N]ART^Ap~]IVF^AtlZ޴ӤJ]GIFT^AXlZ޴ӤJ]ZIFT^w̡AiEhowo|C
]3^ PEE]LH^֥ΡAϥΩYʥFEEPowEEowEC
kʱw
vkʹwѩΫѩʸEʸ\CUgA֥ΤH򽤩ʸE]hCG^AElͦC"	"follitropin alfaAFSHΨLξLӪ
? UCθU~F
? D]hnʧZ_gԸsް_Z_WjΧZ_n~
? ]DX]f]X^
? Z_BlcΨũЪg
LkoĤɡAϥGONAL-f ?AҦpG
? oʧZ_I
? ʾxεLkh
? lcֺFPLkh
? oʸAYI"	Z_Gn] Z_n~^AYhA`g쪺ApkhBoBJB~ȩΨEPA PıߡBæRBUgBhεjˡB	hAΡC	GONAL-f ? AX¨ŴϥΡCb¨ŴAprolactin c|EƧZͤ}wC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-46 j	Ts110.6.16		OI` 	0	OIs 20251124	IGONA-a	IGONA-b	IGONA-c	110.6.16
AC58156212	J01DD62	0	IBROS1	Brosym 2g/vial		Sulbactami ] lactamase  Ic B II B III  IV A H εyL Ia  V ơAҥHioǻï[cefoperazone AG cefoperazone   ʪ ߤ] ܵߤO CC efoperazone ǥѱjOêӵ߼W޴ӭMXHF ߧ@ C	"H
C`q1g/1g2g/2gAj12pɡA⦸ġCYPVAHC龯q
iW[ 4g/4g A⦸ġC
p
C`q C魫 20mg/20mg  40mg/40mg A2~4   CY PV ɡA C龯qiW[ܨC魫80 mg 80mg A 2~4   C"	"1. ֪̳q`|]Ͳz\୰CӮeͰƧ@ΡAi|]ʥFLR K oͥX{HC
2. penicillin tܥͯ Lӥv fw AwoͥJAиԲӰݶEC
3.YxêfwA ]夤@ץbIAn`NqPĶjC
4.Y  êfwA ]夤@ץbIAn`NqPĶjC
5.gf}w̩εLkgfɥRi fw  A} fw A]ʥFLR K ӦXg A]J[ w̪A"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"H
C`q1g/1g2g/2gAj12pɡA⦸ġCYPVAHC龯q
iW[ 4g/4g A⦸ġC
p
C`q C魫 20mg/20mg  40mg/40mg A2~4   CY PV ɡA C龯qiW[ܨC魫80 mg 80mg A 2~4   C"	Cefoperazone/Sulbactam	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	AΩvѷPʲӵߩҤް_UCPVGWBUIlDPVBWBUcDPVBBxnBxުΨ䥦ĤPVBֵoBlcΨ䥦ʹ޹DPVBHγж˿SˡBNᤧGPVC	"]ӵoͥJ̸TϥΡC
󥻾ΪcephemtܥͯLӥv fwTϥΡC"	m] 0.75%0.75%^Ao l 0.45%0.45%^AoN 0.21%CDn{ˬdȲ` AST GOT ^W 3.18%ALT GPT ^W 3.41% ALP Wɡ] 1.05%1.05%^C	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50      4g q12h
CClr15    4g q12h
CClr<15       2g q12h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG}Ƿxs6hrFNxs48 hr
tsGG6~10 ml WFIBNSBD5W
ĳ}@סG-
ۮe}GGD5WBNS
ĳĳ~|tvGIV:>3 min
`NƶG1.iSCBIM
2~NMTT(N-methylthiotetrazole side chain)AӧLRKƪ٭ï(vitamin K epoxide reductase)AiӼvT]l\AbѦ~iAΪ̡Aiಣ;岧`γyXAnɥiR߿`LRKAHwYXC"	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
		0	IPURE3	Puregon 300IU/vial (Follitropin beta)(N)		"Puregont]դFSHCǭDNA޳NӻsyC
FSHOPow`ͪΦAsyʸTJҤiίʡCbkʡA餺FSH@׹owo|_lήɶAHF즨ɾμƶqnC]PuregoniΩYzʸ\êfҡAEowo|λsyTJC~APuregonibUؤHuUʹޭpe[p~/FLӤJ(IVF/ET)AZޤZӤJN(GIFT)κL`gN(ICSI)]PϦhowo|CHPuregonvq`PhCGHowi̫ᶥqAƤί}C "	ϥΫOdv̥b㦳vͨ|Dg窺M~vʵUC 	"1.ưDʸ譱cefC
2.HʸEsɱƧZҧΦhAhLWMIʷ|W[C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC

@X]˪^OwQwYWLAϥδhȳѳ̦h28ѡC
"	Follitropin beta	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	(1)LƧZg(]AhnʧZ_fwBPCOD)ABCLOMIPHENE CITRATEvLkC(2)UZ_LרEAɦhowo|AΦbUؤHuUʹޭpC 	"1.Z_BũСBlcBAYBUΤUC~FC
2.hα¨ŤC
3.gE_DXC
4.DΥξLױӷPC
5.oʧZ_IܡC
6.PhnʧZ_ew(PCOD)LZ_n~ΧZ_ؤjC
7.ʾxLkh̡C
8.lcֺFPLkh̡C
9.oʸAYIܡC "	{ɨϥΫOdĥΦ٦פUΥ֤U`gAb`giɭPJBkhBoB~ȡBooAojhƬLMuȥBO۵MoͪC 	hα¨ŤŨϥpuregon	hα¨ŤŨϥpuregon	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-47 [E]_K-09 j	Ts110.6.16		OI` 	0	OIs 20251124	IPURE3-a	IPURE3-b	IPURE3-c	110.6.16
		0	IMERI1	Meriofert 75 I.U.(N)		gkGѨAHMG(human menopausal gonadotropin)AHMGO@اtFSHMLH(1:1)PXDDn@άFSHPiowͪMDɤlcWͩMZӤJMۧ.	"g٦שΥ֤UġG
ɳ@ZwñƧZG
k@GC뤩k
۵oʤggλɥX媺ĢѨĢѡACѧP75IU-150IU(Max<450IU)A7-12ѡAowܬ۷{(18-22mm)D
Y֥FSHhCqAåζWiMۿEʴ(300-800pg/ml)M¦馱uAlcVHG{סAӵCѵGDYۿE@׼W[ӧ(2-3ѤWL100%)hmerinolq֡D
YSowLרE{HA̫@`gmerinol24-48hAi٦ת`g5000-10000IU HCGAƧZ@`gHCG32-48o͡ApƧZAiƵHCGD
kGGj뤩k
{OCj@뤩merinolAlһPk@ۦPD
q`gHCGe@Ѷ}lܱƧZAҩdCСDƧZiѰ¦ŤɰoAYhAi~ۦP{D

iUNAɦhowͪɡG
̾ڶPX@תqAMWiʱGACӱw̾AqmerinolD
Ĥ@qG
qggĤTѶ}lA`g150-300IU merinolAͪƶqowDY֥FSHAMerinolq֡D
ĤGqG
`g5000-10000IU HCG@ӻɱƧZ
1 amp̦hi3p~75IU merinol"	b{}leAw̩MtʹޯOAˬdDåBhTҪưAw̩Mt襲QiA`gʸE|W[Z_LרEAhLWM۵oʬyMIʡD	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ 25 CHUC 	"human follicle stimulating hormone 75IU
Human luteinizing hormone 75IU"	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	ѩ˥ʹ޸֩ίʥFɩҤް_ƧZgD	"1.h/¨
2.ʵg
3.ʸEwLө
4.oʧZ_I(ʸEL,ʸLC)
5.Z_nݩhnʧZ_gԸs
6.f]X
7.ūPg
8.ҪεǤWް_cf
9.Z_,lcΨũ
10.UFΤUCF"	`gEAoNA`hAȡAhAݳȺ	hM¨ŰkTΦ	hM¨ŰkTΦ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-48 j	Ts110.6.16		OI` 	0	OIs 20251124	IMERI1-a	IMERI1-b	IMERI1-c	110.6.16
		0	IOVID	Ovidrel 250mcg/vial(N)		"1. OvidrelOHDNAէ޳Nso򽤩ʸEC㦳PhCGGsۦPiħǦCC򽤩ʸEXܻPEۦPZ_TӭMWӭMWLH/hCGC
2. bkʤA򽤩ʸEDn\ରPiZӭMƤBow}(ƧZ)BƤζcprogesteroneestradiolC
3. bkʤA򽤩ʸEiNLHpyƧZCOvidrelϥΦbLī~EowAiPowP޵oC
4. bʪsXAiHuʹިU޳NPowP޵oɡA250mcg OvidrelĻP5000IUB10,000IUhCGGs۷CbPƧZ譱A250mcg OvidrelĬ۷5000IUhCGGsC
5. ثebH餤åܷ|OvidrelͧCkʤ{ζȭvP榸ϥΡAbkʤ~shPsC"	"1. OvidrelH֤U`gϥΡC`gѩҪߧYϥΡC
2. OvidrelݥѦvgDg窺vϥΡC
3. ϥξq:a.IHuʹިU޳N(ART)Ap~(IVF)WɱƧZ: P̫@FSHHMGs2448pɫAYowgEFAɾɡAP@~250mcg OvidrelCB.LƧZαƧZLְkɱƧZ: owgEFAɾ2448pɫP@~250mcg OvidrelCĳw̦bϥOvidrelѤιjѶiʥC
1. OvidrelH֤U`gϥΡC`gѩҪߧYϥΡC
2. OvidrelݥѦvgDg窺vϥΡC
3. ϥξq:
a. IHuʹިU޳N(ART)Ap~(IVF)WɱƧZ: P̫@FSHHMGs2448pɫAYowgEFAɾɡAP@~250mcg OvidrelC
b. LƧZαƧZLְkɱƧZ: owgEFAɾ2448pɫP@~250mcg OvidrelCĳw̦bϥOvidrelѤιjѶiʥC"	"1. ܤOvidrelϥΩ󧿲GsL֭Ag{ɸgC
2. }lveApgLARñ_O_LhTҡCרˬdO_Ҫ\CUBǤWֽʥFBcſEΤUCθU~FAAvC
3. Yhiϭ즳ʯeff[AϥOvidreleHĵiC
4. iPƧZL{ɡAѩ󦳦howEo|AZ_LרEgoͤҥiW[C
5. Z_LרEgitܬYASxZ_(Z_n}eF)B]`\ण}ް_Cز{HiHȰϥhCGקKCiw̦ܤ֥|ѤקKЩקKϥξ_kCĳҦw̦bPƧZL{AYKʴestradiol@פΥHWi[Z_C
6. Huʹާ޳N޵ohMLMIPm񪺭FLƥئCǥѫPƧZӹF餺몺w̤޵ohMLҸ۵Mh̰AӤjMLC
7. קKZ_LרEgPhMLo͡AĳiWi[Pʴestradiol@סCbLƧZw̡AY夤estradiol@פj1500pg/ml(=5400pmol/l)BTӥHWow|j14AhoͧZ_LרEgMIW[CIHuʹާ޳NɭY夤estradiol@פj3000pg/ml (=11000pmol/l)B20ӥHWow|j12AhoͧZ_LרEgMIW[CY夤estradiol@פj5500pg/ml(=20000pmol/l)B`@40ӥHWowAhݰϥhCGC
8. ̷OvidrelĳqϥΥBpߺʴvL{AiNoͧZ_LרEgMI̧ܳCCLƧZgw̩άIHuʹިU޳N̡AyҸ@륿`A̰APLgw̬۸õLtOC
9. ۦ`gOvidrelw̻ݸgLA`gVmPɡC
10.ϥιLqiް_Z_LרEgC
11. S]ľLqӤް_rʳiX{C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ 25 CHUC 	Choriogonadotropin alfa	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	1.IHuʹިU޳N(ART)Ap~(IVF)WɱƧZ:POVIDRELiް_̲owPgEowơC2.LƧZLְkɱƧZ:POVIDRELiް_gEowLƧZLְkƧZζơC 	"1. wzѡAOvidrelTΩUCp:aUCθU~FCbDνξLӪ̡CcDhnʧZ_efް_Z_Wjn~Cd]ʹ޾xXCeZ_BlcΨũи~FCfTӤ뤺oͤlc~CfʩʦʴC
2. aoʧZ_o|}Cb]ʹ޾xΤް_CclcֺFް_CdgkC"	"1. @Ƨ@(oͲv1/10~1/100):a.`gkhCB.@g: YhBh¡CC.zGDt: ߡBæRBhCD.ʹިt: 줤תZ_LרEgC
2. ֨Ƨ@(oͲv1/100~1/1000):a.믫ef: ߲zqBġBnʡCB.zGDt: mCC.ʹިt: YZ_LרEgBݵhC
1. @Ƨ@(oͲv1/10~1/100):
a. `gkhC
b. @g: YhBh¡C
c. zGDt: ߡBæRBhC
d. ʹިt: 줤תZ_LרEgC
2. ֨Ƨ@(oͲv1/100~1/1000):
a. 믫ef: ߲zqBġBnʡC
b. zGDt: mC
c. ʹިt: YZ_LרEgBݵhC"	iϥΩhα¨Űk	iϥΩhα¨Űk	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-43 [E]_K-15 j	Ts110.6.16		OI` 	0	OIs 20251124	IOVID-a	IOVID-b	IOVID-c	110.6.16
BC22877100	G03HB01	0	ODIAN	Diane-35 S.C.(21/)		LRwtزXGcyproterone acetate 2mg(@بܶʯ@Ϊ)ethinylestradiol 35gg(@ذʱE)APkʧZ_cѵMXۦAGiΨӧ@kʤfAץġF~ALRwtܶʯ(ʿE|Pϥֽ͹Lho׺ɭPCKk͡A÷|Piͪ)A]iΨӴ֫CKk͡BhٽoMhgC	"g}lHĤ@ѪAβ1AO""A3PA1P""C1AĤҬP@gA~FץĪGA٥iHvCKkC"	"ѰOAĮɡApGb12 pɤɪAAץĪGä|CCGQ_ɪAAU@b`ɶAΡC
pGWL12 pɧѰOAġAץĪGiCAi̷ӤUCWhBzѰOAĪΡABz򥻭hOG
1.os7 ѩ7 ѥHWѪAĿC
2.s7 ѥ_AĤ~RUC-U-Z_-b(hypothalamus-pituitary-ovarian-axis)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Cyproterone/Ethinylestradiol	G03H	ܶE ANTIANDROGENS	0	ڵHB֯׷XBhgBץ	hBšBYx\êBnB{bιLhwxŦ~FBʮfg]]tBߦٱ^ByʳhB{ΪvLΤlcBޯfܪY}fB׽N»êC 	DnƧ@άߡAhA魫W[AYhAC?BܡAݳkhBũĲhCǩʦޤ~?A~]ʪۿEi|oΥ[ޤ~g?C 	hα¨ŴĳϥΥ~	hα¨ŴĳϥΥ~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-02 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIAN-a	ODIAN-b	ODIAN-c	110.6.16
BC12554100	G03HA01	0	OANDR	ĵ Androcur 50mg/tab(Cyproterone)		(1)jOܶʿE@ΡAPؼоxʿEP_vʪXAêʿEC(2)UʸEcC(3)fAC 	150100mgC12550mgA123Cq`12A150mgApݭnɺWq4gCѶq200300mgCܹF즳ĤAӫấqܾApC	"1.Cxf]ҦpCʯfrʨx^PCʰs릳xŦefw̡BѦ~HHΨC龯qjε100@Jw̡AsbYĪʨxl˭IA~pߡC
2.b}Androcur TabletBeA߰ݱw̪xŦfvöix\˴Aܤ֥]AALTBASTBALPM`xC
3.bve6ӤPC3ӤAixͤƩwFYX{xŦrʪHίgɡAPCY󲧱`pAЦҼ{vC
4.Yw̦b}lvX{HUgAĳw̺N:æRBߡBWABLOBֽβoBΤpKeŦC
5.ĳNĪΩeΤwxŦ~Fw̡C
6.u@jM`Ow̶i~|ް_h¡BOIhӭCM`OC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Cyproterone	G03H	ܶE ANTIANDROGENS	0	"kʡGYʼLjBܶʯveC~FC 
kʡGYkʤƼxBCKkBhgC"	hB¨šBxfBehnΫkofvBW?lfvBDubinjohnsongԡBRotorgBβ{x~FBYCʼ~{gBβ{ޮB֦ޯfܪY}ffwBIӭMhB}MeCw̷ޮfvαwIMhΨ֦ޯfܪY}fڸsɦbϥΥ~ep߿ŶqvQoC YkHkʤƪg֥ΪvPɪ`N֥λs~pLRwWTҨƶC 	(1)LӯgGolgC(2)魫W[C(3)GzGߡBæRBhC(4)ũСGkʤƨũСBũеȺPBũеhC(5)ctGƵǥ־୰CC(6)믫gtG{BYhBΡC(7)LGhҷPBʹ޾C 	hα¨ŴϥΥ~	hα¨ŴϥΥ~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-03 j	Ts111.8.19		OI` 	0	OIs 20251124	OANDR-a	OANDR-b	OANDR-c	111.8.19
		0	ORU486	Apano 200mg/tab(RU486)		OտO@ئXܶ\઺TJAPvʪڶCfAq310mg/kgqɡAFPذʪ(ѹBչBߤlPUl)]ʩΥ~]ʪʡCʪA@Ϊ{XפW{HCOտP}ֽTJXALkPqֽ଱XA]bOտAδAʵǤWIܪMIʬOD`LpCbʪ礤A10-25mg/kgqOտ|dexamethasoneͧ@ΡCbH餤Ah۷Τj4.5g/kgqUAigACTHPcortisolNvʪɰAFѥXܿ}ֽTJSʡCMifepristonebʪPD`qpUA{XLܶʲX@ΡC	"OտiϥΩ|T{hAιhƦҽáAΤlc~רҡCEvvҦרҦb뤩īe氩ˬdAWiy/Σ]-HCG˴TwlcW49ѤC
OտѦXuͫOkWwvAbp|ҰϥΡAfH@HeAΡAkpUG
*@fA600mgOտ(200mg 3)C*36-48pɫfAmisoprostol 400mcg (200mcg 2)ApG3pɤXAAB~A1misoprostol 200mcgC"	"1. ϥΥ~ץ@λݪ`NOAAΫA75%HWk|b3ѤAͦgXAز{HO~vT\ҳyC
2. ~|ϱƧZɾܡA䤤jhOϤggAҥHAϥΥ~MץvAoϫgƧZɶAwAҥHAĳ~`WץkC
3. AΥ~ݿAAΫeAѰMvATwO_lchA]1%hOlc~A~äϤlc~yApGSήɵo{Ai|ylc~}AjqXӭPRC
4. ~|LPLiA]`֥ΫeCAӫeCPLiFҥHAYΥ~X֫eCAӥy̡AĳiHuyC
5. ~Qi4źިī~A⦳ިī~nOҪħվA⥻~IvC
bO?AΫ᪺GPAT^ElܡAgѶi@Bk(?ˬdA]-HCGwBWiy)?T{W´O_ƥXAHγDX媺{HO_wg?"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Oտx30C]@Ƿš^HUC	Mifepristone	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	"he]pCg^lcHuyC
bAΫOտ᪺36-48pɡA۵eCĪ]p Misoprostol^C"	"~?iϥΩHU?p:
*CʵǤWIܡC
*wO?ΨLt|͹LӮɡC
*֥Υֽ?TJv?C
*XʯefΨ֥Χܾv?C
*|gѶWiyΥͤƴT{hC
*W?wWL49ѡC
*ælc~C
*]e?ĪӲͪTҡG
-we?LӡC
-δߦޯefH(ߵhB??gίgԸsB??BŦIܡBY)
*35HW?B@ѩ϶WL10HWC
*ǩʬs?ۯfC "	"1. cʹ޾
* X
XGҦϥΪkҦX媺pAӥBH۲פWɤhƼW[AXq]ۼW[C
ǨϥΪk|jqXAi঳1.4%fHݧ@媺BzC
* bϥΫeCĪ᪺XpɤAg`lcYεj(10-50%){HC
2. GzD
bϥΫeCĪAg`|X{ߡBæRBUggC"	ihkYkѤi~hABLi঳ΪMI.	ĳbAΫOտᰱ¨3-4	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_86-1L j	Ts110.6.16		OI` 	0	OIs 20251124	ORU486-a	ORU486-b	ORU486-c	110.6.16
AC47913100	G03XA02	0	ODIME	Gestrin 2.5mg/cap (Gestrinone)		~@XTJXA㦳ܶ଩ʽAivlcC	"2.5mg Q2WDYggĤ@ѪAβ1,ggĥ|ѪAβ2, , TwCgۦPG, B̦nۦPɶAΥ"	" pUCΡAФŪAΥġG
1.hαh
2.
3.wߨxǯef
4.PXvA
ץ,w,ܵī~i୰C
Ĥi@ץ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Gestrinone	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	lc	"XĪv(]Aץ),ӦAg.hΥh,Ṳ̄A"	pBBIXB~BhgBʼCBũܤpBYʳDBYB٦שj	PL/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-06 j	Ts110.6.16		OI` 	0	OIs 20251124	ODIME-a	ODIME-b	ODIME-c	110.6.16
BB24023100	G03XC01	0	OEVIS	Evista 60mg/tab		"RaloxifeneO@ب㦳ܩʪۿEո`(SERM)ݩbenzothiopheneƦX,iCfl@,fl@έC,iW[KפέCoͲvC"	@60mgAɶiA쭹vTC	1.ĳPɪAΥʻۿE2.AδʴTĥ̪o@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Raloxifene	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	wΪvgk貨Pg	ΥihέŪ̸TΡC	λLj	ΥihέŪ̸TΡC 	ΥihέŪ̸TΡC 	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_K2 [2]_K2 [E]_EX12-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.4._20241001.pdf"">OI` 5.5.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.4.,5.6.1."	0	OIs 20251124	OEVIS-a	OEVIS-b	OEVIS-c	110.6.16
BC15152100	G03XA01	qo_n	OLADO	ĵ Ectopal 200mg/cap(Danazol)		Danazolɧʸ誺U骺XUcCiΩvlc´iv}ʪũлêA]AֺʨũЯefAo|ũЪΤjA]iΩvǩʦޤ~C	"1. H: lcΨũмWjHA̱˶}lAήɳ̦nO@Ѭ400 mgAݭnpөwA uqΥ[q(200-800mg ⦸A)CvӤ륪kΪ챡píwC
gLhfHӨA @ѪAά100-400 mgOĪAFָglCѪA200 mgOC
̫ĳ Danazol v令~kӦbggĤ@ѽվζqA YQnȮɰgA oخĪGK৹CbHXӤ뤤tXfHĪGi@BվC
2. ൣ : CKoʹLHA@ѪAά 100-400 mgAfH~֡B魫ζEĪGөwC"	"ץ : M DanazolƧZĪGA]MহĥHFץ\ġAbAδ]ϥΫDXkӨhC
]Danazol i|ް_Yص{תGdAfHbYرpUi|YǦ]AѦpŦεŦêBwBYhvTA]ݭnJӪ[C
xŦणfHݯdNĪϥΡC
Danazol i঳Wjܾ徯@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Danazol	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	lcgBoKoʡBnCʨŸBŸΤjBź|BgLhBֺn~ʨũЯew	DanazolӵhkAΡC	gByBXBũYpBCʼBYhC	"PL/SmҦw
DanazolӵhkAΡC~ϥΥiɭPLಣͶʮĪGC"	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668730?cesid=1eGvrW35tZM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDanazol%26t%3Dname%26acs%3Dfalse%26acq%3DDanazol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.09.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.2.1._19970101_000.pdf"">OI` 5.2.1.</a>              "	OI` 5.2.1.	0	OIs 20251124	DC	DC	DC	114.09.15
BC24622100	G04BE03	0	OREVA	Revatio 20mg (SILDENAFIL)		sildenafil|W[ͦޥƦٲӭMcGMPAϨPCbͰʯ߰w̡AoiɭPͦާɤ`޵αiA̪{פC	20 mg TIDDeGFR<30ml/min/m2AChild-Pugh A.BšAνվ㾯qD	ĳൣϥREVATIOAרOϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCAuBee\xs15XC-30XCC	sildenafil 20mg	G04B	c UROLOGICALS	0	HͰʯ߰(WHO Group I)vHﵽBʯOC	"X֨ϥΥ󾯫vQ(NTG)w̡AL׬OWߩʩζʦaϥΦvQA]oͧCI|ɰ
wSildenafilοB`gΤfAaG󦨤LӪ̡C"	BmBٵhBıê			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_6-03 j	Ts111.5.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.2.2._20130801_000.pdf"">OI` 2.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.2._20250601.pdf"">OI` 2.8.2.2.</a>             "	"OI` 2.8.2.,2.8.2.2."	0	OIs 20251124	OREVA-a	OREVA-b	OREVA-c	111.5.27
		0	OCIAL	Cialis 20mg/tab		"Tadalafil O@ӨܩʡBifCTֿ}? (cyclic guanosine monophosphate, cGMP)-SwC?Ĥ(phosphodiesterase type 5,PDE5)CʨEy@ƴ(nitric oxide)XɡAtadalafilPDE5@γy餺cGMP@׼W[AɭPƦ٩PMyyJӫk_CYLʨEAhtadalafilS@ΡC"	"@ӨARQhĳq 10 @JAbwʦ欰eAΡAiP_
vTCfHA tadalafil 10 @JoAĪGɡAi 20 @JCܤ֦b
欰e 30 AΥġC
Aĳ̦h@Ѥ@C
Tadalafil 10 @J 20 @Jnbwʦ欰eAΡAĳCġC
Yǥ\णfHĳ̤jq 10 @J C"	"bҶqĪveANfvΨˬdHTE_k_\ê٦XPf]C
}lvk_\êeAvfVfHߦުpO_AXϥεRQhA]ʦ欰ŦYص{תIC
fHPɪA tadalafil MĪi|ް_UC}lCѪAtadalafil vɡAfHA{ɵAiݭnվ㭰ĪqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsCOs]ˤC	Tadalafil	G04B	c UROLOGICALS	0	vk_\êC	"UCߦޯeffHϥ tadalafil TҡG
-b̪ 90 Ѥߦٱ몺fHA
-íwߵhδbʥɵoͤߵhfHA
-b̪ 6 Ӥw̯ìŦ|ŬĤGũΥHWŦIܪfHA
-fH߫ߤBC(<90/50 @̨EW)AΥ
A
-̪ 6 Ӥ릳fHC"	"AεRQhvk_\êΨ}@ΤjgfHA̱`}
iYhBƤ}BIhΦ٦׵hA}oͲv|H۵RQhqW[
W[C}iȮɩʡA@ӨLΤתCAεRQh@Ѥ@
fHAjhƪYhiOoͦb}lv1030ѤC"	RQh(tadalafil)AΩkʡCwhkʨϥεRQhAثeõLB}nӲժ{ɸC	RQhAΩkʡC| tadalafil O_|QcܤHťġC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_6-01 [96]_6-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OCIAL-a	OCIAL-b	OCIAL-c	110.6.16
		0	OVIA1	Viagra 100mg/tab(Sildenafil)		~@Φb骺Ʀ٤WAܩʪ_phosphodieastase 5(PDE5)AӴcyclic GMP@סAPϮަ٦PAϦGRJyuk_v{HC	"1. jfHAĳH50mg}lAΡAiW[100mgAδ֬25mgC
2. UCfHyH25mg}lAj65fHAxwƪfHAǥ\णnfHAΨ֪AΧĪfHC
3. fH̦nbŸβMHAΡACѭA@AAīᥭ1pɫ|oͥ\AǯfH2040N@ΡA@ӨAAī304pɬO̾AXiʥͬɶC"	"1. fHY߱YAAYDC
2. ּƯfH|ȮɩźE{A]̦nקK}C
3.pGAεvƥ̪oŦfĤSPɪAΥ~AiϦMUAӳyPRgΥJC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Sildenafil	G04B	c UROLOGICALS	0	"1.צީʶC2.gʶC3.ߦ]ʶC4.VXʪk_\êC5.}fް_ʥ\êC
~kʫk_\êC"	"1. 糧󦨥LӪ̡C
2. i֥Υnitorglycerins(]A`gBޤUBQζK)ΨLvQ(pisosorbide saltsBsod. nitroprussideamyl nitrate)C
3. 󭫫רx\lΧC(C90/50mmHg)B̪񴿦ΤߦٱοǰhƩʵf(pretinitis pigmentosa)w̡A]wʩ|TߡATϥΡC"	(1)10%fH|PıYwYhC(2)3%|uȩʪODApOҽkAάݨŦκ⪺wC(3)MUAYPvƥ̪ovŦfĪ֥ΡAiygΥJC(4)GzABߡBæRC(5)y	iw/SmҦw	iw/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_6-12j	Ts110.6.16		OI` 	0	OIs 20251124	OVIA1-a	OVIA1-b	OVIA1-c	110.6.16
BC26217100	G04BD12	0	OBETM	Betmiga P.R.25mg/tab(Mirabegron)		Mirabegron]3ǤW@ξAgƣ]3ǤWAϱoG٥Ʀ٦bH֥R-ƧgxsܱoPAqӼW[H֮eqC	"׵ǥ\णw,רx\णw,C龯qiWL 25 mg @Ѥ@,bĳqUiHΤHA, wibi"	"1. iH\ΪŸAΡAHɧ]AAiZHBΩHC
2. BetmigaOzP-glycproteinAYPdigoxin֥ζʴdigoxin夤@סC
3. BetmigaiɰCĳwqASOOw̡C 
4. ĳBetmigaϥΩ󥽴ǯfw̡Aέרx\णw̡]Child-Pugh Class C^C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC 	Mirabegron	G04B	c UROLOGICALS	0	v񦳫槿BWM/Ϋ止ʧTgHֹLʯgC	Betmiga TϥΩwmirabegron ο󤧦LӤfHC	ߡBYhBBmBKBYwB߳չLtC	קKϥΰDvn/|qLť	קKϥΰDvn/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669058?cesid=aoI8pBwnJgL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMirabegron%26t%3Dname%26acs%3Dfalse%26acq%3DMirabegron"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.3._20150201_000.pdf"">OI` 1.6.3.</a>              "	OI` 1.6.3.	0	OIs 20251124	DC	DC	DC	110.6.16
BC23568100	G04BD07	0	ODETR4	Detrusitol SR 4mg(Tolterodine-Tartrate)		"~OwvʡBM@ʪAQxPܾAb餺礤H֪ܩʶWLGC~Nª@(5-hydroxymethyllͪ)㦳MlĪۦĲzʡC
bN¥\}n̤ANªtdDnvĪGC
wb|PovĪGC "	"Fx\lHYŦ\l]GFR30ml/min^fwĳqOC2mgB@Ѥ@~A@몺ĳqOC4mgB@Ѥ@CխYBzƧ@εoͮɡAiHNqѨC4mgB@Ѥ@խܨC2mgB@Ѥ@CĮĽniHΤHAΡC]AC 
ӤᥲҼ{i@BvݭnC"	1.ηNAקK}ΦMIʾާ@C 2.iް_f	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(C25XC)C 	Tolterodine tartrate	G04B	c UROLOGICALS	0	v񦳫槿BWΫ止ʧTgHֹLʯg	GdBUCAHι糧LӪ̽ФŨϥΡC	fBƤ}Mֲ\GcC	"|L{ɸC]hAtolterodineuΩ骺qB
jLiधMI{ɪpC"	"ϥtolterodineɥקK¨šA]|tolterodineO_|cܤH
ťĤC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r05-04 [E]_A4-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.3._20150201_000.pdf"">OI` 1.6.3.</a>              "	OI` 1.6.3.	0	OIs 20251124	ODETR4-a	ODETR4-b	ODETR4-c	110.6.16
AC44572100	G04BD02	0	OFOXA	Foxate 200mg/tab(flavoxate)		"iHcʹ޹DƦٵoj\AiΩ󯫸gWACʫeCACʻH֪
WAݧPC"	200 mg TID~QID	"AīAקK}ΦMIʾާ@
1. acʹ޹DֵoPVfwA~өMܷPVĪftv
 2. CwV
3. ާ@αqƩ󶷥e`u@ɡASO`NAĥiް_ΤεOҽk"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иmKAץeAJ30JHU	Flavoxate	G04B	c UROLOGICALS	0	gWBCʫeCBCʻH֪WBݧP	"UCfҪ̤ŨϥΥġG
@(1) 糧~ӷP
@(2) ժΤQGzAz뵥efw
@(3) GzX
@(4) UDcefw"	".æR(GA{Hiw)Yh.Yw.fγYB.(
@CζqδCAĪơA{Hiw)OҽkAiOW[A߸[t
@߱{HAq|yKC"	iw/קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C3 [2]_C3 [ws]_w31-05 [s]_141 [®]_141 [UDx]_U03-06 [E]_B3-19 j	Ts110.6.16		OI` 	0	OIs 20251124	OFOXA-a	OFOXA-b	OFOXA-c	110.6.16
AC36657121	G04BC	0	OKCIT	K-Citrate granules 5mg/pk(660mg/g)		PƾAۧΦA֧ĨIC	C4AC1](5g)AH180 mLΪGĲVXᶺκΫeAΡC	"1) ~t@׹[Aĳ[}AΥHָzGDˮ`AAΥiֽwm@ΡC
(2) C]ХH180 mLΪGĲVXAΡC
(3) AΥ~ЦhܤC
(4)Yǥ\णfHjqϥη|ް_[PrfHD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Potasium citrate	G04B	c UROLOGICALS	0	Pƾ]Ω󶷪OPʤXpDۡBǤpީʻĬrg^C	糧~LӪ̡ATϥΡC	ߡBæRBhBmC	קKϥΰDvn/קKϥ	קKϥΰDvn/קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G2 [2]_G2 [ws]_w35-01 [ws]_w65(2) [UDx]_U01-56 [E]_C3-07 [Ew]_EX101 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.4.2._19950301_000.pdf"">OI` 2.4.2.</a>              "	OI` 2.4.2.	0	OIs 20251124	OKCIT-a	OKCIT-b	OKCIT-c	110.6.16
AC49153100	G04BD04	0	OOXBU	Oxbu Extended-release 5mg/tab		"XxPEʾA@ΩH֤Ʀ٤WAϨ䤣|Muscarinic actionA(1)~iW[CƧɪqAӴֱƧơC(2)iקKnYAӴ檺hWC(3)iXjH֪nAקKnY
"	~YCAΤ@C~ĳ_lqC5@JCiHCW[5@J覡ӽվ㾯qAHbĤέ@פF@ӥš]̤jqC30@J^C@ӨAqվ㶡jCӬPCൣϥΡGĳlqC5 mgCiHCW[5 mg覡ӽվ㾯qAHbĤέ@פF@ӥš]̤jqC20 mg^C 	"1.UCw̨ϥΥĶSOpߡAХivG]`xBGDfyBgٵLOBƧxBxǯefBzGDDpKBzθz뵥C2.ĥiɭPX֡AvקKBLҩάOBʹLסAHKC
3. ~ݦbG骺UU]AACZBH~C 
4.ī~gsLrpΨϥξɤvTA]xPĪAi|yI]ݯv^εızZAifHnpߡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUC 	oxbutynin	G04B	c UROLOGICALS	0	v񦳫槿BWΫ止ʧTgHֹLʯg	"1. w糧~DΨ䥦|LӪfHC
2. dBGGdΨ䥦YGzįʭCpBUCΦioͳoǱpfHC "	fBKBmBߡBıҽkBBBYhBΡBֽLӡC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E2 [2]_E2 [ws]_w41-02 [UDx]_U03-40 [E]_B5-01 j	Ts110.6.16		OI` 	0	OIs 20251124	OOXBU-a	OOXBU-B	OOXBU-c	110.6.16
NC017831G0	G04BX06		OUROG	Urogen 50MG/S.C.TAB		i߽ӭMͧ¾K@ΡC	HC100mgATIDApľq50mg TIDuCpYӵߩʤֵogPVɡAoPܥͯDiĵܵ߾֥ΡC	"1B~iiϥΡC]קKInɭPۦ^
2BAΥAG|eζŦC
3B֪`Nǥ\
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H15-30CǷŤUxs	Phenazopyridine	G04B	c UROLOGICALS	0	H֪BǪBDBcʹ޾߽h	"YxAYǥ\णҥΥ~D
糧LӪ"	ߡBhBƤ}FYwBYhBoNFֽβܶFֽ_lFyBB}~ȵC	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668440?cesid=2347Op1SOVh&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPhenazopyridine%26t%3Dname%26acs%3Dfalse%26acq%3DPhenazopyridine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-01 [s]_340 [®]_340 [E]_A3-14 j	Ts110.6.16		OI` 	0	OIs 20251124	OUROG-a	OUROG-b	OUROG-c	110.6.16
BC23952100	G04CB02	0	OAVOD	Avodart 0.5mg/cap		"DutasterideO5-alpha-reductaseAtdATଡ]testosterone^ܬ5-alpha-dihydrotestosterone(DHT)Ĥ@βĤG5-alpha-reductaseP\c?Ҧ@ΡCDHT@ضʿEADntdeC骺WޡC  
"	ĳqߤ@ѤfA@n]0.5mg^Cnݾ]AC~iPΤP@_A Cǥ\णΦѦ~w̤ݽվ㾯qC	~igѥֽlA]kΤpקKĲlnA]i]ӧldutasterideAӥBkʭLiyLಧ`MICYĲlnAߧYHΨmΤM~ĲBC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~xs30CΨൣ⤣ΤBC	Dutasteride	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	v㦳g@Τjg CӦwѬgA CʧdoͲvA@ΤjgNnʤĪG	"~TΩ:
1.wdutasterideBL5-reductaseλsL@ئLӪ̡C 
2.~TΩkΨൣC"	תk_BʼCC	DutasterideTΩkChkSbdutasterideUA餺夤dihydrotestosteroneqAi]ӧkʭL~ʹ޾o|C	"AVODARTAΩŰkA|odutasterideO_|cܤHťĤC
¨
i"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 [ws]_w28-02 [E]_B3-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.2.2.1._20191201_000.pdf"">OI` 5.2.2.1.</a>              "	OI` 5.2.2.1.	0	OIs 20251124	OAVOD-a	OAVOD-b	OAVOD-c	110.6.16
AB57206100	G04CA02	tyqn0.2@J	OHARN	Tamsulosin SR 0.2mg/cap		"Tamsulosin ܩʤvʦaPĲ᪺ \1Pg鵲XASOO \1A \1DȫADn@ΩPHVH@¶?D쪺٦ױi?AiPϱ???W[C\1B ȫ`?ޥ?٤WA]terazosin Pdoxazosin `
Ω󰪦v?C"	"q`AH1 1 A󶺫fAPTamsulosin Hydrochloride 0.2 mgCYĤΡA~W[0.4 mgC
C̤jϥξq0.4 mgC
ﰪ֪̪P
ѩ֪̦ɦǥ\CUΡAǥ\CU̥0.1 mg }lPAgLR?~Wq0.2 mgCP0.2 mg vӵLkoҹwĪGɡAФŦAWqAyĦLABmC
AήɡGЫɱw̤űNnɫrHαNn}AΡC(tamsulosin HCl wɥRwnAGi|ĪʺA)"	"(1)PϥΨL\1,Pgܾ@ˡAӮצbϥtamsulosin vAi|oͦCAɭPioͩ֡]u^AX{թʧCxɡ]YwBLO^AwӧUνUgCifw}lϥtamsulosin vAקKioͩ֡AɭP˪pC
(2)ϥΨC̤jϥξq(0.4 mg)ɡAקKioͩ־ɭP˪ΡC
(3)vYǥ\णw(ٻMv<10 mL/min)ApߡA]|ow̪{ɬsC
(4)@ǥbϥΩΥHeιLtamsulosin vw̦biդ٤NoͭiPgԸs(Intraoperative Floppy Iris SyndromeA²IFISA@YgԸsf)CiPgԸsi|W[NL{X֯gAwwƭnդ٤Nw̡AĳϥtamsulosinCiդ٤N1-2 gAϥtamsulosin O{UAbդ٤NeĮɶuPUqʡA|TߡC
bNeA?٤NvMζAӦҼ{wwƥդ٤Nw̬O_bϥΩΥHeιLtamsulosin vAHTONoͭiPgԸsɯĨAIC
(5)Tamsulosin DngCYP3A4 PCYP2D6 sxN¡AĤiPCYP3A4 jħ]pketoconazole)X֨ϥΡC
(6)ЯdNĤvëDf]kAӬOgkAGbPĦpLkoݪĪGɡAЦҼ{ĤNkLABmC
(7)oͯtwΡAGqưB@~B}񦳦MIʪ@~ɡA[`NC
(8)ħP}lɡAEfwLPAPɡA`NܤơAX{CUɡAĨqΤPABmC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOsǷ(25JHU)ΤpıĲ줧BC	Tamsulosin	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	eCΤjg(W)ҦHƧê	"tamsulosin ι糧ĥξLӪ̡C
թʧCfvw̡C
Yx\णw"	tw]߮YwBYhBݯv^BGַP]ߡBæRBfBKBGPBGhBBUgB]`ê^	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668553?cesid=66t8doguZlD&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTamsulosin%26t%3Dname%26acs%3Dfalse%26acq%3DTamsulosin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w52-04 [s]_305 [®]_305 [UDx]_U03-55 [E]_C2-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OHARN-a	OHARN-b	OHARN-c	110.6.16
BC25413100	G04CA02	0	OHARN1	Harnalidge OCAS 0.4mg/tab(Tamsulosin)		Tamsulosin ܩʤvʦaPĲ᪺ \1Pg鵲XASOO \1A \1DȫAϫeCMDƦPC	_lq  tamsulosin 0.2 mgACѤ@AYήɡAqiW[ Harnalidge OCAS 0.4mg @Ѥ@ɡAfAC Harnalidge OCAS 0.4 mg yŸϥΡA]|W[ļSqC ĥɧ]AAiiHΩCZA]|zZĦĮġC	X{թʧCx(YwBLO)AwӧUνUgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Tamsulosin	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	}ʫeCΤjgҦHUcDgC 	"1. tamsulosin hydrochloride ι糧ĥξLӪ̡C 2. թʧCfvw̡C
3. Yx\णw̡C"	YwBgêBթʧCBYhBGAPC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w52-03 [s]_149 [®]_149 [UDx]_U03-46 [E]_C2-05 j	Ts110.6.16		OI` 	0	OIs 20251124	OHARN1-a	OHARN1-b	OHARN1-c	110.6.16
		0	OPROP	Propecia 1mg/tab(Finasteride)		"1. FinasterideO@زĢ5\٭?vʱM@F٭?O@إiNEATƦGBAT(DHT)ӭMïCbH餺AĢ5\٭?jhsbֽ(]AY)֯׸ΨxŦA`GBAT(DHT)T@OzLĢ5\٭?@ƦӨӡCĢ5\٭?P\ïhDno{@BnBƸABnHΨxŦA`GBAT(DHT)TGOqLĢ5\٭?@ƦӨӡC
2. bH餺Afinasteride@ξDOĢP\ïu@ΡAbϥΤѵM´(Y֤@)~XsAfinasterideoئP\ïOAGܡAHĢ5\٭?ܩʶWLĢP\ï100CbfinasterideoئP\ïͧ@ΪPɡA|Q٭즨dihydrofinasterideAӳoئP\ïh|PNADP?ΦƦXCïƦXഫtvwCeĢïƦXbI(t?)30ѡAӲĢïƦXh14ѡfC
3. FinasterideﶯEä˩MOA]󪺶EEʡBܶEEʡBۿEEʡBܻۿEEʡBΧUE@ΡCĢ5\٭?@η|_NATƬGBAT(DHT)@ΡAPϦMβ´GBAT(DHT)@۴CCFinasterideiͨϦMGBA(DHT)@קֳtC@ΡAfA뤩@1i24pɤF65%ĪGC
4. PhvY֬ۤAʨr(ʿEyrYAandrogenetic alopecta)w̡ArvY֤nY{HABGBATସCow̧뤩finasterideiCY֤ΦMGBAT(DHT)@סCoǭC{HPfinasterideY|TߡCѩʩwʿEyrYHAfinasterideGiǦ_ΦʿEyrY]lC"	"ĳq@Ѥ@AC1C~iP֪AΪŸAΡC@ӨACѪAīTӤHWA~|ݨBġAĳϥΡAHįqC_vA|b12Ӥ뤧쥻ĪGC
1. LamivudineiWλP@_AΡC
2. HIVPVGXzidovudinevC
a. H12HWC֦~AB魫50HWA@ѤGAC150 mgCH魫<50A@ѤGAC2 mg/kgF魫<50C֦~AʥFĳqơC
b. ĵ3Ӥ12G@ѤGAC4 mg/kgF̤jqG@ѤGAC150 mgC
c. CBxPVG16HWA@Ѥ@AC100 mgC
d. ŦlG16HWAĳqվpUG Clcr (mL/min) ϥΩHIVPVĳվ㾯q ϥΩHBVPVĳվ㾯qF50G @ѤGAC150 mg @Ѥ@AC100 mgF30-49G@Ѥ@AC150 mg _lq100 mgAM@Ѥ@AC50 mgF15-29G_lq150 mgAM@Ѥ@AC100 mg _lq100 mgAM@Ѥ@AC25 mgF5-14G_lq150 mgAM@Ѥ@AC50 mg _lq35 mgAM@Ѥ@AC15 mgF<5G_lq50 mgAM@Ѥ@AC25 mgA_lq35 mgAM@Ѥ@AC10 mgC"	"1. ~äAΩൣfwΰkC
2. x\ಧ`w̡Apߧ뤩~A]finasterideDnObxŦN¡C
3. wghΥihkIĲHί}lfinasterideA]i|lӳykʭL઺bMIʡC~Ц@hAb}lHpUAiקK󥿱`ާ@ɱĲʦC
4. ihkʦQAΥ~A]izLGlk骺{ץC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H15-30CǷŤUxs	Finasteride	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	ʨr(ʿEyrY)C	"1. TΩ糧s󦨥LӪ̡C
2. hĦwݩXšC]gĲNī~γzLʦQGӧlī~{ץAΥihkiĲNHPropeciaABiĲʦQGAΨʦQΥġAHK]lӳykʭL~ʹ޾`C"	ʼCAk_\HήgêAݳĲhεȤjFLӤ(]A֯lBkoBClBHήBPy~)FAYkhC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OPROP-a	OPROP-b	OPROP-c	110.6.16
AC58838100	G04CA04	0	OURIE	Urief 4mg/tab(Silodosin)		Silodosin ǸgѤUcD´(eCBDMH֤T) a1A-adrenergic receptor subtype @Ϊ_PgtζǾɡAyCUcD´Ʀ٪iOPDAӧﵽeCΤjgҦHƧêC	q`AHH1 2 A1 4mg 󦭱\fAP~AåB̯fwgiA־qC	"1. ~}lϥήɡAiް__ߩʧCA]AΥ~Aw̾rpBާ@αqƸMIu@ɶpߡC 2. ׵ǥ\ê̡Asilodosin 夤@פW@iAվ㾯qC 
3. Yx\ê(Child-Pugh score10)ϥΥ~{ɬsA]~TΩYx\ê̡C
4. TPjCYP3A4 (pketoconazoleBclarithromycinBitraconazoleBritonavir)֥ΡC
5. ~PL\-_Įĥ椬@αΩ|TwCO椬@άOiHwC]SilodosinөML\-_֥ΡC
6. ϥΥ~eAХ߰ݯfwLAέAYAΪ̡Apߨ֥ήɪܤơAYoͰ_ߩʧCɡAЭCqΰΥ~ðABmC
7. eCΨ}ʫeCΤjg``ۦPgA]}ʫeCΤjgw̡AݽTˬdHưeCiʡAAϥΥ~C
8. NiPgԸs(Intraoperative floppy iris syndrome)b@ǥAΩγNeAΣ\-adrenergic receptor_fwiդ٤Nɷ|o͡CAΥ~fwQiAYiդ٤NݧivAΥ~ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOsKeBץB25XC HUΨൣ⤣ΤBC	Silodosin	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	eCΤjgҦHƧê	"1. w糧~LӾvw̡C 
2. Yǥ\ê(CCr <30 mL/min)C 
3. Yx\ê(Child-Pugh score10)C 
4. PjCYP3A4 (pketoconazoleBclarithromycinBitraconazoleBritonavir)֥ΡC"	`Ƨ@άgêBfBUgBnKC	iw/SmҦw	iw/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w51-06 [s]_346 [®]_346 [UDx]_U03-62 [E]_B5-27 j	Ts110.6.16		OI` 	0	OIs 20251124	OURIEa	OURIE-e	OURIE-c	110.6.16
BC25021100	H01BA02	0	OMIN1	MINIRIN Melt 60 gg		MINIRIN? MeltҧtdesmopressinO餺Xarginine vasopressinP\CѵMXgBƾǧܡAYbcysteineg@Ρ]desamination^AñNL-arginine令D-arginineAcܫA{ɪܧQ@ήɶAb{ɾqWϥΧh[]pressor^@ΡC	"ϩʧYgG120 gg~720 gg/day(ޤU)C
oʩ]gG120 gg~240ug HS(ޤU)Av3Ӥᰱ@PO_~vD
]gG~240ug HS  (ޤU),GD"	"b}lveݭnҼ{fHO_YH֥\णMƧêC
                                                                                                                                                                                                                                                                bvoʩ]򧿩M]ɳ̦nbīe@pɨīKpɶNG骺q̧CC
                                                                                                                                                                                                                                                                pGo餺dMΧCugxίgYhB"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"iWL25JC
Osbl]ˤץC"	Desmopressin 60ug/tab	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	ϩʧYgBoʩ]g]Ω6HWfH^BH]]hҾɭP]gAY]GqWLH֪eqC	"ߺDʩκ믫ʤfgfH]ɭPGͶWL40 @//24 pɡ^F
- whæߥ\णfvMLdAݭnΧQ̡F
רYǥ\णfH]ٻMvp50 @/^F
- wCugfHF
- ܧQEcgԸsfH (SIADH)F
- desmopressin ΨL᫬LӪ̡C"	"Cug (6%)BYw (3%)B (2%) έGzDef ( (4%)BæR (1%)Bh (3%)Bm (2%)BΫK (1%))C
Cugiް_YhBhBߡBæRB魫W[BYwBVáBwBOЮtBwtB^˩MYרҵj˩MgC"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 [ws]_w26-02 [E]_B2-21 j	Ts111.9.29		OI` 	0	OIs 20251124	OMIN1-a	OMIN1-b	OMIN1-c	111.9.29
		0	IDURA1	ĵDuratocin inj. 100mcg/ml/amp		"wbw~ί¾KU帡lcYFOcarbetocinOĪoxytocin@ξC󲣫᪺lcAcarbetocinW[lc۵MYtvMOqCIcarbetocin|t}llcYAb2ojOYC
XͫAPݭn`XpɪoxytocinۤARߪ`g@100LJcarbetocinNHAתlcYAiHlcFOMjqXC"	X1@ɤt100LJcarbetocinDURATOCIN?AuRߪ`gAݦb|AʷUICb帡XͫIC@DURATOCIN?HWL 1 tסACCICͲn֬IA̦nbLLeCDURATOCIN?uI@AAIhcarbetocinC	"bXͫe@{AyϥcarbetocinA]@q`gAlcY@η|XpɡCoM oxytocin`AĪ@η|ֳtC{HC
pGIcarbetocinlc٬OXAnXX媺]CnҼ{]GLL´ݯdBlcMΤlc״_Bξ岧`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m󢲢JHUץJsC	Carbetocin	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	wbw~ί¾KU帡lcYFO	"XͫehMͲ}hC
- CarbetociniΩ޲]induction of labor^C
- carbetocinBoxytocinΥ@ξLӡC
- xŦefεŦefC
- YߦޯefC
- wC"	YhAŸݡACAAߡAhAkoAPıo	hTϥcarbetocin޲	Carbetocin@`gAֶqcarbetocin]ũMťĤA᭹@{|QzDïѡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-03 [w]_w06-03 [E]_D2-04 j	Ts110.6.16		OI` 	0	OIs 20251124	IDURA1-a	IDURA1-1-b	IDURA1-1-c	110.6.16
BC20824209	H01BA02	0	IDDAVP	MINIRIN 4UG/1ML/AMP(N)		"desmopressinO餺Xarginine vasopressinP\CѵMXgBƾǧܡAYbcysteineg@(desamination)AñN L-arginine令D-arginineAcܫ, {ɪܧQ@ήɶAb{ɾqWϥΧh[(pressor)@ΡC"	"vϩʧYgG
@릨HC 1-2 AC 1-4mcg (0.25-1 ml)A@HWൣC 1-2 AC 0.4-1 mcg
 (0.1-0.25 ml)Ap@ൣC 1-2 AC 0.2-0.4 mcg (0.05-0.1ml)C
ǯfwwgϥ MINIRIN? Q󾯱A]Q󾯪lΩΦ]ݭnʤNAN
 Ϊ`gCĢܧQqA`gQ󾯪 10MC
iW[פΤצͯfwĤK]l@פΧﵽĪɭPpO\ê:
魫C 0.3?g HͲzQ} 50-100mlAR߿`F 15-30 HWA
 Y[ߤĤK]lFzQ@סAi 6-12 pɶAƵ 1-2 Wzl
 qC"	" Ωǥ\ɡAtĵiƶG
- bĪe@pɦܵī 8 pɤAiWL 0.5 ɡAΥHѴC1 
HUw̦b@ɡA|޳NHpߪC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"BcNöJsA2-8CC
Ƿ25CHUsA̦h򢳩PABiA^BcJs."	Desmopressin	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	ϩʧYgBiW[פΤצͯfwĤK]l@סBĪɭPpO\êC	"MINIRIN? iΩUCw̡G
w ߺDʤκ믫ʼ@w
w LNvOŦ\णw̤ΦAΧQw
w U߯g
w Nvʤ߾ण
w IIB  von Willebrands disease"	YhBh¡BߡBkhC	"Tҿ}f˩hA desmopressin ӲͷΨ઺iCܥثew 120 ұ
 desmopressin vkU`઺iC 29 ҩh{S desmopressin 
 AõLͷΨ઺iC "	qQ¨ŰkAGಾܤpĪqܧCACvThһݪqC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-21 [E]_K-05 j	Ts111.2.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.4._20140401_000.pdf"">OI` 4.2.4.</a>              "	OI` 4.2.4.	0	OIs 20251124	IDDAVP-a	IDDAVP-b	IDDAVP-c	111.2.21
AC33429238	H01BA01	0	IPITR	ĵPITRESSIN 20Units/1ML/AMP		~W[ǤpޤWֲ´zLvAӼW[ݵǤpޤAlAiHCyclic AMPCѩ󥻫~[j޻PDޥƦ٪YA]Ӵ֥骺yMGzActΤΤlcƦ٪jˡCaʯߦަY|[jΨϯU߯g[cơC	"1.(NzDwεzn)w_IMSC`g5UAݭniW[10UAC3~4pɥil[@qCΤNe4pɹwʧ뤩20UC
2.XguvNwbve2pɩMbpɡAIM 10U(ĳ`gez)FǪv15-20eSC 10UC
3.YgwIMASC 5U㢱0UApC4-12pɵġC
4.DRߦiXwIV infusion  20U Pitressin+100-200ml D5S 10-20minCpQ1-2hƵġA̦h. "	"wAYhAݡA߰IܡAΥ@زӭM~ֳtW[|wtLtγyMIAC
~TΩ󦳦ޯefAרOaʯ߯efw̡CYbϥvasopressinoͤߵhAiΦޤUNTGC
Vasopressiniް_rA`NrfxApݺΡAS믫YhAHoͥgεjˡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥ	Pitressin	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	DRߦiXAYgANḡȡAưv	"糧~Ψ䦨LӪ̡CẢdCʵǪw̡AbF@׫eATVasopressinC
"	jˡAߡAæRAAfĩPaաA߫ߤA߿Xq֡AߵhAߦٯʦAPަYA utaneous gangreneAoAC¯lAwtAYwA_ŸD	ubvįqjMIʮɤ~ϥΡD	ubvįqjMIʮɤ~ϥΡD	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U06-02 [E]_D2-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IPITR-a	IPITR-b	IPITR-c	110.6.16
AC33873229	H01BB02	0	IPITO	ĵOxocin inj 10IU/ml/amp(oxytocin)		ĤlcGWjlcYOA[֦YWvC䦬YjרMҥξqΤlcͲzACpq[֮c`ߩʦYAQLYXCjqް_lcjʦYAΩ󲣫C	"Ω󻤾ɤYSC/IM 3IU(0.3ml) Q20-30minA10IU[b1000 D5WNS A15w/
Ω0.6-2IU(0.06-0.2ml)[J3-5ml NS wCRߪ`g"	" HUΪ̡A[lAAlcYΡG
1.æL~
2.?WrAߵǦ޻ê̡D
3.æYLšAҤ}NAμsxlcN̡AemLLέL첧`D
4.nDjgAֲAWD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	oxytocin	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	ʲδֲX	oxytocinƦXLӪ̡DYLšAemLLA`LLALj}hAlc}AL~	"a.JG沧`XAФϥΡC
b.lcGLj}hBlc}BV޵ˡBϤgBLz}hBwX嵥{HC
c.LBsͨGL~AJ[AsͨniC
d.`tGߡAR`ᦳUΦWɵ{HC
e.ƨtGߡBæRC
f.LӯgGLӯgX{AΤrgC "	קKϥΰDvn	iw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)GSC/IM 3IU(0.3ml)
q(MD) : 1A in 1000ml l(10U/mL)30-60mU/hr(3-5ml/hr)
}GGD5W  NS
}@סG1amp in 1000ml(10U/mL)
ĳĳtvG30-60mU/hr(3-5ml/hr)
wwʡGߧYϥΡAǷ: 24 hr
ʴءG`ɻݪ`NCUterine activity (eg, tonus, amplitude, and frequency of contractions) and fetal heart rate; during infusion"	ixii[UDx]_U06-10 [w]_w09-01 [E]_D3-05 j	Ts110.6.16		OI` 	0	OIs 20251124	IPITO-a	IPITO-b	IPITO-c	110.6.16
		0	IORGA	Orgalutran(Ganirelix)0.25mg/vial(N)		Orgalutran O@ةʸEE^ܪAiǥvXU餤ʸE?EӱUC-U-ʸbCֳtͩʪʸEAӨSʸ?Eܾ޵ol?EC	"Orgalutran ΥHwbg2 β3 Ѩϥ?w?E(FSH)i?fwoͶ
ΦEpLFΡCOrgalutran (0.25 @J)@b?w?E?
}l`gAĥ֤U`gACѤ@C̥iHbĤѶ}lOrgalutran v?w
ΦELɰCbʥF?wͪpUAOrgalutran v?iHC
Orgalutran P?w?EPɵAMӡAľ?iHVXAӥBϥ?P
`gC
?w?E?Ӯھڵo|?w??PjpөwAӫDGۤGJ
(oestradiol)t?CCѨϥOrgalutran v?ӫ즳?wܾAjpCiH?򽤩ʸE(hCG)o?w̲צCѩganirelix bʹA?Orgalutran `gjHγ̫@Orgalutran`gPH?򽤩ʸE(hCG)`gj?iHWL30 pɡA_hi|o͹LFΦEpC]Ab`gOrgalutran ɡAOrgalutran v?ӧөʸEv?A]Ao?@ѡCbUȪ`gOrgalutranA̫@Orgalutran `gӬObo?e@ѪUȡC"	"Orgalutran Ӹgѥ֤U`gġA̦nObjLCC`gӨ?PAH
w֤UתյYCfwΨtbAɥHαMaĳUi?i?
Orgalutran `gCOrgalutran Ӹgѥ֤U`gġA̦nObjLCC`gӨ?PAH
w֤UתյYCfwΨtbAɥHαMaĳUi?i?
Orgalutran `gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץOsb2 ?30 ?C	ganirelix	H01C	UCPX HYPOTHALAMIC HORMONES	0	wH?E??ʹLFΦEp]LH surge^C	"󬡩ʦνξLӪfwC
? ʸE?E(GnRH)ΨLʸE?E?LӪ̡C
? ?έ?xεǥ\l˪̡C
? hέŰ?C"	Orgalutran i|b`gyֽL(q`OA񦳩?񦳸~)AYhAߡC	bhPŮɨϥOrgalutran OTҪ	bhPŮɨϥOrgalutran OTҪ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-01 j	Ts110.6.16		OI` 	0	OIs 20251124	IORGA-a	IORGA-b	IORGA-c	110.6.16
BC22657238	H01CB02	0	ISAN20	Sandostatin Lar 20mg/vial(Octreotide)(N)		octreotide YѵM(somatostatin) XK`?lͪAoctreotide MѵM㦳Ĳz@ΡAOۧ@ήɶCoctreotide iHͪEHΧѭGzŦctβͤ`?PM(serotonin) fzʹLפcC	"Sandostatin LAR uHv٦ײ`h`g覡ġAv٦ת`gkϥ
1.ϺݪΤjg
Sandostatin LARXIM, 20 mg-40mg Q4W*3monsDCӤ밵@GH IGF1 C
2.vwߴzΤwư쬰DzBӭ줣ƨ}ngcFw
 Sandostatin LARXIM,30 mg-40mg Q4W .b~FLcƴHSandostatin LAR ~FC
3.G- z- ؤc~F
bϥΥĤeiεuĪSandostatin ֤U`gvAq0.1 mgAC3 A2PA[fHέ@ʡD
g֤U`gSandostatin go}nw̡Aĳ_C|g`g@20 mg Sandostatin LAR 3ӤAYgΥͤЬoAiH10mg Q4WFYAiW[30mg Q4WAve2ӤAΪvL{AYpA[AiB~W[uĪsandostatinD

"	"boctreotidevAYnhĳͨ|Okʱw̨ϥΦXAץ
k octreotide vwʱҪ\C
Sandostatin LAR |ͪEBɿ}EMخq񲣥ͧ@ΡA]i|vT}ձC
LRB12 fvw̡A ĳbSandostatin LAR vAʴLRB12 ȡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" Цs2XC 8XC ( sBcNë)CбNem~]˯ȲץC
Sandostatin LAR `giȮɦs25X C HUҤCMӡAЦbni`gɤ~saBGC"	Octreotide	H01C	UCPX HYPOTHALAMIC HORMONES	0	ϺݪΤjgA\ʭGBzBŦc~FCvwߴz(midgut) ΤwưDzBӭ줣ƨ}n(well-differentiated) gcFw̡C	"woctreotide ι糧s~ξLLӪ
"	"GzDABgtλêBxxաBHΥN©MiաAmBhBߡBGzȮBYhBxۯgB
}MKcC

"	Sandostatin ubnpU}Ĥ赹hk	w̦bSandostatin všC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-33 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.3._20201222.pdf"">OI` 5.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.4._20150401_000.pdf"">OI` 5.4.4.</a>             "	"OI` 5.4.3.,5.4.4."	0	OIs 20251124	ISAN20-a	ISAN20-b	ISAN20-c	111.8.19
BC17873209	H01CB02	0	ISAND	SANDOSTATIN 0.1MG/1ML/AMP(N)		octreotide YѵM(somatostatin) XK`?lͪAoctreotide MѵM㦳Ĳz@ΡAOۧ@ήɶCoctreotide iHͪEHΧѭGzŦctβͤ`?PM(serotonin) fzʹLפcC	"ϺݪΤjgXSC/IV, 0.05mg-0.1mg Q8H.C˴GHAIGF-1( vؼЭȡGGH<2.5 L@J/ @ɡFIGF-1 b`d) MAX 1.5 mg/day.
\ʭGzؤcʸ~F XSC, 0.05mg QD or BID. iW[ 0.2mg TIDbfҤApGHow̤j@qv@gᤴLQX{ɡAhvC
ŦNX֯g 
s7 ѡACѤTAC֤U`g0.1 @JCĤ@iNeܤ1 pɶ}lϥΡC
GBDRߦiX X
HCp25 LJqi5 ѪsR߿`CowiHΥͲzQ}ϥΡC
]wƯgӲͭGBDRߦiXfHAHCp50 LJqi5 ѪsR߿`ɡAow}n@
ʡC"	"boctreotidevAYnhĳͨ|Okʱw̨ϥΦXAץ
k octreotide vwʱҪ\C
Sandostatin LAR |ͪEBɿ}EMخq񲣥ͧ@ΡA]i|vT}ձC
LRB12 fvw̡A ĳbSandostatin LAR vAʴLRB12 ȡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" xsɡAowwxs2 8XCC
ФŧNC
CϥήɡAxs30XC HUAiHOsgC"	Octreotide	H01C	UCPX HYPOTHALAMIC HORMONES	0	NBgukdopamine@ξkLĪϺݪΤjgw̡AigAô֥ͪESomatomedineТѪ߭ȡAѰPGzŦc~FgAwŦNֵ᪺ogAvGDRߦiXιwAX; ϺݪΤjgB\ʭGBzBŦc~F	octreotide ΰt褤զw|o͹LӪfHC	mAkhAߡAKAGzȮAxۯgA`g짽ʤA}LAYh	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-34 [E]_K-06 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.3._20201222.pdf"">OI` 5.4.3.</a>              "	OI` 5.4.3.	0	OIs 20251124	ISAND-a	ISAND-b	ISAND-c	111.8.19
AB13578209	H02AB08	0	IKENA1	TRIAMCINOLONE 10 mg/ml/amp		~@ΤXƵǥֽTJADnΩ󻴭gʯewD	"`Ĥ`gG
10-20mg CP~C1~2DnɥiVX¾KX֪`gD`ĤYhq`GAiN`GXAA`JĲGD``gqG5~15mg p``gqG2.5~10mg n´G1~5mg ֤G0.2~0.4mg"	"1.~tGAHպޤεwὤ~`gġD
2.ĸTΩRߪ`g
3.CʷPVgAϥήɻݦX֪vPVD
4.Gűw̻ݯSO`N
5.}fw̽Ъ`NW[خqζqnʡD
6.믫f]̻ݦh[`N
7.иɥRJս
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Triamcinolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	"`BnBLөʥֽBޮݡBLөʻ󪢡B?HBLөʤεoʲew
"	 triamcinolone ΨLξL 	B~BWɡA֦Ƶǥֽ@ΩΥʰƧ@ΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111/08/18		OI` 	0	OIs 20251124	IKENA1-a	IKENA1-b	IKENA1-c	111/08/18
BC04922277	H02AB04	0	ISOM5	SOLU-MEDROL 500MG/VIAL		"MethylprednisoloneOjħܵoTJAPrednisoloneܵo@ΧnAӥBް_udƧ@Τ]֪Ͷ.
"	"C 8 mltMethylprednisolone 500mg
@ͩRMIUkG
30mg/kg (IV> 30min) q4-6h 48h
é`G
1g/day IV 1~4g
1g/mon @p6Ӥ
wgް_߹æRG
250mg methyprednisolone(ܤ>5min) ftLURĪAe1h,}l,X|ɨϥΡD
ʯˮ`G
vݩlˮ`e8pɡAIV ܤ15min 30mg/kgAȰ45minAA5.4mg/kg `23hD
(`ӧ֥ioͤ߫ߤA`IܡA߷i)
LAgGpޮݡAMfAC¯lAhoʵwƪʥ[@
쾯q(uɶjq)i10mg-500mgA25mg-250mg IV`tv>5minA>250mg IV`tv>30min
iHRߩΦ٦ת`gġAĶj̯efY{צөw."	"1.vѦʥJĤT
2.Yж˪Dk
3.i౻PVp
4.jqֳt`i঳߫ߤA`IܡA߸ID
5.ֽTJϥήɥiX{믫
6.ͫǪA觹zDXNAʩʩμʭGšAŦणAA貨PέgٵLOp
7.ֽTJfVϥΩ󲴳?lfHAiy."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAջsLimǷ(15-30J) 48pɤϥΧD	Methylprednisolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	"ǤWणB@PJBީʮݡBefBLӤBxoʷPV
"	"1.߷PV
2.糧ĦL
"	"ֽӯ,貨P,믫,,ƹDŦX֬եX,bʷPV,}ffHخqΤfA}ĪݨDqW[,PʸfHo{ʤŦIܡAߦٱҤް_߫ǯ}A߫ߤD"	קKϥΰDvn/ֽTJ|qLLL	קKϥΰDvn/prednisolone|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-05 [w]_w02-21 [E]_G2-11 j	Ts110.6.16		OI` 	0	OIs 20251124	ISOM5-a	ISOM5-b	ISOM5-c	110.6.16
AC12474209	H02AB02	0	IDECA	Dexamethasone injection 4mg/ml/amp		"ĬXīTJA@μsxAiध@λPҦʤǤWֽଡ]ۦcTJApiQ-cortisol^ۦPC{ΩܵoΧܹLӡASulΤdʧCAGsΡCܪĪGhydrocortisonej28Aprednisolonej7D
"	"HG
`ĩγn´G0.2-6mg Q1W-Q2W
٦שRߪ`gG0.5-20mg BID 
pġG
IVAIMG0.006-0.04mg/kg QD~BID"	"1. tƵǥֽXAAήɽЪ`NUCƶ:
(1) CʷPVgAϥήɽЦPɨ֥ξAƾkΧܥͯī~HvPVefC
(2) ƺ޻ٮ`pGzšAȽЯSO`NC
(3) ]DnƧ@Τް_B~AWɡAץHŦewΰw`NC
(4) }fw̨ϥήɦW[InsulinĶqn̽Ъ`N
(5) ~tGAiHպޤεwὤ~`gġD
(6) ϥΥġA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUC	Dexamethasone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	ޮݡA`AgֽewAˡA|甆AC¯lAժD	"1.߷PV
2.糧ĦL
"	zGAAܤơAW[A~A٦׵hAOҽkA貨PAvW[C	קKϥΰDvn/קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-06 [w]_w01-13 [w]_w02-01 [E]_C5-08 [Ew]_C1-06 j	Ts110.6.16		OI` 	0	OIs 20251124	IDECA-a	IDECA-b	IDECA-c	110.6.16
AC31695209	H02AB	0	IDIPR	BufenconƤ1ml/amp		 BUFENCON INJECTION 1MLDO@إѷηLbetamethasoneҲզA㦳۳tĤΫʪBvΧܹLӪĪGCǤWֽTJpUʪbetamethasone sodium phoshate`gᨳtQlAYvĪGCbetamethasone dipropionateȷLӺCCQlAണѫʧ@ΡAigF|PΧ[C 	"ʧ@ΡGjef}lq1.02.0@ɡAݭnɥiơAΪkObv``gAqΪ`gƬOfHιvөwC
YefpʯTHήݯfAwgAϳBzA}lq2.0@ɡC
@ΡG]A``gB`P`gBn`gB֤`gγжˤ`gC "	" 1.iRߪ`gC
2.BetamethasoneL}ֽTJ@˷|[}fC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUC	Betamethasone(as Dipropionate 5mg+as Phosphate 2mg)	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	٦׻Pfn´ewBLөʯewBֽewBfC	PLTJ@ˡABUFENCON INJECTION 1MLTΩʯu߷PVA]`g󤣦Xy`BPVίջPդC 	MHBUFENCON INJECTION 1MLvƧ@Ϋܤֵo͡A԰OTJ`Ƨ@ΦpBqѽ誺šBf٦סBƹDBֽBgBcBΥN¤譱AC 	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IDIPR-a	IDIPR-b	IDIPR	110.6.16
AC57749255	H02AB09	0	ISAXI1	"HYDROCORTISONE INJECTION 100MG ""CYH"""		~uĿ}ֽTJAiͩʪg誺ΦAPơA]AeCAE?AiA׽?AHθtΡC]ո`H骺K̤C 	"1.H:100 to 500 mg IM or IV over 30 seconds to 10 min every 2 to 6 hours 
2.p:hydrocortisone 50 mg/m(2)/24 hr "	100@Jp~- -RߩΦ٦ת`gɡAHL߾ާ@Nܦh 2 ml tΤt߾ `gΤδƶu`gG[J~CR߿`ɡAHܦh2 ml tΤt߾`gΤδƶu`gG[Jp~AANG[J100-1000 ml 5% dextrose in water 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ts~Gs25JC 	Hydrocortisone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	ǤWֽणB@PJBef(ʬʯTH)BLӤ(ޮ)BLөʥֽew(ѯpHBʥֽ) C	B߷PV̡C 	Gιqѽ貧`A٦׵LOA[yAtwC 	ĨϥΩhkα¨ŰkAŶqĪQqAMiέFLέLधbMIʡC	ĨϥΩhkα¨ŰkAŶqĪQqAMiέFLέLधbMIʡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-13 [w]_w02-13 [E]_G2-08 [Ew]_D1-04 j	Ts110.6.16		OI` 	0	OIs 20251124	ISAXI-a	ISAXI1-b	ISAXI1-c	110.6.16
AB14914209	H02AB08	wն`gG	ISHIN1	Triamcinolone 40 mg/ml/Amp (Shincort)		~@ΤXƵǥֽTJADnΩ󻴭gʯewD	"٦ת`gG
H12HWൣG쾯q60mgAĲ`٦ת`gD
q`qdF40-80mgA̯gΪvGվD
6-12ൣG쾯q40mgA̯gΪvGվD"	"1.~tGAHպޤεwὤ~`gġD
2.ĸTΩRߪ`g
3.CʷPVgAϥήɻݦX֪vPVD
4.Gűw̻ݯSO`N
5.}fw̽Ъ`NW[خqζqnʡD
6.믫f]̻ݦh[`N
7.иɥRJս
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Triamcinolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	`BnBLөʥֽBޮݡBLөʻ󪢡B?HBLөʤεoʲew	 triamcinolone ΨLξL 	B~BWɡA[LƪnA֦Ƶǥֽ@ΩΥʰƧ@ΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-03 [w]_w03-15 [E]_G4-01 j	Ts111/08/18		OI` 	0	OIs 20251124	ISHIN1-a	ISHIN1-b	ISHIN1-c	111/08/18
AC29085245	H02AB04	0	ISOM4	Medason 40mg/vial		"MethylprednisoloneOjħܵoTJAPrednisoloneܵo@ΧnAӥBް_udƧ@Τ]֪Ͷ.
"	"ݭnϥΤjqkɡAMethylprednisoline ˾qO30mg/kg(IV`ɶ>10-20min) Q4-6h 48hAϥΰqTJݵfHpíw~iġA@뤣WL48-72hD(o͸zGDƧ@ΡAitXܻľ@wk^
LAgG
_lqG10-40mg(`ɶ1-Ƥ)A̷ӯfMwD
ʴcƪhoʵwƯgG
200mg QD*1weekA80mg QOD *1mon
4mg methyprednisolone=5mg Prednisolone"	"1.vѦʥJĤT
2.Yж˪Dk
3.i౻PVp
4.jqֳt`i঳߫ߤA`IܡA߸ID
5.ֽTJϥήɥiX{믫
6.ͫǪA觹zDXNAʩʩμʭGšAŦणAA貨PέgٵLOp
7.ֽTJfVϥΩ󲴳?lfHAiy."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(20-25J)xsAջsLGAǷŻݩ48hϥ(ɧ֦b24h ϥΧ)C	Methylprednisolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	ǤWणB@PJBީʮݡBefBLӤBxoʷPV	"1.߷PV
2.糧ĦL
"	"ֽӯ,貨P,믫,,ƹDŦX֬եX,bʷPV,}ffHخqΤfA}ĪݨDqW[,PʸfHo{ʤŦIܡAߦٱҤް_߫ǯ}A߫ߤD"	קKϥΰDvn/ֽTJ|qLLL	קKϥΰDvn/prednisolone|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-22 [w]_w02-04 [w]_w02-20 [E]_G2-12 j	Ts110.6.16		OI` 	0	OIs 20251124	ISOM4-a	ISOM4-b	ISOM4-c	110.6.16
AC46614151	H02AB06	0	LPRED	Kidsolone oral solution 1mg/ml;60ml/bot		PrednisoloneDn㦳޽ֽTJ(glucocorticoids)ʽ褧XǤWֽTJAiΩǤWֽ\णNkA㦳ܵoΧܹLӪ@ΡD	"~prednisolone @סG1mg/ml
HqGC5-60mlAefөwD
ൣqG0.14-2mg/kg/dayA3-4AΡD"	"1. tƵǥֽXAAήɽЪ`NUCƶ:
(1) CʷPVgAϥήɽЦPɨ֥ξAƾkΧܥͯī~HvPVefC
(2) ƺ޻ٮ`pGzšAȽЯSO`NC
(3) ]DnƧ@Τް_B~AWɡAץHŦewΰw`NC
(4) }fw̨ϥήɦW[InsulinĶqn̽Ъ`N"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUץJsC	Prednisolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	"޳ݮBLөʯewB`B㪢Bդf]stillsdisease^ʤߪB~BBj B`Bʯ誢Bh`BCʵhΨLUتgʥֽew

"	"1.߷PV
2.糧ĦL
"	~BWɡBGzAC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-03 [E]_I4-04 j	Ts110.6.16		OI` 	0	OIs 20251124	LPRED-a	LPRED-b	LPRED-c	110.6.16
AC43761100	H02AB04	0	OMEDN	Methylone 4mg (Methylprednisolone^		XǥֽPXAHͩRҥcAܭ@ΡAƵǱ@λPprednisoloneP{סFLuJd@ΡC	1-12/ѡA1-4A	i|oPVgBoʰƵǥֽणBƩʼšB}fC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25CHUxs	Methylprednisolone 4mg	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"		ʼB`ιLөʯg		~BWɡBGzAC	iϥ	iϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r05-01 [s]_225 [®]_225 [E]_A3-06 j	Ts111.4.28		OI` 	0	OIs 20251124	OMEDN-a	OMEDN-b	OMEDN-c	111.4.28
AC29601100	H02AB06	0	OPRED	Prednisolone 5mg/tab		PrednisoloneDn㦳޽ֽTJ(glucocorticoids)ʽ褧XǤWֽTJAiΩǤWֽ\णNkA㦳ܵoΧܹLӪ@ΡD	쾯qGgG30mg/dayFgG20mg/day  BID~QIDAΡD	"1. tƵǥֽXAAήɽЪ`NUCƶ:
(1) CʷPVgAϥήɽЦPɨ֥ξAƾkΧܥͯī~HvPVefC
(2) ƺ޻ٮ`pGzšAȽЯSO`NC
(3) ]DnƧ@Τް_B~AWɡAץHŦewΰw`NC
(4) }fw̨ϥήɦW[InsulinĶqn̽Ъ`N"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUץJsC	Prednisolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	ޮݡBLөʯewB`B㪢Bդf]Stills Disease^BʤߪB~Bդ߰Bj誢B`Bʯ誢Bh`BCʵhΨLUتgֽewC	1.糧~LӪ̡C 2.㦳ʩʯfܤ֯gTϥΡC	~BWɡBGzAC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w06-06 []_01-25 [s]_266 [®]_266 [E]_C4-06 [Ew]_Z-03w9 j	Ts110.6.16		OI` 	0	OIs 20251124	OPRED-a	OPRED-b	OPRED-c	110.6.16
BC25533100	H03AA01	0	OELTR1	Eltroxin 50mcg/tab{Thyroxine)		oĪɽu餧qzʡA]ӽո`(substrate)?CEDn@άW[餺N³tסC´`ͪPo|һݡC۵MXADn@άOѩT3tqAT3T4 35j@ΤO(Hmg)CjT3Pq3040%ܦT4C	HG쾯qC50-100LJA̦nO\eAΡACj|ܤgAW[50LJܥ`N¥\íwAɨC龯qiභF100-200LJC~50HWw̾qyWLC50LJAܩwŦfw̫hq̦nOC25LJΨCj@A50LJAj|gC龯qiAW[25LJC 	"1. ELTROXIN vYƯUCھ{ɵMǺʴҪ\եiMwELTROXIN AqCb̪쪺qվAݭnpߦaivBվMʴקKιLתvGCLqELTROXIN gA򤺷ʥҪrgܦhSI@ˡC
2. H ELTROXIN vxणw̩Φ]L]yǤWणɦVfHAiಣͰƧ@ΡA]ttBzBAB魫BCBεǤWʷlC]BĳofHAҪ(thyroxine sodium)eiǤWֽTJkC
3. Ѧ~w̡Aߦپणgw̡AΤ߹qܦߦٱΧʦ媺fHAHο}fΧYgw̡AĻݯSOpߡC 
4. ELTROXIN |Ϧ}ȤɰAiZåAΧܿ}fĪw̪}íwסC 
̾گgvAHiC6pɧPpropranolol 40mgӱ߷iLtFӨLvhipdiazepam/chlorpromazinevC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	OsūפŶWLǷ25JAץëOe򳬡C 	Levothyroxine sodium	H03A	Ҫs THYROID PREPARATIONS	0	ҪhgC 	"1. ľҧt󦨥LӡC
2. ҪrgC 
3.ʤߦٱ Aߦ٪ΫʥߪD(acute pancarditis)"	(YqLq)߱AgA߰ʹLtC 	w\hΥȥͨ|~֪kAAιLeltroxinAثeAhͲL{åo{{TΦzZCMӡA˥Ҫ\CUΧܶiAiLXͩΰdQvTC	cťĪEltroxine@׫ܧCAHzZsͦӥҪ\णgzˡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-01 [s]_120 [®]_120 [E]_A3-01 j	Ts110.6.16		OI` 	0	OIs 20251124	OELTR1-a	02C25533-1	02C25533-2	110.6.16
AC33933100	H03BB01	0	OCARB	Carbizo 10mg/tab		Carbimazoleb餺itܬmethimazoleAoGĪiۦPAҪͦXD	"쾯qG10-60mg/day
סG5mg TIDF: 10mg TIDF: 20mg TID
qG
0.5-20mg/day
"	h̫3-4Ӥ~ŴФŨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	OsūפŶWLǷ25JAץëOe򳬡C 	carbimazole	H03B	ܥҪs ANTITHYROID PREPARATIONS	0	ҪमiAҪrgAզfAҪNev¦sN¹LC	h̫3-4Ӥ~ŴФŨϥ	ߡAYhAoAoNAɨqզyʥFD	h̫3-4Ӥ~ŴФŨϥ	h̫3-4Ӥ~ŴФŨϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OCARB-a	01C33933-1	01C33933-2	110.6.16
AC433351G0	H03BA02	0	OPROC	Polupi 50mg/tab(Propylthiouracil)		PropylthiouracilҪX͹LѡAC¦N²vAߦ٤ӡAWiŦĲvC	"(1) qG@300mg 3 ~ 4 AΡA󭫯g@400 ~ 600mgCAܯfA@ܥ|gĶqAqѷӰ¦N²vӨMwA@50 ~ 100mgA1 ~ 2 AΡC
(2) pqG10 ~ 14 @200 ~ 300mgA5 ~ 9 100 ~ 200mg 2 ~ 4 AΡCAܯfA@ܥ|gĶqAq@50 ~ 100mgA1 ~ 2 AΡC
(3) qG@150 ~ 300mgA3 ~ 4 AΡCAܯfA@ܥ|gĶqAq@50 ~ 100mgA1 ~ 2 AΡAnɥḨCq뤩C"	"1. pڸsϥPropylthiouracilɡASO`NYxŦrʵo͡C
2. ī~ް_ɩʥզy֯gƧ@ΡAYϥΫᦳoNPVhgAЧY谱AĥBPvpôATwO_}o͡C
3. ϥΥī~ް_xƧ@ΡAYBh¡BߡBæRɡAлPvpô@i@BE_C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUץJsC	Propylthiouracil	H03B	ܥҪs ANTITHYROID PREPARATIONS	0	Ҫमig	"1. 糧LӪw̸TΡC
2. AΥx\ౡpcƪ̸TΡC
  ]ϥΫxcƯfҤA~ϥη|Yx^"	LɩʥզygBAͤ}ʳhBCJզgBĢ]lʥFgBpO֩ʵgBզy֯gBx\êBSLE˯gBʪͪBܶݤʥզyӭM]ANCA^sުgԸsBYhBC¯lB«PBߡBæRBUgC	"קKϥ/
(1)hkT߭L઺wʡALҪ~AҪiC
(2)hkΥihkwIҪˬdABҪAAýո`뤩qC
(3)sͨXͫARa[O_|ҪΥҪमi{HC"	קKϥ/ĥigŤcA¨ŤkקKjq뤩C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w44-01 [E]_B5-22 j	Ts110.6.16		OI` 	0	OIs 20251124	OPROC-a	OPROC-b	OPROC-c	110.6.16
AC501821G0	H03BB02	Ҳ@J	OTAPL	Methimazole 5mg/tab		"Methimazole ҪuEXAĪvҪLgCMethimazole AƦsbҪΦG`thyroxinetriiodothyronine, ]zZfAΪ`gҪE@ΡC"	H쾯qG5-10mg A@TDqG2-5mg A@T.fAl}nD	iX{VhAoNAֽolAYhΤ@ʤAi͡A˴T{զyʥFgO_wo͡D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os25JHUC	Methimazole	H03B	ܥҪs ANTITHYROID PREPARATIONS	0	Ҫमig	"糧~LӪ̸T
¨Ū̸T"	( l )ӭMs@ (2)ֽlBC¯l (3)ɩʥզy֯g (4)x\ಧ` (5) (6)æR (7)g	קKϥ/Methimazolepropyl thiouracileqLLLAiಣͥҪ~MbpgAbYe2-3PġD	¨ŴקKϥ/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669124?cesid=9QGAMoX5kVP&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMethimazole%26t%3Dname%26acs%3Dfalse%26acq%3DMethimazole"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.02.18		OI` 	0	OIs 20251124	DC	DC	DC	114.02.18
KC00735209	H04AA01	0	IGLUC	Glucagen 1mg/ml/vial(Glucagon)(N)		@}O@ؼW}sAPixŦxުʡAϨxޥHglucoseΦiJGCxŦxޤwӺɪfwA@}OSĪC	"1.vWAg(YC}g): Hw̤q:`g1mg pıw̤q:1mgAάO0.5mg ĥ֤UάO٦ת`gC
2.E_WAg(įʧ): ϥ0.2~0.5mgRߪ`g1|ͮĪGA ̶E_ˬdxPAĪGi5~20C 
3.]ӭMc\: ϥ1mgRߪ`gŸw̡AYŸ}@קC 7mmol/lAhյGNPŪC`geΪ`g6ĴC-peptideȡC "	קKAoͧC}AfwvɡAfAҤƦXӦ^_xޡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.|VXGLUCAGENxs2J8JAקKBH˦`gΤ~}C 
2.tGLUCAGEN~ץxsC 
3.ժ`gtGBȭ榸ϥΡC
4.VXѫᤧGLUCAGEN`gGߨϥΡAisϥΡC "	 Glucagon 	H04A	xޤѶPX GLYCOGENOLYTIC HORMONES	0	"1.Ωϥίخqv}fwҭPYC}C
2.ΩƹDˤΩguvNC
3.Ωخq]вӭMc\C "	"1. 糧~lactoseLӪ̡C
2. ݻ̲ӭMFC "	̱`Ƨ@ά߻PæRASOO]`gqWL@@JΪ`gtפӧ֡]@H^Ӥް_AMߤιæR]ib`g23pɭԵo͡C 	ɿ}|LLLA}fhk`vTC	ɿ}byN«ܧ֡AcťĪqܤ֡A|ൣN¤Wˮ`C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-27 j	Ts110.6.16		OI` 	0	OIs 20251124	IGLUC-a	IGLUC-b	IGLUC-c	110.6.16
KC00787216	H05AA02	0	IFORTE	Forteo 250MCG/ML 2.4ML(N)		"FORTEO [teriparatide (DNA)`gG] tդHƥ?Xq(1-34)Ateriparatide ǥ?EP谩Pֽ谩sͦAﵽpٰLpcyAüW[f?Pj?CbHAteriparatide XN§@Ϊ{bf?W[BܦаOPkаOWɻPfj?WjC
ۤϪAͩʰƥ?L?A?pƥ?igAiﰩf`A]k@Υi|WV@ΡC"	"SC, 20 mcg once daily
֤U`gG@Ѥ@AC20mcgC
"	"1.~Né2-8C(ЩbBcUh)AiNA~XɡAЩbpBC
2.ϥΰíFORTEOftC1000@JtA]í`g|E餺y@ΡAҥHPɴѳyơA~৹o~ĥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Né2-8C(ЩbBcUh)AiNA~XɡAЩbpBC	Teriparatide	H05A	ƥҪPXΨ PARATHYROID HORMONES AND ANALOGUES	0	gk貨Pg㰪װ魷I̡AkʭoʩΦoʸ\CUg貨PB㦳װ魷I̡A?ʤΨkʦ]?ƥֽ?TJv?ް_貨PgB㰪?魷I	fw teriparatide ΨξLӡC	i঳թʧCB`gkhάBߡBhθmC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-42 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.2._20210512.pdf"">OI` 5.5.5.</a><a href="""">OI` 5.6.2.</a>             "	"OI` 5.5.5.,5.6.2."	0	OIs 20251124	IFORTE-a	IFORTE-b	IFORTE-c	111.8.19
BC16704248	H05BA01	0	IMIAC	MIACALCIC INJ(N)		~ǪklAӭC夤t@סCǪ_Ǥp޹惡lAlMiǫPitJsӼW[ŦtMCƪnμW[ӭMʡCè㦳h@ΡC 	"ҾܡAϥcalcitoninī~iW[oʹcʸ~FIAG~vḨCľqγ̵uvhC
fPgG
̯fY{רCιj 50IU-100IUAgѥ֤UΦ٦ת`gC
SgG
ĳqC֤U`gΦ٦ת`g100ڳ]I.U^A@gT50I.U.̧Cq{Kb{ɩMͤƭȤ譱FﵽCľqHӧOfHݨDվCYfHX{ĤBgwѡAvCϥcalcitonincʸ~FIҾڡAv{q`WL3ӤASpU]ҦpGx{fzʰ骺fH^AiNv{̱ܳ`6ӤCtAofHiҼ{gʪvAPɱNϥcalcitoninvįqPcʸ~FIҾڦCJҼ{C"	"tMHG
5-10IU/kg/day[J500mlA6pR߿`CΤ2-4CtRߪ`gC
CʰtBzG
5-10IU/kg/Day SC/IM QD~BID"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Né2-8C(ЩbBcUh)AiNC	Calcitonin (salmon synthetic)	H05B	ܰƥҪ ANTI-PARATHYROID AGENTS	0	vSf]Paget's disease^AȾAXNkLĩΤAXokfH]pGǥ\Yl̡^C	XDtΥ?ξL.	ߡAæRAYAyA`hAcʸ~F]ϥΡ^FWvG`C	|LũhsAGĳϥΦġC	|LũhsAGĳϥΦġC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-15 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.2._20140201_000.pdf"">OI` 5.5.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.2.,5.6.1."	0	OIs 20251124	IMIAC-a	IMIAC-b	IMIAC-c	110.6.16
		0	OCINA1	Cinaca F.C. Tablets 25mg (cinacalcet)		cinalcacetO@tsAiW[ƥҪ(PTH)WtPʨӭM~tlӷPסAiӭCPTHM夤t@סAHwefcƤΫʪqN¤}C	25 mg QDA1P˴tA1-4P˴PTHCCW[25mgiPTH150-300pg/mLCǥ\णݽվ㾯qC	cinacalcet|CtAbΤ@§ʴt@סCCt{iOֽPı`AٵhA⵬AjAWCt@קC8.4mg/dLɡA}lvAYoͧCtAiϥΧttCXA/κLRDHW[tCYC7.5mg/dLӰġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os25JHUC	cinacalcet	H05B	ܰƥҪ ANTI-PARATHYROID AGENTS	0	vzRw̪oʰƥҪमiC	CinacalcetTΩ糧~󦨥LӪH	ߡAæRAmC	hkSB}nsAubQqWLL઺bMIɡA~bhɨϥCinacalcetC	Ҽ{Ī¨ŰknʨӨMwO__ΪAġC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-04 j	Ts110.6.16		OI` 	0	OIs 20251124	OCINA1-a	OCINA1-b	OCINA1-c	110.6.16
AB57783248	J01AA12	0	ITIGE	tigelin 50mg/vial(Tigecycline)		TigecyclinesglycylcyclineܥͯA`pUAiĥWtRNAɤ~㦳ʡAiJ30S餤HXJաAtigecyclineiHiJӵߪ30S骺A siteAױaiĪtRNAiJAF`?XĪGAHJսXC	lq 100mgRߪ`gAM50mgC12pɤ@ATYGACILvʥֽPVgνʸĤPVgĳ{5~14ѡCTYGACILvϷPVʪͪĳ{7~14ѡCvuO̾ڷPVPPV{צөwAPɤ]ѦүfH{ɪ{Pӵ߾ǪˬdiC	"YbͪTYGACILv(ҦphbBP
8ĵ)Ai|ɭPä[ܦ(-Ǧ-Ħ)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Os20XC25XC
վnå[JR߿`GUAbǷūOs24pɤ(6pɦsĲ~AѾlɶsR߿`GU)"	Tigecycline	J01A	| TETRACYCLINES	0	Tigecycline㦳PʤӵߩҤް_ʥֽΥֽcPVBʸĤPVgΪϷPVʪͪC	tetracyclineӷPfHTϥTYGACILC	`Ƨ@ΦߡBæRBmC 	hkTYGACILvɡAi|LM`C	"MثeäDtigecyclineO_]iѰkťĤcXӡAϥTYGACILbŪkɤd
Ni઺vT"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.01.14	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.5._20110701_000.pdf"">OI` 10.8.5.</a>              "	OI` 10.8.5.	0	OIs 20251124	DC	DC	DC	114.01.14
BC24443248	J01AA12	0	ITYGA	Tygacil 50mg/vial (Tigecycline)		TigecyclinesglycylcyclineܥͯA`pUAiĥWtRNAɤ~㦳ʡAiJ30S餤HXJաAtigecyclineiHiJӵߪ30S骺A siteAױaiĪtRNAiJAF`?XĪGAHJսXC	lq 100mgRߪ`gAM50mgC12pɤ@ATYGACILvʥֽPVgνʸĤPVgĳ{5~14ѡCTYGACILvϷPVʪͪĳ{7~14ѡCvuO̾ڷPVPPV{צөwAPɤ]ѦүfH{ɪ{Pӵ߾ǪˬdiC	"YbͪTYGACILv(ҦphbBP
8ĵ)Ai|ɭPä[ܦ(-Ǧ-Ħ)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Os20XC25XC
վnå[JR߿`GUAbǷūOs24pɤ(6pɦsĲ~AѾlɶsR߿`GU)"	Tigecycline	J01A	| TETRACYCLINES	0	Tigecycline㦳PʤӵߩҤް_ʥֽΥֽcPVBʸĤPVgΪϷPVʪͪC	tetracyclineӷPfHTϥTYGACILC	`Ƨ@ΦߡBæRBmC 	hkTYGACILvɡAi|LM`C	"MثeäDtigecyclineO_]iѰkťĤcXӡAϥTYGACILbŪkɤd
Ni઺vT"	аѦҾqPΪk	" 100mg ST, 50mg q12h 
(Yx\ण:25mg q12h)"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.}Ƿ24hr(6pɦsĲ~AѾlɶsR߿`GU)FN48hr
tsGG5.3ml NSBD5WBLR
ĳ}@סG1 mg/ml? 
ۮe}GGߧY 5 ml]t50 mg^tsG[100ml NSBD5W
ĳĳ~|tvG30-60min
`NƶG1.tsnGμAYC⤣Phiϥ
2.YPLĪqP@IV line ĮɡA`eᥲHNS D5WLR RbIV line."	ixii[w]_w05-14 [E]_G6-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.5._20110701_000.pdf"">OI` 10.8.5.</a>              "	OI` 10.8.5.	0	OIs 20251124	ITYGA-a	ITYGA-b	ITYGA-c	110.6.16
AC36940100	J01AA08	0	OMINO	Mero 100mg/cap(Minocycline)		Minocycline hydrochlorideݥbX tetracycline. ǥѧJսXӧӵߥͪC	}lv200mgAMC12p100mg	"1.~|wfAץĪĪG
2.~|prothrombinʡAG֥Χܾ徯ɡAӽվܾ徯q C
3.~קKPߩʧܥͯp:penicillin֥ΡC@
4.~l|ľTtKzZC
5.~|ѨťĤcXA~ŰknvšC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Minocycline	J01A	| TETRACYCLINES	0	Pʭ󶧩ʤγʵߡBߧJBoLʯfrҤް_PVg 	ĸTΩw|ܥͪ観LӪ̡C	zGAAӷPAqǬr`(BUNɰ)ALӤAGr`C	",,ĵקKϥΥ~C]|Lr`AB|yo|ä[ܦCܦĦC"	",,ĵקKϥΥ~C]|Lr`AB|yo|ä[ܦCܦĦC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_201 [®]_201 [ws]_w04-09 [E]_A3-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OMINO-	OMINO-b	OMINO-c	110.6.16
AC23648100	J01AA02	0	OVIBR	Doxycycline capsules 100mg		ݥbX tetracycline. ǥѧJսXӧӵߥͪC	}lv200mgAMC12p100mg	ĩyɧ]AAyiΫrHAHK}azʡAbGYѦӨEGFΨľi෻Ѹz罤AGyPɨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Doxycycline	J01A	| TETRACYCLINES	0	󶧩ʡBʵߡBߧJΥoLʯfrPVg	ĸTΩw|ܥͪ観LӪ̡C	ӷPfHbĪvקKgApo{ֽAAhߧYġCϥΥİߡBæRBmBDBֽBުBGBzo͡C	",,ĵקKϥΥ~C]|Lr`AB|yo|ä[ܦCܦĦC"	",,ĵקKϥΥ~C]|Lr`AB|yo|ä[ܦCܦĦC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-01 []_01-14 [s]_96 [®]_96 [E]_A2-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OVIBR-d	OVIBR-b	OVIBR-c	110.6.16
BC26966219	J01CE08	0	IPEN2	Bicillin L-A2.4MIU/4ml/syringe(Penicilli(N)		ӵߪӭMAFߧ@	"ȥΩ٦ת`g
1.AsyߤWIlDPVG
H>27kgൣ:榸`g120U(~4ml]ˡA60U/ml)
<27kgൣ:榸`g60U
2.r:
Ĥ@AĤGμG榸`g240UCĤT(ߴ)GC7Ѫ`g240UAC
3.al(yaws)ADhʱrf(bejel)A~Lf(Pinta)G
榸`g120UC
4.wʵo@᪺ʤŦfεǵyǪlܹwG
G120UQ4WAIw̥iQ3WC
ǵyǪG120UQM(C@)"	קKgRߩΰʯ߳~|ġAΪ`gܥDnP䯫gΦޤΨPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Nī~m 2 ~ 8 צBcF[x3~C	Penicillin G Benzathine	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	"bezathine penicillin G㦳Pʤ߮Ҥް_PVgC
ѷPyߤް_צܤפWIlDPVC
r
al(yaws)ADhʱrf(bejel)A~Lf(Pinta)C
AXHpenicillin G benzathinekwkfgC(ʤŦfAǵyǪ^"	PenicillinĪ͹LӤĤϥθT	mA֯lA`gkhALөʥJC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ĳ~|GIM only
tswwʡGNáAФŧN
tsGGUndiluted
ĳ}@סG-
ۮe}GG-
ĳĳ~|tvG-
`NƶGФŪ`gܰʯߩίgΨPAθgR߳~|`gAλPLRߪ`gGUV"	ixii[N]_B01-38 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IPEN2-a	IPEN2-b	IPEN2-c	110.6.16
AB55966220	J01CR05	Fᴹ`g	ITAZO4	Tapimycin 4.5g/vial		"Piperacillin sodium i{ߤOOaӵߤjΦHβӭMXC
Tazobactam sodium ֦ͩʤLͪĤOADѩCXJդXvƧCtGARichmond-SykesĤT(Bush Class 2b & 2b')C?YUl?beta-lactamaseCĤGβĥ|(2a & 4)C?OhUtC"	"H X 
IV @PVG 4.5g Q6H-Q8H.
@ |PVG 4.5g Q6H ĳtX Aminoglycoside(ĳHY-site)
                          4.5g+150ml }G (NSAD5W)
                          2.25g+50ml }G (NSAD5W)
                          aminoglycoside conc. (amikin:0.75-1.5mg/ml)(gentamycin:0.7-3.32mg/ml)
ǥ\णG
@PV            
 CrCl(ml/min)20-40G2.25g Q6H
 CrCl(ml/min)20G 2.25g Q8H
 GzRG2.25g  Q12H
ൣ:
>9ӤA魫<40kgG100mg  piperacillin/12.5mg Tazobactam/kg  Q8H
>2ӤA<9Ӥ: 80mg piperacillin/10mg Tazobactam/kg  Q8H
>40kgHq"	"1.`NLӤ}AStecen-Johnson SyndromeɡD
2.~ǰIܯfHϥήɡAiW[X孷IAϥ˴yD
3.RߵqɡAioͯg٦פĩεjˡD
4.ﭫgfHϥtapimycinOǰIܪWߦ]lAPVancomycin֥ΥiPʵŦl˪oͲvD
5.~utq54mg/g piperacillinAݭQ`N.ϥΧQι[tqCfHʴ[D
6.v߬mAi]A׸mvzD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUJsD 
tmǷŢ׹FpɩΧNùFpD"	Piperacillin/Tazobactam	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	piperacillin㦳PʡAHιpiperacillinĩʦpiperacillin/tazobactamPʤ]-lactamase͵߮Ҥް_Y{׷PVC	" penicillins, beta-lactamase inhibitors,ΨLξLӤfH,TΥ."	"m,,æR,l,Yh,vD"	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667973?cesid=6TN2ymP2lJo&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTAZOCIN%26t%3Dname%26acs%3Dfalse%26acq%3DTAZOCIN"">LexidrugľǸƮw</a>"	"CClr>40      4.5g q6-q8h
CClr 20-40  2.25g q6h
CClr<20       2.25g q8h
IHD              2.25g q8h
CAPD           2.25g q8h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tsǷxs24hr, Nxs48 hr
2.}Ƿxs24hrFNxs7day 
tsGG1g Piperacillin+ 5ml WFIBNSBD5W
ĳ}@סG50-150ml /dose
ۮe}GG50ml WFIB50-150ml NSBD5W
ĳĳ~|tvG30min
`NƶG1.ŻPaminoglycosideܥͯVX"	ixiij	Ts114.11.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	114.11.06
AC46544210	J01CR01	0	IUNA1	SUBACILLIN INJ 1.5GM/VIAL		"yߡByߡBjzߡBJpߡBFpߡByP_ݦߡBަܧαݡBfcĵݡBʲӵ(Bacteroides,Fusobacterium,Clostridium difficile)BBranhamella catarrhalisް_PVgC"	"IV HX 1.5-3 g Q8-6H; MAX 12g /day.
LPVG1.5g Q12H
׷PVG1.5g Q8-6H
YPVG3g Q6H
ĵ,AAsͨX 150mg/kg/day C6-8pɪ`g@;@PjX75mg/kg/day@12pɪ`g@D
ǥ\IܪfHG 
CrCl(ml/min) 15-29: 1.5-3 g Q12H ;
 CrCl(ml/min) 5-14: 1.5-3 g Q24H"	"1.Paminoglycoside@_`gɷ|ɭPۤhʡAHPIAj@pɡD
2.PɨϥallopurinolMsubacillinoͪEvsubacillinɰD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUxs 
tswwʡGIM@YGtsǷ1hrϥ
}wwʡG
1.WFIBNS}@45mg/mlɫǷ8hrAN48hrF@30mg/mlɧN72hr
2.D5W}@15-30mg/mlɫǷ2hrF@30mg/mlɧN4hrF@3mg/mlɫǷ4hr
3.LR}@45mg/mlɫǷ8hrAN24p
ts}GGIV 3.2ml WFIBNS
ۮe}GGWFIBNSBD5WBLR
ĳĳ~|tvGIMBIV:>3min
IVF: 15-30 min"	Ampicillin/Salbactan	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	"yߡByߡBjzߡBJpߡBFpߡByP_ݦߡBަܧαݡBfcĵݡBʲӵ(Bacteroides,Fusobacterium,Clostridium difficile)BBranhamella catarrhalisް_PVgC"	" penicillins, beta-lactamase inhibitors,ΨLξLӤfH,TΥ."	ߡAæRAmAʵzARߪAl	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>50      1.5~3g q6-q8h
CClr 10-50  1.5~3g q8-12h
CClr<10      1.5~3g q24h
IHD             1.5~3g q24h
CAPD          1.5~3g q24h "	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡG1.IM@YGtsǷ1hrϥ
2.WFIBNS}@45mg/mlɫǷ8hrAN48hrF@30mg/mlɧN72hr
3.D5W}@15-30mg/mlɫǷ2hrF@30mg/mlɧN4hrF@3mg/mlɫǷ4hr
4.LR}@45mg/mlɫǷ8hrAN24p
tsGG3.2ml WFIBNS
ĳ}@סG3-45mg/ml?
ۮe}GGWFIBNSBD5WBLR
ĳĳ~|tvGIMBIV:>3min
IVF: 15-30 min
`NƶG1.󸲵}BΨLww
2.iMGsBLJղGBaminglycosidesVXϥ"	ixii[ws]_w68-02 [ws]_w71-01 [UDx]_U08-02 [w]_w05-22 [E]_G6-03 [Ew]_F5-22 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.2.2._20020701_000.pdf"">OI` 10.2.2.</a>             "	"OI` 10.1.,10.2.2."	0	OIs 20251124	IUNA1-a	IUNA1-b	IUNA1-c	110.6.16
BC22931116	J01CR02	0	LCURA	Curam oral susp.Ƥ 312.5mg/5ml;60ml/~		~O@ؼsĩʧܥͯ]amoxycillin^Σ]-QiJ]clavulanic acid^sƦӦƦXsCSwߺصoͧ@ΡC	"~>12A魫>40kgGCuram(Amoxycillin875mg+ Clavulanate125mg) 1 tab CAΨ⦸
Curam(Amoxycillin875mg+ Clavulanate125mg) uĳΩCClr>30ml/minfH
aBGtmt 250 mg amoxycillin + 62.5mg clavulanate / ml
2-12ൣG3060mg/kg/dayATC 
2-6]魫12-20^G1.25ml-2.5ml q8h
6-12]魫20-40^G2.5ml-5ml q8hC 
2HUൣG3040mg/kg/dayATC
6-24Ӥ(魫G6-12)G0.625ml-1.25ml q8h
iNbApݿiϥaG."	бNĪmൣΤBC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"m30CקKD
sƦnaGxs2-8JABciOs7ѡAϥΫeзnáC"	Amoxycillin +Clavulanic acid	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PV	wSw]-Qiïܥͯ]ҦpCAYU߯^|LӪ̡A]oǤHLӻoJMIC	|oͭGOBߡBæRBȮBnKθmC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_05-03 []_05-04 [E]_J2-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.2.1._20210608.pdf"">OI` 10.2.1.</a>             "	"OI` 10.1.,10.2.1."	0	OIs 20251124	LCURA-a	LCURA-b	LCURA-c	110.6.16
AC01853277	J01CA01	0	IAMPI	AMPOLIN(AMPICILLIN) 500MG/VIAL		w`g@طssxʦXPenicillin sA?ﭲ?󶧩ʵߦ?ġAPɹﭲ?󳱩ʵߥ禳ġA@?ĥTV`gΧܥͯsC	"HG1-2g q4h-q6h`g@C
pġG魫 50 kg HUAC 25- 50 mg /  kg pA|AC6 pɪ`g@C"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUD
tmb@pɤΧD"	ampicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	 Penicillin Lӯgew̤yAΥC	C¯lBooBlέ(LӤ)	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668590?cesid=75yAV73hiNQ&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAMPICILLIN%26t%3Dname%26acs%3Dfalse%26acq%3DAMPICILLIN"">LexidrugľǸƮw</a>"	"CClr>50      1~2g q6h
CClr 30-50  1~2g q6-q8h
CClr 10-30  1~2g q8-q12h
CClr<10       1~2g q12h
IHD              1~2g q12h
CAPD           0.5~1g q12h"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡGϥήɷsAtsAtșn1hr ϥ
tsGGG1.8ml WFI(IM)B 5ml WFI(IV)
ĳ}@סGIVF:2-30mg/ml? 
ۮe}GGNSBD5W? 
ĳĳ~|tvGIV:3-5min
`NƶG1.󸲵}BE}έһQww
2.iMGsBLJղGBaminoglycosidesVXϥ"	ixii[UDx]_U09-05 [w]_w04-01 [w]_w04-11 [E]_G4-04 [Ew]_F5-04j	Ts114.10.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IAMPI-a	IAMPI-b	IAMPI-c	114.10.29
AC49000277	J01CF04	0	IPROS	Ocillina (PROSTAPHYIN) 500MG/VIAL		ǥѧӵ߲ӭMͦXӹF@ΡC Oxacillin jhƪG(+)yߦġA]Abeta-yߡBͪyߤΤͫCCyߡCѩCCoػïܧ@ΡA]iܷ|ͫCCyߡC	"줤פWIlDPVGֽγn´PVG
HΤpĭ40 HWGC4 6 pɵ250 mg 500 mgC
p魫b40 HUG50 mg/kg/day C6 pɵ@C
ηsͨ൹25 mg/kg/day wiFv@סC
YPVGpUIlDδGʪPVG
H魫40 HWൣGC4 6 pɵ1 g Χ󰪾qCMAX 12 g/day.
p魫40 HU̡G100 mg/kg/day Χ󰪾qAC4 6 pɵ@CMAX 400mg/kg/day.
յǥ\णֵǥ\णfHq`Lݽվ㾯q
LoBLgβӵ߰iweʮɡAvܤ48 pɡCbYʪy߷PVAHܫCCC
vֶ̤14 ѡCߤ(endocartidis)ΰ誢(osteomyelitis)vhݧɶC"	"1.߰ݯfHO_CBYUl߯BΨLLӪLӪ{HC
2.HOxacillin @vɡAqʪǡBxγytΪ\[HAO@ơC
3.TwfߤΨ糧ܫCCCPʪӵ߰iAƥC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ЩǷ30JHUץJsC
wn᪺GbǷŤis3 (̰25J)AΦbBc(2J8J)is@PC"	Oxacillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	̤mO CܥͯAΰt褤󦨤LӪw̡C	ߡBæRBmBGB¼˦ީΤ˦(black or hairy tongue)ΨLGzDEgCoNBߡBæRΨx\ƭȤ`	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"2g q4-6h,Max:12g/day
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡG1.~ץxs
2.tsǷ3dayAN1wk
tsGG2.7ml WFI(IM)
5ml WFIBNS(IV)
ĳ}@סG0.5-2mg/ml(IVF)?
ۮe}GGNSBD5WBLR
ĳĳ~|tvG10min(IV)
`NƶG1..ŻPaminoglycosidesVX"	ixii[ws]_w72-01 [UDx]_U09-02 [w]_w05-21 [E]_G5-13 [Ew]_F5-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IPROS-a	IPROS-b	IPROS-c	110.6.16
AC36160110	J01CA04	0	LAMOX	"Amolin Susp 1.5gm, 60ml/bot"		Amoxicillinﬡc޴PʷLͪ@ΡADnOgѲӵ߲ӭMMucopeptideͦXҹFC	"@릨Hq:fAA250mg-500mg Q8HA@ѳ̰q4.5gC [`N]OfvɡAH~12ɻP1g Probenecid@澯qAΡC 
~}ᬰ amoxicillin 50mg/ml
@ൣq:
魫8~20祮@fAA6.7~13.3mg/kgAC8pɤ@C 
魫6HU-fAAC8p25~50mg 
魫6~8-fAAC8p50~l00mg 
魫2020HW@PH@뾯qC [`N]̭q¦p⤧qAΥ|j󦨤HqAC`qoWXHqqC"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Ƿ25CHUD[իЧNéBcAnëϥ.	Amoxicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	 Penicillin Lӯgew̤yAΥC	C¯lBooBlέ(LӤ)	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	LAMOX-a	LAMOX-b	LAMOX-c	110.6.16
AC120511G0	J01CA04	0	OAMOX2	Amoxicillin 250mg/cap		Amoxicillinﬡc޴PʷLͪ@ΡADnOgѲӵ߲ӭMMucopeptideͦXҹFC	"@릨Hq:fAA250mg-500mg Q8HA@ѳ̰q4.5gC [`N]OfvɡAH~12ɻP1g Probenecid@澯qAΡC 
~}ᬰ amoxicillin 50mg/ml
@ൣq:
魫8~20祮@fAA6.7~13.3mg/kgAC8pɤ@C 
魫6HU-fAAC8p25~50mg 
魫6~8-fAAC8p50~l00mg 
魫2020HW@PH@뾯qC [`N]̭q¦p⤧qAΥ|j󦨤HqAC`qoWXHqqC"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15~30J)Bץxs	Amoxicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	"1.糧Ĳ͹LӲ{Hw̸TΥġC
2.ǬVʳ֯gw̡C"	C¯lBooBlέ(LӤ)	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 [ws]_w17-03 []_01-04 [E]_C4-11 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OAMOX2-a	OAMOX2-b	OAMOX2-c	110.6.16
AC25866100	J01CA04	0	OAMOX5	Amoxycillin 500mg/cap(Amoxycillin)		Amoxicillinﬡc޴PʷLͪ@ΡADnOgѲӵ߲ӭMMucopeptideͦXҹFC	"@릨Hq:fAA250mg-500mg Q8HA@ѳ̰q4.5gC [`N]OfvɡAH~12ɻP1g Probenecid@澯qAΡC 
~}ᬰ amoxicillin 50mg/ml
@ൣq:
魫8~20祮@fAA6.7~13.3mg/kgAC8pɤ@C 
魫6HU-fAAC8p25~50mg 
魫6~8-fAAC8p50~l00mg 
魫2020HW@PH@뾯qC [`N]̭q¦p⤧qAΥ|j󦨤HqAC`qoWXHqqC"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15~30J)Bץxs	Amoxicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	"1.糧Ĳ͹LӲ{Hw̸TΥġC
2.ǬVʳ֯gw̡C"	mBlBGzABL	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	110.6.16
BB24808100	J01CR02	0	OAUGM1	Curam 1000mg/tab(Amoxicillin/Clavulanate		~O@ؼsĩʧܥͯ]amoxycillin^Σ]-QiJ]clavulanic acid^sƦӦƦXsCSwߺصoͧ@ΡC	"~>12A魫>40kgGCuram(Amoxycillin875mg+ Clavulanate125mg) 1 tab CAΨ⦸
Curam(Amoxycillin875mg+ Clavulanate125mg) uĳΩCClr>30ml/minfH
aBGtmt 250 mg amoxycillin + 62.5mg clavulanate / ml
2-12ൣG3060mg/kg/dayATC 
2-6]魫12-20^G1.25ml-2.5ml q8h
6-12]魫20-40^G2.5ml-5ml q8hC 
2HUൣG3040mg/kg/dayATC
6-24Ӥ(魫G6-12)G0.625ml-1.25ml q8h
iNbApݿiϥaG."	1.p@AĤϥΤiWL14ѡC 2.]AέbAiCZC 3.\}lɪAΥiǫΧlĪGC 4.ШvܪAΡAžզۧﾯqΰġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs]ˡAŶWL25JAømBOsC	Amoxycillin +Clavulanic acid	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	s@LӪ̸TΩpenicillinn/x\ॢ`fvC	mBߡBæRBC¯lBlC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w23-04 []_01-10 [UDx]_U02-29 [E]_B2-01 [Ew]_EX022 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.2.1._20210608.pdf"">OI` 10.2.1.</a>             "	"OI` 10.1.,10.2.1."	0	OIs 20251124	OAUGM1-a	OAUGM1-b	OAUGM1-c	110.6.16
AC21213100	J01CF01	0	ODICL	Diclocin 250mg/cap(Dicloxacillin)		Dicloxacillinݩisoxazolyl penicillinAǥѧӵ߲ӭMͦXӹF@ΡCܻĩʡAGĤ}aAGiHfAAϥΤWKFӥBpenicillinaseѡAfAlΨ}nA夤@פLؤfApenicillinnӱoFܵߴMΩҦG()ߡAߩʧܥͯAͧĩʵߡALxǻêʡACqYĪGArʤpAw ʨΡAGsΡC	"1.צܤ׷PVgG 
 40HWൣΦHGC125mgAC6pɪAΤ@C
 40HUൣGh12.5 mg/kg/dayA|AHC6 pɪAΤ@C
2.׷PVgG 40HWൣΦHGC250mgC6pɪAΤ@C 40HUൣGh25 mg/kg/dayA|AHC6   pɪAΤ@C 
3.̦nŸɩζe1~2pɪAΡC"	@o͹LӤhW	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Dicloxacillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	penicillin Lӯgfvw	ߡBmBB֯l	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ODICL-a	ODICL-b	ODICL-c	110.6.16
BC26611280	J01DI02	0	IZINF	Zinforo  inj. 600mg/vial		ceftarolineizLXܽLLXJ(PBP)ӧӵ߲ӭMXAG㦳߯O	"Zinforo@ĳqC12pɬ60R߿`600@JCv򪺮ɶ̪vPVBY{שMfH{ɤөwCwҹhåѪ⸲y(Staphylococcus aureusAS. aureus)(ceftarolineMIC <2@J/)ް_cSSTIvAZinforoqC12pɬ60R߿`600@JCȥΩvwҹhåS. aureus (ceftarolineMIC=2@J/ɨ4@J/)ް_cSSTIHfHAZinforoqC8pɬ120R߿`600@JC
pྯq:
?2  A<18(<33kg):12mg/kg q8h `60C
>2Ӥ~2G8mg/kg q8h `60C"	"LӤ
x(Clostridium difficile ) m
wo@fH
wi󪽱綧"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Цs30XCHU
ХHl]xsAקKuӮgC
tsGb}ߧYϥΡC"	ceftaroline fosamil	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	"ZinforoAΩv~2ӤHWൣceftaroline fosamilPʵߺتϩʪͪ
(CAP)νʥֽPn´PV(cSSTI)C"	䤤ĦΥξL	mBYhBߡBkoA{׳q`שΤסC	"hקKϥZinforoAD{ɪpTݭnABbįqi୷IɡA
~ϥΡC"	"ثe|MceftarolineO_|cܤHťġAѩ\h]Qiܵ߾|cܨť
A]ŤkʻݦbT{ɪvįqɡA~iZinforovCĳȰšC"	аѦҾqPΪk	"CClr>50      600mg q12h
CClr 30-50  400mg q12h-q8h
CClr 15-30  300mg q8-12h
CClr 15    300mg q12h
IHD             200mg q12h"	ѦҡuqΥΪkv	"ĳ~|GIV
tswwʡG1.}Ƿxs6hrFNxs24 hr
tsGG20 ml WFI
ĳ}@סG-
ۮe}GGD5WBNSBLR
ĳĳ~|tvGIVF: 60 min
`NƶG-"	ixii[w]_w04-13 [E]_G5-04 [Ew]_F5-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.5._20211101.pdf"">OI` 10.3.5.</a>              "	OI` 10.3.5.	0	OIs 20251124	IZINF-a	02C26611-1	02C26611-2	110.6.16
BC27705214	J01DD52	0	IZAVI	Zavicefta inj. (2g Ceftazidime+0.5g Avibactam)		"CeftazidimebPpenicillinXJ(Penicillin Binding Proteins,PBPs)XAiӵ?E޲ӭMXAӨϲӵ߲ӭMѤΦ`DAvibactamO@non-]-lactam]-lactamase AiPíwïΦ@ƦXӵo@ΡD~iAmbler AC]-lactamaseΤ@D?D]Asĩʣ]-lactamase (ESBLs)AKPC,Oxa-48 carbapenemaseHAmpC?DAvibactam|B?(metallo-]-lactamases)BLk\hD?D"	"2.5gQ8H`2p 
CrCL31-50 ml/min ϥ1g/0.25gC8pɤ@`2p
CrCL16-30ml/minϥ0.75g/0.1875gC12pɤ@`2p
CCL6-15 ml/minϥ0.75g/0.1875gC24pɤ@`2pɡC
zRfHG0.75/0.1875gC48pɬI@,`ɶ2pɡC
x\णfHLվ㾯qC "	ϥΩǥ\णfHɡAĳKʴٻMvpȡCbǯfHWA̾ڦMٻpٻMv|ֳtܤơASOOPVvqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsl]˥HץD
tmߧYϥΡD}@b㢷פUiWL24pɡDbפUiWLpɡD"	Ceftazidime+Avibactam	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	"ZaviceftaAΩvHZaviceftaPʪ󳱩ʷLͪ(susceptible Gram-negative microorganisms)Ҥް_UCPVG
EʸĤPV(complicated intra-abdominal infectionAcIAI)
EʪcDPV(complicated urinary tract infectionAcUTI)A]AǪǪ(pyelonephritis) 
E|PVͪ(Hospital-acquired pneumoniaAHAP)A]AIlͪ(ventilator associated pneumoniaAVAP)ҶqܥͯϥηǫhӦXzϥΧܥͯsC "	"ﬡʦνξ(LߺһĶu]L^)LӡC
cephalosporinܥͯLӡC
L]-lactamܥͯ]ҦpGpenicillinBmonobactam  carbapenem^oYLӡ]ҦpGLөʤBYֽ^C "	oͩj 5% ZaviceftavfH̱`}CoombsܲyJոeʡBߩMmCߤθmY{פ@묰שΤסC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w05-17 [E]_G6-09 [Ew]_F5-16 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.6._20240401.pdf"">OI` 10.3.6.</a>              "	OI` 10.3.6.	0	OIs 20251124	IZAVI1			110.6.16
BC25066265	J01DH04	0	IFINI	Finibax 0.25mg/vial		Doripenem Carbapenem ܥͯA~b~ܵ߬ʲ[\FnPʤ󶧩ʵ߻P󳱩ʵߡC	"18HWHAC8pIwR`500mgAC`gɶжWL 1pɡC 
500 mg IV every 8 hr; administer over 1 hr
Renal impairmentG
 CrCl(ml/min)30-50 : 250mg Q8H
 CrCl(ml/min)10-30 /:250mg Q12H"	"1. HͲzQws`gGǷŤUwwɶ12pɡC2-8JUwwɶ24pɡC
2. H5%}Gws`gGǷŤUwwɶ4pɡC2-8JUwwɶ24pɡC
һsƪaBGΪ`gGiNC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Finibaxm 25J ҤC	Doripenem	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	Doripenem HydratePʤߺتʪcDPV(]AǪǪ)νʸĤPV	ĸTΩwDoripenemΦPī~YLӤ fwAγQi]-lactam ĪLөʥJfwC 	j`}YhBߡBmBol RߪC	קKϥΰDvn/Lm	קKϥΰDvn/Lm	аѦҾqPΪk	"CClr>50      500mg q8h
CClr 30-50  250mg q8h
CClr 10-30  250mg q12h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1. HWFINStsЩ1hrH}G}
2.}N24hr
tsGG10ml WFIB NS
ĳ}@סGts25mg/ml
}
250mg-2.3mg/ml (100ml)
ۮe}GG100ml NSB D5W 
ĳĳ~|tvG>1hr
`NƶG1.~PLī~ۮeʩ|TߡAФŻPLī~VXI"	ixii[w]_w04-04 [E]_G5-07 [Ew]_F5-21 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.3._20100801_000.pdf"">OI` 10.5.3.</a>             "	"OI` 10.1.,10.5.3."	0	OIs 20251124	IFINI-a	IFINI-b	IFINI-c	110.6.16
AC49881209	J01DE01	0	IMACE	Macepim inj. 1gm/vial		Cefepime @߾A@άӵ߲ӭMXCsĩʥiĹܼsjd򤧭󶧩ʤέ󳱩ʲӵߡA]Ajhƹi}̡]aminoglycosides^βĤTNYUlܥͯĩʤ߮C	"@릨Hq0.5-2gA q12h-Q8hCHĳ̤jq]2gm, q8h^vq`7-10ѡGYPVγ\nv[C
fH~֤j2ӤB魫p()40G50mg/kgAC12p1A10ѡC
ѦgBӵߩʸΦXֵoNݤʥզy֯ggkG
fH~֤j2ӤB魫p()40G50mg/kgAC8p1A7-10
魫j40礧pw̡AĳĥΦHq(Ѿ\4)Cpw̤qAiWLHĳ̤jq(2gm>q8h)C
ϥCefepimepPɶiGzRɡAq̤UC覡ġGĤ@ѪvCefepimelq1gAC0.5gFbz
RѡAbzRᵹġCi઺ܡACѵĪɶyTwC"	ǥ\णվΪkζqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Cefepime for Injection ץJsb25ץHUC
Cefepime powder for Injectionb@1-40mg/mLɡAPUCR߿GۮeG0.9%ƶuG
5%}GCoǷGbǷŤU24pɡAMíwC"	Cefepime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	CefepimePʤӵߩʷPVgC	~TΩe惡t褧զBYUlܥͯBLƪLΨL]ФQiܥͯLӤfHC	zGgιLӤC֯l(1.8%)Bm(1.2%)BRߪ(2.9%)εo(0.1%)C	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>60       2g q8h
CClr 30-60   2g q12h
CClr 11-29   2g q24h
CClr<10       1g q24h
IHD              1g q24h
CAPD          1~2g q48h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG}Ƿxs24hr
tsGG1g/10ml WFIBNSBD5W
ĳ}@סGIVG100mg/ml
IVFG1-40mg/ml
ۮe}GGNSBD5W
ĳĳ~|tvGIV:3-5min
IVF:>30min
`NƶGiMaminoglycosidesBmetronidazoleBvancomycinVXϥΡAYݨ֥ΡAiΤ}覡"	ixii[UDx]_U09-11 [w]_w04-20 [w]_w04-25 [E]_G5-05 [Ew]_F5-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IMACE-a	01C49881-1	01C49881-2	110.6.16
BC22115265	J01DH02	0	IMEPE2	Mepem IV inj 250mg/vial		PCXJա]PBPs^ܰ˩MʡAӵ߲ӭMX]ӭMpeptidoglycan[Φ^ 	"H@ζq10.51g Meropenem]Ļ^A23PAg30HWRIw`gCھڦ~֩Mgiվ㾯qAMw̩άOvʷPVw̡ACѾqiW2g]Ļ^C
ൣw̤@ζq@30-60mg(Ļ)/kgA3PAg30HWRIw`gCھڦ~֩MgAiվ㾯qAMw̩άOvʷPVw̡ACѾqW120mg]Ļ^/kgCOWLH@ѳ̤jq2gC"	"Vġ]UCfHVġ^ 
1. Carbapenem BPenicillinCephemܥͯLӥvfHC 
2. HΤAS̩jfް_ޭݡA֯lAC¯l誺fHC 
3. Yǥ\êfHeް_jˡANѻêϯgtίgC
4. Yx\êfHeiް_x\cơfC 
5. Ѧ~HC 
6. i}fHΫDgfPi`gfHAp}fHeiް_ͯKʥFgfC 
7. wfv̩Τϯgêw̡Aް_jˡANѻêϯggC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 25JHUxsC 	Meropenem	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	meropenem㦳Pʤӵߤް_PVg	"hTҡ]hWoΩUCfHA]fSݭnɡAVġ^
糧~LӥvfH
Tҡ]oΩUCfH^ 
(1) 糧~LөʥJfvfH 
(2) ϥSodium ValproatefH "	֯lBmBnKBߡBæRC 	קKϥΰDvn/Lm	קKϥΰDvn/Lm	аѦҾqPΪk	"CClr>50       1g q8h
CClr 25-50   1g q12h 
CClr10-25    0.5g q12h 
CClr<10       0.5g q24h
IHD              0.5g q24h
CAPD          0.5g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG}Ƿ6hrFN24hr
tsGGNS
ĳ}@סG5mg/ml
ۮe}GG100ml NS
ĳĳ~|tvG30min
`NƶG1.iΪ`gΤts ?"	ixiij	Ts114.04.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.1._20100801_000.pdf"">OI` 10.5.1.</a>             "	"OI` 10.1.,10.5.1."	0	OIs 20251124	DC	DC	DC	114.04.29
AC37064212	J01DC09	0	ICEFE	Cefe inj.2gm/vial(Cefmetazole)		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"IV. HX 2g Q12h~Q6h IVDA5~14. pX 25-100 mg/kg/day Q6H-Q12H.
ǥ\णCq"	"1BUCw̷VP
(1)penicillin tܥͪ観LӯgJfv̡C
(2)HˡBS̩nfް_ޮݡBolBC¯lLӯg
誺w̡C
(3)fAl}w̩ιIi`gw̡C
2BĴΧīܤ1 PAקKsC(s|ް_disulfiram like
reactionA椬@ξणC)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ts᷻G֨ϥΡAǷťiOs24 pɡANåiOs7 ѡC	Cefmetazole	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	󥻾cephem tܥͪ観LӯgJfvw̭hWiPAnɽзVPC	GOT WɡBGPT WɡBolBߡBæRC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	"CClr>50      2g q8h
CClr 30-50  2g q12h
CClr 10-30   2g q24h
CClr<10        2g q24h
IHD              2g q24-48h
CAPD          1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVBIM
tswwʡGtsǷŦs24 hrFNxs7
tsGG(IV)10ml WFIBNS
(IM)2.2ml WFIBNS
ĳ}@סG--
ۮe}GGNS
ĳĳ~|tvGIVF:10-60 min
`NƶGfHP24pɤקKΧts릨~"	ixii[ws]_w68-01 [ws]_w69-01 [UDx]_U08-01 [w]_w05-20 [E]_G4-07 [Ew]_F5-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ICEFE-a	ICEFE-b	ICEFE-c	110.6.16
AC48567277	J01DE01	0	ICEFI	Cefim Inj.500mg/vial		Cefepime @߾A@άӵ߲ӭMXCsĩʥiĹܼsjd򤧭󶧩ʤέ󳱩ʲӵߡA]Ajhƹi}̡]aminoglycosides^βĤTNYUlܥͯĩʤ߮C	"Hq: 0.5-2g Q12h~Q8h.
 pྯq: 50 mg/kg (MAX: 2 g/dose) IV Q12h~Q8h. ̵ǥ\վ㾯q"	ǥ\णվΪkζqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Cefepime for Injection ץJsb25ץHUC
Cefepime powder for Injectionb@1-40mg/mLɡAPUCR߿GۮeG0.9%ƶuG
5%}GCoǷGbǷŤU24pɡAMíwC"	Cefepime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	CefepimePʤӵߩʷPVg	~TΩe惡t褧զBYUlܥͯBLƪLΨL]ФQiܥͯLӤfHC	zGgιLӤC֯l(1.8%)Bm(1.2%)BRߪ(2.9%)εo(0.1%)C	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>60       2g q8h
CClr 30-60   2g q12h
CClr 11-29   2g q24h
CClr<10       1g q24h
IHD              1g q24h
CAPD          1~2g q48h"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡG}Ƿxs24hrFNxs7day 
tsGG(IM)1.3ml WFIBNSB D5W
(IV) 5ml WFIBNSBD5W
ĳ}@סGIVG100mg/ml
IMG280mg/ml
IVFG1-40mg/ml
ۮe}GGNSBD5W
ĳĳ~|tvGIV:3-5min
IVF:>30min
`NƶGiMaminoglycosidesBmetronidazoleBvancomycinVXϥΡAYݨ֥ΡAiΤ}覡"	ixiij	Ts114.04.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	114.04.29
BC24790209	J01DD04	0	ICEFT	Ceftriaxone Sandoz 1g/vial		~ߧ@ΥDnOӵ߲ӭMXC 	"HM12HWൣ
@뾯qCeftriaxone1-2gACѤ@]C24pɡ^CbYPVέPf߹CeftriaxonePʶȬOA侯qiW[4gC@ѵĤ@C
sͨ]14ѡ^GC鵹20-50mg/kg魫CC龯qnWL50mg/kgC
Mpġ]15Ѧ12^GC@20-80mg/kgCp魫j50kgNϥΦH@뾯qC
Rߪ`gľq50mg/kg魫ɡAH`ġAӥBĮɶܤֻݶWL30C

MpĪӵߩʸA}lvɡA龯q100mg/kg]̤ji4g^AunPf߳QŲwXӡABPʤ]QT{AqiCܫezqC
ܩif
pĩMHq50mg/kgA̦hi2gAC@A@14ѡCNP´wPV
̾ڷPVMIʡAb}Me30-90뤩@qCeftriaxone 1-2gC "	"iPttG(Ringer's solution,Hartmann's solution)ΫDfAtti~VXC28ѷsͨATbĪvttGΰw"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs30JHUANp~Osb~ץ
tmnGixs2~8JU48pɡA`ŤUJUA24pɡD"	Ceftriaxone	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	"ܥͯ cephalosporinsLӪfHϥCeftriaxoneDPenicillinLӪHAi঳oͥeLӪi. 
xgsͨΦणoϥceftriaxonevDfHoixfi.
CeftriaxoneoPttk֥ΦbsͨਭWAiಣceftriaxone-calciumID"	mBߡBæRBfBުBզy֡BݥyWhBʳhBpO֡BC¯lC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668918?cesid=akkFJfOlLux&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCeftriaxone%26t%3Dname%26acs%3Dfalse%26acq%3DCeftriaxone#"">LexidrugľǸƮw</a>"	"1-2g q12-24h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡGհtε}Ƿ24hrFN48hr
tsGG10ml WFI(IV)
ĳ}@סG10-40mg/ml? 
ۮe}GG2 g40ml WFIBNSBD5W?
ĳĳ~|tvGIV:>2-4min?
IVF: 30min?
`NƶG1.ŻPLtܥͯĪGVX
2.oPttGVXΦPɪ`g
3.sͨ28ѡAYHRߪ`gttī~i~AhA뤩ceftriaxoneAY>28ѡAi~ϥceftriazoneBttī~A`޻ݥHiۮeGR~"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.3._20060601_000.pdf"">OI` 10.3.3.</a>             "	"OI` 10.1.,10.3.3."	0	OIs 20251124	ICEFT-a	ICEFT-b	ICEFT-c	110.6.16
AC56657277	J01DD07	0	ICETI	Ceticin  inj.500mg/vial		@ξରӵ߲ӭMXAMCXJա]PBP^lb ̱j˩MʡA䦸OlaA3Ct~A󳱩ʵߤ~qzʨ}nC	"H1 0.5~2g]O^Ap1 40~80mg]O^/ kgA2~4Rߪ`gC~Ai̦~֡BgAyWCgBvʷPVɡAHiHWq14g]O^ApiHWq1 120mg]O^/ kgC 
ǥ\णG
CrCl(ml/min)>50,@@ 2g Q8H~Q12H;
CrCl(ml/min)10~50,@ 2g Q12H~Q24H;
CrCl(ml/min)<10,@@ 2g Q24H

Rߪ`gɡAΪ`gΤBͲzQθ}`gGѡAwC`gC
t~Ai[J}BqѽBiĵs`GAH30 ~2 pɪɶAIw`JRߤC

tӴuRߪ`g500MG(Ceftizoxime)vGtskG
1. Rߪ`gGtskG
Ceftizoxime 500mg H`gΤ 5mLAts@ 95mg/mLC
2. R߿GtskG
Nts᪺CEFTIZOXIME G(95mg/mL)[J50100@ɤͲzQ5wv%}`gGC"	"1. @`NƶwJAniԲӪݶEC~A̦nbīeֽC
2. UCw̤nPL]ceftizoxime sodium Ӥް_JJw̡C 
3. UCw̭nVP 
(1) penicillin cephem ĪLӬJw̡C 
(2) HBΥS̩nfoޮݡBolBC¯lL褧w̡C
(3) ׵ǻêw̦ɡA]夤@׫[AҥH̵ǻê{צӴ֧PqANPjC
(4) 藍ॿ`iΫDgfiw̡B̡֪B A}w̡C]]i|X{LRK ʥFgAҥHnYK[^C 
4. ѫᶷ֨ϥΡCOsɡAǷūOsUAi|ͨIAҥHb7 pɤϥΤAOsbBcɡAhb48 pɤϥΤC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"25JHUxsC 
ѫᶷ֨ϥΡCOsɡAǷūOsUAi|ͨIAҥHb7 pɤϥΤAOsbBcɡAhb48 pɤϥΤCMѲGi|HۮɶӲLܶAvTϥΡC"	Ceftizoxime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	L]ceftizoxime sodium Ӥް_JJw̤nP 	mBuߡBæRgCuLRK ʥFg]C?gBXɦV^MLRB sʥFgABUN ȤW@AٻȪ@AFBJէǥ\êAҥHnYK[ܡD	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50       2g q8h
CClr 10-50   2g q12h
CClr<10        2g q24h
IHD              2g q24h
CAPD          1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡGtsǷ7hrFN48hr
tsGG5 ml WFIBNSBD5W
ĳ}@סG-
ۮe}GGNSBD5WBLR
ĳĳ~|tvGIV:3-5min
IVF: 30min~2hr
`NƶG-"	ixii[w]_w04-08 [w]_w04-19 [E]_G5-02 [Ew]_F5-11 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ICETI-a	ICETI-b	ICETI-c	110.6.16
AC35991209	J01DB01	0	ICLP	ROLES powder inj.1gm/vial		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	IVXHG2g q8h-86hAG50-100 mg/kg/day	CLӪw̡AϥYU߯SOpߡA]CڻPYU߯ڶi㦳椬LӪʽ(Cross-allergenicity)D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ǷץsD
ѫAbǷŤUOspɡD"	Cephalexin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	YUl߯ܥͯLөʤw̸TΥġC	 mAߡAæRAƤ}θhD~AC¯lΦީʤ~D	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>50      1g q6-8h
CClr 10-50  1g q12h
CClr<10      1g q24-48h
IHD             1g q24-48h
CAPD          1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIMBIV
tswwʡGtsǷŤU24hr
tsGG3ml WFI(IM)
ĳ}@סG-
ۮe}GG-
ĳĳ~|tvG-
`NƶG-"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ICLP-a	01C49130-1	01C49130-2	110.6.16
AC59697209	J01DC14	0	IFLUM	"Flomoxef 1g ""C.C.P.C"""		PL]-QiܥͯۦAFlomoxefi]OqLP@ةΦhثCXJ(PBPs)۵XAêӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"q`H11-2g(O)AGHRߪ`gIwRߪ`gC
q`pྯqH1C60-80mgpAT~|HRߪ`gIwR`PC
q`BsͨH@C20mgAXͤTѤ@2~3AXͥ|ѫ@3~4HRߪ`gIwRߪ`gPC
Ŧêw̤ھڵǥ\վPqAYݬ~ǡAhĳbfw~ǫeUP1 gFlumarin?YiC
H4 mLHW`gΤBD5WNS[JvialARAϧѡC
"	"1.YpenicillinLӪw̡Aϥcephalosporinī~SOpߡC
2.tN-methylthiotetrazole (NMTT)̡A|zZ]lXAiɭPfHXɦVApcefmetazoleBcefoperazoneBlatamoxefBflomoxefC
3.ϥΥ~wˬdx\Aǥ\ΦGD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" 25 ץHUxsD
ջsǷŤUOs6pɡABcOs24pɡD"	Flomoxef	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	糧PʤUCfߩҤް_YPV:yݡBy(zy߰~)BͪyߡBOߡBPeptostreptococcusݡBBranhamella catarrhalisBjzߡBKlebsiellaݡBProteusݡBInfluenzaeߡBBacteroides	"(1) 糧~LӪ̡ATϥΡC
(2) cephalosporinܥͯLӪ̡C"	yƥز`BJBLӡBxǻêBLRKBBʥFBUgBnKBGOT\GPTWɡC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	"CClr>50      1g q8h
CClr 25-50  1g q12h
CClr5-25     1g q24h
IHD            1g q24h
CAPD        1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡGtsǷ6pɡFN24p
tsGGtsG4 ml WFIBD5WBNS
ĳ}@סG-
ۮe}GGNSBD5W
ĳĳ~|tvG30-60min
`NƶG1.Rߤjq`gi|ް_޵hPRߪA`gtwC"	ixii[UDx]_U09-10 [w]_w05-03 [w]_w05-07 [E]_G5-08 [Ew]_F5-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IFLUM-a	IFLUM-b	IFLUM-c	110.6.16
AC50081212	J01DD02	0	IFORT2	Cefdime inj.2gm/vial		īYĤTNYUlܥͯA߾bӵ߲ӭMJս褧ͦXAܤj󶧩ʵߤγʵߡAwͣ]-lactamase @ĩʤߺإ禳	"(1)HqG1 ~6 g/day2-3Aq8 ~q12h IVCjh
YPVgASOOK̨lfHA]AǱwݤʦy̡֪A2g q8~q12hA3g q12hC
󨺨Ǧb[@fФiRߦGzRΰyqGLoǰIܯfwAĳϥξqC1 JAƦD
(2)ൣG[sΦܨӤjൣG] C12p1AC25-60 mg/kgF[WLӤjൣ] C8p1AC30-100 mg/kg (̤jqG6 g/day)FϥΩPVAӧK̨lֺn~ൣAΩwൣCiFCC魫150 @J]̰C6 J^qATġC
"	"p~uR߿`ɡ]ҦpG30 ^AiѥHU覡ջsG
@B NwLL~ʤfAê`J10 @ɵ}GCuŪp|U}GiJCNwLޥXC
GB nʦܷѡGGƺҳQA@ܤGK@MGC
TB N@wLL~ʤfHX~OCwLdbAM[Jlq40 @ɵ}GC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"25JHUxsAץC
H`gΤΤUC@ت`gGջsAĮĥibBc]2-8XC^Os24 pɡC"	Ceftazidime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	CeftazidimeO?ߩYUlߧܥͯBhؤAQi??Bùsd򪺭?󶧩ʤγʲӵߦġC	Ceftazidime TҥΩYUlߧܥͯLӪfHC	RߪΦRߪBmBߡBæRBhBC¯lBLөʤ]]A޵j˩M/ ΧC^Cibǥ\णӥACceftazidime @תfwAoͯgtΪg]AŸݡBٰ}ˡBjˤθfܡC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	"CClr>50      2g q8h
CClr 10-50  2g q12-24h
CClr<10        2g q24-48h
IHD              2g q24-48h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG1.~ץJs
2.tsN24hr
tsGG20ml WFI
ĳ}@סG1-40 mg/ml
ۮe}GGNSBD5W
ĳĳ~|tvGIV:3-5min
IVF:15-30min
`NƶG1.iPaminoglycosidsesVX
2.iPNaHCO3 inj.VX
3.קK٦ת`gɯkhAiH0.5% or  1%Lidocaine HCl inj.}"	ixii[w]_w04-03 [w]_w04-16 [E]_G4-08 [Ew]_F5-15 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IFORT2-a	01C50081-1	01C50081-2	110.6.16
AC55249209	J01DC07	0	ILOTI	Lotiam 1gm/vial (cefotiam)		"ﭲ󳱩ʵߤέ󶧩ʵߨ㦳sxܵߧ@.夤@ׯu}ζq̦s,QN¦ӤjѧƪnCSbxĤQ{}nCb{ɸW{ѦgB~PVgBIlPVgBzDPVgB
PVgۤĪGC"	2-4g/day2-4	"1.chphemo͹LӪ(]Acephalosporin,cephamycin,penicillin)
2.HΪ˦,ol,C¯lLӯg誺w
3.Yǻêw"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץOsAקKLD	Cefotiam	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS		"y,yߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC"	糧ĵoͥJ̸T	"J,LӤ,BUN,ScrWɡApO,eosinophilWhAGOT/GPTWɡA߹æRhAfA]߷PVAYh"	DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	"CClr>50     1g q6-q8h
CClr 5-30   1q8-12h
CClr<5       1g q12-q24h
IHD               0.5g q24h 
CAPD            0.5g q24h  "		"ĳ~|GIVBIVF
tswwʡGĳ}ʫmN8pɤΧ
tsGG5ml WFIBNSBD5W[J100ml }G
ĳ}@סG10mg/ml
ۮe}GGNSBD5W
ĳĳ~|tvG30-120min?
`NƶGuRߪ`g
"	ixii[w]_w04-15 [w]_w04-22 [E]_G4-02 [Ew]_F5-19 j	Ts110/10/4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ILOTI-a	ILOTI-b	ILOTI-c	110/10/4
AC49155277	J01DH02	0	IMEPE1	Mexopem I.V. Inj.500mg/vial		PCXJա]PBPs^ܰ˩MʡAӵ߲ӭMX]ӭMpeptidoglycan[Φ^ 	"HIVq :0.5~1g Q12~Q8H A`gɶ>30Dھڦ~֩Mgվ㾯qDYPVG2g/day 
ൣqG@30-60mg/kg Q8HA`gɶ>30Dھڦ~֩Mgվ㾯qDYPV120mg/kg/day A<2g /dayD
CClr 26-50ml/min: 1g Q12H
CClr 10~25ml/min: 0.5g Q12H
CClr <10ml/min: 0.5g Q24H
GzRwzRᵹ"	"1.Yǥ\êfHް_jˡANѻêϯgtίgC
2.糧~penicillin,cephalosprin,carbapenemLөʯfv̶VġD
3.bϥsod valproatew̡APmexopem֥η|sod valproate@׭C .
4.Yx\ण}̥iv_x\c
5.i}i}w̥iް_ͯKʥF"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 25JHUxsC 	Meropenem	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	meropenem㦳Pʤӵߤް_PVg	"1.糧~LөʥJfvfH
2.ϥSodium Valproate fH"	֯lBmBnKBߡBæR	קKϥΰDvn/Lm	קKϥΰDvn/Lm	аѦҾqPΪk	"CClr>50       1g q8h
CClr 25-50   1g q12h 
CClr10-25    0.5g q12h 
CClr<10       0.5g q24h
IHD              0.5g q24h
CAPD          0.5g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG}Ƿ6hrFN24hr
tsGGNS
ĳ}@סG5mg/ml
ۮe}GG100ml NS
ĳĳ~|tvG30min
`NƶG1.iΪ`gΤts ?"	ixii[UDx]_U09-13 [w]_w04-23 [w]_w05-11 [E]_G6-01 [Ew]_F5-17 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.1._20100801_000.pdf"">OI` 10.5.1.</a>             "	"OI` 10.1.,10.5.1."	0	OIs 20251124	IMEPE1-a	IMEPE1-b	IMEPE1-c	110.6.16
BC26741277	J01DH51	0	ITIEN5	Imipenem/Cilastatin Kabi inj. 500mg/vial		"Imipenem/Cilastatin jĤӵ߲ӭMXAiĦa?(bactericidal)jh?f
-?󶧩ʵߡA?󳱩ʵߡAݮߤιߡC"	"jh?PVC1-2 gm 3-4 Īk?nC襤?PVAiΨC2 A
C1 gm ??v?CPʸtfߩҤް_PVARߧP d񡨬̥?C
`?iW4 gm/dayA50 mg/kg/dayAHC?hC
wγ~G
HwNPVɡAib¾KɮRߧ뤩 1000 mg d񡨬̥?ATpɫA뤩
1000 mgCPV(pzz)NɡAibɫ8 16 pɼW500 mgC
pྯqG
(a) pĤ魫j()40 kg ɥiĥΦH?C
(b) pĤΥध魫p40 kg ɥiC?pɵ15 mg/kgAC`??yWL2 gmC"	"Imipenem/Cilastatin ?AΩv?C
@?ĳimipenem Mvalproic acid divalproex sodium X֨ϥΡCAvalproic acid divalproex sodiumAw?nfHAҼ{ϥΰ?carbapenems ?H~ܵ߾A?v?PVCpGϥ Imipenem/CilastatinAҼ{l[ܵj˪v?
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"s 25XC HU
бNp~s~HץOs
ѩε}ᤧG?YϥΡAѷѶ}lܧ`ɶj?oWO 2 pɡC"	"imipenem monohydrate(۷500mg imipenem anhydrate)
cilastatin sodium(۷cilastatin 500mg)"	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	"Imipenem 㦳Pʤ?󳱩ʵߡA?󶧩ʵ߷PVgC
?GImipenem/Cilastatin ]㷥es?߬ʡAGSOAXΩv?hزӵ߷PVMݮ/
߲VXPVgA]AXΩfߩ|Ųwev?C
Imipenem/Cilastatin AXΩv?U?PʲӵߩҤް_PVG
*ĤPV
*UIlDPV
*PV
*Ѧg
*??ʹ޹DPV
*`PV
*ֽγn´PV
*ߤ"	TΩ糧~󦨤LӪfHC	"̱`???CAohεwARߪC
Qi?gtΰƧ@ΡA?p٦װ}ˡAVcPwo@(seizure)ASOOAζWL̵ǥ\魫p⤧ĳ?̡CpoͧŸݡAٰ}ˡBwAfH?g?pöi?ܵj˪v?ApG?gtίg?AhImipenem/Cilastatin ?ΰϥΡC"	"Imipenem/Cilastatin ϥΩh?譱wʳi|T?ADwwLMIʶi?
?A~ĳϥΡC"	"Ťio Imipenem sbApGfHDĥImipenem/Cilastatin v??iɡA
šC"	аѦҾqPΪk	"CClr>50     500mg q6h
CClr 10-50    250mg q8h
CClr<10      250mg q12h
IHD            250mg q12h
CAPD          250mg q12h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.~ץOs
2.ݥߧYϥΡAqѶ}l짹`ɶjiWL2p
tsGG`Nƶ
ĳ}@סG5 mg/ml
ۮe}GGNSBD5W
ĳĳ~|tvG500mg, >20-30min
>500mg, >40-60min
`NƶG1.[J10 ml NS or D5Wvial RnʫANaBGJ100ml `GFAХ[J10 ml `Gvial ATONvial eJ`eC  
2.iHϥΧtŻQ}G
3.iPLܥͯVXΨ֥"	ixii[w]_w05-10 [E]_G6-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.1._20100801_000.pdf"">OI` 10.5.1.</a>             "	"OI` 10.1.,10.5.1."	0	OIs 20251124	ITIEN5-	ITIEN5-b	ITIEN5-c	110.6.16
AC60278209	J01DD62	0	IZEFO	ZEFOTAM 1g/vial(Cefoperazone0.5g+ Su		Sulbactami ] lactamase  Ic B II B III  IV A H εyL Ia  V ơAҥHioǻï[cefoperazone AG cefoperazone   ʪ ߤ] ܵߤO CC efoperazone ǥѱjOêӵ߼W޴ӭMXHF ߧ@ C	"H
C`q1g/1g2g/2gAj12pɡA⦸ġCYPVAHC龯q
iW[ 4g/4g A⦸ġC
p
C`q C魫 20mg/20mg  40mg/40mg A2~4   CY PV ɡA C龯qiW[ܨC魫80 mg 80mg A 2~4   C"	"1. ֪̳q`|]Ͳz\୰CӮeͰƧ@ΡAi|]ʥFLR K oͥX{HC
2. penicillin tܥͯ Lӥv fw AwoͥJAиԲӰݶEC
3.YxêfwA ]夤@ץbIAn`NqPĶjC
4.Y  êfwA ]夤@ץbIAn`NqPĶjC
5.gf}w̩εLkgfɥRi fw  A} fw A]ʥFLR K ӦXg A]J[ w̪A"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"H
C`q1g/1g2g/2gAj12pɡA⦸ġCYPVAHC龯q
iW[ 4g/4g A⦸ġC
p
C`q C魫 20mg/20mg  40mg/40mg A2~4   CY PV ɡA C龯qiW[ܨC魫80 mg 80mg A 2~4   C"	Cefoperazone/Sulbactam	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	AΩvѷPʲӵߩҤް_UCPVGWBUIlDPVBWBUcDPVBBxnBxުΨ䥦ĤPVBֵoBlcΨ䥦ʹ޹DPVBHγж˿SˡBNᤧGPVC	"]ӵoͥJ̸TϥΡC
󥻾ΪcephemtܥͯLӥv fwTϥΡC"	m] 0.75%0.75%^Ao l 0.45%0.45%^AoN 0.21%CDn{ˬdȲ` AST GOT ^W 3.18%ALT GPT ^W 3.41% ALP Wɡ] 1.05%1.05%^C	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50      4g q12h
CClr15    4g q12h
CClr<15       2g q12h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG}Ƿxs6hrFNxs48 hr
tsGG6~10 ml WFIBNSBD5W
ĳ}@סG-
ۮe}GGD5WBNS
ĳĳ~|tvGIV:>3 min
`NƶG1.iSCBIM
2~NMTT(N-methylthiotetrazole side chain)AӧLRKƪ٭ï(vitamin K epoxide reductase)AiӼvT]l\AbѦ~iAΪ̡Aiಣ;岧`γyXAnɥiR߿`LRKAHwYXC"	ixii[UDx]_U08-05 [w]_w05-18 [w]_w11-02 [E]_G6-10 [Ew]_F5-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IZEFO-a	01C60278-1	01C60278-2	110.6.16
AC17280151	J01DB01	0	LULEX	Ulexin for oral suspension 125mg/5ml;60		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"HΨൣ魫WL25 ̡GC龯q1 4GmAAΡD
qPVA250mg q6hFYPVA500mg q6hD
ൣG~25mg/mlAC龯q25~50mg/kg(1-2ml/kg) |AΡAYPVɾq50-100mg/kg|A
10kg  2.5-5ml |A
20kg 5-10ml |A
40kg 10-20ml |A"	CLӪw̡AϥYU߯SOpߡA]CڻPYU߯ڶi㦳椬LӪʽ(Cross-allergenicity)D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ(30JHU)BJsC
ѫxsBcAéPAΧD"	Cephalexin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡAyߡAͪyߡAyߤΨLPʲӵߤް_PVgD	YUl߯ܥͯLөʤw̸TΥġC	 mAߡAæRAƤ}θhD~AC¯lΦީʤ~D	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_05-05 [E]_I4-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	LULEX-a	LULEX-b	LULEX-c	110.6.16
AB29447277	J01DB04	0	ICEFA	CEFA 500MG/VIAL		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"IV or IM. H@뾯qX 2g Q8H; MAX 12 g/day. pྯq: 25-100 mg/kg/day Q6 -8H; MAX 6 g/day
ǥ\णվ㾯q"	"ǥ\ण}w̡ApߨϥΡC
penicillin tܥͪ観LӯgJfv̡AeLӤIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ץOs.
ѫᶷץAǷŤU48pɤϥΡANâp."	Cefazolin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	YUl߯ܥͯLөʤw̸TΥġC	",æR,m,,`gkh,C¯l"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668915?cesid=3BVjVgOe91T&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dcefazolin%26t%3Dname%26acs%3Dfalse%26acq%3Dcefazolin"">LexidrugľǸƮw</a>"	"CClr>50      1g q6-8h
CClr 10-50  1g q12h
CClr<10      1g q24-48h
IHD             1g q24-48h
CAPD          1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIMBIV
tswwʡG1.ѫǷץ48hrAN96hr
2.YϥNSѡAХߧYϥΧ
tsGG IM: 2.5ml WFI, 3.5ml NS or D5W
IV: 5ml WFI, 7ml NS or D5W
ĳ}@סG--
ۮe}GG50-100ml NSBD5W
ĳĳ~|tvGIV:3-5min
"	ixii[UDx]_U09-03 [w]_w04-02 [w]_w04-17 [E]_G4-09 j	Ts113.04.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ICEFA-a	ICEFA-b	ICEFA-c	113.04.19
AC45699100	J01DD08	0	OCEFS	Cefixmycin 100mp/cap		"1. ܵߧ@
 㭲󶧩ʵߤέ󳱩ʵ߼sx߽ܵdASO󶧩ʵߤStreptococcus spp.,]enterococcus~^ S. pneumoniaeA󳱩ʵߤN. gonorrhoeae, Branhamella Catarrhalis,E. coli, Klebsiella spp., Serratia spp., Proteus spp., H. influenzaeAܵߤO]LfACephemjA@ΧΦOߪC
ѩUزӵ߲ͪ]-LactamasewwAҥH]-Lactamase͵ߤ]uܵߤOC
2. @ξ
@ξରӵ߲ӭMXA@I]ߺؤPӲAOMPenicillinXJ(PBP)1(laAlbAlc)3jO˩MʡC"	"H魫30kgHWpAHCefiximeA150~100mg]O^A@fA2Ci̦~֡B魫BgAyWC
gαĪGfҡAHCefiximeA1200mg]O^A@fA2C"	"1.PenicillinܥͯLӯfvw̡C
2. HBΥS̩nfoޮݡBolBC¯lL褧w̡C
3. ׵ǻêw̡C]аѦҡuΪkDζqAϥΤW`NƶvΡuĪʺAvC^
4.ॿ`iw̩ΫDgfiw̡BA}w̡]]i|X{LRKʥFg
AGYK[C^ 
5.Ѧ~HX{LRKʥFgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsCקKӮgFpoܽιLAiAϥΡC	Cefixime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	CefiximePʵߤް_UzPVgAުBXig]PVɡ^ACʩIltef~oʷPVBͪBǪǪBH֪BӵߩʧDCժBƻu	"(1) 糧~LӪ̡ATϥΡC
(2) cephalosporinܥͯLӪ̡C"	ߡBæRBmBGzAB֯lBYhC	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.4._20060601_000.pdf"">OI` 10.3.4.</a>             "	"OI` 10.1.,10.3.4."	0	OIs 20251124	OCEFS-a	01C45699-1	OCEFS-c	110.6.16
AC25659100	J01DB05	0	ODURA	Cefadroxil 500mg/cap		siӵ߲ӭMXӹFߧ@ΡC	"H40kgHWpġGC1~2gmAYfYiW3~4gmAC8~12 pɥĤ@C
魫C40kg pġGC25~50mg/kgAYfYAiW75~100mg/kgAC8~12 pɥĤ@C
"	"ǥ\ण}w̡ApߨϥΡC
penicillin tܥͪ観LӯgJfv̡AeLӤIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(30JHU)BJsC	Cefadroxil	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	YUl߯ܥͯLөʤw̸TΥġC	ߡBmBlBC¯lBީʤ~C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-09 [s]_52 [®]_52 [UDx]_U02-24 [E]_A1-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ODURA-a	ODURA-b	ODURA-c	110.6.16
AC067471G0	J01DB01	0	OKEF2	Cephalexin 250mg/cap(Cephalexin)		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"(1) HG250-1000 mg Q12~Q6HAC500 mg (̤jqG4 g/day)C
(2) ൣG[1-15] 25-100 mg/kg/dayA6-8pɪA (̤jqG4 g/day)F[>15] C6p1AC250-1000 mgAΨC12p1AC500 mg (̤jqG4 g/day)C
Renal impairmentGCrCl<50 mL/min, give usual dose Q12 H."	CLӪw̡AϥYU߯SOpߡA]CڻPYU߯ڶi㦳椬LӪʽ(Cross-allergenicity)D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Cephalexin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	(1) 糧~LӪ̡ATϥΡC(2) cephalosporinܥͯLӪ̡C	ߡBæRBmBGzAB֯lBYhC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OKEF2-a	OKEF2-b	OKEF2-c	110.6.16
AC156601G0	J01DB01	֤OYn 500@J	OKEF5	Cephalexin 500mg/cap		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"(1) HG250-1000 mg Q12~Q6HAC500 mg (̤jqG4 g/day)C
(2) ൣG[1-15] 25-100 mg/kg/dayA6-8pɪA (̤jqG4 g/day)F[>15] C6p1AC250-1000 mgAΨC12p1AC500 mg (̤jqG4 g/day)C
Renal impairmentGCrCl<50 mL/min, give usual dose Q12 H."	CLӪw̡AϥYU߯SOpߡA]CڻPYU߯ڶi㦳椬LӪʽ(Cross-allergenicity)D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Cephalexin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	"(1) 糧~LӪ̡ATϥΡC
(2) cephalosporinܥͯLӪ̡C"	ߡBæRBmBGzAB֯lBYhC	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669452?cesid=1DAaEev5OPP&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCephalexin%26t%3Dname%26acs%3Dfalse%26acq%3DCephalexin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.01	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	114.07.01
AC27513100	J01DC04	0	OKEFR	U-CLOR 250mg/cap(Cefaclor)		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"1. Hw250500mgAC8p1C
2. ĵ:C2040mg/kgAƦAC8p1(Cѳ̤jq1g)C"	 penicillin tܥͪ観LӯgJfv̡AeLӤIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cefaclor	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡBҤAطyߡBͪyߡBjzߡB_ܧεߡBJpդݡBݦߵfߩҤް_PVg	wCephalosporinܥͯLӪw̡A糧]|LӤC	ߡBæRBm{HC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-01 [s]_347 [®]_347 [E]_A1-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.1._20210608.pdf"">OI` 10.3.1.</a>             "	"OI` 10.1.,10.3.1."	0	OIs 20251124	OKEFR-a	OKEFR-b	OKEFR-c	110.6.16
AC12528221	J01EE01	0	IBACT	*SEVATRIM 5ML/AMP(BACTAR)		sulfamethoxazolevPABAAӧdihydrofolic acidXCTrimethoprimdihydrofolate٭?AG_tetrahydrofolic acid͡C]bܦhӵߤJսPֻĦXGӳseBJ_ C 	"H12 HWpġG
зǾqG10ml/ACѨ⦸AߦU@C
YPVG15ml/ACѨ⦸AߦU@C
12 HUൣG
ĳqC24 pɨϥά6mg trimethoprim 30mg sulfamethoxazole/kg 魫A⦸۵qC
~iH̤UCqķǫhG
6 P~6 ӤG1.25ml/ACѨ⦸C
6 Ӥ~6  G2.5ml/ACѨ⦸C
6 ~12  G5.0ml/ACѨ⦸C
YPVɤpྯqiHW[50%C
~OFfHLkfAvɦӳ]pCYPVqĳ̫e
ܡABnsϥζWL3 ѡC@AĤiݭnWLƤC
ΪkG
1. ~ugR߳~|ġABīe̤UC}tsG
@w`gG]5ml^A[125ml `GC
Gw`gG]10ml^A[250ml `GC
Tw`gG]15ml^A[500ml `GC
2. ϥΫe}C~[ܿ`GAVXGnHTOV
áC`gGVXɩΤeɶX{iVBεC
3.̤WC覡}C~iPUCGVXGGlucose Intravenous
Infusion BP 5% and 10%BSodium Chloride Intravenous Infusion BP
(0.9%)C
4.䥦觡iP~VXAĳ`ɶ1.5 pɡAoi
fHݭnӽվHFšCSQϥΪw}GC "	"1.YX{֯lAϥΥ~C
2.GWLtOi઺ASOOq񦳰򥻤ߪͯeffHC
3.ǥ\ण}w̤Wzܽվ㾯qAB̦nq߿@סAӺAyqC
4.Ѧ~HGvѦ~fHq`nSOpߡA]osHƧ@θӷPBGXYĪGC
5.vbʸįʥFfHҼ{ɥRġApѦ~HC
F~@׾q]iHҼ{ɥRġCY~vASOO
æĥN¤}fHAĳCӤ밵ypơA]ApOqC`uAMӥHUY|ɭP`o͡GStevens-Johnson syndromeA Lyell's syndrome]rʥ֤W´a^BrzʨxŦaBɩʥզyʥFgBAͤʳhBʴcGBIlDL׿ġCݪ`NfHxŦY誺lˮɡAtrimethoprim Msulfamethoxazole lMN¥iܡC
6.bG-6-PD ʥFfHi|oͷgCP~YLөΤީʮݪfHԷVC
7.~ϥΦb]A s]-yߩҤް_|甆WA]ĪG
Penicillin tC
8.Trimethoprim |phenylalanine N¡A o靈A
phenylketonuric]f଻ħg^fHSjvTC
9.קKP~wκægMIsfHAtrimethoprim M
sulphonamides iϵcơ]MSsulfamethoxazole ^C
10.[IfHKʴ[@סC
1. ~ioͤıB~{BNzBi믫}C
2. ~isulphonamideB trimethoprim co-trimoxazole wLӯfvfHC
3. DYتpUA_hiĩYGeffHC
4. ӭMrʯfHӨSζgG譱Ƨ@ήɡAiHXֵġC
5. ~iHgΨͲsͨC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Sulfamethoxazole/Trimethoprim	J01E	Di SULFONAMIDES AND TRIMETHOPRIM	0	v󶧩ʵߤγʵߩҤް_IlDBGzDBDPVgC	"1. TҩxŦˮ`fHC
2. Yǥ\णALk߿@׭дq̡ATϥΡC "	ӷPBmBYwBʥFBߩRBh¡C 	קKϥΰDvn//SmҦw	קKϥΰDvn//SmҦw	аѦҾqPΪk	"CClr>50   ̾TMPq: 5- 
                  20mg/kg/day,divided q6-12h
CClr 10-29  5-10mg/kg/day,divided q12h 
CClr<10   ĳϥ,If used, 5-10mg/kg 
                 q24h
IHD         ĳϥ
CAPD       ĳϥ"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG}ᶷ6 hrsΧ
tsGGD5WBNS
ĳ}@סG1 amp in125ml,fw1 amp in 75ml? 
ۮe}GGD5W
ĳĳ~|tvG>60-90 min
`NƶGiHMLĪVX"	ixii[UDx]_U08-03 [w]_w05-12 [E]_G6-02 [Ew]_F5-18 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IBACT-a	IBACT-b	IBACT-c	110.6.16
AC44321151	J01EE01	0	LSULF	Sulfacotrim(Trimethoprim+Sulfamethoxazole ) 		sulfamethoxazolevPABAAӧdihydrofolic acidXCTrimethoprimdihydrofolate٭?AG_tetrahydrofolic acid͡C]bܦhӵߤJսPֻĦXGӳseBJ_ C	"ĵGgܤӤGCGAC2.5mlCӤܤGCGAC5mlCܤQGGCGAC10mlC 
HGC2AC20mlA\UA@DYsϥΤQ|ѥHWAiאּC⦸AC10mlAg̥iΰqAC30ml"	YgƤ餺ﵽΧYAЧiv1.Ŧۦ氱 2.DfHAЦhܤ 3.`N 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	"Trimethoprim 8mg/ml,Sulfamethoxazole 40mg/ml"	J01E	Di SULFONAMIDES AND TRIMETHOPRIM	0	ѭ󶧩ʵߤγʵߩҤް_IlDBGzDΧDPVC 	"1.xl`AʴcfAYǾणAιDiLӤw̵ҥΥġC
2.~@PηsͨҥΥġC "	ӷPBmBYwBʥFBߩRBh 	ĳϥ/qLLLAêĦX	קKϥ/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.09.03	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	114.09.03
AC249641G0	J01EE01	0	OBAKT	Morcasin Ƥ(SMX+TMP)		sulfamethoxazoleP Trimethoprim O Dihydrofolic acid synthetaseP Dihydrofolic acid reductaseA]ӧ purine XA_DNAPRNAѵӯ}aLͪc޹L{C	"Adult: Chronic bronchitis; travelers diarrheaX 2 tablets PO Q12H. Duration is depending on severity and site of infection.Pneumocystis Jiroveci, Treatmentw 15-20 mg TMP/kg/day PO/IV divided Q8-Q6h.
Pediatric(>2 months): mild-to-moderate infectionX 8-12 mg TMP/kg/day PO divided Q12h. serious infectionX20 mg TMP/kg/day PO divided Q6h; 8-12mg TMP/kg/d IV divided Q6h.
q`H@Ap6~12@@A@TC"	]1^ trimethoprimsulfonamideLӪ̡C]2^ GBxǻٮ`̡ALө̡AVPC]3^ p2Ӥ몺TΡAiysͨnC .	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(1530J)UOsC	Sulfamethoxazole/Trimethoprim	J01E	Di SULFONAMIDES AND TRIMETHOPRIM	0	ѭ󶧩ʵߤγʵߩҤް_IlDBcDBzGDPVgC 	}CQBJʥFg]G6PD^ʥFgw̡C	ֽloB mBLBߡBæRC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D4 [2]_D4 [ws]_w39-04 [s]_212 [®]_212 [UDx]_U03-31 [E]_B4-24 [Ew]_EX045 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OBAKT-a	OBAKT-b	OBAKT-c	110.6.16
BC20266277	J01FA01	0	IERYT	Erythrocin IV.500mg/vial(Erythromycin)		"ͤƾǴܡAerythromycinifߺسJս誺XAӤ|vTֻĪXCwerythromycinMclindamycinBlincomycin chloramphenicol|ܧ@ΡC
ErythromycinǥѻPPӵߪ50Sֿ}馸쵲XAΧJս誺Xӵo@ΡC|vTֻĪXC
@Ωmotilin receptorPizGDįʡC"	"vHΤpĪYPV,ҫĳerythromycin lactobionateR߿`q15-20 mg/kg/day, i̷PV{פPq4J/ѡC`gΫ̾AXHCtΧC@װsʺw`, Cjpɰʪ`g禳ġCRߤerythromycinɦHfAerythromycinNC
wCsʿ`:erythromycin lactobionate}@׬1J/ɡC
v?]?f?(N. gonorrhoeae) ް_ʰ֪
IV 500mg q6h*3days; PO 250mg q6H*7days
v?hxHg (Legionnaires Disease)
1-4g/dayAhD
Gts:
1.̪erythrocin I.V. Gts,YN50010Lߤ,100020Lߤ, erythrocin GȭϥΤtG`gΤӰts,HקKIC"	"ErythromycinDngѨxŦƥXCnx\?fHerythromycinp
erythromycini|ϭgٵL?fwz{H[C
ErythromycinϥΩQTΤ߫Ǥ߫ߤ]Atorsades de pointesfvfH"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~JsǷ15-30JCB}Gi? (2-8J) Js?gΫǷŶJs24pɦ?ܽCMӦAi@B}ᤧRߪ`g}Gh?AXJsAb8pɤΧC	Erythromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	yߡByߡBͪyߡByߤΨL㦳PʲӵߩҤް_PVgC	"ZErythromycinLӪ̸TΡC
Erythromycin?oPterfenadineBastemizoleBcisapridepimozide֥"	"Rߧ?EP?A,LӤ,ߡBæRB⵬θh,N?VcBıBo@MY?."	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡGtsǷ24hr;N14
}Ƿ8pɤ`
tsGG10 ml WFI
ĳ}@סG1-5mg/ml
ۮe}GGNSBLR
ĳĳ~|tvG> 20-60min
`NƶG1.ĳHIV pushġACt`HRߨEC2.ȭϥΤtG`gΤӰts,HקKIC"	ixiij	Ts114.08.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	IERYT-a	ʳf	ʳf	114.08.20
AC55554180	J01FA10	ߤڹFaGί	LAZIT	Azithrom susp.600mg/15ml/bt(AzithromycinߤڹFaGί		"Azithromycin |P 50S ֿ}馸椸23S rRNA۵XAJսXL{?/ (transpeptidation/translocation) Aç 50S 馸椸ոˡAqӪ_JսXC
"	"H>45kgĵGC500mg QD s3ѡF<45kgĵG10mg/kg s3ѡD
eGFR>10ml/min :վ㾯qAeGFR<10ml/minԷVϥΡD"	" 1. pPΨLܥͯ@ˡA~ܤ֦YLӤpޤ~BLӳQiCǦ]~ɭP_ogA@[PvC
2. ׵ǥ\ण} (creatinine clearance>40ml/min)fHϥξqAݧ@վAYǥ\ण}fHϥΥ~qثeMAofHϥΥ~pߡC
3. 󻴫ר줤רx\ण}fHA~MİʾǯSʻPx\ॿ`̵LCfHgѧGư~W[AiOxMvCո`ʸv@ΡC]ר줤רx\ण}fHϥΥ~ݭnվ㾯qCѩxŦO~Dnƪn~|A]Yxefw̨ϥΥ~ɤpߡC
4. fHlͪvɡAY֥άYǥܥͯoͳrCMثeõLܳM~椬@ΡAbzפWoͳriʡA]~iMl֥ͪΡC
5. pPLsħܥͯAϥΥ~|DPLͪ(]Ax)зPV(superinfection){Ho͡C
6. ϥΩHα¨Űw譱Ʃ|إߡA]DOLܡA~˨ϥΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHU
ws᪺fAaBGbǷŤUiOs 10ѡC"	"Azithromycin
47.78 mg/g"	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	󶧩ʡBʤιߤް_UIlDPV]]AުΪͪ^ֽγn´PVBժBWIlDPVMʶǬVfC 	AzithromycinBErythromycinBܥͯKetolideܥͯLӹLӪ.	"mBnKBA(h/j)BߡBæRB
"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_05-01 []_05-02 [E]_J2-01 j	Ts111.9.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	LAZIT-a	LAZIT-b	LAZIT-c	111.9.22
BC21830180	J01FA10	aGί	LZITH	Zithromax syrup 200mg/5ml/15ml/btl		"Azithromycin |P 50S ֿ}馸椸23S rRNA۵XAJսXL{?/ (transpeptidation/translocation) Aç 50S 馸椸ոˡAqӪ_JսXC
"	"aGί-600@J~
ws᪺aBGtazithromycin 40@J/@(@5@ɪqt200@J)C
H
Adult : Usual doseX 500 mg QD on the first day followed by 250 mg QD on days 2-5 or 500 mg QD for 3 days. 
            Chlamydial infectionX 1g as a single dose.
ΩvWIlDPV BUIlDPV BֽPn´PV ΤfķPVɡA qCѤ@A500mg AsA3ѡC
ĵ
 PediatricX 5- 12 mg/kg QD; MAX 500 mg/day or 30 mg/kg as as a single dose; MAX: 1500 mg
C10mg/kgAsAΤTѡC
WL45(t)HWĵAAΪqPHۦP(C500mgAsA3)C
~HCѳ@@qAΡC
"	" 1. pPΨLܥͯ@ˡA~ܤ֦YLӤpޤ~BLӳQiCǦ]~ɭP_ogA@[PvC
2. ׵ǥ\ण} (creatinine clearance>40ml/min)fHϥξqAݧ@վAYǥ\ण}fHϥΥ~qثeMAofHϥΥ~pߡC
3. 󻴫ר줤רx\ण}fHA~MİʾǯSʻPx\ॿ`̵LCfHgѧGư~W[AiOxMvCո`ʸv@ΡC]ר줤רx\ण}fHϥΥ~ݭnվ㾯qCѩxŦO~Dnƪn~|A]Yxefw̨ϥΥ~ɤpߡC
4. fHlͪvɡAY֥άYǥܥͯoͳrCMثeõLܳM~椬@ΡAbzפWoͳriʡA]~iMl֥ͪΡC
5. pPLsħܥͯAϥΥ~|DPLͪ(]Ax)зPV(superinfection){Ho͡C
6. ϥΩHα¨Űw譱Ʃ|إߡA]DOLܡA~˨ϥΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs30JHU
ws᪺fAaBGbǷŤUiOíw 5ѡC"	Azithromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	"󶧩ʡBʤιߤް_UIlDPV]]AުΪͪ^ֽγn´PVBժBWIlDPVMʶǬVf
"	"糧~ʦBerythromycinB@ܥͯketolideܥͯBΥ@ξLӡC
"	"mBnKBA(h/j)BߡBæRB
"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	LZITH-a	LZITH-b	LZITH-c	110.6.16
AC31368212	J01FF01	0	ICLEO	Clincin inj. 300mg/2ml/vial		"1. ~iXӵ߮50sAJս誺ͦXAӹF߮ĪGC
2. ~jhG(+)ߦġAҦpGyߡAyߤΪͪyߡA]AΨӪvʲӵ߷PVAҦpGݡAӱݡAoĵݡAݩMLݮyߡC "	v?߷PVɡA̪ϥΪ`gClindamycinAMAΤfAClindamycinC?:HФ@O 600~12OOmg/;Y 1.2~2.7g/AG~|۵?CͩRMIɡAiCRߧP4.8gCpġ(@ӤHW)Ф@O15~25mg/kg/ (350mg/m2/);Y25~40mg/kg/(450mg/m2/ )AT~|۵?CΪkGI MФ@??iWL600mgAӥB``gC 2 IVХg}@?b12mg/ml HUAMA`PC 	"1. ?nΩv?LӵߩίfrPVC 
2. ]~??iJGAҥH?iΩv?C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~ǷŤUJsC	Clindamycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	ѹߡByߡByߡAͪyߵ㦳PʪӵߩҤް_PgC 	ClindamycinLincomycinLӯffHATҨϥΥ~C 	"Diarrhea, nausea, rash, pseudomembranous colitis (rare; can be severe).
Ъ`gkhBwơBL߿@HBRߪ "	קKϥ/SmҦw	קKϥ/|qLť	аѦҾqPΪk	"600mg q6-8h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIMBIVF
tswwʡG-
tsGGIMGUndiluted
ĳ}@סG12mg/ml 
ۮe}GGWFI,NS,D5W,LR, (300-1200mg/50-100ml?) 
ĳĳ~|tvG1200mg/hr
`NƶG1.IM @qp600mgAB``g
2.ݸg}~iRߪ`g"	ixii[UDx]_U09-06 [w]_w04-07 [w]_w04-18 [E]_G5-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ICLEO-a	ICLEO-b	ICLEO-c	110.6.16
AC31171100	J01FF01	0	OCLIN	Clindamycin 150mg/cap		Clindamycinﵴj{ɤW`󶧩ʤγʯfߡA㦳sxܵ߬ʡA@ξǬӵߤJսXAϨӭMaAӹFߪĪGC	"H
C150~300 mgAC6p1FYPVAC300~450 mgAC6p1C

ൣ
H8~16 mg/kg/day3~4AΡFYPVAH16~20 mg/kg/day3~4AΡC"	wGzefAרOzw̡AԷVPCYϥΥĴoͤUg{HɡAġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)BץxsC	Clindamycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	yߡByߡBͪyߡBߵ㦳Pʵ߮Ҥް_PVg	TΩ󴿹Lincomycin͹LӤfwC	"1. hBDBߡBæRΤUg{HC
2. ̱`Ƨ@άʻצܤפClC"	קKϥ/SmҦw	קKϥ/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669280?cesid=2K5X2QKpu9C&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dclindamycin%26t%3Dname%26acs%3Dfalse%26acq%3Dclindamycin#doa"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	DC	DC	DC	114.07.23
AC44479100	J01FA09	0	OKLAR	Claricin F.C 250mg/tab(Clarithromycin)		ClarithromycinbX Erythromycin A. lͪAgѩMPV 50s ֿ}餧쵲XӲͧܵߧ@ΡAåBJզXCjĥBsxaݮM񪺭󶧩ʩMʵߡCClarithromycin ̤p߿@ (MICs)  Erythromycin p 2 C Clarithromycin 14-B򤧥Nª]ܵ߬ʡANª MICs ۷ΤGĪA H. influenzaeA䬡ʰĪGCClarithromycinYǵߺإ禳ߧ@ (Bactericidal)C	"AdultX 250-500 mg Q12H
PediatricX 7.5 mg/kg/dose Q12H, MAX 1g/day Renal impairmentXCrCl<30 min/ml:1/2 normal dose or interval double.
1. H12HWൣ@ĳq250mgACѤGAC@CYPVAqiW[500mgCѤGC@{5-14ѡAϫͪMuvݪv6-14ѡC
2. ٻMvC30mL/minǥ\णw̡A~qbAY250mgCѤ@AΦbYPVH250mgCѨ⦸CoǯfwosϥζWL14ѡC
3. K߷PVfwGK߷PVHĳq500mgCѤGC 
4. ڰժ۱ߤĳqd򬰡G
TX@k
Clarithromycin 500 mgCѤG֪Alansoprazole 30 mgCѤGamoxicillin 1000 mgCѤGϥ10ѡC Clarithromycin 500 mgCѤGBamoxicillin 1000 mgCѤGomeprazole 20 mgCѤG@_A710ѡC
GX@k
Clarithromycin 500 mgCѤTMomeprazoleC40 mgA@_A14ѡAUӪ14ѨCѪAomeprazole 20 mg40 mgC Clarithromycin 500 mgCѤTPlansoprazoleC60 mg@_A14ѡC
nϼŴ_Ahiݭni@BħC"	"(1) C1arithromycinDngѨxŦMŦƪnAҥHSO`Nx\εǥ\णfwC
(2)έШϥΥiyDӷPߩߪLץͪCpG͹L׷PVAΨõAvC
(3)ժ۱ߦbֳfw|ͧĩʡCpPLܥͯAfwYPɪAθgcytochrome P450tΥNªĪA~i|W[oĪ夤@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxsC	Clarithromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	WBUIlDPʲӵߩҤް_PVgCiPomeprazole֥ΪvPժ۱ߦQGz	"(1)~TΩ泌ܥͯLӪ̡C
(2)iMPlͪPɨϥΡC"	"ߡBæRBUgMhA]fMުiCCi|oͨı˿
LƧ@Υ]AYhHΤP{׹LӤA]AC¯lMLֽlƦܸYLӡC"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w25-01 [UDx]_U02-35 [E]_B2-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	OKLAR-a	OKLAR-b	OKLAR-c	110.6.16
BC23257100	J01FA10	ο250@J	OZITH	Zithromax 250mg/tab(Azithromycin)		Azithromycin |P 50S ֿ}馸椸23S rRNA۵XAJսXL{?/ (transpeptidation/translocation) Aç 50S 馸椸ոˡAqӪ_JսXC	"Azithromycin HCѨϥΤ@C
iP֪AC
H
Ⲵܦ߳yʶǬVLֵogDPlcVG1g@qfAC
Ⲵܦ߳yPⲴGCg@1gA̦hϥΤTgC
vϷPVʪͪɡAbRߪ`gkGCѤ@500mgA{710ѡC
jʵ֤K߽ƦX]MAC^efwGiWCgAΣ1200mgAάO֥ΫĳqrifabutinC
PediatricX 5- 12 mg/kg QD; MAX 500 mg/day or 30 mg/kg as as a single dose; MAX: 1500 mg
ҦLAg]]A]ͪyߩάyʷP_ݦߦӿwϷPVʪͪBw}lfAvEfw^GN1.5g`qbĤ@ѪA500mgAM2ܲ5ѨCѪA250mgAis3ѨCѪA500mgC
"	" 1. pPΨLܥͯ@ˡA~ܤ֦YLӤpޤ~BLӳQiCǦ]~ɭP_ogA@[PvC
2. ׵ǥ\ण} (creatinine clearance>40ml/min)fHϥξqAݧ@վAYǥ\ण}fHϥΥ~qثeMAofHϥΥ~pߡC
3. 󻴫ר줤רx\ण}fHA~MİʾǯSʻPx\ॿ`̵LCfHgѧGư~W[AiOxMvCո`ʸv@ΡC]ר줤רx\ण}fHϥΥ~ݭnվ㾯qCѩxŦO~Dnƪn~|A]Yxefw̨ϥΥ~ɤpߡC
4. fHlͪvɡAY֥άYǥܥͯoͳrCMثeõLܳM~椬@ΡAbzפWoͳriʡA]~iMl֥ͪΡC
5. pPLsħܥͯAϥΥ~|DPLͪ(]Ax)зPV(superinfection){Ho͡C
6. ϥΩHα¨Űw譱Ʃ|إߡA]DOLܡA~˨ϥΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Azithromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	󶧩ʡBʤιߤް_UIlDPV]]AުΪͪ^ֽγn´PVBժBWIlDPVMʶǬVf	TΩ糧~ΥܥͯLӥvΨxlfw	"mBnKBA(h/j)BߡBæRB
"	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669551?cesid=74aB80LMvc0&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAZITHROMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DAZITHROMYCIN"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	"OI` 10.1.,10.4."	0	OIs 20251124	DC	DC	DC	114.05.27
AC24198212	J01GB06	0	IAMIK	Amikacin inj.125mg/ml;2ml/vial		~bXitAkanamycinlͪA㦳ۦPܵC	"Usual adults and adolescents dose:
5 mg/kg q8h뤩  7.5~15 mg/kg  ⦸q12h뤩  7-10 .yWL15mg/kg/day,1.5 g/dayv]yWL 10 days."	BĩMLiޥܥͯ@ˡAjqΪϥΩΤAqɥRAiް_ťgr@ΩMǬr@΢Bǥ\ण}վ㾯qAܤֿ`B~PL@Χ֪Q֥ήɡAW[ťgrʪMIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(25C)xsAקKӮg	Amikacin	J01G	Aminoglycosideܵ AMINOGLYCOSIDE ANTIBACTERIALS	0	"y,y,ͪy,yߤΨL㦳Pʲӵߤް_PVg"	Aminoglycosides Ploop diuretics (pfurosemide)oī~O㦳լrʡĄåήɥi]oťırʥ[P(synergistic)@	ǬrʡAլr	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50       15mg/kg Q24h
60<ClCr<80   12 mg/kg Q24h 
40<ClCr<60    7.5 mg/kg Q24h 
30<ClCr<40     4 mg/kg Q24h 
20<ClCr<30     7.5 mg/kg Q48h
10<ClCr<20      4 mg/kg Q48h "	ѦҡuqΥΪkv	"ĳ~|GIVBIM
tswwʡGbǷ(25J)UAiOs24 p
tsGGIMGundiluted
ĳ}@סG0.25-5mg/ml
ۮe}GGNSBLRBD5W
ĳĳ~|tvG30-60 min
`NƶGPEthacrynic acid Furosemide MLQsϥΡAW[ťgrʪMIAiyi_ŤC             "	ixii[w]_w04-10 [E]_G4-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IAMIK-a	IAMIK-b	IAMIK-c	110.6.16
AC32263212	J01GB03	0	IGENT	Gentamycin 80mg/2ml/amp(Gentamicin)		GentamicinActinomyces organismӱosĩitAXGҦ{ɤW󶧩ʵߤγʵߦġA]A@ʸ媬yߡAwߡBܧαߤΤjzߦbC߾ӵߤJզXAϨӭMaAӹF߮ĪGC	120~80mg (O)2~3^٦ת`gAiIwR`p10.4~0.8mg/KgA12~3^٦ת`gAIwR`ɥH30~2pɪ`JFP7~10AФŶWL10CĭvϥΡC	"1. `gi঳wA`gɽФpߪ`NC
2. ~nRߪ`gɳq`HͲzQ5% Dextrose`gG}䥦gTwͰtXܤƪRingerGA20%G}`gGA5-10% XylitolAŻRingerGA20% D-Mannitose`gGC
3. UCw̽Фŧ뤩Ap뤩nXзV;HΨaڴStreptomycinťıxΨLťıx̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Gentamicin	J01G	Aminoglycosideܵ AMINOGLYCOSIDE ANTIBACTERIALS	0	󶧩ʡBʵߡBߧJΥoLʯfrPVgC	" Streptomycin,Kanamycin,GentamycinAminoglycosidetܥͯBacitracinLӬJfҤw̡C"	"1. J:JgX{AФp[AIlxBݤWeB߱iBCUgX{XAФϥΡC
2. L:LӯgX{ɡAФϥΡC"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50       160mg q24h
CClr <30      160mg q48h(ĳϥ)
CClr<10       160mg q72h(ĳϥ)"	ѦҡuqΥΪkv	"ĳ~|GIMBIVF
tswwʡG-
tsGGIMGUndiluted
ĳ}@סG-
ۮe}GG50-200ml NSBD5W
ĳĳ~|tvG30min-2hr?
`NƶG-"	ixii[UDx]_U09-04 [w]_w05-05 [w]_w05-11 [E]_G5-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IGENT-a	IGENT-b	IGENT-c	110.6.16
AC11518100	J01GB05	0	ONEOM	Neomycin 250mg/cap(Neomycin sulfate)		~qݦӱosĩʧܥͯC@λPkanamycinۦPA̱jg٦ת_Aڳiit餤̬r̡Cܦhf鳣靈NeomycinY۪ĩʡCܤ֦٪`ϥΡA]rʡCq`Odb|ϥΡALܷLͪľLĪfHCCѦ٪`qnWL1gAPɶnh10ѡCfAneomycinDnAΩE.coliҤް_mAMNezߡAtXCCQmbβĤ@neomycineϥΡC~|zZLĪlApatACCfAPɡA߻PmQMC̼sxPkO~ΡAֽMַ߽PVCIı`LӤCYEAoηkoo͡AYġCnIĩjnAΥֽ}lγжˡA]|W[ʧlάrʪo͡C	"1.z޷PVgGH@KA|AΡC

2.zޤNeBzɡAH@16ɡAC|^AΡAsA1-3ѡC
"	"fAȧl3%
zDŪ̡AyԷVϥΡC
wNPVw̡Aݪ`Nķ|[j¾KΦ٦P@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	 Neomycin 	J01G	Aminoglycosideܵ AMINOGLYCOSIDE ANTIBACTERIALS	0	NeΨxgfHΩzD	zιaminogly cosidesLӪw̡C	ߡBæRBmBoB?oBֽFY-g٦ת_BIl·BլrʡBǬrʡC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ONEOM-a	ONEOM-b	ONEOM-c	110.6.16
BC26701100	J01MA14	0	OAVEL	^Floxsafe 400mg/tab (Moxifloxacin)		"ߧ@άOѩzZtopoisomerase IIM IV TopoisomeraseO DNANc
(topology)MU DNAƻsB״_MҥïC
MoxifloxacinߤOP@׬C@ӨA̧C߿@׻P̧C߿@׮thC
MoxifloxaciniĹܣ] ]-lactamM (macrolide)ĩʵߺءC"	@Ѥ@AC400@JC{ھڷPVY{צөwC	ϥΨľMLtBTPLqpKsɡAܤ֥bAMoxifloxacine|pɩΤpɤ~൹C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~JsB xsūפiWL 30JC	Moxifloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	ΩvH]QKHW^Pʲӵߤް_PVgA]AGWIlDΤUIlDPV]ʻuBCʤުʴcơBϩʪͪ^AֽMn´PVAĤPV(]Ahزӵ߷PVg)	"wmoxifloxacinBL quinolonesνξLӪ̡C
hMŰkC"	mBYhBߡBæRBƤ}C	"LAʪwܨ㦳ʹެrʡAHbIثeC
]AĩhϥάOTC"	"pPLquinolonesAĤw|ɭP~ʪt`nlˡA{ɫe
ܤֶq moxifloxacin|cHťĤAثe|LcũέŰkơA]
 moxifloxacinŰkOTC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 [E]_B4-23 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.1._20160801_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.1.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.1."	0	OIs 20251124	OAVE-d	OAVEL-e	02C26491-2	110.6.16
AC58053265	J01MA14	0	IAVEL	Mofacin 400mg/250ml/bag		ߧ@άOѩzZtopoisomerase II MIVAtopoisomeraseODNANcΩMUDNAƻsB״_MҥïC	"ĪĳqO@400@J(250@ɪ`G)AvuMefY{ש{ɤC
Renal impairment and hepatic impairmentXNo dosage adjustment.
HUO@vWIlDΤUIlDPVĳvG
Cʤުʴc- 5ѡC
ϫͪ- ĳv(R߿`ӫfA) `{714ѡC
ʻu- 7ѡC
ֽMn´PVĳv{7-21ѡiDʡG7ѡFʡG721(]A`gM`gfAv)jĤPV- 514(]A`gM`gfAv)C
{ɤWXAiH@}lOR߿`AۧHfAvC
ΩUAgvWLĳvC
`GR߿`F60"	"ī~㦳ϭgٵLOcƤIA㦳gٵLOwקKϥΡC
ĥקKϥΦbUCfHA]|~ϥΦboǯfH{ɸgG
- wQTjfH
- BC[gfH
- ϥclass IA(ҦpGquinidineBprocainamide)class III(ҦpGamiodaroneBsotalol)ܤ߫ߤĪfH
- ߫ߤefHAҦpG{ɤW߸LCΫʤߦٯʦ
- xwƥBLkưO_QTfH
- eɭPQTcĪvTkʩMѦ~H
- Aquinoloneɥi|wpo͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsū׬30JHUAiC15JAsb]ˮeC	Moxifloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"ΩvH(18HW)Pʲӵߤް_PVgA]AG
- WIlDΤUIlDPV(ʻuBCʤުʴcơBϩʪͪ)
- ֽMn´PV
- ĤPV(]Ahزӵ߷PVg)"	wmoxifloxacinBLquinolonesνξLӪ̡CwmoxifloxacinBLquinolonesνξLӪ̡C	߭ƷPVBYhBwtB֦C[gfHQTjߡBæRBGzDMkhBmBi?ɰB`gM`	TϥΡAʹެrʡC	Tϥ	аѦҾqPΪk	"400mg q24h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡGץxsAקKNBN
tsGGUndiluted
ۮe}GGWFIBNSBD5WBRBLR
ĳĳ~|tvG>60min?
`NƶGYnPLī~֥ΡA}"	ixii[UDx]_U10-08 [w]_w12-05 [E]_D5-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.1._20160801_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.1.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.1."	0	OIs 20251124	IAVEL--a	IAVEL-b	IAVEL-c	110.6.16
AC56750248	J01MA12	0	IBACF	Bacflocin 250mg (ëHLevofloxacin)		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"250mg-750mg QD
250@JCravit `gGĳ`gɶܤ30A500@Jܤ60CwϥofloxacinɡA`gi|oiX߸L֤μȮɩʦCCbupUAѩjTCAioʹ`ʵCpGhê`glevofloxacin(ofloxacinLc)CAߧYȰ`gC"	"qLq
̾ڶWLvqʪs{ĲzǬsA̭nCravit `gG
qLqxϯgtίgAҦp믫VáAwtANѼҽkAΩz
jˡAQTjW[C
qLqɡAwgivCi߹qϺʴA]ioQTj
CGzRA]tzRP CAPDAHNlevofloxacinqưC
eSMΪѬrC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"vH]LevofloxacinPʪPfߩҤް_UCPVG
ϩʪͪ
ʪcDPV(]AǪǪ)
CʲӵߩʫeC
ֽMn´PV "	"Cravit `gGoΩG
levofloxacinΥLQuinoloneΥξLӪw̡A
ww̡A
wIFluoroquinoloneٸxfܯfvw̡A
ൣΥͪC֦~A
hA
ŤkʡC"	ٸxΦٸx}AwALӡA޹LCALӡAQTjAP䯫gfܡAC	ʪʹެsSoͨ骺DCLbʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit Ωhk	bʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit ΩŤk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	"Load:750mg
CClr>50     750mg q24h
CClr 20-49   750mg q48h
CClr<20     750mg q48h
IHD           500mg q48h
CAPD         500mg q48h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץ]xsbǷ, Y~hhĴ3 ѡC
2.˲~ֶA3 pɤϥΡAHקKìVC
3.`gɤץ
tsGGUndiluted
ĳ}@סG-
ۮe}GGNSBD5WB2.5% dextrose in Ringer solution?
ĳĳ~|tvG500mg:  60 min
250mg:  30 min
`NƶG1.iPHeparinBPʷGVX(e.g NaHCO3)"	ixii[UDx]_U08-06 [w]_w12-03 [E]_D4-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.3._20080901_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.3.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.3."	0	OIs 20251124	IBACF-a	IBACF-b	IBACF-c	110.6.16
AC56750255	J01MA12	0	IBACF2	BACFLOCIN 500mg (ëHLevofloxacin)		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"250mg-750mg QD
250@JCravit `gGĳ`gɶܤ30A500@Jܤ60CwϥofloxacinɡA`gi|oiX߸L֤μȮɩʦCCbupUAѩjTCAioʹ`ʵCpGhê`glevofloxacin(ofloxacinLc)CAߧYȰ`gC"	"qLq
̾ڶWLvqʪs{ĲzǬsA̭nCravit `gG
qLqxϯgtίgAҦp믫VáAwtANѼҽkAΩz
jˡAQTjW[C
qLqɡAwgivCi߹qϺʴA]ioQTj
CGzRA]tzRP CAPDAHNlevofloxacinqưC
eSMΪѬrC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"vH]LevofloxacinPʪPfߩҤް_UCPVG
ϩʪͪ
ʪcDPV(]AǪǪ)
CʲӵߩʫeC
ֽMn´PV "	"Cravit `gGoΩG
levofloxacinΥLQuinoloneΥξLӪw̡A
ww̡A
wIFluoroquinoloneٸxfܯfvw̡A
ൣΥͪC֦~A
hA
ŤkʡC"	ٸxΦٸx}AwALӡA޹LCALӡAQTjAP䯫gfܡAC	ʪʹެsSoͨ骺DCLbʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit Ωhk	bʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit ΩŤk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	"Load:750mg
CClr>50     750mg q24h
CClr 20-49   750mg q48h
CClr<20     750mg q48h
IHD           500mg q48h
CAPD         500mg q48h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץ]xsbǷ, Y~hhĴ3 ѡC
2.˲~ֶA3 pɤϥΡAHקKìVC
3.`gɤץ
tsGGUndiluted
ĳ}@סG-
ۮe}GGNSBD5WB2.5% dextrose in Ringer solution?
ĳĳ~|tvG500mg:  60 min
250mg:  30 min
`NƶG1.iPHeparinBPʷGVX(e.g NaHCO3)"	ixii[UDx]_U08-07 [w]_w12-02 [E]_D4-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.3._20080901_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.3.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.3."	0	OIs 20251124	IBACF2-a	IBACF2-b	IBACF2-c	110.6.16
AC44809263	J01MA02	0	ICIPR1	Seforce inj.2mg/ml;200ml/vial		ߧ@άO]ӵDNAƻsBB׸ɩMծɪtype II topoisomerase(DNA gyraseMtopoisomerase IV)C 	200-400mg BID-TID	"1. wfHδwϯgժfw(ҦpjH CAj˪fvACyAcܦ)A~uΦbvįqjMIɫA]oǯfH|]i઺ϯgƧ@ΦӾɭPMIC 
2. YϦbӳBܥĪpUAĤ|vTtץHP}ξާ@O|l`CΤרeoͦbPsXήɡC 
CiprofloxacinPQT(Ѩ})Aq`Ѧ~fweī~vTQT϶Aciprofloxacin֥η|ɭPQT϶Ī(ҦpGclass IA or IIIܤ߫ߤĪ)ίfwbtorsade depointsMI]l(ҦpGwQTBgC[g)ɶԷVϥΡC
i`Nƶj]Ī`GӷPסAҥHĲ~bϥΫeAqlXӡCbձޥuUA㪺ĤOuOҺ3ѡCFϥΤWwA`~몺餤Ab~i|ɭP~lC
ާ@
Cxsҥi|ͨIAbǷŤU|A׷ѡCҥHN`GmBcxsC
ĪmpĮ쪺aCLᤣi~ϥΡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"~m澯qe25J HUJsΨŽիǷŤUBקKNץJC
"	Ciprofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"HGciprofloxacinPʲӵߩҤް_IlDPVBժBuBPVBŦΪcDPV(]AOf)BPV(]AzBxnB)Bֽγn´PVB誢B`PVBߦgC
pġGjz(Escherichia coli)ް_ʪcDPVMǪǪ(1-17) 
w(P. aeruginosa)n~ֺƲͫʪͳcƪ{H(5-17) "	"1. ~iϥΩCiprofloxacinΨ䥦QuinoloneƾǪv|LӪfHC 
2. ~iϥΩpġBC֦~BBάOŤˡA]SoǱw̸sϥΦĪwgAʪ窺GA~i|ͪ`nyˮ`Cʪ稴|yέLҾڡC "	ߡBæRBmBtwBYhC 	"]ciprofloxacinbhkwʩ|إߡABʪ窺
GAi|ͪ`nyˮ`AciprofloxaciniΩhkC"	Ciprofloxacin|cťĤAѩ`nˮ`bIAŰkiϥciprofloxacin	аѦҾqPΪk	"CClr>50     400mg q12h
CClr10-50    400mg q24h
CClr<10    400mg q24h
IHD           400mg q24h
CAPD         400mg q24h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ӷPʡAh~ȯOs3
2.ݧNxs(Cxsi|ͨIAbǷŤU|A׷)
3. ciprofloxacin`GPۮe`GVXAb̵uɶϥ
tsGGUndiluted
NSBD5WBLRBR   
ĳ}@סG-
ۮe}GG-
ĳĳ~|tvG>60 min
`NƶG1.wCNĥJjRߡAi֯fHAέCRߨEMI"	ixii[UDx]_U10-07 [w]_w00-01 [E]_D5-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.</a>             "	"OI` 10.1.,10.8.2."	0	OIs 20251124	ICIPR1-a	ICIPR1-b	ICIPR1-c	110.6.16
		0	IPV13	Prevenar(13) 0.5ml		"w13تͪyߦM]1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19FM23F^ɭPJIʯefBͪΤժ"	"The vaccine should be given by intra-muscular injection. 
Infants aged 2 - 6 months: three single doses of 0.5 ml at interval of 1 month, starting at 2 months of age and with a fourth dose given in the second year of life. 
Previously unvaccinated older infants and children: 
Infants aged 7 - 11 months: two doses, each of 0.5 ml, with an interval of at least 1 month between doses. A third dose is recommended in the second year of life. 
Children aged 12 - 23 months: two doses, each of 0.5 ml, with an interval of at least 2 months between doses.
Children aged 24 months V 5years:  one single dose."	"~iPHṶ]]]A@̭]βVX̭]^PɱءGիJ̭]B}˭̭]Bʤy̭]]DӭMΥӭM^Bbݦ̭߬]BƤp̭]BBx̭]BCs轤̭]B¯ḽ]B|̭]Bw¯ḽ]Bk̭]C{ɬsܳoǬ̭]@Ψä|]zZA]|vTwʡC
Pɧ뤩fr̭]P~{ɸܨä|vToǬ̭]wʡC
Pɪ`gP̭]ɡAة󤣦P "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Pneumococcal 13-Valent Vaccine	J07A	ӵ̭߬] BACTERIAL VACCINES	0	"w13تͪyߦM]1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19FM23F^ɭPJIʯefBͪΤժ"	Hypersensitivity reaction to any component of the vaccine or diphtheria toxoid.	`g짽AoNBwB֡BίvɶW[δֵ	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided. 	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-08 j	Ts110.6.16		OI` 	0	OIs 20251124	IPV13-a	IPV13-b	IPV13-c	110.6.16
AC57185255	J01MA12	0	ICRAV	Cravit 500mg/bot(Levofloxacin)		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"250mg-750mg QD
250@JCravit `gGĳ`gɶܤ30A500@Jܤ60CwϥofloxacinɡA`gi|oiX߸L֤μȮɩʦCCbupUAѩjTCAioʹ`ʵCpGhê`glevofloxacin(ofloxacinLc)CAߧYȰ`gC"	"qLq
̾ڶWLvqʪs{ĲzǬsA̭nCravit `gG
qLqxϯgtίgAҦp믫VáAwtANѼҽkAΩz
jˡAQTjW[C
qLqɡAwgivCi߹qϺʴA]ioQTj
CGzRA]tzRP CAPDAHNlevofloxacinqưC
eSMΪѬrC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"vH]LevofloxacinPʪPfߩҤް_UCPVG
ϩʪͪ
ʪcDPV(]AǪǪ)
CʲӵߩʫeC
ֽMn´PV "	"Cravit `gGoΩG
levofloxacinΥLQuinoloneΥξLӪw̡A
ww̡A
wIFluoroquinoloneٸxfܯfvw̡A
ൣΥͪC֦~A
hA
ŤkʡC"	ٸxΦٸx}AwALӡA޹LCALӡAQTjAP䯫gfܡAC	ʪʹެsSoͨ骺DCLbʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit Ωhk	bʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit ΩŤk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	"Load:750mg
CClr>50     750mg q24h
CClr 20-49   750mg q48h
CClr<20     750mg q48h
IHD           500mg q48h
CAPD         500mg q48h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץ]xsbǷ, Y~hhĴ3 ѡC
2.˲~ֶA3 pɤϥΡAHקKìVC
3.`gɤץ
tsGGUndiluted
ĳ}@סG-
ۮe}GGNSBD5WB2.5% dextrose in Ringer solution?
ĳĳ~|tvG500mg:  60 min
250mg:  30 min
`NƶG1.iPHeparinBPʷGVX(e.g NaHCO3)"	ixiij	Ts114.05.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.3._20080901_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.3.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.3."	0	OIs 20251124	DC	DC	DC	114.05.21
AC57185248	J01MA12	0	ICRAV2	Cravit 250mg/ 50ml/bt]Levofloxacin^		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"250mg-750mg QD
250@JCravit `gGĳ`gɶܤ30A500@Jܤ60CwϥofloxacinɡA`gi|oiX߸L֤μȮɩʦCCbupUAѩjTCAioʹ`ʵCpGhê`glevofloxacin(ofloxacinLc)CAߧYȰ`gC"	"qLq
̾ڶWLvqʪs{ĲzǬsA̭nCravit `gG
qLqxϯgtίgAҦp믫VáAwtANѼҽkAΩz
jˡAQTjW[C
qLqɡAwgivCi߹qϺʴA]ioQTj
CGzRA]tzRP CAPDAHNlevofloxacinqưC
eSMΪѬrC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"vH]LevofloxacinPʪPfߩҤް_UCPVG
ϩʪͪ
ʪcDPV(]AǪǪ)
CʲӵߩʫeC
ֽMn´PV "	"Cravit `gGoΩG
levofloxacinΥLQuinoloneΥξLӪw̡A
ww̡A
wIFluoroquinoloneٸxfܯfvw̡A
ൣΥͪC֦~A
hA
ŤkʡC"	ٸxΦٸx}AwALӡA޹LCALӡAQTjAP䯫gfܡAC	ʪʹެsSoͨ骺DCLbʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit Ωhk	bʥFHơABFluoroquinolones㦳}aͪӭni筷IpUACravit ΩŤk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	"Load:750mg
CClr>50     750mg q24h
CClr 20-49   750mg q48h
CClr<20     750mg q48h
IHD           500mg q48h
CAPD         500mg q48h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץ]xsbǷ, Y~hhĴ3 ѡC
2.˲~ֶA3 pɤϥΡAHקKìVC
3.`gɤץ
tsGGUndiluted
ĳ}@סG-
ۮe}GGNSBD5WB2.5% dextrose in Ringer solution?
ĳĳ~|tvG500mg:  60 min
250mg:  30 min
`NƶG1.iPHeparinBPʷGVX(e.g NaHCO3)"	ixiij	Ts114.08.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.3._20080901_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.3.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.3."	0	OIs 20251124	DC	DC	DC	114.08.20
	J07BK03	Ygla?ḽ]	IZOST2	Shingrix Herpes Zoster Vaccinea?ḽ]		"ۤka?lfr(Varicella Zoster Virus, VZV)  glycoprotein E (gE)JէܭOQ DNA է޳N
bܹZ_ӭMsyӱoC
ǥѵX VZV Sܭ(gE)H AS01BtΡAShingrix ]piwka?lfrwws
K̤OHAo䲣ͧܭSʪӭMMGK̤C
D{ɸܡAAS01B izLSwl@ξϥѧK̨tεoͧμȮɩʪơAoU
ϱa gE ܭ쪺ܭe{ӭMbެyOڵEìơAiӫPϨ gE Sʪ CD4+ T ӭMM
ͦCAS01B@άOӦۥ]tbLײɸ餤 MPL P QS-21 椬@εGC
"	"즸خɵ{@]t⾯AC 0.5 @ɡFĤGĤ@I 2  6 ӤIC
K̥\ʥFBK̥\Φ]wefΪvӥiϧK̥\HAHΥi]
ṷ]خɵ{qHAĤGiĤ@I 1  2 ӤI
Shingrix ȨѦ٦ת`gAzQ`gOT"	"iḴؤe
bثedݹLhfv(SOOḙ]ؤκæoͤ}ƥ󪺬)öi{ɶEC
ťHޤB֤Υ֤U`g覡I̭]C
VzL֤U~|I̭]i|ɭPȮɩʪW[CMLH٦ת`g覡I̭]@ˡAwpO֯gΥ󾮦\êfHI Shingrix
ԷVA]oǯfHb٦ת`gi|oͥX媺{HC
bI̭](Ʀܤe)i|]wY`g߲ͤzʤӵoͷw(){HC]@
wnbAҬI̭]AHK]˦ӨˡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Osb 2XC  8XCCpGb 6 pɤ
ϥΡAHC
"	 50 LJ gE ܭ ϥ AS01B	J07B	fr̭] VIRAL VACCINES	0	"AΩUCHAHwa?lΨֵogAp?lᯫgh(post-herpetic neuralgia, PHN)G - 50(t)HWH - 18(t)HWB㦳wa?lIH"	糧̭]ʦΥզYL	"YhzGDg(]AߡBæRBm/θh)
ٵh
`g(pkhBoB~)Bh¡BoNBoN"	ثeõLhkϥ Shingrix 譱ơCwhkקK Shingrix ̭]C	ثe|s˦bI Shingrix Aﱵŭ|઺vT	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-16 j	Ts111.10.20		OI` 	0	OIs 20251124	IZOST2-a	IZOST2-b	IZOST2-c	111.10.20
AC58540100	J01MB08	0	OTAIG	Taigexyn 250mg/cap (Nemonoxacin)		Nemonoxacin @άOgѧ DNA j?(gyrase) Mĥ|ݾ벧c?(topoisomerase IV)AӵDNA XAiӧӵߥͪCDNA j?Mݾ벧c?( ) ͪy(Streptococcus pneumoniae )Ajtt?ܥͯ(fluoroquinolone) 㦳ĩʡC	HfA@0.5 gA@1 AŸA( bieܤ֨pɩζiܤ֨pɪA)CvɶھگgY{ש{ɤMwCĳvɶOsA7 10 ѡC	Ltt?Ī(fluoroquinolone) īoͥHUY}ƥGٸxΦٸx}BgٵLOcơBʸzBYLӤBӤ/ rʡBYpB믫fBϯgfܡBP䯫gfܡBxrʡB}N²`Cĳbī~ϥΤWzY}ƥ󤩥H`Aöi[C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~JsBAxsūפiWL25X CF	Nemonoxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	"vH Nemonoxacin PʪPfߩҤް_PVGA
XEvתϩʪͪC"	w糧ī~󦨤BΨL?(Quinolone) LӪw; hέŤk; ൣΫC֦~C	"ALT (SGPT) ɰAߡBզypƭCBݤʥզy֯gBYwBAST (SGOT) ɰCxï(ALT/
AST) WݼȮɩʪABLHŦXĪ޵oxl (DILI) kh (Hy's Law) зǡC"	T()	T()	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2L-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.4._20220301.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.4.</a>             "	"OI` 10.8.2.,10.8.2.4."	0	OIs 20251124	OTAIG-a	OTAIG-b	OTAIG-c	110.6.16
AB47516100	J01MA12	0	OCRA5	Cravit(Levofloxacin)500mg/tab		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"CIΤ@Cq̾ڷPVPYʡAΰwPff쪺ӷPʦөwC
Ѥ@}lRߪ`gvഫfAv(Cravit 500@J)CѩDzDPfAΦ㦳鵥ĩʡAiHϥάۦPqC
"	UCw̽ԷVA1.YŦêw2. wδwLwj˩ʯefw3.Quinolonetܵ߾LӪw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	vH]levofloxacinPʪPfߩҤް_UPPV:ʻuACʤުʴcơAϩʪͪAʪcDPV(]A:ǪǪACʲӵߩʫeCAֽMn´PV)	1)糧~OfloxacinLӯgw̡C(2)ΥihHC(3)C	YBGzABlBӷP	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_D2 [2]_D2 [s]_54 [®]_54 [UDx]_U03-19 [E]_B4-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2.3._20080901_000.pdf"">OI` 10.8.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.3.</a>            "	"OI` 10.1.,10.8.2.,10.8.2.3."	0	OIs 20251124	OCRA5-a	OCRA5-b	OCRA5-c	110.6.16
AC20910100	J01MB04	0	ODOLC	Dolcol 250mg/tab(Pipemidic acid)		Pipemidic acid êӵDNAƻsA@άߩʡCwߡBjzߡBܧαߡBJpդߡBzߵ󳱩ʱߦjOܵߧ@ΡAyݤιߴXL@ΡC	"(1) HctηPVGC500~2000mgA3~4AΡC
(2) LPVGC1500~2000mgA3~4AΡC
(3)׵ǥ\êΰ֪̽ЩԪĶjC
(4)pĪwʥTߡApקKġC"	"AīYX{LӼxAХߧYġAtNC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(25C)xsAקKӮgFpoܽιLAiAϥΡC	Pipemidic acid	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	ѺwߡBjzߡBܧαߡBJpդߡBeXߡBgߡBzߵҤް_ǪǪBǪBH֪BDBeCBժBgzBƻĪ	"(1) 糧~LӪ̡ATϥΡC
(2) hB¨ŰkC"	ߡBæRBmBGzAB֯lBYhC	wʥTߡA󥥰ΥihHAФŵġC	|qLťġAG¨ŪkĮɡA¨šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.</a>             "	"OI` 10.1.,10.8.2."	0	OIs 20251124	DC	DC	DC	114.06.25
AC40429100		0	OSUPER	Superocin 250mg/tab(Ciprofloxacin)		b~礤ciprofloxaciniHĹܩҦ󳱩ʯfߡAciprofloxacinߧ@άO]ӵDNAƻsBB׸ɩMծɪtype II topoisomerase (DNA gyraseMtopoisomerase IV)C	"HDLBACĳqpUG
IlDPV (ھYפηPVf)G2  250 V 500mg 
cDPVG
ʡBDֵoG2  125 mg  1-2  250mg 
kʻH֪ (ge)G@q 250mg 
ֵoG2  250 V 500mg 
OfG~ʹ޾G2  125mg 
ʡBDֵoG@q250mg 
mG1-2  500mg 
p (1-17) 
ʪcDPVMǪǪ
vʪcDPVMǪɡAC12pɤfAqO10-20mg/kgAC̤jqO750mgC
n~ֺ 
{ɩMİʾǸҹciprofloxacinΩvPw(P. aeruginosa) pn~ֺƲ ʪͳcƪfw(5-17)AϥξqOCѤfA⦸AC20mg/kg(Cѳ̤jqO1500mg)C lJʬjf(Ĳ) CѨ⦸C15mg/kgAC̤jqoWL500mg(Cѳ̤jqO1000mg)C héνTwĲAϥciprofloxacinvC
Mֶq@_]ACeζAάҥiCpGŸAΡAʦl֡C]oˡAΤfAaBGiMŻs~qtq(ҦpBuB[th)֥ΡCOA@\@tä|vT ciprofloxacinlC"	קKŻs~qtq(ҦpBuB[th)Mciprofloxacin֥ΡA]ciprofloxacinli|CCOA@\@tä|vTciprofloxacinlC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(25C)xsAקKӮg	Ciprofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	ciprofloxacinPʤӵߩҤް_IlDPVBժBuBPVBŦΪcDPV]]AOf^BPV]]A^Bֽγn´PVB誢B`PVBߦg	"CiprofloxacinTΩciprofloxacinBLquinoloneĪΥ᫬|LӪfHC
TPɨϥciprofloxacinMtizanidineC"	 BmBlC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 [ws]_w25-03 [UDx]_U02-23 [E]_B2-15 [Ew]_EX025 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.</a>             "	"OI` 10.1.,10.8.2."	0	OIs 20251124	OSUPER-a	OSUPER-b	OSUPER-c	110.6.16
BC24565277	J01XX09	0	ICUBI	Cubicin 500mg/vial(Daptomycin)(N)		"Daptomycin binds to bacterial membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death."	"Complicated infection of skin AND/OR subcutaneous tissue: 4 mg/kg IV once every 24 hrs for 7 to 14 days. Staphylococcus aureus bacteremia, including right-sided endocarditis: 6 mg/kg IV every 24 hrs for a minimum of 2 to 6 weeks. Safety and efficacy in patients under the age of 18 have not been established."	"1.iHϥΧtDextroseR߿`GC
2.bw`daptomycineХHNSRbIV lineC
3. }Rm10Ado not shake."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	28XCNxs	Daptomycin	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	"Treatment of complicated skin and skin structure infections caused by susceptible aerobic gram-positive organisms; Staphylococcus aureus bacteremia, including right-sided infective endocarditis caused by MSSA or MRSA."	"Hypersensitivity to daptomycin

."	"Diarrhea (5% to 12%), vomiting (3% to 12%), constipation (6% to 11%), Anemia (2% to 13%), Rash (4% to 7%), pruritus (3% to 6%), erythema (5%). HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased."	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"CClr>50     6mg/kg q24h (4-8mg/kg)
CClr <30    6mg/kg q48h
CClr<10    6mg/kg q48h
IHD          6mg/kg q48h
CAPD         6mg/kg q48h"	ѦҡuqΥΪkv	"ĳ~|GIVD
tswwʡG1.~Nץxs
2.tsε}Ƿxs12hrFNxs48 hr
tsGG10 ml NS
ĳ}@סG-
ۮe}GG50 ml NS, LR
ĳĳ~|tvG> 30 min
`NƶG1.P}}Gۮe
2.tsɤż@P_ʩηnĲ~AH֪wjΦ
3.YϥάۦPRߪ`g޳s`gXؤPġAb`gdaptomycineAݥHiۮe`gGR~C"	ixii[N]_B01-58 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.7._20090101_000.pdf"">OI` 10.8.7.</a>             "	"OI` 10.1.,10.8.7."	0	OIs 20251124	ICUBI-a	ICUBI-b	ICUBI-c	110.6.16
BC27354266	J01XX08	0	ILINE	"linezolid 600mg ""Kabi"""		"1. LinezolidOs@HuXܥͯAݩoxazolidinoneA{ɥγ~DnAΩvݭnʤ󶧩ʵߩҳyPVC~linezolid@ǭ󳱩ʵߩMߦ@ΡCLinezolidǥѤ@ةMLܥͯP@ξӧӵ߳Jս誺XC]linezolidMLܥͯioͥ椬ĩ(cross-resistance)CLinezolid|Pӵ50Sֿ}p(subunit)W23Sֿ}RNAXM\ʪ70S_l_X骺ΦC_XOӵĶ(translation)L{nCھڮɶ-(time-kill)sܡAzy(enterococci)My(staphylococci)ӨAlinezolidO߾(bacteriostatic)Cy(straptococci)jhƪߺئӨAlinezolidO߾(bactericidal)
2. UCߺخĪG΢wݮʩMݩ(Aerobic and facutative)󶧩ʵߡGEnterococcus facium(ȭvancomycinĩʪߺ)A⸲yStaphylococcus aureus(]Amethicillinͧĩʪߺ)AʨyStreptococcus agalactiaeAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AwyStreptococcus pyogenesC
3. ݮʩMݩʭ󶧩ʵߡGTyEnterococcus faecalis(ȭvancomycinĩʪߺ)AEnterococcus facium(ȭvancomycinĩʪߺ)AָyStaphylococcus epidermidis(]Amethicillinͧĩʪߺ)AStreptococcus harmolyticusAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AViridans group streptococciC
4. ݮʩMݩʭ󳱩ʵߡGPasteurella multocidamC"	"~sĳϥζqC侯qOHC12pɧP@覡PC
1. Vancomycin-ĩʪEnterococcus faeciumPVA]AֵoߦgfҡG600mgRߪ`gAΤfAC12pɤ@As1428ѡC
2. |PVͪBֽMֽ´PVBϷPVͪA]AֵoߦߪfҡG600mgRߪ`gAΤfAC12pɤ@As1014ѡC
3. DֽMֽ´PVG400mgRߪ`gAΤfAC12pɤ@As1014ѡC
4. ~]iNC龯q}ӪA(pGWAĤ@AߤWAĤ@)C"	"1. ϥΧܥͯ|PϫDPʲӵߪLץͪCvL{pGX{ƷPV(superinfection)ɡAӱĨAIC
2. linezolidw̴oͦpO֯giC󦳥XʦMIfwBepO֯gfwBPɨ֥η|֦pOƥةΥ\धĪfwΨlinezolidvݶWL2PfwAʴpOƥءC
3. ~iPΪŸɪAΡC
4. pGfwfvAivC
5. AΥ~ɡAקKΤjqttyraminetqζơCC\tyraminetqC100mgCttyraminetq]AǥѦѤơBoáBMηtHW[DkҲͪܩʳJսC
6. pGAΧtpsudoephedrine HCLphenylpropanolamine HCLī~pP_ĩΥh몺ĪɡAiDvC
7. pGAserotonin re-uptakeΨLܼ~{ɡAiDvC
8. xsG1530JUץOsA`gnUwBCĳbϥΫen}`gnU~]ˡF`gGieAHxsɶW[C|[`AvTĻC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Linezolid	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	AΩvѤUCPʵߺطPVfwGVANCOMYCINЧĩʪENTEROCOCCUS FAECIUMPVA]AֵoߦgfҡCf|PVͪASTAPHYLOCOCCUS AUREUSSTREPTOCOCCUS PNEUMONIAEҤް_CֽMֽ´PVASTAPHYLOCOCCUS AUREUSASTREPTOCOCCUS PYOGEC	linezolidβ~LLӪ̸TΡC	`2%̡GmBYhBߡBæRBvBKB֯lBYBoNF̡G]߯fBBƤ}BhBkoMYܦC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"600mg q12h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץǷxsAīe~h~]
tsGGUndiluted 
ĳ}@סG-
ۮe}GGD5WBNSBLR
ĳĳ~|tvG30-120min?
`NƶG1.űNLī~[JVX@_
2.YPLī~ϥΦP@޽uɡA`eHۮeGR~"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.3._20210607.pdf"">OI` 10.8.3.</a>             "	"OI` 10.1.,10.8.3."	0	OIs 20251124	ILINE-a	02C27354-1	02C27354-2	110.6.16
AC48590263	J01XA02	0	ITARG	Teiconin inj. 200mg/vial (Teicoplanin)		~ݱߩglycopeptideܥͯAActinoplanes teichomyceticusoûsCﭲ󶧩ʪnߤιߧġC	"1.Ǿॿ`HΦѦ~fwG
(1)ֽMn´BctΡBUIlD׷PVAĤ@ѵP[q@Rߪ`g400mgAMĤGѰ_C@Rߪ`g200mgC
(2)`ΰPVBѦgBߤYPVA}lvC12pRߪ`g400mgAg3`gAאּC1Rߪ`g400mgC`g200mg400mg۷C魫`g3mg6mgзǾqC魫WL85kgfwq۹վAϤ׷PVqŦX3mg/kgAYPVqŦX6mg/kgзǡCYYʷPVApYN˩Ϊ⸲yߩʤߤAq`Rߪ`g12mg/kgqC"	"sƫᤧTeicoplanin`gGߧYϥΡAݲGAHTOġCsƫᤧ`gGim4JOs12pɡA12pɫhϥΡC 
sƫᤧ`gGAi`gA]iHUzs}ϥΡG
0.9%Sodium Chloride`gGC
Compound Sodium Lactate`gG(Ringer Lactate solution,Hartmann's solution)C
5%Dextrose`gGC
0.18%Sodium ChlorideM4%Dextrose`gGC
t1.36%3.86%DextrosezRGC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~m25JUץJsC	Teicoplanin	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	y߷PVҾɭPߤB誢BͪBѦgBn´PVBzB߷PVҭPʵzC	"TeicoplaninLӪ̸TΡCVancomycinLӪ̤]`NAHKoͥeLӡAVancomycin|ް_HgԫhOTeicoplaninTҡCoʵǾण}ťıhHΦbvL{Aʴ夤Teicoplanin@פεǩMիex\C
֥ΨLgrʤΡεǬrĪpGAminoglycosides,Colistin,Amphotericin B, Cyclosporin,
Cisplatin, FurosemideMEthacrynic acid,]iʴC"	"GBkhB`gw~C
GzDGߡBæRBmC"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	"Load:12 mg/kg Q12h X 3 dose
CClr>50     12mg/Kg q24h
CClr 10-50    12mg/Kg q48h
CClr<10   12mg/Kg q72h
IHD         12mg/Kg q72h
CAPD        12mg/Kg q72h"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡG1.tsN12hr 
2.~ǷץJs
tsGG3ml WFI
ĳ}@סG-
ۮe}GGtsi`gAYn}AiNSBD5WBLR 
ĳĳ~|tvG30min
`NƶG1.sƮקKnͪwjAYwjɽRm15ݨAϥ"	ixii[UDx]_U09-09 [w]_w05-13 [E]_G6-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1.1._20210604.pdf"">OI` 10.8.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1._20210604.pdf"">OI` 10.8.1.1.</a>            "	"OI` 10.1.,10.8.1.,10.8.1.1."	0	OIs 20251124	ITARG-d	ITARG-b	ITARG-c	110.6.16
BC23186266	J01XX08	0	IZYVO	Zyvox 600mg/vial(Linezolid)		"1. LinezolidOs@HuXܥͯAݩoxazolidinoneA{ɥγ~DnAΩvݭnʤ󶧩ʵߩҳyPVC~linezolid@ǭ󳱩ʵߩMߦ@ΡCLinezolidǥѤ@ةMLܥͯP@ξӧӵ߳Jս誺XC]linezolidMLܥͯioͥ椬ĩ(cross-resistance)CLinezolid|Pӵ50Sֿ}p(subunit)W23Sֿ}RNAXM\ʪ70S_l_X骺ΦC_XOӵĶ(translation)L{nCھڮɶ-(time-kill)sܡAzy(enterococci)My(staphylococci)ӨAlinezolidO߾(bacteriostatic)Cy(straptococci)jhƪߺئӨAlinezolidO߾(bactericidal)
2. UCߺخĪG΢wݮʩMݩ(Aerobic and facutative)󶧩ʵߡGEnterococcus facium(ȭvancomycinĩʪߺ)A⸲yStaphylococcus aureus(]Amethicillinͧĩʪߺ)AʨyStreptococcus agalactiaeAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AwyStreptococcus pyogenesC
3. ݮʩMݩʭ󶧩ʵߡGTyEnterococcus faecalis(ȭvancomycinĩʪߺ)AEnterococcus facium(ȭvancomycinĩʪߺ)AָyStaphylococcus epidermidis(]Amethicillinͧĩʪߺ)AStreptococcus harmolyticusAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AViridans group streptococciC
4. ݮʩMݩʭ󳱩ʵߡGPasteurella multocidamC"	"~sĳϥζqC侯qOHC12pɧP@覡PC
1. Vancomycin-ĩʪEnterococcus faeciumPVA]AֵoߦgfҡG600mgRߪ`gAΤfAC12pɤ@As1428ѡC
2. |PVͪBֽMֽ´PVBϷPVͪA]AֵoߦߪfҡG600mgRߪ`gAΤfAC12pɤ@As1014ѡC
3. DֽMֽ´PVG400mgRߪ`gAΤfAC12pɤ@As1014ѡC
4. ~]iNC龯q}ӪA(pGWAĤ@AߤWAĤ@)C"	"1. ϥΧܥͯ|PϫDPʲӵߪLץͪCvL{pGX{ƷPV(superinfection)ɡAӱĨAIC
2. linezolidw̴oͦpO֯giC󦳥XʦMIfwBepO֯gfwBPɨ֥η|֦pOƥةΥ\धĪfwΨlinezolidvݶWL2PfwAʴpOƥءC
3. ~iPΪŸɪAΡC
4. pGfwfvAivC
5. AΥ~ɡAקKΤjqttyraminetqζơCC\tyraminetqC100mgCttyraminetq]AǥѦѤơBoáBMηtHW[DkҲͪܩʳJսC
6. pGAΧtpsudoephedrine HCLphenylpropanolamine HCLī~pP_ĩΥh몺ĪɡAiDvC
7. pGAserotonin re-uptakeΨLܼ~{ɡAiDvC
8. xsG1530JUץOsA`gnUwBCĳbϥΫen}`gnU~]ˡF`gGieAHxsɶW[C|[`AvTĻC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Linezolid	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	AΩvѤUCPʵߺطPVfwGVANCOMYCINЧĩʪENTEROCOCCUS FAECIUMPVA]AֵoߦgfҡCf|PVͪASTAPHYLOCOCCUS AUREUSSTREPTOCOCCUS PNEUMONIAEҤް_CֽMֽ´PVASTAPHYLOCOCCUS AUREUSASTREPTOCOCCUS PYOGEC	linezolidβ~LLӪ̸TΡC	`2%̡GmBYhBߡBæRBvBKB֯lBYBoNF̡G]߯fBBƤ}BhBkoMYܦC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"600mg q12h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.ץǷxsAīe~h~]
tsGGUndiluted 
ĳ}@סG-
ۮe}GGD5WBNSBLR
ĳĳ~|tvG30-120min?
`NƶG1.űNLī~[JVX@_
2.YPLī~ϥΦP@޽uɡA`eHۮeGR~"	ixii[UDx]_U10-04 [UDx]_U10-05 [E]_F1-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.3._20210607.pdf"">OI` 10.8.3.</a>             "	"OI` 10.1.,10.8.3."	0	OIs 20251124	IZYVO-a	IZYVO-b	IZYVO-c	110.6.16
AC58553212	J01XB01	0	ICOLI	"LOCOLIN 2MU ""GENTLE""(Colistin)"		"Sodium colistimethateݤѦcolistin~㦳ʡA@Φb󳱩ʱ߲ӭMW
୦h(lipopolysaccharides)A}aӭMqz\AFܵߧ@"	"IM/ IV, 2.5-5 mg/kg/day in 2- 4 divided doses, depending on severity of infection; MAX 5 mg/kg/day
"	"1.ǥ\ण}̶վ㾯q
2.֥γ¾KB٦PBAminoglycosides ̷V "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷ	Colistin methanesulfonate	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	Ω@ܥͯLġABhĩʤ󳱩ʵߤYPV	 colistin polymyxin B ͹Lӯgw	ǬrʡBYwBYhBoNBBʥաBGzABlBIl	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	"CClr>50    1-2vial q12h
CClr 20-49  1vial q12h 
CClr<20       0.5vial q12h 
(lJ:40kgHU 0.25 vial Q12h,40kgHW0.5vial q12h,YзPVi1 vial q8h)"	ѦҡuqΥΪkv	"ĳ~|GIMBIVFBHA
tswwʡG1.tsǷ7daysFN2wk
2.}Ƿ24 hr?
tsGG2 ml WFIBNS(IM)B4ml NS(HA)
ĳ}@סG-
ۮe}GGNSBD5WBLR
ĳĳ~|tvGIV:>3~5 min
IVF:5-6 mg/hr
`NƶG1.ī~ɻĲ~HקKͮw?"	ixii[UDx]_U09-16 [w]_w04-21 [E]_G4-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.6._20100201_000.pdf"">OI` 10.8.6.</a>             "	"OI` 10.1.,10.8.6."	0	OIs 20251124	ICOLI-a	ICOLI-b	ICOLI-c	110.6.16
AC39689212	J01XX01	0	IFOLS	Folsmycin 2gm/vial(Fosfomycin)		Ĭ@ߩʧܥͯAiǥѲӭM轤DʹBӧaziJӭMæb̪춥qzZӭMPeptidoglycanͦXAöiӨϲӵ߳ॢӭM@Ӧ`C	"AdultsGSuggest combine with other antibiotics, do not give as a single agent
Usual doseG8-16 g/day in 2 to 3 divided doses (max single dose: 8 g, max daily dose: 24g) (tӴ)
Lower respiratory tract infection, hospital acquired: 12-24 g/day in 2 to 3 divided doses (Lexi-comp)
Meningitis, bacterial: 16-24 g/day in 3 to 4 divided doses (Lexi-comp)
Osteomyelitis, acute: 12-24 g/day in 2 to 3 divided doses (Lexi-comp)"	"1. Fosfomycintu14.5mEq/g(O)A]AwŦŦAuQw̡AbPSO`NC
2. FosfomycinbѮɡA]Ѽo͡A|LŲ{HAvT~C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25JHUxs	Fosfomycin	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	wߡBܧεߡBFpߡByߡBjzߵ㦳PʲӵߩҤް_PVg (ѦgBުBӤުBXigBͪBͤwgBwݡBBǪǪBH֪)C	Hypersensitivity to fosfomycin	"Diarrhea, nausea, elevations in hepatic enzymes, headache, visual disturbances, and skin rash."	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"CClr>50    2g q6h
CClr 10-50   2g q12h
CClr<10   2g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG}Ƿ24 hr; N48p
tsGG20ml WFID5W
ĳ}@סG-
ۮe}GG100~500ml D5W
ĳĳ~|tvGIV:5min
IVF:1~2hr
`NƶG-"	ixii[w]_w05-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IFOLS-a	IFOLS-b	IFOLS-c	110.6.16
AC37290209	J01XA01	0	IVANC1	Vanco inj.1gm/vial		ӭM?(mucopeptide)XAMiˮ`ӵߪӭMC	"IV Adult: 2-3 g/day (20-45 mg/kg/day) in divided dose every 6-12 hours; MAX 3 g/day.
@릨HCp500mgΨC12p1gARߪ`gC
 Pediatric: 10-15 mg/kg/dose Q6H, MAX 2 g/day.
Renal impairment : CrCl(ml/min) >50: 500 mg Q6H-Q12H , CrCl(ml/min)10-50 : 500 mg Q24H-Q48H
, CrCl(ml/min)<10 :500 mg Q48H-Q96H"	夤@׺ʴAЩ⵹īebpɤ(Trough)εīp(Peak)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Vancomycin	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	y߷PVҾɭPߤB誢BͪBѦfBn´PVBzB߷PVҾɭPʵzC	"Hypersensitivity; avoid in patients with previous severe hearing loss.
ǷlˡBťıêB֥ΨLլrʩεǬrĪ"	"Red man syndrome, drug-induced erythroderma, nausea, vomiting.
HŸB(P`tvL֦)εoN{HCY-ǬrʡBլrʡBʹLӤC"	קKϥ/SmҦw	קKϥ/|qLť	аѦҾqPΪk	"Load: 15 ~25mg/kg ST
CClr>50     500mg q6h
CClr 10-50    15mg/kg q24-96h
CClr<10   7.5mg/kg q2-3days"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tsN14d
2.}N96hr
tsGG10ml WFI
ĳ}@סG5 mg/ml
10 mg/ml
()
ۮe}GG200ml?NSBD5WBLR
ĳĳ~|tvG60min
`NƶG1.`gӧ֮ɥiಣRed man syndrome"	ixii[UDx]_U09-17 [w]_w05-02 [w]_w05-16 [E]_G6-08 [Ew]_F5-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1.1._20210604.pdf"">OI` 10.8.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1._20210604.pdf"">OI` 10.8.1.1.</a>            "	"OI` 10.1.,10.8.1.,10.8.1.1."	0	OIs 20251124	IVANC1-a	01C37290-1	01C37290-2	110.6.16
BC19108100	J01XC01	0	OFUCI	Fucidin Tablet 250mg/tab(Fusidate sodium		Fusidic acidOӵ߳JսXwͧܵ߮ĪG@Τ覡@اܥͯCFusidic acidﳡ󶧩ʵߨ㦳jĪ@ΡAyߥ]ALƪLBGҮfCΨLܥͯܩʪߺعfusidic acidSOPʡC{ɸgҩfusidic acidLܥͯLeĩʡC	"1. fAwHG13A1500mgFൣG50mg/kg3AΡC
"	wnĤrYfsͨbAΥ~dNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Fusidate sodium	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	󶧩ʵߤθyߤް_PVgC	Fusidic acidLӪ̸TΡC	"zGDê(Ƥ},,æR,m)A\ɪAΫhiקKC
ǯfHqRߪ`gFusidic acidAX{ifʶnAfAﵽAYnAvABullirubin_`C"	W̫TӤקKA	ŰõLϥΤWTҡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5001682?cesid=8HOaaG7ZnPg&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFusidate%26t%3Dname%26acs%3Dfalse%26acq%3DFusidate#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OFUCI-a	OFUCI-b	OFUCI-c	110.6.16
BC17835255	J01XD01	0	IMETR	Metronidazol inj.5mg/ml;100ml/vial		Ĭ@ر߾AiΩM@ʹ߷PVvA@άOgѹʲӵߥN©ҿWӨϥĦbӭMiƾǩ٭CQ٭ᤧĨ㦳ӭMrAiPDNAۤ@ΡAɭP۵cॢAѪ_A䵲GDֻĤXAӨϲӭM`C	"ʲӵߤް_PVG
~HMWL12ൣGC龯qG魫CQ窺fwAC300ml`GAΨCTAC100ml Metronidazole FreseniusCHC5mltvCtR߿`Co۷22.5mg/kg/dayMetronidazoleC 
p12ൣGqHC22.5mg/kgpAC뤩@AHC5mLtvACtR߿`C"	 UؤPY{תǥ\णɡAgxıqTKƥXMetronidazole|W[CpGLAqn֦C12p400500mgMetronidazoleCYx\णɡAMetronidazoleƥX|ܺCC]AnpߺʴfwMwˬdG@סC  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Osb<25Ca	Metronidazole	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	ʵߤް_PVg	"MetronidazoleΨL Nitroimidazole lͪLӪfwϥΡC
DOLĪLĪM`ͩRPVC
wYxŦêBy\êBϯgζg䯫geffwAϥ Metronidazole enJӵįqMMIʡC 

"	"OH֪ݨAǥXWA򪬦YAުAfĪA߹æRAAmAYhAYAݺΡAvAWjˡAP䯫gfܡA¤AhAֽPı`C(oǤ}@λPqLΨϥιL[Aq֩ΰϥΫN|)C@ΪkOAXR߿`AഫfAC
զyʥFAɩʥզyʥFC"	MetronidazoleuΩhĤ@ɪYM`ͩRPVAhĤGMĤTAugLJӵįqMMIʫ~ϥΡC	ŴAnũΤ_MetronidazolevC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669691?cesid=4qNd2krTnP3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMETRONIDAZOLE%26t%3Dname%26acs%3Dfalse%26acq%3DMETRONIDAZOLE"">LexidrugľǸƮw</a>"	"CClr>10  500mg Q8h
CClr<10  500mg q8-12h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡGǷץxs
tsGGUndiluted
ĳ}@סG-
ۮe}GGD5WBNSBR
ĳĳ~|tvG5ml/min
`NƶG1.űĲtT2.1.C5mLCt`C"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	IMETR-a	IMETR-b	IMETR-c	110.6.16
AB57982248	J02AA01	0	IAMBI	ĵAmpholipad liposome 50mg/vial		"Amphotericin B Liposome for Injection DAmphotericin B PӭMsterol XAiӧܲӭMzʤ
ϲӭM`AAmphotericin B ߲ӭMergosterol ˩MOAiPŰʪӭMcholesterol XͲӭMrC
Amphotericin B Liposome for Injection OAmphotericin B LiposomalsAizܨPʪ߲ӭM䤺(intracellular) Υ~(extracellular)C"	a.Aspergillosis]Tf^ʷPV 3.0-5.0 mg/kg/day gk3.0 mg/kg/dayFb.Candidiasis]]߷PV^ʷPV 3.0-5.0 mg/kg/day gk3.0 mg/kg/dayFc.Leishmaniasis]Qҭίg^K̥` 3.0 mg/kg/day 1-5β14B21 K̯ʳ 4.0 mg/kg/day 1-5β10B17B24B31B38`q20-60 mg/kgFd.HIVPVfHCoccidioidomycosis]yUl߯f^BHistoplasmosis]´Mߵ߯f^Talaromyces marneffeiPVC߯f3.0-5.0 mg/kg/dayFe.]V(pExserohilum rostratum)TJsް_ΰ`5.0-6.0 mg/kg/day	fwǡBxMG\AHΦMqѽ]רOι[^C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25JHUxs	Amphotericin B 	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE		"1. 貾ӫֵoǬrʥX{IJ߷PVC
2. ǥ\णTݡB]ݩnyߺطPVfwC
3. vPVny߸HIV w̡]Ѿ\{ɬs^
4. vTݡB]ݩάOnyߺطPVAάOLkAmphotericin B deoxycholate v¡fwAάOǥ\णεLk@Amphotericin B deoxycholate ҲͪrʤfwC
5. vŦQɰҤfCbK̤BwŦQɰҤfw̨ϥAmphotericin B Liposome for Injection vAbHβMᤴ_ovC]Ѿ\{ɬs^Ѿ\ΪkζqAgĳqC
6. oN׶ݤʥզyʥFgw̥i࿩w߷PVggkC
GoN׶ݤʥզyʥFgYݤʥզyȤp500 cell/mm3 HUΥզyp1000 cells/mm3 HUAF96pɡAް_oN(>38J ) {HC"	"Amphotericin B Liposome for Injection iΩAmphotericin Bdeoxycholate ΨLզLӪ̡ADbvvNUA
QqjMIʡC"	`5%vƧ@ΡA]AB߷iLtBȴHBvB֯lBlʥFBzGDABǬrʡBhBxƤWɡBIlxCLƧ@Φޤ~B޵jˡAoiBͤ~BɩʥզyʥFBXʻH֪C	hGBAȦbQqjMIɤ~ϥΩhHC	קKϥ/SmҦw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ĳ~|GIVF(with pump)
tswwʡGtmb2-824pɡA}6pɤΧD
tsGG12ml WFI ΤOn30sectm4mg/mlG
ĳ}@סG1.0-2.0 mg/ml(H)0.2-0.5mg/ml()
ۮe}GGˤW5ugLo(iƨϥ)A`gD5W
ĳĳ~|tvG120min?
`NƶGϥήɩ`gޤ[mծ|5.0 microno
"	ixii[w]_w04-05 j	Ts110.8.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.5._20040201_000.pdf"">OI` 10.6.5.</a>              "	OI` 10.6.5.	0	OIs 20251124	IAMBI-a	IAMBI-b	IAMBI-c	110.8.17
BC12258248	J02AA01	0	IFUNG	Fungizone 50mg/vial(Amphotericin B)		Amphotericin BOߩαߡAݵbGҹF쪺@סAHߪPʦөwCĦbP߲ӭMP׾J(sterols)XAyqzʪܤơAɭPӭMSCӭM]t׾JAH{AHӭMP߲ӭMl˥igѦ@PҭPC	"250 mcg/kg/ѡAR߿`4-6pɡC
Lצb@رpUAC龯q藍iHWL1.5mg/kgC"	"1. T{Amphotericin BO@ثD`rĪAӥΨӪvӪ߷PVC
2. RߧPnbYK@UAȦ|fHgLE_ҹꬰiʡAͩRMI߷PV~ϥΡC
3. vΡAܤ֨CgwBUNM夤Creatinine@סA̶gAGA夤[wAΨx\CYx\ण`ABUNWL40mg/100mlΦ夤CreatinineWL3mg/100mlɡAhġC
4. wCRߺw`ӥBn[`goקK~A]ΦީRߪ|o͡C
5. հtɭnεLߪޥA]~tGΨ߾C[10mlLߪ`gΤJAnAMi@BPH4.2HW5%Dextrose`gG}(1:5)AnSalineGӽհtA]|ͨHC
6. UCfHn~pߡGAǷlˡAʴcfAgêέGšC
7. vWL7ѮɡAnq̧Cqs}l(@0.25mg/kg)AӥBvW[qC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC	Amphotericin B	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	߯fʷPVgBoN׶ݤʥզyʥFgw̥i࿩w߷PVggkC	S諸TҡAYp¯٦ܥͩRwAݥ[HvC	oNBCBIlֳtBߡBæRBGWj˩ʯkhC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"ݨ̵ǥ\վ
CClr<10 `ξq(20-50mg) q24-48h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.~Nץxs
2.tsǷץ24hrAN7day
3.}ߧYϥΡC
tsGG10ml WFI
ĳ}@סG0.1mg/ml? @
ۮe}GG500ml D5W
ĳĳ~|tvG IVF 2-6h
 `NƶG 1.iϥNSts
2.ϥΧt߾G}
3.iHPLĪΧtqѽ(ҦpNaCl)`GVX
4.Įɤץ                   
"	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IFUNG-a	IFUNG-b	IFUNG-c	110.6.16
AC60897248	J02AX05	0	IMYFU	Myfungin (Micafungin  50mg)̤bᴹ`gG		"O@ݩechinpocandin߾Cmicafungin ߲ӭMݦ1,3]-D-glucanXC"	"HC龯q
LtqACPMicafunginqTѤAq`iHF85%íwA夤@סC()
v]ߦgPL]߷PV :100mg/day
vD]߷PV:150mg/day
wyFӭM(HSCT)fH]߷PV:50mg/day
ൣC龯q
v]ߦgAʼʩ]߷PVA]߸Mw:2mg/kg (max:100mg/day)
vD]߷PV:<30kg:3mg/kg;>30kg:2.5mg/kg(max:150mg/day)
wHSCTfH]߷PV:1mg/kg(Max:50mg/day)"	"bMicafunginvx\X{`fHAʴx\઺HAåB~MicafunginvI/įqC
bMicafunginvǥ\X{`fHAʴǥ\cƪHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}Ҫᴹp~Ƿ25J(77K) xsAe\dǷ(15-30J)OsC
~tsixsbp~AǷ25J(77 K)U̦hOs24pɡC
}GץAǷ25J(77 K)U̦hOs24pɡC"	Micafungin Sodium	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE		"AΩ󦨤HP|ӤHWൣG
v]ߦgPL]߷PVC
vD]߷PVC
wyFӭMӯfH]߷PVC
`NGMicafungin]ߥH~߷PVĩ|TߡC"	TΩwMicafunginB~ҧt󦨤ΨLechinocandinsLӪ̡C	֯lBkoBC~ȤΦ޵αiC 	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	"100 to 150 mg once daily 
ݽվ"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG}GץAǷ25JU̦hOs24pɡC
tsGG5ml NSBD5Wtm10mg/mlG
ĳ}@סG0.5 mg/mL4 mg/mL(j1.5 mg/mL@סAݥѤR߾ɺ޵ġC)
ۮe}GGNSBD5W
ĳĳ~|tvG>?1p
`NƶGj1.5 mg/mL@סAݥѤR߾ɺ޵ġC
}LGץCݭnB\IwĻPIwޡC
"	ixii[w]_w04-06 j	Ts111.4.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.7._20081001_000.pdf"">OI` 10.6.7.</a>              "	OI` 10.6.7.	0	OIs 20251124	IMYFU-a	IMYFU-b	IMYFU-c	111.4.19
AC43000248	J02AC01	0	IDIFL	GENAZOLE 100mg (Fluconazole)		Fluconazoleݩstriazole߾AM@BĪsterolX	"Adult: usual doseXPO or IV 200-800 mg/day; duration and dosage depends on severity of infection. vaginal candidiasisX 150 mg PO as a single dosePediatricX3-12mg/kg/day; duration and dosage depends on severity of infection.
Renal impairmentX CrCl < 50 ml/min, give 50% of the dose."	"hɤϥΡG
ܤ֥Ω󥥰AFluconazoleʪ餧rʶȨ󰪾qϥΡAvqUALצpADOYέPRʪ߷PVABwįqӹLiL઺MIʡA_hקKΩ󥥰C
¨ŰϥΡG
FluconazolebťĤ@שM߿@A]ĳ¨ŰϥΡC
pĤϥΡG
16HUpĨϥFluconazoleƦADSaAX߾A_hȤϥΡAsͨM@HUൣA]ƦAGĳϥΡC
}ξާ@̤ϥΡG
gܡAäzw̾rpξާ@OC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~30J^xsC	Fluconazole	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	]ߧΥPVAny߷PVAwѧK̯ʥFgԸsfH߷PVC	ּƭfw̡AϥΦhqᦺ`Agѭo{xa{HCoǯfH֥ΦhĪvAwĪx㦳bʬrʡAαw̥f]iɭPxaAbưFluconazoleP]GYeAYw̦bvɵo{xïɰɡAh~vįqPMIʡC	̱`Ƨ@άzGDgA]AߡBhBmMȡA䦸Oֽl	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	"Load:400mg
CClr>40       400mg QD
CClr21-40    200mg QD
CClr<20       150mg QD
IHD              400mg after HD"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG}~ᾨ֥Χ
tsGGUndiluted or NSBR
ĳ}@סG-
ۮe}GG-
ĳĳ~|tvG10ml/min
`NƶG1.ĳPĲVXϥ"	ixii[UDx]_U08-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.1.2._20191201_000.pdf"">OI` 10.6.1.2.</a><a href="""">OI` 10.6.2.</a>             "	"OI` 10.6.1.2.,10.6.2."	0	OIs 20251124	IDIFL-d	IDIFL	IDIFL-c	110.6.16
AC44680100	J02AC01	0	ODIF5	FLU-D 50mg/cap(Fluconazole)		Fluconazoleݩstriazole߾AM@BĪsterolX	"Adult: usual doseXPO or IV 200-800 mg/day; duration and dosage depends on severity of infection. vaginal candidiasisX 150 mg PO as a single dose PediatricX3-12mg/kg/day; duration and dosage depends on severity of infection. Renal impairmentX CrCl < 50 ml/min, give 50% of the dose."	"hɤϥΡG
ܤ֥Ω󥥰AFluconazoleʪ餧rʶȨ󰪾qϥΡAvqUALצpADOYέPRʪ߷PVABwįqӹLiL઺MIʡA_hקKΩ󥥰C
¨ŰϥΡG
FluconazolebťĤ@שM߿@A]ĳ¨ŰϥΡC
pĤϥΡG
16HUpĨϥFluconazoleƦADSaAX߾A_hȤϥΡAsͨM@HUൣA]ƦAGĳϥΡC
}ξާ@̤ϥΡG
gܡAäzw̾rpξާ@OC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~30J^xsC	Fluconazole	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	]ߧΥPVAny߷PVAwѧK̯ʥFgԸsfH߷PV	ּƭfw̡AϥΦhqᦺ`Agѭo{xa{HCoǯfH֥ΦhĪvAwĪx㦳bʬrʡAαw̥f]iɭPxaAbưFluconazoleP]GYeAYw̦bvɵo{xïɰɡAh~vįqPMIʡC	̱`Ƨ@άzGDgA]AߡBhBmMȡA䦸Oֽl	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w32-01 [E]_B3-24 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.1.1._20191201_000.pdf"">OI` 10.6.1.</a><a href="""">OI` 10.6.1.1.</a>             "	"OI` 10.6.1.,10.6.1.1."	0	OIs 20251124	ODIF5-a	01C44680-1	ODIF5-c	110.6.16
AB46283100	J02AC02	0	OICOM	*Icomein 100mg/cap(Itraconazole)		~triazoleAܩʧ߲ӭMXһݪcytochrome P-450A]OfAĪ𾯡AUCߺئġG~ߺ(pTrichophyton sppAMicrosporum sppAEpidermophyton floccosum)Aåߺ(Candida sppAPityrosporium spp)AAsperilis sppHΦUبLåߩMߡC~ֽMDH㦳׿˩MOC	"Adult: 100mg-200mg QD-BID; duration and dosage depends on severity of infection.
1. D]y߷PVGߦU@AC2nA@ѧYiΪ̤@2n(200mg)Asv3ѡC
2. ᴳ~G@2n(200mg)A@AΡAs7ѡC
3. }G@Ѥ@ɡAs15ѡAY̥i30ѡC
4. fĩ]y߷PVG@Ѥ@ɡAs15ѡC
5. ߩʨG@ѤGɡA@AΡAs15ѡC
6. ~GҢw@Ѥ@AC200mg(2)sA6gCkҢw @Ѥ@AC200mg(2)sA12gC"	"1. ~DnbxŦN¡AҥHAxfw̨ϥΥ~ypߡC
2. ¨ŰiAΥ~C
3. ĵyϥΥ~ADvįqjbMC
4. ǯfw̹󥻫~վ侯qC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Itraconazole	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	"~iΩvD]߷PVAᴳ~A~AߩʨMfĪ]y߷PVA߷F~Bk~B~B~HΥ~C
ʩβ`߷PVB~]ONYCHOMYOSIS^Bv~]TINEACAPITIS^C"	"A糧~LӪ̡C~TһPUC~֪Aterfenadine, astemidazoe, cisaprideC"	`}]Aä(1.3%)Ah(1.2%)AYh(1.2%)AƤ}(0.7%)AmAAGȮAGC	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D1 [2]_D1 [ws]_w34-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.3.1._20150101_000.pdf"">OI` 10.6.3.1.</a>              "	OI` 10.6.3.1.	0	OIs 20251124	OICOM-a	OICOM-b	OICOM-c	110.6.16
BC25519100	J04AM07	0	OAKUR	Akurit-3ƤTB(INH75+RMP150+EMB275)		"RIFGӵ߸DNA-dependentRNA polymeraseʡA]ӤzZֻĪXCĹܤ@s󶧩ʩM󳱩ʷLͪC

INHG|TwCߩαߨ̿Ī@שMsͪơC@{|zZӷPͪ骺׽AJսAήֻĪͦXCINHWϥΡAg`toiĩʡCٷ|ܺLRB6ʡC

EMBGJս誺XMl˲ӭMN¡A]Ӫ_ӵ߲ӭMWޡCMLľSX{椬ĩʡC"	魫šG3037Kg CfA2A3854Kg C3A5570Kg C4A71Kg̥iҼ{PC5C \e1pɩ\2pɪAΡC 71KgΪkζqAyѨڰefިefEvޡC̰ꤺefިĳAC̤jqIsoniazid 500mgRifampin 600mgC	1.TsC 2.קKϥΤfAץġC 3.קKtβC 4.~|ϧATKܦC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Rifampin/Isoniazide/Ethambutol	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֡BL֯g	1.RifampinBIsoniazidBEthambutolM᫬LӪfvfwTϥΡC 2.HYxŦlˡBIsoniazidoY}AOĪʵoBHŸM`Afw]f]oͫʨxŦefMfwwʵhC 3.wfwwgAEthambutol]OTϥΡAD{ɤWMwϥΡC	ߡBæRBGABP䯫gBOҽkC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided. 	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M05-01 j	Ts110.6.16		OI` 	0	OIs 20251124	OAKUR--a	OAKUR-b	OAKUR-c	110.6.16
AC24894100	J04AK02	0	OEMB	E-butol 400mg/tab		Jս誺XMl˲ӭMN¡A]Ӫ_ӵ߲ӭMWޡCMLľSX{椬ĩʡC	"Tuberculosisdaily therapy, AdultX15-25 mg/kg/dose QD OR 40-55kgX800mg;
 56-75kgX1200mg; 76-90kgX1600mg ; MAX 1600mg/day
 Pediatric>13 yearsX15-20 mg/kg/dose QD; MAX 1 g/day
_lvw15mg/kgC24pɤfA@qAK[INHCAv(eLܵ֯fvfH)25mg/kgC24pɤfA@qAܤֲK[1ع惡LͪӷPLܵġC60ѫ15mg/kgC"	"1. ıUӫשΦmıܡAnߧYivCĩMqfHAOƶgμƤ~i_CҥHAΥ~Cj3~6Ӥ붷@ˬdC
2. UүfHnpߨϥ:xεǥ\ण}AĦgΦʵhfAMC
3. `N~|W[SGPT.SGOT@שM夤ġC
4. AΥ~2pɤAiAΧtTGũΨľC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Ethambutol	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֡BL֯g	gA12HUĵFʨxfAAisoniazidY}̡]]Axl^C	ϯgtwCıUӫ(pC⪺ııҽk)AYhAtw AVáAwVOʥAPı`AıFGzwhAGzAAæRAFLӢwkoAֽAoA`hALmʹLӤFLw@夤ġAʵhAuȪǥ\lˡC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk is minimal.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669723?cesid=7XoLYvyLmrO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEthambutol%26t%3Dname%26acs%3Dfalse%26acq%3DEthambutol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M05-02 [s]_110 [®]_110 j	Ts110.6.16		OI` 	0	OIs 20251124	OEMB-a	OEMB-d	OEMB-c	110.6.16
NC00164100	J04AC01	0	OINA	Isoniazide 100mg/tab(Isoniazid)		|TwCߩαߨ̿Ī@שMsͪơC@{|zZӷPͪ骺׽AJսAήֻĪͦXCINHWϥΡAg`toiĩʡCٷ|ܺLRB6ʡC	"Tuberculosisdaily therapy, AdultX5 mg/kg/day (usual dose : 300 mg/day) as single dose OR 10 mg/kg/day in 1-2 divided doses in patients with disseminated disease. PediatricX10- 15 mg/kg/day in 1-2 divided doses; MAX 300 mg/day
魫C礧@Aζq14mgAqH@q0.050.2Gm]1/22^AƦ]Y35^AΡAfiWqC"	"1. UCfnpߨϥ:CʨxlˡAŦfAŦfAs뤤rAֻêfҡAκ믫fAMέŰC
2. ɥRLRB6(110100mg)ӴINHgrʡAרOi}M}fw̡AMuwCvINHAQƪ(acetylator)(ѬİʤO)CINHsTwXB6s(100mg INH/5mgLRB6, 100mg/10mg, 300mg/30mg)C
3. jտuqnʡAgv\iApקK|AġAΰvA]YvפӦAh_ovAӥBYqAhĩʤ
4. AΥ~v2~3PۡAj90%fHv6ӤAGeʤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Isoniazide	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֡BL֯g	ʨxfC	Pı`A鯫gfg(רOi}A}fζݰsH)Aרx\ण}	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668732?cesid=a1sCVVyoGgU&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DIsoniazide%26t%3Dname%26acs%3Dfalse%26acq%3DIsoniazide"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M05-03 [s]_159 [®]_159 j	Ts110.6.16		OI` 	0	OIs 20251124	OINA-a	OINA-b	OINA-c	110.6.16
AC38104100	J04AK01	0	OPZA	Pyrazinamide 500mg/tab		~D PyrazinamideHֵ H37Rv̤po|@(MIC)200ug/mlAPLܵ־O@ΡAgfPbzGDltAN²pyrazic acidAq`2~5pɫF̰夤@סAYMLܵ־֥ΡAĪGW[iﵽgC	13~4A1~3^A(W)A ĻݥvBϥΡC 	"1. HˡAȘho@fΪ̬OĭȤW@w̡C
2. ǻٮ`κæǻٮ`w̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25 CHUxsC 	Pyrazinamide	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֤ΨL֯gC	xٮ`w̡C	"xŦ:X{xٮ`pAYxಧ`ɧY ġC
`:X{ĭȤW@εho@(`h)gC 
G:nĲyWhgGg
Lӯg:oBolLӯgX{ġC
Gz:B߹æRgC
L:YhB׵hBH۵C "	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M05-04 [s]_258 [®]_258 j	Ts110.6.16		OI` 	0	OIs 20251124	OPZA-a	OPZA-b	OPZA-c	110.6.16
AC24838100	J04AB02	0	ORIFA	Rifampin 300mg/cap(Rifampicin)		RifampicinbXsıߩʧܥͯAǻPDNA-̿RNAEXJ(Polymerase)]椸jOXӧӵRNAXAH۩DNAA]_RNAƻsEo@ΡC	"@릨HqG
1.`󸣽y߱a̡GfA600mgA@@A@4C
2.֯fGPLֵ߾֥ΡGfA600mgACѤ@C@릨HB譭qGC龯q̰iWL600mgC
[`N]LPVWAC龯qF1.8g̡C
@ൣqG
1. 5HUൣGq|TߡC
2. 55HWൣG`󸣽y߱a̡GfAAC魫10~20mgA@@A@4C
֯fGPLֵ߾֥ΡGfAAC魫10~20mgA@@C 
[`N]C̤jqiWL600mgC"	"1. ķ|ɭPGBTKBGBBβ\Gܬ`ĦAi|ϳnβä[ʪܦC 
2. ĳ̦nbŸ]e@pɡAζ2pɡ^P@jM ]240mL^@AAHǫΪlCYoͭGzDEɡAiHPPAC
3. ws뤤rΨxŦ\णfHAĤϥpߦҼ{C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Rifampicin	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	"֯g]͵֡B޵֡Bǵ֤ΨLֱߤް_֯g^
͵֡B`󸣽y߱a̡C"	RifampicinҥΩnfw̤ιLRifampicinLӥvfHC	HXBIlx(iରFlulikegԸs)BΥֽܶ]iରx^BmBGBTKBGBBβ\GѬܬ`ĦC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M05-05 [s]_267 [®]_267 j	Ts110.6.16		OI` 	0	OIs 20251124	ORIFA-a	01C24838-1	01C24838-2	110.6.16
AC37167100	J04AM02	0	ORINA	Rina (Ƥ)/cap		"RIFGӵ߸DNA-dependentRNA polymeraseʡA]ӤzZֻĪXCĹܤ@s󶧩ʩM󳱩ʷLͪC

INHG|TwCߩαߨ̿Ī@שMsͪơC@{|zZӷPͪ骺׽AJսAήֻĪͦXCINHWϥΡAg`toiĩʡCٷ|ܺLRB6ʡC
"	"魫50ΥHWɡACѤ@A2C
"	Hw̱Macox Plus 300v֯fɡAqxŦïBxBMٻBypƤΦpOƥء]Φpȡ^ǭȡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25X CHUBAץxsFקKĵoC  	Rifampicin/Isoniazide	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֡B`󸣽y߱a	RifampicinҥΩnfw̤ιLRifampicinLӥvfHC	HXBIlx(iରFlulikegԸs)BΥֽܶ]iରx^BmBGBTKBGBBβ\GѬܬ`ĦC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M05-06 j	Ts110.6.16		OI` 	0	OIs 20251124	ORINA-a	ORINA-b	ORINA-c	110.6.16
		0	OPRIF	(e޸p)Priftin 150mg/tab (rifapentine)		RifapentineݩrifamycinܥͯA|ܩʧPʵ֤KߪDNA̿૬RNAEX?C|MӵߪDNA̿૬RNAEX?ΦíwƦXAGRNAXþɭPӭM`CRifapentineΨ25-desacetylNª|ֿnHֲӭMlͪӭMA̫ĳqfAĪҹF쪺@׹ӭMβӭM~֤K(M. tuberculosis)Ҧߧ@ΡC25-desacetyl rifapentineʥNªA䬡ʴXGPrifapentine۷C~ܡArifapentinebܥͯi򤺵uȰi@qɶ|׿@YӭMC	"H2HWൣA魫pA10-14 kg: 300mg(2)A14.1-25 kg: 450mg(3)A25.1-32 kg: 600mg(4)A32.1-50 kg: 750mg(5)A>50 kg: 900mg(6)A̰q900mgACP@A@12PC
PINH֪A12PAINHq󦨤H12HWൣG15mg/kg(|ˤJ̱50mg100mgq)F2-11ൣG25mg/kgA̰q900mgACP@C"	xU߬ʸmBG(GBGB\)ܦ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUA[J3~C	Rifapentine 150mg/tab	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	AΩvH2 (t)HWൣ]PV֤K(Mycobacterium tuberculosis) ҾɭP񵲮ַPVABoǱw̦cƬ֯f׭IC	PriftinTΩrifapentineΥLrifamycins(Ҧprifampicinrifabutin)AΥξLӪfHCPriftinTΩ󵵽gfHCھrifampicinϥθgA|wrifapentine]i໤o_-i򥪱۪G}ĦX?(delta amino-levulinic acid synthetase)AGӾɭPgʵo@C	LӤBYhBߡBxBֽ	ubPriftinvұaӪbQqjIɤ~ϥΡCwh̫Xgϥrifampicin|ɭPˤbXA]rifaoentinei঳A]hϥiA˴AiॲLRKvC	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.12.29		OI` 	0	OIs 20251124	OPRIF-a	OPRIF-b	OPRIF-c	110.12.29
		0	OISON	(e޸p)ISONIAZID 300mg/tab(INH)		"|TwCߩαߨ̿Ī@שMsͪơC@{|zZӷPͪ骺
BJսήֻĪͦXC INH WϥΡAg`toiĩʡCٷ|ܺLR
B6 ʡC"	"1.ʵ֯fG
HC 5 mg / kgA@q]1 ѳ̤jq 300mg^C
ĵC 10~20 mg / kgA@q]1 ѳ̤jq 300mg^C
2.wGH 1  300mgA@qCĵ 1  10mg / kgA@qC
"	"1. UCfnpߨϥ:CʨxlˡAŦfAŦfAs뤤rAֻêfҡAκ믫fAMέŰC 2. ɥRLRB6(110100mg)ӴINHgrʡAרOi}M}fw̡AMuwCvINHAQƪ(acetylator)(ѬİʤO)CINHsTwXB6s(100mg INH/5mgLRB6, 100mg/10mg, 300mg/30mg)C 3. jտuqnʡAgv\iApקK|AġAΰvA]YvפӦAh_ovAӥBYqAhĩʤ 4. AΥ~v2~3PۡAj90%fHv6ӤAGeʤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25JHU^AץJáC	Isoniazid 	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	͵֡BY֡Bz֡BHֵ֡Bֽ֡B֩轤B֩wݡBŦ֡C	糧LӪ̡AtĪް_ʨxf̡C	Pı`B鯫gfg]רOi}A}fζݰsH^Aרx\ण}]Ȯɩʪ@夤i?^C	C šG bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.3.15		OI` 	0	OIs 20251124	OISON-a	OISON-b	OISON-c	111.3.15
XCOVID0002		0	OMOLN	Molnupiravir 200mg/cap		"Molnupiravir @ξର fr]տ~ֿnA ]iyfrܡC]A molnupiravir vɡA T꧹㪺{AHfrMvAévHΪv T̷ӫ  j AH C SARS CoV 2 ǼiʡC

Molnupiravir O@ب㦳ܯfrʪeXġAi SARS CoV 2 C~|N¦ M?? NHC M
GiJӭMA NHC bӭM|gCĤƧ@ΧΦĲzʪ ֿ}?TC (NHC TP) C NHC TP |zLf
r RNA EX? nsp12 @λP SARS CoV 2 RNA X H NHC C [NHC MP] Φ ))AɭPfr]տ~
 n Aqӧƻs@ΡC
"	C12 pɤfA@ Molnupiravir 800 @J | 200 @Jn ))AA  ѡCiHΤH֪ACTEɳtA Molnupiravir AéX{g᤭ѤAΡCMolnupiraviråQ ֭ isϥζWL  ѡA] sϥζWL  Ѫ wʻPĩ|T C	"? Molnupiravir  Q֭  18 HUfH
? Molnupiravir å Q ֭ Ω ]w COVID 19 ef   | @ fHC 1 {ɸ礤A ]w COVID
19   | @ ëD  ]j  | ժ̡A  [ϥ molnupiravir vįqC
? Molnupiravir å Q ֭ isϥζWL 5 ѡC
? Molnupiravir   Q ֭ Ω Ĳ COVID 19 TE e Ĳ  ǥH w COVID 19  w ʪv C
? Molnupiravir  ĳ ΩhkC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~xsb30 JHU iOs 24 Ӥ C	molnupiravir	J05			AΩof5 ѤB㦳gI]lHצܤ׷safref (COVID 19 AYSǬVʪͪTE̡A B{ɤWAΨL COVID 19 vܮ C	"pGfHb}lϥ molnupira vir vᶷ|vAfH i   @HP_ U 㪺 5 {
ثe molnupiravir ӽбM׮֭J     o{  ϥ TҡC"	"m,,wt"	"קKϥ/SmҦw
 ĳ hϥ molnupiravir
b   molnupiravir vMϥ ̫@ Ī 4   T ëĨ Ī
ץIC"	"קKϥ/SmҦw
bϥmolnupiravir vMϥγ̫@ molnupiravir  4 ѤĳšC b"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiE2j	Ts111.4.26		OI` 	0	OIs 20251124	OMOLN-a	OMOLN-b	OMOLN-c	111.4.26
		0	OMAVI	Maviret 100/40mg/tab		MAVIRET O glecaprevir M pibrentasvir TwqƤsAئO@Ω C xfrܯfrĪ	MAVIRET fAĳqOC@AH\AΤTA (C`qGglecaprevir 300 mgApibrentasvir 120 mg)	CarbamazepineBefavirenz MiۭC glecaprevir M pibrentasvir 夤@סA]ӴC MAVIRET vĪGCoǤĳP MAVIRET ֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Glecaprevir+Pibrentasvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vHC C xfr (HCV) ] 1B2B3B4B5B 6 PV	"1. w|ﬡʦι 11 `ξ͹LӤC 2.MAVIRET TΩ󭫫רx\णw (Child-Pugh C)C
3. MAVIRET TP t atazanavir s, simvastatin, dabigatran etexilate, t ethinyl oestradiol s, rifampicin ֥ΡC"	YhB«M	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OMAVI-a	OMAVI-b	02C27323-2	110.6.16
		0	OEPCL	EpclusaƤ 400/100mg/tab		"Sofosbuvir HCV NS5B RNA ̿RNA EX?x]AEX?DOfrƻsҥݪïCSofosbuvir O@خ?īeXġAeXķ|gѲӭMN§@ΧΦĲzʪ?TCQ]GS-461203^AMizLNS5B EX?@δOJHCV RNAAqӲפ@ΡCGS-461203
]sofosbuvir ʥNª^ëDHDNA PRNA EX?A]OɽuRNAEX?C
Velpatasvir wHCV NS5AJղͧ@ΪHCVAJդDORNAƻsPզfrɤlҥݪC~ĩʿܻPeĩʬsܡAvelpatasvir|wNS5Aͧ@ΡAo]O@μҦ"	"1.Epclusa ĳqC@HΤHfA@
2 vPgvA֦xwƪw̤Ψ֦Nvʨxwƪw̡AkP{ϥEpclusa v12 g"	Epclusa iPLtsofosbuvir ī~֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUOs	Sofosbuvir+Velpatasvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	Epclusa AΩvHCCxfr]HCV^]1B2B3B4B5 6 PVg	糧Ħo͹LӯgfwAФŧP	YhBh¤	Fetal risk cannot be ruled out.	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-10 j	Ts111.8.19		OI` 	0	OIs 20251124	OEPCL-a	OEPCL-b	02C27547-2	111.8.19
AC57738265	J05AB01	gᴹ`g250@J(ɥi)	IZOVI	Virless inj.250mg/vial]Acyclovir^		DAcyclovirO@اܯfrĪA©ʞ\l(HSV)BΤka\lfrD`ġCAcycloviriJQ\lPVӭMA|CĤƦʤƦXAAcyclovirTCĤƦX|\lSDNA polymeraseMA]iHfrDNAXӤ|zZ`ӭMN§@ΡC	"Hq
1. ©?l]?lʸҥ~^Τka?lPVw̡AC8pɡA5mg/kgAcyclovir`C 2. K̾णw̡Aǥ\ॿ`̡Abvka?lP
VɡAC8pɵ10mg/kgAcyclovir`CK̾णw̡Aǥ\ॿ`̡Abvka?lPVɡAC8pɵ10mg/kgAcyclovir`C
ൣq
1. 3Ӥ12ൣϥAcyclovirR߿`ɡAھڨnp⾯qCw©?l]?lʸ~^άOka?lPVൣAC8pɨϥ250mg/m2AcyclovirR߿`C
2. K̥\णӵǥ\ॿ`ൣAwka?lPVάO?lʸɡAC8pɡA500mg/m2nAcyclovirR߿`C "	"1. ϥθqw̡]Ҧp?lʸ^ASO`Nǥ\ASOOw̦Υǥ\ण{HɡC
2. ts᪺Acyclovir`gGpHȬ11AgѤfAġC 3. ϥΩǥ\णΦѦ~w̡GAcyclovirgѵŦưA]bǥ\णfHWϥΪqӴ֡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Acyclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	a?lfrγ?lfrް_PVCw貾ӤΥզfҤް_K̤fH?lPVCsͨ?lPVC 	Acyclovir |LӤw̡ATϥΡC	`g짽oAߡAæRC 	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668909?cesid=9B6fcslhXtp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcyclovir%26t%3Dname%26acs%3Dfalse%26acq%3DAcyclovir"">LexidrugľǸƮw</a>"	"CClr>50       10mg/kg Q8h
ClCr25-50    10mg/kg Q12H
ClCr10-25    10mg/kg Q24H
ClCr<10        5mg/kg Q24h
CAPD           5mg/kg Q24H (after HD)"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tmnε}ᤧGiNáB}Ƿ12hr,
tsGG10 ml WFIBNS 
ĳ}@סG<5mg/ml  @
ۮe}GGNSB0.45%NaCl
ĳĳ~|tvG> 1hr
`NƶG-"	ixiij	Ts114.10.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.1.1._20190601_000.pdf"">OI` 10.7.1.1.</a>              "	OI` 10.7.1.1.	0	OIs 20251124	DC	DC	DC	114.10.22
BC27570100	J05AR20	0	OBIKT	BiktarvyƤ (TAF+FTC+BIC)		"Bictegravir GBIC|HIV-1OX?ಾʡ]OX?ಾFINSTI^AHIV-1OX?O@ؿHIV-1]ĶXïA]OfrƻsҥݪïCOX?iuHIV-1 DNAOJJD]DNAAqӹKHIV-1frΦPfrcޡC
Emtricitabine GFTCO@ئXcytidine ?AFTC|QӭMïCĤơAΦemtricitabine 5'-triphosphateCEmtricitabine 5'-triphosphate|MѵMdeoxycytidine 5'-triphosphate vA÷|MsͪfrDNAXAqӧHIV-1 ?ʡAþɭPDNAפCEmtricitabine 5'-triphosphateŰʪDNAEX?\B]B` βɽuDNAEX?^ӨO@خzĪC
Tenofovir Alafenamide GTAFtenofovir C୫eXġ]2'- h?C^CTAF ߼SqϨoHziJӭMAMATAF bӭM|zL´J?Aѧ@ƦtenofovirCTenofovir H|AgӭME?CĤƧ@ΧΦʥNªtenofovir diphosphateCTenofovir diphosphate |zLHIV?@δOJfrDNAAɭPDNAפAqӧHIV-1ƻs@ΡC
Tenofovir diphosphate O@خzĪŰʪDNAEX?]]AɽuDNAEX?^^ABbӭMi礤õLҾܨ㦳ɽurʡC"	ĳqC@AHΤHfA@	"1. BiktarvyPttKɥRiPHAΡC
2. iAΧtT/ ζtľ2pɫeŸAΥ~C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Bictegravir+Emtricitabine+Tenofovir Alafenamide	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vPVĤ@HK̯ʥFfr(HIV-1) BwPOJ?ī~BemtricitabinetenofovirĩʬܪHP魫ܤ25窺ൣfH	"Biktarvy TPUCĪ֥ΡG 
1. dofetilideA]i|ɭPdofetilide 夤@פɰAqӤ޵oYB/ ΦMΥͩRƥC
2. rifampinA]|BIC夤@׭CAoi|ɭPĳॢιBiktarvy ͧĩʡC"	ߡBmYhC	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OBIKT-a	OBIKT-b	OBIKT-c	110.6.16
BC27860100	J05AR25	0	ODOVA	DOVATO (DTG 50mg+ 3TC 300mg)		"DolutegravirGDolutegravir|PHIVOX?ʳ쵲XAqӧOX?@ΡAê_frDNAOXL{ಾBJAo]OHIVƻsgnBJCbĥί¤Ƥ]HIV-1OX?PwBzDNAҶi檺ಾͤƤRAҴoIC50Ȭ2.7 nMP12.6 nMC
LamivudineGLamivudineO@ئX?CLamivudinebӭM|QCĤơAΦ䬡5-triphosphateNªlamivudine triphosphate (3TC-TP)C3TC-TPDn@μҦP?XDNAפAqӧ?(RT)@ΡC"	DOVATOO@ةTwqƤ貣~At50@JdolutegravirP300@JlamivudineCDOVATOΩ󦨤HH12HWB魫ܤ40C֦~ĳĤ覡C@ACfA@AiP֪AAiP֪AAĳΩٻMvC50@/fH	"XַPVHIV-1PHBVfHGX{LAMIVUDINEĩBxfrAHΪvBxcƪI
ҦPVHIV-1fHb}lϥDOVATOveζ}lvɡA˴O_PVBxfrC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Цs30JHU	dolutegravir + lamivudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vĤ@HK̤fr(HIV-1)PVgHP12HWB魫ܤ40C֦~ABGاܤfrĪwκæĩʪfHC	"edolutegravirlamivudine͹LӤC
bϥdofetilideA]i|ɰdofetilide߿@סAHεoY/ΦMΥͩRƥ󪺭I"	YhAߡAmAvAh¡AYw	קKϥ/|qLť	קKϥ/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-03 j	Ts111.4.26		OI` 	0	OIs 20251124	ODOVA-a	ODOVA-b	ODOVA-c	111.4.26
BC27001100	J05AR18	0	OGENV	Genvoya(HIV)Ƥ轤10/200/150/150mg		"Elvitegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA. Cobicistat inhibits enzymes of the CYP3A subfamily and enhances systemic exposure to elvitegravir. Emtricitabine is a cytosine analogue and tenofovir alafenamide is converted to tenofovir in vivo; tenofovir is an analog of adenosine 5'-monophosphate. Emtricitabine and tenofovir interfere with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication."	C@ACfA@	C@AC@ɡAH\AΡCũCZBHέb	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Tenofovir alafenamide +Emtricitabine +Elvitegravir +Cobicistat	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩPVHIV-1B|OJHī~Bemtricitabinetenofovirͧĩʬܪ~ΫC֦~(12(t)HWB魫ܤ35)fH	"PUCī~֥ΡAi|yYέPR}BfrॢιGENVOYAͧĩ
? ҫ-1ǤWܾ]alpha 1-adrenoreceptor antagonists^Galfuzosin
? ܤ߫ߤġGamiodaroneBquinidine
? ܵjġGcarbamazepineBphenobarbitalBphenytoin
? ܤKġGrifampicin
? ]ergot^lͪGdihydroergotamineBergometrineBergotamine
? zGPʾGcisapride
? 󥻲~G[ herbal products: St. Johns wort]Hypericum perforatum^]
? HMG Co-A٭?GlovastatinBsimvastatin
? ܺ믫fġGpimozide
? ĤCĤG?]PDE-5 inhibitors^Gsildenafi]l vͰʯ߰^
? RwvġGmidazolam]fA^Btriazolam"	ߡBmBæRBȮB֯lBh¡B`	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-04 j	Ts110.6.16		OI` 	0	OIs 20251124	OGENV-a	OGENV-b	OGENV-c	110.6.16
BC27514100	J05AR21	0	OJULU	JULUCAƤ(DTG/RPV)		"Dolutegravir, an integrase inhibitor, inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor, binds to reverse transcriptase and blocks the RNA-dependent and DNA-dependent polymerase activities, including HIV-1 replication."	"
C@HfA"	"1.H\A(WܳJս趼~äN\)C

2.PttBBTľBwmBΧtKBtɥR~}AĮɶA̦nbAoĪe 4pɩ 6pɫAΦġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Dolutegravir +Rilpivirine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"AΩŦXHUҦpHK̤fr-1 (HIV-1)PVgHfHAN{ܤfrBvG
(1){ܤfrBvqíwBFfrǧĪG(HIV-1 RNA <50 copies/mL)ܤ֤ӤA
(2)LhLvѯfvA
(3)糧~اܤfrĪAҵLwκæĩʡC"	"Hypersensitivity to dolutegravir, rilpivirine, or any component of the formulation."	"Diarrhea, headache, abnormal liver function, hyperlipidemia, hyperglycemia, bone fracture"	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OJULU-a	OJULU-b	OJULU-c	110.6.16
BC27505100	J05AR19	0	OODEF	OdefseyƤ (TAF+FTC+RPV)		"Non-nucleoside, nucleoside, and nucleotide reverse transcriptase inhibitor combination; rilpivirine binds to reverse transcriptase and does not require intracellular phosphorylation for antiviral activity; emtricitabine is a cytosine analogue while tenofovir alafenamide fumarate (TAF) is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication."	"
C@HfA"	Odefseytſ}C]Abſ}@gBLappſ}?ʥFgBθ}-bſ}l}uǰDw̤iϥΥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Emtricitabine+Rilpivirine+Tenofovir Alafenamide	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"eϥιLܯfrĪvRfr(HIV-1)PVvABbv}lɨfrqHIV-1 RNA 100,000 copies/mL12HW(魫ܤ35)w̡FAΩSwíwܤfrkABv}lɤwFfrǧA(HIV-1 RNA <50 copies/mL)w̡AN{ܤfrkCemtricitabine/ rilpivirine/ tenofovir @Aw̹Lhβ{bLĩʯfv~A"	"ﬡʦιҦCξLӡC OdefseyiP|ɭPrilpivirine夤@ש㭰CĪ֥ ]]ӭMP450 [CYP]3Aïɧ@ΩΦ]GpHȤɰҭP^Aoi|ɭPOdefseyĴzAoĪ]AG
1. CarbamazepineBoxcarbazepineBphenobarbitalBphenytoin 
2. RifabutinBrifampicinBrifapentine
3. OmeprazoleBesomeprazoleBdexlansoprazoleBlansoprazoleBpantoprazoleBrabeprazole
4. Dexamethasone]fAP`g^ADȨϥγ@qv
5. St. Johns wort]t^]Hypericum perforatum"	ߡBmYhC	53u.3y94	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OODEF-a	OODEF-b	OODEF-c	110.6.16
BC27263100	J05AR14	0	OPREZ1	Prezcobix 800/150mg/tab		"Darunavir binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles. Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat and increases the systemic exposure of CYP3A substrates (eg, darunavir)."	C@ACfA@	"1.пϥΡAHAPREZCOBIXC
2.pGX{YֽʩΨx]pʨxBӭMѩʨx^BxŦl`xίgAХߧY^EivC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Darunavir+ Cobicistat	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩPLܤfrĪ֥ΡAHvvδgvBodarunavirĩʬN]V11IBV32IBL33FBI47VBI50VBI54LBI54MBT74PBL76VBI84VBL89V^HK̯ʥFfr]HIV-1^PVHw̡C	"PREZCOBIX TΩ󱵨UC֥Īw
? Alpha 1-ǤWܾGalfuzosin
? ܤߵhĪGranolazine
? ܤ߫ߤĪGdronedarone
? wĪGcarbamazepineBphenobarbitalBphenytoin
? ܵhĪGcolchicineAbǥ\/ Ψx\णw
? ܤKġGrifampin
? ܺ믫fĪGlurasidoneBpimozide
? lͪG pdihydroergotamineBergotamineBmethylergonovine
? GzįĪGcisapride
? ĻsG tSt. John's wor]t es¼Hypericum
 perforatum^
? Cx@ΧܯfrĪGelbasvir/grazoprevir
? HMG-CoA٭?GlovastatinBsimvastatin
? PDE-5GΩvͰʯ߰sildenafil
? R/ wvġGfAΪmidazolamBtriazolam"	֯lBhBmBߡBæRBYh	ubL઺bįqjbIɤ~bhϥ	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-02 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OPREZ1-a	OPREZ1-b	OPREZ1-c	111.8.19
BC27613100	J05AR22	0	OSYM	SYMTUZAƤ(DRV/C/TAF/FTC)		"Darunavir binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles. Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates (eg, darunavir). Emtricitabine is a cytosine analogue and tenofovir alafenamide is converted intracellularly to tenofovir (adenosine nucleotide analog) and subsequently phosphorylated by cellular kinases to the active moiety, tenofovir diphosphate. Emtricitabine and tenofovir alafenamide interfere with HIV viral RNA-dependent DNA polymerase activities resulting in inhibition of viral replication."	"
C@HfA"	Lk]`fHAiϥΤľNĤbA}ߧYAΧ㪺q	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC ble~̦hiHs7ѡD	Darunavir+Cobicistat+Emtricitabine+Tenofovir alafenamide 	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"AΩvUCPVHK̤fr1]HIV-1^HfHG
(1)eLܤfrĪvAΨϥíwܤfrkvܤ6Ӥ
(2)wFfrǧĪG]HIV-1 RNAC50 copies/mL^BawdarunavirtenofovirĩʬN"	糧Ħo͹LӯgfwAФŧP	"Diarrhea, Rash, Nausea, Fatigue, Headache, Abdominal discomfort, Flatulence, Increased serum cholesterol, Decreased bone mineral density, Increased serum glucose, Increased serum creatinine, Liver impairment"	Fetal risk cannot be ruled out.	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OSYM-a	OSYM-b	OSYM-c	110.6.16
BC26407100	J05AJ03	0	OTIVI	Tivicay (Dolutegravir DTG) 50mg		"Antiretroviral, Integrase Inhibitor (Anti-HIV). Dolutegravir binds to the integrase active site and inhibits the strand transfer step of HIV-1 DNA integration necessary for the HIV replication cycle."	"1.Treatment naive or treatment-experienced integrase strand transfer inhibitor (INSTI)-naive: 50 mg once daily;
2.Treatment naive or treatment-experienced INSTI-naive when coadministered with carbamazepine, efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir or rifampin: 50 mg twice daily;
3.INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance : 50 mg twice daily."	"1.YѰOAġA@Q_֪AΡCpGZU@Aήɶ4pɡAhLĪAéU@AĮɶAΥ`qFi@AΨ⭿qC
2.Pthlľ(pBT)BwmBSucralfateAthlɥR~(pKBt)}AĮɶA̦nbAoĪ 2pɫe6pɫAdolutegravirC
3.קKPCYP3A4N»ïɾå(pOxcarbazepine, Phenytoin, Phenobarbital, Carbamazepine, Rifampicin)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Dolutegravir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩPLܤfrĪX֥ΩvH12HWC֦~HK̤fr(HIV)PVg	糧Ħo͹LӯgfwAФŧP	">10%: increased serum ALT (?18%; includes patients with hepatitis B and/or C infections); Hyperglycemia 

"	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OTIVI-a	OTIVI-b	OTIVI-c	110.6.16
BC26518100	J05AR13	0	OTRIU	Triumeq Ƥ(ABC+3TC+DTG)		"Triumeq is a fixed dose combination product, containing dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg. Abacavir and lamivudine are synthetic nucleoside analogues that inhibit HIV-1 reverse transcriptase. Dolutegravir is an integrase strand transfer inhibitor that blocks retroviral DNA integration in the HIV replication cycle. Abacavir, dolutegravir, and lamivudine are used as HIV-1 antiviral agents ."	C@ACfA@	"pGæo͹LӤATRIUMEQC
bϥή?(WϥΩλPLĪ֥ΡA]Aabacavir Plamivudine)ΨLܤfrĪɵoͨŻĤrYxŦ~jX֯תըx(]A`f)i
bXַPVB xfr(HBV)PHK̤fr(HIV-1)ðlamivudine(TRIUMEQ @)w̤AB xYʴcƪi"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Abacavir+Dolutegravir+Lamivudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩ󰵬HK̤fr(HIV)PVgvĪAAΪHϥΧܤfrĪvAΩҷPVHIVTriumeqTاܤfrĪwҹ{ɤWæĩʪHw̤12HWC֦~w	"TRIUMEQ TΩUCw̡G
1. a HLA-B*5701 ﰸ]C
2. e abacavir ͹LӤC}lϥTRIUMEQ eA˵w̪vA T{eO_ϥΥtabacavir ~CHLA-B*5701 AAbo abacavir LӤA藍is}lϥTRIUMEQ ΥLtabacavir ~C
3. e dolutegravirlamivudine ͹LӤC
4. bϥ dofetilideA]Pdolutegravir ֥Υi|ɰdofetilide ߿@סAHεoY/ΨͩR¯٩ʤƥ󪺭IC
5. שέרx\णC "	m. LӤ. ~{. . Yh. Yw. v. ֯l. «. 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OTRIU-a	OTRIU-b	OTRIU-c	110.6.16
BC24769100	J05AR03	0	OTRUV	Truvada tablets(TDF+FTC)		"TRUVADA is a combination of Emtricitabine(Nucleoside reverse transcriptase inhibitor) and Tenofovir disoproxil fumarate(nucleotide reverse transcriptase inhibitor), emtricitabine is a cytosine analogue while tenofovir is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication."	"Treatment of HIV-1 Infection: in adults and pediatric patients weighing greater than or equal to 35 kg: One Truvada tablet once daily taken orally with or without food.
Pre-exposure Prophylaxis: in HIV-1 uninfected adults: One tablet once daily taken orally with or without food."	"1.TRUVADAOtTwqEmtricitabineMTenofovir disoproxil fumarateƤī~APLtemtricitabine tenofovir disoproxil fumarateĪ֥ΡA]AATRIPLABCOMPLERABVIREADEmtricitabineC
2.]emtricitabine Plamivudine ۦʡATRUVADAPtlamivudineLĪ֥ΡATRUVADA]PHEPSERA?]tadefovir dipivoxil^X֨ϥΡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Emtricitabine+Tenofovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩPLܤfrĪXΩ󦨤HHIV-1PVvCAΩbXֱĨwʦ欰UiSewʧ(PrEP)AHCMIHoͩʶǬVHIV-1PVI0	糧Ħo͹LӯgfwAФŧP	"Insomnia, headache, dizziness, depression; Skin rash, pruritus ; Abdominal pain, nausea , diarrhea , vomiting"	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M03-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	OI` 10.9.	0	OIs 20251124	OTRUV-a	OTRUV-b	OTRUV-c	110.6.16
BC24071100	J05AB14	0	OVALC	Valcyte 450mg/tab(Valganciclovir)		ValganciclovirL-valyl esterganciclovireXAfAgzDΨxŦ୤ѻïֳtܬganciclovirCGanciclovir 2-deoxyguanosineXA~餺i?lfrƻs;ӷPHfr]AHӭMfr(HCMV)B?lfrĤ@βĤG(HSV 1 and HSV 2)BH?lfrĤBĤCBĤK(HHV-6BHHV-7BHHV-8) BDwOڲӭMFfr(EBV) Bkfr(VZV)BЫxfrC 	"ӭMfr (CMV retinitis) _lvGvʩʥӭMfr (CMV retinitis)Aĳq900 mg]G450 mg^A@ѤGA`{21ѡC_lv{i|W[rʡC

ӭMfr (CMV retinitis) ʪvG_lv{AΫDʩʥӭMfrfwAĳq900 mg]G450mg^A@Ѥ@CYfwpcƥiHư_lv{C(Ѿ\_lv)
wxӯfwoͥӭMfref
󱵨T龹xӤfwA󱵨10Ѥ}lA@ϥΨ첾ӫ100ѡCĳq900 mg]G450 mg^A@Ѥ@C
"	bHValcyte?]Mganciclovir^vfwA[즳Yզy֯gBݤʲy֯gBhBpO֯gBy֯gBrʩMAͤ}ʳh大{HCYfwݤʥզypƤp500 cells/glΦpOp25000/gl Φp8 g/dlӶ}lvC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Valganciclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"1.ΩvRfw̿wӭMfr (CMV Retinits)C

2.iΩwT龹xӯfwA㦳oͥӭMfrefMIʱڸs(ت̦MӭMfrʡت̦MӭMfr [(D+/R-)])C

WzҫT龹xӤfwAȭǡBߩεǢwŦӱw̡AxŦӱw̥ī~äAΡC󱵨䥦T龹xӤfw(pŦӪ)AĻPwʩ|إߡC  "	"TΩwvalganciclovir , ganciclovirΦ~զ|LӤfwCѩValcyte?Paciclovir  valaciclovirۦƾǵcAGioī~|ͥ椬LӲ{HC "	`mBfĩ]߯fBYhίh¡C 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OVALC-a	OVALC-b	02C24071-2	110.6.16
		0	OXOFL1	Xofluza 20mg/tab(Baloxavir marboxil)		"Baloxavir marboxilʪܩʧAByPfrCAP
̦sʤC(Cap-Dependent Endonuclease)CCAP̦sʤ?@دѧOä_JDӭMmRNAeXAqӲͯfrmRNAXݤޤl(primer)RNAqïCBaloxavir marboxilʪACAP̦sʤCAiӪ_frmRNAXAHFfrWާ@)C"	"vyPGĳgoͫ48pɤ榸ϥ

SwyPĳKĲyPfH48pɤ榸ϥΡC

ζqG
魫20HW80窺5HWൣBC֦~ΦHAĳq榸fAP20 mg2(Baloxavir marboxil 40 mg)C

魫80HW̡Aĳq榸fAP20 mg4(Baloxavir marboxil 80 mg)C"	"AĮɡAiPΤP֪AAקKMŻs~Bt~BthlwmBܻľΤfAɥR(ҦpGtBKBBִξN)֪A

רx\णfwVP"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUOs	Baloxavir marboxil	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"AΩv5HWB魫20HWfHAByʷP_frʷPVC
AΩ5HWB魫20HWൣBC֦~ΦHKĲyPfHwyʷP_C"	糧Ħo͹LӯgfwAФŧP	m	Fetal risk cannot be ruled out.	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2R-07 [E]_A5-02 j	Ts114.02.04		OI` 	0	OIs 20251124	OXOFL1-a	OXOFL1-b	OXOFL1-c	114.02.04
			O3TC	3TC 150mg/tab(Lamivudine)		~ܯfrĪAbҦӭMιPVʪA㦳׹BxfrʡC~|gѤwgPVΨSPVӭMN¬triphosphate(TP)lͪAAƦXʧΦCb~礤AtriphosphatebxŦӭMӭMbI1719pɡC]lamivudine-TPBxfrEXï(polymerase)Ө㦳@ΡCLamivudine-TPOJfrDNA줤Ӫ_DNAi@BXʧ@AGɭP쵲_C	HIV infection: 150 mg ORALLY twice a day or 300 mg ORALLY once a day.	bצYǥ\lafHAѩǲMvCALamivudine`nSq(AUC)|W[C]AbٻMvCb50@ɥHUfwAϥξqCC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Lamivudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	PLܤfrX֨ϥΡBvHΨൣHK̯ʥFfr]֢ע^PV	糧~LӪ	̱`Ƨ@Υ]A{BhҡBIlDPVBYhBABߡBæRPUgC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-06 j	Ts110.6.16		OI` 	0	OIs 20251124	O3TC-a	O3TC-b	O3TC-c	110.6.16
AC58335100	J05AF10	0	OBECAV	Entigin F.C. 0.5mg/tab(ܯfr)		"EntecavirTI(guanosine)cA㦳wHBVEXJʡCܧ֦aCĤƬ㦳ʪTCħκAA@κAӭMbI15pɡCgѻP۵MsbMʥhTIݤTC(deoxyguanosine triphosphate)vATCĺAEntecavirƧHBVEXJTӧ@IG
1) ޵o(priming)qF
2) ѫe]հTRNA (pregenomic messenger RNA)X HBV DNA t(negative strand) F
3) HBV DNA(positive strand)XC"	"1.󥼴?vHM16HWC֦~AvCBxfrPVBARACLUDEĳqO0.5@JC@C
2.blamivudinevBxfrgHΦlamivudineĩʬܪHMC֦~]16HW^AĳqO1@JC@C "	"1.ǥ\णGٻMv<50 mL/minw̡A]AGzRCAPDvw̡AĳվBaracludeqC
2.xŦӱw̡GBaracludeΩ󱵨xŦӪ̪wʻPĤC󴿸gΥbi|vTǥ\઺Ķ]pcyclosporinetacrolimus^vxŦӱw̡ApGݭnvAhb}lvePvApߺʴǥ\C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Entecavir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vBxfrƻsHHH2HWCBxw	糧~LӪ	YhBh¡BYwBmBߡBƤ}	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-01 [E]_B3-12 j	Ts110.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.3._20250601.pdf"">OI` 10.7.3.</a>              "	OI` 10.7.3.	0	OIs 20251124	OBECAV-a	OBECAV-b	OBECAV-c	110.8.23
AC59671100	J05AF10	0	OBESA	Besano F.C. 1mg/tab		"EntecavirTI(guanosine)cA㦳wHBVEXJʡCܧ֦aCĤƬ㦳ʪTCħκAA@κAӭMbI15pɡCgѻP۵MsbMʥhTIݤTC(deoxyguanosine triphosphate)vATCĺAEntecavirƧHBVEXJTӧ@IG
1) ޵o(priming)qF
2) ѫe]հTRNA (pregenomic messenger RNA)X HBV DNA t(negative strand) F
3) HBV DNA(positive strand)XC"	"1.󥼴?vHM16HWC֦~AvCBxfrPVBARACLUDEĳqO0.5@JC@C
2.blamivudinevBxfrgHΦlamivudineĩʬܪHMC֦~]16HW^AĳqO1@JC@C "	"1.ǥ\णGٻMv<50 mL/minw̡A]AGzRCAPDvw̡AĳվBaracludeqC
2.xŦӱw̡GBaracludeΩ󱵨xŦӪ̪wʻPĤC󴿸gΥbi|vTǥ\઺Ķ]pcyclosporinetacrolimus^vxŦӱw̡ApGݭnvAhb}lvePvApߺʴǥ\C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Entecavir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vBxfrƻsHHH2HWCBxw	糧~LӪ	YhBh¡BYwBmBߡBƤ}	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-02 j	Ts110.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.3._20250601.pdf"">OI` 10.7.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.4._20220901.pdf"">OI` 10.7.4.</a>             "	"OI` 10.7.3.,10.7.4."	0	OIs 20251124	OBESA-a	OBESA-b	OBESA-c	110.8.23
			OTAMI1	Eraflu 75mg/cap(۶O)		"Oseltamivir phosphateOoseltamivir carboxylate (OC)eXġAOCOjOοܩʪyʷP_frAMBgiĤ?ï(neuraminidase enzymes)CfrgiĤ?(neuraminidase)nʥDnOsΦfrɱqPVӭMXΧi@BǬVfrCgiĤ?]ܰѻPFfriJPVӭML{C 
Oseltamivir carboxylateyʷP_frAMBgiĤ?Fһݭn50%ï(IC50)OC@סAȦbQ@տ@(nanomolar)dFOC]ib~礤yʷP_frPVνƻsOMb餺yʷP_frƻsέPfOC "	"~HMC֦~
bH 13ΥHWC֦~fAĳq 75 @JnAC2A 5ѡC
ĵ
Yൣ魫WL 40AB]AnAhiHA75@JnAC2A 5ѡC
1ΥHWൣAOseltamivir PhosphateĳqG
魫 15 Aĳq30mgAC2
魫 1523 Aĳq45mgAC2
魫 2340 Aĳq60mgAC2
魫 40 Aĳq75mgAC2 
1ൣG 
Oseltamivir PhosphateϥΩ012ӤൣfAĳq 3 mg/kgACGA@5C
1ൣAOseltamivir PhosphateĳqG
魫 3 Aĳq9mgAC2
魫 4 Aĳq12mgAC2
魫 5 Aĳq15mgAC2
魫 6 Aĳq18mgAC2
魫 7 Aĳq21mgAC2
魫 8 Aĳq24mgAC2
魫 9 Aĳq27mgAC2
魫 10Aĳq30mgAC2 
Wzå]tڸsҦi魫C~֥1ҦfwAׯfw魫h֡Aϥ3mg/kgӨMwqC"	"1. YKaʴyPfw]SOOpĩMC֦~^M`欰xC 
2. SҾOseltamivir PhosphateAByʷP_frH~fҤް_efġC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Oseltamivir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	HM1ΥHWൣyʷP_w	糧Ħo͹LӯgfwAФŧP	ߡBæRYh	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-04 [E]_A5-01 j	Ts110.6.16		OI` 	0	OIs 20251124	OTAMI1-a	OTAMI1-b	OTAMI1-c	110.6.16
	J05AF13	0	OVEML1	Vemlidy 25mg/tab		"Tenofovir alafenamide tenofovir C୫eXġ]2'-h?C^CTenofovir alafenamide O@ؿ˯ץBizӭMƦXA|zLQX@ΤΨxŦlBJOATP1B1POATP1B3@ζiJŨxӭMCMtenofovir alafenamide|QƦtenofovirADnOzLŨxӭMn?1]CES1^ѧ@ΡCӭMtenofovir H|AgӭME?CĤƧ@ΧΦĲzʪNªtenofovir diphosphateCTenofovir diphosphate |zLHBV?@δOJfrDNAAɭPDNAפAqӧHBVƻs@
Tenofovir diphosphateO@خzĪŰʪDNAEX?]]AɽuDNAEX?^^ABbӭMi礤õLҾܨ㦳ɽurʡC "	"ĳqC@HfA25@JC
x\णݽվ㾯q
ĳΩ󥽴ǯfBGzRfHD"	"1.ŻĤrYxŦ~jX֯תըx]]A`fҡ^iC
2.ΧBxĪ]]AVEMLIDY^i|ɭPBxYʴcơC
3.XַPVHBVPHIV-1fHoHIV-1ĩʪID
4.soͪǥ\lεǥ\c"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Tenofovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩvNv(compensated)HCBxC	糧~LӪ	"1. ŻĤr/ YxŦ~jX֯תըxC
2. BxYʴcơC
3. soͪǥ\lεǥ\lcơC"	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-04 j	Ts110.8.23		OI` 	0	OIs 20251124	OVMEL-1-a	OVMEL-1-b	18027086-2	110.8.23
			OZEFF	Zeffix 100mg/tab(Lamivudine)		~ܯfrĪAbҦӭMιPVʪA㦳׹BxfrʡC~|gѤwgPVΨSPVӭMN¬triphosphate(TP)lͪAAƦXʧΦCb~礤AtriphosphatebxŦӭMӭMbI1719pɡC]lamivudine-TPBxfrEXï(polymerase)Ө㦳@ΡCLamivudine-TPOJfrDNA줤Ӫ_DNAi@BXʧ@AGɭP쵲_C	"1. LamivudineiWλP@_AΡC

2. HIVPVGXzidovudinevC
a. H12HWC֦~AB魫50HWA@ѤGAC150 mgCH魫<50A@ѤGAC2 mg/kgF魫<50C֦~AʥFĳqơC
b. ĵ3Ӥ12G@ѤGAC4 mg/kgF̤jqG@ѤGAC150 mgC
c. CBxPVG16HWA@Ѥ@AC100 mgC
d. ŦlG16HWAĳqվpUG Clcr (mL/min) ϥΩHIVPVĳվ㾯q ϥΩHBVPVĳվ㾯qF50G @ѤGAC150 mg @Ѥ@AC100 mgF30-49G@Ѥ@AC150 mg _lq100 mgAM@Ѥ@AC50 mgF15-29G_lq150 mgAM@Ѥ@AC100 mg _lq100 mgAM@Ѥ@AC25 mgF5-14G_lq150 mgAM@Ѥ@AC50 mg _lq35 mgAM@Ѥ@AC15 mgF<5G_lq50 mgAM@Ѥ@AC25 mgA_lq35 mgAM@Ѥ@AC10 mgC"	"1. ϥΥ~vAѼxvCBxvӬfwiwʴCb~ϥΫAǺCBxfwAb{ɩιƾڤ譱AiX{_oʨxHApGoǤHٱwxN¤ʨxfAi|ɭPYGC
2. @~ġAfwܤ4Ӥ몺wʴA]A{ɤΦMx\˴(ALTx@)H[O__oʨxHCvoSw_oʨxfwAثeèSҹAϥΥ~vnBC
3. bצYǥ\lafHAѩǲMvCALamivudine`nSq(AUC)|W[C]AbٻMvCb50@ɥHUfwAϥξqCC
4. PɷPVHIVABثebϥΩέpeN37CTM(lamivudine)CombivrTM(lamivudine/zidovudine)vfwAϥΩHIVPVq(q`150AC2)C
5. 󱵨~vAثeSBxfrbLඡǼơC`BxfrK̪kзǫĳ{ǡC
6. ifwAثe|ҹϥΥ~୰CBxfrǬVLHiʡAGSO`NC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Lamivudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vQHWAwCBxαaBxfrƻsHUCw̡G1DCBxʵo@w̡]]BxfrҭP^B2D]䥦efݱĶvw̡B3Dݱgƾkw̡B4DݱxӤw̡C	糧~LӪ	̱`Ƨ@Υ]A{BhҡBIlDPVBYhBABߡBæRPUgC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23		OI` 	0	OIs 20251124	OZEFF-a	OZEFF-b	OZEFF-c	111.8.23
		0	IVEKL	Veklury 100mg/vial(Remdesivir)		RemdesivirǥѧRNA-dependent RNA polymerase (RdRp)ӧRNAEXAFܯfr@	"@뾯q{G令HP魫40 HWൣA1 ѧ뤩200 @JRemdesivir ([JͲzQ
)AMq2 Ѱ_CѤ@뤩100 @JqAH30 120 ɶR߿`ġC魫3.5 
ܧC40 窺ൣAϥέᴹ`gAè魫վ㾯q(1 5 @J/A2 Ѱ_2.5 @
J/)C
bϥECMO ξIlpUA`vɶ10 ѡAbϥECMO ξIlpU
h5 ѡCLAYϥˤWECMO ξIlApGgﵽAiϥέpNv̪10 ѡC(H0.9%ͲzQ})"	"ثeäTϥVekluryvCOVID-19̨ξqP{AĳqP{i|H{ɸƪoӧsC
Sڸs`N : ǵyL
ov(eGFR) < 30 mL/min ̤ĳϥΡAx\ಧ`: ALT(alanine aminotransferase) >5 x ULN (upper limited normal)ĳϥΡF"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"~s30XCHU,xsGsƦn}GbǷ(20XC25XC)Uiww4pɡAb2XC8XCBci24pɡC"	Remdesivir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"֭Ω󭫫׷safr(SARS-CoV-2)PVfHCתwqbϥΧlvU񹡩M? 94%BϥΧl
vBwˤWIlΤwˤWJ(ECMO)fHC"	"ĵiGbVeklury{ɬsA[`MxŦi?ɰ{HCVekluryiΩ
remdesivir󦨤LӪfHCpGX{{ɷNq`xMgAߧY뤩VekluryA
ñĨABmICALT?5`dWfHAФŶ}lϥVekluryFX{ALT?5`dW
{HAALTɰæHX{xŦoxίgεXxBPC?INRɰ{HfHA
vC"	Ƨ@α`xŦïWɡAο`}Ap.. CBߡBæRBoŸݵ	便ΥihkAubbįqWVIpU~i뤩	vŪvįqPŪnBAMҼ{~ΰšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiE2j	Ts110.6.16		OI` 	0	OIs 20251124	IVEKL-a	IVEKL-b	IVEKL-c	110.6.16
BC22396100	J05AR01	0	OCOMB	CombivirƤ(Lamivudine/Zidovudine)		LamivudineMzidovudineHIV-1HIV-2jġBܩʧCbӭMiAHIVƻsWAlamivudinewҹMzidovudine֥Ψ㰪?P@ΡC?Ī|gѲӭMEï(kinase)N¬5'-triphosphate(TP)CLamivudine-TPMzidovudine-TPHIV?ïA]vʧCOADnܯfrʬOHCħΦ(monophosphate)OJfrDNA줤Hy쵲_CLamivudineMzidovudineTC(triphosphate)ƦXHDӭMDNAEXï(polymerases)˩M?CC	"HP魫ܤ30 kgC?G 
COMBIVIRĳ?C?AC@C
魫2130 kgൣG
ĳCOMBIVIRfA?A1/2?ĿHαߤWAΧ㪺1?ĿC 
魫1421 kgൣG
ĳCOMBIVIRfA?CA1/2?Ŀ?C"	SX֤ COMBIVIR B~`NƶPĵy	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Lamivudine+ Zidovudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	PLܤfr֥ΡAHvHIV-1PV	"1. COMBIVIRTΩlamivudineBzidovudineι糧s@ئLӪfw
2. ZidovudineTΩݤʥզy?عLC (< 0.75109/ L )AΦȹLC(< 7.5 g/dL4.65 mmol/L)fw"	ŻĦgBYhBߡBæRBWkhBmB֯l`hB٦ׯf`hB٦ׯfܡBh¡B?ABoN	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M02-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OCOMB-a	OCOMB-b	OCOMB-c	110.6.16
BC22927100	J05AB01	0	OMEDO	Medovir 400mg/tab(Acyclovir)		DAcyclovirO@اܯfrĪA©ʞ\l(HSV)BΤka\lfrD`ġCAcycloviriJQ\lPVӭMA|CĤƦʤƦXAAcyclovirTCĤƦX|\lSDNA polymeraseMA]iHfrDNAXӤ|zZ`ӭMN§@ΡC	"1.vH©ʯplqG
 H4pɪjACA5C200mgA]߮ɪ@ihCv5ѡC
2.H©ʯpl_oqG
 H6pɪjACϥ4C200mgC\hw̡AH12pɪjACϥΤGC400mgC
3.wH©ʯplqG
 H6pɪjACѨϥ4C200mgC
4.vHaplqG
 H4pɪjAC뤩5C800mgA]ߪ@hCv7ѡC
5.ൣqG
2HWൣϥΦHqA2HUൣϥΦHq@bC
6.vk(uptodate)
2-12ΫC֦~G20mg/kg(̰800mg) QID*5days "	пvܪAΧ{AťNġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Acyclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	alfrް_PVB©lfrް_PVg	Acyclovir |LӤw̡ATϥΡC	ߡBæRBmB֯l	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A5 [2]_A5 [E]_B1-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.1.1._20190601_000.pdf"">OI` 10.7.1.1.</a>              "	OI` 10.7.1.1.	0	OIs 20251124	OMEDO-a	OMEDO-b	OMEDO-c	110.6.16
BC26455100	J05AB11	0	OVALA	Valacyclovir MYLAN 500MG		"ValaciclovirOкاܯfrĪA[WL-valine୪aciclovirCAciclovirO@I(TI)?C
ValaciclovirbH餤|tB񧹥ܬaciclovirMvalineAiOѬYغ٬valaciclovir hydrolaseïҭPCAciclovirOMI?lfrA~ʡAܳ?lfr(HSV)Ĥ@MĤGBa?lfr(VZV)BӭMfr(CMV)BEpstein-Barrfr(EBV)MH?l-6(HHV-6)CAciclovirCĤƦʤTCQɡA?lfrDNAX"	"a?lvG
Hq@ѤTAC1000mgACѡCClcr:15-30@ѤGAC1000mg
Clcr:<15@Ѥ@AC1000mg
?lvG
Hq@Ѩ⦸AC500mgC_oʷPVvѡC즸PViYA{ɥFQѡC}lAġC̦nOb?l_oeΥX{_oxɥߧYAΡCClcr:<15@Ѥ@ C500mg
?l_ow()G
bK̰HfwAq@Ѥ@AC500mgCClcr:<15@Ѥ@ C250mg
b@Ǵ_oWvܰfH(ҦpC~10HW)NC500mgqA(@Ѩ⦸AC250mg)ionvįqC
K̤HfwAq@ѤGAC500mgCClcr:<15@Ѥ@ C500mg
HDw̵ĮɶGzRC"	1.аȥA{Aiۦ氱ġC 2. ǥ\ण}ΦѦ~w̽Фpߨϥνվ㾯qC 3. i|Yh{HC i|YhBߵ{HC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Щ30JHUxsC	valaciclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS		alB_oʥʹ޾lwΪvC	valaciclovirBaciclovirλs@ئLӪ̡C	"YhA
K̤OYlw̪Aΰqvalaciclovir(@8g)Ao͵ǥ\णBpޯfܩʷʳhΦpOLCgp(ɬOX֥X{)B㦳ۦPfpAovalaciclovirvw̤]goͳoǪpC"	DnקKϥ/Smܦw	"DnקKϥ/Smܦw
alaciclovirDnN²aciclovir|cťġC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F5 [2]_F5 [E]_C2-16 j	Ts111.1.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.1.1._20190601_000.pdf"">OI` 10.7.1.1.</a>              "	OI` 10.7.1.1.	0	OIs 20251124	OVALA-a	OVALA-b	OVALA-c	111.1.27
			IIMU2	Privigen(IVIG)100mg/ml;50ml/~ (N)		"PrivigenDntاK̲yJ(IgG)P㦳sĥ\ʧөmPVCIgGlFcPFab\ϳQOdCFabϬqPܭ챵XOOgͤƻPͪkҩFFc\ϥѸ鬡ƥHFcո`զyƧ@˴CK̽ƦX黤o鬡ƪ\QOdbPrivigen(M(scavenging)AIVIgsܵo\)CPrivigen|ϱoDSʸtΩάOprekallikrein QơC
Privigen]tsb`As餤اK̲yJ(IgG)AѤ֩1000Wت̪ߩҳƻsCIgGȫʲPѵMH߬۲šAAqPrivigenNIgG@׫_ܥ`dC "	"魫ζWfHiݭnھ魫վ㾯q
oʧK̤gNk(PID)ĳϦMIgĢC@(trough levelAU`eo)ܤ֬6g/LAӱڸs~֪`ѦҽdDqC3-4g0.2-0.8 g/kg bw (28 mL/kg)C
pGw̿L@vAtɱLvAë_C3-4gwvC
IgGtrough levelXPVoͲviqMACӵ߷PVvAnW[qêF󰪪̧C@סD
CʲOکʥզfޭPاK̲yJչLCP_oʲӵ߷PVABwʧܥͯvLĪw̡FhoʰFíwޭP
K̲yJչLCP_oʲӵ߷PVABIͪy̭߬]LĪw̡F
ѩʷRf(AIDS)H_oʲӵ߷PV̪Nk
~oʧK̯ʥFef(pvAgҩwq)qFܤ6g/ĻC@IgGȡAΦbӱڸs~֪`ѦҽdD
ĳqC3-4g0.2-0.4 g/kg bwC
yFӭMӫޭPاK̲yJչLCNkĳqC3-4g0.2-0.4 g/kg bwCMIgĢC@5 g/LC
K̽ո`G
K̩ʦpOʥFg(ITP) ĳqĤ@ѬIH0.8-1g/kg bwAbTѤAiAƵ@P˾qAΨC鵹P0.4g/kg bwAs2-5ѡAY_oΥiƪvDwoͦAAʵǷl˩GenL(Volumn Overload)IfHApqK̳JժvAp1 g/kg bw򢱤ѫeAJӵ۹QqέID 
L-ڧQgԸs(Guillain-Barre Syndrome) 0.4 g/kg bw/dayAP5ѡCĵϥθg禳C
tTg(Kawasaki Disease) ӳ榸q2.0 g/kg bwCfHXֱAQh(acetylsalicylic acid)vC
CʲThoʯg(CIDP) ĳ_lq2 g/kg bwAés2-5ѤPCH1 g/kg bwqAC3g1ѩγs2ѤCC{vĪGApGӤᤴvĪGAvDpG{OĪAvͮھگfHMfVBzDqMjiॲھگeff{iվD
h_ʹBʯgfܡG_lq2g/kg bw ,2-5ѤFqG0.4-2g/kg bwAC2-6gġD
gٵLOc:bNeΩmyasthenic crisis _lq1-2g/kg bwA2-5ѤDq0.4-1g/kg bwAC4-6PġD
ŧBХyٵLOgG_lq2g/kg bwA2-5ѤDq0.4-1g/kg bwAC2-6PġD
xԸsG_lq2g/kg bwA2-5ѤDq1-2g/kg bwAC4-6PġD
Ĥ覡
PrivigenHR߿`C
`tv
~l`tv0.3 mL/kg bw/hr (0.5 mg/kg bw/min) (`g30)C"	"ͪī~ilʡAMOҬIβ~W٩M帹
}i`oͦb`tvӮסAU@}AӴw`tvάO`
ҦfHIIVIGɻݭn`eɥRAAʴGyXqAʴٻ@סAקKPɨϥLoop diureticsA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sФŶWL25CAФŧN	"Immunoglobulins, normal human, for intravascular adm."	J06B	K̲yJ IMMUNOGLOBULINS		"@NkG 
1. oʧK̤gpG (1)ѩʤاK̲yJկʥFgΤاK̲yJչLCg (2)`ܲʧK̤g (3)YƦXK̤g (4)Wiskott-AldrichgԸs 
2. CʲOکʥզfޭPاK̲yJչLCP_oʲӵ߷PV̡ABwʧܥͯvLĪw̡C
3. hoʰFíw(plateau phase) ޭPاK̲yJչLCP_oʲӵ߷PVABIͪy̭߬]LĪw̡C
4. yFӭMӫޭPاK̲yJչLCC
5. ѩʷRf(AIDS)H_oʲӵ߷PV̡C
@K̽ո`G 1.K̩ʦpOʥFgB㰪X孷IΥΩNeDBpOpơC DL-ڧQgԸsC DtTgC(Pacetylsalicylic acid@_ϥ) DCʲThoʯgAĵϥθg禳C 6.h_ʹBʯgf(multiple motor neuropathy,MMN)7.gٵLOc(Myasthenia Gravis exacerbations,MG)8.ŧB-yٵLOg(Lambert-Eaton Myasthenic Syndrome)9.?Ըs(stiff person syndrome)"	DάOξLӪ	NŸAYhAwtAoNAæRALӤAߡA`khACA{פUIh|o	DnקKϥ/iw	DnקKϥ/iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	IIMU2-a	IIMU2-b	IIMU2-c	111.8.19
			IRHOD	RHO(D) IMMUGLOBULIN INJ(BAYRHO D)(N)		"(Rho(D)hRho(D)ʭLAbͲBy(۵MΤHu)BϽθ~ˮɡAoͭL-鶡XCK̤]oͦbRho(D)ʪ̿JFRho(D)ʬyɦӲanti-Rho(D)Aoرpi`gsӹwC
 sͨ઺RhʯefOɦ]Rho(D)ʥ˪DʧĶ@ΡAΥbeYL{BάyBϽBθ~ˮɡARho(D)ʬyiJF骺G`FΪ̦]媺YAy鲣ͧĶ@ΡC
 ~iħRho(D)ʭRho(D)ʬyҲͪK̤A@ξणM"	"٦ת`g
 YwΡGͲ72pɤϥ300mcgC
 XͫewΡGh28gɧĤ@300mcgAYLORhʡAAl[@APɳ̦nbY72pɤĤ@C"	"1.sѤH߻sAZOѤH߻s~itpfrPVӭPfC
2.iRߪ`gAu٦ת`gAPɷsͨťΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Immuneglobulin	J06B	K̲yJ IMMUNOGLOBULINS	0	w]t֦]lPӾɭPyΪͨԧ	"A Rho(D) positive or Du positive individual, A Rho(D) negative or Du negative individual previously sensitized to the Rho(D) or Du antigen."	i|ް_`gkhŲLWɵ	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-27 j	Ts110.6.16		OI` 	0	OIs 20251124	IRHOD-a	IRHOD-b	IRHOD-c	110.6.16
			ISYNA	SYNAGIS 100mg/ml (Palivizumab) (N)		"Palivizumab @ؤHƧK̲yJ(IgG1) A i@ΩIlDĦXӭMfr (respiratory syncytial virus, RSV) ĦXJA ܭ쳡䤤@ӪCPalivizumab RSV 㦳MfrΧӭMĦXʡC "	"ȥiH٦ת`g覡뤩palivizumabC
Palivizumabĳq15@J/魫AwϤRSV pu`CP@C
Ĥ@RSVu`}lePAéRSV u`CӤP@sϥΡCקKƷPVMIAĳpalivizumab vPVRSVൣARSV u`򱵨CӤpalivizumab vC 
Palivizumabq15@J/AC@H٦ת`g覡ġAĳIjLe~CקKˤΧgAHvٰD``gC`gĥμзǵL߾ާ@޳NCCӤ몺q=w魫() x15@J/ 100@J/@ɪpalivizumabCY`gnWL1 @ɡA`gC "	"1. ϥpalivizumab ᴿqLӤA]AD`uLөʤMLөʥJCbYǪpUAqPfҡC
2. ƧYLӤ(]ALөʤMLөʥJ)vĪAHpalivizumab 뤩ϥΡCYoYLӤAWpalivizumab vCpPϥΩ󦹱w̱ڸsLĪApGe@ϥpalivizumab ɵo͸LLӡAU@ϥpalivizumabSO`NC
3. pPL٦ת`gĪApO֯gΥ󾮦efw̡A뤩palivizumab SO`NC
4. Ȩѳ榸ϥΪpalivizumab p~tGC`gGݽհtC
5. צܭתʷPVεoNAiභȽwϥΥ~ADv{YϥpalivizumabA|jIC׵oNApפWIlDPVAq`ȽwϥpalivizumabC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~m󲣫~]ˤi2-8XC ҤOs36 ӤC 	Palivizumab	J06B	K̲yJ IMMUNOGLOBULINS		Palivizumab i@ΩRSV efMIڸsfwA ]Aު͵o| (BPD) B ( pε35 Wg) αwGʤOǤWۤѩʤŦef(CHD) ڸsAw]RSV PVҤް_YUIlDefC	Palivizumab TΩwpalivizumab Ψ䤤᫬LӪw̡C 礣ϥΩwLHƳLӪw̡C	lBoNB`gC 	"ѩpalivizumab AΩ󦨤HA B|iʪʹ޸C ]Lkohkϥ
palivizumab O_|yLˮ`μvTʹޯOC"	"ѩpalivizumab AΩ󦨤HA B|iʪʹ޸C ]Lkohkϥ
palivizumab O_|yLˮ`μvTʹޯOC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-36 j	Ts111.8.19		OI` 	0	OIs 20251124	ISYNA-a 	ISYNA-b 	ISYNA-c 	111.8.19
		0	IPV-13A	Prevenar(13)H۶O;0.5ml/(N)		"M1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23FͪyߧhAXճCRM197JսWD"	س@q0.5mlYiDAؤ@13ͪyߪnʩ|TwD	"pPḼ]@ˡAYʩYoNefɡAȽwبKͪyߤQTX̭]C  
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	NöJs28JAiNC 	"GM1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23Fͪyߪ󽤦hU2.2ugAM6Bͪy߲󽤦h4.4ugAoǲ󽤦h駡PճCRM197Jս鱵XçlCľTW]t0.125mgT^C"	J07A	ӵ̭߬] BACTERIAL VACCINES		"̭]iΩ50(t)HWHDʧḴءAHwM1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23Fͪyߤް_IJʯefC "	惡̭]@νξLөιճrLӪHATϥΨKͪyߤQTX̭]C 	`g짽AoN	DnקKϥ/Smܦw	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.19		OI` 	0	OIs 20251124	IPV-13A-a	IPV-13A-b	IPV-13A-c	111.4.19
		0	IBEXS1	Bexsero Meningococcal Group B Vaccine(N)		"ϥBexseroiḴجOFEͦiѬ̭]ܭNHBABNadABfHbpPorA P1.4 (OMVKʧܭ)ߩʧAqӹwIŧʸy߯ef(IMD)CoǧܭbP߮褤{{צUAܭ{{רy߫ܮeK|Q̭]һoC
yߧܭt(MATS)Q}oHإߤPByߵ߮褧ܭ췧pPHM߯OR(hSBA)ߧ@ΪpʡAHγ̫w߮л\dC"	"Ĥ@I~ A2  5 Ӥj :إk:1.¦Ḵ2 AC 0.5 @ ,jɶ֩ 2 ӤD2.¦Ḵ3 AC 0.5 @ ,jɶ֩ 1 ӤDHWإkl[:A 12 15 ӤjɬI@AB¦tCPl[jܤ 6 Ӥ(l[Iߩ 24 Ӥj)
Ĥ@I~ A6  11 Ӥj:¦Ḵ2 AC 0.5 @ ,jɶ֩ 2 ӤDl[:Xͫ
ĤG~I@AB¦tCPl[jܤ 2 Ӥ
Ĥ@I~ ൣA12  23 Ӥj:¦Ḵ2 AC 0.5 @ ,jɶ֩ 2 ӤDl[:I@
AB¦tCPl[j 12  23 Ӥ
Ĥ@I~ ൣA2  10 AC֦~(11 HW)PH:¦Ḵ2 AC 0.5 @ ,jɶ֩ 1 ӤDl[:S󸣽y߯efIHҼ{I@l[ 
:Bexsero Ω󥼺 8 gj઺wʻPwĪG|TߡC
:Bexsero Ω 50 HW̪wʻPwĪG|TߡC
H`٦ת`gjLe~()ΪWuT(~j)
ϥΦ̭]eХRnAϧΦêaBG"	"1.wYoNʯeffHAᱵBexseroCLAä]X{LPV{H(pP_)өᱵج̭]C
2.ťHޤ`gB֤U`gΥ֤`g覡I̭]C
3.BexseroäwҦy檺Byߵ߮
4.Pൣ(p2)bج̭]i|X{Ťɰ{HCPൣ(p2)Aھڷa޶}lϥΰhNġC
5.﷥(X?h28g)AרOeIltεo|fvAI¦ḴبtCɡAҼ{oͩIlȰbIAHάI48-72pɤʴIlnʡCѩ󱵺ج̭]o઺įqA]Ωᱵج̭]C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ЦsBc(2XC-8XC)C
ŧNC
קKuӮgC"	"1 (0.5 @)tG
 B `󸣽y NHBA ĦXJ 1,2,3 50 LJ
 B `󸣽y NadA J 1,2,3 50 LJ
 B `󸣽y fHbp ĦXJ 1,2,3 50 LJ
B `󸣽y NZ98/254 ~n(OMV)ApqзǬ
t PorA P1.4 Jս誺`q 2 25 LJ
1QέDNA޳NbE. coli ӭMsyӱo
2lBƾT(0.5 @J Al3+)
3NHBA (`xXܭ)BNadA (`HJ A)BfHbp (H ]lXJ)"	J07A	ӵ̭߬] BACTERIAL VACCINES		"AΩ 2 ӤHWൣΦHDʧḴءAHw B `󸣽yߩҤް_IJʸy߯efC
:Bexsero ֭OI̭]wS߮誺K̤(serum bactericidalactivity)ALhؤP߮誺 B `󸣽yߪ̭]ĪG|T{AI Bexsero ҶqPϰy檺 B `󸣽yߵ߮C"	"utPtqvΡuξvqҦCʦΥξLӪ̡C
"	"P(2 HU):`gĲhPoBoNļʡC,ݺΡB`ڭBYhAmBæRA֯l(12  23 Ӥj)A`hAoN(38XC)B`gĲh(]AY`gĲhAwq`gϲʮɧYڭ)B`goB`g~ȡB`g쵲`Bļʡ@
N Bexsero P`W̭]Pɧ뤩ɡA 69% 79%ժ̳qX{oN{H(38XC)AW뤩 Bexsero ɡAoNoWvM`W̭]jP۷C
bC֦~PHA`gkhBAPYh
b̭]بtC򾯦Aåo{}oͲvYפɰ{
HC"	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-10 j	Ts111.2.21		OI` 	0	OIs 20251124	IBEXS1-a	IBEXS1-b	IBEXS1-c	111.2.21
		0	IBOOS	Boostrix 0.5ml/vial(ճB}˭Φʤy(N)		ճB}˭BLӭMʦʤyαjƥhʤp·VX̭]C	̭]ĳIq澯0.5@ɡC뤩覡`٦ת`gA̦n`gbWuTٰϰ	sعwճB}˭BʤyΤp·g̭]ɡAĨŦXkwĳjɶ(q`10~)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	DiphtheriaA PertussisA Tetanus	J07A	ӵ̭߬] BACTERIAL VACCINES	0	BoostrixR PolioAΩ|(t)HW̪l[̭]ءAΥHwճB}˭BʤyΤp·C	1.BoostrixR PolioiΩw惡̭]󦨤LӪ(аѾ\wʻPwqզνξ)AΥe󱵺إճB}˭BʤyΤp·̭]X{LӼx̡C2.b󱡪pUiHRߪ`g覡뤩BoostrixR PolioC	BݺΡB`g(]AkhBoB~)BoNC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-13 j	Ts110.6.16		OI` 	0	OIs 20251124	IBOOS-a	IBOOS-b	IBOOS-c	110.6.16
		0	IVARI1	VARIvax(۶O)k̭] (N)		Varilrix OgMRC 5HVդi״rOka strainkafrᴹs~C	12ӤHW12]t12Aĳϥγ@q(0.5ml)C~٦שΥ֤U`gC	1.~ΩRߪ`gC2.`g̭]|gקKhC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Varicella-Zoster Virus Vaccine Live	J07B	fr̭] VIRAL VACCINES	0	kDʧK̡C	"1.wYefΨLʯfg̡C
2.wզfcʯefΧK̡̤C
3.ϥΧĶΰqǤWֽ̡C
4.gvʩʪ͵ֱw̡C
5.h̡C"	1.سi঳oBkhθ~ȵC2.i঳LoNAoͰNBz{HC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-04 j	Ts110.6.16		OI` 	0	OIs 20251124	IVARI1-a	IVARI1-b	IVARI2-c	110.6.16
		0	ICERV	"Cervarix 0.5ml/vial(HPV Types16,18)"		"PVP HPV wҹOXG@ɩҦlcVfҪDnɦ]C
Cervarix O@رNPHPV 16/18 Dn~L1 Jոgׯ¤Ʀӱofrɤl(VLPs)һsDPVʰ]լ̭]CѩVLPs tfrDNAA]ä|PVӭMBƻsξɭPefCʪsܡAL1 VLP ̭]ĪGDnOۤ޵oGK̤βӭMK̰OЩҲͪ@ΡC "	"9 14 G2 (C0.5 @)AĤGbزĤ@5- 13 Ӥ붡IC
3 (C0.5 @)Ab0B1 M6 Ӥ뱵ءC "	"1. M䥦̭]@ˡAYoNʯefwᱵCervarixCLApGuOX{P_o׷PVAä]өᱵج̭]C 
2. b󱡪pUiHRߪ`gΥ֤`g覡I~C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	"Papillomavirus (human types 16, 18)"	J07B	fr̭] VIRAL VACCINES	0	"Cevarix AX 9-25 kʬI̭]AiΥHwPʤHŬfr(HPV) 16 B18 Ҥް_f:
lcV
2 ?P3 ?lcVW֤ؽF(CIN)MlcV츢(AIS)  1 ?lcVW֤ؽF(CIN)
1 ť~W֤ؽFβ1 ųDW֤ؽF(VIN/VaIN) 
Cervarix iΩ26 HWkʹwPʤHŬfr(HPV)16 B18 Ҥް_Ģ?lcVW֤ؽF(CIN)C "	iΩw惡̭]󦨤LӪ̡C 	YhBٵhB`gA]AkhBoB~ȡBh¡C 	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ICERV-a	ICERV-b	ICERV-c	110.6.16
		0	OROTA1	RotaTeq(FfAʤfr)		fAfr̭]wfrzGTK̾AثeäMC~O@إibpzƻsûoK̤ʯfr̭]C	"Ĥ@612g֮ɧ뤩AMAH410gjɶ뤩򪺾C3i32g֤뤩
űNRotaTeq̭]MḼ]ηGVXϥΡC"	"1.b뤩RotaTeqeA@HT{ثedAAHΥḙ]ذOA]AeO_RotaTeqΨLfr̭]oͤ}C
2.pGo͵oNʯefAiॲᱵRotaTeqADv{ج̭]|{jIC׵oN(<38.1XC [100.5XF])HλתWIlDPVäêRotaTeqءC
3.ثeåb{ɸ礤sLȱؤ@Ψ⾯RotaTeqO@ĪGC
4.MḼ]@ˡARotaTeqä@wҦت̳ͧ㪺O@ĪGC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Rotavirus vaccine	J07B	fr̭] VIRAL VACCINES	0	"wfrҤް_Gz(G1.G2.G3.G4,HΧtP1GMpG9)"	w惡̭]󦨤Lӯfv̡C󱵺ؤ@RotaTeqX{LӯgAARotaTeqC	mAzGAzM|AæRAӤުAͪCLӡAYoNťODɽоtNC	N/A	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-07 j	Ts110.6.16		OI` 	0	OIs 20251124	OROTA1-a	OROTA1-b	OROTA1-c	110.6.16
		ùS߽fr̭]fAaG	OROTA	RotarixùS(Rotavirus vaccine)		fAfr̭]wfrzGTK̾AثeäMC~O@إibpzƻsûoK̤ʯfr̭]C 	"ȨѤfAϥΡCb󱡪pUiH`g覡뤩C 

̭]ص{Ǧ@⾯A̦nbX᤻ͫܤQgءAbXͫGQ|gC⾯jo֩|g"	"1.M䥦̭]@ˡAoͫYoNʯefw̡AᱵءC?PV{HhDج̭]TҡC
2.靈mιæRg?w̡AᱵءC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	"Rota virus, live attenuated"	J07B	fr̭] VIRAL VACCINES	0	AΩwfr]G1PDG1MpG2BG3BG4MG9^Ҥް_zGC 	w惡̭]󦨤LӪ̡BgBGzDΡBκæK̥\ʳC 	mAzGAzM|AæRAӤުAͪCLӡAYoNťODɽоtNC 	N/A	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-06 j	Ts110.6.16		OI` 	0	OIs 20251124	OROTA-a	OROTA-b	OROTA-c	110.6.16
		0	IHAVA	HAVRIX AD 1440(H)(N)		~ݩDʧK̻sAK̫AoAǧ骺ͦӹܥ~ӷLͪIǡAYDʧK̬OzLPܭ쥻ĲӱoAE鲣ͥۤvSӹܥC	"Adult1 mL (1440 ELISA Units) IM x 1 dose; booster dose 6-12 months later.
Pediatric (1-18 yrs) 0.5 mL (720 ELISA Units) IM x 1 dose; booster dose 6-12 months later
19HWHG
H Havrix 1440(1mlaB)@qAΩ¦K{C
118(t18)̤ĵΫC֦~G
ĵHavrix 720(0.5mlaB)@qAΩ¦K{Cëĳ¦K{᪺QGӤ뤧iAl[@AHHavrix 1440ΫĵHavrix 720AHTOO@ĪGC"	"1. Ĥ@`gAgܥXi঳LӤ̡AӪl[`gC
2. Y̭]̦bج̭]ɡAPɱĶvBΥ㦳K̯O̡AF~ᦳiäoK̯OC
3. ~LkO@ѫDAxfrҤް_LxCѩAxܪ(j2050)A]ib~`geNwgQAxfrPVӤ۪C~Lk惡fHѫO@@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Inactivated hepatitis A virus vaccine	J07B	fr̭] VIRAL VACCINES	0	wAx	Hypersensitivity to any hepatitis-A containing vaccine	̱`Ƨ@άOس쪺khAåi۰ʫ_FLƧ@٦w~C	Fetal risk cannot be ruled out.	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-15 j	Ts110.6.16		OI` 	0	OIs 20251124	IHAV1440.a	IHAVA-b	IHAVA-c	110.6.16
		al ʱa?ḽ]	IZOST1	Zostavax virus vaccine 0.65ml/vial (N)		"oͱa?lIGMVZVSʧK̤OIh]GWpʡC
ZOSTAVAXwҹiVZVSʧK̤OA@]{oNO̭]ڥHwa?lΨֵog@ξC "	تس@qCثeäTZOSTAVAXᤧO@ĪGɶCbaplwsAwҹ4~lܴO@ĪGCAتnʩ|TߡC	"1. M̭]@ˡAwnAvǳơA]AǤW`g(1:1000)AHKbo͹L/LӤɥiߧYϥΡC 
2. boN>38.5XCpUAҼ{ᱵج̭]C 
3. ZOSTAVAXbwPVHK̤fr(HIV)B֦Υ֦Ķ{HwʻPwĪGAثe|TߡC
4. ZOSTAVAXiPhʬyP̭]PɱءC
5. ZOSTAVAXPPNEUMOVAX 23PɱءA]Pɱط|ɭPZOSTAVAXK̥ͦʭCC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Zostavax virus vaccine	J07B	fr̭] VIRAL VACCINES	0	w50~79Ha?l	"1. 惡̭]󦨤(]A)͹LӤ
2. Neomycin(Cws᪺̭]tLqNeomycin)͹L/LӤC
3. ]UCefӧe{oʩΫѩʪK̤AG
ʻPCʥզfBOڽFBL|IǰβOڨtΪefBHIV/AIDSҤް_ĶBӭMʧK̥\णC
4. Ķv(]AqֽTJ)CLAZOSTAVAXäTΩ󥿦bϥΧ~Ω/lJʥֽTJΧCqΥֽTJw̡AάObϥΥֽTJɥRvw̡ApǤW\णw̡C
5. gvʩʵ֯fC
6. h(Ѩh)C "	BkhB~ȡBkoBYhB|ϯkhC 	iΩ󥥰Fئ̭]ץ3Ӥ	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.17		OI` 	0	OIs 20251124	DC	DC	DC	114.07.17
		0	IGARD1	Gardasil 9̭]0.5ml/vial(N)		"GARDASIL 9EHŬfr]լ̭]@DPVʰ]9̭]A̭]DON6B11B16B18B31B33B45B52β58HŬfr(HPV)Dn~TJ(L1)ҧΦfrL(VLPs)H¤ƫsƦӱoC

HPVu|PVHCHʪŬfrҶi檺ʪsܡAL1 VLP̭]wĪGiM޵oGK̤CbH譱AGARDASIL 9̭]HPVOҤް_zʹ޾efwĪG@{ik]̭]һoGK̤ATO@ऴMC"	"GARDASIL 9̤UCɶH٦ת`g覡UI@0.5@ɪqJ0B2ӤB6ӤC
Ϊk
ȨѦ٦ת`gϥΡC
ϥΫeХRnáCbϥΤenáAϬ̭]OaBGACGARDASIL 9i}ϥΩλPḼ]VXϥΡCbnäAGARDASIL 9|Φզ⪺VBGCbGPe\ipUA`gΪī~bϥΫeصˬdO_Lɲܦ⪺{HCpGӲ~LɲΥX{ܦ⪺{HAФŨϥΡC
GARDASIL 9H٦ת`g覡IWuTٰϰAάOjLe~ϰC"	" 1 w
ѩ󱵺ج̭]Hi|oͷw֪{HAɨ÷|ɭP^˨ˡA]AĳI̭][15C
bHPV̭]X{w֨æ񦳱j}pʰʧ@ΨLwo@iCoͷw֨æ񦳱j}pʰʧ@ɡAɶq`ܵuȡAåBbY׫(Trendelenburg position)ϸy`_Aq`i_`C
2 LӤBm
HɳƧAκʷIAH]GARDASIL 9o͹LөʤC
3 wpO֯gΥ󾮦êӮ
Ӭ̭]IpO֯gΥ󾮦êfHԷVA]boǭӮצ٦פīioͥX"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxs28XC ҡCŧNCץxsC	Papillomavirus (human types 6A11A16A18A31A33A45A52A58)	J07B	fr̭] VIRAL VACCINES	0	wѤHŬfr(HPV)Ҥް_f	LӤA]Aå(̭]զ@)YLӤAΥe󱵺ؤ@GARDASIL 9GARDASILX{LӤC	`gAoNAߡAYhC	B	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-14 j	Ts110.6.16		OI` 	0	OIs 20251124	IGARD1-a	IGARD1-b	IGARD1-c	110.6.16
		0	IMMR1	PriorixVtetra 0.5ml/vial(MMR۶O̭])(N)		~ݩDʧK̻sAK̫AoAǧ骺ͦӹܥ~ӷLͪIǡAYDʧK̬OzLPܭ쥻ĲӱoAE鲣ͥۤvSӹܥC	֤U`gAiRߪ`gA̦n`gWu~AC0.5mlC 	"1.`g7~28ѫAֶqiglγVƥXAO_ǬVʫhTC
2.friǨťĶǬVC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	"Measles,Mumps,Rubella, live attenuated"	J07B	fr̭] VIRAL VACCINES	0	¯lfrB|frBw¯lfrPVw`gC 	"1.wYef̡A@P_bC 
2.K̤̥]AϥεǤWֽtΧĪ̡C 
3.C "	`goͼȮɬQΨhPAoNALʵolC 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IMMR1-a	IMMR1-b	IMMR1-c	110.6.16
BC22131263	L01AX04	0	IDACA	ĵ Dacarbazine 200mg/vial(Dacarbazine)		"ĬOӭMƻsA|CMӡATإi઺ിQDiG
1.ѩDacarbazinecM5-amino-imidazole-4-carboxamideA@إͪXI諸AizZI諸ͦXMDNAͪXCİ@׮ɽT꦳\AbC@פUiWjDNABRNAMJս誺ͪXC
2.Dacarbazine@Nª diazomethaneO@LƾA@ΩMۦPC
3.ĥi঳B򾯪@ΡA]ӵߥͪ|Qi򲸨C "	"غDξqPĤ覡G
1. 4.5 mg/kg/daysP10ѡACj4PiƧP@10Ѫ{C
`NG2 mg/kg/daysP10ѡAQ@pDHĥΡAo{Mq۵ġC
2. 250 mg/m2/daysP5ѡACj3PiƧP@5Ѫ{C"	"tswwʡGǷ8h
}wwʡGǷ8hBN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>30-60min
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Dacarbazine	L01A	Jƾ ALKYLATING AGENTS	0	cʶ¦~Fgﵽ	"α¨Ū̡C
糧ĦLөʤfHC
eYfHC"	BߡBæRB?P_g?BxŦl`BYv 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-05 j	Ts110.6.16		OI` 	0	OIs 20251124	IDACA-a	IDACA-b	IDACA-c	110.6.16
BC21304263	L01AA01	0	IENDO	ĵ Endoxan 200mg/vial(Cyclophosphamide)		CyclophosphamideOoxazaphosphamideέlͦӥXӭMAcWMlC~ơAgѨxŦLïƦ4-hydroxycyclophosphamideAMaldophosphamide鲧cCӭMrʧ@άLʥNªMDNA_椬@ΦӨӡADNAѲͿ~esγJս赲cܡCӭM`AgG2qDOhƪAӭMrʧ@ιӭMgqSʡAӭMghCMLLƪ@ˡAרOcyӭMApIfosfamideAeĩʤQưC 	"1. R`GHwɡG4050mg/kgAƦP25ѥHWCqG1015mg/kgC7101A35mg/kgCCg2ΨC1.53mg/kgCĵwɡG28mg/kg60250mg/TƦPA@6ѩ6ѥHWCqG1015mg/kgAC7101C30mg/kgC34g1C
2. ﰩfHq??C "	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNSBD5W
ĳ}nG100-500ml
ĳĳ~|tvGIVF 0.5-2h
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Cyclophosphamide	L01A	Jƾ ALKYLATING AGENTS	0	OکʥզfBoʸ~FBCʲOکʥզfBʲOگfBOڦת޸~ΦUغ´ӭMWhgB~F_oC	"1.cylcophosphamideLӪ̡C
2.\Yl(רOHcytotoxic agentvαgʪvfH)
3.H֪C
4.DC
5.PVg(active infection)C
6.hα¨ŴC "	զy֡BpO֥XBhBXʻH֪BƧêBxٮ`BxBCugBߡBæRBBKgBUgBֽolBֽBIۡB«PBYhBߦٻٮ`BߤBCBͯB~BҪiBLlBLgB}Bж˪v¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk has been demonstrated.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669603?cesid=7fPLhxDz1yc&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCyclophosphamide%26t%3Dname%26acs%3Dfalse%26acq%3DCyclophosphamide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IENDO-a	IENDO-b	IENDO-c	110.6.16
BC12601100	L01AA01	0	OENDO	ĵ Endoxan 50mg/}(Cyclophosphamid		CyclophosphamideOoxazaphosphamideέlͦӥXӭMAcWMlC~ơAgѨxŦLïƦ4-hydroxycyclophosphamideAMaldophosphamide鲧cCӭMrʧ@άLʥNªMDNA_椬@ΦӨӡADNAѲͿ~esγJս赲cܡCӭM`AgG2qDOhƪAӭMrʧ@ιӭMgqSʡAӭMghCMLLƪ@ˡAרOcyӭMApIfosfamideAeĩʤQưC	fAGHw115mg/kgFĵwHG28mg/kg60250mg/TA@6ѩ6ѥHWCqG25mg/kgA50150mg/TCg2C	"UCpfHEndoxan`NG
1.զyBpO֯gC
2.褧~FӭMC
3.HeXvLC
4.HeΨLCytatoxic agentvLC
5.x\l`C
]EndoxanK̾ध@ΡAfHpް_ӵߡBߩίfrPVĩΧﾯqAרOPTJĪX֪vAɷ|ϯfH`CboǱpUAk-awlPVרMIC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Cyclophosphamide	L01A	Jƾ ALKYLATING AGENTS	0	OکʥզfBoʸ~FBCʲOکʥզfBʲOگfBOڦת޸~ΦUغ´ӭMWhgB~F_oC	"1.cylcophosphamideLӪ̡C
2.\Yl(רOHcytotoxic agentvαgʪvfH)
3.H֪C
4.DC
5.PVg(active infection)C
6.hα¨ŴC "	̱`Ƨ@άOߡBæR	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk has been demonstrated.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-04 j	Ts111.8.19		OI` 	0	OIs 20251124	OENDO-a	OENDO-b	OENDO-c	111.8.19
BC09146100	L01AA02	0	OLEUK	ĵ LEUKERAN 2mg/tab(Chlorambucil)		ChlorambucilO@تڭ(aromatic nitrogen mustard)lͪAi@@\઺Jƾ(alkylating agent)AF|zZDNAƻs~Achlorambucil]|ϲӭMp53ֿnAi@BƲӭM`Pi]l(Bax)ӻoӭM`C	"0.1-0.2 mg/kg/day or 3-6 mg/m2/day for 3-6 weeks, then adjust dose on basis of blood counts
1. }lɡG10.10.2mg/kgA@36g(fH1412mg)C
2. qG126mgAiWL10.1mg/kgAiC10.03mg/kgC
3. ĵG10.10.2mg/kgA14.5mg/TC"	AΦĴקKhέšC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)	Chlorambucil	L01A	Jƾ ALKYLATING AGENTS	0	CʲOکʥզf()AHodgkin'sfBBZ_BBcʲOڽFBowʲOڽFC	DΥ@᫬LӪ̡C	hBpOCUBզyCUBֽoC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-11 j	Ts111.8.19		OI` 	0	OIs 20251124	OLEUK-a	OLEUK-b	OLEUK-c	111.8.19
BC25681263	L01BC05	0	IGEMZ	ĵ Gemita inj. 200mg/vial(Gemcitabine)		Gemcitabine(dFdc)bӭMQ?E?N¦㦳ʪCQ(dFdCDP)ΤTCQ(dFdCTP)?A]DNAͦXAӲͲӭMrʤ@ΡC@ξ]AӨBJGdFdCDPֿ}?٭?A]ӵLksyhֿ}?TCĥHXDNAC?QAh?@״֡AרOdCTPAMdFdCTPPdCTPvOJDNACӥBֶqGemcitabineiOJRNAA]ӭMdCTP@׭Cɷ|[jdFdCTPPDNAOX(۰ʥ[j@)C]-DNA?EXLkhGemcitabineέ׸ɥͪDNACGemcitabineOJDNAAͪDNA۷|A[J@Ӯ?ġAYDNAX(쥽ݾBפ@)COJDNAAGemcitabine|ɲӭM`AL{٬apoptosisC	"ŦG
ĳq1000 mg/m2H30R߿`AĳĤ覡G18gGCg@s7gAۥ𮧤@gC8gHGCgĤ@A28Ѷg1B8B15ѵPC
DpӭMG
ĳq1000mg/m21B8B15ѡAR߿`30GemcitabineAcisplatin{F1ѿ`ARߵPcisplatin 100mg/m2C
G
ĳq1250 mg/m2 21Ѷg1B8R߿`30A]tpaclitaxelCĤ@ѿ`GemcitabineeA` paclitaxel 175 mg/m2 3pɡC
Z_G
Gemcitabineĳq1000mg/m221Ѷg1B8R߿`Gemcitabine 30CĤ@ѿ`GemcitabineAAR߿`carboplatin AUC 4C
HG
H28Ѭ@gACg1B8B15ѵP1000 mg/m2AR߿`30ACg1ѵPcisplatin 70 mg/m2Cwq|gg@v{CCisplatinϥΤkPɥRAаѨī~C
xDG
@ϥΪĳq 1000 mg/m2AHR߿`30CH|g@vgACgĤ@AsĤTgAۥ𮧤@gAƥHW覡(C|g@g)vC"	"tswwʡGǷ24h
}wwʡGǷ24h
ۮe}GGNS
ĳ}nG100-250ml
ĳĳ~|tvGIVF 30-60min
ī~}~[GL
L`NƶG
1.N÷|ް_
2.Y`ɶWL60AΤ@gIhhrʷ|W[C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Gemcitabine	L01B	ܥN ANTIMETABOLITES	0	DpӭMBŦBHCGEMCITABINEPPACLITAXEL֥ΡAiϥΩ󴿸gϥιL ANTHRACYCLINE_oBLkNಾʤfwCΩ󴿸gϥΧt`Ī(PLATINUM-BASED)v_oBjܤ 6Ӥ뤧Z_A@ĤGuvC	gemcitabine LӪfHTΥ	~@ΡAϥΫiyhAզy֤ΦpO֡FߤΦ񦳹æRߡF׳JէB姿FֽlFIlxALGj20%fwP_gC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7627043"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.4._20160201_000.pdf"">OI` 9.4.</a>              "	OI` 9.4.	0	OIs 20251124	DC	DC	DC	114.10.24
BC27281100	L01BC59	0	OLONS	ĵƼf Lonsurf F.C.15mg/tab(Trifluridine		"ԴOѯݸGr򩳪?trifluridineAthymidine phosphorylase tipiracilA HռƤ1:0.5] q1:0.471^ ҲզCttipiracil itrifluridine Qthymidine phosphorylase N¦ӼW[trifluridine SC
Trifluridine iJӭMA|OJDNA äzZDNA XΧӭMW͡CҹTrifluridine/tipiracil pWKRAS ͫάܫHjzz~FӨܸ~FʡC "	"ԴlĳqC 35mg/m2AܦhC 80 @J]qH trifluridine tqܡ^AC⦸A\@pɤAΡC@Ӷg 28 ѡA 1 Ѧܲ 5 Ѥβ 8 Ѧܲ 12 ѪAġAefcƩάOo͵Lk@Ƨ@ΡFqp⬰i̱ܳ5 ơC 
Clcr30ml/min νվlonsurfq35mg/m2
Clcr<30ml/min ݽվlonsurflq20mg/m2
C{eP15ѴqyơAŦXHU~}lvG
1.ANC1500/m3,neutropenic feverw
2.PLT75000/m3
3.L}wѦܲ0-1"	ihkL઺bIAͨ|OkʦbԴvĨĪץIC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Trifluridine+Tipiracil	L01B	ܥN ANTIMETABOLITES	0	ԴAΩveUCkಾʤjzzHw̡A]A fluoropyrimidineBoxaliplatin  irinotecan ¦AMܦޤ֥ͪ]l]anti-VEGF^kFY RAS ͫ]wild type^AhݱLܪ֥ͪ]l]anti-EGFR^kC 	L	hBݤʥզyCUBLO / h¡BߡBpOCUBhBmBæRBhεoNC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2L-05 [96]_2L-06 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.66._20240601.pdf"">OI` 9.66.</a>              "	OI` 9.66.	0	OIs 20251124	OLONS-a	OLONS-b	02C27281-2	111.8.19
BC26914100	L01BC06	"""㵲F""500@J"	OALVO	ĵCalveda 500mg/F.C tab (Capecitabine )		CapecitabineOfluoropyrimidine carbamatelͪAfA~FƩʤοܩʲӭMrʾCb~capecitabineõLӭMrʡAb餺|ഫӭMrʪ5-fluorouracil(5-FU)A|i@BQN¡C5-FUub~FgѸ~Fޥͦ]l(tumour-associated angiogenic factor)Athymidine phosphorylase(dTHdPase)ʤƦӧΦA]Nd´Sb5-FU|̧CC	"@vzBzzPG
WϥΰzUvġAΰಾʵzzBΧߴಾʨvĮɡAĳ_lqs14 ѨCѧ뤩⦸1250 mg/m2]ߦU@A۷C`q2500mg/m2^AMᰱ7 ѡCIII jzw̡Aĳi欰6Ӥ몺UvC
X֪vzBzzέGG
X֪v(֥irinotecan~)ACapecitabineĳ_lqC8001000 mg/m2ACѨ⦸As14ѡA7ѡF625 mg/m2ACѨ⦸As򵹤CPirinotecan (XELIRI)X֪vɡACapecitabineĳ_lq800 mg/m2ACѨ⦸As14ѡA7ѡAC3g@{AéC{1ѵirinotecan 200 mg/m2CwĤTzfwUvAĳ6ӤC
X֪vG
Pdocetaxel֥ΩvಾʨɡACapecitabineĳ_lqs14ѨCѧ뤩⦸1250 mg/m2AMᰱ7ѡAèC3g@H1pɪɶR߿`75 mg/m2docetaxelC "	Capecitabine|rpξާ@OͻΤתvTC Capecitabinei|޵owtBh¤	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Capecitabine	L01B	ܥN ANTIMETABOLITES	0	BzΤjz(zz)BG	"1.bfluoropyrimidinevX{YΥwF
2. capecitabineΥξfluorouracilLӡF
3. hΥbšF 
4. ֦ץզy֯gBݤʥզy֯gΦpO֯gw̡F
5. ֦רx\l`w̡F
6. ֦׵ǥ\l`(ٻMvC30@/)w̡F
7. bϥsorivudineΨƾ(pbrivudine)vF
8. YsXk@ĪϥθTҡAYiϥθĪC"	"̱`Ƨ@άOGzA, B⨬gԸs(x~kh)Bh¡BLOBC"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk has been demonstrated.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_7-05 [96]_7-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.17._20210310.pdf"">OI` 9.17.</a>              "	OI` 9.17.	0	OIs 20251124	OALVO-a	OALVO-b	OALVO-c	110.6.16
BC22409100	L01BC06	0	OXELO	ĵ Xeloda 500mg/tab(Capecitabine)		CapecitabineOfluoropyrimidine carbamatelͪAfA~FƩʤοܩʲӭMrʾCb~capecitabineõLӭMrʡAb餺|ഫӭMrʪ5-fluorouracil(5-FU)A|i@BQN¡C5-FUub~FgѸ~Fޥͦ]l(tumour-associated angiogenic factor)Athymidine phosphorylase(dTHdPase)ʤƦӧΦA]Nd´Sb5-FU|̧CC	"@vzBzzPG
WϥΰzUvġAΰಾʵzzBΧߴಾʨvĮɡAĳ_lqs14 ѨCѧ뤩⦸1250 mg/m2]ߦU@A۷C`q2500mg/m2^AMᰱ7 ѡCIII jzw̡Aĳi欰6Ӥ몺UvC
X֪vzBzzέGG
X֪v(֥irinotecan~)ACapecitabineĳ_lqC8001000 mg/m2ACѨ⦸As14ѡA7ѡF625 mg/m2ACѨ⦸As򵹤CPirinotecan (XELIRI)X֪vɡACapecitabineĳ_lq800 mg/m2ACѨ⦸As14ѡA7ѡAC3g@{AéC{1ѵirinotecan 200 mg/m2CwĤTzfwUvAĳ6ӤC
X֪vG
Pdocetaxel֥ΩvಾʨɡACapecitabineĳ_lqs14ѨCѧ뤩⦸1250 mg/m2AMᰱ7ѡAèC3g@H1pɪɶR߿`75 mg/m2docetaxelC "	Capecitabine|rpξާ@OͻΤתvTC Capecitabinei|޵owtBh¤	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Capecitabine	L01B	ܥN ANTIMETABOLITES	0	BzΤjz(zz)BG	"1.bfluoropyrimidinevX{YΥwF
2. capecitabineΥξfluorouracilLӡF
3. hΥbšF 
4. ֦ץզy֯gBݤʥզy֯gΦpO֯gw̡F
5. ֦רx\l`w̡F
6. ֦׵ǥ\l`(ٻMvC30@/)w̡F
7. bϥsorivudineΨƾ(pbrivudine)vF
8. YsXk@ĪϥθTҡAYiϥθĪC"	"̱`Ƨ@άOGzA, B⨬gԸs(x~kh)Bh¡BLOBC"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk has been demonstrated.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-05 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.17._20210310.pdf"">OI` 9.17.</a>              "	OI` 9.17.	0	OIs 20251124	OXELO-a	OXELO-b	OXELO-c	111.8.19
AA58033238	L01BC02	0	I5FU2	ĵ 5-FU inj.50mg/ml;20ml/vial(Fluorour		"Fluorouracil O@اܸ~FܥNªCO@جtƦXAcyGrC
Fluorouracil @ΪT|TwAĥiQܤ֥HTؤPkF@ΡCĪֻĿ}A5-fluoro-2-deoxyuridine-5-phosphate |thymidylate synthetaseA
]ӧdeoxyuridylic Ʀthymidylic ĪJƧ@ΡA]zZDNA XCt~Afluorouracil |ֶqaQǤJRNA cΦD۵MRNAFĤTAǵ۪_uracil phosphataseAiRNA XGrQΡCѩDNA MRNA OӭMMҥAfluorouracil iް_ӭMŪM`C"	"Colorectal cancerG
400 mg/m2 bolus on day 1, followed by 1,200 to 1,500 mg/m2/day continuous infusion for 2 days (over 46 hours) every 2 weeks (in combination with leucovorin  either oxaliplatin or irinotecan) .
Breast cancerG
CEF or FEC regimen: 500 mg/m2 on days 1 and 8 every 28 days (in combination with cyclophosphamide and epirubicin) for 6 cycles.
Gastric cancerG
200 to 1,000 mg/m2/day as a continuous infusion over 24 hrs (as part of a platinum-containing regimen); the duration and frequency of each cycle varies based on the dose and regimen.
Pancreatic cancerG
FOLFIRINOX regimen: 400 mg/m2 bolus on day 1, followed by 1,200 mg/m2/day continuous infusion for 2 days (over 46 hours) every 14 days (in combination with leucovorin, irinotecan, and oxaliplatin) until disease progression or unacceptable toxicity occurs for a recommended 12 cycles."	"tswwʡGN/A
}wwʡG72h
ۮe}GGNSBD5W
ĳ}nG250-1000ml
ĳĳ~|tvGVaries by protocol
ī~}~[GL
L`NƶGN÷|ް_"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Fluorouracil	L01B	ܥN ANTIMETABOLITES	0	ƾ]pGBzBz^BBfw	"1. w糧~LӪw
2. w̦biΪA
3. w̦\
4. w̦bYǬVef "	fĪMD(iް_֩M)BmBhBߡBæR	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-01 j	Ts110.6.16		OI` 	0	OIs 20251124	I5FU2-a	I5FU2-b	I5FU2-c	110.6.16
BC25243100	L01BC53	0	OTS-1	ĵ TS-1 Ƥ 20mg/cap		"TS-1tFTBCDHPPOxoAӸgfATS-1᪺ܸ~FʬOFTv餺ഫͪ5-FUCCDHPܩʥifsbxŦ5-FUѥNJ-DPDAӴӦFT5-FU@סCH餺5-FU@תɰA~F´5-FUCĤƲ-5-fluoronucleotidesi@סAiӼWjܸ~FġCOxofAGzDAiܩʥiforotate phosphoribosyltransferaseAӿܩʧ5-FUƬ5-fluoronucleotidesAbvT5-FUܸ~Fʪ@ΤUAPɤ]GzDrʡC
5-FUDn@ξOzL䬡ʥN²FdUMPPdUMPPthymidylate synthasevʵXAPɻP٭쫬ħΦTEAӧDNAXC"	"q`̾nHlq(榸q)CTS-1 󦭡B\@Ѧ@⦸ġAs򵹤28ѡAᰱ14ѡAY@{C
jzz-TS-1PIrinotecanX֨ϥ G
Irinotecanq125mg/m2AR߿`ACgĤ@C TS-1qھگfHnACѨ⦸AsYgAۥ𮧨gAƥHW覡vC
ߴDpӭM-TS-1 WϥΡG
TS-1 qھگfHnA󦭡B\@Ѧ@⦸ġAs򵹤28ѡAۥ14ѡCƥHW覡vAefcƩάOX{Lk@}ƥC"	пA;AΦĥi|yzܤOUAקKĲثeDPVHξXC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Gimeracil+Oteracil+Tegafur	L01B	ܥN ANTIMETABOLITES	0	"(@) GG
1.GNỲUʤATS-1Ω󿩱wTNM Stage II (ưTI)BIIIA IIIBGBLGڰʤN~w̡C
2.TS-1AΩvLkߴGC 
(G) ŦGTS-1AΩvߴಾʯŦw̡C (T) jzzGTS-1PIrinotecanX֨ϥΩwϥΧtOxaliplatinƾkѤಾʤjzzw̡C
(|) ߴDpӭMGTS-1AΩt`ƾkvѪߴಾʤDpӭMC"	"1. TS-1YLӯfvw̡C
2. Yw [i?]C
3. Yǥ\êw [5-FUN?gimeracil?Gư֡A5-FU夤@?WɡAӥiϦp??Wj] 
4. Yx\êw [x\êi?]C
5. Lfluoropyrimidine??ʸ~FA]tTS-1X֦?Īv?Av?w̡C 
6. flucytosinev?w
7. κæh?C "	զy֡Bݤʥզy֡B֡BBߡC	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4671253?cesid=5r6A8MjXvQf&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTS-1%26t%3Dname%26acs%3Dfalse%26acq%3DTS-1#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.46._20240201.pdf"">OI` 9.46.</a>              "	OI` 9.46.	0	OIs 20251124	OTS-1-a	OTS-1-b	OTS-1-c	111.8.19
BC21696212	L01BA01	0	IMTX	ĵ Methotrexate inj. DBL 25mg/ml;2ml		Methotrexate@ܥNªAǥvʪAïdihydrofolate roductaseF쥦ӭMrʪĥΡCï٭folic acidܦtetraphdrofolic acidCtetraphdrofolic acidyzZDNAXMӭMƻsC㦳tvWͲ´pcʽӭMBBFLӭMBֽW֡Bbuccal(U)Mz߽AHΧDHֲӭM糧ĸӷP@ΡC	"Ectopic pregnancy
?Single dose, 1 mg/kg or 50 mg/m2 IM; may repeat in several days if hCG levels do not sufficiently decrease (guideline dosage)
?Two doses, 50 mg/m2 IM on days 0 and 4; give a third dose on day 7 if beta-hCG level has not declined by 15%, and a fourth dose on day 11 if levels increase or have not declined by at least 15% (off-label dosage)
?Multiple doses, 1 mg/kg IM, alternating with leucovorin 0.1 mg/kg IM, until hCG declines by 15%; MAX, 4 daily doses of each drug (off-label dosage)
G
HcyclophosphamideBmethotrexateMfluorouracil`֥ΤƾǪvA@HʵŲOڵ1ڰʨũФNUvAnĪGCmethotrexateqO40 mg/m2Ab1M8ѰI.V.PC
զfG
OڲӭMզfowѡAiCѤfAmethotrexate 3.3 mg/m2Mprednisolone60 mg/m2CFwѩM{ɤWﵽɡAĪqACg⦸I.M.`g30 mg/m2CάOA2.5 mg/kg I.V.C14ѧP@C
OڽFG
bĤTBurkittsOڽFɳq`HĨ֥ΨLؽFCbҦq̡AĪXӱ`{O7-10ѴAJkCbĤTOڦ׽F֥ΥĨCѵP0.625 mg2.5 mg/kgi঳C"	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNSBD5W
ĳ}nG50-500ml
ĳĳ~|tvGIMBIABITBIVF>15min
ī~}~[G"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Methotrexate	L01B	ܥN ANTIMETABOLITES	0	"Low dose therapy: choriocarcinoma, lymphotic leukemia, breast carcinoma.
High dose therapy: malignant melanoma, osteogenic sarcoma, epidermoid carcinoma of neck and head, small cell carcinoma of lung.
ܴcʸ~
ĦsxʧؽFODiBzA?W򽤽FMnLD
PLĪ֥ΰʥզf(SOOʲOڲӭMզf)νwvD
vBrukitt'sOڽFߴ(IHMIV Peter'st)Oڦ׽FASObpĩMߴ˦ת޸~fҡD
qkG
vVMYּA׽FMޭAtXLeucovorinϴD"	ǥ\l`fq`TΥġC	ũʤfBզy֡BߩMhWO̦h@뤣}C	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IMTX-a	IMTX-b	IMTX-c	110.6.16
AC43698100	L01BC53	0	OUFUR	ĵ UFUR (Tegafur+Uracil)		¦ʬsҹtegafurH1G4tXuracilɡAtegafurNª5-FUN³QA~Fܸ~Fʪ@ק@ܩʤɰAWjܸ~FĪGCt~b{ɤ]ݳ̾AtXAҹb~FiHɶ@ת5-FUAGBjzBBzĪGC	fAϥΡAC龯qHtegafurp⬰500-800 mg/day]300-350 mg/m2/day^A2~3AΡC	iX{LBߡBֽo;AΦĥi|yzܤOUAקKĲDPVHξH	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Tegafur+Uracil	L01B	ܥN ANTIMETABOLITES	0	GBjz(zz)BBYV窱WBPCisplatin֥ΪvಾΥ	"1. 惡ī~@LӪw1. 惡ī~@LӪw̡C
2. bAsorivudinew̡C"	BߡBæRθmBզy֯gBpO֯gγhB xŦ`BH	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H3 [2]_H3 [ws]_w61-03 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.11._20110101_000.pdf"">OI` 9.11.</a>              "	OI` 9.11.	0	OIs 20251124	OUFUR-a	OUFUR-b	OUFUR-c	111.8.19
BC22726100	L04AX03	0	OMTX	ĵ Methotrexate 2.5mg/tab(Methotrexat		Methotrexate@ܥNªAǥvʪAïdihydrofolate roductaseF쥦ӭMrʪĥΡCï٭folic acidܦtetraphdrofolic acidCtetraphdrofolic acidyzZDNAXMӭMƻsC㦳tvWͲ´pcʽӭMBBFLӭMBֽW֡Bbuccal(U)Mz߽AHΧDHֲӭM糧ĸӷP@ΡC	fAġG1.ؽFefGfAltDYCqġAioİM@סD2.WihefGfA@15-30mgs򤭤Ѭ@{Aq`Oݭni3-5{D3-4{i󧿲Gʴ24pɧGRHCGq<50IU/24hrAA4-6Piqf_hD3.զfGMethotrexateWϥΩλPTJX֡AiΩʲOڭFӭMզfɤJwѡDɤJkq3.30mg/m2AXprednisolone 60mg/m2Aq`b4-6P50%vfHowѡDkGMethotrexate fA@P⦸A@P`q30mg/m2AY_oi_ɤJqD4.OڽFGBarkittOڽFĤ@GAMethotrexatebYǮרҤͫ[wѡA˾q@ѤfA10-25mgF4-8ѡAĤTŸ~FAMethotrexateq`PLܸ~FĪPɵġDvżƸ~Fq`ݭnƭ{A{7-10ĴDĤTOڦ׽F]AMethotrexateXĪki঳ҤɡAMethotrexateq@0.625mg-25mg/kgD5.~GHGa.CP榸fA{GCP10-25mg.CP`qWL25mgDb.fAq{GC12p2.5-5mgA@TACPƤ@D{qCPiwCW[2.5mgAWLCP`qDWzϥΤ覡@F̨{ɤAqɵ{ɥiխ̧CĪqHγ̪iĶjɶD	bmethotrexateϥΫeAҭnwզyApOqAϯggkPTmethotrexatePɨϥΡAjqmethotrexatekɡAqcalcium folinateġCvɶNGP	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Methotrexate	L01B	ܥN ANTIMETABOLITES	0	򽤸~FBզfBOڦ׽FBnLB~	xBǰêAYvŵĪvQqAjҫ_MIʫhiHpqġCӭMĥΩ󥥰Ab|pvŹL઺MIʤeġAܤֲĤ@ɤnCmethotrexateiqLťġAbvqUALGSMI	"1.`-ũʤfĪBުBiBYhBզy֡BpO֡C
2.Y-xrʡBxwơBBͪB`C"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-04 j	Ts111.8.19		OI` 	0	OIs 20251124	OMTX-a	OMTX-b	OMTX-c	111.8.19
X000235209	L01CA02	0	IVINC1	ĵVincristine 1mg/1ml/vial (Vincristine sulfate		Dn@ΩӭMCvincristine|zZɯ起ΦAҥHӭMC 	"HG
@뾯q0.4-1.4mg/m2ACP@C̤jq2mgC
pġG
@뾯q1.5-2.0mg/m2ACP@C̤jq2mgC
p魫10kgΧ֡AΨn֩1m2A즸q0.05mg/kgA@PP@C"	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNSBD5W
ĳ}nG100ml
ĳĳ~|tvGIVF 10-15min
ī~}~[GL
L`NƶGȯHRߪ`g覡"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vincristine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	ʥզf	㦳Charcot-Marie-ToothYxLTfHC 	զy֡AgkhAKAvC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111/08/19		OI` 	0	OIs 20251124	IVINC1-a	IVINC1-b	IVINC1-c	111/08/19
BC25289209	L01CD02	0	ITAXO	ĵ Taxotere 20mg/1ml/vial(docetaxel)		"DocetaxelO@اܸ~FĪA|PiLަ(tubulin)EXíwLp(microtubules)AçLpުAө㭰CLަ骺@סCDocetaxelMLp޵Xä|ܬpޤ(protofilaments)ƥءC
b~AdocetaxelzZӭMLp޺[c(microtubular network)A[cHβӭMӭM\ҥC "	"G
ΩiNA㦳OڵಾUkCĳqCTgĤ@AC`doxorubicin 50@J/褽ؤcyclophosphamide 500@J/褽1pɫAdocetaxel 75@J/褽ءA@6{(Ԩqվ)CΩvߴಾʨAdocetaxelv(monotherapy) ɤĳq100@J/褽ءFĤ@uv(First-line)ɤĳq75@J/褽nA֥doxorubicin 50@J/褽nC
DpӭMG
󥼴w̡Aĳq75@J/褽ءAHHcisplatin 75@J/褽ص30-60Acarboplatin (@צuUn6@J/E) 30-60AeHt`ƾǪvѤw̡AHdocetaxel 75@J/褽س@ĪvC
eCG
ĳq75@J/褽ءC
GG
Docetaxelĳq75@J/褽ءA`ɶ1pɡAHHcisplatin 75@J/褽ؿ`1-3p(̬ҥuĤ@ѵ)C
YVG
wYVLk}Mi쪬ӭM(SCCHN) ҵgve޾ɩʤATAXOTEREĳq75@J/褽ءA`ɶ1pɡAHᵹcisplatin 75@J/褽ءA`1p(Ĥ@ѵ)A~5-fluorouracil AC龯q750@J/褽ءAs`5ѡC{C3gi@A@4{C"	"tswwʡGN/A
}wwʡGǷ6hAN48h(Non-PVC)
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>1h
ī~}~[GL
L`NƶG1.LӤib`Xo͡AYpCA޵jˡAMʥ֯lAߧY`gC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Docetaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	BDpӭMBeCBGBYVC	"1. TΩdocetaxelΨLξLӤfvw̡C
2. TΩOʥզyƥؤp1500 cell/mm3w̡C 
3. TΩhM¨ŤkC "	ݤʥզyʥFBBvBzBߡBæRBfĪBmBүfܡC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.3._20190101_000.pdf"">OI` 9.3.</a>              "	OI` 9.3.	0	OIs 20251124	ITAXO-a	ITAXO-b	ITAXO-c	110.6.16
BC25289219	L01CD02	0	ITAXO1	ĵ TAXOTERE 80mg/4ml/vial(Docetaxel)		"DocetaxelO@اܸ~FĪA|PiLަ(tubulin)EXíwLp(microtubules)AçLpުAө㭰CLަ骺@סCDocetaxelMLp޵Xä|ܬpޤ(protofilaments)ƥءC
b~AdocetaxelzZӭMLp޺[c(microtubular network)A[cHβӭMӭM\ҥC "	"G
ΩiNA㦳OڵಾUkCĳqCTgĤ@AC`doxorubicin 50@J/褽ؤcyclophosphamide 500@J/褽1pɫAdocetaxel 75@J/褽ءA@6{(Ԩqվ)CΩvߴಾʨAdocetaxelv(monotherapy) ɤĳq100@J/褽ءFĤ@uv(First-line)ɤĳq75@J/褽nA֥doxorubicin 50@J/褽nC
DpӭMG
󥼴w̡Aĳq75@J/褽ءAHHcisplatin 75@J/褽ص30-60Acarboplatin (@צuUn6@J/E) 30-60AeHt`ƾǪvѤw̡AHdocetaxel 75@J/褽س@ĪvC
eCG
ĳq75@J/褽ءC
GG
Docetaxelĳq75@J/褽ءA`ɶ1pɡAHHcisplatin 75@J/褽ؿ`1-3p(̬ҥuĤ@ѵ)C
YVG
wYVLk}Mi쪬ӭM(SCCHN) ҵgve޾ɩʤATAXOTEREĳq75@J/褽ءA`ɶ1pɡAHᵹcisplatin 75@J/褽ءA`1p(Ĥ@ѵ)A~5-fluorouracil AC龯q750@J/褽ءAs`5ѡC{C3gi@A@4{C"	"tswwʡGN/A
}wwʡGǷ6hAN48h(Non-PVC)
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>1h
ī~}~[GL
L`NƶG1.LӤib`Xo͡AYpCA޵jˡAMʥ֯lAߧY`gC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Docetaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	BDpӭMBeCBGBYVC	"1. TΩdocetaxelΨLξLӤfvw̡C
2. TΩOʥզyƥؤp1500 cell/mm3w̡C 
3. TΩhM¨ŤkC "	ݤʥզyʥFBBvBzBߡBæRBfĪBmBүfܡC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.3._20190101_000.pdf"">OI` 9.3.</a>              "	OI` 9.3.	0	OIs 20251124	ITAXO1-a	02C25289-1	02C25289-2	110.6.16
AC57971209	L01CD02	0	ITYXA	ĵ Nolbaxol 20mg/ml/vial(docetaxel)		"DocetaxelO@اܸ~FĪA|PiLަ(tubulin)EXíwLp(microtubules)AçLpުAө㭰CLަ骺@סCDocetaxelMLp޵Xä|ܬpޤ(protofilaments)ƥءC
b~AdocetaxelzZӭMLp޺[c(microtubular network)A[cHβӭMӭM\ҥC "	"G
ΩiNA㦳OڵಾUkCĳqCTgĤ@AC`doxorubicin 50@J/褽ؤcyclophosphamide 500@J/褽1pɫAdocetaxel 75@J/褽ءA@6{(Ԩqվ)CΩvߴಾʨAdocetaxelv(monotherapy) ɤĳq100@J/褽ءFĤ@uv(First-line)ɤĳq75@J/褽nA֥doxorubicin 50@J/褽nC
DpӭMG
󥼴w̡Aĳq75@J/褽ءAHHcisplatin 75@J/褽ص30-60Acarboplatin (@צuUn6@J/E) 30-60AeHt`ƾǪvѤw̡AHdocetaxel 75@J/褽س@ĪvC
eCG
ĳq75@J/褽ءC
GG
Docetaxelĳq75@J/褽ءA`ɶ1pɡAHHcisplatin 75@J/褽ؿ`1-3p(̬ҥuĤ@ѵ)C
YVG
wYVLk}Mi쪬ӭM(SCCHN) ҵgve޾ɩʤATAXOTEREĳq75@J/褽ءA`ɶ1pɡAHᵹcisplatin 75@J/褽ءA`1p(Ĥ@ѵ)A~5-fluorouracil AC龯q750@J/褽ءAs`5ѡC{C3gi@A@4{C"	"tswwʡGN/A
}wwʡGǷ6hAN48h(Non-PVC)
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>1h
ī~}~[GL
L`NƶG1.LӤib`Xo͡AYpCA޵jˡAMʥ֯lAߧY`gC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Docetaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	BDpӭMBeCBGBYVC	"1. TΩdocetaxelΨLξLӤfvw̡C
2. TΩOʥզyƥؤp1500 cell/mm3w̡C 
3. TΩhM¨ŤkC "	ݤʥզyʥFBBvBzBߡBæRBfĪBmBүfܡC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.03	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.3._20190101_000.pdf"">OI` 9.3.</a>              "	OI` 9.3.	0	OIs 20251124	DC	DC	DC	114.12.03
AB44466240	L01CD01	0	IPHYX1	ĵ PHYXOL 6mg/ml;25ml/vial(Paclitaxel)		PaclitaxelO@ط|PiLEXLpުsܷLp޾AiǨhEX@ΦӨϷLpíwAiӧӭM\ҥL`ʺAաC~PaclitaxelgѲӭMgΦhoʷLpެPAϷLpު`ƦCεXC 	"?_G
ĳ?k135 mg/m2 175 mg/m2R߿`3pɡACTgƤ@C
G
?ڵʤw̪Uʪv?Gĳ?k175 mg/m2 R߿`3pɡACTgƤ@A@|?{CPGEMCITABINE֥ΡGH21Ѭ@gA1B8R߿`gemcitabine (1250mg/m2) 30CĤ@ѿ`gemcitabineeA`TAXOL (175mg/m2) 3pɡC
DpӭMG
ĳ?k135 mg/m2 R߿`24pɡAMᵹ cisplatin 75 mg/m2ACTgƤ@C


"	"tswwʡGN/A
}wwʡGǷ27h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 1-24h
ī~}~[GL
L`NƶG1.~ecorticosteroidsѦpdexamethasone, diphenhydramine,H2ܾ(Ѧpcimetidineranitidine)@veġC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Paclitaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	"ߴZ_BŤUOಾA@tDoxorubicinbUƾkBwϥΦXk]DTҡAܤ]AϥAnthracyclineġ^ѪಾBDpӭMBRfdi׽FĤGukFPCisplatin֥ΡA@ߴZ_Ĥ@ukCPGemcitabine֥ΡAiϥΩ󴿸gϥιLAnthracycline_oBLkNಾʤfwBPHerceptin֥ήɡAΩvLƾǪvಾʥBLת{HER-2fHC
"	"1. ~ҥι糧~`gGΨ䥦tpolyoxyethylate castor oil(Cremophor EL)sLӤfHC
2. ~`gGϥΩݤʥզy֯g(Ȭ<1500/?)C "	1.譱wݤʥզyLCgBզyLCgBpOLCgBhBPVXF2.LӤF3.Ŧޤ譱w߸LCBCB߹qϲ`F4.P䯫gfܡF5.٦׵h`hF6.GzD譱wߤιæRAmAHF7.rvF8.x\ಧ`C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5.1._20231201.pdf"">OI` 9.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5._20210311.pdf"">OI` 9.5.1.</a>             "	"OI` 9.5.,9.5.1."	0	OIs 20251124	IPHYX1-a	IPHYX1-b	IPHYX1-c	110.6.16
BC24269100	L01CA04	0	ONAVE	ĵ Navelbine 20mg/soft cap(Vinorelbin		"@ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C
1. VinorelbinebXKͪP]vinca alkaloid^A@ξP䥦KͪP@ˡAgѻPtubulin dimerXtubulin-vinorelbineƦXAiӧLpޡ]microtubule^EX@ΡA_ӭMC
2. @ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C"	"ȥΩfAC
ſեnnA\ɥH]A(iZέ}n)C
ſեnn@ƾkC
ĳq:
eT:nCg60mg/m2@C
ĥ|}l:W[Cg80mg/m2@ADbeTA60mg/m2ɡAfHݤʥզyƥشC500/mm3δg@HWݤʥզyƥؤ500-1000/mm3C
bCg80mg/m2ζqvAYfHݤʥզyƥشC500/mm3δg@HWݤʥզyƥؤ500-1000/mm3AvȽwƥئ^_`ȡAPɥCqܨCg60mg/m2C
b̪TϥΨCg60mg/m2ζqvApGݤʥզyƥؤC500/mm3ζWL@HW500-1000/mm3AiANζqW[Cg80mg/m2"	2-8 XCNáAץxsC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vinorelbine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	DpӭMAʨC	"1. vinorelbineLӪ̡C
2. ɩʥզyƥؤp1000 cells/mm3"	"1. GrʡGɩʥզyL֯g
2. grʡGΤץֽPı`(paresthesia)Ϊıw(hypesthesia)"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-10 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.9._20171101_000.pdf"">OI` 9.9.</a><a href="""">OI` 9.9.2.</a>             "	"OI` 9.9.,9.9.2."	0	OIs 20251124	ONAVE-a	ONAVE-b	ONAVE-c	111.8.19
BC24268100	L01CA04	0	ONAVE1	ĵ NAVELBINE 30mg/soft cap(Vinorelbin		"@ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C
1. VinorelbinebXKͪP]vinca alkaloid^A@ξP䥦KͪP@ˡAgѻPtubulin dimerXtubulin-vinorelbineƦXAiӧLpޡ]microtubule^EX@ΡA_ӭMC
2. @ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C"	"ȥΩfAC
ſեnnA\ɥH]A(iZέ}n)C
ſեnn@ƾkC
ĳq:
eT:nCg60mg/m2@C
ĥ|}l:W[Cg80mg/m2@ADbeTA60mg/m2ɡAfHݤʥզyƥشC500/mm3δg@HWݤʥզyƥؤ500-1000/mm3C
bCg80mg/m2ζqvAYfHݤʥզyƥشC500/mm3δg@HWݤʥզyƥؤ500-1000/mm3AvȽwƥئ^_`ȡAPɥCqܨCg60mg/m2C
b̪TϥΨCg60mg/m2ζqvApGݤʥզyƥؤC500/mm3ζWL@HW500-1000/mm3AiANζqW[Cg80mg/m2"	2-8 XCNáAץxsC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vinorelbine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	DpӭMAʨC	"1. vinorelbineLӪ̡C
2. ɩʥզyƥؤp1000 cells/mm3"	"1. GrʡGɩʥզyL֯g
2. grʡGΤץֽPı`(paresthesia)Ϊıw(hypesthesia)"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-12 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.9._20171101_000.pdf"">OI` 9.9.</a><a href="""">OI` 9.9.2.</a>             "	"OI` 9.9.,9.9.2."	0	OIs 20251124	ONAVE1-a	ONAVE1-b	02C24268-2	111.8.19
AB44466221	L01CD01	0	IPHYX3	ĵ Phyxol 6mg/ml;5ml/vail(Paclitaxel)		PaclitaxelO@ط|PiLEXLpުsܷLp޾AiǨhEX@ΦӨϷLpíwAiӧӭM\ҥL`ʺAաC~PaclitaxelgѲӭMgΦhoʷLpެPAϷLpު`ƦCεXC 	"?_G
ĳ?k135 mg/m2 175 mg/m2R߿`3pɡACTgƤ@C
G
?ڵʤw̪Uʪv?Gĳ?k175 mg/m2 R߿`3pɡACTgƤ@A@|?{CPGEMCITABINE֥ΡGH21Ѭ@gA1B8R߿`gemcitabine (1250mg/m2) 30CĤ@ѿ`gemcitabineeA`TAXOL (175mg/m2) 3pɡC
DpӭMG
ĳ?k135 mg/m2 R߿`24pɡAMᵹ cisplatin 75 mg/m2ACTgƤ@C


"	"tswwʡGN/A
}wwʡGǷ27h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 1-24h
ī~}~[GL
L`NƶG1.~ecorticosteroidsѦpdexamethasone, diphenhydramine,H2ܾ(Ѧpcimetidineranitidine)@veġC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Paclitaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	"ߴZ_BŤUOಾA@tDoxorubicinbUƾkBwϥΦXk]DTҡAܤ]AϥAnthracyclineġ^ѪಾBDpӭMBRfdi׽FĤGukFPCisplatin֥ΡA@ߴZ_Ĥ@ukCPGemcitabine֥ΡAiϥΩ󴿸gϥιLAnthracycline_oBLkNಾʤfwBPHerceptin֥ήɡAΩvLƾǪvಾʥBLת{HER-2fHC
"	"1. ~ҥι糧~`gGΨ䥦tpolyoxyethylate castor oil(Cremophor EL)sLӤfHC
2. ~`gGϥΩݤʥզy֯g(Ȭ<1500/?)C "	1.譱wݤʥզyLCgBզyLCgBpOLCgBhBPVXF2.LӤF3.Ŧޤ譱w߸LCBCB߹qϲ`F4.P䯫gfܡF5.٦׵h`hF6.GzD譱wߤιæRAmAHF7.rvF8.x\ಧ`C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5.1._20231201.pdf"">OI` 9.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5._20210311.pdf"">OI` 9.5.1.</a>             "	"OI` 9.5.,9.5.1."	0	OIs 20251124	IPHYX3-a	IPHYX3-b	IPHYX3-c	110.6.16
BB21157221	L01CD01	0	ITAXOL	ĵ Taxol 30mg/5ml/vial (Paclitaxel)		PaclitaxelO@ط|PiLEXLpުsܷLp޾AiǨhEX@ΦӨϷLpíwAiӧӭM\ҥL`ʺAաC~PaclitaxelgѲӭMgΦhoʷLpެPAϷLpު`ƦCεXC 	"?_G
ĳ?k135 mg/m2 175 mg/m2R߿`3pɡACTgƤ@C
G
?ڵʤw̪Uʪv?Gĳ?k175 mg/m2 R߿`3pɡACTgƤ@A@|?{CPGEMCITABINE֥ΡGH21Ѭ@gA1B8R߿`gemcitabine (1250mg/m2) 30CĤ@ѿ`gemcitabineeA`TAXOL (175mg/m2) 3pɡC
DpӭMG
ĳ?k135 mg/m2 R߿`24pɡAMᵹ cisplatin 75 mg/m2ACTgƤ@C


"	"tswwʡGN/A
}wwʡGǷ27h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 1-24h
ī~}~[GL
L`NƶG1.~ecorticosteroidsѦpdexamethasone, diphenhydramine,H2ܾ(Ѧpcimetidineranitidine)@veġC
2.ϥΥHBPEPolyolefin]˪`GPE褧IV setġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Paclitaxel	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	"ߴZ_BŤUOಾA@tDoxorubicinbUƾkBwϥΦXk]DTҡAܤ]AϥAnthracyclineġ^ѪಾBDpӭMBRfdi׽FĤGukFPCisplatin֥ΡA@ߴZ_Ĥ@ukCPGemcitabine֥ΡAiϥΩ󴿸gϥιLAnthracycline_oBLkNಾʤfwBPHerceptin֥ήɡAΩvLƾǪvಾʥBLת{HER-2fHC
"	"1. ~ҥι糧~`gGΨ䥦tpolyoxyethylate castor oil(Cremophor EL)sLӤfHC
2. ~`gGϥΩݤʥզy֯g(Ȭ<1500/?)C "	1.譱wݤʥզyLCgBզyLCgBpOLCgBhBPVXF2.LӤF3.Ŧޤ譱w߸LCBCB߹qϲ`F4.P䯫gfܡF5.٦׵h`hF6.GzD譱wߤιæRAmAHF7.rvF8.x\ಧ`C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5.1._20231201.pdf"">OI` 9.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.5._20210311.pdf"">OI` 9.5.1.</a>             "	"OI` 9.5.,9.5.1."	0	OIs 20251124	ITAXOL-a	ITAXOL-b	ITAXOL-c	110.6.16
BC24638221	L01CB01	0	IVEPE	ĵ Fytosid 20mg/ml;5ml/vial(Etoposide)		wҹFytosid |yֺ´ӭMӭM?RCMӡADn@ΦGOb?ӭMӭMgG2 Ci???P?̿ʤCb@?U]10gg/ml ?^AiH[iJ?ӭMѡCbC@?U]0.3 10 gg/ml^AhiӭMiJӭM?eC?|zZLpުEXCEtoposide Dnjl@ΦGOǻPDNA ?c?II]topoisomerase II^椬@ΩΧΦۥѰAiӻoNDA_?C 	"1.PLƾ?֥Ωv?AYɡAFytosidRߪ`gG@뾯?dO50~100mg/m2/Ĥ@ѦܲĤѧ뤩A100mg/m2/Ĥ@BTBѧ뤩C 
2.PLƾ?֥Ωv?pӭMʪɡAFytosidRߪ`gG@뾯?dO35mg/m2/?|ѡA50mg/m2/?򤭤ѡC 
"	"tswwʡGN/A
}wwʡG̿@24h-96h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 30-60min
ī~}~[GL
L`NƶGFytosid?iHֳtRߪ`g"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Etoposide	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	g(AYBpӭMʪ)	"1. רx\णw̡C
2. ׵ǥ\ण ( ٻMv < 15mL/min)C 
3.  etoposideBetoposide phosphate λsLLӪw"	ߤιæRBCBifʨrvC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IVEPE-a	IVEPE-b	IVEPE-c	110.6.16
BC22215209	L01CA04	0	INAVE	ĵ Navelbine 10mg/ml/vial(N)		"@ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C
1. VinorelbinebXKͪP]vinca alkaloid^A@ξP䥦KͪP@ˡAgѻPtubulin dimerXtubulin-vinorelbineƦXAiӧLpޡ]microtubule^EX@ΡA_ӭMC
2. @ΩӭMgG2 phaseL޳JսEX@ΡAϱoM phaseLkΦACӭMwr(Mitotic Spindle poisons)C"	25-30 mg/ m2 weekly IV over 6-10 min.	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNSBD5W
ĳ}nG20-50ml
ĳĳ~|tvGIVF 6-10min
ī~}~[GL
L`NƶGȯHRߪ`g覡"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vinorelbine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	DpӭMAʨC	"1. vinorelbineLӪ̡C
2. ɩʥզyƥؤp1000 cells/mm3C"	"1. GrʡGɩʥզyL֯g
2. grʡGΤץֽPı`(paresthesia)Ϊıw(hypesthesia)"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.9._20171101_000.pdf"">OI` 9.9.</a><a href="""">OI` 9.9.1.</a>             "	"OI` 9.9.,9.9.1."	0	OIs 20251124	INAVE-a	INAVE-b	INAVE-c	110.6.16
AB41037229	L01DB01	0	ILIPO	ĵ Lipo-Dox Liposome inj 2mg/ml*10ml(D		"Doxorubicin liposomal is a pegylated formulation which protects the liposomes, and thereby increases blood circulation time. Doxorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix."	"1.AIDS-related Kaposi sarcoma: IV: 20 mg/m(2) once every 21 days until disease progression or unacceptable toxicity.
2.Multiple myeloma: IV: 30 mg/m(2) on day 4 every 21 days (in combination with bortezomib) for 8 cycles or until disease progression or unacceptable toxicity.
3.Ovarian cancer, advanced: IV: 50 mg/m(2) once every 28 days until disease progression or unacceptable toxicity
4.Breast cancer, metastatic (off-label use): IV: 50 mg/m(2) every 4 weeks.
Monitor for infusion reaction. For IV infusion only; do not administer IV push.
 Administer IVPB over 60 minutes; infusing the first dose at initial rate of 1 mg/min to minimize risk of infusion reactions; if no infusion-related reactions are observed, then increase the infusion rate for completion over 1 hour."	"tswwʡGN/A
}wwʡGN24h
ۮe}GGD5W
ĳ}nG250ml(dose<90mg)F500ml(dose>90mg)
ĳĳ~|tvGIVF 1h
ī~}~[G
L`NƶG1.For IV infusion only; don't give as undiluted suspension or as an IV bolus
2.iPDoxorubicin椬ϥ
3.iϥfilter"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Doxorubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ΩvCD4ƶqCU]200CD4 LYMPHOCYTESMM^M߽BֽΤŦfܪAIDS RELATED KAPOSIS SARCOMAfHCΩvĤ@utPLATINUMPACLITAXELƾǪvӥѪ̩ΦA_oiʩಾʧZ_fHC 	惡ī~LӡBΩgvӾɭPBHΦ]PVoNw̡AקKϥΡC	`}]ABx~kh(Palmar-plantar erythro- dysesthesia)BfĪBߡBæRBB֯lBrY	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.14._20101001_000.pdf"">OI` 9.14.</a>              "	OI` 9.14.	0	OIs 20251124	ILIPO-a	ILIPO-b	ILIPO-c	110.6.16
BC22695240	L01DB03	0	IEPIR5	ĵ PHARMORUBICIN 50mg/vial(Epirubicin)		"Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals."	"Breast cancer, Adjuvant therapy for axillary node-positive disease: initial dose range, 100 to 120 mg/m2 IV (either given on day 1 or divided equally and given on days 1 and 8), every 3 to 4 weeks.
H֤(IVCT)
v?H֨Ŭ?LӭMAĳ`50mgKgv?覡Cbͧrʡ]ƾǩʻH֪^fHAĳ?C?30mgC"	"tswwʡGN/A
}wwʡGǷ24hAN48h
ۮe}GGNSBD5W
ĳ}nGIV:50-250mlFIVCT:30-50ml
ĳĳ~|tvGIVF 3-20min
ī~}~[G
L`NƶG1.Cumulative doses : 900 mg/m2
2.Ķ:Anthracycline  Taxane"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Epirubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ŸBcʲOڽFBn´׽FBGBBZ_F	"1.~?ϥΩ󴿱Īv?Ωgʪv?Ӥް_fHC
2.{δŦ\?fv̡A@笰~PTҡC
3.PMitozantroneBMitomycin C Anthracycline?ƦXApGDoxorubicinBDaunorubicinAF̰?n?fHC "	P?drʧ@άΤŦrʧ@	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-15 j	Ts110.6.16		OI` 	0	OIs 20251124	IEPIR5-a	IEPIR5-b	IEPIR5-c	110.6.16
BC19124235	L01DC01	0	IBLEO	ĵ Bleocin 15mg/amp(Bleomycin)		ʪܥͯATAjzߪsܯDNAXAt~BleomycinG|DNAcܪíwAɭPѻPDNA_C 	"Test dose for lymphoma patients: IM, IV, SubQ: Due to the possibility of an anaphylactoid reaction, administering 1 to 2 units of bleomycin before the first 1 to 2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed. IM, SC, IV: 10-20 units/m(2) 1-2 times/wk.
Malignant pleural effusion: Intrapleural: 60 units as a single instillation; mix in 50 to 100 mL of NS."	"tswwʡGɧ֨ϥ
}wwʡGǷ24h
ۮe}GGNS
ĳ}nGIVFBIPLG50-100 ml 
ĳĳ~|tvGIVFBIPLG50-100 ml 
ī~}~[GL
L`NƶG 1. ϥΥ~ioiXͪMֺƵYͯf
2.Bleomycin HCL`qWL300mg(Ļ)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Bleomycin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ֽ(]ABnΤk)BYV(WEBBBB|Bf)BDB(oʩಾʫ󥭤W)BcʲOڸ~(ӵߦ׸~BOڦ׸~BNf)C 	BleomycinLӪ̡FhέŰkҥΡC 	"1.Ƨ@ΡGLoBBߡBæRBmB魫UBvC
2.YƧ@ΡGpO֡BֺͪơC"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IBLEO-a	IBLEO-b	IBLEO-c	110.6.16
BC22712221	L01DB01	0	IADRI	ĵ Adriamycin inj. 2mg/ml;5ml/vial(Dox		"Doxorubicin@ξثe|ĩAwPDNAXOΧֻĦX@ΦCӭMisܡAiֳtzӭMAPӭM֩P򪺬V赲XAֳtʤΧֻĦXAPܩʡA|ͬV鲧`{HC
Doxorubicin㦳Ķ@ΡC~|HϪyopK̤Ҥ޵oΦGĻCbkʤH][쪺ҾܡAdoxorubicinO@ا@αjBȮɩʪĶCDoxorubicinO@عӭMPqSʪӭMrĪC"	"Single- agent therapy: 60 to 75 mg/m(2) IV every 21 days;
Combination therapy: 40 to 75 mg/m(2) IV every 21 to 28 days."	"tswwʡGN/A
}wwʡGǷ24hAN48h
ۮe}GGNSBD5W
ĳ}nG50-500ml
ĳĳ~|tvGIVF 15-60min
ī~}~[G
L`NƶG1.iPHeparinVXϥ
2.Cumulative doses above 550 mg/m2 are associated with an increased risk of cardiomyopathy"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Doxorubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	CʥզyLhgBwFBOڽFBnֺʦ׽FBPӭMBB	"1. doxorubicinΥ~LBLanthracyclinesanthracenedionesLӪ̡C
2. hPŪ̡C
3. ]Lܸ~FĩΩguvӤ޵oʰYfĪC 
4. ʷPVC
5. Y߫ߤC 
6. Yߦ٥\णC
7. ̪񴿵oͤߦٱC 
8. Yx\lC 
9. Lanthracyclinesanthracenediones̤jֿnqv"	oBLOBoNBCBHo/fĪBmBæRBߡBvC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.14._20101001_000.pdf"">OI` 9.14.</a>              "	OI` 9.14.	0	OIs 20251124	IADRI-a	IADRI-b	IADRI-c	110.6.16
BC22695221	L01DB03	0	IEPIR1	ĵ Pharmorubicin 10mg/vial(Epirubicin)		"Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals."	"Breast cancer, Adjuvant therapy for axillary node-positive disease: initial dose range, 100 to 120 mg/m2 IV (either given on day 1 or divided equally and given on days 1 and 8), every 3 to 4 weeks.
H֤(IVCT)
v?H֨Ŭ?LӭMAĳ`50mgKgv?覡Cbͧrʡ]ƾǩʻH֪^fHAĳ?C?30mgC"	"tswwʡGN/A
}wwʡGǷ24hAN48h
ۮe}GGNSBD5W
ĳ}nGIV:50-250mlFIVCT:30-50ml
ĳĳ~|tvGIVF 3-20min
ī~}~[G
L`NƶG1.Cumulative doses : 900 mg/m2
2.Ķ:Anthracycline  Taxane"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Epirubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ŸBcʲOڽFBn´׽FBGBBZ_F	"1.~?ϥΩ󴿱Īv?Ωgʪv?Ӥް_fHC
2.{δŦ\?fv̡A@笰~PTҡC
3.PMitozantroneBMitomycin C Anthracycline?ƦXApGDoxorubicinBDaunorubicinAF̰?n?fHC "	P?drʧ@άΤŦrʧ@	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-19 j	Ts110.6.16		OI` 	0	OIs 20251124	IEPIR1-a	IEPIR1-b	IEPIR1-c	110.6.16
BC26818100	L01EE01	0	OMEKI	ĵMekinist 2mg (Trametinib)		"TrametinibO@إif઺׿ܩʲAiѦ쬡ƤӭM~T  ո`ʿE? 1 (MEK1) P MEK2 Ƨ@λPE?ʡC MEK JդDOӭM~T  E? (~|nզCb¦FPLgA~|`|QܧΦ BRAF ơA BRAF| MEK ΨE~FӭMͪ C Trametinib i BRAF  MEK Ƨ@ΤΧ MEKE?ʡC Trametinib i BRAF V600 ܫ  ¦FӭM  ͪAb BRAF V600 ܫ¦Fʪҫ]ҹiܸͧ~F@ΡC
Pdabrafenib ֥
DabrafenibO RAF E?C BRAF o Pʬܷ| P RAS/RAF/MEK/ERK ~ | oͫ򬡤ơC] trametinib P dabrafenib | ~ |ؿE? MEK M RAF G̨֥Υi @ P ~| C ~ t rameti nib P dabrafenib ֥ι BRAF V600 ܶʶ¦FӭMi{ܸ~FʡAé BRAF V600 ܶʶ¦Fز ѹ  ܯੵw 餺ĩ  C
T{
BRAF ܪA
Atrametinib ΥH trametinib ֥ dabrafenib eAHg L TĪ˴ k ATww̪~FA BRAF V600 ܶʡC"	Trametinib ׳@kλP dabrafenib ֥ΡA ĳq   2 @J C  @C P trametinib֥ΡA dabrafenib ĳq 150 @JC⦸C	"Bm}ɡAiݭnխqBȰvΰΪv
Yoֽͥ쪬WֲӭM( ηsoʶ¦F}ɡAĳվ㾯q  oi@BT AаѾ\ dabrafenib  C
YHdabrafenib֥trametinibɵoͪvrʤAhPɭCkqAΦPɼȰΰγokCuݽվk䤤@ؤqҥ~pwԭzpU: op]AoNB彤BRASܶʤDֽcʸ~FBQT(DnPdabrafenib)B߫ǮgXv(LEVF)CBRߪ(RVO)BW֭(RPED)ζʪͯf(ILD)/ͪ(DnPtrametinib)C
BRAF V600
˴¦FBRAF V600 ˴ʪw̨ϥ t rametinib wʤ  Q C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsBcNë(2 C ~ 8 C) C
иm]ˤx sAHקKӤΨC
Ĳ~ЫO򳬡C}ʫAī~ib 30 C HUxs 30 ѡC"	trametinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	"Trametinib@kλP dabraf enib ֥ΡA i Ωvwo BRAF V600  B Lk
 ಾ {HH ʶ¦FC
beBRAF kɴcƪw̤A trametinib @kåi{X{ɬ"	ﬡʦΥξLӡC	"h ,L,,Oҽk,P~,ıê,,X,߫ǥ\ê,m,,æR"	Trametinib oIΩ󥥰έŤˡCYbhϥ trametinib AέYw̦bA trametinib hAiw̦ĪL઺bM` C	DnקKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B03-13 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.91._20240601.pdf"">OI` 9.91.</a>              "	OI` 9.91.	0	OIs 20251124	OMEKI-a	OMEKI-b	OMEKI-c	111.8.19
	L01EH02	PQw	ONERL1	ĵNeratinib 40mg (NERLYNX)		NeratinibO@ ӭM E?A|P֥ͪ]l ( B HER2 P HER4 ΦifsC b~ neratini b |C EGFR P HER2 CĤơBU媺 MAPK P AKT T ǻ|Aҹ { EGFR M  HER2 ӭMܸ~FʡC Neratinib HNª M3 B M6 B M7 P M11b~ | EGFR B HER2 P HER4 ʡC b餺 fA뤩 neratinib b~FӭM { HER2P EGFR pزӼҫ|~FͪC	"NERLYNXĳqC@ ifA 240 mg (  ))Av 1 ~C
ܯfH CѩjۦPɶA NERLYNX C NERLYNX ]A CZBr_Τ_]A C
YfH ѰOġAФŸɤW|qAë fH ~ӤU@ƩwC龯qA NERLYNX C
󻴫צܤ׵ǥ\ण  fH AqվëDnC 
󻴫צܤרx\ण (Child Pugh A  B   fH AõLqվĳC"	"mwvĳ̪2 Ӫvg (56  ABH۲Ĥ@ NERLYNX i}v
mG󱵨ĳwvUoͪmA{ɪpHLmġBGMqѽɥRnvCoͭשM/ΫmfHȰNERLYNXvCoͲ4YmΦb̤j{׽խqᤴoͲ2ťHWmfHAä[NERLYNXvC
xrʡG}lv̪3Ӥܤ֨CӤʴx\˴ȡAhC3Ӥõ{ɪpiʴAx\णfHiභKʴAԷVġCoͲ3Ũx\ಧ`fHȰNERLYNXvFӵoͲ4Ũx\ಧ`fHhä[NERLYNXvC
FL-LrʡGNERLYNXiLyˮ`CifHNERLYNXL઺bIAHζϥΦץIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ30XCHU	neratinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	NERLYNXAΩw H֥ͪ]l 2 HER2    HfH @ bttrastuzumab U k  j U  v	L	̱`}(>5%)mBߡBhBh¡BæRB֯lBfĪBhB٦׵jˡBƤ}BASTALTɰBүewBֽBȡB魫PcDPVC	ܨͨ|Okʩ NERLYNX vHγ̫@Īܤ 1 Ӥ뤺ϥΦĪץIC	ӵoY}AܭŤkʦbA NERLYNXHγ̫@Īܤ 1 Ӥ뤺 o šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2R-04 j	Ts114.10.28		OI` 	0	OIs 20251124	ONERL1-a	ONERL1-b	ONERL1-c	114.10.28
BC26968100	L01EB04		OTAGR	ĵƼfTagrisso(Osimertinib)80 MG		OsimertinibO֥ͪ]l(EGFR)E?Ab@פͫC9ɡAifaXYEGFRܧΦ(T790MBL858RBM~l19ʥ)COsimertinib fAīAߤio{بĲzʪNª(AZ7550MAZ5104Ab`@׬Ī10%)A㦳Posimertinibۦ@ΡCAZ7550ĤOPosimertinibۦAAZ5104~l19ʥMT790M(8)Mͫ(15)EGFRĤOjC	"TAGRISSOĳqC@80 @JAefcƩεLk@rʬC
TAGRISSOibCۦPɬqŸλP֥ΡC
YL@TAGRISSOAФŸɪALqAӪAĮɶAΤU@C
T]`xfH:uiN50 mLDһĤAͩժYߧYܤUCsƴnHB[ΥζWi_HCAH120-240 mLR~eߧYܤUCYݭnѻGާġANY 15mLDһĤAtH15 mL}R~ݾlĨò魹ŰwAN30mLī~G̻Gިϥλi浹ġAAHAq}R~޹DC"	"iͨ|OkʦbTAGRISSOvMAΥq6gĨץIC
iͨ|OkʦQkʦbAΥq4Ӥ뤺ĨץIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Osimertinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	"TAGRISSO (osimertinib) AΩ~F֥ͪ]l (EGFR) ܤIǩʩಾ NSCLC fHĤ@uvC
TAGRISSOAΩv㦳EGFR T790M]ܤIǩʩಾNSCLCbEGFR TKIvΤefcƪfHC"	L	̱`}mB֯lBֽBҬrʡBfĪBCC	ھڬsƾکM@ξzAwpbhϥη|yLˮ`C	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_7-04 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.80._20241001.pdf"">OI` 9.80.</a>              "	OI` 9.80.	0	OIs 20251124	OTAGR-a	OTAGR-b	02C26968-2	111.8.19
	L01FD04	uo	IENHE1	ĵENHERTU 100@J/~		"ENHERTU (trastuzumab deruxtecan)O@HER2йvʧĪƦXC
b鵲X~FӭMWHER2Atrastuzumab deruxtecanƶiJӭMAbӭMgӭMת{?ïislѡAXӭMz(membrane-permeable)DXdAް_DNAl˻PӭM`CDXdO@exatecanlͪAĤOirinotecanʥNªSN-3810C"	ENHERTUĳq5.4 mg/kgAC3gHR߿`(21Ѷg)AefcƩεo͵Lk@rʬC	"ENHERTUiPtrastuzumabtrastuzumab emtansineۤNC
1.ʴfHO_X{ʪͯf(Interstitial lung disease, ILD/ͪxMg(y¡BIlxBoNM/ΥsoͩδcƪIlDg)
2.ݤʥզy֯gAbENHERTUʪ즸PCIΫeAε{ɻݨDAʴypơC
3.߫ǮgXvC]bv{ɻݨDwLVEFCYT{LVEFC40%Aά۸Uqj20%Aä[ENHERTUC^
שMרx\णfHAԷVIENHERTU"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	tseAxsBc(2XC - 8XC)C}᪺GAץxsbǷ(30J)̦h4pɡAxs2XC8XCBc̦h24pɡCxsɶ۰tsɶ_C	trastuzumab deruxtecan	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	WϥξAΩvಾᴿLإHWHER2{B㦳LkಾHER2ʨHfHC	LC	(79.9%)Bh(60.3%)BæR(48.7%)Bv(46.2%)BK(35.9%)Bh(34.6%)Bh(33.8%)Bݤʥզy֯g(32.5%)Bm(30.8%)BpO֯g(23.1%)By(21.4%)Bզy֯g(20.5%)PYh(20.1%)C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6899734?cesid=03fdgN8zSc5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DENHERTU%26t%3Dname%26acs%3Dfalse%26acq%3DENHERTU"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.5.31		OI` 	0	OIs 20251124	IENHE1-a	IENHE1-b	IENHE1-c	111.5.31
KC01065221	L01FD01	P	IHERC1	ĵƼf Herceptin SC.600mg/5ml/vial(Trast		"1. TrastuzumabODNA]ջsHƳ(humanied monoclonal antibody)AܩʧC@ΦbӭM~HW֥ͪ]l2J(human epidermal growth factor receptor 2 proteinAHER2)FoO@IgG1AcWtH[cϰ(framework region)HθMwϰAYgXѹHER2(murine anti-p185 HER2 antibody)զC
2. b~(in vitro)ΰʪ礤Ao{trastuzumabiHHER2Lת{H~FӭMW͡Cb~礤APLHER2Lת{ӭMɡAgtrastuzumabո`̿૬ӭMCӭMrʧ@(antibody-dependent cellmediated cytotoxicityFADCC)|@ΦbHER2Lת{WӭMC"	ױw魫hAHerceptin SCĳTwq600 mgAC3gĤ@C	"tswwʡGN/A
}wwʡGǷ6hAN48h
ۮe}GGN/A
ĳ}nGN/A
ĳĳ~|tvGSC 2-5min
ī~}~[GL
L`NƶG
1.}lHerceptinveAHER2˴C
2.Herceptin SC injȯ֤U`gAiHRߪ`g"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"HerceptinϥΩUCHER2Lת{HER2]amplificationw̡J1.ಾʨ:(1).WϥΩ󴿱L@]t^HWƾǪvಾʨfHC(2).XPaclitaxelDocetaxelϥΩ󥼴LƾǪvಾʨfHC2.JHerceptin AΩ@gL~NBƾk(NeUvλUv)vᤧHER2Lת{w̪vġC

"	TϥΩw|trastuzumabβ~󦨤LӤfHC	h¡BoNBNŸB߹æRBy¡B֯l	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.18._20250501.pdf"">OI` 9.18.</a>              "	OI` 9.18.	0	OIs 20251124	IHERC1-a	IHERC1-b	IHERC1-c	110.6.16
BC26655229	L01CE02	0	IONIV	ĵƼf Onivyde lipo 5mg/ml;vial(Irinotec		IrinotecanL`gO@ةݾ벧c?IA]Щ׽hcpnMηLCݾ벧c?IiDNA_AHDNAOCIrinotecan Ψ䬡ʥNªSN-38|Pݾ벧c?I-DNAƦXΦifʵXA_BA׳sAiް_PSɶuDNAѯ}aPӭM`CbزӤH~FpA۷irinotecan HClC5qirinotecanLiFۦ~FSN-38SqC 	"ФťHONIVYDENLtirinotecan HClĪC
Х`gONIVYDEAA`gleucovorinM5-fluorouracil C
1.ONIVYDEĳq80mg/m2R߿`90AC2g`g@C
2.bಾʯظ{ɸ礤AONIVYDE`Aleucovorin 400mg/m2R߿`30AHᬰ5--fluorouracil 2,400mg/m2R߿`46pɡCC2gĤ@C
3.wUGT1A1*28ﰸ]PXlw̡AONIVYDEĳ_lq60mg/m2AR߿`90CY@AhgiNONIVYDEqհ80mg/m2C"	"tswwʡGN/A
}wwʡGǷ4hAN24h
ۮe}GGNSBD5W
ĳ}nG500ml
ĳĳ~|tvGIVF:>90min
ī~}~[GLܥզ
L`NƶG
1.Do NOT substitute Irinotecan liposome for Irinotecan.
2.iϥfilter"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Irinotecan	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	ONIVYDE(irinotecanL`g)AΩಾʯظAX5-fluorouracilMleucovorinvLgemcitabinew̡C	"ONIVYDEirinotecan HCloYLӤw̸TϥΡC
TONIVYDEPt(St. John's Wort)֥ΡC "	mBh/LOBæRBߡBCBfĪPoN	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.12.2._20180801_000.pdf"">OI` 9.12.2.</a>              "	OI` 9.12.2.	0	OIs 20251124	IONIV-a	IONIV-b	IONIV-c	110.6.16
BC27320100	L01EF02	Q	OKISQ	ĵƼf Kisqali 200mg/tab(Ribociclib)		Ribociclib OӭMgJը̿E? (CDK) 4 M 6 AoǿE?P D ӭMgJյXN|쬡ơA æbTǻ|tnA޾ɲӭMgiMӭMW͡CӭMgJ D-CDK4/6 ƦXiN ӭMFձJ (pRb) CĤơAHձӭMgiC~o{Aribociclib |C pRb CĤơAϲӭMgb G1 qAô֨ӭM誺ӭMW͡C ܡAbjزӤH~FӭMҫAϥγ@Ī ribociclib vA|ɭP~FnYpABP pRb CĤƪCĥίfHۿE鶧ʨزӼҫo{A֥ ribociclib MܻۿEĪ ( p letrozole) ~FͪĪGjӧOĪ@kC~AbۿEʪزӼҫAribociclib Pfulvestrant ֥ΥiɭP~FͪC	KISQALI ĳqC@fA 600 @J ( T 200 @J) s21 ѡAȰv 7 ѡA@ӧ {@p 28 ѡCKISQALI iH\ΪŸA	"1.קKPɨ֥αj CYP3A (p:clarithromycinBc)AnɭCܨC200mgC
2.רx\ण (Child-Pugh A ) w̤ݽվ㾯qC
3.vΦܰ3PץC
4.ʴyơBx\Τ߹q(ר֥Χܤ߫ߤī~amiodarone)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Ribociclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	KISQALI Pڭƻï֥ΡAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAߴಾʨgklcvC	DLӪ̡C	i|ݤʥզy֡BߡB«BmBզy֡BvBæRBKBYhBIhBCC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_7-06 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.72._20250701.pdf"">OI` 9.72.</a>              "	OI` 9.72.	0	OIs 20251124	OKISQ-a	OKISQ.b	02C27320-2	111.8.19
BC27446100	L01XK01	O	OLYNP	"ĵLynparza? 150 mg/tab
(Olaparib)
/OWSQdѥq"		LynparzaOEIGCĮ޻EX?]PARP^] ]APARP1BPARP2MPARP3^CPARPï|ѻP`ӭM\AҦpDNAMDNA״_Colaparib@kΦbt`IΡAҹ|b~w~FӭM誺ͪAæbHgpزӼҫw~FͪCbʥFBRCAHΫDBRCAJհѻPDNA l˪Pխ״_]]HRR^ӭMMp~FҫAolaparib vӭMrʩMܸ~FʼW[ABPt`k㦳pʡC~ܡAolaparib oӭMrʥiPPARPïʧPARP-DNAƦXΦAyDNAl˩MӭM`C 	"Lynparzaĳq300mg]ϥΨ150mg^ACfA⦸AH\ΪŸAΡAC`q600mgCʹ޲ӭMBRCA1/2]germline BRCA 1/2^ܪH֦]lͪ2]HER2^]-^ಾʨѸg״IǡAĥҹLʹ޲ӭMθ~F˴kAӧPwfHBRCAܡ]BRCAm^AC 
Ч]AɿAiCZBHBѩέbC "	"1.y夣}gԸs/ ʰʥզf]MDS/AML^GfHeɭPGǬrʩ|_]? 1 š^eAФŶ}lLynparza vC@
2.DPVʪͪ]Pneumonitis^:fHX{sIlgίgcơAҦpIlxBy©MoNAάOoͯݵĩgv`AФ_Lynparza våߧYgӷC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30?CHUC 	Olaparib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. Lynparza @kiΩet`ĪӷPB_o״cʪ֧Z_BZ޸~FέoʸAb_ot`]γ^HfHA@vC 
2. Lynparza @kiΩveɩʡBNỲUʩಾʤABʹ޲ӭMBRCA1/2] germline BRCA1/2^PfʩκæPfʬܪHER2]-^ಾʨHfHCwX鶧ʪfHA~bgLXvBΤAXϥβXvpUϥΡC "	LC	ߡB«BæRBhC 	ALynparza Ωhkʥi|Lyˮ`CLynparza vα̫@Lynparza 6 Ӥ뤺nϥΦץI	ѩLynparza i㦳bY}Ai¨ŪkʡAALynparza ̫@1 Ӥ뤺AišC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.85._20251001.pdf"">OI` 9.85.</a>              "	OI` 9.85.	0	OIs 20251124	OLYNP-a	OLYNP-b	OLYNP-c	111.8.23
BC26568100	L01EX09	0	OOFEV	OFEV 150mg/soft.cap (Nintedanib)		NintedanibOhبTiĿE?]RTK^MDTiĿE?]nRTK^plCNintedanibiUCRTKGpOlͤͪ]l]PDGFR^\P]BֺӭMͪ]l]FGFR^1-3Bޤ֥ͪ]l]VEGFR^1-3HΦFmsTiĿE?3]FLT3^C䤤Aswo{FGFRBPDGFRMVEGFRѻPIPFPfतCNintedanib|vʦalWz骺TCĸ?]ATP^XnWA_ӭMֺӭMW͡BಾPഫTǻIPFfzǭnL{A~Anintedanib|UCnRTKGLckBLynPSrcE?CFLT3MnRTK@ιIPFĪ^mפC 	"ĳq150@JA@Ѩ⦸Aj12pɡC󶺫AΡAftG]AC]DܭWAФũCZΫrHnCϥξqФŶWLĳ̤j龯q300@JC 
wX孷IfHubįqjĮɡAiϥΡD
fHϥNintedanibAwǥ\\णεǰIܭIfHypߺʴD"	󱵨OFEVveBe3ӤCӤ@BC3Ӥ@AH{ɦݭnɰx\ˬd(ˬdALTBASTPx@)CxŦï@צpGWɡAi঳nվ㾯qμȮɰġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XC HUC	Nintedanib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	vSoʪֺ(IPF)	L	mB߻PC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.7._20231201.pdf"">OI` 6.2.7.</a>              "	OI` 6.2.7.	0	OIs 20251124	OOFEV-a	OOFEV-b	OOFEV-c	114.12.16
AC48587221	L01CE02	0	IIRIN	ĵ Irican 20mg/ml;5ml/vial(Irinotecan)		"Irinotecan hydrochloride, a camptothecin derivative of topoisomerase 1 inhibitor class, prevents religation of single-strand breaks when it binds to topoisomerase 1-DNA complex. Its cytotoxic action is due to the damage in double-strand DNA when replication enzymes act on the formed ternary complex."	"Īv(wLƾǪvw)G
Irinotecanĳq350mg/m2AR߿`3090ACTgĤ@C
XĪv(LƾǪvw) G
HUCĤ覡AIrinotecanP5-fluorouracil(5-FU)Mfolinic acid(FA)֥ΪwʻPġG Irinotecan[5FU/FAACGgĤ@ 
Irinotecanĳq180mg/m2ACGgĤ@AR߿`30-90AM`folinic acidM5-fluorouracilC "	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W(preffer)
ĳ}nG250-500ml(0.6-20mg/ml)
ĳĳ~|tvGIVF 30-120min
ī~}~[GLܲH
L`NƶG 
1.iPIirnotecan liposomeϥ
2.ĶǡGCPT-11  Leucovorin  5-Fu"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Irinotecan	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	ߴʤjzzĤ@uvĪGP5-FUfolinic acidX֡AϥΩ󥼴LƾǪvw̡CWϥΩ󴿱5-FU{vLĤw̡C 	"1. CʵoʸzDef/θzC
2.  Irinotecan hydrochloride trihydrate Υ@إĪξYLӤfvC
3. hP¨ŴC 
4. x > 3 `dWȡC 
5. Y\IܡC
6. WHO બA > 2C 
7. Pt(St Johns Wort) ֥ΡC "	ʸmB߻PæRBC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-01j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.12.1._20040801_000.pdf"">OI` 9.12.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.12._20180801_000.pdf"">OI` 9.12.1.</a>             "	"OI` 9.12.,9.12.1."	0	OIs 20251124	IIRIN-a	IIRIN-b	IIRIN-c	110.6.16
BC22449219	L01CE01	0	IHYCA	ĵ Hycamtin 4mg/vial(Topotecan HCL)		Topotecanܸ~Fʥ]tݼc?I (]|bƻseeDNAᦱiOAӻPDNAƻsK@ػï)CTopotecangѨϻïΤ_DNA줧@ƦXFíwAӧݼc?IAӽƦXʤƾCTopotecanݼc?IӭMyvToJսDNAѤ_C 	"Z_ΤpӭMG
ĳqC1.5 mg/m2nAs5ѥHC30R߿`覡AU{j3gCY@ʨ}nAhDefcơAiivC
lcVG
ĳqC0.75 mg/m2A1B2M3ѨCѥH30R߿`覡ġCCisplatinb1topotecanīHR߿`覡C50 mg/m2qCC21ѭƦvɶA@i6{ΪefcƬC "	"tswwʡGN/A
}wwʡGN24h
ۮe}GGNSBD5W
ĳ}nG100ml
ĳĳ~|tvGIVF>30min
ī~}~[GL
L`NƶG"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 30XC HUiOsT?	Topotecan	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. Topotecan ΩvZ_ΤpӭMĤGuƾǪv(Ĥ@u]AժƦX)C
2. Topotecan P cisplatin ֥ξAΩvg´ˬdTwwIV-B_oʩΫʤlcVABAXH~N()gkivw̡C "	"TopotecanTΩƥHUΪfw
1. 䬡ʪΥξ㦳YLӯfvC
2. bũh̡C
3. b}l1{ewװΡAwqݤʥզy< 1.5 x 109/lM/ΦpOp< 100 x 109/lC "	"oʶݤʥզy֯gBݤʥզy֯gBpO֯gBhBզy֯gC
ߡBæRθm(Ţiର)BKBhHC
rYC
(iର)C "	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-03j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.16.1._20110601_000.pdf"">OI` 9.16.1.</a>              "	OI` 9.16.1.	0	OIs 20251124	IHYCA-a	IHYCA-b	IHYCA-c	110.6.16
	L01FD02	Pe	IPERJ1	ĵ Perjeta 420mg/14ml/vial(Pertuzumab)		"Pertuzumab @μЪH֥ͪ]lĤG(HER2)Jս誺ӭM~GE@ΰϰ(ϰII)A]_HER2 MLH֥ͪ]l(HER)aڦ(]AEGFR BHER3 HER4) t̿૬GEƧ@(ligand-dependent heterodimerization)C]Apertuzumab gѨӥDnT~|[ƳJս(Mitogen-activated protein, MAP)E?CĦپJ3 E?(phosphoinositide 3-kinase, PI3K)]
t黤oӭMTǻ(ligand-initiated intracellular signaling)CoǰTǻ|AO|ɭPӭMͪέ`C~Apertuzumab ]|ո`̿૬ӭMCӭMrʧ@(antibody-dependent cell-mediated cytotoxicity, ADCC)C
޳Wϥpertuzumab H~FӭMW pertuzumab Ptrastuzumab ֥ιHER2 Lת{زӼҫۼWjܸ~FʡC "	PERJETA _lq840mgAR߿`ɶ60AC3 g420mgAR߿`ɶ3060	"tswwʡGN/A
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVFG840mg:60minF420mg:30-60min
ī~}~[GL
L`NƶG
1.Do not administer as an IV push or bolus.
2.ĶǡG(Trastuzumab ? Pertuzumab) Docetaxel"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Pertuzumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	PERJETAPHerceptin docetaxel ֥Ωvಾ᥼HHER2 Τƾkv HER2 ಾʨfwC	 pertuzumab Υī~LLӪ̡C	mBrvBݤʥզy֯gBߡBh¡B֯lΩP䯫gfܡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-12 j	Ts110.6.16		OI` 	0	OIs 20251124	IPERJ1-a	IPERJ1-b	IPERJ1-c	110.6.16
KC009612B5	L01FD01	P	IHERC	ĵƼf Herceptin I.V.440mg/vial(Trastuzu		"1. TrastuzumabODNA]ջsHƳ(humanied monoclonal antibody)AܩʧC@ΦbӭM~HW֥ͪ]l2J(human epidermal growth factor receptor 2 proteinAHER2)FoO@IgG1AcWtH[cϰ(framework region)HθMwϰAYgXѹHER2(murine anti-p185 HER2 antibody)զC
2. b~(in vitro)ΰʪ礤Ao{trastuzumabiHHER2Lת{H~FӭMW͡Cb~礤APLHER2Lת{ӭMɡAgtrastuzumabո`̿૬ӭMCӭMrʧ@(antibody-dependent cellmediated cytotoxicityFADCC)|@ΦbHER2Lת{WӭMC"	"Loading dose4 mg/kg IV over 90 min, maintenance2 mg/kg IV over 30 min weekly, unapproved dosing8 mg/kg IV load, followed by 6 mg/kg IV over 90 minutes every 3 weeks in combination with paclitaxel 175 mg/m2  IV over 3 hours; normal premedications are administered"	"tswwʡG28 days(Mε}G)
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVF:Initial:90minFMax:30min
ī~}~[GL
L`NƶG
1.Do not administer as an IV push or bolus.
2.Do not dilute with D5W.
3.Do NOT substitute Herceptin for Kadcyla.
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	HerceptinϥΩUCHER2Lת{HER2]amplificationw̡J1.ಾʨ:(1).WϥΩ󴿱L@]t^HWƾǪvಾʨfHC(2).XPaclitaxelDocetaxelϥΩ󥼴LƾǪvಾʨfHC2.JHerceptin AΩ@gL~NBƾk(NeUvλUv)vᤧHER2Lת{w̪vġC	TϥΩw|trastuzumabβ~󦨤LӤfHC	h¡BoNBNŸB߹æRBy¡B֯l	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.18._20250501.pdf"">OI` 9.18.</a>              "	OI` 9.18.	0	OIs 20251124	IHERC-a	IHERC-b	IHERC-c	110.6.16
KC00949255		P	IKAD	ĵKADCYLA 100mg/vial (Trastuzumab Emta		Trastuzumab emtansine Ow HER2 ĪƦXCOH HER2 IgG1 (trastuzumab)CplӭMr DM1 OLާCX HER2 骺 IV pϫA trastuzumab emtansine }lH鬰Ci椺ơA᪺?魰ѹL{ӭMt DM1 ӭMrʥNªCDM1 XL޳J(tubulin)L{|}aӭML޺AɭPӭMPPӭM`C~A~ܡAtrastuzumab emtansine P trastuzumab A]| HER2 Tǻ\Aް_̿ʲӭMCӭMrʡAç HER2 Lת{HӭM HER2 M~ϲ渨C 	KADCYLA ĳq 3.6 mg/kgAC 3 g( 21 ѪP)R߿`@AfcƩΥX{LkrʬCФŬI 3.6 mg/kg  KADCYLA qC	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVF:Initial:90minFMax:30min
ī~}~[GL
L`NƶG
1.Administer through a 0.22? in-line filter.
2.iϥθ}(5%)GA]|ɭPJս辮
3.ФťHKADCYLA NTrastuzumab ΥHTrastuzumab NKADCYLA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab emtansine	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	KadcylaWϥήɯvHER2ʡBeOLtrastuzumabP@taxaneĪvΨXkಾʨfwC]fwŦXUCGewgLಾgvAΦbUkvΧv6Ӥ뤺g_oC^	L	i঳KBYhBf٦ׯkhBߡBhªΡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-22 j	Ts110.7.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.87._20250501.pdf"">OI` 9.87.</a>              "	OI` 9.87.	0	OIs 20251124	IKAD-a	IKAD-b	IKAD-c	110.7.20
KC009492AX		P	IKAD1	ĵKADCYLA 160mg/vial (Trastuzumab Emta		Trastuzumab emtansine Ow HER2 ĪƦXCOH HER2 IgG1 (trastuzumab)CplӭMr DM1 OLާCX HER2 骺 IV pϫA trastuzumab emtansine }lH鬰Ci椺ơA᪺?魰ѹL{ӭMt DM1 ӭMrʥNªCDM1 XL޳J(tubulin)L{|}aӭML޺AɭPӭMPPӭM`C~A~ܡAtrastuzumab emtansine P trastuzumab A]| HER2 Tǻ\Aް_̿ʲӭMCӭMrʡAç HER2 Lת{HӭM HER2 M~ϲ渨C 	KADCYLA ĳq 3.6 mg/kgAC 3 g( 21 ѪP)R߿`@AfcƩΥX{LkrʬCФŬI 3.6 mg/kg  KADCYLA qC	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVF:Initial:90minFMax:30min
ī~}~[GL
L`NƶG
1.Administer through a 0.22? in-line filter.
2.iϥθ}(5%)GA]|ɭPJս辮
3.ФťHKADCYLA NTrastuzumab ΥHTrastuzumab NKADCYLA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab emtansine	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	KadcylaWϥήɯvHER2ʡBeOLtrastuzumabP@taxaneĪvΨXkಾʨfwC]fwŦXUCGewgLಾgvAΦbUkvΧv6Ӥ뤺g_oC^	L	i঳KBYhBf٦ׯkhBߡBhªΡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-23 j	Ts110.7.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.87._20250501.pdf"">OI` 9.87.</a>              "	OI` 9.87.	0	OIs 20251124	IKAD1-a	IKAD1-b	IKAD1-c	110.7.20
BC26032100	L01EB03	0	OGIOT	ĵ Giotrif 30mg/F.C.tab(Afatinib)		"Afatinib@jOBܩʡBifErbB _CAfatinib|PErbB 馨EGFR]ErbB1^BHER2]ErbB2^ErbB4ҧΦҦPGE]homodimers^βGE
]heterodimers^Φ@䵲AiӤifa_oǤGE骺TǻC
ѦpEGFRܤ/ΩjBHER2 jB/ErbB tLת{yErbB Tǻ`Ahgw̤Pcʸ~F{]@C
bErbB|ա]deregulation^{ɫeefҫAafatinib@kYiĦa_ErbB骺TǻAiӧ~FͪAΨϸ~FhC㦳L858RDel19 EGFRܪNSCLCӭMafatinibvSOӷPCbNSCLCӭM]~^HΥѬܺEGFRP\?]]AwEGFRerlotinib gefitinibĩʪ̡AҦpT790M^Xʪ~Fҫ]餺sAزөΰ]޼ҫ^AafatinibO۪ܸ~FʡC "	"@Ĥ@uvAYΩeEGFR-TiĿE?]EGFR-TKI^vfwɡAGIOTRIFĳq40mgfAA@Ѥ@CGIOTRIFiPPɪAΡCibAGIOTRIFeܤ3pɤPܤ1pɤiCtH}ɧ]AC
YLk]Aɿ
iNGIOTRIFJ100mLΤ]Dһ^YAiϥΨLGCNJAnHAͩժYpɡ]15^AߧYܤUGAAH100mLR~MtóܤUCG]iλGC "	"1. pGX{IlxBIlPBLky»PoNAкɧִMDUC
2. bAGIOTRIF(afatinib)nwx\AOpGX{ֽβճX{xCBPıD`hΡB`ί⪺GAХߧYMDUC
3. ˤbqBjLΨधbMIeUA~ihŤέŴϥafatinibC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~JsǷ30JHUC	Afatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	GIOTRIFAΩ㦳EGFR-TKܤߴಾʤDpӭM]NSCLC^w̤Ĥ@uvC	TΩwafatinibΥ~LLӪfwC 	mBæRBIlxBh¡BC[B⨬gԸs	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-01 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.45._20240601.pdf"">OI` 9.45.</a>              "	OI` 9.45.	0	OIs 20251124	OGIOT-a	OGIOT-b	OGIOT-c	111.8.19
BC27770100	L01EB07	ͪY	OVIZI	ĵVIZIMPRO FC 30mg(Dacomitinib)		Dacomitinib O@إH֥ͪ]ƨ(HER) (EGFR/HER1BHER2MHER4) AX֧ܬEGFR~[~l19 ʥΥ~l21 L858R m@ΡCDacomitinib ܩʥBifaXܨHERaڼйvAHѧɶC	"b}lidacomitinib keT{EGFRܪA
ĳqC@fA45 @JCAefcƩΥX{LkrʬC
iHΪŸAΡCקKPɨ֥βBl]PPI^PdacomitinibCiϥΧ@ΫľNPPIAέYO
ϥβ´i2 ]H2^̡ܾAbAH2 ܾeܤ2 pɩΨϥΫ10 pɡAAAdacomitinibC"	"1.Vizimpro vfHiX{iPRILD / ͪ
ҦoͫʩεLkͳg( pIlxBy¡BoN)cƪfHiJӪHưILD /ͪCȰdacomitinibvݳoǯgˬdCYTEILD / ͪAä[dacomitinibõݭnإ߾Av
2.m
bVizimpro vX{miD``A]A׸m
bX{mx( SOOb}ldacomitinib veg)AwʳBmA]t֥Χܸmī~AB
}nK12 pɬCϥΧܸmī~( ploperamide )ABnɼW[̰ܳĳ֭㾯qCfHiݭn_Ĥ/ έCdacomitinib qCfHBfHiݭnR߿GPqѽ
3.ֽ}
Vizimpro vfHiX{֯lBM鸨ʥֽp
4.xrʻP?W
Vizimpro vfHiX{?W( i?(ALT)BѥVi?(AST)B?)
ĳwx\CpfHbϥdacomitinib Y?WɡA_"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30 ?CHUC	Dacomitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"@kAAΩaEGFRܤߴಾʫDpӭM(NSCLC) HfHĤ@uvC
GVizimproaexon 19 deletionexon 21 L858R substitutionH~EGFRܤߴಾʫDpӭMfHĦwʩ|إ"	wﬡʦΥξLӪ̡C	"dacomitinib fH̱`(> 20%) }m(88.6%)B֯l(79.2%)BfĪ(71.8%)BҲ`(65.5%)Bֽ(33.3%)BC(31.8%)B(24.7%)B魫(24.3%)Bv(23.1%)Bkog(22.4%)B?W(22.0%) M(20.4%)C
dacomitinib vfH̱`( ? 1%) iY}m(2.0%)Bʪͯf(1.2%)B֯l(1.2%) M(1.2%)C"	"̾ڨ@ξA便뤩dacomitinib iLyˮ`Cbhɨϥ dacomitinibCibhɨϥdacomitinib
ΦbϥdacomitinibhkʯfHL઺bM`C"	ĳ˦bī~ɤn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2L-03 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.83._20240601.pdf"">OI` 9.83.</a>              "	OI` 9.83.	0	OIs 20251124	OVIZI-a	OVIZI-b	OVIZI-c	111.8.19
BC27769100	L01EB07	ͪY	OVIZI1	ĵ15mg vIZImpro FC(Dacomitinib)		Dacomitinib O@إH֥ͪ]ƨ(HER) (EGFR/HER1BHER2MHER4) AX֧ܬEGFR~[~l19 ʥΥ~l21 L858R m@ΡCDacomitinib ܩʥBifaXܨHERaڼйvAHѧɶC	"b}lidacomitinib keT{EGFRܪA
ĳqC@fA45 @JCAefcƩΥX{LkrʬC
iHΪŸAΡCקKPɨ֥βBl]PPI^PdacomitinibCiϥΧ@ΫľNPPIAέYO
ϥβ´i2 ]H2^̡ܾAbAH2 ܾeܤ2 pɩΨϥΫ10 pɡAAAdacomitinibC"	"1.Vizimpro vfHiX{iPRILD / ͪ
ҦoͫʩεLkͳg( pIlxBy¡BoN)cƪfHiJӪHưILD /ͪCȰdacomitinibvݳoǯgˬdCYTEILD / ͪAä[dacomitinibõݭnإ߾Av
2.m
bVizimpro vX{miD``A]A׸m
bX{mx( SOOb}ldacomitinib veg)AwʳBmA]t֥Χܸmī~AB
}nK12 pɬCϥΧܸmī~( ploperamide )ABnɼW[̰ܳĳ֭㾯qCfHiݭn_Ĥ/ έCdacomitinib qCfHBfHiݭnR߿GPqѽ
3.ֽ}
Vizimpro vfHiX{֯lBM鸨ʥֽp
4.xrʻP?W
Vizimpro vfHiX{?W( i?(ALT)BѥVi?(AST)B?)
ĳwx\CpfHbϥdacomitinib Y?WɡA_"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30 ?CHUC	Dacomitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"@kAAΩaEGFRܤߴಾʫDpӭM(NSCLC) HfHĤ@uvC
GVizimproaexon 19 deletionexon 21 L858R substitutionH~EGFRܤߴಾʫDpӭMfHĦwʩ|إ"	wﬡʦΥξLӪ̡C	"dacomitinib fH̱`(> 20%) }m(88.6%)B֯l(79.2%)BfĪ(71.8%)BҲ`(65.5%)Bֽ(33.3%)BC(31.8%)B(24.7%)B魫(24.3%)Bv(23.1%)Bkog(22.4%)B?W(22.0%) M(20.4%)C
dacomitinib vfH̱`( ? 1%) iY}m(2.0%)Bʪͯf(1.2%)B֯l(1.2%) M(1.2%)C"	"̾ڨ@ξA便뤩dacomitinib iLyˮ`Cbhɨϥ dacomitinibCibhɨϥdacomitinib
ΦbϥdacomitinibhkʯfHL઺bM`C"	ĳ˦bī~ɤn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2L-02 j	Ts111.9.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.83._20240601.pdf"">OI` 9.83.</a>              "	OI` 9.83.	0	OIs 20251124	OVIZI1-a	OVIZI1-b	OVIZI1-c	111.9.19
BC27771100	L01EB07	ͪY	OVIZI2	ĵ45MG VIZIMPRO FC (DACOMITINIB)ͤߧ		Dacomitinib O@إH֥ͪ]ƨ(HER) (EGFR/HER1BHER2MHER4) AX֧ܬEGFR~[~l19 ʥΥ~l21 L858R m@ΡCDacomitinib ܩʥBifaXܨHERaڼйvAHѧɶC	"b}lidacomitinib keT{EGFRܪA
ĳqC@fA45 @JCAefcƩΥX{LkrʬC
iHΪŸAΡCקKPɨ֥βBl]PPI^PdacomitinibCiϥΧ@ΫľNPPIAέYO
ϥβ´i2 ]H2^̡ܾAbAH2 ܾeܤ2 pɩΨϥΫ10 pɡAAAdacomitinibC"	"1.Vizimpro vfHiX{iPRILD / ͪ
ҦoͫʩεLkͳg( pIlxBy¡BoN)cƪfHiJӪHưILD /ͪCȰdacomitinibvݳoǯgˬdCYTEILD / ͪAä[dacomitinibõݭnإ߾Av
2.m
bVizimpro vX{miD``A]A׸m
bX{mx( SOOb}ldacomitinib veg)AwʳBmA]t֥Χܸmī~AB
}nK12 pɬCϥΧܸmī~( ploperamide )ABnɼW[̰ܳĳ֭㾯qCfHiݭn_Ĥ/ έCdacomitinib qCfHBfHiݭnR߿GPqѽ
3.ֽ}
Vizimpro vfHiX{֯lBM鸨ʥֽp
4.xrʻP?W
Vizimpro vfHiX{?W( i?(ALT)BѥVi?(AST)B?)
ĳwx\CpfHbϥdacomitinib Y?WɡA_"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30 ?CHUC	Dacomitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"@kAAΩaEGFRܤߴಾʫDpӭM(NSCLC) HfHĤ@uvC
GVizimproaexon 19 deletionexon 21 L858R substitutionH~EGFRܤߴಾʫDpӭMfHĦwʩ|إ"	wﬡʦΥξLӪ̡C	"dacomitinib fH̱`(> 20%) }m(88.6%)B֯l(79.2%)BfĪ(71.8%)BҲ`(65.5%)Bֽ(33.3%)BC(31.8%)B(24.7%)B魫(24.3%)Bv(23.1%)Bkog(22.4%)B?W(22.0%) M(20.4%)C
dacomitinib vfH̱`( ? 1%) iY}m(2.0%)Bʪͯf(1.2%)B֯l(1.2%) M(1.2%)C"	"̾ڨ@ξA便뤩dacomitinib iLyˮ`Cbhɨϥ dacomitinibCibhɨϥdacomitinib
ΦbϥdacomitinibhkʯfHL઺bM`C"	ĳ˦bī~ɤn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.83._20240601.pdf"">OI` 9.83.</a>              "	OI` 9.83.		OIs 20251124	DC	DC	DC	114.11.27
KC00877238	L01FE01	0	IERBI1	ĵƼf Erbitux 5mg/ml;20ml/vial(Cetuxima		֥ͪ]l(Epidermal Growth Factor Receptor)OPӭMsBӭMgܤơBޥͦBӭMʩMӭMIJ/ಾT~|@lCCetuximabO@تܪ֥ͪ]l骺OX(chimeric)IgG1C骺˩MO񤺥ͩʳs(Ligand)510A]ӥiH_骺\C໤o֥ͪ]l骺bƧ@(internalization)Ai]ӳy֥ͪ]l骺tVձ(down-regulation)CCetuximab]i@ΩӭMrʧK̮ӭMӹ墨Ǩ㦳֥ͪ]l~FӭMͧ@(̿૬ӭMCӭMrʧ@(antibody dependent cell-mediated cytotoxicity))C 	"Colorectal cancer / head and neck cancer, initial dose X 400 mg/m2 infused over 120 minutes , maintenance doseX 250 mg/m2 infused over 60 minutes weekly."	"tswwʡGN/A
}wwʡGN24h
ۮe}GGG
ĳ}nGN/A
ĳĳ~|tvGIVF 120min ->60min
ī~}~[GL
L`NƶGϥΥ~eiLӸARߪ`g~20mgA[10HWAGeʪw̷VΡAʵGä৹ưYLӤo͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Cetuximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	1.Erbitux P irinotecanX֨ϥΡAvgtirinotecan ӭMrʪvѥB㦳֥ͪ]l{ಾʪzzfwC2.ErbituxPgukX֨ϥΡAvߴf|BU|γw̡C3.ErbituxPtplatinumƾkX֨ϥΡAv_o/ಾYV쪬ӭMw̡C	ErbituxTΩwcetuximabYLӤfw	Cetuximaḇ`Ƨ@Φbϯg譱ΪA(Malaise)BoNBYhFbֽ譱ڵHˬl]acneform rashF90%A10%YA^AӶ|cƥֽgAҥHAĴqקKSbӶUFLƧ@ΦpGzABߡBæRBIlxBh¡K.C	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.27._20240601.pdf"">OI` 9.27.</a>              "	OI` 9.27.	0	OIs 20251124	IERBI1-a	IERBI1-b	IERBI1-c	110.6.16
BC27731100	L01ED04	ದ	OALUN2	fĵAlunbrig 90mg/Tab (Brigatinib)		Brigatinib O@ؿE?CBrigatinib iALK CĤơAHΥALK ո`UTǻJսSTAT3BAKTBERK1/2 MS6 CĤơCBrigatinib ]i~{XEML4-ALK PNPM-ALK ĦXJդӭM誺W͡ABbp礤ܹEML4-ALK NSCLC زӥͪ㦳q̿ʪ@ΡC	"ھڸ~FO_e{ALKʡAܥiALUNBRIGvߴDpӭMfHC
e 7 ѤfA90 mgA@Ѥ@FYbe7 ѥi@90 mgAhW[qfA180 mgA@Ѥ@C򵹤ܯefcƩεo͵LkrʡC
󭫫רx\णfH (Child-Pugh C )AALUNBRIG @Ѥ@qC 40% (Y 180 mg  120 mgA120 mg  90 mgA90 mg  60 mg)
󭫫׵ǥ\णfH [ Cockcroft-Gault p⪺ٻMv (CLcr)  15  29 mL/min]AALUNBRIG @Ѥ@qC 50% (Y 180 mg  90 mg  90 mg  60 mg)"	"ܯfH]AĿCФſiHΩCZĿC
]34ILD/DPVʪͪä[ALUNBRIGC
ʴfHO_X{sIlDgέ즳gc (ҦpIlxByµ)AרObvĤ@gCfHYX{IlDgcơAߧYլdO_DPVʪͪCYæDPVʪͪAȰI AlunbrigAõO_Lް_g] (ҦpͮB~FcơBPVʪͪ)Aݭnվ㾯qC
Alunbrig vwʴAYY (?  3 )AȰI AlunbrigA찪_ܲ 1 ũΰ¦ȡAݭnվ㾯qC
Alunbrig ֥ΨLw|ɭP߷iLwĪɡASOԷVAwʴ߸tvMC
 Alunbrig vfHo͵Oê}C
 Alunbrig vfHo CPK ɰCifHAX{󤣩]٦׵hBĲhεLOANCAlunbrig vwʴ CPK @סA CPK ɰY{פάO_P٦ׯkhεLOAȰI Alunbrig vAþAվ㾯qC
ŦïɰA Alunbrig vfHo;?Mת?ɰC
 Alunbrig vfHoͨxŦï (ѪVii?Bii?) MxɰC}lϥ Alunbrig ex\ (]A ASTBALTB`x)AB}lv 3 Ӥ뤺ACj 2 g@Aᤴwʴ
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os30XC HUC	brigatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		AΩbcrizotinibvcƩεLk@ALKʪߴDpӭM(NSCLC)fHC	LC	ѪVii? (AST) ɰBٻCĿE? (CPK)ɰB}Bת?ɰBخqgBmBii? (ALT) ɰB?ɰBhBߡB«BCCBOڲypƴ֡By¡BPC?ɰB֯lBƳ嬡?ɶ (APTT) W[BٵhBYhBBզypƴ֡BIlxMæRC	ALUNBRIG |ɭPLl Aĳ㦳ͨ|OkʦbALUNBRIGvP̫@ܤ4 Ӥ뤺ϥΦĪDXץI	ѩiŤް_}AĳŤkʦbALUNBRIG vM̫@1 gšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6479810?cesid=0JawugAWAp8&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBRIGATINIB%26t%3Dname%26acs%3Dfalse%26acq%3DBRIGATINIB"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.01.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.82._20240601.pdf"">OI` 9.82.</a>              "	OI` 9.82.	0	OIs 20251124	DC	DC	DC	114.01.20
BC25938100	L01ED01	IgF	OXALK	fXALKORI 250MG (crizotinib)		"CrizotinibO@ذwALKTiĿE?(RTK)ΨPܺ(pALKĦXƥPSwALKܺ)ܩʤplCCrizotinib]O@بxӭMͪ]l(HGFR, c-Met) RTKAHRecepteur dOrigine Nantais (RON) RTKCͤƤRcrizotinib|ALKPc-MetE?ʲͨ@ר̿ʪ@ΡAӭMR]crizotinib|CĤƧ@Τνո`E?̿ʪ{CCrizotinib|ͱjĥBܩʪͪ@ΡAûϪ{ALKĦXƥ(]AEML4-ALKPNPM-ALK)ALKMET]mj~FӭMoͲӭM`CCrizotiniba{XALKĦXJդزӸ~F´piܸͧ~FġA]A۪ӭMqʧܸ~FʡCscrizotinibܸ~FĨ㦳q̿ʡAåBM~FALKĦXJ(]AEML4-ALKPNPM-ALK)CĤƧ@ΩҲͪĮľǧ@ΦC "	XALKORIĳq{250@JC⦸(C500@J)sAΡC 	"1.XALKORIrpξާ@񤧯OȦLvTCMӡAѩw̦bϥXALKORIi|o͵ıewBwtίhµA]b}ξާ@ԷVC 
2.קKθcθcġA]i|ɰcrizotinib夤@סFקKϥθtA]i|Ccrizotinib夤@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~ݥSJsC	Crizotinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	v@اt`B褧ALKʪߴDpӭMw̡Cvegå͸p֭㤧覡oALKʡC 	"1.crizotinibLӡC
2.רx\ण"	̬`󵥯Ū} (>20%)ıêBߡBmBæRB~BKBHίh¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-06 j	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.50._20240601.pdf"">OI` 9.50.</a>              "	OI` 9.50.	0	OIs 20251124	OXALK-a	02C25938-1	02C25938-2	
KC00807219	L01FG01	@	IAVAS	ĵ Avastin 100mg/4ml/vial(Bevacizumab)		"Avastin (bevacizumab)O@حժHƳAiܩʦaXܤHޤ֥ͪ]l(VEGF)äMͪʡCBevacizumabtH[c(framework regions)ΥiPVEGFXHƹWܭ쵲X(antigen binding regions)CBevacizumabOQΰ]է޳NAѤܹZ_ŲӭM{tΦbtܥͯgentamicinii򤤲͡AøgLSwfrhƤΥhBJ¤ƹL{CGentamicinb̲ײio@?0.35ppmCBevacizumab214ӮĩҲզAlq149,000 daltonsC
Avastin|VEGFP󤺥ֲӭMWFlt-1KDRXAMVEGFͪʦӭC~FާΦAǦ~FͪCѿwgrزgҦb뤩bevacizumabΨvGioHg]AjzBBŦΫeCgsxܸ~FʡAಾʯefiQBLުqzʥ筰CC
"	"ಾʤjzz(mCRC) G
AvastinĳqAHR߿`pUGĤ@uvG5@J/(魫)ACg@CDĤ@uvG10@J/(魫)ACg@F15@J/(魫)ACTg@CĳHAvastinvܼbefoʹcƬC
ಾʨ(mBC) G
AvastinĳqOR߿`10@J/(魫)ACg@CĳHAvastinvܼbefoʹcƬC
cʯgF(WHO4) - gӭMF G
AvastinĳqOR߿`10@J/(魫)ACg@F15@J/(魫)ACTg@CĳHAvastinvܼbefoʹcƬC
ߴBಾʩδ_oʫD쪬DpӭM(NSCLC) G
AvastinPcarboplatinpaclitaxelX֨ϥΤӪvgA۳WϥAvastin vAefcƬCPcarboplatinpaclitaxelX֨ϥήɡAAvastinĳqR߿`15@J/ (魫)ACTg@C "	"tswwʡGN/A
}wwʡGN24h
ۮe}GGNS
ĳ}nG100-250ml
ĳĳ~|tvGIVF 90min-60min-30min
ī~}~[GL
L`NƶG
1.?iP}G(D5W)VXΦPɨϥ()
2.??????? o͸zGϥAvastin
3.??????? N28ѥBˤf¡XA}lϥAvastinC
4. YXγ̪񴿵oͫy̡AiPC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Bevacizumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"ಾʤjzz(mCRC)G
Avastin (bevacizumab)Ptirinotecan/5-fluorouracil/ leucovorin5-fluorouracil/leucovorin ƾkX֨ϥΡAiH@ಾʤjzΪzw̪Ĥ@uvC
AvastinPt5-fluorouracil/leucovorin/oxaliplatinƾkX֨ϥΡAiH@eLHfluoropyrimidine¦ƾkLĥBLAvastinvಾʤjzΪzw̪vC
ಾʨ(mBC)G
AvastinPpaclitaxelX֨ϥΡAiHHER2 (-) ಾʨw̪Ĥ@uvC
G
1. AvastinPpaclitaxel֥Φbvಾʨw̤ġAȦbLefiis譱iFέpWupaclitaxelWϥΡAثeõLHsDnīФ{ɸҹAvastinPpaclitaxel֥ΩsĪGC
2. AvastinAΩganthracyclinetaxanevಾʨSX{efiifwC
cʯgF(WHO4) - gӭMFG
AvastinWϥΥiΩvзǩguvBtTemozolomide bƾĪvѤhʯgӭMF(Glioblastoma multiforme)_oHw̡C
ߴBಾʩδ_oʫD쪬DpӭM(NSCLC)G
AvastinPcarboplatinpaclitaxelX֨ϥΡAiH@LkߴBಾʩδ_oʫD쪬DpӭMw̪Ĥ@uvC"	"w|UCFLӪw̸TϥAvastinG
?~󦨥C
?ܹZ_ӭMsΨL]դHΤHƪC "	GzաAXAʯ߮CAKAXAAkhCJէARʤŦIܡC 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.7._20250501.pdf"">OI` 14.9.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.37._20251001.pdf"">OI` 9.37.</a>             "	"OI` 14.9.7.,9.37."	0	OIs 20251124	IAVAS-a	IAVAS-b	IAVAS-c	110.6.16
BC24593100	L01EX01	0	OSUTE	ĵƼf Sutent 12.5mg/cap(Sunitinib)		SUNITINIBO@دhعTĿE?骺plƦXA䤤@ǨP~FͪBfzʦޥͦMgಾAiHqLޤ֥ͪ]lBpOlͥͪ]lBzӭM]lBFms-˹TĿE?-3BE]lIMgӭMtlͯgi]l骺TĿE?骺ʡA_~FӭMͪGMiAqӲͧܦޥͦMܸ~F@ΡA~ASutent٥iH˸~FӭMC 	C4ɡA@A4ɡAA1{ݰ[2P~AΡC@{6PC 	"suntinibWĦwʬDC󥥰Mǳh̡AݭnisuntinibFLo|isbbM`CAĴŰkyȰšC
WgGfHϥVEGF|ī~oͰʯ߽F(t})M/ΰʯ߭רҳiA}lϥΫefVҶqfHO_I]l(p:ΰʯ߽Ffv)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Sunitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Sutent AΩimatinib mesylatevX{efcƩιĥX{ԨzGD~FFvߴಾʵǲӭM	suntinibΪī~LLӪ̸TΡC	hҡBmBhBߡBGBæRBhCnɥiAmĩΤRġC1/3fH|X{ֽܦC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_7-08 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.31._20211201.pdf"">OI` 9.31.</a>              "	OI` 9.31.	0	OIs 20251124	OSUTE-a	OSUTE-b	OSUTE-c	111.8.19
KC010222FY	L01FA01	0	IMAB	ĵ Mabthera S.C inj.120mg/ml;11.7ml/vi		RituximabPbBOڲӭMWCD20ܭ쵲XABҰʧK̤AHPBӭMѡCӭMѪi]A̿઺ӭMr@(CDC)Χ̿઺ӭMr@(ADCC)HλɲӭM`(apoptosis)C̫A~sܡArituximabiϹ靈ǤƾǪvӭMr@βͧĩʪHBӭMOڽFܱӷPC	"CcשowʫDNOڽF
_lv֤U`gXCVPCHOPvϥMabThera SCɾbUg0ѩβ1ѡCpG]A}ֽ(glucocorticoids)AӦb䤧IC MabThera IV (R-IV)֥CVPCHOPĳq375@J/褽n(Ĥ@gRߪ`g)AiHHMabThera SC (R-SC) 1400@JTwq(n)i֤U`gC
v
evw̭YﻤɪvAiC2Ӥ@MabThera SC 1400@JTwqvAefcƩγ̪~(@12`g)Cw_o/xTʪw̡AbﻤkĤAYiϥMabThera SCvġAΪkC3Ӥ뤩@1400@JTwqAX{fcƪ{HAΦ̪ܳ~v(@8`g)C 
jʤjBӭMDNOڽF
jʤjBӭMDNOڽFw̡AMabThera SC 1400@JPCHOP (cyclophosphamideBdoxorubicinBprednisonePvincristine)ƾkX֨ϥΡC
MabThera SCĳq1400@JTwqAױw̪nAUgĤ@Rߧ뤩CHOP}ֽ(glucocorticoids)ᵹġA@p8Ӷg(1gR-IVPCHOP+ 7ӶgR-SCPCHOPA@8Ӷg) (CӶg21)C"	"tswwʡGN/A
}wwʡGǷ8hAN48h
ۮe}GGN/A
ĳ}nGN/A
ĳĳ~|tvGSC 5min at abdomen
ī~}~[GL
L`NƶG 1. H֤U`g覡NMabThera SC`JAiIΩ~BBĲhΰwֽAάOiάͲCثeõL`gL쪺ơAG`g]󸡾C
2. MabThera SCvAYL֤U`gĪvA̦nbP`giC
3. MabThera SC 1400 mg`gɶ5C 
4. Y@vQ_Aisi`gΧ󴫦ܨL`gC 
5. Ҧw̪Ĥ@FH`g(MabThera IV)Rߤ覡뤩A֤U`g(MabThera SC)bĤGΥH᪺gIΡC 
6. F֤U`g1400@JȥiΩvDNOڽFC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Rituximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"_oιƾkܩʤCcB-ӭMDNOڽFC

֥CVPƾkΩ󥼸gvMw(´Aow)BӭMDNOڽFfHC

֥CHOPΨLƾkΩCD20ܭ춧ʤjʤjBӭMDNOڽFC

Ω󰵬owʲOڽFw̹ﻤk᪺ͤvġCPmethotrexate֥ΡAAΩv@(t)HW~Fa]l(TNF)kvĪGAεLk@ʩ`Hw̡C

AΩPfludarabinecyclophosphamide֥ΡACD20ʺCʲOڲyʥզf(CLL)w̪Ĥ@uġC

AΩPƾk֥ΡA_o/xTʪCD20ʺCʲOڲyʥզffwvġCת޸~ʦު(GPA)(Wegenersת޸~g)λP}ֽ(glucocorticoids)֥ΡAAΩvHת޸~ʦު(GPAA٬Ǧת޸~g)Lhoʦު(MPA)

"	writuximabΦ~ξιJսLӪw̸TβF(MabThera)C  	̱`ֽ`gB`gkhΪ`g~C  	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-26 j	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.7._20210616.pdf"">OI` 8.2.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.20._20241201.pdf"">OI` 9.20.</a>             "	"OI` 8.2.7.,9.20."	0	OIs 20251124	IMAB-a	IMAB-b	IMAB-c	111.8.23
KC00928229		0	IMAB1	ĵƼf Mabthera 100mg/10ml(Rituximab)		RituximabPbBOڲӭMWCD20ܭ쵲XABҰʧK̤AHձB-ӭMѡCӭMѪi]A̿ӭMr@(CDC)Χ̿ӭMr@(ADCC)C̫Ab~swҩARituximab靈ǤƾǪvͧĩʪB-ӭMOڽFӷPC	зǾqG~fwϥMabthera@kɡAĳq375 mg/T	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGĤ@IVF:50mg/hr,iW[ܤWL400mg/hr
ī~}~[GL
L`NƶG1.Do not administer as an IV push or bolus.
2.Should give premedications:Antihistamine(Diphenhydramine)BGlucocorticoids and Antipyretic(Acetaminophen)."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Rituximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Ω_oιƾkܩʤCcB-ӭMDNOڽFC֥CHOPΨLƾkΩCD20ܭ춧ʤBjʤjӭMDNOڽF60HWfwC	writuximabB~󦨤ιJսLӪfHTΥ~C	"jfHoR߿`}]AӭMEXgԸsABDnbĤ@`ɡAq`b}l12pɶCoǨƥDn]AoNBNŸMHŸCLg]AyBޤ~BߡBC¯l/XlBhҡBYhBkoBIlxB|EB󪢡BæRBM~FkhCbj10%oǮרҤAoǯg|HۧCM޵jˡC֨fHg즳ŦppߵhΥRʤŦIܪcơC
"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.7._20210616.pdf"">OI` 8.2.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.20._20241201.pdf"">OI` 9.20.</a>             "	"OI` 8.2.7.,9.20."	0	OIs 20251124	IMAB1-a	IMAB1-b	IMAB1-c	111.8.23
KC00928248		0	IMAB5	ĵƼf MABTHERA 500mg/50ml(Rituximab)		RituximabPbBOڲӭMWCD20ܭ쵲XABҰʧK̤AHձB-ӭMѡCӭMѪi]A̿ӭMr@(CDC)Χ̿ӭMr@(ADCC)C̫Ab~swҩARituximab靈ǤƾǪvͧĩʪB-ӭMOڽFӷPC	зǾqG~fwϥMabthera@kɡAĳq375 mg/T	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGĤ@IVF:50mg/hr,iW[ܤWL400mg/hr
ī~}~[GL
L`NƶG1.Do not administer as an IV push or bolus.
2.Should give premedications:Antihistamine(Diphenhydramine)BGlucocorticoids and Antipyretic(Acetaminophen)."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Rituximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Ω_oιƾkܩʤCcB-ӭMDNOڽFC֥CHOPΨLƾkΩCD20ܭ춧ʤBjʤjӭMDNOڽF60HWfwC	writuximabB~󦨤ιJսLӪfHTΥ~C	"jfHoR߿`}]AӭMEXgԸsABDnbĤ@`ɡAq`b}l12pɶCoǨƥDn]AoNBNŸMHŸCLg]AyBޤ~BߡBC¯l/XlBhҡBYhBkoBIlxB|EB󪢡BæRBM~FkhCbj10%oǮרҤAoǯg|HۧCM޵jˡC֨fHg즳ŦppߵhΥRʤŦIܪcơC
"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.7._20210616.pdf"">OI` 8.2.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.20._20241201.pdf"">OI` 9.20.</a>             "	"OI` 8.2.7.,9.20."	0	OIs 20251124	IMAB5-a	IMAB5-b	IMAB5-c	111.8.23
KC01094229	L01FA01	Qƺ `g	ITRUX	ĵƼf truxima 100mg/10ml(Rituximab)		RituximabPbBOڲӭMWCD20ܭ쵲XABҰʧK̤AHձB-ӭMѡCӭMѪi]A̿ӭMr@(CDC)Χ̿ӭMr@(ADCC)C̫Ab~swҩARituximab靈ǤƾǪvͧĩʪB-ӭMOڽFӷPC	"1. зǾqG~fwϥMabthera@kɡAĳq375 mg/TnCzLM@`ޡAR߿`MabtheraCg@@4C
2. @wHRߪ`g(i.v. injection)Τjq`(bolus infusion)覡Atsn`GC`MabtheraɡAbiߧYϥΡBUd]ƪ|ҤUMbg窺~Fv/GvYKʴU`C"	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGĤ@IVF:50mg/hr,iW[ܤWL400mg/hr
ī~}~[GL
L`NƶG1.Do not administer as an IV push or bolus.
2.Should give premedications:Antihistamine(Diphenhydramine)BGlucocorticoids and Antipyretic(Acetaminophen)."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC 	Rituximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Ω_oιƾkܩʤCcB-ӭMDNOڽFC֥CHOPΨLƾkΩCD20ܭ춧ʤBjʤjӭMDNOڽF60HWfwC	writuximabB~󦨤ιJսLӪfHTΥ~C	jfHoR߿`}]AӭMEXgԸsABDnbĤ@`ɡAq`b}l12pɶCoǨƥDn]AoNBNŸMHŸCLg]AyBޤ~BߡBC¯l/XlBhҡBYhBkoBIlxB|EB󪢡BæRBM~FkhCbj10%oǮרҤAoǯg|HۧCM޵jˡC֨fHg즳ŦppߵhΥRʤŦIܪcơC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668291?cesid=8YmAT2H0Pl8&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRituximab%26t%3Dname%26acs%3Dfalse%26acq%3DRituximab#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-16 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.7._20210616.pdf"">OI` 8.2.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.20._20241201.pdf"">OI` 9.20.</a>             "	"OI` 8.2.7.,9.20."	0	OIs 20251124	ITRUX-a	ITRUX-b	ITRUX-c	111.8.19
BC27602217	L01XG01	0	IVELC	ĵƼf Velcade(Bortezomib)3.5mg/vial(qjQ)		BortezomibOŰʪӭM26SJ?(26S proteasome)ؾųJ? (chymotrypsin-like activity)ifʧC26S proteasome@ثܤjJսƦXA|ϦubiquitinatedаOJս議ѡCUbiquitin-proteasome~|bո`SwJս誺ӭM@קtۭnA]oHӭMíwC26S J?iSJսѹL{AvTӭMhTǻCإ˸ѥ`íwiɭPӭM`Cb~]in vitro^PwҹbortezomibUgӭMӭMrʡCBortezomibb餺]in vivo^D{ɸ~Fҫ礤|~FͪA]AhoʰC 	Velcadeĳq1.3 mg/m2CVelcadeiH1 mg/mL @Rߪ`gġAΥH2.5 mg/mL @ץ֤U`g	"tswwʡGǷ8h
}wwʡGǷ8h
ۮe}GGNS
ĳ}nGSC
ĳĳ~|tvGSCBIVPG3-5sec
ī~}~[GL
L`NƶG
1. sVelcadeqܤֻݶj72p
2. Do not administer as an IT injection.
3.wP䯫gfܪ̫ĳϥΥ֤U`g"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Bortezomib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. Velcade iX֨Lgvī~ϥΩ󥼱L
vhoʰF]Multiple myeloma^fHδLܤ֤@تv覡BwgΤAy
貾ӪiiʦhoʰfHC
2. QMӭMOڽFMantle Cell Lymphoma] MCL^fHC"	VELCADETΩBortezomibBBoronάOMannitolLӪfwC 	LOʯgAph¡BABzBߡBmBæRpO֤ζg䯫gf	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.28._20230401.pdf"">OI` 9.28.</a>              "	OI` 9.28.	0	OIs 20251124	IVELC-a	IVELC-b	IVELC-c	110.6.16
			OVER20	ĵVERZENIO 150mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	OVER20-a	OVER20-b	OVER20-c	111.8.19
			OVER21	ĵVERZENIO150mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	OVER21-a	OVER21-b	OVER21-c	111.8.19
			OVERZ0	ĵverzenio100mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	OVERZ0-a	OVERZ0-b	OVERZ0-c	111.8.19
			OVERZ1	ĵverzenio100mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		OI` 	0	OIs 20251124	OVERZ1-a	OVERZ1-b	OVERZ1-c	111.8.19
BC27102100	L01EF01	RžA	OIBRA1	ĵƼf Ibrance 75mg/cap(Palbociclib)		PalbociclibO@ب㰪׿ܩʤΥifʪg̿ʿE?(CDK) 4M6CgD1MCDK4/6Ohط|ɭPӭMWͤTǻ|UC 	"qG
ĳq125@JpalbociclibC@Asv21ѫᰱv7(3/1{)AH28Ѭ@ӧ㪺gCunw̥io{ɮįqAYϥIBRANCEvAΫvܥX{LkrʤC
ΪkG 
IBRANCEȨѤfAϥΡC
1. ~P֪AA̦nO\ɪAΡAHTOpalbociclib Sq@PC 
2. n]A(]AeФũCZBrHΥ}n)C
3. ϥΥ~oͤ}ɪĳqվ覡 : 
Ĥ@Cq 100@J/ "	"1. PalbociclibiP cθcĨ֪AC
2. IBRANCEi|ɭPh¡A]Aw̦brpξާ@ԷVC
3. ~tަCbſ}@gBLappſ}CʥFgθ}- bſ}l}uǰDw̤iϥΥġC
4.ge/gekGҶqڭ?ĲzSʡAbϥpalbociclib[ڭ?vɡAX֧Z_KNLHRHPľ@Z_Ī "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Palbociclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. X鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨkΨkʡAIBRANCEiPڭ?(aromatase inhibitor)X֨ϥΡC
2. ۿE鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨfHAIBRANCEiXfulvestrant ΩeLcv̡C "	"1. ﬡʦΥnҦCξLӡC
2. ϥΧtt󦨤(St. Johns Wort)(κ٪)sC "	ݤʥզy֯gBզy֯gBhBpO֯gBCBfĪBߡBæRBmB֯lBrvBh¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_3L-03 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.72._20250701.pdf"">OI` 9.72.</a>              "	OI` 9.72.	0	OIs 20251124	OIBRA1	02C27102-1	02C27102-2	111.8.19
BC27103100	L01EF01	RžA	OIBRA2	ĵƼf IbrANCE 100mg/cap(Palbociclib)		PalbociclibO@ب㰪׿ܩʤΥifʪg̿ʿE?(CDK) 4M6CgD1MCDK4/6Ohط|ɭPӭMWͤTǻ|UC 	"qG
ĳq125@JpalbociclibC@Asv21ѫᰱv7(3/1{)AH28Ѭ@ӧ㪺gCunw̥io{ɮįqAYϥIBRANCEvAΫvܥX{LkrʤC
ΪkG 
IBRANCEȨѤfAϥΡC
1. ~P֪AA̦nO\ɪAΡAHTOpalbociclib Sq@PC 
2. n]A(]AeФũCZBrHΥ}n)C
3. ϥΥ~oͤ}ɪĳqվ覡 : 
Ĥ@Cq 100@J/ "	"1. PalbociclibiP cθcĨ֪AC
2. IBRANCEi|ɭPh¡A]Aw̦brpξާ@ԷVC
3. ~tަCbſ}@gBLappſ}CʥFgθ}- bſ}l}uǰDw̤iϥΥġC 
4.ge/gekGҶqڭ?ĲzSʡAbϥpalbociclib[ڭ?vɡAX֧Z_KNLHRHPľ@Z_Ī "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Palbociclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. X鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨkΨkʡAIBRANCEiPڭ?(aromatase inhibitor)X֨ϥΡC
2. ۿE鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨfHAIBRANCEiXfulvestrant ΩeLcv̡C "	"1. ﬡʦΥnҦCξLӡC
2. ϥΧtt󦨤(St. Johns Wort)(κ٪)sC "	ݤʥզy֯gBզy֯gBhBpO֯gBCBfĪBߡBæRBmB֯lBrvBh¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_3L-02 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.72._20250701.pdf"">OI` 9.72.</a>              "	OI` 9.72.	0	OIs 20251124	OIBRA2-a	OIBRA2-b	02C27103-2	111.8.19
BC27104100	L01EF01	RžA	OIBRA3	ĵƼf IBRANCE 125mg/cap(Palbociclib)		PalbociclibO@ب㰪׿ܩʤΥifʪg̿ʿE?(CDK) 4M6CgD1MCDK4/6Ohط|ɭPӭMWͤTǻ|UC 	"qG
ĳq125@JpalbociclibC@Asv21ѫᰱv7(3/1{)AH28Ѭ@ӧ㪺gCunw̥io{ɮįqAYϥIBRANCEvAΫvܥX{LkrʤC
ΪkG 
IBRANCEȨѤfAϥΡC
1. ~P֪AA̦nO\ɪAΡAHTOpalbociclib Sq@PC 
2. n]A(]AeФũCZBrHΥ}n)C
3. ϥΥ~oͤ}ɪĳqվ覡 : 
Ĥ@Cq 100@J/ "	"1. PalbociclibiP cθcĨ֪AC
2. IBRANCEi|ɭPh¡A]Aw̦brpξާ@ԷVC
3. ~tަCbſ}@gBLappſ}CʥFgθ}- bſ}l}uǰDw̤iϥΥġC 
4.ge/gekGҶqڭ?ĲzSʡAbϥpalbociclib[ڭ?vɡAX֧Z_KNLHRHPľ@Z_Ī "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Palbociclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. X鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨkΨkʡAIBRANCEiPڭ?(aromatase inhibitor)X֨ϥΡC
2. ۿE鬰ʡBĤGH֥ͪ]l(HER2) eʤߴಾʨfHAIBRANCEiXfulvestrant ΩeLcv̡C "	"1. ﬡʦΥnҦCξLӡC
2. ϥΧtt󦨤(St. Johns Wort)(κ٪)sC "	ݤʥզy֯gBզy֯gBhBpO֯gBCBfĪBߡBæRBmB֯lBrvBh¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_8-06 [96]_8-07 [96]_8-08 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.72._20250701.pdf"">OI` 9.72.</a>              "	OI` 9.72.	0	OIs 20251124	OIBRA3-a	OIBRA3-b	02C27104-2	111.8.19
BC24794100	L01EA02	0	OSPRY	ĵ Sprycel F.C.50mg/tab(Dasatinib)		Dasatinib Oh tyrosine kinases A]ABCR-ABL (Breakpoint Cluster Region-Abelson)AiզfӭML?{ͪPcޡAPɤ] SRC kinases䥦T?|A]iϥզy??íw?CC 	Sprycel(dasatinib)ĳq@140mgAߨ⦸AΤfA(@70mgCG[BID])AH\ΪŸAΤC 	"1.SPRYCELO_|cHťġCASPRYCELk¨šC
2.SPRYCELΩ18HUw̪wʻPĩ|TߡC
3.ɧ]AAiΤοiC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Dasatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	vwCʡB[tΫʴCʰʥզfAetimatinibvĩʩεL@ʪHCAΩwOV鶧ʫʲOکʥզfABet imatinibvĩʩεL@ʪHC 	ثe	̱`}ƥ]AGdƥpؽnAGzDƥ]AmBߡBhιæRAHΥXƥC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-08 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.30._20240601.pdf"">OI` 9.30.</a>              "	OI` 9.30.	0	OIs 20251124	OSPRY-a	OSPRY-b	OSPRY-c	111.8.19
BC24834100	L01EA03	0	OTASI	ĵ Tasigna 200mg/cap(Nilotinib hydroc		NilotinibOBcr-AblE?Cnilotinib|XíwAblJտE?ϪLʫCb~AnilotinibiBcr-AblձѹզyӭMPlͦPh+CMLw̤HӭM誺W͡Cb˴ҤUAnilotinibJA33Bcr-AblE?ܾɭPimatinibĩʤ32ҡC餺AnilotinibiCѹBcr-AblزӼҦ~FjpCnilotinibiUzE?ۧCĤƪIC50ȦpUGBcr-Abl]20-60nM^BpOlͥͪ]l]69nM^Bc-Kit(210nM)BCSF-1R(125-250nM)PDDR]3.7nM^C	fA400mgACѨϥ2A2ϥΪj12pɡAӥBP@PAΡC 	nM]ACAīeܤ֨pɻPAīܤ֤@pɤҤoiC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Nilotinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	vCʴΥ[tOV(Philadelphia chromosome)ʪCʰʥզf(CML)~w̡ABӱw̦ܤ֦L@ev(]Aimatinib)ܩʩέ@ʤ}gC	wnilotinibΥ@ξLӪ̡CŨϥΩ󿩱wC[gACg]YC[gACgw̻ݨϥnilotinibeAﵽC[ΧCgAwʴ^QTgԸsw̡C 	̱`֯lBkoBߡBh¡BYhBKθmCY{צhLܤ	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.32.1._20240601.pdf"">OI` 9.32.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.32._20240601.pdf"">OI` 9.32.1.</a>             "	"OI` 9.32.,9.32.1."	0	OIs 20251124	OTASI-a	OTASI-b	OTASI-c	111.8.19
BC26140212	L01XX41	0	IHALA	ĵ Halaven inj. 0.5mg/ml;2ml/vial(Erib		"Eribulin LޤͪӤvTYuAB׷L޳J(tubulin)DͲʻEC
Eribulin ĬOzLtubulin-based antimitotic AɭPG2/M ӭMg_ï}a(mitotic spindles)A󩵪_A̲׳y`?M`C "	HALAVENĳq1.4mg/m2A1ѩM8ѥHRߪ`g25ġAC21Ѭ@gC 	"tswwʡGN/A
}wwʡGǷ4hAN24h
ۮe}GGNS
ĳ}nG100ml
ĳĳ~|tvGIVF 2-5min
ī~}~[GL
L`NƶG
1.i}I
2.W`AŻPLĪϥΦP@޸"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XC HUC	Eribulin mesylate	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	HALAVEN Ωvಾʨw̥BLܤ֨ذwಾʨƾǪvCev]AanthracyclineMtaxaneΩ󻲧UʩಾʪvC 	L	ݤʥզy֯gB hBFO/hҡBrvBP䯫gfܡBߤΫKC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.48._20210310.pdf"">OI` 9.48.</a>              "	OI` 9.48.	0	OIs 20251124	IHALA-a	IHALA-b	IHALA-c	111.8.19
BC26579100	L01EC02	0	OTAFI	ĵTafinlar Capsules 75mg(Dabrafenib)		"Dabrafenib O@RAF E?CBRAF oͭPʬܷ|PRAS/RAF/MEK/ERK ~|oͫʬơCbSwgA˥XBRAF ܪWv۷A]A50% ¦FC̱`BRAF ܬV600EAboͩ¦FBRAF ܤ90%C
bͤƤRo{ɫeܡAdabrafenib iKXl600 ܩҳyƪBRAF E?"	"Dabrafenib ׳@kλPtrametinib ֥ΡAĳqҬ150 @J( 75 @Jn) C⦸( ۷C`q300 @J)CDabrafenib \eܤ1 pɩ\ܤ2 pɪAΡA⾯j12 pɥkCDabrafenib CѪۦPɶAΡAHfHqʡCPdabrafenib֥ΡAtrametinib ĳq2 @JC@(QD)CnΤAΡCiCZΥ}nA]iPβGVXϥΡA]dabrafenib ƾǩʽ褣íwCDabrafenib b\eܤ1 pɩ\ܤ2 pɪAΡC
1.LkΦಾ{H¦Fĳq
Tafinlar ׳@kλPtrametinib ֥ΡAĳqҬfA150 @JC⦸AefcƩΥX{LkrʤCtrametinib ζqTAШtrametinib C
2.¦FUvĳq
Tafinlar Ptrametinib ֥ΡAĳqfA150 @JC⦸Aef_oΥX{LkrʤF1 ~Ctrametinib ζqTAШtrametinib C
3.DpӭMĳq
Tafinlar Ptrametinib ֥ΡAĳqfA150 @JC⦸Aef_oΥX{LkrʤCtrametinib ζqTAШtrametinib C
vɶ
vܯfHLkAoįqΥX{Lkrʤ"	"BRAF V600 
Dabrafenib Ω󳥥ͫBRAF ¦FfHγͫBRAF DpӭMfHĻPwʥثe|TߡA]Adabrafenib i
Ω󳥥ͫBRAF ¦FfHγͫBRAF DpӭMfH"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ФŦs30?C HWҡCקKĲuCиmleJsC	Dabrafenib mesylate	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.¦F
Dabrafenib @kλPtrametinib ֥ΡAiΩvBRAF V600 ܶ
BLkHNಾʪH¦F ( аѾ\5.1 `)C
2.¦FUv
Dabrafenib Ptrametinib ֥ΡAiΩvBRAF V600 ܥBᤧ
III ¦FfHNỲUvC
3.DpӭM
Dabrafenib Ptrametinib ֥ΡAiΩvBRAF V600 ܤߴDpӭM
HfHC"	ﬡʦΥξLӡC	oNBh¡BߡBYhBHŸBmBlB`hBBæRΫy¡C	"Dabrafenib iΩ󥥰AD˪bįqWVLiୱ{ICpGfHbϥdabrafenib hAifHL
iୱ{M`Dͨ|OkʯfHbvĨĪץIAīh~ץ4 ӤC"	DnקKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-07 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.91._20240601.pdf"">OI` 9.91.</a>              "	OI` 9.91.	0	OIs 20251124	OTAFI-a	OTAFI-b	OTAFI-c	111.8.19
AC57314235	L01XA02	0	ICARB	ĵ Carboplatin IV inj.10mg/ml;15ml/via		Carboplatin Mcisplatin @ˡAbDNA ް_㪺椬sAӤODNA Jս誺椬sCoا@MSӭMgSʡC@{carboplatin X@(aquation)|ͬʪAoؤX@Ϊtvcisplatin wCC 	"Non-small cell lung cancerG
Stage IIIb or IV, recurrent, first-line: gemcitabine 1000 mg/m(2) IV over 30 minutes on days 1 and 8 plus CARBOplatin (AUC 5.5) IV over 15 to 30 min on day 1 OR paclitaxel 225 mg/m(2) IV over 3 hours on day 1 plus CARBOplatin (AUC 6) IV over 15 to 30 minutes on day 1 OR plus gemcitabine 1000 mg/m(2) IV over 30 minutes on days 1 and 8 plus paclitaxel 200 mg/m(2) IV over 3 hours on day 1; repeated every 21 days for 6 cycles or until unacceptable toxicity or disease progression was used in a phase 3 randomized trial.
Ovarian cancer, AdvancedG
300 mg/m(2) on day 1 every 4 weeks for 6 cycles OR dose based on the Calvert formula, with a target AUC of 4 to 6 mg/mL x min"	"tswwʡGN/A
}wwʡGǷ8h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>15min
ī~}~[GL
L`NƶG 1. sƩε~ɡAiϥΧtTwYA_hO|ॢ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Carboplatin	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Z_C(TFDA֭㪺Ag)	"1. Carboplatin `gGTΩ󴿹cisplatinBLt`ƦXBmannitol YLӤw̡C 
2. Carboplatin TΩ㦳YΤjX媺w̡C "	hBߡBæRBݤʥզy֯gC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.2._20251001.pdf"">OI` 9.2.</a>              "	OI` 9.2.	0	OIs 20251124	ICARB-a	ICARB-b	ICARB-c	110.6.16
BC25744248	L01XA01	0	IABI5	ĵ Kemoplat 1mg/ml;50ml/vial(Cisplatin		CisplatinƾǪʽA󨺨\઺alkylating agentAĨDNAͤѩMѶe۳sӧDNAXCĨϳJսMDNAXUpdCCisplatinݩCell-cycle specificC 	HMpĤ@몺@뾯q 50-100mg/TACj3-4PI.V.`@CI.V.` 15-20mg/TAsP5ѡACj3-4PƤ@C 	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNS
ĳ}nG250-1000ml
ĳĳ~|tvGIVF:1-2hr(60mg/m2)F6-8hr(high dose)
ī~}~[GL
L`NƶG1. sƩε~ɤiϥΧtTwYA_hͶ¦I
2. Prior to administration, hydrate with 1 to 2 L of fluid infused over 8 to 12 hours; maintain adequate hydration and urinary output for 24 hours after administration
3. Ķ:Taxane?Platium
4.VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m2 PER COURSE."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Cisplatin	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"ಾʸAY~Bಾʥf_~FλH֤ಾӭM~F.

"	"Ŧ\ê
ťı`

bhέŴ
cisplatinι`ƦXLӯfvw "	"1. CisplatinDnrʬOWnʪMqǷl`C
2. PĦWF31HfH޵oջM/ΰWvťOॢC "	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IABI5-a	IABI5-b	IABI5-c	110.6.16
AC55934229	L01XA03	0	IELOX	ĵ Orectalip 5mg/ml;50mg/10ml/vial(Oxa(N)		"Oxaliplatin, a platinum derivative, is an alkylating agent. Following intracellular hydrolysis, the platinum compound binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death. Cytotoxicity is cell-cycle nonspecific."	"Advanced colorectal cancer: I.V.: 85 mg/m2 every 2 weeks until disease progression or unacceptable toxicity (in combination with fluorouracil/leucovorin).
Stage III colon cancer (adjuvant): I.V.: 85 mg/m2 every 2 weeks for 6 months (12 cycles; in combination with fluorouracil/leucovorin)
Advanced/metastatic Carcinoma of stomach: 65 to 85 mg/m2 IV over 2 hours on day 1, 8
Metastatic Pancreatic cancer: (FOLFIRINOX regimen) Oxaliplatin 85 mg/m2 as a 2-hour IV infusion"	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 2-6h
ī~}~[GL
L`NƶG
1.ŨϥNSΨLtⷻGհtε}C
2.ŨϥΧtT`gơAŻPLĪVXC
3.ĶǡGOxaliplatin  5-Fu"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Oxaliplatin	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	M5-fluorouracil (5-FU)folinic acid (FA)֥ΡA@ĤTz(Dukechr(39)s C)o~FN᪺UkCvಾʵzzCOxaliplatinMCapecitabine֥ΥiΩ󧽳ߴδ_o/ಾʭGvC	"Hypersensitivity to oxaliplatin, other platinum or any component of the formulation."	"Abdominal pain, anorexia, diarrhea, nausea and vomiting , stomatitis, back pain, cough, fatigue, fever."	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.10._20221101.pdf"">OI` 9.10.</a>              "	OI` 9.10.	0	OIs 20251124	IELOX-a	IELOX-b	IELOX-c	110.6.16
BC22473221	L01CE02	0	ICAMP	ĵ Campto 100mg/5ml/vial(Irinotecan)		"Irinotecan hydrochloride, a camptothecin derivative of topoisomerase 1 inhibitor class, prevents religation of single-strand breaks when it binds to topoisomerase 1-DNA complex. Its cytotoxic action is due to the damage in double-strand DNA when replication enzymes act on the formed ternary complex."	"Īv(wLƾǪvw)G
Irinotecanĳq350mg/m2AR߿`3090ACTgĤ@C
XĪv(LƾǪvw) G
HUCĤ覡AIrinotecanP5-fluorouracil(5-FU)Mfolinic acid(FA)֥ΪwʻPġG Irinotecan[5FU/FAACGgĤ@ 
Irinotecanĳq180mg/m2ACGgĤ@AR߿`30-90AM`folinic acidM5-fluorouracilC 
FOLFIRINOX:HR߳~|ġA뤩oxaliplatin 85mg/m2 pɡAۧ뤩leucovorin 400mg/m2 pɡAleucovorin}l뤩30AzLYަX֧뤩irinotecan 180mg/m2 90AåߧYHIV bolus뤩fluorouracil 400mg/m2۫`fluorouracil 2400mg/m2 46pɡACP@ӪvgA@6Ӥ
ĤG{HiĪ:ݤʥզy15000/mm3HWApOơG75000/mm3HW
qɪĶq(}lĮ,oxaliplatin 85mg/mm2,irinotecan 180mg/mm2,fluorouracil R`2400mg/mm2)
įŧO-1:,oxaliplatin 65mg/mm2,irinotecan 150mg/mm2,fluorouracil1800 mg/mm2
-2:oxaliplatin 50mg/mm2,irinotecan 120mg/mm2,fluorouracil1200 mg/mm2
-3:oxaliplatin,irinotecan ,fluorouracil
"	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W(preffer)
ĳ}nG250-500ml(0.6-20mg/ml)
ĳĳ~|tvGIVF 30-120min
ī~}~[GLܲH
L`NƶG 
1.iPIirnotecan liposomeϥ
2.ĶǡGCPT-11  Leucovorin  5-Fu"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Irinotecan	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"ߴʤjzzĤ@uvĪGP5-FUfolinic acidX֡AϥΩ󥼴LƾǪvw̡CWϥΩ󴿱5-FU{vLĤw̡C Pcetuximab֥ΡAvtirinotecanӭMrkvѥB㦳W֥ͪ]l(EGFR){KRASͫಾʤjzzw̡DP5-FUL,folinic acidbevacizumabX֪vAಾʤjzΪzfHĤ@uvĪDPcepacitabineX֪v,ಾʤjzzfHĤ@uvĪ.P5-FUleucovorin,oxaliplatinX֪v(FOLFIRINOX)ಾʯŦĤ@uvĪ"	"1. CʵoʸzDef/θzC
2.  Irinotecan hydrochloride trihydrate Υ@إĪξYLӤfvC
3. hP¨ŴC 
4. x > 3 `dWȡC 
5. Y\IܡC
6. WHO બA > 2C 
7. Pt(St Johns Wort) ֥ΡC "	ʸmB߻PæRBC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.12.1._20040801_000.pdf"">OI` 9.12.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.12._20180801_000.pdf"">OI` 9.12.1.</a>             "	"OI` 9.12.,9.12.1."	0	OIs 20251124	ICAMP-a	ICAMP-b	ICAMP-c	110.6.16
BC25071100	L01EB02	0	OTARC	ĵ Tarceva 150 mg/tab (Erlotinib)		Erlotinib{ɧܸ~F@Ϊثe|MCErlotinibi֥ͪ]l(EGFR)TiĿE(tyrosine kinase)ӭMCĤƧ@ΡC䥦TiĿEO_S@Ϋh|MCEGFRY{󥿱`ӭMӭMӭMWC 	"㦳EGFR-TKܤIǩʩಾʤDpӭMfwĤ@uvG
LƾǪvIǩʩಾʤDpӭM(NSCLC)fwAbHTARCEVAveAEGFR˴C
TARCEVAΩDpӭMCĳq150@JAieܤ1pɩζi2pɪAΡC
͸fwĤ@ukΤGuvG
TARCEVAΩ͸Cĳq150@JAieܤ1pɩζi2pɪAΡC
"	ErlotinibDnOzLCYP3A4@ζiN¡A]ACYP3A4@ΪĪw|ɰnSqCMjOCYP3A4 ketoconazole֥η|erlotinibAUCɰ2/3C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Erlotinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. TARCEVAAΩ㦳EGFR-TKܤIǩʩಾʤDpӭM(NSCLC)fwĤ@uvC
2. TARCEVAAΩw4Ӷgtplatinum-basedĤ@uƾkB|cƪߴಾʪ͸kC
3. TARCEVAAΩewLƾǪvAcƩಾ͸fwĤGuġC "	L	֯lPm	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_2L-04 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.29._20250401.pdf"">OI` 9.29.</a>              "	OI` 9.29.	0	OIs 20251124	OTARC-a	OTARC-b	OTARC-c	111.8.19
BC23808100	L01EB01	0	OIRES	ĵ Iressa 250mg/tab(Gefitinib)		"Gefitinib֥ͪ]l(epidermal growth factor receptorAEGFR)TiĿE?ï(tyrosine kinase)M@ʧAq`{WֲӭMYH~FCEGFRTiĿE?ïʡAKF~FͪBಾΦ޼W͡AëPiӭMC
"	 IRESSAq250mgAfAACѤ@AiŸλP֥ΡCpѰOAĮɡAQ_ߨɪA@qAYOUAĮɶ12pɡAhLѰOqAiPɪAΨ⭿q	"1. AIressaw̡Aoͤ֨ʪͯfAiYʵo@AǱw̦]ӭPRCw̭YPɦX֦۵oʪŦֺ/ʪͪ/Ъͯg/gʪͪ/Īް_ͪɡAbرpU䦺`v|W[CpGw̥X{IlgcơApIlxBy¤εoNɡAIressavAåߧYۤլdCT{OʪͯfɡAIressaAõw̾AvC
2. o{LgxŦ?WɡC]ĳwˬdx\CxŦ?צܤפWɪ̡AϥIRESSASOԷVCYܤƸYɡAҼ{
3. |oCYP3A4ʤi|PiN¥BCߤgefitinib@סC]APCYP3A4o(pphenytoinBcarbamazepineBrifampicinBڤSt John's)֥ήɡAi|CĤOC
4. iXGAwarfarinw̡AǵoͰڼзǤƤ(INR)Wɤ/ΥXCAwarfarinw̡Awˬdïɶ(PT)INRܤơC
5. |ϭGĤpHȫWɤĪAi|Cߤgefitinib@סAæ]ӭCĤOC
6. hέšGIRESSAõLbhέŰkϥΤơCʪܦʹެrʡFʪXgefitinibΨ䳡N²|iJťĤC
7. rpξާ@OvTGbIRESSAvAIz{HFgw̾rpξާ@ɡApߺʬݡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Gefitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.AΩ㦳EGFR-TKܤIǩʩಾʤDpӭM]NSCLC^fwĤ@uvC
2.AΩewLƾǪvAcƩಾ͸fwĤGuġC"	TΩw惡ī~ĦΥզ|YLӤw̡C	mB֯lBoBֽέpC}q`oͩvĤ@ӤABq`if	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.4.9	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.24._20240601.pdf"">OI` 9.24.</a>              "	OI` 9.24.	0	OIs 20251124	DC	DC	DC	114.4.9
AC59239100	L01EB01	0	OTERN	ĵ TernibinF.C. 250mg/tab(Gefitinib)		Gefitinib֥ͪ]l(epidermal growth factor receptorAEGFR)TiĿE?ï(tyrosine kinase)M@ʧAq`{WֲӭMYH~FCEGFRTiĿE?ïʡAKF~FͪBಾΦ޼W͡AëPiӭMC	q250mgfAACѤ@AiŸλP֥ΡCpѰOAĮɡAQ_ߨɪA@qAYOUAĮɶ12pɡAhLѰOqAiPɪAΨ⭿q	"1. AGefitinibw̡Aoͤ֨ʪͯfAiYʵo@AǱw̦]ӭPRCw̭YPɦX֦۵oʪŦֺ/ʪͪ/Ъͯg/gʪͪ/Īް_ͪɡAbرpU䦺`v|W[CpGw̥X{IlgcơApIlxBy¤εoNɡAGefitinibvAåߧYۤլdCT{OʪͯfɡAGefitinibAõw̾AvC
2. o{LgxŦ?WɡC]ĳwˬdx\CxŦ?צܤפWɪ̡AϥGefitinibSOԷVCYܤƸYɡAҼ{
3. |oCYP3A4ʤi|PiN¥BCߤgefitinib@סC]APCYP3A4o(pphenytoinBcarbamazepineBrifampicinBڤSt John's)֥ήɡAi|CĤOC
4. iXGAwarfarinw̡AǵoͰڼзǤƤ(INR)Wɤ/ΥXCAwarfarinw̡Awˬdïɶ(PT)INRܤơC
5. |ϭGĤpHȫWɤĪAi|Cߤgefitinib@סAæ]ӭCĤOC
6. hέšGGefitinibõLbhέŰkϥΤơCʪܦʹެrʡFʪXgefitinibΨ䳡N²|iJťĤC
7. rpξާ@OvTGbIRESSAvAIz{HFgw̾rpξާ@ɡApߺʬݡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Gefitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.AΩ㦳EGFR-TKܤIǩʩಾʤDpӭM]NSCLC^fwĤ@uvC
2.AΩewLƾǪvAcƩಾ͸fwĤGuġC"	TΩw惡ī~ĦΥզ|YLӤw̡C	mB֯lBoBֽέpC}q`oͩvĤ@ӤABq`if	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_7-02 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.24._20240601.pdf"">OI` 9.24.</a>              "	OI` 9.24.	0	OIs 20251124	OTERN-a	OTERN-b	OTERN-c	111.8.19
BC26168100	L01EX05		OSTIV	ĵ Stivarga 40mg/F.C.tab(Regorafenib)		RegorafenibhؽWE?βӭME?plAoǿE?ѻPF`ӭM\]Aγ\hfzi{A]A~Fo͡B~F޷sͥHκ~FLҡC~ͤƩβӭMRAregorafenibΨH餺DnʥNªM-2M-5bF{ɵĪ@פU|RETBVEGFR1BVEGFR2BVEGFR3BKITBPDGFR-alphaBPDGFR-betaBFGFR1BFGFR2BTIE2BDDR2BTrk2ABEph2ABRAF-1BBRAFBBRAFV600EBSAPK2BPTK5Ab1C餺ҦAQΤj~Fҹregorafenib޷sͪĪGAӧQΦhӤpزӼҦ(]A@ǤHzz)Aҹregorafenibi~FͪB㦳ܸ~FಾĪGC 	"@ӪAĶg28ѡAĳqCge21ѡACѤfA160mg regorafenib 1(|40mgĿ)C򱵨vfpcƩεo͵LkrʡC
CѦP@ɶACAήɽо]UðtXתէtqC30%Cצ\CCצ\dҡGզRq٤W1jͧC״Ӫo1jͪGA[W240@ɲפ (t319d8.2 gת)F
Ϊ1M\B240@ɲפB1٪G檺RqBīGĥH1M@ةί(t520d2gת)C "	"1. xr
}lveix\˴(ALTBASTx)ABbve2ӤAܤ֨Cgnʴ@FUӡACܤֶʴ@Ψ̷{ɻݭnW[WvCx\˴ƭȤɰfwACgix\˴AƭȧC󥿱`ȤW/TC 
2. X
X{שΦMΥͩRXgfwAХä[CwarfarinfwWcINRȡC
3. ֽr
]ֽrʼȰϥACqΥä[ĪMwMֽrʪYʤΫɶөwCikHwѯgC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs30XCHUABeɪ\ū׽d1530XC (5986XF)C
бNĪxs쥻~lAŲ꾯C}ʫ~\C
}~7gAбN~ϥΪĪCɽпuaWdC "	Regorafenib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.1 jzz
AΩveUCkಾʤjzz(mCRC)wk]tfluoropyrimidine-, oxaliplatin- M irinotecan- ¦AMܦޤ֥ͪ]l(anti-VEGF)kFYKRASͫ(wild type)hLܪ֥ͪ]l(anti-EGFR)kC
1.2 zGD~F
AΩveimatinib mesylatePsunitinib malatevߴBLkNಾʪzGD~F(GIST)w̡C 
1.3 xӭMAΩvsorafenibvxӭM(HCC)fwC"	L	"̱`X{}(?20%)LO/h¡B
HFSRBmBC/֡BB߽Bo`BPVBkh(LSOwدkh)B魫BGzDPkhB֯lBoNPߡC

vw̤AYĪ}xrBXέGzDաC "	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_1R-06 [96]_1R-08 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.51._20240601.pdf"">OI` 9.51.</a>              "	OI` 9.51.	0	OIs 20251124	OSTIV-a	OSTIV-1-b	OSTIV-1-c	111.8.19
BC24727100	L01EX02		ONEXA	ĵ Nexavar 200mg/tab(Sorafenib)		"SorafenibE?Ab~礤iC~FӭMW͡CSorafenibQҹihزӭM(CRAFBBRAFMܫBRAF)βӭME?(KIT, FLT-3BRETBVEGFR-1BVEGFR-2BVEGFR-3MPDGFR-])Cثe{oǿE?ƺػP~FӭMTǻB޼WͩMӭM`CSorafenibHxӭMBǲӭM~FͪΦ޼W͡AbK̥\ʷlpƺؤH~F鲾ӪҦW][ۦPĪGCSorafenibƫҪ~FͪC"	"NexavarCĳq@400@J(2200@J)A@ѪA2AP@_A(ܤ֥\e@pɩΥ\2p)CfAϥΡAH]ACv򪽨fwLkAo{ɮįqεoͤirʡC
xӭMεǲӭMqվ覡
BzæĪ}ɡAiݭnȮɤ_Nexavarv/δ־qCn־qɡANexavarqܨC
400@JAYi@B־qANexavarqiHܨCj@400@JC
ƫҪqվ覡
BzæĪ}ɡAiݭnȮɤ_Nexavarv/δ־qCvƫҪL{n־qɡANexavarqܨC600@JA⦸A(2200@J1200@JAj12p)AYi@B־qANexavarqiH1200@JA@Ѩ⦸AiA1200@JA@Ѥ@CDGǪ}oﵽAiHW[NexavarqC
"	Pת\ɪAΡAiβv|Ÿɴ29%C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Sorafenib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	ಾʩεLkNBAXvΧvѤߴxӭM(HCC)C ߴǲӭM(RCC)Bwinterferon-alphainterleukin-2vѡAΤAXHWĪvfwC gʸKvLĤߴಾʪi(progressive)ƫҪ(DTC)C 	"1.NexavarTΩwsorafenibΨξYLӪfwC
2.ϥcarboplatinMpaclitaxelv쪬ӭMfwɡAT֥NexavarC"	MXlBmBߡBh¡C	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-08 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.34._20250601.pdf"">OI` 9.34.</a>              "	OI` 9.34.	0	OIs 20251124	ONEXA-a	ONEXA-b	ONEXA-c	111.8.19
BC25165100	L01EG02		OAFIN	ĵ Afinitor 5mg/tab(Everolimus)		"Everolimus mTOR ( Rapamycin йv) AmTOR Oi- TiĿE?AbPI3K/AKT |UCmTOR |bjHgLk`B@CEverolimus zLPӭMJսAFKBP12 ׿˩Mʥ椬@ΡAo䬡ʡCEverolimus CS6 JտE?(S6K1) PuֲӭM]l4E XJ(4E-BP) ʡAmTOR UʾA]AJսXCA̡Aeverolimus |ʮ񻤾ɦ]l( pHIF-1 ]l) {AέCޤ֥ͪ]lVEGF {CEverolimus mTOR Ab~M/ 餺siC~FӭMW͡B޷sͤާl@ΡC 
PI3K/Akt/mTOR |ʬƷ|ɭPXvͪܧ@ΡC~sܡAۿE̦sBHER2 鶧ʪӭM|everolimus @ΦA֥ everolimus PAktBHER2 Ϊڭ?vǥѨP@Υi[jeverolimus ܸ~FʡC "	"1. CѦP@ɶAΤ@APΤP֪AiHC
 2. ݥHM]AĿCAFINITOR iCZΫrHCLk]Aw̡ANAfinitor Hͩժ覡@M( 30 @) AåߧYܤUCAMˤJq~AMN~GܱAHTOAU㾯qC 
3. ĳqGvX鶧ʡBHER2 鳱ʪgߴBŦgc~FBߴǲӭMAfinitor ĳζq10 @JC "	YѰOAΤ@AFINITOR ɡAZ`AĮɶ6 pɤiߧYA@AYWL6 pɡAhLoqAĤGѦA󥿱`AĮɶAAFINITORCiAΤGӸvѰOAΪqC @	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~JsǷ30JHUC	Everolimus	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. XexemestaneAΩvX鶧ʡBHER2鳱ʥBeϥletrozoleanastrozole_oδcƤgߴw̡C 
2. AΩiiʡALkಾʤƨ}nΤפ(well-differentiated or moderately-differentiated)Ŧgc~FHw̡C
3. AΩvbgsunitinibsorafenibkLīᤧߴǲӭMw̡C "	DBrapamycin ( p`) lͪΥξLӪ̡Cثe[Lөʤg]A( ) LөʥJBIlxBBݵhΦީʤ~( ҦpIlDΦY~ȦHΥHIlê)C 	fBPVB֯lBhҡBmέUC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-12 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.36.1._20200401_000.pdf"">OI` 9.36.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.36.2._20170401_000.pdf"">OI` 9.36.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.36._20130101_000.pdf"">OI` 9.36.2.</a>            "	"OI` 9.36.,9.36.1.,9.36.2."	0	OIs 20251124	OAFIN-a	OAFIN-b	OAFIN-c	111.8.19
AC57915100	L01EA01	0	OGLIV	ĵƼf Leevk 100mg/F.C.tab(Imatinib)		"1. ~O@ӳJս-pĿE?Ab~餺ӭMiHĦaBcr-AblpĿE?C~ܩʦaӭMW͡AûɱaBcr-AblӭMBOV馨ʤCʰʥզg(CML)AΫʲOڪ޲ӭMʥզg(ALL)w餺sAզyӭMAͲӭM`@ΡC
2. Ѩ۱w餺GΰӭMӶi檺ӭMܧΤRAҹꥻ~Cʰʥզfw̪Bcr-AblʲӭM㦳ܩʪ@ΡC
3. b餺礤AWϥimatinibʪ餺Bcr-Ablʸ~FӭM㦳~F@ΡC~AimatinibpOlͤͪ]l(PDGF)BFӭM]l(SCF)PC-KitpĿE?ӨAO@ӱjOAiHPpOlͤͪ]lPFӭM]lCӭM@"	"1. CʴCʰʥզfw̡AĳCѨϥ400@JFƴ(blast crisis)Υ[tw̡AhĳCѨϥ600@JCnCѤfA@AitX@jM\AΡC
2. unw̦vĪGA~ϥΡCBCʴw̡A侯qiHҼ{q400@JW600@JAө[tΫƴ(blast crisis)w̡A侯qi600@JW800@J(C400@JAC2)C"	~ӰtX@M\AΡAHֳyGzêMIʡCx\l`w̻ݤpߨϥΥ~C|x\l`w̨ϥΥ~{ɸAҥHLkĳw̸ӦpվϥξqCj1-2%ϥιL~w̡AioYʲGWn(ݽGB~BͤءB)A]ĳw̩wq魫FnSO`N魫O_WGwaW[ApGnܡAĨAkΪvIӸѰGWnDC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Imatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	vȫƴ(BLAST CRISIS)B[tθgALPHA-zZvLĤCʴCʰʥզf(CML)w̡Cv~HLkNಾcʭGzDFCΩvE_Cʰʥզf(CML)fH CvE_OV鶧ʫʲOکʥզf]Ph+ ALL^B֥Τ~HCvH_oʩvʶOV鶧ʫʲOکʥզf(Ph+ ALL)@kC	󥻫~DΥ@ξLӪ̡ATϥΥī~C	ߡBæRBmB٦׵hB֤~Φ٦׵j	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-01 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.22._20240601.pdf"">OI` 9.22.</a>              "	OI` 9.22.	0	OIs 20251124	OGLIV-a	OGLIV-b	OGLIV-c	111.8.19
VC00007100	L01XX35	wF 0.5@Jn	OAGRY	Agrylin 0.5mg/cap(Anagrelide HCI)		"Anagrelide ?CpO?تAbsAھڥثes?ܡAAnagrelide ?jpivQ쥨ֲӭM ( megakaryocyte ) ?A]ӥi?CsypO?CAgrylin@Ω󥨮ֲӭMΦAzZֲӭMƦA]ֲӭMe{p?C
bv??UA?|vQզysyξ]lAysyyvQA??ɷNqC?Anagrelide |pOAC?h|?CpOͦA?@ά C-AMP Phosphodiesterase III (PDE III) AiӧpOC "	"Hĳ_lqO0.5mg~1mg BID]0.5mgnAB@gHWCĵlq0.5mgCѤ@ܥ|Aѩĵlqs֡A]ĳൣlq0.5mgC@C??OHΫĵAnվ̧CĪv??AӨϦpO??B600,000/gL HUAƦܨ?Q`ȡCnW[?ɡA@gW[??iWL0.5mg/dayCĵPH?@ˡAC`??iWL10mgA@?]?iWL2.5mgCھڦpOƥؽվ㾯qD
?x\??G
fHĳl?C0.5mgAB@gHWAK?ʴߦޥ\CnW[?ɡA@gW[??iWL0.5mg/dayC
?x\??G
fHanagrelide v?eAv??qPbICثe|LYx\??fHPanagrelide sAYx\??fHTҧPanagrelideC?ʵanagrelide ĪGΨpOL֡Abv?Ĥ@gACj2 Ѵ?pO?ءAMĤGg}lACgܤ֤@A}lAκ?ɬCq`bA?UA7 14 ѤpO?شN|}lU?ApO?ؤU?600,000/gL HUA4 - 12 gCjfHv??O1.5 3mg/dayCwŦefBǥ\??Ψx\??̥pߪAΡC "	"ߦޡG
] anagrelide㦳ʦ٦צYOΨƧ@ΡAҥHveAߦˬdOnABbvA]K[CbHanagrelide vqUAiް_ߦާ@ΡApXiB߸[tB߱ΥRʤŦIܡC
xŦG
ثe|LYx\ण}fHPanagrelidesCרx\ण}fHanagrelideveAvQqPbICרx\ण}fHhCqAåBKʴߦޥ\C
x\णݺʴQTcAPaspirin֥ΦX孷IAͰAʪͯfD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץAxs25JC	Anagrelide	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	oʦpOLhg	Yx\ण}fHTҧPanagrelideC 	YhB߱BUgBLOB~BߤίtwC 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668840?cesid=8Ej3rvNyLZA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAnagrelide%26t%3Dname%26acs%3Dfalse%26acq%3DAnagrelide"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.3._20180601_000.pdf"">OI` 4.3.3.</a>              "	OI` 4.3.3.	0	OIs 20251124	DC	DC	DC	110.6.16
BC23135100	L01XX05	0	OHYDR	ĵ Hydrea 500mg/cap(Hydroxyurea)		~DNAXAS۱M@ĪC	1.kJ20mg/kgAC@C 2.kJ80mg/kgAC3@C	"1.vץC
2.ifHnAyJ|AYqɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Hydroxyurea	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"¦FBܩʺCʥզfB_oʡBಾΤi}MZ_C
guv֥Ω󳱮B~oYV窱ӭMC"	ҥΩ\fHYh̡C	զy֯gApO֯gAhΥFyfFߤιæRAfAֽLӡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-13 j	Ts111.8.19		OI` 	0	OIs 20251124	OHYDR-a	OHYDR-b	OHYDR-c	111.8.19
BC221372CS	L02AE03	0	IZOLA	ĵZOLADEX 3.6MG/AMP		~OXLHRHAP~AUcLHAӭCkʦMtestosterone@שMkʦGoestradiol@סAOifAoا@ι̿EcƨMlc(endometnosis)ġC	"1. ֤U`g3.6mgİwAC28Ѥ@A`gɭn¾KAѦ~HqeAMǰIܩΨxIܯfHAqվC
2. lcAsv6ӤC"	ΩൣC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Goserelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	Y@UvAgeΧ~kvAlc줧vBNeƤlcYplcٽFBHuUʹޡC	ZoladexLHRALӪ̸TΡC	gg(BD)BBʼCBkʤkšBYhBߡByC	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-10 [E]_D2-00j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	OI` 5.5.1.	0	OIs 20251124	IZOLA-a	IZOLA-b	IZOLA-c	111.8.19
BC222332D1	L02AE03	0	IZOLA1	ĵZoladex LA.Depot 10.8mg/syr		~OXLHRHAP~AUcLHAӭCkʦMtestosterone@שMkʦGoestradiol@סAOifAoا@ι̿EcƨMlc(endometnosis)ġC	HC12g֤U`g10.8 mg Zoladex LA.Depot 	ΩൣC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Goserelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	Y@UvAgeΧ~kvAlc줧vBNeƤlcYplcٽFBHuUʹޡC	ZoladexLHRALӪ̸TΡC	gg(BD)BBʼCBkʤkšBYhBߡByC	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-05 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	OI` 5.5.1.	0	OIs 20251124	IZOLA1-a	02C22233-1	02C22233-2	111.8.19
BC259342AA	L02AE02	0	ILEUP	ĵLeuplin Depot 1M 3.75mg S.C.Inj.		"ЧP?LH-RH ΰLH-RH PLeuprorelin acetate ɡA?P?[i[ȮɩʸUXʸt?E@(ʧ@)~FA󸣤UPʸEΦXҷ|?CAi?_θAYPʸEʤ]|?CA|ɭPestradioltestosterone Φ??C(Cʧ@)CLeuprorelin acetate XLH ʬLH-RH100 A丣UXʸ@ΤLH-RH jC
Leuprorelin acetate ʪLH-RH PA㦳j?UXʸ@ΡA?ѬOLeuprorelin acetate PLH-RH ۤɡAJսѻïܩʸjAPɡAe̹LH-RH 㦳˩MʡCA̡A]OwʻsAiNLeuprorelin acetate?aXܦ夤AĦaɭP?_θAY?CAu?UXʸ@ΡC"	"1. lc?
q`C4 g֤U`gLeuprorelin acetate 3.75mg @Abg}l1~5 ѥĤ@wA˪v?6 ӤC
2. ]lcٽFް_gLhγhӹwpi?N?̨ϥΥĮɫĳ?WLTӤC
q`C4 g֤U`gLeuprorelin acetate 1.88~3.75mg @A̱w̪g?iA?վ?Cbg}l1~5 ѥĤ@wC
3. e?ΰge
q`C4 g֤U`gLeuprorelin acetate 3.75mg @C
4. ϩʩʦg
즸ĳ?<20 kgG1.88 mgF?20 kgG3.75 mgFFRĪGɡA<20 kg ̥i1.88 mgW?3.75 mgF?20 kg ̥i3.75 mg W?7.5 mgCI覡C4 g֤U`g@C "	" U?w̽зVPG 
1. lc?BlcٽFBgeC
2. e?C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 25JHU	Leuprorelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	eCθѪvAlcAϩʩʦgA]lcٽFް_gLhγhӹwpiN̡AgeC 	"1.糧ΦXLH-RH LH-RH P鴿o͹Lӯg
2.whΥihHAŤHC 
3.gE_?`DX媺w̡C "	PBYhBvBtwBoC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	OI` 5.5.1.	0	OIs 20251124	ILEUP-a	ILEUP-b	ILEUP-c	110.6.16
BC251932CN	L02AE02	0	ILEUP1	ĵLeuplin Depot(3M)11.25mg S.C inj		"ЧP?LH-RH ΰLH-RH PLeuprorelin acetate ɡA?P?[i[ȮɩʸUXʸt?E@(ʧ@)~FA󸣤UPʸEΦXҷ|?CAi?_θAYPʸEʤ]|?CA|ɭPestradioltestosterone Φ??C(Cʧ@)CLeuprorelin acetate XLH ʬLH-RH100 A丣UXʸ@ΤLH-RH jC
Leuprorelin acetate ʪLH-RH PA㦳j?UXʸ@ΡA?ѬOLeuprorelin acetate PLH-RH ۤɡAJսѻïܩʸjAPɡAe̹LH-RH 㦳˩MʡCA̡A]OwʻsAiNLeuprorelin acetate?aXܦ夤AĦaɭP?_θAY?CAu?UXʸ@ΡC"	HC12g֤U`g11.25 mg Leuplin Depot	" U?w̽зVPG 
1. lc?BlcٽFBgeC
2. e?C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 25JHU	Leuprorelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	eCθѪvAlcAϩʩʦgA]lcٽFް_gLhγhӹwpiN̡AgeC 	"1.糧ΦXLH-RH LH-RH P鴿o͹Lӯg
2.whΥihHAŤHC 
3.gE_?`DX媺w̡C "	PBYhBvBtwBoC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	OI` 5.5.1.	0	OIs 20251124	ILEUP1-a	ILEUP1-b	ILEUP1-c	110.6.16
BC245282CN	L02AE04	0	IDIPH	ĵfDiphereline P.R inj.11.25mg/		"Triptorelin is a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Following the first administration, there is a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol. After chronic and continuous administration, usually 2-4 weeks after initiation of therapy, a sustained decrease in LH and FSH secretion and marked reduction of testicular and ovarian steroidogenesis is observed. These effects are usually reversible after cessation of therapy."	Prostate Cancer or Endometriosis: Diphereline P.R. 11.25mg intramuscular injection repeated every 3 months. The treatment must be initiated in the first five days of the menstrual cycle.	"
1.`geAХNPVXåRnʦܲͧ÷G
2. ίwY`gwNXA[Jp~AanʨϤѡANVXGX ]ФűNp~^FﴫwYåߨ`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	]25JHUץxs	Triptorelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	1. @HΤlcgUvC 2. Pgk֥ΥBgk~뤩AΩvIʩΧߴ@w̡C 3. vϩʩʦ (Nk 8 HeΨk 10 He)	"Hypersensitivity to triptorelin or any other component of the product, other GnRH analogues; women who are or may become pregnant while receiving the drug."	"Hot flushes, decreased libido, impotence, vaginal dryness, dyspareunia, allergic reaction (urticaria, rash, pruritus), glucose increased, hemoglobin decreased, alkaline phosphatase increased (2% to >10%), ALT increased, AST increased, skeletal pain (12% to 13%) and Quinckes oedema."	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669087?cesid=1kgmcCMcK09&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTriptorelin%26t%3Dname%26acs%3Dfalse%26acq%3DTriptorelin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_07-06 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	OI` 5.5.1.	0	OIs 20251124	IDIPH-a	IDIPH-b	IDIPH-c	111.8.19
AC59031157	L02AB01	0	LMEGE	Giga oral suspension 40mg/ml; 120ml/bot		"1. ~O@ئXĪA|vTUAͧܶƧ@ΡA㦳ܸ~FSʾॼADnΨӪvlcC
2. ~iﵽgAIDSw̲ͪcAiW[w̪AW[魫C "	H_lĳq400-800mg/	"1.ϥΥ~v魫eAXiv魫]Coǭ]]Ai઺cʨáBʷPVBvTlzGDewBcefεŦκ믫fC
2.ʮeffvwԷVϥΡC
3.iX}fcơAخqݨDqW[P洵fAaGC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Megestrol acetate	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	ѧK̯ʥFgԸsw̪gΫѧK̯ʥFgԸsw̤gw̤cfް_魫	"1.megestrol acetateΰt褤󦨥LӪw̡C
2.whhkC"	DXBũhBYhBW[B魫W[BhBߡBæRB`R߮BLӡC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.6._20200301.pdf"">OI` 5.3.6.</a>              "	OI` 5.3.6.	0	OIs 20251124	LMEGE-a	LMEGE-b	LMEGE-c	110.6.16
AB46991157	L02AB01	0	LMEGE1	Megest oral susp. 40mg/ml;120ml/bt		"1. ~O@ئXĪA|vTUAͧܶƧ@ΡA㦳ܸ~FSʾॼADnΨӪvlcC
2. ~iﵽgAIDSw̲ͪcAiW[w̪AW[魫C "	H_lĳq400-800mg/	"1.ϥΥ~v魫eAXiv魫]Coǭ]]Ai઺cʨáBʷPVBvTlzGDewBcefεŦκ믫fC
2.ʮeffvwԷVϥΡC
3.iX}fcơAخqݨDqW[P洵fAaGC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Megestrol acetate	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	ѧK̯ʥFgԸsw̪gΫѧK̯ʥFgԸsw̤gw̤cfް_魫	"1.megestrol acetateΰt褤󦨥LӪw̡C
2.whhkC"	DXBũhBYhBW[B魫W[BhBߡBæRB`R߮BLӡC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.6._20200301.pdf"">OI` 5.3.6.</a>              "	OI` 5.3.6.	0	OIs 20251124	LMEGE1-a	01B46991-1	01B46991-2	110.6.16
AC47519100	L02AB02	0	OMEPR	ĵMepro 100mg/tab(Medroxyprogesterone)		"Medroxyprogesterone acetate]MPA^O progesterone lͦӨӡA@XTJAfAġAcPѵM progesterone ۦAPBb \-6 m Methyl group P 17 m acetoxy
groupCMedroxyprogesterone acetate 㦳ପ@λPܨDʻPܦVʸʡCbAqAMedroxyprogesterone acetate vTctλPӭMʡC "	"Ciq100~1,000mg ]qɥiC2~3AΡ^A@CqΩlcAqΩ󥽴ಾʨCMedroxyprogesterone acetateiP䥦ؽFvApƾkΩgukX֪vC
񦳴cf誺gGC1,000mgAi@AΩάOC2AΡC "	hĳϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUAץJsC	Medroxyprogesterone	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	"Nδ_oʩಾʤlcUkAgkA@Φ񦳴cf
褧gC"	RߪAʮ몺աAYx\lˡALyA]XAĪLӪ̥ioͰtC 	P䥦ۦPAiް_ũĲhBŷBD`XBgy`BgB~B魫ܡBlcVSAβ`cBxĺdxAΨSogB믫{C 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 j	Ts110.6.16		OI` 	0	OIs 20251124	OMEPR-a	OMEPR-B	OMEPR-c	110.6.16
		0	IFASL	ĵFaslodex 250mg/5ml		"Fulvestrant O@ػۿEܾAiPۿEvʵXA˩MOiPۤGJ (oestradiol) ۤCFulvestrant
_ۿEi@(trophic actions)AS󧽳Pľ(partial agonistAۿE)@ΡC@ξPVUո`ۿE(ER)Jս観 "	~k(]AѦ~H)GĳĤ@Ӥ뾯q500mgCg@AĤGӤ뤧ᾯq500mg@Ӥ@C 	ϥFASLODEXvAIzLOiܱ`C]A}w̦brpξާ@ɶpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Fulvestrant	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	vwUʧܻۿEkAef_oAΨϥΧܻۿEkefcƪgkABۿE鬰ʪߴಾʨC 	"1. 糧~ĦΥξLӪ̡C
2. hP¨šC 
3. רx\णC "	"̱`q}O`gBIzLOBߤΨxï(ALT, AST, ALP)WɡC "	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-21 j	Ts110.6.16		OI` 	0	OIs 20251124	IFASL-a	IFASL-b	IFASL-c	110.6.16
BC27596100	L02BB05	0	OERLE	fErleada FC 60mg(Apalutamide)		ApalutamideO@ضʯ(AR)A~|PARt鵲XϵXCApalutamide|ARಾ@ΡBDNAX@ΡBê_ARҴC@ΡCDnNªN-desmethyl apalutamideO@ظzĪARANªb~ɰ]Re{ʬapalutamideT@Cb{زӫeCҫ礤A뤩apalutamide|C~FӭMWͧ@ΤΨüW[`@ΡAqӨϱo~FnYpC 	"ERLEADAĳqC@fA뤩240@J(460@J)C
]AC
ERLEADAiHΤHAΡC 
]`xfHAīG(120ml)Pī~VX,iH,,15AͩզA15,ī~δͧ]UVX,H60mlR~e,åߧY,ƨ⦸,TO\qQA,CsAs"	"1. ʵO_X{ʦʤŦfxPgCɥiRnߦަMI]lApB}fΦײ`CpGoͲ3 M4 Ū}ƥAҼ{ERLEADAC
2. fHO_oͰ骺IC̾ڤwTߪv޺ʵγBz魷IfHAҼ{ϥΰf@ĪC
3. fHO_oͶ^˪IC
4. bvowo@fHä[ERLEADAC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Цs30XCHUC 	Apalutamide	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS		"1.ಾʪhձӷPʫeC(mCSPC)
2.DಾʪhէܩʫeC(nmCRPC)"	LC	֯lBmBh¡BߡBæRBΦ姿B^ˡBBwC 	"ERLEADA?ΩkʪwʻPĩ|TߡCھڨ@ξA便뤩ERLEADA?i|ɭPLˮ`Py
DJͨ|OkʦQkʯfHAbvΧ뤩̫@ERLEADA?᪺3Ӥ뤺AĨĪץI"	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_9-05 [96]_9-06 j	Ts110.11.3	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.90._20250601.pdf"">OI` 9.90.</a>              "	OI` 9.90.	0	OIs 20251124	OERLE-a	OERLE-b	OERLE-c	110.11.3
BC26634100	L02BB04	wiZnn40@J	OXTAN	ĵƼf Xtandi 40mg/cap(Enzalutamide)		weCﶯʯӷPAùʯTǻCަM @קCAƦ˴AʯTǻPϯefcơCgѶʯ E~FӭMͪݭnJ֬Ƥ DNA XCEnzalutamide OjĶʯT ǻA_ʯTǻ|XӨBJCEnzalutamide vʧʯPʯ骺XAQƨJ(nuclear translocation)AçQƶ ʯP DNA XAYϦbʯLת{PܶʯĩʪeC ӭMpU]O@ˡCEnzalutamide vCeCӭMͪAï໤ӭM `M~FYCb{ɫesAenzalutamide Sʯ@άʡC 	"ĳqfA enzalutamide 160mg (4  40mg n)CѤ@C DNhժfwAH LHRH ĪhժvC
Xtandi fAϥΡCnHɧ]AAiH\ΪŸAΡC "	ݦM`ĪAĮɽФpߡ]paM^CnHɧ]AAZHB˯}B}οĤ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC 	Enzalutamide	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	"(1)ĪΤNhէܩʪಾʫeCABbʯhkѫݵLgλׯgӤϥΤƾǪv̡C
(2)ĪΤNhէܩʪಾʫeCBwL docetaxel v̡C "	"1.ﬡʦνξM椤ҦC@ξLӡC 
2.ΥihkC"	̱`}LO/hҡBBYhMC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669178?cesid=92INWNL57bg&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEnzalutamide%26t%3Dname%26acs%3Dfalse%26acq%3DEnzalutamide"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.08.30	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.54._20251001.pdf"">OI` 9.54.</a>              "	OI` 9.54.	0	OIs 20251124	DC	DC	DC	114.08.30
BC23097100	L02BG06	0	OAROM	ĵ Aromasin 25mg/tab(Exemestane)		"ExemestaneNOǥѧڭ?Ӫ_ʯƦۿECF餺ۿE@סAFӭMXتCȱo`NOA٬۱ʧ覡AexemestaneMڭ?ifXϪڭ?hʡC
oӾiHexemestaneĤ@qɶA餺ۿE@פMܧC]C "	fAA˾q@25 mgA11AyAΡCĥAROMASINvܸ~FiiCxǥ\णw̵LݾqվC 	"1.B󰱸gecAkiϥΡA{ɨϥΫeqLLHBFSHMEstradiolӽT{kB󰱸g᪬AC
2.BʭVΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Exemestane	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	㦳ۿE鶧ʤgkAϥTamoxifenܤ2~IǩʨUvCwܻۿEӵLĤgkߴ	ĪΥ󻲮ƦLӪ̡BgekBhέŰkC	̱`OMߡCL`}ƥOhҡBXW[MYwC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_1R-03 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.1.1._20160801_000.pdf"">OI` 9.1.1.</a>              "	OI` 9.1.1.	0	OIs 20251124	OAROM-a	OAROM-b	OAROM-c	111.8.19
AC56730100	L02BG03	0	OARIM	ĵ Anastrozole F.C 1mg/tab		"~O@ӱjĨè㦳׿ܩʪDTJaromataseAbgkAoestradiolͥDnOѦg´aromataseïƦXNandrostenedioneܦoestrone,oestroneHAܦoestradiolӨӪCC夤oestradiol@פwQܷ|w̦qC󰱸gkAھڰӷPפkRAC1mgioestradiolF80%HWC"	"1. H(]AѤH)GfA@Ѥ@(1mg)C
2. ǥ\lˡGשΤ׵ǥ\ण}fHAĳվ㾯qC
3. x\lˡG靈רxffHAĳվ㾯qC"	"1. XAðݪfHA䰱gP_HͤƫШӬɩwC
2. Lƥi~Ω󤤫שYxl˯fHYǷl(creatinineMvC20ml / min)fHwʤΦĩʡC
3. ~ӷ|vTfH}ξާ@񪺯OCMӡAiܨϥΥ~|LOMݺΡAGo˪gɡA}ξާ@ɻݤpߡC
4. ķ|zZprogesteroneBandrogensestrogens夤@סAW[夤`xTJLDL@סC
5. LqBzGLqɨõLSwѬrA̯gvCĪLqBzAҼ{fHwAΦhľiʡCYfHNѲMAi[HʦRCѩ󥻫~P夤Jս赲XväA]GzRki঳ҧUqCnɥi@몺kC
6. AΥ~fHwʴGBx\Mתտ@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Anastrozole	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	"1DgۿEʱʩΤMߴಾʨĤ@uvC
2DgkߴAۿEʱʡATAMOXIFENʤ̡C
"	gekBhα¨ŰBYǷl˪fH(creatinineMvC20ml / min)BשYxffHBwanastrozoleΥХܩ~LӪ̡C	`Ƨ@Υ]AADߩMv}A]iް_GzA(ʥFBߡBæRMm)BLOBݺΡBYhεolAuDXBΨx\ܤơC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_1R-05 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.1.2._20040601_000.pdf"">OI` 9.1.2.</a>              "	OI` 9.1.2.	0	OIs 20251124	OARIM-a	OARIM-B	OARIM-	111.8.19
BC22282100	L02BG03	0	OARIM1	ĵ Arimidex 1mg/tab(Anastrozole)		"~O@ӱjĨè㦳׿ܩʪDTJaromataseAbgkAoestradiolͥDnOѦg´aromataseïƦXNandrostenedioneܦoestrone,oestroneHAܦoestradiolӨӪCC夤oestradiol@פwQܷ|w̦qC󰱸gkAھڰӷPפkRAC1mgioestradiolF80%HWC"	"1. H(]AѤH)GfA@Ѥ@(1mg)C
2. ǥ\lˡGשΤ׵ǥ\ण}fHAĳվ㾯qC
3. x\lˡG靈רxffHAĳվ㾯qC"	"1. XAðݪfHA䰱gP_HͤƫШӬɩwC
2. Lƥi~Ω󤤫שYxl˯fHYǷl(creatinineMvC20ml / min)fHwʤΦĩʡC
3. ~ӷ|vTfH}ξާ@񪺯OCMӡAiܨϥΥ~|LOMݺΡAGo˪gɡA}ξާ@ɻݤpߡC
4. ķ|zZprogesteroneBandrogensestrogens夤@סAW[夤`xTJLDL@סC
5. LqBzGLqɨõLSwѬrA̯gvCĪLqBzAҼ{fHwAΦhľiʡCYfHNѲMAi[HʦRCѩ󥻫~P夤Jս赲XväA]GzRki঳ҧUqCnɥi@몺kC
6. AΥ~fHwʴGBx\Mתտ@סC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Anastrozole	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	"1DgۿEʱʩΤMߴಾʨĤ@uvC
2DgkߴAۿEʱʡATAMOXIFENʤ̡C
"	gekBhα¨ŰBYǷl˪fH(creatinineMvC20ml / min)BשYxffHBwanastrozoleΥХܩ~LӪ̡C	`Ƨ@Υ]AADߩMv}A]iް_GzA(ʥFBߡBæRMm)BLOBݺΡBYhεolAuDXBΨx\ܤơC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_1R-01 [96]_1R-02 [96]_1R-04 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.1.2._20040601_000.pdf"">OI` 9.1.2.</a>              "	OI` 9.1.2.	0	OIs 20251124	OARIM1-a	OARIM1-b	02C22282-2	111.8.19
BC22462100	L02BG04	0	OFEMA	ĵ Femara F.C. 2.5mg/tab(Letrozole)		DTJڭ?(ʱX) 	C@Femara 2.5mgC	i|oͯhҩMYAĳקKާ@ξrpT	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Letrozole	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	ܰʱEvѪ۵MΤHugᤧfHvCgᤧߴಾʨkw̤Ĥ@uvġCXeʤLN METASTASIS POSITIVEfH@TAMOXIFENUk᪺vCgXeʤfHUvC 	糧~DΥ@ؽ᫬LӪ̡C 	Yhh¡BGzABBXB٦װYkhBy¡Bg`B魫ܡBrYC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H3 [2]_H3 [ws]_w61-01 [E]_EX12-05 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.1.3._20130801_000.pdf"">OI` 9.1.3.</a>              "	OI` 9.1.3.	0	OIs 20251124	OFEMA-a	OFEMA-f	OFEMA-c	111.8.19
BC22154100	L02BA01	0	OTAMO	ĵ Nolvadex 10mg/tab (Tamoxifen)		~ʿElͪADnvΨNᤧUkC	C20~40mgAi@Ѩ⦸ġAΤ@Ѥ@ġC 	gekϥΥī~v~FɡAg|C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Tamoxifen	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	ಾʨvBNᤧUkC 	oAΡAkbAestrogen receptor antagonistಾʥ~ɩΰīӤĳnC	BDXBDcB~koBθ~F[@( tumor flare)C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H3 [2]_H3 [ws]_w61-02 j	Ts111.8.19		OI` 	0	OIs 20251124	OTAMO-a	OTAMO-b	OTAMO-c	111.8.19
KC00670282		0	IFIL3	Filgrastim 300ug/0.7ml/amp(N)		P|PsbݤʥզDeXӭMܦݤʥզyӭMW鲣ͯSXAݤʥզyeXӭMPiơBWޡAӦp令ݤʥզyhi@ΡC	"Pi貾ӮɶݤʥզyƤW[Aq`Hb貾ӤNݤΤA}lHFilgrastim300ug/TA@@IwRߪ`gCൣbȫݤΤ}lHFilgrastim 300ug/T@@IwRߪ`gFYݤʥզyƼW[5,000/?(զy10,000/?)HWɡA[gӤġClAgΪkζqаѨC
"	"1. PȭݤʥզyʥFfwC
2. `gAwiG˹ASO`NiݤʥզyA(զy)AW[쥲ݼƶqHWCpwWܥnƶqHWɡAĨAĩΰıIC
3. FLӤo͡AϥΫeRݶEAnɩywIֽC
4. iƾkݤʥզyʥFfw̡APƾksFA`gAקKbƾkePC
5. wbo|}gԸsAH۪޲yW[fҡAPʥզfMICҥHbϥΥɡAļ˲ӭMAT{AgL~A޲yWhC
6. ʰʥզfw(ƾkΰ貾Ӯ)PɡAļ˲ӭMAgL~T{CѥEӲͪզfӭMO_W[AåBw@GˬdΰˬdAp޲yW[AhݤġC
7. ൣϥΥAR[AVϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js2-8XC	Filgrastim	L03A	K̼Wj IMMUNOSTIMULANTS	0	"1.ʭyFӭMܩP夤
2.PiyFӭMӮɶݤʥզyƪW[
3.gƾkҤް_ݤʥզy֯g
4. o|}gԸsݤʥզyʥFg
5.ѩʡBSʶݤʥզyʥFgC"	"1. 糧ΨLɲytΦE]lsLӤw̡C
2. 褤޲yèSQ֪ʥզfw̤ΥGiݨ착޲yʥզfw̡C"	"1. ֽGolBoo͡C
2. xŦGɷ|S-GOT,SGPTW@C
3. ƾxGɷ|ߡBæRpo͡C
4. ٦סBftΡGhABɷ|yhBݵhB`hεo͡C
5. LGɤް_AlpBLDHW@BoNBYhB«PB߱BĤW@ΦMCreatinineW@C"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-25 j	Ts110.6.16		OI` 	0	OIs 20251124	IFIL3-a	IFIL3-b	IFIL3-c	110.6.16
KC01108280	L03AA13	0	IFULP	Fulphila 6mg/0.6ml (Pegfilgrastim)		egfilgrastimsE]lA@ΦbyӭMWAgѻPM@ʪӭM鵲XA]ӨEW͡BơBƱM@ʤγ̲ײӭM\ଡơC	"֤U`gC@g뤩 6mg
ǥ\êfHϥpegfilgrastimݽվ㾯qC["	"OWd4.1.2.զyͪE(G-CSF)(101/6/1): 4.1.2.2.ī`g(p pegfilgrastim):(101/6/1) DgX֦IǤw,bʧĪv,Bgoͥզy֩ 1000/cumm,Τʥզy (ANC)֩ 500/cumm ̨ϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	2-8JDϥΫeAбN˦FulphilawRwpѦBcXAFulphilawRwmǷŤ(ܤ30)CmǷŤUWL48pɫhC	Pegfilgrastim	L03A	K̼Wj IMMUNOSTIMULANTS	0	"AΩDgfHbް_{ɤW۵oͲvݤʥզy֯gXֵoNʧĪv,HCݤʥզy֯gXֵoN{PVoͲvC"	pegfilgrastimfilgrastimYLӤfvfHTϥFulphilaC	"hΥ|ϵhC
"	"hC
hkSα}nC"	PegfilgrastimO_|cܨťĤOCLG-CSFܤֳQcťĤηsͨण|fAlG-CSFC¨Űkɶ`NC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-37 j	Ts110/9/10	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.2.2._20250901.pdf"">OI` 4.1.2.2.</a>              "	OI` 4.1.2.2.	0	OIs 20251124	IFULP-a	IFULP-b	IFULP-c	110/9/10
AB50154100	L04AA06	0	OCELL1	Immufine 250mg/cap (Mycophenolate Mofetil )		Mycophenolate mofetil (MMF)Omycophenolic acid (MPA)2-morpholinoethyl esterCMPAܩʡBDvʤΥifjOֺ?CĥhB?(IMPDH)A]I?ĦXs(de novo)|CMPAIMPDHïʪGMMPAcŦQiIGֻĻ]l(nicotinamide adenine dinucleotide cofactor)Τ@ĲClCoا@ΥiKIMPƦxanthose-5-monophosphateAYI?ĥͪsX@(de novo guanosine nucleotide biosynthesis)MwBJC۸䥦ӭMAMPAOڲyi͸jOӭM@ΡA]TOڲyPBOڲyWͷʿsI諸sX@ΡAӨ䥦ӭMhiQαϴ|(salvage pathways)iW͡C 	"wŦƥзǾq
ĳŦӯfHfARߪ`g(`g2ӤpɥHW)qCѤGC1J(C龯q2J)C
wŦƥзǾq
ĳŦӯfHfAqCѤGC1.5J(C龯q3J)C
wxŦƥзǾq
ĳxŦӯfHqCѤfAGC1.5J(C龯q3J)C
vĤ@ιxTŦƥзǾq
ĳvĤ@ιxTƥ{HfAqCѤGC1.5J(C龯q3J)C
"	ѩtmycophenolateī~㦳FLr (embryofetal toxicity)A]hϥθī~|W[y (first trimester pregnancy loss) Υѩʲ` (congenital malformations) IC㦳ͨ|Okb}lveץMhpeԸߡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC 	Mycophenolate mofetil	L04A	Ķ IMMUNOSUPPRESSANTS	0	PcyclosporinMTJX֨ϥΡAHwνwѵŦӤʾxƥBwŦMxŦӤʾxƥC 	"o{CellCeptRLӪfҡA]CellCeptRTΩmycophenolate mofetilmycophenolic acid (MPA)LӪfHC
CellCeptRRߪ`g]TΩwpolysorbate 80LӪfHC
DLANī~iܪpUA_htmycophenolateī~TϥΩ󥼨ϥΰצץk|֤kʡBhkʤέŤkʡC"	KBmBYhBߡBLOC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111/08/18		OI` 	0	OIs 20251124	OCELL1-a	OCELL1-b	OCELL1-c	111/08/18
KC00907229	L04AC07	0	IACTE	Actemra 200mg/10ml/vial(N)		"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
 MTXLk@ΤAX~PMTXAiActemraWvC

 ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"Rheumatoid arthritis: Initially, 4 mg/kg IVF over 1hr Q4W; may increase to 8mg/kg Q4W based on clinical response. NOT to exceed 800 mg/dose Q4W.

"	"HUpקK}lvGANC < 1000; Platelets < 100000; ALT/AST > 1.5* ULNC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Né2XC9XC (]ץxs)	Tocilizumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
 MTXLk@ΤAX~PMTXAiActemraWvC

 ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"Serious infection, hypersensitivity"	"Hypertension, Increases ALT, Diarrhea, Upper respiratory tract infection, Headache, Rash, etc.

"	קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.1._20251001.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.12._20240101.pdf"">OI` 8.2.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.12.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.2.</a>           "	"OI` 8.2.4.,8.2.4.1.,8.2.4.12.,8.2.4.2."	0	OIs 20251124	IACTE-a	IACTE-b	IACTE-c	110.6.16
KC00907219	L04AC07	0	IACTE1	Actemra 80mg/4ml/vial(N)		"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
MTXLk@ΤAX~PMTXAiActemraWvC
ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"`:lq 4 mg/kgRߪ`gWL@pɡAC|g@; iھ{ɤW[q8mg/kgAC|g@C ̤jqWL800 mg/dose C|g@.

"	"HUpקK}lvGANC < 1000; Platelets < 100000; ALT/AST > 1.5* ULNC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Né2XC10XC (]ץxs)	Tocilizumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
MTXLk@ΤAX~PMTXAiActemraWvC
ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"YPVgw
糧~LӪ"	"AALTɰAmAWIlDPVAYhA֯l
"	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.1._20251001.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.12._20240101.pdf"">OI` 8.2.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.12.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.2.</a>           "	"OI` 8.2.4.,8.2.4.1.,8.2.4.12.,8.2.4.2."	0	OIs 20251124	IACTE1-a	IACTE1-b	IACTE1-c	110.6.16
KC01024209	L04AB05	0	ICIMZ	fCimzia 200mg/ml/syringe(N)		Certolizumab pegol MӭMiʤH? TNF\  @Ψ㾯?C	?`  ϥΰ_l?ACimzia Ω?`?w̤ĳ?C2g200@JΨC4g400@JC  ʯժ(AS)  ϥΰ_l?ACimzia ʯժHw̪ĳ?C2g200@JΨC4g400@JC  ~`  ϥΰ_l?ACimzia ﰮ~`Hw̪ĳ?C2g200@JΨC4g400@J	ʩʪ͵֩ΨLYPVB靈ĦΨ䤤᫬LӡB?έ?߰I(NYHA classes III/IV)	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Nxs 2 X C  8 X C 	Certolizumab pegol 200mg/ml/vial	L04A	Ķ IMMUNOSUPPRESSANTS	0	`B~/~`Bʯժ	ʩʪ͵֩ΨLYPVB靈ĦΨ䤤᫬LӡB?έ?߰I(NYHA classes III/IV)	GP?ڨt?`BPVBߡBx	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6.1._20250601.pdf"">OI` 8.2.4.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6._20250601.pdf"">OI` 8.2.4.6.1.</a>         "	"OI` 8.2.4.2.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.6.,8.2.4.6.1."	0	OIs 20251124	ICIMZ-a	ICIMZ-b	ICIMZ-c	110.6.16
KC00897265	L04AA24	0	IOREN	fOrencia 250mg/vial(N)		1.`2.~C` 3.nĭGOrenciaiPLv`(RA)ͪsPɨϥΡC	"Rheumatoid arthritis (Moderate to Severe): 500mg(BW<60kg), 750mg(BW=60~100kg), 1000mg(BW>100kg) IVF over 30 min; repeat doses at 2nd and 4th wks after first infusion and Q4W thereafter. Juvenile idiopathic arthritis (Moderate to Severe), active, polyarticular: (6 yr; BW<75 kg) 10 mg/kg IVF over 30 min; repeat doses at 2nd and 4th wks after first infusion and Q4W thereafter."	}l ORENCIA veAi]A HBV HCV bfrzˡCTPLRAͪs֥ΡCϥ10ml DWѭᴹAL{TjOnAHKͪwjAi@BHNSܤֵ}100mlA~iѿ`C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	N2~8J ץ	Abatacept	L04A	Ķ IMMUNOSUPPRESSANTS	0	1.`2.~C` 3.nĭGOrenciaiPLv`(RA)ͪsPɨϥΡC	 	"Nausea, Infectious disease, Headache, Acute exacerbation of chronic obstructive pulmonary disease.

"	/	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.8._20220201.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.8.</a>            "	"OI` 8.2.4.,8.2.4.2.,8.2.4.8."	0	OIs 20251124	IOREN-a	IOREN-b	IOREN-c	110.6.16
KC00945258	L04AA24	0	IOREN1	Orencia S.C.125mg/ml/syr(N)		1.` 2.~C` 3.nĭGOrenciaiPLv`(RA)ͪsPɨϥΡC	"Rheumatoid arthritis (Moderate to Severe):
500mg(BW<60kg), 750mg(BW=60~100kg), 1000mg(BW>100kg) IVF over 30 min on Day1 and 125 mg SC on Day2, then 125 mg SC QW."	}l ORENCIA veAi]A HBV HCV bfrzˡCTPLRAͪs֥ΡCϥ10ml DWѭᴹAL{TjOnAHKͪwjAi@BHNSܤֵ}100mlA~iѿ`C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	N2~8J ץ	Abatacept	L04A	Ķ IMMUNOSUPPRESSANTS	0	1.`GOrenciaPmethotrexate֥ΡAΩvwצܭ׬ʩ`BLef׹ܭfĪ[]Amethotrexate (MTX)Τ@ظ~Fa]l(TNF)]}έ@ʤΪHw̡C 2.~C`GOrenciaPmethotrexate֥ΡAΩvwצܭץ~C`BLef׹ܭfĪ[]A@ظ~Fa]l(TNF)]}έ@ʤΪ66HWൣw̡C**Orencia6HUൣisC 3.nĭGOrenciaiPLv`(RA)ͪsPɨϥΡC	-------	"Nausea, Infectious disease, Headache, Acute exacerbation of chronic obstructive pulmonary disease."	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.8._20220201.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.8.</a>            "	"OI` 8.2.4.,8.2.4.2.,8.2.4.8."	0	OIs 20251124	IOREN1-c	IOREN1-c	IOREN1-c	110.6.16
KC01039271	L04AB04	0	IHUMI	Humira 40mg/syringe (Adalimumab)(N)		"`GAΩwצܭ`åBg@ةζWL@تDMARDsĪAHfwAigPx(]ADn{ɤM{ɽw)BcWl`cơC

"	"Ankylosing spondylitisSC, 40 mg every other week alone or in combination with NSAIDS,glucocorticoids,methotrexate or other DMARDs.Psoriasis with arthropathySC, 40 mg every other week alone or in combination with other disease-modifying anti- rheumatic drugs (DMARDs).Rheumatoid arthritis (Moderate to Severe)SC, 40 mg every other week; other DMARDs may be continued during therapy; may increase to 40 mg every week in patients not receiving concomitant methotrexate."	" DPVw챱A_hPVo@fH }l Humira vA]ACʩΧPVC
 S󵲮ֵߤUfH AHδ󵲮֯fΦaʪ߯f pA´ߵ߯fBy߯fΪޥ߯f
) IϰȦ檺 fH Ab}lveҼ{ϥ Humira vIPQq"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Nxs 2 X C  8 X C 	Adalimumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	"1.`GAΩwצܭ`åBg@ةζWL@تDMARDsĪAHfwAigPx(]ADn{ɤM{ɽw)BcWl`cơC2.~`3.ʯժ4.Jg5.~6.ũʵz7.zDg8.wʦ9.彤10.~ʦ۵oʦh`11.pJg12.pา彤13.pũʵz

"	humiraL	"Hypertension, injection site reaction, rash, headache

"	iw	HumiraibŴϥΡA|QzGD	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-11 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.1._20251001.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.10._20210616.pdf"">OI` 8.2.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.10.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6.1._20250601.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6._20250601.pdf"">OI` 8.2.4.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.7.1._20250901.pdf"">OI` 8.2.4.6.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.7.2._20250901.pdf"">OI` 8.2.4.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.7._20250901.pdf"">OI` 8.2.4.7.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.1._20250901.pdf"">OI` 8.2.4.7.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.2._20250901.pdf"">OI` 8.2.4.9.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9._20250901.pdf"">OI` 8.2.4.9.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdfKC01039271"	"OI` 8.2.4.,8.2.4.1.,8.2.4.10.,8.2.4.2.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.6.,8.2.4.6.1.,8.2.4.7.,8.2.4.7.1.,8.2.4.7.2.,8.2.4.9.,8.2.4.9.1.,8.2.4.9.2."	0	OIs 20251124	IHUMI-a	IHUMI-b	IHUMI-c	110.6.16
BC25214100	L04AX04	0	OREVL	ĵƼf REVLIMID 25mg/cap(Lenalidomide)		Lenalidomide @ξAݶi@BMA㦳ܸ~Fs͡BK̽ո`Mܦ޷sͪSCLenalidomide PGֲycPioӭMEAüW[ܵoӭMEcCLenalidomide YǲӭMWޡAj(IC50s) h@A]ҦӭMCbչLӭM褤Ao{lenalidomide ঳ħNamalwa ӭM]@ؤHB ӭMOӭMA֤@Ӳ5 V^ͪAMӡAKG-1 ӭM]HFӭMA]֤@Ӳ5 V^MLS5 VʥӭMAͪĪGĤOC Lenalidomide ໤ɲӭMgP`Aqӧѱw̨WohoʰFӭMͪA]MM.1 S ӭM]@ؤHhoʰFӭM^ͪC~o{Alenalidomide 2 X?(COX-2) ʡAäCOX-1C	ĳRevlimid _lqC25 @JAHeAAb28 ѥĶg1 21 ѡACA1 25 @JnC[Ľо]Ai}BZHΥ}nC	"1.Ķȯ}ߵw̡AӥBYϨLHۦgA]iLHAΡC
2.ĥsൣiΤBAYTѵihkC
3.AΥĴAw̤oC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCC	Lenalidomide 25mg	L04A	Ķ IMMUNOSUPPRESSANTS	0	"RevlimidPdexamethasoneX֨ϥΥivewܤ֤@تvѤhoʰF(multiple myeloma, MM)w"	YwTw̹REVLIMID (lenalidomide) Ψ䦨LӡAhTϥΡC	hBP~BKBmB⵬C	X 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.43._20251001.pdf"">OI` 9.43.</a>              "	OI` 9.43.	0	OIs 20251124	OREVL-a	OREVL-b	OREVL-c	111.8.19
KC00911206	L04AB06	0	ISIMP	fSimponi 50mg/0.5ml/(Golimumab)(N)		GolimumabO~Fa]l(TNF-\ blockers)AiHMH骺TNF-\XӤzZTNF-\M鵲XATNF-\ʡAw`~ȻPkhACʵo	50 mg SUBQ once monthly	Yѩ餺TNF-\ʡAiӭCK̨tΧ@ΡA@`GWIlDPV(16%)B`g(6%)BfrPV(5%)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץNé2XC8XC	Golimumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	Pmethotrexate֥ξAΩvܭ׬ʩ`Hw; ʩʻʯժHw̡C	Hypersensitivity to golimumab or to any other component of the product; active tuberculosis or other serious Infections like invasive fungal infections; NYHA Class III / IV Heart failure.	"Upper respiratory infection, injection site reaction, viral disease, ALT/AST level raised, hypertension, dizziness."	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-28 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.1._20250901.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9._20250901.pdf"">OI` 8.2.4.9.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.9.1.</a>        "	"OI` 8.2.4.,8.2.4.2.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.9.,8.2.4.9.1."	0	OIs 20251124	ISIMP-a	ISIMP-b	ISIMP-c	110.6.16
AB48969100	L04AX02	0	OTHAD	ĵ Thado 50mg/cap(Thalidomide)		"THADO(thalidomide)O@K̽ո`B㦳ޥͪ\AK̽ո`|QMA\hoPĶ@ΤsQoA䤤]AݤʥզyͤƩʡBCֲӭM]@ΡBC񤤶(superoxidehydroxyl radicals)BT-ӭM(YCUT-ӭM(helper T-cell)BT-ӭM(suppressor T-cell))BHέCIgMȩMCIgMΦ 2. THADO(thalidomide)iENLfH~Fa]l(Tumor Necrosis Factor -a, TNF-a)HΤzZ-^(Interferon-^, INF-^)@ΡAΥʯgAoӭMܯfܳBC"	"@뾯q:300mg/day;(vϥξqd: 1001200 mg/day)A\@p,AΡC"	1. ĥi|ް_ݺΪΡAקK}ξާ@C2. ĥi|wtB_ߩʧCΡAѪ׫ΧߡAwCBpߡC3. Ĵް_?Ƨ@γiA?fvΦoͷ?MI]lfHAݤpߺʴC4. ĦܱjPL@ΡAiɭPYLέL঺`AhέŪkTΡC~Aihkʦbīe@Ӥܰī@ӤAϥΦܤ֤GץIA䤤]t@ئĤץ覡AYfHϥΤfAץġAݪ`L֥ī~O_|vTץĪGC5. kʱw̦bAΦī~ܰī@ӤACʦ欰{ϥΫOIMC6. ݤʥզyC750/mm3ɡAiϥthalidomideCAĴo{fwզy֪ΡAlܡAYզyCUҼ{ġC7. AĪ̪TӤACw^EˬdAHKo{gWfܡC8. īeAfw\ŪñpATHADO(thalidomide)ukʯfwATHADOPN/kʯfwATHADOPNѡvAȦfw@NӦPNѪܤUA~iBTHADO(thalidomide)w̡CīeAfw\ŪñpATHADO(thalidomide)ukʯfwATHADOPN/kʯfwATHADOPNѡvAȦfw@NӦPNѪܤUA~iBTHADO(thalidomide)w̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Thalidomide	L04A	Ķ IMMUNOSUPPRESSANTS	0	"FDA֥iī~@vUCeft(orphan drug)Gvιw貾Ӥgraft vs host diseaseBvreactionallepromatous leprosyBYδ_ofHʤf(aphthous stomatitis)μšB߷PV(mycobacterial infection)BAIDS HIV)-associated wasting syndromeBdi׽F(Kaposi's sarcoma)Boʸ~FBhoʰF(multiple myeloma)ΧJf(Crohn's isease)C
Ʃʵ`(ERYTHEMA NODOSUM LEPROSUM, ENL)THADOiΩ󤤫צܭENLX{ֽxʴvCiΩwΧENLֽx_oCiWΩvoͤצܭׯgENLC"	1. hΥihӥץkC2. ThalidomideYrʡAYPL@(Teratogenicity)A]AG\ϧLBέLL`CoͪMIbW@g3550ѪhkAYϤ@q|ɭPLC. THADO(thalidomide)LӪ̤iϥΡCLӤ]AGʪֽlBiHoNB߸[֤ΦCC	Thalidomidei|ɭPݺΡBt¡BP䯫gfܡBYB_ߩʧCBզyֵΡCthalidomideް_LӤΤ߸CɡCfwϥthalidomideoͤ߸C(Bradycardia)ΡAثe|L]߸CݭnĪvBmɡC	X 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-09 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.33._20090701_000.pdf"">OI` 9.33.</a>              "	OI` 9.33.	0	OIs 20251124	OTHAD-a	OTHAD-b	OTHAD-c	111.8.19
BC24895100	L04AD02	0	OADVA2	Advagraf PR. 5mg/cap(Tacrolimis)		"?Tacrolimus O@jĪĶA䬡ʦb~P餺礤wQҹCSOOtacrolimus |yDnӱƥ@ΤӭMr?ڲӭMΦC Tacrolimus T ӭMƤT UӭM̿૬B ӭMWͧ@ΡA]|?ڦ]l]pinterleukins-2, -3 Σ^-zZ^ͦPinterleukins-2 骺{C"	"ĳq-ŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.20-0.30 @J//Ѫq}lACѦWAΤ@CӦbӤN24 pɤ}lġC ӤNqվG AdvagrafR qbӤNq`|CC
ĳq-xŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.10-0.20 @J//Ѫq}lACѦWAΤ@CӦbӤN12-18 pɶ}lġC ӳNqվG AdvagrafR qbӤNq`|CC 
ĳq-Prograf vഫAdvagrafR vG A Prograf n@Ѩ⦸AӻݭnഫAdvagrafR @Ѥ@ӱwӮھڨC`q@@]mg:mg^覡ഫCAdvagrafR bWAΡC ഫʴtacrolimus 夤@רȡAݭnɽվ㾯qHۦSqC"	]AdvagrafR ĮĽntſ}A󦳥bſ}@gBʥFLapp ſ}JBΦ}-bſ}lê֨ǯefw̭nSOpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Osb]ˤAøm 30JHUBHKC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xǲӤĤ@uĩΨxǲCyclosporineLĤĤGuġC	tacrolimusΨLmacrolidesΥ~LξLӪ̡C	_ŸBYhBmBߡBǥ\णB}LB}fB[gBC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.1._20130701_000.pdf"">OI` 8.2.2.1.</a>              "	OI` 8.2.2.1.	0	OIs 20251124	OADVA2-a	OADVA2-b	OADVA2-c	110.6.16
BC26219100	L04AA29	0	OXELJ	Xeljanz 5mg/tab (Tofacitinib)		"TofacitinibO@JanusEC(JAK)CJAKsݩӭMïAï|NӭMEΥͪ]lPbӭMWoͥ椬@ΩҲͪTǰeXhAqӼvTyӭMBPK̲ӭM\Cbǻ|AJAKs|PϰTǾɻPƦ]l(STATs)CĤƤάơASTATsh|ո`ӭMA]A]{CTofacitinibiqJAKsoIӽո`ǻ|AêSTATsCĤƻPơCJAKï|zLJAKsҦ(pJAK1/JAK3JAK1/JAK2BJAK1/TyK2BJAK2/JAK2)ǻӭMEҵoXTC
TofacitinibiJAK1/JAK2BJAK1/JAK3JAK2/JAK2զX骺~ʡAIC50O406B56P1377 nMCLAثeäTSwJAKզXPvĪGpʡC "	1. ~ݻPmethotrexateΨLDͪʪefwѫܭĪ(DMARDs)X֨ϥΡCXELJANZĳq5@JC⦸C 2. XELJANZfAġAiP֪AAiP֪AC 	"wʩʷPVg(]APV)w̡AiߧY}lϥXELJANZC
UCw̡Ab}lϥXELJANZeŶqvIPįqG
? wCʩδ_oʷPVgF
? gP֯fw̱ĲF
? oYΦʷPVgfvF
? gb֯f߯f檺aϩ~ήȦF
? wi|OL̸eoͷPVbefF
? ϥαjħĶ(pazathioprinePcyclosporine)w̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 30JHUC 	Tofacitinib	L04A	Ķ IMMUNOSUPPRESSANTS	0	"AΩvwܭ׬ʩ`BmethotrexateLk;AvεLk@methotrexateHw̡C
~ݻPmethotrexateΨLDͪʪefwѫܭĪ(DMARDs)X֨ϥΡC~iPͪDMARDsX֨ϥΡC "	LC	mB|BWIlDPVBYhC	DnקKϥ/SmҦw	DnקKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668506?cesid=414aGcYbxE6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTofacitinib%26t%3Dname%26acs%3Dfalse%26acq%3DTofacitinib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.09.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.1._20251001.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.1._20250901.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9._20250901.pdf"">OI` 8.2.4.9.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.9.1.</a>       "	"OI` 8.2.4.,8.2.4.1.,8.2.4.2.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.9.,8.2.4.9.1."	0	OIs 20251124	DC	DC	DC	114.09.15
BC24894100	L04AD02	0	OADVA	Advagraf PR. 0.5mg/cap(Tacrolimis)		"Tacrolimus @OgѻPӭMʳJսFKBP12 XAӦbӭMWnͮĥΡCFKBP12-tacrolimus ƦX|M@BvʦaP calcinurin XåBcalcinurinA|T ӭMtl̿૬Hǻ|A]sʲOڦ]l(lymphokine)]C Tacrolimus O@jĪĶASOOtacrolimus |yDnӱƥ@ΤӭMrʲOڲӭMΦC Tacrolimus T ӭMƤT UӭM̿૬B ӭMWͧ@ΡA]|Oڦ]l]pinterleukins-2, -3 Σ^-zZ^ͦPinterleukins-2 骺{Cbwomtacrolimus HPrograf n@ѤG覡PAvLxӪGC"	"Kidney transplantXInitial, 0.15-0.2mg/kg once daily.
Liver transplantXInitial, 0.1-0.2mg/kg once daily.
ĳq-ŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.20-0.30 @J//Ѫq}lACѦWAΤ@CӦbӤN24 pɤ}lġC ӤNqվG AdvagrafR qbӤNq`|CC
ĳq-xŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.10-0.20 @J//Ѫq}lACѦWAΤ@CӦbӤN12-18 pɶ}lġC ӳNqվG AdvagrafR qbӤNq`|CC 

ĳq-Prograf vഫAdvagrafR vG A Prograf n@Ѩ⦸AӻݭnഫAdvagrafR @Ѥ@ӱwӮھڨC`q@@]mg:mg^覡ഫCAdvagrafR bWAΡC ഫʴtacrolimus 夤@רȡAݭnɽվ㾯qHۦSqC"	]AdvagrafR ĮĽntſ}A󦳥bſ}@gBʥFLapp ſ}JBΦ}-bſ}lê֨ǯefw̭nSOpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Osb]ˤAøm 30JHUBHKC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xǲӤĤ@uĩΨxǲCyclosporineLĤĤGuġC	tacrolimusΨLmacrolidesΥ~LξLӪ̡C	_ŸBYhBmBߡBǥ\णB}LB}fB[gBC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.1._20130701_000.pdf"">OI` 8.2.2.1.</a>              "	OI` 8.2.2.1.	0	OIs 20251124	OADVA-a	OADVA-b	OADVA-c	110.6.16
BC24896100	L04AD02	0	OADVA1	Advagraf PR. 1mg/cap(Tacrolimis)		xǲӤĤ@uĩΨxǲCyclosporineLĤĤGuġC	"ĳq-ŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.20-0.30 @J//Ѫq}lACѦWAΤ@CӦbӤN24 pɤ}lġC ӤNqվG AdvagrafR qbӤNq`|CC
ĳq-xŦӡG wӱƥ@ΡC fAAdvagrafR vӥH0.10-0.20 @J//Ѫq}lACѦWAΤ@CӦbӤN12-18 pɶ}lġC ӳNqվG AdvagrafR qbӤNq`|CC 
ĳq-Prograf vഫAdvagrafR vG A Prograf n@Ѩ⦸AӻݭnഫAdvagrafR @Ѥ@ӱwӮھڨC`q@@]mg:mg^覡ഫCAdvagrafR bWAΡC ഫʴtacrolimus 夤@רȡAݭnɽվ㾯qHۦSqC"	]AdvagrafR ĮĽntſ}A󦳥bſ}@gBʥFLapp ſ}BΦ}-bſ}lê֨ǯefw̭nSOpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Osb]ˤAøm 30JHUBHKC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xǲӤĤ@uĩΨxǲCyclosporineLĤĤGuġC	tacrolimusΨLmacrolidesΥ~LξLӪ̡C	_ŸBYhBmBߡBǥ\णB}LB}fB[gBC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.1._20130701_000.pdf"">OI` 8.2.2.1.</a>              "	OI` 8.2.2.1.	0	OIs 20251124	OADVA1-a	OADVA1-b	OADVA1-c	110.6.16
BC24770100	L04AA18	0	OCERT	Certican 0.25mg/tab		@WްTCĶ@θgѧ鬡ƪTӭMW͡AqӧTӭMSʪզyzZXʤӭMW͡]clone expansion^ApGզyzZ-2PզyzZ-15Xʪ̡CEverolimusӭMTǾɸ|ATӭMͪ]lXܦU۪ĲoӭMWͩһݤӭMTǾɳ~|Cgeverolimus_TɭPӭMgG1ͲӭMAC	"1. }lκcerticanvuiѩ󾹩xӫĶvg窺vABioeverolimusʴȡC 
2. HGĳŦΤŦӪfwlq0.75mgA@Ѩ⦸A󲾴ӫ֨ϥΡAMᱱq夤̧C@צb3-8ng/mlCCCerticanq⦸]@G^qfAACertican@ePΤPAΪߺDBAήɶPciclosporinLŻsۦPC 
3. CerticanuifA뤩C
4. CerticanP@M]ABAΫeiHC"	bſ}@gBYſ}JʥFgθ}-bſ}l}uǰDfwiϥΦī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץBxs	Everolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	֥δqcyclosporineLŻsTJAwŦΤŦӪHfwK̾xƥ@ΡCxŦӥΩwxŦӯfwxƥC	TҩweverolimusBsirolimusΨξLӯfwC	PVBզy֡Bߥ]nBׯgBͪBBcDPVC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-10 j	Ts110.6.16		OI` 	0	OIs 20251124	OCERT-a	OCERT-b	OCERT-c	110.6.16
BC24772100	L04AA18	0	OCERT1	Certican  0.5mg/tab (Everolimus)		@WްTCĶ@θgѧ鬡ƪTӭMW͡AqӧTӭMSʪզyzZXʤӭMW͡]clone expansion^ApGզyzZ-2PզyzZ-15Xʪ̡CEverolimusӭMTǾɸ|ATӭMͪ]lXܦU۪ĲoӭMWͩһݤӭMTǾɳ~|Cgeverolimus_TɭPӭMgG1ͲӭMAC	"Kidney or heart transplant: initial, 0.75 mg twice daily. Liver transplant: initial, 1mg twice daily. Dosage may be adjusted every 4 to 5 days based on serum blood concentrations.
1. }lκcerticanvuiѩ󾹩xӫĶvg窺vABioeverolimusʴȡC 
2. HGĳŦΤŦӪfwlq0.75mgA@Ѩ⦸A󲾴ӫ֨ϥΡAMᱱq夤̧C@צb3-8ng/mlCCCerticanq⦸]@G^qfAACertican@ePΤPAΪߺDBAήɶPciclosporinLŻsۦPC 
3. CerticanuifA뤩C
4. CerticanP@M]ABAΫeiHC"	bſ}@gBYſ}JʥFgθ}-bſ}l}uǰDfwiϥΦī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץBxs	Everolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	֥δqcyclosporineLŻsTJAwŦΤŦӪHfwK̾xƥ@ΡCxŦӥΩwxŦӯfwxƥC	TҩweverolimusBsirolimusΨξLӯfwC	PVBզy֡Bߥ]nBׯgBͪBBcDPVC	קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-11 j	Ts110.6.16		OI` 	0	OIs 20251124	OCERT1-a	OCERT1-b	OCERT1-c	110.6.16
BC21188100		0	OCYC1	Sandimmun 100mg/cap(Cyclosporin)		"Cyclosporine O11 iĩҺcpolypeptide A]iHT-ӭMWާ@ΡAҥH{ɤWOΨӧ@ĶCCyclosporine ]|OڿE(lymphokines)ͪPXA]Ainterleukin 2CCyclosporine i_bӭMgG0 G1 ƲOڲyAï]ĲܭӬƤT ӭMXOڿE C
Cyclosporine ä|y\A]|vT]ӭM(marcophage)\"	"1.x:5-10 mg/kg/dayAŦӤfwϥΧCq3 mg/kg/day
2.~:HMൣ18:@}l: 1.25 mg/kg bid |g; iCgW[@q 0.5 mg/kg/day, ̤jq: 4 mg/kg/day.
3.`G HMൣ18G@}l 2.5 mg/kg/dayBIDi8g12gW[q increased by 0.5-0.75 mg/kg/day,̤jq4 mg/kg/day."	"ĶYOΩ󾹩xӡAisӤJxةRC]x\δī~}AнTqAġAñK`N鲧ˡC1.ŦۦAΥ⦨ġC2.ŻPcĨ֪AġC3.pGzjѱNA姹A~AΤU@ӾqC4.\hĪi|vTī~夤@סA]dUnۦAΥĪA
PvĮvQסAT{wʤ~iAΡC5.AΦķ|ϱzܤOzAiePVC]̦nקKiX@
ҨûwP_ΨLPVgHsC6.AΦĥi|yziovW[ ]~ȡBy^A]ШCѱ`W
MzAéwܤˬdC7.YzhBŤAΪ̱zŦΨLefAХiDzvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cyclosporin	L04A	Ķ IMMUNOSUPPRESSANTS	0	wxӤΰ貾ӫᤧӱƥBwӤϱJDefBʩʦMIΫ᳡DPVʸ彤BϥζǲkLk̡Bbehcetsf@AoBBwIǵ̡BNkLĩΤAΤY~FзkLĩΤAΤY`FHTJvLĩιTJ̿ʪoʵǯfgԸs]˵]Biopsy^DnLpfܯefΧ`ǵywƯg^AgӭMíw(cytostatic)vLĥBǥ\Ʀb`50%HWfHC	糧~LӪ̡C	hgB_ŸBǥ\zBx\êBiΫpBHέGzê(BߡBæR)BBB[C	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E5 [2]_E5 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.1._20220501.pdf"">OI` 8.2.1.</a>              "	OI` 8.2.1.	0	OIs 20251124	OCYC1-a	OCYC1-b	OCYC1-c	110.6.16
BC25442100	L04AA10	0	ORAPA	Rapamune 0.5mg/tab (Sirolimus)		"SirolimusǥѪ_cytokineTӭM΢вӭMƧ@ΡAӭMgƤμW͡AHFĶĪGCSirolimusbӭMPFKBP-129(FK binding protein, immunophilin)XΦĶƦX(complex)AƦXcalcineurineõL@ΡAӬOP@ʽո`EïmTOR(mammalian target of rapamycin)XAç䬡ʡAǦ_cyokineDɪT-ӭMƶgG1iJSqAiӧ䬡ƻPW͡C"	"1. HG_lq6mgAqC@2mgC
2. 13B魫<40GqHnpA_lq3mg/m2 Aq1mg/m2/dayC
3. x\ण}w̡Aq`q1/3A_lqhվC"	"1. tacrolimusLӪ̡Aϥsirolimus ~pߡAW[LӤC
2. ӤNPfHܷLͪs@~AHwPneumocystis carinii pneumonia CwcytomegalovirusPVAhĤTӤC
3. sirolimus̩oͦxTJΤTĥ̪oפWɡAAvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxs	Sirolimus 0.5MG	L04A	Ķ IMMUNOSUPPRESSANTS	0	PcyclosporinTJX֨ϥΥHwŦӫᤧxƥC	sirolimus sirolimus lͪΥFҧt󦨤LӪfHTΥFC	hBpO֡BTĥ̪oסBxTJgBB|Ϥ~BC[gBCCgBKBƤ}BߡBæRBmBYhB`hΥvC䤤Tĥ̪oסBxTJgBpO֤γhAoͱλPAξqC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-08 j	Ts110.6.16		OI` 	0	OIs 20251124	ORAPA-D	ORAPA-E	ORAPA-c	110.6.16
BC23363100	L04AA10	0	ORAPA1	Rapamune 1mg/tab(Sirolimus)		"SirolimusǥѪ_cytokineTӭM΢вӭMƧ@ΡAӭMgƤμW͡AHFĶĪGCSirolimusbӭMPFKBP-129(FK binding protein, immunophilin)XΦĶƦX(complex)AƦXcalcineurineõL@ΡAӬOP@ʽո`EïmTOR(mammalian target of rapamycin)XAç䬡ʡAǦ_cyokineDɪT-ӭMƶgG1iJSqAiӧ䬡ƻPW͡C"	"1. HG_lq6mgAqC@2mgC
2. 13B魫<40GqHnpA_lq3mg/m2 Aq1mg/m2/dayC
3. x\ण}w̡Aq`q1/3A_lqhվC"	"1. tacrolimusLӪ̡Aϥsirolimus ~pߡAW[LӤC
2. ӤNPfHܷLͪs@~AHwPneumocystis carinii pneumonia CwcytomegalovirusPVAhĤTӤC
3. sirolimus̩oͦxTJΤTĥ̪oפWɡAAvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxs	Sirolimus 1MG	L04A	Ķ IMMUNOSUPPRESSANTS	0	PcyclosporinTJX֨ϥΥHwŦӫᤧxƥC	sirolimus sirolimus lͪΥFҧt󦨤LӪfHTΥFC	hBpO֡BTĥ̪oסBxTJgBB|Ϥ~BC[gBCCgBKBƤ}BߡBæRBmBYhB`hΥvC䤤Tĥ̪oסBxTJgBpO֤γhAoͱλPAξqC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-09 j	Ts110.6.16		OI` 	0	OIs 20251124	ORAPA1-a	ORAPA1-b	ORAPA1-c	110.6.16
BC23086100	L04AD02	0	OTACR	Prograf(Ķ)0.5mg/cap		"1. ħѦp interleukin-2 M interferon-^  lymphokines ͡AHζi@B~Fa]l(TNF) alpha (@تʲӭME)Binterleukin-1 beta M interleukin-6 ͡C
2. ĹK̨tΥH~ӭMWޤ@ΫܮzA]ӧe{FܩʡC
3. Ħbʪ礤TaFPةʨxŦӪӾxƥABFs]Ul)B)Bj)^C
4. Ĩ㦳[jjxӭMW (YAA)ιRߵϪxŦYiWj_ABiPiӭMW)C
5. ĦbӪJDef model A|ӪJDefABFs]p^Bj)^C
6. ĦbŦ model ATaFӾxƥABFs]aa ^B)Bj)^C
7. ĦbjŦ model ATaFӾxƥABFs)C"	"Ŧ-q`ӫe2ѡAfA tacrolimus@Ѩ⦸A@0.15mg/kgCNAfA tacrolimus @Ѩ⦸A@0.15mg/kgCMvqܺq@ 0.06mg/kgA@Ѩ⦸зǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A@0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCŦ-q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUCŦ
q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUC"	HUwV-1.x\णw̡C2.ǥ\णw̡C3.̡֪C4.PVgw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	1. 25JHUxsC2. ЦbĴϥΡC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xBǲӤĤ@uĩΨxBǲCyclosporineLĤĤGuġAŦӥġC	"1.糧ĥ󦨤Lӯgfv̡C
2.bϥciclosporinbosentanw̡C 
3.O[QĤw̡C
4.hΥihkC"	_ŸBYhBmBߡB}LB}fB[gBBvC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.2._20130701_000.pdf"">OI` 8.2.2.2.</a>              "	OI` 8.2.2.2.	0	OIs 20251124	OTACR-a	OTACR-b	OTACR-c	110.6.16
BC22043100	L04AD02	0	OTACR1	Prograf(Ķ)1mg/cap(Tacrolimus)		"1. ħѦp interleukin-2 M interferon-^  lymphokines ͡AHζi@B~Fa]l(TNF) alpha (@تʲӭME)Binterleukin-1 beta M interleukin-6 ͡C
2. ĹK̨tΥH~ӭMWޤ@ΫܮzA]ӧe{FܩʡC
3. Ħbʪ礤TaFPةʨxŦӪӾxƥABFs]Ul)B)Bj)^C
4. Ĩ㦳[jjxӭMW (YAA)ιRߵϪxŦYiWj_ABiPiӭMW)C
5. ĦbӪJDef model A|ӪJDefABFs]p^Bj)^C
6. ĦbŦ model ATaFӾxƥABFs]aa ^B)Bj)^C
7. ĦbjŦ model ATaFӾxƥABFs)C"	"Ŧ-q`ӫe2ѡAfA tacrolimus@Ѩ⦸A@0.15mg/kgCNAfA tacrolimus @Ѩ⦸A@0.15mg/kgCMvqܺq@ 0.06mg/kgA@Ѩ⦸зǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A@0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCŦ-q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUCŦ
q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUC"	HUwV-1.x\णw̡C2.ǥ\णw̡C3.̡֪C4.PVgw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	1. 25JHUxsC2. ЦbĴϥΡC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xBǲӤĤ@uĩΨxBǲCyclosporineLĤĤGuġAŦӥġC	"1.糧ĥ󦨤Lӯgfv̡C
2.bϥciclosporinbosentanw̡C 
3.O[QĤw̡C
4.hΥihkC"	_ŸBYhBmBߡB}LB}fB[gBBvC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.2._20130701_000.pdf"">OI` 8.2.2.2.</a>              "	OI` 8.2.2.2.	0	OIs 20251124	OTACR1-a	OTACR1-b	OTACR1-c	110.6.16
BC21757100	L04AA06	0	OCELL	CellCept 250mg/cap 		Mycophenolate mofetil (MMF)Omycophenolic acid (MPA)2-morpholinoethyl esterCMPAܩʡBDvʤΥifjOֺ?CĥhB?(IMPDH)A]I?ĦXs(de novo)|CMPAIMPDHïʪGMMPAcŦQiIGֻĻ]l(nicotinamide adenine dinucleotide cofactor)Τ@ĲClCoا@ΥiKIMPƦxanthose-5-monophosphateAYI?ĥͪsX@(de novo guanosine nucleotide biosynthesis)MwBJC۸䥦ӭMAMPAOڲyi͸jOӭM@ΡA]TOڲyPBOڲyWͷʿsI諸sX@ΡAӨ䥦ӭMhiQαϴ|(salvage pathways)iW͡C 	"wŦƥзǾq
ĳŦӯfHfARߪ`g(`g2ӤpɥHW)qCѤGC1J(C龯q2J)C
wŦƥзǾq
ĳŦӯfHfAqCѤGC1.5J(C龯q3J)C
wxŦƥзǾq
ĳxŦӯfHqCѤfAGC1.5J(C龯q3J)C
vĤ@ιxTŦƥзǾq
ĳvĤ@ιxTƥ{HfAqCѤGC1.5J(C龯q3J)C
"	ѩtmycophenolateī~㦳FLr (embryofetal toxicity)A]hϥθī~|W[y (first trimester pregnancy loss) Υѩʲ` (congenital malformations) IC㦳ͨ|Okb}lveץMhpeԸߡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC 	Mycophenolate mofetil	L04A	Ķ IMMUNOSUPPRESSANTS	0	PcyclosporinMTJX֨ϥΡAHwνwѵŦӤʾxƥBwŦMxŦӤʾxƥC 	"o{CellCeptRLӪfҡA]CellCeptRTΩmycophenolate mofetilmycophenolic acid (MPA)LӪfHC
CellCeptRRߪ`g]TΩwpolysorbate 80LӪfHC
DLANī~iܪpUA_htmycophenolateī~TϥΩ󥼨ϥΰצץk|֤kʡBhkʤέŤkʡC"	KBmBYhBߡBLOC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-07 j	Ts110.6.16		OI` 	0	OIs 20251124	OCELL-a	OCELL-b	OCELL-c	110.6.16
AC48558100	L04AA13	0	OARHE1	Arheuma 10mg/tab(Leflunomide)		"1. LeflunomideO@ب㦳ܼWާ@Τef׹ʧܭfĪC
2. Leflunomide`BLK̯efPxӦġA㦳K̽ո`/ĶʽAܼWާ@ΦӲͧܵoĪGAbK̯efʪAefoͪPLeflunomideAiF̦nwĪGC
3. b餺ALeflunomideֳtBN¦A771726Ab~㦳ʡAӥBiOĮĪC
4. @ξGLeflunomideʥNªA771726|Hïdihydroorotate dehydrogenase(DHODH)ӲܼͧWާ@ΡC"	"PO, Loading dose X 100 mg/ day for 3 days;
maintenance X 20 mg/ day; may reduce dose to 10 mg daily if higher dose not tolerated.
1. AīeΪAī᪺e6Ӥ륲CӤθuj˴ALT(SGPT)ȡAHCj8g˴C
2. }lLeflunomideveΥī᪺e6ӤCj2g㪺GӭMˬdA]AUإզyӭMPpOƶqAHCj8g˴C
3. Leflunomidev100mg_lq(loading dose)}lA@Ѥ@AA3ѡAq(maintenance dose)ĳ10mg20mgA@Ѥ@C
4. q`46g}lX{vĪGA46ӤĪGnC
5. ܨqն}NĿ]AA|vTLeflunomidelC"	1.ĴקKܰs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץxs	Leflunomide	L04A	Ķ IMMUNOSUPPRESSANTS	0	vH`Aåiwf{`ҳycʷl`(YݩDMARD disease modifying antirheumatic drug)Cv㬡ʩʪH~`C	"1. LeflunomideĪҧt᫬LӪfw(רOwStevens-Johnson xԸsBrʪaPhʬ)TΡC
2. UCfwTLeflunomideGa.x\णfwCB.קK̨tΥ\ʥFfwApAIDSCC.D`ް_㰩\णγhBզy֯gBݤʥզy֯gΦpO֯gfwCD.׷PVfwCE.צܭ׵Ŧ\णfwA]oǯfw{ɥĪg礣CF.קCJզgfwApǯfgԸsCG.hkALeflunomidevϥΦץkihkAunʥNª߿@װ0.02mg/lM?ihA}lLeflunomideveưhiC
3. ALeflunomidevkiH¨šC
4. kʯfw`Ni঳k-ް_LrʡAAĴϥΦĪץkC"	mBߡBæRBBfHef(pfHʤfĪBfļ)BhBx\ƤWɡBWɡBYhBwtBzPBPı`C	PL/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D3 [2]_D3 [ws]_w36-06 [E]_B4-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.5._20201223.pdf"">OI` 8.2.5.</a>              "	OI` 8.2.5.	0	OIs 20251124	OARHE1-a	OARHE1-b	OARHE1-c	110.6.16
BC21189100	L04AD01	0	OCYC25	Sandimmun 25mg/cap(Cyclosporin)		"Cyclosporine O11 iĩҺcpolypeptide A]iHT-ӭMWާ@ΡAҥH{ɤWOΨӧ@ĶCCyclosporine ]|OڿE(lymphokines)ͪPXA]Ainterleukin 2CCyclosporine i_bӭMgG0 G1 ƲOڲyAï]ĲܭӬƤT ӭMXOڿE C
Cyclosporine ä|y\A]|vT]ӭM(marcophage)\"	"1.x:5-10 mg/kg/dayAŦӤfwϥΧCq3 mg/kg/day
2.~:HMൣ18:@}l: 1.25 mg/kg bid |g; iCgW[@q 0.5 mg/kg/day, ̤jq: 4 mg/kg/day.
3.`G HMൣ18G@}l 2.5 mg/kg/dayBIDi8g12gW[q increased by 0.5-0.75 mg/kg/day,̤jq4 mg/kg/day."	"ĶYOΩ󾹩xӡAisӤJxةRC]x\δī~}AнTqAġAñK`N鲧ˡC1.ŦۦAΥ⦨ġC2.ŻPcĨ֪AġC3.pGzjѱNA姹A~AΤU@ӾqC4.\hĪi|vTī~夤@סA]dUnۦAΥĪA
PvĮvQסAT{wʤ~iAΡC5.AΦķ|ϱzܤOzAiePVC]̦nקKiX@
ҨûwP_ΨLPVgHsC6.AΦĥi|yziovW[ ]~ȡBy^A]ШCѱ`W
MzAéwܤˬdC7.YzhBŤAΪ̱zŦΨLefAХiDzvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cyclosporin	L04A	Ķ IMMUNOSUPPRESSANTS	0	wxӤΰ貾ӫᤧӱƥBwӤϱJDefBʩʦMIΫ᳡DPVʸ彤BϥζǲkLk̡Bbehcetsf@AoBBwIǵ̡BNkLĩΤAΤY~FзkLĩΤAΤY`FHTJvLĩιTJ̿ʪoʵǯfgԸs]˵]Biopsy^DnLpfܯefΧ`ǵywƯg^AgӭMíw(cytostatic)vLĥBǥ\Ʀb`50%HWfHC	󥻫~DΥ@ξLӪ̡ATϥΥī~C	hgB_ŸBǥ\zBx\êBiΫpBHέGzê(BߡBæR)BBB[C	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B5 [2]_B5 [ws]_w24-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.1._20220501.pdf"">OI` 8.2.1.</a>              "	OI` 8.2.1.	0	OIs 20251124	OCYC25-a	OCYC25-b	OCYC25-c	110.6.16
AC49283100	L04AX01	0	OIMUR	Asazipam 50mg/Tab		Azathioprine6-mercaptopurine(6-MP)imidazolelͪCb餺ֳtѦ6-MPMmethylnitroimidazoleC6-MPiqLӭMӦbӭMܦLpurine thioanaloguesADn]Aʪ?ĩMthioinosinic acidCܳtv]HӲC?ĵLkzӭMA]|bG`Cު뤩6-MPΥ餺AzathioprineN¦ӨӡA6-MPDnH㬡ʪƥNªthiouric acidƪnCƻïxanthine oxidaseAallopurinol|䬡ʡCmethylnitroimidazoleʨäMAP6-MPbܦhtΤG㦳ո`Azathioprineγ~CAzathioprine6-MP夤@רõLkwG̪ĩάr	xӤq--HΨൣGھکұĥΪĶkAfAlqq`iF5mg/kg魫/dayCqdb1-4mg/kg魫/dayAè̾{ɻݭnMG@ʧ@վCHΨൣG@lqq1-3mg/kg魫/dayAi̾{ɤ]inƶgμƭӤ뤺~^MG@ʡAboǾqd򤺧@A׽վCvĪGۮɡAiҼ{NqܨH~Ī̧CqCpGfHAΤTӤAgLﵽHAhiҼ{ġCݭnqdi1mg/kg魫/dayHUAmg/kg魫 /dayA{ɪvgMfH]]AG@ʡ^ruC	"ϥAzathioprine̪8ӬPAĳ̤֨CP@GpeΦpOƥشqC
qUΦYŦxŦणɧhqCipvִqWvCĳCӤ밵㪺GpqΪ̦ܤֶjnWLTӤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	1. 25JHUxsC2. ЦbĴϥΡC	Azathioprine	L04A	Ķ IMMUNOSUPPRESSANTS	0	ŦӤNƥ@ΪUkBʬTHB׭`BCʥզf	"1. wAzathioprineLӪfHTΡCvݪ`Nw̹6-mercaptopurine (6-MP) |LӪܡAi]|糧ĹLӡC
2. ihΥiYNhfHϥAzathioprinevC"	zGAAvAYwC	D 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w19-02 j	Ts110.6.16		OI` 	0	OIs 20251124	OIMUR-	OIMUR--	OIMUR-c	110.6.16
BC23737100	L04AA06	0	OMYFO	Myfortic 180mg/tab		۸LӭM@ΡAMPA OڲӭMojͪ@ΡA۹LӭMiQθɱϳ~|AT-P B-OڲӭMWͫD`IsͦC]@ξPzZ cytokine Υ T- OڲӭMtC? (Calcineurin) ɡC 	ĳq 720@J]dz 180@J 4 ɩ 360@J 2 ɡ^A@ѤG ( C龯q 1440@J )Cϥ mycophenolate mofetil (MMF) 2Jvw̡AiH Myfortic 720@JCѤGv]C龯q 1440@J^COz窺ʡAMyfortic iiHAΡC	קKbwuǩHGPRT)ʥFfwWϥΡApu Lesch-Nyhan P Kelley-Seegmiller xԸsC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUC	Mycophenolic acid	L04A	Ķ IMMUNOSUPPRESSANTS	0	PcyclosporinTJX֨ϥιwŦӯfwʱƥ{HC	 mycophenolate sodiumBmycophenolic acidBmycophenolate mofetil  Myfortic ξLӤfwTϥΡC	զy֩ʥզfθm	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M04-06 j	Ts110.6.16		OI` 	0	OIs 20251124	OMYFO-a	OMYFO-b	OMYFO-c	110.6.16
	M01AH04	0	IDYNA1	Dynastat 40mg/vial(Parecoxib)		ParecoxibOvaldecoxibeXġCValdecoxibb{ɾqd򤺬O@ؿܩʲĤG񨻨C(COX-2)C񨻨CtdeCͦA~w{XئPc-COX-1 MCOX-2CCOX-2@Pc|QPioEoAQ{DnOtdͯkhBoMoNgeC(prostanoid)CCOX-2]PƧZBۧɡBʯ߾ɺ޳XBǥ\઺ո`ΤϯgtΥ\(ooNBkhPB{\)C¡Xi]tYبCbHGũP򪺲´o{ COX-2A٤TwP¡XYC	"ĳq40mgARߪ`gΦ٦ת`gA۵ݭnC1224pɥiA20mgCpRߪ`gAita`JRߩΪ`JJRߪ`g޽uCpĦ٦ת`gAhݱN`gGwCa`J٦ײ`C 
qվ:50HUBChild-Pugh BBCCR<30ml/minw̫ĳqb"	"R߿`ݶWL15CհtibǷũm24p
1. parecoxib sodiumPacetylsalicylic acid (YϬOCq)֥ήɡAoͭGzD}(GzũΨLGzDֵog)I󰪡C
2. @X{֯lBHf_ΨLLӼxHANӥߧYϥparecoxibC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Parecoxib	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	u(yWL|)ϥΩ~Nkhw	߰IܡAaʯ߯efNAʮƹDũθzGDXA糧~NSAIDLӡAYx\णw 	PıwBkoBBƤ}BȮBP~C	C 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4670856?cesid=4VYDGOTyVvg&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPARECOXIB%26t%3Dname%26acs%3Dfalse%26acq%3DPARECOXIB"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IDYNA1-a	IDYNA1-b	IDYNA1-c	110.6.16
	M01AX07	0	ECOM1	Comfflam Forte Anti-inflammatory Throat		Benzydamine@ܪhAϥΥʿ@פUiĪvgҤ޵okhM~AHiת޸~ΦAbv@פUA㦳¾K@ΡC	"H12HWX 4-8 Qkh~wC]A
6-12yrspġGQG2(1mg)kh~wC]ACpnC1.5-3pɥiƨϥΡC
 Pediatric( 6-12 yrs)Xchildren 4 sprays.May be repeated every 1.5-3 hr.
HΦ~֤j12pġGQG2-4(1-2mg)kh~wC]ACpnC1.5-3pɥiƨϥΡC

~6-12pġGQG2(1mg)kh~wC]ACpnC1.5-3pɥiƨϥΡC

6HUpġGĳϥΡC

DbvܤUAsϥΤWL7ѡC

M仡GϥΫAΰbQLHקKC"	"6HUĳϥ
DbvܤUAsϥΤWL7ѡC
M?GϥΫAΰbQLHקK?C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Benzydamine	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	VѤfĤΫ|khA]AUCefίgް_khG縢BVhBgvް_HBZfHšBfĤΤPNkh	w糧~ʦLӪw̡C	fĪ¤P	קKϥΰDvn/SmҦw	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O01-01 [E]_I3-06 j	Ts111.8.19		OI` 	0	OIs 20251124	ECOM1-a	ECOM1-b	ECOM1-c	111.8.19
AC58382219	M01AE01	0	IIBUP	Ibuprofen  inj.100mg/ml;4ml/amp		"1.Ѽ@ΡGPGE2XA]ӭCUCŽո`ϤHȡAαiPޡAW[ֽyqAPiαƦC勵`Hoͧ@ΡC
2.h@ΡGPGsΨLް_kh誺XACˮ`ӷPʡA㦳h@ΡAѰYhBhB`hBghB٦׻ĵhBghΤN~˪LʯkhC]vФv^
3.ܵo@ΡGֵoPGstqΧ@ΡAC޳qzAB~BBho{HCΩv`B`BwʯժB٦ק˵oC"	"HC̤jqWL2400mgAp17w̨C̤jqWL40mg/kg2400mgAFֵŦ}IAw̦bIbuprofenveRC
h:@nhUvɨC6pɵIbuprofenRߺw`400~800mgA`ɶo֩30C
hN:Rߵ400mg̨C4~6pɵ400mgAΩݭnɥiC|pɵ100~200mgA`ɶp30C
ൣ:6Ӥ~17hhN:C4~6pRߵq10mg/kgA̰澯q400mgA`ɶo֩10A̤j龯q40mg/kg2400mgHC̬ǡC"	"1.ϥήhvDgkAӫD]kC
2.ĥi|B_PVg{A]ΩvPVҤް_gɡAX֨ϥξAܵ߾APɥJ[AVPC
3.pΰֱw̡A׶`N_Ƨ@ΥX{AåḨCľqӷVPC
4.Potential toxic doese<6 200mg/kgC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Ibuprofen	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	ѼBBh	"x\णA糧~LӤ̡C
"	"ߡAæRAG`AGhAmA?oʥX嵥GzêF֯lSGOTɡAYwAYhA~C
"	C	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	IIBUP-a	01C58382-1	01C58382-2	110.6.16
AB28656500	M01AB05	0	EVORS	VOREN SUPP 12.5MG		"diclofenacO@ثDTJAܵoBhBΰhNSʡC
wҹ򥻧@ξରeCͦXCbΦoBkhBPoNL{AeCtۥDnC
~礤APH餺ۦP@ת diclofenac potassiumAä|nJզh (proteoglycan) ͦXC"	ൣ3HUAC1/2ɡF3-5AC1/2-1ɡF6-8AC1ɡF9-11AC1-2ɡC(Ψ0.5-1mg/kgpAC1-2AѨzJz`C	1.~󪽸zP 2.iƫK~ϥΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Diclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	wѵoΦ]oް_kh	"1.GzšC
2.w糧~ʦΥξLӪ̡C
3.PLDTJܵoĪ (NSAIDs) @ˡADiclofenac]TΩwUCefw̡GݡAC¯lAHΥѤAQĩΨLeCXïʤĪҤް_ʻ󪢡C"	ߡBæRBABƤ}BƩʼšBXɶBB~{HBYBBx¡BջBBݡB}LC	C/D (30 weeks gestation)	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-10 [E]_I2-11 j	Ts110.6.16		OI` 	0	OIs 20251124	EVORS-a	EVORS-b	EVORS-c	110.6.16
AC48004210	M01AC06	0	IACHE	Achefree inj.15mg/1.5ml/amp		"1. ~w enolicacid DTJܪ non-steroidal anti-inflammatory drug(NSAID)C㦳ܵoAhθѼ@ΡCMobicwܨ㦳Īܵo@ΡC@ξOgѧeCͦC
2. PžqPܵoľqA~o쪺eCXGHεŦ̧󦳮ĤOCDѩ󥻫~㦳iܩʧCOX-2(۹COX-1)YC"	IM: 7.5-15 mg/day;MAX 15mg/day.izRYǰIܯfHMAX 7.5mg/day.	SO`NfHO_oֽͥH}A@oҼ{ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Meloxicam	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	Ω`ΰ`uΫʤgvC	"1. meloxicamΨξw|LӪ̡C
2. (acetyl salicylic acid)ΨLDTJܵoĪ(NSAIDs)eӷPbʱw̡C
3. ĤiΦbϥacetyl salicylic acidΨLNSAIDsᴿX{ݯgԸsA󮧦סAޤ~C¯lfHC
--ʩʮƩʼšC
--Yx\णC
--Yǥ\णӥ@zRC
--p15 ൣPC֦~C
--hα¨ŰC"	Ƥ}BߡBæRBkBKBȡBmC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-20 [E]_G2-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>             "	"OI` 1.1.2.,1.1.5."	0	OIs 20251124	IACHE-a	IACHE-b	IACHE-c	110.6.16
AC46348209	M01AB15	0	IKETO	Kerolac 30mg/ml/amp(Ketorolac)		"u(5)ϥΩwѵLkfAfH׫ʯkhAq`ϥΩNC

"	"1. ~igRߩΦ٦ת`gPARߪ`gɶoC15A٦ת`gĽwCβ`PC
2. @뤧h@Υiī30{Aӳ̤jĪG]iī1~2pɤX{Ah@Υi4~6p(ezƱ`Hĳ~|ξqPӦҮt)C
3. 澯qġG٦ת`g65HUAC60mgF6565HWAǥ\ण魫C50kg̡AC30mgFRߪ`g65HUAC30mgF6565HWAǥ\ण魫C50kg̡AC15mgF_k(RߩΦ٦ת`g)G65HUAC30mgAC6pɤ@A̰龯qoWL120mgC6565HWAǥ\ण魫C50kg̡AC15mgAC6p @A̰龯qo60mgC
ī~igRߩΦ٦ת`gPARߪ`gɶo֩15AӦ٦ת`ghwCβ`PCϥξqpUG澯qkG 1. <65fwG٦ת`g 60 mg Rߪ`g 30 mgC 2.65B魫<50 kgBεŦHG٦ת`g30 mgRߪ`g15 mgChqkG 1. <65fwG٦שRߪ`gAC6pɤ@AC30 mgA ̤jq120 mg/ѡC 2.65B魫<50 kgBεŦHG٦שRߪ`gAC6pɤ@AC15 mg A̤jq60 mg/ѡC
ൣʤhG0.4-1mg/kgAYregular Q6HġAĳbq0.2-0.5mg/kg Q6H(ĨĤU)"	"1.x\lΨxfwpߨϥΡC
2.ĨpOiੵXɶGTΩNeķ ɶpߨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Ketorolac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	"u(5)ϥΩwѵLkfAfH׫ʯkhAq`ϥΩNC

"	"1.oϥΩ󬡰ʩʭGűw̡C
2.TΩYǥ\णw̤α¨ŰC
3.AspirinB NSAIDsLӤ̸TΡC"	GzDXBšBʵǰIܡBxIܡBLӤC	D 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669806?cesid=9swbvzRlRJ0&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DKetorolac%26t%3Dname%26acs%3Dfalse%26acq%3DKetorolac"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.03.04	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a>              "	OI` 1.1.2.	0	OIs 20251124	DC	DC	DC	114.03.04
AC32917209	M01AC01	0	IPIXT	Pirocam inj.20mg/ml/amp		PiroxicamO@ب㦳hAܪMѼSʪDrܪġCX?]COX-1MCOX-2^|CeC͡AoQ{OhM@Ϊ]C	C2030mg٦ת`gC	B¨ŰBpϥζ`N	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Piroxicam	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`B~`B`]`hBhƩ`^ʯժBʦ٦װflˡBʵhBoʵhg	"1.Ʃʼűw 
2.YG`w
3.Yx\ण}w
4.Yǥ\ण}w
5.Y߾णw
6.Yw
7.糧Lӱw
8.aspirinLӱw 
9.aʯ¶DN14ѤT"	GhBGַPBB~BG`P	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a>              "	OI` 1.1.2.	0	OIs 20251124	DC	DC	DC	110.6.16
AC43152151	M01AE01	0	LIBUP	Ibuprofen 20mg/ml;/60ml/bt()		"1.Ѽ@ΡGPGE2XA]ӭCUCŽո`ϤHȡAαiPޡAW[ֽyqAPiαƦC勵`Hoͧ@ΡC
2.h@ΡGPGsΨLް_kh誺XACˮ`ӷPʡA㦳h@ΡAѰYhBhB`hBghB٦׻ĵhBghΤN~˪LʯkhC]vФv^
3.ܵo@ΡGֵoPGstqΧ@ΡAC޳qzAB~BBho{HCΩv`B`BwʯժB٦ק˵oC"	"1. fAvצܤׯkhGC46pɤ@AC400mgC
2. v`G134C300600mgACѤjqyWL2400mgC
3. ѼGH200mgC46pɡCYoNiW400mgAC̰q1.2gC
                ൣ(6Ӥ12)510mg/kgAC̰q40mg/kgC"	"1.ϥήhvDgkAӫD]kC
2.ĥi|B_PVg{A]ΩvPVҤް_gɡAX֨ϥξAܵ߾APɥJ[AVPC
3.pΰֱw̡A׶`N_Ƨ@ΥX{AåḨCľqӷVPC
4.Potential toxic doese<6 200mg/kgC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Ibuprofen	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	ѼBBh	"x\णA糧~LӤ̡C
"	"ߡAæRAG`AGhAmA?oʥX嵥GzêF֯lSGOTɡAYwAYhA~C
"	C	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-04 [UDx]_U01-40 [E]_J1-03 [Ew]_J3-03 j	Ts110.6.16		OI` 	0	OIs 20251124	LIBUP-a	LIBUP-b	LIBUP-c	110.6.16
AC400111G0	M01AB11	0	OACEM	Acemet 60mg/cap(Acemetacin)		AcemetacinO@indometacinAJୡAO@NSAIDsC Ĳzk]acemetacinΨDnN²indometacinC	"CTAC@,BȡB\A"	"1.YX{YhAζ¦ƫKɡAĨýбvC
2.Щ\ɩ\ߧYAΥī~AnrHAåH}]AC
3.w惡"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Acemetacin	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	BhƩ`]`^BʯժBhB٦תBxTBn	糧~LӪ̸TΪ	zGAB߹æRBGzXBLӵC	קKϥΰDvn	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 [ws]_w19-04 [s]_4 [®]_4 [UDx]_U02-08 [E]_B1-10 [Ew]_EX011 j	Ts110.6.16		OI` 	0	OIs 20251124	OACEM-a	OACEM-b	OACEM-c	110.6.16
BC23983100	M01AH05	0	OARCO	Arcoxia 60mg/tab		"etoricoxibYݩCoxibs `/hĪCARCOXIA O㦳׿ܩʪCOX-2C
COX-2 wҹDnOtdprostanoid XAprostanoid hOkhBoPoNCCϥetoricoxib ܩʦaCOX-2AiĴo{ɤWxPgABGzrʸCA]|vTpO\C"	"`GĳqC@ 60mgC
`GĳqC@ 90mgC
ʯժGĳqC@ 90mgC
ʵh`GĳqC@ 120mgC 
ARCOXIA 120mgȥΩʯgAvɶiWLKѡC
oʸghGĳqC@ 120mgC"	"1. 靈ʦʤŦffvwh[pߡC 
2. MPARCOXIA võLpʡAثewGeGzDաBŤΥX(PUB)fvH65HWw̵oPUB MIʸC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Etoricoxib	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`(OA)P`(RA)xPgCʪvBvʵh`Bvoʸgh	"1. 糧~󦨤LӡC 
2. Rʤ߰I(NYHA II-IV) C
3. wwʦʤŦefBgʯ߯efM/θޯef(]A̪񰵹Laʯ¶DNΦޭ״_N)C"	zLO/h¡BtwBUϤ~BBƤ}BG`BߡBYhBALTɰBASTɰC	MLw|eCXĪ@ˡAbhקKϥARCOXIAA]i|ɭPʯ߾ɺ޹LCثeõLAB}nsCubbįqTwWVL઺bMIɡA~ih̪줻ӤϥARCOXIAC	ѩ\hĪ|ciJHťġAӥBŪi|]ħeCXӲͰƧ@ΡA]AԷVҼ{Ĺ˪nʡAþڥHMwnũάOΥġC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667154?cesid=1SsZQUq6RPn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Detoricoxib%26t%3Dname%26acs%3Dfalse%26acq%3Detoricoxib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.02	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>              "	OI` 1.1.5.	0	OIs 20251124	DC	DC	DC	114.04.02
AB453051G0	M01AB05	0	OCATA	Voren-K 25mg/tab		"diclofenacO@ثDTJAܵoBhBΰhNSʡC
wҹ򥻧@ξରeCͦXCbΦoBkhBPoNL{AeCtۥDnC
~礤APH餺ۦP@ת diclofenac potassiumAä|nJզh (proteoglycan) ͦXC"	HC100150mgA14HWpĨC75100mgA23AΡC	"1.voͭGX嵥ġC
2.Ѧ~w̤SOp魫Lϥγ̧CľqC
3.iɭPx\ïȤɰGϥΪ̶ʴx\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Diclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	UCewίghBGC`Bܼ½贵ܧΩ`gBܧΩʯկgByhgBLgB鯫gfܡByնXgC	"1.GzšC
2.w糧~ʦΥξLӪ̡C
3.PLDTJܵoĪ (NSAIDs) @ˡADiclofenac]TΩwUCefw̡GݡAC¯lAHΥѤAQĩΨLeCXïʤĪҤް_ʻ󪢡C"	GzgAŸhAtwAolAֵo̡ͪGǥ\ಧ`AGzXAxALӡC	C/D (30 weeks gestation)	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	OCATA-A	OCATA-B	OCATA-c	110.6.16
BC23177100	M01AH01	0	OCELE2	Celebrex 200mg/cap		~O@ثDTJġAbʪN㦳ܵoAhθѼʡA@{A~@DOeCu(prostaglandin)XADngѧCOX-2:bvLqUA~ä|J-1(COX-1)P\AҥH~|vTCOX-1`HO@Hκp־@Ϊ\C	"1. ϥγ̧CľqC~̤jϥξqC餣iWL400mgC
2. `GѰ`fxίg˾qC200mgA榸AΡFH100mgCѤG覡ĥiC
3. `GѰ`fxίg˾qC100200mgACѤGC"	ǪAΥ~w̴gX{G麢dP~C]A~Ω㦳G麢ȡBΤ߰Iܪwp	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Celecoxib	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	wѰ`gPxAwѦH`gPxA֮aکʸFׯg(FAP)fw׼ƥءAwѦHʯkhΪvoʸghAwѻʯժgPx	"1.celecoxibLӪ̡C
2.DQi(sulfonamides)g͹LӤ̡C
3.AaspirinΨLNSAIDsAX{ݡBC¯lBιLӤ̡Cw̴oY(ּƬP)LөʥJiC"	hBmBƤ}BȮBߡBIhAg~AYwBYhBvB|BuBWIlDPVB֯l}	C 	ŤsbCelecoxibAϥγ̰ſ@׭poXө۹ﾯq]RID^1.7HAP魫վ᪺龯q200@J/ѬۤAĪRID <10Hɳq`{ų޾iOiH C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I5 [2]_I5 [ws]_w21-05 [ws]_w65(2) [s]_55 [®]_55 [UDx]_U02-33 [E]_B2-12 [Ew]_EX021 j	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>              "	OI` 1.1.5.	0	OIs 20251124	OCELE2-a	OCELE2-D	OCELE2-c	111.8.23
A043262100	M01AX05	0	OGLUC	Glustrong 250mg/cap(Glucosamine)		"1.}iOʪΤH餺@i}AOH㦳HתHhަ]O@ئh骺զ^sbnPl´UBA]OΦnӭM̭ni@CHPʪiHb餺ۦXiAuOHۦ~֪W[AXt׻WѪtסAOo餺`ʥFi{HAiӼvT`ӭMsN¡C
2.}ib餺|QѦiġAiHഫbſ}A]iHഫnCǥѦ۵Mɸ}iɥRAiHPi餺Jզh}HνJժsyAɥR`ƲGAôѨ˫`_dn´ҥơC"	"1. Lצܤ{פ`g:CѤGAC500mgsvPC
2. Yg`
 vGCѤTAC500mgAeAΡCܤ֤KP{C
 ~vGqC2AC500mgAeAΡC~vTܥ|ӤC"	 e15AΡADͦ䥦	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Glucosamine sulfate	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	wѰhƩ`kh	糧~LӪ̡ATϥΡC	WhAmAKB	SmҦw	ưL୷I	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w04-02 [s]_148 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.3._20201218.pdf"">OI` 3.3.3.</a>              "	OI` 3.3.3.	0	OIs 20251124	OGLUC-a	OGLUC-b	OGLUC-c	110.6.16
AC45965100	M01AB15	0	OKETC	Keto F.C.10mg/cap(Ketorolac)		"1. ~R-(+)S(-)ketorolac tromethamine۩ʲVX(racemic mixture)A䤤S(-)c㦳jĲzʡC
2. ~eCXA㦳DTJĪѼBhBTjSʡAAΩUkhvC
3. ~itĦaѰkhBogAuʯkho@vC"	ʯkhɥi10mgC4~6pɪAΤ@C̤jq40 mg/day.	ĨpOiੵXɶGTΩNeķ ɶpߨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Ketorolac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	khukC	"1.oϥΩ󬡰ʩʭGűw̡C
2.TΩYǥ\णw̤α¨ŰC
3.AspirinB NSAIDsLӤ̸TΡC"	GzDXBšBʵǰIܡBxIܡBLӤC	D 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
BC25746100	M01AC06	0	OMOBI	Mobic 7.5mg/tab(Meloxicam)		"1. ~w enolicacid DTJܪ non-steroidal anti-inflammatory drug(NSAID)C㦳ܵoAhθѼ@ΡCMobicwܨ㦳Īܵo@ΡC@ξOgѧeCͦC
2. PžqPܵoľqA~o쪺eCXGHεŦ̧󦳮ĤOCDѩ󥻫~㦳iܩʧCOX-2(۹COX-1)YC"	"7.5 mg QD, MAX 15 mg QD
1. `GC15mgC̾ڪvڮAqiCܨC7.5mgC
2. `GC7.5mgCݭnɡAqiW[ܨC15mgC
3. ʯ誢GC15mgC
4. iW[}MIfHG_lqC7.5mgC
5. YǰIܶiGzRfHGC龯qiWL7.5mgC
6. Cĳ̤jq15mgC"	SO`NfHO_oֽͥH}A@oҼ{ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Meloxicam	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`B`Bλʯժgv	"1. meloxicamΨξw|LӪ̡C
2. (acetyl salicylic acid)ΨLDTJܵoĪ(NSAIDs)eӷPbʱw̡C
3. ĤiΦbϥacetyl salicylic acidΨLNSAIDsᴿX{ݯgԸsA󮧦סAޤ~C¯lfHC
--ʩʮƩʼšC
--Yx\णC
--Yǥ\णӥ@zRC
--p15 ൣPC֦~C
--hα¨ŰC"	Ƥ}BߡBæRBkBKBȡBmC	C	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668738?cesid=6NJYOyhdkTz&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMeloxicam%26t%3Dname%26acs%3Dfalse%26acq%3DMeloxicam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.01	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>              "	OI` 1.1.5.	0	OIs 20251124	DC	DC	DC	114.10.01
AC28136100	M01AE02	0	ONAPO	Seladin 500mg/tab(Naproxen)		N a p r o x e n  @  u D T J   h   o  v    A  D n  @δNO餺ueCv͡A @ƾǪOy`khεoDn]A]iHѰ`AHΰ`Ҥް_`wNkhNoo~{CĦPɥiH@hĨϥΡAiHhػL줤תkhA pYhNkNgh٦ק˩Ҥް_khAHεuϥΩѰʵhް_khC	"Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis250-500 mg twice a day; MAX 1500 mg/day. Dysmenorrhea or mild to Moderate painGinitial 500 mg;maintenance250 mg every 6-8 hours as needed or 500 mg every 12 hours as needed; MAX initial 1250 mg/day, then 1000 mg/day. Gout,acuteinitial 750 mg, followed by 250 mg every 8 hours until attack subsides"	"hα¨ŴkpߪAΡC
GzEʡC
YwBߡBæRAPC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Naproxen	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	hB	糧ĴLӪ̤δ] Aspirin ΨLDTJް_ݡB󪢩C¯l̤yϥΡC	G`BߡBBhBmBYBYhBݺΡBtwB֯lB~	C(Ĥ@BĤG)/D)ĤT)	ưL୷I	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w05-02 [s]_297 [®]_297 [E]_A3-11 j	Ts110.6.16		OI` 	0	OIs 20251124	ONAPO-a	ONAPO-b	ONAPO-c	110.6.16
AC19419100	M01AG01	0	OPONS	Ponstal 250mg/cap(Mefenamic acid)		Mefenamic acidO@ثDTJܵo(NSAID)A|eCXAæbeC鳡XA]㦳ܵoBhΰhN@ΡC	"H14HWC֦~צܤׯkh/`/`GC3AC500mgC
ghGC3AC500mgCbXάgX{ɫK}lAΡC
vդf(Still's)6Ӥ14PൣhN@ΡG19.5-25mg/kg/dayATAΡC"	Mefenamic acidקKPNSAIDsPɨϥΡA]ACOX-2bC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Mefenamic acid	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	ѰCʤBׯkhB]AYhBhBյhBghB~˩ʡB`ʤΦ٦שʯkhBNβᤧkh	ƩʼšAA糧~LӤ C	"1.`-ߡAæRAmF
2.-Ƥ}AYwAhApO֡Aզy֡A߱AIlxAgA믫áF
3.Y-GzXBɩʥզyʥFgC"	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w06-03 [s]_254 [®]_254 [E]_C4-07 [Ew]_EX092 [Ew]_Z-14w9 j	Ts110.6.16		OI` 	0	OIs 20251124	OPONS-a	OPONS-b	OPONS-c	110.6.16
AB46613100	M01AB16	0	OTONE	Tonec 100mg/tab(Aceclofenac)		Aceclofenac ݩDTJܪABh@ΡC@μҦOeCXCAceclofenac OjOAïOͫeCҥC	HCĳq200mgAC2AߦUA1ɡC	ipO	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷ25JC	Aceclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	vhƩ`B`BʯժҤް_khεog	"1.GzXBƩʼũhæoǯfg̤oϥΥC
2.צܭ׵ǥ\êw̤oϥΥC 
3.ih̡ADTnABγ̧CľqC
4.AceclofenacBAspirinΨLNSAIDLӪ̤]iϥΥC"	Ƥ}BhBߡBmFoͯtwgFֽ譱|X{koBFٻƭȤWɳiC	ثe|LhɨϥΥơAbhĤTϥΫDTJܪ|W[lciOAPϤlcYADTJܪiϭLʯ߾ɺަysͨͰAYߵoʩMɶC	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w15-02 [s]_316 [®]_316 [UDx]_U02-07 [E]_B1-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OTONE-a	OTONE-b	OTONE-c	110.6.16
AC43493345	M02AA19	0	EFLUR	Flurbi PAP(4/])		t񬥪O@ثDTJܪġ]NSAID^A㦳hAMѼ@ΡC ڻ{@Τ覡PeCX?C	C1AHKwAgY̡AC鴫K2-3AiΦAjpAhȡAHKwC`渨AiH^a@TwC	" 1.PɲŦXUC󤧯fwϥΡG
(1)@`]^γn´gC
(2)AXfADTJܵos̡C
(3)oPɨ֥ΤfAΨL~ΫDTJosC
(4)C뭭BQHC
2.ФHKlBolBHζˤfC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Flurbiprofen	M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	ܧΩ`gB`P򪢡BٸxxTBxP򪢡BWðWNB׵hB~˫ᤧ~ȡBkhѯghB	糧~LӪ̡ATϥΡC	`BEPC	B/D(ĤT)	LSOĳ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[2]_D6 04[G~]_N06-02 [E]_I2-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.1._20200201.pdf"">OI` 1.1.1.</a>              "	OI` 1.1.1.	0	OIs 20251124	EFLUR-a	EFLUR-b	EFLUR-c	110.6.16
KC00525299	M03AX01	0	IBOTO	Botox 100IU/vial(Botulinum toxin type)(N)		"2.1g٦ת_C
BOTOX (A׬r߬r)¤ƯgrƦXYgѻPBʯg骺mXAiJgAHAQxP(acetylcholine)AӪ_g٦תǾɡFBOTOXʥHvq@٦ת`gɡABOTOXʥHƾǤ覡ϸӦ٦ײͧhgƧ@ΡAGɭP٦׳·F٦רHƾǤ覡hgƮɡA٦׵YAӥioiXgXH~AQxPApiҩgTigѥXޡ]sprout^Aӭs٦׹FHgtʧ@AIifʡC
2.2 ׵
BOTOXʥΩv׵ɡAw뤩BOTOXʸgѻoQ`g٦׵YөA۹aCӦ٦׫ܦ٪YӼvT٦סC
2.3 ¥j
`gBOTOXʹ٦׳y·iΩֲ¥jˤް_٦׹Lײ`YA@ӻ¥j˯fHvfﵽ12.5gA~ݭnAױvC
2.4 j˩ʱV(VٱiO)
BOTOXʪ`gV٦׮ɡABOTOXʫYѵj˩ʱV(VٱiO)[xHHΥD[gA譱ӴѯfwѡA}ĪG]A֯kh/ABYB֪ӻHﰪBCΫp٦תؤoαjסAHι\ʥfpﵽF󦭴Ω󥼴vfHmiGAVٱiOfHBOTOXʪvA40%58%gۧﵽC
2.5 j(~ʳ·ҭP)
BOTOXʪ`g̸zٲ͸}mﵽ(Ψ)HH]}ĲaOW[AoBAﵽC
2.6 oʵźۦhg
BOTOXʥΩhg@ξYgѧ_ۥDgtΥPgxPEʯgֺtAӧxPEXϹLqƦFخĪGYgѱN׬r߬rIbֽu֪ӹFتA]Ω󦹺ؾAg`gD֤`gChg嫬v覡YwϰAH檬Ϯק@h֤`givC
vؼЫYNƦ֦ܯfHiԨͲz`{סALëDvؼСC
2.7 Kܯ
BOTOXʪ`gKܦ٤/λܦٮBOTOXʴzU٦׹L׬ƪYAKܯY{סA]ӧﵽ~[C
2.8 
OaӶުҥͥXɱ׽KAB`BegAO`ֺٰYɭPGC`gBOTOX?iﵽӳYKDC
2.9 Y
YPB٪ʧ@CڨLVm[HXA`gBOTOX?ﵽYYpiF24gC
2.10 Hᤧuj
BOTOX?fﵽ]AGC٦ױiOA٦׬ʽdW[ABΩYǯfHABOTOX?i֦]j˪AɭPfHfoB൥C
2.11 H֥(HֹLʯgHΦ]fܤ޵oGٹL)
H֪`gABOTOX?|AQxPAiӼvTG٧@Ϊ϶ǥX|(efferent pathways of detrusor activity)C
"	"ĳ~|G
٦ת`gFhgĥΥ֤`gF¥j˥iĥΥ֤U`gC`gg}LBOTOXAܱv٦תBʺݪOϡC
sƻP}kG
BOTOX Ĳ~HLߡBtG0.9%ƶu`gG(ĨUSP)isơCHjpAwYAq}AN}wC`JĲ~CpGuŭtåN}lJĲ~AhmĲ~CĲ~AVXBOTOXέQCbҪťճBOUsƪMɶC
BOTOX sƫ72pɤġCboqɶANsƦnBOTOXNxs(2X8XC)C
UAgΪkζqаѾ\C"	"1. ФŶWL~ĳPqWvC
2. ܥثeåBotuinum toxin type ALӤרҳiCNpҦͪs@ˡAǤWMLL˴HƦbAHƹLӤio͡C
3. ֯wӪ`g~ܲٮɥi|ɭPnSBä[ʤWֶˮ`ΨšAרOĤCﯫgeffHCveĨ@BJAppߴղӷPסAקK`gU¥ϥH¥~½AHοnv󲴪ֶˮ`C]iQ@βĤBnIB^aBnβξBβn@Ϊ~C
4. ԭ|M줤ϥΥ~Hvspasmodic torticoliscerebral palsyC
5. YLqεoͮɡAfHbƤѤʴLʵLOΦ٦׳·gC@p~`tqCwpN6kgΧ魫w̲ͥʬrʤwqCSwbotulinum toxinܬrԦb`gbotulinum toxin30`gɤ~ġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"uŰs~ixs2-8JNáB-5J-20JNC
BOTOX?sƫ72pɤġCboqɶANsƦnBOTOX?Nxs(2X8XC)C
γѪBOTOXʨϥε}QķG(0.5%)hƹF5C"	Botulinum toxin type	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	¥jˡBbjˡB٦׵jˡB׵Bj˩ʱVBpรʳ·ް_٦׵jˡBWyK]KܯBYB^BoʵźۦhgBHᤧujˡC]fܩҤް_GٹLʦӾɭPTHfHABgxPĪvLĩεLk@̡CvTBPWHֹLʯgHfHAgxPĪvΩεLk@ġABpݭnɡA@Nίvi氮bʾɧ(Clean intermittent catheterization) ̡CBOTOX?AΩCʰYh(ܤ֦3ӤɶACӤ? 15ѡAC4pɥHWAB䤤ܤ֦@bYhOYh)HfHYhwʪvC(nGBOTOX?}oYh(CYhѼơ14)wʤΦĩʩ|LҾҩ)CvHfHUϵjˡAHֽ`M}k}ٸs(̸z١Bس١BH١B}٩M}k)ٱiOW[Y{	"~TΩwt褤󦨥LӪ̡C
BOTOXʸTΩ󭫯gٵLOEaton LambertgԸsfHC
BOTOXʸTΩĳ`g즳PV{HsbɡC
󿩱wDPVfHAHΥwi氮bʾɧ(CIC)ʧdαƧlqWL200mLfHӨAPBOTOX?"	q`}YX{bBOTOX`g᪺Ĥ@gABȮɩʡApGkhBoB`PıBPıyB~/~hBBPVBXM()CC`g׬r߫]o{oNMP_gCwY`g᪺khM/εJ{]oͦްggʤA]AuȯgʧCηw֡Cz{HD׬r߬rwĲz@ΡC	BOTOXʥΩhkʪvTõLRBgLTӪsAGקKBOTOXʥΩ󥥰	ĬO_cHťġA]\hĪ|cHťġABOTOXʤĳϥΩŰC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-14 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.2.1._20220301.pdf"">OI` 1.6.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.2._20180201_000.pdf"">OI` 1.6.2.1.</a>             "	"OI` 1.6.2.,1.6.2.1."	0	OIs 20251124	IBOTO-a	IBOTO-b	IBOTO-c	110.6.16
X000258221	M03AC11	0	ICISA	Cisatracurium 10mg/5ml/amp(N)		~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"ޤޡG0.15 mg/kg Ab 5  10 ֳtC?b`g 120 i?Q?ACൣ(1Ӥ-12)qPHqۦPD
qG0.0.3mg/kgAi20g٦ת_@ΡDൣ(1Ӥ-12)qG0.02mg/kgi9@ΡD
ICUfЯfHϥξqG_lqG0.18mg/kg/hrAqG0.03mg/kg/hr-0.6mg/kg/hr"	wgٵLOgΨLg٦ׯeffwDhƩʪ_|jӷPʡCofwĳWL 0.02 mg/kg ~_lqC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʮɥixs2~8CץNëOs
}b 25?U 24 p"	Cisatracurium	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"~TΩw cisatracurium B atracurium  benzenesulphonic acid LӪfwC
"	"߷iLC,޵j
"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.8	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.2._20110701_000.pdf"">OI` 1.4.2.</a>              "	OI` 1.4.2.	0	OIs 20251124	ICISA-a	ICISA-b	ICISA-c	111.8.8
		0	IROCU1	ĵRocuronium  Kabi 10mg/ml;5ml/vial(N)		"Rocuronium bromideY@ذ_l@ΨtA@ήɶDhƤg٦ת_A㦳Ī}curariform~ҦĲz@ίSICǵۦbBʲתOnicotinic cholinoceptorsvӲͧ@ΡC@@ΥiǤAQxP?Ҧpneostigmine, edrophoniumpyridostigmine [HܡC"	"PҦLg٦ת_ۦPArocuronium bromidegѼxoĪ@λPΪkmvΦbYKʴUl൹C
PLg٦ת_ۦPArocuronium bromideqӧOw̤HվC"	ѩrocuronium bromide|ް_Il٦פ·Aw̧PĤ@wݭnIl𻲧U_۵MIlCҦg٦ת_ϥΩֳt¾Kɤ覡ɡAn`Nxޱpo͡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Në~GxN2-8JUC~imBc~30JHU7PCpwѧNóBXAhA^JsC
Ƿū~Gx30JHUǷšC"	Rocuronium bromide	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	¾KġAHUޤޡBѤNݧֳt¾Kɮɰf٦PAB[@fФݴޤΨϥΤHuIlɡC	rocuroniumηlΥ@᫬LӪ̡C	̱`oͪ}]A`gkh/AͩRHܻP٦ׯg_C̱`oͪADRs]AͩRHܤƥHίg٦PĪGC	C	SmҦwADnקKϥΡC	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G0.6mg/kg(H60kgҡAY36mg)
q(MD)G0.3-0.6mg/kg/hr(H60kgҡAY18-36mg/hr)
}GG50mgH5mlD5W, NS}10mg/ml
}@סG1mg/ml
ĳĳtvG0.3-0.6mg/kg/hr
wwʡG24hr Ƿ
CVP
ʴءGIlٳ·A"	ixii[w]_w08-07 [E]_D3-08 j	Ts110.6.16		OI` 	0	OIs 20251124	IROCU1-a	IROCU1-b	IROCU1-c	110.6.16
	M03AB01	0	ISUCC	RELAXIN 500MG/VIAL		ݩDv (depolarizingh) uİfPA@ξbPAchv (nicotinic receptor) hơAϦ٦PAiΩNeU@ΡC	(1)HwIV`gw2080mg(_iP10mg羯qAHKMwfHӷP)CIV`w2.5mg/min0.1%0.2%ͲzQ(iϥ)IMw25mg/kgA̤jq150mgC(2)ĵwIV`gw12mg/kgC	" 1. UCefw̨ϥΥ~ypߡGŦޡB͡BǡBxΥN©ʯefFYNˡFF٦׵jˡFCFξrFhFi}FMѦ~HBIzBγ̪ϥΤafHC
2. uiϥηsAsƪGCbGsuccinylcholine|tѡAӥBܧ֥hĤOC
3. b̤jX{An`NIlȮɰ{HApGbX_۵oʪIlANnήӱIlC
4. ~nPܥhƪ_@_ϥΡA]|ĮġC
5. nNsuccinylcholinePbarbiturateGΨLPĪVXA]|ytXTҡC
6. IM`g~ɡAn`٦ת`gAbT٪`gרΡC_쵹p羯qHMwĪӷPʡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Suxamethonium	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	NΩP٦	cʪŹLfw̡AYIl@ΡC	٦שzA߸LCAתIl@ΡA٦׵zAޯgˡAIlȰA߸LCACA߫ߤAyCW[AN᪺khAŹLAW[AٲyJզgAYIlΡC	D	RsҾ	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)GֳtޡG1~2 mg/kg IVP
q(MD)G500mgtm500ml(1mg/ml)
}GGD5W, NS
}@סG500mgHWFI 10 mltm50 mg/ml()
ĳĳtvG2.5mg/min(15ml/hr)
wwʡG24pɤβ
ʴءGIl,cʰ
`NƶG[B`LBN˯fwAXϥ"	ixii[w]_w09-04 [E]_D3-07 j	Ts110.6.16		OI` 	0	OIs 20251124	ISUCC-a	ISUCC-b	ISUCC-c	110.6.16
AC37141100	M03BX01	0	OBACL	Befon 5mg/tab		ĬOGABAlͪAi@ΦbWhBʯg쪺ݡAӲͦ٦תP@ΡC	"1.HG쾯q15~15mgA1~3AΡAFзǥζq130mgA2~3ASpiWq15~lOmgAgWζqC
2.pG쾯q15mgA1~2AΡAFзǥζq(15-125~25mgAl1-75~20mgA6-45~15mg)2~3ASpiWq15mgAgWζqC 
 "	1.wwfwХivC 2.кɶqקKsC 3.AīФp߶}ξާ@MIC 4.PX֨ϥήɡAvĪϥΪA(iUӦh)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~x󳱲D(15~30J)ץBҡC	Baclofen	M03B	"ϩʦ٦P MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS"	0	Mjefηlˤް_٦׵j	糧Lӯgw	i঳RBwtBݺΡBæRBUgBٵLO{HC	קKϥΰDvn	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-06 [s]_42 [®]_42 [E]_A1-03 j	Ts110.6.16		OI` 	0	OIs 20251124	OBACL-a	OBACL-b	OBACL-c	110.6.16
AC48363100	M03BX08	0	OMUSG	Musgud 5mg/tab(Cyclobenzaprine)		"ĦbzZ٦ץ\઺pUѰf٦٦׵jˡC󤤼ϯgtίewҭP٦׵j˵LġCghʪҹꥻĥiwѰf٤ʹLײ{HCʪ,ĨëD@Ω󯫸g٦ץ汵B,D@Ωf;sܥĥDn@ΦbϯgtΤFB,ӫD,MӨ褧@Υi禳U餧fٵαi@ΡCҾܥĤ̲ק@ΤDbֱjʹB,^P\BʨtάҦvTC
@ʪĲzܥĻPT{@ΦۦB, p:reserpineܡBnorepinephrinej,jOgPϧxP@ΡBRCʪiɭPת߸[֡C"	"CA510JA@TAvĳWL3P
Ĺ15HUൣϥΪwʩ|T"	"1.ĥiPMAOIĪ椬@,T{PMAOI֥δBjˡB`iC֥ΤT{߫ߤBuе߸LtBǾɮɶӾɭPU߯gPoͪiC
2.ĥi[jsBڤQΨLϯg@ΡC
3.ѩĦ~]atropine-like^@,ϥΩ󦳧dBʫCBɰfvΪAΧxP@ī~w
pߨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUAýЦsbൣBC	Cyclobenzaprine	M03B	"ϩʦ٦P MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS"	0	wѫʰf٦٦פj	糧Lӯgw̡Bߦٱʵo@Bw߫ߤBߪBRʤ߰IܡBҪLקKϥ	ݺΡBfBwtC	SmҦw	SmҦw/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	DC	DC	DC	110.6.16
AC44174100	M03BX04	0	OMUSO	Musolax 150mg/tab (Tolperisone)		"~٦P,֩P٦׺i."	"HqG150mg TID~QID
pĨCѾqi5~10mg/kgAiƦCqhFvĪGAӫᾯqi֦(CѾqiվ㬰2)CYxBǥ\ण̤ĳAΡC 
"	AīקK}ξާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsKץe,30CHUOs"	Tolperisone	M03B	"ϩʦ٦P MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS"	0	vеoͪkhʦٵjˤθޯfܩҾɭPٱiO`ɰ	 tolperisoneL	٦׵LOBY	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-04 [s]_222 [®]_222 [E]_A4-11 [Ew]_Z-15w9 j	Ts110.6.16		OI` 	0	OIs 20251124	OMUSO-a	OMUSO-b	OMUSO-c	110.6.16
AB25402100	M03BB03	0	OSOLA	Solacon 200mg/tab(Chlorzoxazone)		@ξ|TߡAiPR@ΦCDn@ΩθUֽ賡Aͤκfٵj˪hĲ(multisynaptic)ϮgAf٪jˡAѰkhüW[w٦תʤOC	HC34AC250500mgCfﵽɡAivqCĵC34CC125500mgCiHHMΨLξVXC	"1.CĪLӪfvAx\णnnpߨϥΡC
2.GCܡASǬr(nephrotoxic)C
3.\AΥi֭GzEC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Chlorzoxazone	M03B	"ϩʦ٦P MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS"	0	٦׺igBʸyhBնOgԸsί誢jˡBg٦פಧ`ҦͦٵjˡBjѯewC 	糧~LӪ̸TΡC	"L ,, tw, ݴe, æR, K ,x\ê"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-02 [s]_299 [®]_299 [E]_C4-09 [Ew]_EX093 [Ew]_Z-05w9 j	Ts110.6.16		OI` 	0	OIs 20251124	OSOLA-a	OSOLA-b	OSOLA-c	110.6.16
AC142281G0	M04AA01	0	OALLO	Allopurinol 100mg/tab		"allopurinolΨNªoxipurinol(Alloxanthine)|vʪxanthine oxidase@ΡA֧ĪΦD
Allopurinol]|ǵۧhypoxanthine-quanin phosphribosyltransferaseAW[HypoxanthineMxanthineAQΡAӴ֦MĭȡD"	"HGC200~600mgAAΡC
_lqGѨC100mg}lACgW[100mgܧĭȭ6mg/dlΧCAiWL̰q800mg/day
qG100mg-200mg BID~TIDA300mg QD
׵hqG200-300mg/day
YF۵hqG400-600mg/day
~FѯgsGΩ}le12pɦ3ѡAC600-800mgAqݨ̾ڪv48pɪĭȬ̾ڰv
ܧĵۡG100-200mg/day
ǥ\णվ㾯qG
Clcr  10-20ml/minG200mg/day
Clcr  3-10ml/minG<100mg/day
Clcr  <3 ml/minG@100mg Q2D~Q3D
ĵ:
>6G 50mg TID
6-12G100mg TIDA300mg QD"	"1.ī~ioͨuYֽLӤApvͤjͯgs/rʪַѯg}ApX{VhBLگ}BoBֽlAߧYġAæ^EC
2. AllopurinolibAΡAHGzDEC
3.bϥĪeXӤĳʴǥ\
4.pԷX,oN,,æRεo,ЧiD,iOYLӤ}l.
5.o͹LYP}רҡApsteven-johnson syndrome/Toxic epidermal necrolysis AoADRQo{PHLA-B*5801]ʡA˴]N{ɪ˴."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25JOsAץΨC	Allopurinol	M04A	ܵhs ANTIGOUT PREPARATIONS	0	hgBh`BĵۡBgθgƾǪvͤĦg	"1. ǥ\णΦɦVǥ\ܪfwѦpGRʤŦfB}fBC
2. AllopurinolLӤfv̡C"	XlBkoBoBߡB٦ׯkhBʵhWvȮɼW[	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w16-01 [s]_3 [®]_3 [UDx]_U02-11 [E]_B1-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.11.2._20160201_000.pdf"">OI` 2.11.2.</a>              "	OI` 2.11.2.	0	OIs 20251124	OALLO-a	OALLO-b	OALLO-c	110.6.16
AC413161G0	M04AC01	0	OCOLC	Conicine 0.5mg/tab(Colchicine)		~֥զyͧġA]CĪ餺N¡AMl`զyӭM]ѡAX´㦳MIʪJAoĪ]|PLp޲ӭMJս赲XAҥH|MzZʲӭM(pզy)BʡC	q`H@Colchicine 34mg68fAA̦~֡BgoAqWCwofɡAq`H@Colchicine 0.5~1mgAo@wPɡA@0.5mgfAC	ѩPAɷ|ް_Gٮ`BxBǱb`AGΩwkho@ɡAЪ`N@˧Aˬd(SOOզy)HΨx\wˬdC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץeA1530J HUxsC	Colchicine	M04A	ܵhs ANTIGOUT PREPARATIONS	0	h	"1. YǡAGzAŦAΨxefC 
2. ColchicineLӱw̸TϥΡC"	ߡBmBæRC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w24-06 [UDx]_U02-26 [E]_B2-19 j	Ts110.6.16		OI` 	0	OIs 20251124	OCOLC-a	OCOLC-b	OCOLC-c	110.6.16
AC419951G0	M04AB03	0	OURIN	Benzon 50mg/tab (Benzbromarone)		~@ĪPıƪnADn@ΥiYgѧǤp޹刺QAlA୰CMĤ@סAW[QƪnChw̦bCѤfA@qAϦMĿ@׭C50%-60%AG঳Ĵh`gC	q`HC1-3AC1AgfPA̦~֯gAyWC	"1rzʨxYxŦ}Dn|b}l īeӤ뤺o͡A]̤֦b̪쵹ĤӤ Awix\ˬdC
2. bϥδpxŦ}gp: B«oͮɡAߧYϥΥī~A |ҴN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץeA1530J HUxsC	Benzbromarone	M04A	ܵhs ANTIGOUT PREPARATIONS	0	hBĦgBҤް_Ħgﵽ	"1. ͵ǵۤw̡AYǾêw̡C 
2. ΥihkC
3. x\ಧ`̡C"	"1.Lӯg:C¯lBolBCoBBko PC
2. xŦ:GOTBGPTBAlkaliphosphatase ȤWɡC
3. ƾ:GhBhBGַPBG`BߡBUgBnKC
4. L:B~Bߺ۳ַPBYhD"	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w20-03 [s]_22 [UDx]_U02-17 [E]_B1-24 j	Ts110.6.16		OI` 	0	OIs 20251124	OURI-A	OURI-B	OURIN-c	110.6.16
KC00918209	M05BX04	0	IPROL	Prolia 60mg/syringe(Denosumab)(N)		Prolia|PRANKLXARANKLO@عkӭM(|Ͱk@ΪӭM)ΦB\Psn､JթΥiʳJաCProliaiRANKLƨ䱵AYkӭMΨeXWRANKCKRANKL/RANK椬@ΥikӭMΦB\PsA]iCk@Ρ]bone resorption^Aôֽ谩Τp簩qPjסC	"IProliaѰd@M~H?i?C
Proliaĳ?C6Ӥ@֤U`g澯60@JCХH֤U`g覡NProliaIWuBjLθCҦw̳CѸɥR1000@JtPܤ400 IUͯDC"	" 1. pG?@ProliaAw̤?ɾ֬ICAq̫@`g_AƩwC6Ӥ@`gɶC
2. bIeAiNProliaۦBcXAMbO?l]˲pU۵MFǷ(̰?WL25XC/77XF)CL{q`ݭn1530C?ťH䥦覡NProlia[šC 3. ?Ŧbi?`geN?wO@˸mVe?ʶWLwYF|êê`gCЩ`gҰ?wO@˸m(?ʶWLwY)C
4. Prolia?ĳΩൣfwCProliabൣfwwʤΦĩʩ|T?C
5. Ctgi|]ϥProlia?ơCb}lϥProliav?eABvJCtgC
6. קK?nProliaC
7.ϥproliafHΨLܦAlv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Os28JC	Denosumab	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	"v鰪Iʤgk貨PgC
G
鰪Iʤgk貨PgA]tUC@pG貨PgfvB㦳hMI]lBeL貨PgkѩεLk@L貨PgkfwC
w貨PggkAProliaiCաBDթMb骺oͲvC
v]Dಾ@Ӷi涯ʲXvB㰪װ魷Ikʱw̪y{HC
G
ProliaiCfHհ骺oͲvC"	CtgC	CtgBYPVBֽ}BEahBIhB|ϯkhB٦װfkhC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-19 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.4._20241001.pdf"">OI` 5.5.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.4.,5.6.1."	0	OIs 20251124	IPROL-a	IPROL-b	IPROL-c	110.6.16
BC24692255	M05BA08	Oj`gG5@J/100@	IACLS	Aclasta 5mg/100ml/vial		"Aclastaݩt᪺CQƦXADn@ΦbfCOkӭMAl@ΪC

"	"vgk貨Pg:C~榸R߿`5 mg`GA`ɶo֩15AHTw`tvġC
wgk貨Pg:C~榸R߿`5 mg`GA`ɶo֩15C
kʰ貨Pg:C~榸R߿`5 mgA`ɶo֩15C
TJʰ貨Pg:C~榸R߿`5 mgA`ɶo֩15C
Aclasta`ɶo֩15AHTw`tvġC
bR߿`AH10 mLͲzQR~Rߺ޽uC

ئNSf(Pagets disease of bone):C~榸R߿`5 mgA`ɶo֩15C


"	"AclastaTΩٻMvC35 mL/minHҹ㦳ʵǥ\णfwC
bAclasta`ᵹacetaminophenibuprofeniCʴgC
gkC饭1200mgtP800-1000IUͯDC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs15-30 XC 
Y`gGwNáAb`eN÷G^_ǷšC}~˫AGb2-8XCūפUiO24p"	Zoledronic acid	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	"vgk貨Pg
wgk貨Pg
kʰ貨Pg
TJʰ貨Pg
ئNSf(Pagets disease of bone)

"	"AclastaTΩUCfwG
? Ctg[ĵyP`Nƶ(5.2)]C ? AclastaTΩٻMv< 35 ml/minHҹ㦳ʵǥ\णfwA]o
ǯfwo͵ǰIܪI
? wzoledronic acidAclastaҧt󦨤LӡCLӤ]A֨C¯lMީʤ~AHΫD`uLөʤ/Jרҳi


"	"PAclastaʴxίgG٦׵h(17.1%)BoN(15.7%)Bh(12.4%)B`h(11.1%)Bkh(10.5%)BHŸ(9.8%)BYh(9.8%)ByPef(8.5%)B餣A(5.2%)έIh(3.3%)Ab뤩Aclasta3Ѥo͡CCoǯgjצܤסABjhb}X{3ѤYwѡAǥiݭn7-14Ѥ~wѡCoǯgoͲv|H۫AclastaĦӴ֡C

"	PL/|qLť	PL/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668999?cesid=1Kvq5WfWRTN&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DZoledronic%2Bacid%26t%3Dname%26acs%3Dfalse%26acq%3DZoledronic%2Bacid"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.2.2._20110101_000.pdf"">OI` 5.5.3.2.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.3.2.2.,5.6.1."	0	OIs 20251124	DC	DC	DC	114.12.05
KC009242FO	M05BX04	0	IXGEV	XGEVA 120mg/1.7ml/vial(Denosumab) (N)		XGEVA|PRANKLXARANKLO@عkӭM(|Ͱk@ΪӭM)ΦB\Psn､JթΥiʳJաCXGEVAiRANKLƨ䱵AYkӭMΨeXWRANKC~FoͰಾpAkӭMʦ]RANKLEӤɰDOoͰffܪDnC]C	ĳqC4g@WuBjLθ֤U`g120@JCɥRtPͯҡAHvιwCtgC	"ΩBeC֦kʰಾfwC
b}lϥXGEVAveABvJCtgCʴt@סAõݭnɥRtBκͯDCĻPtMLtĪ֥ήɥi|ϧCtIcơDKʴt@סD
b}lϥXGEVAveΨϥXGEVAvAwifˬdAñĨAfĹwIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 28JNxsC	Denosumab	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	AΩ~FwಾHfwAwoͰfƥC	LC	h/LOBCCQgߡC	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668905?cesid=8pqU2btVm48&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDenosumab%26t%3Dname%26acs%3Dfalse%26acq%3DDenosumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.09	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.4._20241001.pdf"">OI` 5.5.4.</a>              "	OI` 5.5.4.	0	OIs 20251124	DC	DC	DC	114.12.09
AA52339219	M05BA08	0	IZOME	Bolenic 4mg/vial(Zoledronic acid)		"Zoledronic acid ݩĮĸjCQƦX@?ADn@ΦbfCOثeҪ̱jkӭMAl@Ϊ   
?iHfAl@Τ~AZoledronic acid ]֦SʡAiv?gಾ?ġC"	"1.bw multiple myeloma, breast cancer, prostate cancer oͩfβͰಾfww䰩f˨ƥɪĳ?4mg zoledronic acidC@YZoledronic acid`gGi@B100 0.9% w/v ƶuG5% w/v ?G}ACTܥ|gHܤ15R߿`覡ġCPɵfwfAC 500mg tɥR 400 IU ͯ DC
2.v?tgĳ? (ճJծեLMt@?jε12mg/dL 3.0mmol/L)4mgC@惡?Agv?榸A?
ЧġCfHb`Zoledronic acid `gGeᥲObR?AC
zoledronic acid(Zoledronic acid)?iMtΨ䥦tG?l(?pAŻ?G)R߿`GVXAåBP䥦Ī}A?οW?R߾ɺް@Rߪ`gG"	Ĺǥ\णfHAް_Ŧrʤ|iۼW[CܩٻMv(CCr)30-49ml/min fHA@rʤ|iF 30%CG CCR30ml/min fHAĳϥΥġAҦϥΥ֤fHAYKʱŦ\C@o͵Ŧ\cƤ{HAݥߨ谱ġAݵǥ\(H serum creatinine Ө)_ǻ 10%ɡA~iҼ{_ϥΥġC  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC  	ZOLEDRONIC ACID	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	Pзgv֥ΡAAΩhoʰFΩT~F֦fಾfHCΩ@fHfಾɡAܤֱL@زXvӤcƪ̡Cvcʸ~Ftֵog(HCM)C	"?sƿ`G zoledronic acid į?iϥΦbBŰM zoledronic acid ΨL
CQƦXΥ zoledronic acid զξ|?۹LӲ{HfHC
Zoledronic acid `gG?iϥΦbBŰC"	yPgGYįkBoNBhҡB٦׵h	DšAZoledronic acid `gG?iϥΦbBŰC	i¨šAZoledronic acid `gG?iϥΦbBŰC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-03 j	Ts110.5.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.2.1._20110101_000.pdf"">OI` 5.5.3.2.1.</a>              "	OI` 5.5.3.2.1.	0	OIs 20251124	IZOME-a	IZOME-b	IZOME-c	110.5.06
AC57366100	M05BA04	0	OALEN	PlusDmax 70mg/tab(Alendronate)		"Alendronate sodium O pyrophosphateXA|PHydroxyapatiteXC~@BisphosphanateAO@عkӭMҤް_Al@ΦĪM@ʧC
D3GPipztMCʧlCW[ǤpުAlC"	"FPĿFGiӴֹﭹDEiʡAī~ub_ɫH@Mն}AAӥBfHbAīܤֺWb30Aä@YLѲĤ@~iUC
ĳqCg@AC@70@J/2800ڳڳC"	ϥCQĪvɵoEawfĥ~ͪv@AåHӧOįq/IG¦ӧP_ϥCQĪvC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץxsAϥΤeЫOsT䤤C	"Alendronate sodium
Cholecalciferol(Vit D3)"	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	gk貨PgvBkʰ貨Pgv	"1. |𭹹DƪŪD`{HApDUΦwC
 2. LkߩΧܤ30̡C 
3. 糧~󦨤LӪ̡C 
4. CtgC"	hBߡBƤ}B٦װfkhC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.1._20110101_000.pdf"">OI` 5.5.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.3.1.,5.6.1."	0	OIs 20251124	OALEN-a	OALEN-b	OALEN-c	110.6.16
BC26136100	M05BB03	0	OFOSA	Fosamax Plus(Alendronate70mg+VitD3 140mc		"Alendronate sodium O pyrophosphateXA|PHydroxyapatiteXC~@BisphosphanateAO@عkӭMҤް_Al@ΦĪM@ʧC
D3GPipztMCʧlCW[ǤpުAlC"	ĳqCg@AC@70@J/2800ڳ70@J/5600ڳC	ϥCQĪvɵoEawfĥ~ͪv@AåHӧOįq/IG¦ӧP_ϥCQĪvC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץxsAϥΤeЫOsT䤤C	Alendronate/Colecalciferol	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	gk貨PgvAkʰ貨Pgv	"1. |𭹹DƪŪD`{HApDUΦwC 2. LkߩΧܤ30̡C 
3. 糧~󦨤LӪ̡C 
4. CtgC"	hBߡBƤ}B٦װfkhC	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.1._20110101_000.pdf"">OI` 5.5.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.3.1.,5.6.1."	0	OIs 20251124	OFOSA-a	OFOSA-b	OFOSA-c	110.6.16
AC47874100	M05BA02	0	OSINC	*Sinclote 400mg/cap (Clodronate)		~@OӫܱjkӭM@ΧAON¤WAlfܮɤzQCwtgMϰMtl@ץ`ơAwδCsಾX{MΩªಾAC骺MIMkhC	1. clodronateCAΤ@ɡA̦nbMŸɪAġAóܤ@jM}AAī@pɤfwקKMܤC 2. ClodronateiPBttΨLlī~֥ΡC]̷|}aClodronatelCYAΡAb\AΡA̦nOγܤܤ֨pɩέe@pɪAġC 3. C1600mgqi榸ΤGġC	"1.ŸAΡAAī1pɤnYFΪAΨLĪ
2.vAɥRAoR߿`ĮɤΰtεǰIܯfwSOnC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	C25JxsC	Clodronate	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	cʸ~FkʰYAcʰtg	CQ]biphosphonates^LӤfwTΥġCiPLC֥ΡC	ߡBæRPmC	PL/|qLť	PL/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.1._20110101_000.pdf"">OI` 5.5.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.2._20090601_000.pdf"">OI` 5.5.3.2.</a>             "	"OI` 5.5.3.1.,5.5.3.2."	0	OIs 20251124	DC	DC	DC	114.10.13
		0	IART1	Artzfors (۶O)2.5ml/		gĪvLĤ_ӱٳSew	"H@@,sϥΤTg"	i`J	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium hyaluronate	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	gĪvLĤ_ӱٳSew	`gwֽefηPV{Hw ׹LӤw Lh~͹LӤw	`gi঳ȮɩʯkhA~ȡAּƯfwoAoA~APgo͡D	קKϥΰDvn/Sm 	קKϥΰDvn/Sm 	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-03 j	Ts110.6.16		OI` 	0	OIs 20251124	IART-a	IART-b	IART-c	110.6.16
		0	IHYLI	HyLinkpĶ`@w``g			澯qsAC{uݪ`g@AC@`Ī`g3ml(Y@Ӫ`g)	"1.׮ۡBVJաBФBJs~LӪSO`NC
2.Y`nGAMnG~i`gC
3.`g48pɤקK@PʩΪɶt(p߶WL@p)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs1-25XCAiNC	Cross-linked hyaluronate	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM		AΩvwhƩ`(OA)khABgDĪvBDTJ(NSAIDs)ΤAQi(Acetaminophen)@hAvLĤw̡C	"1.ĻsLӪ
2.i`gwֽ̦efηPVAΦY``
3.YLөΦK̯ef"	`~ȡB`nGB`h			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.28		OI` 	0	OIs 20251124	IHYLI-a	IHYLI-b	IHYLI-c	111.4.28
		0	IHYAP	"HYAJOINT PLUS? 60mg/3mL/syringe(Sodium hyaluronate 60 mg )
/짰ͪުѥq"		~iH~ɶǨӪOAOiHO@`̻١C~iO@`Ĳ´BPi`n¡XC	HC{ϥ1䥻~AhƩʽ`wB`gD~AΩ`Ī`gDϥξqΪ`gɶHw̯gӲD{ɸҹꥻ~ӤJᤧįɶF12ӤD	`g~i|ް_~ȡAkhD Y`G{nΡAХLh`GAAH`g~D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	עѤUץxs	Sodium Hyaluronate 20mg/ml	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	ΩOuʫDĪvΤ@hpacetaminophenvLĤhƩʽ`khw̡D	`gwֽefηPV{Hw ׹LӤw Lh~͹LӤw	khA~ȡAλwƧ@ΡD	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-01 j	Ts111.8.19		OI` 	0	OIs 20251124	IHYAP-a	IHYAP-b	IHYAP-c	111.8.19
FBT01HG0019A		0	IHING	Hinge inj. 25mg/2.5ml/(Sodium Hyaluron		~60-120Udalton sodium HyaluronateA`Ĥ`GnզA`g`īi`l_μƪ\ġAνw]`oҲͤkhPD	"1.ĳ{TgA@g@Avi̾ڱw̤gW{gơC
2.~`Ī`gAYL߾ާ@AvϥΡC
3.ift18-25GwYϥΡA̼зǵ{Ǫ`gܦHw̤`ĤΪӮpUƽn ."	"`g~i|ް_~ȡAkhD
Y`G{nΡAХLh`GAAH`g~D"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	עѤUץxs	Sodium Hyaluronate 10mg/ml	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	"vhƩʽ``Ī`gAΩOuʫDĪvLĤΤ@h(p Acetaminophen) vLĤw
gĪvLĤ_ӱٳSew"	"`gwֽefηPV{Hw
׹LӤw
Lh~͹LӤw"	`gi঳ȮɩʯkhA~ȡAּƯfwoAoA~APgo͡D	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-05 j	Ts111.8.19		OI` 	0	OIs 20251124	IHING.a	BT01HG-1	BT01HG-2	111.8.19
		0	IHYAF1	Hyafelic Synovial(۶O)3ml/		~iHP~ɶǨӪOAOO@`̻١A~iO@`Ĳ´BPi`n¡XC	HC{ϥ3ACP1hƩ`wB`gC	"1.ϥΥ~ɥ̷ӳWdѦXvާ@ 
2.ΩOuʫDĪvLĤΤ@hpAcetaminophenvLĤhƩʽ`khw̡C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium hyaluronate	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	hƩʽ`	w糧~ʦLӪw̡C	khB~ȡBw	iw	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-02 j	Ts110.6.16		OI` 	0	OIs 20251124	IHYAF1-a	IHYAF1-b	IHYAF1-c	110.6.16
BC211401G0	N05BA12	0	OXANA	Xanax 0.5mg/tab(Alprazolam)[ޥ|]		Alprazolam YbenzodiazepineܵJ{AiǥѽվʯgǻGABAʡAӵoܵJ{έCi\ġC	"Anxiety0.25-0.5 mg TID; usual effective range is 0.5-4 mg/day (in 2-4 divided doses). MAX 4 mg/day

Panic disorders0.5 mg TID; may increase dosage by up to 1 mg every 3-4 days. Usual dosage range is 1-10 mg/day (mean, 5-6 mg/day)."	vGwCCqAĳ~C龯qCWLCT0.5mgAǯfHiƦܻݭn󬰽wCaCqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Alprazolam	N05B	ܵJ{ ANXIOLYTICS	0	J{A	"1. benzodiazepinesLӪfHATAlprazolamC 
2. ~iϥΦbAksʫCw̡AUʫCOTΡC"	ΡBYwYB«Φ٦׵LOBfBzGABܡBm	Ĥ C	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M03-01 []_E6 []_w78-02 []_s398 j	Ts110.6.16		OI` 	0	OIs 20251124	OXANA-a	OXANA-b	OXANA	110.6.16
BC25713100	N05CD09	0	OLEND	Lendormin 0.25mg/tab(Brotizolam)[ޥ|]		襤ϯgtΤbenzodiazepineSOXOΰ˩MOAiYuJvɶδıơAüW[ίvɶCb˾qAһɪίvcܡC	"PO,0.25 mg hs; dose may required 0.5 mg.
Elderly patients, 0.125 mg hs.
HG0.25
~Ѫ̡G0.1250.25"	i֥ΧtsBc	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Brotizolam	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vgv	Hypersensitivity to brotizolam or any component of the product	ݺΡBP¤BĵıʴCBgVáBh¡BYhBtwB٦׵LO	ĤC	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M03-02 []_E6 []_w78-04 j	Ts110.6.16		OI` 	0	OIs 20251124	OLEND-a	OLEND-b	OLEND-c	110.6.16
		0	ICITO	ĵCitosol 300mg/amp[ޥ|]		WuĤڤQA׷ʰA_ħ֡AĮĵuAO]ĪtѸAGܯתղ´ΰf١Aӥh¾KĪGAG@(redistribution)C	ɪqw3ml5mlt2.5%GA`gtv1ml/5Cqw2.5%GʪIV`gC~A٥iHsw`(0.3%G)Niһݭn¾K`סC	"1.i¾KeThC
2.i¾KHP¾KeĬhC
3.¾K`N޹DZqHɪ`NIl`pC
4.`NNɳ¾K`סAˬḑCn`סC
5.¾KeAlJBl޾B޵HuIlA̦nǳHɥiΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Thiamylal Sodium	N01A	"¾K ANESTHETICS, GENERAL"	0	R߳¾KB¾KɡC	"1.JΤjqX媺`BY߾ण̡C
2.ʡBPorphyring̡C
3.Addison'sw̡C
4.Yޮݪ̡C
5.BarbituratetLӪw̡C"	oʮ	帡NϥήɡAҼ{sͨ઺vTAҥHuγ̤pĶqVC	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ICITO-a	ICITO-b	ICITO-c	110.6.16
		0	IETON	ĵEtomidate USP 20mg/10ml/VIAL		ର GABA ո`A_l@ 30Aɶ4-10 A`Φb޳BmCSʤuIvTMʤOǡB୰C`A]JBCfwi|ϥΦĪA]@ӻݭn`NƧ@ΩMIG|11-]-hydroxylaseAǤW\ ( cortisolͦ)ë 4-8pɡA]iW[PV`IC	"~tEtomidate 2mg/ml(20mg/amp)
¾K:0.15-0.3mg/kg(0.075ml-0.15ml/kg)
15 HUൣΦ~w:0.15-0.2mg/kg(0.075ml-0.1ml/kg)
xwƤΤw뤩믫 (Neuroleptics)w̫h֥ζqC
󤤤wgAΤwgo@S¾KpUA 10 ֳtH`q Etomidate (0.3 mg/kgA۷ 0.15 ml/kg  Etomidate-Lipuro)CYnAiHqƼƦC"	"1.Etomidate iɭPͦC]iϥΩGXǩʻêw̡AD Etomidate AggJӵwT{䭷IPwqBC
2.ϥΰqûPϧĪXήɡAEtomidate iɭPuȩʩIlȰC
3.ɶʦa뤩 Etomidate |uȩʵǤWֽ貧`MICbɶNεǤWֽ\lpUAi
nֽJwʧġAҦp 50 V 100 mgBƥiQ (hydrocortisone)C
4.Etomidate-Lipuro LhĪGCY@u¾KɡAƥΦPɵp FentanyljĤhA綷`Nz ?椬@
5.Etomidate-Lipuro ȯR߿`Aq`wCa`@qһݮɶ 30 AYnAiqC
6.Etomidate-Lipuro ϥקKѰʯ߿`ӳy´aMICRߩP䤧`h|ް_@PkhC
7.뤩 Etomidate-Lipuro eA׫eXĥHקKٰ}˪o͡Cĳ Etomidate-Lipuro īe 1 pɥH٦ת`g 10 
eHRߪ`g覡뤩 BenzodiazepineĪp DiazepamC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsūפiWL 25 XCAiNC
NwJs]˥~HץC
wui榸ϥΡCѾlC"	Etomidate	N01A	"¾K ANESTHETICS, GENERAL"	0	Rߪ`g¾K	Etomidate-Lipuro iϥΩw EtomidateBjoΥ~LLӤw̡C	"ۥD٦׹B(myocloni)CYeXħ뤩~Ī Benzodiazepine ĪhiקKo͡C
Etomidate |TJǤWֽ誺ͦXC@qEtomidate AǤWֽOa֬ 3 V 6p
SOObq EtomidateλPRĪ֥ήɡAioͩIlPIlȰ{HC
Etomidate īiX{ߤιæRAoDnO]Pɵ~ĪΦbeXĮɵ~ĪӤް_C
kh"	קKϥΰDvn/SmҦw	Etomidate |cܨťĤCY¨Ŵ Etomidate-LipuroAī 24 pɤo¨šAcťC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668592?cesid=4Owylh8dw1L&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEtomidate%26t%3Dname%26acs%3Dfalse%26acq%3DEtomidate#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.7.20		OI` 	0	OIs 20251124	IETON-a	IETON-b	IETON-c	110.7.20
BC030771G0	N03AE01	0	ORIVO	Rivotril 0.5mg/tab[ޥ|]		~|[jֽ赲c@ξAثewҹbSwʵo@pUAiƪiqAӥBiHCnBʩwo@q(minor motor seizur discharges)WvA@δAשMXi	"fAvGקK}lv}ACCW[C龯qܾAXUӯfHqCM10 HUĵ (魫30 Kg HU) _lqC0.01 ~ 0.03 mg/KgA10 HWĵ (魫WL30 Kg) ĳ_lqC1 ~ 2 mgCqbM10 HUĵ (魫30 Kg HU) C0.05 ~ 0.1 mg/KgA10 ~ 16 ĵ (魫WL30 Kg) C1.5 ~ 3 mgAHhĳC2 ~ 4 mgC@Fq{סACqiߤW@qCpq}XA̤jqbߤWCq̦nbv1 ~ 3PFCTO̲zQqվAwӫĵ0.5 mg CKHb}lvɡAAθCC龯qA0.5 mg C
H̤jvqC20 mgC "	Ĩ֥Ω󦳰sĪݥΥvfHAD`pߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC 	Clonazepam	N03A	w ANTIEPILEPTICS	0	w	TΩwClonazepam ΨξLӡAΦYIlfHC	h¡BդѩΡB« BٱiOLCB٦׵LOBwtBYBBʥաBwC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M03-03 []_E6 []_w78-05 []_s392 j	Ts110.6.16		OI` 	0	OIs 20251124	ORIVO-a	ORIVO-b	ORIVO-c	110.6.16
AC05857100	R05DA04	0	OCODE	ĵCodeine 15mg/tab[ޤG]		"1.y@ΡGCĥiݦ]PܰئP˥i褧y¤ϡC
2.h@ΡGCĥiݦ]㤤ϩh@ΡC
3.m@ΡGCĥiݦ]jĤm@ΡC"	"1. ~ΩൣAȭ{ɮįqjIɨϥΡC
2. fAC@q 1530mgC"	ݯvBtw{HAAδpݱqƾާ@TBͩվMIʤu@̡ASOpߡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץJsC 	Codeine	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	"yBhC 
"	ൣ縢θNhBwCYP2D6ֳtĪNª̤έŰkC	sϥδptqΰġAi޵oBQBy\BߡBæRBYhBvB_ŸB٦`hBIl止_gC 	C 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_E1 []_w77 []_86-6 j	Ts110.5.06		OI` 	0	OIs 20251124	OCODE-a	OCODE-b	OCODE-c	110.5.06
AC03355212	N05BA01	ow`gG	IVALI	ĵDIANLIN 10MG/2ML/AMP[ޥ|]		J{ABvB٦׵jˡBwnA	"Acute alcohol withdrawalIM / IV, Initial: 5-10 mg then 5-10 mg IM or IV in 3-4 hr if needed. Anxiety disordersIM / IV, 2-10 mg may repeat in 3-4 hr if needed. Sedation in the ICU patientIV: 0.03-0.1 mg/kg every 30 min to 6 hr. Muscle spasmsIM / IV, Initial: 5-10 mg; then 5-10mg repeat in 3-4 hr if needed. Status epilepticus5-10 mg IV every 10-15 min to a total dose of 30 mg; may repeat in 2 hr if needed."	" 1.fH@Benzodiazepines ĪLӡA糧ĥiಣ͹LӡC
2.ķ|qLLLپC 
3.heTӤϥΥķ|W[ѩʷMIAGNϥΤMIPįq[HҼ{A̦nקKϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Diazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{ABvB٦׵jˡBwnA	Hypersensitivity to diazepam or any component of the formulation]cross-sensitivity with other benzodiazpines^; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; acute narrow-angle glaucoma	"Ataxia, drowsiness, fatigue, hypotension, respiratory depression, sedation"	ĤD 	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669814?cesid=8VJuem0QDLI&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDiazepam%26t%3Dname%26acs%3Dfalse%26acq%3DDiazepam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.08.14		OI` 	0	OIs 20251124	DC	DC	DC	114.08.14
		0	EFORT1	Fortacin[l~μQ		Fortacin tYѧ¾KĪGC䬡ʪ lidocaine M prilocaine i_tYg߽ĪǾɡAiӭCtYӷPסCo|ϬMbg멵ɶWAPɤ|g몺Pıy}vTC 	"ζq
ĳqO 3Uľл\tYCC@@t 22.5 @J lidocaine M 7.5 @J prilocaine ( 1 3U)C
Ϊk
QֽWϥΡC Fortacin uIΩtYCbĤ@ϥΫeuȷn̼QBMªŤQTAHǳƧ@~CCϥΫeAuȷn̼QAMQ@HsǳƧ@~CtYhh]֡C󪽥߮(ִ¤W)ɫU 3 AtYI 1  FortacinCC@Uл\T@tYC5 AbʥeٱhlĲG"	ѩಾܦQWIAFfHקKϥ FortacinAΪ̦p@ʾXAbQWQqƩʥeAɥi~btYC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. OsbWL25XC ūסCФŧNC
2. ϥΫAȥiOs12gC "	Lidocaine+Prilocaine	N01B	"¾K ANESTHETICS, LOCAL"		v~kʤoʦoʮgC 	"fHΨQﬡʪι椤ҦC@ξLӡC
fHΨQwQi(amide type)¾KLӡC "	ʹ޾PızMk_\êC 	S lidocaine M prilocaine Ω󥥰ơC̦nקKbhϥ FortacinADwĨĪkʫ̻ץIHi઺LSC	b Fortacin vξqUAʪѨkʯfHಾܤkʦQWw|ܥŪsͨ/yvTC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.17		OI` 	0	OIs 20251124	DC	DC	DC	114.07.17
		0	IROPI	ĵRopica inj.10mg/ml;20ml/vial		"Ropivacaine@ӪQi¾KAPɨ㦳¾KΤhCbqɡA䲣ͤN{פ¾KFbCqɡA䲣ͷPıg_]h^ABBʯgvT礣iʡC
Ropivacaine ML¾K@ˡAǪulqLӭMVgֺʡAϯgİʤǾɨifʤ_C
¾KLiĤӭM]pΤߦ١^Ai঳FpGLhĪiJ`AK|X{rfxίgAiѤϯgtΤΤߦިtΪ{XӡC"	"קKJޤAb뤩DqeΧ뤩Dqɧаw^⤧ʧ@AH25-50mg/tvwC`gγvW[q`gAYKʵfHͩRxHAPfH͸ܡCݧ뤩jqɡAĳϥδվq3-5ml lidocaine (Xylocaine 2%) [ǤWsFpAYpߥJޤA|ʴuȤ߸tvWFYVJպޤAh|X{ժ_xCpGX{rʯgAߧY`gC
ĥεw~_¾KiNɡAΰF250mg 澯qRopivacaineAfH@ʨ}nCLץHw`θgѭг@q`gAiɶ_¾KɡAݦҶq夤ĪFr@פξɭPglˤICH24 pɤֿn뤩800mg RopivacaineӶiNγNhAfH@ʨ}nANHCp6-10ml]12-20mg/ml^w`tvw~w`72 pɤ]@ˡC
vNkhAĳĥΥHU޳NGpGNewgmw~ɺޡAhig޵Ropivacaine 7.5mg/ml Ӷiw~_ɡCjhƤצܭׯkhfHA{ɬsܨCp6-14ml]12-28mg/ml^w`tviѦĤhAu񦳻LӫDiʪBʯg_CĥΦا޳NAfH~hĤݨDUC
jhƯfHAH2mg/kgqA1mg/kgenA@ropivacaine 2mg/ml յw~`gAYibT12HUѦĪNhAgwaϥιLF3mg/kg qCpPзǱЬѩҫĳAiվյw~`genHF줣PGPıg_C
ѷg_AH3mg/kgqA0.6ml/kgenA@ropivacaine 5mg/ml `gAYiѦĤhC
RopivacainePfentanyl ֥Υi[jhĪGA|ް_~ĪƧ@ΡC
bmWA帡N|LϥΤj7.5mg/ml @פOC"	YxffHpߨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	x25JHUAקKNC	Ropivacaine	N01B	"¾K ANESTHETICS, LOCAL"	0	~¾KBʯkhBz(Nβkhΰϰ_¾K)C	RopivacaineTΩamide¾KLӤfH  	CBYhBPı`BwtB߸}wιL֡BæRBGdBŤɰBIhC 	 DvnAקKϥ	 DvnAקKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.5.06		OI` 	0	OIs 20251124	IROPI-a	IROPI-b	IROPI-c	110.5.06
		0	ESOPR1	Sopredin cream 5%;5gm/		 SopredinŻIt lidocaine M prilocaine GQi¾KCoǪzּhίuּhANֳͪ¾K@ΡC¾K{רMťήɶMťξqC ť 1-2 pɦAhл\A¾KĪGj 2 pɡC	"ΪkGŧ[\@hιj
1.p~:(pRߴwά)C20-25cm22.5gĻIAd1pɥHW
2.jnθkhֽӪBzGC10cm22gĻIAdm2pɥHWD
3.~kʤʹ޾ֽGC10cm22gĻIAd15
ĻIHAɳt"	iΩˤfAHAʥֽw̡AβPD	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	J25JHU	Lidocain/Prilocain	N01B	"¾K ANESTHETICS, LOCAL"	0	PUCpֽhG]^wBpRߪ`gɺީΩeC]^֥~BmC]^ʹ޾߽Bp֥~BmeήKeC	Qi¾KLӪ	ֽaաAoAūܤƱӷPA~AooA֯lA@1-2pɫKhD	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ESOPR1-a	ESOPR1-b	ESOPR1-c	110.6.16
		0	IMAR4	ĵMARCAINE SPINAL 0.5% 4ML/AMP		BupivacaineML¾K@ˡAǪulgLgӭMVʡAifʦa_gİʪuۯgֺǼCgӭMulqDQ{O¾KCBupivacaineOīQi¾KAݨ¾KPh@ΡCbqɡAN¾K@ΡFbC@׮ɡA|ͷPıg_@(h)ABʯgֺ_@ΤpC	w0.25%Fw~/w0.250.75%F鯫g_w0.250.5%FPg_w0.25%F̤j@qO200mg(250mgO[epinephrine)C 	1.Ѫl|y`g~ȡA]`gݳASO`NC 2.@}ҶtϥΡAѾlľA]󤣥ΡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Bupivacaine	N01B	"¾K ANESTHETICS, LOCAL"	0	¾KC 	amideī~ΨξLӪ	CB߳ծ}wίջĨYhC 	便ΥihkAubbįqWVIpU~i뤩	便ΥihkAubbįqWVIpU~i뤩	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.5.06		OI` 	0	OIs 20251124	IMAR4-a	IMAR4-b	IMAR4-c	110.5.06
		0	IMARH	ĵMARCAINE HEAVY SPINAL 0.5% 4ML/AMP		BupivacaineML¾K@ˡAǪulgLgӭMVʡAifʦa_gİʪuۯgֺǼCgӭMulqDQ{O¾KCBupivacaineOīQi¾KAݨ¾KPh@ΡCbqɡAN¾K@ΡFbC@׮ɡA|ͷPıg_@(h)ABʯgֺ_@ΤpC	w0.25%Fw~/w0.250.75%F鯫g_w0.250.5%FPg_w0.25%F̤j@qO200mg(250mgO[epinephrine)C 	1.Ѫl|y`g~ȡA]`gݳASO`NC 2.@}ҶtϥΡAѾlľA]󤣥ΡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Bupivacaine	N01B	"¾K ANESTHETICS, LOCAL"	0	¾KC 	amideī~ΨξLӪ	CB߳ծ}wίջĨYhC 	便ΥihkAubbįqWVIpU~i뤩	便ΥihkAubbįqWVIpU~i뤩	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.5.06		OI` 	0	OIs 20251124	IMARH-a	IMARH-b	IMARH-c	110.5.06
AC000591G0	N05BA01	0	OVALI	Diapin 2mg/tab (Diazepam)[ޥ|]		"Benzodiazepines ϯgtΧAHqjpӲͦۻRBwvܩgP@ΡC
MUا@ξల]A@ΤTmξॼTߡA@۫HBenzodiazepinesObP@M@ʯg콤]Neuronal membrane^ۤ@ΫAΫPiFGABAʯgǾɧ@ΦӲ͡CGABAOCbϯgtΦU줧Ĳe᪺@ΡC"	"@릨HqG
ܵJ{BwvФfAA@5-30mgΫe@ΤA@2-4C
ʰs_ФfAAĤ@10mgAݭn@3-4AqHRhC
ܵj˾ФfAA2-10mgA@3-4C
fPФfAA2-10mgA@3-4C
e`Nf~ѤzfHФfAA2-2.5mgA@1-2Aݭnέ@ʳvW[qC
@ൣqG
6HUൣyϥΡC
66HWൣФfAA1-2.5mgΨC魫0.04mg-0.2mgAC褽n1.17-6mgA@3-4Aݭnέ@ʳvW[qC"	ΥġAקKM_gAvCqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Diazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{ABvB٦׵j	"1.糧Ĳ͹LӤw̡C
2.ʯUCw̤gٵLOw̸TΥġC"	ݺΡBRBBʥ	ĤD 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M04-01 []_E6 []_w78-03j	Ts110.6.16		OI` 	0	OIs 20251124	OVALI.a	OVALI.c	01C00059-2	110.6.16
AC440291G0	N05CD04	0	OESTA	Kinzolam 2mg/tab(Estazolam)[ޥ|]		OBZDwvġAݩ󤤮īAMDiazepamANitrazepamBenzodiazepineƦXۦPĲz@(pRAܵJ{AɯvAWjίvAܵjˤΦ٦P@)CSOίvA@αjBwwC~ʯvPBenzodiazepineƦXۦPAQ{OjtΤUCʾΤUCFıAëD@ΩıA]PɭP¾KAC	"1-2 mg at bedtime; start at dose of 0.5 mg in debilitated or small elderly patients
ζqNw̯fB~֡BewWC
@릨HGNe@fA1-2 mgC"	ŶsBAīAФŶ}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 30 װBҡFpoܽιLAiAΡC	Estazolam	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vC	"ٵLOgw̡BC
bϥRitonavirvw̡C"	}B©ΤíBYwBΡBfMBߨ`BJKC	ĤX	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M04-01 []_E6 []_w78-06 j	Ts110.6.16		OI` 	0	OIs 20251124	OESTA-a	OESTA-b	OESTA-c	110.6.16
AC44332229	N01AH01	0	IFENT	ĵFENTANYL 0.05MG/ML;10ML/AMP[ޤG]		"hZO@ئX~ĪA㦳 g PľĲz@ΡC
hZOjĪ¾KhAiΰ¾KhUγW¾KϥΡChZbqɯOŦíwʤνwM]OɭP餺XܡC100gg(2.0ml)hZh@ά 10 mg  morphineChZ@ΨtAO̤jhĪGΩIl@ΥiݭnƤ~FCq`Rߪ`g 100gg hZ 30 h@ΡCh`׻Pq"	"`gqyھڱw̦~֡B魫B骬pBbefBO_֥Ψ䥦ĪBNγ¾KөwCC~Ѥεzf
H_lqC
¾KhU : Cq : 2gg/kg ~Cq̾AXkhpNCq : 2-20gg/kg NɫhݭnqA@ήɶhqөwCq : 20-50gg/kg bɶjNɡA骺OH馳`AΥ~20-50gg/kgP֥ܯHWOANϥΦd򰪾qHi঳NIl{HA]bNK`NIlñK[C

¾K : NɪOD`nɡAi 50-100gg/kg AûPΦ٦P֥ΡCoا޳Nണѳ¾K@ΦӤݲK[B~¾KC~oبϥΪk`QΩ}ߤNΨLݭnO@ߦ٧Kʮ񤧭WnNC"	"1.Il@λPqҡASw¾Kܾ(p naloxone)i@ΡAѩIl@η|¾KܾĮīɶA]HiݦAP¾KܾC`פh`H۪Il@ΡA@Υi|δ_oNᶥqC
2.íwfHnקKֳt`g~ĪFfHʯߦȮɩʭCӷ|ֵouɶ`yCC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"~iPƶuθ}R߿`GVXC}Gi˩콦`eCհt 24 pɤnΧC
"	Fentanyl	N01A	"¾K ANESTHETICS, GENERAL"	0	¾KM¾KeġBʼ@PkhvC	w糧~@Ψ䥦 morphine ~LӪw̸TϥΡC	Rߪ`g~ĪۦPƧ@ΡApIlBB٦׻w(]Aݳ٦)Bٰ}˹BʡB߸LCB(uȩ)CBߡBæRMwtC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w77 []_86-9 j	Ts110.5.06		OI` 	0	OIs 20251124	IFENT1	IFENT1-b	IFENT1-c	110.5.06
AC44332212	N01AH01	0	IFENT1	ĵFentanyl inj. 0.05mg/ml;2ml/amp[ޤG]		"hZO@ئX~ĪA㦳 g PľĲz@ΡC
hZOjĪ¾KhAiΰ¾KhUγW¾KϥΡChZbqɯOŦíwʤνwM]OɭP餺XܡC100gg(2.0ml)hZh@ά 10 mg  morphineChZ@ΨtAO̤jhĪGΩIl@ΥiݭnƤ~FCq`Rߪ`g 100gg hZ 30 h@ΡCh`׻Pq"	"`gqyھڱw̦~֡B魫B骬pBbefBO_֥Ψ䥦ĪBNγ¾KөwCC~Ѥεzf
H_lqC
¾KhU : Cq : 2gg/kg ~Cq̾AXkhpNCq : 2-20gg/kg NɫhݭnqA@ήɶhqөwCq : 20-50gg/kg bɶjNɡA骺OH馳`AΥ~20-50gg/kgP֥ܯHWOANϥΦd򰪾qHi঳NIl{HA]bNK`NIlñK[C

¾K : NɪOD`nɡAi 50-100gg/kg AûPΦ٦P֥ΡCoا޳Nണѳ¾K@ΦӤݲK[B~¾KC~oبϥΪk`QΩ}ߤNΨLݭnO@ߦ٧Kʮ񤧭WnNC"	"1.Il@λPqҡASw¾Kܾ(p naloxone)i@ΡAѩIl@η|¾KܾĮīɶA]HiݦAP¾KܾC`פh`H۪Il@ΡA@Υi|δ_oNᶥqC
2.íwfHnקKֳt`g~ĪFfHʯߦȮɩʭCӷ|ֵouɶ`yCC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"~iPƶuθ}R߿`GVXC}Gi˩콦`eCհt 24 pɤnΧC
"	Fentanyl	N01A	"¾K ANESTHETICS, GENERAL"	0	¾KM¾KeġBʼ@PkhvC	w糧~@Ψ䥦 morphine ~LӪw̸TϥΡC	Rߪ`g~ĪۦPƧ@ΡApIlBB٦׻w(]Aݳ٦)Bٰ}˹BʡB߸LCB(uȩ)CBߡBæRMwtC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G50-100 mcg(1-2mL)`1-2min
q(MD)G3000 mcg(6A)tm300 mL(10ug/mL)
}GGD5WANS
}@סG10 mcg/mL
ĳĳtvG0.7~10 gg/kg/h(70kg5-10ml/hr)
wwʡG30 (RT)
ʴءGKA¤kAߡAæRAdAuݾ"	ixii[]_w77 []_86-8 j	Ts110.6.16		OI` 	0	OIs 20251124	IFENT1	IFENT1-b	IFENT1-c	110.6.16
AC50018311	N02AB03	0	EFEN25	:)Fentanyl transdermalK25ug/hr PPCD[ޤG]		FentanylO@~hADn@Φbu-~CDn@άhPRC良ϥιL~Īw̦ӨAfentanyļCĤhM@׬0.3-1.5 ng/mlAM@װ2 ng/mlɡAƧ@εoͤvWC̤p@ο@פεoͬrʪ@׷|Hۭ@ʪW[ӼW[C@ʲֺͤC]ӤHӦjtC  	"ĶvBϥΡC
~qHfwpPӲAbϥΫөwɵCfentanylܥ`tv۷25mcg/hAYCX0.6mgfentanylC
KΡB}ΥH覡}aA]i|}aKwC "	"1.]uɶϥεLkAqվABiɭPYΦMΥͩR𤣨AʩγNkhŨϥΥ~C
2.Fentanyl|y߸CA]߸LC߫ߤefwpߨϥΡC
3.FentanylDngѨxŦN¦DʥNªA]xŦefi|wưCxwƱw̦ӨADurogesic@qPAMfentanyl夤@׸AĪʤOǤܡCx\lfwϥΥ~A`NO_fentanylrxAnɭC~C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Fentanyl 	N02A	P OPIOIDS	0	ݭnϥ~sCʯkhMxTʯkhC   	wfentanylζKHKLӤfwATfentanylֶKC 	~PRߪ`g~ĪۦPƧ@ΡApIlBB٦׻w(]Aݳ٦)Bٰ}˹BʡB߸LCB(uȩ)CBߡBæRMwtC 	C  קKϥΰDvn	sͨiyIlAiϥΩŰk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669815?cesid=0kLVRFf5PqH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFENTANYL%26t%3Dname%26acs%3Dfalse%26acq%3DFENTANYL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_w76 []_86-7 j	Ts111.8.22		OI` 	0	OIs 20251124	EFEN25-a	EFEN25-b	EFEN25-c	111.8.22
BC25981100	N02AB03	0	OPAIN	ĵPainkylfU200mcg/(Fentanyl citrate)[ޤG]		FentanylO@~hADn@Φbu-~C 	"_lqG
1. qվ̭ӧOfwΦөwAϯfwoRhĪGBi@Ƨ@ΡCfwH@200mcgfU}lvC
2. YϥΤ@200mcgfUᤴF쨬khwѡAhH200mcgfUi澯qվ]YĤG 200mcgfU`qF 400mcgBAĤT 200mcgfU`qF600mcgBΫ򵹤ܲĥ| 200mcgfU`qF800mcg^C 
3. U榸q۹jܤ2pɡACokhƥȨϥΤ@uvfUAYP@khƥ󤤤hfUC
vG
vAYB辯qAHBmokhƥsƦAШ̫ezqվkդɾqC@qվACƥ󳣱NHtվ㾯qfU榸qvCPAINKYLϥb@ѥ|HUFYfwCgWL|okhƥAhiҼ{vkh]s(around-the-clock)~ĪqC
PAINKYL Ϊk 
1. ΦYfĨUΥβMfAKWfUBCЩϥΤfUe@~}]ˡAMNfUm@yB]¤W^ëOTwCNfUKfyUAúfUTwmW5AϤfUTwHKWCfwYiβGC 
2. ϥ PAINKYLfUeiNΩμC
3. ŤWAPAINKYLfUN1530CfUHYΤĲˡABfUeקKiC "	"~hivTḬ̄榳bMI@~]prpξާ@^믫ΡΥͲzOFVϥPAINKYLfwĵiӵMIsbAþڦĳC 
IlB~ĪBݥέIC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ЫOs20?-25?CAwƨϥήɥi\ūܰʽd 15?-30?CC
קK PAINKYL ΨFYT]ƥw}ʡAФŨϥΡC "	Fentanyl 200ug	N02A	P OPIOIDS		gfwoʯkh(breakthrough pain)BmABAιHȭ18(t)HWBbϥ~Īvbkhè@ʪ̡C 	"1. ѩ~Ī@fwӨA󾯶qҥi޵o¯٩ʩRIlA]~TΩʩγNkhBmA]tYhYhBhΫEҤUϥΡCsTϥΩ~Ī@fwC 
2. TΩw PAINKYL󦨤ΧhZĪ@ιLӤfwCbϥΨLfHhZsɡAʹLӤPLӤiC "	YwBߡBæRBݺΡBKBhBzC 	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w77 []_86-3L j	Ts111.4.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.9._20220201.pdf"">OI` 1.1.9.</a>              "	OI` 1.1.9.	0	OIs 20251124	OPAIN-a	OPAIN-b	OPAIN-c	111.4.20
AC375771G0	N05BA17	ο0.25@J]tGᥭ^	OERIS	޶^ ERA 0.25mg/tab (Fludiazepam)		"1.ܵJ{@
(1)J{Awѧ@(ܹ)
PܵJ{@pʳ̰xP欰礤A{XDiazepam 8
jġC
(2)JļAwѧ@(ѹ)
Qιqo欰礤A{XDiazepam 6.5jġC
2.RBʯv@
۵oʹBʧ@(ѹ)
jɡA۵oʹBʶqDiazepamC1/4C"	q`HC0.75mg3fAġC	AΥsw̽ФűqƾrΨ㦳MIʾާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷūOsC	Fludiazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{AAvA٦׵jˡC	"(1)ʯʫCw(]xP@ή޵oWɡBgcƤ)C 
(2)YgٵLOw(]٦P@ή޵ogcƤ)C"	ݺΡBYwدtB«PBPBfC	Ĥ D	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669734?cesid=93y2fDo50Ma&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFludiazepam%26t%3Dname%26acs%3Dfalse%26acq%3DFludiazepam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.06		OI` 	0	OIs 20251124	DC	DC	DC	114.05.06
AC484721G0	N05CD03	0	OMODI	:)Fallep 2mg/tab(Flunitrazzepam)[ޤT]		FlunitrazepambenzodiazepinePľA襤ϯgbenzodiazepine㦳˩MOCĨ㦳ܵJ{Bܵj˩MR@ΡAä޵o믫BʩʦʿwBѡB٦שPΦwvC	"1-2 mg for insomnia; 0.5 mg may be adequate in insomnia
Hw̪ĳq0.5-1 mg/dayASpUiq2 mgC"	fwsĪݥίfvɡAϥbenzodiazepinesASOp	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Flunitrazepam	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	v	ٵLOg̽ФŪAΡC	믫VáB`BıBkQBݺΡBYhBwtBĵıʭCBѡBBʥաC	ĵX. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_E1 []_w74 []_86-6 j	Ts110.6.16		OI` 	0	OIs 20251124	OMODI-a	OMODI-b	OMODI-c	110.6.16
	D01AE12	unI	ESALI	SALIC OINTMENT 10G/TUBE 				"1.jdΪϥη|yĮ(ջBwtBߡBæR)C
2.nĲIByBBHC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	 SALICYLIC ACID	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	h		"BkoBhPBĮ(ջBwtBߡBæR)C
"		RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		OI` 	0	OIs 20251124	ESALI.a	ESALI-b	ESALI-c	110.6.16
	D01AE12		ESALI1	Salic oint 25mg/g; 10gm/tube (Salicylic acid)			C1-2AuqũwC	"1.jdΪϥη|yĮ(ջBwtBߡBæR)C
2.nĲIByBBHC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	 SALICYLIC ACID	D01A	Χܯu ANTIFUNGALS FOR TOPICAL USE	0	h	糧~LӪ̡ATϥΡC	"BkoBhPBĮ(ջBwtBߡBæR)C
"		RsҾ	аѦҾqPΪk		ѦҡuqΥΪkv	  	ixii[G~]_O04-06 [E]_H3-26 j	Ts113.12.27				OIs 20251124	ESALI1-a	ESALI1-b	ESALI1-c	113.12.27
A040164151	N02BE01	0	LPANA	Anti-Phen syr 24mg/ml/60ml/btl		"1. h@ΡG@ΦbϯgtΡAkh֭(pain threshold)AFhĪGC
 2. hN@ΡG@ΦbϯgtΪո`ϡAͦXi{HA]iW[gѥֽലtסACšAFѼĪGC"	"oNλݭnɪAΡAYgAhC4-6pɥiƪAΡAC24pɤiWL5C
HC20~30@ɡA12HWAΦHqF
6HW12AC10~15@ɡF
3HW6AC5~7.5@ɡF
3HUAЬvEvAyۦϥΡC"	" DvĮvľͫܡAп`UCpAΡG
(1)3HUĳۦϥΡC
(2)g]Īް_Lӯg̤oϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 бKxs 25JHUA𶷦BsקKgC	Acetaminophen	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS	0	"hNBh]wYhBhB|hB`hBghB٦׻ĵhBgh^C

"	acetaminophenLӪ̡C	"AΫAYolBoBߡBæRBBYwBջﵥgɡAĨôNC
"	קKϥΰDvn/SmҦw	iw/i	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-03 [UDx]_U01-41 [E]_J1-01 [Ew]_J3-04 j	Ts110.6.16		0	0	OIs 20251124	LPANA-a	LPANA-b	LPANA-c	110.6.16
A022122100	N02BE01	0	OLACT	LactAM (Acetaminophen) 500mg		"1.khH۵oɡAĥiohN@ΦӹFhѼ\ġC
2.Ĩ㦳hBѼ@ΡA٦סB`HίgkhwѦġC"	"H12HWGoNλݭnɪAΡAYgAhC46pɥiƪAΡAC12A즸ϥγ̤pĳqAAgWζqCC24pɤiWL4C
6HW12AAΦHq1/2C
3HW6AAΦHq1/4C
3HUAЬvEvC "	"1. UCΪ AФŨϥΡG
(1) ]Ħް_LӪHC
2. UCΪ̡AϥΫeЬvEvG 
(1) 3HUC 
(2) HsAΥĶWL7ѡA12HUpĶWL3ѡAgwѪHC 
(3) xŦefHC
3. UCΪ̡AϥΫeХԸvĮvľ͡G 
(1) BihkέŰC
(2) PɪAΧtAcetaminophenhBhNκXP_ī~C
4. LϥΤW`NƶG
(1) ൣ~ЧOޡC 
(2) קKgC 
(3) ŶWLĳϥζqC 
(4) AιLqAcetaminopheniO]Qn֩ΧjhĪGAάOb DΥ`NpUƪAΧtAcetaminophenī~AOCѪA AcetaminophenWL4,000@J(mg)|oͨxŦl`C 
sĵyGo֪Ats붼ơA]AcetaminophenʨxIܪIC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUOsC 	Acetaminophen 	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS		"hNBhC 
( wYhBhB|hB`hBghB٦׻ĵhBgh ) "	LD	AΫAYolBoBߡBæRBBYwBջﵥgɡA ĨôNC  	B 	 DvnAקKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r04-01 [ws]_w10-02 []_01-03 [s]_245 [s]_246 [®]_245 [UDx]_U01-47 [E]_C4-05 [Ew]_EX084 [Ew]_Z-09w1 [Ew]_Z-11w9 [Ew]_Z-18w3 j	Ts110.11.3		0	0	OIs 20251124	OLACT-a	OLACT-b	OLACT-c	110.11.3
KC01113209	N02CD02	0	IEMGA	fEmgality inj. 120mg/ml/pen (Galcanezumab)(N)		GalcanezumabHƳA|Pt]`?(CGRP)t鵲XAê_P餧XC  	"1. Emgalityĳq@`g240 mg (s⦸֤U`gAC120 mg)tq(loading dose)AC֤U`g120 mgqC 
2. pG|@EmgalityAֵġCAiH۱̫@_wƨC@EmgalityġC
3. EmgalityȾAΩ֤U`gC
4. ֤UīeAEmgalitybǷŤURm30C
5. 󸡳BjLBWu᰼v֤U`gEmgalityCФŪ`gֽhBBoεwֳC 
6. wR`g@qA൹㾯qC "	W禳ʹLӤ(anaphylaxis)Φީʤ~רҳqCYoͭjYLӤAߧYEMGALITYñĨAvALӤiīƤѤ~oͨåBi@qɶC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. m~Næs2XC8XCAHO@EmgalityKuӮgܨϥάC 
2. iNC 
3. in̡C 
4. ۰ʪ`gb~ixsBc~Bū׳̰30XCHU̦h7ѡCYwxsbBc~AФűNEmgality^BcC
5. YWLoxsAEmgalityC
6. ϥΫNEmgality澯wR`g󨾬OsC "	Galcanezumab	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	AΩwHYhC 	Emgality TΩ galcanezumab Υ󥻫~ξYLӪfHC 	̱`}O`gC 	便ΥihkAubbįqWVIpU~i뤩	vŪvįqPŪnBAMҼ{~ΰšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.02.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.5._20220301.pdf"">OI` 1.6.5.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.02.17
BC23741438	N02CC01	0	EIMIG	IMIGRAN NASAL SPRAY 20mg/spray		"SumatriptanwQҹO@ؿܩʦ5-hydroxytrytamine-1-(5-HT1D)@ξALȫ5-HT(5-HT2-7)SvTCު5-HT1DDnG󸣳ޡAPަYC
ʪo{sumatriptanܩʦaVʯߴ`yY@ΡAätܸyCVʯߴ`Ytd`M`~´GAp轤C@{oǦުαiΡΤ~OyHYhDnC~AҾڷtsumatriptan|TegʡCoا@ΥiOPsumatriptanbHܰYh@Ϊ]C"	"H(18HW)G
1.ĳ̾Aq@յ20@JCѩw̦bYho@M糧ħl{ת鶡M餺tAYǱw̤o@piϥ10@JNġC
2.pGw̹ĪĤ@qSAĤGqiHΩP@o@C
3.ĥiHΩ󤧫᪺o@C
4.pGw̹ĪĤ@qAgAץX{Ahib24pɥHĤGqAoGӾqܤ֬۹j2pɡC
5.Ħb24pɪjiϥζWLG20@JμQGC

ൣ(12HU)G
ĹൣwʩMĩʩ|TߡC

Ѧ~H(65HW)G
ĨSϥΩ65HWw̪gC"	YhΥĪvi|ɭPݺΡCqƧ޳Nʤu@A}ξާ@wSOpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs2-30J	Sumatriptan	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	εLYho@ʽwѡAĶȸեΩ󦳩TE_Yh(Migraine)C	"s@ئLӪ̡C
1. ĤyϥΩ󴿱wߦٱBʦʤŦf(IHD)BPrinzmetal/a޵jˡBPޯefBΦŦXIHDgμxԪw̡C
2. ĤyϥΩ󦳸(CVA)εuȩʯʦgo@(TIA)fvw̡C
3.ĤiϥΩ󰪦w̡C
4.ĤyΩx\Ylw̡C
5.ĤiPti(ergotamine)γilͪ(methylsergide)s֥(Ī椬@)C
6.ĩMiƻï(MAOI)iPɧ뤩CĤ]ibiƻïīPHϥΡC"	wtBηPBıáBPı`BWɡByBߡBæRBIlx	קKϥΰDvn/SmҦw/|qLť	wҹ֤U`gsumatriptanN|ƤJťĤCGקKī12pɤšAHNnSĤi୰̧ܳC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O01-02 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.3.1._20190501_000.pdf"">OI` 2.3.1.</a>              "	0	0	OIs 20251124	EIMIG-a	02023741-1	EIMIG-c	111.8.19
BC24380100	N02CC01	0	OIMIG	Imigran FDT 50 mg/F.C.tab (Sumatriptan)		"SumatriptanM@ʩMܩʤ5-HTlʰʾALȫ5-HT25-HT3SvTC
5-HTlDnG`ޡAbʪ礤o{sumatriptanܩʦaﶵʯߴ`yY@ΡAä|ܸyCVʯߴ`Ytd`M`~´GAp轤C@{oǦުαiOyHYhDnC"	"1.@}l:50 mg; ݭnɨpɪA1; 
2.̤jq:100 mg/dose, 300 mg/24hr."	ī~ȾAΩ󦳩TE_Yh	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js30JHUBC	Sumatripan succinate	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	¾KC	"1. s@ئLӪ̡C
2. ĤyϥΩ󴿱wߦٱBʦʤŦefPrinzmetalU߯g/a޵j˪̡C
3. ĳϥΩ󰪦w̡C
4. Sumatriptany֥Χti(ergotamine)sergotaminelͪ
5. yPɵiƻïAΦbiƻïīPϥΡC"	wtBηPBıå]tPı`MPıhCīuɶȮɦWɡCCIlxC߻PæR	קKϥΰDvn/SmҦw	קKbAī12pɤ|iC౵ĲĪ|C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w51-01 [E]_C2-07 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.3.1._20190501_000.pdf"">OI` 2.3.1.</a>              "	0	0	OIs 20251124	OIMIG-a	OIMIG-B	OIMIG-c	111.8.19
	N02CD02	0	IEMGA0	()Emgality inj. 120mg/ml/pen(Galcanezumab)(N)		GalcanezumabHƳA|Pt]`?(CGRP)t鵲XAê_P餧XC  	"1. Emgalityĳq@`g240 mg (s⦸֤U`gAC120 mg)tq(loading dose)AC֤U`g120 mgqC 
2. pG|@EmgalityAֵġCAiH۱̫@_wƨC@EmgalityġC
3. EmgalityȾAΩ֤U`gC
4. ֤UīeAEmgalitybǷŤURm30C
5. 󸡳BjLBWu᰼v֤U`gEmgalityCФŪ`gֽhBBoεwֳC 
6. wR`g@qA൹㾯qC
bī~ϥΨL}hPi(oxytocin, dinoprost)ɡA]ĪۭĪGAeo͹Lj}hAnRYʵVġC "	W禳ʹLӤ(anaphylaxis)Φީʤ~רҳqCYoͭjYLӤAߧYEMGALITYñĨAvALӤiīƤѤ~oͨåBi@qɶC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. m~Næs2XC8XCAHO@EmgalityKuӮgܨϥάC 
2. iNC 
3. in̡C 
4. ۰ʪ`gb~ixsBc~Bū׳̰30XCHU̦h7ѡCYwxsbBc~AФűNEmgality^BcC
5. YWLoxsAEmgalityC
6. ϥΫNEmgality澯wR`g󨾬OsC "	Galcanezumab	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	AΩwHYhC 	Emgality TΩ galcanezumab Υ󥻫~ξYLӪfHC 	̱`}O`gC 	便ΥihkAubbįqWVIpU~i뤩	vŪvįqPŪnBAMҼ{~ΰšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		0	0	OIs 20251124	IENGA-1	10C01113-1	10C01113-2	44322.49692
NC00140100	N02CA52	0	OCAFE	Ergoton 100mg/tab(Ergotamine+caffeine)		"Ergotamine tartrate`~ʯߵȤj㦳S޺i@ΡA\hYho@ΨLީYhgA@ئ]caffeine\[tμWiiErgotamine tartratebzlC
"	"q`H12AHCjbpɪA1AA`q@̦hiWL6C
hWH1餧̤jAζq6A1P̤jAζqiWL10C"	(1)קKAΧt@ئ]Ap@ءBi֡BA]@ئ]|W[ī~lAi]yr{HC(2)קKPcĨ֪A(3)ergot alkaloidPmacrolides]ҦpGerythromycin^X֨ϥήɡApߺʴO_ergotr{]ҦpGP޵j)C(4)o{o@eXgɧYAΥiu}vĪGC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiA	Ergotamine	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	ީYhpYhB´iYh	޻êBʦ޻êBU߯gBaʯߵwƯgYw̡CxŦεǾêw̡CѦgw̡CCw̡CΥihkC¨ŰC糧γAlkaloid(Ergotamine)LөʤLhfvw̡C	gLӤf̩ΥgvɦөvAioߤιæRAPı`A|ϯkhεzC	]Ergotamine Tartrate㦳lcY@ΡAGΥihkŨϥΡC	]Ergotamine Tartrate|bHŤAG¨ŤkŨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-03 [s]_123 [®]_123 [E]_A2-07 j	Ts110.6.16		0	0	OIs 20251124	OCAFE-a	OCAFE-b	OCAFE-c	110.6.16
AC57356100	N02CA01	0	OSEGL	Lesiton 5mg/cap (Dihydroergotamine)		"Dihydroergotamine㦳UCʽG
w`~VʯߨtΪ@ΡASOO@ΦbM(serotoninergic receptors)㦳(E@)C
wޣ\-ǤW馳ʡAbRߴ`ۡGgҹ޺Y@Υi঳OXeC(prostaglandin-like)ҳyC
bqɡAdihydroergotaminealpha-ǤW_Mserotoninergic_@ΡC"	q`@ѤGɽnAߦUfA@ɡA\ɶAΡAyPhqɧ]AC	"1.ĳŸAΡC
2. YxणYǥ\णӥ@GzRw̡AԷVϥΡC
3. ʯ߯effv̫ĳiʴ(SOOaʯ߯efMװw)C
4.g(r)hBߡBæRBYhB߸L֩ιLCBHCBIlxBtwB|ϷPı`(]ʦ)C
5.YT{ީʳrAb|ivGpݭnA`G@]AheparinAXiεǤWֽ(corticosteroids)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Dihydroergotamine methanesulphonate(t1.5mgF3.5mg)	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	YhC	wergotlͪLӪ̡C	ߡAM}kPı`AʦMo淥uC	zפWlcYMC]AndNiणnbhPdihydroergotamineC	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w26-05 [UDx]_U02-38 [E]_B2-27 [Ew]_EX024 j	Ts110.6.16		0	0	OIs 20251124	OSEGL-a	OSEGL-b	OSEGL-c	110.6.16
AC39626209	N05BA06	0	IATIV	ĵAnxicam 2mg/ml/amp(Lorazepam)(N)[ޥ|]		"1. ~benzodiazepineܵJ{A12HUĵnϥΡAqӧOwFvW[qӴ֤}C
2. ~ѩΰIzfHA}lqC12mgC
3. ѩSʥNªͦA]LlͪASnWMIʡC"	"RߡB٦ת`gCRAbƾǪve30-35ġGHAC0.025-0.05 mg/kg (̤jq 4mg)F2-15ൣAC0.05 mg/kg (̤jq 2mg)C¾KeġAbNe2pɵġGHAC 0.05 mg/kg (̤jq 4mg)CnwGHA4 mgH2 mg/mLġAnɥib10-15ƵA̤jq 8 mgFPൣAC0.05-0.1 mg/kgACqnWL4 mgApGݭniHb10-15H0.05 g/kgƵC
IMA}CIVAݥεnNSW}wCġA`tviWL2 mg/minC

RߡB٦ת`gCRAbƾǪve30-35ġGHAC0.025-0.05 mg/kg (̤jq 4mg)F2-15ൣAC0.05 mg/kg (̤jq 2mg)C¾KeġAbNe2pɵġGHAC 0.05 mg/kg (̤jq 4mg)CnwGHA4 mgH2 mg/mLġAnɥib10-15ƵA̤jq 8 mgFPൣAC0.05-0.1 mg/kgACqnWL4 mgApGݭniHb10-15H0.05 g/kgƵC"	"i֥ΧtsBcơF
AīiݺΡAp߶^ˡF"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	NëOsCGpܦΨIͫh󤣥ΡC	Lorazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{A	"i֥ΧtsBcơF
AīiݺΡAp߶^ˡF"	ΡBYhBtwBջBıҽkBzBíBCBkool	Ĥ C	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B02-17 []_K1 j	Ts110.6.16		0	0	OIs 20251124	IATIV-a	IATIV-b	IATIV-c	110.6.16
BC24651166	N03AX14	0	LKEPP	Keppra oralG100mg/ml;300ml/~		"1. ĥDlevetiracetamݩpyrrolidonelͪ(\-ethyl-2-oxo-1-pyrrolidine acetamideS蹳c)C
2. |TwAwPL{swsõLC~M餺oAlevetiracetam|ܲӭM򥻯SʩM`gǾɡC
3. Levetiracetam@ʪMoʥʵo@޵oO@@ΡAB|ް_pro-convulsant@ΡC"	"1. ĬfAAAήɥHqA]JAeζ᧡iCĳC龯qBߨ⦸ϥΡC
2. HΤQHWC֦~GlqC1000(C⦸AC500)Cqilv1ѡC
3. fH{ɤέ@ʡAC龯qiW[̰C3000(⦸AC1500)CܾqɡAHCGܥ|PWqδq1000(C⦸ACW/500)@qiC"	̾{ɸgAYAKeppraSĮɡAĳqʴqAҦpGCGܥ|Pq1000(GACU500)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Levetiracetam	N03A	w ANTIEPILEPTICS	0	QHWfwwo@(֦Τ֦oʥo@)WvC|HWĵΦHfwwo@(֦Τ֦oʥo@)AQGHWC֦~PHfw٩Dwo@AHΤQHWC֦~PHwʪxowoʪxoʱj}˵o@UvC	DlevetiracetamӷPιLpyrrolidonelͪΥĨLӷP̡AФŨϥΥġC	ݺΡBLOPBtwBzBYhBBʥաB_ŸBСBߡBƤ}BmB	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M07-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.4._20220201.pdf"">OI` 1.3.2.4.</a>              "	0	0	OIs 20251124	LKEPP-a	LKEPP-b	LKEPP-c	110.6.16
BC22395271	N03AG01	0	IDEPA	Depakine Lyophilized inj. 400mg/vial		~|@CNSGABA(@اʯgǻ)@פΨ\AӭCϯg`qC	"IV for epilepsy same as oral dosage. Adult: Initial dose: 10-15mg/kg/day, increased by 5-10mg/kg daily weekly intervals until seizures are controlled. MAX: 60mg/kg/day. Children ?10 years: Refer to adult dosing.
? IV formulation for use only in patients who temporarily cannot use oral form; use for more than 14 days has not been studied; switch to oral valproic acid as soon as clinically feasible.
? Administer infusion over 60min or at a rate of 20 mg/min with the same frequency as oral products. Total daily IV dose should be equivalent to the total daily dose of the oral valproate product.
"	"tswwʡGǷ24p
}wwʡGߧYϥ
ۮe}GGD5W,D10W, NS
ĳ}nGIn 50 ml
ĳĳ~|tvGĮɪ`g 1 hrAΫ24 hrw`
L`NƶG1.IVĤ@묰uϥ(<14)AYfAtאּfAC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷšCwtī~2-8JA@ѫ߱	Sodium valproate	N03A	w ANTIEPILEPTICS	0	LkHfA~|wC	"Hypersensitivity to valproate acid, derivatives or any component of the formulation; hepatic disease or significant impairment; urea cycle disorders"	ߡBæRBGhBm	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Valproate is excreted into breast milk	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-16 [w]_w03-21 [E]_C5-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.1._20131001_000.pdf"">OI` 1.3.2.1.</a>              "	0	0	OIs 20251124	IDEPA-a	IDEPA-b	IDEPA-c	110.6.16
AA57956221	N03AX14	0	IKEPP	Levetir inj.100mg/ml;5ml/vial		"1. ĥDlevetiracetamݩpyrrolidonelͪ(\-ethyl-2-oxo-1-pyrrolidine acetamideS蹳c)C
2. |TwAwPL{swsõLC~M餺oAlevetiracetam|ܲӭM򥻯SʩM`gǾɡC
3. Levetiracetam@ʪMoʥʵo@޵oO@@ΡAB|ް_pro-convulsant@ΡC"	"WvG
HΤQHWC֦~G
ϥήɫĳHCѨ⦸C250 mg}lAPW[qCѨ⦸C500 mgF_lvqCfH{ɤAqiAհAHCPWq500 mg(⦸ACW[250 mg)@qiC̰qC3000 mg(⦸AC1500 mg)C
UvG
H(QKHW)魫QHWC֦~(QGܤQC) lqC1000 mg(C⦸AC500 mg)CqilvĤ@ѡCfH{ɤέ@ʡAC龯qiW[̰C3000 mg(⦸AC1500 mg)CܾqɡAHCGܥ|PWqδq1000 mg(⦸ACW/500 mg)@qiC
ĵ(|ܤQ@)魫QHUC֦~(QGܤQC)G
lqCѨ⦸AC10 mg/kgCfH{ɤέ@ʡAqiW[̰C30 mg/kgAC⦸CܾqɡAqiCHCGPWqδq20 mg/kg(⦸ACW/10 mg/kg)Cb̧CľqC魫QHWĵ侯qjPPHۦPC  
İʤO"	"tswwʡGߧYϥΡA ̦hi4 hrs
}wwʡGN24 hrs
ۮe}GGNS, LR, D5W
ĳ}nGin > 100 ml
ĳĳ~|tvGw`15 min;  IV bolus over 3 to 5 min and IV continuous infusion of 200 to 400 mg/hr have also been used in ICU patients.
L`NƶG3.ثeõLsϥu@Y`GRߪ`gWL 4 ѪgC()"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Levetiracetam	N03A	w ANTIEPILEPTICS	0	ȮɤyεLkfAwĪvUCww̡GQHWfwwo@(֦Τ֦oʥo@)WvC|HWĵΦHfwwo@(֦Τ֦oʥo@)AQGHWC֦~PHfw٩Dwo@AHΤQHWC֦~PHwʪxowoʪxoʱj}˵o@Uv	DlevetiracetamӷPιLpyrrolidonelͪΥĨLξӷP̡AФŨϥΥġC	̱`Qq}wtBݺΡBYhBLOPB«C	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-17 [w]_w02-03 [w]_w02-18 [E]_G2-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.4._20220201.pdf"">OI` 1.3.2.4.</a>              "	0	0	OIs 20251124	IKEPP--a	IKEPP-b	IKEPP-c	110.6.16
BC26283238	N03AX18	0	IVIMP	Vimpat 10mg/ml ; 20ml/vial (Lacosamide)		Lacosamide bHow@νTݧĩC~qͲzsܡALacosamide ܩʼWjulqDƹhAϱoשEgӭMíwC	"魫50ΥHWൣPC֦~AHΦH
@Īv
ĳ_lqCѨ⦸C50@JA@gᴣ100@JCѨ⦸lvqC LacosamideiھvwﭰCwo@nʬ۸bƧ@ΪAHCѨ⦸100@J}lġCھڤM@ʡAqii@BCgW[50@JCѨ⦸(100@J/)AܨC̤jĳq200@JCѨ⦸(400@J/)C
Uv
ĳ_lqCѨ⦸50@JAb@gᴣ100@JCѨ⦸lvqC ھڤM@ʡAqiHi@BCgW[50@JCѨ⦸ܨC̤jĳq400@J(200@JACѨ⦸)C
魫C50窺ൣ(4HW)PC֦~
@k
ĳ_lq2@J//ѡA@g4@J//ѪlvqC
ھڤM@ʡAqiHi@BCgW[2@J//ѡCqvW[ܹF̨ΤC魫C40窺ൣAĳ̤jq12@J//ѡC魫b40줣50窺ൣAĳ̤jq 10@J//ѡC
Uk
ĳ_lq2@J//ѡA@g4@J//ѪlvqC
ھڤM@ʡAqii@BCgW[2@J//ѡCqvվAܹF̨ΤC魫p20窺ൣAѩMvHAĳ̤jqF12@J//ѡC魫b20줣30HUൣAĳ̤jq10@J//ѡA魫b30줣50窺ൣAĳ̤jq8@J//ѡC
ϥΤk
1. LacosamideiHHfAΰw覡}lvC
2. ȮɵLkHfAĮɡA`gGiHNϥΩfHC RߤLacosamidevͨMwF {ɸ窺gAHUkCѨ⦸Lacosamide`gĪF5ѡC
3. LacosamideCѧĨ⦸(q`ߦU@)C
4. Vimpat`GH1560ɶi`ACѨ⦸CC`>200@J(Y> 400@J/)A`ɶ̦nOܤ30C
5. VimpatGGiε}YiiR߿`AΥiδƶu9@J/@(0.9 %)`gGB}50@J/@(5 %)`gGΨŻĪL`gGi}C"	Lacosamide v|HYwAi|W[N~ˮ`ζ^˪o͡C]AifHnԷVAL̼xĪbvT	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb 25XC HUC	Lacosamide	N03A	w ANTIEPILEPTICS	0	"Lacosamide AΩ:
1. QHWεLoʥo@wo@w̪@ĪvC
2. QHW(1)ʧwo@P (2)©νʧo@X֦oʥo@ww̤UvC"	"1. 糧~DΨξLӪ̡C
2. ww2 ũ3 ũЫǪ_C"	̱`ϥΥ~v}YwBYhBߡBƵC	Lacosamide ӦbhϥΡADTݭn]p˪qBjLbI^CpGkM whAϥΥ~JӭsC	ʪs Lacosamide |cܰʪŤCҼ{Ī˪nʡAMwO_ũΰϥ LacosamideC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-17 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.9._20180801_000.pdf"">OI` 1.3.2.9.</a>              "	0	0	OIs 20251124	IVIMP	IVIMP.b	02C26283-2	110.6.16
AC45701221	N03AB02	0	IALEV	ALEVIATIN 250MG/5ML/AMP(PHENYTOIN)		íwgӭMθgѪ_ulqDӭCgQEo|A㦳@ΡC	"1.swAG
_lq(LD)GswAG10-15mg/kg(H70kgҡA1000mg(4A)+100mlts10mg/ml run <5ml/min(Y<300ml/hr)
q(MD)G100mg q6~q8h POIV
}GGNS
}@סGH50-100ml NStsϿ@פWL10mg/ml
ĳĳtvGwC`gA<50mg/min(Bϥ0.22-0.50micronsu(in line)oD`geHNSR~AקKī~PʷGR߳yED
wwʡGiNáAts󢰤pɤ`
ʴءG߹qϡAAIl\୰CA夤@׽T{qO_AalbuminD
2.g~NG
wqG100-200mg(2-4mlG) IM q4h(`٦ת`g)
POIMN즳POqW[50%H@סAIM_POɡAĤ@P٦פ|XĪAGPOqݤPOqA50%AwM@׹LAitX夤@˴AHվ㾯qD(ĳ夤@סG10-20ug/ml)"	"tswwʡGɧ֨ϥ
}wwʡGߧYϥ
ۮe}GGNS, LR
ĳ}nGin 50-150 ml
ĳĳ~|tvGIV 50 mg/min, (Pediatric) Maximum IV rate 1 to 3 mg/kg/min or 50 mg/min
L`NƶG]pHȬ12APLĪVXCPHU|phenytoinRXAiϥΡCw`ХHNSNIV lineRbC2.YLӯgߧY`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUOs 	Phenytoin	N03A	w ANTIEPILEPTICS	0	jo@wAwΪvg~NҤް_wo@	PhenytoinΨLhydantoinsLӪfHC 	iΫpB}BíBNѲVcByŸʡBfMC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Phenytoin is excreted in breast milk.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-28 [w]_w03-09 [E]_G3-13 j	Ts110.6.16		0	0	OIs 20251124	IALEV-a	IALEV-b	IALEV-c	110.6.16
AA48161145	N03AG01	0	LVALP	Sod.Valproate 200mg/ml(Valproic acid)		~|@CNSGABA(@اʯgǻ)@פΨ\AӭCϯg`qC	"q
C 24 pɥqpUG
ĵG30mg/kg (ĳϥΤfAG)C
C֦~ΦHG20~30mg/kg(ĳϥοΫĮĿ)C
BH mg AC~ҩfAGHĪ@䦳q(mg)׫ܪվwC
Ϊk
fAϥΡCȥiϥβ~ҪվwqC
C龯qAΦpUAĳP\IPɪAΡC
@HUfH⦸AΡC
@HWfHTAΡC
ҩfAGHֶqDowʶƵ}AΡC "	"1. AΥ~w̩yƫeˬdx\AٱowˬdC
2. AΥ~w̤y}αqƦMIʪu@C
3. ~|y絲G~PA}fˬdɩyԷVC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC  	Valproic acid	N03A	w ANTIEPILEPTICS	0	"wjo@Bpo@VXGwC

"	"1.糧ĹLӪ
2.Yxefw
3.~AδФŨ֪ACarbapenemtܥͯ"	ߡBæRBGhBm	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Valproate is excreted into breast milk	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M06-05 [ws]_w73-06 [E]_I4-07 j	Ts110.6.16		0	0	OIs 20251124	LVALP-a	LVALP-b	LVALP-c	110.6.16
BC26285100	N03AX18	0	OVIMP	VIMPAT 100mg/tab (Lacosamide)		Lacosamide bHow@νTݧĩC~qͲzsܡALacosamide ܩʼWjulqDƹhAϱoשEgӭMíwC	"@ĪvLwĪvw̥i}lHLacosamide @ĪӪvC
ĳ_lq100mg@Ѩ⦸ (200mg/day)A@gᴣ150mgvq,@Ѩ⦸(300mg/day)CھڤM@ʡAqii@BCgW[50mgA@Ѩ⦸Aĳ̰q200mgA@Ѩ⦸]400mg/day^C
Uv
ĳ_lq50mgA@Ѩ⦸A@gᴣ100mglqA@Ѩ⦸CھڤM@ʡAqii@BCgW[50 mgA@Ѩ⦸AĳC̰q400mg]200mgA@Ѩ⦸^C"	"1. Lacosamide i໴Lܤ׼vTrpMϥξOC
2. Lacosamide v|HYwεOҽkC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb 25XC HUC	Lacosamide	N03A	w ANTIEPILEPTICS	0	"Lacosamide AΩ:
1. QHWεLoʥo@wo@w̪@ĪvC
2. QHW(1)ʧwo@P (2)©νʧo@X֦oʥo@ww̤UvC"	"1. 糧~DΨξLӪ̡C
2. ww2 ũ3 ũЫǪ_C"	̱`ϥΥ~v}YwBYhBߡBƵC	Lacosamide ӦbhϥΡADTݭn]p˪qBjLbI^CpGkM whAϥΥ~JӭsC	ʪs Lacosamide |cܰʪŤCҼ{Ī˪nʡAMwO_ũΰϥ LacosamideC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D2 [2]_D2 [ws]_w37-01 [E]_B4-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.9._20180801_000.pdf"">OI` 1.3.2.9.</a>             "	0	0	OIs 20251124	OVIMP.a	OVIMP-b	02C26285-2	110.6.16
AC41247100	N03AF01	0	OCAMA1	Carpine 200mg/tab (Carbamazepine)		W[A֤ʡAqPֽMt\঳hĲ~|C~iCjĤOۭ@ΡA~A٨㦳xPEʡAܧ{M٦P@(zZg٦תǻ@)C~iHwjSoʤTeghw̪}oʯkhCbs}gԸs譱A~iwQCֻ֭ȡA]Ӵ֯fgoMIʡCåitaﵽ믫ʻPۥDgʯgwgCbYg譱A~iHtCqAѰPC	"1. wwH12HWൣG_lq200mgAC2AMCѼW[200mgAAΡAܲ;AyA̤jqC1600mgF@qd򬰨C8001200mgC
2. 612ൣG쾯q100mg bidCCgհq1AC̦hW[100mgA34AΡCC̰q1,000mgAqC400800mgC
3. 6HUൣG쾯qC5mg/kgAC57ѽհq1ܨC1020mg/kgCΨC1020mg/kgAAΡAݭnɨC12gհq1C
4. Teghw_lq100mgAC12pɼW[100mgA@몺dC400800mgCܤ֨C3ӤYխCqΰġC "	"1. wǡBxΤŦefBBCw̡AHΦѤHBα¨ŪfHϥΥ~ypߡC
2. ĭnCCվ㾯qAYMܡAi|ɭPws򪬺A(status epilepticus)C
3. TegretolbʴUpߨϥΡCAΥ~y}αqƦMIʤu@C
4. Yߦޤ譱efAΪ̨xǥ\ಧ`ΦѦ~HAϥTegretol`Nվ㾯qC
5.i঳ɭPuYֽL:v-jͯgԸs/rʪַѯg(steven-johnson syndrome/toxic epidermal necrolysis )"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Carbamazepine	N03A	w ANTIEPILEPTICS	0	wgBTeghBǭʧYgeʯew	fAMYBCarbamazepineLӪ̡AŦЫǪ_fHC	ī~ioͨuYֽLӤApvͤjͯgԸs/rʪַѯg]Steven-Johnson Syndrome/ToxicEpidermal Necrolysis SJS/TEN^}ApX{VhBLگ}BoBֽlAߧYġA^EDvvC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Safe	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 [ws]_w22-01 [UDx]_U02-21 [E]_B2-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.6._20110801_000.pdf"">OI` 1.3.2.6.</a>              "	0	0	OIs 20251124	OCAMA-a	OCAMA-b	OCAMA-c	110.6.16
BC14899100	N03AG01	0	ODEPA	Depakine 200mg/tab(Valproate sodium)		~|@CNSGABA(@اʯgǻ)@פΨ\AӭCϯg`qC	"fAϥΡCC龯qGTAΡAĳP\IPɪAΡC}lϥsodium valproate v
- YfHwAΨLwĪvɡA Hi覡v[Jsodium valproateAbGPW[ܳ̾AqAYݭnAwĪibfUCCqC 
- SAΨ䥦wĪfHACj 2 3 ѳvW[sodium valproate qAb@PiF̾AvqC
- pGn[JLwĪAHi覡v[JC"	"1. bDepakine vex\աAæbv̪줻Ӥ뤺wʴASOOMIsfHC
2. THUĵYvalproate sodium vAbvevįqMiް_fHoͨxfMI "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	JsbǷŤU(C25J)BC	Valproate sodium	N03A	w ANTIEPILEPTICS	0	xoʻPwgBൣzΨൣʩzB欰`æwg	"-  valproateBdivalproate, valpromide ΥĨLLӪ̡C 
- ʨxw̡C 
- Cʨxw"	ߡBæRBGhBm	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Valproate is excreted into breast milk	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w09-02 [UDx]_U01-48 [E]_A4-15 j	Ts110.6.16		0	0	OIs 20251124	ODEPA-a	ODEPA-b	ODEPA-c	110.6.16
NC00817100	N03AB02	0	ODILAN	Dilantin 100mg/cap(Phenytoin)		íwgӭMθgѪ_ulqDӭCgQEo|A㦳@ΡC	fAGHw}lɨC3AC100mgA@뾯qd򬰨C300400mgCĵw}lɨC5mg/kgA23P C	"1. AΥ~w̤y}αqƦMIʪu@C
2. ~|CץĪĪGAyĥΨLץkC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Phenytoin	N03A	w ANTIEPILEPTICS	0	jo@Χo@wAwΪvg~NҤް_wo@C	PhenytoinΨLhydantoinsLӪfHC	iΫpB}BíBNѲVcByŸʡBfMC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Phenytoin is excreted in breast milk.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w06-02 [s]_91 [®]_91 [E]_A4-01 j	Ts110.6.16		0	0	OIs 20251124	ODILAN-a	ODILAN-b	ODILAN-c	110.6.16
BC23889100	N03AX14	0	OKEPP	Keppra 500mg/F.C tab(Levetiracetam)		"1. ĥDlevetiracetamݩpyrrolidonelͪ(\-ethyl-2-oxo-1-pyrrolidine acetamideS蹳c)C
2. |TwAwPL{swsõLC~M餺oAlevetiracetam|ܲӭM򥻯SʩM`gǾɡC
3. Levetiracetam@ʪMoʥʵo@޵oO@@ΡAB|ް_pro-convulsant@ΡC"	"1. ĬfAAAήɥHqA]JAeζ᧡iCĳC龯qBߨ⦸ϥΡC
2. HΤQHWC֦~GlqC1000(C⦸AC500)Cqilv1ѡC
3. fH{ɤέ@ʡAC龯qiW[̰C3000(⦸AC1500)CܾqɡAHCGܥ|PWqδq1000(C⦸ACW/500)@qiC"	̾{ɸgAYAKeppraSĮɡAĳqʴqAҦpGCGܥ|Pq1000(GACU500)C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Levetiracetam	N03A	w ANTIEPILEPTICS	0	QHWfwwo@(֦Τ֦oʥo@)WvC|HWĵΦHfwwo@(֦Τ֦oʥo@)AQGHWC֦~PHfw٩Dwo@AHΤQHWC֦~PHwʪxowoʪxoʱj}˵o@UvC	DlevetiracetamӷPιLpyrrolidonelͪΥĨLӷP̡AФŨϥΥġC	ݺΡBLOPBtwBzBYhBBʥաB_ŸBСBߡBƤ}BmB	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D3 [2]_D3 [ws]_w36-02 [s]_192 [®]_192 [UDx]_U03-16 [E]_B4-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.4._20220201.pdf"">OI` 1.3.2.4.</a>              "	0	0	OIs 20251124	OKEPP-a	OKEPP--b	OKEPP-c	110.6.16
BC20509100		0	OLAMI	Lamictal 50mg/tab(Lamotrigine)		ĲzsGLamotrigine@ΩqӷPuqDAHwwgΧgǾɪADnGlutamateAĩʮĹwo@tw䨤C	"1. H12HWpĹ󨺨ǨSASodium valproate̡A쾯q¤50mgA@Ѥ@AGPCۨCѧ뤩100mgA⦸뤩AGPCAɤqC200400mg⦸뤩AiF̦nĪGC󥿦bASodium valproatefHA쾯qjѧ뤩25mgAGPCۨCѧ뤩25mgAGPCᥭɤq100200mg/ѡA@ѧ뤩@Τ⦸뤩AiF̨ήĪGC
2. 󥿦bASodium valproatefHA쾯qjѧ뤩25mgAGPCۨCѧ뤩25mgAGPCᥭɤq100200mg/ѡA@ѧ뤩@Τ⦸뤩AiF̨ήĪGC"	AΥ~w̤y}αqƨMIʪu@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Lamotrigine	N03A	w ANTIEPILEPTICS	0	wgιLwĵLkNwBxoʱjʰ}˩wUkLENNOX-GASTAUTxԸsC	LamictalTΩwLamotrigineLӤC	ֽlBƵBOҽkBtBݺΡBYhBwBhҡBGzдeΩ	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D2 [2]_D2 [ws]_w36-05 [s]_197 [®]_197 [E]_B4-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.5._20220201.pdf"">OI` 1.3.2.5.</a>              "	0	0	OIs 20251124	OLAMI-a	OLAMICT-b	OLAMI-c	110.6.16
BC24995100	N03AX16	0	OLYRI	Lyrica 75mg/hard capsule		pregabalinwҹiC褤tl̿ʪPhgǾɪX@ΡAi઺@Τ覡_talpha2-deltal椸tlqDyqʤ()CtlyqCq䥦glPʯkhʪҫ礤oҾܡApregabalini]|zLP۸FU楿ǤWEʳqΦMEʳqoͥ椬@(@Υiո`褤khǾ)覡ͤh@ΡC	"a?lᯫghG
ٻMv60 mL/minHWw̡AĳqO75-150 mgCѤG50-100 mgCѤT (150-300 mg/)Cq75 mgCѤG50 mgCѤT (150 mg/) }lġAھĩM@ʥib@gNqW[ 300mg/ѡC
HwUvG150-600mg/ѪqUOHwo@ĻUvCC`qӤGܤTġC"	"i|ް_YwPݺΡAqƽѦprpξާ@u@Фp
LYRICAPϯgt(CNS)(]A~Ī)PɵġAΦbIlêIpUA|ɭPYBMΥͩRέPʪIlC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Pregabalin	N03A	w ANTIEPILEPTICS	0	awlᯫghBHwUvBֺٵhB}fP䯫gfܤް_gʯkh	TΩw pregabalin Υ~L󦨤LӪw̡Cϥpregabalin w̵oͦީʤ~PLӪ{HC	YwPݺΡC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w49-03 [s]_200 [®]_200 [UDx]_U03-38 [E]_B5-14 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.6._20210501.pdf"">OI` 1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.7._20241201.pdf"">OI` 1.1.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a>            "	0	0	OIs 20251124	OLYRI-a	OLYRI-b	OLYRI-c	110.6.16
BC22823100		0	ONEUR1	Neurontin 100mg/cap(Gabapentin)		GabapentinbƶʪwҫAiiJùwwo@CGabapentinGABAAGABAB 餣˩MOA]|GABAN¡CGabapentin|PLgǾɪ鵲XAB|PulqD椬@ΡCGabapentin|PqձtlqD\2_ (alpha 2-delta)椸H˩MOXAP\2_XQ{iMgabepentinbʪwo@@ΦC	"1.H12HWൣw̡GľqO900-1800mg/ѡC_lqOCѤT(TID)AC300mg
2.3-12ൣw̡G Gabapentin_lqO10-15mg/kg/ѡATA(CѤT)"	ѩwgabapentinvoͷwtMݺΤiifHAbTwĤ|vTḺqƦʪOeAn}ξާ@MIʪC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ15XC30XCxsC 	Gabapentin	N03A	w ANTIEPILEPTICS	0	vHΤTHWൣwo@UkBalᯫghC	TΩgabapentinī~󦨤LӪfHC	h¡BYhBߡBæRBݯvC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w05-06 [s]_247 [s]_248 [®]_247 [E]_A2-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.6._20210501.pdf"">OI` 1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a>             "	0	0	OIs 20251124	ONEUR1-a	ONEUR1-b	ONEUR1-c	110.6.16
AC48357100	N03AX12	0	ONEUR3	Gapatin Capsules 300mg		GabapentinbƶʪwҫAiiJùwwo@CGabapentinGABAAGABAB 餣˩MOA]|GABAN¡CGabapentin|PLgǾɪ鵲XAB|PulqD椬@ΡCGabapentin|PqձtlqD\2_ (alpha 2-delta)椸H˩MOXAP\2_XQ{iMgabepentinbʪwo@@ΦC	"1.H12HWൣw̡GľqO900-1800mg/ѡC_lqOCѤT(TID)AC300mg
2.3-12ൣw̡G Gabapentin_lqO10-15mg/kg/ѡATA(CѤT)"	ѩwgabapentinvoͷwtMݺΤiifHAbTwĤ|vTḺqƦʪOeAn}ξާ@MIʪC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ15XC30XCxsC 	Gabapentin	N03A	w ANTIEPILEPTICS	0	vHΤTHWൣwo@UkBalᯫghC	TΩgabapentinī~󦨤LӪfHC	h¡BYhBߡBæRBݯvC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-08 [s]_147 [®]_147 [E]_A2-11 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.6._20210501.pdf"">OI` 1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a>             "	0	0	OIs 20251124	ONEUR3-a	01C48357-1	01C48357-2	110.6.16
BC27054100	N03AX16	0	OPREG	^Pregabalin 75mg/cap (Pregabalin)		pregabalinwҹiC褤tl̿ʪPhgǾɪX@ΡAi઺@Τ覡_talpha2-deltal椸tlqDyqʤ()CtlyqCq䥦glPʯkhʪҫ礤oҾܡApregabalini]|zLP۸FU楿ǤWEʳqΦMEʳqoͥ椬@(@Υiո`褤khǾ)覡ͤh@ΡC	"a?lᯫghG
ٻMv60 mL/minHWw̡AĳqO75-150 mgCѤG50-100 mgCѤT (150-300 mg/)Cq75 mgCѤG50 mgCѤT (150 mg/) }lġAھĩM@ʥib@gNqW[ 300mg/ѡC
HwUvG150-600mg/ѪqUOHwo@ĻUvCC`qӤGܤTġC"	i|ް_YwPݺΡAqƽѦprpξާ@u@Фp	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Pregabalin	N03A	w ANTIEPILEPTICS	0	awlᯫghBHwUvBֺٵhB}fP䯫gfܤް_gʯkh	TΩw pregabalin Υ~L󦨤LӪw̡Cϥpregabalin w̵oͦީʤ~PLӪ{HC	YwPݺΡC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.6._20210501.pdf"">OI` 1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.7._20241201.pdf"">OI` 1.1.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a>            "	0	0	OIs 20251124	OPREG.a	OPREG.b	OPREG.c	110.6.16
AC278491G0	N05BA06	0	OATIV	Lowen 0.5mg/tab(Lorazepam)[ޥ|]		"1. ~benzodiazepineܵJ{A12HUĵnϥΡAqӧOwFvW[qӴ֤}C
2. ~ѩΰIzfHA}lqC12mgC
3. ѩSʥNªͦA]LlͪASnWMIʡC"	"Anxiety disorders2-6 mg/day in 2-3 divided doses; MAX. 10 mg/day.
Insomnia2-4 mg HS.
@fw쾯qC1~3mgi2~3AYOvvhibNe@龯q2~4mgC
2HWൣvMwqϥΡC
Ѧ~HΨIzw̡A쾯qĳĨC1mg2mgAΡAi̷ӱpݭnίfH@{פHվAקKƧ@CCW[qAqߤW}lնqA@NeĪkAĳNe]ΤNe@BGpɵ2mg4mgC"	bALorazepam AsMLϯgt@ʱN|CAҥHקKܰsΨLϯgtC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷxsABAЩmൣΤ쪺aC	Lorazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{A	Lorazepam iΩwbenzodiazepine ĪLӪ̡C	}po͡Ahq`ObvA ~AΩδqAYwѩήCBenzodiazepine Ī̱`ް_}ΡBtwBzαíC	Ĥ C	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M04-04 []_E6 []_w78-08 []_s387j	Ts110.6.16		0	0	OIs 20251124	OATIV-a	OATIV-b	OATIV-c	110.6.16
BC22507100	N03AX11	0	OTOPA	Topamax 50mg/tab (Topiramate)		~OعswĪAtsulfamateN򪺳CѯgӭMiqͲzǤΥͤƾǬsAo{TدSʥi~wĥΡC~|_hƯgлoʧ@qAت_ɶʡABPuqD_@ΦC~|W[^-aminobutyrate(GABA)GABA骺WvA]ӼWjGABAoliJgOAܥ~|WjʯgǾɪ誺ʡC~|KainateĩiGlutamatePKainate/AMPA(\-amino-3-hydroxy-5-methylisoxazole-4-propionic acid non-AMPA)ȫOAN-methyl-D-asparate(NMDA)bNMDAȫʤۡC	̤pľqC200mgC`ΨC龯q200600mgA⦸AΡCYǯfHC龯qiݰFW1600mgCWL400mg/dayqä|[jfH糧~CC龯qWL1600mg̥sCĳnqCq}lvAvWqܦľqC	~|@ΦbϯgtΥBi|yΡBwtΨ䥦gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Topiramate	N03A	w ANTIEPILEPTICS	0	Ω󦨤HΨⷳHWൣwΨ֦lennox-gastautgԸswέoʥʱj}wUvAΩpartial onset seizurefw@ĪvBwYh	󥻫~DΥ@ξLӪ̡ATϥΥī~C	ݯvBtwBBʥաByêάyDB믫BʩʿwBy_ŸηPı`	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w54-01 [s]_314 [®]_314 [UDx]_U03-48 [E]_C2-06 [Ew]_EX063 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.3._20211201.pdf"">OI` 1.3.2.3.</a>              "	0	0	OIs 20251124	OTOPA-a	OTOPA-b	OTOPA-c	110.6.16
BC23524100	N03AF02	0	OTRIL	Trileptal 300mg/F.C.tab		"1. TrileptalĲz@ΥDnOaoxcarbazepineNªMHDӵoAoxcarbazepineMHDQ_qӷPu޹DAíw׿ĪgAƪgE@ΤδzĲİʪ@ΡC
2. [lǾɼW[ΰqƪtqո`@ΡAiPoǦܵjˮĪGFõLo{PgǾɪνո`줧㪺椬@ΡC
3. OxcarbazepineΨ䬡ʥNªMHDAʪӨOjOBĪܵj˾CoǦO@jʪKʪj-}ˤδ}˩ʵo@AiδTȤJRhesusUlͺCʦAoʳo@WvC"	"1. C龯qWL2400@JΪk|b{ɸ礤չLAثeuD`gϥιLFC4200@JqC
2. HΦѦ~fwGa.WvGTrileptal}ϥζqC600mg(810mg/Kg/day)⦸ġACѾq600mg2400mgiѲzQġCY{ɤWݭnAqiHĨCg̦hW[600mg覡CHoΪ{ɤCb.UvGTrileptal}ϥζqC600mg(810mg/Kg/day)⦸ġACѾq600mg2400mgiѲzQġCY{ܡAqiHĨCg̦hW[600mg覡CHoΪ{ɤC
3. ൣGൣHC810@J/魫Trileptal}lvA⦸PC󻲧UvAHjC30@J/魫qAYo}nvĪGCpG{ɤWݭnAiHĨCg̦h_lqW[10@J//ѪqA̤ܳjq46@J//ѡAHo檺{ɤCTrileptal|ϥΩ2HUൣ{ɸgC
4. x\l`fwGܤרx\l`fwäվ㾯qCTrileptal|Yx\l`fwi{ɸC
5. ǥ\l`fwGǥ\ण}w(ĲMvC30ml/min)AHTrileptalv쾯q@_lq@b(C300mg)AAvW[qHFzQ{ɮĪGC
"	iX{YwAYhAߩιæR;}ξާ@h[`N	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Oxcarbazepine	N03A	w ANTIEPILEPTICS	0	Hwo@@λUvAj@Ӥĵwo@Uv	wDΥLξLӡC	twBYhBݺΡBߡBæR	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w40-03 [E]_B4-30 j	Ts110.6.16		0	0	OIs 20251124	OTRIL-a	OTRIL-B	OTRIL-c	110.6.16
AC60265100	N03AX11	0	OTROK	Trokendi XR 50mg(Topiramate XR )n		Topiramate oܩzΰYhwĪGҾǪT??FMӡA?ɫewܥ|iPtopiramate wv?ΰYhw㦳ĪGʽCq?ΥͤҾܡAtopiramate b?ǤWNq@?UA_q̿૬u?lqDBWj?gǾɪ^-iBĦbGABA-A ȫW@ΡBAMPA/kainate ؾiĨȫAçһ?ï]רOII MIVP\?^C	"1.w@?kΪk
o@έoʥʱj}w?ΤQHWൣw
Topiramate @?kb?ΤQHWൣw̪ĳ?A400 mg CѤfA@C
b?ܥQw̤AΪkOH魫̾ڡCTROKENDI XR l?25 mg/dayAbĤ@gCߪAΤ@C@ʦөwA?ibĤGgդɦ50 mg/dayCpGi@A?ibC@gH25-50 mg/day դɡCbӾ?վ5-7 gAձN?զ̤ܳp?C@ʻP?ɤөwAiH25-50 mg/day C@gվAB~զ?
?]̰̤ܳj?^C
2.o@wBoʥʱj}wLennox-Gastaut gԸs?]17 HW^w
TROKENDI XR bo@wLennox-Gastaut gԸs?w̤U?kɡAĳC`?200 mg 400 mg CѤfA@Fwoʥʱj}wAh400 mg CѤfA@C
6 16 ൣw - o@wBoʥʱj}wLennox-Gastaut gԸs
TROKENDI XR bo@wBoʥʱj}wLennox-Gastaut gԸswൣ
w̤U?kɡAĳC`?j5 mg/kg 9 mg/kg CѤfA@CбqHUl?}lվ㾯?GĤ@gɡACѩ]@25 mg]H1 mg/kg/day 3 mg/kg/day d򬰷ǡ^CHH@g?g@ACվ1 mg/kg 3 mg/kg t?դɾ?AHF̨?ɤCվ㾯?H?ɮĪG̾ڡCpnAi??վ㤧jCboʥʱj}w礤A6 mg/kg CѤ@Ҥt?Y8 gɹF
3.YhΪk
TROKENDI XR?v?H12 HWC?HwYhYhg?ɡAĳC`?100 mg C
Ѥ@C"	"1.Atopiramate fHoͻPoʳCʪgԸsCg?]A?@?CM/βykhCˬdio{BeܲLByR]o^βW[Ci|?|X{թjCgԸsiP?WGyέiVe첾AiӤް_oʳCCg?q`oͩ}ltopiramate v?@Ӥ뤺
2.ITROKENDI XR e6 pɤקKsC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUAקKΤӮgC	topiramate	N03A	w ANTIEPILEPTICS	0	"1.w@?k
Ω󦨤H?HWൣw]partial onset seizure^@Īv?C
2.wU?k
Ω󦨤H?HWൣwB֦LENNOX-GASTAUT gԸswέoʥʱj}
wU?k
3.Yh
Ω12 HWw̤wYh"	1.]YA TROKENDI XR e6 pɤ^2. ?wN©ʻĤrBb֥ metformin	"??Bʩʿ𺢡]4.0%^BOлê]3.2%^Bh?]3.2%^BN?V?]3.1%^BݺΡ]3.2%^BM/M`ê]2.9%^B
]2.7%^B~{]2.6%^BY?]2.5%^B魫]2.5%^B??i]2.3%^BBʥա]2.1%^HηPı?`]2.0%^C"	opiramate IΩ󥥰ɥiLyˮ`Chn??w?XAlctopiramate ??঳B?M/E?]f?^έLp󧳮W?ֵoͭIC	DnקKϥ/SmҦw.Ť??topiramate vT?C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L5 [2]_L5 [ws]_w54-06 [E]_C2-11 [Ew]_EX064 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.3._20211201.pdf"">OI` 1.3.2.3.</a>              "	0	0	OIs 20251124	OTROK-a	OTROK-b	OTROK-c	110.6.16
AC57199100	N03AX15	0	OZONE	Zonegran F.C 100mg/tab		ZonisamideOf}(benzisoxazole)lͪA@wĪAb~㦳LzһĲCʡCƾǵcPLwۦC 	_lqC100mgCH@GgjvqܨC200mg400mgA13AΡCC̰q500mgC	Ǳw̥i|PΩH`NOASOObvμW[qCiw̡AqƻݭnĵıʪʮԷVAҦprpξާ@C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC 	Zonisamide	N03A	w ANTIEPILEPTICS	0	"ZONEGRANAΩsE_Hwo@@ĪvΦHwo@UvC ZONEGRANAΩUCwo@Go@G 
1. ©ʧwo@C 
2. ʧwo@C 
3. wo@oʱj-}˩ʵo@C "	zonisamideBB褤ξDiĪ(sulphonamides) LӪ̡C 	֯lBYwBݺΡC 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Avoided	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.2._20210501.pdf"">OI` 1.3.2.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.8._20180201_000.pdf"">OI` 1.3.2.8.</a>             "	0	0	OIs 20251124	OZONE-a	OZONE-b	OZONE-c	110.6.16
AC470441G0	N04AA02	0	OAKIN	Akinfree 2mg/tab(Biperiden)		"ĥiĪvĪް_ˤgAΦUةˤgUvC
ˤfް_O]ϳ쪺餺xʯgĩʤΦhiʯgũҭPA@ΦbCNScholinergic synapsesACHbP骺XAiv٦׻wMʧ@LOPδֳGcC"	C3-4AC1ɡC	"1. DnФŨϥΥC
2. pĨϥΥwʩMĩʩ|QAGФŨϥΥC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb 25XC HUC	Biperiden	N04A	xP ANTICHOLINERGIC AGENTS	0	ˤg	1.㦳UʫCBzêBz̤ιbiperidenLӪ̧?iϥΡC2.Hypersensitivity to biperiden or any component of the formulation	fB믫EBOҽkBݺΩΩwVOêBթʧCBKB欰êƧ@εo͡C	C 	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w20-04 [s]_9 [®]_9 [E]_B1-22 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OAKIN-a	OAKIN-b	OAKIN-c	110.6.16
AC395971G0	N04AA01	0	OARTA	Switane 2mg/T(Artane)		~䥽@ΡAi@ΩƥPgAèϥƦٵΦC঳ĭCٵj˻AwѩˤgS믫LOgΧ{C	"1.}l1mgAC35ѼW[2mgACѳ̤jq15mgA@몺d򬰨C610mgA34PC 
2.ᩬˤgGC`q1215mgC
3.ĪɩˤgG@`q5-15mgA}lPq1mg_AgLkﵽɡAAqW[ܯfoC"	1. UCw̸TΥ~GŦʮBJBoʹBʧxw̡C2.ʯߵwƱw̤쾯qru	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb 25XC HUC	Trihexyphenidyl	N04A	xP ANTICHOLINERGIC AGENTS	0	ˤgs	UCw̸TΥ~GŦʮBJBoʹBʧxw̡C	fBߡBOҽkBgBCC	C 	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w54-03 [s]_283 [®]_283 [E]_C2-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OARTA-a	OARTA-b	OARTA-c	110.6.16
AC57731100	N04BD02	0	ORAKI	Rakinson 1mg/tab		Rasagiline @رjġBifB iƞJAiHϯ餤ӭM~hi@׼W[CRasagilinebhiEɩʰʧ@\ಧ`ҫҤް_qA۩䴣hi@׻PHW[hiEɩʬʡC	"0.5 mg-1mg QD.

C@fAϥRasagiline1mgAiWvλPLevodopa X֪vCiWAΩλP@PAΡC"	" Pܼ~{X֨ϥ
ɫXܼ~{(ҦpGܩʦM^-SSRIBM-ǤW-SNRIBTܼ~{B|ܼ~{BTriazolopyridine ܼ~{)PUCī~X֨ϥη|ް_pŹLϯgrʡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25J HUOs	Rasagiline	N04B	hi DOPAMINERGIC AGENTS	0	voʤڪˤg	"1. DnΥξLӪ̤iϥΡC
2. TϥΩ󦳭רx\lˤfwC
3. TPMeperidine ֪AAX֨ϥη|ް_YƧ@ΡuMgԸsvAYɥi|ɭPfH`C]Rasagiline PMeperidinevɡAܤֶj14 ѡC
4. TPSt.Johns wort MCyclobenzaprine(T٦P)X֪AΡC
5. iP¾KpTramadolBMethadoneBPethidine Mpropoxyphene @_ϥΡCRasagiline PWzī~vɡAܤֶj14 ѡC
6. iPDextromethorphan @_AΡAɫX֪Aɷ|yuȩʺ믫欰`C
7. iPMAOI X֨ϥΡĄ֪A|W[DܩʳiƞJʡAiӥi|W[ް_ICRasagiline PiƞJvɡAܤֶj14 ѡC"	YhB٦װfkhByPB~{B󪢡BBtw	קKϥΰDvn/|qLť	קKϥΰDvn/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	ORAKI-a1	ORAKI-b	ORAKI-c	110.6.16
BC25120100	N04BC04	0	OREQU8	ReQuip PD 8mg/tab(Ropinirole)		"jĪDergolineD2/D3hiPľACRopinirole iǥѫfE餧hi骺@ΨӴoئhiʥF{HC
"	0	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Ropinirole	N04B	hi DOPAMINERGIC AGENTS	0	DROPERIDOLAΩ󭰧CѩNζE_{ǩҳyߡBæRC 	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OREQU8-a	OREQU8-b	OREQU8-c	110.6.16
BC23248100	N04BX02	0	OCOMT	Comtan 200mg/tab(Entacapone)		"~ݩ@طsvī~ACOMT(Catechol-O-methyl transferase inhibitor)AO@إifʡBM@ʡAj@Ωg䪺COMTASO]pΨӻPlevodopas֥ΡCѩentacaponeCOMTïӴ֤FlevodopaN¦3-O-methyldopa(3-OMD)lAӼW[levodopaiβvA]ϸiHϥΪlevodopaW[A{ɬsXGXentacaponePlevodopaϥΡAiW[""ON""timeF16%Aô ""OFF"" timeF24%CEntacaponejg´COMTïAyCOMT@λPߤentacapone@צAaXentacaponeCOMT@άifʡC"	"200 mg with each dose of levodopa/carbidopa, MAX. 1600 mg/day
1. PkGEntacaponePɻPlevodopa/carbidopalevodopa/benserzideX֤fACWz levodopat褧BƥAΩPentacaponeX֨ϥήɡC
2. qG~C200mgtXC levodopa/dopa decarboxylaseqAC̰˾qGC200mgA@10AY@`pqentacapone 2gCEntacapone|[j levodopa@ΡA]F levodopaް_dopaminergicƧ@ΡApLʯg(dyskinesias)BߡBæRΤıCq`}lAentacaponeƤѦܼƶgAݭnվ levodopaqCھڱw̤{ɪpAiHǥѩAĶj/δ֨C levodopa q1030%C"	"1. ]~P levodopa֪A|ް_wtA]rpξާ@SOpߡC
2. ~|ϯfHGeľAD`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Entacapone	N04B	hi DOPAMINERGIC AGENTS	0	֥levodopa/benserazide Ϊlevodopa/carbidopaī~vˤgfHC	"1. entacaponeθĤ@ξӷP̸TϥΡC
2. Wα¨ŰkC
3. x\l`C"	`}@ΡGʤBߤΧGܦC}@ΦGmBtwBhBvBfBh¡BıBKB٦ױiOBGW[BYhBLjˡBcڡB^ˡBթʧCξ_ŸC	קKϥ	"ʪsAentacapone|ۨťĤcXAentacapone઺wʥAGkϥ
entacaponeɡAšC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-04 [s]_62 [®]_62 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OCOMT-a	OCOMT-b	OCOMT-c	110.6.16
BC09796100	N04BA02	0	OMAD2	Madopar 200/50mg/tab		"Dopamine OgǻAbڪˤfw򩳮֨SdopamineCLevodopa (INN)  L-DOPA (3,4-dihydroxy L-phenylalanine) dopamine ͦXɤCLevodopa (dopamine X)@eXĥΨӼW[dopamine @סA]L-پAdopamine LkL-پC@levodopa iJϨt(CNS),|Qaromatic L-amino acid decarboxylase N¦dopamineC
īA bj~Mj´Alevodopa |thn򦨬dopamineA ]Ajlevodopa LkF򩳮֡ABbPtβͪdopamine |ް_Ƨ@ΡCҥHSOݭnhj~levodopa hnCPɵlevodopa MPhn
J benserazide iF즹ĪGC
MadopartoGئH4G1 ҲզXs VҤwb{ɸMvϥΤWQҩO̾AXVBPlevodopa WjqAΪĬۦPC"	"зǾq
vHi覡ġFӧOνվ㾯qHFAĪGA]HUqΪkɤwC
_lv
ĳ}lvڪˤgɡACѥb Madopar 125mg3-4A@T{_l{@ʫAAھگfHCCW[qC
v
qOCѪA 3-6  1 125@J Madopar CվAΦ(p3)MCѪAήɶHF̾AĪGC"	"1. ĳsʫCfHwqA]levodopa zפWi|W[C
2. ~{giڪˤgw̤{ɪx@AϥMadoparvw̤]i|o͸ӯgC
3. ϥlevodopa vBX{ݺΤ()Mεۤw̡AnDLקKrpαqƨǦ]ĵıOlAӥi|ϥL̦ۤvΥLH{Y˩Φ`IC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ФxsWL30XC ҤUC	Benserazide 50mg + Levodopa 200mg	N04B	hi DOPAMINERGIC AGENTS	0	ڪˤf	"1.糧~LӪ̡C
2.iPMAOI֥ΡC
3.xǥ\ಧ`ʫCcLNvOw̸TΡC
4.α¨ŰTΡC"	", æR,m"	D 	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r04-07 [ws]_w04-08 [s]_203 [s]_204 [®]_203 [E]_A3-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OMAD2-a	OMAD2-b	OMAD2-c	110.6.16
BC23280100	N04BC05	0	OMIRA	Mirapex 0.25mg/tab(Pramipexole)		"1. PramipexoleO@ثD(nonergot)hiʰʾAD2hi~M@ʤΧ餺ʡAD3˩MOjD2D4CD3bˤgҧt|MC
2. MpramipexoleQ{kO]㦳E(striatum)줧hiOAOpramipexolevˤgT|MCbʪҶi檺qͲzsסAspramipexoleǥѬƯζ½(substantianigra)(½賡쪺g|ǰeTܯ)hiAӼvT鯫gEotvC"	"Parkinson s Diseasew0.125 mg PO TID initially; gradually titrate upward qWeek to target range of 1.5-4.5mg/d PO divided TID. Renal impairment(for IR tab.)wCrCl 35-59 ml/min: start 0.125mg BID, not to exceed 1.5mg BID; CrCl 15-34 ml/min: start 0.125mg QD, not to exceed 1.5mg QD; Restless Legs SyndromewInitial 0.125 mg PO 2-3hr before HS, may increase q4-7d up to 0.5mg/d.
a. _lqGѨC0.375(TP)_lqAvհqCӥBܦhHCj5-7ѽհ@qWvվ㾯qC
b. vGLר֥levodopa(800)P_AbC1.5-4.5(TP)qdA~㦳ĦӥB@ʨ}nC
c. HڪˤgfwHҶi檺TwqsܡAC3B4.5M6qåѥuC1.5{ɮĪGC
d. ~ålevodopaҼ{ClevodopaqAHߴڪˤgfwHҶi檺Ӹlevodopaq27%C

ǥ\lfwG
a. `ܻרl(ٻMv>60mL/min)G_lq0.125ACTF̤jq1.5ACTC
b. רl(ٻMv=35-59mL/min)G_lq0.125ACGF̤jq1.5ACGC
c. Yl(ٻMv=15-34mL/min)G_lq0.125AC@F̤jq1.5AC@C"	Aīi|ͪߩʧC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Pramipexole	N04B	hi DOPAMINERGIC AGENTS	0	v۵oʤڪˤgέoʻLļʯg	s@LӪ̸TΡC	ߡBwtBݯvBvBKBLOBıBٱiO`BBﲧ`BLBfBѩMW	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w45-01 [E]_B5-13 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OMIRA-a	OMIRA-f	OMIRA-c	110.6.16
BC25260100	N04BC05	0	OMIRA1	Mirapex PR.1.5mg/tab(Pramipexole)		"PramipexoleݫDPhiPľAb~D2ȱڪhi㦳۹M@ʡA禳bʡAD3ȫX˩MOD2D4ȫC
PramipexoleΩvˤgT@ξॼAӻPﯾ]striatum^hi骺E@ΦCץoʪqͲzǬsGAoǬsܡApramipexoleiǥѬƯP½]substantia nigra^]gӭMǰeTܯ骺^hiӼvT骺gEotv]neuronal firing rates^CD3骺XPˤgpʥثeC"	"0.125 mg PO TID initially; gradually titrate upward qWeek to target range of 1.5-4.5mg/d PO divided TID.
1. MIRAPEX PR@ѤfA@AŸĩλP֥ΧiC 
2. MIRAPEX PR]AAiZHBHΤΡC
3. YMIRAPEX PRv_L[ANiॲsվvqC

bˤgw̪ĤkGlq0.375mgA@Ѥ@CiھĻP@ʡAvհqAվWvihC57Ѥ@ (not more frequently than every 5 to 7 days)Aզܤ@0.75mgAMCW[0.75mgA̦hWܤ@4.5mg]̤jĳq^C"	MIRAPEX PR]AAiZHBHΤΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC	Pramipexole	N04B	hi DOPAMINERGIC AGENTS	0	vڪˤgxԤίg	pramipexoleλs@LӪ̸TΡC	BʧxBx¡BߡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w45-04 [E]_B5-15 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OMIRA1-a	OMIRA1-d	OMIRA1-c	110.6.16
AC30257100	N04BB01	0	OPKME	Amanda  F.C 100mg/tab(Amantadine)		"1. ~|[jdopamineqĲegXAb½(corpus striatum)S\ʪdopamineJsɡA~ĤO|jjCC㦳xPEʪʡC
2. ~ܯfr@άOѩ󥦯frֻĶiJJDӭMC|zZyʷP_Afr̭]C"	1. ڪ˯fGWϥΥɡAH@뾯q11A@2Cb48pɤ}l@ΡC 2. wΪvϫyʷP_gGHWpġA@Ѥ@AC100mgCQHWΤj45窺pġA@Ѩ⦸AC100mgC 64HUHG@Ѩ⦸AC100mgAΤ@Ѥ@AC200mgC 65HWHG@Ѥ@AC100mgC	"1.iJMġA]Ǥڪ˯fw̡AJMķ|ިt۴cơC
2.PxEĪ֥έYoatropineɡA̤@qC
3.ǥ\ॢաARʤ߰IܡAP~ΪOCw̡AϥΥɥiභվ㾯qC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25xsC	Amantadine	N04B	hi DOPAMINERGIC AGENTS	0	ˤfBwΪvϫyʷP_g	w糧LӪ̸TΤCPq2gmC	ġBJ{BߡBtwBBʤBߴVáBת~{AKAGdB~AC]ֽܤơ^C	 C 	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w18-04 [UDx]_U02-03 [E]_B1-17 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OPKME-a	OPKME-b	OPKME-c	110.6.16
BC22882100	N04BC04	0	OREQU	Requip 0.25mg/F.C tab(Ropinirole)		"jĪDergolineD2/D3hiPľACRopinirole iǥѫfE餧hi骺@ΨӴoئhiʥF{HC
"	"1.Parkinson's disease:Initial 0.25mg tid increase gradually by 0.25mg/dose every 7 days; max 24mg/dayC
2.RLS:Initial 0.25mg/day hs increase gradually by 0.25mg/dose every 4-7 days, max 4mg/day"	1.֦YߦޯefwpߪvC2.vfwX{İʱêgԸsA]AfAջPʼijgC3.֥REQUIPML-dopaˤgfwAibBqվo͹BʻêA{ɸܡACL-dopaqiﵽBʻêC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Ropinirole	N04B	hi DOPAMINERGIC AGENTS	0	v۵oʩˤgPoʸ}ļʯg	RequipΨξLӪ̸T	ıBݺΡBtwBAʧCBߡBhBƤ}BKBPʤ~	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-03 [ws]_w50-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OREQU-a	OREQU-b	OREQU-c	110.6.16
BC25118100	N04BC04	0	OREQU2	Requip PD 2mg/tab(Ropinirole)		"RopiniroleO@رjĪDergolineD2/D3hiPľC
ˤgSxO½课tΩʥFhiCRopiniroleiǥѨE餧hi骺@ΨӴoئhiʥF{HC"	"Parkinson's disease:(Extended-release) Initial, 2 mg orally once daily for 1 to 2 weeks; based on response may titrate in 2 mg/day at weekly intervals or longer to therapeutic response and tolerability; MAX dose 24 mg/day; patients with advanced Parkinson disease should generally be maintained with 8 mg/day or lower and patients with early Parkinson disease should generally be maintained with 12 mg/day or lower.

Restless legs syndrome :HInitial, 0.25 mg orally administered 1 to 3 hours prior to bedtime; after 2 days may titrate nightly doses when appropriate, based on clinical response and efficacy as follows: 0.5 mg/day on days 3 to 7; week 2, 1 mg/day; week 3, 1.5 mg/day; week 4, 2 mg/day; week 5, 2.5 mg/day; week 6, 3 mg/day; week 7, 4 mg/day; MAX, 4 mg/day."	 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Ropinirole	N04B	hi DOPAMINERGIC AGENTS	0	v۵oʩˤgPoʸ}ļʯg	ropiniroleνξLӪ̡C	hBߡBƤ}BKC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r06-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OREQU2-a	OREQU2-b	OREQU2-c	110.6.16
	N05AH04	0	LQTIN	Qting oral sup. 25mg/ml;120ml/~(Quetiap		Quetiapine@ξApLbvıկgMʯewĪĪ@ˡCOH{Quetiapine ıկgĤΨbʯew{gMļgíwʽAOzLĤGhi]D2^MĤGM]5HT2^ܧ@ά۵XҭPCbhiM5HT2 H~A˩MOܧ@ΥiHQuetiapine@ǨLvTC	"HG
ıկgG
ve|ѤC龯qĤ@50 mgAĤG100 mgAĤT200 mgAĥ|300 mgCĥ|ѥHAqvվܨC300-450 mg @릳ľqC̭ӧOfH{ɤιĪ@ʡAC龯qdq`b150-750 mg C
ʯewļgo@G
@@kΧ@íwUvCve|ѤC龯qĤ@100mgAĤG200 mgAĤT300 mgAĥ|400 mgCqi̭ӧOfH{ɤιĪ@ʦbC200-800 mg[HվA@릳ľqbC400-800 mg d򤧶C"	"1. AΧܺ믫fĪѦ~gfH`ICQuetiapine֭ΩvѦ~gfHC
2. w{gfw]]AHMൣ^AޥL̬O_bAΧ{Aig~{g[MΥX{۱NM欰ΤM`欰ܤơAحI|gwѬC
3. ~@ثD嫬ܺ믫fī~AϥΫD嫬ܺ믫fĪ|X{}μW[w}@ʤ}ο}fICKdN}gA]AhB@BhεLOAĴYX{}gAߨq}ȡC
4. Quetiapinei޵oթʧCAYwB߷iLtAǯfH|֡ASOOb̪쪺qվAiϬM\1 ǤWʫܾʽC
5. iܨϥ quetiapine ɥX{ίvIlgCbHϥΤϯgtΧfHBίvIlgΦίvIlgIfH]pGL/έDΨkʡ^bϥquetiapine ɶ`NC
6. pPLܺ믫fĪ@Awo@fvΪ̥i୰Cwo@֭Ȥef]pqg^fHAϥquetiapinevpߡC
7. ]Quetiapine i|l`P_BҩιBʧޥAĵifHbXzaTwquetiapine vL̨S}vTeAp߱qƻݭn믫ĵıʪʡAҦprp]]A}^ξާ@MICݺΥiɭP^ˡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷš]25JHU^AץC	Quetiapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	vıկgBʯew{go@Bļgo@βVXʵo@C{@ĪvĪGΪ{g(MDD)fHAi@{go@[vC	糧~󦨥|LӪfHҪA Quetiapine C	ݺΡBY?BfB?BALTɰB魫W[M??C	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LQTIN-a	01C59884-1	01C59884-2	110.6.16
AA48352143	N05AX08	0	LRISP	Seridol Sol'n 30mg/30ml		"믫ggAʯewļgo@CvgfHYʡAκ믫gg

"	"Bipolar maniainitial dose : 2-3 mg QD; if needed, adjust dose by 1mg/day in intervals 24 hours. Dosage rang : 1 to 6 mg/day; the safety of doses higher than 6 mg/day has not been studied. Psychotic disordersInitial, 1 mg BID, then 2 mg BID on the 2nd day, 3 mg BID on the 3rd day,as tolerated dose of 3 mg BID. Dosage rang : 4 to 16 mg/day

"	 Risperidonei|zZݭnĵıʪʡC]AĵifHb_ӤHӷPץHeorpξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Risperidone	N05A	ܺ믫f ANTIPSYCHOTICS	0	"믫ggAʯewļgo@CvgfHYʡAκ믫gg

"	"Hypersensitivity to risperidone, or any component of the formulation

"	"Sedation, headache, blood dyscrasias, dry mouth, constipation, blurred vision, urinary retention, palpitations

"	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M06-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	LRISP-a	LRISP-b	LRISP-c	110.6.16
BC24732100	N05AX13	0	OINVE3	Invega 3mg/Extended Release Tablets		risperidoneDnʥNªCA믫gvʤDO襤Ϫhi2(D2)PM2(5HT2A)Pɲͫܧ@ΪGC	"PO, Initial 6 mg/day , adjust by 3 mg/day at intervals of more than 5 days, MAX 12 mg/day
1.Hq:6mgACѤ@C̤jq:12mg/day
2.pľq:12-17 yr: 3 mg ACѤ@, may increase by 3 mg/day increments at intervals of more than 5 days."	ķ|zPt¡BQΡBıҽkAקK}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Paliperidone	N05A	ܺ믫f ANTIPSYCHOTICS	0	ıկg	󥻫~DΥ@ξLӪ̡ATϥΥī~C	YhB魫W[BvBAʧCBGcLhB@~gBٱiO	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r05-03j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OINVE3-a	OINVE3-b	OINVE3-c	111.8.19
BC24731100	N05AX13	0	OINVE6	INVEGA() 6mg/Extended Release Tablets		"P a l i p e r i d o n e O r i s p e r i d o n e DnʥNªCP a l i p e r i d o n e @ξNpPL믫gĤĪOAĪ믫gĬOǥѵX襤d o p a m i n e T y p e 2 ( D 2 ) H s e r o t o n i n T y p e 2 ( 5 HT 2 A) ܧ@ΦӲ͡C
P a l i p e r i d o n e ]O\1  \2 a d r e n e r g i c HH 1 h i s t a m i n e r g i c 餧ܾAo]\iHĪL@ΡCP a l i p e r i d o n e Sc h o l i n e r g i c m u s c a r i n i c  ] 1 - HΣ]2 - a d r e n e r g i c 骺˦XʡC( + ) V p a l i p e r i d o n e  ( - ) - p a l i p e r i done 蹳c~ĲzʦbwqΩwʤWҬۦC"	"PO, Initial 6 mg/day , adjust by 3 mg/day at intervals of more than 5 days, MAX 12 mg/day
1.믫g
H
a.C3-12mgAbPCݭn}lqվC 
b.qW[ܰC6mgɡA@WLѽվAĳCW[3mgA̤jq12mg/dayC 

C֦~(12-17)
a.ĳ_lqC@AC3@JC
b.qɡAHCj5ѥHWW[3@J/骺覡qC
2.Pʯew
a.ĳq6@JC@AᶡAΡC
b.ݭnվ㾯qAq`j4ѥHWAqAĳCW[3@JA̰ĳq12@J/C
3.׵ǥ\णw(ٻMv50-80 ml/min)C̤jq6mgF쭫׵ǥ\णw(ٻMv10-50 ml/minC̤jq3mgC"	ķ|zPt¡BQΡBıҽkAקK}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Paliperidone	N05A	ܺ믫f ANTIPSYCHOTICS	0	ıկg	"Hypersensitivity to paliperidone, risperidone, or any component of the formulation"	YhB魫W[BvBAʧCBGcLhB@~gBٱiO	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	DC	DC	DC	111.8.19
BC22324100	N05AH03	0	OZYPR	Zyprexa 5mg/tab(Olanzapine)		"OlanzapinedopamineserotoninܾA\h(p5-HT2A,2CBD1,2,4BM1B\1BH1)Ҧ_@ΡA믫gVfp(kQBıBQêBfA欰)HέtVfp(NHBʥFM_OΰʾοBһyehFΪhY)ҦġC"	"1.ļ{g: 
H @}l: 10-15 mg qd, q: 5-20 mg qd; ̤jq: 20 mg/day. 
C֦~: @}l: 2.5~5 mg qd, at increments of 2.5-5 mg at weekly interval to 10 mg, ̤jq: 20 mg/day.
 2.믫gG
 H @}l: 5-10 mg qd, q: 10-20 mg qd; ̤jq: 20 mg/day. adolescents: initially, 2.5-5 mg qd, at increments of 2.5-5 mg at weekly interval to 10 mg, ̤jq: 20 mg/day."	X{YwAW[AfAKAoݩŸ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץΨáA25JHUJsC	Olanzapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫gΨ䥦㦳ʤ/έtʤ믫fAʯewļo@Awʯew_o	"1. TΩw惡ī~󦨤(Ħνξ)LӪ̡C
2. TΩwwUʫCfHC"	ݺΩM魫W[C	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w41-04 [E]_B5-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OZYPR-a	OZYPR-b	OZYPR-c	110.6.16
AC45355209	N05AD08	0	IDROP	DROPEL INJECTION 2.5MG/ML		"Dropelbutyrophenone믫_CĲz@ΥDnhک_alpha 1ǤW@ΡCxPΧܲ´i@ΡC
Dropel㦳۪믫wwPR@ΡAѰߨåiѱw̺믫WWMβߪPıAӯϮgĵıʡCDropeliͤR@ΡAiC~NL{߻PæRo͡ANᴣѤRO@@ΡC
Dropeli[jϯg@ΡC仴Lalpha 1ǤW_@ΡAϥXiôֵǤWҤް_ɰ@ΡCDropeliͧCAOAiCͰʯCiH֦]ǤWҤް_߫ߤAwL]߫ߤC "	"q̷Ӧ~֡B魫B骬pB{fzpBLϥΤī~PϥΤ¾KΤN{ǭӧOƽվCPɻݶiҦʤVital signs  ECGʴC
HqG̤jlq?2.5 mg IM or slow IVAti?[P1.25 mg qHF椧@ΡAMӼW[PqbbQqjbMIʮɤpߧġC
pľqG2 12 ?pġA̤jlq?CP0.1 mg IM or slow IVAñNfH~֤ΨL{ɦ]lǤJҶqAMӼW[PqbbQqjbMIʮɤpߧġC "	" Droperidol whæQT ifHɻݷפp(pGRʤ߰IܡA߻KLCAϥΧQBC[BCΨLwϥΫ|QT iĪ^ALMI]l]A~ֶWL65 AsݥΡBΨϥΨLī~pGbenzodiazepines. volatile anesthetics. IV opiatesC
Ǳw̱Droperidol ĳqΧCqvAQT i/torsades de pointes Ӯ׳iC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Droperidol	N05A	ܺ믫f ANTIPSYCHOTICS	0	AΩ󭰧CѩNζE_{ǩҳyߡBæR	"1.w糧~ΨLNªLӪfHC
2.Y{gfHC
3.gfHParkinsongw̶iΥ~C"	ϯg@ΡGDropedol iಣˤgιBʤʤ@~|Ƨ@ΡAMƧ@ΩܩĪΧxPĪvᬰifʤCּƯfҥi঳fzA]AıBRμ~{C 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-15 [E]_G1-11 j	Ts110.6.16		0	0	OIs 20251124	IDROP-a	IDROP-b	IDROP-c	110.6.16
BC19338209	N05AD01	0	IHADO	Haldol 1mg/ml/amp		ļfB믫fABߡBæRBʻP}aʤ欰êBRЯf	Psychotic disorders (moderate symptomatology)0.5-2 mg bid-tid (MAX 100 mg/day). Psychotic disorders (severe symptomatology)3-5 mg bid-tid (MAX 100 mg/day). Tourettechr(39)s disorder6-15 mg/day; may increase dosage by 2 mg increments as needed and tolerated; usual maintenance dose is 9 mg/day. Hyperactive children (ages 3-12 yr (weight range 15-40 kg))0.05-0.075 mg/kg/day; begin at 0.5 mg/day; may increase dosage by 0.5 mg/day increments every 5-7 days (divided into 2-3 daily doses).Max.0.15 mg/kg/day	1)q`HIMC2)YHIV~|ġAPɺʴ߹qϡC`tvĳWL 5 mg/minC3)fHīקK}ξާ@C3)i|vTŽո`AfHקK@PBʡBnSLҤβΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Js15-30XCAקK	Haloperidol	N05A	ܺ믫f ANTIPSYCHOTICS	0	ļfB믫fABߡBæRBʻP}aʤ欰êBRЯf	"Hypersensitivity to chlorpromazine or any component of the formulation, coma, severe CNS depression, Parkinsons disease, bone marrow suppression; severe cardiac or hepatic disease"	"Akathisia, dystonic extrapyramidal effects, parkinsonian extrapyramidal effects, blurred vision, ocular changes, epithelial keratopathy, pigmentary retinopathy, constipation, decreased sweating, dry mouth, nasal congestion, dizziness, drowsiness, hypotension, orthostatic hypotension, photosensitivity
i঳KBfB٦׵LOBݺΡBεOҽk"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-12 [E]_G2-06 j	Ts110.6.16		0	0	OIs 20251124	IHADO-a	IHADO-b	IHADO-c	110.6.16
AC27716209	N05AB04	0	INOVA	NOVAMINE 5MG/1ML/AMP		"믫fABߡBæR
"	Nausea and vomiting (Severe)PO: 5-10 mg 3-4 times/ day.MAX 40 mg/day IM: 5-10 mg (1-2 ml) IM; may repeat every 3-4 hr if needed (total IM dosage should not exceed 40 mg/day). IV: 2.5-10 mg (0.5-2 ml) by slow IV injection or infusion at a rate not to exceed 5 mg/min; a single dose should not exceed 10 mg and the total IV dosage should not exceed 40 mg/day.	 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 	Prochlorperazine	N05A	ܺ믫f ANTIPSYCHOTICS	0	"믫fABߡBæR
"	"Hypersenitivity; severe CNS depression; coma; pediatric surgery; Reyes syndrome; should not be used in children2 years of age or 9 kg
"	"Akathisia, dystonic extrapyramidal effects, parkinsonian extrapyramidal effects, tardive dyskinesia, tardive dystonia, blurred vision, ocular changes, epithelial keratopathy, pigmentary retinopathy, constipation, decreased sweating, dry mouth, nasal congestion, dizziness, drowsiness, hypotension, orthostatic hypotension, photosensitivity
"	/	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-31 [w]_w03-06 [w]_w03-13 [E]_C5-04 j	Ts110.6.16		0	0	OIs 20251124	INOVA-a	INOVA-b	INOVA-c	110.6.16
BC24046100	N05AX12	0	OABIL	Abilify 5mg/tab(Aripiprazole)		AripiprazolehiD2BD3BM5-HT1AB5-HT2AAaripiprazole{X˦XO(KiȤO0.34B0.8B1.7BM3.4 n M)FhiD4BM5-HT2cB5-HT7B\1-ǤWʱA´iH1MMAlhe{˦XO(KiȤO44B15B39B57B61M98 nM)CAripiprazolexPrʱSܦn˦XO(IC501000nM)CAripiprazole\O@hiD2MM5-HT1A骺Pʧ@ξF]OM5-HT2A骺ܾC	"1.ıկg
H :ĳ_lqPؼоqC1015@JA@@AҼ{]C
C֦~ :ĳؼоq10@J/C
2.ʯew
H
@Īkĳ_lq15@J/A@@AӰYQvalproateUvĳ_lq10-15@J/CҼ{]C"	 ~åQ֭Ωvൣ~{gw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(25CHU)xs	Aripiprazole	N05A	ܺ믫f ANTIPSYCHOTICS	0	"1. HMC֦~(1317)ıկgCC
2. HMൣ(1017)ʯewļgo@βVXo@AiWϥΩΰYQValproateUvC
3. Ĥ@ʯewvYQvalproateUvC
4. {gUvC
5. ൣ(617)۳ʯewHļC 
6. gC"	wOTSUKA ABILIFYLӪ̡Cd]tko/C¯lܹLөʤC	ߡBæRBKBYhBwtBRBJ{BvC	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A2 [2]_A2 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OABIL-a	OABIL-b	OABIL-c	110.6.16
AC31505100	N05AD01	0	OHALD	Halin 5mg/tab(Haloperidol)		"1.HaloperidolOݩbutyrophenones 믫wwA@jĤϯgפک(Dopamine)ܾA]QjO믫wwCHaloperidolõLܲ´iΧxP\C]襤ϫפک_@ΡAHaloperidol۷QMı۷۪ĥ(iOPֽMt´@)M@Ω򩳯g(basal ganglion)(¯nigostriatal bundle)C2.Haloperidol iͦĺ믫Bʩʪww@ΡAoiHbļg
ΨL믫EįgԸsħ@ΡC
3.bttΧ@Ϊ¦WAHaloperidolgww@ΨҹCʯkhUʪġC
4.b򩳮֪@ΡAγ\|@~BʩʪƧ@(٦ױiO}ARAΤڪˤg(Parkinsonism)C
5.ܶgפک@ΥiHߤιæRv(gѤƾǱEoϰ)AGzDA٪PAMW[cſEc(gѹ︢ʸUcſE]l@)C"	"Psychotic disorders (moderate symptomatology)0.5-2 mg bid-tid (MAX 100 mg/day). Psychotic disorders (severe symptomatology)3-5 mg bid-tid (MAX 100 mg/day). Tourettechr(39)s disorder6-15 mg/day; may increase dosage by 2 mg increments as needed and tolerated; usual maintenance dose is 9 mg/day. Hyperactive children (ages 3-12 yr (weight range 15-40 kg))0.05-0.075 mg/kg/day; begin at 0.5 mg/day; may increase dosage by 0.5 mg/day increments every 5-7 days (divided into 2-3 daily doses).Max.0.15 mg/kg/day
Hq`12~3A11AC0.5~5mgA̯guqWC"	1.AĴAn}ξާ@C2.קKPs@_ϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Haloperidol	N05A	ܺ믫f ANTIPSYCHOTICS	0	ļfB믫fABߡBæRBʻP}aʤ欰êBRЯf	"1.]sΨL{ĪygAɸTΡC
2.haloperidoLӪ̡C"	BʤBRBϮgLjB}ϱiBʦMHBBʧxB骺HNBʡBvBwBYhBgbBtwΤıC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_151 [®]_151 [r]_r04-06 [E]_A2-14 j	Ts110.6.16		0	0	OIs 20251124	OHALD-A	OHALD-b	OHALD-c	110.6.16
BC27011100	N05AH04	0	OMEGA	Megazon PR 50mg/tab (Quetiapine)		Quetiapine O@ثD嫬ܺ믫fĪCQuetiapine ΨbHߤʥNªN-desalkyl quetiapine Phدg]receptor^@ΡC	"Ouetiapine CѪAΨ⦸APΤP֪AiC
H
믫g: ve|ѤC龯qĤ@50mgAĤG100mgAĤT200mgAĥ|300mgCĥ|ѥHAqvվܨC300-450mg @릳ľqC̭ӧOfH{ɤιĪ@ʡAC龯qdq`b150-750mg C
ʯewļgo@G
@@kΧ@íwUvCve|ѤC龯qĤ@100mgAĤG200mgAĤT300mgAĥ|400mgCqi̭ӧOfH{ɤιĪ@ʦbC200-800mg [HվA@릳ľqbC400-800mg d򤧶C"	ѩQuetiapine iyݺΡA]fHާ@MIʪA]ArpTbASOpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷš]25JHU^AץC	Quetiapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	vıկgBʯew{go@Bļgo@βVXʵo@C{@ĪvĪGΪ{g(MDD)fHAi@{go@[vC	糧~󦨥|LӪfHҪA Quetiapine C	ΡBCBYhBYBKBGzA	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	DC	DC	DC	110.6.16
NC050401G0	N05AB04	0	ONOVA	Prochlorperazine 5mg/tab		"1.R@-ѧ褧ƾǱ޵oϦӲ͡C

2.ܺ믫f@-@{Ѫ_bj]hi(dopamine)ӧﵽ믫fAA]ialpha-ǤWEɩʪ_@ΡAӧUCΫ餧EXC

3.R@-@{ɭPCFtΤĦӲ͡C"	"Nausea and vomiting (Severe)PO: 5-10 mg 3-4 times/ day.MAX 40 mg/day IM: 5-10 mg (1-2 ml) IM; may repeat every 3-4 hr if needed (total IM dosage should not exceed 40 mg/day). IV: 2.5-10 mg (0.5-2 ml) by slow IV injection or infusion at a rate not to exceed 5 mg/min; a single dose should not exceed 10 mg and the total IV dosage should not exceed 40 mg/day.

@릨HqGfAA۷Prochlorperazine 5~10mgA@3-4Aݭnέ@ĩʳvվ㾯qC
i`Nj~ѡBGzεzfHq`ݭnC쾯qAMݭnέ@ĩʳvW[qC
@릨HB譭qGCѳ̰q150mgC
@ൣqGAX\hൣfwAHΤfAGο}߾AyC"	1.YŦfw̡BѤHݨ̷vܡAԷVA 2.ŶsλPϯg֪A 3.iް_ݺ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Prochlorperazine	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫fABߡBæR	@phenothiazineLӪ̡A糧ĥ|͹LӡAVΡC	yBVBΤ}٦׵jˡBCZʧ@աBOҽkBmıܩΩ]xBh·PBfC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w43-02 [s]_265 [®]_265 [UDx]_U03-35 [E]_C4-15 [Ew]_EX072 j	Ts110.6.16		0	0	OIs 20251124	ONOVA-A	ONOVA-b	ONOVA-c	110.6.16
BC22767100	N05AX08	0	ORIS1	Risperdal 1mg/tab(Risperidone)		"Risperidoneܩʤiܧ@ΡASerotoninergic 5-HT2Dopaminergic D 2㰪׿˩MOCRisperidoneiP
\1-adrenergic鵲XAH1-histaminergicΣ\2-adrenergic餧˩MOCAӹCholinergic hL˩MOARisperidonejĤD2ܾAiﵽ믫gʯgAøL嫬믫_ް_Bʥ\`MLO]catalepsy^C襤ϥiեSerotonin PDopamine ܾӭC@~|Ƨ@ΡAåiXj믫gtʻPgġC"	"Bipolar maniainitial dose : 2-3 mg QD; if needed, adjust dose by 1mg/day in intervals 24 hours. Dosage rang : 1 to 6 mg/day; the safety of doses higher than 6 mg/day has not been studied. Psychotic disordersInitial, 1 mg BID, then 2 mg BID on the 2nd day, 3 mg BID on the 3rd day,as tolerated dose of 3 mg BID. Dosage rang : 4 to 16 mg/day
1.ļ{g:
H:@}l2-3 mg qd; max. 6 mg/day. 
ൣMC֦~10-17:initially 0.5 mg qd, increased by 0.5-1 mg/day to 2.5 mg/day.
 2.ļP۳g: 
5MC֦~, @}l 0.25 mg/day (< 20 kg) or 0.5 mg/day (  20 kg), may increase dose to 0.5 mg/day (< 20 kg) or 1 mg/day (  20 kg) after  4 days,q:f 14 days.
 3.믫g: 
H, @}l, 1-2 mg/day; increased by 1-2 mg/day to target dose, q:4-8 mg/day; adolescents 13-17 yrs., initially 0.5 mg qd, increased by 0.5-1 mg/day to 3 mg/day."	7. ]Quetiapine i|l`P_BҩιBʧޥAĵifHbXzaTwquetiapine vL̨S}vTeAp߱qƻݭn믫ĵıʪʡAҦprp]]A}^ξާ@MICݺΥiɭP^ˡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm30JHUAץJs	Risperidone	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫ggAʯewļgo@CvgfHYʡAκ믫gg	w糧ĹLӪ̸TϥΡC	vBEļBJ{BYhC	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-03 [s]_268 [®]_268 [E]_A4-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	ORIS1-a	ORIS1-b	ORIS1-c	110.6.16
BC24887100	N05AH04	0	OSER2	Seroquel XR 200MG/TAB		"Quetiapine O@ثD嫬ܺ믫fĪCQuetiapine ΨbHߤʥNªN-desalkyl quetiapine Phدg]receptor^@ΡC
Quetiapine N-desalkyl quetiapine jserotonin]5HT2^Mdopamine D1 D2 㦳˩MOC۫HNOoبܧ@ΥHι5HT2 骺ܩʤD2 鰪XPFQuetiapine {ɧܺ믫fʽPC@~|Ƨ@ζɦV]EPS^C~AN-desalkyl quetiapine norepinephrine B]NET^]㦳˩MOCQuetiapine MN-desalkyl quetiapine ]histaminergic Σ\l -adrenergic 㦳˩MOA\2 -adrenergic  serotonin 5HT1A ˩MOhCAOcholinergic muscarinic benzodiazepine hL㪺˩MOC"	"Acute bipolar maniainitial, 50 mg BID on day 1, increase dosage by up to 50 mg BID on the second and third day, to 200 mg BID on day 4, maintenance, dosage adjustments should occur by day 6 in increments of not more than 200 mg/day. Usual dosage range: 400- 800 mg/day; MAX 800 mg/day. Schizophreniainitial, 25 mg BID, may increase dosage by 25-50 mg BID-TID on the second and third day, as tolerated, to a target dose range of 300-400 mg daily by the fourth day, given in 2-3 divided doses"	3. ~@ثD嫬ܺ믫fī~AϥΫD嫬ܺ믫fĪ|X{}μW[w}@ʤ}ο}fICKdN}gA]AhB@BhεLOAĴYX{}gAߨq}ȡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷš]25JHU^AץC	Quetiapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫gAʯewļgo@	糧~󦨥|LӪfHҪA Quetiapine C	ݺΡBYwBfBLLOBKB߷iLtBթʧCήƤ}	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 [ws]_w50-01 [UDx]_U03-60 [E]_B5-22 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OSER2-a	OSER2-b	OSER2-c	110.6.16
BC22543100	N05AH04	0	OSER25	Seroquel 25mg/tab(Quetiapine)		"Quetiapine O@ثD嫬ܺ믫fĪCQuetiapine ΨbHߤʥNªN-desalkyl quetiapine Phدg]receptor^@ΡC
Quetiapine N-desalkyl quetiapine jserotonin]5HT2^Mdopamine D1 D2 㦳˩MOC۫HNOoبܧ@ΥHι5HT2 骺ܩʤD2 鰪XPFQuetiapine {ɧܺ믫fʽPC@~|Ƨ@ζɦV]EPS^C~AN-desalkyl quetiapine norepinephrine B]NET^]㦳˩MOCQuetiapine MN-desalkyl quetiapine ]histaminergic Σ\l -adrenergic 㦳˩MOA\2 -adrenergic  serotonin 5HT1A ˩MOhCAOcholinergic muscarinic benzodiazepine hL㪺˩MOC"	"Ouetiapine CѪAΨ⦸APΤP֪AiC
H
믫g: ve|ѤC龯qĤ@50mgAĤG100mgAĤT200mgAĥ|300mgCĥ|ѥHAqvվܨC300-450mg @릳ľqC̭ӧOfH{ɤιĪ@ʡAC龯qdq`b150-750mg C
ʯewļgo@G
@@kΧ@íwUvCve|ѤC龯qĤ@100mgAĤG200mgAĤT300mgAĥ|400mgCqi̭ӧOfH{ɤιĪ@ʦbC200-800mg [HվA@릳ľqbC400-800mg d򤧶C"	2. w{gfw]]AHMൣ^AޥL̬O_bAΧ{Aig~{g[MΥX{۱NM欰ΤM`欰ܤơAحI|gwѬC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷš]25JHU^AץC	Quetiapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫gAʯewļgo@	糧~󦨥|LӪfHҪA Quetiapine C	ݺΡBYwBfBLLOBKB߷iLtBթʧCήƤ}	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 [ws]_w50-02 [s]_278 [®]_278 [UDx]_U03-58 [E]_B5-21 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OSER25-a	OSER25-b	OSER25-c	110.6.16
AC429461G0	N05AL01	0	OSULP	Sulmatyl Film  50mg/tab(Sulpiride)		"1.~㦳jODopamine@ΡAjOApomorphineMeta-AmphetamineDopamine˨E@ΡC
2.~㦳¡X@ΡAUC᳡HqEyGHyӲͳh{HC"	"Schizophrenla200 to 400 BID, MAX 1200 mg/ daly.

Antidepressant200-1000mg/day.

Duodenal ulcer50-100mg TID"	4. Quetiapinei޵oթʧCAYwB߷iLtAǯfH|֡ASOOb̪쪺qվAiϬM\1 ǤWʫܾʽC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Sulpiride	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫fABƩʼ	æݻ̲ӭMFw̡C (ް_@Wɤ)C	ΡB]`xBRB ʧ@wB˯gԸsB~BkʨťĲ`cBkʤkšC	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w51-04 [s]_292 [®]_292 [E]_C2-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OSULP-a	OSULP-b	OSULP-c	110.6.16
AC33387100	N05AL01	0	OSULP2	Surin 200mg/tab(Sulpiride)		"~㦳jODopamine@ΡAjOApomorphineMeta-AmphetamineDopamine˨E@ΡC
~㦳¡X@ΡAUC᳡HqEyGHyӲͳh{H"	"Schizophrenla200 to 400 BID, MAX 1200 mg/ daly.

Antidepressant200-1000mg/day.

Duodenal ulcer50-100mg TID"	5. iܨϥ quetiapine ɥX{ίvIlgCbHϥΤϯgtΧfHBίvIlgΦίvIlgIfH]pGL/έDΨkʡ^bϥquetiapine ɶ`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Sulpiride	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫fABƩʼ	æݫӭMFw̡C	ΡB]`xBRB ʧ@wB˯gԸsB~BkʨťĲ`cBkʤkšC	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w10-01 [s]_286 [®]_286 [E]_A4-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OSULP2-a	OSULP2-b	OSULP2-c	110.6.16
AB43859100	N05AH02	0	OUSPE	Uspen 100mg/tab(Clozapine)		~믫wwAiwѥMt믫gA|@~|g	"Schizophrenia, Suicidal behaviorinitial, 12.5 mg 1-2 times a day, then continued with daily dosage increments of 25-50 mg/day, if well-tolerated, to achieve a target dose of 300-450 mg/day (in 2-3 divided doses) by the end of 2 weeks;
maintenance: dosage adjustments should be made no more than 1-2 times per week, in increments not to exceed 100 mg; MAX 900 mg/day.
_lq25mgA C1~2A qC150300mg"	1.iX{GcLh 2.AīAФŶ}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Clozapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	LĪvĪ믫gfw	"1.euspenLӪ 
2.fHLĪް_ɩʥզyʤ֩εLɩʥզyfv̡AίfHWͲ`̬ҤϥΡC 
3.Lkw 
4.sʩάrʺ믫fwAĪr̡Bg 
5.YxŦεŦew"	f..K.GWh	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B2 [2]_B2 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.1._19950301_000.pdf"">OI` 1.2.2.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>             "	0	0	OIs 20251124	OUSPE-a	OUSPE-b	OUSPE-c	110.6.16
AC41547100	N05AA01	0	OWINT	Morefine F.C 100mg/tab		ݩphenothiazineA_hiAӨϸhitq۴֡Aֺ믫gCĨ㦳RBRBʯvΧܺ믫f@ΡAiHv믫`C	"400 to 800 mg/day in 1-4 divided doses, MAX 2 g/day"	ĥi|h¡BΪƧ@ΡAAīᤣy}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0	Chlorpromazine	N05A	ܺ믫f ANTIPSYCHOTICS	0	ļfB믫fABߡBæRBʻP}aʤ欰ê	"1.XͥӤ뤧BൣBȾvڤΩgB`JBB~ˡBݡBͮ~w̧yAΥġC
2.fH@PhenothiazineLӡA糧ĥ|͹LӡC"	UBh¡BOzB]BfBUgBKBBIlxBoNC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[s]_202 [®]_202 [r]_r04-04 [E]_A1-10 j	Ts110.6.16		0	0	OIs 20251124	OWINT-a	OWINT-b	OWINT	110.6.16
BC26668100	N05AE05	0	OLATU	Latuda(Lurasidone 40mg)		"iOgѵXϦhiĤG(D2)MMĤG(5-HT2A)ܧ@Ωҽձ
"	"Schizophrenia:
Adult:40~160mg/d
Adolescent:40~80mg/d
Bipolar depression:
Adult:20~120mg/d
Child and Adolescent:20~80mg/d

"	"ס]xwƫ79^Y]xwƫ1015 ^x\णw̡Aĳ
վ㾯qCĳ_lqC20@JCרx\णw̪C龯qoWL
80@JAYx\णw̪C龯qoWL40@J
ס]ĲMv30ܡ50@/^Y]ĲMv30@/^
\णfwAĳݽվ㾯qCĳ_lqC20@JAC龯qoWL
80@J
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		"Lurasidone hydrochloride
"	"N05A
"	ܺ믫f ANTIPSYCHOTICS		"BıկgGΩvHMC֦~(1317)ıկgC
 BĤ@ʯew{go@G@?kΩvwĤ@ʯew{go@HMൣΫC֦~(1017)fHCtXYQValproateU?kΩvwĤ@ʯew{go@HfHC
"		ֽoBlByBLBBYBV~	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w37-03 j	Ts111.5.04	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	OLATU-a	OLATU-b	OLATU-c	111.5.04
BC23731100	N06BA04	0	OCON18	:)Concerta 18mg/tab(Methylphenidate)[ޤT]		v`NOLʨg	"18-36 mg once daily in the morning. MAX 72 mg/day.
1.H:Individualize dosage ,2-3 times daily. 10-15mg/day  40-60mg/day.2.ൣ(HW) Ѥpq}l,CgvW[q,(Ҧp߶e5mg),vHCg510mgW[q,pqgվWL@Ӥ뤴ﵽh."	AĪ̿ʩΰs뤤rOApߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Methylphenidate	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	v6 ]t^HW65 ]t^HUw`NOLʯgൣBC֦~ΦHfwC	"1.TwJ{BiαEʪw̡A]ĥi|cƳoǯgC 
2.wmethylphenidateΥĨLLӪw̡C 
3.Cw̡C 
4.TourettesgaگfvζE_w̡C"	olB`hA鸨ʥֽACvAwAJļġBgLӡBıBkQBYhBwtB_ŸB{BA`NxC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w75 []_86-2L j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	0	0	OIs 20251124	OCON18-a	OCON18-b	OCON18-c	110.6.16
BC23999100	N06BA04	0	OCON27	:)Concerta 27mg/tab[ޤT]		v`NOLʨg	"18-36 mg once daily in the morning. MAX 72 mg/day.
1.H:Individualize dosage ,2-3 times daily. 10-15mg/day  40-60mg/day.2.ൣ(HW) Ѥpq}l,CgvW[q,(Ҧp߶e5mg),vHCg510mgW[q,pqgվWL@Ӥ뤴ﵽh."	AĪ̿ʩΰs뤤rOApߨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Methylphenidate	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	v6 ]t^HW65 ]t^HUw`NOLʯgൣBC֦~ΦHfwC	"1.TwJ{BiαEʪw̡A]ĥi|cƳoǯgC 
2.wmethylphenidateΥĨLLӪw̡C 
3.Cw̡C 
4.TourettesgaگfvζE_w̡C"	olB`hA鸨ʥֽACvAwAJļġBgLӡBıBkQBYhBwtB_ŸB{BA`NxC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w75 []_86-2L j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	0	0	OIs 20251124	OCON27-a	OCON27-b	OCON27-c	110.6.16
BC23880100	N06BA04	0	OCON36	:)Concerta 36mg/tab[ޤT]		v`NOLʨg	"18-36 mg once daily in the morning. MAX 72 mg/day.
1.j󤻷pġGC1AHW覡ӽվ㾯qA]ݩ`īAAī12pɤĮġAĳ󦭤WAΡAݾ]AAiCZA}HC

2.ثeϥιLmethylphenidatefH_lq18mgAھڥثeg礣ĳCWL54 mg"	"HG黲U]A,CZB}HC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Methylphenidate	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	v6 ]t^HW65 ]t^HUw`NOLʯgൣBC֦~ΦHfwC	"Hypersensitivity to methylphenidate or any component of the formulation; use with or within 14 days of MAO inhibitors; narrow-angle glaucoma; marked anxiety, family history or diagnosis of Tourettes syndrome"	zBvBwtBhBæRBYh	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	0	0	OIs 20251124	OCON36-a	OCON36-b	OCON36-c	110.6.16
BC27080100	N06BA04	0	ORITA	:)Ritalin 10mg/tab(Methylphenidate)[ޤT]		Ritalin@zϯgľA߲zWĪGBʩʧۡCH餧@μҦ|QѡAҳyħ@γQ{ObohiXUAhi󯾪骺AlҭPC	"ൣ(66HW)G - _lqCѤ@ΤGAC5@J(pGb\Τ\ɪA)ACPW[5-10@JAC龯qPC
HG - C龯q20-30@JA2-3PCǯfHCѥi40-60@JAӦǤHCѥu10-15@JNwCYfHߪAķ|yLkJΪΡAhU6IHeAγ̫@qC"	~i|ywtMηNA]rξާ@αqƨLMIʪʳ`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Methylphenidate	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	LʨgԸsBo@ʶݺίg	"1.methylphenidateιLξLӪ̡C
2.ҪxमiC
3.QE_ܼw (Tourettes) gw̩ΦaگfvfwC"	gBvC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w74 []_86-3L j	Ts110.6.16		0	0	OIs 20251124	ORITA-a	ORITA-b	ORITA-c	110.6.16
BC25333100	N06BA04	0	ORITA1	Ritalin LA 20mg/cap[ޤT]		"Ritalin ۪]racemate^Ad-methylphenidate]d-MPH^Ml-methylphenidate]l-MPH^@@VXզC
Ritalin @zϯgľA߲zWBʩʧۡCH餧@μҦ|QAѡAҳyħ@γQ{ObohiXUA󯾪(striatum) hiAlҭPC"	"Ritalin LA ѧCq}lPACPvBW[CĥίF캡NgÇCq@vqC
ൣC龯qWL40 @JCY~PtľXήɡAҦPmethylphenidate hydrochloride `qiWLC60 @JC
HC龯qWL60 @JCY~PtľXήɡAҦPmethylphenidate hydrochloride `qiWLC60 @JC 
vez
}lϥRitalin LA veAfHO_ߦޯefB믫`AήaڥvO_`B߫ǩʤ߫ߤκ믫`bveAq魫PAåB@OC

ADHD vw
ĪvݵLAvzLĸwvi歫sAHfHĪɪ\Afﵽi|bȮɩʩΪīUhC
ΩADHD ൣɡAq`ibCKΤᰱġC
ൣ(6 6 HW)
Ritalin LA ĮĽn (methylphenidate hydrochloride extended-release capsules) CѤ@AbWPAĳ_l
q10 @JCqվi̷ө[쪺@ʤΪvĪGACgW[10 @JAܨC̤jq40 @JC
H
Ritalin LA @Ѥ@C
sϥmethylphenidate vfHGثeϥmethylphenidate vfHARitalin LA ĳ_lq20 @
JACѤ@C ."	 Ritalin pߨϥΩ󥿱@vfwA]iಣͰMHARitalin TΩ󥿦bCMAO vΰ2 gfHC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Methylphenidate	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	"LʨgԸsBo@ʶݺίg
v 6 ]t^HW 60 ]t^HUw`NOLʯgൣBC֦~ΦHfHC"	"1. methylphenidate ιLξLӪ
2.wߦޯefA]AYBߵhBʯ߳ʤŦfB߰IܡBʤOǵoͩܤƪѩʤŦefBߦٯfܡBߦٱBiPR߫ߤlqDfܡ]]lqD\ಧ`yef^ 
3. Hi (MAOI) vAMAOI 2 gfHA]oͰMHMIʡC"	YhAߡAUAvC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w74 []_86-3R j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	0	0	OIs 20251124	ORITA1-a	ORITA1-b	ORITA1-c	110.6.16
AC46285209	N05CD08	0	IDORM	ĵMidatin(p)5mg/ml/amp[ޥ|]		ıRBϥ[@fRB¾KɤκBNeġC	"Conscious sedation: IV, 0.5-2 mg slow IV over at least 2 min; may repeat dose every 2-3 min if needed; usual total dose:2.5-5 mg Anesthsia,Induction(Unpremedicated patients) : IV, 0.3-0.35 mg/ kg. MAX 0.6 mg/kg total dose
In ICU long term sedation : Adult, Initial doseX0.02-0.08 mg/kg; maintenanceX 0.04-0.2 mg/kg/hr. Childrent, Initial doseX0.05-0.2 mg/kg; maintenanceX 0.06-0.12 mg/kg/hr]1-2 mcg/kg/min^"	"1. In obese pediatric patients, the dose should be calculated based on ideal body weight.
 2. Sedative doses should be individually titrated, taking into account patient age, clinical status and concomitant use of other
CNS depressants.
3. Continuous monitoring of respiratory and cardiac function is required (ie, pulse oximetry).
4. Immediate availability of specific reversal agents (flumazenil), resuscitative drugs, age- and size-appropriate equipment, and
personnel trained in their use and skilled in airway management should be assure"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Midazolam	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	ıRBϥ[@fRB¾KɤκBNeġC	"Narrow-angle glaucoma, concurrent use of potent inhibitors of CYP3A4]erythromycin, ketoconazole or cimetidine^; pregnancy"	"Hiccoughs, nausea, vomiting, coughing, oversedation, headache, drowsiness"	ĤD 	קKϥ/SmҦw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G1-2.5 mg
q(MD)G120mg(A)tm120 mL
}GGD5W D10W  NS  R
}@סG1 mg/mL
ĳĳtvG0.03-0.2mg/kg/hr(H60kg 1.8ml-12ml/hr)
wwʡG24hr (RT)
ʴءGIlΤߦާA_g
`NƶGu Axǥ\णiභխq"	ixii[]_U05-03 []_D3-06 j	Ts110.6.16		0	0	OIs 20251124	IDORM-a	IDORM-b	IDORM-c	110.6.16
AC46285216	N05CD08	0	IMIDA1	ĵMidatin 5mg/ml;3ml/amp(Midazolam)[ޥ|]		ıRBϥ[@fRB¾KɤκBNeġC	"Conscious sedation: IV, 0.5-2 mg slow IV over at least 2 min; may repeat dose every 2-3 min if needed; usual total dose:2.5-5 mg Anesthsia,Induction(Unpremedicated patients) : IV, 0.3-0.35 mg/ kg. MAX 0.6 mg/kg total dose
Anesthsia,Induction (Premedicated patients) : 0.15-0.35 mg/kg; Maintenance : 0.05-0.3 mg/kg as needed, or continuous infusion 0.25-1.5 mcg/kg/min
In ICU long term sedation : Adult, Initial doseX0.02-0.08 mg/kg; maintenanceX 0.04-0.2 mg/kg/hr. Childrent, Initial doseX0.05-0.2 mg/kg; maintenanceX 0.06-0.12 mg/kg/hr]1-2 mcg/kg/min^"	"1. ~ok믫fMY~{gBvgAXϥΡApWzfghHvC
2. MLwAʸˮ`AYIl̩Ψ@몬p(W[ĪӷP)AP~ɭnSOpߡC
3. gٵLOfHA]٦תLOA뤩~ɭnSO`N C
4. hDݭnA_hPĪC
5. ӫܧĨõLo{~tݾlĪGCfA6pɤAfHo}ξާ@MIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Midazolam	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	ıRBϥ[@fRB¾KɤκBNeġC	"Narrow-angle glaucoma, concurrent use of potent inhibitors of CYP3A4]erythromycin, ketoconazole or cimetidine^; pregnancy"	"Hiccoughs, nausea, vomiting, coughing, oversedation, headache, drowsiness"	ĤD 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_U05-05 []_D3-07 j	Ts110.6.16		0	0	OIs 20251124	IMIDA1-a	IMIDA1-b	IMIDA1-c	110.6.16
AC05891209		0	IMORP1	ĵMORPHINE 10mg/ml/amp[ޤ@]		Īh@ξܤ|RAѡCw̳qL@Ω󤤼ϯg´鵲cSBiMӰ_ġCäw[ĥiܩʦaYǿĩʯgİʶǻAovʧ@ΡAqӸѰkhPMH۪߲z欰CҩA`JŴֳi֦۵oBHΥѶˮ`ʨEް_İʵoCP˱ĥlɤJܰة车ϡAiˮ`ʨEް_IgqAvTLPıgǻCEʫᲣͪPiӨȫAYgBeB_MmA䤤gSg1Mg2ӨȫC䤤gPhY̱KAûPIlBY֦}CgsxG󤤼ϯgAרOttΡ]pjּhBMB֡B^BBUCBɤީPǽϵCeDnsbMjּhCĪmOqLMϪ@ΡAܸzDįʥ\CyOĪFMy¤ϮgϡCܩĹ藍P鿳īSphıİʪǻhMCwҩAīiϯgyAQxPBhҵǤWBhi΢ު赥g誺֡C~Aĥi??AϯgӭMcAMP@״֡AܪĪ@λPcAMP@wYCܩO_PlqרOuBtlqA|@XTסC 	@q10mgA@q20mgC 	"1.Ī̿ʤiAϥή`N[ApߧġC
2.ݺΡBtw{HCϥΥ~pݱqƾާ@TBͩվMIʤuʪSOpߡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Morphine	N02A	P OPIOIDS	0	hC 	YIl̡A޳ݮo@̡AYxê̡ACʪͳewֵoߤ̡Aj˪A̡Aʰs뤤rAͪPLӪ̡C	"βߡBæRBKBwtB駿ޤx޵j˵{HCqeɭPIlBUAgCൣBΫ͵j˲{HϥΩyfVC
IlBߡBܰʡBݺΡBwtBwBoBߡBæRBKC "	D 	קKϥΰDvn/SmҦw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G2-5mg Q3-4hr
q(MD)Gh-0.8-10mg/hr ΩIlfw-H70笰5-35mg/hr
}GGD5W, NS
}@סG100 mgtm100 mLtm1mg/ml
ĳĳtvG0.8-10mg/hr
wwʡGǷץ14(RT)
ʴءG"	ixii[]_E1 []_w77 []_86-7 j	Ts110.5.06		0	0	OIs 20251124	IMORP1-a	IMORP1-b	IMORP1-c	110.5.06
AC05886209		0	IMORP2	ĵMORPHINE 20MG/1ML/AMP[ޤ@]		Īh@ξܤ|RAѡCw̳qL@Ω󤤼ϯg´鵲cSBiMӰ_ġCäw[ĥiܩʦaYǿĩʯgİʶǻAovʧ@ΡAqӸѰkhPMH۪߲z欰CҩA`JŴֳi֦۵oBHΥѶˮ`ʨEް_İʵoCP˱ĥlɤJܰة车ϡAiˮ`ʨEް_IgqAvTLPıgǻCEʫᲣͪPiӨȫAYgBeB_MmA䤤gSg1Mg2ӨȫC䤤gPhY̱KAûPIlBY֦}CgsxG󤤼ϯgAרOttΡ]pjּhBMB֡B^BBUCBɤީPǽϵCeDnsbMjּhCĪmOqLMϪ@ΡAܸzDįʥ\CyOĪFMy¤ϮgϡCܩĹ藍P鿳īSphıİʪǻhMCwҩAīiϯgyAQxPBhҵǤWBhi΢ު赥g誺֡C~Aĥi??AϯgӭMcAMP@״֡AܪĪ@λPcAMP@wYCܩO_PlqרOuBtlqA|@XTסC 	@q10mgA@q20mgC 	"1.Ī̿ʤiAϥή`N[ApߧġC
2.ݺΡBtw{HCϥΥ~pݱqƾާ@TBͩվMIʤuʪSOpߡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Morphine	N02A	P OPIOIDS	0	hC 	YIl̡A޳ݮo@̡AYxê̡ACʪͳewֵoߤ̡Aj˪A̡Aʰs뤤rAͪPLӪ̡C	"βߡBæRBKBwtB駿ޤx޵j˵{HCqeɭPIlBUAgCൣBΫ͵j˲{HϥΩyfVC
IlBߡBܰʡBݺΡBwtBwBoBߡBæRBKC "	D 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w77 []_86-8 j	Ts110.5.06		0	0	OIs 20251124	IMORP2-a	IMORP2-b	IMORP2-c	110.5.06
	N05CC01	0	ECHLO	ĵClodrin oral sol'n 30ml/		"Chloral hydrate@ضʯvMRA㦳PڤĪCNS@ΡCĪ@ξ|oAO{Chloral hydrate CNS
@ΥDnOѩ󬡩ʥNªTrichloroethanolC"	"1.sͨ]fġAz^NeRG25mg/kg/doseQ
2.Mൣ]fġAz^RAJ{GC6-8p25-50 mg / kg /dayA̤jqG500 mg /doseQ
3.qˬdeG30-60A25-50mg / kg /doseF i|b30Ƥ@A̤j`q100 mg / kg`q1 gAൣ`q2 gRQ
4.LhNGNe30-60A50-75 mg / kg /doseFpݭnAib즸ī30ơA̤j`q120 mg / kg`q1 gAൣ`q2 gQ
5.ʯvġGNɶ50 mg / kg /qF ̤jqG1g /qF `p̤jGC1JAൣC2J
6.H]fġAz^G
  RAJ{G250@J/3
  ʯvġGNɶΤNe30AJ500-1000 mgAWL2g / 24p"	 YPsΨLϯX֨ϥη|ϦwvĪGͥ[@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Chloral hydrate Solution	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	ˬdΪRwvġBΨL{ɥγ~C	"1.㪺xεǷl`C
2.פŦfC
3.GAުέGΤQGzšC 4.gC
5.ҧtξLӡC"	 ΡBYwB߹æRBmBLӥ֯lC	C	榸ϥξqUiw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-08 j	Ts110.6.16		0	0	OIs 20251124	ECHLO-a	ECHLO-b	ECHLO-c	110.6.16
AC56306100	N02AA01	0	OMORP1	ĵMorphine Sulfate 15mg/tab[ޤ@]		"ܰتDn@ΦbϯgtΤήƨtΡC
@B襤ϯgtΤ@ΡGAιBʤϪıgXLvTqɡA|ϵhıCAjPIlΫy¤ϡAjhʯv@ΡC
GBƨtΤ@ΡGϮƹDƦ٦YAGθzDBʡA֭GGxĤΤŦGcAzAٺiAXHW@ΦӧejPm@ΡC"	"@릨HqGC4pɵkhpfA5-30@JCqi]fwӧOtbvBUCϥμƶqC15@J̡AĳĥβĶܰؤfAGվC
YYCʯkhfwAC4pɩwɵiFhĪĢCqC
ѩܰبIl@ΡA~̡Bf̤ΦIlDDfwqġC"	AΫi|K{Ho	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC	Morphine Sulfate	N02A	P OPIOIDS	0	ׯkhwѡC	ܰعLӡBYx\êBYIl̡BYϯg̡BݡBCʪͳew~oŦIܡB߫ߤB`ɰ̡BYl˪̡B~F̡Bʰs뤤r̡Bj˪A̡Bx޳NBPɨϥMAO̡C	ܰت̥DnMIbIl	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_E1 []_w76 []_86-6 j	Ts110.6.16		0	0	OIs 20251124	OMORP1-a	OMORP1-b	01C56306-2	110.6.16
AB55108100	N05BA16	0	OCALM	Nargin.F.C. 5mg/tab (Nordazepam)[ޥ|]		Ĩ㦳RwvĪGA]iΩνwJ{Φ٦׵jˡC	5 mg 2-3 times daily	"YgٵLOefAΪs̡ANEɽаȥivAvO_iϥΡC
Aīi|zPıݺΩΪ`NOLkAb|T{zoĪeAкɶqקKqƻݥe`ΥiyMIʡAp}Bާ@񵥡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Nordazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{BiҤް_믫êC	󥻫~DΥ@ξLӪ̡ATϥΥī~C	ݺΡBĵıʭCBwtBYhBnBŸݡBʧ@կOCC	ĵD. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
AB270821G0	N05BA91	0	OSERE	Secorin 10mg/tab(Oxazolam)[ޥ|]		fGᥭϯgAi[jGABAXGABA骺@ΡAW[ϧʰTǻAӦRBʯvĪGC	"Anxiety:10-30 mg 3-4 times/day;
Ethanol withdrawal:15-30 mg 3-4 time/day;
Hypnotic: 15-30mg

CѤTAC10~20mgA~֡BgAyWqC"	"(1)xǥ\ण}BʯfܡBIz̩MpBBŴkVΡC
(2)yΩrpTξާ@HC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Oxazolam	N05B	ܵJ{ ANXIOLYTICS	0	J{A	TΩUCBgٵLOC	ηNB}Bڶ\BtwBYhB߸[tBߡBæRBBGABolKKC	Ĥ D	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M04-06 []_E6 []_w78-13 j	Ts110.6.16		0	0	OIs 20251124	OSERE-a	OSERE-b	OSERE-c	110.6.16
BC26421100	N02AA05	0	OOXYN	ĵOxyNorm I.R 5mg/cap[ޤG]		iݦ]ବO@د~mu ]sb۹ܩʡ^PiAbqU]iML~鵲XADnv@άhCpPҦ~PiAثeåq̤߳jqCb{ΤWAqվYHiFRhĪGǡAӤhĪGWhH}@зǡAY}]AIlMϯgtΧC	"ѤHζWL18 HG
լnC6pɪAΤ@AqMkhY{פίfwehĤݨDpC

vG
fwAݭnHiݦ]ପvɡAקK޵o_gAнwwխqC"	"ĤiZHοiAHKvTĮġC Ф@]A@լAtHq}AnJfAߧY]UC
}B ݥΤΤϥ
լ (OxyNorm) sbϥΪ̦}BݥΤΤϥΪIAiӾɭPĹLqM`C }߳BeAеUfwIAPɩwlܬO_ͦ欰MpC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	Oxycodone	N02A	P OPIOIDS	0	"1. ݭnkhgkhfwC 
2. ݭnkhCʤ׫DgkhfwABgL~ĪӵLkıkh̡C"	"լoΩ㦳UCfgΪpfwG
-YIlC 
-ʩYޮݥʴεLϳ]ơC 
-wκæ·ʸzθzGDC
-iݦ]ହLӡ]LӤ^"	KBߡBݺΡBæRBhҡBYhBwtPhC	קKϥΰDvnϥ~hAsͨi|bXͫᤣ[YX{Ͳz̿ʩM~Ī_gԸsC	"קKϥΰDvnNiyRΩIl@ΡC
"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668984?cesid=3ecfMHQNA1X&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOxycodone%26t%3Dname%26acs%3Dfalse%26acq%3DOxycodone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_w76 []_86-2R j	Ts110.6.16		0	0	OIs 20251124	OOXYN-a	OOXYN-b	OOXYN-c	110.6.16
	N02AB02	0	IDEME	ĵPethidine 50mg/ml/amp[ޤG]		QİtŬ㦳ܰئh@Τ¾KʤhF@Ω󤤼ϯgtΤΥƦپxCDnvγ~hRFҾܡAPFPhqܰج۸AtŸLƦٵjˡBKBy¤Ϯg@εo͡C60mg~80mg`gq10mgܰؤhĪGC_l@β֩ܰإB@ήɶuC 	"@BΩkhѰG
ϥξqHkh{פίfHӽվCMYǳXAϥΥ֤U`gAƵĮɤH٦ת`gΡCtŤfAĪG`gtAPPhenothiazinesΦhبL믫wwåήҴq]q`25~50%^A]Ī|WjtŤ@ΡC
HG`ξq 50mg  100mgA٦ת`gΥ֤U`gCnɡAC3~4pɰl[@AɥiwCRߪ`gCPethidine 75mg Rߪ`gAĤOMorphine 10mg Rߪ`gC
pġG`ξqC魫 1.1mg ~ 1.76mg ]ߤoWLHq^C٦ת`gΥ֤U`gCnɡA3~4pɤ@C
GBNeġG
HG`ξq 50mg  100mgA٦ת`gΥ֤U`gC¾Ke30~90ġC¾KUGH5%}`gGΥͲzQ} 10mg/mLAC 10~15mg Rߪ`gC
pġG`ξqC魫 1mg ~ 2.2mg ]ߤoWLHq^C٦ת`gΥ֤U`gC¾Ke 30~90ġC
TBhG
khܬWhɡA`ξq 50mg  100mgA٦ת`gΥ֤U`gABi 1 ~ 3 pɭƵġC
`NGYϦb`ǥ\धHAsϥζWL48pɡAΨCWL 600mgC"	"1.߸M[̡֪ApߨϥΡC 2.Aη|Φ}{HC 3.`gGn׶}uJsC 4.nKץJsC 5.Rߪ`g|ް_XiAyUALq`geo͵j˱ΡC
gG
tYLq|ɭPIl]CIlvμyqBvJhGIlBo^BYݯvܩgBf٦wBoNHֽBɷ|ɭP߰ʮ}wΧCCYLqƦܷ|oͲB`B߸Φ`C
BmG
n`NgѴѯSDλUʩκިʪHؾAC¾Kī~ܾQĨoJQOܥѰtŵ¾Kī~Lqγ¾Kī~LөҤް_IlSѬrA]̦nbiIl_dPɡAHRߪ`gثܾCbSIlΤߦާgɡA¾Kī~ܾC
BRߤyBޥ[ΨLUki̫ܨϥΡC
p֥DiazepamThiopentonehiѰjˡC  "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץJsǷŤUC 	Pethidine 	N02A	P OPIOIDS	0	hC 	tŹLӡGtŹ勵bϥΩΪϥMonoamine Oxidase (MAO) inhibitors̬ϥθTҡF14ѤAMAOw̡ApvqQİtŷ|ް_iwBY BƦܭPRFg]AgBYIlBoBCBʳ¾Kī~LqgFؤऴAiPJsHyperphenylalaninemiaefCLDnLʡBjˡB߰ʧֳtBBCML¾Kī~_oǦMIAtūowiCpTݵow̳¾Kī~ɡAӷPʸ FkbsƤpɹL{J[UϽƥHpqBvW[qaܰءCY̥iRߪ`gHydrocortisonePrednisoloneAﰪΰ̥iֵRߪ`gChlorpromazineC¾Kī~ܾBzAΩʻPwʫhTC 	tṲ̄jMIPL¾KhĤ@ˡA|oͩIlAάYǵ{ת` F]ioͩIlBJBΤ߸{HC̱`Ƨ@Υ]ALightheadednessBtwBRBߡBæRByCoǯgשoͦbBʤΥgYkhw̡FoǱw̡AĳCqFBʤw̥iϽץHwMƧ@ΡC	"D  ,קKϥΰDvn/SmҦw"	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_w77 []_86-6 j	Ts110.5.06		0	0	OIs 20251124	IDEME-a	IDEME-b	IDEME-c	110.5.06
BC22868248	N01AX10	0	IFRES	ĵFresofol 1% MCT/LCT 10mg/ml;50ml/vail[ޥ|]		PropofolOصuĤ@¾KADgzDĤ`gC@ξणFѡAHfHӨA@¾Kɶb30-60CPropofoliCAoخĪGiΩ󲴬NCPropofolֳ\histamineXĪGA̪o{PropofolǥѾ~iwo{HΨxefC	"ζq:
H¾KG
¾KɡG
ޤJ¾KɭFresofol 1% MCT/LCTn̯fHӺww(jC1020V40@J)AfHiJ¾KCp55HjݭnC魫1.5-2.5@JpropofolC
Fresofol 1% MCT/LCTItv[jC102@(20@J)]CWL55̤ASA grade 3M4fHCq1mg/kgC
¾KG
¾KiHάIFresofol 1% MCT/LCTӺALץγs򪺿`άOƤ@jq`gҥiCγs`Ӻ¾KAqnӤHơA@뾯qbCpɨC魫4-12@JpropofolCbfHOpN (ҦpCIJʪN) iH֥ζqܨCpɨC魫4@JpropofolC
b~ѪfHBpíwΧCeʪfHAMASAĤTũMĥ|ŪfHAĳFresofol 1% MCT/LCTn־qCpɨC魫4@JC
ϥέƤ@jq`g¾KfHAqW[25-50@Jpropofol (= 2.5-5@Fresofol 1% MCT/LCT)C
E_Υ~NL{RG
jfHݭnC魫0.5V1 @J1V5HFRCRqR@Ϊ{װվAjhƪfHݭnCpɨC魫1.5-4.5@JHRC
~ֶWL1ӤHWpĪ¾KG
¾KɡG
]FgAFresofol 1% MCT/LCTiϥΩp1Ӥ몺pġC
WL8pĤjnC魫2.5@JpropofolӾɤJ¾KCFresofol 1% MCT/LCTϥΩ1Ӥ3iݭnqC魫2.5V4 @JC I~fH(ASAĤTMĥ|)ĳθCqC
¾KG
Ϋ`覡¾KAqbCpɨC魫9-15@JpropofolC
p3~pġAM~jfHA]\|bĳd򤺸qݭnC
[@~fHRG
qn̷R{׽վC`UqCpɨC魫0.3V4.0@JpropofolC
tvyWLCpɨC魫4.0@JC
ΪkG
Fresofol 1% MCT/LCTο`kɥi}AYn}uH}5%R߿`GάO0.9%ƶuR߿`G (Bݦb`~l)C
ĮɶGĮɶiWL7ѡC
CϥΥHWLCQGpɬhA̯f{ݭnܦhܤCѡCWLTѤϥλvfwbDRBRAUϥΡABݰwPropofolֵogC"	"iHPLRߪ`gVXC
Fresofol 1% MCT/LCTLNiϥΡC
}wβ~\žWϥΡC
t}Fresofol 1% MCT/LCT㥲b}~12pɧ󴫡Cθ}5%άOƶu0.9%}LRߪ`gGAbL߷ǳƫߧYϥΡAoWL6pɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUCnNC	Propofol	N01A	"¾K ANESTHETICS, GENERAL"	0	"uĩRߪ`g¾KC
ϥΩ󦨤H1ӤHWൣ@ɩκ¾KΡC
ϥΩ󦨤HfHE_Υ~NL{RΡAiWϥΩλPL¾KΥʳ¾KX֨ϥΡC
wb[@fФϥΤHuIlWL16HfH@RΡC"	"1.wPropofolBjBͩλsξLӪ̦CTҡC
2.Fresofol 1% MCT/LCTiHϥΩ~֤p1Ӥ몺ൣ¾KAH16HUb[@fЪൣRvC"	CAȮɩʲA߸LCBּƯfHb_|ߡAæRBYhAwʧ@B~A٥io`g짽khC	"Propofol bhOTΡAPropofol |gLLLysͨCҥH Propofol
b¾KOTΡC"	"p¨ť˨ϥ PropofolA઺wʥQإߡAG
ĳΩ¨Ŵk"	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G
q(MD)G0.3-4mg/kg/hr(w)(H70kg2.1mL-28mL/hr)
}GGG,D5W, NS
}@סGG(10mg/mL)}AY}ݡ2 mg/mL
ĳĳtvG0.3-4mg/kg/hr(w)(H70kg2.1mL-28mL/hr)
wwʡG G(10mg/ml)AY}ᤣiWL6pɡC
CVP
ʴءGBP,xǥ\,EKG
dose >5 mg/kg/h for > 48 hourspropofol infusion syndrome(H70kg35mL/hr*48hr)gN©ʻĤrA߷i}wAٷѡAʵǰI
`NƶGī~ĴܦhCѡCϥΡCī~`ɶyWL 12 pɡA`޸γѾlī~HþA󴫡CiHPLRߪ`gVXC"	ixii[]_w10-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.1._20200201.pdf"">OI` 1.4.1.</a>              "	0	0	OIs 20251124	IFRES-a	IFRES-b	IFRES-c	110.6.16
BC22868238	N01AX10	0	IPROP	ĵFresofol 1%;MCT/LCT10mg/ml;20ml/amp[ޥ|]		PropofolOصuĤ@¾KADgzDĤ`gC@ξणFѡAHfHӨA@¾Kɶb30-60CPropofoliCAoخĪGiΩ󲴬NCPropofolֳ\histamineXĪGA̪o{PropofolǥѾ~iwo{HΨxefC	"ζq:
H¾KG
¾KɡG
ޤJ¾KɭFresofol 1% MCT/LCTn̯fHӺww(jC1020V40@J)AfHiJ¾KCp55HjݭnC魫1.5-2.5@JpropofolC
Fresofol 1% MCT/LCTItv[jC102@(20@J)]CWL55̤ASA grade 3M4fHCq1mg/kgC
¾KG
¾KiHάIFresofol 1% MCT/LCTӺALץγs򪺿`άOƤ@jq`gҥiCγs`Ӻ¾KAqnӤHơA@뾯qbCpɨC魫4-12@JpropofolCbfHOpN (ҦpCIJʪN) iH֥ζqܨCpɨC魫4@JpropofolC
b~ѪfHBpíwΧCeʪfHAMASAĤTũMĥ|ŪfHAĳFresofol 1% MCT/LCTn־qCpɨC魫4@JC
ϥέƤ@jq`g¾KfHAqW[25-50@Jpropofol (= 2.5-5@Fresofol 1% MCT/LCT)C
E_Υ~NL{RG
jfHݭnC魫0.5V1 @J1V5HFRCRqR@Ϊ{װվAjhƪfHݭnCpɨC魫1.5-4.5@JHRC
~ֶWL1ӤHWpĪ¾KG
¾KɡG
]FgAFresofol 1% MCT/LCTiϥΩp1Ӥ몺pġC
WL8pĤjnC魫2.5@JpropofolӾɤJ¾KCFresofol 1% MCT/LCTϥΩ1Ӥ3iݭnqC魫2.5V4 @JC I~fH(ASAĤTMĥ|)ĳθCqC
¾KG
Ϋ`覡¾KAqbCpɨC魫9-15@JpropofolC
p3~pġAM~jfHA]\|bĳd򤺸qݭnC
[@~fHRG
qn̷R{׽վC`UqCpɨC魫0.3V4.0@JpropofolC
tvyWLCpɨC魫4.0@JC
ΪkG
Fresofol 1% MCT/LCTο`kɥi}AYn}uH}5%R߿`GάO0.9%ƶuR߿`G (Bݦb`~l)C
ĮɶGĮɶiWL7ѡC
CϥΥHWLCQGpɬhA̯f{ݭnܦhܤCѡCWLTѤϥλvfwbDRBRAUϥΡABݰwPropofolֵogC"	"iHPLRߪ`gVXC
Fresofol 1% MCT/LCTLNiϥΡC
}wβ~\žWϥΡC
t}Fresofol 1% MCT/LCT㥲b}~12pɧ󴫡Cθ}5%άOƶu0.9%}LRߪ`gGAbL߷ǳƫߧYϥΡAoWL6pɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUCnNC	Propofol	N01A	"¾K ANESTHETICS, GENERAL"	0	"uĩRߪ`g¾KC
ϥΩ󦨤H1ӤHWൣ@ɩκ¾KΡC
ϥΩ󦨤HfHE_Υ~NL{RΡAiWϥΩλPL¾KΥʳ¾KX֨ϥΡC
wb[@fФϥΤHuIlWL16HfH@RΡC"	"1.wPropofolBjBͩλsξLӪ̦CTҡC
2.Fresofol 1% MCT/LCTiHϥΩ~֤p1Ӥ몺ൣ¾KAH16HUb[@fЪൣRvC"	CAȮɩʲA߸LCBּƯfHb_|ߡAæRBYhAwʧ@B~A٥io`g짽khC	"Propofol bhOTΡAPropofol |gLLLysͨCҥH Propofol
b¾KOTΡC"	"p¨ť˨ϥ PropofolA઺wʥQإߡAG
ĳΩ¨Ŵk"	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G
q(MD)G0.3-4mg/kg/hr(w)(H70kg2.1mL-28mL/hr)
}GGG,D5W, NS
}@סGG(10mg/mL)}AY}ݡ2 mg/mL
ĳĳtvG0.3-4mg/kg/hr(w)(H70kg2.1mL-28mL/hr)
wwʡG G(10mg/ml)AY}ᤣiWL6pɡC
CVP
ʴءGBP,xǥ\,EKG
dose >5 mg/kg/h for > 48 hourspropofol infusion syndrome(H70kg35mL/hr*48hr)gN©ʻĤrA߷i}wAٷѡAʵǰI
`NƶGī~ĴܦhCѡCϥΡCī~`ɶyWL 12 pɡA`޸γѾlī~HþA󴫡CiHPLRߪ`gVXC"	ixii[]_F3 []_w10-07 j	Ts111.6.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.1._20200201.pdf"">OI` 1.4.1.</a>              "	0	0	OIs 20251124	IPROP-a	IPROP-b	IPROP-c	111.6.29
AC56725161	N06AB10	0	LTALO	TalopramfAG1mg/ml;150ml/bot(Escitalop		"{gvιw_oAWgAJ{gAxJ{gαjgvC

"	"PO, InitialX5-10 mg/day as a single dose in the morning or evening. MaintenanceX10-20 mg/day.

"	 ѩ QT jgԸs.(long QT Syndrome)C Escitalopram Ψ䥦ξ|LӤ̡CPDܩʥBif MAO ֥Ϊ̡C(Ѧҥ椬@) TP Pimozide ֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Escitalopram	N06A	ܧ{ ANTIDEPRESSANTS	0	"{gvιw_oAWgAJ{gAxJ{gαjgvC


"	"Hypersensitivity to escitalopram or any component of the formulation;
concurrent use MAO inhibitors, including linezolid or IV methylene blue (within 14 days); concomitant us with pimozide.

"	"Headache, diarrhea, nausea, sleep disorder, somnolence or insomnia, ejaculation disorder, impotence, fatigue.

"	ĵC. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M02-06 [E]_I4-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	LTALO-a	LTALO-b	LTALO-c	110.6.16
BC26996100	N06AX26	0	OBRIN	Brintellix 10mg/tab(Vortioxetine)		Vortioxetine@ξMMʪո`ΦM(5-HT)BeJժC	"1.65HfHABrintellix_lΫĳ뤩qvortioxetine10@JAC@C
2.̭ӧOfHAqiHW[̰ܨC20@Jδ̧֦ܳCC5@JC
3.gѰAĳܤֶAv6ӤHdTܼ~{ĪGC"	"]Brintellix󦹱ڸswʻPĩʸƩ|QsAĳϥΩ18HUfHC
AĴYKʱfH~{gΡAHoͦ۱欰D
wo@OAΧܼ~{Ī@ؼbMI
MgԸs]߸LtAíwAoNAߴAܡAļʤıgAϮgiAաAߡAæRAUg^AX{HWλݥߨ谱ġD
ļgλļgwߧYΡDYfHʡAw欰[@MDUD
YAΧܾĪμvTpO\धĪA`N`X{HD
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Vortioxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	H{g(major depressive disorder)	"1.DΤt᫬LӪ̡C
2.T֥ΫDܩʳiQ (MAOIs) BܩʳiQ-A (MAOI-A)C
3.VortioxetineoϥΩhkBļgo@fHC"	ߡBæRBzGDABUgBKB`cڡBwtBkogC	קKϥ		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4720836?cesid=55E0yGHyI19&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVortioxetine%26t%3Dname%26acs%3Dfalse%26acq%3DVortioxetine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OBRIN.a	OBRIN.b	OBRIN.c	110.6.16
BC24240100	N06AX21	0	OCYMB3	Cymbalta 30mg/cap		DuloxetineH骺ܼ~{BϩʯkhΧܵJ{T@ξऴA۫Hoǧ@λPWjϯgM(serotonergic)PǤW(noradrenergic)C	"Diabetic neuropathy- pain60 mg once daily. Generalized anxiety disorder60 mg once daily, may start at 30 mg once daily for 1 week and then titrate up to 60 mg once daily, depending on tolerabilityFMAX 120 mg/day.
Major depressive disorder20 mg ORALLY twice daily to 60 mg daily (once or as 30 mg twice daily).
~@ѨϥΤ@AҼ{iP_C"	ͶnΦҾܲ{ɤW㪺x\êAӰCymbaltavT{yWzefL]~iAרϥCymbalta	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@xs30JHUC	Duloxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	{gB}fg䯫ghBsxʵJ{gC	"iQ(MAOI)G
XCymbaltaΦbCymbaltav5ѤATϥMAOIHv믫ewA]|yMgԸsIW[CMAOIv14ѤATCymbaltaӪv믫ewCѩ|yMgԸsIW[AbMAOI]ҦplinezolidPRߪ`gȥš^vfwATCymbaltaC
UʫCG
ACymbaltaiW[IA]wUʫCfwקKAΥġC"	ߡBfBݺΡBKBCBhC	קKϥΰDvn		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668711?cesid=2KPGtTsDGJs&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDuloxetine%26t%3Dname%26acs%3Dfalse%26acq%3DDuloxetine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.8._20241201.pdf"">OI` 1.1.8.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>             "	0	0	OIs 20251124	OCYMB3-a	OCYMB3-b	OCYMB3-c	110.6.16
BC24239100	N06AX21	0	OCYMB6	Cymbalta 60mg/cap(Duloxetine HCI)		DuloxetineH骺ܼ~{BϩʯkhΧܵJ{T@ξऴA۫Hoǧ@λPWjϯgM(serotonergic)PǤW(noradrenergic)C	"Diabetic neuropathy- pain60 mg once daily. Generalized anxiety disorder60 mg once daily, may start at 30 mg once daily for 1 week and then titrate up to 60 mg once daily, depending on tolerabilityFMAX 120 mg/day.
Major depressive disorder20 mg ORALLY twice daily to 60 mg daily (once or as 30 mg twice daily).
~@ѨϥΤ@AҼ{iP_C"	ͶnΦҾܲ{ɤW㪺x\êAӰCymbaltavT{yWzefL]~iAרϥCymbalta	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@xs30JHUC	Duloxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	{gB}fg䯫ghBsxʵJ{gC	"iQ(MAOI)G
XCymbaltaΦbCymbaltav5ѤATϥMAOIHv믫ewA]|yMgԸsIW[CMAOIv14ѤATCymbaltaӪv믫ewCѩ|yMgԸsIW[AbMAOI]ҦplinezolidPRߪ`gȥš^vfwATCymbaltaC
UʫCG
ACymbaltaiW[IA]wUʫCfwקKAΥġC"	ߡBfBݺΡBKBCBhC	קKϥΰDvn		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668711?cesid=2KPGtTsDGJs&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDuloxetine%26t%3Dname%26acs%3Dfalse%26acq%3DDuloxetine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.8._20241201.pdf"">OI` 1.1.8.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>             "	0	0	OIs 20251124	OCYMB6-a	OCYMB6-b	OCYMB6-c	110.6.16
BC23960100	N06AB10	"""f"" ߴཤ10@J"	OLEXA	Lexapro 10mg/tab(Escitalopram)		"Escitalopram @ܩserotonin(5-HT)AlADnX㦳˩MOC]|HCF1000 ˩MOXMBJդWCMBJժո`Piescitalopram XDnXAӾɭP󧹾aMAlCEscitalopram \h]AM5-HA1A, 5-HT2,Φhi D1 D2 receptorsA\1-A\2-A] adrenoceptors A histamine H1 A muscarine cholinergic AbenzodiazepineAopioid receptors S˩MOΦC˩MOCEscitalopram O(citalopram)S-cA]O㦳vʪcC"	"PO , InitialX 10 mg/day as a single dose in the morning or evening. MaintenanceX 10-20 mg/day.
65HWѦ~HAx\঳DfHAHΨϥ omeprazole  cimetidine GĪfH escitalopram ĳC̤jq 10 @J C
~{gG`ξqC 10@JA̦UOw̪pAqiW[̰C 20@JCͧܧ{ĪGq` 2 ~ 4 gAbgѰAvܤֶ 6ӤHjƮĪGCC龯qWL 20 @JwʥQҹ Escitalopram HC@q뤩AWλP֪AҥiC"	"EscitalopramiɭPPqQT interval 
SSRIss]Aescitaloprami|vTդjpAɭPմjAoش@ΡA|ϲܯAɰζʫC(angle-closure glaucoma)
YescitalopramP㦳M@Τī~֥ΡAҦp:triptans(]Asumetriptan),~Ī(tramadol)(tryptophan)ɥpߪ`NMgԸs"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץAé25JHUxsC	Escitalopram	N06A	ܧ{ ANTIDEPRESSANTS	0	{gvιw_oAWgBJ{gBxJ{gαjgv	ѩ QT jgԸs.(long QT Syndrome)C Escitalopram Ψ䥦ξ|LӤ̡CPDܩʥBif MAO ֥Ϊ̡C(Ѧҥ椬@) TP Pimozide ֥	ߡBvBݺΡBhҡC	"ĵC. [ʼƾ,bXͫe@Ӥ뤺SSSRISNRIAX孷IW[]p󢱭^"	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669393?cesid=a8Z6dj7RtqA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEscitalopram%26t%3Dname%26acs%3Dfalse%26acq%3DEscitalopram#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OLEXA-a	OLEXA-b	OLEXA-c	110.6.16
AC33664100	N06AX05	0	OMESY	Mesyrel 50mg/tab(Trazodone)		~ܩʪj^M(serotonin)AӥBಣCNSE@ΡC	"Depression50 mg TID; may increase dosage by 50 mg/day every 3-7 days; MAX 600 mg/day
_lqC150mgAAΡAMC34ѫ50mg/dayqW[AoAC̤jqGEfH400mg/dayF|fH600mg/dayC"	ѧCq}lvAvWqCX{ݺαήɡAiNjqΫeAΩδCq	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Trazodone	N06A	ܧ{ ANTIDEPRESSANTS	0	vUثA{gC	Hypersensitivity to trazodone or any component of the formulation	ΡAtwAYȡA«AfC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-07 [s]_214 [®]_214 [E]_A4-12 j	Ts110.6.16		0	0	OIs 20251124	OMESY-a	OMESY-b	OMESY-c	110.6.16
AC032911G0	N06AA09	0	OPINS	Pinsaun 25mg/tab(Amitriptyline)		AmitriptylineO@ؤTܼ~{(TCA)AhĲz@ΡA]AǤWѡBܲ´iBxPΪ_5-HT3CDn@ΦbgA]QΨӪv~{gAiHPǦ^khTܤ֡C	Adult1-2 tab TID	  1.Cw̡C 2.糧~LӪ̡C 3.ߦٱ_w̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Amitriptyline	N06A	ܧ{ ANTIDEPRESSANTS	0	~{f	糧ĦLӪ̸T	YwAΡAfA	ĵC. 	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668901?cesid=aBWSPwQGhAL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAmitriptyline%26t%3Dname%26acs%3Dfalse%26acq%3DAmitriptyline#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_A1 [2]_A1 [ws]_w15-04 [UDx]_U02-02 [E]_B1-18 j	Ts114.04.29		0	0	OIs 20251124	OPINS-a	OPINS-b	OPINS-c	114.04.29
AB41606100	N06AB03	0	OPROZ	Sinzac 20mg/cap(Fluoxetine)		~serotoninAlAӤ|NorepinephrineAlA]Ӳܼͧ~{@ΡC	"Depressioninitial, 20 mg/day in the morning; maintenance, may increase to 20-80 mg/day (single or divided) after 2 weeks. Bulimia nervosa60-80 mg/day. Obsessive-compulsive disorder40-80 mg/day. Panic disorder10 mg/day for 1 week then increase to 20 mg/day; dosage increases of up to 60 mg/day may be considered after several weeks if there is no clinical response. Premenstrual dysphoric disorder20 mg/day continuously, or 20 mg/day only on days 14 through the first full day of menses]repeat with each cycle^
1.~{gGC馭WA20mgA@ѳ̰q80mgAYC龯qj20mgAPC
2.믫ʳggG20mg/dayAC̤jq60mg
3.jgG@20mgAq20~60mg/day
 4.PTSDG20~80 mg/dayC"	xwƪfHCqδ֪AWv	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Fluoxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	{gBɭgBjg	"1.ǯfH]֪A~AάO谱ϥΥ~AK}lϥMAOIAyYƩέPRA]A~iPiq]MAOI^@֨ϥΡC
2.糧~Lөʱw̡C"	֭BߡBEʡBvBhҡBYh	ĤC 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C2 [2]_C2 [ws]_w32-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OPROZ-a	OPROZ-b	OPROZ-c	110.6.16
AA56761100	N06AX11	0	OREME	Mirtazapine 30mg/tab		"MirtazapineO@ا@Ω󤤼Ϭʯgثe\2ܾAiW[ϵǤWΦMgǾɧ@ΡC䤤MgǾɪW[DOSʸg 5-HT1A] 5-HT2M5-HT3駡 Mirtazapine _CMirtazapineG蹳cUܼ~{@ΡC䤤 S(+)蹳c_ \2 P 5-HT2AR(-)蹳chi_ 5-HT3C 
Mirtazapine´iH1-ܬʫhɭPRĪGA@뻡Mirtazapine@ʨ}nAS誺xPʡAbvqUA]|vTŦެʡC"	"15 mg/day at bedtime; may increase in dose every 1-2 weeks to a max dose of 45 mg/day

ĿfAϥΡAit]ACZC

HG_lqC15mgC{ɻݭnC龯qq`15~45mgAĳΫeAΡC

Ѧ~HݼW[qYKʴC"	"]1^Ωv18HUൣΫC֦~
 ]2^קKqƻݰĵıʩM`NOMIʤu@AҦp}ξާ@C
 ]3^Cqq`|ֶݺΡRoͲvAi|zܼ~{ĮġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Mirtazapine	N06A	ܧ{ ANTIDEPRESSANTS	0	{g	Mirtazapine LӪ̡C	W[P魫W[C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D4 [2]_D4 [ws]_w38-02 [s]_224 [E]_B4-18 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OREME-a	OREME-b	OREME-c	110.6.16
AC483441G0	N06AA12	0	OSINE	Colian Capsules 25mg/cap(Doxepin)		ܼ~{AAΩ믫ίg믫êҤް_~{MJ{wCXѤNͧܵJ{ĥΡAܼ~{hݼƶgCbvA۪OR@ΡCs|PiĤOCfA@Y~iΤAGĩMAbPe[H}C~i_H?M H?AjOܲ´i@ΡC	"Depression and/or anxiety (outpatients)75 mg/day (divided into 1-3 doses); MAX 150 mg/day.
Depression and/or anxiety (inpatients)150 mg/day (divided into 1-3 doses); MAX 300 mg/day"	ts뤧Ʒ|[jRƧ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Doxepin	N06A	ܧ{ ANTIDEPRESSANTS	0	J{AB~{f	"1. doxepinΨLT{ī~LӪ̡C
2. α¨ŰkBCw̡Bdw̡C
3. AMAOIsw̡C"	L֨Ƨ@άfBBfBYhBtwBܤơBıܵC	ĤC 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [E]_B2-26 j	Ts110.6.16		0	0	OIs 20251124	OSINE-A	OSINE-b	OSINE-c	110.6.16
AC479661G0	N06AA02	0	OTOFR	Tone 25mg/tab(Imipramine)		"Imipramine㦳hĲz@ΡA]A\-ǤWѡBܲ´iBxPΪ_5-HT3C
Imipramineܼ~{ॼAiDnOg勵ǤW]NA^Mserotonin(5-HT)AlA]A襤ϯgtΪE@ΡC"	"Depression (outpatients)75 mg (divided into 1-3 doses per day); MAX 200 mg/day. Depression (inpatients)100 mg (divided into 1-3 doses per day); MAX 300 mg/day. Depression (maintenance)50-150 mg at bedtime. EnuresisG children 6-12 yrinitial, 25 mg 1 hr before bedtime, may increase in 25 mg; MAX 50 mg.;children over 12 yr25 mg 1 hr before bedtime, may increase in 25 mg. MAX 75 mg."	iX{YwAΡAfA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Imipramine	N06A	ܧ{ ANTIDEPRESSANTS	0	~{fB]	"1. PMAO֥ΡAi|ɭPLAYjˤΩzAĢĶjܤֻ14ѡC 
2. ߦٱM̡C
3. w糧ĤDibenzazepineTܼ~{LӪ̡C"	h¡B魫W[BYwBKBfC	ĵD. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w34-03 [E]_B3-35 j	Ts110.6.16		0	0	OIs 20251124	OTOFR-a	OTOFR-b	OTOFR-c	110.6.16
BC25451100	N06AX22	0	OVALD	Valdoxan F.C 25mg/tab(Agomelatine)		"AgomelatineO@melatonergicPľ (MT1PMT2) H5-HT2CܾC@ǵXʪsXagomelatineiS@ΡA\B]ǤWE (adrenergic)B´iEɩ (histaminergic)BxPEɩ (cholinergic)BhiEɩ (dopaminergic)BHbenzodiazepineS˩MʡC
AgomelatineʪͲzVüҦiHAվͲzCAgomelatineiW[ǤW( noradrenaline)Phi(dopamine)qjֽeAåBMPi (serotonin) ӭM~@רSvTC"	"(74 years) 25 mg ORALLY at bedtime; if no response after 2 weeks, may increase to 50 mg ORALLY at bedtime for at least 6 months duration"	iŸλP֪ACwtΧx¬O`}A}ξާ@MI̶fVC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Agomelatine	N06A	ܧ{ ANTIDEPRESSANTS	0	H{g	"1. 靈ĦΤ@ξLӪ̡C
2. x\ण̡ASOOwxwƩάʩʨxŦefAΨxiJƶWL3`ȤW̡C
3. ֥CYP1A2j(pfluvoxamineBciprofloxacin)C"	YhBߤηwtC	SmҦw	קK/Ҽ{Ź葉Υ˪qBAMwΩvaldoxanv	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w15-03 [E]_B1-15 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OVALD-a	OVALD-b	OVALD-c	110.6.16
BC25106100	N06AX12	0	OWELL	Wellbutrin XL 150mg/tab		BupropionO@بi(catecholamine)g^ܩʧAM^vT۷LzA]|iQC	"Initial, 150 mg in the morning for 3 days, then increase to 150 mg BID for several weeks. Max.200mg BID"	"1.iiΫrH
2.b}lAΥīeAiDvLhfvAרOwBggίgʹgBsݥΡBJM_sRBľδCĪB}fBxǯefC
3.AīAקKqƮeް_ˮ`MIʡAp}Bާ@񵥡C
4.AĴiܰs"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Bupropion	N06A	ܧ{ ANTIDEPRESSANTS	0	v~{g	"1.TΩBupropionλsL@ئLӪ̡C
2.TΩww̡C
3.TΥثeΥeQE_wggίgʹʪw̡C
4.iPiQ(MAOIs)PɨϥΡAϥMAOIsAܤ֥۹j14ѡA~i}lWellbutrin SRvC"	i঳ıҽkBwtBh֡BfBhB٦ש`hBߡBæRBmBKB魫ܵg	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-08 [s]_341 [®]_341 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1.1._20101001_000.pdf"">OI` 1.2.1.1.</a>              "	0	0	OIs 20251124	OWELL-a	OWELL-b	OWELL	110.6.16
BC21780100	N06AB06	0	OZOLO	Zoloft 50mg/tab(Sertraline)		ĪOܩʪM(serotonin)AlA|sǤW(norepinephine)AlAҥHΨӪv~{gg	"Depression, Obsessive-compulsive disorder50 mg/day as a single dose in the morning or the evening; dosage may be increased at intervals of at least 1 week to a maxium of 200 mg/day.

Panic disorder, Posttraumatic stress disorder, Social anxiety disorder25 mg/day for 1 week, then increase to 50 mg/day; dosage may then be increased at intervals of at least 1 week to a maxium of 200 mg/day."	"1.iݭn4-6gAHǫΪĪGC
2.i|vTrpξާ@񤧯OC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Sertraline	N06A	ܧ{ ANTIDEPRESSANTS	0	{gBjgBWgBж˫OgԸs(PTSD)Ϊ殣߯gθgeg(PMDD Premenstrual Dysphoric Disorder)C	"1. TΩwSertralinLӪfHC 
2. TΩApimozidefHC"	hҡBŸݡBߡBvBݺΡBtwC	ĵC. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w51-05 [s]_356 [®]_356 [UDx]_U03-53 [E]_B5-26 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OZOLO-a	OZOLO-b	OZOLO-c	110.6.16
A0493221T0	N06AX12	0	OZYBA	Buprotrin 150mg/tab(Bupropion)		"Bupropion O@بi(catecholamines)G[ǤW noradrenaline][hi dopamine]g^
ܩʧC"	"_lq 150mg C@A̰榸qiWL 150mgABuprotrin qWL 150mg/ɡAHC⦸覡AΡC
ӥBs⦸qܤ֥j 8 pɡC"	AĴYKʵw̤~{gΡAHoͦ۱欰C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	bupropion hydrochloride	N06A	ܧ{ ANTIDEPRESSANTS	0	v~{gAΪvjB̿gA@ٷϤUC	"ĸTΩww̡AMϥΰsRw̡AiPi?(MAOIs)PɨϥΡCΤif MAOIs Aܤ֥۹j 14 ѡA
~i}lΥĪvC"	LӤpC¯lBBwBJ{BYhBıêBɰ]Y^B	hį? CAקKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A4 [2]_A4 [ws]_w21-04 j	Ts110.6.16		0	0	OIs 20251124	OZYBA-a	OZYBA-b	OZYBA-c	110.6.16
AB50206163	N06BX03	0	LPIRA	Piracetam oral solution 200mg/ml;200ml/b		"Piracetamݩnootropics,|bʪΤH餺[j{\,oǥ\]AǲߡBOСB`NOηNѵC󥿱`Hλ{OfH,|Rκ믫E ʧ@ΡCPiracetam@Ω󤤼ϯgtΪ覡:ո`gǾɡBPigΦBO@ gNµí,Hhaemorrhaological@μWjLq`,@Ψä|yX iC󸣳\êfwϥpiracetam,|۪ܸqi(EEG),y alphaibetaiW[,íCdeltai,ĵıʻP{\WjCʪUظ l(ҦpʮBrBqv),piracetam|O@ë_{OCPiracetami WΦX֨LĪvֽʰ}oʩzC"	"1.v޻êΦѤƩҤް_OêGvɪC龯q6ml12mlCbvAC̰qiF24mlC 
2.vֽʰ}oʩzG_lqC36mlAC34ѼW[24ml / ѡF̰WܨC120mlAGܤTġC
3.̷ӵǥ\վ㾯qpҥ"	 1.whBwhα¨iDvC 2.nۦܾqΰġC 3.iNeivϥΦġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs15-30JHUץBC	Piracetam	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	޴`ﵽBֽʰ}oʩzUkC	"XfHT,ķ|vTpOAY`X屡pαNiNAЧiv"	GzABŸݡBYBYh	Piracetam|JťġA]¨ŴקKϥΥġC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M06-01 [ws]_w73-05 [E]_I4-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	LPIRA-a	LPIRA-b	LPIRA-c	110.6.16
AB49770221	N06BX03	0	INOO2	Noesin inj. 200mg/ml; 5ml/amp (Piracetam		︣޻êΦѤƩҤް_Oêi঳ġBֽʰ}oʩzUkC	10-15 g/day IV. maintenance 1 g TID IV/IM.	"1.]Piracetam |vTpOA]󦳤Ҷqw(SOOʤNYX)AݯSO`NC
2.ֽʰ}oʩWw̡AקKJMġA_hiɭPJM_oΦ]_ް_o@C
3.ѩPiracetamb餺OgѵŦưAGŦणw̭nSO`NC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Piracetam	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	︣޻êΦѤƩҤް_Oêi঳ġBֽʰ}oʩzUkC	Hypersensitivity to piracetam or any component of the formulation; Huntingtonchr(39)s chorea	"Abdominal pain, diarrhea, nausea, vomiting, ataxia, headache, insomnia, agitation, anxiety, confusion, pruritus, urticaria"	"קKϥΰDvn
"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-24 [w]_w03-05 [w]_w03-11 [E]_G3-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	INOO2-d	INOO2-b	INOO2-c	110.6.16
AC39058212	N02AX02	0	ILIMA	ĵLimadol inj.50mg/ml;2ml/amp)[ޥ|]		"TramadolO@ا@Ω󤤼ϯgtΪ~hCO@Ωg, _Mk~Dܩʯ­PľAg˩MOCLyh@ΪgAlǤWAHΫPiMC"	H14HWC֦~AHRߡB٦שΥ֤U`g1-2ml(50-100mg)Aq`C龯qoWL400mgC	"1. ¾KɡALIMADOLϥζqYWLĳqƦhAhưIliʡC
2. YϬOӫܵġAi|vTfHOAҦp:rpTPާ@񤧯OAרOPs@_֥ήɡC
3. ]ϥΥi|ͨ̿ʡAGvMwvɶuHάO_nȮɰġC
4. LIMADOLiPӶWLvһݡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XC HUxsC	Tramadol	N02A	P OPIOIDS	0	?YʪCʯkhC	"Tramadol Injection TΩG
- DΥCξ|͹LӤfHC
- ʰsBwvġBhB~ΨL믫ĪrfHC
- fHAΩΪ14 ѤAMAO  (аѾ\椬@)C
- AavwfHC
- Ω}ʳ¾Kī~_{HvC
- o۩IlfHC"	oBtwBߡBæRBfHίhҡC	קKϥΰDvn	bŴĳϥ tramadolCΪ̡Ab tramadol vTšCb榸P tramadol Aq`ݭn_šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_U05-02 []_D3-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.3._19980401_000.pdf"">OI` 1.1.3.</a>              "	0	0	OIs 20251124	ILIMA-d	ILIMA-b	ILIMA-c	110.6.16
AC56706100	N02AJ13	0	OULTR1	ĵTraceton(Tramadol37.5mg+Acetaminophn[ޥ|]		TramadolOا@Ω󤤼ϤhƦXCܤ֦ؤɪ@ξA쫬MM1NªPu~sAnorepinephrineserotoninAlLz@ΡCAcetaminophenOt@ا@Ω󤤼ϤhĪA|Mh@ΤTmM@ξCϥμзǰʪҫAtramadolacetaminophenƤ観P@ΡC	"qVH16]t^HWൣ
~̤j榸qC|ܤpɪAΤ@ܨAݭnkhA@ѳ̦hAΤKC
fAϥΡAiP֪AΤP֪AC"	"1. ԷVϥΩ󥼺12ൣA{ɮįqjIɡAiҼ{ϥΡCԷVϥΩ󥼺18縢θNhCԷVϥΩέDB㦳뫬ίvIlgBYͳefΤfHA]iW[YIlDICĴĳšA]iಣY}A]AG`ݺΡBŧxYIlDC
2. ~i|zfHqƦbMIu@]prξާ@^һݪߴΥͲzOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	J25JC	Tramadol/Acetaminophen	N02A	P OPIOIDS	0	ϥΫD~hLĪצYʯkh	"Tramadol/AcetaminophenƤTΩG
1. etramadolBacetaminophenB~䥦ξ~LӪfHC 2. oͰsBUvġB¾KġBϧ@ΤhB~κ믫ĪʤrɡC
3. PɩιLh14Ѥϥγi?]MAOIs^fHC"	ߡBwtBݯv	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M05-01 []_E6 []_w78-14 []_s397 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.4._20060501_000.pdf"">OI` 1.1.4.</a>              "	0	0	OIs 20251124	OULTR1-a	OULTR1-b	OULTR1-c	110.6.16
BC215311G0	N05CF02	0	OSTIL	*Stilnox F.C 10mg/tab (Zolpidem)[ޥ|]		"ZolpidemܩʦaPomega 1(BZI)XC
bHAzolpidemiHYuJΪɶB֩]ӪơBW[`ίvɶAHΧﵽίv~CoǮĪGPqϪSʦAPbenzodiazepineһo̤PC]ίvsҹzolpidemiHĤGqίvP`׺ίv(ĤTqPĥ|q)CZolpidembĳqU|vTֳtʲίv(paradoxical sleepAREM)`C"	γ̧Cľq}lvAĳ_lqGkʬ5@JAkʬ5@J10@JCY5 @JqLġAqiW[10@JCC̰qiWL10@JC	"1.ϥΥĪvApקKqƾrpξާ@O欰AHקKMI
2.yPs֪ACs|WjĪR@ΡCĵıʴzi|Ͼrpξާ@񦳦MIC
3.ϥstilnox(L׬O_Ps֪A)i|oͽʺίv欰(p:ڹCAھrAΦbMpUqƨLʡ^poͽкɳt^EðΡAקKoͶˮ`D"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25 CHUxsC	Zolpidem	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vg	"ĸTΩUCpG
1. zolpidemΥĨLDʦLӡC
2. Yx\णC 
3. ʤ/YIl\णC
4. ίvIlȤxԸsC 
5. ٵLOC"	YwAݺΡAߡAYhC	ĤB 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M05-04 []_E6 []_w78-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.3._20131101_000.pdf"">OI` 1.2.3.</a>              "	0	0	OIs 20251124	OSTIL-a	OSTIL-b	OSTIL-c	110.6.16
AC47569100	N06BX03	0	ONOO2	Pisanta 1200mg/tab(Piracetam)		Piracetam@Ω󤤼ϯg覡Gո`gǾɡBPigΡBO@gN¡F@ΩOǤ覡GWjyӭMܧίOBpO\BCHYסBWjL޴`A@Ψä|ɦܦXiC󸣳\êfwAPiracetamA|ܸۧqi(EEG)AyalphabetaiWjACdeltaiAWjĵıʤλ{\CܷʪUظl(]AʮBrιqv)APiracetam|O@ӭMë_{OC	"1.2-2.4 g/day, divided in 2-3 doses; MAX 4.8 g/day

1. ޻êΦѤƤް_OêG wѴGvC4.8 gAvɨC龯qאּ2.4 gC
2. ֽʰ}oʩzG _lqC鬰7.2gAC34ѼW[4.8g/dayA̰WܨC24gCpľq魫pAC3050mg/kgC"	piracetamLӡAι糧Ĥ󦨤LӡAιpyrrolidonelͪLӪw̡AקKϥΥġCXAεǯe]End Stage Renal Disease^fHATΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Piracetam	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	︣޻êΦѤƩҤް_Oêi঳ġBֽʰ}oʩzUk	piracetamLӡAι糧Ĥ󦨤LӡAιpyrrolidonelͪLӪw̡AקKϥΥġCXAεǯe]End Stage Renal Disease^fHATΥġC	GzABŸݡBYBYh	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	ONOO2-a	ONOO2-b	ONOO2-c	110.6.16
BC24677100	N05CF02	0	OSTIL1	Stilnox C.R 6.25mg/tab[ޥ|]		"ZolpidemܩʦaPomega 1(BZI)XC
bHAzolpidemiHYuJΪɶB֩]ӪơBW[`ίvɶAHΧﵽίv~CoǮĪGPqϪSʦAPbenzodiazepineһo̤PC]ίvsҹzolpidemiHĤGqίvP`׺ίv(ĤTqPĥ|q)CZolpidembĳqU|vTֳtʲίv(paradoxical sleepAREM)`C"	"1.Stilnox CRHĳq6.25@JAΫeAΡC
2.AΩѦ~Hεzw̤Ψx\णw̡C
3.Stilnox CRĿ]AAibBHΩCZC
4.StilnoxP֪AΦb\ߨAη|ĮĴwC"	"1.b{TΧts몺ơC
2.`NĹrpHξާ@̥i|ɭPݯvMIʡC
3.ϥstilnoxioͽʺίv欰(pڹC,ھr,ΦbMpUqƨL),Yoͽʺίv欰,кɳt^Eð."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Zolpidem	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vg	"1.15HUpġC
2.hAŰC"	ıYhAݺΩΫ¡A鱫AWĪPıA{AJ{AļAƵAڹC	ĤB 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_M05-05 []_w78-09 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.3._20131101_000.pdf"">OI` 1.2.3.</a>              "	0	0	OIs 20251124	OSTIL1-a	OSTIL1-b	OSTIL1-c	110.6.16
AC52566157	N06DA03	0	LRIVA	Rivast fAG2mg/ml;120ml/bt		צܤתqgCPˤצܤ׷b()g	"Initial dose: 1.5 mg orally twice a day
; Maintenance dose: After a minimum of 2 weeks of treatment, if the initial dosage is well tolerated, it can be increased to 3 mg twice a day; subsequent increases to 4.5 mg and 6 mg twice a day should be attempted"	"1.ŦefBݡBʪͯffH ݭnpߨϥ C
2.ĥi|W[GĪcA]i|cƧDwo@AfHpߨϥ C
3.i|PYwζݺΡCYOݭn}ξާ@ɡAOݩwѪvv@C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Rivastigmine	N06D	ܷb ANTI-DEMENTIA DRUGS	0	צܤתqgCPˤצܤ׷b()g	fwpGwRivastigmineγB褤LΨLCarbamatelͪӷPʡ]hypersensitivity^AhTϥRivastigmineCYx\ڸss|إߡAGiϥΥ~Ӥ@ڸsfHC	YwBߡBæRBmBC	"קKϥΰDvn

"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M06-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	LRIVA-a	LRIVA-b	LRIVA-c	110.6.16
BC252343FA	N06DA03	0	ERIVA	Exelon patch 9mg/patch;4.6mg/24hr		vפΤפqfèb]^gCPˤgצܤ׷b]^gCExelon patchwצܤתqfèb()g	"Initial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4 weeks and good tolerability, increase to 9.5 mg/24 hr patch once daily"	 gi|vyrpξާ@Ol`Cϥrivastigminevgw̮ɡAvvww̾rpξާ@OC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Rivastigmine	N06D	ܷb ANTI-DEMENTIA DRUGS	0	vפΤפqfèb]^gCPˤgצܤ׷b]^gCExelon patchwצܤתqfèb()g	"Hypersensitivity to rivastigmine or any component of the formulation

"	"Anorexia, dyspepsia, nausea, vomiting, asthenia, dizziness, weight loss, diarrhea"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	ERIVA-a	ERIVA-b	ERIVA-c	110.6.16
AC42556100	N06DA02	0	OARIC	Aricept 5mg/tab(Donepezil HC1)		ثe{qg{\êf]A@OʥFxʯgǾɪҭPCDonepezil hydrochloride ifʧAQx୞Jѧ@ΡAW[AQx@סA]ӥ[jxʯg\A{ɪvĪGCpG@ξTAfp[YɡAѩ󥿱`\धxʯg֡AdonepezilĪGi|CC|LҾdonepezil|ܥgfoiL{C	ĳϥηRЪYCѤ@@5@JA@ӤAվܷRЪYCѤ@@10C	"1. Adverse events most often occur during dose initiation or escalation; frequency of adverse events may be affecte by the rate of dosage titration

2. Adverse events occur more commonly in patients who are 85 years of age or older, female, or of low body weight"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Donepezil	N06D	ܷb ANTI-DEMENTIA DRUGS	0	סФתqfèb]^g	Donepezil Piperidine lͪLӤfwTΡC	̱`}mBߡBæRBvB٦׵jˡB«έhC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	OARIC-a	OARIC-b	OARIC-c	110.6.16
AC46989100	N06DA02	0	OARIC1	Aricept 10mg/tab(Donepezil HCl)		ثe{qg{\êf]A@OʥFxʯgǾɪҭPCDonepezil hydrochloride ifʧAQx୞Jѧ@ΡAW[AQx@סA]ӥ[jxʯg\A{ɪvĪGCpG@ξTAfp[YɡAѩ󥿱`\धxʯg֡AdonepezilĪGi|CC|LҾdonepezil|ܥgfoiL{C	ĳϥηRЪYCѤ@@5@JA@ӤAվܷRЪYCѤ@@10C	"1. Adverse events most often occur during dose initiation or escalation; frequency of adverse events may be affecte by the rate of dosage titration

2. Adverse events occur more commonly in patients who are 85 years of age or older, female, or of low body weight"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Donepezil	N06D	ܷb ANTI-DEMENTIA DRUGS	0	סФתqfèb]^g	Donepezil Piperidine lͪLӤfwTΡC	̱`}mBߡBæRBvB٦׵jˡB«έhC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	OARIC1-a	OARIC1-b	OARIC1-c	110.6.16
BC24274100		0	OREM16	Reminyl PR 16mg/cap(Galantamine)		"v?qg?ܤ?YèbC
"	̪쬰8@J/ѡA4gC qGCѦܤ16@J/ѡAܤ4gA̰iW[24@J/ѡC	|αΡAqקK}ξާ@MI	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Galantamine Hydrobromide 	N06D	ܷb ANTI-DEMENTIA DRUGS	0	v?qg?ܤ?YèbC	pfvA{ɶE_uީʥgvAΦYŦǾɪ_]heart block^fwAĳϥΡC	ߡAæRAmAhAƤ}AAhҡAYwAYhAݺΡA魫A믫áA^ˡAˡAvA󪢡C	"קKϥΰDvn

"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w33-06 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	OREM16-a	OREM16-d	OREM16-c	110.6.16
BC260293C8	N06DA03	0	ERIVA2	Exelon Patch 18mg/10cm2/9.5mg/Patch		"qfgfzܤƥDnP۫e򩳮֦ܤjֽϻPjxPg|CoǸ|wP`NOBǲ߰OФΨL{L{CRivastigmineT@ξऴAǥѫPixP\ӲġAǥѥifʦaxP?ѧ@ΦӼW[AQxP@סCY]OTAhrivastigmine@Υibּƥ`\xPgsbpUAwf{oiC|LҾrivastigmineiܼbgf{C  
 
"	1. Exelon PatchCѤ@AKMBBLvB㰷dֽWAK߶Kaܤ|]ۦӿiKCĳ߶K쬰WIΤUIA]fHiಾoǳ쪺KAYLkKbIɡAiKWuίݳCKKoBEγζ˪ֽC 2. MKisKۦPѭǳ]ҦpWIPI^AĳCܴP߶KAHקKֽͨEʡCۦPI14ѤyHKC 3. KTVUtKCK~λżѮ𵥱pUi~ϥΡC 4. C24p󴫷sKC 	gi|vyrpξާ@Ol`Cϥrivastigminevgw̮ɡAvvww̾rpξާ@OC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. WLExelon Patch~ΫO@UWХܪĴAФŨϥΡC
2. Ƿ25JHUxsC"	 rivastigmine	N06D	ܷb ANTI-DEMENTIA DRUGS		צܤתqfèb]^gC	fwpGwRivastigmineALcarbamatelͪAΥ~B褤L( ī~Sʡ)Lӡ]hypersensitivity^AhTϥΡC 	ߡBæRBmB/h魫C	"hB/bįqjL઺M`
pUiϥExelon PatchC"	"DnקKϥ/Smܦw
ҶqĪ˪nʡAMwO_
ũΰĪC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-01 j	Ts111.5.4	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	ERIVA2-a	ERIVA2-b	ERIVA2-c	111.5.4
AC55958221	N06DX02	0	IGINK	Enbosun inj 0.84mg/ml;5ml/amp(Ginkgo)		`êvAXiADvwt/ջ///}fgǾɻê/_浥`ê	"2-5mlA11-2C`٦ת`gBwCRߩIw`gIwG@25~50ml[J500ml`GAIw2~3pɡC
iΥͲzQClqDextran}GCФŲVXLĪ"	"1.ФŲVXLĪ@P`gAiΥͲzQBClq DextraneDHAES(Poly{o-2-hydroxyethyl}-Starke)@}GC
2.UCw̸TΥ:G}BT୯ʥF@ʪ̡BҾJr̡B[g̡BFructose-6diphosphatase ʥF̡C
3.GAPίSOLӯg:`ո` (CBYwBYk)ΥֽAY즸Rߪ`gB`ɡAio͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	GINKGO BILOBA EXTRACT	N06D	ܷb ANTI-DEMENTIA DRUGS	0	`êvAXiADvwt/ջ///}fgǾɻê/_浥`ê	UCw̸TΥ:G}BT୯ʥF@ʪ̡BҾJr̡B[g̡BFructose-6diphosphatase ʥF̡C	X孷IW[	"קKϥΰDvn

"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-10 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	IGINK-a	IGINK-b	IGINK-c	110.6.16
BC24220100	N06DX01	Хν10@J	OEBIX	Ebixa 10mg/tab (Memantine)		hҾܡGiĩʯgǾ(glutamatergic neurotransmi-ssion)xêAרbNMDALרEɡA|PghƩʥgg{ίefiiCMemantine@qձB׿˩MOBDvʤNMDAܾAi_]i(glutamate) jפɰ@γygêC	"Ĥ@g@Ѥ@5mgAvBվ㾯qC
1. Yվ㬰@10mgAh@ѤGU5mg C
2. Yվ㬰@15mgAhW10mgBߤW5mgC
3. ̤jqC20mgC"	LYǥ\lfHϥθơ]ٻMv9 ml/min/1.73 m2^A]ĳϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Memantine	N06D	ܷb ANTI-DEMENTIA DRUGS	0	vפέפqgC	Hypersensitivity to memantine or any component of the formulation	ıBxbBwtBYhBh¡C	iw/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669059?cesid=7lW4UGVU1dn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMemantine%26t%3Dname%26acs%3Dfalse%26acq%3DMemantine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	OEBIX-a	OEBIX-b	OEBIX-c	110.6.16
AC39863100	N06DX02	0	OGINC	Gincare 40mg/tab(Ginkgo Biloba)		ê	(1) HGC3AC40 mgC(2) ൣGwʤΦĩʩ|TߡC	ĻPAspirin Warfarin ܾ徯֥ήɥi|W[X媺MIʡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Ginkgo biloba extract	N06D	ܷb ANTI-DEMENTIA DRUGS	0	ê	糧Ĳ͹LӤw̸TΥ	ߡBæRBmBYhBwtC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-07 [s]_145 [®]_145 [E]_A2-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	OGINC-a	OGINC-b	OGINC-c	110.6.16
NC01976209	N07AA01	0	INEOS	Neostigmine inj.0.5mg/ml/amp		z޳·BLOgB޵j˩ʯewBLOg 	Initial parenteral doses are 0.5 to 2 mg 	GzDΧB̸TΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Neostigmine	N07A	ƥPgĪ PARASYMPATHOMIMETICS		z޳·BLOgB޵j˩ʯewBLOg 	"Hypersensitivity to neostigmine methylsulfate, intestinal or urinary tract obstruction, mechanical, peritonitis "	"Bradycardia, psychosis, restlessness, agitation, anxiety, porphyria, constipation, abdominal distention, fecal impaction, and, when given intrathecally, nausea, vomiting "	קKϥ	CšGʪܹL঳`ʥF}nFίʥFʪΥƾڡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-23 [E]_G3-04 j	Ts110.11.16		0	0	OIs 20251124	INEOS-a	INEOS-b	INEOS-c	110.11.16
AC57883100	N07AX03	0	OEVOX	Evoxac 30mg/cap(Cevimeline HC1)		CevimelineO@ػP muscarinic receptorsX cholinergic agonistCq muscarinic agonistiW[GPc骺cAåiW[zGDPDƦ٪iסC	ĳqC30mgA@ѪAΤTC	cevimeline i޵oızZӼvTrpɪwʡAרb]C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Cevimeline HCL	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	vsjogren's syndrome Ҥް_fgC	CevimelineiϥΩݱ}ΤwcevimelineLӪfHAӥByΦboզYfwAҦpAoͫʭiPUCw̤yϥΡC	jqXBߡB󪢡BmBGLhBWBLOByoBhgC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-05 [s]_111 [®]_111 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.5.2._20130201_000.pdf"">OI` 1.5.2.</a>              "	0	0	OIs 20251124	OEVOX-a	OEVOX-b	OEVOX-c	110.6.16
AC48908100	N07AA02	0	OPYRI	" (Pyridostigimine) 60mg ANTILON ""Y.C."" "		~ifʪxP୧C	"1-3 tablets 2-4 times daily
C24AC13C"	fHwݩεj˩ʮުɡAϥΥ~nSOԷVC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Pyridostigmine	N07A	ƥPgĪ PARASYMPATHOMIMETICS		gٵLO(Myasthenia gravis)	"Hypersensitivity to pyridostigmine or any component of the formulation, GI or GU obstruction"	ߡBæRBmBYC	קKϥΰDvn/SmҦw		аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w44-02 j	Ts44496		0	0	OIs 20251124	OPYRI-a	OPYRI-b	OPYRI-c	44496
BC23548100		0	OSALAG	*Salagen 5mg/tab		~xPƥPgsA{XsxĲz@ΡASOOmuscarinic@ΡCAqpilocarpineW[~ccCB踢B\BGBzΩIlDHӭMQECϥγ澯q󲴳ɷ|yYpBjˤβͼȮɩʲWɱۦʪCCzDƦ٪EOPqh観AiyiפάʤOW[Bj˩M̫᭫C ޥƦ٪i׷|W[CDBxnBxޥƦ٪iפάʤO|W[CPilocarpineߦިtΪvT|TCMuscarinic agonist@OXiAApilocarpine|bͰeo͵uȪCCϥpilocarpinei|߸wCΤ߸[֡ALiC	"Radiation-induced xerostomia5 to 10 mg TID.
Sj&ouml;gren's syndrome - Xerostomia5 mg QID.

1.YVfwGSalagen tabletsĳ_lq5mgA@ѤTCqi̪vΧԨװվC@뾯qC3~615~30mg (CqiWL2)CMAΪYiBAbvWA12P󦳯q `Ƨ@εoͲv|H۾qWӼWjCHԨΦĪ̧CqqC 
2.Sjogren's SyndromefwGSalagen tabletsĳq@@5mgA@ѥ|C ܦh6PYiإߩTĪGC"	"1.ޮݯfw̨ϥΩypߡASOOʨϥήɡA]~|yަY@ΡC 
2.UifHYoByCBjMߪgߨniA]oOʤro@xC 
3.~nץA]ܤíwC 
4.űNw޻P¥ĲAHKoͦìVΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Pilocarpine	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	"1.]YVguvy踢\CӤް_fgC
2.Sjogrens syndrome Ҥް_fgC"	靈ݡBpilocarpineLӡBfܩʪY(pʭiMʫC)w̡A~TҡC	ٵjˡAYhAHOAtBOCAE@ΡAGcAW[C	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w06-07 [s]_287 [®]_287 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.5.1._20130201_000.pdf"">OI` 1.5.1.</a>              "	0	0	OIs 20251124	OSALAG-a	OSALAG-b	OSALAG-c	110.6.16
AC442541G0	N07AB02	0	OWECO	Bethanchol 25mg/tab		Dn@άOϰƥPgtοġCiW[H֯}٪iOA]ӳq`iͨHPϱƧMHֱƪŪ}lCBethanecholiEGʤOAW[GiOA]ӥi_wl`ߩįʡC	"Initial X 5 to 10 mg repeated hourly until satisfactory response; MAX 50 mg; usual dose range X10 to 50 mg 3 or 4 times daily
1. Hq10~30mgA@3~4C}li5~10mgAHCpɭеPAΨ30mgoNĪGCĩA30~60YiX{ĪGA@Υi~1pɡC
2. ĵCѨC0.6mgAAΡC"	AΥPg`_ĪfH`NAHKް_L׭CAq`L׭CoͫeA`gAxdw̡ApXٵLkPɡAiKQ^y駿ޤεǪAɦp߯gsbɡAiް_gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Bethanechol	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	NBᤧDʧxdAgʻHֺiOCΧxd	ťΩҪ\LgBhBGšBޭݡB߷i}wBCF߫aʯ߯efBwBˤgBGzΪcDʪfҡC	ߡBmBABYhBC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668520?cesid=4OLqJPnJWNE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBethanechol%26t%3Dname%26acs%3Dfalse%26acq%3DBethanechol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OWECO-A	OWECO-D	OWECO-c	110.6.16
AC059251G0	N07CA01	0	OMERI	Merislon 6mg/tab(Betahistine)		gԸsҤް_twBťOê	"(1)HGC3AC6-12 mgAΨC2AC24 mgC
(2)ൣGwʤΦĩʩ|TߡC"	ĤiPܲ´iĪ֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Betahistine	N07C	ܯtw ANTIVERTIGO PREPARATIONS	0	gԸsҤް_twBťOê	Hypersensitivity to betahistine any component of the formulation; peptic ulcer disase; pheochromocytoma	ߡBæRBolC	hPɤwʩ|TwA]bhΦihkϥζP_vWqʤjMIʤ~iϥΡC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w20-01 [s]_220 [®]_220 [UDx]_U02-13 [E]_B1-23 j	Ts110.6.16		0	0	OIs 20251124	OMERI-a	OMERI-B	OMERI-c	110.6.16
AC47232100	N07CA01	0	ONILA	Nilasen 24mg/tab		"1.êGiwզިtӺޫeA١Aվ޹BʡAW[զyq50%HWAiW[Vʯߦy50%HWAPƫeAΪܲ´iLܧ@ΡC 
2.Oڤ~GӺ޾zLʡAPiӭM~GflAϤOڤ~C"	"24mg PO BID

CѨ⦸AC@"	ݡBݻ̲ӭMFBůfvw̻ݤpߨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Betahistine	N07C	ܯtw ANTIVERTIGO PREPARATIONS	0	gԸsҤް_wtBťOêCexʷwtgv	糧ĦLӪ̸T	LGAB֯lBC¯l	קKϥ/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w20-02 [UDx]_U02-19 [E]_B1-25 j	Ts110.6.16		0	0	OIs 20251124	ONILA-a	ONILA-b	ONILA-c	110.6.16
AC282831G0	N07CA03	0	OSIBI	Sufuni 5mg/cap (Flunarizine)		@ܩʪtl_AਾӭMtlLtAvTŦΦޥƦٲӭM`tlqC	5 to 10 mg once daily	"]1^voͯh¥BvY{HAġC
]2^ϥΪ̻ݩwAvYoĭCB{gBˤgB@~|ΨLLkĪ}ɡAݰġC
]3^PsBRBwvĨ֥ήɷ|͹LR@ΡC
]4^ѩi|Ͷݺβ{H]SOO}lvɡ^AҥHrξާ@MISOpߡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Flunarizine	N07C	ܯtw ANTIVERTIGO PREPARATIONS	0	ߡBtwBgêBwʯfB޴`ê	{vw̡AΥثeˤggw̡AΨL@~|`w̡C	ݺΩίh¡B魫W[BW[Avɻݪ`N@~|g(pBʧxBRB_Ÿ)BˤgB~{C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I4 [2]_I4 [ws]_w33-01 [s]_290 [®]_290 [UDx]_U03-07 [E]_B3-18 [Ew]_EX037 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	OSIBI-a	OSIBI-b	OSIBI-c	110.6.16
	B05BA01	0	ICERE1	CEREBROLYSIN 2152MG/10ML/AMP tQM`gG		"iķGADnѴӷHXJսC 
Cerebrolysin(tQM)giAUO@jέ״_gAQϥΩCʤϨtίefAH_AﵽBʥ\APıBʺAﵽ{\D
"	"vC2tQM٦שRߪ`gAMvj[ܨΤTѡCgC@vL{10~15wAghݭni[ܼƭӪvL{Cqϥ510wˡGC5-40wCRߪ`gIw`gCھگfpC@vL{ 1015wApݭnisƭӪvL{C 

IV infusion 10ml-50ml 
diluted to at least 100ml total volume with Saline, Ringer solution or 5% glucose solution,Infuse within 15 minutes
G󤤭3pɤAr-tpAw̪vʯʦʤAr-tpav1pɫᵹAq20-50ml/dayA{1P~30(ƨӷ:t)
ж˩ʸlˡGVֵĶVnAq20-50ml/dayA{1P~30(ƨӷ:t)
ީʥ:VֵĶVnAq10-30ml/dayA{1P5(1 cycle)/AC~2-4cycle(ƨӷ:t)
"	ī~}ǷťiOs 24 pɡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(25JHU)xsC 	Amino acids	N07X	䥦gtΥ OTHER NERVOUS SYSTEM DRUGS	0	Aw̤ɧUvAJս褧ƧlΦXQλêAYжˡBˡBɳJս褧ɵAJսiկgC 	Yǥ\ण̡C 	`gtפӧ֮ɡA|L`PA֦cHŤWɤLӤC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-11 [w]_w01-20 j	Ts111.8.19		0	0	OIs 20251124	ICERE1-a	ICERE1-b	ICERE1-c	111.8.19
NC01811100	P01AB01	0	OFLAG	"Metrozole S.C. tablets 250mg""JOHNSON""(me"		Ĭ@ر߾AiΩMʹ߷PVvA@άOgѹʲӵߥN©ҿWӨϥĦbӭMiƾǩ٭CQ٭ᤧĨ㦳ӭMrAiPDNAۤ@ΡAɭP۵cॢBѪ_A䵲GDֻĤXAӨϲӭM`C	"Adult : Anaerobic infection500 mg Q6H-Q8H; MAX 4 g/day. Amebiasis500-750 mg Q8H.
Trichomoniasis250 mg Q8H or 500 mg BID for 7 days or 2 g as a single dos.
Pediatric : Amebiasis35-50 mg/kg/day Q8H, MAX 750 mg/dose.
@릨Hq: 
ܵ߾(tΩ)X 
߷PV : fAAC魫7.5mgA@̰F1gACpɤ@A7ѡC
ժ۱߬QGz(vU) : fAA500mgA@ѤTAPBismuth SubsalicylateΨ䥦fAܥͯpAmpicillinAmoxicillin֪AAɤ@ܤGgC 
ܭξ X 
̤گf : fAA500-700mgA@ѤTA5-7ѡC
wίf : fAA2gAH澯qPA1gA@ѤGAɤ@;250mgA@ѤTA 7ѡC
Xξ(tΩ)X 
sίf(Dracunculiasis) : fAA250mgA@ѤTA10ѡC
@릨HB譭q : ܵ(tΩ) : Cѳ̰iWL4gC @ĵq:
ܵ߾(tΩ)G
߷PV : fAAC魫7.5mgACpɤ@AΨC魫10mgAC8pIC 
ܭξG
̤گf : fAAC魫11.6-16.7mgA@ѤTA10ѡC 
wίf : fAAC魫5mgA@ѤTA7ѡC 
Xξ(tΩ) G 
sίf(Dracunculiasis) : fAAC魫8.3mgA@̰F250mgA@ѤTA 10ѡC"	Yxfw̱»PɽЯSO`N	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Metronidazole	P01A	ܪ̤ڤΨLίefs AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	0	vDwηPVҤް_DBձaB̤ڵgeB̤ڨxw~ιMetronidazole㦳PʤߩҤް_YPVC	"1. MetronidazoleΨLNitroimidazolelͪLӪ̡C 2. wGefw̡C]i|զy֤gX{^ 
3. wBefw̡C]|{Xϯgtg^ 
4. hTӤ뤧kC"	ߡBæRBmBYwBr֪ݨBWBֽlC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w05-01 [s]_209 [®]_209 [E]_A3-08 j	Ts110.6.16		0	0	OIs 20251124	OFLAG-e	OFLAG-b	OFLAG-c	110.6.16
AC42899100	P01BA02	0	OPLAQ	Geniquin 200mg/tab(Hydroxychloroquine)		|FѡAMOPįeΪDNAlͽƦXAӧRNAƻsAצӧֻĪXA~Yǭlͪ]㦳ܪ̤ڧ@ΡAHΧܵoMܲ´iʡC	"Chemoprohylaxis of malaria400 mg/wks on the same day each week ; begin 2 wks before expousure; continue for 4 wks after leaving endemic area. If suppressive therapy is not begun prior to the exposure, double the initial dose and give in 2 dose, 6 hours apart and continue for 8 wks. Acute attack of malaria Initially, 800 mg, then 400 mg at 6, 24, and 48 hours. Rheumatoid arthritis :InitiallyX 400-600 mg QD for 4-12 wks; maintenanceX 200-400 mg QD. Systemic lupus erythematosus : Initially 400 mg QD-BID until remission; maintenance 200-400 mg QD.
ĥHfAġACAĮP\IΤ֥ΡC
įe~LAgG
~]]AѦ~H^
ĪḩCľqA ӥBHWL6.5mg/kg/dayh]̨zQ魫pAӫD魫^AC龯q200mg400mgCCAξq400mgfwGv_lqC400mgäAMӡAvĪGYi@B㪺ﵽAhqi200mgCYqC200mgAvzAhqӦAW[ܨC400mgC
ൣ
qľqAӥB̨zQ魫pAHWL6.5mg/kg/dayhA]AൣzQ魫p31kg̡AAXA200mgAAĮPΤ֪AC
įeG
įeGHGCPP@ѪA400@JCMpġGCPBC魫q6.5mgA̰iWLHqC"	ĥHfAġACAĮP\IΤ֥;AīeˬdAåBܤ֨Cj12Ӥ뭫Ф@C;Hydoxychloroquinevw̭nSO`NC}IM{ɯgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Hydroxychloroquinin	P01B	ܺįe ANTIMALARIALS	0	LΥʬʯTHBCʦhΤlBCʭ`B쪬ĭΩMĭΤް_įe	"lAܡAhAΩvpĪefAηĪvefC
QuinineӷPHGlucose-6-phosphated ehydrogenaseʥFfHT"	mBOҽkBYhBֽkoBtBzGAC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
BC27134100	P02CF01	0	OSTROM	Stromectol (ܬνH)3mg/tab(Ivermectin)		IvermectinqLEĲeg骺ʯgA^-Bġ]GABA^Auαqg쿳ĩʹBʯgTǻC	"榸fAqC魫ivermectin 200LJC

ĬO׷ʤƦXABתն|ɰĪ夤@סC]ASTROMECTOLŸAΡC
νH- 榸fAqC魫ivermectin 200LJC b즸ī815ѤAwYΦPVApX{sTνHf_αHξˬdʤAiҼ{뤩ĤGӾqC]kogΧ˲sbӧ뤩ĤGӾqCĤGӾq笰Civermectin 200LJC"	"1.pG糧~oͥLӤAYiAġC
2.STROMECTOLŸAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Ivermectin	P02C	ܽuλs ANTINEMATODAL AGENTS	0	νHC	糧~󦨤L	YhA`hC	קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C5 [2]_C5 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.16._20240401.pdf"">OI` 13.16.</a>              "	0	0	OIs 20251124	OSTROM-a	OSTROM-b	02C27134-2	110.6.16
		0	EBBE	B.B.Lotion 100ml/~		~fAcarus Scabei	"1.ΩvηPVAХNDñNֽAAqĲG٩(qV})A24pɫAHŤΪΨmM~bC
2.ΩvYAХNYv~bAAqĲG˦bYvMY֤WARb|A12-24pɫH@몺~vΪΨmMŤR~bAYvAAHӾv޹갣vWZνhC"	"ɥiणnϥΩൣਭWAYowϥήɡApHUNī~HҪN}AhH1:2N}T@@סAHCEʡC
ĤĳϥΩ󥥰C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Benzyl benzoat	P03A	"~ξ ECTOPARASITICIDES, INCL. SCABICIDES"	0	~BPVC	糧~󦨤L	1. ֽi|LE2. νHfHbvAkogi|F2 gA`{HAëDvѡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_N03-01 [E]_I2-05 j	Ts110.6.16		0	0	OIs 20251124	EBBE-a	EBBE-b	EBBE-c	110.6.16
		0	EDYMI1	Dymista Q137/50gg/dose; 120dose/~		"DymistaGDymistatazelastine hydrochlorideMfluticasone propionate ئA]AHUUӦ@
ξAAΩDymistaCoī~NؤPĪOA´iH1ܾ(histamine
H1-receptor antagonist^MXֽTJ(synthetic corticosteroid^C"	CզUQ 1 UACѨϥΤG(WMߤW)C	"AקKbϥDymistaAqƻݭnױM`M}nBʨժMIu@AҦpާ@ξrpʨCקKPɨϥ Dymista PsΨ
LϯgtΧA]i|i@BCĵıʩMl`ϯgtΪ\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Azelastine/Fluticasone 	R01A	hRs DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	0	 AΩv6HWൣΦHצܭ׹Lөʻ󪢪gC	DΥĤ󦨤LӤfwTΡC	AyBļšB󤤹jաBˤf¡XlMզ]߷PV	"DymistaWᦳϥθܡAo{PDymistay(miscarriage)Bѩʯʳ
]birth defects^ΨL`έLधIAثe٨Sazelastine hydrochloridefluticasone propionateO_|cŰkťĹBιťĥͦvTƾڸơC"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EDYMI-1.a	EDYMI-1.b	0	110.6.16
BC248774FK	R01AD12	0	EAVAM	Avamys nasal spray 27.5mcg/dose		Fluticasone furoateXTtƥֽTJAjOܵo\ġCFluticasone furoateLӯgTCֽTJwhػPoӭM(pӭMBݻĩʥզyBʥզyBӭMBOڲy)Τ(´iBGQġBդTmBӭME)㦳sxĪGC餺~ܡAfluticasone furoateଡƿ}ֽBeo]lpNFkBBHΦbLӤƪjܭ޵oͳݻĩʥզyWhC	"1. Ĥ@ϥΦ(Avamys)QeAnáA׶}yŴիCY(Avamys)QWL30ѥϥΩάO5 HW[\Ahի짡QXCCϥΦ(Avamys)QenáC 
2. H12HWC֦~Gĳ_lq110LJ(mcg)@Ѥ@AզUϥΨӼQq(CӼQq27.5LJ)C 3. 211ൣGĳ_lq55LJ@Ѥ@AզUϥΤ@ӼQq(CӼQq27.5LJ)CYw̹55LJ@Ѥ@X{ĪAi110LJ@Ѥ@(զUӼQq)CgoAAiNq55LJ@Ѥ@C"	ϥΫeХn	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Fluticasone	R01A	hRs DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	0	v2HWൣBC֦~PHLөʻ	DΥĤ󦨤LӤfwTΡC	XBšBզ]߷PVBˤf¡XBդ٤ΫC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-05 [E]_I3-04 j	Ts110.6.16		0	0	OIs 20251124	EAVAM-a	EAVAM-b	EAVAM-c	110.6.16
AA579194E5	R01AD11	0	ETRIS	TrisoninQ55gg/dose;120dose/~(Tria		Hu`ʤθg~ʹLөʻ	"1.H12HWൣGĳ_lq220 mcgAYC@AC@ĦUQUA@gɡAiϥ110 mcgq(YC@AC@ĦUQ@U)C 
2.612ൣGĳq110 mcgAYC@AC@ĦUQ@UAgYfwiϥ220 mcgAg@ɡAhϥγ̧CľqqC 
3.DƧRA_h12HUൣĳsϥ3ӤHWCثe|LϥΥ~6HUൣ{ɸgAG~ĳϥΩ6HUൣC"	ϥΫeзn	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Triamcinolone acetonide	R01A	hRs DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	0	Hu`ʤθg~ʹLөʻ	DΥĤ󦨤LӤfwTΡC	0	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-06 [E]_I3-05 j	Ts110.6.16		0	0	OIs 20251124	ETRIS-a	ETRIS-b	ETRIS-c	110.6.16
A035546429	R01AA05	0	ESWIN	Sindecon nasal spray0.5mg/ml; 10ml/~		Oxymetazoline hydrochloride@إPgľަYA㦳jOަY@ΡAH~λRw̯ϸ~ȤΥRKYAӥBĮĨtB[C	H6HWൣCѼQ1-3ACզUQ@UC	"1.QФŻPLH@ΡAHKyPVC
2.ϥΤTѫgY̵MsbAhбvC
3.ŦfAAҪefA}f@~jfHgvܨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Oxymetazoline 0.5mg/ml	R01A	hRs DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	0	ʻ󪢡BLөʻ󪢡B޵Yʻ󪢡BuB|C	糧@LӪ̸TΡC	iX{`BQBy	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O01-04 [E]_I3-07 j	Ts110.6.16		0	0	OIs 20251124	ESWIN1-a	ESWIN-b	ESWIN-c	110.6.16
AC269841G0	R01BA52	0	OACTI	Peace 2mg/tab(Actifed)		"PseudoephedrinePgľAY@ΥiϻġBH~ȮA֥RM~{HC

Triprolidineĩʧܲ´iA@ΫɶiF12pɡCݨƥPgB_@ΦӴ󷸡ALөʻ󪢡BuiwѹLӲ{HC"	"Adult and Pediatric (>12 yrs)X 1 tab TID-QID.
Pediatric: 3-5 yrsX 0.25 tab TID-QID 6-12 yrsX 0.5 tab TID-QID"	"1.קKbΫe2pɥHAΡC
2.ŻPOTCĪ֥ΡA]ܦhtEphedrineΨLPg@ΩΨLܲ´iĪA|jƥ~@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Pseudoephedrine/Triprolide	R01B	ʥhRs NASAL DECONGESTANTS FOR SYSTEMIC USE	0	wѹLөʻ󪢡B\Ҥް_g(ByBQBγﳡko)	YAaʯ߯efAϥMAOb14ѥHA¨ŤˡACAҪमiAeCΤjC	iް_«PBfAıWxZAĤ(HΦѦ~H`)C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w46-03 []_01-30 [UDx]_U03-44 [E]_B5-04 [Ew]_EX053 j	Ts110.6.16		0	0	OIs 20251124	OACTI-a	OACTI-b	OACTI-c	110.6.16
AC57121100		0	OCLAR	Lorapseudo S.RƤ 5/120mg/tab		Loratadine@رjOBĪTܲ´i㦳g´H1ܩʪܧ@ΡCPseudoephedrine sulfate@ؤѵM¶PAfA㦳ަY@ΡAWIlDRHPiYӦvB򪺸ѥR@ΡA]Pg@ΦӨϩIlDWH͸ѥR大GC	HΤQGHWpĤ@@ACѨC	pߨϥΩCAժQGzAeCΤjλHVBŦޯefAWο}ffHC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Loratadine/Pseudoephedrine sulfate	R01B	ʥhRs NASAL DECONGESTANTS FOR SYSTEMIC USE	0	wѹLөʻ󪢤ηP_gApBQByBkoάy\	Pseudoephedrine/ LoratadineεǤWĪεcĪ|yLӤ̡AҤAXPCPɪAΩΦbQѤAΩΰMAO inhibitorfHΦUʫCBdAװA׫aʯ߯efΥҪमifHAĦP˦tTҡC	vBfC	iw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D2 [2]_D2 [ws]_w36-03 [UDx]_U03-15 [E]_B4-09 [Ew]_EX042 j	Ts110.6.16		0	0	OIs 20251124	OCLAR-A	OCLAR-B	OCLAR-c	110.6.16
BC26315143	R03AL03	0	EANOR	Anoro Ellipta inh. 30dose/~ 55+22gg/		"ANORO ELLIPTA t umeclidinium P vilanterol ئC
Umeclidinium O@تīܬrPĪAq`S٬xPĪCrPȫ M1  M5 ˩MOjPۦPC~bDĲz@Ϊ覡zLƦ٤W M3 AqӾɭPXiC
Vilanterol O@ LABAC~ܡAvilanterol \ܩʻP salmeterol C"	"1. HCѧlJ @覡ġABȥigflJC 
2. CѩۦPɶġCC24pɤiϥζWL 1C
3. Ѧ~w̡Bǥ\lw̩Τרx\lw̡Aվ㾯qC"	ANORO ELLIPTA ϥWviWLĳϥWvAϥξqiĳqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. ĲXA~̤[is 6 gC 
2. ŦsWL 30XC ҡC"	Umeclidinium and Vilanterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	Cʪʪͯf(COPD)w̤Dgv	TΩYųJչLӰDw̡AΤwҹumeclidiniumBvilanterol ΥξLӪw̡C	|BuBUIlDPVBKBmC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-03j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EANOR-a	EANOR-b	EANOR-c	110.6.16
BC26735443	R03AL06	0	ESPIO	Spiolto RespimatƤlJ		SPIOLTO RESPIMATttiotropium(@تīrPܾ)ܤަYMolodaterol(@تī b2-ǤWPľ)PiXiAĮĥi24pɡA (LAMA/LABA)TwqƦXlJʷGAHSPIOLTORESPIMAT soft mistlJġC	inhalation:: 2 puff once daily .Maximum: 2 puff/day.	"1.: ~iΩݱw̡C
2.i@Ϩϥ:AΩʤ޵j˪v]Yϴk^C
3.ϱ`ʤ޵jˡ]Paradoxical bronchospasm^:Yoͤϱ`ʤ޵jˡAߧYΥ~AӥHLkNC
4.UʫCB@ΤjλHV:ѩtiotropium㦳 xPʡAUʫCB@ΤjλHV몺fwpߨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	"2.5ugOlodaterol and 2.5ugTiotropium
(ξ:benzalkonium chloride 0.0011mg)"	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	Cʪʪͯe(]ACʤުΪͮ~)v	"1.atropineΨlͪ(pipratropium)L
2.iΩݱw
3.AΩʤ޵j˪v
4.iPtLtģ]2-adrenergic agonistĪ֥"	"1. xPĪ(Tiotropium)}pGf(oͲv1.7%)BCBKBz(]A·ʸz)PdC
2. &szlig;-ǤWĪ(Olodaterol)}pG߱B߷iLtPC"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-10j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ESPIO-a	ESPIO-b	02C26735-2	110.6.16
BC27395443	R03AL08	ͼֳߩQF	ETREL	Trelegy Ellipta inh. 30dose/~		"TRELEGY ELLIPTAtfluticasone furoateBumeclidiniumPvilanterolTئCHUӧO@ξAΩTRELEGY ELLIPTACo3ĪDOPOĪ(@ICSB@اxPEĪΤ@LABA)A{ɫлPͲzЪvTUۦPC
Fluticasone Furoate
Fluticasone furoateO@ئXTtƥֽTJA㦳ܵo@ΡC
Umeclidinium
UmeclidiniumO@تīrPܾAq`S٬xPEĪCrPȫM1M5˩MOjPۦPC~bDĲz@Ϊ覡OƦ٤WM3AqӾɭPXiC
Vilanterol
VilanterolO@LABAC~ܡAvilanterol\ܩʩMsalmeterolC"	"1. TRELEGY ELLIPTAHCѧlJ@覡ġABȥigflJC
2. lJAwΤfABi]UAoOFUCoͤf|]߯fIC
3. TRELEGY ELLIPTACѩۦPɶġC
4. C24pɤiϥTRELEGY ELLIPTAWL1C
5. Ѧ~w̡Bǥ\णw̩Τרx\णw̡Aվ㾯qC"	"1. TRELEGY ELLIPTAäAΩvݡC
2. TRELEGY ELLIPTAw̤i]]ӨϥΥt@اtLABA]psalmeterolBformoterol fumarateBarformoterol tartrateBindacaterol^ĪC
3. ĳw̦blJĪΤfABi]UAǥHUCoͤf|]߯fIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluticasone 92mcg+Umeclidinium55mcg+Vilanterol 22mcg	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	TRELEGY ELLIPTAO@اlJʪֽTJ/xPEĪ/ī]2ǤW@ξƤsAAΩwlJʥֽTJPģ]2@ξX֪vAΤwwϥΨاlJĤXiX֪vAӤΪCʪʪͯf(COPD)w̡AHvDCTRELEGY ELLIPTA]AΩ󭰧CcƯfvw̤COPDcơC	"TΩUCw̡G
1. YųJչLӰDC
2. wҹfluticasone furoateBumeclidiniumBvilanterolΥξLӡC"	IlDPVBͪBުBfĩ]߷PVB`hByPBuB|B󪢡BKBDPVPoxC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6544211?cesid=3l78rchhRaE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTrelegy%26t%3Dname%26acs%3Dfalse%26acq%3DTrelegy#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M01-13j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ETREL.a	ETREL.b	02C27395-2	110.6.16
BC27672457	R03AL09	0	ETRIM	Trimbow 120dose/~100/6/12.5gg / dose		Ω󭫫ץHWIy(FEV1֩wȤ50%)ΦcƯfvCʪʪͯf(COPD)~fHAbwϥΧlJֽTJPbeta 2PľXkoRvɡA@vϥΡAHgέCдcƵo͡C	"H
ĳqCѨ⦸AClJ⾯C
̤jqCѨ⦸AClJ⾯CѦ~]65 HW^fHݽվ㾯qC"	ĳfHblJB辯qAH~fĩκf	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʡGOs2XC8XCC
}ʫGiOs25XCHU]̪is4Ӥ^C"	beclometasone and formoterol and glycopyrronium	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	Ω󭫫ץHWIy(FEV1֩wȤ50%)ΦcƯfvCʪʪͯf(COPD)~fHAbwϥΧlJֽTJPbeta 2PľXkoRvɡA@vϥΡAHgέCдcƵo͡C	令LӪ̡C	"i঳ͪ, }@פW,C[,xPg"	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-07 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ETRIM-a	02C27672-1	02C27672-2	110.6.16
BC23473129	R03AL01	0	EBERO	Berodual N metered aerosol _10ml/~		"Fenoterolܩʵuģ]2-agnoistAΩﵽ޵jˡBʩIlDefMwBʤް_޵jˡC
Ipratropium bromide |ŻϤƦXAxP(ƥPg_)@ΡAb{ɫeAgѫܰggXǻ衦AQxP@Φӧggҽո`ϮgCAQxPPޥƦ٤Wrʱ@ΡAӨϲӭM Ca++@׼W[AxPĪ{HCCa++X IP3 (TCĦپJ)P DAG (GQ̪o)cĤGǰTtΩҴCC
 lJipratropium bromide AͤXi@ΥDnʥB@ΩSwAӫD@"	"Adult & children > 6 years:
ʮݵo@
jhƯfwQ2 өwYiwѡC
ʩMv
CQ1 V 2 өwqAC̦hQ8 өwqC"	CϥΫeAȥR_nC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fenoterol and Ipratropium	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	UC޵j˯ewwMv:ޮݡBʤުBCʤުB~M޵jˤͤ޻ٮ`C	ĪULӪ̤oϥΡC	y¡BfB|YBfٻL_ŸB믫iBYhBwtB߸LtΤ߱C	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-05 [E]_I3-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EBERO-a	EBERO-b	EBERO-c	110.6.16
BC27524457	R03AL07	0	EBEVE	Bevespi Aerosphere 7.2/5.0mcg/puff		"GlycopyrroniumO@تħܬrPAq`S٬xPĪAzLƦ٤WM3AqӾɭPXiC
Formoterol fumarate dihydrateO@بt}l@ΪĿܩʣ]2ǤWʧ@ξ]]2@ξ^ClJformoterol fumarate dihydratebͤ@Xio@"	"2 puff BIDȨѤfħlJϥ

"	}lϥBEVESPI AEROSPHEREɡAPɫܤ@WߨϥΧlJʵuģ]2@ξ(ҦpC4)fHAWߨϥγoĪAåBȱNlJʵuģ]2@ξΩwѫʩIlDgCv}BEVESPI AEROSPHEREBɡA]PɳB@اlJʵuģ]2@ξAåBɯfHӦpϥΡClJʣ]2@ξϥμW[AOefcƪHAݭnߧYNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsb25XCHUC	glycopyrronium/formoterol fumarate dihydrate 7.2LJ/5.0LJ	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"		"BEVESPI AEROSPHERE?OglycopyrroniumMformoterol fumarate dihydrateզXī~AAΩCʪʪͯf(Chronic Obstructive Pulmonary Disease, COPD)fHy몺vCnϥέGBEVESPI AEROSPHEREAΩwѫʤ޵j˩Ϊv"	"ҦLABATΩLϥΪݱĪݯfH
BEVESPI AEROSPHEREAΩvݡC
BEVESPI AEROSPHERETΩglycopyrroniumBformoterol fumarate dihydrateΥ~󦨤LӪfH"	LӤB}gBίvêBEļBļwB_ŸBߡB߷iLtB߱B߫ߤ(ߩֺŸʡBǤWʤ߷iLtM~Y)C	"hĤC
ubwįqjL઺bMIɡA~iHbhϥBEVESPI AEROSPHERE"	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-04j	Ts110.11.3	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EBEVE-a	EBEVE-b	EBEVE-c	110.11.3
BC250921FL	R03AK08	0	EFOST	FOSTER 100/6mcg/dose 120dose/bot(Beclome		AΩݳWߨϥΧlJֽTJPbeta 2 PľX֪vݯfw	"Adult(>18 yr )G 1-2 puffs BID. MAX. 4 doses/day
H] 18 ΥHW^w̪qĳG@ 2 AClJ 1  2 CC龯qW 1  4 C"	lJBĪAХHMR~fĩκfBΪ̨AHCf|]߷PVIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Beclomethasone and formoterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	AΩݳWߨϥΧlJֽTJPbeta 2 PľX֪vݯfw	beclomethasone dipropionateBformoterol fumarate dihydrate Υ󥻫~ҧtξ͹LӤ̡C	|Bfĩ]߷PVBYhBox	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EFOST-a	EFOST-b	EFOST-c	110.6.16
BC26318143	R03AK10	0	ERELV	Relvar ELLIPAƤlJ 30DOSE/~		Fluticasone furoateO@ئXTtƥֽTJA㦳ܵo@ΡCVilanterolO@LABAC	RELVAR ELLIPTA 92 mcg/22 mcg (eq)HCѧlJ@覡ġABȥigflJC	lJAwΤf	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluticasone and Vilanterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	~AΩCʪʪͯf(COPD)w̤DgvC	RELVAR ELLIPTATΩYųJչLӰDw	|AuAWIlDPVC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-07j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ERELV-a	02C26318-1	02C26318-2	110.6.16
BC23481157	R03AK06	0	ESERE1	Seretide 250 Evohaler 25mcg/250mcg/~		"AΩifʩIlDef(ROAD)`WvA]AAXϥΤXiΥֽTJզXkൣPHCoi]AbϥΪĤA@ξ(]-agonist)ΧlJֽTJĺqw̡CblJֽTJkAӤgw̡CXi`WvAӻݭnlJֽTJw̡C

"	"2 puff BID

"	"should not be used for transferring patients from systemic corticosteroid therapy

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluticasone and Salmeterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	"AΩifʩIlDef(ROAD)`WvA]AAXϥΤXiΥֽTJզXkൣPHCoi]AbϥΪĤA@ξ(]-agonist)ΧlJֽTJĺqw̡CblJֽTJkAӤgw̡CXi`WvAӻݭnlJֽTJw̡C

"	"Hypersensitivity to any component of this product

"	"Headache, hoarseness, oral candidiasis, tachycardia, throat irritation

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-09 [E]_I3-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ESERE1-a	ESERE1-b	ESERE1-c	110.6.16
BC232651E7	R03AK07	0	ESYM	Symbicort Turbuhaler 160/4.5/DOSE		"ݡCAXϥTJΪbeta2@ξ(]2-agonist)X֪vޮ(Bronchial asthma)CCʪʪͳef(COPD):wYCʪͯe(FEV1֩wȤ50%)ΦдcƯfvAwwϥΪīXiAӤYgfwvC

"	"Pediatric: 6-12 yrsX1 inhalation BID
>12 yrs and AdultX1-2 inhalation BID


"	 wYߦޯef(]AΫpʪʤߦٯfܡBDʯäUUBװB޽FBʮʤŦfB߳չLtB߫ߤέפŦI)B}fBBvC[gBݻ̲ӭMFΥҪrgw̡ASymbicort TurbuhalervɡASOp[C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Budesonide and Formoterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	"ݡCAXϥTJΪbeta2@ξ(]2-agonist)X֪vޮ(Bronchial asthma)CCʪʪͳef(COPD):wYCʪͯe(FEV1֩wȤ50%)ΦдcƯfvAwwϥΪīXiAӤYgfwvC

"	"Hypersensitivity to any component of this product; status asthmaticus or other acute episodes of asthma, primary treatment

"	"Headache, insomnia, dyspepsia, dry mouth, abdominal pain, oral candidiasis, dysphonia, respiratory infection, tremor, restlessness, hypokalemia, nausea

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-11j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ESYM-a	ESYM-b	ESYM-c	110.6.16
BC26301443	R03AL04	0	EULTI	Ultibro BREEZHALERƤlJn		PUltibro Breezhaler ɷ|PɧlJindacaterol MglycopyrroinumAGئ@ξणPA@ΦbPAͥƦ٦P@Ϊ|礣PAG|ĥ[@ΡC]beta2- ǤWMM3- rPbDMPDKצtOAbeta2- ǤWPDP@θjAӧxPbD@θjC]AbMPDFzQXi@ΡA֥beta2- ǤW@ξMrPܾ]muscarinic receptor^OqC	"ثĳq@@ɽnAϥUltibro Breezhaler lJCѧl@CUltibro Breezhaler ĳbCۦPɶϥΡCYL@qAtbP@ѤġCɯfH@ѤiϥζWL@ӾqC

Ĥk
ȥilJϥΡCni]AC"	1.~PtP~PObeta-ǤW@ξΪĿrPܾī~֥ΡC2.~iΨӪvݡA]ʥFvAgơC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Glycopyrronium and Indacaterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	Cʪʪͯe(chronic obstructive pulmonary disease ; COPD)vC	"wDindacaterol, glycopyrroniumνξ󦨤LӪ̡ATϥΡC"	y¡Af|kh]AVEAYhA󪢡C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.26	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.11.26
BC23357114	R03AL02	0	ECOMB	Combivent UDV 0.5/2.5mg/2.5ml/vial(Iprat		"Ipratropium@ذƥPgAbCqUAު@Ψ㦳תܩʡA]A୰CCyclic GMP@סAXiުf|C 

DSalbutamol@ܩbeta-2 sympathomimeticAiǥѼW[ޥƦٲӭMcAMPtqAPj˪ޥƦ١C~Asalbutamol٥iͳ´´iPLP[t֤XM@ΡC"	"Adult/ childn >12 yr Acute attacks 1 unit dose vial. Maintenance 1 unit dose vial tid-qid. MAX. 6 doses per 24hr

UCĳqAΩ󦨤H(]tѦ~H)12HWC֦~G vʵo@ GjhƯfHA@~@qlJGYitwѯgC pYfHAY@~@qlJGLġAiݭnϥΨ~@qlJGAboǱpAfwݥߨбvδN|C ʪv GC@~@qACTܥ|CݭnɾqiW[AC@ѤiWL12өwqC"	HQlJϥΡFקKQ체	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Ipratropium and Salbutamol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	vʩIlDefֵoifʤ޵j˻ݭn@إHWXiv	LӯgACAeCΤjgAҪiAA߸L	y¡AYhAYP_ŸAAA߱AOҽkAWARסAdA߱A߸L֡AW[A_ŸAgAtwAvAYhAߵhADM`ıAf|C	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-38 [UDx]_U08-09 [w]_w03-20 [E]_C3-01 [Ew]_C1-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ECOMB-a	ECOMB-b	ECOMB-c	110.6.16
BC25033161	R03BB04	0	ESPIR	Spiriva Respimat 2.5mcg/puff(Tiotropium)		Cʪʪͯe (]ACʤުΪͮ~)v	2 puff Daily	"SPIRIVA RESPIMAT C@ʤXiA?iΩʤ޵j˪̪v?AY?iΩϪv?C
blJ SPIRIVA RESPIMAT Ai|o?YLӤC
P䥦xPʾۦPAUʫCB@ΤjBλHV?fHpߨϥΥġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Tiotropium bromide	R03B	"LlJʪʮD OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS"	0	Cʪʪͯe (]ACʤުΪͮ~)v	"hypersensitivity to ipratropium, tiotropium, or any component of product"	"Upper respiratory infection, Xerostomia, Pharyngitis, Sinusitis, Constipation."	ĳhקKϥSPIRIVA	SPIRIVA? RESPIMAT? ϥΩhα¨ŰkADҹwQqWLioͩ󥼥XͪĤl઺I	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-08j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ESPIRI-a	ESPIR-b	ESPIR-c	110.6.16
BC24786151	R03BA08	0	EALVE	Alvesco 160gg/dose;60dose/~(Ciclesonid		CiclesonideǤWֽ˩MOCCѤfħlJAciclesonide|bͳgïNƬܵoʪDnʥNªdes-ciclesonideC	"Adult: 1-2puffs QD-BID,MAX 4 puffs BID. Pediatric(4-11y): 1 puff QD
1. ĳqAൣ( 4 - 1 1 ) C80~160mcgA HPC֦~fwhC80~1280mcg C
2. fw̨ӧOY{׵AAlvesco_lqC 3. QE_XwݡAάOeϥιLlJTJsvfwзǰ_lqGHMC֦~fwĳqGLݡG80 mcg/@Ѥ@׮ݡG160-320 mcg/@Ѥ@YݡG320~640 mcg/@Ѥ@A320 mcg/@Ѩ⦸fATJ̿ʤݡG320~640 mcg/@Ѩ⦸C 
4. YǦHMC֦~fwAϥξq80mcg/@Ѥ@AiରĺqC
5. ൣ(4-11)ĳqGLYݡG80-160mcg/@Ѥ@A8mcg/@Ѩ⦸C 
6. Alvesco@ѧP@ɡAĳbߤWPAMbWP]OĪCfwݨ̷vܡATw󦭤WαߤWPC"	AlvescoäΩwʮݯgAɻݭnPuīXilJCĳfwƦī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	etWGAЩǷŤUxsC	Ciclesonide	R03B	"LlJʪʮD OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS"	0	HBC֦~Υ|HWൣʮ	Alvescoҧt@LӪfwϥΡC	lά	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EALVE-a	EALVE-b	EALVE-c	110.6.16
NC08061209	R03CA02	0	IEPHE	ĵ EPHEDRINE(¶)40MG/AMP		ީʮݡB޹Bʯgʻ󪢡BLөʻ󪢡Bճ¾KɭPʧC	"Bronchodilators, nasal decongestantGIM/SC/IV, AdultX12.5-25mg.Children > 2 yearsX 2-3mg/kg daily in 4-6 divided doses, 6-12 yearsX 6.25-12.5 mg Q4H. HypotensionGAdultX IM/SC, 10-50 mg, Slow IV 10-25 mg. ChildrenX 3 mg/kg/day in 4-6 divided doses, MAX 75mg/day."	 ~iΩXamphetamineAGĦCިġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Ephedrine	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	ީʮݡB޹Bʯgʻ󪢡BLөʻ󪢡Bճ¾KɭPʧC	"Anesthesia with cyclopropane or halothane; diabetes; hypersensitivity to ephedrine, sympathomimetic amines; hypertension or other cardiovascular disorders; pregnancy with maternal blood pressure > 130/80; thyrotoxicosis"	"Nausea and vomiting, hypertension, palpitations, tremor"	קKϥ	0	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G5~25 mg slowly IV push
q(MD)G
}GGG
}@סG-
ĳĳtvGMax total cumulative dose: 150 mg/24hr
wwʡGJ|CCѡBܶ¡AGץJsC
ʴءGtachycardiaABP"	ixii[w]_w07-02 [E]_D2-12 j	Ts110.6.16		0	0	OIs 20251124	IEPHE-a	IEPHE-b	IEPHE-c	110.6.16
AB43122151	R03CC08	0	LMEPT	MEPTIN LIQUID 5UG/ML/60ML/BTL		ޮݡBCʤުBͮ~ѯewDʻê	"Adult50 mcg once before bed or bid (in the morning and before bed). Pediatric, 0-6 yrs 1.25 mcg/kg/dose 2-3 times/day; >6 yrs 25 mcg once before bed or bid (in the morning and before bed).

"	"1. LqϥΡAi|y߫ߤAƦܤް_߸C
2. hϥΥwʩ|إߡAAΥfVC 3. ʪprocaterol|cťĤAG}lϥΥeAšC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Procaterol	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	ޮݡBCʤުBͮ~ѯewDʻê	"Hypersensitivity to procaterol

"	"Nervousness, tremor, headache, tachycardia, ventricular arrhythmias

"	PL	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-02 [E]_J2-07 j	Ts110.6.16		0	0	OIs 20251124	LMEPT-a	LMEPT-b	LMEPT-c	110.6.16
AB45041100	R03CC12	0	OBAMB	Baburol 10mg/tab		ޮ	CGABߨϥΡC	"1. 㦳Yǥ\णw̡A_lqHqC
2.Pɱw}ffHAAΥĮɫĳdN}C
3.PgiĪӷPʼW[w̡AҦpLkAҪमi̡ApߨϥBambuterolC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Bambuterol	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	ޮ	"Hypersensitivity to bambuterol, terbutaline, or other sympathomimetic amines"	ŸݡBYhB߱	קKϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-07 [s]_41 [®]_41 [E]_A1-02 j	Ts110.6.16		0	0	OIs 20251124	OBAMB-a	OBAMB-b	OBAMB-c	110.6.16
AC20084100	R03CC04	0	OBERO	Fenoterol 2.5mg/tab(Fenoterol)		Fenoterolܩʵuģ]2-agnoistAΩﵽ޵jˡBʩIlDefMwBʤް_޵jˡC	HJC 3 AC 1 ɡCq̯fHgWC	"1. UCefw̡AݸgvԷVϥ:}fBx\णBǥ\णC
2. ު뱡pcƩΤﵽAۦW[]2-agnoistqAݭsC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fenoterol	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	UCew޵jˤwMvGޮݡBʤުBCʤުBͮ~񦳤޵jˤުͯewB͡BXigB֡B	ҪमigADʯ߯UA߸L֤߫ߤ	fٻL_Ÿκ믫iBYhBwtB߸LtΤ߱C	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OBERO-a	OBERO-b	OBERO-c	110.6.16
AB437001G0	R03CC08	0	OMEPT	Meptin-mini 25mcg/tab(Procaterol)		~3N]2@ξA㦳ܰܩʡA_l@ΨtA@ήɶAӥB٦ܹLӪ@ΡAPiIlD֤\ʡC	"Adult50 mcg once before bed or bid (in the morning and before bed). Pediatric, 0-6 yrs 1.25 mcg/kg/dose 2-3 times/day; >6 yrs 25 mcg once before bed or bid (in the morning and before bed).
HC1A12ɡAΫeAΡCΦBΫeUA1ɡC"	" 1. LqϥΡAi|y߫ߤAƦܤް_߸C
2. hϥΥwʩ|إߡAAΥfVC 3. ʪprocaterol|cťĤAG}lϥΥeAšC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Procaterol	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	ޮݡBCʤުBͮ~ѯewDʻê	 procaterolLӪ̸T	ߡBæRBYhB߱C	קKϥΰDvn/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_E4 [2]_E4 [ws]_w45-03 []_01-29 [s]_211 [®]_211 [UDx]_U03-43 [E]_B5-16 j	Ts110.6.16		0	0	OIs 20251124	OMEPT-a	OMEPT-b	OMEPT-c	110.6.16
NC00805100	R03CA91	0	OMETH	DL-Methylephedrine 30mg/tab		ޮݡBy¡Bުް_y	"1 tab TID, MAX 5 tabs/ day.
q`H龯q5ACA1~2C"	CBƧxw̸TΡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Methylephedrine	R03C	ʵǤWE ADRENERGICS FOR SYSTEMIC USE	0	ޮݡBy¡Bުް_y	CBƧxC	߱BYhBvBgBh¡BߡBȡBֽlC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r04-05 [E]_A2-05 j	Ts110.6.16		0	0	OIs 20251124	OMETH-a	OMETH-b	OMETH-c	110.6.16
KC00835261	R03DX05	߷֭ᴹ`g150@J	IXOLA	fXolair 150 mg inj.(Omalizumab) (N)		"  IgE MӭMζPӭMFc`RI( ˩MOIgE ) XAéMLӭ
esɡA|}lҰʹLӤAɭPoǧ@βӭMhɤƦX´iB
TmBӭME]cytokines^ΨLCCoǴCMLөʮݪfzͲzǬA]AIlD~ȡBƦ٦YΧܻPoL{ӭMʡAóyLөʯefgAҦpަYBHG͡BݡBIlxBݳ^BBQBkoByλoBy\C
Omalizumab MIgE XAHIgE MFc`RI XA]֤FiHҰʹLӤIgE q"	"߷֭ᴹ`gCp~t150 @JomalizumabAH`gΤհtᤧ߷֧t125 @J / @ɪomalizumab]150 @J / 1.2 @ɡ^Cuѥ֤U`gϥΡCoHRߪ`gΦ٦ת`g覡뤩C߷־AqPWvOھڶ}lveK̲yJE (immunoglobulin EA
IgE)]ڳ/ @ɡ^q򩳭Ȥ魫]^өwC
 Lөʮݾq
H50-60KGҡAIgE(IU/ml)30-100A߷֨C|g֤U`gq150]@J^;IgE(IU/ml)>100-300A߷֨C|g֤U`gq300]@J^;IgE(IU/ml)>300-400A߷֨C|g֤U`gq450]@J^;IgE(IU/ml)>400-600A߷֨C|g֤U`gq600]@J^;IgE(IU/ml)>600-700A߷֨CGg֤U`gq375]@J^;IgE(IU/ml)>700-900A߷֨CGg֤U`gq450]@J^;IgE(IU/ml)>900-1000A߷֨CGg֤U`gq525]@J^;IgE(IU/ml)>110-1200A߷֨CGg֤U`gq600]@J^
YnRfwO_߷֦Aܤֻݭn12 gvC
Cʦ۵oC¯l(CSU) q
C|gH֤U`gP߷150 300 @JC
bCSU w̤߷֪qPMIgE ( @ש`@) 魫LC
|LΩCSU AvCЩwƵ~vnC"	"즸Ϋϥγ߷֤A|X{LmʹLӤLmʹLӤ(anaphylactoid reaction)CjOb2 pɤo͡C
߷֤AΩvʮݴcơAʤ޵j˩ήݭng(status asthmaticus)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	߷b2-8JNáAiNCհtb2-8J8 pɡAΩ25JiWL2 pɡC	Omalizumab	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	"Lөʮ
߷֬[kΩﵽwqlJTJsΪĤAG@ξ(?2-
agonist) vUWc鶡gΩ]ıB㦳h׮ݴcưO
LөʮݦHBC֦~Ψൣ(6 ΥHW) ݱCoǮݱw̥
gѥֽթ~ܪŮ𤤹LӭeʥBͥ\୰C (FEV1 <
80%)C߷ֶȾAΩҹꬰIgE CݯfHC
Cʦ۵oC¯l(Chronic Spontaneous Urticaria, CSU)
߷־AΩvH1 ܲ´isvΤCʦ۵oC¯lHΫC
~(12 ΥHW) w̧@[vC"	 Dνξ󦨥LӪ̡C	YhA`hAWkhAoNA`gpkhBBkoB~ȡAVhM( |)	 DvnAקKϥ.|LXolair whki}n{ɸCDvnAקKϥ	 DvnAקKϥΡD ҶqŹo|MdqBɡAӥ[W˹Xolair {ɻݨDBHomalizumab ΥJef󱵨઺b}C	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668522?cesid=8vQuqcMMYvK&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOmalizumab%26t%3Dname%26acs%3Dfalse%26acq%3DOmalizumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.6._20220201.pdf"">OI` 6.2.6.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.05.13
NC09994229	R03DA05	0	IAMIN	Asiphylline 250mg/10ml/AMP		ݤΤ޵j/ߦ]ʤޮݤΤ޵j	"
Xi:250mg-500mg q6h
ʵo@:IVF(1Awb100-200ml NS)(`tv<25mg/min)
@릨H:6mg/kg`ɶ>20
~ѥBͩʤŦf:0.6mg/kg/h*12pɡA0.3mg/kg/h
lҤdH:0.7mg/kg/h*12pɡA0.5mg/kg/h
Rʤ߰IܩΨxIܤfH:0.5mg/kg/h*12pɡA0.1-0.2mg/kg/h
~lҦH:1mg/kg/h*12pɡA0.8mg/kg/h
Ħ夤@׫ĳ10-20ug/mlAWL20ug/mliಣͬr
"	Theophylline|ƪnťĤAGŤ?ϥΥĮɹ|ް_?EʨLƧ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Aminophylline	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	ݤΤ޵j/ߦ]ʤޮݤΤ޵j	"Hypersensitivity to theophylline, ethylenediamine, or to any product component"	"Nausea, vomiting, palpitation, arrhythmia"	Theophylline|ƪnťĤAGŤ?ϥΥĮɹ|ް_?EʨLƧ@ΡC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-08 [E]_G1-07 j	Ts110.6.16		0	0	OIs 20251124	IAMIN-a	IAMIN-b	IAMIN-c	110.6.16
AC36330151	R03DA04	0	LVENT	Ventol 60ML/BOT		~|PhosphodiesteraseʡACyclic AMPQ}aѡF Cyclic AMP@׼W[|PުƦ١AӥB|ͩʪLӭAp´iASRS -AqӷPƪΤjӭMXCL@Υ]Aߦ٨E@ΡAתQ@ΡACNSħ@ΡAW[Il@ΡAxޤѧ@ΡA׸ѧ@ΩMPepinephrineqǤWXC	"ൣ(5HW)G
Ĥ@q4-5mg/kgAC6pɵĤ@FC̤jqiWL15mg/kgC
q3-4mg/kgAC6-8pɪAΤ@Fq`C̤jqb9-12mg/kgC"	~зǪXanthinelͪAsx@@ؤXiCPɤ]㦳jߧQ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Theophylline 	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	޵jˡC	LhϥxanthineľӦYƧ@Ϊ̸TΡC	LhϥxanthineľӦYƧ@Ϊ̸TΡC	קKϥΰDvn/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LVENT-a	LVENT-b	LVENT-c	110.6.16
BC22778100		0	OSING1	Singulair 10MG/TAB(Montelukast sodium)		~O@ب㦳ܩʤΤfAĪդTm (leukotriene)ܾAiM@acysteinyl leukotriene CysL T1AӲͤXi@ΡC	"Pediatric, 2-5 yrs 4 mg in evening; 6-14 yrs 5 mg in evening; >15 yrs and Adult10 mg in evening.
1. 15HWHϥξqCΫeAΤ@10mgC
2. 6HUൣw̨ϥΥ~wʤĸƫh|إߡC
3. ~ݤ\ġAiϥΫ@餺o͡C~iŸAΩλP֪ACYϯfwݤwAΪ̤bcƤAܯfHZAΥ~CѦ~w̡Bǥ\ण̡Bצܤרx\l̡AΪ̤PʧOw̡ALݽվ㾯qC"	Montelukast should not be used as monotherapy for treatment and control of exercise-induced asthma and not for acute asthma (but continue in periods of worsening asthma if already started).	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Montelukast	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	AΩwPvHΤp઺ݡA]tw鶡Ω]ݯgAΨBʤް_ަYCwѦHΤp઺鶡Ω]Lөʻ󪢯g(Allergic rhinitis)	糧~t󦨥LӪ̡C	ޤ~BkoBC¯lBڹҲ`BΡBMwRC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_C5 [2]_C5 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.4._20240801.pdf"">OI` 6.2.4.</a>              "	0	0	OIs 20251124	OSING1-a	OSING1-b	OSING1-c	110.6.16
BC23398100	R03DC03	0	OSING4	Singulair 4mg/chewable(Montelukast)		~O@ب㦳ܩʤΤfAĪդTm (leukotriene)ܾAiM@acysteinyl leukotriene CysL T1AӲͤXi@ΡC	"1. 614ൣw̪qCΫeAΤ@5mgCZCb~ּhw̤ݽվ㾯qC6HUൣw̨ϥΥ~wʤĸƫh|إߡC
2. ~ݤ\ġAiϥΫ@餺o͡C~iŸAΩλP֪ACYϯfwݤwAΪ̤bcƤAܯfHZAΥ~CѦ~w̡Bǥ\ण̡Bצܤרx\l̡AΪ̤PʧOw̡ALݽվ㾯qC
3. ~PLkvGiN~[JfHJĤ(a)i֨L֥kݭnGiN~[LkȥΤXiӾAݯf{CϥΥ~{ɮĪG(q`AβĤ@)AB@{פ\UAiNXiqC(b)ħlJʥֽTJvkGϥΥ~iW[lJʥֽTJvw̤{ɮįqCb@d򤺡AiuֽTJqCqbv@UvBiCYǯfHlJʥֽTJqivB֦ܧC~iJMNlJʥֽTJvC"	~fAiΩvʮݵo@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Montelukast	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	AΩwPvHΤp઺ݡB]tw鶡Ω]ݯgBΨBʤް_ަYC	糧~t󦨥LӪ̡C	ޤ~BkoBC¯lڹҲ`BΡBMwR	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-23 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.4._20240801.pdf"">OI` 6.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.5._20240801.pdf"">OI` 6.2.5.</a>             "	0	0	OIs 20251124	OSING4-a	OSING4-b	OSING4-c	110.6.16
BC22779100	R03DC03	0	OSING5	Singulair 5mg/chewable(Montelukast)		~O@ب㦳ܩʤΤfAĪդTm (leukotriene)ܾAiM@acysteinyl leukotriene CysL T1AӲͤXi@ΡC	"Pediatric, 2-5 yrs 4 mg in evening; 6-14 yrs 5 mg in evening; >15 yrs and Adult10 mg in evening.
1. 614ൣw̪qCΫeAΤ@5mgCZCb~ּhw̤ݽվ㾯qC6HUൣw̨ϥΥ~wʤĸƫh|إߡC
2. ~ݤ\ġAiϥΫ@餺o͡C~iŸAΩλP֪ACYϯfwݤwAΪ̤bcƤAܯfHZAΥ~CѦ~w̡Bǥ\ण̡Bצܤרx\l̡AΪ̤PʧOw̡ALݽվ㾯qC
3. ~PLkvGiN~[JfHJĤ(a)i֨L֥kݭnGiN~[LkȥΤXiӾAݯf{CϥΥ~{ɮĪG(q`AβĤ@)AB@{פ\UAiNXiqC(b)ħlJʥֽTJvkGϥΥ~iW[lJʥֽTJvw̤{ɮįqCb@d򤺡AiuֽTJqCqbv@UvBiCYǯfHlJʥֽTJqivB֦ܧC~iJMNlJʥֽTJvC"	~fAiΩvʮݵo@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Montelukast	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	AΩwPvHΤp઺ݡA]tw鶡Ω]ݯgAΨBʤް_ަYC	糧~t󦨥LӪ̡C	ޤ~BkoBC¯lBڹҲ`BΡBMwRC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-19 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.4._20240801.pdf"">OI` 6.2.4.</a>              "	0	0	OIs 20251124	OSING5-a	OSING5-b	OSING5-c	110.6.16
BC196241G0	R03DA04	0	OXANT	Xanthium 200mg/cap(Theophylline)		~|PhosphodiesteraseʡACyclic AMPQ}aѡF Cyclic AMP@׼W[|PުƦ١AӥB|ͩʪLӭAp´iASRS -AqӷPƪΤjӭMXCL@Υ]Aߦ٨E@ΡAתQ@ΡACNSħ@ΡAW[Il@ΡAxޤѧ@ΡA׸ѧ@ΩMPepinephrineqǤWXC	"Adult10 mg/kg/day, 600-1000 mg/day.

Pediatric, 6-9 yrs 20 mg/kg/day, 400 mg/day; 9-12 yrs18 mg/kg/day, 400-600 mg/day; 12-16 yrs16 mg/kg/day, 600-800 mg/day. Elder 6-8 mg/kg/day, 400-600 mg/day

HĳqC400-600mgA榸뤩C6-16ൣΫC֦~C200-400mg(16-20mg/kg/day)C"	~зǪXanthinelͪAsx@@ؤXiCPɤ]㦳jߧQ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Theophylline	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	ݤΤ޵j	LhϥxanthineľӦYƧ@Ϊ̸TΡC	ߡB߸L֡BYB߱	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_F4 [2]_F4 [ws]_w53-02 [s]_357 [®]_357 [UDx]_U03-56 [E]_C2-04 j	Ts110.6.16		0	0	OIs 20251124	OXANT-a	OXANT-b	OXANT	110.6.16
AC43835480	R05CB05	0	EMESA	Mesa inh. soln 200mg/ml; 3ml/amp(Mesna)		Mesna঳Ī_HGclAϨˤơC@Τ]HG㦳ӭCABuPHGl@ΡAQHlC~ֵ֤L}vTA]AiPiHGưӤ|l`HC~AMesna|ycEΦ^D{H]rebound phenomenon^A襤ϯgBIlHδ`tΤ]S}@ΡC	Nebulizations: 1-2amp q6-24hAig}ΥHn]HNS}ϥΡC Instillations:1-2ml mesnaHn]HΥͲzQ}Aw`ޤήMޡACpɺw`@AcGƨñƥXFvWBuɡA~uw`2-3mlg}mesnaACj2-3ѥiƤ@C	~Hw]ˡAD`gΤlJʲG	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Mesna	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	޻êƷC	"UCw̸Tϥ:
1) SHG뤧ݱw̡C
2) Q@ʯʥF̡C
3) DtIީlA_h঳׶Ϋyª̡C
4) cMGƥiް_ͳy]pulmonary flooding^̡C"	޵jˡBæRBܶ	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-19 [E]_I3-01 j	Ts110.6.16		0	0	OIs 20251124	EMESA-a	EMESA-b	EMESA-c	110.6.16
AC38614216	R05CB01	0	IFLU3	Kotan 100mg/ml;3ml/amp(Acetylcysteine)		WNΰoAcetaminophenrѬr	"IV: 3 Doses: loading dose 150mg/kg, mix in 200ml D5W and infuse over 1hr;
Dose 2: 50mg/kg in 500ml D5W over 4hr;
Dose 3: 100mg/kg in 1000ml D5W over 16hr."	" 1.ൣ~AĽЧOޡC
2.ŶWLĳqC
3.AīYAp͡AϥΨýбvĮvľ͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Acetylcysteine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	WNΰoAcetaminophenrѬr	Hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components in the preparation	"Decreased prothrombin time, hypotension, nausea, vomiting, diarrhea (oral), rash, urticaria, pruritus (intravenous)"	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[E]_G1-03 [Ew]_D1-06 j	Ts110.6.16		0	0	OIs 20251124	IFLU3-a	IFLU3-b	IFLU3-c	110.6.16
BC25729148	R05CB02	0	LBISO	Bisolvon 2mg/ml;50ml/bot(Bromhexine)		׶]ޯewҾɭPط]g^	"Inhalation : Adult4 ml BID. Pediatric, <2 yrs2 ml BID; 2-6 yrs2-4 ml BID; >6 yrssame as adult."	 wbromhexineλsLLӪ̸T	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Bromhexine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	׶]ޯewҾɭPط]g^	Hypersensitivity to bromhexine or any component of the formulation	"GI disturbance, headache, dizziness, skin rash"	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w08-00 [E]_J2-05 j	Ts110.6.16		0	0	OIs 20251124	LBISO-a	LBISO-b	LBISO-c	110.6.16
A034950100	R05CB02	0	OBH8MG	Shitan 8mg/tab(Bromhexine)		(1)~㦳HGMPi߲GcACޤcHYסAѰy¡C (2)~W[ܥͯbf_@סAġC (3)~޲´IgA@סAW[ުܤOC	"1.HB10HWൣGC@ACT
2.510pGC1/2C|
3.5HUGC1/2CG"	sBjqPA|MTransaminaseȡWɪΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Bromhexine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	׶]ޯewҾɭPط]g^	wbromhexineλsLLӪ̡C	fHAĤA߲GQѡAqW[Ay¥i|yL[@CmBߡBæRΨLLGzƧ@γiC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OBH8MG-a	OBH8MG-b	OBH8MG-c	110.6.16
A037598116	R05CB01	0	OFLU2	Actein 200mg/3g/pk(Acetylcysteine)		"IlDHGcHסADnMwHGJդ@פDNA 
hCY]ӭM}ahADNA @׼W[AhHGܦwHGC
Acetylcysteine lSulfhydryl group iNHGdisulfide 쥴}A]ӭCHסAW[䷻ѫפάyʩʡAϩƥXC"	"Mucolytic, AdultXPO,granules, 100- 200mg TID;
ChildrenX 10-20 mg/kg/day in 3-4 divided doses. 

1. @3 CHC3gmA12 HWAΦHqF6 HW12 AC1.5gmF3 HW6 AC0.75gmF3 HUAЬvEvC
2. Acetaminophen LqѬrwȨѤfAϥΡA_lq140mg/kgAP5%ĬGVXAMC4pɳsP17A70mg/kgqC"	AīYAp͡AϥΨýбvĮv	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKgAyOs󳱲DBC	Acetylcysteine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	֩IlD߽c߸YʡC	"UCpĳۦϥΡG
1.(ީ)ݤΦ񦳩Il\णfHC
2.̡֪C"	ߡBæRBBLD𷸥XPC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D6 01[1]_J2 [2]_J2 [ws]_w65(1) []_01-01 []_02-04 [UDx]_U01-51 [E]_Z-19 [Ew]_EX131 j	Ts110.6.16		0	0	OIs 20251124	OFLU2-a	OFLU2-b	OFLU2-c	110.6.16
AB45993100	R05CB01	0	OFLU6	Actein ow600mg/tab(Acetylcysteine)		"Aqbi(Acetylcysteine, NAC)O~ʦCqL߳JսƦXBֻġANwʦΨ䥦cq߸YܬzӵojP߲G@ΡC
~ANAC 㦳ܮƧ@ΡAѤ@ӯP˹qlưάۤoͧ@ΪۥѲB(ˮ֪-SH)CSO쪺O̪ҹANAC (HOCL)\1-ܯسJ՞J(\1-antitrypsin)MuʳJ՞J(elastase)}aCĬO@رjƾAƧ]ӭMӲͪLƪJ(myeloperoxidase)CѩWz@ΡAϱo~ʩMCʪIltηPVҤް_@YʤΤwʤcΤ\ġC~ANAC lczLӭMAbӭMѦL-Cysteine(L-bi)AiĬOXGlutathione(GSH)DnCGSH O@إiצAƤT`AMsbUذʪ´AѲӭMO@AӫOӭM\MӭM~ΤWʡCGSH ṊnO@\AL餺A~A٬OLjhƤӭMrAOܮƧ@ΡC
NAC b餺GSH ŤAtnCGSH UO@ӭMKrǵۤ_GSHAӲͲӭMrʧ@ΡApAcetaminophen rpCѩ㦳oا@ξAbAcetaminophenrɡANAC ]i@@دSѬrC"	owmMA[JֶqѫᶼΡCHWΦH@Χtī~600mgGA@Ѥ@ܤGC	~tڲ (Aspartame)AGfଧw̤yϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Acetylcysteine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	֩IlD߽c߸YʡC	糧~tLӪ̡AФŧPC]~tڲ (Aspartame)AGfଧw̤yϥΡC	~fAAi঳ߡAæRA֯lM޵j˵LӤC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_J2 [2]_J2 [ws]_w65(1) [UDx]_U01-52 [E]_B1-11 [Ew]_EX012 j	Ts111.8.22		0	0	OIs 20251124	OFLU6-a	OFLU6-b	OFLU6-c	111.8.22
AC43362157	R05DB13	0	LSUTU	Sutussi liquid 0.8mg/ml; 120ml/bot (Buta		"y]P_BުBݩʤުҤް_y¡^C

"	"Adultw7.5ml TID-QID; Chidrenw5ml TID, OR 0.25-0.5 ml/kg TID-QID, MAX 2ml/kg/day.

"	 YgƤ餺ﵽΧYAЧivC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Butamirate citrate	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	"y]P_BުBݩʤުҤް_y¡^C

"	 DButamirate citrateLӵ۸T	"(<1%) Rash, Diarrhea, Nausea, Dizziness.

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-04 [E]_J2-03 j	Ts110.6.16		0	0	OIs 20251124	LSUTU-a	LSUTU-b	LSUTU-c	110.6.16
AC29594100	R05DB07	0	OZECO	Zeco 100mg/tab(Oxolamine)		ĭݨyή@ΡA֨çIlDHoPX@	`ξqHC3-4A@@	fAAfĥi঳uȪ¤PA¤Pq`5C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Oxolamine	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	y]P_B|YBުBCʩIlDPVgް_y¡^	1.Ω3ӤHU2.Ω󥿦bϥΧܾsfH3.T	GABv{H	PL/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.28		0	0	OIs 20251124	DC	DC	DC	114.05.28
AC59035157	R05FA02	0	LBM	Liquid Brown Mix.liq 120ml/btl		yB׶	 HGC5 @ɡA@3~4 AfpuW	" 1. 㦨}ʡAVĤŶWLĳqC
2. o֪Ats붼ơC
3. A᰸ΡBtw{HAקK}ξާ@C
4. olBkoBLӮɡAYġC
5. ~tLq CamphorAШvBϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Glycyrrhiza fluid extract/Opium tincture	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	 1.YIlfwTΡBYxêBߦ٤w̡Bʰs뤤rw̧TΡC2.έŰGDWn@뤣ĳġC	 IlBߡB`BΡBwBtwBġBoBıҽkBߡBæRBK	bʪʪiX|ͷέLAB|gѥŦӤް_sͨIlA@뤣ĳġADWnC 	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G5 [2]_G5 [ws]_w73-03 [E]_J2-09 [Ew]_J3-01 j	Ts110.6.16		0	0	OIs 20251124	LBM-a	LBM-b	LBM-c	110.6.16
AC40706157	R05FA02	0	LSORT	"Sortuss? cough liquid 120 ml/bot
C@( ml )t
Dextromethorphan HBr 1 mg
Glyceryl Guaiacolate 10 mg
/Լwjļtѥq"		"1. Dextromethorphan HydrobromideGD`sεL`yAy¤ϮgAĪGtAyįPCodeine Phosphate ۷AӵL}ʡALʯv@ΡAް_KAGCodeine ΡC
2. Glyceryl GuaiacolateG𾯡AĪG[AiW[޹DcACcHסAإXC
3. Ipeca Fluid ExtractG𾯡C"	"C|pɪAΤ@F
HGC10~20 @ɡF
ൣG6~12 AC6~10 @ɡF2~6 AC2~6 @ɡC
AΫeЮáC"	"1. o֪Ats붼ơAVĤŶWLĳqC
2. olBkoBLӮɡAYġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	бKxs25JHUA𶷦BsקKgC	Dextromethorphan 1mgBGlyceryl Guaiacolate 10mgBIpeca Fluid Extract 0.005mg	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yBC	糧~LӪ	olBkoBLӮɡAYġC	DnקKϥ/LƦҦw	DnקKϥ/LƦҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-02 [E]_J1-05 j	Ts110.6.16		0	0	OIs 20251124	LSORT-a	LSORT-b	LSORT-c	110.6.16
A040833157	R05X	0	LSECO	SECORINE SYR.120ML/BTL		"wѷP_Uدg]yBBQBط^

"	"Adult: 10 ml TID-QID. Pediatric: 5 ml TID-QID

"	"1.AīAФp߶}ξާ@MIC
2.nAΥĶWLCѡC
3.YgSﵽAΨֵoNTAĥߧYNC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Dl-methylephedrine	R05X	LP_s Other cold preparations	0	"wѷP_Uدg]yBBQBط^

"	"Hypersensitivity to components of secorine

"	"Dizziness, GI disturbance, headache, palpitation, dry mouth

"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_04-01 [UDx]_U01-42 [E]_J1-04 [Ew]_J3-02 j	Ts110.6.16		0	0	OIs 20251124	LSECO-a	LSECO-b	LSECO-c	110.6.16
NC02967209	R06AA02	QĤGfi`gGH	IVENA	Diphenhydramini HCl inj.30mg/ml/amp		VenaRXwѹLөʻ󪢡B\Ҥް_g]yBQBγﳡko^ιLөҤް_koBֽolCDiphenhydramine HCLRXLөʯewBC¯lBֽBïl	"Allergic reaction or motion sicknessPO, 25-50 mg every 6-8 hrs. AntitussiveGPO,25-50 mg every 4-6 hrs.MAX.150 mg/day. Inj.10-50 mg IM/IV per dose; MAX 100 mg/dose (400 mg/day)."	 1.PϯgֳζsA|W[@ΡAq÷VϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Diphenhydramine HCl	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	VenaRXwѹLөʻ󪢡B\Ҥް_g]yBQBγﳡko^ιLөҤް_koBֽolCDiphenhydramine HCLRXLөʯewBC¯lBֽBïl	"Hypersensitivity to diphenhydramine or any product or system components, acute athma; breastfeeding; use as a local ansthtic]injection^"	"Dizziness, dryness of mouth,nose,or throat, dyskinesias, sedation, sleepiness, thickening of bronchial secretions"	קKϥ	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669807?cesid=8j6f5EOm1Zy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDIPHENHYDRAMINE%26t%3Dname%26acs%3Dfalse%26acq%3DDIPHENHYDRAMINE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.21		0	0	OIs 20251124	DC	DC	DC	114.05.21
AC42932151	R06AX17	0	LATHM	"Athmin? syrup 60ml/bot
C@ɧtKetotifen fumarate
0.276mg
/Լwjļtѥq"		~(1)ƾǤ誺XAӧΤjӭMltlC(2)ާltlC(3)ܲ´iMSRS-Aު@ΡC(4)CުLөʡC(5)AΡAiۭC޹AQxPLפC 	3HWAC5mlACѤGCR@αӷP̡GG2.5~5mlAΫe@C@gGC5mlACѤGC 	"1.}lAketotifenvɡAiHJMLݪgvĤιwġCרOfATJA]ϥΤfATJfHAbMĮɡAi|͵ǤWpCoظUеǤW\pAiݮ1~~|_Cܤ֥֨γݪ̩wΤfA}ĪfHAͥifʦpOƥش֪{HCҥHoدfHAˬdpOpơC
2.uiXAbϥketotifenfHͩ⵬{HC]ketotifeni|Cj˪֭ȡAҥHΦbwfHnSOpߡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Ketotifen(0.2MG/ML) 	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	ޮݡBLөʤުBPݯgBwΪvLөʻ󪢡BLөʥֽC  	ketotifenξ䥦LӪHC 	Ÿݵ	DnקKϥ/LƦҦw	DnקKϥ/LƦҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-03 j	Ts114.09.12		0	0	OIs 20251124	LATHM-a	LATHM-b	LATHM-c	114.09.12
AC44023151	R06AE07	0	LCETI	Cetirizine oral solution 1mg/ml;60ml/bot		 CetirizineAnti-H1ܹLӪvABL㪺Anti-CholinergicAnti-Serotonin@ΡCbľqCetirizine|qL޻پA襤ϯgS@ΡA|ͦwvΦ欰`{HC	" 3HWĵAΡC
3-6ĵG@Ѥ@AC 5 @J(Y5ml)A\ɪAΡCΤO󦭡BߦUA2.5@J(Y2.5ml)C
6HWGC10@J(Y10ml)A@Ѥ@A\ɻPGAC
ǥ\णw̪AΥĮɡA侯qbC"	" 1.bvqUACetirizine|[s(夤s@׬0.8g/L)@ΡAקKC
2.ҩA勵`H뤩2025mg/ѪqA|vT`ίvάʮɶCqƾrξާ@̡AФpߨϥΡAqnLqAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Cetirizine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	ܹL	 糧Ĥ󦨤LӪ̡C	 ܷ|oͻLBuȪD[ʰƧ@ΡAҦpGYhBtwBݯvB믫EBfBGzAC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_02-01 [E]_J2-06 j	Ts110.6.16		0	0	OIs 20251124	LCETI-a	01C44023-1	01C44023-2	110.6.16
AC43588151	R06AX02	0	LPERI	Cypromin 0.4mg/ml(Cyproheptadine)		~bĲᱵ鳡A|PMB´iMAQxP(i)vʫܧ@ΡCƾǵcPphenothiazinesA٥iͻתCNS@ΡAHΥi@ΦbUCAӨEC	"Adult: initial 4-20 mg/day in divided dose, MAX 0.5 mg/kg/day.
Pediatric : 2-6 yrs 2 mg BID-TID, MAX 12 mg/day;
 7-14 yrs 4 mg BID-TID, MAX 16 mg/day.
HGvdA@C10~15mlAjfwζqC30~40mlAfi[ܨC80mlAĳϥΪ̨C3AC10mlACѳ̦hWL0.5mg/kg魫C 7-14GC2~3AC10mlACѳ̦hWL40mlC 2 - 6GC2~3AC5mlACѳ̦hWL30mlC"	ΪƧ@η|Mo	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cyproheptadine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	\BLөʻ󪢡BĲʥ֪BֽBgʥֽBlʥֽBlBC¯lBĪΦMLӤBޯgʤ~BݯgBu`ʮݡB]ʮ	"Angle-closure glaucoma, elderly, debilitated patients, hypersensitivity to cyproheptadine products,
MAOI therapy, newborn or premature infants, nursing mothers, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction"	ΡAfAGhߡAYhA魫W[	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-01 [E]_J1-02 j	Ts110.6.16		0	0	OIs 20251124	LPERI-a	LPERI-b	LPERI-c	110.6.16
BC230161G0	R06AX26	Ӣ	OALLE	Allegra 60mg/tab(Fexofenadine)		FexofenadineterfenadineDnʥNªAO@ب㦳ܩʥyH1ܬʪܲ´iCFexofenadine蹳ci{ĤO۷ܲ´i@ΡC	u`ʹLөʻ󪢡BCʦ۵oC¯lGHGC60mgA@2F611ൣGC30mgA@2C	1.ŶsC 2.AīAФŶ}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fexofenadine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wѦHΤHWൣu`ʹLөʻ󪢤κCʦ۵oClg	Hypersensitivity to fexofenadine or any of the ingredients	YBYhBΡBߡBƤ}	קKϥΰDvn	"hα¨ŴϥΥ~ADbgLP_{~LέŤधbQq
jbIɤ~oHϥΡC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669732?cesid=1TqmTGAuYKM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFexofenadine%26t%3Dname%26acs%3Dfalse%26acq%3DFexofenadine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OALLE-a	OALLE-b	OALLE-c	110.6.16
AC60441100	R06AX26	"""z""өw180@J "	OALLE2	FEXOFENadine 180mg (Naxodine) 		"FexofenadineterfenadineDnʥNªAO@ب㦳ܩʥyH1ܬʪܲ´i,Ħb@pɤYi}loܲ´i@ΡA2-3pɫiF̤jĪG"	"u`ʹLөʻ󪢡G
HGFexofenadine HClĳqC60@JA@Ѩ⦸FΨC180@JA@Ѥ@C
ǥ\zw̪ĳ_lqC60@JA@Ѥ@
611ൣGFexofenadine HClĳqC30@JA@Ѩ⦸Cǥ\zw
ĳ_lqC30@JA@Ѥ@
Cʦ۵oC¯lG
HGFexofenadine HClĳqC60@JA@Ѩ⦸Cǥ\zw̪ĳ_l
qC60@JA@Ѥ@
611ൣGFexofenadine HClĳqC3060@JA@Ѩ⦸Cǥ\z
w̪ĳ_lqC30@JA@Ѥ@
"	"a.Fexofenadine HCliwѩu`ʹLөʻ󪢩κCʦ۵oC¯l(C¯l)gCfwu
bv}߳Bɤ~Afexofenadine HClCФŪAζWLĳqCAfexofenadine
HClYX{󤣨}AФHĨÿԸvC
b.Yw̹糧~󦨥LӡAhФŪA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUKeOs	Fexofenadine 180mg	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wѦH6HWൣu`ʹLөʻ󪢤κCʦ۵oC¯lgC	Fexofenadine HClTΩw󦨤LӤw̡C	}(]Aݺ)oͲvPqLAl}]A:frPV(˭ByʷP_)AߡAhgAݺΡAƤ}Ah¡AYhAIh	"hα¨ŴϥΥ~ADbgLP_{~LέŤधbQq
jbIɤ~oHϥΡC"	"hα¨ŴϥΥ~ADbgLP_{~LέŤधbQq
jbIɤ~oHϥΡC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669732?cesid=1TqmTGAuYKM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFexofenadine%26t%3Dname%26acs%3Dfalse%26acq%3DFexofenadine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_I4 [2]_I4 [ws]_w32-06 [UDx]_U03-01 [E]_B3-22 [Ew]_EX034 j	Ts110/9/30		0	0	OIs 20251124	OALLE2-a	OALLE2-b	OALLE2-c	110/9/30
AC51197100	R06AX27	"""u""vӼֽ 5 @J"	ODENO	DESORA 5mg/tab]Desloratadine^		u`ʹLөʻ󪢤ް_gAwѺCʭoC¯lg	12 HWĵΦHA@Ѥ@AC5mgC	PsBRĪ֥ήɡA|[~R@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUBC	Desloratadine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	u`ʹLөʻ󪢤ް_gAwѺCʭoC¯lg	糧~loratidineLӪ	YhBߡBhҡBwtBΡBٵhBfBƤ}B|Y	קKϥΰDvn/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B4 [2]_B4 [ws]_w26-04 [E]_B2-17 j	Ts110.6.16		0	0	OIs 20251124	ODENO-a	01C51197-1	ODENO-c	110.6.16
N013550100		Jw	ODIME5	Trimin 50mg/tab (Dimenhydrinate)		wνwѰʷwg]wBwBw^ް_YwBߡBæRBYhg	"Adult X 50-100 mg 30 min prior to travel; repeat every 4-6hrs; MAX 400 mg/day.
Pediatric (2-5 yrs)X 12.5-25 mg every 6-8 hrs; MAX 75 mg/day;
6-12 yrsX 25-50 mg every 6-8 hrs; MAX 150 mg/day
fAGH3~4/ѡAC50mgAwήɩ30-60eAA1ѳ̤jq200mgACjb6pɥHWC6-12AΥb"	2.ΦWiʤ?AϥΥ~ɡASOVC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Dimenhydrinate	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wνwѰʷwg]wBwBw^ް_YwBߡBæRBYhg	o֪Ats붼ơC ݡBCBeC~jfiϥΥC	ΡB «PB fBıҽkB 	iw/i	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-07 [s]_315 [®]_315 [E]_A2-01 j	Ts110.6.16		0	0	OIs 20251124	ODIME5-a	ODIME5-b	ODIME5-c	110.6.16
AC04737100	R06AX02	اAw	OPERI	Pilian 4mg/tab(Cyproheptadine)		"1.ݨܲ´iΧܦMY褧@ΡAĤOjAvĪGTA@§ܲ´iLkĤUعLӯgηkogpAhiHowĪGC
2.@ީʮݡBu`ʮݡB]ʮݯgIδqݪvLĮɡAiHAΥӱoVĪGC 
3.uRBݯv{HA{H@ֽLӡBkogw̤ϦӦ}nĪGAiϱwֽ̥PıwơAwMiӴַkoPC"	"Adult: initial 4-20 mg/day in divided dose, MAX 0.5 mg/kg/day. Pediatric : 2-6 yrs 2 mg BID-TID, MAX 12 mg/day; 7-14 yrs 4 mg BID-TID, MAX 16 mg/day
q`HC3~4AΤAC1A2~6C1/4A7~14C1/2A@3~4ϥΡC"	ĦΧ@ΡAGAδקK}ξާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15~30XC)AץxsC	Cyproheptadine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	\BLөʻ󪢡BĲʥ֪BֽBgʥֽBlʥֽBlBC¯lBĪΦMLӤBޯgʤ~BݯgBu`ʮݡB]ʮ	"Cw̡AUʭGűw̡AժQGzw̡AeCΤjC
Uʯefw̡A޳ݮʵo@w̡AsͨBB֥BIzw̡AιcyprohepatadineLӪ̸TϥΥġC"	LӤA魫W[AzGAA«AݯvC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_01-07 [s]_262 [®]_262 [E]_A1-12 j	Ts110.6.16		0	0	OIs 20251124	OPERI-a	OPERI-b	OPERI-c	110.6.16
N005124100	R06AA02	f10@J	OVENA	Vena 10mg/tab(Diphenhydramine)		Diphenhydramineܲ´iĪA|M´iӭMH1鲣ͫܧ@ΡC	"Allergic reaction or motion sicknessPO, 25-50 mg every 6-8 hrs.
AntitussiveGPO,25-50 mg every 4-6 hrs.MAX.150 mg/day"	3.`gɱw̨鳡줧ܤΪ`NG	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Diphenhydramine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wѹLөʻ󪢡B\Ҥް_g]yBQBγﳡko^ιLөҤް_koBֽol	YN©ʨxǯefw̤oAΡA糧ĹLӪ̸T	"x,߸L,f"	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-09 []_01-13 [s]_353 [®]_353 [E]_A2-02 j	Ts110.6.16		0	0	OIs 20251124	OVENA-a	OVENA-b	OVENA-c	110.6.16
AC49558420	S01AD03	0	PZOVO	Devirus oph. Oint. 3%		©lʨ	5 times daily at approximately Q4H. Continue for 3 days after healing.	}1ӤAݾlī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Acyclovir	S01A	ܷPV ANTIINFECTIVES	0	©lʨ	Hypersensitivity to acyclovir or any component of the formulation.	Transient ocular stinging	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-06j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.2._19950301_000.pdf"">OI` 14.2.</a>              "	0	0	OIs 20251124	PZOVO-a	PZOVO-b	PZOVO-c	110.6.16
BC24398421	S01AE05	0	PCRAV	Cravit ophthalmic solution 25mg/5ml/bot		"levofloxacinӷPyݡByݡBͪyߡBzyݡBӲyݡBԤݡBΪݡBJpդݡBjzPߡBFpݡBܧαݡB󼯮ڵߡByʷP_ݦߡBJζݦ[J-¤G]BPseudomonas sp.BwߡBStenotrophomonas(Xanthomonas) maltophiliaBAcinetobacter sp.BPropionibacterium acnesҤް_UƷPVgG¥Bɸ~B\nBB¥OB(t)C 

levofloxacinOofloxacinǬ()A㦳ofloxacin 2ܵ߬ʡCDnOêDNAJʡAܵߧ@ά߫C̤pӵ߿@(MIC)M̧C߿@(MBC)õLӤjtAMIC@פUAX{߲{HC"	1 drop tid	1.ȭIΡC2.ӵߩʵΥ~PVgɡAβC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Levofloxacin	S01A	ܷPV ANTIINFECTIVES	0	~ӵߩʷPVg	糧BofloxacinMquinolonetLӤJfvw̡C	jʨlB¥BEP	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-04 [E]_H1-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.4.1._20070501_000.pdf"">OI` 14.4.1.</a>              "	0	0	OIs 20251124	PCRAV-a	PCRAV-b	PCRAV-c	110.6.16
AC47370417	S01AA17	0	PERYT	Erythromycin 0.5% oph oint 3.5gm/tube		DnG+ߡASO@ĩʪߦġFBBBߧJ鵥]ġC	"Intraocular infections: 1 cm ribbon applied up to 6 times daily (depending on severity of infection)
@@ܼƦAgI󲴱wC"	YPɨϥΤ@إHWġAĳܤֶj5C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Erythromycin	S01A	ܷPV ANTIINFECTIVES	0	vPߤް_CʵBB\nBɸ~B¥tBšBⲴCwsͨधOy(N. gonococcus)Aܦfr(C. trachomatis)PVC	糧~LӪ̡ATϥΡC	`BEPC	iw/i	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669687?cesid=25mR8RaQQSa&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DErythromycin%26t%3Dname%26acs%3Dfalse%26acq%3DErythromycin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PERYT-A	PERYT-b	PERYT-c	110.6.16
AC47124421	S01AA11	oĻI 3 @J/J(ĵ߯)	PGENO	Gendermin oph. oint. 3% 5gm/		GentamicinO@Amino-glycoside Antibiotics㦳sxܵ߯OA󵲽¥β\Yʲӵ߷PVC㦳uVvĪGC	2-4 times daily	~Χܥͯ|ް_DPʷLͪLqcޡAҦpߡCppΦEBLӵpo͡AhΥìIAvC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Gentamicin	S01A	ܷPV ANTIINFECTIVES	0	B¥tBB\nBɸ~Bim骢C	糧~Lӥvw̡C	uȪEPC	קKϥΰDvn/i	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669716?cesid=aCPZEJbdclc&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DGentamicin%26t%3Dname%26acs%3Dfalse%26acq%3DGentamicin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.12.31	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	113.12.31
AC22198421	S01AA11	0	PGENS	Gentamicin oph soln 3mg/ml;5ml/bt		GentamicinO@Amino-glycoside Antibiotics㦳sxܵ߯OA󵲽¥β\Yʲӵ߷PVC㦳uVvĪGC	"3-4 times daily
12wA134C"	ܥͯϥΡAi|ϫDPʪӵ߹LץͪAרOߡAboرΤUĨñĨABmC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Gentamicin	S01A	ܷPV ANTIINFECTIVES	0	¥tBBBim骢Bɸ~B\nC	GentamicinLӤw̸TΡC	LӤio͡AɥġCEBhBΨ`io͡AbYǱpiݭnġC	קKϥ/i	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-06 [E]_H1-10 j	Ts110.6.16		0	0	OIs 20251124	PGENS-a	PGENS-b	PGENS-c	110.6.16
AC45960435	S01AB91	0	PSINO	Sinomin oph soln/15ml(Sulfamethoxazole)		"1. UCӵߩҭPPVgGⲴfA媬yߡByߡAͪyߡACʵ(Morax-Axenfeld bacillus)A(Koch-Weeks bacillus)C
2. kĦw:D-pbͲɨϥΡC"	1-2 drops QD-TID	X{Lӯgߨ谱	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Sulfamethoxazole	S01A	ܷPV ANTIINFECTIVES	0	BⲴByʨB¥B¥tBɸ~B\nBim	惡ĪLӪ̸TΡC	EPARALӡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-02 [E]_H1-16 j	Ts110.6.16		0	0	OIs 20251124	PSINO-a	PSINO-b	PSINO-c	110.6.16
AC58129421	S01AA09	0	PTC	Tetracycline oph oint 10mg/gm 5gm/tube		"~߽ܵdƼsAsħܥͯCD@ĩG(+)AG(-)ӵߦĥ~Aڦ̡BߧJέYzjΤoLʯfr秡ġC
|ӷPnӵߦ:yߡBy(Pʵߺ)BͪyߡBߧJBJpդߡB`ߡCSO|ӷPߺج:yʷP_ݦߡBͪyߡByߡBճΪߡBjzߡC
~ʽOxytetracyclineChlortetracyclinewwAƧ@Τ]CC"	"Ophthalmia neonatoruma thin strip (1 cm) of oint as a single dose.
Ocular infectiona thin strip(1 cm) of oint. Q2H-Q4H or more frequently

C@ܼƦAgI󲴱wC"	λsAФŧ]AF}4gAΧĽХC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Tetracycline	S01A	ܷPV ANTIINFECTIVES	0	FBoMʵB©ʨwloLʬrPVg	糧~LӪ̡ATϥΡC	`BEPC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-03 [UDx]_U01-67 [E]_H1-19 j	Ts110.6.16		0	0	OIs 20251124	PTC-a	PTC-b	PTC-c	110.6.16
BC17400421	S01BA04	0	PPRED	Econopred plusoph.1%5ml/~(Prednisolone)		CorticosteroidsUبEҤް_gĪGAPɤ]iwˤf¡XɶCCorticosteroidsi~AֺIAӺXiBW͡BզyʡAֺӭMW͡AIΦ]gҧΦˬ͡CMAΤCorticosteroids@ξ|QT{AMӡA]Corticosteroids໤Phospholipase A2ʳJաAYLipocortinsAӳQ{\CJսǥѧArachidonic AcidAް_on(pprostaglandinsleukotrienes)eXAӥiӭn褧XCArachidonic AcidOgPhospholipase A2 ʤƦӱqӭMnZCפXӡCCorticosteroidsi|yWɡC	1-2 drops 2-4 times daily and may up to 1-2 drops/hour	YϥΥ~WL10ѥHWA`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Prednisolone	S01B	ܪ ANTIINFLAMMATORY AGENTS	0	Lөʲ¥tBXBũʨBJIҤް_g	"1. ©ʞ\l(K)BkBkBK߷PVA߷PVC
2. 令@ι䥦Corticosteroids|LӪ̡C"	Wɥi|ɭPCAֵo͵glAUnʥդ٤ΦAˤf¡XC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PPRED-a	PPRED-b	PPRED-c	110.6.16
AC43589421	S01BA07	0	PFLU1	FLUORONEIaG0.1%;5ml/bot		ǤWֽTJi]ʡBƾǩʤΧK̩ʩҳyoC{ɪsܡA~oAFluorometholone AcetatevĪGnFluorometholonenC ¥BBBimBim骢BjBWj	"C12w,C24,}lv2448pɤ, C4pɥiW[12wC"	"p糧ĦLӤ,ߧYΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~JsץγDB;ýиmĵ쪺aC	Fluorometholone	S01B	ܪ ANTIINFLAMMATORY AGENTS	0	~MegʯewC	"1.oLʯfrBB©ʯplBkBkBߩίu߷PVeC
2.DΨ䥦TJLӪ̡C"	"ϥΥ~iɭPCBglaεê,iΦդ١C"	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.08.20		0	0	OIs 20251124	DC	DC	DC	114.08.20
AC45145423	S01BA07	0	PFLU2	FOXONE 0.2mg/ml;6ml/bt		ǤWֽTJi]ʡBƾǩʤΧK̩ʩҳyoC	1-2 drops 2-4 times daily	ϥΫeйnC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluorometholone	S01B	ܪ ANTIINFLAMMATORY AGENTS	0	¥BBBimBim骢BjBWj	ʪ¯plʨBkBkβyε]LfrҳyefB´߷PVB֡BFluorometholoneLӱw	Li|yCAglAϵOIhεܯAΦnU᳡դ٤γy_wC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-02 [E]_H1-09 j	Ts110.6.16		0	0	OIs 20251124	PFLU2-a	PFLU2-b	PFLU2-c	110.6.16
AC04975421	S01CA05	0	PRINS1	Eye Rinderon AνƦXG5ml/~(N)		"1.BetamethasoneY@ئX޽ǤWֽXAܪg@ΡBܹLӧ@ΡC

2.Fradiomycinbպޤ󶧩ʵߪyݡBMoraxellalacunata(Morax-Axenfeld bacillus)BHaemophilus aegyptius(Koch-Weeks bacillus)Ҩܵߧ@ΡC"	"1-2 drops 3-4 times daily
q`@I3-5AC1-2wC"	"ݧN(2-8XC);}ʫiOs@Ӥ;ϥΫe~,PɨϥΨLλs,ݶj5"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Nī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC	Betamethasone	S01C	ܪĩMܷPVĦX ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	0	¥ewBewBdewBߵew	"1.糧LӤw̡C

2.StreptomycinBKanamycinBGentamicinBFradiomyciniܥͯBacitracinLӤw̡C"	ɰAuϥάۦPƧ@ΡAקKsϥΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-01 [E]_K-03 j	Ts110.6.16		0	0	OIs 20251124	PRINS1-a	PRINS1-b	PRINS1-c	110.6.16
AC43619423	S01CA05	0	PSENC	SENCORT OPH SOL		"tTJΧܥͯĤ,v¥,,d,ߵew"	C1~2wAC1~ƦAڻݭnվ	1.Űt 2.YnϥζWLƬPAݲwˬd	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKBåOgAǷxsC	Betamethasone	S01C	ܪĩMܷPVĦX ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	0	¥ewBewBdewBߵewC	糧~LӤ	Oҽk	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-04 [E]_H1-18 j	Ts110.6.16		0	0	OIs 20251124	PSENC-a	PSENC-b	PSENC-c	110.6.16
AC10414417	S01CA	0	PWINA	Winacort eye oint.Ƥ3.5gm/(Group4)		ҧtTriamcinolone AcetonideY1955~BernsteinҳлsGlucocorticoidݤƵǥֽTJA㦳ܱjܪg@ΤΧAllergic@ΡAϥΥ~vPVBLөʤB~ˤΤNϺغرpAĤOHydrocortisone10APrednisolone35AB㦳ﵽή@ΡAϯgtnAo}nGAttXNeomycin SulfateY@ؼsĩʧܥͯAﭲ]ϡ^B]С^έ@ĩʲӵ߬ҦġAiϥΩwΪvPVgANQ쪺ġA|TJʰƧ@ΤηsƧ@ΡAvouVvĪGӵL}Ƨ@ΡA{ɦhƯfҬs򵲪GAҩĪGWVLƥֽTJΧܲ´iĪC	"3-4 times daily, MAX Q2h apply once.

NĻIAq٩UnAYU¥PyACTܥ|YiFnɥiHWܨCpɶ٤@AɥiѩĻI\󨤽WAΦ@LʤuҽkC"	 pҦĪGjPī~AĥԷVӾAϥΡA@X{AYϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Triamcinolone Acetonide+Neomycin	S01C	ܪĩMܷPVĦX ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	0	¥BBdBimgʲewBCʡBLөʤΤNᤧew	sLөʪ̡AҼ{ΡC	pEgΩҪvefcƩΥ[WLطPVAΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-05 [E]_H1-22 j	Ts110.6.16		0	0	OIs 20251124	PWINA-a	PWINA-b	PWINA-c	110.6.16
BC23695421	S01EA05	0	PALPH	Alphagan Poph.sol'n 0.15% 5ml/bot		~D۹W㦳ܩʤ\-2 ǤWEʧ@ξ(\-2 adrenergic agonist)AīpɥX{ypĪGAʪΤHiåЬsBrimonidine tartrateǥѴֲФqPW[彤dyXqA㦳@ξC	"1 drop q8h
ĳqCTACww@wAj8pɡC"	YPɨϥΤ@إHWġAĳܤֶj5C Ķ}ʫAixsǷ25JHUAOs@ӤC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Brimonidine	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	}񨤶Cΰ	TΩbrimonidine TartrateΥĥ󦨤LӯfHA]TΩ󥿦b(MAO)vfHC	LөʵBRBMkoC	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-01 [E]_H1-01 j	Ts110.6.16		0	0	OIs 20251124	PALPH-a	PALPH-b	PALPH-c	110.6.16
BC22934421	S01EC04	0	PAZOP	Azopt 1% eye drop suspension 10mg/ml		Brinzolamide@غһJiФcAӭC	1 drop of a 1% suspension instilled in the affected eye(s) TID	" LDi?ĪLӪ̡A?ܭ?ǥ\Ψx\?̡A
ХiDvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Brinzolamide	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	gζ}ʫCw	Di(sulfonamide)ĪLӡC	ı`.IΫƬܼƤX{ȮɩʵOҽk	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a><a href="""">OI` 14.6.</a>            "	0	0	OIs 20251124	PAZOP-a	PAZOP-b	PAZOP-c	110.6.16
BC23337421	S01ED51	0	PCOSO	Cosopt 5ml/bot		"DorzolamideGһJO@ئb\h´]Aio{ïAiʤƻPGƺҤXκһĲifC_һJAiCcAQ{OgѴwһĲBlͦAHH᭰CuβG骺BA̫ᵲGOCCbgˮ`ΫCॢf]AO@ӥDnMI]lCbrinzolamideOһJ II AbODncJC 

TimololGOA-1MA-2 (Dܩʪ)ǤW_A㦳㪺ͩPgBߦ٧Χ¾K]íw^ī~ʡCTimololǥѴ֤WֲӭMΦФ@ΨӭCCثeäMtimololCu@ξAiOϦ]ͩʤAǤWE@ΦӼW[XcAMPΨCTimololä|vTG-Ф̻ٻP߳JնzʡCߤlbtimololvAo{timolol什yä|oͧ@ΡC"	1 drop in the affected eye(s) BID	bƧ@ΡAҦpOҽkAi|vTfHrpHΩξާ@񪺯OC   ~tGBenzalkonium chlorideAi|ް_EC뤩ĤeKUβAõݦܤ15~WβCBenzalkonium chloride|ynβܦC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. }ʫA1Ӥ뤺ϥΧC
2. ФxsWL30JC
3. m]ˤץxsC"	Timolol	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	gB}ʫCBʭʫCҳyɰ	䤤@ةΨجʦΩҦCξLӡCDiĪLӪ̸TΡC	`PhC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.2._20170201_000.pdf"">OI` 14.1.2.</a><a href="""">OI` 14.6.</a>             "	0	0	OIs 20251124	PCOSO-a	PCOSO-b	PCOSO-c	110.6.16
BC26678414	S01EE04	0	PIZBA	IZBA eye drop 0.003%		Travoprost O@ؤHuXeCF2\ CTravoprost ġ]@ثeC^O@ؿܩFPePľA@{iɸ彤dq]uveoscleral outflow^yXtסAǦCC	ĳζqCѱߤW󿩯fwJ@wĤC	1.Travoprost IGQq|ϧt´ܤơC2. iϱvWMX ( vellus hair ) vX{ܤơC3. Ωiʲo ( p彤 ) w̮pߨϥΡA]oi[@C4.Lhϥtravoprost IGvL{q~ ( ]An~ ) רҡC5.ϥΦhqĲ~ī~ɡAoͲӵߩʨרҡC6.IIZBA eUβAéIī15 AsWC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. }ʫA1Ӥ뤺ϥΧC
2. ФxsWL30JC
3. m]ˤץxsC"	Travoprost	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	Cζ}ʫC~w̤C	糧~LӪ̡ATϥΡC	`BEPBiܡBWhC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-08 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a><a href="""">OI` 14.7.</a>            "	0	0	OIs 20251124	PIZBA-a	PIZBA-b	02C26678-2	110.6.16
BC23537414	S01ED51	0	PXALAC	[]Xalacom2.5ml/Bot(Catanoprost+Timolol(N)		"1. XalacomtGئGlatanoprostMtimolol maleateCoGئOgѤP@ξ୰CwɰAӥBXkϥγ@k୰CC
2. LatanoprostO@prostaglandin F2\lͪA@ܩprostanoid FP@ξAiǥѼW[ФGyXqӴֲCDn@ξରW[彤dФGyXqC~AHiXAiǷLW[~ye(֤p٥~yO)CLatanoprostﲴФG͵L@ΡA祼o{latanoprostGФپβ`@ΡC
3. TimololOA-1MA-2 (Dܩʪ)ǤW_A㦳㪺ͩPgBߦ٧Χ¾K]íw^ī~ʡCTimololǥѴ֤WֲӭMΦФ@ΨӭCCثeäMtimololCu@ξAiOϦ]ͩʤAǤWE@ΦӼW[XcAMPΨCTimololä|vTG-Ф̻ٻP߳JնzʡCߤlbtimololvAo{timolol什yä|oͧ@ΡC"	"1 drop in the affected eye(s) once daily.
1. Hĳq (]AѦ~H)Gĳv覡C馭I@wĤfCYѰOP@ϥξqɡAUĮɤ̥`qPCfC骺qiHWL@wC
2. Ĥ覡GpG֥ΨLϥΪλsɡAPUIGɡAܤֻݶjC
3. ൣMC֦~GܤإߨൣMC֦~ϥXalacomwʤΦĩʸơC"	" w㦳~MI]lw̡C
ĳoǱw̨ϥlatanoprostSOpߡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ҪĲ~G2-8XCNáCѾ\~Х
}ҫ᪺eG4gC"	Latanoprost	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	}ʫCΰgAB什]BLOCKERvLĮ	"Latanoprost-timolol maleateTΩ󦳤UCpw
̡G
 - IlDefA]AީʮݡBީ
 ݤfvBYCʪʪͯfC
 - uʤ߸LCFfAuXgAuЪ_A
 pacemarkerLkBĤGũβĤTũЫǶǾ
 _F㤧߰IܡFߦ]ʥJC
 - latanoprostBtimololΥ~󦨤LӡC
"	EPA]AhB`Moo(12%)FR(7.4%)Ff(3.0%)FX(3.0%)F¥(2.5%)Fkh(2.3%)FYh(2.3%)F֯l(1.3%)CϥXalacomɡA禳i|X{WϥlatanoprosttimololɩҲͪ䥦}C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.2._20170201_000.pdf"">OI` 14.1.2.</a><a href="""">OI` 14.7.</a>             "	0	0	OIs 20251124	PXALAC-A	PXALAC-b	PXALAC-c	110.6.16
BC22540414	S01EE01	0	PXALAT	[]Xalatan 0.005% 2.5ml/Bot(Latanoprost(N)		"1. ʦLatanoprost@prostaglandin F2\lͪA@ܩprostanoid FP@ξAiǥѼW[ФGyXqӴֲCHbījTܥ|pɶ}lCAbīKܤQGpɹF̤j@ήĪGA䲴U@Υiܤ֤GQ|pɡC
2. Dn@ξରW[彤dФGyXqC
3. uϥLatanoprost|ް_ʤgfHqå|
4. {ɨϥξqLatanoprostAŦޤΩIltΦ㪺Ĳz@ΡC"	1 drop in affected eye(s) once daily in the evening	xsN	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ҪĲ~G2-8XCNáC
}ҫ᪺eGxs25XCHUABϥΤŶWL
4gC"	Latanoprost	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	HWൣPHCBC	"Hypersensitivity to latanoprost, benzalkonium chloride or any component of the formulation"	"Conjunctival hyperemia, ocular irritation, burning, Blurred vision, itching, eyelash formation, hypertrichosis of eyelid, eyelid skin darkening, iris pigmentation"	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B05-04 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a><a href="""">OI` 14.7.</a>            "	0	0	OIs 20251124	PXALAT-A	PXALAT-b	PXALAT-c	110.6.16
BC24977414	S01ED05	0	PART2	Mikelan LA 2% oph solu 5ml (Carteolol)		s]_A@λPpropranololPAiΨӭCsCw̪C	"1 drop in affected eye(s) BID

MikelanIG2%AC1 1wA1 1 C"	}~iOs@Ӥ;YݯfvAЧiv	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Carteolol	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	CB	wΥX{ޮݡA޵j˯gYCʪͪ몺w;糧󦨤LӪw̡C	ıҽkBkoC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a>             "	0	0	OIs 20251124	PART2-a	PART2-b	PART2-c	110.6.16
BC16483435	S01EB01	RίS}ĤH	PPIL2	Isopto-carpine 2% 15ml/bt(Pilocarpine)		~ઽxPEʪAG|ɭP٩M骺YAiֲФͦӭCC	"1-2 drops to the conjunctiva in affected eye(s) up to 4 times per day

CIGw󲴷ACITAΨ̷vܨϥΡC"	 Fתٵj˩ҭPȮɩʵOC~ASwƧ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Pilocarpine	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	YΩ󱱨CʫC	ʭimATϥΥC	ӷPʫhuCϥΥiɭPĲʹLӡC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668752?cesid=6sejMSq2W1S&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPilocarpine%26t%3Dname%26acs%3Dfalse%26acq%3DPilocarpine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.16		0	0	OIs 20251124	DC	DC	DC	114.05.16
BC19259421	S01ED01	0	PTIM5	TIMOPTOL(TIMOLOL)		TimololGOA-1MA-2 (Dܩʪ)ǤW_A㦳㪺ͩPgBߦ٧Χ¾K]íw^ī~ʡCTimololǥѴ֤WֲӭMΦФ@ΨӭCCثeäMtimololCu@ξAiOϦ]ͩʤAǤWE@ΦӼW[XcAMPΨCTimololä|vTG-Ф̻ٻP߳JնzʡC	1 drop in affected eye(s) QD or BID	MLλs@ˡA~i঳ʧl	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Timolol	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	CBC	"1.wʮDefBݩΦݯfvYCʪʪͳewfg̡C 
2.uʤ߷iLCFuжǾɪFGשΤTשЫǶǾɪF߰IܡFߦ]ʥJC
3.糧~LӪ"	ȮɩʵOҽk	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-06 []_08-05 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a>             "	0	0	OIs 20251124	PTIM5-d	PTIM5-b	PTIM5-c	110.6.16
AC07819100	S01EC01	0	OACETA	Acetazolamax 250mg/tab(Acetazolamide)		"1. ~carbonic anhydraseAӭCǤpާΦH+MHCO3-A]i֪ݵǤpަAlHCO3-]|֨ѵݵǤpީMްNa+ -H+洫H+lqCѩW[GƥXNa+MHCO3-K+A]ӭQ@ΡAɶv|ɭPN©ʻĤr(ӭM~Na+MHCO3-||)AYi@BAΡA|ϧQ@δzC
2. CA|֤UCĪǤpަAlAӭC̪Glithium, barbiturates, nitrofurantoin, salicylatesMLĩʪC"	"@릨Hq:
sCG쾯q250mgAfAA@1~4Cq̯fHӼЩwC
oʫCΤNeC-250mgAfAAC4pɤ@AǯfH@Ѩ⦸YCb@ǫʪpUA쾯q500mgAӫCj4p125250mgΡC
־GfAACѨC魫830mg]q`쾯q10mg^A̦h4AΡCq`@375mg~1gC
QGfAAC魫5mg]q`250375mg^A@Ѥ@A󦭱AΡCCj@ѩΤGѪAΡC
@ൣqG
CGfAACѨC魫830mgAq`OC魫1015mgΨC褽n300900mgAAΡC
־GP@릨HqPC
QGfAAC魫5mgAΨC褽n150mgA@Ѥ@A󦭱AΡACj@ѩΤGѪAΡC"	"1.Amphotericin BB CorticosteroidsCorticotropinPĨ֥ήɡAiಣYC[gASOdNC
2.PDigitalis Glycosides֥ήɡAWjPC[gDigitalisrʪiC
3.InsulinΤfAܿ}fĪPĨ֥ΡA}@η|CC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	JsKeAx󳱲D1530JBҡC	Acetazolamide	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	CΤUCewUvG~Bw	DνξLӪ̽ФŪA	Bh¡BzC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-02 [s]_10 [®]_10 [E]_A1-01 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a>             "	0	0	OIs 20251124	OACETA-a	OACETA-b	OACETA-c	110.6.16
AC46990429	S01EB06	0	PNEOS	Eyehelp eye drop 0.01%/10ml(Neostigine)		~OWSxP୞JAbxPEʱ骺xP୞JʩMACh˪@ΡASOObg٦ױXC~iٷ|W[Ĳe(presynaptic)gXAChC	2 drops TID	 ץB׼F}ʤ@ӤAФ~ϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Neostigmine methylsulfate	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	y٦ׯgﵽ	糧~LӪ̡ATϥΡC	ϥΥ~ɥi|YpBCBjˡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-05 [E]_H1-06 j	Ts110.6.16		0	0	OIs 20251124	PNEOS-a	PNEOS-b	PNEOS-c	110.6.16
BC16711421	S01FA06	·I	PMYD1	Mydriacyl 1% Oph Sol'n 5ml/bot		Tropicamide O@λPatropine ۪񪺧xPsALPٳ·@Ϊɶ֥B uC wJ20 25 YiF̤jĪGA5 6 pɤi_`C MYDRIACYLR I @اxPĪAi_լA٤ηٹxPEAiөj()C	"Examination of fundus, 1-2 drops 0.5% solution in the eye(s) 15-20 min prior to exam

̱pݭnCI12wC"	קK}λݭnıʪu@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Tropicamide	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	ηٳ·	1.ШUʤCw̸TΡC 2.Y糧ī~͹LӲ{H̽аϥΡC	OҽkBEPBYhC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PMYD1-a	PMYD1-b	PMYD1-c	110.6.16
		0	PAT001	Atropineξ 0.01%		~O@anticholinergic AѸ`xPg@Ω󥭷Ʀ٩M\A̪Ĳz@άOѩAQxiƥPg@ΡC	"C1-3,C1w"	ϥΫ|͵OUkAקKrpTC Ĭi^\]recap^tG߱󦡤p]˲ĤAݩ24pɤϥΧC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Atropine	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	Bٳ·C	~ΩCAΪ̦ʫCɦVfHC	ȥBZվA@ΤC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-01j	Ts110.6.16		0	0	OIs 20251124	PAT001-a	PAT001-B	PAT001-c	110.6.16
AC49016421	S01FA01	εIG 0.125H	PATR01	Kintropine eye drop 0.125% 5ml/bot		~O@anticholinergicAѸ`xPg@ Ω󥭷Ʀ٩M\A̪Ĳz@άOѩAQxiƥPg@ΡC	"Uveitis: 0.125% ophthalmic solution, 1 drops OPHTHALMICALLY 1~3 times a day
Pediatric: cycloplegic refractionX1 drop of 0.125% (age 1 yr) ophthalmic solution instilled in eye(s) up to 1~2 times a day.

A. Ωٳ·ʧg(}): Ω󵲽A112AC1wC 
(1) (j1):ϥο@:0.125%AΥvܨϥΡC 
(2) p(15):ϥο@:0.25%AΥvܨϥΡC
(3) p(5Mj5ABOŭi):ϥο@:0.25%AΥvܨϥΡC
(4) p(5Mj5ABOti):ϥο@:0.5%1%AΥvܨϥΡC
B. Ω󸲵彤:Ψ쵲Aϥο@:0.125%1%A1 13AC1wC
C. ΩNթj: Ψ쵲Aϥο@:0.5%1%A 113ΥvMwAC1wC"	Щ}ʫ1Ӥ뤺ϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Atropine	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	Bٳ·	~ΩCAΪ̦ʫCɦVfH	ϥήɡA|ȥΪZո`O{HC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5767295?cesid=1fNsQ3jfmTb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAtropine%26t%3Dname%26acs%3Dfalse%26acq%3DAtropine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.09.23		0	0	OIs 20251124	DC	DC	DC	114.09.23
AC58058429	S01FA01	0	PATR5	Santone oph.soln 0.5% 5mg/ml;10ml/bot		~O@anticholinergic AѸ`xPg@Ω󥭷Ʀ٩M\A̪Ĳz@άOѩAQxiƥPg@ΡC	q`@12wA@24AguWC	"1. 靈CΦɭPUʫCɦVw̸TϥΥ~C
2. קKsϥΡACʫCw̨ϥΫᶷ@lˬdC
3. eCw̨ϥέn`NC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Atropine	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	Bٳ·C	靈CΦɭPUʫCɦVw̸TϥΥ~C	@ʹLqɡGVBoNBhB߸[֡ByBKB~j̷|믫鱫BC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-04 j	Ts110.6.16		0	0	OIs 20251124	PATR5-a	PATR5-b	PATR5-c	110.6.16
AC37866421	S01FA06	0	PMYD5	SINTROPIC 0.5% oph.;5ml/bot (Tropicamide		~@اxPĪAi_լA٤ηٹxPEAiөj()C	"}ɡGN1% Solution 12wAwJAb5Ƥ@ΤGApGfHb20'~30'Qݨ}ɡAB~Iw]\|vĪGC
 fundusˬdɡGˬde15'~20'0.5% solution 12wC
Yۦ⪺iӮ׮ɡA]\ݧjqC
 
 
"	"PLPAWββeвLɥήɩy`NC
(})Aݭnٳ¾K@ΩɡAuݭnt~[@wYiC
TropicamideIGiyɰCYǯfH(pGֱw)AiॼE_XwCC}lve˴MⲴeШת`סC
pGw̹xPĪPʸATropicamidei໤o믫fʤΦ欰ê
TropicamideIGwJA(¥P汵B)ܤ֨H֥ʧlC
~tBenzalkonium chlorideAӦiﲴyEAåiϳnβܦCקKPnβ豵ĲC
ITropicamideIGeAUβAéIΫܤ15A^C

ൣfHڸsG
TropicamideIi|޵oϯgtλêAΨൣyM`C
ൣLqϥΥi|ͥʤrgCϥΩBBgൣBj˩ʳ·θl˪̶SOpߡC
`NTropicamideIGൣfArʡAĳϥΫM~ۤvPൣC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" 25JHUOsC
 "	Tropicamide	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	ˬdթjγ·١C	"ťΩШUʫC(narrow angle glaucoma)C
糧~󦨤LӪHC"	"YwBYhBOҽkBȥBkhBEPBRB֡BCBߡB֯lBĪ@()
ٳ·Īi|W[Aåi㦳P̵oͩШUʫC
woĪ|ް_믫fʤΦ欰êqASOObൣ
xP(anticholonergic)ĪLrʯg]AGֽBHBֽB߸[t۬O߸LwBƦֻPfBGzįʭCPKBdλġB޻P\c֡C"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-07 j	Ts111.8.30		0	0	OIs 20251124	PMYD5-a	PMYD5-b	PMYD5-c	111.8.30
BC22856421	S01GX06	0	PEMAD	Emadine oph.sol'n 5ml/bot(Emedastine)		"EmedastineO۹ܩʪH1_C

P󵲽A]´EҭP޳qzʨ㦳@ר̿ʪC"	"1 drop in affected EYE(s) up to four times daily
ĳqOCI@wwACѤGCpݭnAi@I|C"	FקKìV~~ηGA`Nn~fIĲ¥ΩP䳡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Emedastine	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	LөʵgμxԪȮɩʽw	wEmedastine difumarateEMADINE@LӪ̸TΡC	Yh	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PEMAD-a	PEMAD-b	PEMAD-c	110.6.16
AC55989421	S01GA51	0	PLEMI	Lemin eye drops 5ml/bot		"ChondroitinΦ.,yS´,Ywew,´ChondroitinfƤ´ƥX,ϰӭMᬡ@,PiN©,Ѱh
NaphazolineHަY@,ihRYp~,ivLөʤΪgHRP~"	"1-2 drops bid-qid
@1~2wIA@I2~4C"	ϥμƤAӯgﵽΦR夣h{HϥΨçYvƶEC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Chondroitin	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	BhҡBRB	糧~LӪ̡ATϥΡC	קKϥΡAHۭPRC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-07 [E]_H1-13 j	Ts110.6.16		0	0	OIs 20251124	PLEMI-A	PLEMI-b	PLEMI-c	110.6.16
AC49334429	S01GA52	0	PSPER	Curzolan eye dropƤ10ml/bot		Χܵo	ʵo@CjTpI1wAkC2~3CHC1wAൣC1~2w[UʫC.ⷳHU.ԷVϥ][gw̪`Nϥ]	 ʻ󪢱wpߨϥΡAѩ󥻲~iͥPg@ΡA}fBYŦfBBҪमiζݻ̲ӭMFw̨ϥΥ~ɶh[dNC~i|BPVgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	ANTAZOLINE HCL0.5 MG/ML+TETRAHYDROZOLINE HCL 0.4 MG/ML	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	LөʵB¥tBC	糧~LӪ̡ATϥΡC	iಣ͵uȦӻL`PAּƤHX{gCĥi|oͤʥRg 	h:C ¨Ŧw:	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-02 [E]_H1-04 j	Ts110.6.16		0	0	OIs 20251124	PSPER-a	PSPER-b	PSPER-c	110.6.16
BC23793421	S01GX08	0	PZADI	Zaditen eye drops.0.25mg/ml;5ml/bot		Ketotifen O@ز´iH1-ܾAåBĤ@(?Y)LӤӭM(ΤjӭMBݥʥզyBPʥզyBMʲy)񤶽(pG´iBդTmBe?BpOE]l)CKetotifen iHֶݥʥզyͤƩʡBƻPh?Ƨ@ΡC	"@@w,@ѤG,wJnC"	"bϥΥ~enβ,ӥBϥΫ15oAW
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Ketotifen 0.25mg	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	Ȯɹw]Lөʵް_oC	 Ketotifen ι䤤ξLӤ̡C	`/hBIWַl	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668541?cesid=aBEOttVwQrM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DKetotifen%26t%3Dname%26acs%3Dfalse%26acq%3DKetotifen#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PZADI-			110.6.16
	S01HA04	0	PALC	Alcaine 0.5% 15ml/bt(proparacine)		"Proparacaine hydrochlorideOjĪ¾KADnΩ󲴬C
¾K|gѯgֺifʦa_g߽ĪҰʩMǾɡAF짽¾K@ΡC¾K@ΪDn
쬰gӭMAǷLhƪӭM󤺳ͯlɡAProparacaine|bӭMzZul
ɤjTɰqzʡCHۯgvͳ¾K@ΡAqE{ɭȤ]vɰABǾɦwʫY
]HCF@ΥRΦɡAKiF_Ǿɪ@ΡCثeProparacainePL¾K
vTӭMqzʪTCMӡAhsܡA¾KilqLgӭMתռh
qzʡCح@ΥiͰʧ@qһݪܤơCProparacaineG@اֳtBAΩ󲴳¾KA@ibXͳ¾K@ΡAB۹uɶCժ̪iC⤣|proparacaine¾K@γyvTC"	"`~¾K@~ɡ]pդٺK^AϥΡAC51-2ws4-6C
_uKeI1-2wC
weI1-2wC"	"1.ĳbIīᳬX\ީλWCoiHIĪgѲqDҳyʧlB]
Cʤ}CYϥζWL@إ~IAhC۹jܤ5CĻI̫ϥ
2.Ω󲴬¾KCiΩ`gC
? Ŧfw̩ΥҪमigϥΥnSOdNC
? ϥΧ¾Ki|C¾KɶC
? ϥΩݥΥiɭPW֬rʡ]xiରW֯ʷlAåicƬä[ʨˮ`^
? ϥΥi|ˤfv¡C
? w̡AL̪|]¾KĪGܱoӷPA]pߪ`NBקKN~ˡC
? ϥΥקKEBiJøT|CϥΥ]pդٺK^Aݭnnл\C
? DProparacainePֽĲɥiyLӤAקKPֽĲC
? ALCAINEIGtbenzalkonium chlorideAiyEPABw|ϳnβܦC~A¾KĪG|heAĳtβC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Jsb2-8XC]Bc^C
}ʫ4gNī~C"	Benzalkonium Chloride 0.1 mgC	S01H	"¾K ANESTHETICS, LOCAL"	0	AΩݭnֳtεuɶΪ¾K 	ﬡʦΥξLӪ̡C	LӡB֡BSBVBBBOҽkBȥBթjBkhBEB~ȡBΪABRB\GW[(LרϥΩݥΥ~ANi]¾KW֪rʼvTӾɭPf_)	hĳϥALCAINEIGC	vŭŹ઺qBΪvkįqAMwO_ũΰALCAINEIGvC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[E]_K-01 j	Ts111.8.26		0		OIs 20251124	PALC-a	PALC-b	PALC-c	111.8.26
KC00936248	S01LA05	0	IEYLE	EYLEA inj.100uL/vial;4mg/ml(Aflibercept)(N)		ޤ֥ͪ]l-A(VEGF-A)MLLͪ]l(PlGF)ݩޥͦ]lVEGF@Ai@ֲӭMBͤƧ@ΤΦ޳qzʦ]lCVEGFǥѻPֲӭM2ر骺TiĿE?(VEGFR-1MVEGFR-2)XӲͧ@ΡCPlGFȷ|PVEGFR-1XAVEGFR-1Pɤ]sզyCoǱVEGF-AL׬ơAiɭPfzʪsͦީMLת޳qzʡCboǹL{APlGFiPVEGF-AͨP@ΡAëPiզyΦ޵oC	"1.޷sͫ(é)~֬ʶhƯf(wAMD)
Eyleaĳq2mg afliberceptA۷50LɡC Eylea}lvɬeTӤCӤ`g1As`g3AhC2Ӥ`g1Cw̩v@~AYfݭnAĳ`g覡C4~12g1vC
2.Rߪ(CRVO)o~
Eyleaĳq2mg aflibercept (۷50L)CCӤ`g1C
3. }f~
Eyleaĳq2mg afliberceptA۷50LɡC Eyleav}lɬCӤ`g1As`g5AhC2Ӥ`g1C
4. Rߪ(BRVO)o~ҾɭPOl`C
Eyleaĳq2mg aflibercept (۷50L)CCӤ`g1"	 `gβˬdi|ȮɤzZOAEylea`grpOξާ@O|L\vTCfwbO\R_HeArpξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ЧNëOs(2XC8XC)CФŧNCNĲ~˩~AקKugC
ϥΫeA}ʪEyleaĲ~ibǷ(25XCHU)mF24pɡC"	Aflibercept	S01L	ޯfgվ OCULAR VASCULAR DISORDER AGENTS	0	hƯf	"1. ﬡʪafliberceptΩҦCξLӡC
2. ʩʩκæβPPVC
3. ʩʭײoC"	̱`}(ܤ5%EYLEAvfw)XBkhBդ١BɰBP}BC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-12 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.2._20250501.pdf"">OI` 14.9.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.7._20250501.pdf"">OI` 14.9.7.</a>             "	0	0	OIs 20251124	IEYLE-a	IEYLE-b	IEYLE-c	110.6.16
B020735429	S01XA20	0	PARTE	Artelac oph soln/10ml(cellulose)		ȮɽwѦ]ĲBΨLELҤް_AAi@O@ϥΡAקKhEAνwѲߡC	1 drop 3 to 4 times a day	"1.}ʫiOs@Ӥ2.ϥΫeХ~,YPɨϥΨLλs,жj5ϥ,Ĥ,ᲴĻI"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	cellulose	S01X	L OTHER OPHTHALMOLOGICALS	0	"ȮɽwѲߩҤް_`PPEPC
ȮɽwѦ]tβyAC"	wզ@LӪ̤iϥΡC	EBN`P	w/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-06 [E]_H1-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.5._20240701.pdf"">OI` 14.5.</a>              "	0	0	OIs 20251124	PARTE-a	PARTE-b	PARTE-c	110.6.16
BC21277429	S01XA20	0	PVIDI	Vidisic gel 10g/tube(Carbomer)		"1. Vidisic GelY@ج˳zGAtPolyacrylic acidHʻEXAHʧLߪHu\GAϥήɽGJ\iCCܦGΦAKAξACIɺޤlyApiΦpwAQq޼LUCѩ󥻫~HʰA󲴤sdɶAAΩ󭫯gfvA۩ʱjAiɫO@AϨMOAҥHAYϬOYfҡAC45AYigC
2. Vidlsic Gel@ʦnAiݭnո`IơC"	"1 drop 3-5 times or more frequently during day and before retiring for night

CѤκΫe35AYݭniW[ϥΦơAC@wI󵲽nAϥήβݨUC"	ϥΫi঳ȮɩʵuҽkA}Mާ@ɨϥΩy`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Polyacrylic acid	S01X	L OTHER OPHTHALMOLOGICALS	0	g	糧~LӪTΡCCertrimideLӪTΡC	ϥΫi঳ȮɩʵuҽkA}Mާ@ɨϥΩy`NC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-07 [E]_H1-21 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.5._20240701.pdf"">OI` 14.5.</a>              "	0	0	OIs 20251124	PVIDI-a	PVIDI-b	PVIDI-c	110.6.16
BC21628421	S01XA	0	PKARY	Kary-uni oph0.05mg/ml;5ml/bot(Pirenoxine		"ھQuinoidǻAѤHʥդ٪]OѩtryptophanN»êA䵲GquinoneӤް_Jժܩʲ{HC
_quinoneApirenoxine骺ʳJզj˩MOA]vܦӪquinoneMJյXAqӨJժܩʡC"	@12wA@I35C	ĲGìVAɯfwbIɡA`NűNe~fĲC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Pirenoxine	S01X	L OTHER OPHTHALMOLOGICALS	0	ѤHʥդ١C	椤SSOC	¥BĲֽCjʪhBRBBEPBkoPBOҽkBcBy\BhB`PBP	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-02 [E]_H1-20 j	Ts110.6.16		0	0	OIs 20251124	PKARY1-a	PKARY-b	PKARY-c	110.6.16
A022473429	S01XA03	0	PPATE	Patear eye lotions 10ml/bot		"CMLt
Sodium chloride       3.2mg, 
Potassium chloride    1.4mg, 
Sodium borate           1mg, 
Sodium phosphate      0.4mg, 
Benzalkonium chloride 0.1mg, 
Boric acid              9mg
iﵽߵg"	2-3 drops 5-6 times daily	"1.IɤŨϮefĲβC
2.ϥΫYNee\ʺC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Sodium Chloride	S01X	L OTHER OPHTHALMOLOGICALS	0	ߡB~	ĸTΩ󦹦褧զLӤfH	EBN`P	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-08 [E]_H1-15 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.5._20240701.pdf"">OI` 14.5.</a>              "	0	0	OIs 20251124	PPATE-a	PPATE-b	PPATE-c	110.6.16
B001973421	S01XA98	0	PSANC	Sancoba0.2mg/ml;(Cyanocobamin)		ǥVitamin B12 IPﵽո`\ASOո`ʲhҵoĮġC	"1-2 drops 3-5 times daily

@34AC12wC"	}1ӤAݾlī~C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Cyanocobamin	S01X	L OTHER OPHTHALMOLOGICALS	0	h	ﲴλsDnBGΨLξLӪ̡A˨ϥΡC	sϥ3ѯgѰɡAΨϥΫᲣͲ@hBOҽkβoB~BBEPpAߧYĴNC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P06-01 [E]_H1-17 j	Ts110.6.16		0	0	OIs 20251124	PSANC-A	PSANC-b	PSANC-c	110.6.16
BC23964453	S02AA30	զh٨IղG	EOTOZ	Otozambon ear drops 8ml/BTզh٨IղG 		sĩʧܥͯApolymycinMneomycinA|㧽¾KlidocainwѦժɪkhAFhĪGD	"HG4-5w BID~QID
pġG2-3w TID~QID"	"1.﹪թΪժwԷVϥΡD
2.ϥΧܥͯժw̡Aĩʵ߮iW[AĳϥΤWL10ѥHW
3.Paminoglycoside(gentamycin,kanamycin,paromonmycin,kanamycin)֥ΥiyLӡD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25CHUץxsD	Polymyxin B Sulfate 10000IUneomycin 5mglidocaine 40mgbenzalkonium chloride 0.1mgpropylene glycol 0.44m1glycerol 0.265m1	S02A	ܷPV ANTI-INFECTIVES	0	ӵߩʤް_ճPVΦճ~ťDoC 	դΡAҧtLӤw̡D	ndNҧtNeomycin|ް_LӲ{HiʡD	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O01-05 j	Ts111.9.13		0	0	OIs 20251124	EOTOZ-a	EOTOZ-b	EOTOZ-c	111.9.13
AC47116421	S02AA16	մ_Y	ETARI1	պwEarflu otic 5ml (ofloxacin)		~s}opyridone carboxylic acidXܵ߾A߽ܵd۷sxAѺw(Pseudomonas aeruginosa)GramʵߨGramʵ߳ܥXsx߽ܵd	q`C鵹Ĩ⦸ACN 6 10w Earflu IղGwJդAĤdbզ 10Cq(ϥΦ)hi̾گgHվC	"1. UCw̽ФŨϥΡA糧LӬJҪ̡C
2. UCw̽зVϥΡAYǻêw̡C
3. 便B¨ŰPC(1)hĦwʩ|TwA]ΧYNh̤iPC(2)|ಾܥŤAGPקKšC
4. pĪPA|TwwʡAGpĤŨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Ofloxacin 	S02A	ܷPV ANTI-INFECTIVES	0	~ժBCʤժC	糧~Lӥvw̡C	olBkoBߡBæRBGzΪABUgBvBtwBYhBCreatinineS-GOTAS-GPTAALPiW@	"kĦw:C-WkʭnȷVϥ , SOOWĤ@C"	DnקKϥ/Smܦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669294?cesid=7cLlYRHeIbR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOfloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DOfloxacin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.3.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=12.3._19990801_000.pdf"">OI` 12.3.</a>              "	0	0	OIs 20251124	ETARI1-a	ETARI1-b	ETARI1-c	111.3.15
AC22867421	S02CA04	0	EMYCO	Mycombպw 5ml/bot(ܷPVƤ)		Triamcinolone acetonideGֽTJAoΧܹLӤ@ΡCNeomycinGramicidinGneomycini}ܥͯAgramicidinpolypeptideܥͯAGاܥͯզXϥĨ㦳sĤߧ@ΡAﲣͭ@ĩʤӵߡAjߤOCNystatinG㦳ߤġAרOiΨӪvզ]ߤް_~չDPVC	ϥΫeݥnáFCϥΤT|AC23wAwJչDAΥHֲygĶչDC	iΩIζŲ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Triamcinolone and Neomycin and Nystatin	S02C	Ƥ褤ֽrEMܷPV CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	0	~չD]߷PVBӵ߷PVBʥֽBlʥֽBLӱĲʥֽBoEʱĲֽB֯׷XʥֽBXʥֽBgʥֽ	1.糧~UΨlͪLӪ̡AקKϥΡC 2.woͦսժ~ժfHAקKϥΥ~AHKoͦլrʡC	յhBճ~oBլrʡBwtB֨EPC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-03 [E]_I3-09 j	Ts110.6.16		0	0	OIs 20251124	EMYCO-a	EMYCO-b	EMYCO-c	110.6.16
		0	OACAR1	Acarizax (Hp)Oral Lyophilisate		"C@?ޤUt12 SQ-HDM*зǤƹLӭѨGAѨGDѼڬwǹ?Pwǹ??ӱoC
SQ-HDM OJ?ޤU ?C SQ O@بwͪĻBDnLӭt?HιLӭѨGзǤƤkCHDM hOǹ?^YgC
ACARIZAX O@عLӧK?kCHLӭsҶi?LӧK?kеLӯfHLӭAHܯfHLӭ쪺K̤CLӧK?kOH@ΩK̨t??ĮľǯSʡA ?Lثe?ɧ@ΤT?@ξऴ?ѡCJ?ޤUwҹiW[ǹ?M@ʪ IgG4 åBoPIgE vǹ?Lӭ쵲XʧAiv?4 g[C
J?ޤUiѨMgǹ?yIlLӯefA HĪv?wҹWUIlDҦ?ɮĪGCJ?ޤUѪbO@@ΡA gѯg?wѡB֨Lī~ݨDHδg??ƭI@?efçﵽͬ~C "	"?fHĳ?C@ (12 SQ-HDM)C
?ɮĪGӦb}līj8 14 g|X{C
Ĥ覡
ĳĤ@fA?b?|ҤAΡAfHAΫ?|[ܤ֥bpɡA??Yoͪ??AiHWB?CJ?ޤUO@حᴹfAC@}J?ޤU]˪wߡA?YΰNfAJޤUϨYѡCj1 ~iH]UCU?5 ?iHYFγܶ?Ci?J?ޤU?kɡA]G_v?A?_v??7 ѤAfHi???{F?_v?WL7 ѡANAvs}?BC "	"
wݬOYʹLӤMI]lC}lϥΥ~v?Lөʻ󪢫eAT{fHO_ݯfvCfHPɦݯfvɡAifwAݬM?ƮɡA?YNC?fHPɦYB?íwݮɡA?ĳϥΥ~C
fĵo
Yfĵo(?pGfī󥭭a~ BfļũZfH)BfĶˤfέʧfĤNpޤαήɡA}lJ?ޤUv? A?wgbϥΪJ?ޤUfwAhȰġAfĶˤf¡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	?WL30 XCAømp?ΤBC	12 SQ-HDM	V01A	Lӭ Allergens		v?H(18-65 )?ް_Lөʻ	"1. 糧~ξ(GelatineBMannitolBSodium hydroxide)LӪ̡C
2. }li?v?ɡAĤ@Ren(FEV1)pw70%fH(bAĪv?)C
3. ̪3 Ӥ뤺X{?Ƥw̡C
4. 㦳ʩIlDPVݱw̡APVv¡~}li?J?ޤU?kC 
5. 㦳ʩʩα?nK̯efBK̯ʳBK̯ʥFBĶλP{
6. ef?ʸ~Fw̡C
7. 㦳YfĤoΤfĤˤffHC "	|BV?PBLB~BL~BfoC 	"h?ϥΪJ?ޤU C?bJ?
ޤUv?hAigѵfw?p(]tͥ\) HίfHeϥΪ
J?ޤUpAӨMw~ġCĳݯfvfHAh
K?ʴC"	ثe|bJ?ޤUv?¨Ū?ɸ?	аѦҾqPΪk	  		  	ixiij	Ts114.10.29		0	0	OIs 20251124	DC	DC	DC	114.10.29
AC58837277	V03AX	0	IPG2	PG2 500mg/vial		Ĳz絲GҹAhS_`g㦳EyMWjK̥\઺@ΡC	~HCq500mgAH2.53.5pIwRߺw`ACgGܥ|Cϥ2g4gC 	"q500ml NS10mlts,AH500ml NS} .tsǷťi24hrC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~}ʥi25JHUOsAmBAgC 	"Polysaccharides of Astragalus membranaceus
~Ϧh(Polysaccharides of Astragalus membranaceus) Ѩ 500mgC"	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	AΩg]efiiҾɭPׯhүgﵽC 	LC	Ƨ@Ψä`AjhLBuȡAkoBL֯lYwC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_07-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.20._20210325.pdf"">OI` 3.3.20.</a>              "	0	0	OIs 20251124	IPG2-a	IPG2-b	IPG2-c	110.6.16
BC17124221	V03AB25	0	IANEX	ANEXATE 0.5MG/5ML/AMP		Ω¾KΥ[@fЮɦ^benzodiazepineR@ΡC	"For conscious sedation or general anesthesia reversalintravenously as 0.2 mg followed by 0.2 mg every 60 seconds until the patient awakens or until a total dose of 1 mg is reached.
Benzodiazepine overdoseintravenous administration of 0.3 mg up to a total of 1.5 to 10 mg."	"If a patient has not responded 5 minutes after receiving a cumulative dose of 5 mg of flumazenil, the major cause of sedation is likely not to be due to benzodiazepines, and additional flumazenil is likely to have no effect"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Flumazenil	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	Ω¾KΥ[@fЮɦ^benzodiazepineR@ΡC	"Hypersensitivity to flumazenil, benzodiazepines, or any component of the formulation; patient who are showing signs of serious cyclic-antidepressant overdosage"	"Agitation, dizziness, headache, increased sweating, abnormal or blurred vision, injection site pain"	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-08 [E]_G2-02 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=11.2.1._19950301_000.pdf"">OI` 11.2.1.</a>              "	0	0	OIs 20251124	IANEX-a	IANEX-b	IANEX-c	110.6.16
AC48184209	V03AB15	0	INALO	Naloxone 0.4mg/ml/amp(Naloxone)		¾Kī~LqѬr	"Opioid overdose0.4-2 mg IV/IM/SC, repeat every 2-3 min as needed; if no response after 10 mg, reconsider diagnosis of opioid toxicity."	" ?ϥΥĥ~Ab~?ī~ʤrɡAL?dkpOIlDZqAHuIlAŦPަYA󥲭nɡAϥΥH^ͩRC
NMf~Rī~Ҳͪ@ΡAi|ɭPߡA
RAoAŸݡA߷iLtAWɡAA߫ǩI~\iLtή
ŸAͤ~M߸åiɭP`C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Naloxone	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	¾Kī~LqѬr	"Hypersensitivity to naloxone or any component of the formulation

"	"Arrhythmias, hypertension, hypotension, ventricular fibrillation, hepatotoxicity, opiate withdrawal symptoms, pulmonary edema

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[E]_G3-03 j	Ts110.6.16		0	0	OIs 20251124	INALO-a	INALO-b	INALO-c	110.6.16
BC24603100	V03AC03	0	OEXJA	Exjade 125mg/i(Deferasirox)		~O@بfAʥBTK׿ܩʪgXCO@ӤTet(ligand)iH2G1ҵX˩MʪKlC~PiKƥXADnƥXTKC~ɩMN˩MOCAä|yoǪݪM@׫CgC	"Initial, 20 mg/kg once daily (on an empty stomach, 30 min before food)Fmaintenance, adjust in increments of 5 or 10 mg/kg every 3 to 6 months based on serum ferritin trends; MAX 30 mg/kg/day.
C@eΪŸɪAΡC_lq20mg/kgCC36Ӥվexjade dqAH5~10mg/kgվA̾ڨC@w̪ΪvؼнվCĳϥζWL30mg/kgqC"	1.Ŀtſ}2.~PtTľ@PAΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Deferasirox	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	v]ӾɭPCKHۯg(ʦKIn)~H2HWൣw̡C	󦳮ĦΥ@ξLӪ̡C	GzDAB֯l	קKϥΰDvn/SmҦw/|qLť	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.1._20190701_000.pdf"">OI` 4.3.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.10.13
AC48426229	V03AF03	0	ILEUC3	Folina (Leucovorin) 100 mg / 10 ml / vial		Leucovorin QlͪAB?ġ]folic acid^ƺcyA?ɤWΩ󨾤?٭?@ΡC	"?īܾѬrG
~ϥξ?Dn̾MTX MзǡA@ӨAb`gMTX infusion 2~4pɫĤ@ϥΥ~?6~12mg/m2Ab72 pɤACj3~6 pɦAۦP?v?A?X{YƧ@ΡAh[jév?C "	"~?Av?]ʥFͯB12 ҭP?ʳhΨLyhA]GǤWg?wѲ{H?gHh~i?C
v?W?ϥ?īܾɡA~ib1 pɨϥΡAq`4 pɥHϥήɡAݵLġC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm 2~8JץxsA?OsC	Leucovorin	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	?īܾ]pMethotrexate^L?ѬrC 	ʥFͯ B12 ?ʳhΨLyʳh?TҡC 	]ALөʤMC¯lC 	D 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ILEUC3-a	ILEUC3-b	ILEUC3-c	110.6.16
AC02394238	V03AB04	0	IPAMP	PAMPARA inj.25mg/ml;20ml/amp		CrѬr	"Anticholinesterase overdosageinitial, 1-2 g IV, maintenance, 250 mg IV every five minutes. Organophosphate poisoninginitial,1-2 g in 100 ml NS IV infused over 15-30 min or 5% solution in SWFI over not less than 5 min, repeat, 1-2 g in 1 hour if muscle weakness persists."	Not effective in poisonings due to organophosphates without anticholinesterase activity	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 жJsb1530JC	Pralidoxime	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	CrѬr	Hypersensitivity to pralidoxime or any component of the formulation; poisonings due to pesticids of carbamate class	"Blurred vision, dizziness, headache, laryngospasm, hyperventilation, nausea"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-12 [E]_G3-09 j	Ts110.6.16		0	0	OIs 20251124	IPAMP-a	IPAMP-b	IPAMP-c	110.6.16
BC18485271	V03AF01	0	IUROM	Uromitexan 400mg/4ml/AMP(Mesna)		MesnaOtSHΤƦXAѩPOxazaphosphorineʥN²䵲ӨDHˮ`AƪntvOxazaphoshporineΨN²֡C	Rߪ`gAq۷Oxazaphosphorineq20%CPOxazphosphorine@_ġAMC4pɤ@C	gΰ貾ӯfҨϥΤjqEndoxanFIfosphamideĪɨϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Mesna	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	O@GOXAZAPHOSPHORINESĪҤް_XʻHֵoC	gΰ貾ӯfҨϥΤjqEndoxanFIfosphamideĪɨϥΡC	pGC魫ĶWL60mgAhiಣߡBæRMmBfĲC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=11.2.3._19950301_000.pdf"">OI` 11.2.3.</a>              "	0	0	OIs 20251124	IUROM-a	IUROM-b	IUROM-c	110.6.16
AC367941G0	V03AE07	0	OCALA	Procal 667mg/tab(Calcium acetate)		"~LĶtQACt۷169mgtAa׵ǥ\णfHAN|e{CQxdάYص{תCQg(Hyperphosphatemia)ѩCQxdNɭPGʪƥҪiް_YMn´tơC
]vWwCĦgBzC
vWCĦ媺q: 
(1)֭WCQC 
(2)pzlCQC
(3)gѦĪzRkq餤CQC"	ΩzRHC\GAjzRfHݭnΨC\3-4AfH夤CQȧC6mg/dlAfHϥΥ~|HypercalcemiaX{ӶCCalciferol or Vit.DDoseA~b\e\AΡC	ī~̦nb\e\A	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץtBxsC	Calcium acetate	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	ǰIܥCQg	fHwtQgTҡC	"(1){ɤWϥΥfHǦ߲{HC 
(2)~ϥη|ް_tQgC"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_B1 [2]_B1 [ws]_w25-02 [UDx]_U02-20 [E]_B2-05 [Ew]_EX102 j	Ts110.6.16		0	0	OIs 20251124	OCALA-a	OCALA-b	OCALA-c	110.6.16
BC13086121	V03AE01	0	OKALI	Kalimate powder 5gm/pk		fAPΪ`zᤣQƤΧlAbzޤרbzAtlPzޤ[l洫APolystyrene sulfonateצӨSܤơAӭ˩TKƪnXӡA䵲GNzޤ[ƥX~C	"1. fAGq`H1 1530gA23^A1^qΤ3050ml aBfAC
2. `zPGH1^ 30gΤ 2% MethylcelluloseG100mlaB`zCNūץ[ŵ{פaBG`zmzޤ 301pɡCpĲG~XɥHEY԰vAμȮɱĽݪ׫C
5H}GN  2% MethylcelluloseGiC"	"fVϥΡG
(1) Gް_Kfw]iް_zBzެա^C
(2) zޯUfw]iް_zBzެա^C
(3) ƹDŤfw]iϯgcơ^C
(4) ƥҪमigfw]l洫iϦ夤t@פWɡ^C
(5) hoʰ~fw]l洫iϦ夤t@פWɡ^C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Calcium polystyrene sulfonate	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	ʤκCʵǤH񤧰[gC	z뤧fw]iް_zެա^C	KBBߡBC[gC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I2 [2]_I2 [UDx]_U01-53 [E]_C2-19 j	Ts110.6.16		0	0	OIs 20251124	OKALI-a	OKALI-b	02C13086-2	110.6.16
AC49388121	V03AE01	0	OKAYE	Chalian powder		fAPΪ`zᤣQƤΧlAbzޤרbzAtlPzޤ[l洫APolystyrene sulfonateצӨSܤơAӭ˩TKƪnXӡA䵲GNzޤ[ƥX~C	"PO, 15 g 1-4 times daily as a slurry in water or 70% sorbitol.
Rectal, 30-50 g every 6 hr as a warm emulsion in 100 mL aqueous vehicle (sorbitol or D20W), retain 30-60 min.
1. fAGq`H1 1530gA23^A1^qΤ3050ml aBfAC
2. `zPGH1^ 30gΤ 2% MethylcelluloseG100mlaB`zCNūץ[ŵ{פaBG`zmzޤ 301pɡCpĲG~XɥHEY԰vAμȮɱĽݪ׫C
5H}GN  2% MethylcelluloseGiC"	ƥҪमigfw]l洫iϦ夤t@פWɡ^C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Calcium polystyrene sulfonate	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	ʤκCʵǤH񤧰[g	z뤧fw]iް_zެա^C	KBBߡBC[gC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_I2 [2]_I2 [UDx]_U01-55 [E]_C3-08 [Ew]_EX112 j	Ts110.6.16		0	0	OIs 20251124	OKAYE-a	OKAYE-b	01C49388-2	110.6.16
AC44248100	V03AF03	0	OLEUC	Folina 15mg/tab(Ca Folinate)		Leucovorin QlͪABġ]folic acid^ƺcyA{ɤWΩ󨾤٭J@	"Methotrexate rescuePO,15mg
Megaloblastic anemia15 mg Orally once daily; for children under 12, 0.25mg/kg/da
q`C1AC1"	vWqϥθīܾɡA~ib1 pɨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Calcium Folinate	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	WqϥθīܾɡArʤΩ@ΡBv]ciʥFBWΨ䥮ֵް_yʳh	ʥFͯ B12 cʳhΨLyʳhCTҡC	ߡBzGABLӡBC¯lB	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_H3 [2]_H3 j	Ts110.6.16		0	0	OIs 20251124	OLEUC-a	OLEUC-b	OLEUC-c	110.6.16
BC18273100	V06DD	0	OKETO	KetosterilƤ630mg/tab(ĸɥR)		  ĸɥR	"fACvBϥΩΥHCѨC魫@ɡATAYɤ@A 
70礧HA@48A@ѤTC\AΡC"	"iP (ӧ]A, iCZ/HA). 
ttī~(ҦpGacetolyte)iް_MttqfzʼW[CѩKetosterilϧrgAYAβBƾTqC`NMCQ֡CFקKzZlAŦPɧPMtΦƦXĪ(ҦpGtetracycline)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	AMINO ACIDS+ L- LYSINE ACETATE+ L-THREONINE+ L-TRYPTOPHAN+ L-HISTIDINE+ L-TYROSINE	V06D	䥦i OTHER NUTRIENTS	0	CʵǤɮĤɵCϥήɴGǸyLov5-15 ml/minABJս褧@Ѥ֩40 gfwC 	tgBiĥN¯áCثe|LΩ󥥰Υधi	tgCwˬdMttqCTwfwdC	 DvnAקKϥ	 DvnAקKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_D1 [2]_D1 [ws]_w34-07 [E]_B4-02 j	Ts44322.4969212963	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.2._20151201_000.pdf"">OI` 3.3.2.</a>              "	0	0	OIs 20251124	OKETO-a	OKETO-b	OKETO-c	44322.49692
		0	OXOFL	Xofluza 20mg/tab (Baloxavir marboxil)		Baloxavir marboxilʪܩʧAByPfrCAP̦sʤC(Cap-Dependent Endonuclease)CCAP̦sʤ?@دѧOä_JDӭMmRNAeXAqӲͯfrmRNAXݤޤl(primer)RNAqïCBaloxavir marboxilʪACAP̦sʤCAiӪ_frmRNAXAHFfrWާ@)C	"vyP
ĳgoͫ48pɤ榸ϥΡC
SwyP
ĳKĲyPfH榸ϥΡC
ζqG
魫4080窺H12HWൣAĳq榸fAP
20mg2(Baloxavir marboxil 40mg)F魫80HWfHh榸fAP20mg4(Baloxavir marboxil 80mg)C
AĮɡAiPΤP֪AAקKMŻs~Bt~BthlwmBܻľΤfAɥR(ҦpGtBKBBִξN)֪AC "	UCfwзVPGרx\णfwC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUOsC 	Baloxavir marboxil	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0	"AΩvH12HWൣAByʷP_frʷPVC
AΩ󦨤H12HWൣKĲyPfHwyʷP_C "	糧Ĥ@o͹LӯgfwC 	m	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
	L01EH02	0	ONERL0	ĵNeratinib 40mg (NERLYNX)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"						wH֥ͪ]l2 (HER2)ʤHfHA@bttrastuzumabUk᪺jƻUʪv 					аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124	ONERL0-a	ONERL0-b	ONERL0-c	
		0	OIBR10	ĵ Ibrance 75mg/cap(Palbociclib)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	OIBR10-a	OIBR10-b	OIBR10-c	
		0	EGLYC	Glycerin 10ml/Bot (ե)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124	EGLYC-a			
		0	OMACU1	Macutein Ƥ					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	OMACU2	*Macutein-Comax Ƥ					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XISO1	Omnipaque (Iohexol) 10ml/bot		IohexolO@ثDlAEXAXTӸKXyv	"Rߪ`gG
HcDyvIohexol(300mgK/ml)40-60mlFൣ7kgAIohexo(300mgK/ml) 3ml/kgAൣ7kgAIohexol(300mgK/ml) 2ml/kg (Max:40ml)ALv(300mgK/ml)G20-100ml/LFƦƦvG(300mgK/ml) C`g20-60mlFq_hWjvA(300mgK/ml)HG100-200mlA`Kqq`30-60gFൣG1-3ml/kgAܦh40mlD
ʯߪ`gG
Dʯߤ}(300mgK/ml):30-40ml/Aܩʸʯ(300mgK/ml):5-10ml/AѰʯ(300mgK/ml):30-50ml/ADʯ(350mgK/ml):40-60ml/
ŦvG
߫ǤΥDʯ߮ڳ`gG(350mgK/ml):30-60ml/Fܩʫa'ʯߦ޳yvG(350mgK/ml):4-8ml/Fൣ(350mgK/ml):~魫ίfpөwA̦h8ml/kgDƦv(DSA)(300mgK/ml)G1-15ml/kgD
`g:Vv:7-10ml]קKƧ@`KqiWL3g)
ĨϥΡGa.`v:4-10mlAb.lcZvG15-25mlFc.GvG0.5-2ml
q_hWjv]fA^:H]@ץΦۨӤ}6mgK/ml^Aɬqϥ800-2000ml}GAൣ]@ץΦۨӤ}6mgK/ml^G15-20ml}G/kgA"	"Lөήݯfv̡AibˬdeITJH1.H2ܲ´i
޳yveR
קKŦyB~tAyve48pȰǬrʪī~(pmetformin)AٻScrҫ_`D
`gᶷ[30 A]jYƧ@γbbɶo͡A"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Iohexol	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		yvA޳yvAq_hyWjyvAcDyvD	㪺ҪrgAomnipaqueLӪ	ʪżPıAȮɩʪݨDDLIlΥֽgAҦpGIlxAAC¯lAkoAΦީʤ~Di`gHYoͩμƤѫ~o͡D	קKguӮgAvŧQoMwO_ϥvD	tKyvƤ֤cܨťġABƤָgzGDl	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XISO1-a	XISO1-b	XISO1-c	
		0	PH2O2	H2O2 35%					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PHEM	MAYER'S HEMATOXYLIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PHEM1	GILL'S HEMATOXYLIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PHER	MOUSE*HER2(c-erb-2)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PHIS	HISTO-SP BROAD SPECIFIC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PMHEM	*GILL'S HEMATOXYLIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PMPAS	MERCK PASV					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PNFOR	FORMALDEHYDE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PPBS	PBS(PH7.6) 1000ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PPRO	M*PROGESTERONE RECEPTOR					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PRAP	Rapid-decal(tG)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XLIP	Lipiodol (Iodised poppy-seed oil) 10ml/bot		LipiodolOĢߤloҥXӪ@دתջġANcy̪oHAJ୤ơAYoyʩʧjL߸KvLipiodol Ultra-FluidCLipiodotKqAҥHXzLC~PGVXAӥB񭫤jAGZΤvLkӥXۤɡAϥΥ~̾AyC~|@uIAY餺`ֲķӬۮɡAϥξXΤvĪGΡAiHLipiodol U-FӨNAoMXӤAҦpOڷӬۡB?޷ӬۡBzDӬ۵C 	"Rߪ`g覡y~ALUخg覡i
OڷӬۡG氼Oںޤζq5~6mlC
lcӬۡG5~l0mlC
ũзӬۡG0.25~4mlC
踢ӬۡG|2~5mlXUlm1C
DӬۡG10ml20ml30mlA̻ݭnөwC
`gɡAaww[AHU`g"	"1.KLӤΥҪ\ण}Ϊ;णHASOpߡC
2.?ު`gɻݷpߡAHKޡC
3.`gLipiodol U-FPEH޳NAӬ۳줣PAˬd骬pAԷVh[`NC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		lcZޡBDB踢Bw~BxޡB?ޡBOڸvΡC 	"KLӤΥҪ\ण}Ϊ;णHASOpߡC
?ު`gɻݷpߡAHKޡC
sX媺fHAyϥΥ~C"	Lipiodol by[ɡAyʩʷ|W[Altפӧַ|ͬrʡCGϥH׾AAlp}nLipiodol U-FĪGΡC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XLIP-a	XLIP-b	XLIP-c	
		0	PTHY	e					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XOMN1	Omnipaque (Iohexol) 100ml/bot		IohexolO@ثDlAEXAXTӸKXyv	"Rߪ`gG
HcDyvIohexol(300mgK/ml)40-60mlFൣ7kgAIohexo(300mgK/ml) 3ml/kgAൣ7kgAIohexol(300mgK/ml) 2ml/kg (Max:40ml)ALv(300mgK/ml)G20-100ml/LFƦƦvG(300mgK/ml) C`g20-60mlFq_hWjvA(300mgK/ml)HG100-200mlA`Kqq`30-60gFൣG1-3ml/kgAܦh40mlD
ʯߪ`gG
Dʯߤ}(300mgK/ml):30-40ml/Aܩʸʯ(300mgK/ml):5-10ml/AѰʯ(300mgK/ml):30-50ml/ADʯ(350mgK/ml):40-60ml/
ŦvG
߫ǤΥDʯ߮ڳ`gG(350mgK/ml):30-60ml/Fܩʫa'ʯߦ޳yvG(350mgK/ml):4-8ml/Fൣ(350mgK/ml):~魫ίfpөwA̦h8ml/kgDƦv(DSA)(300mgK/ml)G1-15ml/kgD
`g:Vv:7-10ml]קKƧ@`KqiWL3g)
ĨϥΡGa.`v:4-10mlAb.lcZvG15-25mlFc.GvG0.5-2ml
q_hWjv]fA^:H]@ץΦۨӤ}6mgK/ml^Aɬqϥ800-2000ml}GAൣ]@ץΦۨӤ}6mgK/ml^G15-20ml}G/kgA"	"Lөήݯfv̡AibˬdeITJH1.H2ܲ´i
޳yveR
קKŦyB~tAyve48pȰǬrʪī~(pmetformin)AٻScrҫ_`D
`gᶷ[30 A]jYƧ@γbbɶo͡A"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Iohexol	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		yvA޳yvAq_hyWjyvAcDyvD	㪺ҪrgAomnipaqueLӪ	ʪżPıAȮɩʪݨDDLIlΥֽgAҦpGIlxAAC¯lAkoAΦީʤ~Di`gHYoͩμƤѫ~o͡D	קKguӮgAvŧQoMwO_ϥvD	tKyvƤ֤cܨťġABƤָgzGDl	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XOMN1-a	XOMN1-b	XOMN1-c	
		0	PXYLE2	XYLENE 4L/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XAMPI	(Ampicillin)(Subacillin)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XANG	ANGIOGRAPHIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XOMN5	Omnipaque (Iohexol) 50ml/bot		IohexolO@ثDlAEXAXTӸKXyv	"Rߪ`gG
HcDyvIohexol(300mgK/ml)40-60mlFൣ7kgAIohexo(300mgK/ml) 3ml/kgAൣ7kgAIohexol(300mgK/ml) 2ml/kg (Max:40ml)ALv(300mgK/ml)G20-100ml/LFƦƦvG(300mgK/ml) C`g20-60mlFq_hWjvA(300mgK/ml)HG100-200mlA`Kqq`30-60gFൣG1-3ml/kgAܦh40mlD
ʯߪ`gG
Dʯߤ}(300mgK/ml):30-40ml/Aܩʸʯ(300mgK/ml):5-10ml/AѰʯ(300mgK/ml):30-50ml/ADʯ(350mgK/ml):40-60ml/
ŦvG
߫ǤΥDʯ߮ڳ`gG(350mgK/ml):30-60ml/Fܩʫa'ʯߦ޳yvG(350mgK/ml):4-8ml/Fൣ(350mgK/ml):~魫ίfpөwA̦h8ml/kgDƦv(DSA)(300mgK/ml)G1-15ml/kgD
`g:Vv:7-10ml]קKƧ@`KqiWL3g)
ĨϥΡGa.`v:4-10mlAb.lcZvG15-25mlFc.GvG0.5-2ml
q_hWjv]fA^:H]@ץΦۨӤ}6mgK/ml^Aɬqϥ800-2000ml}GAൣ]@ץΦۨӤ}6mgK/ml^G15-20ml}G/kgA"	"Lөήݯfv̡AibˬdeITJH1.H2ܲ´i
޳yveR
קKŦyB~tAyve48pȰǬrʪī~(pmetformin)AٻScrҫ_`D
`gᶷ[30 A]jYƧ@γbbɶo͡A"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Iohexol	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		yvA޳yvAq_hyWjyvAcDyvD	㪺ҪrgAomnipaqueLӪ	ʪżPıAȮɩʪݨDDLIlΥֽgAҦpGIlxAAC¯lAkoAΦީʤ~Di`gHYoͩμƤѫ~o͡D	קKguӮgAvŧQoMwO_ϥvD	tKyvƤ֤cܨťġABƤָgzGDl	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XOMN5-a	XOMN5-b	XOMN5-c	
		0	XBAR	BARITOP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFA	(Cefazolin)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFO	(Cefotaxime)(Claforan)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFP	(Cefpirome)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFR	(Ccfrom)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFT	(Ceftazime 30mcg)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFTR	(Ceftriaxone)(Rocephrin)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCEFU	(Cefuroaime)(Zinacef)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCIPR	(Ciprofloxacin 5mg CIP-5)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XOPTI100	Optiray 350 (Ioversol)  100 ml/bot		DlʧCzʡAzguʹ񾯡ARߪ`gΡD	"ʯXvGH@q20-50mlAqݭniƵD
ܩʫaʯXvG2-10ml
DʯߤΤŦʯXvG20-50ml
R߹q_hy[jGY:50-100ml;:30-100ml
RXvG20-100ml
ƪnʧXvG50ml
pߦXv:1-1.5mg/kg
"	LAޮݩΨLLӲ{HAxǥ\efA~ΥIzAf̡AߦޯefAǲӱw̡AįqέIDScr>3mg/dLƥXʧXvAΨLgʵ{ǡADįqjID	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷťHUBBAץOsFקKbĵeoaC	Ioversol	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		HaʯvM߫ǢguvBgMŦvBq_hyYΨ餧R߹ӼWjBƪnʧguvBR߼ƦkޢguvMRߢguvCൣŦޢguvC 	hùIverosolLӪfH{ɤWwxǥ\ê	",Yw,C¯l,LӤ "	קKguӮgAvŧQoMwO_ϥvD	"]񾯷|ѥűƥX, ϥΫᰱŦܤ48pɡC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XOPTI100-a	XOPTI100-b	XOPTI100-c	
		0	XULT1	"Ultravist (Iopromide) 370 mg iodine/ml,100 ml/bot"		~DlʤGyvC~DDlʤlAGCzAjjC@yviಣͤrʡAӥB۪ﵽFβ´@ʡAYϬOH餤QӷL´ApޡB֤ΤϯgtΡC 	"@ӻA1.5gK/kg}n@ʡAP`gɶ´G^ޤAϼWz^íD
ǲΪv:
Dʯߤ}v:50-80ml(300mg I/ml);ܩʪv:6-15m(300mg I/ml)l;ݵĥDʯv:50-80ml(300mg I/ml370mg I/ml);Dʯv:40-60ml(300mg I/ml)
ʯvGWϡG8-12ml(300mg I/ml)UϡG20-30ml(300mg I/ml)AŦv:߫:40-60ml(370mg I/ml)AaʯvG5-8ml(370mgI /ml)
RߤƦƴv޳yvN(DSA):FjޫĳH30-60ml`gH20-40ml 0.9%NaCl`AHvqD"	"ˬdeGpɥTAGpɤei`D
ˬdeRɥRD
ˬdeNv[37סAiHCvHYצӤe`g.
Ǥߦޥ\णfHAϥΪvqɶq֡Aˬd[ǥ\3.
iɭPw?ȤUD
tKvi޵oҪ\मiΥҪrD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 
}~ᢰpɥ"	Iopromide	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		q_hvAƦƴv޳yvNAR߳yvARߤyvARX-yvΨŵĳ(p`vAlcZX-vAὺ޳yv)ճyvAθvθv~D	evLӪ̡AޮݩΦLfv	YwAYhAıPı`AkhAżA~D	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XULT1-a	XULT1-b	XULT1-c	
		0	XCRAV	(Cravit)(Levofloxacin)paper disk					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XENTA	Entapenem(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XERTA	Ertapenem(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XEXAC	Exacin (ISP)(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XFINI	Finibax(Doripenem)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XFLUM	Flomoxef DISC(Flumarin)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XFORT	Fortum(Ceftazidime) DISK					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XGEN	(Gentamicin)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XIMIP	Imipenem(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XVISI	"Visipaque (Iodixanol) 320 mg/ml,100 ml/bot"		IodixanolO@ثDlAEXAXӸKXyvA{ɤWҨϥΤUؿ@תIodixanolGAά۷jתDlAEG㦳CzD	ʯߪ`gG1.ܩʸʯ(320mg/ml)C`g5-10mlF2.Dʯ(320mg/ml)C`g40-60ml;3.Pʯ(320mg/ml)C`g30-60mlFŦ޳yvGH߫ǩΥDʯ߮ڳ`g(320mg/ml)C30-60mlFܩʫaʯߦ޳yv(320mg/ml)GC4-8mlFൣG(320mg/ml)̦~魫өwAWL10mg/kg	fHb`gveAAǥ\णfHAiAyveᢳpɰΨǬrʪī~ApmetforminAٻíwA}lAΡD	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	C󢲢עץxsA~˥iϥΫeעxs@Ӥ	Iodixanol 320mg/ml	V08A	"XguyvAKƾ X-RAY CONTRAST MEDIA, IODINATED"		X ΩŦޡBޡBPʯ߳yvBİʯ߳yvBcDyvBR߳yvBq_hv[jCyաBݴդVդyvC	"㪺ҪrgD
糧~YLӡD"	̱`}OLΧNPıAP޳yv̱`PAkhALLӤiOYAߧYvD	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XVISI-a	XVISI-b	XVISI-c	
		0	XMEPE	Mepem(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XMERO	Meropenem Sensi Disc					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XMOXI	Moxifloxac(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XGADO	ĵGadovist 1.0ml/7.5ml/syringe		"´zʨΩίʥF帣̻(blood-brain barrier)A]`{קܩβӭM~Ŷ[jAҦpGoʤ~oʸ~FAoʯefAhTeffҪE_Cb`g\hAio©MRI˧nE_TC
\h`gGSOAΩ󶷨ϥΰqAgAҦpG|vTfHvγBmf_㹳αưCLpf_ΥOlvf_SXӡC
\h]AX`ϰ쪺sAҦpGE_Aʦ媺θ~F`ΡC
wwκæwaʯ߯ef(coronary artery disease, CAD)~fHAΩŦϮyvHO(stress)P𮧪A(rest)ߦ`AHεv(late gadolinium enhancement)C"	ϥξq̾ھAgөwCq`C1魫`g0.1 ml(Y0.1 mmol@gadobutrol)~YwC̰`gqC1魫`g0.3 ml(Y0.3 mmol gadobutrol)~C@ӨAC1魫`g0.1 ml~wѪR{ɤWDCpG@ζqܪƤIζi@BT{f_ƥءBjpBdHTwv覡PBmkɡAi`g30Ah0.1Ʀ0.2 ml/kg魫~AHWjE_GC	"NSFoͩtgadoliniumvưΤfHAרOϥθī~ĳqέƵĤΡA䭷IW[C
(1) ưtgadoliniumvΤfHAiW[fHo͵ǥͩʤֺf(NSF)IC
(2) ī~ϥΩCYŦef(GFR< 30mL/min/1.73 m2)ΫʵǷlˤfHAoNSFIF̰C
(3) ϥΥī~e˵fHŦ\ౡΡAܤ˵fH3Ӥ뤺serum creatinine˴GAõfHO_ʵǷl˩ΨLi୰CŦ\ध(pj60BB}f)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~20-25XCi24píwALаȥC	gadobutrol	V08C	Ϧ@yv MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	0	"~ݶE_ġC
GadovistAΩ󦨤HΩҦ~ּhൣ(]Asͨ)Ϯy
vWj@(MRI)A]AG
`MϮyv(MRI)Wj@
ũкϮyv(MRI)Wj@
Ϯyv(MRI)Wj@(xŦ)
ֺϮyv(MRI)Wj@(eCMlc)
ḡĺϮyv(MRI)Wj@(Ŧ)
ϺݩM٦װftκϮyv(MRI)Wj@
޺ϮyvWj@(CE-MRA)
ŦϮyv(Cardiac MRI)Wj@"	ϥΥ~S諸TүgC	YhA	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XGADO-a	XGADO-b	XGADO-c	
		0	XOFLO	Ofloxacin(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XOMNI	Omniscan 20ml/bot(Gadodiamide)		Gadoteric acid㦳ƺ(Paramagnetic)ʽAi[jMRICSĮľǬʡAץͲzkʡC	"Rߪ`gC
jHApĤC魫0.2mlC
ggˬdɡAiϥΨC魫0.4mlq`gĤGC
ϰ쪺޳yvɡAiϥΨC魫0.2mlq`gĤGC "	"1.fHYǰIܮSO`NC
2.iѻjU(εw~)`gC
3.iΩժ`gC 
4.ר쭫׵Ŧefw̡AbMRIMRAɡA뤩tgadoliniumviް_ǥͩʤֺf(Nephrogenic System Fibrosis or Nephrogenic Fibrosing Dermopathy, NSF/NFD)AֵogiɭPfw᪺IzΦ`C
5.ר쭫׵Ŧefw̻ݳyvsɡAiܤ`gGadoliniumMRIΨLˬdAխYoǯfwgadoliniumvɡAyҼ{twƳzRC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Gadodiamide	V08C	Ϧ@yv MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	0	ֺϦ@vG-ggǡ]neuroradiology^GդΩP´~FB`~FC-gǡ]abdominal radiology ^Goʤoʸ~FC-γn´oʸ~FC- ΩLΦvC 	"1.a߽߫վ㾹̡C
2.aާ̡C
3.Gadolinium saltsLӯfv̡C"	"1.ǯfҦb`g~ˬdߡBæRΥֽC
2.Yī~XRߥ~ɡAi|khC
3.`gƺϤƦXAibuΤUAͥJLөʤAiݭnBzC  "	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XOMNI-a	XOMNI-b	XOMNI-c	
		0	XPRIM	ĵPrimovist 2.5mmol/10ml/syringe		"xO`gAE_WunbxwƤUACTMRI e{x嫬ޯSxYiFYOCTMRI E_xAiϥιvWiASOOɶdxŦSonazoidA󦳧UE_F]iϥΨxӭMSʹPrimovist-MRIAbxӭMxD
e{vj׭CA]UE_pxC"	"~iWϥΤݵ}Rߪ`gGAHj2@/ytIC~ϥΫAR߯dmwΥͲzQR~C
C魫`g0.1@ɥ~(۷C魫25 gmol gadoxetic acid)"	"(1) ưtgadoliniumvΤfHAiW[fHo͵ǥͩʤֺf(NSF)IC
(2) ī~ϥΩCYŦef(GFR < 30mL/min/1.73m2)ΫʵǷlˤfHAoNSFIF̰C
(3) ϥΥī~e˵fHŦ\ౡΡAܤ˵fH3Ӥ뤺 creatinine˴GAõfHO_ʵǷl˩ΨLi
୰CŦ\ध(pj60BB}f)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	0.25@gadoxetate disodium	V08C	Ϧ@yv MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	0	AΩ T1 [vyֺϳyvC	LC	ߡBYhBPıBɰPYC~YĪ}OLөʥJCoʤLӤ(ƤpɫܼƤ)ܤ֨C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XPRIM-a	XPRIM-b	XPRIM-c	
		0	XPIPE	Piperacillin(PAPER DISC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XPPD	sֵ߯					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRDTPA	Tc-99m DTPA					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRFDG	18FDG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRGA67	Gallium-67 citrate injection(ʵoef)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRI131	I-131 Diagnostic Capsule					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRINA	Rina(Rifampin)paper disk					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRMIBI	Tc-99m MIBI (Sestamibi)(Ŧެ)ߦ`					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRPHYT	Tc-99m PHYTATE(ũǬ)(eOڵˬd)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRPYPV	PYP kit					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRT120	Thallium-201 Chloride injection(Ŧެ)ߦ`					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRTC1-	Tc-99m Pertecnetate					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XRTC8-	Tc-99m Pertecnetate					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XTARG	(Targocid)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XTAZO	(Tazobactam)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XTIGE	(Tigecycline)(Tygacil)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
				Dotarem(Gadoteric acid)20ml/bot		Gadoteric acid㦳ƺ(Paramagnetic)ʽAi[jMRICSĮľǬʡAץͲzkʡC	"Rߪ`gC
jHApĤC魫0.2mlC
ggˬdɡAiϥΨC魫0.4mlq`gĤGC
ϰ쪺޳yvɡAiϥΨC魫0.2mlq`gĤGC "	"1.fHYǰIܮSO`NC
2.iѻjU(εw~)`gC
3.iΩժ`gC 
4.ר쭫׵Ŧefw̡AbMRIMRAɡA뤩tgadoliniumviް_ǥͩʤֺf(Nephrogenic System Fibrosis or Nephrogenic Fibrosing Dermopathy, NSF/NFD)AֵogiɭPfw᪺IzΦ`C
5.ר쭫׵Ŧefw̻ݳyvsɡAiܤ`gGadoliniumMRIΨLˬdAխYoǯfwgadoliniumvɡAyҼ{twƳzRC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Gadoteric acid	V08C	Ϧ@yv MAGNETIC RESONANCE IMAGING CONTRAST MEDIA		ֺϦ@vG-ggǡ]neuroradiology^GդΩP´~FB`~FC-gǡ]abdominal radiology ^Goʤoʸ~FC-γn´oʸ~FC- ΩLΦvC 	"1.a߽߫վ㾹̡C
2.aާ̡C
3.Gadolinium saltsLӯfv̡C"	"1.ǯfҦb`g~ˬdߡBæRΥֽC
2.Yī~XRߥ~ɡAi|khC
3.`gƺϤƦXAibuΤUAͥJLөʤAiݭnBzC "	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XVAN	(Vancomycin)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XVANC	Vancomycin E TEST					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XZYV	(Zyvox)PAPER DISC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XCON1	Conray (Iothalamate meglumine) 100ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XCON1-a	XCON1-b	XCON1-c	
		0	XCON5	Conray (Iothalamate meglumine) 50ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XCON5-a	XCON5-b	XCON5-c	
		0	XMAG2	Magnevist (Gadopentetate dimeglumine) 20ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XMAG2-a	XMAG2-b	XMAG2-c	
		0	POG	OG-6					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XOPTI50	Optiray 350 (Ioversol)  50 ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XOPTI50-a	XOPTI50-b	XOPTI50-c	
		0	XOPTIM	Optimark (Gadoversetamide)  20 ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Ioversol 									аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XOPTIM-a	XOPTIM-b	XOPTIM-c	
		0	PTIS	FCS22Nξ118ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		``g(Ĥ@T@)	XICG	Diagnogreen 25mg/vial(Indocyanine green)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ESAFE	Safederm antiseptic liquid 200ml/bot 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	XULT5	"Ultravist (Iopromide) 370 mg iodine/ml,50 ml/bot"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124	XULT5-a	XULT5-b	XULT5-c	
۶O		0	OGLUT3	L-Glutamine ۾Qi(۶Oi~)		(~) 			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			0000	~iɥR~	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii|U10j	Ts		0	0	OIs 20251124	OGLUT3-a	OGLUT3-b	OGLUT3-c	
		0	XCEFM	Cefmetazon 30MG paper disk					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	OSUG	MEPO }					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	ODEX2	75g Dextrose Powder }@ʸ					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
				Hirsutin 5mg					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	OBIOF1	Biofermin-R powderִ 		@ʨŻĵߧYϩܵ߾sbU]|WޡAǵ۲ͨŻġAiﵽzO`Aӵoz@ΡC	1g TID	]PAminophyllineBIsoniazideVXɷ|o͵ۦ{HAG̦nקKVXC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷūOs	Antibiotics-resistant lactic acid bacteriae	A07F	mLͪ ANTIDIARRHEAL MICROORGANISMS		PUCܥͯBƾkɸzO`Ҥް_ѯgﵽAҦpGPenicillintBCephalosporintBAminoglycosidetBMacrolidetBTetracyclinetBNalidixic acidC					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.28		0	0	OIs 20251124	OBIOF1-a	OBIOF1-b	OBIOF1-c	111.4.28
AC59292100	J01DD08	AYn100@J	OCEFI	Ceficin 100mg/cap (Cefixime)		"1. ܵߧ@
 㭲󶧩ʵߤέ󳱩ʵ߼sx߽ܵdASO󶧩ʵߤStreptococcus spp.,]enterococcus~^ S. pneumoniaeA󳱩ʵߤN. gonorrhoeae, Branhamella Catarrhalis,E. coli, Klebsiella spp., Serratia spp., Proteus spp., H. influenzaeAܵߤO]LfACephemjA@ΧΦOߪC
ѩUزӵ߲ͪ]-LactamasewwAҥH]-Lactamase͵ߤ]uܵߤOC
2. @ξ
@ξରӵ߲ӭMXA@I]ߺؤPӲAOMPenicillinXJ(PBP)1(laAlbAlc)3jO˩MʡC"	"H魫30kgHWpAHCefiximeA150~100mg]O^A@fA2Ci̦~֡B魫BgAyWC
gαĪGfҡAHCefiximeA1200mg]O^A@fA2C"	"1.PenicillinܥͯLӯfvw̡C
2. HBΥS̩nfoޮݡBolBC¯lL褧w̡C
3. ׵ǻêw̡C]аѦҡuΪkDζqAϥΤW`NƶvΡuĪʺAvC^
4.ॿ`iw̩ΫDgfiw̡BA}w̡]]i|X{LRKʥFg
AGYK[C^ 
5.Ѧ~HX{LRKʥFgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsCקKӮgFpoܽιLAiAϥΡC	Cefixime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS		CefiximePʵߤް_UzPVgAުBXig]PVɡ^ACʩIltef~oʷPVBͪBǪǪBH֪BӵߩʧDCժBƻu	"(1) 糧~LӪ̡ATϥΡC
(2) cephalosporinܥͯLӪ̡C"	ߡBæRBmBGzAB֯lBYhC	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-04 []_01-06 [s]_64 [®]_64 [E]_A1-09 j	Ts112.5.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.4._20060601_000.pdf"">OI` 10.3.4.</a>             "	0	0	OIs 20251124	OCEFI-a	OCEFI-b	OCEFI-c	112.5.15
		0	OVORT	Vortagen E.M 50mg/cap					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
A012393417	S01CA05	0	PRINAO	*BenemycinƤ貴ĻI3.5gm/(Betamethaso					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23749209	J01DH03	0	IINVA	Invanz 1g/vial(Ertapenem) 		b~礤Aertapenem sxܦhح?󶧩ʩM?󳱩ʻݮߩMߡCErtapenem ?ߧ@ξOӭMXAo઺oOǥertapenem Ppenicillin XJ(penicillin binding proteins; PBPs) XӦ	"INVANZ 13 HWfHA@ϥξ?OCѤ@AC1 JC3 Ӥ
j12 f@ϥξ?15 @J/@?(̦h?WL@1 J)C
INVANZ iHĨR߿`Φ٦ת`gCĨRߧPɡA`INVANZ ɶ
WLTQC
YǷPVpGAΦ٦ת`gv?ɡAiHΦ٦ת`gINVANZ NR߿
`CӪv?uOѥD
vvھگfHPVMY{?ίfH?@MwC
INVANZ @몺v?O3 14 ѡA̷PVAMfߦӦ?P"	"ϥvalproic acid divalproex sodium ?nwfHAv?PVɡAҼ{ϥΰ?carbapenems~ܵ?CpGnϥINVANZ ɡAҼ{ɥR֪v?
XGҦܥͯ(]Aertapenem)?ް_ʵz(pseudomembranous
colitis)AY{?qLܨͩR¯٩ʪCӪ`NfHbܥͯv?AO_X{mΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ᴹxs?iWL25XC(77XF)C
ѫᤧī~GHtn`G:
Ƿš]25XC^6 pɤϥΡA]i?á]5XC^ܦh24 pɡA?èXᶷ
4 pɤϥ"	Ertapenem	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	"INVANZ AΩv?fwѨPʤLͪҤް_?ܭ?PVAӥBA
U?PVb|ŲwXfߤeg窺v?B?(empiric therapy)G
? ĤPV
? ֽMֽ´PV
? PVʪͪ(Community Acquired Pneumonia)
? ?DPVA]AǪǪ
? ʰַPVA]Alc٪BѦ?MNPV"	"w糧~@LөιLP?ĪLөι]-lactams LӤ
fHTΥġC
ѩϥlidocaine HCl @}AwQi(amide)?¾KLӪfH
wYJΤŦ?fHATĥθgѦ٦ת`g覡PINVANZ"	m(4.3%)BR߿`쪺ֵog(3.9%)B(2.9%)MYh(2.1%)C	ثe|Lh?Aγ]p?nӸCȦbέL઺b?BjMIʮɡA~ibhϥINVANZC	ثe Ertapenem |?ܤH?ťĤ(???ǡAG)C¨Ű?INVANZ v?ɡAԷVpߡC	аѦҾqPΪk	"CClr>50      1g q24h
CClr <30     0.5g q24h 
CClr<10      0.5g q24h 
IHD            0.5g q24h 
CAPD          0.5g q24h "	ѦҡuqΥΪkv	"ĳ~|GIMBIVF
tswwʡG1.IMGtsǷš1hr
2.IV,tsε}᧹`GǷ6pɤġAN24pɤġCۧNèXᶷ4pɤϥ
tsGG3.2ml 1%  lidocaine(tepinephrine) (IM)B 10ml N/SBWFI(IVF)
ĳ}@סG-
ۮe}GG50ml NS
ĳĳ~|tvG30min
`NƶG1.iHϥΧtGlucose `G
2.iPLī~VXΦPɿ`?"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.5.2._20071201_000.pdf"">OI` 10.5.2.</a>             "	0	0	OIs 20251124	DC	DC	DC	110.6.16
BC24139414	S01EE04	0	PTRAV	*Travatan oph.soln 2.5ml/bot(Travoprost					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1.1._20220701.pdf"">OI` 14.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.1._20250601.pdf"">OI` 14.1.1.</a><a href="""">OI` 14.7.</a>            "	0		OIs 20251124				
		0	PBSS	B.S.S 500ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	PMIO	MIOSTAT 0.01% 1.5ml/vial(Carbachol)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PMYDRP	Mydrin-PƤ貴10ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	IRAPI1	Rapiacta inj.300mg/60ml/bag 		ܩʧH A  B yPfrgi?CyPfrgi?㦳_ sialic acid ʡA_ Oligosaccharide ݪ sialic acid ɡAfrlN|}l۷PVӭMXӡCPeramivir hOǥѧgi?ӧlNfr۷PVӭMXӡAHfrXܨLӭMAGfrWަ@ΡC	"1. ygoͫ48pɤϥΥġC
2. Hĳq300mgAC̦hoWL600mgA15HW榸IwRߪ`gC
3. ൣĳq10mg/kgAC̦hoWL600mgA15HW榸IwRߪ`gC"	1)yyPgo{48pɤġC2)榸뤩AH15HWR߿`ġC3)fHηU̪`NfHO_믫gg(NѤMB欰`B믫áBıBkQBj˵)AHΥvͯgԸs(lBֽ/H_w)άOhʬAYoߧYNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Peramivir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vHAByPfrʷPV	糧Ħo͹LӯgfwAФŧP	mBKBvΰC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	"CClr>50         300mg q24h
CClr 30-50     100mg q24h 
CClr 10-30     50mg q24h 
IHD            50mg  q24h after HD"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG25JHU
tsGG-
ĳ}@סG-
ۮe}GGNS
ĳĳ~|tvG>15min
`NƶGygoͫ48pɤϥΥ"	ixii[UDx]_U10-02 [E]_I1-01 j	Ts110.6.16		0	0	OIs 20251124	IRAPI1-a	IRAPI1-b	IRAPI1-c	110.6.16
AC49561421	S01BA04	_dĤ1%	PPRED2	Prednisolone 1Moph soln (PREDNICONE)		CorticosteroidsUبEҤް_gĪGAPɤ]iwˤf¡XɶCCorticosteroidsi~AֺIAӺXiBW͡BզyʡAֺӭMW͡AIΦ]gҧΦˬ͡CMAΤCorticosteroids@ξ|QT{AMӡA]Corticosteroids໤Phospholipase A2ʳJաAYLipocortinsAӳQ{\CJսǥѧArachidonic AcidAް_on(pprostaglandinsleukotrienes)eXAӥiӭn褧XCArachidonic AcidOgPhospholipase A2 ʤƦӱqӭMnZCפXӡCCorticosteroidsi|yWɡC	1-2 drops 2-4 times daily and may up to 1-2 drops/hour	YϥΥ~WL10ѥHWA`NC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Prednisolone	S01B	ܪ ANTIINFLAMMATORY AGENTS	0	Lөʲ¥tBXBũʨBJIҤް_g	"1. ©ʞ\l(K)BkBkBK߷PVA߷PVC
2. 令@ι䥦Corticosteroids|LӪ̡C"	Wɥi|ɭPCAֵo͵glAUnʥդ٤ΦAˤf¡XC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_P03-05 [E]_H1-14 j	Ts111.12.15		0	0	OIs 20251124	PPRED2-a	PPRED2-b	PPRED2-c	111.12.15
BC24884100	C09XA02	0	ORASI	Rasilez film-coated tablets(Aliskiren) 		Aliskiren ǯA୰Cߵǯ (PRA) HΧަYഫ Ang ICثe|M aliskirenO_vTL RAAS ~|AҦpGACE ΫD ACE |C	@ĳ Rasilez? (aliskiren) _lq 75-150 mg C@A~PQ֥ήɫĳ_lq 75mgCAfwAC龯qiW 300 mgCq 300 mg HW|ɭA|mvC㪺ĪG (85%-90%) |b 2 gFC	"bWϥΪ@ΩǯަYtΪĪA|o|
Lyˮ`Ʀܷ|y`Co{hɡAפϥ Rasilez?
C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"J 30XC HUBC
קKC"	Aliskiren 150mg	C09X	@Ωǯ-޺itΪ䥦Ī OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	0	"ΩvCiWϥΩλPLܰĪX֨ϥΡC
P̰q ACE X֨ϥΩ|gRasC"	"糧~ʦΥξӷPw̡C
X֨ϥΥ~ ACEIs  ARBs }fwεǥ\णw (GFR < 60 ml/
min/1.73 m2)C
2 HUൣC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	ORASI-a	ORASI-b	ORASI-c	111.8.19
AB27629100	G02CB01	0	OPARO	Volbro 2.5mg/tab(Bromocriptine) 		ĥDBromocriptine MesylateO@ب㦳Dopamine receptor agonist activitylͪCigѧEŨt(Prolactin)cӧͲzʪcũΪvfzʨź|gGS]㦳Dopaminergic@ΡAGiΩvڪˤgC	"1.ź|gζʨů_]gAgêΤgG
2.5-5mg BID-TIDA\AΡAcŰΤgg`D
2.]owǲzѡAwΧ᪺ͲzʪcšG
10mg BIDAA14ѡA\AΡD
3.wcšA󲣫άyɦ}lAΡD
ī2-3ѰֶqƨšApHۦPqAΤ@PYio{HD
4.gegG
gg14Ѷ}lA5mg QDAvW[5mgA10mg BIDAgӼ鬰D
5.ʨů_]kʩʸhG
20-40mg QD
6.ʨůcFG
5mg BID-TIDAvW[qܥiHAacſED
7.ϺݪΤjgG
}lq5mg BIDA@ܨPW[ܨC40-80mg A{ɮįqΰƧ@ΦөwAC龯q4AΡD
8.ˤgG
]Ħdopaminergic effectAiﵽX{on-off{HAϥlevodopaSĪˤgAiClevodopaqABﵽˤgfH~{D
C20-40mg AΡD
i1.25mg QD~BIDAC3W[qWL2.5mgAF.ǯfҢТYġD"	"w믫efBYŦޯefBGũθzGX大fHpߦaϥΥC
ź|gζʨſEҤް_gϥΥi_ͨ|OAh̶ĥξAץID
YfHX{AݵhAYAcƩεLkwѪYh(׬O_Hıê)AΤϯgtΤrgߧYĨõfHpD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOs25JHUΨൣ⤣ΤBC	Bromocriptine	G02C	L OTHER GYNECOLOGICALS	0	oʸ~FĪҤް_ź|gD	"(1) BromocriptineΨLPLӪ
(2) hBYβȴA
(3)aʯ߯efΨLߦޯfv̡AΨ㦳LY믫efgίfv̡D
(4)TΥ~cũΨLDMΥͩRAgD"	äߡBtwBh©ιæRBCC	iw/|qLť	ŴקKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.2._19950301_000.pdf"">OI` 5.4.2.</a>              "	0	0	OIs 20251124	OPARO-a	OPARO-b	OPARO-c	110.6.16
BC22770221	M03AC11	٦A`gG	INIMB1	Nimbex 10mg/5ml/amp (Cisatracurium) 		~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"ޤޡG0.15 mg/kg Ab 5  10 ֳtC?b`g 120 i?Q?ACൣ(1Ӥ-12)qPHqۦPD
qG0.0.3mg/kgAi20g٦ת_@ΡDൣ(1Ӥ-12)qG0.02mg/kgi9@ΡD
ICUfЯfHϥξqG_lqG0.18mg/kg/hrAqG0.03mg/kg/hr-0.6mg/kg/hr"	wgٵLOgΨLg٦ׯeffwDhƩʪ_|jӷPʡCofwĳWL 0.02 mg/kg ~_lqC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʮɥixs2~8CץNëOs
}b 25?U 24 p"	Cisatracurium	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"~TΩw cisatracurium B atracurium  benzenesulphonic acid LӪfwC
"	"߷iLC,޵j
"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.12.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.2._20110701_000.pdf"">OI` 1.4.2.</a>              "	0	0	OIs 20251124	INIMB1-a	INIMB1-b	INIMB1-c	111.12.15
BC26270100	L02BB03	0	OCASO	ĵ Bicalutamide-acepharm 50mg/F.C.tab 		"1. ~O@ثDTJܶʯALLcE@ΡC~|Xandrogen receptorsAӤư]{A]iʯEAǥѦ@Φӳy@~FhC
2. ~O@خ۩ʲcAܶʯ@δXGӦ(R)c"	~klA]AѤHG@Ѥ@(50)C~PLHRHΤNhkPɶ}lϥΡC	"1. ~sxѨxŦN¡CܡAYx\l˪fH󥻫~ưiCAo|ɭPֶq~b餺ֿnC]A󤤫שέרx\ॢժfHAΥ~ԷVC
2. ~TΩkʡAӥBiΩ󥥰α¨ŰC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Bicalutamide	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	PLHRHkΤNhk֥Ωii@C	TΩkʤΨൣιĹLӥfH	BkoBmBߡBæRBֽ	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.40._20120701_000.pdf"">OI` 5.2.4.</a><a href="""">OI` 9.40.</a>             "	0	0	OIs 20251124	OCASO-a	OCASO-b	OCASO-c	111.8.19
AC09299100	N05AN01	Y罦n	OLIGI	Ligilin 300mg/cap(Lithium) 		~gļS@ξ|MCoĪܯgݪuBAҥHAܯgӭMqͲzʽAPig^norepinephrineMserotoninA]Ay󨳳tƧ@ΡA~]norepinephrineXMicyclic AMPΦC	"Mania(Acute)1800 mg/day in 2-3 divided doses; desired serum lithium level ranging between 1-1.5 mEq/L;
Mania(maintenance)  900-1200 mg/day in 2-3 divided doses; desired serum lithium levels ranging between 0.6-1.2 mEq/L
ļ{gw̡G`ΤAqCAΥ~600mg(),CTCؾqq`i;YĿ@1.0-1.5mEq/L C kGCAΥ~300mg(1 ),CTΥ|.(夤Y@Ob0.6-1.2mEq/l C"	6. pPLܺ믫fĪ@Awo@fvΪ̥i୰Cwo@֭Ȥef]pqg^fHAϥquetiapinevpߡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Lithium	N05A	ܺ믫f ANTIPSYCHOTICS	0	ļfBwļ{f	"Hypersensitivity to lithium, or any component of the formulation; sever cardiovascular or renal disease, or debilitation, dehydration,or sodium depletion; pregnancy"	TAߡAoݡAYh C	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OLIGI-a	OLIGI-b	OLIGI-c	110.6.16
۶O		0	LCD341	CD34ͧޮɥ 		(~) 	eŸM΢~ACŶWL5~AhLqD		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	10-20CNáAקKΰšD	Bio-StemåJաAi	0000	~iɥR~	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LCD341-a	LCD341-b	LCD341-c	110.6.16
		0	IATRA	GENSO INJECTION(ATRACURIUM)10MG/ML 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixii[N]_B03-14 [E]_K-19 j	Ts		0		OIs 20251124	IATRA-a	IATRA-b	IATRA-c	
AC356781G0	N07AB02	"""""GiR10]Ƥ맿x¡^"	OWECO1	"Wecoli 10mg (Bethanechol) ""YY"""		Dn@άOϰƥPgtοġCiW[H֯}٪iOA]ӳq`iͨHPϱƧMHֱƪŪ}lCBethanecholiEGʤOAW[GiOA]ӥi_wl`ߩįʡC	"Initial X 5 to 10 mg repeated hourly until satisfactory response; MAX 50 mg; usual dose range X10 to 50 mg 3 or 4 times daily
1. Hq10~30mgA@3~4C}li5~10mgAHCpɭеPAΨ30mgoNĪGCĩA30~60YiX{ĪGA@Υi~1pɡC
2. ĵCѨC0.6mgAAΡC"	AΥPg`_ĪfH`NAHKް_L׭CAq`L׭CoͫeA`gAxdw̡ApXٵLkPɡAiKQ^y駿ޤεǪAɦp߯gsbɡAiް_gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Bethanechol	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	NBᤧDʧxdAgʻHֺiOCΧxd	ťΩҪ\LgBhBGšBޭݡB߷i}wBCF߫aʯ߯efBwBˤgBGzΪcDʪfҡC	ߡBmBABYhBC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668520?cesid=4OLqJPnJWNE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBethanechol%26t%3Dname%26acs%3Dfalse%26acq%3DBethanechol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts112.02.16		0	0	OIs 20251124	OWECO1-a	OWECO1-b	OWECO1-c	112.02.16
BC181581G0	N05CF01	0	OIMOV	Imovane 7.5mg/tab(Zopiclone)[ޥ|]		"MM@ʫܤGABA macromolecul-ar complex receptor , iձCL Channel }ҡA㦳wvARܵJ{B٦PΧܵj˵@; iYuJήɶA֩]MơAWίvɶCĴֺίvĤ@BW[ĤGBΩδ(ĤTB|)"	3.75-7.5 mg ΫeA; prolonged use (longer than 28 days) should be avoided	1.ŶsC2.AīAФp߶}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Zopiclone	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	vg	"HUpŨϥΥ~--- 
1BZopicloneΥĤ@LӡC 
2BgٵLO]Cʶiʦܡ^C 
3BIlIܡC 
4BYίvIlȰg]ίvIlȰ^C 
5BYx\णC"	RBΡB`NOxBfBfW	ĤC 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.3._20131101_000.pdf"">OI` 1.2.3.</a>              "	0	0	OIs 20251124	OIMOV-a	OIMOV-d	OIMOV-c	110.6.16
X000253100	C02DC01	0	OMIDI	Midil 5mg/tab (Minoxidil)		"1.Minoxidil |zLXi@έCPުOAiӭCɰYMαiC
2.Minoxidil ʥNª|ƥATP ո`[l]K+-ATP^qDAK+yXB͹LƻPƦ٩PC
"	"1.QGHWfHG
ĳ}lqC@5 mgCǫΦ@ΡAC龯qiW10B20 mg MW40 mgA@ĩΥƦġCľqd򬰨C10 40 mgA
̰ĳqC100 mgC
2.QGHUfHG
}lqC@0.2 mg/kgAi50100% ǫΦ@ΡCľqdq` 0.25  1.0 mg/kg/A̰ĳqC50 mg"	sϥΥ~36ӬPAi|ϷLʡAA[	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~Os20X25XC]68X77XF^ǷšC	minoxidil 10 mgC	C02D	"@ΩpʯߥƦ٪Ī Arteriolar smooth muscle, agents acting on"	0	Y	"1.TΩݻ̩ʲӭMFfH
2.TΩ糧@ӷPfH"	hg(|[AܲʩMA[`)AȮɩʤ~A߸L֡AMudC	Minoxidil ĳϥΩhMץUihkChSminoxidil ᴿqoͷsͨvW͡C	iwminoxidil |cܤHťĤCLkư઺ICMwO_ũΰ/קKminoxidil ɡAҶq઺IMkvįq	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.4.4		0	0	OIs 20251124	OMIDI-a	OMIDI-b	OMIDI-c	112.4.4
AC27338100	G03GB02	0	OCLOM	Clomiphene 50mg/tab		~W[FSHLHq鸢ʳXӡCPiZλoƧZCQĪܻۿEʧ@Φb鸢ʳ(adenohypophysis)AhۿEotjXAXʸE(gonadotropin)A]iHW[Z_XͦX	"Ĥ@vGۤgӼĤѶ}lAġACѤ@ AsAѡC 
ĤGvGeAΫ᥼FƧZتAUgӼĤѦAתAġACѤGAsAѡC 
ĤTvGgGvAFƧZ̡ADL~E_ίfHu AiAiĤTvAΪkBζqPĤGvۦPC"	AΫAiಣ͵OҽkAФp߾rpξާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Clomiphene	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	ƧZêް_goƧZ	"(1) 糧~LӪ̡ATϥΡC
(2) D]Z_~FΦhnʧZ_gԸsҤް_Z_~jC(i|]Z_LרEӨϱoZ_[~j)
 (3) xl`Φxef̡C
(4) hkC"	ߡBæRBUhBYhBıҽkC	PL	hα¨ŴϥΥ~	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667979?cesid=4oM0NoSCuFb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCLOMIPHENE%26t%3Dname%26acs%3Dfalse%26acq%3DCLOMIPHENE#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OCLOM-a	OCLOM-b	OCLOM-c	110.6.16
AC058111G0	A02AX	0	OSTRO	Strocain Ƥ 		"1.¾K@
2.Gc@ΡGfAPoxethazaine|acetylcholineEժް_GcC
3.GĤc@ΡGfAPoxethazaine]|pentagastrinһoάOEް_GĤc@ΡC
4.GzDBʧ@ΡGfAP|GBʡFbGPQGzAoxethazaine]|ƾXһoj˩ʦY@ΡC"	q`HC3-8A3~4fAϥΡCqi̱w̪~֤ίgӽվC	"1.קKsAΡC
2.AΡA`NnrHάOCZAHקKݯdfӲͳ¤PC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Oxethazaine	A02X	vPGĤcef䥦Ī OTHER DRUGS FOR ACID RELATED DISORDERS	0	GBzBDҦHGhBGĹLhBGAΨ`P	糧~󦨤Lӯfvw̡C	", f,ߡBKBYhBΡAol{HC"	DnAקKϥΡC	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OSTRO-a	OSTRO-b	OSTRO-c	110.6.16
AB52308100	A10BX02	0	ONOVO	ĵReglide 1mg/tab (Repaglinide)		"Repaglinide uĪPiخqc(insulin secretagogue)CRepaglinide oHֳtC}ADgѨEخq\ध ] ӭMc خqӨӡCRepaglinide P ] ӭM@γXAq ] ӭMW ATP-̦sʹ[lqD(ATP-dependent potassium channels)AP ] ӭMhơA}ҶtlqD (calcium channels)AW[tlyJ(calcium influx)A ] ӭMXخqC
"	" 2 }fwAH\fA repaglinide  30 ioPخqcĪGAæb\ɫF쭰}ĪGC夤repaglinide @רtaCAA 4 pɫA 2 }fw̪夤Ī@׫ܧCC2}fw̨ϥ 0.5  4 mgrepaglinide ɡAqP}CC {ɹ絲GܡArepaglinide b\e 15 AΡAO]iHbYN\ɪAΩάO\e 30 AΡC
ĳlq0.5mg}lCYfHϥΨLfA}Aĳlq1mg}lC
榸Ḭ̄ĳqe4mgAC̰qoWL16mgC"	"1.~\eAΡAihݪAġAקKC}
2.קKPɨϥ Gemfibrozil P RepaglinideCMӡAnX֦ĪɡApߺʴ}A] Repaglinide qiݭnվC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Repaglinide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	2}f]NIDDM^LkgѶBΥ[jBʵkAF}n	"1.w糧ī~DRepaglinideΨLLӪ
2.خq̿૬}f(Type1}f)
3.}f଻Ĥr
4.~p12pġC"	C}BߡBæRBƤ}C	C 	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	0	0	OIs 20251124	ONOVA-d	ONOVO-e	ONOVO-c	110.6.16
BC25080277	B05AA07	0	ITETR	Tetraspan 6% 500ml/~(Poly starch)		ߥNΫ~M߳J	"̪쪺 10-20 mL wC`AζqiHF
50 @/魫"	"ʴG饭šBMqѽ@סBxǥ\BPŤξ
ơC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" 1.xsūפo 30 X
2.}ʪAOs 3 ~
3.}ʫAߨ赹"	Poly (O-2-hydroxyethyl) starch (HES)/Sodium Chloride	B05A	Gάī~ BLOOD AND RELATED PRODUCTS	0	Wϥδ`GLkvʥXɭPCenfHA~LkNyΦߤ]l	"Ѧg
YNS
YxŦef
GWLt(餺Lh)AרOͤ~P{ʤ߰I
YΥXʯew
ǰIܥB֦DGenLCɭP觿gεLg
ŦzRv
YugYg
`X
x
Y[g(ȾAΩt[l~)"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ITETR-a	ITETR-b	ITETR-c	110.6.16
AC433061G0	R06AE07	HFZ	OZYRT	Cetia 10mg/tab(Cetirizine)		"CetirizineAnti-H1ܹLӪvABL㪺Anti-CholinergicAnti-Serotonin@ΡCbľqCetirizine|qL޻پA襤ϯgS@ΡA|ͦwvΦ欰`{HC@Υ]AG
1. t~ͩʲ´iC
2. 鷺ͩʲ´iX@(p48/80´i)C
3. VIP(Vasoactive Intenstinal Polypetide)MSubstance PҤް_LӤC
4. ۪Cݱw̪޹´iLפC
5. CѯSLӭް_LӤCoǧ@ΡAѤߴQuantified EEGoA襤ϯg|ͥ@ΡC"	6HWGC10@JA@Ѥ@Cǥ\णw̪AΥĮɡA侯qbCǥ\( Ccr (ml/min)  30qվ5mg qD )C	b.gGϰקK`gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Cetirizine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	u`ʻ󪢡BXBLөʻ󪢡BC¯lBLөʷkoLӲ{H	糧Ĥ󦨤LӪ̡C	fBYhBݺΡBhҡBLOB󪢡B|甆BhBYh	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OZYRT-a	OZYRT-b	OZYRT-c	110.6.16
BC24250100	C10BA02	0	OVYTO	Vytorin(Ezetimibe/Simvastatin)10/20mg 		"1.Ezetimibe-ipzxTJl@ΡAqӭC夤xTJC
2.Simvastatin㬡ʪ(lactone)AgfAAxŦѦʪ]-hydroxyacidA঳ħHMG-CoA٭?@(3-hydroxy-3-methylglutaryl CoA reductase)AϨLkʤHMG-CoAƦmevalonateAHxTJͦXγtvMwBJC"	"qѨC10/10@J10/40@JCĳ_lqC10/20@JC
(Child-Pugh7-9)έ(Child-Pugh>9)x\
êw̡AĳϥΡC"	}lϥVYTORINμW[qɡAifHoͦٯfܪIABY٦ׯkhBhεLOɡAߧYiA@E_κæٯfܮɡAߧYġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUKxsC	Ezetimibe 10mg/Simvastatin 20mg	C10B	"׽ո`AƤ LIPID MODIFYING AGENTS, COMBINATIONS"	0	"1. VYTORIN (EZETIMIBE 10mgXSIMVASTATIN 40mg)AΩQ餧]ʫa߯gԸsӦ|w̡Ai֥Dnߦިƥ(major cardiovascular events)o͡C
2.oʰxTJg
3.PXlaکʰxTJg(HoFH)"	"1.糧~ҧtLӪ̡C
2. ʩʨxfΦM?(serum transaminase)]WɡC
3. α¨Ű(hα¨Ű)C
4. ֥CYP3A4jħ(ҦpitraconazoleBketoconazoleBposaconazoleBvoriconazoleBHIVJս?BboceprevirBtelaprevirBerythromycinBclarithromycinBtelithromycinBnefazodoneΧtcobicistatī~)
5.֥gemfibrozilBcyclosporinedanazolC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.3._20231201.pdf"">OI` 2.6.3.</a>             "	0	0	OIs 20251124	OVYTO-a	OVYTO-b	OVYTO-c	110.6.16
BC24532100	C07AG01	0	OTRAE	Trandate 200mg/tab(Labetalol) 		Labetalol @غ٬u]_vġC @ΩŦAϤ߸tvNŦGXqCC åBSඡaϦ޵αiPAGbޤ󶶺ZayqA]ӯF쭰تC ĦPɯ୰CŦu@qNŦһݭn𪺮ӡA]iΨӹwŦʮɭPӭMaΤߵho͡C	"G
lq@CѨ⦸  C100@J
qШCѨ⦸AC200-400 @J.
̰q800@J/ѡAHA⦸

YxTʰ
2400 @J/ (GΥ|)

W
lq@CѨ⦸  C100@J; 
YʰhiH@TĤ覡A@ѳ̰qiWG2400@J
"	"1.YzݯfvAЧiv
 2.viX{YhBh¡AvAoǲ{H|vzήC
3.BC}MҪrgx"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~Js30JHUxs	Labetalo HCl 200@J	C07A	]_ BETA BLOCKING AGENTS	0		"1.TҨϥΩĤGβĤTŦǾɪ_BŦJHΨLYΫCwY߰ʮ}wpw̡C
2.TҨϥΩw糧LӤ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OTRAE-a	OTRAE-b	OTRAE-c	110.6.16
BC25433100	L01EX03	0	OVOTR	ĵ Votrient 200mg/tab(Pazopanib) 		PazopanibO@ئhTi?A@ΥؼХ]tޤ֥ͪ]l (vascular endothelial growth factor receptor)VEGFR-1BVEGFR -2BVEGFR -3ApOlͥͪ]l (platelet-derived growth factor receptor) PDGFR-\P-]AֺӭMͪ]l(fibroblast growth factor receptor) FGFR-1P-3AӭME(cytokine receptor) (Kit)AĤGկ黤TӭME?(interleukin-2 receptor inducible T-cell kinase) (Itk)AզySwJսTi?(leukocyte-specific protein tyrosine kinase) (Lck)AHά､޳JըTi?(transmembrane glycoprotein receptor tyrosine kinase) (c-Fms)C~o{ApazopanibiVEGFR-2BKitPPDGFR-]oͰt黤ɪCĤơC餺hܡApazopanibipͳVEGFɪVEGFR-2CĤơBp޷s͡AHΤp餺H~F鲾ӪͪC 	"VOTRIENTĳq@Ѥ@AŸɤfA800 mg]ܤ֩\e1pɩΥ\2pɡCVOTRIENT qWL 800 mgC
ФHĿA]i|W[ltvӼvTSqC
|A@ɡApGPUAĮɶjp12ӤpɡAФŸɪAC "	{ɸ礤[YBPRxrʡC̫ĳʴx\AnȰϥΡBqΰĪC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~JsǷ30JHUC	Pazopanib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	ߴǲӭMĤ@uvAΥΩwӭME(cytokine)vѤߴǲӭMw̡C 	L	xrʡBQTBTorsades de pointes(@ئhʤ߫Ǥ߫ߤ)BXƥBʯߦƥBGzDդ?ޡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.41._20211201.pdf"">OI` 9.41.</a>              "	0	0	OIs 20251124	OVOTR-a	OVOTR-b	OVOTR-c	111.8.19
BC16863100	N02AX02	0	OTRAM	ĵTramal 50mg/CAP(Tramadol)[ޥ|] 		"TramadolO@ا@Ω󤤼ϯgtΪ~hCO@Ωg, _Mk~Dܩʯ­PľAg˩MOCLyh@ΪgAlǤWAHΫPiMC"	"fAi25~100mg Q6H ,Max:400mg/day
ĳϥΩ12HUൣ"	"1. ¾KɡALIMADOLϥζqYWLĳqƦhAhưIliʡC
2. YϬOӫܵġAi|vTfHOAҦp:rpTPާ@񤧯OAרOPs@_֥ήɡC
3. ]ϥΥi|ͨ̿ʡAGvMwvɶuHάO_nȮɰġC
4. LIMADOLiPӶWLvһݡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XC HUxsC	Tramadol	N02A	P OPIOIDS	0	צYʪCʯkh	PsBwvġBhΨLϯgtΧ@Ī֥ήɷ|yʤrC	oBtwBߡBæRBfHίhҡC	קKϥΰDvn	bŴĳϥ tramadolCΪ̡Ab tramadol vTšCb榸P tramadol Aq`ݭn_šC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.3._19980401_000.pdf"">OI` 1.1.3.</a>              "	0	0	OIs 20251124	OTRAM-a	OTRAM-b	OTRAM-c	110.6.16
AC486761G0	N02BE71	0	OSUPL	SuplaxƤ 		"~hθѼPfPƤ覨
Mephenoxalone@Φbֽ誺AƨtΩΦۥDgtεLS@ΡAͰf٤PFAcetaminophen㦳Ѽh@"	"H15HWĵ:C1-2,C2-4 6-15C1/3-1,@Ѩ⦸"	AΥī~ФŶs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Acetaminophen/Mephenoxalone	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS	0	UCѯΦ٦׵jˤް_kh㦳wѧ@ΡGVB٩ʭhB٦׻wBVĵhBٵhByhB`B`BiB٦׵jˤް_٦׵hBʯkh⵬jˡC	1.Hypersensitivity2.wG6PDfHФŨϥ	ݺ.GzA.Yw.f.ֽko	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OSUPL-a	OSUPL-b	OSUPL-c	110.6.16
BC24256100	N06AB05	0	OXET1	Seroxat CR 12.5mg/tab(Paroxetine)		vHG{gAWgAgegA߯gA(J{g)C	"DepressionInitial 25mg PO QD, may increase by 12.5mg QW to no more than 62.5mg/d. Panic disorderInitial 12.5mg PO QD, may increase by 12.5mg QW to no more than 75mg/d. Social phobiaInitial 12.5mg PO QD, may increase by 12.5mg QW to no more than 37.5mg/d. Premenstural dysphoric disorderInitial 12.5mg PO QD, may increase at 1 wk interval to no more than 25mg/d."	"1.p24w̦bϥΪiW[۱N
2.SEROXAT CR iHCZάOHAɧ]AC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Paroxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	vHG{gAWgAgegA߯gA(J{g)C	"]1^w paroxetine PξLӤfwC
]2^iPMAOI(2g)BthioridazineBpimozidePɨ֥ΡC
]3^linezolid  methylene blue IVv̡ATϥΥġC
]4^SEROXAT CR iϥΦbC 18 ൣΫC֦~C"	ߡBݺΡBXBŸݡBzLOBfBvBʥ\ê	ĵD. 	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OXET1-a	OXET1-b	OXET1-c	110.6.16
BC24421100	N06AX16	0	OEFE37	Efexor XR 37.5mg/cap		"@{ Venlafaxine bH餤ܼ~{󤤼ϯgtΡAP[jg誺ʦC{ɫesܡAVenlafaxine P䬡ʥNª O-desmethylvenlafaxine (ODV)A|[jgʦM(serotonin)ΥǤW(norepinephrine)Al@ΡA dopamine Al@θzCVenlafaxineMODVb~礤muscarinic cholinergicBH1-histaminergicΣ\1-ǤWLۿ˩MOC@AoǨĲzʥiML믫ĩ[쪺UاxP(anticholinergic)BR(sedative)Τߦ޵@ΦCVenlafaxineMODV㦳iƻï(monoamine oxidase, MAO)ʡC"	"Depression (inpatients)75 mg/day (2-3 divided doses); may increase dosage by 75 mg/day increments every 4 days to MAX 375 mg/day (3 divided doses).
Depression, Generalized anxiety disorder, Social Anxiety Disorder (extended release capsule)37.5-75 mg/day (single dose); may increase dosage by 75 mg/day increments every 4 days to MAX 225 mg/day.
1._lqC@75mgAGܤTAΡC{ɻݭnAC龯qiW[150mgA`NqWL75mg/dayɡAվɶoC|ѡC
2.̰qiW[ܨC375mgC
3.M@_]AHGEC"	Ĥγiƻï(MAOI)PɨϥΡAΦܤ֦bMAOIQ|ѫA~iϥΥġC̾ڥĪbIAϥMAOeAĦܤΤCѡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Venlafaxine	N06A	ܧ{ ANTIDEPRESSANTS	0	AΩv~{g]depression^A]A{g]melancholia^C	"1.w|Venlafaxine͹LӪfwC
2.PɪAγiƻï]MAOIs^fwC"	ߡBYhBݺΡBfBKBwtBvBgiBsC	קKϥΰDvn/SmҦw/|qLť		аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OEFE37-a	OEFE37-b	OEFE37-c	110.6.16
BC07538100	C02DC01	10@J	OLONI	Loniten 10mg/tab(Minoxidil)		"1.Minoxidil |zLXi@έCPުOAiӭCɰYMαiC
2.Minoxidil ʥNª|ƥATP ո`[l]K+-ATP^qDAK+yXB͹LƻPƦ٩PC
"	"1.QGHWfHG
ĳ}lqC@5 mgCǫΦ@ΡAC龯qiW10B20 mg MW40 mgA@ĩΥƦġCľqd򬰨C10 40 mgA
̰ĳqC100 mgC
2.QGHUfHG
}lqC@0.2 mg/kgAi50100% ǫΦ@ΡCľqdq` 0.25  1.0 mg/kg/A̰ĳqC50 mg"	sϥΥ~36ӬPAi|ϷLʡAA[	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~Os20X25XC]68X77XF^ǷšC	minoxidil 10 mgC	C02D	"@ΩpʯߥƦ٪Ī Arteriolar smooth muscle, agents acting on"	0	Y	"1.TΩݻ̩ʲӭMFfH
2.TΩ糧@ӷPfH"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[r]_r05-02j	Ts110.6.16		0	0	OIs 20251124	OLONI-a	OLONI-b	OLONI-c	110.6.16
۶O		0	OETHA2	Ethanzyme 155g/bot[o		"(~) UƧlBƹDBܲӵOͺA
"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]25JHU^	ơBGįBʪGįBCĶtBͯVX( hĶt2 @Jx)BP?i( 4 @JP)BQ?i(ͯB1)79mcgB1mcgBͯB12 0.01mcg	0000	~iɥR~		iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.5.03		0	0	OIs 20251124	OETHA21-a	OETHA21-b	OETHA21-c	111.5.03
۶O		0	OISP1	Isolater Soy ProteinuJ		(~) 	"/HG1]/ѡFnɡG2]/A2/
ΩάO[JBGġBƤ"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		jJ(Isolated Soy Protein)Bi(BCAA)20g/pack 33]/	0000	~iɥR~		iU	jLӪ̽ФŨϥ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.19		0	0	OIs 20251124	OISP1-a	OISP1-b	OISP1-c	111.4.19
	J01AA08	"""""թᴹ`g100@J"	IMENO1	"Menocik (MINOCYCLINE)""""թᴹ`g100@J"		|ߤOOǥѧJս誺Xӵoܵ߮ĪGAMinocycline|e󳱩ʵߡB󶧩ʵߪ߽ܵdθjܵߤOC	"@뾯qG쾯q200@JAC12p100@JCCѾqoWL400@J
쾯q4@JAHCj12p2@JC"	"1.ǾêAWw̭YRߪ`g|vAC龯qWL2JNPxIܡC
2.bo|(WbAΤKHUൣ)ϥΥ|iۭPä[ܦ(--Ŧ)AҥHbo|yϥΥ|ĪAؤh󦹾ϥΡAѩuϽƨϥΦӤް_̥禳iAWo|稣ѳiC
3.YǤHϥΥ|ھo{ӷPް_LתͲ{HCw̦pnͩUε~uUɡA|iް_ӷPwVw̻AӤ@o{ֽߧY
4.Ǿ঳ۻêw̡Ap夤|@׸ɡAiް_gBLCgHλĦgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	mǷ(25XCHU)DBץxsC	Minocycline	J01A	| TETRACYCLINES	0	󶧩ʡBʵߡBߧJΥoLʯfrް_PVgC	إ|ڧܥͯLӯfvw̡AMinocyclineoϥΡC	"YhBtw  ,BߡBæRBm ,夤BUNWɻPq㪺Y"	WϥMinocyclinewʩ|TwC	קKϥΰDvn/SmҦw (|fAo{̰ͪvC{HAز{HifʡAĤYi_C)	аѦҾqPΪk	"200mg ST,100mg q12h(ǥ\णWL 200mg q24h)"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡGǷŤU24p
tsGGWFI
ĳ}@סG0.2mg/ml(100-200mg}5001000mlϥ)
ۮe}GGNS ,D5W,D5S,LR
ĳĳ~|tvGקKֳt`J
`NƶGoPttG}ϥΡCpϥRߪ`gAi໤PRߪC
"	ixiij	Ts110.6.16		0	0	OIs 20251124	IMENO1-a	IMENO1-b	IMENO1-c	110.6.16
BC17283100	M01CC01	0	OMETA	Metalcaptase 300mg/tab(Penicillamined)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
A013382100	A02AA02	0	OMGO	Magnesium oxide 250mg/tab 		"@Bľ:ĨävTGĤcAӬOǥѤƾǩʪPMwĹLhG
GBhqm@ΡATKYܬ}AƪnƼW[C"	"HG@34C
12HWGAΦHqC
612GAΦHq1/2C
36GAΦHq1/4C
3HUAЬvC"	ŶWLĳqAYN~ΰƧ@β͡AߧYĴNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Magnesium oxide	A02A	ܻ ANTACIDS	0	wѭGAΨ`PAθgE_GΤQGzšBGBDҦHGĹLhC	TΩGzDBhBߡBæRw̡C	m	B	i/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OMGO-	OMGO-b	OMGO-c	110.6.16
A023521100	A06AD02	0	OMGO1	Magnesium Oxide 250mg/tab 		"@Bľ:ĨävTGĤcAӬOǥѤƾǩʪPMwĹLhG
GBhqm@ΡATKYܬ}AƪnƼW[C"	"HG@34C
12HWGAΦHqC
612GAΦHq1/2C
36GAΦHq1/4C
3HUAЬvC"	ŶWLĳqAYN~ΰƧ@β͡AߧYĴNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Magnesium oxide	A02A	ܻ ANTACIDS	0	wѭGAΨ`PAθgE_GΤQGzšBGBDҦHGĹLhC	TΩGzDBhBߡBæRw̡C	m	B	i/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w12-01 []_01-20 [s]_205 [s]_206 [®]_205 [®]_206 [E]_C4-03 [Ew]_EX081 [Ew]_Z-06w9 j	Ts111/08/18	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OMGO1-a	OMGO1-b	OMGO1-c	111/08/18
		0	EEVE-1	Summer's EVE cleansing Mist 59ml/bot 		0	0	{ĤƮw	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	0		0		0	0	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EEVE-1-a	EEVE-1-b	EEVE-1-c	110.6.16
		0	ELAMI	(LAMINARIA) 		llclcVXjAFlcVnƻPXiت	ϥήΩmJlcVAg12-24pɧ@ΫAPϤlcVnơC	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Laminaria	0		0	޲	0	0	TϥΡC	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ELAMI-a	ELAMI-b	ELAMI-c	110.6.16
۶O		0	LYOUN1	Youngbao (i_-۶O)10ml/];15]/ 		(~) wѤw̰Ƨ@;ﵽmw̯gC	C1]AH300mlHWޥΤ}ΡAeBᶼΧiC	 pIݦ۵M{HAЦw߶ΡC~LK[HuơBBGAiC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	 jÿ@YG	0000	~iɥR~	0	iU	jLӪ̡CŻPwvġBľB@ئ]åΡAקK椬@ΡC	έYAAдbζqC	SmҦw	ư઺IC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LYOUN-a	LYOUN-b	LYOUN-c	110.6.16
۶O		0	LIMMU1	Immunped syr. (q)@100ml/~ 		(~) ѾNκͯC iɥR; ɧK̡AwΪvзP_BfH״_ιൣͪBipMۼvT  	1~3 G2.5 ml QDF4 HWtHG5 ml QD.	ĳ\301pɫAΡFקKP@_ΡA]ӪʭӻĻPֺQNlAĳŸΡAϥΪ̷|ͤAgC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m󳱲DBOsAOsūפ25סF}ʫĳ3Ӥ뤺ϥΧC	"Vitamin C 2000 mg, zinc 200 mg"	0000	~iɥR~	0	iU	糧~LӪ̸TΤC		έŰiHwߨϥΡC	έŰiHwߨϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		0	0	OIs 20251124	LIMMU-1			44322.49692
۶O		0	OBIOG1	BioGaia (_ĨȩCZ) 450mg/tab;30/ 		(~) 	@Ѥ@	Щbൣ쪺aAקKQ}G	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	ùŻıL. reuteri DSM 17938κͯD3	0000	~iɥR~	0	iU	糧~LӪ̸TΤC	ĹLqɰtgAǵۤfҵo͡C	iwC	iwC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OBIOG1-a	OBIOG1-b	OBIOG1-c	110.6.16
AC36863500	A03FA03	0	EDOMP	Domper 10mg/supp 		"1. [t\᪺GƪšA]iWiNA٪iOAëPiժA٩\᪺įXi{סC
2. Domperidone@hiܾAi_D1D2A@ΩPΫḣپ~ƾ鱵E(CTZ)AGPiGzDƦ٬ʤΤR@ΡC"	"1.uHvΡu12HW魫j35kgC֦~vG110-30mgAC̦h2C
2.u12HUൣvΡu12HW魫p35kgC֦~vG110mgAC̦h3C"	pX{߫ߤ㤧xίgAϥdomperidone	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Domperidone	A03F	GzʤO PROPULSIVES	0	LkfApUAΩߡBæRgvA}fް_Gzįʲ`	"1. צYx\ê̡C
2. wsbŦǾɶjASOOQTcA۹qѽ貧`έ즳Ŧef]p{ʤ߰Iܡ^̡C
3. ֥Υiް_QTī~C
4. ֥αjOCYP3A4]ެO_QT@Ρ^C"	fBfBȮɩʥ֯lηkoBYhBzGABmBݺεCucſE@פɰBkʤkůgC	"SmҦw
DnAקKϥΡC"	MO_sͨ঳`C]AbϥDomperidoneĳ˦ۭšC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
BC24785221	A04AA05	0	IALOX	Aloxi inj. 0.05mg/ml;5ml/vial 		PalonosetronO@ب㰪׿˦Xʪ5-HT3ܾALXGS˦XʡC 	"ĳqGHqGb}lƾǪv30eARߪ`gWL30A뤩@q0.25@JC
ΪkG ALOXIRߪ`gΡAALOXIPLĪVXC
PALOXIeP᧡ݥΥͲzQR~`޽u]infusion line^C
DgzGD뤩ĪAunGMee\pUAīe˵Ī~O_LɪοƦ⪺ΡC"	wQiMgԸsIASOO~PLM@Ī֥ή C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Palonosetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	R	L5-HT3ܾLӪfwi|͹LӤC	YhBKC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	0	0	OIs 20251124	IALOX-a	IALOX-b	02C24785-2	110.6.16
AC09250500	A06AB02	0	EDULC	Bisadyl(꾯)10mg/supp(Bisacodyl) 		~|Q餺lAȻPz߽ĲAEz߽PıAӤް_gϮgAϵzįʦYW[AӦ۵MƫKC~pzS@ΡAGܤ֤ް_hPKC	"꾯wpݧYɱƫKɥiϥΧCbNeAXˬdeAιׯfw̡A@KĤzNΫ~C
HGq`ζq10gm꾯@ӡCubSUݭnGӡCb30Yiް_ƫKC
pGϥ5mgpή꾯C"	"1. wmvYzXAYhAθz\MܮɡAnWqvC
2.SԸvpUAnϥνwmWL12gAӥBnקK~LĮɡAզۼW[qA|oͽwm̿ʩιqѽ褣šC
3.jըnΩMʭ~AH֫KoͩMYKCzQ]Aѥ]AM\AͪMA尮AMCAG(610M/)P˦anC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Bisacodyl	A06A	m DRUGS FOR CONSTIPATION	0	nK	æʸhBj˩ʫKAgwKw̡B꾯GzHBũʲ֡C	hALӡAzEPC	B	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EDULC-a	EDULC-b	EDULC-c	110.6.16
KC00914216	A10BJ02	0	IVICT	ĵVictoza 6mg/ml;3ml/syringe (N) 		LiraglutideO@Glucagon-Like Peptide-1 (GLP-1)agonistAliraglutideƯŦ]ӭMGLP-1AǥѨEGJ(Gs)Ӭadenylyl cyclaseӲͧ@ΡC}@׼W[ɡAliraglutideW[cAMPӾɭPخqcCӷ}@פUB񥿱`}ɡAخqc|zCLiraglutide]|̸}@צhӴ֪@}cC}]]tFGƪšCѩsxsbDPP-IV neutral endopeptidase (NEP)ïѡAGLP-1(7-37)bI1.5-2CͩGLP-1AliraglutidebߤOwwAåB㦳ܫe̻ïN©ʤѧ@ΡFg֤U뤩AߥbI13ӤpɡCLiraglutideĪʤOǯSʡAϤAX@Ѥ@Ī뤩CDOۧڵXɭPlAP߳JժXAHΧDPP-IV NEPïwwʡC	"Victoza?ibɶC뤩@AH֤U`g覡`gbBjLΤWuALݮھڶi\ɶġC`gPĮɶܮɤݽվ㾯qCҦw̡AVictoza?_lqC0.6 mgAϥΤ@PCϥ0.6mg @_lqOFn֦bվ㾯qL{ҳyzGAgAӾqLkı}CbC0.6 mg@PAqW[C1.2 mgCpG1.2 mgqèSFzQ}ɡAiW[q1.8 mgCb}lϥVictoza?AֵoͧC}IAӦҼ{֪֨APخqcq(Ҧpsulfonylureas)
"	"1.pĶWL3AĳH0.6 mgqs}lC
2.bC`geˬdVictoza?GAubGe{MLBL󲧪ɤ~ϥΡC
3.ҪCӭM~FIB
4.Ŧ:Cb}lϥVictoza?HΦbW[qA`Nw̬O_Ŧxίg(]AYkhAɷ|IAåi঳ΨSHæRp)CpGhìOŦAVictoza?ΨLhêĪߨ谱ΡAiˬdT{άAICYTwŦAhAϥVictoza?CŦfvwpߨϥΡC
5.ФŹեh0.6 mg, 1.2 mg1.8 mgH~qCȥqܵƦrPܽuAHTOzoTqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1.bϥΫe:Né2XC8XCs즳Ĵ
2.bϥΫ:isǷŤU 15XC  30XCΧNé2XC8X@30
"	Liraglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	2}fCw̤wmetforminsulphonylurea@v̤ܳjiԨqFzQ}ɡAPmetformin sulphonylurea֥ΡFηw̤wmetformin[Wsulphonylureametformin[WthiazolidinedioneĪvF zQ}ɡAPmetformin[Wsulphonylureametformin[Wthiazolidinedione֥ΡC	"(1) Victoza?TΩӤHάOaڦҪ (MTC)fvw̡AHΦ2hoʤc~FXgw( MEN 2)C
(2) TΩ糧ī~DΥ@᫬LӪ̡C"	C}B ߡBæRBmBƤ}ΫKB YhBŦBʵǰI	C 	"SmҦwADnקKϥΡC
LkTVictoza?O_|cHťĤCbŶqĪ˪nʫAMwO_¨ũΰϥVictoza?C"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[Ʈw]_Ʈw j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3.2._20201201.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3._20190701.pdf"">OI` 5.1.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.3.2.</a>            "	0	0	OIs 20251124	IVICT-a	IVICT-b	IVICT-c	110.6.16
		0	OKREM1	Kremezin 2g/pack 		QΨ㦳lʪyLɬʺҪAibzGDܩʪlISeXp-cresolAH֤Hl|Aӥo|QH骺zGҧlC	"1. H12HWൣGʤrɡA֨ϥ50-100JʺҡCYrɡAAΪ쾯qAC46pAA20JʺҡAsƤѡC
2. 12HUൣGʺҥΦbpĤ˾qOC魫1JʺҡCʤrɡA̤pĤ魫Mr{׵10-50JʺҡF쾯q10-20JʺҡAƤھvܡAiƵġFjpīhqjq30-50JʺҡC"	"1. wƩʼũέDRߦifHAbAΥ~pߪ`NC(~OHTAAUgLƹDAi|EgLϰ)
2. ѩGkʪް_rLġA]ApTwOѻGkʪް_rAקKϥΥ~C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	SPHERICAL ABSORPTIVE CARBON	A07B	zDl INTESTINAL ADSORBENTS	0	"vĪΤƾǫ~rfHC
lzZGzDӵߩʬrBƩʬrΨLʼoBѰzdΦgC"	"1. w̥ϥΤfAľΤfASѬrɡAiϥάʺҡC
2. wƹDe(transit disorder)fHA~i|zZƪnC"	KB«KBmC	Sm	Sm	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OKREM1-a	OKREM1-b	02024722-2	110.6.16
AC48722251	B01AD04	0	IUROK	"ĵUrokinase-Green Cross Inj. 60,000IU"		~NplasminogenƦplasmin(fibrinolysin)AMiNֺJժѡC	R߮g:Ĥ@60000-240000IUAấ־qAsϥ7ѥkC	"1.PLfHioͥXʸC
2.ϥΥ~n`NY۵oʥXAg`@GˬdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Urokinase	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʪͮAʫaʯ߮AMR߾ɺ	"1.ī~󦨤LӯfvfwC
2.XBI~NB72pɤLw´BCYx\êBCֺJխpΩX̧ҥΡCHypersensitivity to "	`-`gˤfBXκyF-LӡBYhBBoNBR?BߡBooB۵oʥXC	B	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w09-05 [E]_E7-03 j	Ts110.6.16		0	0	OIs 20251124	IUROK-a	IUROK-b	IUROK-c	110.6.16
BC26233100	B01AE07	0	OPRAD1	ĵPradaxa 75 mg/cap (Dabigatran) 		Dabigatran Pacyl glucuronides N²vʾJC]󾮦tCL{Aserine proteaseNֺJխ]fibrinogen^ܬֺJա]fibrin^A]Yiwo͡CAMPXBHξJһopOEA|oǬʦҧC	"wDäʤߩֺŸʯfwoͤPʮG
ĳϥξqCfA110~150mgA@Ѩ⦸AŸζAΧiAfHӤH{ɪpϥΤC@150mgniΨ75mgnNCXʭI̩yϥξqCfA110mgA@Ѩ⦸AҦpG~֤j󵥩75BCHADS 2> 3B魫<50kgBeGzXB׵ǥ\l]ٻMv30-50mL/min^fwC
[qվ]
Yǥ\ण]CrCL< 30 mL/min^fwT Pradaxa vC
׵ǥ\ण]CrCL30-50 mL/min^ĳqCA150 mg]75 mgn^A@Ѥ@C


ʲ`hRߦ(DVT) ΡΪͮ (PE) v:
H
ĳ`gܾ徯vܤ֤ѤAϥΤ@300 mgqPRADAXA]CfA@150 mgnA@Ѩ⦸^Av6ӤC"	"1.pN(]AN)AΫIJˬdeAШƥivAbAΧܾ徯C
2.ЧifwNn]AA˯}BCZΨXnĲɧiɭPĪSqW[C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dabigatran	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1. ΩRߦ갪MIsfwAHw󱵨UϭjNᤧRߦg (VTE)C
2. wDäʤߩֺŸʯfwoͤPʮC
3. ʲ`hRߦ (DVT) /Ϊͮ (PE) vC"	"1.wdabigatrandabigatran etexilateΥ~@᫬LӡC
2.Yǥ\l]ٻMv< 30 ml/min^
3.Xg{BsbX]BΦ۵oʩĪʤ\lfwC
4.sb{YX孷IʯfܡA]ALh6Ӥ뤺oͪXʤC
5.Pɱketoconazole, cyclosporine, itraconazolevC
6.HuämC"	XBhBߡC	SmҦw	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.5._20230301.pdf"">OI` 2.1.5.</a><a href="""">OI` 2.1.5.2.</a>             "	0	0	OIs 20251124	OPRAD1-	OPRAD1-b	OPRAD1-c	110.6.16
AC22314100	A12BA05	0	ORADIK	Radi-K 595mg/tab(Potassium gluconate) 		[OӭMGDnlAǾɤŦAjMf٤gİʦnC ŦAfMƦ٪YF `ǥ\APšAҤƦXN©MGGcC~[ltq ]K:2.54mEq/tab^fAKCt[QAzGHEC	"@3~92~3AΡC
wC[g]20mEq /ѡ^ι[Ӻܡ]40-100mEq /ѡ^C"	"1. C[Aɧ@[ɥRAϥΫeˬdM[ȡBuȤΧqC 
2. ϥΤwˬdM[ȡBqM[ȶuȪvHεǥ\C
3. ϥήɡA夤?[ȡBǥ\B߹qϳ̦nwˬdC
4. Addison's disease]w}ͤf^w̡AIHAw}ͤfkC
5. ѩoAldosteronism]ǩTହLhg^ް_C[gAлPǩTଫܾ֥ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Potassium gluconate	A12B	[ POTASSIUM	0	[LCgC(]NeAϥĪBmBŦfް_[LCg)	ǥ\Bǥ\CUβӧޡB駿ޯfܱw̽ԷVAΡC	"1. ߡBæRBBUgBhBݴeBKBθȷPC 
2. ֯lBkoX{C"	B/C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ORADIK-a	ORADIK-b	ORADIK-c	110.6.16
BC21379265	B01AD04	0	IUROK1	ĵUrokinase 250000I.U/VIAL 		~NplasminogenƦplasmin(fibrinolysin)AMiNֺJժѡC	"GC1Aq60,000 IUAsĬ7
yR߳gGCq60,000~240,000 IUAHấA7C"	"1.PLfHioͥXʸC
2.ϥΥ~n`NY۵oʥXAg`@GˬdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Urokinase	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʪͮAʫaʯ߮AMR߾ɺ	"1.ī~󦨤LӯfvfwC
2.XBI~NB72pɤLw´BCYx\êBCֺJխpΩX̧ҥΡCHypersensitivity to "	`-`gˤfBXκyF-LӡBYhBBoNBR?BߡBooB۵oʥXC	B	SmҦwADnקKϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.25		0	0	OIs 20251124	IUROK1-a	IUROK1-b	IUROK1-c	111.8.25
AC308891G0	B03BA05	0	OVB12	Kobal 0.5mg/cap 		Kobal O@غͯB12AΩvgPefByhHΧ@ٵYwƯgBv覡C	C0.5-1.5 mgA1-3AΡCi̦~֡BgAyWC	קKӮgī~FpoܽιLAiAϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mecobalamin	B03B	ͯB12M VITAMIN B12 AND FOLIC ACID	0	LRB12ʥFҤް_yʳhΥ鯫gê	w糧~ʦLӪw̡C	zGA..m	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2.1._20110801_000.pdf"">OI` 3.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.1.</a>             "	0	0	OIs 20251124	OVB12-a	OVB12-b	OVB12-c	110.6.16
KC00955206	B03XA02	0	IARAN1	NESP inj. 20mcg/0.5ml(Darbepoetin \) 		vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"CʵǰIܱw̡J
~ľqRߪ`gΥ֤U`gCg@C
GzRfHAĳHRߪ`gPC
_lq:
vhG
HRߪ`gΥ֤U`gCg@ĳ_lqC魫0.45mcg/kgC
qG
ľqӤHƥHȦb1012g/dLC
qվG
~ľqվCw̪ȯFӥBȦb10g/dL12g/dLC"	1.󦳬YǦGf]ҦpGʳhBIMyʳhBahBg^w̡AåTߥHDarbepoetin alfavwʤΦĩʡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~ib2-8JUxsCץC	Darbepoetin \	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"~TΩG
1.Lkw̡C
2.DARBEPOETIN ALFA ΨLyͦJĪv}l¬yo|(PRCA)C
3.w DARBEPOETIN ALFA YLӤ̡C"	ΧCB~BYhBhBmBߡBæRB٦`khBWIlDPVC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.1._20160901_000.pdf"">OI` 4.1.1.</a>              "	0	0	OIs 20251124	IARAN1-a	IARAN1-b	IARAN1-c	110.6.16
AC03619277	B05BB02	0	IGS5	5% DEXTROSE IN 0.9% SALINE (D5S) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IGS5-a			
NC02980277	B05XA03	3%ƶu`gG	INAC3	ĵNACL 3% 500ML/BTL		R`~Uؿ@סAiGMqѽӡAi@G`JޡAiGzC 	q魫ίfݭnӽվ	"1.IwCRߪ`g
2.`tפŶWL 100ml/hr
3.ʴJ@XvΦ夤qѽ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHU 	"
sodium chloride  30@J"	B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	uδlɥR]Guδl@פ^w}ͤMHο}fʩg	RʤŦIܡAYǷlˡAζudҤް_~				аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G-
q(MD)G6-8mEq/L/24hr,̦h12meq/L/24h̦uȽվ(H70kgkʬҡA魫*0.642LACtotal SNaW6meq, 3%NaCl run 20ml/hr)
}GGG
}@סGG
ĳĳtvG<100ml/hr; 0.5meq/L/h,,ʯgi1mEq/L/hr
wwʡGǷ24p
ѤjRߵ(z)
ʴءGNa,K,~,gǯg"	ixii[w]_w11-08 [E]_F3-06 j	Ts113.07.05		0	0	OIs 20251124	INAC3-a	INAC3-b	INAC3-c	113.07.05
BC22022255	B05BA01	0	IAMI6	*Aminosteril Ƥ 6% 		iĿ`G	"R߿`C̤j`tvG0.1J/魫/p=1.67@/魫/pɡF
̤j龯qG(1)1HG1.52.5J/魫F
                        (2)1G1.5J/魫F
                        (3)24G1.5J/魫C"	w˴BPšBqѽBxïB׽@(YPɿ`תըž)B	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKg;xsbǷŧC25J	amino acids	B05B	Rߪ`gG I.V. SOLUTIONS	0	BΥधz~i	iĥN¤}BĬrgBLhBC[g				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IAMI6-a	IAMI6-b	IAMI6-c	110.6.16
		0	IEPIP1	EpiPen Epinephrine Auto-injector 0.3mg 		"gѧ@Ω\AʹLӤɩҤް_ޤGen֩MCAwXiμW[޳qzʡCgѧ@Ω]AޥƦPAwѥʹLӤް_޵jˡBݩMIlxCǤW]wѷkogBC¯lΦީʤ~AB]
㦳GBzBlcBH֥ƦPĪGAiwѻPʹLӤGzDΥʹުctίgC"	30 HWG0.3mg/ABYLөʤAYnɩvʷUiAl[IC	1.uIjLe~AiIVBIvΥ|ϥݡC2.榸ϥΡAϥΫ1.7 @ɷGdbޤAϥΡAC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUץJsAФŧNáC	Epinephrine	C01C	Dglycosidej߾ CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES		ǤWΦbΥmrBBĪMLLӭHέoʩιBʤް_YʹLӤ(anaphylaxis)vC㦳Lөʤfvw̥iߧYۧڨϥΤĪALӤibXoͤ@sꪺyB~{Bw֡B߸[tB߷iLz[WUBWBæRBmBhBDۥDʱƪnBݡB|Yjˤ޵oIlxBkoBXlBC¯lBީʤ~CuΦbʤkAN|@C	L	J{B~{BߤwBŸݡBzBYBsB߱BaաBߡBæRBYhBIlxC	ǤWOvLөʤĤ@uĪAv覡PDh̡C	ǤWOvLөʤĤ@uĪAv覡PDŪ̡C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.2.15		0	0	OIs 20251124	IEPIP1-a	IEPIP1-b	IEPIP1-c	111.2.15
AA29836277	B05XA03	0	INAC04	"500ML/BAG ""N.K""0.9% saline inj (n) "		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC04-a			
BC27344100	C03XA01	0	OJIN60	Jinarc 60mg/tab (Tolvaptan)  		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixii[]_03-08 j	Ts111.4.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.13.2._20210201.pdf"">OI` 2.13.2.</a>              "	0	0	OIs 20251124	OJIN60-a	OJIN60-b	OJIN60-c	111.4.27
AB29447209	J01DB04	0	ICEFA1	CEFA inj.1gm/vial(Cefazolin)		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"IV or IM. H@뾯qX 2g Q8H; MAX 12 g/day. pྯq: 25-100 mg/kg/day Q6 -8H; MAX 6 g/day
ǥ\णվ㾯q"	"ǥ\ण}w̡ApߨϥΡC
penicillin tܥͪ観LӯgJfv̡AeLӤIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ץOs.
ѫᶷץAǷŤU48pɤϥΡANâp."	Cefazolin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	YUl߯ܥͯLөʤw̸TΥġC	",æR,m,,`gkh,C¯l"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668915?cesid=3BVjVgOe91T&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dcefazolin%26t%3Dname%26acs%3Dfalse%26acq%3Dcefazolin"">LexidrugľǸƮw</a>"	"CClr>50      1g q6-8h
CClr 10-50  1g q12h
CClr<10      1g q24-48h
IHD             1g q24-48h
CAPD          1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIMBIV
tswwʡG1.ѫǷץ48hrAN96hr
2.YϥNSѡAХߧYϥΧ
tsGG IM: 2.5ml WFI, 3.5ml NS or D5W
IV: 5ml WFI, 7ml NS or D5W
ĳ}@סG--
ۮe}GG50-100ml NSBD5W
ĳĳ~|tvGIV:3-5min
"	ixii[UDx]_U09-01 [w]_w05-19 [w]_w12-01 [E]_G4-05 [Ew]_F5-01 j	Ts113.04.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	ICEFA1-a	ICEFA1-b	ICEFA1-c	113.04.19
		0	OJINA	Jinarc 45+15mg/tab(Tolvaptan)(28+28/ 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@AᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
E ALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨ	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m2CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 15 mg  7 Tolvaptan 45 mg A@ 56	ixiij	Ts110.6.16		0		OIs 20251124	OJINA15	OJINA45	OJINA-c	110.6.16
		0	OJINA1	Jinarc 60+30mg/tab(Tolvaptan)(28+28/ 		"Tolvaptan O@ب㦳SO_Ǥݳ V2 PiĦ޼W(AVP)X
޼WܾCTolvaptan H V2 骺˩MOѵM AVP  1.8 "	"1.CP⦸
᪺@ Jinarc b\ 30 eAΡACѪĤGibiΫDiɪAΡC
2H 45 mg + 15 mgB60 mg + 30 mg  90 mg + 30 mg ؾq(split dose regimen)C
3.qվ
_lqC 60 mg tolvaptanAH 45 mg + 15 mg ؾq(οɡB\eA 45 mgA8 pɫA 15 mg)AYi@AhiNqհܨC 90 mg  tolvaptanAHؾq(60 mg + 30 mg)AHհܥؼоqAC 120 mg  tolvaptanA
Hؾq(90 mg + 30 mg); C@qվ㶥q Aܤֶj@g"	"b}li Jinarc veAxŦi?xGˬdAH/ΤifʤxŦl˪IABU 18 ӤOC@Ӥˬd@A
ᬰC 3 Ӥwˬd@CPɫĳʴiNxŦl˪g(Ҧp:h¡B
BߡBkWABæRBoNB֯lBkoBt⧿Gζn)C
ä[ĤĳǫhpUG
E ALT  AST > 8  ULN
E ALT  AST > 5  ULN 2 gHW
E ALT  AST > 3  ULN H(BT >2  ULN ΰڼзǤƤ[INR] >1.5)
 EALT  AST > 3  ULNAB㦳WzxŦlˤʯgC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC]xsAHuӮgΨC	Tolvaptan	C03X	䥦Q OTHER DIURETICS	0	AΩʦhnʵŦf(ADPKD)BeGFRj25mLmin1.73m3CʵŦfHw̡AwX{ftcƸHAΥHwʦhnʵŦfnwͪεǥ\઺cơC	"1.靈ĦΥ@ؽξL 
2.b}lveAX{ŦXä[ tolvaptan WwxŦïɰ/ΨxŦl
˼xԩίg
3L E GʥF(volume depletion)
4 ug
5LkPΤf E h
6 "	hg(Polydipsia)AYhBYwAmBfA]gBWgBhgAh	hɤoAJinarc/SmҦw	ŴTJinarc/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	C 7 Tolvaptan 30 mg  7  Tolvaptan60 mg A@56	ixiij	Ts110.6.16		0		OIs 20251124	OJINA30	OJINA60	OJINA1-c	110.6.16
A027289338	D02AE01	0	EUREA	Winsolve Urea Cream 		ĥDUrea㦳跻@	"@2-3AAqw

"	~ΤoAA礣oΩ󲴷|PH(pfġBġBDB nB~)AlABBtY~˪wC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 @2-3AAqw	Urea 100 mg	D02A	ĩM@ EMOLLIENTS AND PROTECTIVES	0	h	"1.ϥΦĤް_L
2.ˤfά~
3.ywμ
4.ˤfm{H"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EUREA-a	EUREA-b	EUREA-c	110.6.16
BC20230343	D05AX02	0	EDAIV	DAIVONEX OINT 50MCQ/GM/30GM/TUBE 		~LRDlͪACalcipotrioliƻPֽӭM(ӭM)W͡A]iϤ~ֽ`ӭMWͩMƫ_`C	CѤG٩wBCYǱw̦bviݴ֨ϥΦơCCPϥξqWL100gC	ĳϥΩyA]eyEC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsūפiWL 30JC	 Calcipotriol 50gg (0.005% w/w)	D05A	Ϊv~ ANTIPSORIATICS FOR TOPICAL USE	0	M`ʤ~	DΥ~󤧽ξLӪ̡Cѩ󥻫~t CalcipotriolAtN¥ժT				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.1._20101201_000.pdf"">OI` 13.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.3.3._20101201_000.pdf"">OI` 13.3.3.</a>             "	0	0	OIs 20251124	DC	DC	DC	110.6.16
BC24391100	C10BX03	0	OCADU	Caduet 5/10mg/tab 		"Amlodipine/atorvastatinXا@ξG
amlodipinedihydropyridine
tlܾ(tlܾκCtqD_)@ΩMatorvastatin
HMG-CoA٭쨻C@ΡCAmlodipine/atorvastatinamlodipine
tlLӭMyJӶiJޥƦ٤Τߦ٤C
Amlodipine/atorvastatinatorvastatinOHMG-CoA٭쨻CܩvCo٭쨻COHMG-CoAܬmevalonatetvMwïAmevalonateDO]AxTJbTJeXC "	qdamlodipine/atrovastain 5 mg/10 mg10 mg/80 mg̰qACѤ@C_lqMq̨CӦﰪ/ߵhMצgĪGM@ʦӭӧOMwC~ib@ѥɶAΪŸBAΤC	x\णΡBhα¨Ū̽Хiv pGX{]٦ׯkhΦ٦׵LOAкɳt^EC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs15-30XCC 	Amlodipine/Atrovastatin	C10B	"׽ո`AƤ LIPID MODIFYING AGENTS, COMBINATIONS"	0	]Mײ`oإiBMI]l֦sAӨϤߦަMIW[w̡FΦ]ߵh{a߯f(CHD)֦iBײ`MI]lAӨϤߦަMIW[w̡CCa߯fMIsߦިƥoͲv{ɤWSa߯fw̡AOܤ֦TӨLa߯fMI]lA]AĤG}fB~j󵥩55BLճJէγJէBlϡBβĤ@˦b55(k)60(k)egoͫa߯fƥAAΩGCߦٱ몺IBCIBCަAyNPߵhI	dilhydropyridineƦXBamlodipine BatrovastainΥ~󦨤LӤw̡CʩʨxfΤ]MಾïWɶWL`ȤW3HWw̡CB¨ŰkC				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	0	0	OIs 20251124	OCADU-a	OCADU-b	OCADU-c	110.6.16
AC35696335	D06BX01	0	EMETR	FREE GEL R0.75% (7.5mg/gm);15gm/ 		Ĭ@ر߾AiΩMʹ߷PVvA@άOgѹʲӵߥN©ҿWӨϥĦbӭMiƾǩ٭CQ٭ᤧĨ㦳ӭMrAiPDNAۤ@ΡAɭP۵cॢBѪ_A䵲GDֻĤXAӨϲӭM`C	NwM~bA@⦸AߨϥΡA٤@hwCϥ3PYġCϥ9Phfﵽ	"Yϥ3P᥼ﵽίgVAݧivC
ϥΫeεLEʪM侯MwA٫|XEPN`PAYgAݨ̷vܴ֨ϥΦƩΰϥΡC
ī~i٩󲴷PAHKDy\AYƱĲ체AiΤjqMR~CϥΥ~iϥΤƧ~A̦nOLoƧ~Aű`@
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷŦs15~30J	Metronidazole	D06B	Τ CHEMOTHERAPEUTICS FOR TOPICAL USE	0	]sް_oʥClBwͤά~C	糧ĦLӪ				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_O03-01 j	Ts		0	0	OIs 20251124	EMETR-a			
KC01082212		0	IDUPI1	Dupixent 300mg/2ml/syringe(Dupilumab) 		DupilumabO@IgG4HAM@ʦaX󤶥կ-4 (IL-4)Τկ-13 (IL-13)ƦXWIL-4R\Aiӧկ-4 (IL-4)Τկ-13 (IL-13)TǻCDupilumabiǥѻPI鵲XӧIL-4TǻAHǥѻPII鵲XӦPɧIL-4IL 13TǻC Dupilumab_կ-4 \(IL-4R\)iIL-4 IL-13ӭMEһoA]APoӭME (proinflammatory cytokines)BͤƯ (chemokines)ΧK̲yJE (IgE)C 	"1. DUPIXENTH֤U`gġC 
2. DUPIXENT󦨤Hfwĳq@_lq600 @J (300 @J`g⾯)AۥH300 @Jjg`g@C 
3. DUPIXENT_lq600 @JA󤣦P`g⾯300@JC "	"i`g`Nƶj
1. ֤U`gjLθAo`g{P 2 T( 5)HdCYѷ@̬w̪`gAi`gWuC 
2. C`g󴫪`gCi`gֽhBˡBCεͳBC
3. `geN Dupilumab w`gqBcXAnްw\Ϥ^ŦܫǷ(45)C
4. `geHײˬdO_X{ɤܦCDupilumab MܲHťզALܲH⪺GCYG餺ײiɡBܦΧe{VBhoϥΡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. DUPIXENTLߥBtGC󥼨ϥΪC 
2. mb즳ȲxsBc2XC- 8XC HקKӡC
3. nɡAw`gimǷŤUWL25XC̦hF14ѡCixs25XCCqBcXADUPIXENTb14ѤϥΡA_hHC
4. `giΪ/ӥC
5. 󥼨ϥΪĪμo̷ӷaWw󤧡C
6. iNCiCi_nC "	Dupilumab	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS	0	"DUPIXENTiΩvצܭײʥֽB什BvΩΤAXϥθkHw̡C
DUPIXENTi֥ΩΤ֥ΧֽTJvC "	DUPIXENT TΩwdupilumab ΨξLӪfwC	`gBB¥Bf?lBBoBL?lBgC 	|LDUPIXENTϥΩhkƾڡA]LkѥPĪIơC	"DupilumabO_|cܤHťġBlmŤ઺vTAιťͦvTAثe|LơCҶqŹo|ΰdqBɡAPɦҼ{˹DUPIXENT{ɻݨDAHDUPIXENTΥ˪bfplmŪiy󤣨}vTC
8.4"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B01-22 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.17.1._20250601.pdf"">OI` 13.17.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.17.2._20240201.pdf"">OI` 13.17.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.17._20250601.pdf"">OI` 13.17.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.9._20240201.pdf"">OI` 6.2.9.</a>           "	0	0	OIs 20251124	IDUPI1-a	IDUPI1-b	10C01082-2	111.8.19
		0	OPROSE	*Prostarmon.E 0.5mg/tab(Dinoprostone) 		" ProstarmonEE YXProstaglandin E2(PGE2:@Wdinoprostone)wwƪdinoprostone betadex(PGE2ECD)sC
PGE2P۵MYo;ǦKsAfAlcVƧ@ΤΥͲzʤlcY@ΡA󧳮W}hoΰ}hPiġC "	"1. q`fA11ACp1@6AH1`q6]dinoprostone 3mg^1ӹL{C
2. 魫Bgίf{AWζqC
3. Ķ}lAT{}hoAYiĪGɤġC
4. 1`qdinoprostone 3mg(6)T{LĮɡAϥΡAݤΨA}lϥΡC ĶvBϥΡC
  "	"1) ]Iw`gʥFո`ʡAhWnbHYʵ˸mɱ`ʵˡALબAU
ϥΡC
2) ]ѩLj}hαjʤlcYް_L঺`BlcVˡBlc}BϤ뵥iA
nΤYʵ˸m@lcYAML߭[AT`NOĶjAbT{}ho
ΤYiĪGKϥΡAnVϥΤnLqġC
nΩHUfH
1) LUAYLAXAL쵥L첧`fHC
2) iMέLधֵogfHC
HUfHnԲ[Vϥ
1) CifHC
2) ݩΦffHC
3) 帡ffHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUAt Silica gel BKeOsC	Dinoprostone  	G02A	lcY UTEROTONICS	0	 W}hoΰ}hPiC 	" dinoprostoneL
hL?W(6Lh6ӤHW)
æҹL~"	" 1) }hLj ]ɷ|}hLjAMoͭLxԡ]}ߡBWߡBϤVB^AnԲӧ@[AX{oدgɭԡAnqΤϥΡC
2) G z ɷ|X{תݤߡBæRBUgC
3)   ɷ|X{C
4)  L ɥX{YBYhBtwBתW@ΤUC"	C 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts44322.4969212963		0	0	OIs 20251124	OPROSE-a	OPROSE-b	OPROSE-c	44322.49692
		0	EREME1	Remelone cream Ƥ5gm/ 		"~tTئ:
1.fG:@ξG
fGOǲΤWΩժ`ΤƾǪAP¦eͪcۦAfGiTiĭlͪDOPAƬ¦A]㦳HĪGAwQҩiC90%Ti?ʡAiDNAMRNAXAѶ¦p(melanosomes)A㦳wxͩδ_o@ΡC~AfGivT¦ӭMӭMcA̫Ӷ¦ӭMaCѩƧ@Τ譱ҶqAĳsϥιfGWLӤC
2.ͯA:
@ξG
 ~κLRAĥiPiΦӭM(keratinocytes)W͡AüW[fGb֪z@ΡCͯAlͪbդ譱ھ| TAbʪ礤o{oTi?Cb1975~KligmanMWillisҵ۪פ夤A{ͯAtretinoinizLNɤbΦӭMAϰ򩳼hhѶ¦melaninΦuӭM֤WUv(supranuclear cap)cyAҥHio⪺ĪGC~AͯAlͪ]izZΦӭMಾAå[t֥N¡AϨΦӭM(䤤t¦)[t渨AiӲͲHĪGC
3. TJG֥~AĻPfGҤ޵oEʤ
@ξGĪG"	C1~2wAHۯg(1~2뤧)AivֶġCϥδiϥΰΫYƪľCĻݥvBϥΡC	"קKALBλHPĲC
קK׶nΡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(J)xsAקKӮgFpoܽιLAiAϥΡC	Hydroquinone 50mg+Tretinoin 0.3mg+Dexamethasone 0.3mg	D11A	䥦vֽfĪ OTHER DERMATOLOGICAL PREPARATIONS	0	¦ް_LרHۡAҦpBJֽ(Berloque Dermatitis)BĲʥֽBBѤHB¾~faӪLרHۡBդ¦Hۯg(Riehls Melenosis)άͲLרH	"AĹLӪ̡AiϥΡC
YLef]yINC"	"ϥάtTJAרOyAi|ް_ֽYAӦXiAHίC
u(1~3Ӥ)ϥΥiX{ֽC
"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EREME1-a	EREME1-a	0	110.6.16
BC20826100	H01BA02	0	OMINI	Minirin 0.1mg/tab(Desmopressin acetate) 		"desmopressinO餺Xarginine vasopressinP\CѵMXgBƾǧܡAYbcysteineg@(desamination)AñN L-arginine令D-arginineAcܫ, {ɪܧQ@ήɶAb{ɾqWϥΧh[(pressor)@ΡC"	"ϧYgGpĤΦHlqA0.1mgCѤTAA̱w̱p[HվCھ{ɹ AC龯qd0.2mg1.2mgCjhƯfH̨ξq@ѤTAC0.1-0.2@ JCpdΧCǯg{HĩMվ㾯qC

oʩ]g]ΩCHWfw^GlqΫe0.2mgCpCqĪGΡA̰iW[0.4mgCv3ӤHᶷAAMinirinvܤ֤@PCQ[AаѦҪ`NƶCpdvC

H]]hҾɭP]gG
b]fwAbveαƧƤαƧqܤ֨ѨӶE_]hgC]qͶWL
\ʻH֮eqζWL24pɧqͪ1/3iE_]hgCĳ_lqΫe0.1mgCpv@gĪGΡAiW[0.2mgMM@gA[0.4mgCGC"	"1. b}lveݭnҼ{fwO_YH֥\णMƧêC
2. bѦ~HMCuȪfwi|W[CugMIʡC
3. fwY]GM/ιqѽ褣ũҤް_ʨֵogg(ҦpʪPVAoNAzG)ɡAߧY_desmopressinvC 
4. `Nfw`ɰMIC
5. DesmopressinpߨϥΦbfwGM/ιqѽ褣ŪpC 
6. קKPĪX֨ϥήɵoͧCugAbHUpUAv`NGMɱ`ʴuȡGPw|ް_ܧQEAcgԸs(SIADH)ĪpTܼ~{BܩʪMAlBchlorpromazineBcarbamazepineX֨ϥήɩMPNSAIDsX֨ϥήɡC 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	iWL25JC	Desmopressin	H01B	UḭPX POSTERIOR PITUITARY LOBE HORMONES	0	"MINIRIN?ΥHvϧYgAֱw̪qAæH̼W[GzA֦夤zAp
YiUw̫_`ͬӴWΩ]{HC
~ΥHv7HW]gw̡C
H]X֩]hgvAY]GͶWLH֪eqC"	"MINIRINiΩUCfw̡G 
1. ߺDʩκ믫ʤfgw(ɭPGͶWL40 @//24p)F 
2. whæߥ\णfvMLdAݭnΧQ̡F
3. רYǥ\णfw(ٻMvp50@/)F
4. wCugw̡F 
5. ܧQEcgԸsw(SIADH)F 
6. desmopressin ΨL᫬LӪ̡C"	YhBCugBYwBBߡBæRB魫W[BVáBFOBOлêBtwB^ˡBzBgBhBmBKC	desmopressiinvYg窺hkAƾܦbhkέLsͨషdL}A}BhkSOԷVC	qQ¨ŰkAGಾܤpĪqܧCACvThһݪqC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OMINI-a	OMINI-b	OMINI-c	110.6.16
AC11476221	H02AB08	0	IKENA	SHINCORT 10mg/5ml/vial(Triamcinolone) 		~@ΤXƵǥֽTJADnΩ󻴭gʯewD	"`Ĥ`gG
10-20mg CP~C1~2DnɥiVX¾KX֪`gD`ĤYhq`GAiN`GXAA`JĲGD``gqG5~15mg p``gqG2.5~10mg n´G1~5mg ֤G0.2~0.4mg"	"1.~tGAHպޤεwὤ~`gġD
2.ĸTΩRߪ`g
3.CʷPVgAϥήɻݦX֪vPVD
4.Gűw̻ݯSO`N
5.}fw̽Ъ`NW[خqζqnʡD
6.믫f]̻ݦh[`N
7.иɥRJս
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Triamcinolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	"`BnBLөʥֽBޮݡBLөʻ󪢡B?HBLөʤεoʲew
"	 triamcinolone ΨLξL 	B~BWɡA֦Ƶǥֽ@ΩΥʰƧ@ΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IKENA-a	IKENA-b	IKENA-c	110.6.16
		0	IPREG	Pregnyl 5000IU/vial (HCG) 		PregnyltH򽤩ʸE(HCG)Pregnyl֦E(LH)ʡCb`kʻPkʰtlo|PBʸTJͦAE(LH)OiίʪCPregnylOͩʶgE(LH)HoowVƧZN~CPregnylPɤ]OͩʶE(LH)N~CPregnyliEAYӭMHPiATପ͡C	"kʤ譱
ʸEcҤް_ʸ\णg
CgG~TAC500~1,000I.U.
CKw(PUPʸ\ण)
CgGAC1,500I.U.ܤ֪vӤHWC
 Ag(D]ѭWҤް_)
HUGCg⦸AC500I.U.svgC
HWGCg⦸AC1,000I.U.svgCnɥiгoتv覡C
 YǺlͦg
q`ACg3,000I.U.MHMGsX֨ϥΡC
kʤ譱
owαƧZʥFg
q`AbHMGs(ҦpHumegon)vA5,000~10,000I.U.@ѩγsTѡCCѫA`g5,000I.U.i\઺C"	"bvʩʸEceAiˬdHDʸ譱c`]pGҪBǤWο}f^ξASwvC
˴ʸEӱưoʧZ_\IܪiC
ϥΩʸEɱƧZh̡Ai|W[yΦhMLWIC
HuUʹާ޳NҥͲLѷv۵M̡C
קZ_LרEgԸsOHSS{ɪ{jZ_n~BʸhBBؽnBݡBIlxB֧BG`魫W[CbupUioͻPOHSSRߩΰʯߦC
FʱZ_LרEgԸs (OHSS)IAveΪvwHWiowo|pFPɴqۤGJM@ץ|UC
MI]lkApӤHήaگfvAתέD(BMI> 40 kg/m2 )Φg( thrombophilia)AϥΩʸEvi|W[RߩΰʯߦvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	x2-8JUtBC	H򽤩ʸE(HCG)OhkGAE(LH)ʡC	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	CKHeAgAѩ󸣤Ucް_ʹ޸êAêC	"whè̿ʲX~FApkʪZ_BũлPlcgΨkʨB@C
w򱱨Dʸcef]pGҪBǤWθUef^C"	DnxOb`gmX{khάlCLʼxApG~BhҡCALqiಣͧZ_LרEgԸs(OHSS)	PregnyliΩAϥΩy᪺hAoϥΩ¨ŴC	PregnyliΩAϥΩy᪺hAoϥΩ¨ŴC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IPREG-a	IPREG-b	IPREG-c	110.6.16
		0	OESMY1	Esmya 5mg/tab(Ulipristal acetate) 		"Ulipristal acetate@بfAʪXܩʶո`]lA㳡ܧ@ΡA㦳´SʡC  

"	"v]t@ؾq5 mgĿACfA@A̪3ӤC
iƤ@3Ӥ몺{CĤG{̦Ĥ@{᪺ĤGg}lC
gĤ@gi}vC
ѩʥFwʸơAvWL2U3Ӥ몺{C
YfwѰOAΤ@qAhfwtɪAulipristal acetateCYѰOAάYqWL12pɡAhfwӸɪA
ѰOqAuݩ@몺UAĮɶ~AħYiC


Ĥ覡
ĿiHΤHAΡC
"	"iveưhiC
ĳP֥ΡAi|P~vӭC~ġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	קKuӮgC	ulipristal	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	Ulipristal acetateϥΩwY{פlcֺFgͨ|~֦~kʡA@NevΡC 	"󦳮ĦΨξLӪ̡C
hPŪ̡C
Ѥ]ΫDѤlcֺFfް_ʹ޾xXC
lcBlcVBZ_ΨC "	̱`}C 	hATAΥī~C	ŴATAΥī~C	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OESMY-1-a	OESMY-1-b	18026312-2	110.6.16
AC11475209	H02AB08	0	ISHIN	Shincort 40mg/ml/AMP(Triamcinolone) 		~@ΤXƵǥֽTJADnΩ󻴭gʯewD	"٦ת`gG
H12HWൣG쾯q60mgAĲ`٦ת`gD
q`qdF40-80mgA̯gΪvGվD
6-12ൣG쾯q40mgA̯gΪvGվD"	"1.~tGAHպޤεwὤ~`gġD
2.ĸTΩRߪ`g
3.CʷPVgAϥήɻݦX֪vPVD
4.Gűw̻ݯSO`N
5.}fw̽Ъ`NW[خqζqnʡD
6.믫f]̻ݦh[`N
7.иɥRJս
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	m25JHUJsC	Triamcinolone	H02A	"TJA CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN"	0	`BnBLөʥֽBޮݡBLөʻ󪢡B?HBLөʤεoʲew	 triamcinolone ΨLξL 	B~BWɡA[LƪnA֦Ƶǥֽ@ΩΥʰƧ@ΡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ISHIN.a	ISHIN-b	ISHIN-c	110.6.16
AC54647277	J01CG01	0	ISULB	Sulbactam inj. 500mg/vial 		Sulbactam ]-lactamases ?ifʧAisxBĦaܲӵߤ]-lactamaseCSulbactam ȥiP]-lactam ?ܥ֥ͯΡCK[Sulbactam AҿΤ]-lactam ?ܥͯ]O@?P|Q]-lactamase ҤѡAϨܵߧ@?sĩʡAüWjh?wͣ]-lactamase ӵߪķ߯?C	"H
C 6 ~ 8 12 pɥHSulbactam 0.5 ~ 1.0 gm PX֨ϥΤܥͯ@RߩΦ٦ת`gAC̰?(?tPɩҥΧܥͯ?)4.0gmC
ൣB
@?Sulbactam 50mg/kg/day A?A6 ~ 8 12 pɶjϥΡAൣCܦh80mg/kgC"	pw?౵uQA`NC500mg Sulbactam sodium t2 @նuC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~30XC HUǷxsCts`gGᶷb24 pɤϥΡC	Sulbactam	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	sulbactam]-lactamase APAmpicillin ֥ΡAAΩv??Yӵ߷PVC	"w]-lactam ?ܥͯLӮɡATϥSulbactam sodiumC
bϥSulbactam ɡA??PɨϥΣ]-lactam ?ܥͯhLNqA]Sulbactam sodium ?ߧ@ΡC"	`?ֽΥ֤UƧ@ΡAMGeBߡBæRB?BȺUmC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>50      1g q6h (Max:4g/day)
CClr15-30   1g q12h
CClr<15       1g q24h"	ѦҡuqΥΪkv	"ĳ~|GIMBIV
tswwʡG1.tsB}24hrϥΧ
2.PampicillinVX}IM-1 hrϥ
IVF-(WFIBNS)Ƿxs8hrFNxs48hr
(LR)Ƿxs8hrFNxs24hr
tsGG2ml WFIBNS(IM/IV)
ĳ}@סG45mg/ml(sulbactam+ampicillin)
ۮe}GG֥ampicillinɰt40-100mlGNSBWFIBLR(IVF)
ĳĳ~|tvGIVF:15-30 min.
`NƶGYMampicillin֥ΡAݦbtm3-5min~i[J
֥ήɪ`N
1.󸲵}BΨLww
2.iMGsBLJղGBaminglycosidesVXϥ
"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	ISULB-a	ISULB-b	ISULB-c	110.6.16
AC28099289	J01DC02	0	IZINA	Furoxime 750mg/vial(Cefuroxime) 		Cefuroxime߾ରPDnؼгJս赲XAӵ߲ӭMXC	"HG
@PV: 750mg Q8H IVIMC
YPV 1.5 gm Q8H-Q6HAIVIMAC`qiF 3~6 gm C
ΨൣG
C30~ 100 mg/kg A 3  4 ` g C
sͨGC 30~100 mg/kg  2  3 `gC
OfG@`g 1.5 gm AwACw 750mg APɤO`g󤣦Pm pvⰼ CiH֪A 1.0gmProbenecid C
GӷPʪ߮AicefuroximeD3g q8h IV"	penicillin tܥͪ観LӯgJfv̡AeLӤIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" ץOs.
tmbǷŤU5pɡAN48pɡD"	Cefuroxime	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	CephalosporinܥͯLӤw̡C	"ݥyWh, ݤʥղy,m,,æR,xŦïuȤW"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	"CClr>50      1.5g q8h
CClr 10-50  1.5g q8-12h
CClr<10      1.5g q24h
IHD            1.5g q24h (750mg q12H)
CAPD          1.5g q24h (i֤JzRG)"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡG1~ץOs
2.tsǷŤU5hrFN48hr
3.}ǷŤU24p
tsGG3ml WFI(IM)
      6 ml WFI(IV)
ĳ}@סG-
ۮe}GG1.5g Cefuroxime+15ml WFIA[50 or 100ml NSBD5WBRBLR
ĳĳ~|tvGIV:>3-5min
IVF:> 15-30min
`NƶG1.ŻPaminoglycosidesVX"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	IZINA-a	IZINA-b	IZINA-c	110.6.16
BC24758255	J02AX06	0	IERAX	Eraxis inj 100mg/vial(Anidulafungin) 		"Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1, 3-]-D-glucan, an essential component of fungal cell walls."	"Candidemia/ Disseminated candidiasis, Intra-abdominal and peritonitis: 200 mg IV on day 1, then 100 mg IV once daily continue for at least 14 days after the last positive culture.
Candidiasis of the esophagus (HIV-infection): 100 mg IV on day 1, then 50 mg IV every day for a minimum of 14 days and for at least 7 days following resolution of symptoms OR for a total duration of 14 to 21 days (guideline dosing)."	ϥΥī~кʴx\ܤ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. tsEraxis`gp~xs2-8J; u{Beɤ\bWL25Jū96pɡAMisNp~xsb2-8JC
"	Anidulafungin	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	vDզyCUH]ߦgA]߸Ω]߸ĤwšC	Hypersensitivity to anidulafungin or any component of the solution	"Diarrhea (3.1%), hypokalemia (3.1%), and elevated ALT (2.3%)"	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	"Loading dose:200mg
100mg QD
ݨ̨xǥ\վ"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.~Nxs
2.tsǷ24hr3.ܦ
3.}bǷťi48pɡAiN@
tsGG30ml WFI
ĳ}@סG0.77mg/ml
ۮe}GG100mlNSBD5W@
ĳĳ~|tvGi>1.1 mg/min
100mg(30mltm,}130ml):90min(84ml/hr)
200mg(60mltm,}260ml):180 min@(84ml/hr)
`NƶG1.iPLĪιqѽ@_`"	ixii[N]_B01-57 j	Ts114.08.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.9._20220501.pdf"">OI` 10.6.9.</a>              "	0	0	OIs 20251124	IERAX-a	{	{	114.08.20
AC48355100	J02AX01	0	OFLUS	Flusine 500mg/tab()(Flucytosine) 		Flucytosine penetrates fungal cells and is converted to fluorouracil which competes with uracil interfering with fungal DNA synthesis. It has a narrow spectrum of activity and is used with other antifungals because resistance develops rapidly when used alone in Candida or Cryptococcus sp.infections.	"25-150 mg/kg/ day orally in 4 divided doses, at 6 hour intervals; administer a few capsules at a time over a 15-min period to minimize nausea and vomiting."	"1.惡Īo͹LӤw̸TϥΡC
2.\ण}εǥ\ण}w̻ԷVϥΥYC
3.ϥCytarabine (Cytosar)|ϥYĪGCAy֥ΡC
4.@뤣|WϥΥYӪv߷PVAYzo{uWAΦĪЩMvT{C
5.ϥΥYi|ӷPAĳnαIקKζˡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷŤUAץB׼B㤧B	Flucytosine	J02A	tΥĪܯu ANTIMYCOTICS FOR SYSTEMIC USE	0	Treatment of susceptible fungal infections caused by Candida or Cryptococcus.	Hypersensitivity to flucytosine	"Nausea or vomiting in high dose; diarrhea; elevated LFTs, skin rashes; bone marrow suppression"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.6.8._20070601_000.pdf"">OI` 10.6.8.</a>              "	0	0	OIs 20251124	OFLUS-a	OFLUS-b	01C48355-2	110.6.16
AC37556100	J01FF01	0	OCLEO	Vicin 150mg/cap(Clindamycin) 		Clindamycinﵴj{ɤW`󶧩ʤγʯfߡA㦳sxܵ߬ʡA@ξǬӵߤJսXAϨӭMaAӹFߪĪGC	"H
C150~300 mgAC6p1FYPVAC300~450 mgAC6p1C

ൣ
H8~16 mg/kg/day3~4AΡFYPVAH16~20 mg/kg/day3~4AΡC"	wGzefAרOzw̡AԷVPCYϥΥĴoͤUg{HɡAġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)BץxsC	Clindamycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	yߡByߡBͪyߡBߵ㦳Pʵ߮Ҥް_PVg	TΩ󴿹Lincomycin͹LӤfwC	"1. hBDBߡBæRΤUg{HC
2. ̱`Ƨ@άʻצܤפClC"	קKϥ/SmҦw	קKϥ/|qLť	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	OCLEO-a	OCLEO-b	OCLEO-c	110.6.16
			OATRI	AtriplaƤ(HIV) 		"ATRIPLA is a fixed-dose combination of antiviral drugs efavirenz(EFV), emtricitabine(FTC) and tenofovir disoproxilfumarate(TDF). EFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. FTC is a synthetic nucleoside analog of cytidine, inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5' triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Tenofovir disoproxil fumarate (TDF) is an analog of adenosine 5'-monophosphate; it interferes with the HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication."	Oral: One tablet once daily.	ŸA(b\e1pɩ\2p)AĳΫeA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	"Emtricitabine 
+Efavirenz 
+Tenofovir disoproxil fumarate "	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	HIV infections in in adults	"Concomitant use with voriconazole

Clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz."	"Hypercholesterolemia, diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash."	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OATRI-a	OATRI-b	OATRI-c	110.6.16
			OISEN	Isentress 400mg/tab(Raltegravir) 		"RaltegraviriHIV-1OX?ʤƬʡAOX?OHIV-1ҽsXAfrƻsݪïC
OX?iPVHIV-1]@JδOJJDӭM]@ΡCOXѪHIV-1]LkͦsPVʯfrɡA]AOX@ΥiKfrPV[XjCRaltegravirä|HCಾ?A]ADNAEX?\B]Σ^"	ΩvHIV-1PVw̮ɡAISENTRESSqfA뤩400mgAC⦸	Jsx\ಧ`fHA]ACʨxAbϥΤfrX֪vɡAoͨx\ಧ`WvA̷Ӽзǵ{ǺʵCYfHX{xef[AҼ{ΰv	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC 	Raltegravir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	ISENTRESSPܤfrĪ֥ΡAAΩRfr HIV-1 PVw	糧Ħo͹LӯgfwAФŧP	mBߡBYhB|BhҡBWIlDPVBުBoN	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
			OHARV1	Harvoni Ƥ400/90mg 		"Ledipasvir inhibits the HCV NS5A protein necessary for viral replication; sofosbuvir is a nucleotide prodrug converted to its pharmacologically active uridine analogue triphosphate (GS-461203), inhibits NS5B RNA-dependent RNA polymerase, also essential for viral replication, and acts as a chain terminator."	C@ACfA@	"ĳNHARVONI PLtsofosbuvir~
]SOVALDI^֥"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUOs	Ledipasvir+Sofosbuvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"AΩvwCCxfr]hepatitis C virus, HCV^]1B4B56PVgw"	糧Ħo͹LӯgfwAФŧP	h»PYh	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OHARV-a	OHARV-b	02C26675-2	110.6.16
			OHCV12	Maviret]1-6;8g{ 		MAVIRET O glecaprevir M pibrentasvir TwqƤsAئO@Ω C xfrܯfrĪ	MAVIRET fAĳqOC@AH\AΤTA (C`qGglecaprevir 300 mgApibrentasvir 120 mg)	CarbamazepineBefavirenz MiۭC glecaprevir M pibrentasvir 夤@סA]ӴC MAVIRET vĪGCoǤĳP MAVIRET ֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Glecaprevir+Pibrentasvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	vHC C xfr (HCV) ] 1B2B3B4B5B 6 PV	"1. w|ﬡʦι 11 `ξ͹LӤC 2.MAVIRET TΩ󭫫רx\णw (Child-Pugh C)C
3. MAVIRET TP t atazanavir s, simvastatin, dabigatran etexilate, t ethinyl oestradiol s, rifampicin ֥ΡC"	YhB«M	Fetal risk cannot be ruled out.	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	OMAVI-a	OMAVI-b	02C27323-2	111.8.19
			OHCV15	Epclusa]1B2B3B4B56A12g 		"Sofosbuvir HCV NS5B RNA ̿RNA EX?x]AEX?DOfrƻsҥݪïCSofosbuvir O@خ?īeXġAeXķ|gѲӭMN§@ΧΦĲzʪ?TCQ]GS-461203^AMizLNS5B EX?@δOJHCV RNAAqӲפ@ΡCGS-461203
]sofosbuvir ʥNª^ëDHDNA PRNA EX?A]OɽuRNAEX?C
Velpatasvir wHCV NS5AJղͧ@ΪHCVAJդDORNAƻsPզfrɤlҥݪC~ĩʿܻPeĩʬsܡAvelpatasvir|wNS5Aͧ@ΡAo]O@μҦ"	"1.Epclusa ĳqC@HΤHfA@
2 vPgvA֦xwƪw̤Ψ֦Nvʨxwƪw̡AkP{ϥEpclusa v12 g"	Epclusa iPLtsofosbuvir ī~֥	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUOs	Sofosbuvir+Velpatasvir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	Epclusa AΩvHCCxfr]HCV^]1B2B3B4B5 6 PVg	糧Ħo͹LӯgfwAФŧP	YhBh¤	Fetal risk cannot be ruled out.	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	OEPCL-a	OEPCL-b	02C27547-2	111.8.19
			OREYA	Reyataz 200mg/cap(Atazanavir) 		"Atazanavir is an azapeptide HIV-1 protease inhibitor. It selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions."	Adults: The recommended dose is 400 mg once daily. Must be taken with food.	H\ɧ]AAi}n	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Atazanavir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	In combination with other antiretroviral agents for the treatment of HIV-1 infection	糧~LӪ	"Abdomen pain, diarrhea, nausea, rash, headache, peripheral neurologic symptoms"	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OREYA-a	OREYA-b	OREYA-c	110.6.16
			OROBA	Robatrol 200mg/cap(Ribavirin) 		"Ribavirin@Xֻ,b~礤i{XܬYRNAfrPDNAfrʡCRibavirinΨlֻĥN²bͲz@פUäHCV-M@ïHCVƻsC

Ribavirin@kvCxgL612Ӥ몺vHΫ6Ӥv,ä|vTMx(HCV-RNA)MΧﵽx´κACM,bCxvX֨ϥinterferon alfa-2b,RibaviriniHĪPiinterferon alfa-2bĤOWϥinterferon alfa-2bɪ10CPiĪG]AMiHCV-RNA򪺴,xŦooﵽPALT`ơC], Ribavirin uiΩP interferon alfa-2bX֨ϥΡC"	"Chronic hepatitis C infection(combination with interferon alfa-2b )Adult : <75kgX400 AM, then 600 mg PM; 75 kgX600 AM, then 600 mg PM
Chronic hepatitis C infection(combination with peginterferon alfa-2b)X400 mg BID

1. ]ribavirin@kvCxLġAGiWPribavirinnC 
2. RibavirinPpeginterferon alfa (1.5mcg//g)interferon alfa (TʸUڳ (MIU)ACg3 (TIW)) ֥ΪvCܥHب֥Ϊ覡AhfHӧOpөwC 
3. RibavirinnPpeginterferon alfaG֥ΡG Ribavirinq̾گfH魫өwCRibavirinnCGPûP@PA (Mı)C"	bHribavirin֥peginterferon alfainterferon alfavoͯh¡BݺΩΧxbfH`NקKrpξާ@C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Ribavirin	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	"1. Ppeginterferon \  interferon \֥ΪvG(1)gϥinterferon \ @kvS_oCCxC(2)vCCxC(3)XַPV{íwHIVCCxC 
2. Peginterferon \ ֥Ϊv󴿥Hinterferon \ ֥ ribavirinvLĩδ_oCCxC

fHF18HWBwNvʨxfC"	"1. ribavirin νn󦨥LӪfvC
2. 㦳ewsbYߦޯeffvA]AeӤ뤤oͤíwΥߦޯefC
3. hkF祥GҹꬰʬAi}lribavirinXkC
4. khkʡC 
5. ŪkC
6. `ef (pGahBIMh)
7. YzpA]ACʵǰIܩΦٻMvp50 ml/minuteC
8. Y믫effvAרOY{B۱YΥϦ۱C
9. YxŦ\ॢ (Child-PughBC) ΥNv}ʨxwơC
10. K̩ʨxGΨ㦳K̯effvC"	YhBhҡBߡB٦׵hC	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OROBA-a	OROBA-b	OROBA-c	110.6.16
BC24662100	J05AF11	0	OSEBI	Sebivo 600mg/tab(Telbivudine) 		TelbivudineXthymidine ?AǥvBxfrreverse transcriptase DNA polymeraseAӲͧBxfrƻs@	C@ACfA600mg	"1.TelbivudineĳΩlamivudineentecavirĩʪfwC
2.ǥ\णݨ̦ٻMvվ㵹ĶjC(>50 C@B30-49 j@B< 30TѤ@BESRD|Ѥ@~ǫᵹ)
3.ݪ`N@PBʷ|PoCKɰΦ٦ׯfܵo͡C
4.ϥSebivoAäBxǬVLHMIApߨdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Telbivudine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	Ω㦳frƻsάʩʨxŦoҾڪCBxw̪v	糧~LӪ	YhBYwBߡBæRB֯lBh	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-05 j	Ts110.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.3._20250601.pdf"">OI` 10.7.3.</a>              "	0	0	OIs 20251124	OSEBI-a	OSEBI-b	OSEBI-c	110.8.23
		0	IGARD	Gardasil 0.5mg/vial(N)| 		"GARDASIL@DPVʰ]ե|̭]A̭]DON6B11B16 β18HŬfr(HPV)Dn~TJ(L1)ҧΦfrL(VLPs)Hׯ¤ƫsƦӱoC

HŬfr(HPV)|޵o쪬ӭMlcV(Ψ´ǫeXfܡA]A1 ŤlcVW֤ؽF[Cervical Intraepithelial Neoplasia; CIN]λײӭMܩʡAHβ2/3CIN ΤܰײӭMܩ)MlcV(cervical adenocarcinoma ΨeXfܭ츢[adenocarcinoma in situ; AIS])C~PD]35-50%ik]HPVC2/3 ť~W֤ؽF(Vulvar Intraepithelial Neoplasia; VIN)P2/3 ųDW֤ؽF(Vaginal Intraepithelial Neoplasia; VaIN)DOogeXfܡC"	"1.٦ת`gAC0.5mlC
2.b~ITAخɶ0B26ӤCĤGqZح1ӤHW~IAĤTZĤGIܤ3Ӥ뤧~ICYLkӮɵ{ءA̱Ӧb@~THPV̭]`gC"	"1.ج̭]enilcVHPV DNAz
2.Sʦ欰kʡBثeݭnilcV٤ˬd
3.LפlcV٤ˬdO_gL`BHPV DNA յGO_ʡBHεL׬O_δgLʹ޾С]^AiHIC
4.ʦ欰kʤ]iHIC
5.pGzwgPVHŬfrAإ|lcV̭]MiѫO@C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Quadrivalent human papillomavirus (type 6A11A16A18 )	J07B	fr̭] VIRAL VACCINES	0	w̭]ҧtHŬfrOҤް_gBeΤƤ}fܡBʹ޾ХHηPVC	"1.hkʡAĳإ|HPV̭]
2.̭]͹LӤ
3.gBO_whBO_peYNh
4.oN37.8JHWef
5.bAΩΧYNAΪĪA]AܥĤΦ
6.XʰDΤbuWw"	̱`Ƨ@Υ]AGL`ghB~ȡBoMoBHλLoNC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IGARD-a	IGARD-b	IGARD-c	110.6.16
			OVACY	Vacyless F.C. 500mg/tab(Valaciclovir) 		"1. ValaciclovirO@اܯfrĪA[WL-valine୪aciclovirCAciclovirO@I(TI)?C
2. ValacicIovirbH餤|tB񧹥ܬaciclovirvalineAiOѬYغ٬valaciclovirhydrolaseïҭPCAciclovirOMI?lfrA~ʡAܳ?lfr(HSV)Ĥ@MĤGBa?lfr(VZV)BӭMfr(CMV)BEpstein-Barrfr(EBV)MH?l 6 (HHV-6)C
3. AciclovirCĤƦʤTCQɡA?lfrDNAXCbCĤƪĤ@ӨBJAݭnfrM@ʻïƧ@ΡCbHSVBVZVMEBVAoرM@ʪïfrthymidinekinase(TK)ḀubQfrPVӭMX{CCMVCĤƧ@ΡAܤ֦@Og97Cಾ?]ҽո`CѩoCĤƹL{AǥѯfrSwïӬƧC]iHFѬaciclovirpܩʤFC
4. CellularkinaseӭMCĤƹL{(qCܦTC)CAciclovirTCQvʧfrDNAEX?A÷|rJDNAADNAXA]Ӫ_frƻs@ΡCK̥\షw̡AYaciclovirvιwAlܨPV߮Aܷ֦fr|CaciclovirӷPʡAּƧK̥\Yw̡Ai|WzΥX{ApGxөΰ貾Ӫw̡AƾǪvcʸ~Fw̩MPVHK̯ʥFfr(HIV)w̡C"	"1. HqGva?lA@ѤTAC1000mgACѡC_oʷPVvѡA즸PViYA{ɥFQѡC}lAġC̦nOb\l_oeΥX{_oxɥߧYAΡC
2. ൣqG|LơC
3. ѤHqGǥ\YlˡA_hLݽվ㾯qAAqC"	ǥ\Ylw̡Aݽվ㾯qC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Valaciclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	aplB_oʥʹ޾plwΪv	"valaciclovir,aciclovirλs@ئLӪ̡C"	LYhM	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Infant risk is minimal	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OVACY-a	OVACY-b	OVACY-c	110.6.16
		0	IHBIG1	HEPATITIS B IMMUNE GLOBULIN 0.5ML(۶O) 		SbBxfr(HBV)UHABxK̲yJ(H)iѳQʧK̡AϨDBxfrIŧҭCCb@몺ĳqA夤|X{ioanti-HBsqAäjiӤΧ[C	ΩʼStHBsAgGGS24pɤ٦ת`g0.06ml/kgC	ѩbYA~iRߪ`gCu٦ת`gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC	Hepatitis B immunoglobulin (Human)	J07B	fr̭] VIRAL VACCINES	0	"wЫxPV

"	w糧~ʦLӪw̡C	`g짽khBC¯lΦޤ~C	C	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IHBIG1-a	IHBIG1-b	IHBIG1-c	110.6.16
		0	IHAV72	pAx̭](qFFt)VAQTA 		~O@إѰibHMRC-5ֺӭMAxfrlͦӱoƥfr̭]	"~g٦ת`gAרHT٬zQ٦ת`gC
̭]جO]t@Ӱ¦qP@l[qC
/C֦~G
~֤12Ӥj18̶bؤ`g0.5mL@]25U^Ab618l[`gt@0.5mL]25U^C
HG
19HWHbؤ鱵س澯q1mL]50U^A618ӤHᱵذl[q1mL]50U^C
Ҧ~ּhAĳbزĤ@A618Ӥ뤧AAذl[qAHͦ@תO"	L	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	"Hepatitis A, inactivated, whole virus"	J07B	fr̭] VIRAL VACCINES	0	wAx	"糧~󦨥LӤ̸TΥ̭]C
eAx̭]Υ@̭]Y̡AiϥAx̭]"	`gkhB~ȩMo	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-12 j	Ts110.6.16		0	0	OIs 20251124	IHAV72-a	IHAV72-b	IHAV72-c	110.6.16
	L01FF05	¡	ITEC20	ĵTECENtriq 1200mg (Atezolizumb) 		111.8.19	ĳqC3g@AC1200@JH60R߿`AvefcƩΥX{LkrʬCYi@Ĥ@`AiH30ɶi`CoHR߱`(push)Χֳt`(bolus)覡TecentriqC 	"`Gxs
~tGCsƧAߧYϥΡCY}᪺Tecentriq`GߧYϥΡAiHUC@覡xsG
ǷŤUAqsƮɰ_⤣WL6pɡCo]AǷŤU`G˩`UAHο`ĪɶC
Né2XC8XCUWL24pɡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Np~˩˯ȲHץxsANé2XC8XCUCiNCin̡C 	Atezolizumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. ߴಾʪcDW AΩvUCߴಾʪcDWfHG1) t`ƾǪvefcơA 2) AXtcisplatinkB~FPD-L1{ ? 5%A 3) AXt`ƾǪv̡AhݦҼ{~FPD-L1{qC

2. ߴಾʫDpӭM WϥΡAAΩvt`ƾǪvAefcƤߴಾʫDpӭMfHCfHY㦳EGFRALK~F]`AhgEGFRALKvAYvefcƤiϥTecentriqC PAvastin (bevacizumab)BpaclitaxelMcarboplatin֥ΡAಾʡA㦳EGFRALK~F]`D쪬DpӭMĤ@uvĪC Pnab-paclitaxelMcarboplatin֥ΡAಾʡAEGFRALK~F]`D쪬DpӭMĤ@uvC

3. pӭM PcarboplatinMetoposide֥ΡAAΩĤ@uvHXpӭM (extensive stage small cell lung cancer)C 

4. xӭM PAvastin (bevacizumab)֥ΡAAΩvkBLkಾxӭMfHABx\ରChild-Pugh AC "	LC 	h¡BCBmߡC 	קKϥ	ѩTecentriqiyY}AikʦbvP̫@ܤ5Ӥ뤺ošC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	ITEC20-a	ITEC20-b	ITEC20-c	111.8.19
BC18479212	L01AA06	0	IHOLO	ĵ Holoxan 2mg/vial (Ifosfamide) 		IfosfamideOJƾAOCyclophosphamidelͪA]bxŦN¦ʥNªArʸp@	"@Holoxan HRߪ`g뤩ACѥH1.2-2.4g/m2 n(60mg/kg 魫) Ʀ뤩As뤩(̪`gqөw,`gɶ30-120 )C
Holoxan ]i뤩@qA24 pɳs`CӨCg@
뾯q5g/m2 n(125 mg/Kg 魫)ABWL8g/m2 n(200mg/Kg 魫)C"	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF 0.5-2h(High dose:24h)
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 װB	Ifosfamide	L01A	Jƾ ALKYLATING AGENTS	0	"NAYNn´׽F(Ʀ٦׽FN٦׽FNn׽F) N׽FNNlcNǤWδc
Ow"	"Holoxan TΩUCfH
? wIfosfamideAιNªLӪ
? װ\ण(רbӭMrľ/ΩgkvfH)
? PV
? ǥ\ण/Χy
? Hֵo(H֪)
? Ť"	"1. `Ƨ@ΡJݯvB믫VáBıBߡBæRB?vC
2. YƧ@ΡJݤʥզy֯gApO֯gAXʻH֪C "	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IHOLO-a	IHOLO-b	IHOLO-c	110.6.16
BC25401255	L01AA09	0	IINNO	ĵInnomustine inj. 100mg/vial(Bendamusti 		"As a bifunctional mechlorethamine derivative, bendamustine hydrochloride and its derivatives form covalent bonds with electron-rich nucleophilic moieties, leading to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells."	"1.@kΩCʲOڲyզf(CLL)
ĳqGb28ѪgA1M2ѥH30R߿`100 mg/m?AF6ӶgC
2.@kΩrituximabvѪMwʫDNOڽF(NHL)
ĳqGb21ѶgA1M2ѥH60R߿`120 mg/m?AF8ӶgC
3.XRituximabΩ@uvDNO(non-hodgkin lymphoma, NHL)γQMӭMO(mantle cell lymphoma, MCL)
ĳqGb28ѪgA1M2ѥHR߿` 90 mg/m?AF6ӶgC"	"tswwʡGN/A
}wwʡGǷ3.5hAN48h
ۮe}GGNS
ĳ}nG500ml
ĳĳ~|tvGIVF 30-60min
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Bendamustine	L01A	Jƾ ALKYLATING AGENTS	0	"1.Binetstage BCCʲOڲyզf (chronic lymphocytic leukemia, CLL)
2.ܤ֤@ؤMwʫDNOڽF(indolent Non-Hodgkin Lymphoma)AӤ뤺HrituximabvѤ@v
3.BendamustineXRituximabAΩevCD20ʡB III / IV MwʫDNO(non-hodgkin lymphoma, NHL)CBendamustineXRituximabAΩevBAXFӭMӪ III / IV QMӭMO(mantle cell lymphoma, MCL)C"	InnomustineTϥΩwbendamustine  mannitolLӤfwC	LӡBզy֡BKBmBߡBæRBvBHo	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_03-03 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.42._20240201.pdf"">OI` 9.42.</a>              "	0	0	OIs 20251124	IINNO-a	IINNO-b	IINNO-c	110.6.16
BC27282100	L01BC59	0	OLONS2	ĵƼf LONSURF F.C.20mg/tab(Trifluridine 		"ԴOѯݸGr򩳪?trifluridineAthymidine phosphorylase tipiracilA HռƤ1:0.5] q1:0.471^ ҲզCttipiracil itrifluridine Qthymidine phosphorylase N¦ӼW[trifluridine SC
Trifluridine iJӭMA|OJDNA äzZDNA XΧӭMW͡CҹTrifluridine/tipiracil pWKRAS ͫάܫHjzz~FӨܸ~FʡC "	"ԴlĳqC 35mg/m2AܦhC 80 @J]qH trifluridine tqܡ^AC⦸A\@pɤAΡC@Ӷg 28 ѡA 1 Ѧܲ 5 Ѥβ 8 Ѧܲ 12 ѪAġAefcƩάOo͵Lk@Ƨ@ΡFqp⬰i̱ܳ5 ơC 
Clcr30ml/min νվlonsurfq35mg/m2
Clcr<30ml/min ݽվlonsurflq20mg/m2
C{eP15ѴqyơAŦXHU~}lvG
1.ANC1500/m3,neutropenic feverw
2.PLT75000/m3
3.L}wѦܲ0-1"	ihkL઺bIAͨ|OkʦbԴvĨĪץIC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Trifluridine+Tipiracil	L01B	ܥN ANTIMETABOLITES	0	ԴAΩveUCkಾʤjzzHw̡A]A fluoropyrimidineBoxaliplatin  irinotecan ¦AMܦޤ֥ͪ]l]anti-VEGF^kFY RAS ͫ]wild type^AhݱLܪ֥ͪ]l]anti-EGFR^kC 	L	hBݤʥզyCUBLO / h¡BߡBpOCUBhBmBæRBhεoNC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.26	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.66._20240601.pdf"">OI` 9.66.</a>              "	0	0	OIs 20251124	OLONS2-a	OLONS2-b		111.8.26
BC24084277	L01BA04	0	IALIM	ĵ Alimta 500mg/vial (Pemetrexed) 		īܾĪAǥѪ_ӭMƻsĨ̿ʥN¹L{AHFܸ~F@ΡC~pemetrexed ithymidylate synthase (TS)dihydrofolate reductase (DHFR)glycinamide ribonucleotide formyltransferase (GARFT)AoǻïҬfolate-dependent ïAѻPthymidine purine nucleotides ͦXCPemetrexed ǥ٭츭ĸ(reduced folate carrier)PӭMĵXJնǿtΡAiJӭMCiJӭMApemetrexed folylpolyglutamate synthase ï@ഫpolyglutamate CPolyglutamate idsӭMATS PGARFT CPolyglutamation L{PɶBĪ@צAioͩ~FӭMAֵoͩ󥿱`´CPolyglutamated N²ӭMbIA]iī~~FӭM@ΡC	"1.֥CisplatinΩDpӭMδcʦؽӭMFG
ALIMTAĳq500 mg/m2A21Ѷg1ѡAHR߿`覡P10Acisplatinĳq75 mg/m2AAlimta`30AHR߿`覡P2pɡCcisplatinPe/ΧPAfwɥRAqCcisplatinhơAаѾ\ī~C
2.ϥγ@ĪDpӭM
ALIMTAĳq500 mg/m2A21Ѷg1ѡAHR߿`覡P10HWC"	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG100ml
ĳĳ~|tvGIVF 10min
ī~}~[GL
L`NƶG
PremedicationsG
Dexamethasone 4 mg bid for 3 consecutive days.
Folic acid 400 to 1000 mcg orally daily and continuing for 21 days after the last pemetrexed dose.
Vitamin B12 1 mg IM beginning 1 week prior to pemetrexed and then given every 3 cycles(thereafter,may give on the same day as the pemetrexed infusion).Do not substitute oral vitamin B12 for IM."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Pemetrexed	L01B	ܥN ANTIMETABOLITES	0	"1.ALIMTA֥cisplatinOvߴಾʫDpӭM(쪬ӭM´~)Ĥ@uġC
2.ALIMTA@ĪOߴಾʫDpӭM(쪬ӭM´~)fH4Ӷgt`ĪĤ@uefåcƤkC
3.ALIMTA@ĪOvߴಾʫDpӭM(쪬ӭM´~)ĤGuvġC
4.ALIMTAPcisplatin֥ΩvcʦؽӭMFC"	ALIMTATΩwpemetrexedΨξYLӤfv̡C	hҡBߡBæRBʥFBݤʥզy֯gΫK	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.26._20251001.pdf"">OI` 9.26.</a>              "	0	0	OIs 20251124	IALIM-a	IALIM-b	IALIM-c	110.6.16
BC23324100	L01AX03	0	OTEMO	ĵƼf TRMODAL 100mg/cap(Temozolomide) 		TEMOZOLOMIDEO@Ө㦳ܸ~FʡAtImidazotetrazineJƧ@ξCiJHAb`ͲzPȤUA|ֳtgƾǧ@βͬʤƦXMTIC (Monomethyltriazeno imidazole carboxamide)CzפWAMTICDnOǥѻPTPĤlJƧ@ΡAPɻPĤCloͦnJƧ@ΡAӲͲӭMrʹF~FӭMĪGC	"Anaplastic astrocytoma of brain, refractory (following disease progression on nitrosourea and procarbazine)PO, initial dose: 150 mg/m2 every day for 5 days; cycle every 28 days; if the absolute neutrophil count and platelet count on day 29 (day 1 of next cycle) and day 22 are equal to or greater than 1.5 x 109/L and 100 x 109/L respectively, increase dose to 200 mg/m2/day for 5 days."	"1. ϥΫeTwզyơ1500/mm3ApOơ100000/mm3F~i|ȮɩʭCզyBpOAӴfHPVMX媺oͲvC
2. xBǥ\lfHνվ㾯qApߨϥΡC
3. pĤΦѤHpߨϥΡFTHUĵʥF{ɸgACQHWѤHeYC
4. nYV}AקKֽHĲ콦䯻C
5. æbpĵLkoBC
6. ϥΥĴű¨šBh(hĦwŬD)CpGhAbī6ӤHC
7. TΩ糧ĩDTICLӪ̡BYh̡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Temozolomide	L01A	Jƾ ALKYLATING AGENTS	0	v_oʴcʯgFC	TΩ糧ĩDTICLӪ̡BYh̡C	}BzGA(רOߩMæRAۭ)BYhBh¡ALoNBLOBKBmMݺεC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_6-05 [96]_6-06 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.25._20090901_000.pdf"">OI` 9.25.</a>              "	0	0	OIs 20251124	OTEMO-a	OTEMO-b	OTEMO-c	111.8.19
BC23323100	L01AX03	0	OTEMO2	ĵƼf Temodal 20mg/cap(Temozolomide) 		TEMOZOLOMIDEO@Ө㦳ܸ~FʡAtImidazotetrazineJƧ@ξCiJHAb`ͲzPȤUA|ֳtgƾǧ@βͬʤƦXMTIC (Monomethyltriazeno imidazole carboxamide)CzפWAMTICDnOǥѻPTPĤlJƧ@ΡAPɻPĤCloͦnJƧ@ΡAӲͲӭMrʹF~FӭMĪGC	"Anaplastic astrocytoma of brain, refractory (following disease progression on nitrosourea and procarbazine)PO, initial dose: 150 mg/m2 every day for 5 days; cycle every 28 days; if the absolute neutrophil count and platelet count on day 29 (day 1 of next cycle) and day 22 are equal to or greater than 1.5 x 109/L and 100 x 109/L respectively, increase dose to 200 mg/m2/day for 5 days."	"1. ϥΫeTwզyơ1500/mm3ApOơ100000/mm3F~i|ȮɩʭCզyBpOAӴfHPVMX媺oͲvC
2. xBǥ\lfHνվ㾯qApߨϥΡC
3. pĤΦѤHpߨϥΡFTHUĵʥF{ɸgACQHWѤHeYC
4. nYV}AקKֽHĲ콦䯻C
5. æbpĵLkoBC
6. ϥΥĴű¨šBh(hĦwŬD)CpGhAbī6ӤHC
7. TΩ糧ĩDTICLӪ̡BYh̡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Temozolomide	L01A	Jƾ ALKYLATING AGENTS	0	v_oʴcʯgFC	TΩ糧ĩDTICLӪ̡BYh̡C	}BzGA(רOߩMæRAۭ)BYhBh¡ALoNBLOBKBmMݺεC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[96]_6-07 [96]_6-08 [96]_6-09 j	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.25._20090901_000.pdf"">OI` 9.25.</a>              "	0	0	OIs 20251124	OTEMO2-a	OTEMO2-b	OTEMO2-c	111.8.19
BC25781255	L01BC07	0	IVIDA	ĵ Vidaza 100mg/vial(Azacitidine) 		Vidaza O@حMGrGr?A@{AVidaza OǥѤް_DNA CҰ (hypomethylation)AHιﰩ褤`yӭMͪӭMrʧ@ΡAӵoܸ~F@ΡC~礤ADNA ҰƳ̤jĪGazacitidine @סAä|yDNA XDnC󨺨ǦbƩMWͤ譱۷n]ACҰƥiiH_̪`\C Azacitidine ӭMrʧ@η|yֳtӭM`A䤤]AǤwg`ͪ౱ӭMC۸UADWͪӭMVidaza ӷPʴNCC 	"Ĥ@{G
ׯfwǽuGƭȬAҦfwbĤ@{_lĳqҬ75mg/m2AH֤U`g覡ġAC@sCѡCfwwAΨߤιæRĪC
{G
C|gƤ@{Cp⦸{᥼ġABߤιæR~LLrʤAiNqW[100 mg/m2Cĳfwܤֱ4~6{FMӡAiݭnl[{~F짹γCunfw򦳪vįqAKi~򥻪vC
ʴfwGǤεŦrʡAӥBiݭnӤUC覡ᵹĩδ־qC"	"tswwʡGǷ1hBN8h
}wwʡGǷ45min
ۮe}GGNS
ĳ}nG50-100ml
ĳĳ~|tvGSCFIVF 10-40min
ī~}~[GtsᬰզaBGB}ᬰL
L`NƶG1.?֤U`gWL4mLq˨ӰwFéӤP`gCGWuBjLθA
2. ھڦGȡBǥ\BMqѽվ㾯q
3.?tT : D5WBHespanBtbicarbonateGC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Azacitidine	L01B	ܥN ANTIMETABOLITES	0	"vWͤ}gԸsMIʪfwHigh Risk MDSGxTʳh֦Lq޲ӭM(RA with excess blastsARAEB)BܤxTʳh֦Lq޲ӭM(RAEB in transformationARAEB-T)BκCʰֲӭMʥզf(chronic myelomonocytic leukemia, CMMoL)C "	"1. cʨxŦ~F
Vidaza TΩcʨxŦ~FfwC
2. azacitidineΥSJ]mannitol^L
Vidaza TΩwazacitidine ΥSJ]mannitol^LӪfwC "	ߡBhBpO֯gBæRBoNBզy֯gC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.44._20250801.pdf"">OI` 9.44.</a>              "	0	0	OIs 20251124	IVIDA-a	IVIDA-b	IVIDA-c	110.6.16
BC01879277	L01BC01	0	ICYTA5	ĵCYTOSAR U 500MG/VIAL(CYTARABINE) 		"ʦӭMgqSʡADnOwBS(YXDNA)ӭMoͧ@ΡCA̡AbYǱpU|_ӭMqG1iJSCMA@ξAGcytarabineOzLDNAEXCӵo@ΡCiXcytarabine|MDNABRNA۪ͦX@(incorporation)CӭMiܡAcytarabine޵osxVlˡA䤤]AiV(chromatids)_ΤpӭM~FܩʡC
DeoxycytidineiΩcytarabineӭMrʧ@ΡA|ӭMrʧ@ΡCCytarabinebiӭMܨܯfrʡAMӦo{|bawlΤkө{ɸ礤oҹC"	ʫDOڲӭMզfkA@cytarabineP䥦Ī֥ΤqsR߿`100 mg/m2/(1~7)ΨC12pRߪ`g100 mg/m2 (1~7)CvʲOڲӭMզf{ĳζqAаѦҤm	"tswwʡGN/A
}wwʡGǷ6hAN12h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF >1h(6h or 12h)
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Cytarabine	L01B	ܥN ANTIMETABOLITES	0	ɥզfΨLʥզf	糧~ĪʪνξLӪ̡C	"BߡBæRBmBfΨzšBx\êBoNB֯lBRߪC
ֳtRߪ`g`oߡBæR"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.13		0	0	OIs 20251124	DC	DC	DC	114.10.13
BC21880229	L01CA01	0	IVINB	ĵ Vinblastine inj. 1mg/ml;10ml/vial 		~bӭMA|PLӺ޳Jս赲XAαN̨HUӡAA]ӪAEX@ΡCb@פUAoǻs]|̿DNAXC 	~ĳC 7 ѧP@AH@Rߪ`g쾯q 3.7 mg/m2/bsa]body surface area^CHզyƴwfH糧~ӷPʡCHiWL 18.5mg/TCpĤiWL 12.5mg/TC	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNSBD5W
ĳ}nG100ml
ĳĳ~|tvGIVF 10-15min
ī~}~[GL
L`NƶGȯHRߪ`g覡"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vinblastine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	ʥզfBOڦ׽FBNfC	"1.糧ĹLӡC
2.D~Fް_զy֯gC
3.Yӵ߷PVApΡAveH߾ΧܥͯN䱱C
4.պޤ`gC "	BvBKBߡBæRC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-14 j	Ts110.6.16		0	0	OIs 20251124	IVINB-a	IVINB-b	IVINB-c	110.6.16
BC22047209	L01CA02	0	IVINC	ĵ Vincristine 1mg/1ml/vial(Vincristin 		Dn@ΩӭMCvincristine|zZɯ起ΦAҥHӭMC 	"HG
@뾯q0.4-1.4mg/m2ACP@C̤jq2mgC
pġG
@뾯q1.5-2.0mg/m2ACP@C̤jq2mgC
p魫10kgΧ֡AΨn֩1m2A즸q0.05mg/kgA@PP@C"	"tswwʡGN/A
}wwʡGǷ24h
ۮe}GGNSBD5W
ĳ}nG100ml
ĳĳ~|tvGIVF 10-15min
ī~}~[GL
L`NƶGȯHRߪ`g覡"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Vincristine	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	ʥզf	㦳Charcot-Marie-ToothYxLTfHC 	զy֡AgkhAKAvC 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-20 j	Ts110.6.16		0	0	OIs 20251124	IVINC-a	IVINC-b	IVINC-c	110.6.16
BC20882100	L01CB01	0	OVEPE	ĵ Vepesid(Etoposide) 50mg/cap 		wҹFytosid |yֺ´ӭMӭM?RCMӡADn@ΦGOb?ӭMӭMgG2 Ci???P?̿ʤCb@?U]10gg/ml ?^AiH[iJ?ӭMѡCbC@?U]0.3 10 gg/ml^AhiӭMiJӭM?eC?|zZLpުEXCEtoposide Dnjl@ΦGOǻPDNA ?c?II]topoisomerase II^椬@ΩΧΦۥѰAiӻoNDA_?C 	"ĪfAqRߪ`gq⭿Aվ̱50mgC
~fA@뾯q100-200mg/TѪAΡCC3-4gƤ@A2/ѡA1-5ѳsAΡA200mg/T/ѡA1B3B5ѪAΡCC3-4gƤ@APLgҹAΩұvefĪ֥ΡC"	AΦĥi|yzܤOUAקKĲثeDPVHξXC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Etoposide	L01C	ӪPMLѵM PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	0	g(AYBpӭMʪ)	"1. רx\णw̡C
2. ׵ǥ\ण ( ٻMv < 15mL/min)C 
3.  etoposideBetoposide phosphate λsLLӪw"	"rv
GzGߤιæRDnGzDrʡAq`iHRkC禳BfĪθmiC"	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	OVEPE-a	OVEPE-b	OVEPE-c	111.8.19
BC25053235	L01DC04	0	IIXEM	ĵ IXEMPRA (IXABEPILONE)省`g 15 MG/VIAL 		Ixabepilone Oepothilone BbXCIxabepilone PLp(microtubules)W]-Lޯ (]-tubulin) ȳ쵲XAiӧLpްʤOǡCIxabepilone\]-II P\]-III LpުʺAíwʡCIxabepilone hظ~Fĩʾ㦳C~PʡA]AĪƥXe (efflux transporters)AҦpMRP-1PP-޳J (P-gp)CIxabepilone_ӭMbӭMgAɭPӭM`C 	"1. IXEMPRAĳqO40mg/m2R߿`3pɡAC3g@Cn(BSA)j2.2 m2w̪qھ2.2 m2pC 
2. `GqL0.21.2L(micron)LսA޽uLoġC "	"1. P䯫gfܱ`CʴIXEMPRAvw̬O_X{gfܪgAҦp`PBPıLӡBPıwBPı`BAίgfܩʯkhC
2. PqADn{Oݤʥզy֯gC
3. Ҧw̦b`IXEMPRAe1pɳnw@H1ܾP@H2ܾAñLӤʴ(ҦpB֯lBIlxP޵j)C
4. Ω󦳤ŦffvwpߡCoͤŦʦΤŦ\lw̡AҼ{ϥIXEMPRAC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ץOsb2 ~ 8XCC
@ο`G}AӷGǷŻPǤuU̦hww6pɡC}LIXEMPRAbo6pɤħC "	Ixabepilone	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	IXEMPRA (ixabepilone)XcapecitabineAΩvanthracyclineMtaxanevĩʡAιtaxaneĩʤS౵i@BanthracyclinevಾʩΧߴw̡C 	"1. IXEMPRATΩtCremophor? ELΨlͪ(Ҧppolyoxyethylatedɳªo)sY(CTC3/4)LӤfvw̡C 
2. IXEMPRATΩݤʥզyp< 1500 cells/mm3ΦpOp< 100,000 cells/mm3w̡C
3. IXEMPRA֥capecitabineTΩASTALT > 2.5 x ULNx> 1 x ULNw̡C "	̱`QIXEMPRAvw̳q}(? 20%)OPPıgfܡBh/IzLOBٵh/`hBrvBߡBæRBf/HBmΦ٦װfkhC 	D	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.88._20210310.pdf"">OI` 9.88.</a>              "	0	0	OIs 20251124	IIXEM-a	IIXEM-b	IIXEM-c	110.6.16
AC57985240	L01DB03	0	IEPIR3	ĵ EPIRUDO inj.50mg/25ml/vial(Epirubic 		"Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals."	"Breast cancer, Adjuvant therapy for axillary node-positive disease: initial dose range, 100 to 120 mg/m2 IV (either given on day 1 or divided equally and given on days 1 and 8), every 3 to 4 weeks.
H֤(IVCT)
v?H֨Ŭ?LӭMAĳ`50mgKgv?覡Cbͧrʡ]ƾǩʻH֪^fHAĳ?C?30mgC"	"tswwʡGN/A
}wwʡGǷ24hAN48h
ۮe}GGNSBD5W
ĳ}nGIV:50-250mlFIVCT:30-50ml
ĳĳ~|tvGIVF 3-20min
ī~}~[G
L`NƶG1.Cumulative doses : 900 mg/m2
2.Ķ:Anthracycline  Taxane"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Epirubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ŸBcʲOڽFBn´׽FBGBBZ_F	"1.~?ϥΩ󴿱Īv?Ωgʪv?Ӥް_fHC
2.{δŦ\?fv̡A@笰~PTҡC
3.PMitozantroneBMitomycin C Anthracycline?ƦXApGDoxorubicinBDaunorubicinAF̰?n?fHC "	P?drʧ@άΤŦrʧ@	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IEPIR3-a	IEPIR3-b	IEPIR3-c	110.6.16
AC57985221	L01DB03	0	IEPIR2	ĵ Epirudo inj. 10mg/5ml/vial 		"Epirubicin is an anthracycline antineoplastic agent; known to inhibit DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs; active throughout entire cell cycle. Intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Also inhibits DNA helicase, and generates cytotoxic free radicals."	"Breast cancer, Adjuvant therapy for axillary node-positive disease: initial dose range, 100 to 120 mg/m2 IV (either given on day 1 or divided equally and given on days 1 and 8), every 3 to 4 weeks.
H֤(IVCT)
v?H֨Ŭ?LӭMAĳ`50mgKgv?覡Cbͧrʡ]ƾǩʻH֪^fHAĳ?C?30mgC"	"tswwʡGN/A
}wwʡGǷ24hAN48h
ۮe}GGNSBD5W
ĳ}nGIV:50-250mlFIVCT:30-50ml
ĳĳ~|tvGIVF 3-20min
ī~}~[G
L`NƶG1.Cumulative doses : 900 mg/m2
2.Ķ:Anthracycline  Taxane"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Epirubicin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	ŸBcʲOڽFBn´׽FBGBBZ_F	"1.~?ϥΩ󴿱Īv?Ωgʪv?Ӥް_fHC
2.{δŦ\?fv̡A@笰~PTҡC
3.PMitozantroneBMitomycin C Anthracycline?ƦXApGDoxorubicinBDaunorubicinAF̰?n?fHC "	P?drʧ@άΤŦrʧ@	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IEPIR2-a	IEPIR2-b	IEPIR2-c	110.6.16
	L01FF05	¡	ITEC2 	ĵƼfTECENtriq 1200mg/20ml/vial (Atezolizumb) 		"PD-L1i{~FӭM/θ~FK̲ӭMWAi~FLҤܸ~FK̤CPD-L1PTӭMΧܭe{ӭMWPD-1MB7.1鵲XӧӭMrTӭMʡBTӭMWͻPӭMEsyC
AtezolizumabO@سA|PPD-L1XӪ_PPD-1MB7.1骺椬@ΡCYFPD-L1/PD-1CK̤A]AƧܸ~FK̤Ӥo̿ʲӭMrʡCbPp~FҫA_PD-L1ʥiy~Fͪ֡C "	ĳqC3g@AC1200@JH60R߿`AvefcƩΥX{LkrʬCYi@Ĥ@`AiH30ɶi`CoHR߱`(push)Χֳt`(bolus)覡TecentriqC 	"`Gxs
~tGCsƧAߧYϥΡCY}᪺Tecentriq`GߧYϥΡAiHUC@覡xsG
ǷŤUAqsƮɰ_⤣WL6pɡCo]AǷŤU`G˩`UAHο`ĪɶC
Né2XC8XCUWL24pɡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Np~˩˯ȲHץxsANé2XC8XCUCiNCin̡C 	Atezolizumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. ߴಾʪcDW AΩvUCߴಾʪcDWfHG1) t`ƾǪvefcơA 2) AXtcisplatinkB~FPD-L1{ ? 5%A 3) AXt`ƾǪv̡AhݦҼ{~FPD-L1{qC

2. ߴಾʫDpӭM WϥΡAAΩvt`ƾǪvAefcƤߴಾʫDpӭMfHCfHY㦳EGFRALK~F]`AhgEGFRALKvAYvefcƤiϥTecentriqC PAvastin (bevacizumab)BpaclitaxelMcarboplatin֥ΡAಾʡA㦳EGFRALK~F]`D쪬DpӭMĤ@uvĪC Pnab-paclitaxelMcarboplatin֥ΡAಾʡAEGFRALK~F]`D쪬DpӭMĤ@uvC

3. pӭM PcarboplatinMetoposide֥ΡAAΩĤ@uvHXpӭM (extensive stage small cell lung cancer)C 

4. xӭM PAvastin (bevacizumab)֥ΡAAΩvkBLkಾxӭMfHABx\ରChild-Pugh AC "	LC 	h¡BCBmߡC 	קKϥ	ѩTecentriqiyY}AikʦbvP̫@ܤ5Ӥ뤺ošC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	ITEC2-a 	ITEC2-b 	ITEC2-c 	111.8.19
		P	IKAD11	ĵ KADCYLA 160mg/vial(Trastuzumab Emta 		Trastuzumab emtansine Ow HER2 ĪƦXCOH HER2 IgG1 (trastuzumab)CplӭMr DM1 OLާCX HER2 骺 IV pϫA trastuzumab emtansine }lH鬰Ci椺ơA᪺?魰ѹL{ӭMt DM1 ӭMrʥNªCDM1 XL޳J(tubulin)L{|}aӭML޺AɭPӭMPPӭM`C~A~ܡAtrastuzumab emtansine P trastuzumab A]| HER2 Tǻ\Aް_̿ʲӭMCӭMrʡAç HER2 Lת{HӭM HER2 M~ϲ渨C 	KADCYLA ĳq 3.6 mg/kgAC 3 g( 21 ѪP)R߿`@AfcƩΥX{LkrʬCФŬI 3.6 mg/kg  KADCYLA qC	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVF:Initial:90minFMax:30min
ī~}~[GL
L`NƶG
1.Administer through a 0.22? in-line filter.
2.iϥθ}(5%)GA]|ɭPJս辮
3.ФťHKADCYLA NTrastuzumab ΥHTrastuzumab NKADCYLA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab emtansine	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	KadcylaWϥήɯvHER2ʡBeOLtrastuzumabP@taxaneĪvΨXkಾʨfwC]fwŦXUCGewgLಾgvAΦbUkvΧv6Ӥ뤺g_oC^	L	i঳KBYhBf٦ׯkhBߡBhªΡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	IKAD11-a	IKAD11-b	IKAD11-c	111.8.19
	L01FD03	P	IKADC1	ĵ Kadcyla 100mg/vial(Trastuzumab Emta 		Trastuzumab emtansine Ow HER2 ĪƦXCOH HER2 IgG1 (trastuzumab)CplӭMr DM1 OLާCX HER2 骺 IV pϫA trastuzumab emtansine }lH鬰Ci椺ơA᪺?魰ѹL{ӭMt DM1 ӭMrʥNªCDM1 XL޳J(tubulin)L{|}aӭML޺AɭPӭMPPӭM`C~A~ܡAtrastuzumab emtansine P trastuzumab A]| HER2 Tǻ\Aް_̿ʲӭMCӭMrʡAç HER2 Lת{HӭM HER2 M~ϲ渨C 	KADCYLA ĳq 3.6 mg/kgAC 3 g( 21 ѪP)R߿`@AfcƩΥX{LkrʬCФŬI 3.6 mg/kg  KADCYLA qC	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVF:Initial:90minFMax:30min
ī~}~[GL
L`NƶG
1.Administer through a 0.22? in-line filter.
2.iϥθ}(5%)GA]|ɭPJս辮
3.ФťHKADCYLA NTrastuzumab ΥHTrastuzumab NKADCYLA"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Trastuzumab emtansine	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	KadcylaWϥήɯvHER2ʡBeOLtrastuzumabP@taxaneĪvΨXkಾʨfwC]fwŦXUCGewgLಾgvAΦbUkvΧv6Ӥ뤺g_oC^	L	i঳KBYhBf٦ׯkhBߡBhªΡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	IKADC1-a	IKADC1-b	IKADC1-c	111.8.19
BC21032229	L01XX02	0	ILEUN1	ĵ Leunase 10000KU/10ml/vial 		L-Asparaginase ]ѦG L-AsparagineAϻݭn  L-Asparagine ӭMʥFiӹF@ΡC	@뾯q50-200ku/kgAHRIw覡PACιj@Cqi̯fH~֩ίfվC 	"tswwʡGǷ4h
}wwʡGɧ֨ϥ
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGIVF>30min
ī~}~[GL
L`NƶG
1.?קKHN/S`JA]i|ް_eVB
2.?Ie֤UA]i|ް_J
3.TestG1~10ku in 0.1ml"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Asparaginase	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	ʥզf(]AѺCʥզfܦʪ)BcʲOڽFC	ﬡʦΥ@ξLӡC	"1.ߡBæRGiϥΤRgC
2.LӤGĤ@ϥֽC
3.զy֡BpO֡GקK~ˡBIAPVA`NiC
4.oNG`g2-5pɫ|oNAi۵MѼC "	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	ILEUN1-a	ILEUN1-b	02C21032-2	111.8.19
KC01056221	L01FC01	`g20@J/@(Daratumumab)	IDARZ	fĵDarzalex 20mg/ml (Daratumumab) 		DaratumumabO@ط|Pת{hoʰFӭMA]|HP{ת{LӭM M´WCD38JյXIgG1eH(mAb)CCD38Jը㦳hإ\ApzL CH@ΡBǰT@ΤλïʡC 	"뤩`eĻP`ġAHC daratumumab ޵o`(IRRs)IC
@kλP lenalidomide ֥ήɪзǧĮɵ{(4 ggk)G DARZALEXĳq16@J/魫̷ӥ椤 1 Įɵ{R߿`ġC
Ϊk 
DARZALEX YR߿`ϥΡC
~ϥδƶu 9 @J/@(0.9%)`gG}R߿`ġC "	"1. bϥ DARZALEX veAϥΧܲ´iBѼMֽTJw̶i`e ġAHCoͿ`IC
2. C5@ɻP20@ɤp~˪ DARZALEX Ot0.4@ջP1.6@(9.3 @JP 37.3@J)uC勵bi歭uw̡ANoIǤJҼ{C 
3. ~ϥθ˦yqո`κ޽umBLߡBLBCJյXʡBE?(PES)sLo(ծ|0.220.2L)`MR߿`}᪺GCϥΧ謰Ei (PU)BEBGm(PBD)BPVCBPP  PE ĮMաC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. }qLͪǪ[IӬݡAD}/}kưoͷLͪìVIA_hߧYϥΡCpߧYϥΡAϥΪtdϥΤsɶPFbץNêAU (2XC-8XC) iWL24pɡAbǷ(20XC-25XC)ΫǤuUiWL 15p(]t`ɶ)C 
2. ЦsBc(2XC-8XC)C ŧNC
3. иml]ˤJsAHקKuӮgC "	daratumumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS		"1. H@vİeܤ֤Tk(]A@سJ?P@اK̽ո`)BΦbJ?MK̽ո`vUoͯefc(double-refractory to a protease inhibitor and an immunomodulatory agent)hoʰFHw̡C
2. P lenalidomide [ dexamethasone λP bortezomib [ dexamethasone ֥ΡAveܤ֤@kvhoʰFHw̡C "	ﬡʦΥ椤ҦCξLӡC 	`Bh¡BߡBmB٦׵jˡBoNBy¡BIlxBݤʥզy֯gBpO֯gΤWIlDPVC 	"קKϥ/SmҦw
bϥDARZALEX?v~ץ3ӤC"	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts114.11.07	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.78._20250901.pdf"">OI` 9.78.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.11.07
KC00964248	L01FX05	0	IADCE	ĵƼf Adcetris 50mg/vial(Brentuximab)		"Brentuximab vedotin is an antibody drug conjugate (ADC, ĪƦX) that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells."	"evHLG
֥Τ (doxorubicin [A]Bvinblastine [V]Bdacarbazine [D] [AVD]) ĳq 1.2 mg/kgAb 28 { 1 ѩM 15 R߿` 30 A 6 {C
_oδcƭI HLG
ĳq 1.8 mg/kgAH 30 R߿`覡ġAC 3 g@C
i ASCT A_oδcƭI HL fHAADCETRIS v{ɧP_bASCT _줧}lAfH{16)C
_oιxT HLG
ĳq 1.8 mg/kgAH 30 R߿`覡ġAC 3 g@C
vAefc(disease progression)ΥX{LkrʬCFfpíw]stable disease, SD^ΧﵽfH̤ 8{A̦h16{( 1 ~)vC
evPTCLG
֥Τ (cyclophosphamide [C]Bdoxorubicin [H]Bprednisone [P] [CHP])ĳq 1.8 mg/kgAH 30 R߿`覡ġAC 3 g@A@ 6  8 {C
_oιxT sALCLG
ĳq 1.8 mg/kgAH 30 R߿`覡ġAC 3 g@C
vAefc(disease progression)ΥX{LkrʬCFfpíw]stable disease, SD^ΧﵽfH̤ 8{A̦h16{( 1 ~)vC
CTCLG
ĳq 1.8 mg/kgAH 30 R߿`覡ġAC 3 g@C
CTCL fH̦h 16{C"	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNSBD5W
ĳ}nG100-250ml(0.4-1.2 mg/ml)
ĳĳ~|tvGIVF>30min
ī~}~[GL
L`NƶG
1.w̥X{ߧYʻPʿ`(infusion-related reactions; IRR) HιLөʤC ԷVʱw̦b`L{P`᪺pC
2.oͿ`w̡Ab`eAw뤩AĪCwĥiH]AAcetaminophenBܲ´iΥֽTJC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Brentuximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.Ω󦨤Hw̡Av_oιxT CD30+NOڽF(HL)G(1)wFӭM(ASCT)A (2)LkϥASCTΦhĪABeܤ֤wتvC
2.Ω󦨤Hw̡Av_oιxTʰhƫjӭMOڽF(systemic anaplastic large cell lymphomaFsALCL)C"	"1.糧~ʦΨξLӤfHC
2.֥bleomycinPADCETRIS|ޭPͬr"	"Peripheral sensory neuropathy, fatigue, nausea, diarrhoea, neutropenia, vomiting, pyrexia, and upper respiratory tract infection."	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668329?cesid=aqxFyu8mGXb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBrentuximab%26t%3Dname%26acs%3Dfalse%26acq%3DBrentuximab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-04 j	Ts113.5.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.56._20220201.pdf"">OI` 9.56.</a>              "	0	0	OIs 20251124	IADCE-a	IADCE-b	IADCE-c	113.5.29
KC01025219		NιF	IKEY11	ĵKeytruda 100mg/4ml/vial(Pembrolizumab) 		PD-1t(PD-L1PPD-L2)PTӭMWPD-1X|TӭMWͧ@ΤβӭMEͦ@ΡCbYǸ~F|X{PD-1tW[{HAӳzL|ǻTh|TӭM~FK̺ʵ@ΡCPembrolizumabO@سA|PPD-1Xê_PPD-L1PD-L2椬@ΡAѰPD-1|ҴCK̤ (]Aܸ~FK̤) @ΡCbPp~Fҫ礤A_PD-1ʷ|C~FͪC 	"¦FĳqG
KEYTRUDAĳq2@J/AC3g@ACHR߿`30AX{efcƪ{HεLkrʤC
DpӭMĳqG
KEYTRUDAĤ覡C3g@ACHR߿`30AYX{efcƩεo͵LkrʤB24ӤSX{efcƫhHġC
嫬NOڽFĳqG
KEYTRUDAĳq200@JAC3g@ACHR߿`30AYX{efcƩεo͵LkrʤB24ӤSX{efcƫhHġC
YVĳqG
KEYTRUDAĳq200@JAC3g@ACHR߿`30AYX{efcơBo͵Lkrʤ24ӤSX{efcƫhHġC
cDWĳq G
KEYTRUDAĳq200@JAC3g@ACHR߿`30AYX{efcƩεo͵LkrʤB24ӤSX{efcƫhHġC
Gĳq G
KEYTRUDAĳq200@JAC3g@ACHR߿`30AYX{efcơAo͵Lkrʤ24ӤSX{efcƫhHġC"	"tswwʡGN/A
}wwʡGǷ6hAN96h
ۮe}GGNSBD5W
ĳ}nG100ml
ĳĳ~|tvGIVF 30min
ī~}~[GL
L`NƶG 
1.Administer through a 0.22? in-line filter.
2.W`AŻPLĪϥΦP@޸
3.pGONæsAīe}᪺G^_ܫǷ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Pembrolizumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1.¦ӭMFG
vLkಾʶ¦Fw̡C
2.DpӭMG
WϥΡAΩĤ@uvgTĤ˴X~Fת{PD-L1 (tumor proportion score (TPS) ? 50%)ಾDpӭMw̡Aw̤㦳EGFRALK~F]`̡C
Ppemetrexedcarboplatin֥ΡAಾʡA㦳EGFRALK~F]`D쪬DpӭMĤ@uvĪC
3.嫬NOڽFG
vwxTʩΥeܤ֤wTتv_o嫬NOڽFw̡C
4.YV쪬ӭMG
vbϥΧt`ƾǪvΪvX{efcƪ_oಾYV쪬ӭMw̡C
5.cDWG
vt`ƾǪvΪvX{efcƲ{HߴಾʪcDWw̡C 
6. GG
vw_oʧߴಾʭGέGDXAgTĩʸ˴X~FPD-L1{(Xʤ[Combined Positive Score, CPS]?1)ABebϥΨ(t)HWk(]AtfluoropyrimidineΧt`ƾkAHHER2/neuйvk[pGAX])vɩΪvX{efcƲ{HfHC "	L	mBߤηkoC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-24 j	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.69._20251001.pdf"">OI` 9.69.</a>              "	0	0	OIs 20251124	IKEY11-a	IKEY11-b	IKEY11-c	110.6.16
BC26656100	L01EL01	0	OIMBR	ĵƼf Imbruvica 140mg/cap(Ibrutinib) 		IbrutinibO@ؤplBTKCIbrutinib|PBTKʳ줤biĴݰ(cysteine residue)Φ@Ӧ@AiӧBTKïʡCBTKOBӭMܭ(BCR)βӭME餧@θ|TǾɤlCBTKBӭM骺TǻtnAOBӭMʡBͤƩMHnCD{ɬsܡAibrutinibb餺|cBӭMWͻPsAb~]|ӭM@λPH@ΡC 	"ΪkG 
IMBRUVICACjۦPɶACѤ@fAϥΡCnH]ACť}B}aΩCZnC
ĳqG
QMӭMOڽFPtϲOڽFG
IMBRUVICAΩvMCLPMZLĳqC@fA560@JAefcƩεLkӨrʤC
CʲOڲyʥզf/pOڲyʲOڽFPWaldenstr?m󥨲yJզgG
IMBRUVICAWΩvCLL/SLLPWMĳqC@fA420@JAefcƩεLkӨrʤC
ΩvCLL/SLLɡAIMBRUVICAiWϥΩλPrituximabobinutuzumab֥ΡApGObP@ѵġAҼ{뤩IMBRUVICAAA뤩rituximabobinutuzumabC
ΩvWMɡAIMBRUVICAiWϥΩλPrituximab֥
CʲܱJDef
IMBRUVICAΩvcGVHDĳqC@fA420@JAcGVHDcơB¦cʸ~F_oεLkӨrʤCfHAnϥΪvcGVHDĪɡAӧOfHGIMBRUVICAC "	"IMBRUVICAi|W[ܦpOΧܾĪvw̪X孷IA]ʵw̬O_X{X媺xC
̾ڤNMX孷IAbNeΤNAIMBRUVICAܤ37ѪįqPIC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Ibrutinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. QMӭMOڽF :AΩeܤ֤@kvQMӭMOڽF Mantle Cell Lymphoma (MCL)~fHC
2. CʲOڲyʥզf/pOڲyʲOڽF :AΩvCʲOڲyʥզfChronic Lymphocytic Leukemia (CLL)/pOڲyʲOڽFSmall Lymphocytic Lymphoma (SLL)~fHC 
3. 17pʥʤCʲOڲyʥզf/pOڲyʲOڽF: AΩvw17pʥʤCʲOڲyʥզfChronic Lymphocytic Leukemia (CLL)/pOڲyʲOڽF(SLL)~fHC
4. Waldenstr?m󥨲yJզg: AΩvWaldenstr?m󥨲yJզg:(Waldenstrom's macroglobulinemia(WM)~fHD
5. tϲOڽFGAΩvʪvBeܤ֤@اCD20ktϲOڽFMarginal Zone Lymphoma (MZL)~w̡CAgY̾ھv(Overall response rate)Go[t֭CAg֭ݭnT{ʸ(confirmatory trials)ҩTF{ɤWįqC 
6. CʲܱJDefGAΩvϥΤ@uΦhukvѫ᪺CʲܱJDefchronic Graft-Versus-Host Disease (cGVHD)~w̡C "	L	̱`oͪ}(20%)pO֯gBmBݤʥզy֯gBhBh¡B٦װfkhBP~BWIlDPVBߡBˡBIlxBKB֯lBhBæRBHέCC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.61._20251001.pdf"">OI` 9.61.</a>              "	0	0	OIs 20251124	OIMBR-a	OIMBR-b	OIMBR-c	111.8.19
		¡	ITECE1	ĵ Tecentriq 840mg/14ml/vial(Atezoumb) 		"Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that binds to programmed death ligand 1 (PD-L1) to selectively prevent the interaction between the programmed cell death-1 (PD-1) and B7.1 (also known as CD80) receptors, while still allowing interaction between PD-L2 and PD-1. PD-L1 is an immune check point protein expressed on tumor cells and tumor infiltrating cells and down regulates anti-tumor t-cell function by binding to PD-1 and B7.1; blocking PD-1 and B7.1 interactions restores antitumor t-cell function. Immune checkpoint inhibition combined with the mitogen-activated protein kinase (MAPK) pathway increase antigen presentation and T-cell infiltration/activation to suppress tumor growth and improve tumor immunogenicity (when compared to targeted therapy alone)."	"Wϥ TecentriqĳqG
C3g@AC1200@JH60R߿`AvefcƩΥX{LkrʬCYi@Ĥ@`AiH30ɶi`CoHR߱`(push)Χֳt`(bolus)覡TecentriqC D쪬DpӭMG
TecentriqPAvastin (bevacizumab)BpaclitaxelMcarboplatin֥ήɪĳqC3g@AC1200@JH60R߿`AefcƩΥX{LkrʬCYi@Ĥ@`AiH30ɶi`CoHR߱`(push)Χֳt`(bolus)覡TecentriqCTecentriqbAvastin (bevacizumab)BpaclitaxelMcarboplatineC
ߴಾʤTʨG
TecentriqĳqR߿`840@J(H60`)AHᵹ100 mg/m2nab-paclitaxelCbC28ѶgATecentriqb115ѵAnab-paclitaxelb1B815ѵAefcƩΥX{LkrʬCĲĤ@`H60zL˩Τ˦LߡBDPʡBCJյXʪ޽umLo(ծ|ؤo0.20.22L)Rߺ޽uCYfHi@Ĥ@`AiH30ɶi`C"	"tswwʡGN/A
}wwʡGǷ6hAN24h
ۮe}GGNS
ĳ}nG250ml
ĳĳ~|tvGIVFG60min-30min
ī~}~[GL
L`NƶG
1.For IV infusion only; don't give as undiluted suspension or as an IV bolus
2.Ĥ@`H 60 zL0.22 L̪filterCYw̥i@Ĥ@`AiH 30 ɶi`
3.ФŸgѬۦPRߺ޽uPɵLĪ
4.ĶǡGAtezolizumab(Avastin+Paclitaxel+Carboplatin)
5. Tecentriq vw̴oͧK̴Cʪͪ(pneumonitis)ζʪͯfAwqݭnϥΥֽTJBLTLf]"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡGJs2-8XCץB	Atezolizumab 	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	1. ߴಾʪcDWAΩvt`ƾǪvefcƩΤAXtcisplatinkߴಾʪcDWw̡C 2. ߴಾʫDpӭMWϥΡAAΩvt`ƾǪvAefcƤߴಾʫDpӭMw̡Cw̭Y㦳EGFRALK~F]`AhgEGFRALKvAYvefcƤiϥTecentriqCPAvastin (bevacizumab)BpaclitaxelMcarboplatin֥ΡAಾʡA㦳EGFRALK~F]`D쪬DpӭMĤ@uvĪC 3. Tʨ TecentriqPnab-paclitaxel֥ΡAAΩvLkߴಾʤTʨAB~FPD-L1{(tumor-infiltrating immune cells (IC) ? 1%)BΩಾʨfwC	L	h¡BCBm	Fetal risk cannot be ruled out.	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ITECE1-a	ITECE1-b	ITECE1-c	110.6.16
BC24878100	L01EH01	0	OTYKE	ĵ Tykerb 250mg/cap(Lapatinib) 		LapatinibO@ب㦳s@ξ઺s4-anilinoquinazolineE?Ai@ΩEGFR (ErbB1)PHER2+/neu (ErbB2+)骺ӭM?iĿE?ͱj?BifBBܩʪ@(Kiapp pȤO3nMP13nM)APoǱ骺?t?]۷wC(bIWLε300)Cso{A?t?ns䥦4-anilinoquinazolineE??wCC~ΦU?PʪҫsGܡAlapatinibiErbBһɪ~FӭMͪ@ΡC	TYKERBĳ??CAΤ@1250@J(Y5)CTYKERBieܤ1pɩζiܤ1pɪAΡC?A??iAAAU@ӹwqCAĮɶs}lAġC 	"1.TYKERBQɩMX{߫ǮgX?[LVEF]?CC?fH֦i|z߫ǥ\धefB뤩TYKERBɡAh[pߡCbϥTYKERBv?A~ʴLVEFAHTwLVEFåU??i{?C
2.TYKERBQɻPʪͯe/ͪCfHͳg?ܬʪͯe/ͪQʴC
3.ϥlapatinibioͨxrʦYxrʬOu?A}lϥΥĤΤCάO?ɫܩһݡAi?x\(i?BxBPC?)ʱC?x\?ƦYAAlapatinibBfH?A?AΡCL?i?紿xrʤiC
4.襤?έ?x\l`w̳BTYKERBɡAȥh[pߡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Lapatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"bMcapecitabine֥ΪpUATYKERBAΩv?~FHER2+/neu (ErbB2+)L?{{HåBeanthracycline, taxaneHtrastuzumabv?fp?Ƥw̩ಾʨw̡C"	ثeõLMTYKERBwĸTҡC 	Tykerḇ`Ƨ@Υ]AmBߡBæRBlAHΤШgԸs]i]A¤BhBoB~ȥHΤP}AP^CbּƯfHo{Ŧ\UΡ]iɭPIlP^F@ӨOiH_C	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.47._20250201.pdf"">OI` 9.47.</a>              "	0	0	OIs 20251124	OTYKE-a	OTYKE-b	OTYKE-c	111.8.19
KC00991209	L04AC10	0	ICOSE	Cosentyx inj.150mg/ml/ 		Secukinumab OĤ@ӥHկ-17(Interleukine-17)o]lͪsCSecukinumab ܩʦaPIL-17Ai浲XAĽwѱw̪~gC	"1.ʰ~ĳq
ĳCqsecukinumab 300 mgC_lɩ0A1A2A3 M4 g֤U`gA
۩4 g}lC4 g֤U`gCC300 mg qP⦸150 mg ֤U`gC
ǯfH( Ҧp魫̡A<=60 kg)AiP150 mg qC
2.~`ĳq
ĳCq150 mgA_l0A1A2A3 M4 g֤U`gA۩4 g}
lC4 g֤U`gC"	 1.PV-COSENTYXiW[PVIC2.Jg(Crohns Disease)cơC3.LӤ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Né2XC10XC (]ץxs)	Secukinumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	Ω~ΰ~`v	COSENTYXTΩ󤧫esecukinumabΨLξYLӤfH	E WIlDPVAg]AVhP(|B)E fH(fįpl)E mE ko֯l(C¯l)E y	B	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.1._20251001.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6.1._20250601.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.6._20250601.pdf"">OI` 8.2.4.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.6.1.</a>        "	0	0	OIs 20251124	ICOSE-a	ICOSE-b	ICOSE-c	111.8.19
X000211100	L01XX05	0	OHYDR1	ĵHydrea 500mg/cap(Hydroxyurea) 		~DNAXAS۱M@ĪC	1.kJ20mg/kgAC@C 2.kJ80mg/kgAC3@C	"1.vץC
2.ifHnAyJ|AYqɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Hydroxyurea	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"¦FBܩʺCʥզfB_oʡBಾΤi}MZ_C
guv֥Ω󳱮B~oYV窱ӭMC"	ҥΩ\fHYh̡C	զy֯gApO֯gAhΥFyfFߤιæRAfAֽLӡC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19		0	0	OIs 20251124	OHYDR-a	OHYDR-b	OHYDR-c	111.8.19
KC00977208	L04AC07	0	IACTE2	Actemra 162mg/ (S.C.inj.) 		"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
 MTXLk@ΤAX~PMTXAiActemraWvC

 ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"Rheumatoid arthritis: Initially, 4 mg/kg IVF over 1hr Q4W; may increase to 8mg/kg Q4W based on clinical response. NOT to exceed 800 mg/dose Q4W.

"	"HUpקK}lvGANC < 1000; Platelets < 100000; ALT/AST > 1.5* ULNC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Né2XC8XC (]ץxs)	Tocilizumab	L04A	Ķ IMMUNOSUPPRESSANTS	0	"`(RA) -Actemra XMethotrexate(MTX)iΩv~Hצܭ`AϥΤ@ةΤ@
HWDMARDĪvθ~Fa]lܾ(TNF antagonist)vӤΩεLk@w̡CboǱw̤AYfw
 MTXLk@ΤAX~PMTXAiActemraWvC

 ʥ~o`(SJIA) -ActemraAΩv2(t)HWʩʥʥ~o`w̡ABNSAIDTJvΩεLk@̡C"	"Serious infection, hypersensitivity"	"Hypertension, Increases ALT, Diarrhea, Upper respiratory tract infection, Headache, Rash, etc.

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.29	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.2.</a>             "	0	0	OIs 20251124	DC	DC	DC	114.10.29
BC13027148	L04AD01	0	LCYCL	Sandimmun NeoralfG100mg/ml;50ml/~ 		"Cyclosporine O11 iĩҺcpolypeptide A]iHT-ӭMWާ@ΡAҥH{ɤWOΨӧ@ĶCCyclosporine ]|OڿE(lymphokines)ͪPXA]Ainterleukin 2CCyclosporine i_bӭMgG0 G1 ƲOڲyAï]ĲܭӬƤT ӭMXOڿE C
Cyclosporine ä|y\A]|vT]ӭM(marcophage)\"	"1.x:5-10 mg/kg/dayAŦӤfwϥΧCq3 mg/kg/day
 2.~:
HMൣ18:@}l: 1.25 mg/kg bid for 4 wks.; increased by 0.5 mg/kg/day once every 2 wks., ̤jq: 4 mg/kg/day.
 3.`G
 HMൣ18G@}l 2.5 mg/kg/day in 2 divided doses increased by 0.5-0.75 mg/kg/day after 8 and 12 wks., max. 4 mg/kg/day."	"ĶYOΩ󾹩xӡAisӤJxةRC]x\δī~}AнTqAġAñK`N鲧ˡC1.ŦۦAΥ⦨ġC2.ŻPcĨ֪AġC3.pGzjѱNA姹A~AΤU@ӾqC4.\hĪi|vTī~夤@סA]dUnۦAΥĪA
PvĮvQסAT{wʤ~iAΡC5.AΦķ|ϱzܤOzAiePVC]̦nקKiX@
ҨûwP_ΨLPVgHsC6.AΦĥi|yziovW[ ]~ȡBy^A]ШCѱ`W
MzAéwܤˬdC7.YzhBŤAΪ̱zŦΨLefAХiDzvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Cyclosporin	L04A	Ķ IMMUNOSUPPRESSANTS	0	wxӤΰ貾ӫᤧӱƥBwӤϱJDefBʩʦMIΫ᳡DPVʸ彤BϥζǲkLk̡Bbehcetsf@AoBBwIǵ̡BNkLĩΤAΤY~FзkLĩΤAΤY`FHTJvLĩιTJ̿ʪoʵǯfgԸs]˵]Biopsy^DnLpfܯefΧ`ǵywƯg^AgӭMíw(cytostatic)vLĥBǥ\Ʀb`50%HWfHC	󥻫~DΥ@ξLӪ̡ATϥΥī~C	hgB_ŸBǥ\zBx\êBiΫpBHέGzê(BߡBæR)BBB[C	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.1._20220501.pdf"">OI` 8.2.1.</a>              "	0	0	OIs 20251124	LCYCL-a	LCYCL-b	LCYCL-c	110.6.16
BC25215100	L04AX04	0	OREVL1	ĵƼf Revlimid 15mg/cap(Lenalidomide) 		Lenalidomide @ξAݶi@BMA㦳ܸ~Fs͡BK̽ո`Mܦ޷sͪSCLenalidomide PGֲycPioӭMEAüW[ܵoӭMEcCLenalidomide YǲӭMWޡAj(IC50s) h@A]ҦӭMCbչLӭM褤Ao{lenalidomide ঳ħNamalwa ӭM]@ؤHB ӭMOӭMA֤@Ӳ5 V^ͪAMӡAKG-1 ӭM]HFӭMA]֤@Ӳ5 V^MLS5 VʥӭMAͪĪGĤOC Lenalidomide ໤ɲӭMgP`Aqӧѱw̨WohoʰFӭMͪA]MM.1 S ӭM]@ؤHhoʰFӭM^ͪC~o{Alenalidomide 2 X?(COX-2) ʡAäCOX-1C	ĳRevlimid _lqC25 @JAHeAAb28 ѥĶg1 21 ѡACA1 25 @JnC[Ľо]Ai}BZHΥ}nC	"1.Ķȯ}ߵw̡AӥBYϨLHۦgA]iLHAΡC2.ĥsൣiΤBAYTѵihkC
3.AΥĴAw̤oC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCC	Lenalidomide 15mg	L04A	Ķ IMMUNOSUPPRESSANTS	0	"RevlimidPdexamethasoneX֨ϥΥivewܤ֤@تvѤhoʰF(multiple myeloma, MM)w̡C"	YwTw̹REVLIMID (lenalidomide) Ψ䦨LӡAhTϥΡC	hBP~BKBmB⵬C	X 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.43._20251001.pdf"">OI` 9.43.</a>              "	0	0	OIs 20251124	OREVL1-a	OREVL1-b	02C25215-2	111.8.19
BC22044100	L04AD02	0	OTACR2	Prograf(Ķ)5mg/cap(Tacrolimus) 		1. ħѦp interleukin-2 M interferon-^  lymphokines ͡AHζi@B~Fa]l(TNF) alpha (@تʲӭME)Binterleukin-1 beta M interleukin-6 ͡C	"Ŧ-q`ӫe2ѡAfA tacrolimus@Ѩ⦸A@0.15mg/kgCNAfA tacrolimus @Ѩ⦸A@0.15mg/kgCMvqܺq@ 0.06mg/kgA@Ѩ⦸зǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCxŦӳq`fA tacrolimus@Ѩ⦸A@0.15mg/kgCMvqܺq 0.10mg/kg/ѬзǡAi̯fwgAaվCŦ-q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUCŦ
q`fA tacrolimus@Ѩ⦸A@0.03~0.15mg/kgCYOƥX{~}lĮɡAq`fA tacrolimus@Ѩ⦸A@0.075~0.15mg/kgCq̯fwgiAaվApGfwpíwAiCCqbĪ̧CqC]b򰪦夤@׮ɡAio͵ǥ\णAҥHb뤩j12pɫᾨiaN夤@׺b20ng/mLΥHUC"	HUwV-1.x\णw̡C2.ǥ\णw̡C3.̡֪C4.PVgw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	1. 25JHUxsC2. ЦbĴϥΡC	Tacrolimus	L04A	Ķ IMMUNOSUPPRESSANTS	0	xǲӤĤ@uĩΨxǲCYCLOSPORINLĤĤGuġAŦӤĤGuġAŦӤĤ@uġC	"1.糧ĥ󦨤Lӯgfv̡C
2.bϥciclosporinbosentanw̡C 
3.O[QĤw̡C
4.hΥihkC"	_ŸBYhBmBߡB}LB}fB[gBBvC	C	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.2.2._20130701_000.pdf"">OI` 8.2.2.2.</a>              "	0	0	OIs 20251124	OTACR2-a	OTACR2-b	OTACR2-c	110.6.16
B021417329	A01AD11	0	EMUND	Mundisal Gel 10gm/tube(Choline Salicylat 		Choline salicylateAcetylsalicylic acid@ӸjPo@ΡAӥBGؤUACholine salicylateqHBˮ`WC	Nī~٩khηPVAAHbCȻݵpܨ몺?NCī~|Φ@hA\khηPVC̷ӯg?Y{?AiCj2~3pɨϥΤ@C	ī~t43% (v/v)s?A󥲶ϥΪpUϥΡCPɨϥήɥ̷Ī뤩ɶjC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Choline salicylate	M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	oBkhB¯pHC	salicylic acidsalicylateΥī~䥦LӪ̡C	ϥΥī~|X{Ȯɩ?ξA(pG`P)CpGX{ī~楼ZƧ@ήɡAЧivĮvC	"LSOĳ
~ts"	"LSOĳ
~ts"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EMUND-a	EMUND-b	EMUND-c	110.6.16
BC26541221	M03AC11	0	INIMB	ĵCisatracurium Kabi inj. 2mg/ml;5ml/amp(N) 		~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"ޤޡG0.15 mg/kg Ab 5  10 ֳtC?b`g 120 i?Q?ACൣ(1Ӥ-12)qPHqۦPD
qG0.0.3mg/kgAi20g٦ת_@ΡDൣ(1Ӥ-12)qG0.02mg/kgi9@ΡD
ICUfЯfHϥξqG_lqG0.18mg/kg/hrAqG0.03mg/kg/hr-0.6mg/kg/hr"	wgٵLOgΨLg٦ׯeffwDhƩʪ_|jӷPʡCofwĳWL 0.02 mg/kg ~_lqC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʮɥixs2~8CץNëOs
}b 25?U 24 p"	Cisatracurium	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	~@ܩʤvʪDhƯg٦ת_Ci@N¾KUΥ[@fШϥΡAΥHPf١AU޴ޤλPHuIl	"~TΩw cisatracurium B atracurium  benzenesulphonic acid LӪfwC
"	"߷iLC,޵j
"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	0	ѦҡuqΥΪkv	"ݨϥPUMP
_lq(LD)G10mg
q(MD)G50mg(5A)w50mL in syringe
}GGD5W, NS, D5NS
}@סG1mg/mL
ĳĳtvGa.ޤޡG0.15 mg/kg Ab 5  10 ֳtCB.ICUfЯfHϥξqG_lqG0.18mg/kg/hrAqG0.03mg/kg/hr-0.6mg/kg/hr
wwʡG24hr (RT)
iѩP䵹
ʴءG߸,Il "	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.2._20110701_000.pdf"">OI` 1.4.2.</a>              "	0	0	OIs 20251124	INIMB-a	INIMB-b	INIMB-c	110.6.16
		0	IXYL2M	ĵXYLOCAINE 2% 20ML/BTL(FOR IM) 		"pP󧽳¾K@ˡAlidocaineiǥѨulVgVʡAӥifagİʪuۯgֺǾɡCQi(amide)¾KQ{OPgul޹D@ΡC
¾Ki󸣳Τߦ٤E(excitable membrane)ۦ@ΡC"	"`gSOpߡAHKVRߤAӤް_ʬrʤCĳb`geΪ`gɱ`ԷVa˩@UCnjqɡApw~_ɡAĳHtǤW lidocaine 3-5 @ɥկfHCYVRߤAiǨϤ߸ȮɩʼW[ӹıC
DnqHC 100  200 @JtvwC`gAΦbW[qɡAPfH͡CYoͬrʤAߧY`gC@ӨAn_jgҦgyɡAݭnϥθ@סFӷ_һݤj׸pɡ]pYkhѰ^AhϥθC@קYiCĪϥΤen|vT¾KGdC
ϥΧtǤWGAiW[@Τɶ]Ѿ\q^C
b楽ݤqACX`Τ¾K޳N@릨HĳqAHѰѦҡCbpݨDqɡAvgίfH骬pTA۷nCɶϥΪ_¾KɡApĥέеĤ覡AҶqĪbߤ@רFr@סAξɭPgˮ`MIʡC"	"ϰΧ¾K{ǡAbA]ƤΤHҹIAϤκʵһݤĪγ]ơAƧBiߧYϥΡCIj_¾KɡAb`g¾KeARߦsdɺ޲աCvnI椧{ǡAwAίSwVmABƧ@ΤE_ΥʬrʡAΨLֵogv۷xC

lidocaine bpH Ȥj6.5 HWɡA䷻ѫפjCFGn[JPʷG]pGһQ^ɭnSOҼ{IA_h|oͨHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" Xylocaine]tǤW^hqĲ~FJs󤣰25JBAiNC
hqĲ~b}~WL3 ѤAiAϥΡC"	Lidocaine	N01B	"¾K ANESTHETICS, LOCAL"	0	¾KC	"wQi(amide)¾KAηGL]ptǤWGmethylpar ahydroxybenzoatesodium metabisulphin)|o͹LӤ̡C
wҰΤmfһୡ]methyl-/propyl paraben^AιNªifһġ]PABA^LӪ̡C¾KΨNªPABALӤfwקKϥΧtmfһ୤lidocainet"	"pGOĪLqλ~JޤA¾Kܤ֤ް_}C
YhBVáBݺΡB wtBߡBæR"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IXYL2M-a	IXYL2M-b	IXYL2M-c	110.6.16
		0	IBOTO1	Botox 50IU/vial(Botulinum toxin type A) 		"2.1g٦ת_C
BOTOX (A׬r߬r)¤ƯgrƦXYgѻPBʯg骺mXAiJgAHAQxP(acetylcholine)AӪ_g٦תǾɡFBOTOXʥHvq@٦ת`gɡABOTOXʥHƾǤ覡ϸӦ٦ײͧhgƧ@ΡAGɭP٦׳·F٦רHƾǤ覡hgƮɡA٦׵YAӥioiXgXH~AQxPApiҩgTigѥXޡ]sprout^Aӭs٦׹FHgtʧ@AIifʡC
2.2 ׵
BOTOXʥΩv׵ɡAw뤩BOTOXʸgѻoQ`g٦׵YөA۹aCӦ٦׫ܦ٪YӼvT٦סC
2.3 ¥j
`gBOTOXʹ٦׳y·iΩֲ¥jˤް_٦׹Lײ`YA@ӻ¥j˯fHvfﵽ12.5gA~ݭnAױvC
2.4 j˩ʱV(VٱiO)
BOTOXʪ`gV٦׮ɡABOTOXʫYѵj˩ʱV(VٱiO)[xHHΥD[gA譱ӴѯfwѡA}ĪG]A֯kh/ABYB֪ӻHﰪBCΫp٦תؤoαjסAHι\ʥfpﵽF󦭴Ω󥼴vfHmiGAVٱiOfHBOTOXʪvA40%58%gۧﵽC
2.5 j(~ʳ·ҭP)
BOTOXʪ`g̸zٲ͸}mﵽ(Ψ)HH]}ĲaOW[AoBAﵽC
2.6 oʵźۦhg
BOTOXʥΩhg@ξYgѧ_ۥDgtΥPgxPEʯgֺtAӧxPEXϹLqƦFخĪGYgѱN׬r߬rIbֽu֪ӹFتA]Ω󦹺ؾAg`gD֤`gChg嫬v覡YwϰAH檬Ϯק@h֤`givC
vؼЫYNƦ֦ܯfHiԨͲz`{סALëDvؼСC
2.7 Kܯ
BOTOXʪ`gKܦ٤/λܦٮBOTOXʴzU٦׹L׬ƪYAKܯY{סA]ӧﵽ~[C
2.8 
OaӶުҥͥXɱ׽KAB`BegAO`ֺٰYɭPGC`gBOTOX?iﵽӳYKDC
2.9 Y
YPB٪ʧ@CڨLVm[HXA`gBOTOX?ﵽYYpiF24gC
2.10 Hᤧuj
BOTOX?fﵽ]AGC٦ױiOA٦׬ʽdW[ABΩYǯfHABOTOX?i֦]j˪AɭPfHfoB൥C
2.11 H֥(HֹLʯgHΦ]fܤ޵oGٹL)
H֪`gABOTOX?|AQxPAiӼvTG٧@Ϊ϶ǥX|(efferent pathways of detrusor activity)C
"	"ĳ~|G
٦ת`gFhgĥΥ֤`gF¥j˥iĥΥ֤U`gC`gg}LBOTOXAܱv٦תBʺݪOϡC
sƻP}kG
BOTOX Ĳ~HLߡBtG0.9%ƶu`gG(ĨUSP)isơCHjpAwYAq}AN}wC`JĲ~CpGuŭtåN}lJĲ~AhmĲ~CĲ~AVXBOTOXέQCbҪťճBOUsƪMɶC
BOTOX sƫ72pɤġCboqɶANsƦnBOTOXNxs(2X8XC)C
UAgΪkζqаѾ\C"	"1. ФŶWL~ĳPqWvC
2. ܥثeåBotuinum toxin type ALӤרҳiCNpҦͪs@ˡAǤWMLL˴HƦbAHƹLӤio͡C
3. ֯wӪ`g~ܲٮɥi|ɭPnSBä[ʤWֶˮ`ΨšAרOĤCﯫgeffHCveĨ@BJAppߴղӷPסAקK`gU¥ϥH¥~½AHοnv󲴪ֶˮ`C]iQ@βĤBnIB^aBnβξBβn@Ϊ~C
4. ԭ|M줤ϥΥ~Hvspasmodic torticoliscerebral palsyC
5. YLqεoͮɡAfHbƤѤʴLʵLOΦ٦׳·gC@p~`tqCwpN6kgΧ魫w̲ͥʬrʤwqCSwbotulinum toxinܬrԦb`gbotulinum toxin30`gɤ~ġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"uŰs~ixs2-8JNáB-5J-20JNC
BOTOX?sƫ72pɤġCboqɶANsƦnBOTOX?Nxs(2X8XC)C
γѪBOTOXʨϥε}QķG(0.5%)hƹF5C"	Botulinum toxin type	M03A	"P@Φ٦P MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS"	0	¥jˡBbjˡB٦׵jˡB׵Bj˩ʱVBpรʳ·ް_٦׵jˡBWyK]KܯBYB^BoʵźۦhgBHᤧujˡC]fܩҤް_GٹLʦӾɭPTHfHABgxPĪvLĩεLk@̡CvTBPWHֹLʯgHfHAgxPĪvΩεLk@ġABpݭnɡA@Nίvi氮bʾɧ(Clean intermittent catheterization) ̡CBOTOX?AΩCʰYh(ܤ֦3ӤɶACӤ? 15ѡAC4pɥHWAB䤤ܤ֦@bYhOYh)HfHYhwʪvC(nGBOTOX?}oYh(CYhѼơ14)wʤΦĩʩ|LҾҩ)CvHfHUϵjˡAHֽ`M}k}ٸs(̸z١Bس١BH١B}٩M}k)ٱiOW[Y{	"~TΩwt褤󦨥LӪ̡C
BOTOXʸTΩ󭫯gٵLOEaton LambertgԸsfHC
BOTOXʸTΩĳ`g즳PV{HsbɡC
󿩱wDPVfHAHΥwi氮bʾɧ(CIC)ʧdαƧlqWL200mLfHӨAPBOTOX?"	q`}YX{bBOTOXʪ`g᪺Ĥ@gABȮɩʡApGkhBoB`PıBPıyB~/~hBBPVBXM()CC`g׬r߫]o{oNMP_gCwY`g᪺khM/εJ{]oͦްggʤA]AuȯgʧCηw֡Cz{HD׬r߬rwĲz@ΡC	BOTOXʥΩhkʪvTõLRBgLTӪsAGקKBOTOXʥΩ󥥰	ĬO_cHťġA]\hĪ|cHťġABOTOXʤĳϥΩŰC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IBOTO1-a	IBOTO1-b	IBOTO1-c	110.6.16
AC481761G0	M03BX02	0	OSTID	Tizaflex 2mg/tab 		"Tizanidine O@ؤϧ@ΩʰfPADn@ΦmbAܩʧtd٦׹LױiOhĲADnb֤g쿳ĩiĪXC~vTg٦תǾɡC
Tizanidine @ʨ}nA঳Ĺܫʯkhʦ٦׵jˤκCʯΤj_j˪AAֳQʹBʮɪܤOAwѵjˤΰ}˨üWjHN٪OqC "	gewҤް_j˯gGq̯fHӧOݨDվA}lɨC龯qiWL6mgAT뤩ACbgΤ@gW[2 ~4mgAq`bC龯q12 ~ 24mgA뤩3 4 P˪jqɵoͳ̲zQvCC̤jĳq36mgC 	ŦΨxŦ\lfHݽվ侯qC}lvɡAfH|Ϊ{HAiniݰĵıʪʡAp}ξާ@C 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	OsǷ 25JHUC 	Tizanidine	M03B	"ϩʦ٦P MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS"	0	"gewҤް_j˯gBkhʦ٦׵jˡC  
"	糧Lӯgw	Ƨ@Υ]AΡBhҡBYwBfBߤλLUC 	קKϥΰDvn	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.1.1._20011001_000.pdf"">OI` 1.3.1.1.</a>              "	0	0	OIs 20251124	OSTID-a	OSTID-b	OSTID-c	110.6.16
																																		
	N01AX03	0	IKETA	Ketalar 50mg/ml; 10ml/vial(ketamine)[ޤT] 		~͸A@بt@Ϊ¾KAiͲ`תh@ΡAۥ`fٱiOM諸ϮgAMUؤŦޤΩIlE@ΡC@{@άObͷPı~|M@ʪeAB_pQ~|C 	ɾqw14.5mg/kgAb60IV`g6.513mg/kgIM`gCqwpGnܡAiWܥɾq1.5AHfHݭnAվC 	"1. s뤤rBBG@fHAHΥbϥΥ~yp
2. ~nwCIV`gP(WL1)AקKyLתIlMAnIV`g@׬100mg/mlA]iHSߪBͲzQθ}G}̡C
3. nNketaminePϥιLbarbiturates`gVXA]|yƾǩʪtXTҡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Ketamine	N01A	"¾K ANESTHETICS, GENERAL"	0	¾KC 	W@B㦳MIʪfHAAʯ߽FAҪiA{ʤ߰IܡAU߯gM믫fwC 	W@A߸L֡AIlEC 	Ħbwʩ|TߡAĳϥ	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_E1 []_w75 []_86-3R j	Ts110.5.06		0	0	OIs 20251124	IKETA-a	IKETA-b	IKETA-c	110.5.06
		0	OSUBO	ĵSuboxone 2mg/tab(Buprenorphine)[ޤT] 		Buprenorphine~Pħ@ΡANaloxone~ܧ@ΡASuboxoneH4:1ҦX֨ئAӴ~}_@ΤAPD	ޤUA:C龯q12~16mgDSuboxone]tNaloxoneGAXΦbqAĳؼоqOC4-16mgAHCP@ΨCP覡ġACH2-4mgվ㾯qAקK_gX{DC{H3~6붷sAft߲zvλɡAvĩΪ.	"CʪʪͯfAͤ߯gACIlOAA񤣨AһĦgApߨϥΪ`NIl@ΡD
PL¾KʤhġA¾KAwAwvġAΰs֥ήɶҼ{C䤤@ī~qD
ϥη|;~̿ʡAYMĩδqӧַ|ͧ_gD
vw˴x\"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC	Buprenorphine/naloxone	N02A	P OPIOIDS	0	~覨}Nk	wBuprenorphinenaloxoneL	YhAkhAhA_gԸsAXiAߡAKAvAsD	קKϥΡAsͨ_g	¨ŴקKA	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OSUBO-a	OSUBO-b	OSUBO-c	110.6.16
AC33920209	N03AA02	0	ILUMI	Phenobital 100mg/ml/amp (Phenobarbital) 		Phenobarbital 㦳zZulι[lqzӭM@ΡAo|yƨtΨ챱AbϯgtΤҦϰ줧hĲǾɨCPhenobarbital ä|Pbenzodiazepine XAo|W[lyJgӹFwR@ΡCٷ|ָӮqӹF¾K@ΡAbĪLqɷ|ɭPIlӲͦ`C	"٦ת`g̨ΡC
֤U`gi;YTRߪ`g(`giX{IlAU)
1.ʯv: IM
-H, 100-300 mg hs.
-ൣ, 3-5 mg/kg hs
 2.NeJ{AR@: IM
-H:100-200 mg Ne60-90 minsP
-ൣ: 1-3 mg/kg Ne60-90 mins P
3.w򪬺AMʵo@AGIM
Ψൣ:15-20 mg/kg (max. 1 g/dose) in a single or divided dose; may repeat dose after 15 mins as needed (̤j`q 40 mg/kg).
ĳv@׽d:15-30ug/ml()F15-40ug/ml(H)"	"TΩporphyriaBx\laB񦳩IlxΪ뤧IlDefw̡C
ϥΥAX{}ʩΧ_gvܰATiMġAV}}qϥΡD̡֪AzSO`ND
ϥΥ̡Awˬdxǥ\ΦGˬdD
X{steven-johnson syndromeAֽlβ渨ArʤaD
`gi৽~ȵw


"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUOs	Phenobarbitol 100mg/amp	N03A	w ANTIEPILEPTICS		w	"phenobarbitolLӡAߨxǻêAhA¨ŰΦihkTΥ
̡֪Az̡AIlCU̡AHeRʯv}f̶V뤩"	ݺΡBYwBʧ@աBuҽkBߡBæRBSGfA`NOC	"A¨ŰCihkTΥC
1. ķ|qLLLAYhΤYɨϥΡAisͨ ( SOO  ) ް_IlADѩx\|GC
2. hϥήɡAѩ|Cͯ K- ̿ʾ]qAӤް_sͨ X ( ͯ K sͨध]l )C
3. ϥήɡA|ͨ̿ʡAsͨh_}gC
4. Υħ@h־ϥΡA|W[XͯʳoͲvANϥ WMIPįq[HҼ{C"	"A¨ŰCihkTΥC
Phenobarbital|ƪnťĤAGŤkϥΥĮɡA|ް_ϯgtΧApߨϥΡC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110/10/19		0	0	OIs 20251124	ILUMI-a	ILUMI-b	ILUMI-c	110/10/19
AC29375100	N03AF01	0	OCAMA	Camapine 200mg/tab (Carbamazepine) 		W[A֤ʡAqPֽMt\঳hĲ~|C~iCjĤOۭ@ΡA~A٨㦳xPEʡAܧ{M٦P@(zZg٦תǻ@)C~iHwjSoʤTeghw̪}oʯkhCbs}gԸs譱A~iwQCֻ֭ȡA]Ӵ֯fgoMIʡCåitaﵽ믫ʻPۥDgʯgwgCbYg譱A~iHtCqAѰPC	"1. wwH12HWൣG_lq200mgAC2AMCѼW[200mgAAΡAܲ;AyA̤jqC1600mgF@qd򬰨C8001200mgC
2. 612ൣG쾯q100mg bidCCgհq1AC̦hW[100mgA34AΡCC̰q1,000mgAqC400800mgC
3. 6HUൣG쾯qC5mg/kgAC57ѽհq1ܨC1020mg/kgCΨC1020mg/kgAAΡAݭnɨC12gհq1C
4. Teghw_lq100mgAC12pɼW[100mgA@몺dC400800mgCܤ֨C3ӤYխCqΰġC "	"1. wǡBxΤŦefBBCw̡AHΦѤHBα¨ŪfHϥΥ~ypߡC
2. ĭnCCվ㾯qAYMܡAi|ɭPws򪬺A(status epilepticus)C
3. TegretolbʴUpߨϥΡCAΥ~y}αqƦMIʤu@C
4. Yߦޤ譱efAΪ̨xǥ\ಧ`ΦѦ~HAϥTegretol`Nվ㾯qC
5.i঳ɭPuYֽL:v-jͯgԸs/rʪַѯg(steven-johnson syndrome/toxic epidermal necrolysis )"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Carbamazepine	N03A	w ANTIEPILEPTICS	0	wgBTeghBǭʧYgeʯew	fAMYBCarbamazepineLӪ̡AŦЫǪ_fHC	ī~ioͨuYֽLӤApvͤjͯgԸs/rʪַѯg]Steven-Johnson Syndrome/ToxicEpidermal Necrolysis SJS/TEN^}ApX{VhBLگ}BoBֽlAߧYġA^EDvvC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Safe	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.2.6._20110801_000.pdf"">OI` 1.3.2.6.</a>              "	0	0	OIs 20251124	OCAMA-a	OCAMA-b	OCAMA-c	110.6.16
A016373100	N02BE01	0	OPAN5	"Acetaminophe500mg/tab REH NAR TONG""O.Y."" "		"1. h@ΡG@ΦbϯgtΡAkh֭(pain threshold)AFhĪGC
 2. hN@ΡG@ΦbϯgtΪո`ϡAͦXi{HA]iW[gѥֽലtסACšAFѼĪGC"	"H12HWGoNλݭnɪAΡAYgAhC46pɥiƪAΡAC12A즸ϥγ̤pĳqAAgWζqCC24pɤiWL4C
6HW12AAΦHq1/2C
3HW6AAΦHq1/4C
3HUAЬvEvC"	1.xŦefHAϥΫeпԸ߻PiͩĮv 2.o֪Ats붼	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHUC	Acetaminophen	N02B	䥦Ѽh OTHER ANALGESICS AND ANTIPYRETICS	0	hNBh]wYhBhB|hB`hBghB٦׻ĵhBgh^C	]Ħް_LӪHT;sĵyGo֪Ats붼	ϥιLq[CWL4000mg]AΨϥīX{HUgGGzDABBߡBæRBaդΥXC	קKϥΰDvn/SmҦw	iw/i	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OPAN5-d	OPAN5-b	OPAN5-c	110.6.16
BC25352100	N04BA02	0	OMAD1	Madopar 100/25mg/cap 		"~ҧtbeserazide L-dopa n,ӼW[ L-dopaC"	"}lɥ""125""1ɨC3, HCgW[@(YĤGgC4, ĤTgC5, ĥ|, ĤgC6ɵ)CCѦĶqq`b4-8, 3-4AΡCYC""125""ζqWζqWL6, i""250""Cѳ̨ξqHӤHӲC"	"1.iM,|ɭPŹLM٦׻,߲zWi઺,oǥiͩR¯١C
2.v,oͭGz}i֥έ,ΤκCCW[qӱC
3.GiC,q`RmѲHt"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAA	"Levodopa 100mg, Benserazide 25mg"	N04B	hi DOPAMINERGIC AGENTS	0	ڪˤf	"1.糧~LӪ̡C
2.iPMAOI֥ΡC
3.xǥ\ಧ`ʫCcLNvOw̸TΡC
4.α¨ŰTΡC"	", æR,m"	D 	קKϥ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0	0	OIs 20251124	OMAD1-a	OMAD1-b	OMAD1-c	110.6.16
AC49345100	N05AX11	0	OLODO	Zonin S.C.50mg/tab(Zotepine) 		㦳R@ΡA|yNѻêAﵽıBkQ믫fgίണɺ믫OܳyEʡCĮĥX{|tC	"HG1.5~3  / DayF MaxG9 C
"	"1. B~FBY~˫gBx\êBG
êBŦewBݻ̲ӭMFBCOPDBIlDPV
gBwBѦ~HBB¨ŰBBB
iΪ̡C
2. ΩvѦ~w̤`vwMIʰ
ǡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm25JHUB	Zotepine	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫?gC	"1. bϥEpinephrineBTerfenadineBAstemizole
w̡C
2. ?AB`BϥBarbituratelͪB
¾KBϯgAϩ?A?ƪMIC
3. 糧ĥBphenothiazine ƦXL
̡C"	"1. ݺΡBLO«PBvBfB?BtwC
2. NMS?ʯgԸsGBʤʰׯgB·ʸzB
]`xB߹qϲ`BܤơBj˵o@.B
NBNѻêɡAġC"	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OLODO-a	01C49345-1	OLODO-c	110.6.16
AC59884157	N05AH04	0	LQTIN1	Qting oral susp. 25mg/ml;120ml/~ 		Quetiapine@ξApLbvıկgMʯewĪĪ@ˡCOH{Quetiapine ıկgĤΨbʯew{gMļgíwʽAOzLĤGhi]D2^MĤGM]5HT2^ܧ@ά۵XҭPCbhiM5HT2 H~A˩MOܧ@ΥiHQuetiapine@ǨLvTC	"HG
ıկgG
ve|ѤC龯qĤ@50 mgAĤG100 mgAĤT200 mgAĥ|300 mgCĥ|ѥHAqvվܨC300-450 mg @릳ľqC̭ӧOfH{ɤιĪ@ʡAC龯qdq`b150-750 mg C
ʯewļgo@G
@@kΧ@íwUvCve|ѤC龯qĤ@100mgAĤG200 mgAĤT300 mgAĥ|400 mgCqi̭ӧOfH{ɤιĪ@ʦbC200-800 mg[HվA@릳ľqbC400-800 mg d򤧶C"	"1. AΧܺ믫fĪѦ~gfH`ICQuetiapine֭ΩvѦ~gfHC
2. w{gfw]]AHMൣ^AޥL̬O_bAΧ{Aig~{g[MΥX{۱NM欰ΤM`欰ܤơAحI|gwѬC
3. ~@ثD嫬ܺ믫fī~AϥΫD嫬ܺ믫fĪ|X{}μW[w}@ʤ}ο}fICKdN}gA]AhB@BhεLOAĴYX{}gAߨq}ȡC
4. Quetiapinei޵oթʧCAYwB߷iLtAǯfH|֡ASOOb̪쪺qվAiϬM\1 ǤWʫܾʽC
5. iܨϥ quetiapine ɥX{ίvIlgCbHϥΤϯgtΧfHBίvIlgΦίvIlgIfH]pGL/έDΨkʡ^bϥquetiapine ɶ`NC
6. pPLܺ믫fĪ@Awo@fvΪ̥i୰Cwo@֭Ȥef]pqg^fHAϥquetiapinevpߡC
7. ]Quetiapine i|l`P_BҩιBʧޥAĵifHbXzaTwquetiapine vL̨S}vTeAp߱qƻݭn믫ĵıʪʡAҦprp]]A}^ξާ@MICݺΥiɭP^ˡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷš]25JHU^AץC	Quetiapine	N05A	ܺ믫f ANTIPSYCHOTICS	0	vıկgBʯew{go@Bļgo@βVXʵo@C{@ĪvĪGΪ{g(MDD)fHAi@{go@[vC	糧~󦨥|LӪfHҪA Quetiapine C	ݺΡBY?BfB?BALTɰB魫W[M??C	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[G~]_M06-02 j	Ts110.5.06	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	LQTIN-a	01C59884-1	01C59884-2	110.5.06
BC22769100	N05AX08	0	ORIS3	Risperdal 3mg/tab(Risperidone) 		"1.~benzisoxazolelͪAܩʤiܧ@ΡASerotoninergic 5-HTDopaminergic D2㰪׿˩MOC
2.~iP \-adrenergic鵲XAH1-histaminergicΣ\-adrenergic餧˩MOCAӹCholinergichL˩MOC
3.~jĤD2ܾAiﵽ믫gʯgAøL嫬믫_ް_Bʥ\αjʩ(catalepsy)C"	"Bipolar maniainitial dose : 2-3 mg QD; if needed, adjust dose by 1mg/day in intervals 24 hours. Dosage rang : 1 to 6 mg/day; the safety of doses higher than 6 mg/day has not been studied. Psychotic disordersInitial, 1 mg BID, then 2 mg BID on the 2nd day, 3 mg BID on the 3rd day,as tolerated dose of 3 mg BID. Dosage rang : 4 to 16 mg/day
1.ļ{g:
H:@}l2-3 mg qd; max. 6 mg/day.
ൣMC֦~10-17:initially 0.5 mg qd, increased by 0.5-1 mg/day to 2.5 mg/day.
 2.ļP۳g:
5MC֦~, @}l 0.25 mg/day (< 20 kg) or 0.5 mg/day (  20 kg), may increase dose to 0.5 mg/day (< 20 kg) or 1 mg/day (  20 kg) after  4 days,q:f 14 days.
 3.믫g:
H, @}l, 1-2 mg/day; increased by 1-2 mg/day to target dose, q:4-8 mg/day; adolescents 13-17 yrs., initially 0.5 mg qd, increased by 0.5-1 mg/day to 3 mg/day."	󥻫~\-_@ΡAiಣͪߩʧCAb̪쾯qվSO`NC~pߨϥΩŦޯefw(pŦIܡBߦٱBǾɲ`BBen֩θޯef)Cè(Ϊkζq)椧ĳvվ㾯qCpC{HҼ{CqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	иm30JHUBAץJs	Risperidone	N05A	ܺ믫f ANTIPSYCHOTICS	0	믫ggAʯewļgo@CvgfHYʡAκ믫gg	wRISPERDALΨ@LӤfHT	"ݺΡBYhBi, fBKBuҽkBƧxB߱, ʥ\ê, c, gWh"	Ĥ C	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.2.2._20230701.pdf"">OI` 1.2.2.2.</a>              "	0	0	OIs 20251124	ORIS3-a	ORIS3-b	ORIS3-c	110.6.16
BC24516100	N06BA09	0	OSTR25	StratteraHard 25mg/cap 		ܩʥǤW(norepinephrine^AlAiܩʪ_ĲeǤWAlǿAW[ĲǤW@	"Children6 years, and < 70 kg : Initial, 0.5 mg/kg/day (at least for 3 days), then increased to 1.2 mg/kg/day. MAX1.4 mg/kg /day or 100 mg/day. Children6 years, and > 70 kg and adult: Initial, 40 mg/day (at least for 3 days),then increased to 80 mg/day. MAX 100 mg/day"	"1.AtomoxetineﲴE,Gi}n.
2.yi"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Atomoxetine	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	`NOʷl/Lʯg(ADHD)	"1. iPMAOIX֪A, MAOIg~i}lϥ(i|W[Ŧr)
2. ĳΩUʫCfw"	Ƥ}BߡBæRBh¡BCBwtBKBfBGd	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.5._20251001.pdf"">OI` 1.3.5.</a>              "	0	0	OIs 20251124	OSTR25-a	OSTR25-b	OSTR25-c	111.8.23
	N06BC01	0	IPEYO1	Peyona  20mg/1ml/amp 		PޥƦ٤μW[߸tvΤ߿Xq	LvA30wCRߪ`gC魫caffeine citrate 20 mg_lq(loading dose)Cj24pɭԡAi10wCRߪ`C魫5 mgqAC24pɤ@C	"1.iĥR߿`PfAFoĥΦ٦ת`gB֤U`gBT`gθĤ`g覡C
2.ԷVΩwGDfyA]i[oaʤpzzC
3.Caffeine Ptheophylline|b餺ഫA]oX֨ϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Caffeine citrate 20mg/ml	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	voʦIlȰC	令LӪ̸TΡC	jˡBļʡB}LB߳չLtB`RߪB`oC	qCaffeine㦳FLrʻPPLʡCoǧ@λPڸsuȨϥεLC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w01-10 j	Ts110.6.16		0	0	OIs 20251124	IPEYO-a	IPEYO-b	IPEYO-c	110.6.16
AC14361209	N07AA01	0	INEOS2	VAGOSTIN 0.5MG1ML/AMP 		"z޳·BLOgB޵j˩ʯewBLOg

"	"Initial parenteral doses are 0.5 to 2 mg

"	 GzDΧB̸TΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Nesotigmine methylsulfate	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	"z޳·BLOgB޵j˩ʯewBLOg

"	"Hypersensitivity to neostigmine methylsulfate, intestinal or urinary tract obstruction, mechanical, peritonitis

"	"Bradycardia, psychosis, restlessness, agitation, anxiety, porphyria, constipation, abdominal distention, fecal impaction, and, when given intrathecally, nausea, vomiting

"	קKϥ	CšGʪܹL঳`ʥF}nFίʥFʪΥƾڡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	INEOS2-a	INEOS2-b	INEOS2-c	110.6.16
B024649100		0	OCHAM	Champix 0.5mg/tab(Varenicline) 		VareniclineO@ؤtjBٵĪAiPjBXAC不jBݨDAiOlҮɪַPA֧ٵҮeͪ_gC	fAAH: 0.5mg C@b13; 0.5mg CGb47; M 1mg CGq8Ѩ12gv	"1.AΡAåH@MtA 
2.AΪi|C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Varenicline	N07B	v}ʯefĪ	0	ٵһU	TΩ糧~LӪ̡C	ߡBYhBvBKBȮBæRκίvêC	קKϥΰDvn	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7161795"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_07-01 [96]_07-03j	Ts114.10/17		0	0	OIs 20251124	OCHAM-a	OCHAM-b	OCHAM-c	114.10/17
B024648100		0	OCHAM1	Champix 1mg/tab(Varenicline) 		VareniclineO@ؤtjBٵĪAiPjBXAC不jBݨDAiOlҮɪַPA֧ٵҮeͪ_gC	fAAH: 0.5mg C@b13; 0.5mg CGb47; M 1mg CGq8Ѩ12gv	"1.AΡAåH@MtA 
2.AΪi|C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Varenicline	N07B	v}ʯefĪ	0	ٵһU	TΩ糧~LӪ̡C	ߡBYhBvBKBȮBæRκίvê	קKϥΰDvn	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7161795"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_06-06 j	Ts114.10/17		0	0	OIs 20251124	OCHAM1-a	OCHAM1-b	OCHAM1-c	114.10/17
AC36008100	N07AA02	0	OMEST	Mestinon 60mg/tab(Pyridostigmine) 		~ifʪxP୧C	"1-3 tablets 2-4 times daily
C24AC13C"	fHwݩεj˩ʮުɡAϥΥ~nSOԷVC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Pyridostigmine	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	gٵLO(Myasthenia gravis)	"Hypersensitivity to pyridostigmine or any component of the formulation, GI or GU obstruction"	ߡBæRBmBYC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OMEST-a	OMEST-b	OMEST-c	110.6.16
A0386463EH		0	ENIC15	Smokfree Nicotinell TDDS 15 		UٵҡC	"Cl20HW: 1-2g  ( 15C1) A3-6g (15C1) A7-8g(10C1)
Cl19HU: 1-2g  ( 15C1) A3-6g (10C1) A7-8g( 5C1)
"	"1.ϥΧī~n~C
2.~ά~ɤμUC
3.ϥήɰҡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Nicotine 	N07B	v}ʯefĪ	0	UٵҡC	nicotineζKLӯfH	`oֽͥ~ΨhPƧ@ΡAbuɶAgΥiC	yϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[M]_M01-02j	Ts110.6.16		0	0	OIs 20251124	ENIC15-a	ENIC15-b	ENIC15-c	110.6.16
AC217671G0	N07CA	0	OCEPH	Diphenidol 50mg/tab(Diphenidol) 		]ջêް_tw]]A޻êYV~˫gtw^Bg	q`HC12A@TfAϥΡA̦~֡BgiAyW C	iPts뤧ƨ֥ΡFAīiݺΡAp߶^ˡF	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Diphenidol	N07C	ܯtw ANTIVERTIGO PREPARATIONS	0	]ջêް_tw]]A޻êYV~˫gtw^Bg	ĪLӤfHεǾ঳׻ٮ`̤yϥΡC	wtPBıҽkBΡC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OCEPH-a	OCEPH-b	OCEPH-c	110.6.16
AC20964329	P03AB02	0	ESCAB	Scabi cream 10mg/gm;10gm/tube 		νHBBYΨΧZPV	NwBHŤ~bAAH~AqwAg8-12pɫi~hCȻݨϥΣAYiġC	iXAƨϥΩάOLindane ϥήɶA|ywo@Φ`	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Gamma-BHC	P03A	"~ξ ECTOPARASITICIDES, INCL. SCABICIDES"	0	νHBBYΨΧZPV	"Hypersensitivity, premature infants, seizure"	ֽEC	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ESCAB-a	ESCAB-b	ESCAB-c	110.6.16
BC21905100	N07XX02	0	ORILU	Rilutek F.C. 50mg/tab 		(1)ﾢiĪ㦳@ΡC(2)q̿૬ulqDhƧ@ΡAM(3)zZgǾɪPĩiı餧XC	C12pɤfA1(50mg)Abe1pɩζ2pɪAΡAqW[wĬ۹[jAϦӡAƧ@η|YC	"1. ΩX֯gfHGΩX֦x/εǥ\णfHfVCSObΩRILUTEKͨxŦˮ`Ӫ{XxŦï@פɰxfHfVFxŦˮ`糧~N§@ΪvTC
2. ΩѦ~fHfVA]Lxεǥ\i]ѤƦܮtCt~kʩM饻HѩM~N¯OikʩMպؤHCAGϥΥ~ɤ]fVC
3. ifH󱵨~vpGo͵oN{HYVviC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Riluzole	N07X	䥦gtΥ OTHER NERVOUS SYSTEM DRUGS	0	"(1)AΩvٵY谼wƯg(amyotrophic latcral sclcrosis, ALS)fHAisɶ/ήޤ}ɶC(2)uٵY谼wƯgv(amyotrophic latcral sclcrosis, ALS)f]Mfz@ΥAwgoiXhذC䤤@ذOGBʯgѩǦ]Ҧ]ܯܮzAӨi(glutamate)}aCYǮaکALSfҤAo{Lƪ[?(superoxide dismutase)ʳC
ٵYHwƯg]AMYOTROPHIC LATERALSCLEROSISAALS^C"	TΩriluzoleΥ@ئYLӤfvfHC	IzBߡBtwBͥ\zAUgAhAͪAæRAAvASGPTW@C	iϥ	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.1._20230701.pdf"">OI` 1.6.1.</a>              "	0	0	OIs 20251124	ORILU-a	ORILU-b	ORILU-c	110.6.16
AC06827100	R03DA05	0	OAMIN	Aminophylline 100mg/tab		"LPOvʧPhosphodiesteraseAïiHCyclic 3',5'-adenosine monophosphate(Cyclic AMP)C 
1. ܵj˧@ΡAminophylline ѦTheophylline |PxDƦ١AѰxhC
2. Xi@ΡTheophylline P޻PͦުƦ١AѰ޵j˨åBW[ytPͬqC
3. Ŧħ@ΡAminophylline ߦ٦Wj٦צYOĪGABuеW[YvĪGCŦ@ΤȬObPhosphodiesterase PӭMCyclic AMP qW[ӥB٥]AӭMtbC 
4. Q@ΡAminophylline ͧQ@ΤDOѩ󥦹ŦGʤOǻPǤpުAl@ΡAiW[ŦGXAåBXiǥXPǤJŦǤpʯߡAɭPǤpyLotv(GFR)PŦyqW[C]ulPlb񰼵ǤpުAlC"	"@릨HqG
XiкCʪvGfAA쾯qGC魫۷LAminophylline 18.7mgAΨC467mg(ξqC)A4 AΡFY@AiCj2~3 ѼW[q25%AiFCѨC魫15.2mg ΨC1.1g(ξqC)̤jqŶ˴M@סC
@ൣqG
XiЦP@릨HqGY@iCj2~3 ѼW[q25%AŶ˴M@סAiFCѳ̤jqpUG 9 HUC魫28.2mgA9 ~12 C魫23.5mgA12 ~16 C魫21.2mgC16 HWC魫15.2mgAΨC1.1g(ξqC)C"	"1. UCfHfʵSOnGުή~fHbϥΥīeθgL@qvɶͥ\˴HMwO_~ġCʪ[jvλݭnvqɡAMTheophylline @˴HTwAqC
2. Aοɳ̦nŸ(e30 1 pɩζ2 p)AUH[tlAib\ζߨAΡAH֭GzDEC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	x󳱲D(15~30J)ץBĵoBҡC	Aminophylline	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	ݤΤ޵j/ߦ]ʤޮݤΤ޵j	"Hypersensitivity to theophylline, ethylenediamine, or to any product component"	֯lBC¯lBYhBߡC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OAMIN-a	OAMIN-b	OAMIN-c	110.6.16
AC44620421	R01AX30	0	EENTO	ENT NASAL OINTMENT 5gm/TUBE 		0	0	0	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC		R01A	hRs DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	0	0	0	0	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	EENTO-a	EENTO-b	EENTO-c	110.6.16
A036094157	R05CA03	0	LRUBI	Guaphen 20mg/ml/120ml/btl(Guaifenesin) 		"ط

"	"AdultX 10-20 ml QID, MAX 2400 mg/day.
Pediatric : <2 yrs X1.25-2.5 ml Q4H, MAX 300 mg/day; 2-6 yrs X 2.5 -5 ml Q4H, MAX 600 mg/day; 6-12 yrsX 5-10 ml Q4H, MAX 1200 mg/ day; >12 yrs Xsame as adult.

"	" .UCΪ̡AФŨϥΡG
 (1)]Ħް_LӪHC
 (2)fଧgHA]ħtڲ
(Aspartame)ξC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Guaifenesin	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	"ط

"	"Hypersensitivity to guaifenesin or component of the foumulation.

"	"Hypersensitivity to guaifenesin or component of the foumulation.

"	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LRUBI-a	LRUBI-b	LRUBI-c	110.6.16
BC23480127	R03AK06	0	ESERE	SERETIDE 50 evohaler 		"AΩifʩIlDef(ROAD)`WvA]AAXϥΤXiΥֽTJզXkൣPHCoi]AbϥΪĤA@ξ(]-agonist)ΧlJֽTJĺqw̡CblJֽTJkAӤgw̡CXi`WvAӻݭnlJֽTJw̡C

"	"2 puff BID

"	"should not be used for transferring patients from systemic corticosteroid therapy

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluticasone and Salmeterol	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	"AΩifʩIlDef(ROAD)`WvA]AAXϥΤXiΥֽTJզXkൣPHCoi]AbϥΪĤA@ξ(]-agonist)ΧlJֽTJĺqw̡CblJֽTJkAӤgw̡CXi`WvAӻݭnlJֽTJw̡C

"	"Hypersensitivity to any component of this product

"	"Headache, hoarseness, oral candidiasis, tachycardia, throat irritation

"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ESERE-a	ESERE-b	ESERE-c	110.6.16
BC25282443	R03AC18	0	EONBR	Onbrez Breezhaler 150mcg/dose(Indacatero 		"Indacaterol OWĪAGPgAi@ѵĤ@C]2 ǤW@ξĲz@ΡA]AindacaterolAܤֳOk]EӭM@ضʤƻïadenyl cyclaseA adenosine triphosphate (ATP) Ʀcyclic-3, 5-adenosine monophosphate (cyclic monophosphate)CW[cyclic AMP @׷|ϤޥƦPC"	ĳq@Ѥ@150 LJnAϥOnbrez Breezhaler lJlJnī~C	CsB觡[@Onbrez BreezhalerlJClJϥ30ѫC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Indacaterol maleate	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	CʪʪͯevC	DBſ}ΨLξLӪ̡C	|By¡BWIlDPVMYhC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	EONBR-a	EONBR-b	EONBR-c	110.6.16
A032323114	R05CB01	0	OFLU1	Flucil 100mg/2.5g/pk(Acetylcysteine) 		Acetylcysteine lSulfhydryl group iNHGdisulfide 쥴}A]ӭCHסAW[䷻ѫפάyʩʡAϩƥXC	"Mucolytic, AdultXPO,granules, 100- 200mg TID; effervescent tablet, 600mg QN-BID.
ChildrenX 10-20 mg/kg/day in 3-4 divided doses.
C1]A@A 3"	~ǳ\O`	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Acetylcysteine	R05C	"𾯦y§ EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"	0	֩IlD߽c߸YʡC	"UCpĳۦϥΡG
1.(ީ)ݤΦ񦳩Il\णfHC
2.̡֪C"	ߡBæRAolLӤA޵j	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OFLU1-a	OFLU1-b	OFLU1-c	110.6.16
AB57991100	R05DB01	0	OBENS1	Bensau 200mg/cap(Benzonatate) 		Ѱy¯g	"HCTAC1ɡAC̤jq600mg.
(1) HGC3AC100-200 mgC
(2) ൣG[>10] C3AC100-200 mgC"	о]AAiCZAHKͧ¾KӦPC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Benzonatate	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	Ѱy¯g	"Hypersensitivity, children"	ߡBzGABKBYhBwtC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
AC05865100	R05DA04	0	OCODE1	!!Codeine 30mg/tab 		"1.y@ΡGCĥiݦ]PܰئP˥i褧y¤ϡC
2.h@ΡGCĥiݦ]㤤ϩh@ΡC
3.m@ΡGCĥiݦ]jĤm@ΡC"	"1. ~ΩൣAȭ{ɮįqjIɨϥΡC
2. fAC@q 1530mgC"	ݯvBtw{HAAδpݱqƾާ@TBͩվMIʤu@̡ASOpߡC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUץJsC 	Codeine	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	"yBhC 
"	ൣ縢θNhBwCYP2D6ֳtĪNª̤έŰkC	sϥδptqΰġAi޵oBQBy\BߡBæRBYhBvB_ŸB٦`hBIl止_gC 	C 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.5.06		0	0	OIs 20251124	OCODE1-a	OCODE1-b	OCODE1-c	110.5.06
AC21678151	R05FA02	0	LCODI	Codin-P syrup (60ml/bt) 		yB׶	ĳ@3AHC10ccA12-15C6cc	"UCΪ̡AФŨϥΡG
(1) ]Ħް_LӪHC
(2) 㦳CYP2D6WŧֳtĪN»ïH(ultra-rapid metabolizers)C
(3) ŰC
(4) 12C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Codeine/Methylephedrine/Chlorpheniramine	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	B1HU12AĳϥΡC212ൣqϥΡC	ݺΡBfBwt	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	LCODI-a	LCODI-b	LCODI-c	110.6.16
AC217581G0	R05FA01	0	OMEDA	Medicon-A cap(Ƥ) 		"Dextromethorphan HBr@ΩHy¤ϡAy¤ϮgӲy@ΡC
Potassium Cresolsulfonate}ޤ߸YסAeC
Lysozyme ChlorideHYAeC"	H(15HW)G@3AC1ɡC	AΥAi঳ݺΤΡAФžrpξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Detromethorphan	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	"1.oĪLӯg̡C
2.bϥMAOIvw̡C"	olBoBߡBæRBBtw	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OMEDA-a	OMEDA-b	OMEDA-c	110.6.16
AC42829100	R05FA02	0	OMEDA1	Antholin 		"Dextromethorphan HBr@ΩHy¤ϡAy¤ϮgӲy@ΡC
Potassium Cresolsulfonate}ޤ߸YסAeC
Lysozyme ChlorideHYAeC"	H(15HW)G@3AC1ɡC	AΥAi঳ݺΤΡAФžrpξާ@C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Detromethorphan	R05F	"y§ COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS"	0	yB׶	"1.oĪLӯg̡C
2.bϥMAOIvw̡C"	olBoBߡBæRBBtw	קKϥΰDvn/SmҦw	Safe	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.6.6		0	0	OIs 20251124	OMEDA1-a	OMEDA1-a	OMEDA1-a	111.6.6
AC44807100	R06AE06	"""HF"" ڸ֬30@J"	OOXAM	Oxamide 30mg/tab 		CUؤƾǴC褧XP@ΦӧLӤCi_δzHistamineBSerotonin(5-HT2)BLeukotrienesPPlatelet Aggregation Factor(PAF)CC	"HGC⦸AC30mgC
ĵGC⦸AC0.5mg/kg魫C
魫15-35KgFC2AC15mg (1/2)C
魫35KgHWFC2AC30mg (1)C
YAĤ@P|LﵽAi[AΤWzqC"	a.٦ת`gɺ?קKˤίg´C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Oxatomide	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	@Lӯg(pG᯻BLӡBCl)C	w糧ĹLӪ̸TΡC	ߡBæRBYwB٦׵LOBfC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OOXAM-a	OOXAM-b	OOXAM-c	110.6.16
BC19595426	R07AA30	0	ISURV	SURVANTA 200MG/8ML/VIAL		"ͩʪͳɭʾbIlɭCͪwiOABíwͪwHקKbRɪͶOU򳴡CͳɭʾʥF玲|ͩIl~g]RDS^C
SurvantaɥRɭʾë_oǷsͨ઺ͳʡC"	ȨѮޤϥΡCSurvantaCqX魫(4@/)C絹100mgC׽AԲӰѨ椤SurvantaqCĤkGCӾq|AC1/4qObPծɵCǦpUG(1)YMyVUɱסAYVk(2)YMyVUɱסAYV(3)YMyVWɱסAYVk(4)YMyVWɱסAYVC	̱`}oͦbĪL{Abhq{ɸեΤ쪺Ƨ@άȮɩʤ߸wC(11.9%)B񹡦XqC(9.8%)FLƧ@εoͲv1%A]AޤްjyΪByaաBަYBCBBCΰGƺҦgβC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"}ʤp~Né 2 ~ 8 סCץC
wǳƦnnϥήɤ~Np~ۥ~XCp~Ȩѳ榸ϥΡC@}ʡAΧnC"	Beractant	R07A	LIltΥ OTHER RESPIRATORY SYSTEM PRODUCTS	0	"wMvधIl~g(RESPIRATION DISTRESS SYNDROME)C

wG
X魫C1500JθHܦʥFʾAtPSurvantaA̦nbX15C

v]ϡ^G
vwXT{RDSBݭnIlAtPSurvantaA̦nbX8pɤC"	LwTҡC	̱`}oͦbĪL{Abhq{ɸեΤ쪺Ƨ@άȮɩʤ߸wC(11.9%)B񹡦XqC(9.8%)FLƧ@εoͲv1%A]AޤްjyΪByaաBަYBCBBCΰGƺҦgβC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.1._20240901.pdf"">OI` 6.2.1.</a>              "	0	0	OIs 20251124	ISURV-a	ISURV-b	ISURV-c	110.6.16
AC05812100	R06AE91	0	OHOMO	Homoclomin 10mg/tab(Homochlorcyclizine) 		ܲ´i (antihistamines) b H1-vʫܲ´i@ΡA|}a ´iʩΧXA]|鲣ͤΧЧܭCܲ´i ٦RBoBܤAQxPPR@ΡC	H10~20mg/A3/	קKqƹ}Φ񦳦MIʤާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Homochlorcyclizine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	@LөʵolBBClBֽkogBSʥֽBֽBįlBޮ	BPH	ݺΡBfB«BGzêBLӡC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OHOMO-a	OHOMO-b	OHOMO-c	110.6.16
BC22283421	S02AA16	0	ETARI	TARIVID OTIC5ML 3MG/ML 		"HΤp~ժBHΫC֦~դCʤժB˦yfުpʤժC
"	q`C鵹Ĩ⦸ACN 6 10w Earflu IղGwJդAĤdbզ 10Cq(ϥΦ)hi̾گgHվC	"1. UCw̽ФŨϥΡA糧LӬJҪ̡C
2. UCw̽зVϥΡAYǻêw̡C
3. 便B¨ŰPC(1)hĦwʩ|TwA]ΧYNh̤iPC(2)|ಾܥŤAGPקKšC
4. pĪPA|TwwʡAGpĤŨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Ofloxacin	S02A	ܷPV ANTI-INFECTIVES	0	"HΤp~ժBHΫC֦~դCʤժB˦yfުpʤժC
"	"Hypersensitivity to ofloxacin, other quinolone or any component of formulation.
"	"Skin eruption, pruritus, rash, eczema, taste sense altered"	iw/SmҦw	DnקKϥ/Smܦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669294?cesid=7cLlYRHeIbR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOfloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DOfloxacin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=12.3._19990801_000.pdf"">OI` 12.3.</a>              "	0	0	OIs 20251124	ETARI-a	ETARI-b	ETARI-c	110.6.16
		0	OSUNV1	Sunvepra 100mg/cap(Asunaprevir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	EBIA5	Sindine Alcoholic Solution 500ml/~ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
BC18617421	S01CA01	0	PTOBR	Tobradex Oph Suspension 5ml/bt 		ǤWֽTJoAåBi|wˤf¡XC	1-1.5 qIbnAC3 ~ 4 C	ϥ?TJiɭP߷PVAϥΧܥͯhiಣͥ]AߵDPʪߺعL?ͪC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Dexamethasone+Tobramycin	S01C	ܪĩMܷPVĦX ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	0	TJ㦳PʤewC	"1.Wֳ©?l(K?)BkBkγ\h䥦εfrPVF
K߷PVF߷PVC
2.糧󦨥LӪ̡C
3.W?̡C"	Τ Tobramycin ̱`?Ƨ@άO¥oB~ȤεAoǤu֩4%w̷|o͡C	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	PTOBR-a	PTOBR-b	PTOBR-c	110.6.16
B017603335	D11AF	0	EDUOF	Duofilm soln 15ml 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124	DC	DC	DC	
AC48220421	S02CA03	0	ESIPR	պwSiproxan otic drops 5ml/bot 		CIPROXIN HC OTIC(ciprofloxacin hydrochloridehydrocortisoneեaG)tXsħܥͯciprofloxacin HydrochlorideAܵoֽTJhydrocortisoneFΫOsեaGC	"ϥΫeߧYRnC
󥮨(@HW)ΦH,ITwaBGܱw,CѤG,CѡCbϥΥ~ei~l1-2,HקK]NGIJչDɩҥiɭPwtCwUAwմ¤W,MIJGCo˫սк30-60,HUĤzJդ,Yݭn,ЭƤWzBJt@աCbf¡ХѾlĤC"	"w̰pֽlιLӤo:ߨ谱,æVvԸߡCťΩ󲴷CFקKìV~f,Ф~fIĲզ,ΨLaCbv,Х󥼥ΧĤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsǷ25JAŧNAץC	Ciprofloxacin+Hydrocortisone	S02C	Ƥ褤ֽrEMܷPV CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	0	]wߡB⸲yߤΩ_ܧεߵPfҭPHΤ@HWʥ~ժvC	"1. HydrocortisoneBCipofloxacianΥQuinoloneܥͯLӥvw̸T,pw,ŨϥΦDLߤ~C
2. ~չDfrPV,]Akγ©?l,ťΥ~C"	YhηkoC	קKϥΰDvn/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=12.4._20080401_000.pdf"">OI` 12.4.</a>              "	0	0	OIs 20251124	ESIPRO-a	01C48220-1	01C48220-2	110.6.16
KC01041248	V03AB37	0	IPRAX	Praxbind 50mg/ml;50ml/vial;2/ 		Idarucizumab-dabigatranƦXSʬtXѷwCANӽƦX鷥íwCIdarucizumabPdabigatranΨNªijOBM@ʪXAäMܾ@ΡC	"Praxbindĳq5 gC
50 mlˤp~(2 x 2.5 g)躡@㾯qC
㪺5 gqHRߪ`g覡IΡA⦸U5-10s`AάO@`gC"	"Idarucizumab |Pdabigatran oͱM@ʵXAܾ@ΡA|Lܾ徯@ΡC
Praxbind viftW\зǤ䴩ʱIϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"ϥΫeN}ʪOsbǷ(25J)UA]ˤOsקKӡA̪iOs48pɡF
wӥh̪uiOs6pɡC
ī~Ĳ~XAbǷŤUƩʽíwɶ1pɡC"	Idarucizumab	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	"Praxbindݩ@رM@ʪdabigatran@ξAAΩ󱵨F (Pradaxa) vBݭnֳtdabigatranܾ@ΪfHGѺN{ǨϥΡC
¯٥ͩRα}XɨϥΡC"	LC	å[줣}C	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IPRAX-a	10C01041-1	10C01041-2	110.6.16
		0	EAQUA	J߹G2% ; 4L/(Chlorhexidine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC43692335	D01AE22	0	EJIAM	Jia Mei cream 10mg/gm;15gm/(Naftifine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC33887343	D07AC06	0	ENERI1	Enfulon cream 1mg/gm(diflucortolone)30gm 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC11917277	V03AC01	0	IDESF	Desferal 500mg/vial(Desferrioxamine) 		~KXAKl(Fe+3)MTl(Al+3)ܱj˩MOAiPXXAѵŦֳtwƥXC	"1. ʤrw1g٪`AۨC4p0.5g@2AMݭnC412pɤ@
2. Rߺw`wqM٪`ۦPAt׬1p15mg/kgC
3. CKtqLhG٪`w10.51gF֤Uw11g2gC`g824pɥHWAiϤ@طLq`(Miniinfusion pump)C"	"1. ~`gƩ󧿤A|ϧGeApYeŦAܦMK@פAٶ~vC
2. ΰqϥΥ~|yC餺KLqAҥHnwˬdťOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Deferoxamine	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	KHۯgBKrBTHۯgC	KB糧ĪΨ᫬LӪ̡C	֯lB`gkhACB߸[tAIl~gAOBťılC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IDESF-a	IDESF-b	IDESF-c	110.6.16
B021073248	L01AA03	0	IALKE	!!Alkeran 50mg/vial (Melphalan) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ELIDC	Lidopin cream 5%;907gm/ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	EMETH1	Acety-B-methylcholine chloride 25Gm/~ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC20936238		0	ICAV	CORVERJECT 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.4.1._19970901_000.pdf"">OI` 2.4.1.</a>              "	0		OIs 20251124				
		0	ERIV	RINAVOL(į) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ESOFT	Softa-Man߲G 1000ml/~(Ethanol 96%) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	ONEPH1	Nephoxil 500mg/cap(Ferric citrate) 		h[׾	Nephoxil qĳd1.5 g/day~6.0 g/dayACTH\\ߧYAΡCvھگfHC@׾AyWqACiW[δ1g(2)C龯qC@׹FؼЭȡAOwʴCݾɧ]AAibC	"ŻPtTs֪A,H\ɧ]A,HUĵ`Nϥ,`TK`{H?YPɵdoxycyclineܤֶj1p"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	FERRIC CITRATE	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	AΩ󱱨GzRv~Cʵǯfw̤Cg	"ŻPtTs֪A,H\ɧ]A,HUĵ`Nϥ,`TK`{H?YPɵdoxycyclineܤֶj1p"	AݵhAʤ~A߰ʹLtC`TKC	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ONEPH1-a	ONEPH1-b	01058595-2	110.6.16
AC42449216	B05DB	0	ICCVA	CVVH SOLUTION A S.T. 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC242122D9	B05XA03	0	ICCVB	SODIUM CHLORIDE INJECTION 0.45% S.T. 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22232277	J05AB06	0	ICYME	*Cymevene 500mg/vial(Ganciclovir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124				
B022297212	B05DB	0	IDIAN	Dianeal low Ca.(2.5MEQ/L) peritoneal dia 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ICETR	*Cetrotide(Cetrorelix) 0.25mg/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC09768221	H02AB	0	IDIPR5	*Diprospan 5ml/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IDPT	INFANRIX 0.5ml(TX@@) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IDYSP1	Dysport inj 500IU/vial(Botulinum toxin t 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000828245	B03XA01	0	IEPRE	Eprex 40000IU/ml (Epoetin alfa) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.1.1._20160901_000.pdf"">OI` 4.1.1.</a>              "	0		OIs 20251124				
		0	IDPT2	DTP VACCINE 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IFEN	:)FENTANYL 0.05MG/ML/10ML/AMP 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000682299	A10AD01	0	IMHI	*MIXTARD HUMAN INSULIN 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	0		OIs 20251124				
A034352255	J01AA08	0	IMIRO	*Mirosin 100mg/vial(Minocycline) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.9._20250101.pdf"">OI` 10.8.9.</a>             "	0		OIs 20251124				
KC00878248	B02BD08	0	INOVO7	NovoSeven 50KIU(1.0mg)/vial(eptacog alfa 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.2._20201201.pdf"">OI` 4.2.2.</a>              "	0		OIs 20251124				
BC25360200	S01BA01	0	IOZUR	Ozurdex 0.7mg//дӤJ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.4._20210607.pdf"">OI` 14.9.4.</a>              "	0		OIs 20251124				
AC27456265	B05XA02	0	IROL	ROLIKAN INJECTION 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC46072100	M01AB11	0	OACEM1	*Acemet retard 90mg/cap(Acemetacin) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC47621221	V03AF03	0	ILEUC	Covorin 10mg/ml;5ml/amp 		"īܾѬrA
PТԢ֥ΪvjzzC"	"1.Methotrexate rescue10 mg/m2 IM or IV every 6 hours until methotrexate serum levels are below 5 X 10-8M.
2.Advanced colorectal cancera dose of leucovorin 200 mg/m2 by slow intravenous injection (over 3 minutes) followed by fluorouracil (370 mg/m2) is recommended.
3.Megaloblastic anemiaup to 1 mg IM daily ; for children under 12 : 0.25mg/kg/day.



"	" ~?Av?]ʥFͯB12 ҭP?ʳhΨLyhA]GǤWg?wѲ{H?gHh~i?C
v?W?ϥ?īܾɡA~ib1 pɨϥΡAq`4 pɥHϥήɡAݵLġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" иm 2~8JץxsA?OsC
иmൣ?ΤBC"	Folinate Ca	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	īܾѬrAPТԢ֥ΪvjzzC	"hypersensitivity to leucovorin.
megaloblastic anemias due to vitamin B12 deficiency. pernicious anemias due to vitamin B12 deficiency"	"Diarrhea, nausea,
stomatitis, vomiting, fatigue"	קKϥΰDvn	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_B06-17 j	Ts110.6.16		0	0	OIs 20251124	ILEUC-a	ILEUC-b	ILEUC-c	110.6.16
		0	OCHOL1	*Trilipix1 MR 135mg/cap 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	OMAGN1	Magnesium Ultra direct.(ⷻ) 20/ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	EHIBI	Antigerm solution(HIBISCRUB) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC23920100	J05AF08	0	OHEPA	*Hepasera 10mg/tab(Adefovir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.4._20220901.pdf"">OI` 10.7.4.</a>              "	0		OIs 20251124				
AC46046100	C08CA09	0	OLACI	*Lacipil 4mg/tab(Lacidipine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IADI	AdimFlu-S |0.5ml/()yP 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts111.9.29		0		OIs 20251124				111.9.29
		0	IREPA1 	Repatha 140mg/ml/pen(Evolocumab) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts110.6.16		0	0	OIs 20251124	IREPA1-a	IREPA1-b	IREPA1-c	110.6.16
NC01681209	J01GA01	0	ISTRE1	Streptomycin 1gm/vial(eާO) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124				
		0	IVOL1	Voluma  1ml/(MΦ۶O) 		"`gӤJAΩ^_yWٽAtlidocainikh
iΩ^_Wy´AAɸ`hBdjֽʳAiΩ֤UBWP`hu֪`gA`gޥP`רMv쪺tOAiΩ٦ת`gA]i`gܲP򪺰ϰApW¥ۥWBU¥UϡBϰAoǸӽoϰA"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs2~25	ľAQLidocain			0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
HCVDAA0010		0	OHCV10	"HAR+RIB(1,4,5,6]);12g{ "					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.8._20250601.pdf"">OI` 10.7.8.</a>              "	0	0	OIs 20251124				
A026080100	N05BA08	0	OLEXO	Bromazin 3mg/tab 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
A042534100	N02AA01	0	OMST3	*:)Morphine Sulfate SR 30mg/F.C.tab 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC24094100	J05AE08	0	OREYA1	Reyataz 150mg/cap(Atazanavir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"						2. v͵ֱߩҤް_PVgC					аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	0		OIs 20251124				
AC55909421	S01GA52	0	PDELL	Dellergy eye drop.Ƥ0.5% 5ml/bot 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	EFOLU	Folux foaming sol'n 5%50mg/ml(Minoxild 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
KC00711280		0	IFIL15	FILGRASTIM inj. 150gg/0.6ml/amp 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ECID	CIDEX OPA SOLUTION 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124	ECID-a	ECID-b	ECID-c	
		0	EEND	*ENDOZIME 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000650237	L03AC01	0	IIL2	ĵProleukin(rIL-2) 18MIU/ml(Aldesleukin) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.13._20040801_000.pdf"">OI` 9.13.</a>              "	0		OIs 20251124				
		0	EMETH	Acetyl-]-Methylcholine Chloride+Crystal 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
HCVDAA0016		0	OHCV16	Epclusa+ RIB]1B2B3B4B56A 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.11._20250601.pdf"">OI` 10.7.11.</a>              "	0	0	OIs 20251124				
		0	IAHDF	Allergenic Extract of Standardized Mite 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IAHDP	Allergenic Extract of Standardized Mite 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
X000014238	M03CA01	0	IDAN	DANTROLENE 20MG IV 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0	0	OIs 20251124				
KC00841248	J06BA02	0	IIMU1	Human Immunoglobulin 3g/Vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.1.3._20251001.pdf"">OI` 8.1.3.</a>              "	0		OIs 20251124				
A033445229	L01DB07	0	IMITOX	ĵMitoxantrone 20mg/10ml/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6940824?cesid=35JRW7eVBC2&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMITOMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DMITOMYCIN"">LexidrugľǸƮw</a>"	  		  	ixiij	Ts		0		OIs 20251124				
KC01050238	L01FF05	0	ITEC2	ĵƼfTECENtriq 1200mg/20ml/vial (Atezol 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixii[]_B06-25 j	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.69._20251001.pdf"">OI` 9.69.</a>              "	0	0	OIs 20251124				
		0	IVAR	VARILRIX 0.5ML/AMP(۶Ok) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
YC000022E3	L03AB07	0	IREBI	Rebif 44mcg/syringe (Interferon beta-1a) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.3.1._20230301.pdf"">OI` 8.2.3.1.</a>              "	0		OIs 20251124				
B023479235	S01LA01	0	IVISU	*Visudyne 15mg/vial (Verteporfin) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.2._20250501.pdf"">OI` 14.9.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.9.5._20200201.pdf"">OI` 14.9.2.</a><a href="""">OI` 14.9.5.</a>            "	0		OIs 20251124				
		0	ODAKL1	Daklinza 60mg/tab (Daclatasvir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
HCVDAA0002		0	OHCVD2	VIE + EXV(1B); LxwƩΨNvʨxw 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.6._20180601_000.pdf"">OI` 10.7.6.</a>              "	0	0	OIs 20251124				
HCVDAA0003		0	OHCVD3	VIE + EXV + RIB (1A)Lxw12g{ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.6._20180601_000.pdf"">OI` 10.7.6.</a>              "	0	0	OIs 20251124				
		0	OIBR20	ĵ IbrANCE 100mg/cap(Palbociclib) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	OIBR30	ĵ IBRANCE 125mg/cap(Palbociclib) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
HCVDAA0004		0	OHCVD4	VIE + EXV + RIB (1A)Nvʨxw24g 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.6._20180601_000.pdf"">OI` 10.7.6.</a>              "	0	0	OIs 20251124				
		0	EBIS2	SINDINE SCRUB SOL'N (BETTER IODINES) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	EBOS	Epirenin.solu'(Epinephrine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
BC248423CS	N02AB03	0	EFEN5	ĵ50mcg/h DUROGESIC D-TRANSK(Fentanyl 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			N02A	P OPIOIDS	0	ݭnϥ~sCʯkhMxTʯkh	" wfentanylζKHKLӤfwTϥDUROGESIC?C
"				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669815?cesid=0kLVRFf5PqH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFENTANYL%26t%3Dname%26acs%3Dfalse%26acq%3DFENTANYL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	EFEN5-a	EFEN5-b	EFEN5-c	
		0	ELUG	LUGOL SOLUTION(ƤK̪o) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000584212	V01AA03	0	IAHO10	Allergen house dust ext(1:10) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC13059238	L01DB02	0	IDAUN	ĵDaunoblastina 20mg/vial(Dunorubicin H 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	EXYLS	Lido-anes SPRAY 10%/50ML 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	IESME	ĵEsmeron 50mg/vial(Rocuronium) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC21026229	L01DC03	0	IMITO1	ĵ Mitomycin-C kyowa 10mg/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6940824?cesid=35JRW7eVBC2&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMITOMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DMITOMYCIN"">LexidrugľǸƮw</a>"	  		  	ixiij	Ts		0		OIs 20251124				
		0	IMMR-1	MMR II 0.5ml/vial(۶O̭]) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixii[N]_B04-03 j	Ts		0		OIs 20251124				
BC18876221	L01BA01	0	IMTX5	ĵMethotrexat 100mg/ml;5ml/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC26602100	J05AR08	0	OCOMP	CompleraƤ(TDF+FTC+RPV) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	0		OIs 20251124				
B023074163	R03AC04	0	EBERO1	Berotec N Metered Aerosol 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0		OIs 20251124				
		0	EWAV	WAVICIDE 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	EBIW5	Sindine Solution 500ml/~ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	EACRI	Acrinol solutionĤ500ml/~ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IFIBR1	Fibrin Sealant´״_X2ml/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	EMELQ1	Melquine oint 40mg/gm;10gm/]Hydroquin 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
AC37386343	G03CA03	0	EOEST	Ladiol gel 0.6mg/gm;30gm/(Estradiol) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.1.1._20040501_000.pdf"">OI` 5.3.1.1.</a>              "	0		OIs 20251124				
		0	EHIBI1	Antigerm solution 500ml/~ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
AC28650277	J01DD01	0	ICLAF	CETAX 500MG/VIAL 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0		OIs 20251124				
NC01681209	J01GA01	0	ISTRE	STREPTOMYCIN 1GM/VIAL 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	0	ѦҡuqΥΪkv	"ĳ~|GDeep IM?
tswwʡGtsݥߧYϥ
tsGG3-5 ml WFIBNS
ĳ}@סG-
ۮe}GG-
ĳĳ~|tvG-
`NƶG-"	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0		OIs 20251124				
		0	IXYLE	ĵLidophrine 20ml/vial 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	IFIBR2	Fibrin Sealant(´״_X)4ml/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
AC29833100	P02BA01	0	OKAIC	Kaicide 600mg/tab(Praziquantel) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124	DC	DC	DC	
BC19316109	L01XX	0	OKRES	fKrestin powder 1Gm/] (Kawaratak) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.7._20201001.pdf"">OI` 9.7.</a>              "	0		OIs 20251124				
		0	OPROTO	Protos 2gm/pk (Strontium ranelate) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	EANT	ANTI-A SOLUTION 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
AC23169500	G01AF02	0	ECANV	CLOMAZOLE VAG.TAB 100MG(CLOTRIMAZOLE) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	EEASY1	Disinfection sprayb簮~Q 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
AC44187209	N04AA02	0	IAKIN	BIPIDEN INJECTION 5MG/ML/AMP 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.4._20220301.pdf"">OI` 1.3.4.</a>              "	0		OIs 20251124				
BC21808100	M05BA02	0	OBONE	Bonefos 400mg/cap(Clodronate) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.1._20110101_000.pdf"">OI` 5.5.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.2._20090601_000.pdf"">OI` 5.5.3.2.</a>             "	0		OIs 20251124				
AC481911G0	H03AA01	0	OELTR	Thyroid-S 100mcg/tab (Levothyroxine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
AC05860100	N02AA01	0	OMORP	:)Morphine hydrochloride 10mg/tab 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
BC25473100	J05AE03	0	ORTV	Norvir 100mg/F.Ctab(Ritonavir) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	0		OIs 20251124				
BC24708100	H03AA01	0	OELTR2	Eltroxin 100mcg/tab (Levothyroxine) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
BC26237100	J05AG03	0	OSTOC	EFAMAT 600mg/tab (Efavirenz) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.9._20241201.pdf"">OI` 10.9.</a>              "	0		OIs 20251124				
K000585212		0	IA100	Allergen house dust ext(1:100) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
K000586212		0	IA1000	Allergen house dust ext(1:1000) 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	IFIBR3	Fibrin Sealant ´״_X10ml/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	OCALC1	Calcimed (t) 40/ 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS							аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	EH2O2	3% H2O2() 450ML/BOT 					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0	0	OIs 20251124				
																																		
BB24847297	J01CR02	0	IAUGM1	Curam 1.2gm/vial 		~O@ؼsĩʧܥͯ]amoxycillin^Σ]-QiJ]clavulanic acid^sƦӦƦXsCSwߺصoͧ@ΡC	"~tamoxycillin1000mgMclavulanate 200mg (Curam 1.2g)
IV , H12HWൣX1.2 g IV Q6H-Q8H. 
3Ӥ~12ൣX 30 mg/kg/dose Q6H-Q8H.
0~3ӤX30 mg/kg/dose Q12H-Q8H
ǥ\णG
CrCl(ml/min)10-30G Loading Dose: 1.2g, maintenance 600mg Q12H
CrCl(ml/min)10G  Loading Dose:  1.2g, maintenance 600mg Q24H"	curamvfwx\iX{ܤơAǥ\णwվζq.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ѱts20ϥΡC}Ƿťis4pɡANåi8pɡC	Amoxycillin +Clavulanic acid	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	s@LӪ̸TΩpenicillinn/x\ॢ`fvC	mBߡBæRBC¯lBlC	קKϥΰDvn	קKϥΰDvn	аѦҾqPΪk	"CClr>50      1.2g q6-q8h
CClr 10-30  1.2g q12h
CClr<10       1.2g q24h
IHD              1.2g q24h"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡG1.??? HWFINS}Ƿ4hrFN8hr
2.???? HLRR}Ƿ3hr
tsGG20 ml WFI
ĳ}@סG--
ۮe}GG100 ml NSBWFIBLRBR 
ĳĳ~|tvGIV:3-4min?
IVF:30-40 min
`NƶG1.󸲵}BE}έһQww
2.iMGsBLJղGB׽žBaminoglycosidesVXϥ"	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.2.1._20210608.pdf"">OI` 10.2.1.</a>             "	0	0	OIs 20251124	DC	DC	DC	110.6.16
B017091435	S01XA20	0	PTEAS	Tear Naturale Oph Soln/15ml (Ƥ覨) 		"1.Ĥi@]\GcթHդް_gC

2.ĤA]tʻEXDuasorbAiP\GXӫPiC

3.ĤDHYʡAibdɶC

4.ī~pξAC"	"Instill 1-2 drops as frequently as required to relieve eye irritation symptoms
  
@12wAݭnɨϥΡC"	"]tBenzalkonium ChlorideAGtnβɽФŨϥΡC
}1ӤAݾlī~C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Duasorb	S01X	L OTHER OPHTHALMOLOGICALS	0	ȮɽwѦ]ߩҤް_`PPEP	]tBenzalkonium ChlorideAGnβɽФŨϥΡC	LCsϥ3ѯgѰɡAΨϥΫᲣͲ@hBOҽkΫoB~BBEPpAХߧYNC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=14.5._20240701.pdf"">OI` 14.5.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.11.05
BC23181100	J01XX08	0	OZYVO	*Zyvox 600mg/tab(Linezolid) 		"1. LinezolidOs@HuXܥͯAݩoxazolidinoneA{ɥγ~DnAΩvݭnʤ󶧩ʵߩҳyPVC~linezolid@ǭ󳱩ʵߩMߦ@ΡCLinezolidǥѤ@ةMLܥͯP@ξӧӵ߳Jս誺XC]linezolidMLܥͯioͥ椬ĩ(cross-resistance)CLinezolid|Pӵ50Sֿ}p(subunit)W23Sֿ}RNAXM\ʪ70S_l_X骺ΦC_XOӵĶ(translation)L{nCھڮɶ-(time-kill)sܡAzy(enterococci)My(staphylococci)ӨAlinezolidO߾(bacteriostatic)Cy(straptococci)jhƪߺئӨAlinezolidO߾(bactericidal)
2. UCߺخĪG΢wݮʩMݩ(Aerobic and facutative)󶧩ʵߡGEnterococcus facium(ȭvancomycinĩʪߺ)A⸲yStaphylococcus aureus(]Amethicillinͧĩʪߺ)AʨyStreptococcus agalactiaeAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AwyStreptococcus pyogenesC
3. ݮʩMݩʭ󶧩ʵߡGTyEnterococcus faecalis(ȭvancomycinĩʪߺ)AEnterococcus facium(ȭvancomycinĩʪߺ)AָyStaphylococcus epidermidis(]Amethicillinͧĩʪߺ)AStreptococcus harmolyticusAͪyStreptococcus pneumoniar(ȭpencillinPʪߺ)AViridans group streptococciC
4. ݮʩMݩʭ󳱩ʵߡGPasteurella multocidamC"	"~sĳϥζqC侯qOHC12pɧP@覡PC
1. Vancomycin-ĩʪEnterococcus faeciumPVA]AֵoߦgfҡG600mgRߪ`gAΤfAC12pɤ@As1428ѡC
2. |PVͪBֽMֽ´PVBϷPVͪA]AֵoߦߪfҡG600mgRߪ`gAΤfAC12pɤ@As1014ѡC
3. DֽMֽ´PVG400mgRߪ`gAΤfAC12pɤ@As1014ѡC
4. ~]iNC龯q}ӪA(pGWAĤ@AߤWAĤ@)C"	"1. ϥΧܥͯ|PϫDPʲӵߪLץͪCvL{pGX{ƷPV(superinfection)ɡAӱĨAIC
2. linezolidw̴oͦpO֯giC󦳥XʦMIfwBepO֯gfwBPɨ֥η|֦pOƥةΥ\धĪfwΨlinezolidvݶWL2PfwAʴpOƥءC
3. ~iPΪŸɪAΡC
4. pGfwfvAivC
5. AΥ~ɡAקKΤjqttyraminetqζơCC\tyraminetqC100mgCttyraminetq]AǥѦѤơBoáBMηtHW[DkҲͪܩʳJսC
6. pGAΧtpsudoephedrine HCLphenylpropanolamine HCLī~pP_ĩΥh몺ĪɡAiDvC
7. pGAserotonin re-uptakeΨLܼ~{ɡAiDvC
8. xsG1530JUץOsA`gnUwBCĳbϥΫen}`gnU~]ˡF`gGieAHxsɶW[C|[`AvTĻC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Linezolid	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	AΩvѤUCPʵߺطPVfwGVANCOMYCINЧĩʪENTEROCOCCUS FAECIUMPVA]AֵoߦgfҡCf|PVͪASTAPHYLOCOCCUS AUREUSSTREPTOCOCCUS PNEUMONIAEҤް_CֽMֽ´PVASTAPHYLOCOCCUS AUREUSASTREPTOCOCCUS PYOGEC	linezolidβ~LLӪ̸TΡC	`2%̡GmBYhBߡBæRBvBKB֯lBYBoNF̡G]߯fBBƤ}BhBkoMYܦC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.3._20210607.pdf"">OI` 10.8.3.</a>             "	0	0	OIs 20251124	DC	DC	DC	110.6.16
BC12640221	V03AB14	0	IPROT	PROTAMINE SULPHATE 10mg/ml;5ml/amp 		MLqHeparin	"1 mg IV for every 100 units of heparin remaining in the patient; doses of 50 mg should not be exceeded within a 10-minute period to decrease the risk of adverse effects; the dose is usually administered by IV bolus over 1 to 3 minutes, but a constant infusion over 30 minutes may also be given."	Too-rapid administration may cause severe hypotensive and anaphylactoid reactions	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 жJsb1530JC	Protamine sulphate	V03A	䥦Uتvī~ ALL OTHER THERAPEUTIC PRODUCTS	0	MLqHeparin	Hypersensitivity to protamine or any component of the formulation	"Hypotension, bradycardia, flushing and a feeling of warmth"	iw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w03-14 [E]_G3-10 j	Ts110.6.16		0	0	OIs 20251124	IPROT-a	IPROT-b	IPROT-c	110.6.16
AC39239100	M09AB	0	OBROE	Broen-C Enteric F.C.tab 20000U/20mg (Bromelain/L-Cysteine) 		"1. 㦳jOܪĪG:߸gfPѸzާlAtaϤʪPlasminogenܦFibrinѪPlasmin,Gi]FibrinnEҲͪG`ٔ¦Ӥް_B~B~ȡBkhεo{HAt@譱ϦMProtease]lAH
ProteaseL׬ʡA]PolypeptidenEҤް_g{HC
2. vTGTɶ:߹ް_gFibrin㦳ܩʪѮĪGAӹGTҥFibrinogenS@ΡAGvTGTɶC
3. aӭMAPi´s͡AYuvɶ:NaӭMѦӲbƯf_ܩʪAϲOڲGAlAƲӭMN§@ΡAGiU´s͡APiv¡tסC
4. 㦳Τw@:@Kߤc跻ѡAêwơAϷeإXAy¡AﵽͳAèweƥXC
5. |ް_Lӯg:YgfPAGPް_GBTBUBIlxƧ@ΡC
6. A²KAwPqWeABGѦӼvTĮġC"	13~6A3~4^AA̦~֤ίgWC	"1.JƾxšAgxBǾٔ©ΦGTणɡAiϥΥC 
2.񦳷PVg̩y֥ξAܥͯΤƾkC 
3.y]AAiZHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЩǷ25JHUDBJsC	"
Bromelain 20,000 Units
L-Cysteine 20 mg"	B06A	䥦Gǥ OTHER HEMATOLOGICAL AGENTS	0	NΥ~˫~ȤwѡBƻĪBũ{nBIlewHطإXxBޤ¾KᤧطإXxB	"ƾx, YxBǥ\ण, GTण"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	OBROE-a	OBROE-b	OBROE-c	110.6.16
BC13159209	G02AB01	0	IMETH	Methergin 0.2mg/ml/amp(N)		MetherginO@ؤѵMͪsP(ergometrine)bXlͪAO@رjOBM@ʪlcYC@ΩlcƦ١AüW[`ߩʦY򩳱iOBWvαjסCҰsPjOBܩʪ@ΡAOѩM@ʪ@μҦAҰsPOMBhialpha-ǤW骺@ξΫܾC	"1. fAw0.2mgC34A̦hu൹1ӬPC
2. IMAIVwbeӥXӫALLƥXβAP0.2mgCpGݭnܡAb۹j24pɡAiƤ@C"	"1. ~iҦIV`gAӥBnYKʵfHC
2. ѦgAʦޯefAMxŦ\ॢ`AAΥ~ypߡC
3. pG~GCܡAiϥΡA~nJæbNtBAӥBPץ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC	Methylergometrine	G02A	lcY UTEROTONICS	0	lcX	AhrgC	ߡBæRBBtwBջBoB߱BݵhBIlPC	hTϥΡA㦳jOlcY@ΡC	iyťĤc֡AĳŴϥΡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IMETH-a	IMETH-b	IMETH-c	110.6.16
A029917100	A03AX13	0	OGASC	Kascoal 50mg/tab(Dimethylpolysiloxane)		ĩGzǥѭCwiOAӨϭӮIGzHWw]iOܡAiӯ}AéHЩαƮ覡NƥX~C	"1.134AλݭnɪAΡC 
2.HC1A 3HW (t)AAΦHqC 
3.3HUAЬvEvAyۦϥΡC"	1.קKκһĶơBήeyȪ2.X{ߵ{H	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Dimethylpolysiloxane	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	ѰȮBwѮȬg	糧Ĳ͹LӤw̸TΥġC	nKBGַPBUgBhBæRBîBGPέ{HC	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
BC21439212	C01EB10	0	IADEN	ĵADENOCOR 6MG/2ML/VIAL		v}oʤW߫Ǥ߷iLtBUE_QRSiܼeܯʤW߫Ǥ߷iLt	"쾯qGֳtRߪ`g 3mg(WL 2 )C
ĤGqGp쾯qLkb 1-2 ưW߫Ǥ߷iLtAhAֳtRߪ`g 6mgC
ĤTqGpĤGqLkb 1-2 ưW߫Ǥ߷iLtAhAֳtRߪ`g 12mgC
W[Ϊ`g󰪪qhĳC"	" 1.C~ 2ml  0.9% w/v Lߪ`gΥͲzQ

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ĤnNáC	Adenosine  6mg 	C01E	䥦vŦf OTHER CARDIAC PREPARATIONS	0	v}oʤW߫Ǥ߷iLtBUE_QRSiܼeܯʤW߫Ǥ߷iLt	"fuеxԸsBĤGβĤTũЫǶǾɪ_(DfwHu`߾㦳\)C
E Cʪʪͯf (ҦpGݱw)C
E QT gԸsC
E YCF߰IܥNvqC
E  Adenosine LӪ̡C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w06-02 [w]_w08-04 [E]_D2-01 j	Ts110.6.16		0	0	OIs 20251124	IADEN-a	IADEN-b	IADEN-c	110.6.16
BC25427100	M04AA03	0	OFEBU	Feburic 80mg/tab(Febuxostat)		FeburicO@ضIƞJAiCMĹFv@ΡCbv@׮ɤ|ѻPbIBG䪺XPN¹L{Lï@ΡC	"1.vhw̪ĦgAFeburicĳqO40mg80mgCѤ@Cĳ_lqO40mgCѤ@Cϥ40mgGgMĿ@(sUA)C6mg/dLw̡AĳϥFeburic 80mgC
2.~FѯgԸsGFEBURICĳqO80mgCѤ@C
FEBURICbӭMrĪv}leGѶ}lġAåB~ĳ̤7ѡFMӮھڤ{ɧP_Avi9ѡC
AFeburicLU{ΨľϥΡC
hGYǥ\णfH(Clcr 15-29mL/min) Feburic q 40 mg CѤ@ "	"}lϥ Feburic Ag`[ho@W[AoOѩMĿ@׭CAQq´InಾҭPC
Fho@Aĳ}lϥ Feburic ɡAPɵDTJܵo(NSAID)άPwʪv"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	Febuxostat	M04A	ܵhs ANTIGOUT PREPARATIONS	0	"vCʵhw̪ĦgCĳΩLgĦg̡C
Ω]G~FAo͸~FѯgԸs(Tumor Lysis Syndrome)צܰ׭I~fHAHwMvĦgC"	"FebuxostatΥ~ξLӪ̸TΡC
bϥazathioprinemercaptopurinew̸TFeburicC"	x\ಧ`B֯lBߡB`h	קKϥΰDvn	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.11.1._20191201.pdf"">OI` 2.11.1.</a>              "	0	0	OIs 20251124	OFEBU-a	OFEBU-b	OFEBU-c	110.6.16
AC37685100	C10AB04	0	OLOPI	GEMD F.C.600mg/tab(Gemfibrozil)		"GemfibrozilbH餤g´תշѧ@ΡAô֨xŦVתջġAϨxŦTĥ̪oצX֡C]iǥѧ׳JեB (apoliporotein B-aΧCKׯ׳J(VLDL))XAëPiMAiӴVLDLͦC
Gemfibrozil|ɰKׯ׳J(HDL)sHDL2HDL3AHapoliporoteins AIAIICʪXgemfibrozil|W[xTJqxŦưΦ^(turnover)C"	Cĳq900-1200mgA̰q1500mgCH榸q900mgA\e30AΡCHĳqC1200mgA2A󦭡B\e30AΡC	"1.i|PixTJƪnxĤAӴΦx۪iʡC
2.PHMG CoA֥ήɡAi|oYٯfܡAٷѤΫʵǰIܪMIʤjbįqC
3.Ĩ֥Χܾ徯ɡAܾ徯qݴqAúprothrombin time󥿱`AHXC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JUץxsAmĵLkoBC	Gemfibrozil 600mg	C10A	"׽ո`A LIPID MODIFYING AGENTS, PLAIN"	0	צg	"1.x\णYǥ\णw̡AewsbxnefAιgemfibrozilΨLtLӪ̸TΡC
2.TPUC@֥ΡGsimvastatinBrepaglinideBdasabuvirBselexipagC"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	0	0	OIs 20251124	OLOPI-a	OLOPI-b	OLOPI-c	110.6.16
AC43214345	M02AA07	0	EFOCU	FOCUS GEL 40GM		PiroxicamO@ب㦳hAܪMѼSʪDrܪġCX?]COX-1MCOX-2^|CeC͡AoQ{OhM@Ϊ]C	C@ܼƦAuqũwûJC	ФŶ٩󲴷HBˤf	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Piroxicam	M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	`B`]`hBhƩ`^BʯժBʦ٦װflˤΫʵhB٦׵h~˫ᤧ~Ȥίkh	糧~LӪ̡ATϥΡC	`BEPC	B/D(ĤT)	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.1._20200201.pdf"">OI` 1.1.1.</a>              "	0	0	OIs 20251124	EFOCU-a	EFOCU-b	EFOCU-c	110.6.16
AB20785216	M01AB05	0	IVORE	VOREN 75MG/3ML/AMP		"diclofenacO@ثDTJAܵoBhBΰhNSʡC
wҹ򥻧@ξରeCͦXCbΦoBkhBPoNL{AeCtۥDnC
~礤APH餺ۦP@ת diclofenac potassiumAä|nJզh (proteoglycan) ͦXC"	H@3 mLA@@A~v٦ײ`wC`gAɱ`ﴫkv`g	"1.voͭGX嵥ġC
2.Ѧ~w̤SOp魫Lϥγ̧CľqC
3.iɭPx\ïȤɰGϥΪ̶ʴx\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Diclofenac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	"LkfApU,uϥΩwѵoY]oް_khC"	"1.GzšC
2.w糧~ʦΥξLӪ̡C
3.PLDTJܵoĪ (NSAIDs) @ˡADiclofenac]TΩwUCefw̡GݡAC¯lAHΥѤAQĩΨLeCXïʤĪҤް_ʻ󪢡C"	ߡBæRBABƤ}BƩʼšBXɶBB~{HBYBBx¡BջBBݡB}LC	C/D (30 weeks gestation)	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a>              "	0	0	OIs 20251124	IVORE--a	IVORE-b	IVORE-c	110.6.16
NC08167100	M01AB01	0	OINDO	Indomen 25mg/cap(Indomethacin)		hPLNSAID@ˡA㦳ܪAѼMh@ΡC [?]COX-1MCOX-2^iɭPeCX֡C	"ʵh` 50 mg tidC
jʯWBID-TID 25-50 mgACѳ̤j200mgACq100 mgC 
n75-150 mg /ѡA3-4AΡA̦h7-14ѡC 
` 25-50 mgC⦸A̰200 mg /ѡA100 mg /qC 
` 25-50 mgC⦸A̰200 mg /ѡA100 mg /qC
ٸx75-150 mg / dayA3-4AΡC
q`H@1ɡA@1~3󶺫ζiAΡAqΪkɤ@1~2A@1ɡAH̹ڻݭnC"	֥ΰsΨLġAŮ|W[C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Indomethacin	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`Bܼ½贵BܧΩ`ggBhBѼHΨLew	"1.糧ĩΡuAQġvLӪ̸TΡC
2.wAspirinݩιLDTJLӤw̡C
3.Ʃʼűw̡C"	ߡBæRBƤ}BUgB򭢩ίkhBKAGzX	B/D(ĤT)	iw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	DC	DC	DC	110.6.16
BC25114100	B01AC04	0	OPLAV	Clopidogrel 75mg/tab		"1. Clopidogrel@jӱM@pOCpObʯߵwƩMeffzǤWtnAϥΧܦpOĪ󵰪ʯߵwƩMʯ߮fvfHAiCBߦٱΨL]ޯfܤް_`oͲvC
2. Clopidogrel@άܩʪpOWADPPADPXApK|gADPCGPIIb/IIIaƦX骺Ƨ@ΡAiӧpOCClopidogrelgLഫ~iͧpO@ΡCFADP~ALiƦpOADPAClopidogrel禳pO@ΡCClopidogrel@ΥDnOܦpOWADPA@άOifA]AZĲClopidogrelpOAb餺ةR|vTC"	"Clopidogrel @ĳqC 75mgA@Ѥ@AiM PɪAΩΤ}AΡC
1.ʫaʯߺXgBDSTqɰߦٱGl-300 mg@A-75 mgACѤ@]֥ΪqǪL75 mg325 mgACѤ@^C
2.ʫaʯߺXgBSTqɰߦٱ:75 mgAC@A֥ΪqǪLC 
3.޷N~BߦٱBPʯߪʯef:75 mgACѤ@C"	YfHܤNvåBƱbNܦpO@ΡANie 7Ѱϥ clopidogrelC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Clopidogrel	B01A	ܦ ANTITHROMBOTIC AGENTS	0	CoͤBߦٱζgʯߦޯefʯߵwƯfHʯߵwƨƥ(pGߦٱBΨL]ޯfܤް_`)o͡CPaspirin֥έCDSTqWɤʫa߯g(íwʤߵhMDQiߦٱ)fHʯ߮ƥCPaspirin֥ΥiΩHvSTqWɤʤߦٱfHC	"1. ī~DΨLDʦLӪ̡C
2. Yx\ण}w̡C
3. bX媺w̦pƩʼũ`X媺w̡C
4. hα¨ŰC"	ˡByB姿BGzDX	B	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.6._20121201_000.pdf"">OI` 2.1.1.6.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.8._20121201_000.pdf"">OI` 2.1.1.8.</a><a href="""">OI` 2.1.7.</a>            "	0	0	OIs 20251124	DC	DC	DC	110.6.16
AC03775100	J01FA01	0	OILOS	Erythromycin 250mg/tab(Erythromycin)		"ͤƾǴܡAerythromycinifߺسJս誺XAӤ|vTֻĪXCwerythromycinMclindamycinBlincomycin chloramphenicol|ܧ@ΡC
ErythromycinǥѻPPӵߪ50Sֿ}馸쵲XAΧJս誺Xӵo@ΡC|vTֻĪXC
@Ωmotilin receptorPizGDįʡC"	"HGfA250-500 mgC6-8pɤ@F MAX 4 g/day.ൣGfA30-50 mg/kg/ѨC6pɤ@C MAX 2 g/day
PiGįʡGPO:250mg-500mg TIDAC;IV:3mg/kg Q8H
"	"1.gv\BYıonBФŦۦ氱ġC
2.ϥΩx\ण}fwC 
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Erythromycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	y߷PVgBy߷PVgBͪy߷PVgBO߷PVgBnʤUiBrΤ@߯Pʵߤް_PVgC 	"ZErythromycinLӪ̸TΡC
Erythromycin?oPterfenadineBastemizoleBcisapridepimozide֥"	ABߩιæR	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.4._20220301.pdf"">OI` 10.4.</a>             "	0	0	OIs 20251124	OILOS-a	OILOS-b	OILOS-c	110.6.16
A039349345	M02AA15	0	EVORG	VOREN-G GEL 10mg/40gm		"1.ĬDTJBDLthA㦳uqhBܪ@ΡCbDTJAĤLPĪbBh譱ġCifaCOX-1MCOX-2?AqӴ֫eCe骺ΦF 㦳ѼAhMܪSʡC
2.Ĭ~ΤܵoΤhsAtD1%ADiclofenac SodiumAPɥīYHS򾯡AiUʦήɵoĮġABϥηPMDoC
3.ħϥήɡADitzJֽAäG֤U´ӯ঳ĦaܫʤκCʤoAGĥiۦawѦ]`ιBʶˮ`ҳy~ȵoίkh{HC
"	khjpөwAXAqwBAϥήɽлJC	ֽ~ΤoAAΨϥΩ󲴷A礣oI󲴷|gH	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Diclofenac	M02A	`M٦׵hs TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0	uϥΥHwѦ]oް_kh	w糧~ʦΥξLӪ̡C	ֽksB`PBoιLөʥֽ	C 	קK	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.1._20200201.pdf"">OI` 1.1.1.</a>              "	0	0	OIs 20251124	EVORG-a	EVORG-b	EVORG-c	110.6.16
			OTAMI	(O)Tamiflu 75mg (Oseltamivir)		"1. ~gi?Ai@ΨyʷP_frC
2. gi(neuraminidase)OyʷP_fr@ӭnJսAPϷsΦfrqJDӭMXAӥBUfrLIlDHӭMC
3. frgiĝ@ΥiHsΦfrqPVӭMXACyPfrC"	"vΡG
1.H@2AC1n(75mg)AsAΤѡFCrC1 1030mL/ minGCqܨC1nAs5ѡC
2.1HWൣĳqG15AC30mgAC2F>15-23AC45mgAC2F>23-40AC60mgAC2F>40AC75mgAC2C
3. UAΡAĪGUnCFϥ~ĵo̤ܳjAfHbgoͫ48pɤAΦġC"	"1. ~iUfH23Ѧ^_`ʤOAܦhiYufHgɶ60%C
2. ~BġAgvBץiAΡAAΫ24pɥi[dvĪGC
3. yʷP_goͫ24pɤAΥĪ̡A40pɤAΪ̮ĪGnAgɶOi2Ѥ1.3ѡC
4. MFDA֭㥻ĥΩyʷP_vPwANѦ~HΦMIڸsC~Tw̭]ءC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Oseltamivir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS		HM1HWൣBC֦~yʷP_wΪvC	oseltamivir phosphateβ~@LӪ̡C 	`G(SæR)BæRBmFGުBhBwtBYhBy¡BvBtwBh¡C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  		  	ixiiE2j	Ts110/9/30		0	0	OIs 20251124	OTAMI-a	OTAMI-b	OTAMI-c	110/9/30
		0	XAUMI	 Auxmin PET/CT scanӥl_hyyv					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Fluciclovine (18F)				l_hy (PET) yvAAΩev]夤@Sܭ(PSA) @פWɦh@_okʡAHUE_@_oC					аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	XNEURA	 NeuraCeq (florbetaben F18 injection)ߴ`g					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		F18-Florbetaben				ߴ`g@l_hyyvvAHp]˳Jկg(]-amyloid neuritic plaque)KסA{\êHw̥bqg(Alzheimers Disease)ΨLɭP{C]ɨϥΡC					аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC17214112	R03AC03	0	EBRIC	BRICANYL SOLN FOR NEBULIZER 		TerbutalineO@ؿܩʵǤWbeta 2PEA@ήɰwަ٦סAbeta 2EνwޥƦ١AiwHGBeAPɥiiH֤򪺲MΦPt٦תwѡC	"InhalationGbody weight20kg5 mg is inhaled up to 4 times in a 24 hour period; body weight20kg2.5 mg is inhaled up to 4 times in a 24 hour period.
C@@q 5mg/2mlA@ϥΥ|AY@澯qβAisQJsѡA24pɤwwiϥΡC"	PgiLӪԷVϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Terbutaline	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	ޮݡBުΪͮ~ҦH޵jˤw	߷iLtH߫ߤC	ŸBjˡB߱	iw/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	110.6.16
BC11315100	N06CA02	0	ODEAN	Deanxit Dragees(Flupentixol+melitracen)		"1.flupentixolO㦳gw믫ww,pq,iܧ{ѵJ{
2.MelitracenO@بⷥʺ믫ww,Cq,믫ᬡ@"	C2C@AMȪAΡApfᾯqiW2ɡC	Aī~קKܰs	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Flupentixol/Melitracen	N06C	wwĩM믫ĪƤ PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0	J{gB~{g	"1.ʰsARAhĩpsychopharmaceuticalr
2.ĸk
3.C
4.eCF
5.y\ê"	vBuҽkBƧxBf	קKϥΰDvn/קKϥ/SmҦw/|qLť	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ODEAN-a	ODEAN-b	ODEAN-c	110.6.16
																																		
		Uk̭]JYNNEOS (e޸pO)	IMPV	Uk̭]JYNNEOS֤		ѪUk̭] (JYNNEOS?) OϥήzƬkfrsyA|ް_ѪBUkΥLǬVfC	"@BSew(PrEP)G
(@) kfrݤǾާ@HC 
(G) PTEUkӮ״ΦʱĲIĲ̡AعLSw(PEP)̭]C
(T)  6 Ӥ뤺Iʦ欰̡AҦpGhʦQBʥAȪ̡B~ҵoͩʦ欰̡Bʯfw̵C 
(|) UUkTEӮפ@PMHAHΨUæUkӮ˩ΰUk̭]ا@~HC
(a)֤UءA2 AC0.5mLA2 jܤֹF4 gHW;(b)֤*A2 AC0.1mLA2 jܤֹF4 g
HW;C~̭](0.5mL)Ai3-4 HϥΡC
GBSw(PEP)G
b̫@S 4 ѤtءAHF̨ιwĪGCwX{UkgAhĳءC
(@) ֤UءA2 AC0.5mLA2 jܤֹF4 gHWC
TB2 ؤ覡iۦPؤ覡(ҦpG1 YH֤ءA2i֤ءAiĥ֤Υ֤U)C
JYNNEOS? q`H@tC۹j 4 g 2 `gCYLhعLѪ̭]Aiuݭn
1 CYSѪBUkΨLkfrIAĳC 2  10 ~@l[q

ĳةWuTٳ"	"18 ڸsAΨɨ~fv̡AYK̤**AAΥ֤`gAĥ֤U
YK̡̤A]AGߴαΪR(HIV)PV(HIV PVB
CD4<200 cells /mm3)BզfBOڽFBʴcʸ~FBBxӡF
ϥJƾ(alkylating agents)BܥN(antimetabolites)B~Fa]l
5
sΰqֽTJvFyFӭMӱ̦bӳN 24 Ӥ뤺AγN24 ӤHWwӪܱJDfίef_oFK̯efX֧K̯ʳC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"2-8J12 pɡA@}ʡAb8 pɤѱءApϥΧh
"	"0.5 x 108 IU 3.95x 108 IU Dƻsg׹kfr(non-replicating, live Modified Vaccinia Virus Ankara - BavarianNordic) "	J07B	fr̭] VIRAL VACCINES	0	"wUk
JYNNEOS? Ωw~ 18 㦳פѪεUkPVIHAHwѪMUkC"	̭]LӪ	"kh(85%)Bo(61%)B~(52%)Bw(45%)Mko(43%)
٦ׯkh(43%)BYh(35%)Bh(30%)B(17%)BoN(10%)"	" קKϥΰDvn/SmҦwD
YhP k]¾~ΰISݱصUk̭]ɡAĳPvQ׵AMwO_ءC"	" קKϥΰDvn/SmҦwD
YhP k]¾~ΰISݱصUk̭]ɡAĳPvQ׵AMwO_ءC"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts112.5.16		0	0	OIs 20251124	IMPV-a	IMPV-b	IMPV-c	112.5.16
AC42244100	C10AB04	"""j""{]ᥬ^"	OLOPI1	Gembril F.C 600mg/tab(Gemfibrozil)			600mg BID AC 30min		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[ws]_w03-05 [s]_143 [®]_143 [E]_A2-13 j	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.6.1._20210329.pdf"">OI` 2.6.1.</a>              "	0	0	OIs 20251124				
		0	XMULT	ĵMultiHance inj. 0.5M/15ml/vial(Gadoben		"bxŦE_MultiHance bT1 [vѥ`´ӭMjӫTK״ɡCϥ0.05 0.10 mmol/kgqiTK״ɦb̰ܤ2pɡCbT1 [vʺAvΪ`(2-3)NiߧYݨxŦf_P`´C]LSwf_Wjb㹳ɶIj״NzCMӦbϥΥ~40120 AMultiHance qf_´vN±ưHΥ`´Hj׼WjɭPWjf_˥XHιf_mC˴֭ȡC
qxfwi楻~PLvA(ҦpIJʤNWi q_h޳yvθgʯߪ`gKƪo׹q_hv )Phase IIMPhase IIIϯéʸ礤,~WjϮyv˹󦳨xಾcưhäfHAӷPץ95%AӱM@ʥ80%C"	"1.x ŦϮyv H魫 MultiHance ĳ ϥ qO 0.05mmol/kg ۷ C魫 Rߪ`g~ 0.5(M) G 0.1ml C
2.MϮyv H  jⷳൣ 魫 MultiHance ĳϥξqO0. 1 mmol/kg ۷ C魫 Rߪ`g~ 0 .5( G 0.2ml C
3.޺Ϯyv : H魫 MultiHance ĳϥξqO 0. 1 mmol/kg ۷ C魫 Rߪ`g~ 0.5(M) G 0.2ml C
4. ũкϮyv H魫 MultiHance ĳϥξqO 0.1mmol/kg A۷C魫Rߪ`g~ 0.5(M) G 0.2ml C
5. ~ ϥΫe Hw  ߧYϥΡA i} C  Χ v ߧY åBoϥΩU@ˬd C
6. C~q ޥ~|ܳn´ b MI  T{wYYְwO_Ta  Jޤ OܭnC
7. xŦ B ME_ ~ i H R Ϊ` ΥH C 10 @ R `覡 wC  C
8. ޺Ϯyv : ~ i HR Ϊ`覡 ΨϥΤ B ۰ʪ`gtε C
9. ~`g A`ͲzQ C"	"ǥ\ê
Ҧfwb~eǥ\C
׵ǥ\êBʩκCYǥ\ê ٻ  MvC 30 @  /1.73 褽 w̩άO ]xǺXxΨxӤNYʵǥ\णw̧뤩tGadoliniumviް_ǥͩʤֺf(Nephrogenic SystemicFibrosis or Nephrogenic Fibrosing Dermopathy, NSF/NFD)ADE_iOnӥBLkzqLL覡oA_hקKϥΥ~C
ϥ MultiHanceuȪzRiiHıư MultiHanceݯdCثe٨SҾڤ@}lϥγzRiHwάOv |zRfwֺfܡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~yN (15-30 )C	Gadobenate dimeglumine	V08C	Ϧ@yv MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	0	"~ȨѶE_γ~ϥ
MultiHanceO@ضϩʳyvAΩϮyvE_]A:
@B xŦ Ϯyv :Ω E_wh o xŦ~F pGx β  ʯef w̤xŦ f_C
GBMպϮyv:Ω[jf_E_AiѫDWjʺϮyvҵLkoB~E_TC
TBWj޺Ϯyv:héΤwζgʯߦ{ɤWޯUΪefw̤E_(t`/Vʯ߯UE_)AiE_ǽTʡC
|BũкϮyv:iΩE_whæcʨfܪfHC"	"1.g@vL ̡AyϥΥ~C
2. gϥΥ@L ] Gadolinium gXAӭPLөΦƧ@β̡ͪAyϥΥ~C"	YhAߡA`gLӡBo	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	XMULT-a	XMULT-b	XMULT-c	
	A03AX13	0	LWILC	Wilcon 300ml (ˬd)(simethicone)GdaBG		ɭʮw@ΡG㦳ɭʧ@ΡAϪiOCUAõoVwĪGA󸡳PzΥwѮĪGCSϭGzLƤp˴wiOC}ӦX@ӤjAӳQƥX~C 	@34CHC2mlC3HW]t^AAΦHqG3HUAЬvEvCyۦϥΡC 	ϥΫeݮnáAèϥμtөҪqqĶqC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷץAKeOsC 	Dimethylpolysiloxane	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS		ѰȮAwѮȬgC 	L	"1. ƾGnKAGַPAUgAhAæRAGPAC 
2. LGYhC "	SmҦw	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.12.29		0	0	OIs 20251124	LWILC-a	LWILC-b	LWILC-c	110.12.29
	B03XA02	0	JNESP	NESP inj.20mcg/0.5ml(~ǱMΤp^		vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"CʵǰIܱw̡J
~ľqRߪ`gΥ֤U`gCg@C
GzRfHAĳHRߪ`gPC
_lq:
vhG
HRߪ`gΥ֤U`gCg@ĳ_lqC魫0.45mcg/kgC
qG
ľqӤHƥHȦb1012g/dLC
qվG
~ľqվCw̪ȯFӥBȦb10g/dL12g/dLC"	1.󦳬YǦGf]ҦpGʳhBIMyʳhBahBg^w̡AåTߥHDarbepoetin alfavwʤΦĩʡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~ib2-8JUxsCץC	Darbepoetin \	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	vPCʵŦ\ॢզhgΦ]ӻݭn媺w̡AvPgƾǪvgʳh	"~TΩG
1.Lkw̡C
2.DARBEPOETIN ALFA ΨLyͦJĪv}l¬yo|(PRCA)C
3.w DARBEPOETIN ALFA YLӤ̡C"	ΧCB~BYhBhBmBߡBæRB٦`khBWIlDPVC	C	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IARAN1-a	IARAN1-b	IARAN1-c	110.6.16
AC46869209	A03AB02	0	IGLYC	Glycopyrodyn inj. (Glycopyrrolate) 0.2MG/ML		GlycopyrrolateApPLxE(ܿrE)sAiAQxP(acetylcholine)@Φb`xEʯg(postganglionic cholinergic nerves)ǾɪcyAHΦb|AQxPAʥFxEʯgǾ(cholinergic innervation)Ʀ٤WCoǩPxEʨ(peripheral cholinergic receptors)bƦ٪ۥDgʾӭM(autonomic effector cells)Bߦ(cardiac muscle)Buе(sinoatrial node)BЫǵ(atrioventricular node)B~c(exocrine glands)AHάYǦۥDgC]A~iH֭GcqλīסAñLq|BޡBޤcCGlycopyrrolateiܥxEĪpx?Ҥ޵orEʯg(muscarinic symptoms)Ap޺|(bronchorrhea)B޵j(bronchospasm)B߷i}w(bradycardia)BpzL(intestinal hypermotility)C	"ī~vϥΡC~ig}A٦שRߪ`gġC
HG
¾KeġX~ĳqCS魫0.002@J(0.01@)٦ת`gAb¾K}le30-60ġAάOP¾Ke¾K(preanesthetic narcotic)MR(sedative)PɵġC
NġX~ibNġAHܥĪ޵oΰggϮg߫ߤAҦp߷i}w(bradycardia)C䵹Ĥ覡gRߪ`gġA@q0.1@J(0.5@)AnɨC2-3ƵġCҦ檺qAHTwy߫ߤ㪺]FPɡAFɥƥPg(parasympathetic imbalance)DӰNγ¾Kާ@]QC
g٦ת_^_(Reversal of Neuromuscular Blockade)X~ĳqC1.0@Jneostigmine5.0@Jpyridostigmineϥ0.2@J(1.0@)~CFNŦ譱Ƨ@ΤX{v̧CAoĥiPɸgRߪ`gġA]iHVXbP@Ӫ`gwC
ĵG(аѦҸTүg)
¾KeġX~ĳq@ӤQGjpġACS魫0.002@J(0.01@)٦ת`gAb¾K}le30-60ġAάOP¾Ke¾K(preanesthetic narcotic)MR(sedative)PɵġC@ӤⷳjpĥiݭnW[CS魫0.004@J(0.02@)C
NġX]~Φb¾KeĮɪĮīܤ[A]NFxEʮĪGӦAl[`g~|Oܤ֪FpGuݭnɡAൣĳqOCS魫0.002@J(0.01@)Rߪ`gA@qnWL0.1@J(0.5@)AnɨC2-3ƵġCҦ檺qAHTwy߫ߤ㪺]FPɡAFɥƥPg(parasympathetic imbalance)DӰNγ¾Kާ@]QC
g٦ת_^_(Reversal of Neuromuscular Blockade)X~ൣĳqC1.0@Jneostigmine5.0@Jpyridostigmineϥ0.2@J(1.0@)~CFNŦ譱Ƨ@ΤX{v̧CAoĥiPɸgRߪ`gġA]iHVXbP@Ӫ`gwC"	"1. ~ig}A٦שRߪ`gġC
2.PɨϥJ¾K(cyclopropane anesthesia)MRߪ`gxEĪ(anticholinergic)|ɭP߫Ǹ`ߤ(ventricular arrhythmias)A]A~ϥΦbJ¾KAݭnSOpߡCpG~OHΤp0.1@JLqW[覡ġAhɭP߫Ǹ`ߤ㪺iʴN|CC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	s25aCHUǷŤAקKӮgC	Glycopyrrolate	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	"NeΤNΥHֳGBޡB|ncAMGcġF
KδުvɥΥH_ŦggϮg@ΡBƩʼŤUvC"	wGlycopyrrolateLӪ̡Cѩ󥻫~tBenzyl AlcoholAGiΩsͨ(p@Ӥ몺)C~AΨӪvƩʼŪfHA]@ήɶܪAG~iΦbPɦC(glaucoma)fHWCt~AUCeffH]ФŨϥΡGʧf(obstructive uropathyAҦp]@ΤjɭPHV)BGzDʯef(Ҧpw(achalasia)BժQGzU(pyloroduodenal stenosis))B·ʸzj(paralytic ileus)BѦ~zDw(intestinal atony of the elderly)εzfHB|ʥX媺ߦޤíwA(unstable cardiovascular status in acute hemorrhage)BYũʤjz(ulcerative colitis)BrʥzHũʤjz(megacolon complicating ulcerative colitis)BgٵLO(myasthenia gravis)C	fBƧxMdBթjɭPOҽkB߱BYhBߡBKC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts111.8.19		0	0	OIs 20251124	IGLYC-a	IGLYC-b	IGLYC-c	111.8.19
AC24113277	B05BB02	0	IGS51	Dextrose 5% and Sodium Chloride 0.9% Inj. 500ml/Bt		"ҤƦXGADnΧ@ѤfALkoһݭniʥFfHd(q)βGӷC
R`Sodium chlorideUؿ@סAiGMqѽӷAi@G`JޡAiGzC 
"	Rߪ`gΥ֤U`AζqfHpλݭnqөwAq`@^100mL1000mLC	"pLӤAY谱ϥΡAõAB
mC
ήɡG
ơBL{Aei]B_ʡAӭPͯ}
B_ةβ~PʡAYo{WzήɡAФŨϥΡC
ƢYĲGMBܦBΨ䥦`{HɡAФ
ϥΡC
GMΤδJkG
ơШ̿GMϥΤkTϥΡC
ƢШϥΪLo˸mGMAɤJwH覡
JֶAJФŧAHK]w (Coring) 
HC
ƣϥΫeЦA˵ATwLAiϥ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡApoܽιLAiAϥΡC 	"Dextrose        50.0 mg
Sodium chloride 9 mg
"	B05B	Rߪ`gG I.V. SOLUTIONS	0	@gB^_վBCʤr					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111/08/18		0	0	OIs 20251124	IGS51-a	IGS51-b	IGS51-c	111/08/18
AC22682271	B05BB02	0	ITAI51	TaiTa No.5 inj 400ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	ITAI51-a			
NC06066277	B05BA03	0	IG05	VITAGEN 5% 500ML/BT(D5W)		"~YĨ妬 Glucose Injection s~CDextrose (Glucose)H Glycogen κAAJsxŦA
CCaܦiӷAPϥӭMमiAWi骺N¥\AΩNB¾Kv
TBNθgLغܤƵyN»ٮ`CɵBQBѬr\C
"	q`H 1 ^ 500~1000mLAѥ֤URߡAwCaIw`gA̯gAyWC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	DEXTROSE MONOHYDRATE	B05B	Rߪ`gG I.V. SOLUTIONS	0	NΨLewiɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668360?cesid=3wZMNIjOHkr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDEXTROSE%26t%3Dname%26acs%3Dfalse%26acq%3DDEXTROSE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IG05-a			
NC05342277	B05BA03	0	IG0501	Gitose 5% Dextrose Monohydrate 500ml		"~YĨ妬 Glucose Injection s~CDextrose (Glucose)H Glycogen κAAJsxŦA
CCaܦiӷAPϥӭMमiAWi骺N¥\AΩNB¾Kv
TBNθgLغܤƵyN»ٮ`CɵBQBѬr\C
"	q`H 1 ^ 500~1000mLAѥ֤URߡAwCaIw`gA̯gAyWC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJsC	DEXTROSE MONOHYDRATE	B05B	Rߪ`gG I.V. SOLUTIONS	0	NΨLewiɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668360?cesid=3wZMNIjOHkr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDEXTROSE%26t%3Dname%26acs%3Dfalse%26acq%3DDEXTROSE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IG0501-a			
NC03058238	B05BA03	0	IG20	20% Vitagen 20ml/vial					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0	0	OIs 20251124	IG20-a			
AC29835255	B05BA03	0	IGITO	5% Gitose inj.50mg/ml;100ml/bag(D5W)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IGITO-a			
AC29835265	B05BA03	0	IGITO1	5% Gitose inj. 250ml/bag(D5W)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	ʶǬVfwɵBGWq					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IGITO1-a			
AC15246277	B05BB02	0	IGS3	5% DEXTROSE IN 0.33% SALINE(500ml/bt)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IGS3-a			
AA13718277	B05BB02	0	IGS4	}Q`g5%DEXTROS IN 0.45 SALINE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IGS4-a			
AC02801209	B05BB01	0	ILR01	Lactated Ringer's B inj.1000ml/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	ILR01-a			
NC00577277	B05BB01	0	ILR5	LACTED RINGER'S 500ml/BT					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	ILR5-a			
AC21632277	B05BB02	0	ITAI1	TaiTa No.1 inj. 500ml/BAG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	ITAI1-a			
AA01085265	B05XA03	0	INAC02	NACL 0.9% 250ML/BAG		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC02-a			
AC36014277	B05XA03	0	INAC4	NACL 0.45% 500ML/bag					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC4-a			
AC21630277	B05BB02	0	ITAI2	TaiTa No.2 inj. 500ml/BAG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	ITAI2-a			
AC35639312	B05CB01	0	INAC2	0.9% NaCl (R~) 2000ML/Bag					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05C	R~G	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC2-a			
AA01085277	B05XA03	0	INAC01	NACL 0.9% 500ML(nU) 		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC01-a			
AA29836255	B05XA03	0	INAC03	0.9% saline inj.100ml/bag(NaCl)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC03-a			
AA29836265	B05XA03	0	INAC05	"250ml/bag ""N.K.""0.9% saline inj n"		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC05-a			
AA01085209	B05XA03	0	INAC1	NACL 0.9% 1000ML/BAG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC1-a			
AC24212238	B05XA03	0	INAC42	0.45% SODIUM CHLORIDE 20ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC42-a			
	B05CB01?	0	INACI	NACL 0.9% 500ml FOR IRRIGATION					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05C	R~G	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INACI-a			
AA01085265	B05XA03	0	INACL1	0.9% NaCl inj.250ml(in 500ml콦~)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INACL1-a			
AA01085277	B05XA03	0	INACL2	0.9% Sodium chloroide inj.500ml/PP~		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INACL2-a			
COVID19ModS	J07BX03	0	ICOMS	Spikevax(Moderna@N)BA.1/BA.5		"̭]tiƻsSARS-CoV-2frɡA|]إ̭]ӿwCOVID-19C
2iw94%gPV"	"1.12HWC֦~ΦHAؾq0.5 mL(@0.2 mg/mLA̭]tq100 mcg)C
6-11Aൣؾq0.25 mL(@0.2 mg/mLA̭]tq50 mcg)C
6Ӥ-5A౵ؾq0.25 mL(@0.1 mg/mLA̭]tq25 mcg)C
2.¦ؾ2Aثe̽åͺ֧QǬVfvԸ߷|wز(ACIP)ĳA18HWضjܤ28 ѡF6-11ൣκ6Ӥ-5⾯ضj4-8gHWAĳHPtPءFtŶqضjԪi঳Ṷ]K̤OɻPi୰Cuߦ٪/ߥ]}ƥIA12-17C֦~⾯ضjH12ghC
3.5HWwK̤ΧĶCUfHAgvfíw̡Aز3¦[jAضjPe@jܤ28ѡC䤤12HWitPءAĳϥmRNA̭](BioNTechBModerna)γJս覸椸̭](ݺ20HWBNovavax18HW)ءAYHModerna̭]ءAؾq0.5 mL(@0.2 mg/mLA̭]tq100 mcg)F5-11ĳHPtPءAثeꤺȮ֭Pfizer-BioNTechൣiΩ5-11¦[jءC
4.ثeACIP ĳw粒¦BLoY}̡AĳP̫@¦ضjܤ12g(84)HWذl[C
?????????????????????18HWA¦mRNA̭](BioNTechBModera)γJս覸椸̭](ݺ20HWءBNovavax)̡Gl[iܱإbqModera (50 mcg)BqHBioNTechBJս覸椸̭](ݺ20HWءBNovavax)AZ̭]C¦AZ ̭]̡Gl[iܱModerabq(50 mcg)BqHBioNTechγJս覸椸̭](ݺ20HWءBNovavax)C
12-17AثeȮ֭BioNTech̭]Hl[ءC??????????????
5.س~|٦ת`gC"	"oNΥwʤׯef̡AyݯfíwAءC
̭]PḼ]iPɤ}PuءAijɶءAHQثPOC
K̥\CU̡A]AĶvHA̭]K̤izC(|LĶCU̩ΥbĶv̪ƾ)

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Nx
-25~-15XCNOsAoC-50XCBoϥΰBNBNxC
Ym2~8XCNó]ƫOs30ѤϥΧC"	25LJ쫬mRNA25LJOmicron BA.1ܲmRNA^	J07B	fr̭] VIRAL VACCINES	0			`gkhAh¡AYhA٦׵hAȴHA`hA/æRAŤU~/hAoN(>38)A`g~ȡAo	"ثeSƾګĳi`WCOVID-19̭]AYPVIi]wCOVID-19ɭPYֵogΡAigvO_ج̭]C
"	YŤkĳؤIH(pƤH)AءCثeŤkCOVID-19̭]wʡB̭]ũΨधvT|oA@{ä|yICCOVID-19̭]AišC	аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
	B05XA03	0	INAC92	0.9% NACL 20ML/AMP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	INAC92-a			
COVID19AZ		0	ICOAZ	AZ Covid-19 Vaccine (Ĥ@)		SQd(AstraZeneca) COVID-19 ̭]̭]Aϥγ@աBaƻsʳµVVfr (ChAdOx1) Ai SARS-CoV-2 S ޳JսsXC̭] SARS-CoV-2 S K̭쬰TEeĦXcΡFFíweĦXcΤ S JաAå׹sXǦCCI̭]Ai{ SARS-CoV-2 S ޳JաAEMβӭMK̤AU COVID-19C 	"q
~ 18 HWC֦~ΦHI⦸(٦ת`g)AC0.5 mlFĤ@`gPĤGj412g(28  84 ) CYSǬVʪͪy̱߫ĳGj8-12gC 1. ثe|LSQd(AstraZeneca) COVID-19 ̭]O_iPL COVID-19̭]ϥΨӧI{ǪơCISQd COVID-19 ̭]Ĥ@HhAIĤGSQd(AstraZeneca) COVID-19 ̭]ӧ㪺I{ǡC
Ϊk
1. SQd(AstraZeneca) COVID-19 ̭]ȭH٦ת` g覡IΡA̦n`gWuT١C
2. ibޤB֤UΥ֤`g̭]C
3. ̭]iPḼ]ī~bP@`gVXϥΡC "	Ĥ@SQd(AstraZeneca) COVID-19 ̭]I 3 g}l㦳O@OAĤGI 15 ѫ~Ƨ㪺O@OCpPҦ̭]ASQd(AstraZeneca) COVID-19 ̭]@wҦ̭]IHhಣͫO@@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"mBcN (2X8XC)C
iNC
NĲ~m~AץxsC
}ʪĲ~:
Ĳ~b} (Ĥ@w) ibWL30XCpUOsMϥΡAߤiWL6pɡCWLϥδ~CФũ^BcNáC
qLͪ[IӬݡA̭]}ʫߧYϥΡCYߧYϥΡAϥΪtdϥήɤsɶΪp(ϥΪ̭nTO̭]bWL30XCpUAWL6p)C "	Ḣfr	J07B	fr̭] VIRAL VACCINES	0	SQd(AstraZeneca) COVID-19 ̭]AΩ18HWC֦~ΦHDʧḴءAHw2019~afref(COVID-19AΥkWҺ١uYSǬVʪͪv)C 	靈ĦΥ椤ҦCξLӡC 	YhBߡB`gkhB«C 	SQd(AstraZeneca) COVID-19 ̭]Ωhkʪg禳C	ثeäMSQd(AstraZeneca) COVID-19 ̭]O_|cHťĤC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ICOAZ-a	ICOAZ-b	ICOAZ-c	110.6.16
																																		
COVID19PBNT		0	ICOBN	PfizerBNT Covid-19 Vaccine					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			J07B	fr̭] VIRAL VACCINES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ICOBN-a	ICOBN-b	ICOBN-c	110.6.16
COVID19Mod		0	ICOMO	Moderna Covid-19 Vaccine (Ĥ@)		ModernaCOVID-19̭]OSARS-CoV-2frƳJ(S protein)mRNA̭]C 	"1.ثe̾ڬ̭]椧Aα?֬18HWAؾq0.5mLC
2.ؾ2Aثḛګޤνåͺ֧QǬVfvԸ߷|wز(ACIP)ĳضjܤ28 ѡC
3.س~|٦ת`gC  "		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	1.-25~-15XCNOsAoC-40XCBoϥΰBNBNxC2.Ym2~8XCNó]ƫOs30ѤϥΧC 	messenger RNA	J07B	fr̭] VIRAL VACCINES	0	wCOVID-19̭]AΩ18HWC֦~ΦHDʧḴءAHw2019~afref(COVID-19AYSǬVʪͪ)C 	̭]YLӤvAιeؤ̭]oYLӤ̤ءC	`gkhBh¡BYhB٦׻ĵhBoNC 			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	ICOMO-a	ICOMO-b	ICOMO-c	110.6.16
COVID19NVX	J07BX03	0	ICONU	Nuvaxovid Vaccine		Nuvaxovid ѯ¤ƪ SARS-CoV-2 մ (S) JղզAӴƳJiħǦCۭlZ~SARS-CoV-2frCtm?D Matrix-M U󬡤ƥѧK̨tβӭMAqӼWj S JձM@ʧK̤TסCoج̭]|޵o B ӭMM T ӭM S JժK̤]䤤]AM^Aoi঳Uw COVID-19C	Nuvaxovid ٦ת`gA̭]ص{ǬI 2 AC 0.5 @ɡCĳbĤ@ܤ3gᵹĤG		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	b 2XC  8XC ҤUץiOs 6 Ӥ	0.5 @ɤt 5 LJSARS-CoV-2ƳJ*HΦMatrix-MatP (Quillaja saponaria Molina)ѨA (42.5LJ)MѨC (7.5LJ)b	J07B	fr̭] VIRAL VACCINES	0	Nuvaxovid AΩ 18 HWHDʧḴءAHwsafref (COVID-19AYSǬVʪͪ)C	̭]YLӤv	YhBߩιæRB٦׵hB`hB`ghB`gkhBh¡BLO	DnקKϥ/LƦҦw	DnקKϥ/LƦҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.8.22		0	0	OIs 20251124	ICONU-a	ICONU-b	ICONU-c	111.8.22
J000138206	J07BB02	ww񡨵ѫ|yP̭]	IVAXS	"AdimFlu-S 0.5ml/]
|KOyP̭]^ 0.5mL/syringe"		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"	"٦ת`gC
ضqG3 HWൣΦHG@ 0.5mLC
 9 ൣAYe`gLyP̭]̡Aݱ 2 ABjܤ 4 gC"	"Qت̦bثevݶEA˷ŤζE]EBťE^dAլdC
pPҦ`g̭]AǳƦnAIκʷHI̭]X{LӤAΥioͪw()C
YbeجyP̭]oͮL-ڧQgԸs(Guillain-Barr? Syndrome)AbҶqbįqPIAAMwO_
إ̭]C
̭]i`gܦޤC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES	0	wyPC	"󥻬̭]󦨤oYLӤ(ҦpGʹLӤ)AιLhb`gyP̭]oYLӤ
C
"	"YhAߡBæRA`gkh/~ȡBA(malaise)ABy¡BVh
"	"hα¨ŴiѱzvP_O_ӱإ̭]C
wWL 2000 쥥بLu`ʬyP̭]siܨõLLಣͤ}vTC
"	"hα¨ŴiѱzvP_O_ӱإ̭]C
wWL 2000 쥥بLu`ʬyP̭]siܨõLLಣͤ}vTC
"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.10.20		0	0	OIs 20251124				111.10.20
			IANTA	ܦʨBDrMᴹ`g		rDrˮɡApTwDAh`gӳDrܬrMΡCpTwAhe{Xʩίgʯg̡AO`gXʩίgʧܳDrhMC~YhK̰MA䤤thإiMDrA2A@OܥXʳDrMAiΩʨBDA|Atߪ᪺rˡFt@OܯgDrMAiΩBʸ`ADrˡC	1q20mlAq`@b(10ml)`gbr˳P֤U(SC)At@b(10ml)hIVIMCj10̨C1ӾqFp10̨C2ӾqCpGݭnܨC0.5Ӥpɦ2Ӥpɭ1	"1.~ѫ2pɤΧC
2.Qr˫4pɪ`gܳDrM̦ġAWL8pɪ̮ĪGtAjq`gSOdNMfo͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Snake venom antiserum	J06A	K̦M IMMUNE SERA	0	ʨBDr˦SʤvĪG	w̬O_MLӥTweAקKRߪ`g	MJBcHoBMf	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkW"	No data available	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IANTA-a	IANTA-b	IANTA-c	110.6.16
			IANTB	ܫBʸ`ζͭųDrM		rDrˮɡApTwDAh`gӳDrܬrMΡCpTwAhe{Xʩίgʯg̡AO`gXʩίgʧܳDrhMC~YhK̰MA䤤thإiMDrA2A@OܥXʳDrMAiΩʨBDA|Atߪ᪺rˡFt@OܯgDrMAiΩBʸ`ADrˡC	1q20mlAq`@b(10ml)`gbr˳P֤U(SC)At@b(10ml)hIVIMCj10̨C1ӾqFp10̨C2ӾqCpGݭnܨC0.5Ӥpɦ2Ӥpɭ1	"1.~ѫ2pɤΧC
2.Qr˫4pɪ`gܳDrM̦ġAWL8pɪ̮ĪGtAjq`gSOdNMfo͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Snake venom antiserum	J06A	K̦M IMMUNE SERA	0	ʨBDr˦SʤvĪG	w̬O_MLӥTweAקKRߪ`g	MJBcHoBMf	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkW"	No data available	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IANTB-a	IANTB-b	IANTB-c	110.6.16
		0	IPNEU	PNEUMOVAX 23 0.5ML/AMP		~(hʪͪy̭߬])@Ѧ٦ת`gΥ֤U`g߲G̭]C̭]tgׯ¤ƨӦ23س̴MΨIǩʪͪyߤӵ޽(capsular polysaccharides)FѬWϥΪgoA̭]ҧt23ص߮󽤲[\Fܤ90%bLҤU۪ͪfH夤ıo߮Aβ[\Fܤ85%۩ҦͪfHıoءCwgҹ¤ƪͪy޽󽤡AH黤ɥXAا঳Ĺwͪy߯efCbH礤`ghʬ̭]A23ز󽤨޾ɥXK̤O(O)wQҹCҦ~ּhH`g̭]ಣͧK̤OCbAHt12ز󽤤14ز󽤤ͪy̭߬]22HWĵBHsAܧK̤O͡Ab̭]`g᪺3P|̦ͨU󽤫һɥX	~֤U(subcutaneous)Φ٦(intramuscular)`g(̦nWuT٩ΤjL~)0.5mlAB[H`NקKRߪ`g	"1. Y̭]Ω󥿱Ķʪvw̡AiLkowĪGC֤U`gi|yYC
2. wYŦ/Ϊͥ\lˡAʤiɭPMIʪfHAb`g~ᵹ`NξAUC
3. w]oʩIlDefΨLʷPVg(active infection)̥Ƚw`g~ADOv{Ȱ`g~|󰪪MIɤ~ϥΡC
4. ݭnHpenicillin(ΨLܥͯ)ӹwͪy߷PVfwAb`g~AϥΦwʪܥͯC
5. ~i]Y`򳡯}ǥѸӤJI~ɶǬVefҤް_PVSwĪGC
6. ubTDnI̭]pUA~`g̭]C`g~¨Űk`NC
7. pⷳ糧~wʤΦĩʩ|إ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	"Pneumococcus, 23types antigen"	J07A	ӵ̭߬] BACTERIAL VACCINES	0	wͪyߩʪͪΪͪyߩʵߦg	"1. iΩ糧̭]󦨥LӪ̡BY]̭]󦨥oͫʹLӤɥW`gepinephrine(@פ1:1000)C
2. DOͪy߷PVMIs̡A_h`g̭]ᤣiAl[`gC
3. oͱwHodgkin'sgfwAbĶʪve710Ѫ`g̭]Aoͨ餺ܭȧC󥼪`g̭]eȡA]دfHbĶʪve10Ѥi`g̭]C
4. iܱƾkΩεߩʿgk(nodal irradiation)Hodgkin'sgw̡Ab`g12ͪy̭߬]|z骺B]@ǥHK覡vfHA`g̭]|Csb餺靈ǪͪyߦĪA]󥿥HoǪv覡vHodgkin'sgfHĳ`g~C"	]A`gĵhB`Bθ~ȱ``o͡Aq`|b48pɤh	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IPNEU-a	IPNEU-b	IPNEU-c	110.6.16
K000906206		0	IPREV1	Prevenar(13)O		"C0.5mlKͪyߤQTX̭]AtGM1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23Fͪyߪ󽤦hU2.2ugAM6Bͪy߲󽤦h4.4ugAoǲ󽤦h駡PճCRM197Jս鱵XçlCľTW]t0.125mgT^C"	̭]H٦ת`g覡뤩C̨Ϊ`gmbରjLe~ѥ~١]vastus later muscle^AάOWuT١C	pPḼ]@ˡAYʩYoNefɡAȽwبKͪyߤQTX̭]C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	NöJs28JAiNC 	"M1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23Fͪyߪ󽤦hAM6Bͪy߲󽤦h"	J07A	ӵ̭߬] BACTERIAL VACCINES	0	"KͪyߤQTX̭]iΩX2Ӥ5j઺DʧḴءAHwM1,3,4,5,6A,6B,7F,9V,14,18C, 19A,19F23Fͪy(Streptococcus pneumoniae)ް_IJʯefCKͪyߤQTX̭]]iΩw2HUM4,6B,9V,14,18C,19F23Fͪyߤް_ժC̭]iΩ50(t)HWHDʧḴءAHwM1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F23Fͪyߤް_IJʯefC "	惡̭]@νξLөιճrLӪHATϥΨKͪyߤQTX̭]C	`g짽AoNBwB֡BίvɶW[δֵC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IPREV1-a	IPREV1-b	IPREV1-c	
X000176206	J07AM01	0	ITETA1	Tetanus Vaccine 0.5ml/amp (Tetanus toxoi		~`JHAi͹ܯ}˭۰ʧK̤OC	" `h֤U`gA@󰪦Wu٦(T)`gC~YTޤ`gC
¦K̡G
¦K̤@@ݱؤTC
Ĥ@MĤGءACq 0.5mLA⦸j4-6gC
ĤTءACq 0.5mLAĤGث6~12ӤiC
l[K̡G
Q~LعLt}˭r̭]̡Aؤ@il[K̡ACq 0.5mLC"	"1. bhe@Ψ⾯̭]kbh̭]حpC
2. hYnAZWؤwWLQ~̡Al[ؤ@C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxs2~8JAYTᵲAYᵲC	Tetanus toxoid 	J07A	ӵ̭߬] BACTERIAL VACCINES	0	w}˭C	"1. }˭ι̭]LLӪ̡CLӯgi]t: oo֯lBIlxByPY~ȡC
2. ʵoʯefC׷PVAp@P_gɡAOظTҡAƥivC
3. CʯefbcƶqCᱵءAfnC
4. æPV(}˭~)C
5. go͹LpO֡Aث|W[XBίgtΤAIC
v󱵺ظTһPPV}˭IC"	oNBֽ~B`gkhB«C	" B󥥴έŴBihέpehkʡA󱵺إ̭]eAݶťüxvĳC
G
ةΥ¦Ḵت̡AءC
bhe@Ψ⾯̭]kbh̭]حpC
hYnAZWؤwWLQ~̡Al[ؤ@C"	"ثḙ]LTC
"	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.5.06		0	0	OIs 20251124	ITETA1-a	ITETA1-b	ITETA1-c	110.5.06
			IANTT	tߪΨ|DrM		rDrˮɡApTwDAh`gӳDrܬrMΡCpTwAhe{Xʩίgʯg̡AO`gXʩίgʧܳDrhMC~YhK̰MA䤤thإiMDrA2A@OܥXʳDrMAiΩʨBDA|Atߪ᪺rˡFt@OܯgDrMAiΩBʸ`ADrˡC	1q20mlAq`@b(10ml)`gbr˳P֤U(SC)At@b(10ml)hIVIMCj10̨C1ӾqFp10̨C2ӾqCpGݭnܨC0.5Ӥpɦ2Ӥpɭ1	"1.~ѫ2pɤΧC
2.Qr˫4pɪ`gܳDrM̦ġAWL8pɪ̮ĪGtAjq`gSOdNMfo͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Snake venom antiserum	J06A	K̦M IMMUNE SERA	0	ʨBDr˦SʤvĪG	w̬O_MLӥTweAקKRߪ`g	MJBcHoBMf	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkW"	No data available	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IANTT-a	IANTT-b	IANTT-c	110.6.16
K000456206		0	IHAVR	s_J 720ĵAx̭]		~ݩDʧK̻sAK̫AoAǧ骺ͦӹܥ~ӷLͪIǡAYDʧK̬OzLPܭ쥻ĲӱoAE鲣ͥۤvSӹܥC	ĵHavrix 720(0.5mlaB)@qAΩ¦K{Cëĳ¦K{᪺QGӤ뤧iAl[@AHHavrix 1440ΫĵHavrix 720AHTOO@ĪGC	"1. Ĥ@`gAgܥXi঳LӤ̡AӪl[`gC
2. Y̭]̦bج̭]ɡAPɱĶvBΥ㦳K̯O̡AF~ᦳiäoK̯OC
3. ~LkO@ѫDAxfrҤް_LxCѩAxܪ(j2050)A]ib~`geNwgQAxfrPVӤ۪C~Lk惡fHѫO@@ΡC
4. pP䥦̭]`g`NƶA`g~NǤWī~ǳơAHLӤo͡C
5. 󾮦\঳ʥӰ٦ת`giް_XHA`g~SOpߡC
6. pP䥦̭]A~w`giLkѩҦPVت̫O@ĪGC󦳷PVεoNHA̦nw~`gADv{ӾioͪMIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC 	"Hepatitis A, inactivated, whole virus"	J07B	fr̭] VIRAL VACCINES		wϫxC	"糧~󦨤LӤ̡C
"	̱`Ƨ@άOس쪺khAåi۰ʫ_FLƧ@٦w~C 	קKϥ/SmҦw	קKϥ/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.26		0	0	OIs 20251124	IHAVR-a	IHAVR-b	IHAVR-c	111.4.26
K001126206		y¾AyP̭](|)	IVAF	Flucelvax Quad 0.5ml/		"1. PVyPfr|oͬyPefΨֵogCǥѥyʴ@~PRyPfrAiŲOC~ܭܲC1977~_AAyPfr]H1N1H3N2^MByPfr_yHu`ʬyPDnfrCإhʬyP̭]Aһoy(hemagglutination inhibition; HI) 骺SwĻPyPO@Os|إߡCbYǬsXAHIĻ ?1:40ɡAF50%ժ̥idyPefC
2. ܬYجyPfrΨȫt@جyPfrXGSήڥSO@@ΡC~AYجyPfrܭܲ骺AiLkdۦPΨȫfrsX{ܭܲCzLܭ}(antigenic drift)oiXܭܲOu`ʬyffrA]OC~yP̭]@Φhدfrq`|ܤƪ]C]AݭnzLwyPuiy檺yPfr@зǡAHs@hƬyP̭]C "	"1.̭]ȥiΩ٦ת`gC
2.FLUCELVAX QUADϥξq٦ת`g@0.5@ɡAĳI쬰WuT١AФŬIvΪ񦳥DngOC
3.38:@Ψ⾯1AC0.5@ɡAYݱب⾯A⾯ܤֶj4gHWC
4.9HW:@AC0.5@ɡAAΡC "	Yw̥eجyP̭]ᴿoGBSAhҶqbįqPIAAMwO_IFLUCELVAX QUADC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	~ЧNxs2XC8XCCФŧNBקKӡBФŨϥιL~C	"Influenza, inactivated, whole virus"	J07B	fr̭] VIRAL VACCINES	0	AΩ3HWൣΦHDʧḴءAw̭]Ҳ[\AΨByPfrҤް_yPefC 	]̭]޵oYLӤ]ҦpLөʥJ^̡AoIFLUCELVAX QUADC	̱`P`gkhBYhBh»PٵhB`goεwC 	ثe󥥰FLUCELVAX QUADƾڤA|LkTߩhPج̭]IC	ثeMFLUCELVAX QUADO_|cŤC|LƾڥiFLUCELVAX QUADιŲqcvTC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IVAF-a	IVAF-b	IVAF-c	110.6.16
K000351206		0	IHBV2	qJLE]Bx̭]		\hyfǬswgҹAPVBxfrᲣBx(anti-HBs)HAAױĲfrɡAiO@קKoͦefC	"iRߪ`gΥ֤`gCH-B-VAX IIѦ٦ת`gΡC令H̦n٦ת`gOT١C
H-B-VAX II(qJLE]Bx̭])ൣAC֦~tΦHt]tG^AXzReγzRfwϥΡC
T`g{
UCɶT`g{̩ҥΡG
Ĥ@GwɶC
ĤGG󱵺زĤ@@Ӥ뤧C
ĤTG󱵺زĤ@Ӥ뤧C
pGb7ѤTwˬHBsAgʡAߧY`g@BxK̲yJ(HBIG)(0.5 mL)CĤ@H-B-VAX IIiPBxK̲yJ(HBIG)Pɧ뤩A`gbPjLe~C
whñĲHBsAg
bĲ24pɤ֦٦ת`g뤩HBxK̲yJ(HBIG)(0.06 mL/kg)CbĲ7Ѥ󤣦P٦ת`g뤩H-B-VAX IIAæbزĤ@@ӤPӤ뤧AOزĤGPĤTC"	"ؤX{Lӯgw̡AAئ̭]
ѩBxܪAibج̭]ɤwgPVAo{C̭]iLkww̤BxC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"бNp~Js2-8 XCCŧNA]N|}aĻCץC
Jsū׭YΧCĳūסAiCĻC"	ൣ/C֦~t]tG^A10 gg/mLG5 ggBxܭC	J07B	fr̭] VIRAL VACCINES		wBxC	åߩΦ̭]@LӪ̡C	"`gDnĵhF]AkhBĲhBkoBBﴳB~ȡBoBHΧΦ`C
̱`ʤ]Ah/zPFYhFoN( ? 37.8XC)FHΨ餣ACߡFmC|YFWIlDPVC"	"hC
DnקKϥ/Smܦw"	DnקKϥ/Smܦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts111.4.26		0	0	OIs 20251124	IHBV2-a	IHBV2-b	IHBV2-c	111.4.26
X000153206		0	IPEDI	PediacelX@O		"ճBʤyB}˭Bp·b ??ʷP_ݦ̭߬]
[ճB}˭?rΫDӭMʦʤyḽ]AX?Ƥp·g̭]P b ݦ߱X̭]]P}˭JձX^]AO@صLߡBáBVBBզܦ̥զaBGA]taBAӧOlbCľTճB}˭?rΫDӭMʦʤy̭]A?ƪ 1B2B3 p·g̭] (IPV)]vero cell origin^AΩM}˭Jզ@X b ??ʷP_ݦ߲󽤦h]PRP^AѪ`gϥΡCDӭMʦʤy̭]A]t 5 د¤ƪʤyܭ]PTBFHABPRN P FIM^C"	"?oHRߪ`g PEDIACEL?FнT{wY?JޡC
?oϥΥ֤Υ֤U`gC
PEDIACEL? ?IvC@HU઺jLe~٦׭n̤jAOA`gC?ൣATٳq`jAiHb`g̭]C
1  = 0.5 mL
PEDIACEL? خɵ{`aǫhCPEDIACEL? ϥηǫhG?ϥ 4 Aq 2 ֶ}lACj 2 ӤI@A@T
AĤT 12 ӤAl[@Cbi?pUA? 4 ϥ PEDIACEL?A]ثeèS?ɸ?V PEDIACEL? PL֭㪺DӭMʦʤyVX̭]C"	"D?oͫʯg?εog?AᱵءCLoN?ᱵ
48 pɤš40.5XC (105XF)ABDѨLi?]yF
P48 pɤX{?J?A]CiʧCg?^F
P48 pɤAx3 pɡF
P3 Ѥo͵jˡ]??O_oN^C
D?몺]W?28 g^i?򥻧K̪`gɡAҼ{IsbA]ݶi?48-72 pɪIlʴA󦳩Ilo|?fv̤`NCӬ̭]عosऴqBA]?ڵΩ̭]ءC
DPEDIACEL? ?ϥΩp 2 ֡AΤj 7 ̡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 2XC  8XC?i?C	ճ?rA}˭?rADӭMʦʤyAʤy?r]PT^Afilamentous haemagglutinin]FHA^Apertactin]PRN^Afimbrial agglutinogens 2+3]FIM^A?Ƥp·g̭] 1  (Mahoney)A 2  (MEF1)A 3  (Saukett)	J07C	"ӵ̭߬]Mfr̭]Ƥ BACTERIAL AND VIRAL VACCINES, COMBINED"	0	"iϥXͫGӤܤCĵճB}˭BʤyBp·gΫIŧb ??ʷP_ݦ߷PVgͧK?C 
ثe?ĳN b ݦ߱X̭]Ω 2 ֥HUC
YϨൣg?wʤyB}˭Bճ b ??ʷP_ݦ (Hib) PVefAѩ?ɷPV?@w|ͧK?A]ج̭]C
PVH?K?fr (HIV) ̡A??O_X{g?A̾ڼзǱخɵ{AإճB}˭BʤyBp·g b ??ʷP_ݦ̭߬]C
PEDIACEL? ?oΩv?ճ?ߡB}˭ߡBʤyߡBp·fr b ??ʷP_ݦ߷PVC
p
PEDIACEL? ?AΩp 2 ֡AΤj 7 ̡C
??H
PEDIACEL? ?AΩ󦨤H?"	"D?w PEDIACEL? 󦨥ͥʹLӤ
Deاtդy̭] 7 Ѥo͸fܡ]pAgBg??CBwo@^ABDѨLi?]yC
Diʯg\ॢաA]tIYj (infantile spasm)B?wBiʸfܡCw?X{?g?AݥT?v?覡BíwfAiϥΦʤy̭]C"	`gĲhB~ȡBoBoN (38.0XC)BxB?֡BļB??CCmBæRC	̭]?ϥΩh?ʡC	̭]?ϥΩ?ʡC	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IPEDI-a	IPEDI-b	IPEDI-c	
	L01FD03	P	IKADC	ĵKadcyla 100mg/vial (Trastuzumab Emtansine)		Trastuzumab emtansine Ow HER2 ĪƦXCOH HER2 IgG1 (trastuzumab)CplӭMr DM1 OLާCX HER2 骺 IV pϫA trastuzumab emtansine }lH鬰Ci椺ơA᪺?魰ѹL{ӭMt DM1 ӭMrʥNªCDM1 XL޳J(tubulin)L{|}aӭML޺AɭPӭMPPӭM`C~A~ܡAtrastuzumab emtansine P trastuzumab A]| HER2 Tǻ\Aް_̿ʲӭMCӭMrʡAç HER2 Lת{HӭM HER2 M~ϲ渨C	"KADCYLA ĳq 3.6 mg/kgAC 3 g( 21 ѪP)R߿`@AfcƩΥX{LkrʬCФŬI 3.6 mg/kg  KADCYLA qCФťH KADCYLA N Trastuzumab  Trastuzumab N KADCYLAC
bIĪAХJӺʴ`iX{֤UC
 1 `G` 90 Cb`L{άI_lqܤ 90 A[fwO_X{oNBNŸΨL`C
`GYe`@pܦnAп` 30 Cb`L{ο`ܤ 30 [fwC "	"ts᪺GiNC

Nts᪺ trastuzumab emtansine G`J˦ 0.9%ƶu`gG 0.45%ƶu`gGEAm(PVC)`UΤtŽBt PVC EmL`U}AbϥΫei 2-8XC ūפUOsF 24 pɡCpGOH 0.9%ƶu`gG}Asi|X{LɪA]A`Įɥϥ 0.2-0.22 L̡B|lJս誺uE?(In-line non-protein adsorptive polyethersulfone)LoC

ۮe
iϥθ}(5%)GA]|ɭPJս辮C Trastuzumab emtansine iPLĪVXϥΩΥHLĪi}C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"бNp~ī~xs 2-8XC ҤC

HLߪ`gΤtsp~ī~tsߧYϥΡCYߧYϥΡAts᪺p~ī~i 2-8XC ūפUOsF 24 pɡAhC
"	Trastuzumab emtansine	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"KADCYLA Wϥήɯv HER2 ʡBeOL trastuzumab P@ taxane ĪvΨXkಾʨfwC 
: fwŦXUCG
ewgLಾgvA
bUkvΧv 6 Ӥ뤺g_oC"	LC 	i঳KBYhBf٦ׯkhBߡBhªΡC 	D 	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts110.6.16		0	0	OIs 20251124	IKADC-a	IKADC-b	IKADC-c	110.6.16
		0	IHBV-1	ENGERIX-B(Hepatitis-B Vaccine)		wЫxPV	"Hepatitis prophylaxis, postexposureIM, 0.06 mL/kg as soon as possible after exposure (ie,within 24 hours of
needlestick,ocular, or mucosal exposure and within 14 days of sexual exposure); repeat at 28-30 days after exposure in nonresponders to hepatitis B immune or in patient who refused vaccination.
Postexposure prophylaxis of neonates born to HBsAg-positiveIM, 0.5 ml within 12 hours after birth"	IM only.	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Hepatitis-B Vaccine	J07B	fr̭] VIRAL VACCINES	0	wЫxPV	Hypersensitivity to hepatitis B immune globulin or any component of the formulation; severe allergy to gamma globulin or anti-immunoglobulin therapies; IgA deficiency (increased risk of anaphylactoid reaction)	"Erythema and pain at injection site, headache, myalgias, joint stiffness, malaise, nausea, vomiting"	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[N]_B04-09 j	Ts110.6.16		0	0	OIs 20251124	IHBV-1-a	IHBV-1-b	IHBV-1-c	110.6.16
		0	EDESF	ĵDESFLURANE(SUPRANE)		_N-methyl-D-aspartate (NMDA) ΫPi ^-aminobutyric acid (GABA) ʡC	"1.¾Ke
wpDesflurane¾Kfwq`|HRߪ`g覡¾KeĪAҦp~]Opioids^MBenzodiazepineC
bHAY¾Ke~ĪAq`_l@׬3% DesfluraneAHۯfHC2-3IlW[0.5-1%C𥽡]End-tidal^Desflurane@׬4-11%]̬O_VXN2OӤP^b¾K2-4FCHDesflurane@ɳ¾KɡAWIlDEoͤv]IlBjˡBy¤ΤcW[^CbHɹL{Aoͦ񹡩MLקC]SpO2 < 90%^v6%C
2.
bHAY¾Ke~ĪAq`_l@׬3%DesfluraneAHۯfHC2-3IlW[0.5-1%C𥽡]End-tidal^Desflurane@׬4-11%]̬O_VXN2OӤP^b¾K2-4FCHDesflurane@ɳ¾KɡAWIlDEoͤv]IlBjˡBy¤ΤcW[^CbHɹL{Aoͦ񹡩MLקC]SpO2 < 90%^v6%C
YϥRߪ`g¾KĻɡ]pGthiopentalpropofol^Desfluranel@ץi]w0.5-1 MAC]O2N2O/O2aөw^C
lJDesflurane@װ12%bɴbfHWwϥιLCѩ󦹿@׷|ҪCʤAGYPɨϥN2OΪŮACخ餧ʤC
3.¾K
׬O_VXN2OADesfluraneHNһݤ`׬2.5-8.5%@סFӺpĤNһݤ@׬5.2-10%C
H2L/minΥHWyq¾KɡAͪwDesflurane@׬lJ@פ10%
b¾KA|HqܤơC¾KL`iɭPװCAiǥѧDesfluranelJ@װվC
Desflurane@װ1 MACɡA߸|W[Cؤ߸W[päవ¾K`פСC"	"1.cʰg
ӷPAjħlJʳ¾Ki|޵ofٵogA]ӳyݨDΨL{ɯgAQ٬cʰCg{ɯgһĹLA٦׻A߸L֡AIlPAoA߲vAígC]n`NYǫDSwxi|X{b׳¾KApGʯʮBһĹLhBen֡C
wcʰv]Aoī~AøgRߪ`gdantrolene sodiumMʪv]Ѿ\dantrolene sodiumī~HFѯfHUB~T^CǰIܥiy|͡A]pGiGyqC
DesfluranecʰPRiC
2.N[
lJʳ¾Kľibpfwް_u[AӾɭPN߲vΦ`C[oͩʯg٦ׯeffwASOODuchenne٦׵Ygw̡Cfwhơ]ëD^֥succinylcholine]fP^PgҦpʡCoǯfwҦMٻ?@ש㴣pAӥBfHGܲͦٲyJէCoǯfwgMPcʰpPAOҵLfw٦׻wΰN¤gCĳΦÿnv[pP߫ߤA]fwO_񤧯g٦ׯefC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsbǷ15-30	DESFLURANE	N01A	"¾K ANESTHETICS, GENERAL"	0	lJʥ¾KC	"EĦbwh÷|ʹcʰgfHWTϥΡC
EAΩTI¾KfwC
E¾KɡC
EwDesfluraneγ¾KLӪ
Ebtƾ¾KDesfluraneᤤצܭרx\êALL]"	y34%AIl30%A15%AcW[*AަY*AyM]SpO2 < 90%^*A|甆*Cߡ]27%^BæR]16%^	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.5.06		0	0	OIs 20251124	EDESF-a	EDESF-b	EDESF-c	110.5.06
		0	ESOJO	ĵSojournlJβG250ml/~		oʳlJ¾KġAmI 58.6JA 25J] 26.7kPa(200mmHg)Cƾǩʽ褣íwAPuۦǱĲiް_ѡC¾KḣqϪ{TWjAWvUAzqʡC︣N¦@ΡAiW[yA1MAC(̧CͪwĿ@)`LۼvTA2MAC`iɰC`tμvTpA`¾K]iߦ٦YʤΩPުOCW[ߦٹiӷPʡAO߫íwCIltΧLA]iCʪͦަYAPqAtJzCEIlDAW[DcAPޥƦ١C㦳@wxrʻPlJ@׬AtJnpC  	lJJɳ¾KA@1.8-5%Nitrous oxide/oxygenA侯qӧOwC 	  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC 	Sevoflurane	N01A	"¾K ANESTHETICS, GENERAL"	0	lJʥ¾KC 	c?Lfvήaڥv	1.PqŦIlFbɤĹBʡC 2.NߡBæRFǬrʡF`oAc?LiC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.5.06		0	0	OIs 20251124	ESOJO-a	ESOJO-b	ESOJO-c	110.5.06
۶O	V07AB	0	IWAT1	ĵWater for inj. 1000ml/U		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IWAT1-a			
		0	F014	pHo()13g/BOT					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IBLEU	Bleu Patente V sodique Guerber 2.5% -2ml		Oں޳쪺wBʯ߰ϰ줧w	OںޡG`g 1mlPatent blue V֤U´C}ۤj}kCWϦ۴xA()Τpڬ_AάOۨyCʯ߰ϰGʯߪ`gPatent blue VNު´VA]ӯΥHMwܮ֤kϰAʯߤChimotherapywwɺޤTmC@`]tG80mliuGB40ml 2.5% Patent blue VGB20ml 1%XylocaineGG50mlC	"нTϥ, žզۼWĶqΰ, ýЫɦ^E"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Patent blue V	V04C	䥦E_ OTHER DIAGNOSTIC AGENTS	0	Oں޳쪺wBʯ߰ϰ줧w	0	Patent blue Viಣ͹LӪƧ@ΡC	0	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts110.6.16		0	0	OIs 20251124	IBLEU-a	IBLEU-b	IBLEU-c	110.6.16
۶O	V07AB	0	IWAT2	ĵWATER FOR IRRIGATION 2000ML/BAG(R~)		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IWAT2-a			
۶O	V07AB	0	IWAT	WATER 20ML/AMP		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IWAT-a			
		0	ICOM	Spikevax(Moderna@N					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts111.10.3		0		OIs 20251124				111.10.3
COVID19ModB		0	ICOMX	Moderna(Spikevax)(4/51~4l[)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
۶O	V07AB	0	IWAT3	ĵ WATER FOR IRRIGATION 500ML/BT		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124	IWAT3-a			
K000456206		0	I2HEPA	Ax̭]p(O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IGAZY1	ĵGazyva inj. 25mg/ml;40ml/vial					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IHAV	HAVRIX 720/0.5ML/VIAL()					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IHBV1	Bx̭]0.5ml H-B-VX					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124	IHBV1-a	IHBV1-b	IHBV1-c	
		0	IHDASE	Hyaluronidase inj.1500IU/amp					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ICOAZ-1	COVID-19 ̭]AstraZeneca					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
COVID19MVC		0	ICOGD	MVC Covid-19 Vaccine(Ĥ@)/(ĤG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
K000702206		@礭X@̭](ճ\}˭\LӭMʦʤy\hʤp\byʷP_ݦ߲VX̭])	INFAN	"InfanrixX@O̭](GSK)
"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
X000154206		0	IDTPIP	"DTaP-IPV1,DTaP-IPV2 DTaP-IPV3, DTaP-IPV4"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IFLU	FLUCELVAX 0.5ml/ |					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts111.9.29		0		OIs 20251124				111.9.29
		0	IHEPB	ˬHbsAg(+)HbeAg(-)LWBx̭](O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IHIB	bݦ̭߬]Ĥ@(O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IJBE	JAPANESE E VACCINEĤ@					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IPERL1	Perlane 1ml/(MΦ۶O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IRADI1	G(Radiesse) 1ml/(MΦ۶O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IREPA0	Repatha(ث~) 140mg/ml/pen(Evolocumab)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000967206		0	IJECV	ʴrOX饻O̭]					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	ITECE0	ĵ Tecentriq 840mg/14ml/vial(Atezoum					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
X000159209		0	IJELA	ʴr饻O̭]					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IVAX	AdimFlu-S 0.5ml/wwѫ		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES		wyPC					аѦҾqPΪk	  		  	ixiij	Ts111.10.3		0		OIs 20251124				111.10.3
J000082209		0	IJEVC	VeroӭMƤ饻O̭]					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
NC09997209	B05XA03	0	INAC5	Isotonic sodium chloride 1L inj (0.9%)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
																																		
K001036206		ڴw|yP̭]	IVAXI	Vaxigrip 0.5ml/TETRAڴw		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES		wyPC					аѦҾqPΪk	  		  	ixiij	Ts111.10.3		0		OIs 20251124				111.10.3
		0	IVIT1	Vital 1ml/(MΦ۶O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
N006941209	J01GB04	0	IKANA	Kanamycin 1gm/vial(eާO)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124				
		0	IVAX21	AdimFlu-S 0.5ml/(3-6KOyP)		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES		wyP   					аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BR00091223	V10XX03	0	IXOFI	fXofigo solution for injection6.6MBq/6ml/vial(ħo)Jv			Xofigo q{C魫 55 kBq gʡACj 4 gA@ 6 `gC |wWL 6 wʻPĶisC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	̩gʪWw xs40ץHU	Radium-223 chloride 6.6MBq (=3.48 ng J-223)/6ml/vial				~Ωvhէܩ@(castration-resistant prostate cancer)fwAX֦gಾB|Ŧಾ̡C		mBߡBæRBy			аѦҾqPΪk	  		  	ixiij	Ts111.9.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.68._20210427.pdf"">OI` 9.68.</a>              "	0		OIs 20251124	IXOFI-a	IXOFI-b	IXOFI-c	111.9.20
		0	ITDAP	Tdap-IPVO̭](åͩҴ)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
																																		
۶O	V07AB	0	IWAT4	"ĵ""HF""Water for inj. 500ml/bot"		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124	IWAT4-a	IWAT4-b	IWAT4-c	
BC23901214		0	J15171	"Balance1.5%,1.75mmoltzRG 2.5L/"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC23901221		0	J15172	"Balance1.5%,1.75mmoltzRG 5L/ U"			"vΦB洫eqBdɶMϥΦƵݭnvwCϥήɦpGıo@ΤӱjΤӮzAЧivC
HΦѦ~HG
@ĳqC2000 @ɡA θzRɺ޽wCa`JĤAɬ 5~20 CzRGdbĤ 4 8 pɫAA
ެyXӡCBJC魫ƥ|C
θjHBŦ\৹ॢfHBΥiӨheqfHACvi 2500 3000 @ɤqC
Yb}lzRɡAo͸ȵhACvq֦500 1500 @ɡC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"sbpĦLkĲΪa
nxb4 ץHU
WLĤAФnϥΡC
Ul}lΦɡAФnϥΡC
VXóƥΪzRGWϥΡAmɶiWL24 pɡC
ΧzRGC"				0	AΦbY[lLC]C[g^BYtlL]tg^fHC	"̪񪺸}MΨˡA]A gLNֵogθHFNˡFzDաFֽo]ֽ^Foʸz
Def]JùefBũʵzBͫǪ^FĤo]^FὺޡFFθzD~FFzD]z^C
ЪͳefASOOͪ
ХN²`]ŻĦg
ЦGr]Ѧg
зת魫Ai}
Ц夤תտ@׷]
ХHzRvLĩΤAyrg"	zRvg`ݨ쪺Ƨ@άOAAiƥXGVBAõo͸hB餣ABoNgAY[HvAiɭPѦgCt@`Ƨ@άOɺުoAg]A~BGBmBkhCƥXGo{VBɡAݥߧYqvAñNzRެyGεL@Uʦ浹vAH˴Pwoͭ]CzRv]iy~ȤιȷPBBӻHhBJ@ӾɭPIluPBmΫKCzRGyJMyXĪL{]iêCzRGƧ@Υ]AqѽMGšApC[ΰtBGWn]Ҧp~BIluP^B]ҦpwtB٦ש⵬^B}B]saJ}魫W[BרN²`C߸[֡BCBƧ@Τ]gQiC			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC23907214		0	J23171	"Balance 2.3%,1.75 mmol/L tzRG2.5"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
AC59035157	R05FA02	0	JBROWN	Brown Mixture					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JCVV1	SODIUM CHLORIDE INJECTION 0.45%					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JCVV2	SODIUM CHLORIDE INJECTION 0.45%					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22199210		0	JD13B1	9865TB 1.5%zRG1.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22199212		0	JD13B2	9866TB 1.5%zRG2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22199214		0	JD13B5	9868TB 1.5%zRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22299214		0	JD22A2	9728 2.5%CtzRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22299221		0	JD22A5	5202 2.5%CtzRG5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22299212		0	JD22B0	9776 2.5%CtzRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23907221		0	J23172	"Balance 2.3%,1.75 mmol/LtzRG 5L/"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22299214		0	JD22B2	9778TB 1.5%CtzRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198214		0	JD23A2	5178 2.5%zRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198221		0	JD23A5	5194TB 2.5%zRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198212		0	JD23B0	9876TB 2.5%zRG2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198210		0	JD23B1	9875TB 2.5%zRG1.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198214		0	JD23B2	9878TB 2.5%zRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298214		0	JD42A2	9748 4.25%CtzRG2.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298221		0	JD42A5	5203 4.25%CtzRG5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22299210		0	JD22B1	9775TB 2.5%zRG1.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298212		0	JD42B2	9796 4.25%CtzRG2.L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22218221		0	JD43A5	5195TB 2.5%zRG5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22218210		0	JD43B1	9895TB 4.25%zRG1.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22218212		0	JD43B2	9896TB 4.25%zRG2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298210		0	JD42B1	9795TB 4.25%zRG1.5L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AC22049209	R06AA02	0	JDIPHE	DIPHENHYDRAMINE HCL					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23901212	B05DB	0	JB1517	"Balance1.5%,1.75mmoltzRG 2L/ U"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22297214	B05DB	0	JDLC12	Dianeal Low Ca. 1.5%zR2.5L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23907212	B05DB	0	JB2317	"Balance 2.3%,1.75 mmol/L tzRG 2L"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC24920214	B05DB	0	JBA231	"Balance 2.3%,1.25 mmol/LtzRG 2.5"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC23906212	B05DB	0	JBA425	Balance 4.25%Ƥ踡zRG;2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22297221	B05DB	0	JDLC1	Dianeal Low Ca. 1.5%zR5L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22297214	B05DB	0	JDLC1U	Dianeal Low Ca. 1.5% 2.5L(UzR)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22299221	B05DB	0	JDLC2	Dianeal Low Ca. 2.5%zR5L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JDOXAB	Doxaben2mg					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JDUCOL	Ducolax					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23687212		0	JE73A2	4974RhzRG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.6._20190801_000.pdf"">OI` 3.3.6.</a>              "	0		OIs 20251124				
BC23687212		0	JE73B2	4984RhzRG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.6._20190801_000.pdf"">OI` 3.3.6.</a>              "	0		OIs 20251124				
		0	JENPEX	Enpex					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JENZDA	ENZDASE E. C. T					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
	B03XA01	0	JEPO-1	EPREX INJECTION 4000 U/ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JEPO10	yOQ1000U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
	B03XA01	0	JEPO-2	EPREX INJECTION 2000 U/ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JEPO20	yOQ2000U (b)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JEPO-T	yOQ2000U ()					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22299214	B05DB	0	JDLC22	Dianeal Low Ca. 2.5%zR2.5L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22299214	B05DB	0	JDLC2U	Dianeal Low Ca. 2.5% 2.5L(UzR)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JFENOT	Fenoterol					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JFOL10	Folic Acid 10mg HH					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JFOLIC	Folic Acid 5mg HH					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JFUCOU	Fucou					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JGASCO	Gascon [w					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JGLIDI	Glidiab (Minidib)75s t					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JGUTRO	Gutron 2.5mg O					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JHOU	nGHOU WE MING					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JHYCOM	Hycomin					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JIND10	Inderal 10mg(Cardolol)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JINDER	Inderal 40mg(Cardolol)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JINNOH	Innohep t					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JISORD	Isordil 10mg ùF					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JKETOP	Ketoprofen wP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JKETOT	ӳ(KETOTIFEN)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JLANVI	Chinlivita (Lanvita)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JLONIT	Loniten 10mg					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JLOPID	JLOPID					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JMIRCE	EPO-MIRCERA50					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JMUBRO	Mubroxal					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298212	B05DB	0	JDLC42	Dianeal Low Ca. 4.25%zR2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JNS100	N/S 1000U (SODIUMCHLORID INJ) ٥					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JNS500	N/S 500U ( SODIUM) wP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JOMELO	OMELON					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JOSTAL	Ostalfa					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22915212		0	JN12B2	9696 2.5%CtzRG2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.5._20100501_000.pdf"">OI` 3.3.5.</a>              "	0		OIs 20251124				
BC22199214	B05DB	0	JPD212	PD-2 1.5%zR2.5L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22198212	B05DB	0	JPD222	PD-2 2.5%zRG 2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC24219212	B05DB	0	JPD411	Nutrineal PD4+1.1%A.A 2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.5._20100501_000.pdf"">OI` 3.3.5.</a>              "	0		OIs 20251124				
BC22298221	B05DB	0	JDLC45	Dianeal Low Ca. 4.25% 5L/U zR					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JPEACE	Unflu (Peace)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JPREDN	Prednisoline					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JS1000	N/S 1000U (SODIUMCHLORID INJ) wP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JSENNA	Sennapur 12.5mg					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JSENOK	Senokot 154mg t					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JSTERM	STERMIN F.C.T100mg(PTP)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JSYNBO	Synbot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JTINTE	Tinten					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JTRANE	Tranexam 250mg					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JVENA	Vena-Cal-B6 5ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23687212	B05DB	0	JEXPD	Extraneal PD+7.5% Icodextrin 2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.6._20190801_000.pdf"">OI` 3.3.6.</a>              "	0	0	OIs 20251124				
		0	JVITAG	Vitagen50%20ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JVV1	SODIUM CHLORIDE INJECTION 0.45% S.T.					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	JVITAC	Vitacal					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0001	w					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0002	RAt(Fiber Source)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0003	qOd800G					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0004	ըK250CC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0006	O					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0007	jӱd8sq					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0008	ThCJ()					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0009	Qd-DELIVER II					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0010	޹~					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0011	t90					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0012	Q8s					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0013	Phdi~					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0014	Ǹɯ 8OZ					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0015	Чִ_					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0016	(Чִ_)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0017	qO300g					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0018	M1KG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0019	ӯ250CC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0020	w(Osmolite 8oz)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0021	ROOsmolite HN 8oz/237ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0022	AŦf					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0023	O8oz(Jevity 8oz)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0024	d					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0025	RtdŰtG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0026	Rtdδ 237ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0027	A2.0					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0028	RO[250CC/1.2d/1C.C					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0029	ΩoS㧡					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0030	ӯSR()					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0031	}A					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0032	RA(t)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0033	}i					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0034	ThhJ700gm					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0035	ThhŰt					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0036	kֺ					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0038	Rtdu ISOCAL PREMIUM					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0039	Ȱ-R|					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0040	RA1.5					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0041	dHN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0042	dt					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0043	Thd 865G					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0044	Nepro475d/237@/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	N0045	Thd 3KG/PK					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NALB	ALBUMIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NBLA	ISM2 10ML/BOT					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NBLAT	BLASTOCYCST THAWING PACK					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NDLL	DL-LATIC ACID					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NDMS	DMSO					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NEMBR	ISM1FLiG 10ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NETH	ETHYLENE GLYCOL					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NGLY	GLYCEROL					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NHEP	HEPARIN SODIUM CELL(H3149)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NHTF	HTF POWER HEPES (IRVINE SCIENCE)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NHYA	Hyaluronidase 80U/ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NHYAS	HYASE-10X (Hyaluronidase zQ)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NICS	ICSI PVP					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NIVF	IVF MEDIUM 60ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NIVFM	IVF Medium 125ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NOIL	OIL FOR TISSUE CULTURE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NOSM	zMήեG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPARM	Liquid Paraffin Oil					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPRO	PROTEASE TYPE I					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPUR	PURE SPERM 100%					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPVP	PVP 10% νwC					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NQAC	QA CLEAVAGE MEDIUM					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NQAF	QA FERTILIZATION MEDIUM					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NQAM	QA MEDIUM W/HEPES					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NQUI	QUINN'S SPERM WASH					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSODB	SODIUM BICARBONATE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSODC	SODIUM CITRATE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSPEG	ORIGIO GRADIENT 100					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSPER	SPERM MAR TEST KIT					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSPERU	SERUM PROTEIN SUBSTITUTE					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NTES	TEST EGG YOLK IRVINE 90128					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	OEZEE1	EZeeX (˩\I) 45gm/] ; 3]/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
AB44136100	B01AC23	0	OPLET	*Pletaal 50MG/TAB					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.1.5._20160501_000.pdf"">OI` 2.1.1.5.</a><a href="""">OI` 2.1.6.</a>             "	0		OIs 20251124				
		0	JVV2	CVVH SOLUTION A S.T.					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PACI	ACID FAST STAIN					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PBOS1	*BOSTONi@zG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PBOS2	G(REWETTING DROPS)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PBOS3	MG(CLEANNER)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PCIT	CITRATE BUFFER(1000CC)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PEOS	EOSIN(̬)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PEXT	MEXTROGEN RECEPT					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IAVAS0	ĵ Avastin 100mg/4ml/vial(Bevacizuma					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IENHE0	ĵENHERTU 100@J/~		"ENHERTU (trastuzumab deruxtecan)O@HER2йvʧĪƦXC
b鵲X~FӭMWHER2Atrastuzumab deruxtecanƶiJӭMAbӭMgӭMת{?ïislѡAXӭMz(membrane-permeable)DXdAް_DNAl˻PӭM`CDXdO@exatecanlͪAĤOirinotecanʥNªSN-3810C"	ENHERTUĳq5.4 mg/kgAC3gHR߿`(21Ѷg)AefcƩεo͵Lk@rʬC	"ENHERTUiPtrastuzumabtrastuzumab emtansineۤNC
1.ʴfHO_X{ʪͯf(Interstitial lung disease, ILD/ͪxMg(y¡BIlxBoNM/ΥsoͩδcƪIlDg)
2.ݤʥզy֯gAbENHERTUʪ즸PCIΫeAε{ɻݨDAʴypơC
3.߫ǮgXvC]bv{ɻݨDwLVEFCYT{LVEFC40%Aά۸Uqj20%Aä[ENHERTUC^
שMרx\णfHAԷVIENHERTU"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	tseAxsBc(2XC - 8XC)C}᪺GAץxsbǷ(30J)̦h4pɡAxs2XC8XCBc̦h24pɡCxsɶ۰tsɶ_C	trastuzumab deruxtecan	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	WϥξAΩvಾᴿLإHWHER2{B㦳LkಾHER2ʨHfHC	LC	(79.9%)Bh(60.3%)BæR(48.7%)Bv(46.2%)BK(35.9%)Bh(34.6%)Bh(33.8%)Bݤʥզy֯g(32.5%)Bm(30.8%)BpO֯g(23.1%)By(21.4%)Bզy֯g(20.5%)PYh(20.1%)C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6899734?cesid=03fdgN8zSc5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DENHERTU%26t%3Dname%26acs%3Dfalse%26acq%3DENHERTU"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts111.5.31		OI` 	0	OIs 20251124	IENHE0-a	IENHE0-b	IENHE0-c	111.5.31
		0	IFASL0	ĵFaslodex inj.(ث~)250mg/8ml/syringe					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124		IFASL0-a		
		0	OPMS	PMS Sugar-Coated 0.625mg/tab					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IHER10	ĵ Herceptin SC.600mg/5ml/vial(Trast					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IHERC0	ĵ Herceptin I.V.440mg/vial(Trastuzu					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC22298214	B05DB	0	JDLC4U	Dianeal Low Ca. 4.25% 2.5L/(UzR					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IKAD10	ĵ KADCYLA 160mg/vial(Trastuzumab Em					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IKADC0	ĵ Kadcyla 100mg/vial(Trastuzumab Em					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ILIPO0	ĵLipo-Dox Liposome inj 2mg/ml*10ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	INITR	ĵNitroprusside sod. inj.50mg/vial					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IPERJ0	ĵ Perjeta 420mg/14ml/vial(Pertuzuma					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	ITHYR	Thyrogen 1.1mg/vial(Thyrotropin alfa)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixii[N]_B01-41j	Ts		0		OIs 20251124				
		0	NFLU	FLUSHING PH7.4 MEDIUM					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NHYAM	Hyaluronidase					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPAR	PARAFFIN OIL 60ML					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NPVPM	PVP Medium 1ml					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	NSPE	SPERM PREPARATION MEDIUM(PHENOL RED)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IEVIC1	Evicel Fibrin SealantֺJվX					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
																																		
		0	IEVI11	Evicel Fibrin Sealant 2ml/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PALC99	fzVη100NP 4L/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	PEA	EA-50					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IFLUO	Fluorescite 10% 5ml/vial					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiiƮw_Ʈw j	Ts		0		OIs 20251124				
		0	IGLIA1	Gliadel WaferӤJ7.7mg/;(Carmustine)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
BC23687212	B05DB	0	JEXPD1	Extraneal PD+7.5% Icodextrin 2L(U)		"Icodextrin?h޻EXADn@άObsiʦzR]CAPD^?ͺzCEXTRANEALbF12pɤsiʦzR]CAPD^AiíwįF۹ۦįध4.25%}zRGAEXTRANEALifHѸzRGlqtCC100ml EXTRANEALtG
Icodextrin]h}^ 7.5 g
Sodium Chloride]ƶu^ 538 mg
Sodium Lactate]ŻĶu^ 448 mg
Calcium Chloride]ƶt^ 25.7 mg
Magnesium Chloride]^ 5.08 mg
C1000 mlqѽ跻GtG
Sodium ]u^ 132 mmol
Calcium]t^ 1.75 mmol
Magnesium]^ 0.25 mmol
Chloride]^ 96 mmol
Lactate]Żġ^ 40 mmol
z׺z?284]milliosmoles / ɡ^C"	zRGb1020ɶAǥѯfHıoξAtסA`JġC髬~fHA`JqiWL2ɡCpGoؼWɡA`J1.5ɡCsiʦzR(CAPD)fHĳdm612pɡCӥ۰ʸzR(APO)fHĳdm14-16pɡC?ֱw̪ΪAAiNzRG[37J]98.6 X F^C?קKyw̶ˮ`ΤAAuĥΰ覡]ҦpqBOŪO^AibΦbLil[C	"HUw̸zRɡAԷVާ@G1^efGĽMJ]NBѩʲ `γж˯}l̡A¡XeB~FBPVBBTbBzyfΦ^zyfB`oʾͫǪBzDoθzDʦʯefBhnǩΨLl`θθĪefFM2^LefG]ADʯ߲ӡBתͯfC
b`[@שΧC[pUAi঳nK[ƹ[ (@׳̰?4mEq/L)AHקC[CM[M`[iJӵAԿvɶiC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xsC30XCҡC				0	Cʵǥ\IܡC	"㦳HUgfwAXϥEXTRANEALG
? EX(Ҧpɦ̾)M/IcodextrinL
? ޿}β޿}@}
? x޶Jng
? wYŻĩʻĤr
? LkBʯʳAϱoPD঳ĶiAΨϱoPVIW[
Oܸ\ʥΦ]jd߳sPϸ\l"		ĳbhέŴϥEXTRANEAL	ĳbhέŴϥEXTRANEAL	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.6._20190801_000.pdf"">OI` 3.3.6.</a>              "	0	0	OIs 20251124				
BC22297212	B05DB	0	JPD412	PD-4 1.5%CtzRG 2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC22299212	B05DB	0	JPD422	PD-4 2.5%CtzRG 2L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	LGASC	Simethicone emulsion 30%;300ml/bt					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
K000301209		0	IHBV	*ENGERIX-B(Hepatitis-B Vaccine)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
		0	IPEN1	Penicilina Atral 1MIU/vial(Benzilpencili					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"											аѦҾqPΪk	  		  	ixiij	Ts		0		OIs 20251124				
KC00452206	J06BB04	0	IHBIG	HEPATITIS B IMMUNE GLOBULIN 0.5ML(O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.1.1._19950301_000.pdf"">OI` 8.1.1.</a>              "	0	0	OIs 20251124				
BC25387221	B05ZA	0	IPRIS	ĵPrismasol B0GzRG5L/bag					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiiƮw_Ʈw j	Ts		0	0	OIs 20251124				
BC24922214	B05DB	0	JBA151	"Balance1.5%,1.25mmol/LtzRG 2.5L/"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC24922221	B05DB	0	JBA152	"Balance1.5%,1.25mmol/LtzRG 5L/"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
																																		
BC24920221	B05DB	0	JBA232	"Balance 2.3%,1.25 mmol/L tzRG 5L"					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC24922212	B05DB	0	JBA15	Balance 1.5%Ƥ踡zRG;2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JBIBAG	ĵBibag 650g/bag(B)(sod.bicarbonate)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JHE110	ĵHemodialysis(Ca.3.0).No.110(AG)3.8L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
AC33867209	R03CA02	0	IEPHE1	ĵEphedrine 40mg/ml/amp(Ephedrine Hcl)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
AC24212277	B05XA03	0	INAC43	0.45% SODIUM CHLORIDE INJECTION S.T.					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	JHE111	ĵBibag(5008) 650g/bag (sod.bicarbonate)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JHE16	ĵHemodialysis(Ca.3.5).No.16(AG)3.8L/					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	IIPV	Ƥp·̭]					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	IMMR	PriorixVtetra 0.5ml/vial(åͩ)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	JHE17	ĵHemodialysis (Ca.2.5).No.17(AG)3.8L					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
BC24920212	B05DB	0	JBA23	Balance 2.3%Ƥ踡zRG;2L/U					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
		0	JBIBA1	(5008)Bibag 650g/bag(sod.bicarbonate)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	IVAX1	Flublok 0.5ml/TETRA]KOyP̭]^		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES	0	wyPC					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
		0	IALC95	*99.5%L߰s 5ml/vial					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
J000085216		0	IBCG	*BCG					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
NC06489212	B01AC07	0	IPOSI	Posintin 10 mg/2 ml/Amp(ˬd)(Ŧެ)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[w]_w02-11 j	Ts		0		OIs 20251124				
K000480206		0	IVAR1	VARILRIXk̭](O)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
AB484841G0	A10BA02	ߧJ޽w500@J	OANSU	ĵGlucomin X.R.500 mg/tab (Metformin)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ĤG}fC 					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w63-02 [E]_E4-08 j	Ts	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	0		OIs 20251124	OANSU-a	OANSU-b	OANSU-c	
		ݥ|yP̭]	IVAM	fLuvacgent FLU 0.5ml/		"yP̭]]Ƥܭ^̭]YNyPfr豵ةo|JĤAiAXtfrĲGAg}KױߪkNfr@b`g23gNO@A`gۦfrܺةα̭]frܺزͧK̤A{ɸs
yP̭]O@ĤOu]HӲA4-6 ӤO@ĪGYiUC

ɤlο@YAHAűNfrɤlѡA HA qCHְLƫACĽwķG}ջsAϷG
tWwqfr HAC"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЧNxsb 2~8J		J07B	fr̭] VIRAL VACCINES	0	wyP   					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
AC029471G0	G03DC02	Hq}	ONORE1	SHITON S.C. 5mg/tab (Norethindrone)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			G03D	 PROGESTOGENS	0	ʤβߺDʬyBgLhgBXʤlcYBgxBoʤέoʵLgBťĤcPi  					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.12		0		OIs 20251124	DC	DC	DC	114.12.12
K000492206		0	IPNEU2	(O)23ͪy̭߬]0.5ml/(65HWKO)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
K000906206		0	IPREV5	(O)QT ͪy̭߬]0.5ml/(65HWKO)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
COVID19ModB		0	ICOMXB	Moderna XBB.1.5 (12HW0.5ml)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"					0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0		OIs 20251124				
AC57881421	S01GX06	qwĤ	PEMAD1	EMENTIN OPHTHALMIC SOLUTION		"EmedastineO۹ܩʪH1_C

P󵲽A]´EҭP޳qzʨ㦳@ר̿ʪC"	"1 drop in affected EYE(s) up to four times daily
ĳqOCI@wwACѤGCpݭnAi@I|C"	FקKìV~~ηGA`Nn~fIĲ¥ΩP䳡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Emedastine	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	LөʵgμxԪȮɩʽw	wEmedastine difumarateEMADINE@LӪ̸TΡC	Yh	iw/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668045?cesid=aM2qAQuCxRR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEmedastine%26t%3Dname%26acs%3Dfalse%26acq%3DEmedastine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-01 j	Ts112.10.17		0	0	OIs 20251124	PEMAD1-a	PEMAD1-b	PEMAD1-c	112.10.17
AC466811G0	N06BX03	YZ1200@J	ONOO3	SYNTAM 1200MG (Piracetam)		Piracetam@Ω󤤼ϯg覡Gո`gǾɡBPigΡBO@gN¡F@ΩOǤ覡GWjyӭMܧίOBpO\BCHYסBWjL޴`A@Ψä|ɦܦXiC󸣳\êfwAPiracetamA|ܸۧqi(EEG)AyalphabetaiWjACdeltaiAWjĵıʤλ{\CܷʪUظl(]AʮBrιqv)APiracetam|O@ӭMë_{OC	"1.2-2.4 g/day, divided in 2-3 doses; MAX 4.8 g/day

1. ޻êΦѤƤް_OêG wѴGvC4.8 gAvɨC龯qאּ2.4 gC
2. ֽʰ}oʩzG _lqC鬰7.2gAC34ѼW[4.8g/dayA̰WܨC24gCpľq魫pAC3050mg/kgC"	piracetamLӡAι糧Ĥ󦨤LӡAιpyrrolidonelͪLӪw̡AקKϥΥġCXAεǯe]End Stage Renal Disease^fHATΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Piracetam	N06B	"믫ġAΩv`NOʳhʯgĩMq PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"	0	︣޻êΦѤƩҤް_Oêi঳ġBֽʰ}oʩzUk	piracetamLӡAι糧Ĥ󦨤LӡAιpyrrolidonelͪLӪw̡AקKϥΥġCXAεǯe]End Stage Renal Disease^fHATΥġC	GzABŸݡBYBYh	קKϥ/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4671131?cesid=1rFMIKU7TlO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPiracetam%26t%3Dname%26acs%3Dfalse%26acq%3DPiracetam#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w49-01 [E]_B5-18 j	Ts112.10.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.8.1._19980401_000.pdf"">OI` 2.8.1.</a>              "	0	0	OIs 20251124	ONOO3-a	ONOO3-b	ONOO3-c	112.10.17
BC26406100	A10BK03	ƿ}10@J	OJAR10	ĵjarDiance 10mg (empagliflozin)		Empagliflozin Y@ SGLT2 Cǥѧ SGLT2Aempagliflozin iֵŦwLo}Al@ΡAíCŦ︲}Al֭ȡAǦW[}ƪnqC	"JARDIANCEiWϥΥiPmetforminBmetformin֥sulfonylureaBpioglitazone(֥ΩΤ֥metformin)Bخq(֥ΩΤ֥metformin/sulfonylurea)X֨ϥΡA@[󶼭ιBʤ~vĪAǥHﵽĤG}ffH}ĪGCJARDIANCEĳqC馭W@BC10 mgAiP@_AΡAiŸAΡC@ʨ}nAqiɦ25 mgwGeq֪fHAĳb}lAJARDIANCEeBv@p
[qվ]
}lϥJARDIANCEeĳǥ\Aé󤧫wC
ǵyLov<30 mL/min/1.73 m2:ĳAJARDIANCEC
ǵyLov>30mL/min/1.73 m2:Lվ㾯qC"	"1.JARDIANCEĳΩĤ@}ffHΥΩv}f଻ĤrC
2.Jardiancei޵oޤeq֡Dǥ\णfHAѦ~HAYCfHAHΥbϥΧQfHWD
jardiancevfHpGץN©ʻĤrALצ}hAhìO_଻ĤrAv଻ĤrɡAiݭnخqAøɥRҤƦXD
3.ʵŦIܪ](QAACEIAARBANSAIDs)ANPOAGyACʵǥ\णéwʴǥ\.
4.i|W[cDPVI"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Empagliflozin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	1BĤG}fG (1)}GĤG}fC (2)wߦިƥ:ΩĤG}fBwߦޯefHfHɡAiCߦޭ]`IC 2BŦIܡGΩìŦǷ|(NYHA)ĤGŦܲĥ|ŪŦIܦ~fHAiG Cߦަ`MŦIܦ|IC wwǵyLov(eGFR)UC 3BCʵŦfGAΩwCʵŦfHfHAHCHUIG (1)Ŧefcơ]wǵyLov (eGFR) 򭰧CBŦefεŦ`^Τߦަ`C (2)]ʦ|C	"1.  JARDIANCE YLӤC 
2. w׵ǥ\णBǯfΥzRC"	CBʵŦlˤεǥ\णC	C 	"קK
ĳbŴϥΡC(ivTLŦ)"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5280392?cesid=6aoePQvBUvO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEmpagliflozin%26t%3Dname%26acs%3Dfalse%26acq%3DEmpagliflozin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w58-04 [E]_E4-02 j	Ts112.10.18	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.16._20250301.pdf"">OI` 2.16.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.5.</a>            "	0	0	OIs 20251124	OJAR10-a	OJAR10-b	OJAR10-c	112.10.18
X000252251	B01AD04	0	IUROK2	ĵUrokinase 60000I.U 60KIU/~(Urokinase)		~NplasminogenƦplasmin(fibrinolysin)AMiNֺJժѡC	"GC1Aq60,000 IUAsĬ7
yR߳gGCq60,000~240,000 IUAHấA7C"	"1.PLfHioͥXʸC
2.ϥΥ~n`NY۵oʥXAg`@GˬdC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Urokinase	B01A	ܦ ANTITHROMBOTIC AGENTS	0	ʪͮAʫaʯ߮AMR߾ɺ	"1.ī~󦨤LӯfvfwC
2.XBI~NB72pɤLw´BCYx\êBCֺJխpΩX̧ҥΡCHypersensitivity to "	`-`gˤfBXκyF-LӡBYhBBoNBR?BߡBooB۵oʥXC	B	SmҦwADnקKϥΡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4671013?cesid=7ZegtBQSIPy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DUrokinase%26t%3Dname%26acs%3Dfalse%26acq%3DUrokinase#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts112.10.18		0	0	OIs 20251124	IUROK2-a	IUROK2-b	IUROK2-C	112.10.18
AC55913209	A04AA02	BRߪ`gG 1 @J/@	IGRAN2	VOMSTOP 1 mg/ml/amp]Granisetron^		wΪvܸ~Fƾkް_ߡBæRΪvܸ~Fgukް_ߡBæRCwʤΥbʧܸ~Fgukް_ߡBæRCvNް_ߡBæR	"H
w:Grenisetron@q13J(10~40?g/kg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}20~50ml`GHR߿`覡`ɶݤj󤭤C
v:Grenisetron@q13J(10~40?g/kg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}20?50ml`GHR߿`覡`ɶݤj󤭤CYl[vqPe@qjܤ֤QHW~iAGrenisetron̰q24pɤWL9mgC
ൣ
w:Grenisetron@q魫C10~40?g/kg(̦h3mg)Aܸ~Fk}leA覡CtRߪ`g(ɶj30)ε}10?30ml`GHR߿`覡`ɶݤj󤭤CYݭn24pɥHi@l[qAl[qP_lqj10HW~iC
"	1.KytriliVXLī~ϥΡC 2.wʧPb}lƾkeγ¾KieC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Granisetron	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0		惡ΨL selective 5-HT3 antagonists o͹LӪw	LYhBCzįʡC	B	MO_sͨ঳`C]bϥΥ~vQqjधbMIɤ~iϥΡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668958?cesid=10gyHCzZlLO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DGranisetron%26t%3Dname%26acs%3Dfalse%26acq%3DGranisetron#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-11 [E]_G2-04 j	Ts112.10.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.1._20130901_000.pdf"">OI` 7.2.1.</a>              "	0	0	OIs 20251124	IGRAN2-a	IGRAN2-b	IGRAN2-c	112.10.17
AC25025100	A07AA02	"""z""g50U]@߯^"	ONYST1	Nystatin Table 500000 U/tab 		PolyeneܥͯAiP߲ӭMTJ(Sterols)۵Xӧܨ亯zʡAϨӭMeX]Ӧ`AGRoWS@ΡC	"q`C12ɡA@ѤT|AΤC
({ɯgᤴ~A48pɥHWAH_o^C"	AΤ覡G (1) fAGeζ᧡iC (2) faBGGC@ɥH 10 25 @ɪN}wsCϥΫeХnáAN ĲGtfUAqRaf(3-5 )AMЧ]UΦRX (̷v)C (3) wsnaBGGN(2-8XC)OsA̦hiOsCѡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Nystatin	A07A	zDܷPV INTESTINAL ANTIINFECTIVES	0	zD]߷PVgwPvBsĩʧܥͯTJkɨ֥ά]߹L׼WޤwkC	糧YolBkoPLӯgoͤfATϥΡC	fAjqɷ|{mέGzêC	C	SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669628?cesid=9MvSArWylZP&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNystatin%26t%3Dname%26acs%3Dfalse%26acq%3DNystatin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-27 [s]_215 [®]_215 [E]_A3-13 j	Ts112.10.17		0	0	OIs 20251124	ONYST1-a	ONYST1-b	ONYST1-c	112.10.17
	L01EX23	0	OGAVR1	ĵGAVRETO Capsules 100 mg		PralsetinibOͫRET(wild-type RET)BPRETĦX(CCDC6-RET)MRET(RET V804LBRET V804MPRET M918T)E?CPralsetinibbtPRETĦXάܪiӭMMʪ~FӤJҫ{ܸ~FʡC	400mg QD	"Чi㦳ʹ޼?kʡA?GAVRETOvHγ̲׾q2gA?ĪDXץ?kCGAVRETOi|ϲXץĥġC
ĳ㦳?޼?kʦQkʡAGAVRETOvHγ̲׾q1g?ץIC

pGbA?GAVRETOX{æRΡAФnAAġA?p~U??ġCаѷӥĳqALk@C?A?100@Jf?AХä[?GAVRETOC
PjCYP3Aɾ?ɪqվAаѷӥ
PP-glycoprotein]Pgp^PjCYP3A@P?ɪqվAаѷӥ
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	}ʫiwwʮɶ3ӤCxs25XC (77XF)HUCШC	Pralsetinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	"1.AΩv?ߴಾRETĦXʫDpӭM(non-small cell lung cancer, NSCLC)HfHC 2.AΩݱʪv?ߴಾRETܥ?(medullary thyroid cancer, MTC)HfHC 3.AΩݱʪv?BggʸKv?L(pAΩgʸKv?)ߴಾRETĦXʥ?HfHC"		̱`}]25%^KBBh¡B٦װfkhMmC̱`3-4Ź絲G`]2H^]AOڲy֡Bݤʲy֡BUBCQUBt֡]ե@ס^Bu֡BѥV?]AST^ɰB?]ALT^ɰBpO֩MPC?ɰC	X	"ثeSŤO_sbpralsetinibΨN²AΨiĤlιﲣ
qvTƾڡCѩiൣi|X{Y}A]ĳkʦb
GAVRETOvHγ̲׾q1gnHiC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6992056?cesid=0ZhEr9yuyX4&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPralsetinib%26t%3Dname%26acs%3Dfalse%26acq%3DPralsetinib#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_8-02 j	Ts112.10.23		0	0	OIs 20251124	OGAVR1-a	OGAVR1-b	OGAVR1-c	112.10.23
		0	IETON1	ĵEtomidate USP 20mg/10ml/VIAL		ର GABA ո`A_l@ 30Aɶ4-10 A`Φb޳BmCSʤuIvTMʤOǡB୰C`A]JBCfwi|ϥΦĪA]@ӻݭn`NƧ@ΩMIG|11-]-hydroxylaseAǤW\ ( cortisolͦ)ë 4-8pɡA]iW[PV`IC	"~tEtomidate 2mg/ml(20mg/amp)
¾K:0.15-0.3mg/kg(0.075ml-0.15ml/kg)
15 HUൣΦ~w:0.15-0.2mg/kg(0.075ml-0.1ml/kg)
xwƤΤw뤩믫 (Neuroleptics)w̫h֥ζqC
󤤤wgAΤwgo@S¾KpUA 10 ֳtH`q Etomidate (0.3 mg/kgA۷ 0.15 ml/kg  Etomidate-Lipuro)CYnAiHqƼƦC"	"1.Etomidate iɭPͦC]iϥΩGXǩʻêw̡AD Etomidate AggJӵwT{䭷IPwqBC
2.ϥΰqûPϧĪXήɡAEtomidate iɭPuȩʩIlȰC
3.ɶʦa뤩 Etomidate |uȩʵǤWֽ貧`MICbɶNεǤWֽ\lpUAi
nֽJwʧġAҦp 50 V 100 mgBƥiQ (hydrocortisone)C
4.Etomidate-Lipuro LhĪGCY@u¾KɡAƥΦPɵp FentanyljĤhA綷`Nz ?椬@
5.Etomidate-Lipuro ȯR߿`Aq`wCa`@qһݮɶ 30 AYnAiqC
6.Etomidate-Lipuro ϥקKѰʯ߿`ӳy´aMICRߩP䤧`h|ް_@PkhC
7.뤩 Etomidate-Lipuro eA׫eXĥHקKٰ}˪o͡Cĳ Etomidate-Lipuro īe 1 pɥH٦ת`g 10 
eHRߪ`g覡뤩 BenzodiazepineĪp DiazepamC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xsūפiWL 25 XCAiNC
NwJs]˥~HץC
wui榸ϥΡCѾlC"	Etomidate	N01A	"¾K ANESTHETICS, GENERAL"	0	Rߪ`g¾K	Etomidate-Lipuro iϥΩw EtomidateBjoΥ~LLӤw̡C	"ۥD٦׹B(myocloni)CYeXħ뤩~Ī Benzodiazepine ĪhiקKo͡C
Etomidate |TJǤWֽ誺ͦXC@qEtomidate AǤWֽOa֬ 3 V 6p
SOObq EtomidateλPRĪ֥ήɡAioͩIlPIlȰ{HC
Etomidate īiX{ߤιæRAoDnO]Pɵ~ĪΦbeXĮɵ~ĪӤް_C
kh"	קKϥΰDvn/SmҦw	Etomidate |cܨťĤCY¨Ŵ Etomidate-LipuroAī 24 pɤo¨šAcťC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668592?cesid=4Owylh8dw1L&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEtomidate%26t%3Dname%26acs%3Dfalse%26acq%3DEtomidate#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.10.13		0	0	OIs 20251124	DC	DC	DC	114.10.13
AC19799212	A11HA06	0	IPYRI1	PYRIDOXAL PHOSPHATE (Vit.B6) 10mg/2ml/amp		"1.BsͯOݤʺͯAΩwΪvͯBʥFCدʥF|ѩ󤣾AiέGzDl}Ҥް_AӧOBsͯ©iO֨A]APOyhغͯCͯB6wQΩYSideroblastic ancmiasvWC 
2.Pyridoxineb餺QܦPyridoxal phosphatePyridoxamine phosphateC̬OUإN¥\઺J|vTJսBҤƦXί׽誺N¡CbiܦүĪഫWAPyridoxine]ѻP䤤C"	"1.@5-30 mg ֤U`gB٦ת`gBRߪ`gҥiAq~ֻC
2.ĥiGzRҲCzRfHPyridoxineݭnqW[C"	"1.ĤyPlevodopa֥ΡA]|levodopaantiparkinsonism@βͰfApNcarbidopaPlevodopa֦XϥΡAhPo͡C
2.LSjqpyridoxinelc|ɭPpyridoxine̿gC
3.ħΩC饿`ݭnqŰwʩ|إߡC
4.ѰOAΤߡA]ĤN»ݮɫܪAqOӫܮɶAΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pyridoxal phosphate	A11H	䥦ͯs OTHER PLAIN VITAMIN PREPARATIONS	0	BClBC¯lBֽkogBfBfBBުBLRЯʥFg	L	Pı`AݺΡAMĭC	"A
LSjqpyridoxinelc|ɭPpyridoxine̿gC"	SmҦw	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-34 [E]_G3-06 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.2._19950301_000.pdf"">OI` 3.2.</a>              "	0	0	OIs 20251124	IPYRI1-a	IPYRI1-b	IPYRI1-c	112.10.27
KC01094248	L01FA01	Qƺ `g	ITRUX5	ĵƼf TRUXIMA 500mg/50ml(Rituximab) 		RituximabPbBOڲӭMWCD20ܭ쵲XABҰʧK̤AHձB-ӭMѡCӭMѪi]A̿ӭMr@(CDC)Χ̿ӭMr@(ADCC)C̫Ab~swҩARituximab靈ǤƾǪvͧĩʪB-ӭMOڽFӷPC	"1. зǾqG~fwϥMabthera@kɡAĳq375 mg/TnCzLM@`ޡAR߿`MabtheraCg@@4C
2. @wHRߪ`g(i.v. injection)Τjq`(bolus infusion)覡Atsn`GC`MabtheraɡAbiߧYϥΡBUd]ƪ|ҤUMbg窺~Fv/GvYKʴU`C"	"tswwʡGN/A
}wwʡGǷ12hAN24h
ۮe}GGNSBD5W
ĳ}nG250-500ml
ĳĳ~|tvGĤ@IVF:50mg/hr,iW[ܤWL400mg/hr
ī~}~[GL
L`NƶG1.Do not administer as an IV push or bolus.
2.Should give premedications:Antihistamine(Diphenhydramine)BGlucocorticoids and Antipyretic(Acetaminophen)."	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 2 ~ 8 צBc(ŧN)FpoܽιLAiAϥΡC 	Rituximab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	Ω_oιƾkܩʤCcB-ӭMDNOڽFC֥CHOPΨLƾkΩCD20ܭ춧ʤBjʤjӭMDNOڽF60HWfwC	writuximabB~󦨤ιJսLӪfHTΥ~C	jfHoR߿`}]AӭMEXgԸsABDnbĤ@`ɡAq`b}l12pɶCoǨƥDn]AoNBNŸMHŸCLg]AyBޤ~BߡBC¯l/XlBhҡBYhBkoBIlxB|EB󪢡BæRBM~FkhCbj10%oǮרҤAoǯg|HۧCM޵jˡC֨fHg즳ŦppߵhΥRʤŦIܪcơC	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668291?cesid=8YmAT2H0Pl8&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRituximab%26t%3Dname%26acs%3Dfalse%26acq%3DRituximab#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-11 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.7._20210616.pdf"">OI` 8.2.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.20._20241201.pdf"">OI` 9.20.</a>             "	0	0	OIs 20251124	ITRUX5-a	ITRUX5-b	ITRUX5-c	112.10.27
BC28404100	A04AD12	0	OAPRE	Apreto 80MG(Aprepitant)		"1. Aprepitant㦳WS@μҦAHsubstance P neurokinin1(NK1)A㦳ܩʻP׿˦XOܾC
2. AprepitantiHziJAæڸNK1C{ɫesܡAaprepitant襤ϨtΪ@ήɶܪAiHcisplatinް_ʴPæRAåiWjR@Ϊ5-HT3-ܾondansetronPֽTJdexamethasonecisplatinҤް_æR@ΡC"	"1. EMENDoĥΤTѵĪ覡A֤J]A@إֽTJM@5-HT3ܾv{@_ϥΡC
2. EMENDĳqĤ@ѦbƾǪvie@pɤfA125mgAbĤGѩMĤTѦCѪAΤ@80mgC"	ϥEMENDɥi୰CfAץĪ\ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aprepitant	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	PLRľ֥ΡAiHѷް_æRgĪ(]AqCISPLATIN)b즸έШϥήɩҤް_ʩΩ߻PæRC	"1. EMENDiΩ惡~|LӪfHC
2. EMENDiPpimozideBterfenadineBastemizolecisapridePɨϥΡCAprepitantcytochrome P450 isoenzyme 3A4(CYP3A4)@ΡA|ɭPoĪ夤@פɰAi|޵oYΦMΥͩRC"	СBzLO«BxALTɰBKBYhMC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668672?cesid=7YFxReCGEzV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAprepitant%26t%3Dname%26acs%3Dfalse%26acq%3DAprepitant#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_1L-01 [96]_1L-02 [96]_1L-03 [96]_1L-04 [96]_1L-05 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.2._20130801_000.pdf"">OI` 7.2.2.</a>              "	0	0	OIs 20251124	OAPRE-a	OAPRE-b	OAPRE-c	112.10.27
BC28403100	A04AD12	0	OAPRE1	APRETO 125mg(Aprepitant)		"1. Aprepitant㦳WS@μҦAHsubstance P neurokinin1(NK1)A㦳ܩʻP׿˦XOܾC
2. AprepitantiHziJAæڸNK1C{ɫesܡAaprepitant襤ϨtΪ@ήɶܪAiHcisplatinް_ʴPæRAåiWjR@Ϊ5-HT3-ܾondansetronPֽTJdexamethasonecisplatinҤް_æR@ΡC"	"1. EMENDoĥΤTѵĪ覡A֤J]A@إֽTJM@5-HT3ܾv{@_ϥΡC
2. EMENDĳqĤ@ѦbƾǪvie@pɤfA125mgAbĤGѩMĤTѦCѪAΤ@80mgC"	ϥEMENDɥi୰CfAץĪ\ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Aprepitant	A04A	RĩM ANTIEMETICS AND ANTINAUSEANTS	0	PLRľ֥ΡAiHѷް_æRgĪ(]AqCISPLATIN)b즸έШϥήɩҤް_ʩΩ߻PæRC	"1. EMENDiΩ惡~|LӪfHC
2. EMENDiPpimozideBterfenadineBastemizolecisapridePɨϥΡCAprepitantcytochrome P450 isoenzyme 3A4(CYP3A4)@ΡA|ɭPoĪ夤@פɰAi|޵oYΦMΥͩRC"	СBzLO«BxALTɰBKBYhMC	B	Ҽ{Ī˪nʮɡAݨMwũΰA	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668672?cesid=7YFxReCGEzV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAprepitant%26t%3Dname%26acs%3Dfalse%26acq%3DAprepitant#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_1L-06 [96]_1L-07 [96]_1L-08 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.2.2._20130801_000.pdf"">OI` 7.2.2.</a>              "	0	0	OIs 20251124	OAPRE1-a	OAPRE1-b	OAPRE1-c	112.10.27
BC28240443	R03AL08	ͼֳߩQF	ETREL1	184/55/22()TRELEGY ellipta inh. 30dose/~		"TRELEGY ELLIPTAtfluticasone furoateBumeclidiniumPvilanterolTئCHUӧO@ξAΩTRELEGY ELLIPTACo3ĪDOPOĪ(@ICSB@اxPEĪΤ@LABA)A{ɫлPͲzЪvTUۦPC
Fluticasone Furoate
Fluticasone furoateO@ئXTtƥֽTJA㦳ܵo@ΡC
Umeclidinium
UmeclidiniumO@تīrPܾAq`S٬xPEĪCrPȫM1M5˩MOjPۦPC~bDĲz@Ϊ覡OƦ٤WM3AqӾɭPXiC
Vilanterol
VilanterolO@LABAC~ܡAvilanterol\ܩʩMsalmeterolC"	"1. TRELEGY ELLIPTAHCѧlJ@覡ġABȥigflJC
2. lJAwΤfABi]UAoOFUCoͤf|]߯fIC
3. TRELEGY ELLIPTACѩۦPɶġC
4. C24pɤiϥTRELEGY ELLIPTAWL1C
5. Ѧ~w̡Bǥ\णw̩Τרx\णw̡Aվ㾯qC"	"1. TRELEGY ELLIPTAäAΩvݡC
2. TRELEGY ELLIPTAw̤i]]ӨϥΥt@اtLABA]psalmeterolBformoterol fumarateBarformoterol tartrateBindacaterol^ĪC
3. ĳw̦blJĪΤfABi]UAǥHUCoͤf|]߯fIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fluticasone 184mcg+Umeclidinium55mcg+Vilanterol 22mcg	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	AΩ֥ΧlJʪī]2-ǤW@ξMlJʥֽTJvݤΪ~fHAݺvC	"TΩUCw̡G
1. YųJչLӰDC
2. wҹfluticasone furoateBumeclidiniumBvilanterolΥξLӡC"	IlDPVBͪBުBfĩ]߷PVB`hByPBuB|B󪢡BKBDPVPoxC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6544211?cesid=3l78rchhRaE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTrelegy%26t%3Dname%26acs%3Dfalse%26acq%3DTrelegy#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M01-12 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.1._20240801.pdf"">OI` 6.1.</a>              "	0	0	OIs 20251124	ETREL1-a	ETREL1-b	ETREL1-c	112.10.27
	A05BA08	ƨx	OMAGH1	Miyaphargen Film Coated Tablets		"Glycyrrhizin ̿uqѬr@ΡAO@xŦAﵽxŦAtӭMᬡAո`ƵǥֽXcAcorticoid餺ʡAܪg@ΡAܹLӧ@ΡAΤBqѽN½ո`@ΡCSƵǥֽଡʤơAiϥSteroid Hormone(TJX)sҲͤƵǥֽ褧YA]iܦӸSteroid Hormoneܦתާ@Φӧתާ@ΡC氣Cholesterol@ΡA夤CholesterolȤWɡAjʯߤwơC
DL-Methionine ݮħtĤ@ءAѬr@λPܯתըx@ΡAO@xŦPiधﵽC
Glycine ܹLӧ@λPѬr@ΡAæGcīפwĽո`@ΤΫPiQ@ΡC"	H@3AC2~3AൣOHbqC\AΡAiP֪AC	"i1jѦ~HC[gƧ@ΪoͲvAĮ`N[fi2jӦC[g,W@,NalcdB~,魫W[gX{,@夤Klȴw,ðġi3jPFurosemideBEtacynic Acid ThiazidetQ֥ή, oľQ@ΡAϥҧtͤglycyrrhizin[ƪn@μWjAeoͦ[ȭC{HA]`N[VPC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Glycyrrhizin/Glycine/DL-Methionine			0	xBxŦêBGBGĹLhgBGšBQGzšBlBֽBC¯lBꫬgB󪢡B޵j	iΩC[fH	dNg٦פAg	|TwﵹĪwʡA]ubvqBjIɤ~	|TwﵹĪwʡA]ubvqBjIɤ~	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_06-03 [E]_B4-15 j	Ts112.10.27		0	0	OIs 20251124	OMAGH1-a	OMAGH1-b	OMAGH1-c	112.10.27
BC27039100	A10BD20	}12.5/850@J	OJARDD	ĵDUO jARDiance 12.5/850mg Film-Coated Tablets		"}t empagliflozinAOĤGu-}BqD (SGLT2) ;t metforminAOg (biguanide)ĪC
Empagliflozin ĤGu-}BqD (SGLT2) YtdlѵǵyLo^`}DnBqDC Empagliflozin Y@ SGLT2 Cǥѧ SGLT2Aempagliflozin iֵŦwLo}Al@ΡAíCŦ︲}HȡAǦɧ}ƪnqC Metformin HCl Metformin O@??ĪAﵽĤG??ffH?@ʡA?C¦ζ夤?CbƾǵcWĲzǤWAPL?fA??ĪLpʡCMetformin ֨xŦ?ͦB?CzD︲?lAåiǥѼW[P´︲?lM?ΦӧﵽخqӷPʡC?PDQĪAmetformin ĤG??ffHΥ`H]DbS?pU^|yC} [аѾ\ĵyΪ`Nƶ (5.5)]A]|޵oخqgCH metformin v?ɡAخq??ܡAӪŸخq@?ΥѪ夤خqڤWi֡C"	"? wGeq֥BeempagliflozinvfHAĳb}lAή}eB@pC
? ЮھگfHv{pվ㮦}lqG
- 󥿦bmetforminvfHAдtempagliflozin    5mgλPmetforminC`q}F
- 󥿦bempagliflozinvfHAдtmetformin 500 mgΪempagliflozinC`q}F
- wPɱempagliflozinMmetforminvfHAдUҧtC`qһPӬۦP}C
? Ф@Ѩ⦸H\Aή}FqդvBHmetforminް_zGƧ@ΡC
? ھڦĩʤέ@ʽվ㾯qAiWL̰ĳC龯q]metformin2000 mgAempagliflozin25 mg^C"	}TΩ󭫫׵ǥ\णfH]ǵyLovpȤp30 mL/min/1.73 m2^C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25XCHUAקKӮgC
ЦsൣLkowBҡC"	Empagliflozin 12.5mg/ METFORMIN HCL 850mg	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"AΩmetforminempagliflozinɦ}ΡAΦwPɱmetforminempagliflozinX֪vӪpíw̪ĤG}fHfHAbPBʥ~Aﵽ}UvC
EmpagliflozinΩĤG}fBwߦޯefHfHɡAiCߦޭ]`ICMӡA~}ΩĤG}fBwߦޯefHfHɡA䭰Cߦޭ]`Iĩʩ|QإߡC"	"}TΩ󦳤UCpfHG
? צܭ׵ǥ\ण]ǵyLovpȧC45 mL/min/1.73 m2^Bǯf (ESRD) γzRfH
? ʩκCʥN©ʻĤrA]A}f଻ĤrC}f଻ĤrHخqivC
? empagliflozinmetforminYLӤC
? LTүgаѾ\metforminC"	CBʵŦlˤεǥ\णC	C 	"קK
ĳbŴϥΡC(ivTLŦ)"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5808606?cesid=84RgHdXaKk7&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDUO%2BjARDiance%26t%3Dname%26acs%3Dfalse%26acq%3DDUO%2BjARDiance#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_G4 [2]_G4 [ws]_w59-02 [E]_E4-10 j	Ts112.10.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.5.</a>              "	0	0	OIs 20251124	OJARDD-a	OJARDD-b	OJARDD-c	112.10.27
		ݦΰĪ`gG	ISPOR1	SportVis(Sodium Hyaluromate)1.2mg/1.2ml		"νwΨU_Ĥ@βĤGŤ`ˡBw
а~WN(yy)CʯkhBPwѯfwӱٸsٸxCʯkhC
"	@ 2 `g]j1g^BvLĪC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium Hyaluromate	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	"νwΨU_Ĥ@βĤGŤ`ˡBw
а~WN(yy)CʯkhBPwѯfwӱٸsٸxCʯkhC
"	w糧~ʦLӪw̡C	khB~ȡBw	iw	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii[]_08-04 j	Ts112.11.08		0	0	OIs 20251124	ISPOR1-a	ISPOR1-b	ISPOR1-c	112.11.08
	A06AH05	AĽ0.2@J	OSYMP1	Symproic 0.2mg(Naldemedine tosylate)		"1. ~骺X˩M
b鵲Xʸ礤AܥĹHգgB_Be~
㦳X˩M)C
2. ~骺\ଡ
HգgB_Be~Aܨܾ(antagonist)
ĪGBPi(agonist)ĪG)C
3. K@
b֤U`gܰؤoxycodoneojpzBJժ_ҫA
PɳªoojmҫA榸fAP0.03mg/kgHWA
ﵽܰػoK)C
4. ܰؤh@ΪvT
榸fAPĳ̰3mg/kgAj֤U`gܰؤhĪG
LvT)C
5. ~Ī_gԸs
ܰب̿ʪj榸fAPĳ̰1mg/kgɡAo{
ϩ~Ī_gԸs)C"	"HĳqCfA10.2 mgC
P~ĪɡAPġC"	"1. VP(UCfHзVP)
(1) wκæwjʸzGD޾cʭCeffH(pGzGDšBͫǪBʸzGDgBಾBΧJg)[i|W[zGDժIC
(2) wF(]tಾ)帣پ}aκæ帣پ\णfH[i|X{~Ī_gԸsδChĪGC]"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25XCHUxsC	Naldemedine	A06A	m DRUGS FOR CONSTIPATION	0	vH]~Īް_KC	"1. 糧Ĥ@o͹LӯgfHC
2. ~TΩwκæzGDθzGDդfHAΥi_oʸzGD뭷IfHA]iyzGDաC"	mAhC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6451718?cesid=6uNyFJN8GqE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNaldemedine%26t%3Dname%26acs%3Dfalse%26acq%3DNaldemedine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_3R-01j	Ts112.11.08		0	0	OIs 20251124	OSYMP1-a	OSYMP1-b	OSYMP1-c	112.11.08
AC59063421	S02AA16	մYIղG0.3%	ETARI2	պwOFLOXIN otic 5ml  (ofloxacin)		"HΤp~ժBHΫC֦~դCʤժB˦yfުpʤժC
"	q`C鵹Ĩ⦸ACN 6 10w Earflu IղGwJդAĤdbզ 10Cq(ϥΦ)hi̾گgHվC	"1. UCw̽ФŨϥΡA糧LӬJҪ̡C
2. UCw̽зVϥΡAYǻêw̡C
3. 便B¨ŰPC(1)hĦwʩ|TwA]ΧYNh̤iPC(2)|ಾܥŤAGPקKšC
4. pĪPA|TwwʡAGpĤŨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Ofloxacin	S02A	ܷPV ANTI-INFECTIVES	0	HΤp~ժBHΫC֦~դCʤժB˦yfުpʤժC	"Hypersensitivity to ofloxacin, other quinolone or any component of formulation.
"	"Skin eruption, pruritus, rash, eczema, taste sense altered"	iw/SmҦw	DnקKϥ/Smܦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669294?cesid=7cLlYRHeIbR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOfloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DOfloxacin#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_O02-04 [E]_I3-08 j	Ts112.11.08	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=12.3._19990801_000.pdf"">OI` 12.3.</a>              "	0	0	OIs 20251124	ETARI2-a	ETARI2-b	ETARI-c	112.11.08
AC60482100	L01BC53	gn20@J	OGOLF	ĵƼfGOLFER 20MGƤ		"TS-1tFTBCDHPPOxoAӸgfATS-1᪺ܸ~FʬOFTv餺ഫͪ5-FUCCDHPܩʥifsbxŦ5-FUѥNJ-DPDAӴӦFT5-FU@סCH餺5-FU@תɰA~F´5-FUCĤƲ-5-fluoronucleotidesi@סAiӼWjܸ~FġCOxofAGzDAiܩʥiforotate phosphoribosyltransferaseAӿܩʧ5-FUƬ5-fluoronucleotidesAbvT5-FUܸ~Fʪ@ΤUAPɤ]GzDrʡC
5-FUDn@ξOzL䬡ʥN²FdUMPPdUMPPthymidylate synthasevʵXAPɻP٭쫬ħΦTEAӧDNAXC"	"̾nplqAqifHpiվC
~󦭡B\@Ѧ@⦸ġAs򵹤28ѡAᰱ14ѡAY@{C
BSA < 1.25m2 : 40 mg/ (80mg/)
BSA < 1.25  < 1.5m2 : 50 mg/ (100mg/)
BSA 1.5m2 : 60 mg/ (120mg/)"	пA;AΦĥi|yzܤOUAקKĲثeDPVHξXC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Gimeracil+Oteracil+Tegafur	L01B	ܥN ANTIMETABOLITES	0	(@)GG1BGNỲUʤA~Ω󿩱wTNM STAGE II (ưT1)BIIIAIIIBGBLGڰʤN~w̡C2B~AΩvLkߴGC(G)ŦG~AΩvߴಾʯŦw̡C(T)jzzG~PIrinotecanX֨ϥΩwϥΧtOxaliplatinƾkѤಾʤjzzw̡C		"զyCUBmBߡBIC
"	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4671253?cesid=5r6A8MjXvQf&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTS-1%26t%3Dname%26acs%3Dfalse%26acq%3DTS-1#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-10 j	Ts112.11.08	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.46._20240201.pdf"">OI` 9.46.</a>              "	0	0	OIs 20251124	OGOLF-a	OGOLF-b	OGOLF-c	112.11.08
AC49704100	J01XC01	_g߽ 250 @J	OFUCI1	Disfect F.C. Tablets 250mg		Fusidic acidOӵ߳JսXwͧܵ߮ĪG@Τ覡@اܥͯCFusidic acidﳡ󶧩ʵߨ㦳jĪ@ΡAyߥ]ALƪLBGҮfCΨLܥͯܩʪߺعfusidic acidSOPʡC{ɸgҩfusidic acidLܥͯLeĩʡC	"1. fAwHG13A1500mgFൣG50mg/kg3AΡC
"	wnĤrYfsͨbAΥ~dNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC 	Fusidate sodium	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	󶧩ʵߤθyߤް_PVgC	Fusidic acidLӪ̸TΡC	"zGDê(Ƥ},,æR,m)A\ɪAΫhiקKC
ǯfHqRߪ`gFusidic acidAX{ifʶnAfAﵽAYnAvABullirubin_`C"	W̫TӤקKA	ŰõLϥΤWTҡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5001682?cesid=8HOaaG7ZnPg&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFusidate%26t%3Dname%26acs%3Dfalse%26acq%3DFusidate#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts112.11.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	OFUCI1-a	OFUCI1-b	OFUCI1-c	112.11.20
AC60876421	S01GX08	ͭ}ⲴĤ	PZADI1	Kedifen Eye Drops (ketotifen)0.025%;5ml/bot		Ketotifen O@ز´iH1-ܾAåBĤ@(?Y)LӤӭM(ΤjӭMBݥʥզyBPʥզyBMʲy)񤶽(pG´iBդTmBe?BpOE]l)CKetotifen iHֶݥʥզyͤƩʡBƻPh?Ƨ@ΡC	"@@w,@ѤG,wJnC"	"bϥΥ~enβ,ӥBϥΫ15oAW
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Ketotifen 0.25mg	S01G	ѥRĤΧܹL DECONGESTANTS AND ANTIALLERGICS	0	Ȯɹw]Lөʵް_oC	 Ketotifen ι䤤ξLӤ̡C	`/hBIWַl	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668541?cesid=aBEOttVwQrM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DKetotifen%26t%3Dname%26acs%3Dfalse%26acq%3DKetotifen#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-01 j	Ts112.11.24		0	0	OIs 20251124	PZADI1-a	PZADI1-b	PZADI1-c	112.11.24
BC21304277	L01AA01	0	IENDO5	ĵENDOXAN500mg/vial (Cyclophosphamide)		CyclophosphamideOoxazaphosphamideέlͦӥXӭMAcWMlC~ơAgѨxŦLïƦ4-hydroxycyclophosphamideAMaldophosphamide鲧cCӭMrʧ@άLʥNªMDNA_椬@ΦӨӡADNAѲͿ~esγJս赲cܡCӭM`AgG2qDOhƪAӭMrʧ@ιӭMgqSʡAӭMghCMLLƪ@ˡAרOcyӭMApIfosfamideAeĩʤQưC 	"1. R`GHwɡG4050mg/kgAƦP25ѥHWCqG1015mg/kgC7101A35mg/kgCCg2ΨC1.53mg/kgCĵwɡG28mg/kg60250mg/TƦPA@6ѩ6ѥHWCqG1015mg/kgAC7101C30mg/kgC34g1C
2. ﰩfHq??C "	"tswwʡGN24h
}wwʡGN24h
ۮe}GGNSBD5W
ĳ}nG100-500ml
ĳĳ~|tvGIVF 0.5-2h
ī~}~[GL"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 15 ~ 25 װB	Cyclophosphamide	L01A	Jƾ ALKYLATING AGENTS	0	OکʥզfBoʸ~FBCʲOکʥզfBʲOگfBOڦת޸~ΦUغ´ӭMWhgB~F_oC	"1.cylcophosphamideLӪ̡C
2.\Yl(רOHcytotoxic agentvαgʪvfH)
3.H֪C
4.DC
5.PVg(active infection)C
6.hα¨ŴC "	զy֡BpO֥XBhBXʻH֪BƧêBxٮ`BxBCugBߡBæRBBKgBUgBֽolBֽBIۡB«PBYhBߦٻٮ`BߤBCBͯB~BҪiBLlBLgB}Bж˪v¡C 	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Infant risk has been demonstrated.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669603?cesid=7fPLhxDz1yc&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCyclophosphamide%26t%3Dname%26acs%3Dfalse%26acq%3DCyclophosphamide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-04 j	Ts112.11.24		0	0	OIs 20251124	IENDO5-a	IENDO5-b	IENDO5-c	112.11.24
	A10BJ06	筿A	ORYB11	()ĵ Rybelsus 3mg/tab 30tab/box		Semaglutide O@ GLP-1 APH GLP-1  94% ǦCۦסCSemaglutide @ GLP-1 PľAiܩʵX GLP-1 ñN䬡ơAPͩ GLP-1 ؼФ@PC	"Semaglutide _lqC 3 mgA@ӤC@ӤANqW[C@ 7 mgqCC@ 7 mgܤ֤@ӤApݶi@Bﵽ}AiW[ܨC@ 14 mgqC

semaglutide C@̤jĳq 14 mgCAΨ 7 mgHF 14 mgĪG|gLsA]ĳAΤ覡C

Semaglutide ֥ metformin /ζu-}@PBJ2  (SGLT2i) thiazolidinedioneɡAmetformin/SGLT2i  thiazolidinedione iثeqC Semaglutide ֥DQ?ĪίخqɡAiҼ{խDQ?ĪίخqqAH֧C}IC
semaglutide qվ㤣ݭni}ۧںʴADQ?ĪMخqqվAhݭn}ۧںʴAרO@}lϥ semaglutide íCخqqɡAĳخqĨvB֪覡C
PP~|
筿A@ΦAC@ѤfAϥΡC
(1) ī~ŸAΡAib@ѤɶAġC
(2) ftֶq (̦hbMA۷ 120 @) ]AC}BHΩCZA]|MO_|vT semaglutide lC
(3) fHAīݦܤ30AiBܤΪAΨLfAĪCݮɶ֩ 30 |C semaglutide lC"	"!!ii(SNACS) 

Semaglutide ϥΩĤ@}ffHΪv}f଻ĤrCخq̿૬fHb}l GLP-1 PľvɡAYֳtίخqέCqA}f଻ĤriC{ɤWSΩìŦǷ| (NYHA)  IV {ʤŦIܯfHgA]ĳN semaglutide ΩofHC{ɤWSNfH semaglutide vgC
GzD@
ϥ GLP-1 Pľiް_GzD}AiӳyAupUiɭPǥ\cơCi semaglutide vfHAGzDƧ@ΥiɭPIAê`NקKGC
ʯŦ
ϥ GLP-1 PľfHoͫʯŦAifHʯŦ嫬gCæoͯŦɡA semaglutideCpGTEAis}lϥ semaglutideCw㦳ŦfvfHAϥήSOԷVC
rpξާ@OvT
semaglutide |vTrpξާ@񪺯OAμvTLCpGPDQ?Īίخq֥ΡAĳfHbrpξާ@ɪ`NקKC}o͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sT]ˤAקKuӮgΨCī~Цs30XCHUC	Semaglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"ftιBkAΩv}}ĤG}fHfHAHﵽ}C
(1) YfH]@}ΦTүgӤAXϥ metforminAi@kC
(2) PL}fĪX֨ϥΡC"	"1. ήaڦҪ (MTC) fvAοwĤGhoʤc~FgԸsC
2. w semaglutide  RYBELSUSLLӡC"	ߡBmιæRC	ĳϥ	ĳϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6577214?cesid=9xfmvfdepU6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSemaglutide%26t%3Dname%26acs%3Dfalse%26acq%3DSemaglutide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_5-01 [96]_5-04 [96]_5-07 [96]_5-10 j	Ts112.11.24		0	0	OIs 20251124	ORYB11-a	ORYB11-b	ORYB11-c	112.11.24
	A10BJ06	筿A	ORYB21	()ĵ Rybelsus 7mg/tab 30tab/box		Semaglutide O@ GLP-1 APH GLP-1  94% ǦCۦסCSemaglutide @ GLP-1 PľAiܩʵX GLP-1 ñN䬡ơAPͩ GLP-1 ؼФ@PC	"Semaglutide _lqC 3 mgA@ӤC@ӤANqW[C@ 7 mgqCC@ 7 mgܤ֤@ӤApݶi@Bﵽ}AiW[ܨC@ 14 mgqC

semaglutide C@̤jĳq 14 mgCAΨ 7 mgHF 14 mgĪG|gLsA]ĳAΤ覡C

Semaglutide ֥ metformin /ζu-}@PBJ2  (SGLT2i) thiazolidinedioneɡAmetformin/SGLT2i  thiazolidinedione iثeqC Semaglutide ֥DQ?ĪίخqɡAiҼ{խDQ?ĪίخqqAH֧C}IC
semaglutide qվ㤣ݭni}ۧںʴADQ?ĪMخqqվAhݭn}ۧںʴAרO@}lϥ semaglutide íCخqqɡAĳخqĨvB֪覡C
PP~|
筿A@ΦAC@ѤfAϥΡC
(1) ī~ŸAΡAib@ѤɶAġC
(2) ftֶq (̦hbMA۷ 120 @) ]AC}BHΩCZA]|MO_|vT semaglutide lC
(3) fHAīݦܤ30AiBܤΪAΨLfAĪCݮɶ֩ 30 |C semaglutide lC"	"!!ii(SNACS) 

Semaglutide ϥΩĤ@}ffHΪv}f଻ĤrCخq̿૬fHb}l GLP-1 PľvɡAYֳtίخqέCqA}f଻ĤriC{ɤWSΩìŦǷ| (NYHA)  IV {ʤŦIܯfHgA]ĳN semaglutide ΩofHC{ɤWSNfH semaglutide vgC
GzD@
ϥ GLP-1 Pľiް_GzD}AiӳyAupUiɭPǥ\cơCi semaglutide vfHAGzDƧ@ΥiɭPIAê`NקKGC
ʯŦ
ϥ GLP-1 PľfHoͫʯŦAifHʯŦ嫬gCæoͯŦɡA semaglutideCpGTEAis}lϥ semaglutideCw㦳ŦfvfHAϥήSOԷVC
rpξާ@OvT
semaglutide |vTrpξާ@񪺯OAμvTLCpGPDQ?Īίخq֥ΡAĳfHbrpξާ@ɪ`NקKC}o͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sT]ˤAקKuӮgΨCī~Цs30XCHUC	Semaglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"ftιBkAΩv}}ĤG}fHfHAHﵽ}C
(1) YfH]@}ΦTүgӤAXϥ metforminAi@kC
(2) PL}fĪX֨ϥΡC"	"1. ήaڦҪ (MTC) fvAοwĤGhoʤc~FgԸsC
2. w semaglutide  RYBELSUSLLӡC"	ߡBmιæRC	ĳϥ	ĳϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6577214?cesid=9xfmvfdepU6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSemaglutide%26t%3Dname%26acs%3Dfalse%26acq%3DSemaglutide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_5-02 [96]_5-05 [96]_5-08 [96]_5-11 j	Ts112.11.24		0	0	OIs 20251124	ORYB21-a	ORYB21-b	ORYB21-c	112.11.24
	A10BJ06	筿A	ORYB31	()ĵ Rybelsus 14mg/tab 30tab/box		Semaglutide O@ GLP-1 APH GLP-1  94% ǦCۦסCSemaglutide @ GLP-1 PľAiܩʵX GLP-1 ñN䬡ơAPͩ GLP-1 ؼФ@PC	"Semaglutide _lqC 3 mgA@ӤC@ӤANqW[C@ 7 mgqCC@ 7 mgܤ֤@ӤApݶi@Bﵽ}AiW[ܨC@ 14 mgqC

semaglutide C@̤jĳq 14 mgCAΨ 7 mgHF 14 mgĪG|gLsA]ĳAΤ覡C

Semaglutide ֥ metformin /ζu-}@PBJ2  (SGLT2i) thiazolidinedioneɡAmetformin/SGLT2i  thiazolidinedione iثeqC Semaglutide ֥DQ?ĪίخqɡAiҼ{խDQ?ĪίخqqAH֧C}IC
semaglutide qվ㤣ݭni}ۧںʴADQ?ĪMخqqվAhݭn}ۧںʴAרO@}lϥ semaglutide íCخqqɡAĳخqĨvB֪覡C
PP~|
筿A@ΦAC@ѤfAϥΡC
(1) ī~ŸAΡAib@ѤɶAġC
(2) ftֶq (̦hbMA۷ 120 @) ]AC}BHΩCZA]|MO_|vT semaglutide lC
(3) fHAīݦܤ30AiBܤΪAΨLfAĪCݮɶ֩ 30 |C semaglutide lC"	"!!ii(SNACS) 

Semaglutide ϥΩĤ@}ffHΪv}f଻ĤrCخq̿૬fHb}l GLP-1 PľvɡAYֳtίخqέCqA}f଻ĤriC{ɤWSΩìŦǷ| (NYHA)  IV {ʤŦIܯfHgA]ĳN semaglutide ΩofHC{ɤWSNfH semaglutide vgC
GzD@
ϥ GLP-1 Pľiް_GzD}AiӳyAupUiɭPǥ\cơCi semaglutide vfHAGzDƧ@ΥiɭPIAê`NקKGC
ʯŦ
ϥ GLP-1 PľfHoͫʯŦAifHʯŦ嫬gCæoͯŦɡA semaglutideCpGTEAis}lϥ semaglutideCw㦳ŦfvfHAϥήSOԷVC
rpξާ@OvT
semaglutide |vTrpξާ@񪺯OAμvTLCpGPDQ?Īίخq֥ΡAĳfHbrpξާ@ɪ`NקKC}o͡C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	sT]ˤAקKuӮgΨCī~Цs30XCHUC	Semaglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"ftιBkAΩv}}ĤG}fHfHAHﵽ}C
(1) YfH]@}ΦTүgӤAXϥ metforminAi@kC
(2) PL}fĪX֨ϥΡC"	"1. ήaڦҪ (MTC) fvAοwĤGhoʤc~FgԸsC
2. w semaglutide  RYBELSUSLLӡC"	ߡBmιæRC	ĳϥ	ĳϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6577214?cesid=9xfmvfdepU6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSemaglutide%26t%3Dname%26acs%3Dfalse%26acq%3DSemaglutide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_5-03 [96]_5-06 [96]_5-09 [96]_5-12 j	Ts112.11.24		0	0	OIs 20251124	ORYB31-a	ORYB31-b	ORYB31-c	112.11.24
KC01107216	A10BJ06	اg`g	IOZEM1	ĵOzempic solution for injection 4mg/3ml		Semaglutide O@ GLP-1 APH GLP-1  94% ǦCۦסCSemaglutide @ GLP-1 PľAiܩʵX GLP-1 ñN䬡ơAPͩ GLP-1 ؼФ@PC	"1. _lqCg@֤U`g 0.25 mgAs|gC0.25 mg OlvqA}SĪGC
2. 0.25 mg q|gAW[ܨCg@ 0.5 mgC
3. Cgq 0.5 mg ܤ֥|gApGݭn[j}AiW[ܨCg@ 1 mgC ̤jĳqCg@ 1 mgC
4. اgPPخqc(Ҧp sulphonylureas)ίخq֥ήɡAʴ}AæҼ{֫PخqcίخqqAHֵoͧC}IAרO@}lϥίاgíCخqqɡAĳخqĨvB֪覡C
5. ֥ήDQ?ĪMخqqվAݭn}ۧںʴFuվاgqAhݭnۧںʴ}C
6. pGL@ĪAb 5Ѥ֬ICpGWL 5ѫhLA̭qɵ{~`gU@CJopAfHi_Cg@Įɵ{C
P覡
اgCg`g@Aib@Ѥɶ`gA׬O_iC اg֤U`g측BjLΤWuAiHܪ`gAݽվ㾯qCاgiHRߪ`gΦ٦ת`g覡PCnɥiܨCg`gA⦸`gܤ֬۹j 3  (WL 72p)Cws`g餧ACg`g@C"	"1. Semaglutide ΩĤ@}ffHΪv}f଻ĤrASemaglutide ]NخqCخq̿fHb}l GLP-1 PľvɡAYֳtίخqέCqA}f଻ĤriC
2. Semaglutide Ω NYHA  IV {ʤ߰IܯfHʥFvgA]ĳoǯfHϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"즸ϥΫeGЦsBcN (2XC~8XC)AקKĲNoC
즸ϥΫGЦs30XC HUΦBcN (2XC~8XC)CФŧNاgA]nϥΧNLاgC`gϥΫᥲM^`g\AHקKuӮgC
ϥΤOsG6 gC"	Semaglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	"1. @kλPL}fvĪ֥ΡAvΪĤG}fHfHA@ιBʤ~UvC
2. ΩwߦޯefĤG}ffHɡAiCoͥDnߦިƥ(MACEG]Aߦޯef`BDPRʤߦٱBDPRʤ)IC"	"1. ήaڦҪ (MTC) fvAοwĤGhoʤc~FgԸs(MEN 2)fHC
2. ĪʦΥ@ξLӡC"	ߡBmιæRC	ĳϥ	ĳϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6577214?cesid=9xfmvfdepU6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSemaglutide%26t%3Dname%26acs%3Dfalse%26acq%3DSemaglutide#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-54 j	Ts112.11.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3.2._20201201.pdf"">OI` 5.1.3.2.</a>              "	0	0	OIs 20251124	IOZEM1-a	IOZEM1-b	IOZEM1-c	112.11.24
AC15849100	G03GB02	0	OCLOM2	CLOMIPHENE 50MG/cap 		~W[FSHLHq鸢ʳXӡCPiZλoƧZCQĪܻۿEʧ@Φb鸢ʳ(adenohypophysis)AhۿEotjXAXʸE(gonadotropin)A]iHW[Z_XͦX	"Ĥ@vGۤgӼĤѶ}lAġACѤ@ AsAѡC 
ĤGvGeAΫ᥼FƧZتAUgӼĤѦAתAġACѤGAsAѡC 
ĤTvGgGvAFƧZ̡ADL~E_ίfHu AiAiĤTvAΪkBζqPĤGvۦPC"	AΫAiಣ͵OҽkAФp߾rpξާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Clomiphene	G03G	PʸEMLƧZE GONADOTROPINS AND OTHER OVULATION STIMULANTS	0	ƧZêް_goƧZ	"(1) 糧~LӪ̡ATϥΡC
(2) D]Z_~FΦhnʧZ_gԸsҤް_Z_~jC(i|]Z_LרEӨϱoZ_[~j)
 (3) xl`Φxef̡C
(4) hkC"	ߡBæRBUhBYhBıҽkC	PL	hα¨ŴϥΥ~	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667979?cesid=4oM0NoSCuFb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCLOMIPHENE%26t%3Dname%26acs%3Dfalse%26acq%3DCLOMIPHENE#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-06 [s]_63 [®]_63 [E]_A1-13 j	Ts112.11.29		0	0	OIs 20251124	OCLOM2-a	OCLOM2-b	OCLOM2-c	112.11.29
	S01XA20	0	PTEAS1	Tear Naturale Oph Soln/15ml (Ƥ覨) 		"1.Ĥi@]\GcթHդް_gC

2.ĤA]tʻEXDuasorbAiP\GXӫPiC

3.ĤDHYʡAibdɶC

4.ī~pξAC"	"Instill 1-2 drops as frequently as required to relieve eye irritation symptoms
  
@12wAݭnɨϥΡC"	"]tBenzalkonium ChlorideAGtnβɽФŨϥΡC
}1ӤAݾlī~C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Duasorb	S01X	L OTHER OPHTHALMOLOGICALS	0	ȮɽwѦ]ߩҤް_`PPEP	]tBenzalkonium ChlorideAGnβɽФŨϥΡC	LCsϥ3ѯgѰɡAΨϥΫᲣͲ@hBOҽkΫoB~BBEPpAХߧYNC	קKϥ/SmҦw	0	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.05		0	0	OIs 20251124	DC	DC	DC	114.11.05
AC55939100	N06DX01	Bн 10 @J	OEBIX1	EXMEM FC TAB 10 MG(Memantine)		hҾܡGiĩʯgǾ(glutamatergic neurotransmi-ssion)xêAרbNMDALרEɡA|PghƩʥgg{ίefiiCMemantine@qձB׿˩MOBDvʤNMDAܾAi_]i(glutamate) jפɰ@γygêC	"Ĥ@g@Ѥ@5mgAvBվ㾯qC
1. Yվ㬰@10mgAh@ѤGU5mg C
2. Yվ㬰@15mgAhW10mgBߤW5mgC
3. ̤jqC20mgC"	LYǥ\lfHϥθơ]ٻMv9 ml/min/1.73 m2^A]ĳϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Memantine	N06D	ܷb ANTI-DEMENTIA DRUGS	0	vפέפqgC	Hypersensitivity to memantine or any component of the formulation	ıBxbBwtBYhBh¡C	iw/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669059?cesid=7lW4UGVU1dn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMemantine%26t%3Dname%26acs%3Dfalse%26acq%3DMemantine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 [ws]_w39-01 j	Ts112.12.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.3.3._20251001.pdf"">OI` 1.3.3.</a>              "	0	0	OIs 20251124	OEBIX1-a	OEBIX1-b	OEBIX1-c	112.12.19
AC58784100	N06AB10	wuֽ10@J	OLEXA1	STALOP F.C. 10mg /tab(Escitalopram)		"Escitalopram @ܩserotonin(5-HT)AlADnX㦳˩MOC]|HCF1000 ˩MOXMBJդWCMBJժո`Piescitalopram XDnXAӾɭP󧹾aMAlCEscitalopram \h]AM5-HA1A, 5-HT2,Φhi D1 D2 receptorsA\1-A\2-A] adrenoceptors A histamine H1 A muscarine cholinergic AbenzodiazepineAopioid receptors S˩MOΦC˩MOCEscitalopram O(citalopram)S-cA]O㦳vʪcC"	"PO , InitialX 10 mg/day as a single dose in the morning or evening. MaintenanceX 10-20 mg/day.
65HWѦ~HAx\঳DfHAHΨϥ omeprazole  cimetidine GĪfH escitalopram ĳC̤jq 10 @J C
~{gG`ξqC 10@JA̦UOw̪pAqiW[̰C 20@JCͧܧ{ĪGq` 2 ~ 4 gAbgѰAvܤֶ 6ӤHjƮĪGCC龯qWL 20 @JwʥQҹ Escitalopram HC@q뤩AWλP֪AҥiC"	"EscitalopramiɭPPqQT interval 
SSRIss]Aescitaloprami|vTդjpAɭPմjAoش@ΡA|ϲܯAɰζʫC(angle-closure glaucoma)
YescitalopramP㦳M@Τī~֥ΡAҦp:triptans(]Asumetriptan),~Ī(tramadol)(tryptophan)ɥpߪ`NMgԸs"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץAé25JHUxsC	Escitalopram	N06A	ܧ{ ANTIDEPRESSANTS	0	{gvιw_oAWgBJ{gBxJ{gαjgv	ѩ QT jgԸs.(long QT Syndrome)C Escitalopram Ψ䥦ξ|LӤ̡CPDܩʥBif MAO ֥Ϊ̡C(Ѧҥ椬@) TP Pimozide ֥	ߡBvBݺΡBhҡC	"ĵC. [ʼƾ,bXͫe@Ӥ뤺SSSRISNRIAX孷IW[]p󢱭^"	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669393?cesid=a8Z6dj7RtqA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEscitalopram%26t%3Dname%26acs%3Dfalse%26acq%3DEscitalopram#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w29-02 [s]_178 [®]_178 [UDx]_U03-11 [E]_B3-11 j	Ts112.12.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OLEXA1-a	OLEXA1-b	OLEXA1-c	112.12.19
BC24790212	J01DD04	0	ICEFT2	Ceftriaxone 2g/vial		~ߧ@ΥDnOӵ߲ӭMXC 	"HM12HWൣ
@뾯qCeftriaxone1-2gACѤ@]C24pɡ^CbYPVέPf߹CeftriaxonePʶȬOA侯qiW[4gC@ѵĤ@C
sͨ]14ѡ^GC鵹20-50mg/kg魫CC龯qnWL50mg/kgC
Mpġ]15Ѧ12^GC@20-80mg/kgCp魫j50kgNϥΦH@뾯qC
Rߪ`gľq50mg/kg魫ɡAH`ġAӥBĮɶܤֻݶWL30C

MpĪӵߩʸA}lvɡA龯q100mg/kg]̤ji4g^AunPf߳QŲwXӡABPʤ]QT{AqiCܫezqC
ܩif
pĩMHq50mg/kgA̦hi2gAC@A@14ѡCNP´wPV
̾ڷPVMIʡAb}Me30-90뤩@qCeftriaxone 1-2gC "	"iPttG(Ringer's solution,Hartmann's solution)ΫDfAtti~VXC28ѷsͨATbĪvttGΰw"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs30JHUANp~Osb~ץ
tmnGixs2~8JU48pɡA`ŤUJUA24pɡD"	Ceftriaxone	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVgC	"ܥͯ cephalosporinsLӪfHϥCeftriaxoneDPenicillinLӪHAi঳oͥeLӪi. 
xgsͨΦणoϥceftriaxonevDfHoixfi.
CeftriaxoneoPttk֥ΦbsͨਭWAiಣceftriaxone-calciumID"	mBߡBæRBfBުBզy֡BݥyWhBʳhBpO֡BC¯lC 	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668918?cesid=akkFJfOlLux&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCeftriaxone%26t%3Dname%26acs%3Dfalse%26acq%3DCeftriaxone#"">LexidrugľǸƮw</a>"	"1-2g q12-24h
ݨ̵ǥ\վ㾯q"	ѦҡuqΥΪkv	"ĳ~|GIVBIVF
tswwʡGհtε}Ƿ24hrFN48hr
tsGG10ml WFI(IV)
ĳ}@סG10-40mg/ml? 
ۮe}GG2 g40ml WFIBNSBD5W?
ĳĳ~|tvGIV:>2-4min?
IVF: 30min?
`NƶG1.ŻPLtܥͯĪGVX
2.oPttGVXΦPɪ`g
3.sͨ28ѡAYHRߪ`gttī~i~AhA뤩ceftriaxoneAY>28ѡAi~ϥceftriazoneBttī~A`޻ݥHiۮeGR~"	ixii[UDx]_U09-14 [w]_w04-09 [w]_w04-14 [E]_G5-03 [Ew]_F5-20 j	Ts112.12.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.3.3._20060601_000.pdf"">OI` 10.3.3.</a>             "	0	0	OIs 20251124	ICEFT2-a	ICEFT2-b	ICEFT2-c	112.12.19
AC478901G0	R06AX26	ƱӾA	OALLE1	NASAGA 60mg/tab (Fexofenadine)		FexofenadineterfenadineDnʥNªAO@ب㦳ܩʥyH1ܬʪܲ´iCFexofenadine蹳ci{ĤO۷ܲ´i@ΡC	u`ʹLөʻ󪢡BCʦ۵oC¯lGHGC60mgA@2F611ൣGC30mgA@2C	1.ŶsC 2.AīAФŶ}ξާ@MIC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Fexofenadine	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	wѦHΤHWൣu`ʹLөʻ󪢤κCʦ۵oClg	Hypersensitivity to fexofenadine or any of the ingredients	YBYhBΡBߡBƤ}	קKϥΰDvn	"hα¨ŴϥΥ~ADbgLP_{~LέŤधbQq
jbIɤ~oHϥΡC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669732?cesid=1TqmTGAuYKM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFexofenadine%26t%3Dname%26acs%3Dfalse%26acq%3DFexofenadine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_C3 [2]_C3 [ws]_w32-05 [s]_217 [UDx]_U03-08 [E]_B3-17 [Ew]_EX033 j	Ts113.01.03		0	0	OIs 20251124	OALLE1-a	OALLE1-b	OALLE1-c	113.01.03
AC006391G0	N06AA09	wQ}@J	OPINS1	 (^)Trynol SC 25mg/tab(Amitriptyline) 		AmitriptylineO@ؤTܼ~{(TCA)AhĲz@ΡA]AǤWѡBܲ´iBxPΪ_5-HT3CDn@ΦbgA]QΨӪv~{gAiHPǦ^khTܤ֡C	Adult1-2 tab TID	  1.Cw̡C 2.糧~LӪ̡C 3.ߦٱ_w̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Amitriptyline	N06A	ܧ{ ANTIDEPRESSANTS	0	~{f	糧ĦLӪ̸T	YwAΡAfA	ĵC. 	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668901?cesid=aBWSPwQGhAL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAmitriptyline%26t%3Dname%26acs%3Dfalse%26acq%3DAmitriptyline#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.07.02		0	0	OIs 20251124	DC	DC	DC	114.07.02
BC27691100	L01ED05	FQg25@J	OLORV	ĵƼfLorviqua FC 25mg/tab (Lorlatinib)		"Lorlatinib O@ؿE?A ALK M ROS1 H TYK1BFERBFPSB
TRKABTRKBBTRKCBFAKBFAK2 M ACK 㦳~ʡCLorlatinib i{
X ALK ?hجܧΦ~ʡA]Ab crizotinib ML ALK 
ĥX{efcƮɡA~F˴쪺@ǬܡC
b֤UӤJaĦX EML4 P ALK  1  ALK ]]Ab ALK
ĥX{efcƮɩ~F˴쪺 G1202R M I1171T ^~F
{A뤩 lorlatinib |ܸͧ~FʡCb`ӤJ EML4?ALK X
~FӭM誺{ALorlatinib i{Xܸ~FʡAé{s
Cb餺ҫAlorlatinib `ܸ~Fʨ㾯q̿ʡAûP ALK C
ƪC"	"LORVIQUA ĳqfA100@JAC@AiHΤHAΡAefcƩεo͵Lk@rʡC
ɧ]ACФũCZBiHέb"	1. Y|qɪAADUӾqAĮɶb4pɥHCФŬFɨ|AqӦPɪA2ӾqC 2. YbALORVIQUA o͹æRAФŪAB~qA~AΤUӱƩwqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 30?C HU	Lorlatinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	AΩALKʤߴDpӭM(NSCLC)HfHC	oYxŦrʪiʡALORVIQUA TϥΩ󥿦bjCYP3A ɾfHC	~BmBP䯫 gfܡBIlxB {vTBxTJ gBTĥ̪o gBhB} gBAST/ALT ɰ	ثe|L LORVIQUA bh kϥΪơC	|LHΰʪťĤt lorlatinib ΨNªAΪ̦ĹΨ ĥͦvTơC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6724487?cesid=4Bs23kspLkg&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLorlatinib%26t%3Dname%26acs%3Dfalse%26acq%3DLorlatinib#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-02 j	Ts113.01.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.81._20240601.pdf"">OI` 9.81.</a>              "	0	0	OIs 20251124	OLORV-a	OLORV-b	OLORV-c	113.01.19
BC28599100	N06AX26	0	OBRIN1	Brintellix FC 10mg/tab (Vortioxetine)		Vortioxetine@ξMMʪո`ΦM(5-HT)BeJժC	"1.65HfHABrintellix_lΫĳ뤩qvortioxetine10@JAC@C
2.̭ӧOfHAqiHW[̰ܨC20@Jδ̧֦ܳCC5@JC
3.gѰAĳܤֶAv6ӤHdTܼ~{ĪGC"	"]Brintellix󦹱ڸswʻPĩʸƩ|QsAĳϥΩ18HUfHC
AĴYKʱfH~{gΡAHoͦ۱欰D
wo@OAΧܼ~{Ī@ؼbMI
MgԸs]߸LtAíwAoNAߴAܡAļʤıgAϮgiAաAߡAæRAUg^AX{HWλݥߨ谱ġD
ļgλļgwߧYΡDYfHʡAw欰[@MDUD
YAΧܾĪμvTpO\धĪA`N`X{HD
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Vortioxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	H{g(major depressive disorder)	"1.DΤt᫬LӪ̡C
2.T֥ΫDܩʳiQ (MAOIs) BܩʳiQ-A (MAOI-A)C
3.VortioxetineoϥΩhkBļgo@fHC"	ߡBæRBzGDABUgBKB`cڡBwtBkogC	קKϥ		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4720836?cesid=55E0yGHyI19&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVortioxetine%26t%3Dname%26acs%3Dfalse%26acq%3DVortioxetine#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_L4 [2]_L4 [ws]_w54-08 [E]_C2-14 j	Ts113.01.22	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>              "	0	0	OIs 20251124	OBRIN1-a	OBRIN1-B	OBRIN1-C	113.01.22
BC28160100	L01EL03	ʮAn80@J	OBRUK	ĵƼfBRUKINSA Capsules 80mg		"Zanubrutinib O BTK ??CZanubrutinib |P BTK ʦmb֮ĴݰΦ
@Aq? BTK ʡCBTK O B ӭMܭ (BCR) MӭM]?~|Tǻ
?Cb B ӭMABTK Tǻiƥn~|AH B ӭMi?W?BBBͤƩMg
H@?CbD{ɸ礤AZanubrutinib |c B ӭMWިç~F??C"	"Zanubrutinib ĳqCѦ@?A 320 mgCiC?A?320 mg (| 80 mg n) ;ΨCѨ⦸AC?A 160 mg ( 80 mg n)A?efcƩΥX{Lk@rʡC
"	pGbwwɶAġAibѤ֪A??A?Ѧ^_`AĮɵ{C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Zanubrutinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	"1. AΩeܤ֤@تvQMӭMOڽF(Mantle Cell Lymphoma, MCL)HfHC 2. AΩv?ؤ󥨲yJզg(Waldenstr?m's macroglobulinemia, WM)HfHC 3. AΩeܤ֤@اCD20k_oιxTtϲOڽF (Marginal Zone Lymphoma, MZL)HfHC 4. AΩvCʲOڲyʥզf(Chronic Lymphocytic Leukemia, CLL)/pOڲyʲOڽF(Small Lymphocytic Lymphoma, SLL)HfHC 5. ֥ obinutuzumab AΩeܤ 2 تvowʲOڽF (Follicular Lymphoma, FL)HfHC"		"զy֡BWIlDPVBpO֡BXB٦װf`kh
"	קKϥ	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6884023?cesid=99vwSp32jGz&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DZANUBRUTINIB%26t%3Dname%26acs%3Dfalse%26acq%3DZANUBRUTINIB#"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_9-01 [96]_9-02 j	Ts113.01.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.104._20251001.pdf"">OI` 9.104.</a>              "	0	0	OIs 20251124	OBRUK-a	OBRUK-b	OBRUK-c	113.01.23
BC27358100	L01XX52	0	OVENC5	ĵƼf()vENCLexta FC 50mg/tab		Venetoclax @ب㦳ܩʡBfABiQΪBCL-2 (@اܲӭM`J) plCBCL-2wQҹbCLLӭM|Lת{Aiո`~FӭMsAiPĪĩʦCVenetoclax X BCL-2JաANPӭM`Jզp BIMAĲoɽu~z(mitochondrial outer membrane permeabilization)M`J?ơAU_ӭM`L{CbD{ɸ礤Avenetoclax ҹLת{BCL-2~FӭM㦳ӭMrʡC	"1. ҶqfHSʦ]AH~FѯgԸs(TLS)IC{סA æbVenetoclaxĤ@veAwʸɥRάIέĪAHC~FѯgԸs(TLS)IC
2. ܯfHCbjۦPɶAH\H}AΡC
3. ]AAiCZBrHέ}C
4. CʲOڲyʥզf(CLL) ҦVENCLEXTAĬѬ5gqվ}lC VENCLEXTA5gqվĮɵ{G VENCLEXTAq̾ڨCgqվɵ{Ab5gFĳqC400@JC VENCLEXTAXRituximabvfH5gVENCLEXTAqվAåBVENCLEXTA 400@Jq7ѫA}lrituximabġCbC28{1ѧPrituximabA@6{A1{R߿`q375 mg/m2A2-6{qh500 mg/m2Crituximab1{1Ѷ}lAfH~C@A 400 @JVENCLEXTA24ӤC VENCLEXTA@ĪvfHqվAVENCLEXTAĳqC400@JCVENCLEXTAC@fAϥΡAX{efcƩεLk@rʡC
5. ʰʥզf(AML) ʰʥզf(AML)fHqվĮɵ{GĤ@ 100@JAĤG 200@JAĤT 300@JAĥ|Τ֥ΧCҰƾ 400@JA֥ΧCqcytarabine600@JC VENCLEXTA֥ΧCҰƾ(hopomethylating agent)Ψ֥ΧCqcytarabineɡA뤩AX{efcƩεLk@rʬC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Venetoclax	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. CʲOڲyʥզf (CLL)GVENCLEXTAAΩveܤ֤@uv㦳Τ㦳17pʥCʲOڲyʥզf (CLL) fHC
2. ʰʥզf (AML)GVENCLEXTA֥ΧCҰƾΨ֥ΧCqcyt
arabineAΩLkjפƾǪvE_ʰʥզf (AML) fHC"	}l VENCLEXTA vξqվAѩi|W[~FѯgsIACLLfHT֥αj CYP3A C	ݤʥզyCUBmBߡBWIlDPVBhBhҡBpOCUB٦װfkhB~By¡B~FѯgԸsC	ھڨ@ξΰʪ窺GAVENCLEXTA Ωhkʥi|FL-Lyˮ`CHpiFLLsAbhʪvenetoclax۷HCĳq 400 @JUSqA|ɭPFLۧɫyML魫֡Chkʨϥ VENCLEXTA |iLAӸCiͨ|OkʡAbvץCYhϥ VENCLEXTAAΩvhAiw VENCLEXTA LधiMI	|LVENCLEXTAO_|ƤJHťġBﱵ઺vTAιŤc@ΡC\hĪ|ƤJšAثe|MVENCLEXTAO_iyY}AiŤkʦbVENCLEXTAvšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6008897?cesid=8rhamcxR6y5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVenetoclax%26t%3Dname%26acs%3Dfalse%26acq%3DVenetoclax"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-12 j	Ts113.02.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.71._20251001.pdf"">OI` 9.71.</a>              "	0	0	OIs 20251124	OVENC5-a	OVENC5-b	OVENC5-c	113.02.21
BC27359100	L01XX52	0	OVENC	ĵƼf()Venclexta FC 100mg/tab		Venetoclax @ب㦳ܩʡBfABiQΪBCL-2 (@اܲӭM`J) plCBCL-2wQҹbCLLӭM|Lת{Aiո`~FӭMsAiPĪĩʦCVenetoclax X BCL-2JաANPӭM`Jզp BIMAĲoɽu~z(mitochondrial outer membrane permeabilization)M`J?ơAU_ӭM`L{CbD{ɸ礤Avenetoclax ҹLת{BCL-2~FӭM㦳ӭMrʡC	"1. ҶqfHSʦ]AH~FѯgԸs(TLS)IC{סA æbVenetoclaxĤ@veAwʸɥRάIέĪAHC~FѯgԸs(TLS)IC
2. ܯfHCbjۦPɶAH\H}AΡC
3. ]AAiCZBrHέ}C
4. CʲOڲyʥզf(CLL) ҦVENCLEXTAĬѬ5gqվ}lC VENCLEXTA5gqվĮɵ{G VENCLEXTAq̾ڨCgqվɵ{Ab5gFĳqC400@JC VENCLEXTAXRituximabvfH5gVENCLEXTAqվAåBVENCLEXTA 400@Jq7ѫA}lrituximabġCbC28{1ѧPrituximabA@6{A1{R߿`q375 mg/m2A2-6{qh500 mg/m2Crituximab1{1Ѷ}lAfH~C@A 400 @JVENCLEXTA24ӤC VENCLEXTA@ĪvfHqվAVENCLEXTAĳqC400@JCVENCLEXTAC@fAϥΡAX{efcƩεLk@rʡC
5. ʰʥզf(AML) ʰʥզf(AML)fHqվĮɵ{GĤ@ 100@JAĤG 200@JAĤT 300@JAĥ|Τ֥ΧCҰƾ 400@JA֥ΧCqcytarabine600@JC VENCLEXTA֥ΧCҰƾ(hopomethylating agent)Ψ֥ΧCqcytarabineɡA뤩AX{efcƩεLk@rʬC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Venetoclax	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. CʲOڲyʥզf (CLL)GVENCLEXTAAΩveܤ֤@uv㦳Τ㦳17pʥCʲOڲyʥզf (CLL) fHC
2. ʰʥզf (AML)GVENCLEXTA֥ΧCҰƾΨ֥ΧCqcyt
arabineAΩLkjפƾǪvE_ʰʥզf (AML) fHC"	}l VENCLEXTA vξqվAѩi|W[~FѯgsIACLLfHT֥αj CYP3A C	ݤʥզyCUBmBߡBWIlDPVBhBhҡBpOCUB٦װfkhB~By¡B~FѯgԸsC	ھڨ@ξΰʪ窺GAVENCLEXTA Ωhkʥi|FL-Lyˮ`CHpiFLLsAbhʪvenetoclax۷HCĳq 400 @JUSqA|ɭPFLۧɫyML魫֡Chkʨϥ VENCLEXTA |iLAӸCiͨ|OkʡAbvץCYhϥ VENCLEXTAAΩvhAiw VENCLEXTA LधiMI	|LVENCLEXTAO_|ƤJHťġBﱵ઺vTAιŤc@ΡC\hĪ|ƤJšAثe|MVENCLEXTAO_iyY}AiŤkʦbVENCLEXTAvšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6008897?cesid=8rhamcxR6y5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVenetoclax%26t%3Dname%26acs%3Dfalse%26acq%3DVenetoclax"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-13 j	Ts113.02.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.71._20251001.pdf"">OI` 9.71.</a>              "	0	0	OIs 20251124	OVENC-a	OVENC-b	OVENC-c	113.02.21
BC27766100	L02BX03	0	OZYTI1	ĵƼfABIRATRED FC 250mg/tab		"Abiraterone acetateb餺|ƦAbirateroneAoO@ضʯͦXA|17\m?/C17, 20 ??
]17\-hydroxylase/C17, 20-lyaseGCYP17^@ΡCï{AYBǤWΫe?~F´AåBOʯͦX
@?iίʪïC
CYP17 |ʤ??G1^pregnenolone Pprogesterone |zL17\m?@Ʀ17\ mlͪA2^M
zLC17, 20 ??@ΤOΦdehydroepiandrosterone]DHEA^PandrostenedioneCDHEAPandrostenedioneҬ
AåBOATପeXCCYP17 QAbiraterone ]|ɭPǤWqֽEͦ?W[C
ʯӷPʫe?i?Cʯt??k㦳v?Cʯh?k]pϥGnRHPiv??AY^
i?CAYʯͦ?ALkvTǤWθ~Fʯͦ?C
b?PHwӲդ3?ɸ窺fHAAbiraterone acetate i?CATତΨ䥦ʯ夤@?C?
ʴAbiraterone acetate 夤ATି@?vTCΥi[夤e?Sʧܭ]PSA^@?ܤơAPӧOfw
?ɮ??ʥثe|ҹC"	"ĪΤNhէܩʪಾʫe?Abiraterone acetateĳ?C@fA뤩1,000@J]2500 @J
4250@J^AX֨C?fA뤩prednisoneprednisolone 5@JC
XӷPಾʫe?Abiraterone acetateĳ?C@fA뤩1,000 @J]2500@J4250
@J^AX֨C@fA뤩prednisone prednisolone 5@JC
Abiraterone acetateŸAΡCAAbiraterone acetateeܤ2p?iiAAAbiraterone acetate
1p?ii"	HeACФHZHC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs25XCHUC	Abiraterone Acetate	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	O@CYP17APprednisoneprednisolone֥ΡAHv(1)ĪΤNhէܩʪಾʫeCABbʯhkѫݵLgλׯgө|ݭnϥΤƾǪv(chemotherapy is not yet clinically indicated)̡C(2)ĪΤNhէܩʪಾʫeCBwLdocetaxelv̡C(3)sE_㰪׭IXӷPಾʫeC~kʡABPʯhk֥ΡC			"Abiraterone acetateΩkʪwʻP?ĩ|TߡCھڨ@ξPʪ窺o{A便뤩Abiraterone acetate
|yLˮ`AåiɭPyC"	Abiraterone acetateΩkʪwʻP?ĩ|TߡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669139?cesid=3UjmENpTOJw&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAbiraterone%26t%3Dname%26acs%3Dfalse%26acq%3DAbiraterone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_9-03 [96]_9-04 j	Ts113.02.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.49._20250601.pdf"">OI` 9.49.</a>              "	0	0	OIs 20251124	OZYTI1-a	OZYTI1-b	OZYTI1-c	113.02.21
BC27642100	L01EF03		OVERZ	ĵƼfverzenio100mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.03.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.107._20240601.pdf"">OI` 9.107.</a>              "	0	0	OIs 20251124	OVERZ-a	OVERZ-b	OVERZ-c	113.03.27
BC27357100	L01XX52	0	OVENC1	ĵƼf()vENCLexta FC 10mg/tab		Venetoclax @ب㦳ܩʡBfABiQΪBCL-2 (@اܲӭM`J) plCBCL-2wQҹbCLLӭM|Lת{Aiո`~FӭMsAiPĪĩʦCVenetoclax X BCL-2JաANPӭM`Jզp BIMAĲoɽu~z(mitochondrial outer membrane permeabilization)M`J?ơAU_ӭM`L{CbD{ɸ礤Avenetoclax ҹLת{BCL-2~FӭM㦳ӭMrʡC	"1. ҶqfHSʦ]AH~FѯgԸs(TLS)IC{סA æbVenetoclaxĤ@veAwʸɥRάIέĪAHC~FѯgԸs(TLS)IC
2. ܯfHCbjۦPɶAH\H}AΡC
3. ]AAiCZBrHέ}C
4. CʲOڲyʥզf(CLL) ҦVENCLEXTAĬѬ5gqվ}lC VENCLEXTA5gqվĮɵ{G VENCLEXTAq̾ڨCgqվɵ{Ab5gFĳqC400@JC VENCLEXTAXRituximabvfH5gVENCLEXTAqվAåBVENCLEXTA 400@Jq7ѫA}lrituximabġCbC28{1ѧPrituximabA@6{A1{R߿`q375 mg/m2A2-6{qh500 mg/m2Crituximab1{1Ѷ}lAfH~C@A 400 @JVENCLEXTA24ӤC VENCLEXTA@ĪvfHqվAVENCLEXTAĳqC400@JCVENCLEXTAC@fAϥΡAX{efcƩεLk@rʡC
5. ʰʥզf(AML) ʰʥզf(AML)fHqվĮɵ{GĤ@ 100@JAĤG 200@JAĤT 300@JAĥ|Τ֥ΧCҰƾ 400@JA֥ΧCqcytarabine600@JC VENCLEXTA֥ΧCҰƾ(hopomethylating agent)Ψ֥ΧCqcytarabineɡA뤩AX{efcƩεLk@rʬC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Venetoclax	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1. CʲOڲyʥզf (CLL)GVENCLEXTAAΩveܤ֤@uv㦳Τ㦳17pʥCʲOڲyʥզf (CLL) fHC
2. ʰʥզf (AML)GVENCLEXTA֥ΧCҰƾΨ֥ΧCqcyt
arabineAΩLkjפƾǪvE_ʰʥզf (AML) fHC"	}l VENCLEXTA vξqվAѩi|W[~FѯgsIACLLfHT֥αj CYP3A C	ݤʥզyCUBmBߡBWIlDPVBhBhҡBpOCUB٦װfkhB~By¡B~FѯgԸsC	ھڨ@ξΰʪ窺GAVENCLEXTA Ωhkʥi|FL-Lyˮ`CHpiFLLsAbhʪvenetoclax۷HCĳq 400 @JUSqA|ɭPFLۧɫyML魫֡Chkʨϥ VENCLEXTA |iLAӸCiͨ|OkʡAbvץCYhϥ VENCLEXTAAΩvhAiw VENCLEXTA LधiMI	|LVENCLEXTAO_|ƤJHťġBﱵ઺vTAιŤc@ΡC\hĪ|ƤJšAثe|MVENCLEXTAO_iyY}AiŤkʦbVENCLEXTAvšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6008897?cesid=8rhamcxR6y5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVenetoclax%26t%3Dname%26acs%3Dfalse%26acq%3DVenetoclax"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-11 j	Ts113.02.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.71._20251001.pdf"">OI` 9.71.</a>              "	0	0	OIs 20251124	OVENC1-a	OVENC1-b	OVENC1-c	113.02.21
BC27641100	L01EF03		OVER2	ĵƼfVERZENIO150mg/tab(abemacicilib)		AbemaciclibO@ؤfAĪE?(kinase inhibitor)AAbemaciclibOӭMgJը̿ʿE?4M6 (CDK4MCDK6)CoǿE?bPDӭMgJ(D-cyclins)XQơCbۿE鶧(ER+)ӭM褤AӭMgJD1MCDK4/6PiӭMFJ(Rb)CĤơBӭMgiiMӭMW.b~礤AsSabemaciclibFRbCĤƨê_qӭMgG1iJSAɭPӭMIѩMӭM`CbزӼҫAC餣_WabemaciclibΨ֥ΧܻۿEĪAɭP~FؤoYpC	"PfulvestrantΪڭ?֥ήɡAVERZENIOĳq150 mgACfA⦸C
WϥήɡAVERZENIOĳq200 mgACfA⦸CvefcƩΥX{Lk@rʡCVERZENIOiH\ΪŸϥ,fH]AVERZENIOAiNCZBHΤb]A
ϥVERZENIOoͤ}ɡAiC50mgϥΡAѤU50mg BIDAYfHLk@C⦸50 mgqAhVERZENIOvCשΤ׵Ŧ\ण(CLcr ? 3089 mL/minAHCockcroft-Gault [C-G])fHݽվ㾯qC"	"m̱`}
fH@o{}KpxԡA}lmv(ploperamide)BW[fAGAp@̥HQ䴣Ѷi@BܤξAlܡCYoͲ34ŸmAΦ]mݭn|AhVERZENIOvrʽwѦ?1šAHU@hVERZENIOq_v
ERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@A{ɻݭnɳʴypơC
xrʡERZENIOv}leB}lve2ӤC2g@B᪺2ӤC@Aη{ɻݭnɺʴALTBASTPMxC
oͲ2ũΦA׵oͲ2šAβ3(> 5.020.0ULN)Ao`xW[ܰ2ULNAȰĪrʽwѦܰǭȩβ1šCåHUŧOhq_vC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	abemaciclib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"֥Ϊڭ?(aromatase inhibitor)AivgX(HR)ʡBĤGH֥ͪ]l(HER2)ʤߴಾʨkĤ@uck(endocrine-based therapy)C
֥fulvestrantAivX(HR)ʡBĤGH֥ͪ]l(HER2)ʡABckefcƤߴಾʨkC
WΩvX(HR)ʡBĤGH֥ͪ]l(HER2)ʡAgLcvΩಾᱵƾǪvSoͯefcƤߴಾʨHfHC"	"VERZENIOĦνξLӪ
VERZENIOtſ}?ſ}@gBſ}?ʥFθ}-ſ}l`ǯeffHϥΦ?"	mBPVBݤʲyCUgBhBh¡BߡBæRM?	ĪiLybM`CbVERZENIOvܱ̫@VERZENIOvܤ3gĨĪץI	ѩVERZENIOiϱ¨oY}AiŰkVERZENIOvα̫@vܤ3gišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6548930?cesid=0S8t6Kvjpdn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dabemacicilib%26t%3Dname%26acs%3Dfalse%26acq%3Dabemacicilib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_4L-01 [96]_4L-02 [96]_4L-03 [96]_4L-04 j	Ts113.03.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.107._20240601.pdf"">OI` 9.107.</a>              "	0	0	OIs 20251124	OVER2-a	OVER2-b	OVER2-c	113.03.27
	N01BB02	x'Qd]`gG	ILIDO2	ĵLIDOCAINE inj. 2% 20ml/vial		"pP󧽳¾K@ˡAlidocaineiǥѨulVgVʡAӥifagİʪuۯgֺǾɡCQi(amide)¾KQ{OPgul޹D@ΡC
¾Ki󸣳Τߦ٤E(excitable membrane)ۦ@ΡC"	"`gSOpߡAHKVRߤAӤް_ʬrʤCĳb`geΪ`gɱ`ԷVa˩@UCnjqɡApw~_ɡAĳHtǤW lidocaine 3-5 @ɥկfHCYVRߤAiǨϤ߸ȮɩʼW[ӹıC
DnqHC 100  200 @JtvwC`gAΦbW[qɡAPfH͡CYoͬrʤAߧY`gC@ӨAn_jgҦgyɡAݭnϥθ@סFӷ_һݤj׸pɡ]pYkhѰ^AhϥθC@קYiCĪϥΤen|vT¾KGdC
ϥΧtǤWGAiW[@Τɶ]Ѿ\q^C
b楽ݤqACX`Τ¾K޳N@릨HĳqAHѰѦҡCbpݨDqɡAvgίfH骬pTA۷nCɶϥΪ_¾KɡApĥέеĤ覡AҶqĪbߤ@רFr@סAξɭPgˮ`MIʡC"	"ϰΧ¾K{ǡAbA]ƤΤHҹIAϤκʵһݤĪγ]ơAƧBiߧYϥΡCIj_¾KɡAb`g¾KeARߦsdɺ޲աCvnI椧{ǡAwAίSwVmABƧ@ΤE_ΥʬrʡAΨLֵogv۷xC

lidocaine bpH Ȥj6.5 HWɡA䷻ѫפjCFGn[JPʷG]pGһQ^ɭnSOҼ{IA_h|oͨHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	" Xylocaine]tǤW^hqĲ~FJs󤣰25JBAiNC
hqĲ~b}~WL3 ѤAiAϥΡC"	Lidocaine	N01B	"¾K ANESTHETICS, LOCAL"	0	¾KC	"wQi(amide)¾KAηGL]ptǤWGmethylpar ahydroxybenzoatesodium metabisulphin)|o͹LӤ̡C
wҰΤmfһୡ]methyl-/propyl paraben^AιNªifһġ]PABA^LӪ̡C¾KΨNªPABALӤfwקKϥΧtmfһ୤lidocainet"	"pGOĪLqλ~JޤA¾Kܤ֤ް_}C
YhBVáBݺΡB wtBߡBæR"	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669686"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[w]_w06-10 j	Ts113.03.27		0	0	OIs 20251124	ILIDO2-a	ILIDO2-b	ILIDO2-c	113.03.27
KC00978206	A10BJ05	0	ITRUL	ĵTRULICITY injection 1.5mg/0.5mL		g}tdulaglutideA@ؤHGLP-1PiA90%iħǦCPͩʤHGLP-1 (7-37)PCDulaglutide^OӭMWBӭMGLP-1 Ai@BƯŦ]ӭM??(adenylyl cyclase)CDulaglutideW[betaӭMCĸ?(cAMP)qAɭP}̿ʪخqCDulaglutide]|֪@}cAåB|GƪšC	"1. ĳ_lq0.75 mgCg@AΪ}AqiW[1.5 mgCg@C̤jĳqO1.5 mgCg@C
2. ib@ѷɶġAҼ{iP_AH֤U`g覡`gbBjLΤWuC
3. YL@ABZU@wwĮɶܤ3(72p)Ah֨ϥΡCYZUwwĮɶ3AhLLqA쥻wwU@qCWzرpUAfwi_쥻Cg@Įɵ{C"	"TΩӤHάOaڦҪ(MTC)fvw̤β2hoʤc~FXgw(Multiple Endocrine Neoplasia syndrome type 2, MEN 2)CifwϥΩg}󿩱wMTCbIοwҪ~Fg(Ҧp:V~A]`xAIlxAʪnR)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. xs2XC8XCBcC
2. YݭnAC榸q`giOsǷŤUAWL30XCAܦh14C
3. iNCYDNAhoϥΡC
4. ץOsC"	dulaglutide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	2}fC	"1. TΩӤHάOaڦҪ(MTC)fvw̤β2hoʤc~FXgw(Multiple Endocrine Neoplasia syndrome type 2, MEN 2)C
2. gdulaglutideβ~󦨤YLӯfwAФŨϥΡC
IWw "	ߡBmBæRBhBC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5355313?cesid=2XNwhwAPOcL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTRULICITY%26t%3Dname%26acs%3Dfalse%26acq%3DTRULICITY"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-52 j	Ts113.04.12	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3.1._20180401_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3.2._20201201.pdf"">OI` 5.1.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.3._20190701.pdf"">OI` 5.1.3.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.3.2.</a>           "	0	0	OIs 20251124	ITRUL-a	ITRUL-b	ITRUL-c	113.04.12
	J05AB01		IZOVI2	ASIMPLEX 250mg Lyophilized IV infusion		DAcyclovirO@اܯfrĪA©ʞ\l(HSV)BΤka\lfrD`ġCAcycloviriJQ\lPVӭMA|CĤƦʤƦXAAcyclovirTCĤƦX|\lSDNA polymeraseMA]iHfrDNAXӤ|zZ`ӭMN§@ΡC	"Hq
1. ©?l]?lʸҥ~^Τka?lPVw̡AC8pɡA5mg/kgAcyclovir`C 2. K̾णw̡Aǥ\ॿ`̡Abvka?lP
VɡAC8pɵ10mg/kgAcyclovir`CK̾णw̡Aǥ\ॿ`̡Abvka?lPVɡAC8pɵ10mg/kgAcyclovir`C
ൣq
1. 3Ӥ12ൣϥAcyclovirR߿`ɡAھڨnp⾯qCw©?l]?lʸ~^άOka?lPVൣAC8pɨϥ250mg/m2AcyclovirR߿`C
2. K̥\णӵǥ\ॿ`ൣAwka?lPVάO?lʸɡAC8pɡA500mg/m2nAcyclovirR߿`C "	"1. ϥθqw̡]Ҧp?lʸ^ASO`Nǥ\ASOOw̦Υǥ\ण{HɡC
2. ts᪺Acyclovir`gGpHȬ11AgѤfAġC 3. ϥΩǥ\णΦѦ~w̡GAcyclovirgѵŦưA]bǥ\णfHWϥΪqӴ֡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Acyclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	a?lfrγ?lfrް_PVCw貾ӤΥզfҤް_K̤fH?lPVCsͨ?lPVC 	Acyclovir |LӤw̡ATϥΡC	`g짽oAߡAæRC 	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668909?cesid=9B6fcslhXtp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcyclovir%26t%3Dname%26acs%3Dfalse%26acq%3DAcyclovir"">LexidrugľǸƮw</a>"	"CClr>50       10mg/kg Q8h
ClCr25-50    10mg/kg Q12H
ClCr10-25    10mg/kg Q24H
ClCr<10        5mg/kg Q24h
CAPD           5mg/kg Q24H (after HD)"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tmnε}ᤧGiNáB}Ƿ12hr,
tsGG10 ml WFIBNS 
ĳ}@סG<5mg/ml  @
ۮe}GGNSB0.45%NaCl
ĳĳ~|tvG> 1hr
`NƶG-"	ixiij	Ts113.04.19		0	0	OIs 20251124	IZOVI2-a	IZOVI2-b	IZOVI2-c	113.04.19
			IRHOD1	HYPERRHO S/D FULL DOSE 		"(Rho(D)hRho(D)ʭLAbͲBy(۵MΤHu)BϽθ~ˮɡAoͭL-鶡XCK̤]oͦbRho(D)ʪ̿JFRho(D)ʬyɦӲanti-Rho(D)Aoرpi`gsӹwC
 sͨ઺RhʯefOɦ]Rho(D)ʥ˪DʧĶ@ΡAΥbeYL{BάyBϽBθ~ˮɡARho(D)ʬyiJF骺G`FΪ̦]媺YAy鲣ͧĶ@ΡC
 ~iħRho(D)ʭRho(D)ʬyҲͪK̤A@ξणM"	"٦ת`g
 YwΡGͲ72pɤϥ300mcgC
 XͫewΡGh28gɧĤ@300mcgAYLORhʡAAl[@APɳ̦nbY72pɤĤ@C"	"1.sѤH߻sAZOѤH߻s~itpfrPVӭPfC
2.iRߪ`gAu٦ת`gAPɷsͨťΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 2 ~ 8 צBc	Immuneglobulin	J06B	K̲yJ IMMUNOGLOBULINS	0	w]t֦]lPӾɭPyΪͨԧ	"A Rho(D) positive or Du positive individual, A Rho(D) negative or Du negative individual previously sensitized to the Rho(D) or Du antigen."	i|ް_`gkhŲLWɵ	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Infant risk is minimal.	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts113.04.19		0	0	OIs 20251124	IRHOD1-a	IRHOD1-b	IRHOD1-c	113.04.19
KC01206262	 L01FX17	ݹF	ITROD	ĵƼfTRODELVY inj. 180mg/vial		"Sacituzumab govitecanO@Trop-2ɦVĪƦX(ADC, antibody-drug conjugate)CSacituzumabO@ѧOTrop-2 HƧCplSN-38O@topoisomerase IAzLslH@䵲XWCĲzǸܡAsacituzumab govitecanP{Trop-2ӭMXAgLƧ@ΫAzLslѥHXSN-38CSN-38Ptopoisomerase I椬@ΡAtopoisomerase Iɤ_s^CѦͪDNAl˾ɭPӭM`MӭM`CbTʨpزӼҫAi[sacituzumab govitecanC~FͪC"	"TRODELVY ĳq10 mg/kgAbC21 Ѫvg1 ѩM8 R߿`뤩@CvܯefcƩΥX{LkrʡCTRODELVY 뤩qoWL10 mg/kgCTRODELVY ȥiĥR߿`覡ġCiĥR߱`(push)Τjq`(bolus)覡ġC `G
`iɶWL3 pɡCb`M_lqܤ30 [fHO_X{`xίgC
`G
pGe`㦳@ʡAh`ɶib1 2 pɥHWCb`M`ܤ30 [fHC
wʥ
bCTRODELVY eAĳϥιwʥĥHw`Mwް_ߩMæR(Chemotherapy-induced nausea and vomiting, CINV)C `eϥθѼBH1 MH2 _iwʥġAX{`fHiϥΥֽTJC ϥΨةΤTب֥ĪHwߩMæR (Ҧpdexamethasone ֥5-HT3 ܾNK1 ܾHΨLAĪ)iwʥġC"	"ts
1.ϥεL߰wAN20 mL 0.9% ƶu`gGwC`JCTRODELVYĲ~CCӤp~tWqRī~AHvջsL{GlFbtsA~Ω`ĲG@׬10 mg/mLC
2.nĲ~èϨ䷻ѹF15CФťΤOnC
}
ھگfH魫ApF쥻~AqһݪTRODELVYtsGqC HTRODELVY@׽d1.1 mg/mL3.4 mg/mLMwts`G̲׶q (魫pε 170kg fHA`eqWL 500mL) C
魫WL170 kgfHANpXTRODELVY`qt500 mLGUCb TRODELVY `p`ɶ̧ǿ`ӿGUAHTO`㾯qC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"tseANĲ~xsb2XC8XCBcAøm˯ȲHץxsCФŧNC

ī~ջs᪺}GߧYϥΡCpߧYϥΡAiNt~GGU2-8XCNץOs̪24pɡCNëOsA}G̰25XCǷŤUAb8pɤ(t`һݪɶ)뤩C
ФŧNήnC"	Sacituzumab govitecan	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	AΩvew⦸HWʪvL(䤤@ݬvߴef)LkߴಾʪTʨ~fHC	TΩ糧~oYLӤfHC	ߡBݤʥզy֯gBmBhҡBvBhBæRBKB֯lBhMhC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6943319?cesid=5ceYmPULdW7&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSacituzumab%26t%3Dname%26acs%3Dfalse%26acq%3DSacituzumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-18 j	Ts113.4.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.106._20251001.pdf"">OI` 9.106.</a>              "	0	0	OIs 20251124	ITROD-A	ITROD-B	ITROD-C	113.4.24
AC44365100	N07AB02	θѿ	OWECO2	Dampurine 25mg/tab (bethanechol)		Dn@άOϰƥPgtοġCiW[H֯}٪iOA]ӳq`iͨHPϱƧMHֱƪŪ}lCBethanecholiEGʤOAW[GiOA]ӥi_wl`ߩįʡC	"Initial X 5 to 10 mg repeated hourly until satisfactory response; MAX 50 mg; usual dose range X10 to 50 mg 3 or 4 times daily
1. Hq10~30mgA@3~4C}li5~10mgAHCpɭеPAΨ30mgoNĪGCĩA30~60YiX{ĪGA@Υi~1pɡC
2. ĵCѨC0.6mgAAΡC"	AΥPg`_ĪfH`NAHKް_L׭CAq`L׭CoͫeA`gAxdw̡ApXٵLkPɡAiKQ^y駿ޤεǪAɦp߯gsbɡAiް_gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Bethanechol	N07A	ƥPgĪ PARASYMPATHOMIMETICS	0	NBᤧDʧxdAgʻHֺiOCΧxd	ťΩҪ\LgBhBGšBޭݡB߷i}wBCF߫aʯ߯efBwBˤgBGzΪcDʪfҡC	ߡBmBABYhBC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668520?cesid=4OLqJPnJWNE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBethanechol%26t%3Dname%26acs%3Dfalse%26acq%3DBethanechol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[ws]_w01-03 [s]_78 [®]_78 [E]_A1-05 j	Ts113.05.28		0	0	OIs 20251124	OWECO2-a	OWECO2-b	OWECO2-c	113.05.28
B020548100	C01BC04	߳էJ@J	OTAMB	Tambocor 100mg/tab(Flecainide)		ǥѪ_ߦٲӭMulqDAwߦٶǾɪ ʧ@qAyLAӲ ܤ߫ߤ㪺ĪGC	"HGW߫ǩʤ߫ߤ-˰_lq50mg,@Ѩ⦸,̤jq300mg
ǩʤ߫ߤ-˰_lq100mg,@Ѩ⦸,̤jq300mg
pGĳ12HUpĨϥ
"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷšBץB	Flecainide acetate	C01B	"ܤ߫ߥ`,M ANTIARRHYTHMICS, CLASS I AND III"	0	"oʤWǤ߷iLt,oʤߩֺŸ,Y߫ǩʤ߷iLt"	TΤ߰IܤΤߦٱfvw	ߡBæRBOҽkBֽӷP	L	L	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669782?cesid=4N6Wic2GV1K&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFlecainide%26t%3Dname%26acs%3Dfalse%26acq%3DFlecainide"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_C3 [2]_C3 j	Ts113.06.04		0	0	OIs 20251124	OTAMB-a	OTAMB-b	OTAMB-c	113.06.04
	M09AX01	q`Ī`g	IVEJO	VEJOKNEE(k})q@w``g		`hƩ`C	HC{ϥ1䥻~AhƩʽ`wB`gD~AΩ`Ī`gC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷxsAJsū׳̰iWL30XCAקK춧ӮgMN᪺ҡC	Sodium Hyaluronate (Cross-link)	M09A	Lg٦רtΥ OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM	0	`hƩ`C	w糧~ʦLӪw̡C	khB~ȡBw	iw	RsҾ	аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.04		0	0	OIs 20251124	IVEJO-a	IVEJO-b	IVEJO-c	113.06.04
AC41836255	J01XD01	ߨαo`gG5@J/@	IMETR2	METRONIDAZOLE inj. 5mg/ml;100ml/vial		Ĭ@ر߾AiΩM@ʹ߷PVvA@άOgѹʲӵߥN©ҿWӨϥĦbӭMiƾǩ٭CQ٭ᤧĨ㦳ӭMrAiPDNAۤ@ΡAɭP۵cॢAѪ_A䵲GDֻĤXAӨϲӭM`C	"ʲӵߤް_PVG
~HMWL12ൣGC龯qG魫CQ窺fwAC300ml`GAΨCTAC100ml Metronidazole FreseniusCHC5mltvCtR߿`Co۷22.5mg/kg/dayMetronidazoleC 
p12ൣGqHC22.5mg/kgpAC뤩@AHC5mLtvACtR߿`C"	 UؤPY{תǥ\णɡAgxıqTKƥXMetronidazole|W[CpGLAqn֦C12p400500mgMetronidazoleCYx\णɡAMetronidazoleƥX|ܺCC]AnpߺʴfwMwˬdG@סC  	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 Osb<25Ca	Metronidazole	J01X	䥦ܵ OTHER ANTIBACTERIALS	0	ʵߤް_PVg	"MetronidazoleΨL Nitroimidazole lͪLӪfwϥΡC
DOLĪLĪM`ͩRPVC
wYxŦêBy\êBϯgζg䯫geffwAϥ Metronidazole enJӵįqMMIʡC 

"	"OH֪ݨAǥXWA򪬦YAުAfĪA߹æRAAmAYhAYAݺΡAvAWjˡAP䯫gfܡA¤AhAֽPı`C(oǤ}@λPqLΨϥιL[Aq֩ΰϥΫN|)C@ΪkOAXR߿`AഫfAC
զyʥFAɩʥզyʥFC"	MetronidazoleuΩhĤ@ɪYM`ͩRPVAhĤGMĤTAugLJӵįqMMIʫ~ϥΡC	ŴAnũΤ_MetronidazolevC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669691?cesid=4qNd2krTnP3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMETRONIDAZOLE%26t%3Dname%26acs%3Dfalse%26acq%3DMETRONIDAZOLE"">LexidrugľǸƮw</a>"	"CClr>10  500mg Q8h
CClr<10  500mg q8-12h"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡGǷץxs
tsGGUndiluted
ĳ}@סG-
ۮe}GGD5WBNSBR
ĳĳ~|tvG5ml/min
`NƶG1.űĲtT2.1.C5mLCt`C"	ixii[w]_w12-03 [E]_D5-02 [Ew]_D1-07 j	Ts113.06.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	IMETR2-a	IMETR2-b	IMETR2-c	113.06.05
NC09997277	B05XA03	HFͲzQ`gG500ML	INAC06	NACL 0.9% 500ML(HFPP~) 		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.05		0	0	OIs 20251124	INAC06-a	INAC06-b	INAC06-c	113.06.05
AB45016100	A02BC01	0	OLOSE1	OMEZOL 20mg/cap(OMEPRAZOLE)		Omeprazole@zPA|bGӭMӭMpޡAƦʫAi:H+-K+-ATPïC㾯q̿ʡAB¦GĤcΨEUGĤc(LצبE)AjPĪGC	"GšGĳqOmeprazole 20mgACѤ@CgitwѡABjhƱw̷|b4g¡C
QGzšGwʩʤQGzŤfHĳqOmeprazole 20mgA CѤ@C
fyʭDGĳqOmeprazole 20mgACѤ@AgitwѡABjhƱw̷|b4g¡C
Zollinger-EllisongԸsGvZollinger-EllisongԸsqݨ̭ӤHӽվABun{ɤWݭnANvUhCĳqCOmeprazole 60mgC"	ϥΩ㦳貨PIw̮ɡAAɥR vitamin D P CalciumC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Omeprazole	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	QGzšBGšBfyʭDBZollinger-EllisongԸs	wOmeprazole|o͹LӤ	YhBGzDAC	C	ư઺IC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669537?cesid=7KVIxvO2yl1&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOMEPRAZOLE%26t%3Dname%26acs%3Dfalse%26acq%3DOMEPRAZOLE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_I3 [2]_I3 [ws]_w40-04 [s]_243 [UDx]_U03-39 [E]_B5-02 j	Ts113.06.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	OLOSE1-a	OLOSE1-b	OLOSE1-c	113.06.05
AA56776100	N06AX21	U~n30@J	ODULO3	dUXtine 30MG/cap (Duloxetine)		DuloxetineH骺ܼ~{BϩʯkhΧܵJ{T@ξऴA۫Hoǧ@λPWjϯgM(serotonergic)PǤW(noradrenergic)C	"Diabetic neuropathy- pain60 mg once daily. Generalized anxiety disorder60 mg once daily, may start at 30 mg once daily for 1 week and then titrate up to 60 mg once daily, depending on tolerabilityFMAX 120 mg/day.
Major depressive disorder20 mg ORALLY twice daily to 60 mg daily (once or as 30 mg twice daily).
~@ѨϥΤ@AҼ{iP_C"	ͶnΦҾܲ{ɤW㪺x\êAӰCymbaltavT{yWzefL]~iAרϥCymbalta	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@xs30JHUC	Duloxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	{gB}fg䯫ghBsxʵJ{gC	"iQ(MAOI)G
XCymbaltaΦbCymbaltav5ѤATϥMAOIHv믫ewA]|yMgԸsIW[CMAOIv14ѤATCymbaltaӪv믫ewCѩ|yMgԸsIW[AbMAOI]ҦplinezolidPRߪ`gȥš^vfwATCymbaltaC
UʫCG
ACymbaltaiW[IA]wUʫCfwקKAΥġC"	ߡBfBݺΡBKBCBhC	קKϥΰDvn		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668711?cesid=2KPGtTsDGJs&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDuloxetine%26t%3Dname%26acs%3Dfalse%26acq%3DDuloxetine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w26-06 [E]_B3-04 j	Ts113.06.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.8._20241201.pdf"">OI` 1.1.8.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>             "	0	0	OIs 20251124	ODULO3-a	ODULO3-b	ODULO3-c	113.06.05
AA57743100	N06AX21	U~n60@J	ODULO6	DuxTINE 60MG/cap (Duloxetine)		DuloxetineH骺ܼ~{BϩʯkhΧܵJ{T@ξऴA۫Hoǧ@λPWjϯgM(serotonergic)PǤW(noradrenergic)C	"Diabetic neuropathy- pain60 mg once daily. Generalized anxiety disorder60 mg once daily, may start at 30 mg once daily for 1 week and then titrate up to 60 mg once daily, depending on tolerabilityFMAX 120 mg/day.
Major depressive disorder20 mg ORALLY twice daily to 60 mg daily (once or as 30 mg twice daily).
~@ѨϥΤ@AҼ{iP_C"	ͶnΦҾܲ{ɤW㪺x\êAӰCymbaltavT{yWzefL]~iAרϥCymbalta	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	@xs30JHUC	Duloxetine	N06A	ܧ{ ANTIDEPRESSANTS	0	{gB}fg䯫ghBsxʵJ{gC	"iQ(MAOI)G
XCymbaltaΦbCymbaltav5ѤATϥMAOIHv믫ewA]|yMgԸsIW[CMAOIv14ѤATCymbaltaӪv믫ewCѩ|yMgԸsIW[AbMAOI]ҦplinezolidPRߪ`gȥš^vfwATCymbaltaC
UʫCG
ACymbaltaiW[IA]wUʫCfwקKAΥġC"	ߡBfBݺΡBKBCBhC	קKϥΰDvn		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668711?cesid=2KPGtTsDGJs&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDuloxetine%26t%3Dname%26acs%3Dfalse%26acq%3DDuloxetine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_B3 [2]_B3 [ws]_w27-02 [E]_B3-05 j	Ts113.06.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.8._20241201.pdf"">OI` 1.1.8.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.2.1._20180301_000.pdf"">OI` 1.2.1.</a>             "	0	0	OIs 20251124	ODULO6-a	ODULO6-b	ODULO6-c	113.06.05
BC28315229	L01DC03	Khڧᴹ`g	IMITO2	ĵMITONCO FOR INJ. 10MG		Mitomycin is an antibiotic with antimetabolite activity. Mitomycin causes cross-linking of DNA and inhibits DNA synthesis and to a lesser extent also inhibits RNA and protein synthesis. Mitomycin is not cell cycle specific but has its maximum effect against cells in late G and early S phases.	"1. Intermittent dosing: 4-6mg intravenously once or twice a week.
2. continuous daily dosing: 2mg intravenously once a day.
3. High-volume intermittent dosing: 10-30mg, to be injected intravenously every 1-3 weeks or longer.
4. Combination with other anti-tumor agents: 2~4mg, 1~2 times per week. (If necessary
Intra-arterial, intra-costal or intra-peritoneal injection: 2~10mg).
5. Use in patients with bladder tumor:
For prophylactic use against recurrence, 4 to 10mg (potency) of Mitomycin is usually administered intravesically once every day or every other day.
For therapeutic use, 10 to 40mg (potency)/day of mitomycin is administered intravesically once a day. The dosage may be adjusted depending on the age and symptoms of the patient."	C vial ݥ[ 25ml Normal Saline wsϥΡA}ʡBվxs] 25J HUAis 24pɡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Mitomycin	L01D	ӭMrܥͯά CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	0	GBH(`ϥ)BB׽FBզfgwѡC					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6940824?cesid=35JRW7eVBC2&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMITOMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DMITOMYCIN"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-01 j	Ts113.06.07		0	0	OIs 20251124	IMITO2-a	IMITO2-b	IMITO2-c	113.06.07
BC26600100	B01AF03	0	OLIXI2	ĵLixiana F.C.Tablets 30mg		LixianaO@ب㦳׿ܩʡBBifXa]l(Factor Xa)FXa]l(Factor Xa)s̲צ@P|(final common pathway)iĳJ՞JCLixianaiAXa]l(Factor Xa)AHξJJ(prothrombinase)ʡCsXa]l(Factor Xa)YAi־J(thrombin)ͦBɶAíCΦIC	"ĳqCLixiana 60mg QDC
[qվ]
ǯf(ESRD)(CrCl)<15 mL/min:קKϥΡC
שέ׵ǥ\ण(CrCl) 15-50mL/min:ĳqC30mg QD
׵ǥ\ण(CrCl) >50-80mL/min:C60mg QD"	pGzpN(]AN)AΫIJˬdeAШƥizvAzAΧܾ徯C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Edoxaban	B01A	ܦ ANTITHROMBOTIC AGENTS	0	"1.wDäʤߩֺŸ
2.LixianaiΩvR߮CR߮]A`hR߮ΪͮC"	"1. ﬡʦλsҧt@ξLӡC
2. {ɤWjʩʥXC
3. xŦefX־\êB㦳{ɬX孷IC
4. wg{wiaӬ۷{פjX孷If_ίfgC
5. ΤYC
6. PɱLܾ徯vApǲΨx(UFH)BClqx(enoxaparinBdalteparin)Bxlͪ (fondaparinux)BfAܾ徯(warfarinBdabigatran etexilateBrivaroxabanBapixaban)ApHUpbGഫfAܾ徯vAΨϥζǲΨx(UFH)qȥHRߩΰʯ߾ɺ޺ZqһݤqC
7.׵ǥ\णw(CrCl<15 mL/min)C"	̱`}]Aֽn´XPyB姿AhAzGDXAʹުcDXC	C	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5488128?cesid=3qnGAevn3Vx&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEdoxaban%26t%3Dname%26acs%3Dfalse%26acq%3DEdoxaban"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_H3 [2]_H3 [ws]_w57-02 [E]_E5-11 j	Ts113.06.07	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.1.4.4._20220201.pdf"">OI` 2.1.4.4.</a>              "	0	0	OIs 20251124	OLIXI2-a	OLIXI2-b	OLIXI2-c	113.06.07
BC243822AA	L02AE04	FLĪ`g3.75@J	IDIPH1	ĵ(f)Diphereline P.R. 3.75mg		"Triptorelin is a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Following the first administration, there is a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol. After chronic and continuous administration, usually 2-4 weeks after initiation of therapy, a sustained decrease in LH and FSH secretion and marked reduction of testicular and ovarian steroidogenesis is observed. These effects are usually reversible after cessation of therapy."	Prostate Cancer or Endometriosis: Diphereline P.R. 11.25mg intramuscular injection repeated every 3 months. The treatment must be initiated in the first five days of the menstrual cycle.	"1.`geAХNPVXåRnʦܲͧ÷G
2. ίwY`gwNXA[Jp~AanʨϤѡANVXGX ]ФűNp~^FﴫwYåߨ`gC

IDIPH1  (wBϥ) ݨƼf 
IDIPH12 (wcBG~Fϥ)"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Triptorelin	L02A	EΨĪ HORMONES AND RELATED AGENTS	0	1. @HΤlcgUvC 2. Pgk֥ΥBgk~뤩AΩvIʩΧߴ@w̡C 3. vϩʩʦ (Nk 8 HeΨk 10 He)	"Hypersensitivity to triptorelin or any other component of the product, other GnRH analogues; women who are or may become pregnant while receiving the drug."	"Hot flushes, decreased libido, impotence, vaginal dryness, dyspareunia, allergic reaction (urticaria, rash, pruritus), glucose increased, hemoglobin decreased, alkaline phosphatase increased (2% to >10%), ALT increased, AST increased, skeletal pain (12% to 13%) and Quinckes oedema."	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669087?cesid=1kgmcCMcK09&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTriptorelin%26t%3Dname%26acs%3Dfalse%26acq%3DTriptorelin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_07-09 j	Ts113.06.07	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.1._20240601.pdf"">OI` 5.5.1.</a>              "	0	0	OIs 20251124	IDIPH1-a	IDIPH1-b	IDIPH1-c	113.06.07
	C03DA05	iӹF 20 @J	OKERE1	Kerendia 20 mg FC tab		Finerenone Oqʥֽ(MR) DTJܩʫܾAMR iQǩT଩MֽJƨýո`]CFinerenone bW( ҦpŦ) MDW( ҦpŦM) ´_MR ɪuAlMMR L׬ơCMR L׬ƳQ{PֺƩMoCFinerenone MR 㦳ܰĻMܩʡAﶯʯBBۿEM}ֽhS˩MOC	"ھeGFRPwKerendia ĳ_lqAeGFR ?60: C120@JAeGFR ?25<60: C110@JAeGFR <25: ĳϥΡC

LkHf]AĿfHAī~iiHPγn譹( pīGd) VMߧYAΡC"	LkHf]AĿfHAī~iiHPγn譹( pīGd) VMߧYA	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Finerenone	C03D	O[ POTASSIUM-SPARING AGENTS	0	"ΩwĤG}f(T2D)CʵŦf(CKD)~fHAiCʵǵyLov(eGFR)UBǯf(ESKD)Bߦަ`BDPRʤߦٱHΦ]߰Iܦ|IC
"	"Kerendia TΩHUfHG
1. fHjCYP3A4 ֥ΪvAҦpG ItraconazoleBketoconazoleBritonavirBnelfinavirBcobicistatBclarithromycinBtelithromycinBnefazodoneC
2. wǤW\णC"	? 10%[		"IKn
ثefinerenone ΨNªiJHťĤB@ΩĪťĥͦvTơCbsī~bXͫeMo|rʸ礤AbHw4 AUC XSqU[iW[j`vHΥj魫Co
o{Nfinerenone X{jťĤ[ аѾ\Sڸsϥ( 8.1 `) P] C
ĪX{ʪťĤANĪi|X{HťĤCYoϥKerendiaAhšC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7121045?cesid=8pBfmAXN0qM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFinerenone%26t%3Dname%26acs%3Dfalse%26acq%3DFinerenone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_03-05 j	Ts113.06.07		0	0	OIs 20251124	OKERE1-a	OKERE1-b	OKERE1-c	113.06.07
	M01AH04	NAoᴹ`g40@J	IDYCO1	Dycox 40mg/vial (Parecoxib)		ParecoxibOvaldecoxibeXġCValdecoxibb{ɾqd򤺬O@ؿܩʲĤG񨻨C(COX-2)C񨻨CtdeCͦA~w{XئPc-COX-1 MCOX-2CCOX-2@Pc|QPioEoAQ{DnOtdͯkhBoMoNgeC(prostanoid)CCOX-2]PƧZBۧɡBʯ߾ɺ޳XBǥ\઺ո`ΤϯgtΥ\(ooNBkhPB{\)C¡Xi]tYبCbHGũP򪺲´o{ COX-2A٤TwP¡XYC	"ĳq40mgARߪ`gΦ٦ת`gA۵ݭnC1224pɥiA20mgCpRߪ`gAita`JRߩΪ`JJRߪ`g޽uCpĦ٦ת`gAhݱN`gGwCa`J٦ײ`C 
qվ:50HUBChild-Pugh BBCCR<30ml/minw̫ĳqb"	"R߿`ݶWL15CհtibǷũm24p
1. parecoxib sodiumPacetylsalicylic acid (YϬOCq)֥ήɡAoͭGzD}(GzũΨLGzDֵog)I󰪡C
2. @X{֯lBHf_ΨLLӼxHANӥߧYϥparecoxibC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Parecoxib	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	u(yWL|)ϥΩ~Nkhw	߰IܡAaʯ߯efNAʮƹDũθzGDXA糧~NSAIDLӡAYx\णw 	PıwBkoBBƤ}BȮBP~C	C 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4670856?cesid=4VYDGOTyVvg&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPARECOXIB%26t%3Dname%26acs%3Dfalse%26acq%3DPARECOXIB"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-27 [w]_w03-02 [w]_w03-08 [E]_G3-05 j	Ts113.6.12		0	0	OIs 20251124	IDYCO1-a	IDYCO1-b	IDYCO1-c	113.6.12
		0	OCOZA2	Cozaar 50mg/tab )		"1. LosartanD(nonpeptide)imidazolelͪADnO_bޤβ´ޥ[IIAT-1(typel angiotensin II receptor)Fbefoͤޥ[II(Angiotensin)tަY(vasoconstriction)ް_WɩMǾJT(aldosterone)XnCثeAޥ[ƞJ(Angiotensin converting enzyme;ACE)sxΨӪvADnO_angiotensin Iangiotensin IIAOangiotensin IIP˦a|ѨLïʤƧΦAä৹Ѧޥ[ƞJ]|_wE(bradykinin)ް_prostaglandinN§ܡF]ޥ[IIܾ(Angiotensin II receptor antogonist)bM@ǿܩʪޥ[ƞJ(ACE)Ae̸৹aǯwޥ[t(renin angiotensin system)C
2. kĦw-D:bWĤGβĤTϥ"	"
_lqκqC50 mgAC@ ; W[ܨC100 mgAC@
vII}fǯf
@_lqC50 mgAC@CUΡAiNqW[ܨC100 mgAC@C"	P~w̥ioͦM[lƧ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	"
Losartan 100 @J"	C09C	"޺iIIġA ANGIOTENSIN II ANTAGONISTS, PLAIN"	0	BvII}fǯf	"1.TΩ糧~զLӪ
2.COZAARPaliskireniX֨ϥΩ}ffHεǥ\णfH (GFR < 60 ml/min/1.73 m2)C"				аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts		0	0	OIs 20251124				
NX15737277	B05XA03	"(M)""٥""ƶu`gG"	INX07	(M)Solutio Natrii Chloridi 0.9% 500ml(w~)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.14		0	0	OIs 20251124	INX07-a	INX07-b	INX07-c	113.06.14
X000305277	B05XA03	0	INX02	(M) ()B.Braun NaCl 0.9 % 500ml(w~)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.14		0	0	OIs 20251124	INX02-a	INX02-b	INX02-c	113.06.14
X000313277	B05XA03	(M)MץͲzQ500ml (DEMO S.A)	INX09	(M) Sodium Chloride 0.9% Solution for Infusion 500mlw~		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.14		0	0	OIs 20251124	INX09-a	INX09-b	INX09-c	113.06.14
X000312277	B05XA03	(M)NS 500mlMץͲzQ(Vn)	INX10	(M) Sodium chloride 0.9% 500ml/nU		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.17		0	0	OIs 20251124	INX10-a	INX10-b	INX10-c	113.06.17
X000304209	B05XA03	߮ī~MץͲzQ500ml	INXT3	(M) Ͳz?G1000ml FUSO		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.17		0	0	OIs 20251124	INXT3-a	INXT3-b	INXT3c	113.06.17
X000311209	B05XA03	(M) ʯSMץͲzQ1000ml	INXT8	(M) (Baxter)1000ML/nUSODIUM CHLORIDE 0.9%		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.25		0	0	OIs 20251124	INXT8-a	INXT8-b	INXT8-c	113.06.25
X000302277	B05XA03	(M) ʯSMץͲzQ1000ml	INX01	(M)j?ͭ`500ml(nU) Otsuka 0.9% Normal Saline		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.25		0	0	OIs 20251124	INX01-a	INX01-b	INX01-c	113.06.25
X000306277	B05XA03	(M) ()xWf?MץͲzQ500ml	INX03	(M)()Sodium Chloride Solution for infusion 0.9% 500ml(w~)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.06.26		0	0	OIs 20251124	INX03-a	INX03-b	INX03-c	113.06.26
X000316277	J01CA01	M-AMPICILLIN 500mg/vial w`g	IAMPI2	M-Sterile Ampicillin 500mg/vial		AmpicillinO@طssxʦXPenicillin sA?ﭲ?󶧩ʵߦ?ġAPɹﭲ?󳱩ʵߥ禳ġA@?ĥTV`gΧܥͯsC	"HG1-2g q4h-q6h`g@C
pġG魫 50 kg HUAC 25- 50 mg /  kg pA|AC6 pɪ`g@C"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUD
tmb@pɤΧD"	ampicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	 Penicillin Lӯgew̤yAΥC	C¯lBooBlέ(LӤ)	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668590?cesid=75yAV73hiNQ&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAMPICILLIN%26t%3Dname%26acs%3Dfalse%26acq%3DAMPICILLIN"">LexidrugľǸƮw</a>"	"CClr>50      1~2g q6h
CClr 30-50  1~2g q6-q8h
CClr 10-30  1~2g q8-q12h
CClr<10       1~2g q12h
IHD              1~2g q12h
CAPD           0.5~1g q12h"	ѦҡuqΥΪkv	"ĳ~|GIMBIVBIVF
tswwʡGϥήɷsAtsAtșn1hr ϥ
tsGGG1.8ml WFI(IM)B 5ml WFI(IV)
ĳ}@סGIVF:2-30mg/ml? 
ۮe}GGNSBD5W? 
ĳĳ~|tvGIV:3-5min
`NƶG1.󸲵}BE}έһQww
2.iMGsBLJղGBaminoglycosidesVXϥ"	ixiij	Ts114.10.31	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.10.31
X000303209	B05XA03	(M)j?MץͲzQ1000ml	INXT1	(M)j?ͭ`1000ml Otsuka 0.9% Normal Saline (nU)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.07.01		0	0	OIs 20251124	INXT1-a	INXT1-b	INXT1-c	113.07.01
X000248343	P03AC04	βb30J	EPERM1	Miteout 5% cream 30g/tube		νHBBYΨΧZPV	NwBHŤ~bAAH~AqwAg8-12pɫi~hCȻݨϥΣAYiġC	iXAƨϥΩάOLindane ϥήɶA|ywo@Φ`	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs 25JHUC	Permethrin cream 5%	P03A	"~ξ ECTOPARASITICIDES, INCL. SCABICIDES"	0	νHBBYΨΧZPV	"Hypersensitivity, premature infants, seizure"	ֽEC	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669229?cesid=4LxT0Rh97er&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPermethrin%26t%3Dname%26acs%3Dfalse%26acq%3DPermethrin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.15._20241201.pdf"">OI` 13.15.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.05.21
	J05AB01		IZOVI3	ACTAVIR 250 (acyclovir)		DAcyclovirO@اܯfrĪA©ʞ\l(HSV)BΤka\lfrD`ġCAcycloviriJQ\lPVӭMA|CĤƦʤƦXAAcyclovirTCĤƦX|\lSDNA polymeraseMA]iHfrDNAXӤ|zZ`ӭMN§@ΡC	"Hq
1. ©?l]?lʸҥ~^Τka?lPVw̡AC8pɡA5mg/kgAcyclovir`C 2. K̾णw̡Aǥ\ॿ`̡Abvka?lP
VɡAC8pɵ10mg/kgAcyclovir`CK̾णw̡Aǥ\ॿ`̡Abvka?lPVɡAC8pɵ10mg/kgAcyclovir`C
ൣq
1. 3Ӥ12ൣϥAcyclovirR߿`ɡAھڨnp⾯qCw©?l]?lʸ~^άOka?lPVൣAC8pɨϥ250mg/m2AcyclovirR߿`C
2. K̥\णӵǥ\ॿ`ൣAwka?lPVάO?lʸɡAC8pɡA500mg/m2nAcyclovirR߿`C "	"1. ϥθqw̡]Ҧp?lʸ^ASO`Nǥ\ASOOw̦Υǥ\ण{HɡC
2. ts᪺Acyclovir`gGpHȬ11AgѤfAġC 3. ϥΩǥ\णΦѦ~w̡GAcyclovirgѵŦưA]bǥ\णfHWϥΪqӴ֡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Acyclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	a?lfrγ?lfrް_PVCw貾ӤΥզfҤް_K̤fH?lPVCsͨ?lPVC 	Acyclovir |LӤw̡ATϥΡC	`g짽oAߡAæRC 	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668909?cesid=9B6fcslhXtp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcyclovir%26t%3Dname%26acs%3Dfalse%26acq%3DAcyclovir"">LexidrugľǸƮw</a>"	"CClr>50       10mg/kg Q8h
ClCr25-50    10mg/kg Q12H
ClCr10-25    10mg/kg Q24H
ClCr<10        5mg/kg Q24h
CAPD           5mg/kg Q24H (after HD)"	ѦҡuqΥΪkv	"ĳ~|GIVF
tswwʡG1.tmnε}ᤧGiNáB}Ƿ12hr,
tsGG10 ml WFIBNS 
ĳ}@סG<5mg/ml  @
ۮe}GGNSB0.45%NaCl
ĳĳ~|tvG> 1hr
`NƶG-"	ixiij	Ts113.07.05		0	0	OIs 20251124	IZOVI3-a	IZOVI3-b	IZOVI3-c	113.07.05
AC59880417	S01AA17	0	PERYT2	Erythrocin 0.5% oph oint(Erythromycin)		DnG+ߡASO@ĩʪߦġFBBBߧJ鵥]ġC	"Intraocular infections: 1 cm ribbon applied up to 6 times daily (depending on severity of infection)
@@ܼƦAgI󲴱wC"	YPɨϥΤ@إHWġAĳܤֶj5C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Erythromycin	S01A	ܷPV ANTIINFECTIVES	0	vPߤް_CʵBB\nBɸ~B¥tBšBⲴCwsͨधOy(N. gonococcus)Aܦfr(C. trachomatis)PVC	糧~LӪ̡ATϥΡC	`BEPC	iw/i	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669687?cesid=25mR8RaQQSa&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DErythromycin%26t%3Dname%26acs%3Dfalse%26acq%3DErythromycin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P04-04 [E]_H1-07 j	Ts113.07.05		0	0	OIs 20251124	PERYT2-A	PERYT2-b	PERYT2-c	113.07.05
B027835161	N07BA01	jMٵҼQ	ENICO	Nicorette QuickMist Spray		ٵһUC	NQLVfġAúɥiNQLCUQ~ݤ@UHQXQCQxɽФŧlAHKQlJVCF̨ܳήĪGAQxƬФŧ]`C }lϥήɡACpɤiWL4QACѤiWL64QAv֥ζqC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Nicotine	N07B	v}ʯefĪ	0	ٵһUC			"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669735?cesid=5WO5S8T8no1&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNicorette%26t%3Dname%26acs%3Dfalse%26acq%3DNicorette"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M01-01 j	Ts113.07.06		0	0	OIs 20251124	ENICO-a	ENICO-b	ENICO-c	113.07.06
	B01AC22	w 20@J	OEFIE2	EFIENT F.C. 20mg/TAB		Prasugrel hydrochloride @ثeXĪ(prodrug)Abഫ䬡ʥNªAzLܩʥBifXܦpOP2Y12 ADPApO@ΡC	"Efient_lq榸ϥ20mgfAq, HqC@3.75mgfAq"	(1) ЯdN_lqMaspirin֥ήɡAi|W[X媺IC (2) EfientҤ޵opO@ΡAi|nNfwyDAĳ{vbNeܤ14ѰϥEfientC(3)㦳XɦVΥX(`Xfv)iyXD(4)㦳μȮɩʸʦ媺fH(TIA)ϥefient60mg(LD)+10mg(MD)QDX孷IW[D(5)򰾰fHD(6)clopidogrelLӪfHiX{LӡD(6)魫CfH(50kg)X孷IiW[D(7)ǥ\णi|W[X孷ID(8)רx\णiW[X孷ID	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Prasugrel	B01A	ܦ ANTITHROMBOTIC AGENTS	0	EfientAΩݭnaʯߤJʪv(PCI)ʫaʯ߯gԸs	"1. Xgfw(ͯfB`XBƹDXBDXByBX嵥)C
2. ī~󦨤LӯfvfwC"	DnĪ}]t֤UXByB姿Bެ볡~HΥ֤U~C	C 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668756?cesid=6lTNcc5zzlY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPrasugrel%26t%3Dname%26acs%3Dfalse%26acq%3DPrasugrel"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[96]_6-04 j	Ts113.07.09		0	0	OIs 20251124	OEFIE2-a	OEFIE2-b	OEFIE2-c	113.07.09
X000308316	B05CB01	(M)RINSMרR~ΥͲzQ3000ml	INXI31	(M)RINS 0.9 % NS(R~) 3000ml (nU)		R~			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC		B05C	R~G	0	R~					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6479810?cesid=ahYk5TF379N&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBrigatinib%26t%3Dname%26acs%3Dfalse%26acq%3DBrigatinib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.07.12		0	0	OIs 20251124	INXI31-A	INXI31-B	INXI31-C	113.07.12
X000297100	L01ED04	ALUNBRIG	OALUN3	fĵ(M)ALUNBRIG FC 90mg/tab(BRIGATINIB)		Brigatinib O@ؿE?CBrigatinib iALK CĤơAHΥALK ո`UTǻJսSTAT3BAKTBERK1/2 MS6 CĤơCBrigatinib ]i~{XEML4-ALK PNPM-ALK ĦXJդӭM誺W͡ABbp礤ܹEML4-ALK NSCLC زӥͪ㦳q̿ʪ@ΡC	"ھڸ~FO_e{ALKʡAܥiALUNBRIGvߴDpӭMfHC
e 7 ѤfA90 mgA@Ѥ@FYbe7 ѥi@90 mgAhW[qfA180 mgA@Ѥ@C򵹤ܯefcƩεo͵LkrʡC
󭫫רx\णfH (Child-Pugh C )AALUNBRIG @Ѥ@qC 40% (Y 180 mg  120 mgA120 mg  90 mgA90 mg  60 mg)
󭫫׵ǥ\णfH [ Cockcroft-Gault p⪺ٻMv (CLcr)  15  29 mL/min]AALUNBRIG @Ѥ@qC 50% (Y 180 mg  90 mg  90 mg  60 mg)"	"ܯfH]AĿCФſiHΩCZĿC
]34ILD/DPVʪͪä[ALUNBRIGC
ʴfHO_X{sIlDgέ즳gc (ҦpIlxByµ)AרObvĤ@gCfHYX{IlDgcơAߧYլdO_DPVʪͪCYæDPVʪͪAȰI AlunbrigAõO_Lް_g] (ҦpͮB~FcơBPVʪͪ)Aݭnվ㾯qC
Alunbrig vwʴAYY (?  3 )AȰI AlunbrigA찪_ܲ 1 ũΰ¦ȡAݭnվ㾯qC
Alunbrig ֥ΨLw|ɭP߷iLwĪɡASOԷVAwʴ߸tvMC
 Alunbrig vfHo͵Oê}C
 Alunbrig vfHo CPK ɰCifHAX{󤣩]٦׵hBĲhεLOANCAlunbrig vwʴ CPK @סA CPK ɰY{פάO_P٦ׯkhεLOAȰI Alunbrig vAþAվ㾯qC
ŦïɰA Alunbrig vfHo;?Mת?ɰC
 Alunbrig vfHoͨxŦï (ѪVii?Bii?) MxɰC}lϥ Alunbrig ex\ (]A ASTBALTB`x)AB}lv 3 Ӥ뤺ACj 2 g@Aᤴwʴ
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os30XC HUC	brigatinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	AΩbcrizotinibvcƩεLk@ALKʪߴDpӭM(NSCLC)fHC	LC	ѪVii? (AST) ɰBٻCĿE? (CPK)ɰB}Bת?ɰBخqgBmBii? (ALT) ɰB?ɰBhBߡB«BCCBOڲypƴ֡By¡BPC?ɰB֯lBƳ嬡?ɶ (APTT) W[BٵhBYhBBզypƴ֡BIlxMæRC	ALUNBRIG |ɭPLl Aĳ㦳ͨ|OkʦbALUNBRIGvP̫@ܤ4 Ӥ뤺ϥΦĪDXץI	ѩiŤް_}AĳŤkʦbALUNBRIG vM̫@1 gšC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6479810?cesid=0JawugAWAp8&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBRIGATINIB%26t%3Dname%26acs%3Dfalse%26acq%3DBRIGATINIB"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-02 j	Ts113.07.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.82._20240601.pdf"">OI` 9.82.</a>              "	0	0	OIs 20251124	OALUN3-a	OALUN3-b	OALUN3-c	113.07.17
BC28217216	J05AG05	dĮĪ`gaB3 ML	IRILP	Rekambys 900mg/3ml (Rilpivirine) PR suspension Inj.		"Rilpivirine ݩD??
(non-nucleoside reverseVtranscriptase inhibitors,NNRTIs)Ai HIV-1 ?ͫDvʧӪ HIV-1 ƻsA"	֥Vocabria Prilpivirine C@AĤGβĤTӤO٦ת`gVocabria İw600 @JHRekambys İw900 @J@AĤӤ_C2 Ӥ٦ת`g@Vocabriaİw600 @JHRekambys İw900 @J	"1.~@wnPVocabria֥ΡC󤣦Pv`g`gC
2.iHzLfAɤJΤϥΤfAɤJ]`g^}lC
3.٦ת`gA`g󸡰vέIvC
4.{̵WvHUءG
(1)C1Ӥ@{G
a._l`gG٦ת`g澯900@JAثeܤfrkΤfAɤJ{̫@Ѷi`gC
b.`gGC@٦ת`g澯600@JCiC@{p`ge7Ѥi`gC
(2)C2Ӥ@{G
a._l`gG@⦸Aj1ӤA٦ת`g澯900@JAثeܤfrkΤfAɤJ{̫@Ѷi`gC
b.`gGC2Ӥ@٦ת`g澯900@JCiC2Ӥ@{p`ge7Ѥi`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		Rilpivirine	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	AΩPcabotegravir`g֥ΡAvbíwܤfrkUwFfrǧĪG(HIV-1 RNA< 50 copies/mL)BcabotegravirrilpivirinewκæĩʤHHK̤fr1fr(HIV-1)PVgC	"ﬡʦΦC1.2`ξLӡC
PrifampicinBrifapentineBcarbamazepineBoxcarbazepineBphenytoinphenobarbital֥"	`gBYhBoNC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668500?cesid=27fKLLaXOrI&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRilpivirine%26t%3Dname%26acs%3Dfalse%26acq%3DRilpivirine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-17 j	Ts113.07.24		0	0	OIs 20251124	IRILP-A	IRILP-B	IRILP-C	113.07.24
BC28218216	J05AJ04	Ī`g 3ml	ICABO	Vocabria 600mg/3ml (Cabotegravir) PR suspension Inj.		"Cabotegravir|PHIVOX?ʳ쵲XAê_frhֿ}ֻ(DNA)OXL{ಾBJAo]OHIVƻsgDnBJAq?OX?@?C
"	֥Vocabria Prilpivirine C@AĤGβĤTӤO٦ת`gVocabria İw600 @JHRekambys İw900 @J@AĤӤ_C2 Ӥ٦ת`g@Vocabriaİw600 @JHRekambys İw900 @J	"1.~@wnPRekambys֥ΡC󤣦Pv`g`gC
2.iHzLfAɤJΤϥΤfAɤJ]`g^}lC
3.٦ת`gA`g󸡰vέIvC
4.{̵WvHUءG
(1)C1Ӥ@{G
a._l`gG٦ת`g澯600@JAثeܤfrkΤfAɤJ{̫@Ѷi`gC
b.`gGC@٦ת`g澯400@JCiC@{p`ge7Ѥi`gC
(2)C2Ӥ@{G
a._l`gG@⦸Aj1ӤA٦ת`g澯600@JAثeܤfrkΤfAɤJ{̫@Ѷi`gC
b.`gGC2Ӥ@٦ת`g澯600@JCiC2Ӥ@{p`ge7Ѥi`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30XCHUCŧNC	Cabotegravir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	A?Prilpivirine`g?AvwFfrǧĪG(HIV-1 RNA <50copies/mL)Bcabotegravirrilpivirinewκæĩʤ?HIV-1PVgC		`gBYhBoNC	便ϥcabotegravirƬ۷C]TVocabriaHhvTC	"ھڰʪ窺ơA@{cabotegravirӷ|ciJHťġA޳o|gLH窺ҹCb`g̫@cabotegravirF12ӤΧɶAcabotegraviri|X{HťġC
"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7041880?cesid=06r45fLechA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCabotegravir%26t%3Dname%26acs%3Dfalse%26acq%3DCabotegravir"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-16 j	Ts113.07.24		0	0	OIs 20251124	ICABO-A	ICABO-B	ICABO-C	113.07.24
	A07AA06	s	OHUMA	Humatin 250mg/cap(Paromomycin)		Paromomycin̤Χ@ΡCParomomycinzGDLPfʤΨPfʪLͪܥͯ\ġC	̤ڷPVGHĪvѷ´ʪ̤(Entamoeba Histolytica)֩H̤(Dientamoeba Fragilis)Ҥް_̤ڵge(Intestinal Amebiasis)AĳHMൣqOCѪA`q25 ~ 35 mg/kgATH\AΡAsA5 ~ 10ѡC	"1. ԷVϥparomomycinwũʵz(ulcerative colitis)fHAi]LקlyǬrʡC

2. iy惡ĨSPʪLͪLץͪC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs15 ~ 30JKʮeC	paromomycin	A07A	zDܷPV INTESTINAL ANTIINFECTIVES	0	̤کʵge	"1. aminoglycosideLӪ̡Bz̡C
2. 1ӤjHUsͨC
3. exΦսxeglC
4. gٵLOw̡C"	"1. ֽ譱GĲʥֽlC
2. ƨtΡGhBjˡBߡBmBظC
3. L譱GǬrʤťıॢBjˡC"	Ʃ|إ	Ʃ|إ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667924?cesid=aZ6c10nBZ4X&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPAROMOMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DPAROMOMYCIN"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.08.01		0	0	OIs 20251124	OHUMA-A	OHUMA-B	OHUMA-C	113.08.01
		0	OLEFL	(TBO)LEFLODAL F.C. TABLETS 500 MG		@@Fluoroquinolonesܲӵ߷PVĪAlevofloxacin@ΦbDNA-DNA-P(gyrase)ƦXPĥ|ݾ벧c(topoisomerase IV)C 	"CIΤ@Cq̾ڷPVPYʡAΰwPff쪺ӷPʦөwC
Ѥ@}lRߪ`gvഫfAvCѩDzDPfAΦ㦳鵥ĩʡAiHϥάۦPqC
"	UCw̽ԷVA1.YŦêw2. wδwLwj˩ʯefw3.Quinolonetܵ߾LӪw̡C	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAΡC	Levofloxacin	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	vH]levofloxacinPʪPfߩҤް_UPPV:ʻuACʤުʴcơAϩʪͪAʪcDPV(]A:ǪǪACʲӵߩʫeCAֽMn´PV)	1)糧~OfloxacinLӯgw̡C(2)ΥihHC(3)C	YBGzABlBӷP	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669838?cesid=03QlzPaiyXp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLevofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3DLevofloxacin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.08.07		0	0	OIs 20251124	OLEFL-a	OLEFL-b	OLEFL-c	113.08.07
KC01013230	L01FF01	Oe 120mg/vial	IOPDI3	ĵƼfOPDIVO (NIVOLUMAB) inj 120mg/12mlvial		PD-1t(PD-L1MPD-L2)PTӭMWPD-1۵XATӭMWͩMӭMEͦCYǸ~F|հPD-1t骺{AózL~|HǾɧʩTӭM~FK̺ʱCNivolumabO@ؤHK̲yJG4 (IgG4) AiPPD-1鵲Xê_PPD-L1MPD-L2椬@ΡAiXո`PD-1~|Ķ@ΡA]Aܸ~FK̤C	"Lkಾ??FBߴD?ӭMBߴǲӭMB嫬N??OڽFBYV쪬ӭMBߴಾʪcDW?
BLkߴδ_oʭGB㦳?׷LìPíw(MSI-H)ο~t״_ʳ(dMMR)ಾ?zz: ĳq3mg/kg sR߿`30AC2g@A 240mg sR߿`30AC2g?A 480mgsR߿`30AC4g?AefcƩΥX{LkrʬC
D쪬ӭM:ĳq 240mg sR߿`30AC2g?A 480mgsR߿`30AC4g?AefcƩΥX{LkrʬC
??FUv:ĳq3mg/kg sR߿`30AC2g@A 240mgsR߿`30AC2g?A 480mgsR߿`30AC4g?Aef_oΥX{Lkrʬ?A?h1~C
cDW?Uv:ĳq 240mg sR߿`30AC2g?A 480mgsR߿`30AC4g?Aef_oΥX{Lkrʬ?A?h1~C
DέGDUv:ĳq 240mg sR߿`30AC2g?A 480mgsR߿`30AC4g?A16gvAۥH480mgC4g?AefcƩΥX{Lkrʬ?A`v1~C"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. Nxs2J-8XCC
2. ϥΫeץxsAæs]ˤCФŧNηn̡C

`Gxs?
~tGC
sƫAHUC??xsOPDIVO`GG
? qsƶ}l?`AmǷŤUɶoWL8?ɡCpGbsƫ᪺8?ɤ?AХ}GF
qsƶ}l?`ANé2J-8XC (36XF-46XF)ɶoWL24?ɡCpGbsƫ᪺24?ɤ?AХ}GC
"	Nivolumab	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	"1. Lkಾʶ¦FG
@kΨ֥ipilimumabAΩvLkಾʶ¦FfHC
2. ¦FUvG
AΩ¦FIǦܲOڵΤwಾBi槹ʤNfHUvC
3. iDpӭMNeUvG
֥Χt`ƾǪvAΩi]~F4βOڵʡ^BEGFRALK~F]`DpӭM(NSCLC)~fHNeUvC
4. DpӭMG
(1)֥ipilimumabAΩaPD-L1 (1%)BEGFRALK~F]`ಾʩδ_oʫDpӭM(NSCLC)~fHĤ@uvC
(2)֥ipilimumab2Ӷgt`ƾǪvAΩ󤣨EGFRALK~F]`ಾʩδ_oʫDpӭM(NSCLC)~fHĤ@uvC
(3)֥ carboplatinBpaclitaxel bevacizumabAΩ󤣨EGFR ALK~F]`ಾʩδ_oʫD쪬DpӭM(non-squamous NSCLC) ~fHĤ@uvC
(4)AΩ󱵨t`ƾǪvɩΤefcƪߴDpӭM(NSCLC)fHAfHY㦳EGFRALK~F]`̡AhgEGFRALKvX{efcƲ{HC
5. cʦؽֽFG
֥ipilimumabAΩLkcʦؽֽFHfHĤ@uvC
6. ǲӭMG
(1)AΩegܦ޷skv(anti-angiogenic therapy)ߴǲӭMfHC
(2)֥ipilimumabiΩv/׭I(intermediate/poor-risk)evߴǲӭMfHC
(3)֥cabozantinibAΩ󥼴vߴǲӭMfHC
7. YV쪬ӭMG
AΩ󱵨t`ƾǪvɩΤefcƪ_oಾYV쪬ӭM(SCCHN)fHC
8. 嫬NOڽFG
AΩgUC覡v_oδcƪ嫬NOڽFHfHG
(1)yFӭM(HSCT)Pbrentuximab vedotinA(2)3ة3إHWkA]AyFӭM(HSCT)C AgY̾ګ[v(objective response rate)o[t֭CAg֭㶷nT{ʸ(confirmatory trial)ҩTF{ɮįqC
9. cDWG
(1)AΩvt`kΤcƪߴLkಾʪcDWfHCAgY̾ڸ~Fv(tumor response rate)Ϊvɶ(duration of response)o[t֭CAg֭㶷nT{ʸ(confirmatory trial)ҩTF{ɮįqC
(2)AΩbڪvʤNA״_oIcDW10. GBGDέDG
(1)֥fluoropyrimidineΧt`ƾǪvAΩvߴಾʡAB㦳HER2Lת{GέGD(Gastroesophageal Junction, GEJ)έDfHC
(2)AΩvegةΨإHWƾǪvߴδ_oʭGέGDfHC
11. xӭMG
֥ipilimumabAΩvesorafenib vxӭM(HCC)fHC
12. ಾʤjzzG
@ĪΨ֥ipilimumabAΩ󱵨fluoropyrimidineBoxaliplatinMirinotecanvefcƤ㦳׷LìPíw(MSI-H)ο~t״_ʳ(dMMR)ಾʤjzz(CRC)HfHCAgY̾ګ[vo[t֭AAgT{ʸHҩ{ɮįqC
13. D쪬ӭMG
(1)֥ΧtfluoropyrimidineΧt`ƾǪvAΩߴಾʭD쪬ӭM(ESCC)fHĤ@uvC
(2)֥ipilimumabAΩߴಾʭD쪬ӭM(ESCC)fHĤ@uvC
(3)AΩ󴿱X֧t`fluoropyrimidine ƾǪvcƪLkߴδ_oʭD쪬ӭM(esophageal squamous cell carcinoma)fHC
14. DέGDUvG
AΩ󴿱NePBƾǻPgv(neoadjuvant concurrent chemoradiotherapy)PNAgfzˬdT{´ݯd~FDέGDfHUvC"					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5467517?cesid=5xm3BSvYcR5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNivolumab%26t%3Dname%26acs%3Dfalse%26acq%3DNivolumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-28 j	Ts113.08.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.69._20251001.pdf"">OI` 9.69.</a>              "	0	0	OIs 20251124	IOPDI3-A	IOPDI3-B	IOPDI3-C	113.08.15
X000326209	B05XA03	(M) Greenflex 0.9%NS 1L inj	INXT4	(M) Greenflex1000mlnUNormal Saline Inj		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.08.15		0	0	OIs 20251124	INXT4-a	INXT4-b	INXT4c	113.08.15
X000327209	B05XA03	(M)1LͲzQ(DEMO S.A)	INXT9	(M)(DEMO)1000ML/w~ NACL 0.9%*1000ml		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.08.23		0	0	OIs 20251124	INXT9-a	INXT9-b	INXT9-C	113.08.23
JC00143209	L03AB15	ʴw˪`gG500LJ/@	IBESR	fBESREMI 500mcg/ml (ropeginterferon alfa-2b)			"թwq
qݨ̯f?ӧOվAĳ_lq100LJAYf?Pɱt~ӭMk(cytoreductive therapy)AhBesremi_lq50LJCqݳvդɡAC2gդ50LJ(Pɩұt~ӭMk]Aa۴)?GǰѼƭ(haematological parameters)FíwA(?e45%A??O400x109/L??y10x109/L)C?q500LJAC2g?U`g?Cnɥiݭn??@ϴkAC?G?HYרϨF`dC
q
HC2g?U`g?AF?GíwqAC2g?1.5~AiҼ{̯f?ӧOΩ?`gjA?iC4g?U`g?Cf?bഫC4g?U`giݭn^_C2g`gC
vYo?}AqݭCμȮɰĪ줣}CA?CqsġA?DHo?}qġC
Y[f??GǰѼƭȼW?(?eB??OpƩ??yp)A̯f?ݭnվ㵹ľqΪ`gjC
"	"Ȩ?U`g?C
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Цs2-8XC Nd!
Ф?!
ץxsb]ˤI"	ropeginterferon alfa-2b	L03A	K̼Wj IMMUNOSTIMULANTS	0	vgʵʸ~jHuʬyWhgfHC	"DΦC1.2`ξLӡC
? Ҫeff?(?`Wkḭ~)
? Y믫ef̩δfv̡AרOY{B?Y?ϦY??ޯef̡AY౱??B{??I (? NYHA class 2)BY?ߤBYaʯ߯UBíw?hΪ?ٱC
? ?K̯effvΦ?K̯ef̡C
? ĶxӪ̡C
? PtelbivudineX֪v
? Nvxw(Child-Pugh BC)f? 
? Ŧf?(ǵyLov?15 mL/min) "	"*The most common adverse reactions are leukopenia (19.1%), thrombocytopenia (18.5%), arthralgia (12.9%), fatigue (12.4%), increased gamma-glutamyltransferase (gamma-GT) (11.2%), influenza-like illness (10.7%), myalgia (10.7%), pyrexia (8.4%), pruritus (8.4%), increased alanine aminotransferase (ALT) (8.4%), anaemia (7.9%), pain in extremity (6.7%), alopecia (6.7%), neutropenia (6.7%), increased aspartate aminotransferase (AST) (6.2%), headache (6.2%), diarrhoea (5.6%), chills (5.1%), dizziness (5.1%) and injection site reaction (5.1%).
Serious adverse reactions are depression (1.1%), atrial fibrillation (1.1%) and acute stress disorder (0.6%)."	C	Limited human data-probably compatible	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7167160?cesid=6XiSmI6bJHb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dropeginterferon%2Balfa-2b%26t%3Dname%26acs%3Dfalse%26acq%3Dropeginterferon%2Balfa-2b"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-39 j	Ts113.08.28	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.5._20250201.pdf"">OI` 4.3.5.</a>              "	0	0	OIs 20251124	IBESR-A	IBESR-B	IBESR-C	113.08.28
X000322277	B05XA03	(M)GrifolsMץͲzQ500mlnU	INX04	(M)Grifols Salina Fisiologica 0.9% 500ml(nU)		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.09.13		0	0	OIs 20251124	INX04-a	INX04-B	INX04-C	113.09.13
X000329209	B05XA03	"(M) NSS NORMAL SALINE 0.9H 1,000ml (nU)"	INXT6	"(M) NSS NORMAL SALINE 0.9H 1,000ml (nU)"		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.09.13		0	0	OIs 20251124	INXT6-a	INXT6-B	INXT6-C	113.09.13
BC26359100	L01EJ01	iÿ 5@J	OINC42	ĵƼfJAKAVI 5mg/tab (Ruxolitinib)		Ruxolitinib O@ب㦳ܩʪJanus E?(JAKs) JAK1 PJAK2 ( JAK1 PJAK2 ïIC50ȤO3.3 nM P2.8 nM)CoǿE?iC\hy@ΤΧK̥\෥nӭMEPͪ]lǻ@ΡCJAK ǻ@ίASTATs ( TǾɻPƦ]l) QܲӭME?BiӬSTATsBSTATs iӭM֤EAqӲͽո`]{@ΡCJAK-STAT |շ|޵ohgA÷|Wjcʸ~FӭMWͯOPsOC 	"_lq
pOpƤ100,000 M200,000/mm3w̡AJakavi ĳ_lq15 @JCfA⦸ApOp>200,000/mm3 w̫h20@JC⦸C
pOpƤ50,000 M100,000/mm3w̡Aѩ{ƦA]LkѰ_lq譱ĳC
ow̪̰ĳ_lq5@JC⦸Ap߽վ㾯qC "	"ypƭC
ϥJakavi vi|޵oGǤ}A]ApOCUBhζݤʥզyCUCb}lϥΪveiyp˴C
[GܡA}lvɤpOpưC(<200,000/mm3) w̸ibvX{pOCU{HC
pOCUg@볣㦳ifʡABq`bCqμȮɰJakavi KioCLApG{ܦnA]iභ`pOC
X{h{Hw̥i|ݭnCX{h{Hw̡AinҼ{վ㾯qμȮɰ C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XC HUC	Ruxolitinib	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"AΩvInternational Working Group (IWG) Consensus Criteria ׭I-2 ΰIֺơA]AoʰֺơBuʬyWhgᰩֺơBΦpOWhgᰩֺơC
AΩ󱵨hydroxyurea vᦳĩʩεL@ʪuʬyWhgw̡C "	ﬡʦΥ@ξLӡC	̱`Ī}pO֤γhC	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7155658?cesid=4Y8IXqazBkr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRuxolitinib%26t%3Dname%26acs%3Dfalse%26acq%3DRuxolitinib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_02-07 j	Ts113.09.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.55._20251001.pdf"">OI` 9.55.</a>              "	0	0	OIs 20251124	OINC42-a	OINC42-b	OINC42-c	113.09.16
BC20999100	J04AB04	bֽn150@J	OMYCO1	Mycobutin 150mg/cap(Rifabutin) 		RifabutinwQҹbӷPֲӭM߮(jz[Escherichia Coli]M\[Bacillus subtilis])|̿DNARNAEXC(DNA dependent RNA polymerase)AbӭMå@ΡCbrifampicinĩʪ֤K(M. tuberculosis)ݸGr(thymidine)X֨DNAAҥHrifabutini]|DNAXApiHrifampicinĩʤߺب̵M㦳ʡC	"MycobutinfA뤩A@Ѥ@A\AΡC
HG
Mycobutin@kGwĶfHMACPVG300 mg (2ɽn)C
MycobutinXkG
1. D֤KߡG450~600 mg (3~4ɽn)v6Ӥ몽Li߲͡C
2. hĪĩʤCʵ֡G300~450 mg (2~3ɽn)v6Ӥ몽Li߲͡C
3. ̪E_X͵֡G150 mg (1ɽn)v6ӤC"	Mycobutin|ϧGBֽPHceC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC	Rifabutin	J04A	֪v DRUGS FOR TREATMENT OF TUBERCULOSIS	0	1. wĶfHӭMV֤K߷PVC	TΩRifabutinBRifamycin(pRifamycin)LӥvfHC	GܦAֽlApO֡AxïW[θzGtΪߡBæR{HC	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668763?cesid=afpIYrR1YVn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRifabutin%26t%3Dname%26acs%3Dfalse%26acq%3DRifabutin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[M]_M05-07 j	Ts113.10.02		0	0	OIs 20251124	OMYCO1-a	OMYCO1-B	OMYCO1-C	113.10.02
	A11DA01	0	OTHIA1	VITAMIN B1 TABLETS 100MG		PATP椬@ΡAΦthiamine pyrophospateb\-଻ĩM଻Īn\WM޸ghexose-monphosphate shunt~|QΤWAһݦQC	HGq`CfA1FpGq~ְuC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷšBץOsC	Thiamine	A11D	ͯ B1BB6BB12 զX	0	}BgBhҡBi}Φ]ʥFLRAҤް_UewΪv	󥻫~DΥ@ξLӪ̡ATϥΥī~C	ooAIlxAyALBβָ~	A		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669116?cesid=2FVeUXwys6S&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVITAMIN%2BB1%26t%3Dname%26acs%3Dfalse%26acq%3DVITAMIN%2BB1"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-34 j	Ts113.10.25		0	0	OIs 20251124	OTHIA1-a	OTHIA1-b	OTHIA1-c	113.10.25
۶O		0	OVB21	Vitamin B2 10mg/tab		(~) 	"HqGC1-2C
Vitamin B2 deficiency: Adult, 5-10 mg/day.
p̦HquC
Vitamin B2 deficiency: Child, 2-10 mg/day."	Aī᰸GܦF	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUץBC	Riboflavin	0000	~iɥR~	0	iU					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668162?cesid=aNxXTQCPYRM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVitamin%2BB2%26t%3Dname%26acs%3Dfalse%26acq%3DVitamin%2BB2"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-35 j	Ts113.10.25		0	0	OIs 20251124	OVB21-a	OVB21-b	OVB21-c	113.10.25
۶O		0	OGLUT4	AMINOPURE()(L-Glutamine)		(~) L-GlutamineHtq״IiġAsb߻Pf٤AOf١Bתղ´BzDӭMΧK̨tΪӭM]ݸӭMBݤʥզyBOڲyBӭM^DnqӷAר䴣ѸzGDӭMqAjFHQξQ`q 40%CzGDlAoͩpz򪺤WֲӭMAOѵpzӭMn෽CfH~˩ηPVAθzGD\ಧ`ɡAOzDl\ΧK̥\൥譱AQtܭnC 	"`ξqΧP~|G
H@10J30JA23ΡC
ൣCѨC魫0.5JAΡC
ήɡAC5J[J300@40JHU}ζ~AͩէëAb@pɤΧC
"	PΨL~VXհtϥΡAoJfC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	L-Glutamine	0000	~iɥR~	0	iU					аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixii|U10j	Ts113.10.25		0	0	OIs 20251124	OGLUT4-a	OGLUT4-b	OGLUT4-c	113.10.25
X000323209	B05XA03	(M) 1000ml JW-Choong Wae NSnUInj	INXT5	(M) 1000ml JW-Normal SalinenUInj		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.10.25		0	0	OIs 20251124	INXT5-a	INXT5-b	INXT5-c	113.10.25
AC23844212	A02BA01	Go`gG	ICIME1	wstogamet INJ 200mg/amp (CIMETIDINE)		򥻤GĤcAæħUبEҤް_GĤcAδCGJսcqCvʪ´ib´iH2 骺@ΡAݩ´iH2 ܾCFĤc@Τ]O@H@ΡA]iĦaGHêqtC	"H`gPAigѦ٦ת`gARߪ`g覡ġC
 ٦ת`gqq`O 300@JACj 6-8 pɦ٦ת`g@A`g촿ȮɩʯkhiC
Rߪ`giϥζRIwA 300@J}b 100mL D5W(ΨLAXRߪ`gG)ARIw 15-20 HWACj 6-8 pɡA RIw@C"	Gűw̨ϥΥvɡAhcʼŤiA]|cʭGůgApi|~E_vɾC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Cimetidine	A02B	"vƩʼũMGDĪfyʯefADRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL
REFLUX DISEASE"	0	|fH񶦦fzʭGĤcLgAxTʡ]v^QGzšAΤfAfHƩʼŤuNkC	ثe|o{TҡC	ּƯfw׼ȮɩʪUgBh¡BwtBolBּƨkʤkůgAgi]ĦӮC	B	"1.i|cšC
2.઺IܤpC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669111?cesid=56EAqyfkRYv&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCIMETIDINE%26t%3Dname%26acs%3Dfalse%26acq%3DCIMETIDINE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-05 [w]_w01-03 [w]_w01-12 [E]_G1-09 j	Ts113.10.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=7.1._20240801.pdf"">OI` 7.1.</a>              "	0	0	OIs 20251124	ICIME1-a	ICIME1-b	ICIME1-c	113.10.25
AC50142100	P01BA02	H罤 200 @J	OPLAQ1	HYDROQUINE 200mg/tab(Hydroxychloroquine)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			P01B	ܺįe ANTIMALARIALS	0	LΥʬʯTHBCʦhΤlBCʭ`QB쪬ĭΩMĭΤް_įeC					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669129?cesid=970lrVTQdXt&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DHydroxychloroquine%26t%3Dname%26acs%3Dfalse%26acq%3DHydroxychloroquine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_C4 [2]_C4 [ws]_w33-05 [E]_B3-34 j	Ts113.10.25		0	0	OIs 20251124	OPLAQ1-a	OPLAQ1-b	OPLAQ1-c	113.10.25
BC26216100	G04BD12	ZQĮĿ50@J	OBETM2	Betmiga P.R.50mg/tab (Mirabegron)		Mirabegron]3ǤW@ξAgƣ]3ǤWAϱoG٥Ʀ٦bH֥R-ƧgxsܱoPAqӼW[H֮eqC	"׵ǥ\णw,רx\णw,C龯qiWL 25 mg @Ѥ@,bĳqUiHΤHA, wibi"	"1. iH\ΪŸAΡAHɧ]AAiZHBΩHC
2. BetmigaOzP-glycproteinAYPdigoxin֥ζʴdigoxin夤@סC
3. BetmigaiɰCĳwqASOOw̡C 
4. ĳBetmigaϥΩ󥽴ǯfw̡Aέרx\णw̡]Child-Pugh Class C^C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUxsC 	Mirabegron	G04B	c UROLOGICALS	0	@vGv񦳫槿BWM/Ϋ止ʧTgHֹLʯgC PrPʫܾ֥ΡGPrPʫܾsolifenacin succinate֥ΥiΩv񦳫槿BWM/Ϋ止ʧTgHֹLʯgC	Betmiga TϥΩwmirabegron ο󤧦LӤfHC	ߡBYhBBmBKBYwB߳չLtC	קKϥΰDvn/|qLť	קKϥΰDvn/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669058?cesid=aoI8pBwnJgL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMirabegron%26t%3Dname%26acs%3Dfalse%26acq%3DMirabegron"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_E1 [2]_E1 [ws]_w38-04 [E]_B4-19 j	Ts113.10.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.6.3._20150201_000.pdf"">OI` 1.6.3.</a>              "	0	0	OIs 20251124	OBETM2-a	OBETM2-b	OBETM2-c	113.10.25
BC27957212	N05CM18	wĳq`g100L@J/@	IDEXM	ĵDexmedetomidine 100ug/ml		Dexmedetomidineܩʣ\2ǤW@ξ (agonist)AR@ΡCʪo{AHCtR߿`PCqܤq]10-300 mcg/kg^dexmedetomidinei[ܩʪ\2@ΡFӥHCtR߿`q]1000mcg/kg^ΧֳtR߿`hi[\1P\2ҦʡC	"ICU sedation
 Adult: initial 0.5-1mcg/kg IV over 10min; followed by 0.2-0.7mcg/kg/hr continuous IVF for a max of 24hr
Procedural sedation
 Adult: initial 0.5-1mcg/kg IV over 10min; followed by 0.2-1mcg/kg/hr continuous IVF for a max of 24hr"	"1.xs15-30JC}~}xs2-8JAŶWL24pɡC
2.x\णfwҼ{CqC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs󱱨UǷ25JAi15- 30JC 	Dexmedetomidine	N05C	wvĩMRAHYPNOTICS AND SEDATIVES	0	b[@fЪv챵ޤΤHuIl@fHR@ΡBDޯfHNΨL{ǫe/ΤNε{Ƕi椤R@ΡALפWzرpAR߿`PPrecedexɶAҤoWL24pɡC	TΩwDexmedetomidine LӤfHC	"Hypotension, Nausea, Xerostomia, Bradycardia"	ĤC 	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668812?cesid=0Xe9oopoV2L&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDexmedetomidine%26t%3Dname%26acs%3Dfalse%26acq%3DDexmedetomidine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[w]_w07-05 j	Ts113.10.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.4.5._20190301_000.pdf"">OI` 1.4.5.</a>              "	0	0	OIs 20251124	IDEXM-a	IDEXM-b	IDEXM-c	113.10.25
	B03XA08	ô_u 300 @J	OVAFS1	VAFSEO Tablets 300 mg		Vadadustat O?دʮ񻤾ɦ]?im?Aǥíwʮ񻤾ɦ]?APiʬ?y? (EPO) ?Ai?Eʬ?y? (EPO) ?AW[K貾ʩM?y?Aϱo?@׳v?	?q_lqC???A 300 @J vadadustatCi̾گf?pվ㾯qA?qC?? 600 @JC	"iH\ΪŸ?A?AB]AAiCZC
Vafseo ibzReBΤɶA?C
Vafseo b?AKɥRBDntKī~ΧtKCXe? 1 ?ɪA?Cѩvadadustat iPh?ΦgXAVafseo bDtKCXΨLDnth? (ҦptBξT) ī~e? 1 ?ɩΤ? 2 ?ɪA?"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHU	vadadustat	B03X	LܳhsAOTHER ANTIANEMIC PREPARATIONS	0	vzRHfH]CʵŦefɭPhC	靈ĦΥξLӯfvf?C	"Bx\êB/CBjˡBm
"			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7449087?cesid=abfa2IlTZBw&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dvadadustat%26t%3Dname%26acs%3Dfalse%26acq%3Dvadadustat"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_06-02 j	Ts113.10.25		0	0	OIs 20251124	OVAFS1-a	OVAFS1-b	OVAFS1-c	113.10.25
	V04CJ01	Aնiᴹ`g	ITHYR1	THYROGEN 1.1MG/VIAL		EKBEҪXXΤcC	ĳϥ2`gĪkC1v٦ת`g0.9 mgA24pɫA2v٦ת`g0.9 mgC	"(1) ЧNxs2-8JAץxsC
(2) H1.2 mL`gΤtsAȨѦ٦ת`gϥΡC
(3) tsAmǷťis3pɡAm2-8JNåis24pɡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	N(2- 8J)xsAקKӮgFpoܽιLAiAϥΡC	THYROTROPIN ALFA	V04C	䥦E_ OTHER DIAGNOSTIC AGENTS	0	ҪvUE_sCAΩ]ҪӱXGΥҪBBSಾʥҪHfHATHYROGEN (thyrotropin alfa for injection)iΨӰҪݯd´gKhUC		 ߡBæRBYhC			аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts113.10.25		0	0	OIs 20251124	ITHYR1-a	ITHYR1-b	ITHYR1-c	113.10.25
AC49193100	A03AB06	z 40 @J	OCATI	CATILON TABLETS 40MG		"1.ܩʧzD٦ײӭMB~tlʡC
2.vʧrPM2 receptorsC
3.Tachykinin NK receptorsC
BƹDƦ٨㦳ܩʩMjOjpwѧ@ΡA]{ɤWϥΩ󥭷ƦֺӭMfzʦYҳyįʹLεj˪vAiĽwѸzļgkhΦUDngC"	"HGC2-3AC40 mgC
ൣGwʤΦĩʩ|TߡC"	C.@ΤjΫժUw̻ݤpߨϥ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Otilonium	A03A	v\ʭGzDefĪADRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	0	zļghgw	"1.糧~LӪ̡ATϥΡC
2.zC"	ߡBæRBfBYhBwtC	SmҦw	SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6577910?cesid=71b2yGJRq4h&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOtilonium%26t%3Dname%26acs%3Dfalse%26acq%3DOtilonium"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w39-06 [E]_B5-07 j	Ts113.10.25		0	0	OIs 20251124	OCATI-a	OCATI-b	OCATI-c	113.10.25
AC042211G0	H03BB02	Qҿ@J	OTAPL2	LICA 5mg/tab(Methimazole)		"Methimazole ҪuEXAĪvҪLgCMethimazole AƦsbҪΦG`thyroxinetriiodothyronine, ]zZfAΪ`gҪE@ΡC"	H쾯qG5-10mg A@TDqG2-5mg A@T.fAl}nD	iX{VhAoNAֽolAYhΤ@ʤAi͡A˴T{զyʥFgO_wo͡D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Os25JHUC	Methimazole	H03B	ܥҪs ANTITHYROID PREPARATIONS	0	Ҫमig	"糧~LӪ̸T
¨Ū̸T"	( l )ӭMs@ (2)ֽlBC¯l (3)ɩʥզy֯g (4)x\ಧ` (5) (6)æR (7)g	קKϥ/Methimazolepropyl thiouracileqLLLAiಣͥҪ~MbpgAbYe2-3PġD	¨ŴקKϥ/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669124?cesid=9QGAMoX5kVP&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMethimazole%26t%3Dname%26acs%3Dfalse%26acq%3DMethimazole"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[1]_D4 [2]_D4 [ws]_w39-05 [UDx]_U03-32 [E]_B4-20 j	Ts113.10.31		0	0	OIs 20251124	OTAPL2-a	OTAPL2-b	OTAPL2-c	113.10.31
AC25128421	S01AA11	"߯γnI/J
(ĵ߯)
"	PGENO2	GENTAMYCIN oph.oint.3% 5gm/		GentamicinO@Amino-glycoside Antibiotics㦳sxܵ߯OA󵲽¥β\Yʲӵ߷PVC㦳uVvĪGC	2-4 times daily	~Χܥͯ|ް_DPʷLͪLqcޡAҦpߡCppΦEBLӵpo͡AhΥìIAvC 	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Gentamicin	S01A	ܷPV ANTIINFECTIVES	0	BšBB¥BdB\n	糧~Lӥvw̡C	uȪEPC	קKϥΰDvn/i	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669716?cesid=aCPZEJbdclc&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DGentamicin%26t%3Dname%26acs%3Dfalse%26acq%3DGentamicin"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[G~]_P04-07 [E]_H1-11 j	Ts113.10.31	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	PGENO2-a	PGENO2-b	PGENO2-c	113.10.31
AC61867100	A10BD05	Re 15/850 @J	OACTM2	ĵActosmet 15/850mg(M׻sy)		"@PioglitazoneAthiazolidinedione ĪخqWĪADn@άW[g串}QΡC
t@metforminAbiquanide ĪCDn@Ω󭰧CͩʨxŦ}ͦC"	"C`q 13C@ΨCGfAC
ھڦĩʩM@ʡAbWLC̤jĳq(pioglitazone O45mgAmetformin O3000mg)pUA̭ӤHpqwqMΪkC"	"1.oΩĤ@}fw̡AΪv}f଻ĤrC
2.C}GApioglitazoneX֯خqΤfA}Īw̡Ai঳C}MIAiݭnC֥ĪqC
3.ߦޡGּƦŦefvw̨֥p i o g l i t a z o n eMخqo{ʤŦIܡC
4.~G~w̨ϥACTOSMETԷVCThiazolidinediones]tACOTSA|yGdAӥ[ξɭP{ʤ߰IܡC]AACTOSMETpߨϥΦb߰IܭIfHC[fHO_߰I(]AL׫t魫W[AIlx/Τ~)gμxHC
5.魫W[Gpioglitazone@kM֥ΨL}Īo{q魫W[(3)C魫W[णAiPd[WתհnC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Pioglitazone/Metformin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	H@ĪkLkFAĤG}f	Rʤ߰IܡBǥ\ण̡BN©ʻĤrT	YhB~BhBߡBæR	C	קKϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668448?cesid=9KEnc8uzY1W&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dactosmet%26t%3Dname%26acs%3Dfalse%26acq%3Dactosmet"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[1]_G4 [2]_G4 [ws]_w58-02 [E]_E4-05 j	Ts113.10.31	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	0	0	OIs 20251124	OACTM2-a	OACTM2-b	OACTM2-c	113.10.31
KC01053216	A10AD06	կرoկS	IRYZO	ĵRyzodeg FlexTouch 100U/ml; 300U/		خq(]ARyzodeg)Dnʬո`}N¡CخqΨ|EP串}l(רOf٤ίת)ΧxŦ}ͦӭC}Cخq]|תդѩMJսѡAëPiJսXCRyzodeginsulin degludec`g֤U´|ΦhEA֤ͥUinsulin degludecΡCRyzodeg[ɶ@ίSʡADnOѩinsulin degludecq֤U´liJ`ɶA֤@Oѩinsulin degludec|P`ճJյXCInsulin aspart|tiJ`C 	"(1) `gRyzodegjLBWuθ֤UC 
(2) 󦨤HfHAC12\ɥ֤U`g~FൣΫC֦~fHAC1\ɡC 
(3) bL\ɵݭn뤩tīεuīخqC 
(4) ھگfHӤHN»ݨDB}ʴGΦ}ؼг]pýվRyzodegqC
(5) ھڦ\e(Ÿ)}qȽվRyzodegqC
(6) ĳCW[qj34ѪɶC 
(7) iݭnHଡʧܡB\A(Yqitqέɶ)BŦΨxŦ\ܩΦbʯefվ㾯qAHCC}ΰ}IC 
Ω󤣴خqvfH_lq
1}f 
bخqv1}fH̡AĳRyzodeg_lqCخq`q1/31/2ClCخq`qh뤩uīγtīخqAéCT\뤩C@뱡pUAbخqv1}fH̡AiϥΨC魫0.20.4خqӭplvCخq`qC 
2}f
bخqv2}fH̡AĳRyzodeg_lq10C1C
ΩwwV(premix)Φ۲V(self-mix)خqC12(WvΨCh`g{@)1β2}fH̪_lq 
1}fP2}fHfHG 
ϥλPwVΦ۲VخqۦPqƩM`gɵ{}lRyzodegvCPɩ\ɨϥεuīγtīخqfHAb`gRyzodeg\~ϥάۦPquīγtīخqC
1}fβ2}fൣfH(@HW)G 
HVXخqC`q80%qƶ}lRyzodegvAHקKC}ICC1֥\ϥΡCPɩ\ɨϥεuīγtīخqfHAb`gRyzodeg\~ϥάۦPquīγtīخqC
Ωwϥΰ¦خqC12(WvΨCh`g{@)1β2}fH̪_lq 
1}fP2}fHfHG 
qȧt¦خqC12Wv{ഫv2}fH̡AHۦPqƩM`gɵ{}lRyzodegvCq¦خqC1ഫRyzodegC1fHAѩRyzodegttīخqA}lvʴ}C qt¦خq\ɨϥεuīγtīخqCѦh`g{ഫvfHA\ɨϥλP¦خqۦPqƶ}lRyzodegvCb`gRyzodeg\ɡA~ϥάۦPquīγtīخqC
1}fβ2}fൣfH(@HW)G
HīΤīخqC`q80%qƶ}lRyzodegvAHקKC}ICC1֥\ϥΡCPɩ\ɨϥεuīγtīخqfHAb`gRyzodeg\~ϥάۦPquīγtīخqC "		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. ϥΪī~N(2-8XC)AФŧNC 
2. ϥΤī~N(2-8XC)ΫOsǷŤU(C30XC)AקKӤΨA}ʫiϥΪF28(4g)C "	Insulin Degludec 70 +Insulin aspart 30	A10A	خqΨPt INSULINS AND ANALOGUES	0	AΩ@HWw}ffHAHﵽ}C	"TΩG
C}o@ɡC H
RyzodegΨ@ؽξLӪfHC 

ϥέ:
ĳΩv}f଻ĤrC
ĳΩݭnp5ӳRyzodegൣfHC "	C}BLӤB`gC 			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5871321?cesid=1y0kZ9gffMG&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRyzodeg%26t%3Dname%26acs%3Dfalse%26acq%3DRyzodeg"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B03-08 [N]_B03-21 [E]_K-11 j	Ts113.11.05	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.</a>              "	0	0	OIs 20251124	IRYZO-a	IRYZO-b	IRYZO-c	113.11.05
AC615393A5	N02AB03	hZֶK12.5 LJ/p	EFEN12	"ĵfentanyl transdermal patch 12.5 mcg/h ""PPCD"""		ĬֶKAണѫ72p(ī)AĪFentanylO@رjĪ~hAgֽlFhĪG¾Kī~ADnΨӱCʯkhC	"FENTANYL TRANSDEMAL PATCHq̷ӯfwӧOpөwAæbϥΫwɶiC
 pe24pɩһݤh(]AfAMIV)ζqC
eϥιL~hĪĳqtĪmorphine,tramadol,codeine}lA24pɤһݪhľq⦨KD
60-134mg/day morphine(PO)ĳഫ25ug/hr Fentanyl K
135-224mg/day morphine(PO)ĳഫ50ug/hr Fentanyl K
225-314mg/day morphine(PO)ĳ|75ug/hr Fentanyl K
HAYIM morphine10mgi۷fA30mg morphine
ԲӽаѦҥΰ|khv
DUROGESIC?isK72pɡCKAsKnKbPe@PmCP@쪺ֽ۹jƤ~iAKW@sKC
ϥιLDUROGESIC?HJ]˯ȳUAú^(|)ħPCpϥΤKhٵ(|)ħC"	"`N[fHIlt
]uɶϥεLk@AqվAӥBi|ɭPYΦMΥͩR𤣨AGʩγNkhŨϥDUROGESIC?CoYƧ@ΪfwAbDUROGESIC?Aܤ[24pɡA] fentanyl夤@׫YvUA17pɫ(13-22p)~|ܭӪ 50%C
YfHoNiW[fentanyliJ餺qD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	J25JHU	Fentanyl	N02A	P OPIOIDS	0	ݭnϥ~sCʯkhMxTʯkh	" wfentanylζKHKLӤfwTϥDUROGESIC?C
"	LӡAߡBæRBKBmBƤ}BfIlBݤξj`BIl	קKϥΰDvn/SmҦw/|qLť	קKϥΰDvn/SmҦw/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669815?cesid=0kLVRFf5PqH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFENTANYL%26t%3Dname%26acs%3Dfalse%26acq%3DFENTANYL<a href="""		ѦҡuqΥΪkv	  	ixii[]_w76 []_86-7 j	Ts113.11.08		0	0	OIs 20251124	EFEN12-a	EFEN12-b	EFEN12-c	113.11.08
	G03DB01	oL10@J	ODUPH1	Duphaston FC 10mg/tab gM		Dydrogesterone@fAĪAۿE@ΪlcͧcʪlcA]ӴקKۿEϤlcWͤ/ΤlcMIʼW[CDydrogesteroneAΩҦͩʶfҡCDydrogesteroneSۿEʡBʤơBPũʡBXNªεǤWֽTJʪ@ΡC	"XɥRkG

Ps򶶧ǩ (continuous sequential) ۿEk֥ήɡA28ѤggsA14ѡACѪA10 mg dydrogesteroneC
PgʻۿEk֥ήɡAۿEvɳ̫᪺12-14ѡACѪA10 mg dydrogesteroneC
YζWi{XʪABP20 mg dydrogesterone
ghGgg5Ѧ25ѤAC10mgAC2C

lcgGgg5Ѧ25ѤAΪ̳saAC10mgAC23C

\ण}ʥXGs57ѡAC2AC10mg (X)C

\ण}ʥXGgg11Ѧ25ѡAC10 mgAC2 (wX)C

gGbgg1Ѧ25ѡACAλۿE@A11Ѧ25Ѥ[AȰoLAC2AC10 mgC

gegԸsGgg11Ѧ25ѡAC10 mgAC2C

gWhGgg11Ѧ25ѡAC10 mgAC2C

ʬyG}lɤ@A40mgAMC8pɪA10mgAgѰC

ߺDʬyGC2AC10mgAsϥΦh20gC

]Ҥް_gGgg14Ѧ25ѡAC10 mgC{Aܤֶ6ӤggC靈ߺDʬyfHӨAhYXӤ̦nѷӡߺDʬyAĤ覡C

ĤϥΩ18HUĵA]|LRwʤĮĩʸơC

HuʹުvɤɥRGC3AC10mg(C30mg)AۨZ}lAΡAT{hɡAs~A10gC"	wbſ}@g (galactose intolerance)BLappſ}ïʥFg (Lapp lactose deficiency) θ}-bſ}l} (glucose-galactose malabsorption) uǩʯeffHФŪAΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUC	DYDROGESTERONE	G03D	 PROGESTOGENS	0	oʤoʳgAgewBhgBgΥʩMߺDʬyC HuʹުvɤɥRC	"w惡DΥ@LӪ̡C
wΥiw~F(pAF)C
gE_DX̡C
YΩHuʹުvɥRA@T{yANġC
YOΩwlcW (ϥλۿEk)GŨ֥λۿEAҦpdydrogesteroneC"	̱`Ƨ@άDXBYh/YhBߡBæRBhBgéMũЯkh/hC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667159?cesid=1GYPgJaAMOV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Ddydrogesterone%26t%3Dname%26acs%3Dfalse%26acq%3Ddydrogesterone"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w46-02 j	Ts113.11.27		0	0	OIs 20251124	ODUPH1-A	ODUPH1-B	ODUPH1-C	113.11.27
VC00080100	L01XX35	wOn0.5@J	OANAG	ĵAnagrevitae 0.5mg/cap (Anagrelide HCI)		"Anagrelide ?CpO?تAbsAھڥثes?ܡAAnagrelide ?jpivQ쥨ֲӭM ( megakaryocyte ) ?A]ӥi?CsypO?CAgrylin@Ω󥨮ֲӭMΦAzZֲӭMƦA]ֲӭMe{p?C
bv??UA?|vQզysyξ]lAysyyvQA??ɷNqC?Anagrelide |pOAC?h|?CpOͦA?@ά C-AMP Phosphodiesterase III (PDE III) AiӧpOC "	"Hĳ_lqO0.5mg~1mg BID]0.5mgnAB@gHWCĵlq0.5mgCѤ@ܥ|Aѩĵlqs֡A]ĳൣlq0.5mgC@C??OHΫĵAnվ̧CĪv??AӨϦpO??B600,000/gL HUAƦܨ?Q`ȡCnW[?ɡA@gW[??iWL0.5mg/dayCĵPH?@ˡAC`??iWL10mgA@?]?iWL2.5mgCھڦpOƥؽվ㾯qD
?x\??G
fHĳl?C0.5mgAB@gHWAK?ʴߦޥ\CnW[?ɡA@gW[??iWL0.5mg/dayC
?x\??G
fHanagrelide v?eAv??qPbICثe|LYx\??fHPanagrelide sAYx\??fHTҧPanagrelideC?ʵanagrelide ĪGΨpOL֡Abv?Ĥ@gACj2 Ѵ?pO?ءAMĤGg}lACgܤ֤@A}lAκ?ɬCq`bA?UA7 14 ѤpO?شN|}lU?ApO?ؤU?600,000/gL HUA4 - 12 gCjfHv??O1.5 3mg/dayCwŦefBǥ\??Ψx\??̥pߪAΡC "	"ߦޡG
] anagrelide㦳ʦ٦צYOΨƧ@ΡAҥHveAߦˬdOnABbvA]K[CbHanagrelide vqUAiް_ߦާ@ΡApXiB߸[tB߱ΥRʤŦIܡC
xŦG
ثe|LYx\ण}fHPanagrelidesCרx\ण}fHanagrelideveAvQqPbICרx\ण}fHhCqAåBKʴߦޥ\C
x\णݺʴQTcAPaspirin֥ΦX孷IAͰAʪͯfD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ץAxs25JC	Anagrelide	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	oʦpOLhg	Yx\ण}fHTҧPanagrelideC 	YhB߱BUgBLOB~BߤίtwC 	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668840?cesid=8Ej3rvNyLZA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAnagrelide%26t%3Dname%26acs%3Dfalse%26acq%3DAnagrelide"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[r]_r04-02 j	Ts113.12.02	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.3.3._20180601_000.pdf"">OI` 4.3.3.</a>              "	0	0	OIs 20251124	OANAG-a	OANAG-b	OANAG-c	113.12.02
AC52537100	N02CC04	ùk 5 @J	ORIZA	Rizatan 5mg/tab (rizatriptan)		Rizatriptan @ذYhĪAO@ܩʤ5-hydroxytryptamine IB/ID (5-HT IB/ID)@ξC	"ĳq5@J10@JC{ɸgܦqണѾA{ɮĪGC30AgYiﵽ (pGYhCܻL{שή)C
l[qGݦܤֶj2pɦAl[qG24pɤyWL30@JC"	䥦5-HT IB/ID@ξ(psumatriptan)iPRizatriptan Pɨ֥ΡCPi(ergotamine)s(pergotamine ..dihydro-ergotaminemethysergide)᤻pɤAĳARizatriptanC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUJáC	Rizatriptan	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	H617ൣεLYho@ʽwѡC	"~TϥΩUCfwG
1. Rizatriptan λs@LӪ̡C
2. Pɨϥγiƻï(MAO)AΦbiƻïīPϥΡC
ھڦī~Ĳz@ξARizatriptan 礣iϥΩ㦳UCgfwG
1. 
2. wTߪaʯ߯efA]AʦʤŦef(ߵhBߦٱfvεLfxʦʯef)BʦʤŦefgμxԩPrinzmetal U߯gC"	Rizatriptan ̱`Ƨ@άOYwBݺΩMLOPMh¡C			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668700?cesid=9FLW52ihD4p&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Drizatriptan%26t%3Dname%26acs%3Dfalse%26acq%3Drizatriptan"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[1]_F2 [2]_F2 j	Ts113.12.02	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.3.1._20190501_000.pdf"">OI` 2.3.1.</a>              "	0	0	OIs 20251124	ORIZA-a	ORIZA-b	ORIZA-c	113.12.02
AC415191G0	N05BA17	֦w0.25@J]tGᥭ^	OERIS2	޶^ FLUPINE 0.25 mg/tab (Fludiazepam)		"1.ܵJ{@
(1)J{Awѧ@(ܹ)
PܵJ{@pʳ̰xP欰礤A{XDiazepam 8
jġC
(2)JļAwѧ@(ѹ)
Qιqo欰礤A{XDiazepam 6.5jġC
2.RBʯv@
۵oʹBʧ@(ѹ)
jɡA۵oʹBʶqDiazepamC1/4C"	q`HC0.75mg3fAġC	AΥsw̽ФűqƾrΨ㦳MIʾާ@	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷūOsC	Fludiazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{AAvA٦׵jˡC	"(1)ʯʫCw(]xP@ή޵oWɡBgcƤ)C 
(2)YgٵLOw(]٦P@ή޵ogcƤ)C"	ݺΡBYwدtB«PBPBfC	Ĥ D	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669734?cesid=93y2fDo50Ma&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFludiazepam%26t%3Dname%26acs%3Dfalse%26acq%3DFludiazepam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_M04-03 []_E6 []_w78-07 j	Ts113.12.02		0	0	OIs 20251124	OERIS2-a	OERIS2-b	OERIS2-c	113.12.02
AC37134329	D10AF01	H]JLF^	ECLEO1	B.B. GEL 1H(Clindamycin)		ClindamycinwgQҩﭱpBCKkġAb~Clindamycinް_pӵߪPropion bacterium acnes(ı)i䦳Ŀ@׶0.4mcg/mL Aֽ֥תջġC	C2A٩wAĻݥvBϥΡC	o͸mALӲ{HаΥġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC	Clindamycin(as phosphate)	D10A	ΧڵH ANTI-ACNE PREPARATIONS FOR TOPICAL USE	0	M`ڵHC	糧ĩLinomycinLӪ̡AФŨϥΥC	pϥΫᦳUg͡AаġAýжE_ް_Ug]C	|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC	|Lwʸ AקKĲLC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669279?cesid=5gOSEmQwRhL&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DClindamycin%26t%3Dname%26acs%3Dfalse%26acq%3DClindamycin"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[G~]_O04-05 [E]_H3-24 j	Ts113.12.02		0	0	OIs 20251124	ECLEO1-a	ECLEO1-b	ECLEO1-c	113.12.02
AC55238500	G01AX03	Oz糱D꾯	EALBO2	POLININ VAG.SUPP(Policresulen)		~aίfܲ´㦳ܩʧ@ΡAϯfܲ´өưA`쪬W֫hvTC٥iDUدfLͪAPɫO@Ͳz߸sͪADĩҡAïਲ਼tAgC~A|বĤMPiЭ¡XC	"1. lcVSJϥο@YGCg1-2ANwM~AΪgGlw1-3YiC
2. lcVaUBlcVJHXl~֪yA`lcVDAC1-2ACg1-2C
3. ձaJϥή꾯ACѩιj1As4ASgA2C"	"1.Albothyl|bvL{ͨE@ΡCpGa´ѯfϲ渨AYϬOjqɡAL宣C
2.bvɤiΨEʪΨmM~ΩʥC
3.PLDs@ˡAAlbothylbgӮɤiϥΡC
4.קKĲAlbothylC
5.p´Υ֭PAlbothylĲAbsOά~bC
6.D꾯WIAOѮ꾯򾯲ͪ۵M{HAvTϥΡAĪGέ@ʡC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 25 ץHUBҡFpoܽιLAiϥΡC 	Policresulen	G01A	"ܷPVΨGֽ֥TJ ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS"	0	lcVSBձaBDBlcV]tѤwΤΩ]ߤް_̡^	hФŨϥΡC	bHAlbothyl|bvL{ͨE@ΡAq`tahC 	hФŨϥΥ	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6517063?cesid=2ilm7EhDdD4&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPolicresulen%26t%3Dname%26acs%3Dfalse%26acq%3DPolicresulen"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[G~]_M01-05 [E]_I2-01 j	Ts113.12.11		0	0	OIs 20251124	EALBO2-a	EALBO2-b	EALBO2-c	113.12.11
	N01AH06	hZᴹ`g2@J	IREMI1	ĵRemifentanil 2mg/vial		@ا@ΧֳtB@ήɶuܩ g-~Pi	"1. H¾KɡGHWL30ɶ``1 mcg/kgA`_ltv0.5 mcg/kg/minC
2. H¾KAPisoflurane(_lq0.5MAC)֥ΡGH0.25 mcg/kg/min_ltv`Aqd0.05-1 mcg/kg/minFtX1 mcg/kgsupplemental bolusC
3. 65HWѦ~H¾KϥremifentanilpߡA}lqOHq@bAMھگfHݨDվC
4. έDfHھڲzQ魫CqC
5. ǥ\णfHݽվ㾯qC
6. רx\णfHKʴoǯfHB̾گfHݨDվ㾯qC

General anesthesiaG
1. Induction, 0.5-1mcg/kg/min IV; 1mcg/kg IV over 30-60s may be used if intubated within 8mins of initiation. Administer with a hypnotic or volatile agent, do not use as sole agent for induction.
2. Maintenance, 0.25mcg/kg/min IV (range 0.05-2mcg/kg/min) plus isoflurane or propofol; supplemental bolus of 1mcg/kg every 2-5mins if needed.
3. Maintenance, 0.4mcg/kg/min IV (range 0.1-2mcg/kg/min IV) plus nitrous oxide; supplemental bolus of 1mcg/kg every 2-5mins if needed.
4. Concomitant medication, coadministered thiopental, propofol, isoflurane, and midazolam may require dose reduction of up to 75%."	" 
1.ĤGźިī~
2.ȨRߪ`gAPī~HMIV linei浹ġAī~YMIV lineAHקKN~Ψ즹ī~
3.THLactated Ringer}BiPLī~VXIBĳ`JPG//MP@R߿`޸
4.ubƥiHʴκIlΤŦޥ\৹]ƪpUABѱL¾Kī~VmBoıγBzj~ĪiwƧ@(]Aߪʹ_dN)H~iHϥΡC
5.Hremifentanil¾K᪺fHi}ξާ@Aųܧts붼
6.~Nt~ANǱ`ƻ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 xs25JHUCts᷻G24pɤϥΧC	Remifentanil	N01A	"¾K ANESTHETICS, GENERAL"	0	"(1) 󦨤H¾KɮɡA@hC 
(2) 󦨤H¾KɡA@hC
"	tglycineiw~ίժ`gBiWϥΩ󻤾ɳ¾K	ߡBæRBֽkoB٦׻BYBIlB߷iLCBCC	Unknown	Unknown	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668593?cesid=4fHmBU3SFZu&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRemifentanil%26t%3Dname%26acs%3Dfalse%26acq%3DRemifentanil"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[]_86-3R j	Ts113.12.11		0	0	OIs 20251124	IREMI1-a1	IREMI1-b1	IREMI1-c	113.12.11
X000336277	B05XA03	(M) Satoria 500ml-Normal Saline ~Inj	INX06	(M) Satoria 500ml-Normal Saline ~Inj		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.12.27		0	0	OIs 20251124	INX06-a	INX06-B	INX06-C	113.12.27
X000335277	B05XA03	(M)Baxter 500ml-Normal Saline nUInj	INX08	(M)Baxter 500ml-Normal Saline nUInj		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts113.12.27		0	0	OIs 20251124	INX08-a	INX08-b	INX08-c	113.12.27
KC01172235	LO1XY01	P֤U`g	IPHE1	ĵƼfPhesgo 1200/600mg (Pertuzumab 1200mg+trastuzumab 600mg)		HER2ʪBಾʨC	"1. _lqG15 @ɡ]1,200 mg pertuzumabB600 mg trastuzumab^AH 8 ֤UIC
2. qGC 3 gI@AC 10 @ɡ]600 mg pertuzumabB600 mg trastuzumab^AH 5 ֤UIC
3. G
a.NeUvGC 3 gIPHESGO@A 3-6 ӶgAXtrastuzumabPƾkIĳ{ApUG
(1).NeoSphereGPHESGOMdocetaxel֥ 4 ӳNevgA۱fluorouracilBepirubicinPcyclophosphamide 3 ӳNvgC
(2).TRYPHAENAMBERENICEGWcyclophosphamide 34 ӳNevgAۦA֥PHESGOPdocetaxel 34 ӳNevgC
(3).TRYPHAENAG֥PHESGOPdocetaxelBcarboplatin 6 ӳNevg(ĳdocetaxelqWL 75 mg/m2)C
(4).BERENICEGqKdoxorubicinMcyclophosphamideWϥ 4 ӳNevgAۦA֥PHESGOPpaclitaxel 4 ӳNevgC
(5).NAfH~򱵨PHESGOH1~v(̦h18Ӷg)AΪef_oΥX{LkBmrʬC
b.NỲUvGC 3 g@Ai欰1~v(̦h18Ӷg)Ϊef_oεoHBzrʬC
(1).ĥ]AtanthracyclineM/taxaneзǤAPHESGObĤ@ӧttaxanevg 1 Ѷ}lġC
(2).tanthracycline{fHAPHESGO󧹦anthracycline{vᵹC
4. ಾʨG
a.docetaxelMPHESGO֥ΪvɡAdocetaxel_lĳq 75 mg/m2AR߿`CY_lq@ʨ}nAhiq 100 mg/m2AC 3 g@C
b.IPHESGOef_oΥX{LkBmrʬC
5. ο|qqվAH⾯`gɶG
a.u6gGIqCݭnUwwĪɶC
b.6gΥHWGsI_lqMᵹC 3 g@qC
6. oLVEF\ण}ɫĳqվаѦҥ2C
7. ثeR߿`pertuzumabMtrastuzumabvfHഫPHESGOɡAĤ覡HۤW@R߿`pertuzumabMtrastuzumabjɶG
a.u6gGPHESGO 600mg pertuzumab/600 mg trastuzumab@qAC3g@ġC
b.WL6gGPHESGO_lq1,200 mg pertuzumab/600 mg trastuzumabAHC3g@600 mg pertuzumab/600 mg trastuzumabqC"	"PHESGOi|ɭPL{ɯgP{ɯgŦIܡC
PHESGO֥Χtanthracyclineƾkv(anthracycline-containing chemotherapy regimens)fHAoͲvPY{׳̰C
bHPHESGOvePvŦ\CbX{{ɤW߫ǥ\ۭCpUAUvfHPHESGOvAಾʨfHhȰPHESGOv
PHESGOĥiɭPYBPRͳrʡC]oͥʹLӡBީʤ~BʪͯfΫʩIl~gԸsӰPHESGOvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. N2-8JץOsCiNC
2. Ywqp~wAi 2-8 XCNæșh24pɤΫǷ25XCHUșh4pɡC"	Pertuzumab trastuzumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1 (EBC)PƾǪvĪX֨ϥΩG
? NeUkAΩHER2ʡAߴBoʩΦ(~F|j2 cmβOڵ)fHA@vB褧@C
? NỲUvAΩ HER2 ʥB㦳_oIfHC
2 ಾʨ(MBC)Pdocetaxel֥Ωvಾ᥼H HER2 Τƾkv HER2 ಾʨfH
"					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6968267?cesid=0NiCxcyBnpQ&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPhesgo%26t%3Dname%26acs%3Dfalse%26acq%3DPhesgo"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-29 j	Ts113.12.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.112._20250501.pdf"">OI` 9.112.</a>              "	0	0	OIs 20251124	IPHE1-a	IPHE1-b	IPHE1-c	113.12.27
KC01173229	LO1XY01	P֤U`g	IPHE2	ĵƼfpHesgo 600/600mg (Pertuzumab 600mg+trastuzumab 600mg)		HER2ʪBಾʨC	"1. _lqG15 @ɡ]1,200 mg pertuzumabB600 mg trastuzumab^AH 8 ֤UIC
2. qGC 3 gI@AC 10 @ɡ]600 mg pertuzumabB600 mg trastuzumab^AH 5 ֤UIC
3. G
a.NeUvGC 3 gIPHESGO@A 3-6 ӶgAXtrastuzumabPƾkIĳ{ApUG
(1).NeoSphereGPHESGOMdocetaxel֥ 4 ӳNevgA۱fluorouracilBepirubicinPcyclophosphamide 3 ӳNvgC
(2).TRYPHAENAMBERENICEGWcyclophosphamide 34 ӳNevgAۦA֥PHESGOPdocetaxel 34 ӳNevgC
(3).TRYPHAENAG֥PHESGOPdocetaxelBcarboplatin 6 ӳNevg(ĳdocetaxelqWL 75 mg/m2)C
(4).BERENICEGqKdoxorubicinMcyclophosphamideWϥ 4 ӳNevgAۦA֥PHESGOPpaclitaxel 4 ӳNevgC
(5).NAfH~򱵨PHESGOH1~v(̦h18Ӷg)AΪef_oΥX{LkBmrʬC
b.NỲUvGC 3 g@Ai欰1~v(̦h18Ӷg)Ϊef_oεoHBzrʬC
(1).ĥ]AtanthracyclineM/taxaneзǤAPHESGObĤ@ӧttaxanevg 1 Ѷ}lġC
(2).tanthracycline{fHAPHESGO󧹦anthracycline{vᵹC
4. ಾʨG
a.docetaxelMPHESGO֥ΪvɡAdocetaxel_lĳq 75 mg/m2AR߿`CY_lq@ʨ}nAhiq 100 mg/m2AC 3 g@C
b.IPHESGOef_oΥX{LkBmrʬC
5. ο|qqվAH⾯`gɶG
a.u6gGIqCݭnUwwĪɶC
b.6gΥHWGsI_lqMᵹC 3 g@qC
6. oLVEF\ण}ɫĳqվаѦҥ2C
7. ثeR߿`pertuzumabMtrastuzumabvfHഫPHESGOɡAĤ覡HۤW@R߿`pertuzumabMtrastuzumabjɶG
a.u6gGPHESGO 600mg pertuzumab/600 mg trastuzumab@qAC3g@ġC
b.WL6gGPHESGO_lq1,200 mg pertuzumab/600 mg trastuzumabAHC3g@600 mg pertuzumab/600 mg trastuzumabqC"	"PHESGOi|ɭPL{ɯgP{ɯgŦIܡC
PHESGO֥Χtanthracyclineƾkv(anthracycline-containing chemotherapy regimens)fHAoͲvPY{׳̰C
bHPHESGOvePvŦ\CbX{{ɤW߫ǥ\ۭCpUAUvfHPHESGOvAಾʨfHhȰPHESGOv
PHESGOĥiɭPYBPRͳrʡC]oͥʹLӡBީʤ~BʪͯfΫʩIl~gԸsӰPHESGOvC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"1. N2-8JץOsCiNC
2. Ywqp~wAi 2-8 XCNæșh24pɤΫǷ25XCHUșh4pɡC"	Pertuzumab trastuzumab	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	"1 (EBC)PƾǪvĪX֨ϥΩG
? NeUkAΩHER2ʡAߴBoʩΦ(~F|j2 cmβOڵ)fHA@vB褧@C
? NỲUvAΩ HER2 ʥB㦳_oIfHC
2 ಾʨ(MBC)Pdocetaxel֥Ωvಾ᥼H HER2 Τƾkv HER2 ಾʨfH
"					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6968267?cesid=0NiCxcyBnpQ&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPhesgo%26t%3Dname%26acs%3Dfalse%26acq%3DPhesgo"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-30 j	Ts113.12.27	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.112._20250501.pdf"">OI` 9.112.</a>              "	0	0	OIs 20251124	IPHE2-a	IPHE2-b	IPHE2-c	113.12.27
X000339277	B05XA03	(M) sBaxter 500ml- NS nUInj	INX11	(M) sBaxter 500ml- NS nUInj		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.02.10		0	0	OIs 20251124	INX11-a	INX11-b	INX11-c	114.02.10
AC45375100	M01AC06		OMOBI2	Melocam 7.5mg/tab(Meloxicam)		"1. ~w enolicacid DTJܪ non-steroidal anti-inflammatory drug(NSAID)C㦳ܵoAhθѼ@ΡCMobicwܨ㦳Īܵo@ΡC@ξOgѧeCͦC
2. PžqPܵoľqA~o쪺eCXGHεŦ̧󦳮ĤOCDѩ󥻫~㦳iܩʧCOX-2(۹COX-1)YC"	"7.5 mg QD, MAX 15 mg QD
1. `GC15mgC̾ڪvڮAqiCܨC7.5mgC
2. `GC7.5mgCݭnɡAqiW[ܨC15mgC
3. ʯ誢GC15mgC
4. iW[}MIfHG_lqC7.5mgC
5. YǰIܶiGzRfHGC龯qiWL7.5mgC
6. Cĳ̤jq15mgC"	SO`NfHO_oֽͥH}A@oҼ{ġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Meloxicam	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`B`Bλʯժgv	"1. meloxicamΨξw|LӪ̡C
2. (acetyl salicylic acid)ΨLDTJܵoĪ(NSAIDs)eӷPbʱw̡C
3. ĤiΦbϥacetyl salicylic acidΨLNSAIDsᴿX{ݯgԸsA󮧦סAޤ~C¯lfHC
--ʩʮƩʼšC
--Yx\णC
--Yǥ\णӥ@zRC
--p15 ൣPC֦~C
--hα¨ŰC"	Ƥ}BߡBæRBkBKBȡBmC	C	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668738?cesid=6NJYOyhdkTz&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMeloxicam%26t%3Dname%26acs%3Dfalse%26acq%3DMeloxicam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[s]_210 [®]_210 [ws]_w04-07 j	Ts114.09.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>              "	OI` 1.1.5.	0	OIs 20251124	OMOBI2-a	OMOBI2-b	OMOBI2-c	114.09.16
AC58391100	M01AH05		OARCO2	Ecoxia F.C. 60mg (etoricoxib)		"etoricoxibYݩCoxibs `/hĪCARCOXIA O㦳׿ܩʪCOX-2C
COX-2 wҹDnOtdprostanoid XAprostanoid hOkhBoPoNCCϥetoricoxib ܩʦaCOX-2AiĴo{ɤWxPgABGzrʸCA]|vTpO\C"	"`GĳqC@ 60mgC
`GĳqC@ 90mgC
ʯժGĳqC@ 90mgC
ʵh`GĳqC@ 120mgC 
ARCOXIA 120mgȥΩʯgAvɶiWLKѡC
oʸghGĳqC@ 120mgC"	"1. 靈ʦʤŦffvwh[pߡC 
2. MPARCOXIA võLpʡAثewGeGzDաBŤΥX(PUB)fvH65HWw̵oPUB MIʸC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Etoricoxib	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	`(OA)P`(RA)xPgCʪvBvʵh`Bvoʸgh	"1. 糧~󦨤LӡC 
2. Rʤ߰I(NYHA II-IV) C
3. wwʦʤŦefBgʯ߯efM/θޯef(]A̪񰵹Laʯ¶DNΦޭ״_N)C"	zLO/h¡BtwBUϤ~BBƤ}BG`BߡBYhBALTɰBASTɰC	MLw|eCXĪ@ˡAbhקKϥARCOXIAA]i|ɭPʯ߾ɺ޹LCثeõLAB}nsCubbįqTwWVL઺bMIɡA~ih̪줻ӤϥARCOXIAC	ѩ\hĪ|ciJHťġAӥBŪi|]ħeCXӲͰƧ@ΡA]AԷVҼ{Ĺ˪nʡAþڥHMwnũάOΥġC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667154?cesid=1SsZQUq6RPn&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Detoricoxib%26t%3Dname%26acs%3Dfalse%26acq%3Detoricoxib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_C1 [2]_C1 [ws]_w29-04 [E]_B3-14 j	Ts114.03.03	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.5._20220701.pdf"">OI` 1.1.5.</a>              "	OI` 1.1.5.	0	OIs 20251124	OARCO2-a	OARCO2-d	OARCO2-c	114.03.03
AC60316100	A07AA09	Zi_n125@J	OVANC	VANCOVER 125mg/cap (vancomycin)			"@0.5-2gATܥ|fAAv7-10ѡC

1. Initial episode, severe or nonsevere: 125 mg qid for 10 days.
2. Fulminant disease: 500 mg qid plus IV metronidazole 500 mg q8hs; if complete ileus, consider adding vancomycin retention enema (500 mg in 100 mL NS) rectally q6h.
3. First recurrence, vancomycin or fidaxomicin used in initial episode, use a prolonged tapered and pulsed regimen: 125 mg qid for 10-14 days, bid for 1 week, qd for 1 week, and then q2-3d for 2-8 weeks.
4. First recurrence, metronidazole used in initial episode: 125 mg qid for 10 days.
5. Second recurrence: 125 mg qid for 10 days, followed by rifaximin 400 mg tid for 20 days OR use a prolonged tapered and pulsed regimen: 125 mg qid for 10-14 days, bid for 1 week, qd for 1 week, and then q2-3d for 2-8 weeks."	"N Vancover 125 mg nwsGG
1.}HnGNn]Lݥhߡ^VHκVAL{n~gC(eHVpAѮɶVuC)
2.ѡG 4nĳHܤ 20 ml 45-60XC ΤѽnAHÿ_ͩզܲH⤺eѡC
3.ѫ 1 pɤAġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25JHUC	Vancomycin	A07A	zDܷPV INTESTINAL ANTIINFECTIVES	0	y߸zBߩҤް_ʵzC		ߡBoBBݻĩʲyWhBLӤC			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668997?cesid=aBPpjtVPkew&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DVANCOMYCIN%26t%3Dname%26acs%3Dfalse%26acq%3DVANCOMYCIN"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[]_06-05 j	Ts114.02.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1.2._20210604.pdf"">OI` 10.8.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.1._20210604.pdf"">OI` 10.8.1.2.</a>             "	0	0	OIs 20251124	OVANC-a	OVANC-b	OVANC-c	114.02.20
X000320277	J01CA01	M-GDH Ampicillin 500mg/vial	IAMPI3	"M-GDH Ampicillin 500mg/vial
^ݺʸsqyFͧަqxWq"		AmpicillinO@طssxʦXPenicillin sA?ﭲ?󶧩ʵߦ?ġAPɹﭲ?󳱩ʵߥ禳ġA@?ĥTV`gΧܥͯsC	"HG1-2g q4h-q6h`g@C
pġG魫 50 kg HUAC 25- 50 mg /  kg pA|AC6 pɪ`g@C"	"1.~便vTwסANϥΤWMIPįq[HҼ{C
2.~|ƪnťġAť˨ϥήNMIPįq[HҼ{A]i|LӡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUD
tmb@pɤΧD"	ampicillin	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	 Penicillin Lӯgew̤yAΥC	C¯lBooBlέ(LӤ)	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668590?cesid=75yAV73hiNQ&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAMPICILLIN%26t%3Dname%26acs%3Dfalse%26acq%3DAMPICILLIN"">LexidrugľǸƮw</a>"	"CClr>50      1~2g q6h
CClr 30-50  1~2g q6-q8h
CClr 10-30  1~2g q8-q12h
CClr<10       1~2g q12h
IHD              1~2g q12h
CAPD           0.5~1g q12h"	ѦҡuqΥΪkv	  	ixiij	Ts114.08.01	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	0	0	OIs 20251124	DC	DC	DC	114.08.01
	A06AD10	@֤O	LNIFL1	NIFLEC POWDER@֤O		~Niflec Powdert|QAòK[Polyethylene Glycol 4000@iƾsC GEach gm containsGSodium chlorideKKKK21.36mg Potassium chlorideK..K.10.83mg Sodium bicarbonateKK...24.57mg Sodium sulfate anhydrous...82.9mg 	"1. ĶvBϥΡC
2. ~@UH 2 ɷѫϥΡC
3. q`H 1 ϥ 2~ 4 ɡAHCpɬ 1 ɪt׸gfA覡ġC@ƪnGܳzɬA̦hnWL 4 ɡC
4. jzˬdeBzG
a.ˬdѪ\T(uiH)Aˬdwwɶ}le 4 pɥk}lPC
5. jzNeBzG
a. Ne 1Ѥ\YLA}lT(uiH)\LgL 3 ӤpɡA}lPC"	"1. WȰˬd:
a.ˬde@Ѧ\B\iΧC(pGNGסB]JBGѱ)C
b.\hiL (pGB@ءBeο})AߤW 12 IL}lTC
c.@֤Ows 2000mLAˬde@ѱߤW 7 I}lA 1000mLAMAܤ 500~1000mLC
d.ˬde 4 pɶ}lAέ@֤O 1000mLAMhܤܱƪnXGeMz(ĳt@֤O`qŶWL 4000mL)C
2. UȰˬd:
a.ˬde@ѤȡB\ΧC(pGNGסB]JBGѱ)C
b.ˬdѤiΦ\B\C
c.ˬde 6~8 pɶ}lAέ@֤O 2000mLAMhܤܱƪnXGeMz(ĳt@֤O`qŶWL 4000mL)C
3. @֤OAΧˬdeApGfBjYC}{HAihΥն}BBʶƩο}C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ǷūOsCѫɳtϥΡAY~ϥΤΡAݧNëOsAé48pɤϥΡC	"POLYETHYLENE GLYCOL 4000
SODIUM CHLORIDE
POTASSIUM CHLORIDE 
SODIUM BICARBONATE
SODIUM SULFITE ANHYDROUS
"	A06A	m DRUGS FOR CONSTIPATION	0	jzˬdΤjzNebzC		ȺPBhBϭGBtwPB«PBߡBzkhC			аѦҾqPΪk		ѦҡuqΥΪkv	  	ixii[1]_H2 [2]_H2 [ws]_w66-02 [E]_C3-04 j	Ts114.02.13		0	0	OIs 20251124	LNIFL1-A	LNIFL1-B	LNIFL1-C	114.02.13
NC04899277	B05BB01	"""٥""ŻĤƪL`gG"	ILR52	٥({)LACTATE RINGER'S 500ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	ĤrBNáBgeB˴HBۮargmɪɵBŦIzBrgnɤqѽΤɵ					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.02.14		0	0	OIs 20251124	ILR52-A	ILR52-B	ILR52-C	114.02.14
AC29837277	B05BB01	"""n""ְҪ`gG"	ILR53	"n({) haforman INJECTION ""N.K."""					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	`yq֩Ҥް_FεǾणΡA@gB}MeᤧɵBpUggBөʯewBˡBɡBĤrC					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.02.14		0	0	OIs 20251124	ILR53-A	ILR53-B	ILR53-C	114.02.14
AC10069277	B05BB01	֦hRw`gG	ILR54	j({)HARTMANN'S INJECTION					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	NΨ䥦ewιqѽ誺ɵ					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.02.14		0	0	OIs 20251124	ILR54-A	ILR54-B	ILR54-C	114.02.14
AC42412209	M01AB15		IKETO2	KETO INJECTION 30MG/ML (KETOROLAC)		"u(5)ϥΩwѵLkfAfH׫ʯkhAq`ϥΩNC

"	"1. ~igRߩΦ٦ת`gPARߪ`gɶoC15A٦ת`gĽwCβ`PC
2. @뤧h@Υiī30{Aӳ̤jĪG]iī1~2pɤX{Ah@Υi4~6p(ezƱ`Hĳ~|ξqPӦҮt)C
3. 澯qġG٦ת`g65HUAC60mgF6565HWAǥ\ण魫C50kg̡AC30mgFRߪ`g65HUAC30mgF6565HWAǥ\ण魫C50kg̡AC15mgF_k(RߩΦ٦ת`g)G65HUAC30mgAC6pɤ@A̰龯qoWL120mgC6565HWAǥ\ण魫C50kg̡AC15mgAC6p @A̰龯qo60mgC
ī~igRߩΦ٦ת`gPARߪ`gɶo֩15AӦ٦ת`ghwCβ`PCϥξqpUG澯qkG 1. <65fwG٦ת`g 60 mg Rߪ`g 30 mgC 2.65B魫<50 kgBεŦHG٦ת`g30 mgRߪ`g15 mgChqkG 1. <65fwG٦שRߪ`gAC6pɤ@AC30 mgA ̤jq120 mg/ѡC 2.65B魫<50 kgBεŦHG٦שRߪ`gAC6pɤ@AC15 mg A̤jq60 mg/ѡC
ൣʤhG0.4-1mg/kgAYregular Q6HġAĳbq0.2-0.5mg/kg Q6H(ĨĤU)"	"1.x\lΨxfwpߨϥΡC
2.ĨpOiੵXɶGTΩNeķ ɶpߨϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Ketorolac	M01A	"DTJܵoܭs ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"	0	"u(5)ϥΩwѵLkfAfH׫ʯkhAq`ϥΩNC

"	"1.oϥΩ󬡰ʩʭGűw̡C
2.TΩYǥ\णw̤α¨ŰC
3.AspirinB NSAIDsLӤ̸TΡC"	GzDXBšBʵǰIܡBxIܡBLӤC	D 	קK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669806?cesid=9swbvzRlRJ0&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DKetorolac%26t%3Dname%26acs%3Dfalse%26acq%3DKetorolac"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-16 [w]_w02-16 [w]_w02-28 [E]_C5-07 [Ew]_C1-03 j	Ts113.02.20	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=1.1.2._20080701_000.pdf"">OI` 1.1.2.</a>              "	0	0	OIs 20251124	IKETO2-a	IKETO2-b	IKETO2-c	113.02.20
X000343238	A12AA03		ICALG2	ĵ(M)Calcium Gluconate 104.2mg/ml;20ml/amp		"1.qLʧ@qHȽո`ӽո`gM٦ת{C
2.bHFSA}ĶtѤFtlӷAiHXtlèέCrʡC ٦Uȥtƪް_CtgC"	"@.Ctg(Rߪ`g)G
1.ס]tl@סG45mg/dL[11.2mmol/ml]^G12JA2pɡFLgw̥iHfA覡t
2.ר쭫ס]Lwo@Τ⨬zFtl@סG<4 mg / dL [<1 mmol / L]^G4JA4p
3.Yg]ҦpwA⨬z^G1012JFC60Ƥ@MAg
!!`NGī610ӤpɡAƶiltqCˬdO_sbCgApGsbAЧ󥿡CpG򪺷lܥiɭPCtg_oAЦҼ{`C
!!s`G520 mg / kg /hrFҪǸ\CUw̡Abi檺pUɧֶ}lfAtMʺͯD]Ycalcitriol^AtΤtergocalciferol cholecalciferol C
G.ŦJΤŦr([gACtgΰgsb)G25Rߪ`g1.53 g
!!q==>~䬰2.084gCalcium gluconate

~tltqpG1amp Ca=195.3mg; (0.4873mEq/mL, 9.765mg/mL) "	"1.Cal. Gluconateݰ_pĪARߪ`gpקK|CiH IM  SC  ġC
PUCī~ۮeGAmphotericin B, Ceftriaxone, Diazepam, Foscarnet, Lansoprazole, Methylprednisolone, oxacillin sodiumBphenytoin sodium, NaHCO3BPotassium phosphate, Co-trimoxazol.
2.] Ceftriaxone inj]Rocephin^|PtXͨInAY̦PɨϥΡA䤤@صīᥲNR߿`޸RbAAt@ءC
3.~PsVX|RXIAG`gpϥΰsrɡASs봧oϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC		A12A	t CALCIUM	0	1.Ctް_⨬zάg 2.[g	"1.tg
2.bsͨ(<28)PɨϥRߪ`g}ĶttMceftriaxone
3.߫ŸʡC"	Y`gɺ|Rߥ~Aް_gBB`BajƧ@			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669353?cesid=4HJ6QKBmDeY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCALCIUM%2BGLUCONATE%26t%3Dname%26acs%3Dfalse%26acq%3DCALCIUM%2BGLUCONATE"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiij	Ts114.11.27		0	0	OIs 20251124	DC	DC	DC	114.11.27
X000338277	B05XA03	(M) 500ml Greenflex0.9%NS	INX12	(M) 500ml Greenflex0.9%NS		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.02.25		0	0	OIs 20251124	INX12-a	INX12-b	INX12-c	114.02.25
NC01727100	A02AH	"""j""һĲBu"	ONAHC2	Sodium bicarbonate 600mg/tab		"1.vN©ʻĤrA~ϦߤһĲBڿ@פɰAMBlAqӪȥĤrC
2.PƧGAΥ~ɡAѩ󧿤һĲBڿ@פɰAGpHɰAϧġBDiĤΦJյbΦλEC
3.ġAfAਲ਼tMνwĭGġAӤvTGĤcC]ӭGpHtɰAwѰGĤް_gC"	1~5g֤URߪ`g	"1.x\णBǥ\णBŦefBhέQw̡BѦ~HקKϥΡC
2.ɥRu|WAyGdΪͤ~IAGLPƷ|cƯfC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium bicarbonate	A02A	ܻ ANTACIDS	0	N©ʻĤrPƾC	"1.BŦfBǯewBB~w̸TϥΥC
2.Ъ`Nī~tT"	GzȮ	C	ư઺IC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669504?cesid=66ox1kr8jQY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSodium%2Bbicarbonate%26t%3Dname%26acs%3Dfalse%26acq%3DSodium%2Bbicarbonate"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.12	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.7._20071201_000.pdf"">OI` 3.3.7.</a>              "	OI` 3.3.7.	0	OIs 20251124	DC	DC	DC	114.11.12
KC01179255	L01FD04	uoᴹ`gENHERTU  100@J	IENHE	ĵƼfENHERTU 100@J/~		"ENHERTU (trastuzumab deruxtecan)O@HER2йvʧĪƦXC
b鵲X~FӭMWHER2Atrastuzumab deruxtecanƶiJӭMAbӭMgӭMת{?ïislѡAXӭMz(membrane-permeable)DXdAް_DNAl˻PӭM`CDXdO@exatecanlͪAĤOirinotecanʥNªSN-3810C"	ENHERTUĳq5.4 mg/kgAC3gHR߿`(21Ѷg)AefcƩεo͵Lk@rʬC	"ENHERTUiPtrastuzumabtrastuzumab emtansineۤNC
1.ʴfHO_X{ʪͯf(Interstitial lung disease, ILD/ͪxMg(y¡BIlxBoNM/ΥsoͩδcƪIlDg)
2.ݤʥզy֯gAbENHERTUʪ즸PCIΫeAε{ɻݨDAʴypơC
3.߫ǮgXvC]bv{ɻݨDwLVEFCYT{LVEFC40%Aά۸Uqj20%Aä[ENHERTUC^
שMרx\णfHAԷVIENHERTU"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	tseAxsBc(2XC - 8XC)C}᪺GAץxsbǷ(30J)̦h4pɡAxs2XC8XCBc̦h24pɡCxsɶ۰tsɶ_C	trastuzumab deruxtecan	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	WϥξAΩvಾᴿLإHWHER2{B㦳LkಾHER2ʨHfHC	LC	(79.9%)Bh(60.3%)BæR(48.7%)Bv(46.2%)BK(35.9%)Bh(34.6%)Bh(33.8%)Bݤʥզy֯g(32.5%)Bm(30.8%)BpO֯g(23.1%)By(21.4%)Bզy֯g(20.5%)PYh(20.1%)C	קKϥΰDvn/SmҦw	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6899734?cesid=03fdgN8zSc5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DENHERTU%26t%3Dname%26acs%3Dfalse%26acq%3DENHERTU"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-27 j	Ts114.3.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.115._20250201.pdf"">OI` 9.115.</a>              "	OI` 9.115.	0	OIs 20251124	IENHE-a	IENHE-b	IENHE-c	114.3.24
AA10654277	B05XA03	"""j""ըFL`gG 500ml/bag"	INAC08	"Norm-saline inj otsuka""(500ml)"		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.03.24		0	0	OIs 20251124	INAC08-a	INAC08-b	INAC08-C	114.03.24
BC240391G0	C07AB07	d1.25@J	OCONC2	Concor 1.25mg/tab (bisoprolol fumarate)		"1. ~@jOAפŦܩʤ]1ǤW_A㤺]ʥPgE@(ISA)ALww@ΡC
2. pPL]-_@ˡAﰪ@ξ|AFOA~㦳C߳ճtvHΧߵǯ@ΡC
3. U߯gfwA]_ߦ٤]-1Ӵ֤ŦʡAiӭCߦ٤ݭnqA~㦳δU߯ggγ~C
4.PޤΦޥƦ٤W]2AλPN½ո`]2骺˦XO۷CC]A@{bisoprolol fumarate|vTIlDOA]|vT]2-ո`N§@"	"fHbLh6gLʤ߰Iܵo͡ABbLh2gLܰ򥻪vAYAqACE inhibitors]ΩACE inhibitorsLkԨUAϥΨLXi^MQBj߰tUAA֥bisoprololCĳvvObv߰Iܤ譱g̡CϥΥ~v߰IܡAѧCq}lAvW[qF̨ġCվ̾ڦpUCBJG
1.25mg11Aϥ1PAfHA}nUW[
2.5mg11AAϥ1PAfHA}nUW[
3.75mg11AAϥ1PAfHA}nUW[
5mg11AAϥ4PAfHA}nUW[
7.5mg11AAϥ4PAfHA}nUW[
10mg11A@ʪvC"	"1. ~ԷVϥΩ󦳤UCpfwGPRǾɶjA߿qΡAHΥ`êpRaynaud{HC
2. wʦʤŦefw̡AJMΥġC
3.ЦHG]AAnZHC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25XCHU	Bisoprolol fumarate	C07A	]_ BETA BLOCKING AGENTS	0	íwCʤצܭפ߰I	"? ʤ߰IܡAΥB߰IܳॢNvOӥݭnRߪ`gĪHW[ŦYOɡC
? Ŧ\ê޵oJ]ߦ]ʥJ^C
? SˤWŦ`߾YЫǶǾɻê]?GũβĤTŪЫǪ_^C
? fAugԸsC
? uе_C
? gʤ߷iLwC
? gʧCC
? YޮݡC
? Ygʯߦ޳efRaynaud gԸsC
? ǤW|v~F]ݻ̲ӭMF^C
? N©ʻĤrC
? bisoprolol fumarateνξ󦨤LӪ"				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668521?cesid=aENKtX4CZ1g&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBisoprolol%26t%3Dname%26acs%3Dfalse%26acq%3DBisoprolol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_A3 [2]_A3 [ws]_w21-02 [s]_60 [®]_60 [UDx]_U02-16 [E]_B1-21 j	Ts113.04.11		OI` 	0	OIs 20251124	OCONC2-a	OCONC2-b	OCONC2-c	113.04.11
AC317961G0	R05DB07	yS@J	OZECO2	Oxola 100mg/tab (Oxolamine)		 ~DOxolamine Citrate@ĤyBAAΩ󦨤HΤpĦ񦳪 gΨEʫy¤ܩIlDPVByAåi֤ΧIlD߽oBX@ΡAýwѤަ٦פj˦Ӥê޵򤧱Ʒ\C	HC100mg150mgA1ѤTܥ|Ap2~10C50mg100mgA̦~֤ίgAyWC	㻴L߽¾K@ΡAϤf߽¤PA5ivC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	ץOs(25J)C	OXOLAMINE CITRATE	R05D	"y§ COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"	0	y]P_BުB縢B|甆ް_y¡^	"pϥΡG wʩ|إߡATHŨTϥΡC
"	" 1.㻴L߽¾K@ΡAϤf߽¤PA5ivC
 2.GE()C"	"ϥΡGwʩ|إߡAy䦳qʤjioͤƧ@ΫAruġC
"		аѦҾqPΪk		ѦҡuqΥΪkv	  	ixii[1]_E3 [2]_E3 [ws]_w41-03 [s]_244 [®]_244 [UDx]_U03-41 [E]_B4-32 j	Ts113.04.14		OI` 	0	OIs 20251124	OZECO2-a	OZECO2-b	OZECO2-c	113.04.14
AC11552277	B05BA03	"""j""w֪`gGH"	IG0503	"5HDEXTROSE 500ml ""OTSUKA"""		"~YĨ妬 Glucose Injection s~CDextrose (Glucose)H Glycogen κAAJsxŦA
CCaܦiӷAPϥӭMमiAWi骺N¥\AΩNB¾Kv
TBNθgLغܤƵyN»ٮ`CɵBQBѬr\C
"	q`H 1 ^ 500~1000mLAѥ֤URߡAwCaIw`gA̯gAyWC		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	30JHUJsC	DEXTROSE MONOHYDRATE	B05B	Rߪ`gG I.V. SOLUTIONS	0	NΨLewiɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668360?cesid=3wZMNIjOHkr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDEXTROSE%26t%3Dname%26acs%3Dfalse%26acq%3DDEXTROSE"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiij	Ts114.04.17		OI` 	0	OIs 20251124	IG0503-a	IG0503-b	IG0503-c	114.04.17
AC26357277	B05BB02	ƶukۿ}Iw`gG	IGS52	"DEXTROSE-SALINE INJECTION ""TAI YU"" 500ml/~"		"ҤƦXGADnΧ@ѤfALkoһݭniʥFfHd(q)βGӷC
R`Sodium chlorideUؿ@סAiGMqѽӷAi@G`JޡAiGzC 
"	Rߪ`gΥ֤U`AζqfHpλݭnqөwAq`@^100mL1000mLC	"pLӤAY谱ϥΡAõAB
mC
ήɡG
ơBL{Aei]B_ʡAӭPͯ}
B_ةβ~PʡAYo{WzήɡAФŨϥΡC
ƢYĲGMBܦBΨ䥦`{HɡAФ
ϥΡC
GMΤδJkG
ơШ̿GMϥΤkTϥΡC
ƢШϥΪLo˸mGMAɤJwH覡
JֶAJФŧAHK]w (Coring) 
HC
ƣϥΫeЦA˵ATwLAiϥ"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1720C"	ī~m 15 ~ 25 װBҡApoܽιLAiAϥΡC 	"Dextrose        50.0 mg
Sodium chloride 9 mg
"	B05B	Rߪ`gG I.V. SOLUTIONS	0	@gB^_վBCʤr					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.04.17		OI` 	0	OIs 20251124	IGS52-a	IGS52-b	IGS52-c	114.04.17
AC57949277	B05XA03	"""βG""ͲzQ`gG0.9H"	INX13	"""βG""Sodium Chloride Inj 0.9H 500ml/]"		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	餺qѽ褧ɥRBNγжˤΨLfgް_pɥRC					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.04.17		OI` 	0	OIs 20251124	INX13-a	INX13-b	INX13-c	114.04.17
AC24490100	J01MB04	Qǽn250@J	ODOLC2	 piperan 250mg/cap (Pipemidic acid) 		ĥiӵDNAXAӦߧ@ΡC	ctεo̡Aq`C3~4^A@500~2000mgAlofgfwC1500~2000mgCھqA̯gAyWC	"1.׵ǻêΰ̡֪AԷVϥΡC
2.ĴpolBC¯lBkoεog?oͮɡAΥġC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	Ƿ25XCHUAקKӮgC	PIPEMIDIC ACID (TRIHYDRATE)	J01M	Quinoloneܵ QUINOLONE ANTIBACTERIALS	0	ѺwߡBjzߡBܧαߡBJpդߡBzߡBeXߡBgߡBztߩҤް_ǪǪBǪBH֪BDBeCBժBӵߩʨgBzBƻĪ	糧ĹLӪ̡C	"1.`Ƨ@άwtBBߵCp`YġAõABmC
2.X{ujƧ@ΡApJBolBkoBֽHgԸsHΤrʪagAĨõABmC"	|TwĪwʡA]nʤΨ䭷IA~ϥΡC	ķ|cܨťġAAĴišC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6568161?cesid=1flpZFN8uuy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPipemidic%2Bacid%26t%3Dname%26acs%3Dfalse%26acq%3DPipemidic%2Bacid"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[ws]_w06-05 [s]_256 [®]_256 [E]_A4-02 j	Ts114.04.21	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.8.2._20191201_000.pdf"">OI` 10.8.2.</a>             "	"OI` 10.1.,10.8.2."	0	OIs 20251124	ODOLC2-a	ODOLC2-b	ODOLC2-c	114.04.21
۶O	B05BA10	JR߿`G	ISMKA1	ĵSmofKabiven Central (TX@)493 ml/bag		Ri`C	"1. q:
a. SmofKabivenq 13~31@/魫/ѡCqdijfHݨDC
b. έDfHݭn̴XӪzQ魫ӭp⾯qC
2. `tviWL 2@/魫/p)Cĳ`ɶ14~24pɡC
3. C̤jq: C̤jqHfH{ɪpܤơAƦܥiCѳPCĳC̤jq 35@/魫/ѡC
4. Ϊk: RߤϥΡA`ܤRߡC

IV infusion. Individualized per patient needs. Adult, max. 35 mL/kg/day. Infusion rate2.0 mL/kg/hr.

ൣ(2-11):
1. q: ̰q 35 @/魫/ѡApݨDqܲ~HjAݭnھڻݨDվ㾯qC
2. ĳ̤j`tv 2.4@/魫/pɡCDSpñKʱA_hϥΫĳ̤j`tvɪ`ɶoWL 14p30C
3. ĳ`ɶ 14~24pɡC
4. C̤jq: ĳC̤jq 35@/魫/ѡC
5. Ϊk: RߤϥΡA`ܤRߡC

Child, 2-11 yrs, max. 35 mL/kg/day. Infusion rate2.4 mL/kg/hr.
ñЭI 1.Щw󴫾ɺޡATrC 2.`N޸Ϊ`g쪺ZPMApo{æPVκ|AɧִNC
Os 1. ǷūOsCVXߧYϥΡCǷ(WL25J)is24pɡC
2. pYKPTL߾ާ@iK[AhVXžbtLRpUAN2-8Jis6ѡAY2-8JOsūײXAb24pɤϥΤC
tmk IV infusionAĳ`14-24pɡAαb 3.0 ml/kg/hrC"	1.Щw󴫾ɺޡATrC 2.`N޸Ϊ`g쪺ZPMApo{æPVκ|AɧִNC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	"1. ǷūOsCVXߧYϥΡCǷ(WL25J)is24pɡC
2. pYKPTL߾ާ@iK[AhVXžbtLRpUAN2-8Jis6ѡAY2-8JOsūײXAb24pɤϥΤC"	FISH-OIL RICH IN OMEGA-3 ACIDSBTRIGLYCERIDES MEDIUM CHAINBSOYBEAN OIL ( EQ TO SOYA BEAN OIL)BOLIVE OILBGLUCOSE MONOHYDRATEBL-PHENYLALANINEBMAGNESIUM SULPHATE HEPTAHYDRATE BSODIUM ACETATE TRIHYDRATE (EQ TO SODIUM ACETATE 3H2O )BL-SERINEBL-ISOLEUCINEBCALCIUM CHLORIDE DEHYDRATEBL-TYROSINEBL-LEUCINEBL-THREONINEBSODIUM GLYCEROPHOSPHATEBL-VALINEBL-HISTIDINEBL-TRYPTOPHANBPOTASSIUM CHLORIDEBL-ARGININEBL-LYSINE ACETATEBGLYCINE (EQ TO AMINOACETIC ACID)(EQ TO GLYCOCOLL)BTAURINE (EQ TO AMINOETHYL SULFONIC ACID )BL-METHIONINEBZINC SULPHATE HEPTAHYDRATEBL-PROLINEBL-ALANINE	B05B	Rߪ`gG I.V. SOLUTIONS	0	Ri`AAΩLkѤfĶiθgzDiAθTѤfĤθzDi~w̤2HWൣC					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668880?cesid=5SsEaNocKz1&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSmofKabiven%26t%3Dname%26acs%3Dfalse%26acq%3DSmofKabiven"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[w]_w11-07 j	Ts114.04.21		OI` 	0	OIs 20251124	ISMKA1-A	ISMKA1-B	ISMKA1-C	114.04.21
۶O	H05BX02	uǪ`gG5LJ/@	IPARI1	Paricalcitol inj. 5mcg/ml		~㦳ͪʪͯ D ۦAgѻPͯ D Xӿܩʬƺͯ D ͪ~|AƥҪͦPcӭCƥҪXȡC	"1)izRɪiġAparicalcitol _l`gĳq0.04 mcg/kg0.1 mcg/kg (2.8-7 mcg)AWvWLCѤ@C
2)_lq (mcg) = 㫬ƥҪǭ (pg/mL)/80C"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1720C"		PARICALCITOL	H05B	ܰƥҪ ANTI-PARATHYROID AGENTS	0	ϥΩHCʵǥ\I(CʵŦefĤ)oʰƥҪमiwPvC	ParicalcitolTΩͯDrBtιparicalcitolΥ~ξLӪfwC	",,[,C,~,|,ܤ"	YDuݭnAparicalcitolnhɨϥΡC		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668436?cesid=3IyhzqHkDtE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPARICALCITOL%26t%3Dname%26acs%3Dfalse%26acq%3DPARICALCITOL"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[UDx]_U01-04 [E]_G1-01 j	Ts114.04.21		OI` 	0	OIs 20251124	IPARI1-A	IPARI1-B	IPARI1-C	114.04.21
AC27850212	N05BA01	֥`gG	IVALI2	ĵ޶^DUPIN 10MG/2ML/AMP(DIAZEPAM)		J{ABvB٦׵jˡBwnA	"Acute alcohol withdrawalIM / IV, Initial: 5-10 mg then 5-10 mg IM or IV in 3-4 hr if needed. Anxiety disordersIM / IV, 2-10 mg may repeat in 3-4 hr if needed. Sedation in the ICU patientIV: 0.03-0.1 mg/kg every 30 min to 6 hr. Muscle spasmsIM / IV, Initial: 5-10 mg; then 5-10mg repeat in 3-4 hr if needed. Status epilepticus5-10 mg IV every 10-15 min to a total dose of 30 mg; may repeat in 2 hr if needed."	" 1.fH@Benzodiazepines ĪLӡA糧ĥiಣ͹LӡC
2.ķ|qLLLپC 
3.heTӤϥΥķ|W[ѩʷMIAGNϥΤMIPįq[HҼ{A̦nקKϥΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װB	Diazepam	N05B	ܵJ{ ANXIOLYTICS	0	J{ABvB٦׵jˡBwnA	Hypersensitivity to diazepam or any component of the formulation]cross-sensitivity with other benzodiazpines^; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; acute narrow-angle glaucoma	"Ataxia, drowsiness, fatigue, hypotension, respiratory depression, sedation"	ĤD 	קKϥΰDvn/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669814?cesid=8VJuem0QDLI&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDiazepam%26t%3Dname%26acs%3Dfalse%26acq%3DDiazepam"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_U05-04 []_E1 j	Ts114.04.21		OI` 	0	OIs 20251124	IVALI2-a	IVALI2-b	IVALI2-c	114.04.21
۶O	R02AA20		ELUG2	ƤK̪oG(glycerium iodi compositum)					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"		IODINEBPOTASSIUM IODIDE	R02A	VBmĪ THROAT PREPARATIONS	0	|甆					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.04.21			0	OIs 20251124	ELUG2-A	ELUG2-B	ELUG2-C	114.04.21
AC22049209	R06AA02	QĤGfi`gG(x)	IVENA2	DIPHENHYDRAMINE inj.30mg/ml/amp		VenaRXwѹLөʻ󪢡B\Ҥް_g]yBQBγﳡko^ιLөҤް_koBֽolCDiphenhydramine HCLRXLөʯewBC¯lBֽBïl	"Allergic reaction or motion sicknessPO, 25-50 mg every 6-8 hrs. AntitussiveGPO,25-50 mg every 4-6 hrs.MAX.150 mg/day. Inj.10-50 mg IM/IV per dose; MAX 100 mg/dose (400 mg/day)."	 1.PϯgֳζsA|W[@ΡAq÷VϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Diphenhydramine HCl	R06A	ʧܲ´i ANTIHISTAMINES FOR SYSTEMIC USE	0	ֽew]lBֽ^\BLөʻ󪢡Bʻ󪢡Bޯgʻ	"Hypersensitivity to diphenhydramine or any product or system components, acute athma; breastfeeding; use as a local ansthtic]injection^"	"Dizziness, dryness of mouth,nose,or throat, dyskinesias, sedation, sleepiness, thickening of bronchial secretions"	קKϥ	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669807?cesid=8j6f5EOm1Zy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDIPHENHYDRAMINE%26t%3Dname%26acs%3Dfalse%26acq%3DDIPHENHYDRAMINE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[UDx]_U01-07 [w]_w01-04 [w]_w01-14 [E]_C5-03 [Ew]_C1-05 j	Ts114.04.24		0	0	OIs 20251124	IVENA2-a	IVENA2-b	IVENA2-c	114.04.24
AC26468435	S01EB01	QĤG孻PĤH	PPIL3	Pilocarpine oph soln 2H		~ઽxPEʪAG|ɭP٩M骺YAiֲФͦӭCC	"1-2 drops to the conjunctiva in affected eye(s) up to 4 times per day

CIGw󲴷ACITAΨ̷vܨϥΡC"	 Fתٵj˩ҭPȮɩʵOC~ASwƧ@ΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsAקKC	Pilocarpine	S01E	ܫCsY ANTIGLAUCOMA PREPARATIONS AND MIOTICS	0	YBΩvoʶ}ʫCMʶʫC	ʭimATϥΥC	ӷPʫhuCϥΥiɭPĲʹLӡC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668752?cesid=6sejMSq2W1S&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPilocarpine%26t%3Dname%26acs%3Dfalse%26acq%3DPilocarpine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P05-06j	Ts114.04.24		0	0	OIs 20251124	PPIL3-a	PPIL3-b	PPIL3-c	114.04.24
BC27000100	L04AA29	0	OXELJ1	Xeljanz XR 11mg/tab		TofacitinibO@JanusEC(JAK)C	11MG C@AiŸλP\֪AC	b XELJANZ vfHAoͲӵߡBKߡBIJߡBfrΨ䥦ʯfҤް_YPVg ( ɬƦܳy` ) iC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	30JHUץBxs	Tofacitinib	L04A	Ķ IMMUNOSUPPRESSANTS	0	AΩvwܭ׬ʩ`BmethotrexateLk;AvεLk@methotrexateHw̡C	L	mB|BWIlDPVBYhC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668506?cesid=414aGcYbxE6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTofacitinib%26t%3Dname%26acs%3Dfalse%26acq%3DTofacitinib"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_03-11 j	Ts114.04.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.1._20250901.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9._20250901.pdf"">OI` 8.2.4.9.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4._20251001.pdf"">OI` 8.2.4.9.1.</a>        "	"OI` 8.2.4.,8.2.4.2.,8.2.4.3.,8.2.4.4.,8.2.4.5.,8.2.4.9.,8.2.4.9.1."	0	OIs 20251124	OXELJ1-a	OXELJ1-b	OXELJ1-c	114.04.25
۶O	G03XX01	Y㳱D꾯	EINTR1	Intrarosa D꾯6.5mg/28/		Ytʦ prasteroneAYdehydroepiandrosterone (DHEA)Ab?ƾǩM?ǤWP?DHEAۦPAPrasterone?ѵMTJƦXA?LʡASۿEBEΨLEʡCbDīAbDӭM|ƬۿEMEC]AYP۩ʯsPA]]ѶʯNªCbӭM?TJ]ibۦPӭMAq?קKS_L´CP`gk[쪺?z\۷A̪P´ȳqL`prasterone?Υ??ӭMTJAoF򰱸gMDY?MۿEMEOC@סCbDHo{۩ʯɪhMhӭMƶqW[Hήǰ򩳲ӭMƶq֡C~ADpHȭ?`dAq?Pi`ӵߵO??C	?Ѫeľ??ġACѺΫeDm?ӯY㳱D꾯C	"1.ī~Ct28ӳD꾯6ӰeľC
2.eľM~G}ӹsAHR~30AHȤy˦^쪬AM䰮BsAeľҥΤ@PC
3.ȾAΩ󰱸gk"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	xs 5XC  30XCAקKũMg	DEHYDROEPIANDROSTERONE SODIUM	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	AΩvgᤧ~DYC	"TE?޾`X?GgkYTEAδ_o?޾X?AbҼ{}l?Y
veAHTwX?]C"	wתժĤƻPDcW[AiɭPձaƥXC	"YȾA?󰱸gkC?eL?Y㪺ĪIƾڡC|i?
prasteroneʪ?ެsC"	"YȾA?󰱸gkC?eL?ťĤsbprasteroneB?ų޾i઺vTBιﲣ
qvTTC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6341059?cesid=8w2zFy5GZZ6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDEHYDROEPIANDROSTERONE%26t%3Dname%26acs%3Dfalse%26acq%3DDEHYDROEPIANDROSTERONE"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[G~]_M01-03 j	Ts114.05.05		OI` 	0	OIs 20251124	EINTR1-A	EINTR1-b	EINTR1-c	114.05.05
۶O	J07BX06	wݥzfr71̭]	IENVA1	EnVAX-A71/ 0.5 mL / 1syringe / 		"wݥioܸzfr 71 MAi?ѥDʧK̨ӹwzfr 71 PVҤް_
efC
"	"H?`g?Ṋ]`g?uAh`g?Le~CC 1  0.5 mLA@⾯
A⾯j28ѡC̭]O_ݭni?l[K̩|TߡC
"	"?eṊ]^?ǷšA?eХnáA?[T{S`VBBܧe?B
ML`C?̭]Pӫ~̷akWC
?e|Ḽ]PLzfr̭]?ơA?I̭]A?I
̭]H㱵ؤ{ǡC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	2 ~ 8 J ץNáCбN`gwm~]˲xsC	tƤzfr 71 frɡ]֩ 1.5 Unit* ܭtq^lBƾTC̭]tGC	J07B	fr̭] VIRAL VACCINES	0		"̭]i?eإ̭]o?YLӤ̡AΤw惡̭]󦨤ΥݦsLqpǡ]Formaldehyde^o?YLӪ̡C
"	ʡGkh(21.57%)Bh(17.59%)Bo(13.42%)B~(7.36%)BC(3.88%)C	A?C̭]Iڸs2?HW?6C?e|Ḽ]?hkơC	A?C̭]Iڸs2?HW?6C?e|Ḽ]?¨ŴkơC	аѦҾqPΪk		ѦҡuqΥΪkv	  	ixii[N]_B04-05 j	Ts114.05.05		OI` 	0	OIs 20251124	IENVA1-a	IENVA1-b	IENVA1-c	114.05.05
۶O	N02CD06	õήf	ONURT1	Nurtec ODT 75 mg		Rimegepant iܩʦaH˩MOXܤHt]`? (CGRP) Aù CGRP \ಣͫܧ@ΡC	"q
YhʪvĳqݭnɨCѤ@ 75 @J rimegepantC Cѳ̦hq 75 @J rimegepantC
NURTEC iH\ΪŸAΡC
֥ī~
 rimegepant P CYP3A4 ħ֥ήɡAb 48 pɤקKAΥt@ rimegepantC
Ϊk
fAC
fmޤWΦޤUC|bfѥBiΰtAΡC"	"ĳbHUΤUϥ NURTECG
? bרx\णfHF
? bǯffH]CLcr <15 @/^F
? Pj CYP3A4 ֥ΡF
? PjĩΤ CYP3A4 ɾ֥ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1720C"	xs30JHUC	Rimegepant	N02C	ܰYh ANTIMIGRAINE PREPARATIONS	0	Yhʪv : AΩ󦨤HεLwYhʪv	ﬡʦΥC椤ξLӡC	ʪv̱`}ߡC	"?eS󥥰? NURTEC o|I?ƾڡCʪ?AbxΦ?A
? rimegepantAbSq?{ɼSqABH?rʪqUA[FLL
o|}vT]L魫֤ΰfܲo?vW[^]"	b?椤?礤A12 WŤkʱ?q rimegepant 75 @JvA[ťĤrimegepant @׷֡Cǻ઺?龯q۹ʤp֩ 1%C?e|Lť?vTơCŪo|MdįqAP?˹ NURTEC {ɻݨDM rimegepant μb?鱡p?઺iण}?֦Ҽ{	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6925018?cesid=8zpP7HnlEbX&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DRimegepant%26t%3Dname%26acs%3Dfalse%26acq%3DRimegepant"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[]_06-05 j	Ts114.05.05		OI` 	0	OIs 20251124	ONURT1-a	ONURT1-b	ONURT1-c	114.05.05
AB47811100	A10BF01	U޽100@J	OGLUB2	ĵTaglu F.C. 100mg/tab		\-glucosidase inhibitorAiPpzW\-glucosidase@ifʪvAHwbpzѡA]AilAHקKᰪ}Ȫ{HAӹFí}C	C3AC50-100 mgA\eAΡC	"1.ĳ\eAΡC
2.AΥ~Aν}Χt}ɡAiް_ABmC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Acarbose	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	ݩĤG}ffHfA}Ī	"1. 糧ĪoĪLӪw̡C
2. ĵΫC֦~ĮĤέ@ʪƤMA~iϥΩ~֤p18̡C 
3. CʸzDAAHơBlê̡C 
4. ~iϥΩYǥ\णfw(CrCl<25ml/min)C"	i|GzȮBBӸmBh	B	"קK
ư acarbose gѥŹध@ΡAhWĳvB Acarbose ŰkC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668825?cesid=0NtFW6txgRM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcarbose%26t%3Dname%26acs%3Dfalse%26acq%3DAcarbose"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_G5 [2]_G5 [ws]_w58-01 [E]_E4-11 j	Ts114.05.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.1._20091201_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.1.</a>             "	"OI` 5.1.,5.1.1."	0	OIs 20251124	OGLUB2-a	OGLUB2-b	OGLUB2-c	114.05.13
KC01062209	R03DX05	߷֪`gG150@J/@	IXOLA1	fXolair 150mg/mL wRw.(Omalizumab)		"  IgE MӭMζPӭMFc`RI( ˩MOIgE ) XAéMLӭ
esɡA|}lҰʹLӤAɭPoǧ@βӭMhɤƦX´iB
TmBӭME]cytokines^ΨLCCoǴCMLөʮݪfzͲzǬA]AIlD~ȡBƦ٦YΧܻPoL{ӭMʡAóyLөʯefgAҦpަYBHG͡BݡBIlxBݳ^BBQBkoByλoBy\C
Omalizumab MIgE XAHIgE MFc`RI XA]֤FiHҰʹLӤIgE q"	"߷֭ᴹ`gCp~t150 @JomalizumabAH`gΤհtᤧ߷֧t125 @J / @ɪomalizumab]150 @J / 1.2 @ɡ^Cuѥ֤U`gϥΡCoHRߪ`gΦ٦ת`g覡뤩C߷־AqPWvOھڶ}lveK̲yJE (immunoglobulin EA
IgE)]ڳ/ @ɡ^q򩳭Ȥ魫]^өwC
 Lөʮݾq
H50-60KGҡAIgE(IU/ml)30-100A߷֨C|g֤U`gq150]@J^;IgE(IU/ml)>100-300A߷֨C|g֤U`gq300]@J^;IgE(IU/ml)>300-400A߷֨C|g֤U`gq450]@J^;IgE(IU/ml)>400-600A߷֨C|g֤U`gq600]@J^;IgE(IU/ml)>600-700A߷֨CGg֤U`gq375]@J^;IgE(IU/ml)>700-900A߷֨CGg֤U`gq450]@J^;IgE(IU/ml)>900-1000A߷֨CGg֤U`gq525]@J^;IgE(IU/ml)>110-1200A߷֨CGg֤U`gq600]@J^
YnRfwO_߷֦Aܤֻݭn12 gvC
Cʦ۵oC¯l(CSU) q
C|gH֤U`gP߷150 300 @JC
bCSU w̤߷֪qPMIgE ( @ש`@) 魫LC
|LΩCSU AvCЩwƵ~vnC"	"즸Ϋϥγ߷֤A|X{LmʹLӤLmʹLӤ(anaphylactoid reaction)CjOb2 pɤo͡C
߷֤AΩvʮݴcơAʤ޵j˩ήݭng(status asthmaticus)C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	߷b2-8JNáAiNCհtb2-8J8 pɡAΩ25JiWL2 pɡC	Omalizumab	R03D	LʪʮD OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0	"Lөʮ
߷֬[kΩﵽwqlJTJsΪĤAG@ξ(?2-
agonist) vUWc鶡gΩ]ıB㦳h׮ݴcưO
LөʮݦHBC֦~Ψൣ(6 ΥHW) ݱCoǮݱw̥
gѥֽթ~ܪŮ𤤹LӭeʥBͥ\୰C (FEV1 <
80%)C߷ֶȾAΩҹꬰIgE CݯfHC
Cʦ۵oC¯l(Chronic Spontaneous Urticaria, CSU)
߷־AΩvH1 ܲ´isvΤCʦ۵oC¯lHΫC
~(12 ΥHW) w̧@[vC"	 Dνξ󦨥LӪ̡C	YhA`hAWkhAoNA`gpkhBBkoB~ȡAVhM( |)	 DvnAקKϥ.|LXolair whki}n{ɸCDvnAקKϥ	 DvnAקKϥΡD ҶqŹo|MdqBɡAӥ[W˹Xolair {ɻݨDBHomalizumab ΥJef󱵨઺b}C	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668522?cesid=8vQuqcMMYvK&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOmalizumab%26t%3Dname%26acs%3Dfalse%26acq%3DOmalizumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B01-35 j	Ts114.05.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=6.2.6._20220201.pdf"">OI` 6.2.6.</a>              "	0	0	OIs 20251124	IXOLA1-A	IXOLA1-B	IXOLA1-C	114.05.13
BC25923100	G03DA04	uqnn100@J	OUTRO	Utrogestan soft capsule 100mg		~㦳ܻۿE@ΡAܶE@ΡAܵǤWֽ@ΥHκ믫ww@ΡA~AӺ޺zʤ]vTC	"fA~|ġG
@зǥζq 200mg  300mgA@GAΡAҦpG]ߴNeA 200mgAnɥibA 100mgC
]gegԸsBgWhBgeB}ʨŸf^GCӥͲz`gܤ֨ϥζ 10 ѡAq`q 17 Ѩ 26 ѨϥΡC
~kGĳWϥλۿECiHbsϥ 3 gۿEk̫ 2 g֥ΡAUӳo@ghҦġFӦbĪo@gi|oͳDXC 
ioͦGھګʮɴ{ɶE_GөwAC 6  8 pɧ]A 400mgAhĺq]ҦpG@ 200mgA@ѤT^h 36 gC
D~|ġG
CnnJD`BC
@Ѵqq 200mgCiϥεľAB߱qD`Ji@ 100mg nCiHھڭӧOfwqC
cê]ƧZxBgWh^G@Ѿq 200mgACӶgϥ 10 ѡAq`qg 17 Ѷ}l 26 ѨϥΡC
LkcҾɭP]Zlء^Glq@ 100mgAqӴ 13 ѻP 14 ѨϥΡA۲ 15 Ѱ_ 25 ѤABߦUϥΤ@ 100mg nCq 26 Ѱ_ApGwghAHgjjgW[ 100mg nAC̤jqiF 600mgATCqܲ 60 ѤC
Huʹާ޳NɥRkGĳqC 600mgABȡBߤTAñqӫѱߤW}lϥΡC
ioͬyιw]cް_ߺDʬyG@Ѿq 200mg  400mgAGAioӾqh 12 gC"	"ī~Ω󨾤hΧ@ץĨϥΡC
pG{}lӦAר䦭 15 ѡAgiYuεoͥXC "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Jä覡GХH]˦sAm 30JHUC
лൣuébൣLkBC "	Progesterone	G03D	 PROGESTOGENS	0	"fA~|ġG
G
- yաADnGgegԸsA]`ƧZΰƧZް_gWhA}ʨŸfAgegC
- ~v]ۿEkUī~^C
- êyC
G 
- w]êyߺDʬyC
D~|ġG
- ]êް_ũΦŤ]DnΩGƧZxA@HuΧZlخɪɥR^C
- wêyߺDʬyC"	Yx\êMī~DΨ䥦ξeLӪ̤AXġC	"pGCӤ몺vg}lӦAרOggĤQѫeġAhiygYuΥXC
~YqӰhi|oͩΡBݺΪΡA@CqAhƧ@ΧYA|CġC
"	hA]AheXPAϥΥ~äOTҡC	ŴɶqקKϥζC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669038?cesid=6YuHEY0WM8R&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DProgesterone%26t%3Dname%26acs%3Dfalse%26acq%3DProgesterone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_F1 [2]_F1 [ws]_w46-01 [E]_B5-17 j	Ts114.05.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.3.4._20211201.pdf"">OI` 5.3.4.</a>              "	OI` 5.3.4.	0	OIs 20251124	OUTRO-a	OUTRO-b	OUTRO-c	114.05.13
BC26476100	A10BK01	־Aν10@J	OFORX	Forxiga FC 10mg/tab		bݵ?ު{u-}@PBJ?2 (SGLT2)Atdq??޵ĦAl?QLo}CDapagliflozinOSGLT2CDapagliflozingѧSGLT2ֳQLo}AlA]Pi}gѧGƪnC Dapagliflozin]|CuAlüW[ue??ޡAivT??z@?A]AG?ŦetΫtBPgʪVUձ@?A?Ŧ (remodelling) Mαi\ಣ?qvTFεǵyCAQ{O?޵ǵy^XW[GC	"}l?Forxigae
b}lForxigaveǥ\A{ɻݭni? C
?eq?f?Ab}lForxigave?eqAAnB?eq?ΡC


̷ӵǵyLov (eGFR) ĳq
eGFR 45ΥHWĳq :
?ﵽ?}AForxigaĳ_lqO5@JC?A1Cb@Forxiga 5@JC1f?AݭnB~?}ɡAqiW?10@JC?A1C*
? ҦLAgĳ_lqOC?A110@JC

eGFR 25??45ĳq :
? C?A110@JC*

eGFR?25ĳq :
w惡f?ĳ}lvAM?ForxigavAeGFRC??25mL/min/1.73 m2f?Ai?HCeGFRUBESKDB??
`M?Iܦ|IC"	"?eq?
ForxigaiɭP?ޤen֡Aɥiް_gʧC?ΦٻʵuܤơCWiXASGLT2]]tForxiga^v?}ff?o?ʵǷlˡAרһݭn|γzRCǥ\णf?]eGFR?60 mL/min/1.73 m2^BѦ~f?Ψ?Q (loop diuretics) f?Ao??eq?ΧC?IiW[Cf?Wz?دSxɡAb}l?ForxigaeA?eqAMǥ\Aæb}lvʴC?xHMgPǥ\C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	dapagliflozin	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	1.ĤG}fG (1)}GtXMBʡAHﵽĤG}fHfH}C (2)wߦިƥGΩĤG}fBwߦޯef (CVD) ΦhߦޭI]lHfHɡAiC߰Iܦ|IC (3)wŦfGCCʵŦf (CKD) soͩδcƪIC 2.CʵŦfG ΩvcƭICʵŦfHfHɡAiCʵǵyLov (eGFR) UBǯf (ESKD)B߰Iܦ|Mߦަ`IC 3.߰IܡG Ω߰IܪHfHɡAiCߦަ`B߰Iܦ|M߰IܺN媺IC	ForxigaYLӤfvApLӤ?ީ?~C	ʹ޾߷PVB|BPVBIhBƧW[C	"C šG
bӪʪs礤ܸľǪFL}]PLʩαFLʩΨL^AiHhksFΪ̩|LӪHhkΰʪsCubi઺QqjbMIA~iϥΦĪC"		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4927696?cesid=8EgyaYaR6a5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDAPAGLIFLOZIN%26t%3Dname%26acs%3Dfalse%26acq%3DDAPAGLIFLOZIN"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[1]_G3 [2]_G3 [ws]_w64-02 j	Ts114.05.13	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=2.16._20250301.pdf"">OI` 2.16.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1.5._20190701_000.pdf"">OI` 5.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.1._20250601.pdf"">OI` 5.1.5.</a>            "	"OI` 2.16.,5.1.,5.1.5."	0	OIs 20251124	OFORX-a	OFORX-b	OFORX-c	114.05.13
۶O	V07AB	٥ͪ`gλ]H 1000ml/bot	IWAT5	AQUA DESTILLATA PRO INJ 1000ml/bot		`gī~ѥΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"		WATER DISTILLED	V07A	䥦ҦDvΫ~ ALL OTHER NON-THERAPEUTIC PRODUCTS	0						аѦҾqPΪk	  	ѦҡuqΥΪkv	  	ixiij	Ts114.05.16		0		OIs 20251124	IWAT5-a	IWAT5-b	IWAT5-c	114.05.16
AC15218265	B05BA03	kۿ}`gGH	IGITO2	5% DEXTROSE 250ml/bot					пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05B	Rߪ`gG I.V. SOLUTIONS	0	~ˡBNް_Bж˩ʩΥXʥJBBʥFBiɵ					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.05.19		0	0	OIs 20251124	IGITO2-a			114.05.19
۶O		qM\Żĵ߽n(H~p)	ORENO1	(H~p)RenobiomeqM\Żĵ߽n		(~) ƹDAϱƫKZCܲӵOͺAAո`ͲzCPisN			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	Ƿ25XCHUAקKӮgC		0000	~iɥR~	0	iU					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiiMϡj	Ts114.05.23			0	OIs 20251124	ORENO1-A	ORENO1-B	ORENO1-C	114.05.23
AA24516209	B05XA03		INAC12	"1000ml SODIUM CHLORIDE 0.9HINJ ""TAI YU"""		ɵ			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"			B05X	Rߪ`gGK[Ī I.V. SOLUTION ADDITIVES	0	ɵ					"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668994?cesid=4EBwzh4yJd9&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSODIUM%2BCHLORIDE%26t%3Dname%26acs%3Dfalse%26acq%3DSODIUM%2BCHLORIDE"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.04		0	0	OIs 20251124	INAC12-a	INAC12-b	INAC12-C	114.06.04
BC28672100	L02BX03		OZYTI2	ĵƼfABIRATRED FC (j)500mg/tab		"Abiraterone acetateb餺|ƦAbirateroneAoO@ضʯͦXA|17\m?/C17, 20 ??
]17\-hydroxylase/C17, 20-lyaseGCYP17^@ΡCï{AYBǤWΫe?~F´AåBOʯͦX
@?iίʪïC
CYP17 |ʤ??G1^pregnenolone Pprogesterone |zL17\m?@Ʀ17\ mlͪA2^M
zLC17, 20 ??@ΤOΦdehydroepiandrosterone]DHEA^PandrostenedioneCDHEAPandrostenedioneҬ
AåBOATପeXCCYP17 QAbiraterone ]|ɭPǤWqֽEͦ?W[C
ʯӷPʫe?i?Cʯt??k㦳v?Cʯh?k]pϥGnRHPiv??AY^
i?CAYʯͦ?ALkvTǤWθ~Fʯͦ?C
b?PHwӲդ3?ɸ窺fHAAbiraterone acetate i?CATତΨ䥦ʯ夤@?C?
ʴAbiraterone acetate 夤ATି@?vTCΥi[夤e?Sʧܭ]PSA^@?ܤơAPӧOfw
?ɮ??ʥثe|ҹC"	"ĪΤNhէܩʪಾʫe?Abiraterone acetateĳ?C@fA뤩1,000@J]2500 @J
4250@J^AX֨C?fA뤩prednisoneprednisolone 5@JC
XӷPಾʫe?Abiraterone acetateĳ?C@fA뤩1,000 @J]2500@J4250
@J^AX֨C@fA뤩prednisone prednisolone 5@JC
Abiraterone acetateŸAΡCAAbiraterone acetateeܤ2p?iiAAAbiraterone acetate
1p?ii"	HeACФHZHC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	жJs25XCHUC	Abiraterone Acetate	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	O@CYP17APprednisoneprednisolone֥ΡAHv(1)ĪΤNhէܩʪಾʫeCABbʯhkѫݵLgλׯgө|ݭnϥΤƾǪv(chemotherapy is not yet clinically indicated)̡C(2)ĪΤNhէܩʪಾʫeCBwLdocetaxelv̡C(3)sE_㰪׭IXӷPಾʫeC~kʡABPʯhk֥ΡC			"Abiraterone acetateΩkʪwʻP?ĩ|TߡCھڨ@ξPʪ窺o{A便뤩Abiraterone acetate
|yLˮ`AåiɭPyC"	Abiraterone acetateΩkʪwʻP?ĩ|TߡC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669139?cesid=3UjmENpTOJw&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAbiraterone%26t%3Dname%26acs%3Dfalse%26acq%3DAbiraterone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.06.04	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.49._20250601.pdf"">OI` 9.49.</a>              "	0	0	OIs 20251124	OZYTI2-a	OZYTI2-b	OZYTI2-c	114.06.04
BC27902100	L04AF03	UĮĿ15@J	OUPAD	fRINVOQ ER 15 mg/tab		RINVOQ?OupadacitinibsA䬰?JAKC	"Hq
1. `B~`BʯժGC@ 15 mgC
2. ʥֽG
a.<65HGC@ 15 mg  30 mgC
b.65 HGC@ 15 mgC
3. ĳΩChild-Pugh C̡C

15 mg qd with or without food as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

ൣqGʥֽG12-17 B魫 40 窺C֦~GC@ 15 mgC"	"ɧ]A, ZH,ib,ii,iF
TΡF"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30JHUBC	Upadacitinib	L04A	Ķ IMMUNOSUPPRESSANTS	0	1.`Gvwܭ׬ʩ`Bܤ֤@دefwѫܭĪ(DMARDs)Lk;AvεLk@HfHCiΩ@kλPmethotrexateX֨ϥΡC 2.~`Gvwʩʰ~`Bܤ֤@دefwѫܭĪ(DMARDs)Lk;AvεLk@HfHCRINVOQiΩ@kλPDͪsefwѫܭĪ(non-biologic DMARDs)X֨ϥΡC 3.ʯժGvDTJܵoĪ(NSAID)Ωέ@ʤ}ʩʻʯժHfHC 4.ʥֽGvwצܭײʥֽAAXkH12(t)HWC֦~C 5.ũʵzGǲΩΥͪsvΡBhBεLk@צܭ׬ʩʼũʵzHfHC 6.JgGǲΩΥͪsvΡBhBεLk@צܭ׬ʩʧJgHfHC 7.LgvT{bʯ`(Non-radiographic axial spondyloarthritisA²nr-axSpA)GΩvYʩʵLgvT{bʯ`BŦXUCҦ󪺦HfHG ()DTJܵoĪ (NSAID)vΩεLk@C () CJ (C-reactive proteinA² CRP)@פɰC ()ֺϦ@yv (MRI)ˬdҾܦo[HC ()HLA-B27ʡC	UpadacitinibΨξ㦳wLӪf?ҪA?RINVOQ?C	WIlDPVBߡBy¡BoNC	Tw	"Contraindicated
ثe|LRINVOQ?O_|sHťġB]SܨyvTιﲣŶqvTƾڡC{ʪ礤Įľ/rzǼƾupadacitinib|ƩܨťġCpGY@Ībʪ餺|ƩܨťġA򦳥iĪΩH]|ƩܤHťġCѩi঳Y}A]ĳbRINVOQ?vHγ̫@ī6(j10ӥbI)yšC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6853134?cesid=a7BkTh91orE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DUpadacitinib%26t%3Dname%26acs%3Dfalse%26acq%3DUpadacitinib"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[]_03-09 j	Ts114.06.12	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.17.1._20250601.pdf"">OI` 13.17.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=13.17._20250601.pdf"">OI` 13.17.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.2._20250901.pdf"">OI` 8.2.4.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.3._20250901.pdf"">OI` 8.2.4.3.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.4._20250201.pdf"">OI` 8.2.4.4.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.5._20250201.pdf"">OI` 8.2.4.5.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.7.1._20250901.pdf"">OI` 8.2.4.7.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.7._20250901.pdf"">OI` 8.2.4.7.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9.1._20250901.pdf"">OI` 8.2.4.9.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=8.2.4.9._20250901.pdf"">OI` 8.2.4.9.1.</a>     "	0	0	OIs 20251124	OUPAD-a	OUPAD-b	OUPAD-c	114.06.12
AC15660100	J01DB01	֤OYn 500@J	OKEF52	"Cephalexin Capsules 500mg ""TBC"""		êӵ߲ӭMͪXAqӹFӵ߬ʪ@ΡC	"(1) HG250-1000 mg Q12~Q6HAC500 mg (̤jqG4 g/day)C
(2) ൣG[1-15] 25-100 mg/kg/dayA6-8pɪA (̤jqG4 g/day)F[>15] C6p1AC250-1000 mgAΨC12p1AC500 mg (̤jqG4 g/day)C
Renal impairmentGCrCl<50 mL/min, give usual dose Q12 H."	CLӪw̡AϥYU߯SOpߡA]CڻPYU߯ڶi㦳椬LӪʽ(Cross-allergenicity)D	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsAקKӮgFpoܽιLAiAϥΡC	Cephalexin	J01D	䥦]-Lactamܵ OTHER BETA-LACTAM ANTIBACTERIALS	0	yߡByߡBͪyߡByߤΨL㦳Pʲӵߤް_PVg	"(1) 糧~LӪ̡ATϥΡC
(2) cephalosporinܥͯLӪ̡C"	ߡBæRBmBGzAB֯lBYhC	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669452?cesid=1DAaEev5OPP&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DCephalexin%26t%3Dname%26acs%3Dfalse%26acq%3DCephalexin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_J3 [2]_J3 [ws]_w22-03 []_01-08 [s]_53 [®]_53 [UDx]_U02-22 [E]_C4-13 [Ew]_EX071 j	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OKEF5-a	OKEF5-b	OKEF5-c	114.06.25
KC01234299	B02BD02	ᴹ`g250 IU	IALTU4	()ALTUVIIIO inj 250 IU		"ALTUVIIIOĦO?إ]տĦXJ?A]t첾Bϰ(BDD)?ĤK?]?
@䵲?K̲yJ?G1 (IgG1) FcϰB?ŭB?]?(VWF)ĤK?]?s
D'D3ϰH2XTENh`?cCALTUVIIIO]t2829iġA?q312 kDaC
ALTUVIIIO2Ӧh`?XAQ?2Fc?@쵲C?FVIII-XTEN-Fch`?]
tĤK?]?A1A2ϰPBϰ쪺5i(1-745i)P288-XTENh`?ĦXANѵM
ĤK?]?BϰBĤK?]?A3C1C2ϰ(1649-2332)H?IgG1FcϰC?
VWF-XTEN-a2-Fch`?]tŭB?]?D'D3ϰ(1-477i)P144-XTENh`?ĦX
AoOĤK?]?P?IgG1Fcϰ쪺??iλĩʰϰ2ǦCCFcϰ쳡]tIgG1
BCH2MCH3ϡC?FcBVWFPXTENi?ALTUVIIIOb?ߤbIC"	"?PC֦~GC?~1-2C
? ൣGY魫WLε20 kgAC?~2-3FέY魫C20 kgAC?~6"	"ȭtsRߨ?
nPLĪ@?޽uήeӵts᪺ALTUVIIIOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	2-8Jץ	Efanesoctocog alfa	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	AΩAͯf(ѩʲĤK]lʥFg)fHAiΩG 1.`WwH֥XWvC 2.ݭnɪvαXƥC 3.N{BmC ϥέ: ~AΩvŭBf(von Willebrand disease)C		YhP`hC	"SALTUVIIIO?hk?oĪIơC|i?ALTUVIIIOʪo|?
ެsC?eäMhkʧ뤩ALTUVIIIOO_|vT?ޯ?AιFLyˮ`C"	"ALTUVIIIOO_|c?ŤBť઺vTιcŪvTA?eSơC
q¨Ź葉o|MdnBPɡAҼ{?ALTUVIIIO{ɻݭnHALTUVIIIOP
?befť઺Ҧb}vTC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7314111?cesid=3VXzMZmQBs3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DALTUVIIIO%26t%3Dname%26acs%3Dfalse%26acq%3DALTUVIIIO"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiiB05-03j	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALTU4-A	IALTU4-B	IALTU4-C	114.06.25
KC01235299	B02BD02	ᴹ`g500 IU	IALTU5	()ALTUVIIIO inj 500 IU		"ALTUVIIIOĦO?إ]տĦXJ?A]t첾Bϰ(BDD)?ĤK?]?
@䵲?K̲yJ?G1 (IgG1) FcϰB?ŭB?]?(VWF)ĤK?]?s
D'D3ϰH2XTENh`?cCALTUVIIIO]t2829iġA?q312 kDaC
ALTUVIIIO2Ӧh`?XAQ?2Fc?@쵲C?FVIII-XTEN-Fch`?]
tĤK?]?A1A2ϰPBϰ쪺5i(1-745i)P288-XTENh`?ĦXANѵM
ĤK?]?BϰBĤK?]?A3C1C2ϰ(1649-2332)H?IgG1FcϰC?
VWF-XTEN-a2-Fch`?]tŭB?]?D'D3ϰ(1-477i)P144-XTENh`?ĦX
AoOĤK?]?P?IgG1Fcϰ쪺??iλĩʰϰ2ǦCCFcϰ쳡]tIgG1
BCH2MCH3ϡC?FcBVWFPXTENi?ALTUVIIIOb?ߤbIC"	"?PC֦~GC?~1-2C
? ൣGY魫WLε20 kgAC?~2-3FέY魫C20 kgAC?~6"	"ȭtsRߨ?
nPLĪ@?޽uήeӵts᪺ALTUVIIIOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	2-8Jץ	Efanesoctocog alfa	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	AΩAͯf(ѩʲĤK]lʥFg)fHAiΩG 1.`WwH֥XWvC 2.ݭnɪvαXƥC 3.N{BmC ϥέ: ~AΩvŭBf(von Willebrand disease)C		YhP`hC	"SALTUVIIIO?hk?oĪIơC|i?ALTUVIIIOʪo|?
ެsC?eäMhkʧ뤩ALTUVIIIOO_|vT?ޯ?AιFLyˮ`C"	"ALTUVIIIOO_|c?ŤBť઺vTιcŪvTA?eSơC
q¨Ź葉o|MdnBPɡAҼ{?ALTUVIIIO{ɻݭnHALTUVIIIOP
?befť઺Ҧb}vTC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7314111?cesid=3VXzMZmQBs3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DALTUVIIIO%26t%3Dname%26acs%3Dfalse%26acq%3DALTUVIIIO"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiiB05-04j	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALTU5-A	IALTU5-B	IALTU5-C	114.06.25
KC01236299	B02BD02	ᴹ`g1000 IU	IALTU1	()ALTUVIIIO inj 1000 IU		"ALTUVIIIOĦO?إ]տĦXJ?A]t첾Bϰ(BDD)?ĤK?]?
@䵲?K̲yJ?G1 (IgG1) FcϰB?ŭB?]?(VWF)ĤK?]?s
D'D3ϰH2XTENh`?cCALTUVIIIO]t2829iġA?q312 kDaC
ALTUVIIIO2Ӧh`?XAQ?2Fc?@쵲C?FVIII-XTEN-Fch`?]
tĤK?]?A1A2ϰPBϰ쪺5i(1-745i)P288-XTENh`?ĦXANѵM
ĤK?]?BϰBĤK?]?A3C1C2ϰ(1649-2332)H?IgG1FcϰC?
VWF-XTEN-a2-Fch`?]tŭB?]?D'D3ϰ(1-477i)P144-XTENh`?ĦX
AoOĤK?]?P?IgG1Fcϰ쪺??iλĩʰϰ2ǦCCFcϰ쳡]tIgG1
BCH2MCH3ϡC?FcBVWFPXTENi?ALTUVIIIOb?ߤbIC"	"?PC֦~GC?~1-2C
? ൣGY魫WLε20 kgAC?~2-3FέY魫C20 kgAC?~6"	"ȭtsRߨ?
nPLĪ@?޽uήeӵts᪺ALTUVIIIOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1720C"	2-8Jץ	Efanesoctocog alfa	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	AΩAͯf(ѩʲĤK]lʥFg)fHAiΩG 1.`WwH֥XWvC 2.ݭnɪvαXƥC 3.N{BmC ϥέ: ~AΩvŭBf(von Willebrand disease)C		YhP`hC	"SALTUVIIIO?hk?oĪIơC|i?ALTUVIIIOʪo|?
ެsC?eäMhkʧ뤩ALTUVIIIOO_|vT?ޯ?AιFLyˮ`C"	"ALTUVIIIOO_|c?ŤBť઺vTιcŪvTA?eSơC
q¨Ź葉o|MdnBPɡAҼ{?ALTUVIIIO{ɻݭnHALTUVIIIOP
?befť઺Ҧb}vTC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7314111?cesid=3VXzMZmQBs3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DALTUVIIIO%26t%3Dname%26acs%3Dfalse%26acq%3DALTUVIIIO"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiiB05-01j	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALTU1-A	IALTU1-B	IALTU1-C	114.06.25
KC01237299	B02BD02	ᴹ`g2000 IU	IALTU2	()ALTUVIIIO inj 2000 IU		"ALTUVIIIOĦO?إ]տĦXJ?A]t첾Bϰ(BDD)?ĤK?]?
@䵲?K̲yJ?G1 (IgG1) FcϰB?ŭB?]?(VWF)ĤK?]?s
D'D3ϰH2XTENh`?cCALTUVIIIO]t2829iġA?q312 kDaC
ALTUVIIIO2Ӧh`?XAQ?2Fc?@쵲C?FVIII-XTEN-Fch`?]
tĤK?]?A1A2ϰPBϰ쪺5i(1-745i)P288-XTENh`?ĦXANѵM
ĤK?]?BϰBĤK?]?A3C1C2ϰ(1649-2332)H?IgG1FcϰC?
VWF-XTEN-a2-Fch`?]tŭB?]?D'D3ϰ(1-477i)P144-XTENh`?ĦX
AoOĤK?]?P?IgG1Fcϰ쪺??iλĩʰϰ2ǦCCFcϰ쳡]tIgG1
BCH2MCH3ϡC?FcBVWFPXTENi?ALTUVIIIOb?ߤbIC"	"?PC֦~GC?~1-2C
? ൣGY魫WLε20 kgAC?~2-3FέY魫C20 kgAC?~6"	"ȭtsRߨ?
nPLĪ@?޽uήeӵts᪺ALTUVIIIOC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1721C"	2-8Jץ	Efanesoctocog alfa	B02B	ͯKM䥦 VITAMIN K AND OTHER HEMOSTATICS	0	AΩAͯf(ѩʲĤK]lʥFg)fHAiΩG 1.`WwH֥XWvC 2.ݭnɪvαXƥC 3.N{BmC ϥέ: ~AΩvŭBf(von Willebrand disease)C		YhP`hC	"SALTUVIIIO?hk?oĪIơC|i?ALTUVIIIOʪo|?
ެsC?eäMhkʧ뤩ALTUVIIIOO_|vT?ޯ?AιFLyˮ`C"	"ALTUVIIIOO_|c?ŤBť઺vTιcŪvTA?eSơC
q¨Ź葉o|MdnBPɡAҼ{?ALTUVIIIO{ɻݭnHALTUVIIIOP
?befť઺Ҧb}vTC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7314111?cesid=3VXzMZmQBs3&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DALTUVIIIO%26t%3Dname%26acs%3Dfalse%26acq%3DALTUVIIIO"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiiB05-02j	Ts114.06.25	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=4.2.3._20250301.pdf"">OI` 4.2.3.</a>              "	OI` 4.2.3.	0	OIs 20251124	IALTU2-A	IALTU2-B	IALTU2-C	114.06.25
۶O	J07BX05	KIlDĦXfr̭]	IABRY1	"Abrysvo, RSV, Vaccine(H) 0.5 ml"		Abrysvo tN RSV-A M RSV-B ȸsحíw RSV ĦXe F ܭCĦXe F ܭO_ RSV PVM骺DnؼСC٦ת`gAĦXe F ܭ|޵oK̤Aqӹw RSV frUIlDefC	?q0.5@	"AbrysvoΩ٦ת`gܤWuTٰϰC
̭]PḼ]ī~VXC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1722C"	"xsNîw]2J - 8J^CФŧNCpGȲwNAбmC
}ʪĲ~b 8J ? 30J ūפUxsɡAwwʬ 5 ѡC"	"RSV subgroup B stabilised prefusion F antigenB
RSV subgroup A stabilised prefusion F antigen"	J07B	fr̭] VIRAL VACCINES	0	"1.bhءAѥXͦ 6 ӤjQʧK̡AHwIlDĦXfrҤް_UIlDef (lower respiratory tract diseaseALRTD)C
2.60 HWHDʧḴءAHwIlDĦXfrҤް_UIlDef (lower respiratory tract diseaseALRTD)C
3.oRSVefI1859HDʧḴءAHwIlDĦXfrҤް_UIlDef (lower respiratory tract diseaseALRTD)C"	ﬡʦΥCξYLӡC	 kh]41%^BYh]31%^Mٵh]27%^60HWHسkh]11%^	"hkʪơ]WL4000 ӨϥεG^LҾܦΩέL/sͨrʡC

Abrysvo|bh24gisCѩO@KIlDĦXfrPVMzLLLಾ{סAbh2436gIAbrysvo"	ثe|MAbrysvo O_|iJHťġCAbrysvo bعḼ]˭ŤsͨतܥX}C	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7346833?cesid=aLr1SOKgxiS&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAbrysvo%26t%3Dname%26acs%3Dfalse%26acq%3DAbrysvo"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B04-01 j	Ts114.09.10		OI` 	0	OIs 20251124	IABRYA-a	IABRYA-b	IABRYA-c	114.09.10
BC11326265	J05AB01	¼֯`g 250@J	IZOVI4	ZOVIRAX I.V. 250MG/vial(acyclovir)		DAcyclovirO@اܯfrĪA©ʞ\l(HSV)BΤka\lfrD`ġCAcycloviriJQ\lPVӭMA|CĤƦʤƦXAAcyclovirTCĤƦX|\lSDNA polymeraseMA]iHfrDNAXӤ|zZ`ӭMN§@ΡC	"Hq
1. ©?l]?lʸҥ~^Τka?lPVw̡AC8pɡA5mg/kgAcyclovir`C 2. K̾णw̡Aǥ\ॿ`̡Abvka?lP
VɡAC8pɵ10mg/kgAcyclovir`CK̾णw̡Aǥ\ॿ`̡Abvka?lPVɡAC8pɵ10mg/kgAcyclovir`C
ൣq
1. 3Ӥ12ൣϥAcyclovirR߿`ɡAھڨnp⾯qCw©?l]?lʸ~^άOka?lPVൣAC8pɨϥ250mg/m2AcyclovirR߿`C
2. K̥\णӵǥ\ॿ`ൣAwka?lPVάO?lʸɡAC8pɡA500mg/m2nAcyclovirR߿`C "	"1. ϥθqw̡]Ҧp?lʸ^ASO`Nǥ\ASOOw̦Υǥ\ण{HɡC
2. ts᪺Acyclovir`gGpHȬ11AgѤfAġC 3. ϥΩǥ\णΦѦ~w̡GAcyclovirgѵŦưA]bǥ\णfHWϥΪqӴ֡C "	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿš]15~25J^JC	Acyclovir	J05A	@Ϊܯfr DIRECT ACTING ANTIVIRALS	0	a?lfrγ?lfrް_PVCw貾ӤΥզfҤް_K̤fH?lPVCsͨ?lPVC 	Acyclovir |LӤw̡ATϥΡC	`g짽oAߡAæRC 	"B šG
bӪʪʹެs礤ܸĪFLrʡA|L㪺HhksơFΪ̦bʪʹ޹Ӭs礤o{Ī}]j󭰧Cͨ|O^AbӪHhks礤AܸĪFLrʡC"	|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668909?cesid=9B6fcslhXtp&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAcyclovir%26t%3Dname%26acs%3Dfalse%26acq%3DAcyclovir"">LexidrugľǸƮw</a>"	"CClr>50       10mg/kg Q8h
ClCr25-50    10mg/kg Q12H
ClCr10-25    10mg/kg Q24H
ClCr<10        5mg/kg Q24h
CAPD           5mg/kg Q24H (after HD)"	ѦҡuqΥΪkv	  	ixii[w]_w01-05 [w]_w01-17 [E]_G1-04 j	Ts114.07.09	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.7.1.1._20190601_000.pdf"">OI` 10.7.1.1.</a>              "	OI` 10.7.1.1.	0	OIs 20251124	IZOVI4-a	IZOVI4-b	IZOVI4-c	114.07.09
AC56643100	J01FF01	un150@J	OCLIN2	Bibi-U 150mg/cap (clindamycin)		Clindamycinﵴj{ɤW`󶧩ʤγʯfߡA㦳sxܵ߬ʡA@ξǬӵߤJսXAϨӭMaAӹFߪĪGC	"H
C150~300 mgAC6p1FYPVAC300~450 mgAC6p1C

ൣ
H8~16 mg/kg/day3~4AΡFYPVAH16~20 mg/kg/day3~4AΡC"	wGzefAרOzw̡AԷVPCYϥΥĴoͤUg{HɡAġC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)BץxsC	Clindamycin	J01F	" MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS"	0	yߡByߡBͪyߡBߵ㦳Pʵ߮Ҥް_PVg	TΩ󴿹Lincomycin͹LӤfwC	"1. hBDBߡBæRΤUg{HC
2. ̱`Ƨ@άʻצܤפClC"	קKϥ/SmҦw	קKϥ/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669280?cesid=2K5X2QKpu9C&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dclindamycin%26t%3Dname%26acs%3Dfalse%26acq%3Dclindamycin#doa"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[ws]_w02-03 [s]_351 [®]_351 [E]_A1-11 j	Ts114.07.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	OCLIN2-a	OCLIN2-b	OCLIN2-c	114.07.15
۶O	J06BD08	ְߪ`g()100@J/@	IBEY11	(100)BEYFORTUS 100mg/mL (Nirsevimab)		BEYFORTUSO?ئ-RSVʪ	"1.XͩĤ@RSVyuA
ΥniJĤ@RSVyu@HUൣAi榸٦ת`gC
(1)<5 kgG50 mgC
(2)5 kgG100 mgC
2.㦳PVYRSVefI]lA]Aު͵o|αwGʤOǤWۤѩʤŦf@HWܥⷳൣG
榸200 mgA٦ת`gCĳPe@j6ӤHWC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	"xsMBz
NëOs2XC- 8XC (36XF-46XF)CBEYFORTUS isbǷ20XC-25XC (68XF-77XF)?h8?ɡCqBcXABEYFORTUSb8?ɤ?A_hХC"	Nirsevimab	J06B	K̲yJ IMMUNOGLOBULINS	0	wIlDĦXfr(RSV)ް_UIlDefAAΩG ?@HUൣC ?㦳PVYRSVefI]lA]Aު͵o|(BPD)αwGʤOǤWۤѩʤŦf(CHD)@HWܥⷳൣC	"BEYFORTUS T?NirsevimabΥξYLӥv(]A?ʹLӤ [anaphylaxis])
Ψൣ"	?l `g	BEYFORTUS?A??|?kC	BEYFORTUSA??|?kC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7341219?cesid=2xU7etx6ejH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNirsevimab%26t%3Dname%26acs%3Dfalse%26acq%3DNirsevimab"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B01-32 j	Ts114.07.16		OI` 	0	OIs 20251124	IBEY11-a	IBEY11-b	IBEY11-c	114.07.16
۶O	J06BD08	ְߪ`g()50@J/0.5@	IBEY51	ְߪ`g()50@J/0.5@		BEYFORTUSO?ئ-RSVʪ	"1.XͩĤ@RSVyuA
ΥniJĤ@RSVyu@HUൣAi榸٦ת`gC
(1)<5 kgG50 mgC
(2)5 kgG100 mgC
2.㦳PVYRSVefI]lA]Aު͵o|αwGʤOǤWۤѩʤŦf@HWܥⷳൣG
榸200 mgA٦ת`gCĳPe@j6ӤHWC"		пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	"xsMBz
NëOs2XC- 8XC (36XF-46XF)CBEYFORTUS isbǷ20XC-25XC (68XF-77XF)?h8?ɡCqBcXABEYFORTUSb8?ɤ?A_hХC"	Nirsevimab	J06B	K̲yJ IMMUNOGLOBULINS	0	wIlDĦXfr(RSV)ް_UIlDefAAΩG ?@HUൣC ?㦳PVYRSVefI]lA]Aު͵o|(BPD)αwGʤOǤWۤѩʤŦf(CHD)@HWܥⷳൣC	"BEYFORTUS T?NirsevimabΥξYLӥv(]A?ʹLӤ [anaphylaxis])
Ψൣ"	?l `g	BEYFORTUS?A??|?kC	BEYFORTUSA??|?kC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7341219?cesid=2xU7etx6ejH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DNirsevimab%26t%3Dname%26acs%3Dfalse%26acq%3DNirsevimab"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiij	Ts114.07.16		OI` 	0	OIs 20251124	IBEY51-a	IBEY51-b	IBEY51-c	114.07.16
BC28434100	L02BB04	wiZ40@J	OXTAN2	ĵƼfXtandi FC 40mg/TAB (Enzalutamide)		weCﶯʯӷPAùʯTǻCަM @קCAƦ˴AʯTǻPϯefcơCgѶʯ E~FӭMͪݭnJ֬Ƥ DNA XCEnzalutamide OjĶʯT ǻA_ʯTǻ|XӨBJCEnzalutamide vʧʯPʯ骺XAQƨJ(nuclear translocation)AçQƶ ʯP DNA XAYϦbʯLת{PܶʯĩʪeC ӭMpU]O@ˡCEnzalutamide vCeCӭMͪAï໤ӭM `M~FYCb{ɫesAenzalutamide Sʯ@άʡC 	"ĳqfA enzalutamide 160mg (4  40mg n)CѤ@C DNhժfwAH LHRH ĪhժvC
Xtandi fAϥΡCnHɧ]AAiH\ΪŸAΡC "	ݦM`ĪAĮɽФpߡ]paM^CnHɧ]AAZHB˯}B}οĤ	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	25JHUxsC 	Enzalutamide	L02B	EĤΨĪ HORMONE ANTAGONISTS AND RELATED AGENTS	0	"(1)ĪΤNhէܩʪಾʫeCABbʯhkѫݵLgλׯgӤϥΤƾǪv̡C
(2)ĪΤNhէܩʪಾʫeCBwL docetaxel v̡C "	"1.ﬡʦνξM椤ҦC@ξLӡC 
2.ΥihkC"	̱`}LO/hҡBBYhMC 	"X šG
׬OʪΤH骺s礤ܸĪFL}vTABĪhkҲͪįqܧCAhĹ麟WkΥihkTҨϥΡC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669178?cesid=92INWNL57bg&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DEnzalutamide%26t%3Dname%26acs%3Dfalse%26acq%3DEnzalutamide"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-09 j	Ts114.07.16	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.54._20251001.pdf"">OI` 9.54.</a>              "	OI` 9.54.	0	OIs 20251124	OXTAN2-a	OXTAN2-b	OXTAN2-c	114.07.16
AC45704220	J01CR05	F`g	ITAZO2	Tapimycin  4gm/0.5gm/vial		"Piperacillin sodium i{ߤOOaӵߤjΦHβӭMXC
Tazobactam sodium ֦ͩʤLͪĤOADѩCXJդXvƧCtGARichmond-SykesĤT(Bush Class 2b & 2b')C?YUl?beta-lactamaseCĤGβĥ|(2a & 4)C?OhUtC"	"H X 
IV @PVG 4.5g Q6H-Q8H.
@ |PVG 4.5g Q6H ĳtX Aminoglycoside(ĳHY-site)
                          4.5g+150ml }G (NSAD5W)
                          2.25g+50ml }G (NSAD5W)
                          aminoglycoside conc. (amikin:0.75-1.5mg/ml)(gentamycin:0.7-3.32mg/ml)
ǥ\णG
@PV            
 CrCl(ml/min)20-40G2.25g Q6H
 CrCl(ml/min)20G 2.25g Q8H
 GzRG2.25g  Q12H
ൣ:
>9ӤA魫<40kgG100mg  piperacillin/12.5mg Tazobactam/kg  Q8H
>2ӤA<9Ӥ: 80mg piperacillin/10mg Tazobactam/kg  Q8H
>40kgHq"	"1.`NLӤ}AStecen-Johnson SyndromeɡD
2.~ǰIܯfHϥήɡAiW[X孷IAϥ˴yD
3.RߵqɡAioͯg٦פĩεjˡD
4.ﭫgfHϥtapimycinOǰIܪWߦ]lAPVancomycin֥ΥiPʵŦl˪oͲvD
5.~utq54mg/g piperacillinAݭQ`N.ϥΧQι[tqCfHʴ[D
6.v߬mAi]A׸mvzD"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"Ƿ25CHUJsD 
tmǷŢ׹FpɩΧNùFpD"	Piperacillin/Tazobactam	J01C	"]-LactamܵġAC BETA-LACTAM ANTIBACTERIALS, PENICILLINS"	0	piperacillin㦳PʡAHιpiperacillinĩʦpiperacillin/tazobactamPʤ]-lactamase͵߮Ҥް_Y{׷PVC	" penicillins, beta-lactamase inhibitors,ΨLξLӤfH,TΥ."	"m,,æR,l,Yh,vD"	קKϥΰDvn	קKϥΰDvn	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4667973?cesid=6TN2ymP2lJo&hitReason=international-brand-name&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTAZOCIN%26t%3Dname%26acs%3Dfalse%26acq%3DTAZOCIN"">LexidrugľǸƮw</a>"	"CClr>40      4.5g q6-q8h
CClr 20-40  2.25g q6h
CClr<20       2.25g q8h
IHD              2.25g q8h
CAPD           2.25g q8h"	ѦҡuqΥΪkv	  	ixii[ws]_w67-01 [UDx]_U09-08 [w]_w05-15 [E]_G6-05 [Ew]_F5-14 j	Ts114.08.12	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=10.1._20250101.pdf"">OI` 10.1.</a>              "	OI` 10.1.	0	OIs 20251124	ITAZO2-a	ITAZO2-b	ITAZO2-c	114.08.12
۶O	L01EK04	zgn1@J	OFRU11	ĵFruzaqla 1 mg/cap(Fruquintinib)		FruquintinibO@ذܩʡBjĪfAVEGFR-1B-2-3C	"5mg QD e21ѤfA5@JCѤ@AH28Ѭ@Ӷg`AoͯefcƩεLkr

FRUZAQLAĳCq
Ĥ@qCGfA4@J@Ѥ@
ĤGqCGfA3@J@Ѥ@
Lk@fA3@J@Ѥ@f?ä[?FRUZAQLAC"	]AFRUZAQLAnC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	xs30CHU	Fruquintinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	AΩveUCkಾʤjzz(mCRC)HfHA]Afluoropyrimidine-Boxaliplatin-Birinotecan-¦AMܦޤ֥ͪ]l(anti-VEGF)kFYKRAS ͫ(wild type)AhݱLܪ֥ͪ]l(anti-EGFR)kC		BXƥBxrʲ`BJէBϺݬ~gԸs(P PE)		ثeSƾfruquitinibΨNªsbHťĤAΨŭ|ΨťĲqvTCѩŭ|ணbY}AĳkbFRUZAQLAvγ̫@ī᪺gקK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7393002?cesid=0bt8OrCuRoR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFruquintinib%26t%3Dname%26acs%3Dfalse%26acq%3DFruquintinib"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiij	Ts114.08.13		OI` 	0	OIs 20251124	OFRU11-a	OFRU11-b	OFRU11-c	114.08.13
۶O	L01EK04	zgn5@J	OFRU51	ĵFRUZAQLA 5mg/cap(Fruquintinib)		FruquintinibO@ذܩʡBjĪfAVEGFR-1B-2-3C	"5mg QD e21ѤfA5@JCѤ@AH28Ѭ@Ӷg`AoͯefcƩεLkr

FRUZAQLAĳCq
Ĥ@qCGfA4@J@Ѥ@
ĤGqCGfA3@J@Ѥ@
Lk@fA3@J@Ѥ@f?ä[FRUZAQLAC"	]AFRUZAQLAnC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	xs31CHU	Fruquintinib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	AΩveUCkಾʤjzz(mCRC)HfHA]Afluoropyrimidine-Boxaliplatin-Birinotecan-¦AMܦޤ֥ͪ]l(anti-VEGF)kFYKRAS ͫ(wild type)AhݱLܪ֥ͪ]l(anti-EGFR)kC		BXƥBxrʲ`BJէBϺݬ~gԸs(PPE)		ثeSƾfruquitinibΨNªsbHťĤAΨŭ|ΨťĲqvTCѩŭ|ணbY}AĳkbFRUZAQLAvγ̫@ī᪺gקK	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7393002?cesid=0bt8OrCuRoR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFruquintinib%26t%3Dname%26acs%3Dfalse%26acq%3DFruquintinib"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[96]_2R-02 j	Ts114.08.13		OI` 	0	OIs 20251124	OFRU51-a	OFRU51-b	OFRU51-C	114.08.13
AC31280100	G03XA01	Fսn200@J	OLADO2	ĵDANOL 200mg/cap(Danazol)		Danazolɧʸ誺U骺XUcCiΩvlc´iv}ʪũлêA]AֺʨũЯefAo|ũЪΤjA]iΩvǩʦޤ~C	"1. H: lcΨũмWjHA̱˶}lAήɳ̦nO@Ѭ400 mgAݭnpөwA uqΥ[q(200-800mg ⦸A)CvӤ륪kΪ챡píwC
gLhfHӨA @ѪAά100-400 mgOĪAFָglCѪA200 mgOC
̫ĳ Danazol v令~kӦbggĤ@ѽվζqA YQnȮɰgA oخĪGK৹CbHXӤ뤤tXfHĪGi@BվC
2. ൣ : CKoʹLHA@ѪAά 100-400 mgAfH~֡B魫ζEĪGөwC"	"ץ : M DanazolƧZĪGA]MহĥHFץ\ġAbAδ]ϥΫDXkӨhC
]Danazol i|ް_Yص{תGdAfHbYرpUi|YǦ]AѦpŦεŦêBwBYhvTA]ݭnJӪ[C
xŦणfHݯdNĪϥΡC
Danazol i঳Wjܾ徯@ΡC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs25ץHUAKץxsC 	Danazol	G03X	LʶPXMʹިtνո` OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0	lcgBoKoʡBnCʨŸBŸΤjBź|BgLhBֺn~ʨũЯew	DanazolӵhkAΡC	gByBXBũYpBCʼBYhC	"PL/SmҦw
DanazolӵhkAΡC~ϥΥiɭPLಣͶʮĪGC"	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668730?cesid=1eGvrW35tZM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDanazol%26t%3Dname%26acs%3Dfalse%26acq%3DDanazol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_01-10 j	Ts114.08.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.2.1._19970101_000.pdf"">OI` 5.2.1.</a>              "	OI` 5.2.1.	0	OIs 20251124	OLADO2-a	OLADO2-b	OLADO2-c	114.08.19
AC44483421	S01AA01	ĤDH	PCHLO2	Chloramphenicol eye drops 0.25%/5mL/bot		ĬO׷ʥiXqLӵ߲ӭMAMӵֿ߮}(Ribosome)50S쵲XAiġAΦ`G]iରpeptidyl transferaseʳQ^]`GMJս誺XӹFӵߤĪGC	C1-4p1AC1wC	"ĶsN,ץקKsN"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ(15-30J)xsC	Chloramphenicol	S01A	ܷPV ANTIINFECTIVES	0	FByߡByߡBͪyߡBjzߵҤް_ew	糧ĦνξLӪ̸T	`BEPC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6576375?cesid=1DYbAAyUEmA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DChloramphenicol%26t%3Dname%26acs%3Dfalse%26acq%3DChloramphenicol"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[N]_B05-02 [E]_K-02 j	Ts114.09.11		OI` 	0	OIs 20251124	PCHLO2-a	PCHLO2-B	PCHLO2-C	114.09.11
AC47473421	S01FA01	~Ĥ 0.125H	PATR02	()0.125%Atropine eye drops 5ml/bot		~O@anticholinergicAѸ`xPg@ Ω󥭷Ʀ٩M\A̪Ĳz@άOѩAQxiƥPg@ΡC	"Uveitis: 0.125% ophthalmic solution, 1 drops OPHTHALMICALLY 1~3 times a day
Pediatric: cycloplegic refractionX1 drop of 0.125% (age 1 yr) ophthalmic solution instilled in eye(s) up to 1~2 times a day.

A. Ωٳ·ʧg(}): Ω󵲽A112AC1wC 
(1) (j1):ϥο@:0.125%AΥvܨϥΡC 
(2) p(15):ϥο@:0.25%AΥvܨϥΡC
(3) p(5Mj5ABOŭi):ϥο@:0.25%AΥvܨϥΡC
(4) p(5Mj5ABOti):ϥο@:0.5%1%AΥvܨϥΡC
B. Ω󸲵彤:Ψ쵲Aϥο@:0.125%1%A1 13AC1wC
C. ΩNթj: Ψ쵲Aϥο@:0.5%1%A 113ΥvMwAC1wC"	Щ}ʫ1Ӥ뤺ϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs25JHUAקKΤOgAnm󰪷ūҩΦBcA~\\C
mpıĲ줧BC "	Atropine	S01F	XĤηٳ MYDRIATICS AND CYCLOPLEGICS	0	Bٳ·	~ΩCAΪ̦ʫCɦVfH	ϥήɡA|ȥΪZո`O{HC	קKϥΰDvn/SmҦw	0	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5767295?cesid=1fNsQ3jfmTb&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAtropine%26t%3Dname%26acs%3Dfalse%26acq%3DAtropine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[G~]_P02-02 [E]_H1-12 j	Ts114.09.11		OI` 	0	OIs 20251124	PATR02-a	PATR02-b	PATR02-c	114.09.11
NC017271G0	A02AH	һĲBu(T)	ONAHC3	Sodium bicarbonate 600mg/tab (T)		"1.vN©ʻĤrA~ϦߤһĲBڿ@פɰAMBlAqӪȥĤrC
2.PƧGAΥ~ɡAѩ󧿤һĲBڿ@פɰAGpHɰAϧġBDiĤΦJյbΦλEC
3.ġAfAਲ਼tMνwĭGġAӤvTGĤcC]ӭGpHtɰAwѰGĤް_gC"	1~5g֤URߪ`g	"1.x\णBǥ\णBŦefBhέQw̡BѦ~HקKϥΡC
2.ɥRu|WAyGdΪͤ~IAGLPƷ|cƯfC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	Ƿ25XCHUAקKӮgC	Sodium bicarbonate	A02A	ܻ ANTACIDS	0	N©ʻĤrPƾC	"1.BŦfBǯewBB~w̸TϥΥC
2.Ъ`Nī~tT"	GzȮ	C	ư઺IC	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669504?cesid=66ox1kr8jQY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSodium%2Bbicarbonate%26t%3Dname%26acs%3Dfalse%26acq%3DSodium%2Bbicarbonate"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_F3 [2]_F3 [ws]_w51-02 [s]_296 [®]_296 [E]_B5-30 [Ew]_EX065 j	Ts114.10.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=3.3.7._20071201_000.pdf"">OI` 3.3.7.</a>              "	OI` 3.3.7.	0	OIs 20251124	ONAHC3-a	ONAHC3-b	ONAHC3-c	114.10.15
BC28556100	L01EA06	YVO40@J	OSCEM	ĵScemblix 40mg FC Tab		Asciminib @ؤfAPjĪABL/BCR-ABL1TiĿE?CAsciminibǥѯSOwABLרM?fU(myristoyl pocket)ӧBCR-ABL1ĦXJժABL1E?ʡC	"ĳq
eإHWTiĿE?vCʴOV鶧ʤCʰʥզf(Ph+CML-CP) ScemblixĳC`q80 mgCScemblixiCjۦPɶfA80 mg@AάObj12pɪjCAΨ⦸40 mgCScemblixv[{ɮįqAΪX{౵rʤC

CʴOV鶧ʥBaT315IܤCʰʥզf(Ph+CML-CP with T315I mutation) Scemblixĳq200 mgACfA⦸Aj12pɡC

ǥ\ण
סBשέ׵ǥ\णfHAScemblixLվ㾯qC׵ǥ\णfHC⦸Scemblix 200 mgqɡApԷV

x\ण
סBשέרx\णfHAScemblixLվ㾯qCרx\णfHC⦸Scemblix 200 mgqɡApԷV(аѨuĲzSʡv`)C

ൣfH(18)
ثe|TScemblixΩൣfH(18)wʻPġC

Ѧ~fH(65HW)
 65HWfHݭnվ㾯qC75ΥHWfHϥθg礣ALkO_sbwʩΦĩʪt"	"Scemblix]ABo}lBHΩCZC
H\efA覡ϥScemblixABP֪ACAScemblixܤ2pɫeMA1pɫAקKi"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	xs30JHUC	Asciminib	L01E	JսE? PROTEIN KINASE INHIBITORS	0	"BveإHWTiĿE?vCʴOV鶧ʤCʰʥզf(Ph+ CML-CP)HfHC 
BvCʴOV鶧ʥBaT315IܤCʰʥզf(Ph+ CML-CP with T315I mutation)HfHC
"	LC	Scemblix vfH̱`ŧO( oͲv? 20%) Ī}O٦װfkh(38.8%)BWIlDPV(29.5%)Bh(28.9%)BpO֯g(28.1%)BYh(26.4%)B`h(24.4%)BŦïɰ(23%)Bm]22.5%^Bh]22.2%^B֯l(21.1%)B(20.8%) M(20.8%)CbScemblix vfHA? 3( oͲv? 5%) ̱`Ī}OpO֯g(18.5%)Bݤʥզy֯g(15.7%)BŦïɰ(12.9%)B(11.2%) Mh(5.3%)C	C	"It is not known if asciminib is transferred into human milk after administration of Scemblix. There are no data on the effects of asciminib on the breastfed child or on milk production.
Because of the potential for serious adverse drug reactions in the breastfed child, breast-feeding is not recommended during treatment with Scemblix and for at least 3 days after the last dose."	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7163575?cesid=0XpcVZyIA1U&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DAsciminib%26t%3Dname%26acs%3Dfalse%26acq%3DAsciminib"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[96]_6-10 j	Ts114.10.15	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.122._20250901.pdf"">OI` 9.122.</a>              "	OI` 9.122.	0	OIs 20251124	OSCEM-A	OSCEM-B	OSCEM-C	114.10.15
BC27328100	L01XG03	KF n4@J	ONINL	ĵƼfNINLARO Capsules 4 mg		"Ixazomib O@@ΥifJ?CIxazomibnP20S J? ] 5 椸Xç
ųJլʡC  
Ixazomib b~礤iohoʰFӭM貣ͲӭM`Cϥδhv (]A 
bortezomibBlenalidomideBdexamethasone) _ofHҤXFӭM~礤AIxazomib
㦳~ӭMrʡCsҹA֥ ixazomib  lenalidomide hoʰFӭM観[ʪ
page  14 of 25 
ӭMr@ΡC餺譱{hoʰ~FزӼҫܡAixazomib㦳ܸ~FʡC"	"beܤ 1 pɩάOܤ 2 pɤjۦPɶAΡCnHeAAi}BCZΥ}C
1. ֥ lenalidomide  dexamethasoneG4 mgACg@A 28 { 1B8B15ѪAΡC
a.]}խqG1խ 3mgA2խ 2.3mgA3аġC
2. hoʰFFӭMӫBFӭMӪvG4 mgACg@A 28 { 1B8B15ѪAΡC
a.vq 3mg}lApGe4{@ʨ}nAb5{1ѻW 4mgCv 24 ӤAΪefcƩΥX{LkrʬC
b.]}խqG
(1).1-4{G_lq 3mgA1խ 2.3mgA2аġC
(2).5{G_lq 4mgA1խ 3mgA2խ 2.3mgA3аġC
3.שέרx\ण]`x > 1.5ULN^έ׵ǥ\ण]CrCl < 30mL/min^ESRDݭnzRfHG
a.֥ lenalidomide  dexamethasoneG_lqխ 3mgC
b.vG_lqխ 2.3mg}lApGe4{@ʨ}nAۦb5{1ѻW 3mgC
4. pGAīæRAФŭƪAġAU@ɶAAĪC

1. AL amyloidosis, Relapsed or refractory, combination therapy: 4 mg qd on days 1, 8, and 15; give with lenalidomide 15 mg on days 1-21, and dexamethasone 40 mg qw of a 28-day cycle.
2. Multiple myeloma, In combination with lenalidomide and dexamethasone in patients who have received at least 1 prior therapy: 4 mg qd on days 1, 8, and 15 of a 28-day treatment cycle, plus lenalidomide 25 mg qd on days 1-21 and dexamethasone 40 mg qd on days 1, 8, 15, and 22, continue until unacceptable toxicity or disease progression occurs.
3. Multiple myeloma, Newly diagnosed, maintenance therapy:
(1).After autologous stem cell transplant[ASCT]: 3 mg qd on days 1, 8, and 15 every 28 days within 115 days after transplant; continue for 24 months or until disease progression or intolerable toxicity; if tolerated during cycles 1-4, increase to 4 mg.
(2).Without ASCT, after standard induction therapy: 3 mg qd on days 1, 8, and 15 of 28-day cycles continued for 24 months or until disease progression or intolerable toxicity; if tolerated during cycles 1-4, increase to 4 mg.
4. Waldenstrom macroglobulinemia, In combination with rituximab and dexamethasone:
(1).Relapsed/Refractory disease: 4 mg qd on days 1, 8, and 15 plus dexamethasone 20 mg qd on days 1, 8, 15, and 22, q28d for 8 induction cycles, plus rituximab 375 mg/m(2) IV on day 1 of cycle 3, then rituximab 1400 mg flat dose subQ on day 1 of cycles 4 to 8; followed by maintenance therapy (in patients with a minor response or better) with rituximab 1400 mg subQ on day 1 q3m for 2 years.
(2).Previously untreated disease: 4 mg qd on days 1, 8, and 15 plus dexamethasone 20 mg qd on days 1, 8, and 15, q28d for 6 induction cycles, plus rituximab 375 mg/m(2) IV on day 1 of cycles 3-6; followed by maintenance therapy (in patients with at least a minor response or clinical benefit with rituximab 375 mg/m(2) IV q8w for 1 year."	"ɧ]A, ZHF"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	xs30JHUCбNns]ˤAAήɦAXC	IXAZOMIB CITRATE	L01X	䥦ܸ~F OTHER ANTINEOPLASTIC AGENTS	0	X lenalidomide  dexamethasone Ω󱵨Lܤ֤@uvhoʰF~fHC	LC	pO֯gBݤʥզy֯gBmBKBP䯫gfܡBߡB~B֯lC	"AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned 
FLέLr :̾ڧ@ξMʪso{ANINLARO Ωhkʷ|Lyˮ`CNINLARO yhjMߤlͭFLέLrʪSqAfHĳqCihkʹLi઺MIAĳͨ|OkʡAb NINLARO v̫@ 90 ѤAĥΦĪDXץIFĳ㦳ͨ|OkʦQkʡAb NINLARO v̫@ 90 ѤAĥΦĪץI"	" NINLARO ΨNªO_sb?ŤBĪŤs?઺@?άOĪcŪ@
?AõLƾڡCѩ NINLARO Ťs?઺bY}Aĳkʦb
NINLARO v?̫? 90ѤA?šC"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/5933483?cesid=3EAK6MI5udS&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DIXAZOMIB%2BCITRATE%26t%3Dname%26acs%3Dfalse%26acq%3DIXAZOMIB%2BCITRATE"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[96]_6-11 j	Ts114.10.17	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.77._20230401.pdf"">OI` 9.77.</a>              "	OI` 9.77.	0	OIs 20251124	ONINL-A	ONINL-B	ONINL-C	114.10.17
AC09633255	B05BC01		IMANN2	MANITON 20%/100 ML/Bot(Mannitol)		QB	"1.z@ΡGR߿`AC魫 0.5g2gm H1525%GAIw` 3060 C
2.E_Ρ]ǥ\^GR߿`AC魫200mg H1525%G3-5 `J餺C"	1.ѩ󥻾iGAGHNɩRXAХ[Ŧ40~50XCAݷѫAŵ{רϥΡC 2.bY~ˡAY\X大iʮɡAVϥΤC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 ǷŤU25JHUxs	Mannitol	B05B	Rߪ`gG I.V. SOLUTIONS	0	QB`B~BPirưBǤpyLotvw]E_Ρ^	LgBYͤ~{ʤ߰IܡB`XBYB12HUൣC				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6063397?cesid=aKmEXt5nrzA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DMANNITOL%26t%3Dname%26acs%3Dfalse%26acq%3DMANNITOL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[w]_w00-02 [E]_F2-06j	Ts114.10.17		OI` 	0	OIs 20251124	IMANN2-a	IMANN2-b	IMANN2-c	114.10.17
AB47872223	L01BC05	K`gG38@J/@	IGEMZ2	ĵ Gemmis Inj 38mg/ml 6ml/vial(Gemcitabine)		Gemcitabine(dFdc)bӭMQ?E?N¦㦳ʪCQ(dFdCDP)ΤTCQ(dFdCTP)?A]DNAͦXAӲͲӭMrʤ@ΡC@ξ]AӨBJGdFdCDPֿ}?٭?A]ӵLksyhֿ}?TCĥHXDNAC?QAh?@״֡AרOdCTPAMdFdCTPPdCTPvOJDNACӥBֶqGemcitabineiOJRNAA]ӭMdCTP@׭Cɷ|[jdFdCTPPDNAOX(۰ʥ[j@)C]-DNA?EXLkhGemcitabineέ׸ɥͪDNACGemcitabineOJDNAAͪDNA۷|A[J@Ӯ?ġAYDNAX(쥽ݾBפ@)COJDNAAGemcitabine|ɲӭM`AL{٬apoptosisC	"ŦG
ĳq1000 mg/m2H30R߿`AĳĤ覡G18gGCg@s7gAۥ𮧤@gC8gHGCgĤ@A28Ѷg1B8B15ѵPC
DpӭMG
ĳq1000mg/m21B8B15ѡAR߿`30GemcitabineAcisplatin{F1ѿ`ARߵPcisplatin 100mg/m2C
G
ĳq1250 mg/m2 21Ѷg1B8R߿`30A]tpaclitaxelCĤ@ѿ`GemcitabineeA` paclitaxel 175 mg/m2 3pɡC
Z_G
Gemcitabineĳq1000mg/m221Ѷg1B8R߿`Gemcitabine 30CĤ@ѿ`GemcitabineAAR߿`carboplatin AUC 4C
HG
H28Ѭ@gACg1B8B15ѵP1000 mg/m2AR߿`30ACg1ѵPcisplatin 70 mg/m2Cwq|gg@v{CCisplatinϥΤkPɥRAаѨī~C
xDG
@ϥΪĳq 1000 mg/m2AHR߿`30CH|g@vgACgĤ@AsĤTgAۥ𮧤@gAƥHW覡(C|g@g)vC"	"tswwʡGǷ24h
}wwʡGǷ24h
ۮe}GGNS
ĳ}nG100-250ml
ĳĳ~|tvGIVF 30-60min
ī~}~[GL
L`NƶG
1.N÷|ް_
2.Y`ɶWL60AΤ@gIhhrʷ|W[C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ʡG 15 ~ 25 ץB	Gemcitabine	L01B	ܥN ANTIMETABOLITES	0	DpӭMBŦBHCGEMCITABINEPPACLITAXEL֥ΡAiϥΩ󴿸gϥιL ANTHRACYCLINE_oBLkNಾʤfwCΩ󴿸gϥΧt`Ī(PLATINUM-BASED)v_oBjܤ 6Ӥ뤧Z_A@ĤGuvC	gemcitabine LӪfHTΥ	~@ΡAϥΫiyhAզy֤ΦpO֡FߤΦ񦳹æRߡF׳JէB姿FֽlFIlxALGj20%fwP_gC	"D šG
bӪHs礤ܸĪFL}vTAYįaӤįqWL䥦ĪϥΡA]YϦbMIʪsbUAiĪΩhkWC"	Fetal risk cannot be ruled out.	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7627043"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_B06-08j	Ts114.10.23	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.4._20160201_000.pdf"">OI` 9.4.</a>              "	OI` 9.4.	0	OIs 20251124	IGEMZ2-a	IGEMZ2-b	IGEMZ2-c	114.10.23
۶O	A10BX16	r֪`g5@J/0.6@	IMOU51	mounJARO 5mg/0.6mL KwikPen		"TirzepatideGIPMGLP-1PiAOiħǦCA㦳C20ת?(C20 fatty diacid moiety)AiP?J?X??bICTirzepatideܩʪXìGIPMGLP- 1AY?饻?GIPMGLP-1йvC
TirzepatideH}̿?Wj?M?qخqcAíC@}@סC"	"1. ĳ_lqG@g@ 2.5 mg֤U`gC4 gANqW[ܨCg@ 5 mgC
2. YݧΪ}Aibϥηeqܤ4gAH 2.5 mgvW[qC
3. ̤jqGCg@ 15 mgC


1. Obesity, Or overweight with at least 1 weight-related complication: initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; may increase dose in 2.5mg increments after at least 4 weeks on the current dose to a maintenance dose of 5mg, 10mg, or 15mg qw; MAX, 15mg subQ qw.
2. Obesity - Obstructive sleep apnea (Moderate to Severe): initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; may increase dose in 2.5mg increments after at least 4 weeks on the current dose to a maintenance dosage of 10mg or 15mg qw; MAX, 15mg subQ qw.
3. Type 2 diabetes mellitus: initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; if additional glycemic control is needed, increase dose in 2.5mg increments after at least 4 weeks on the current dose; MAX, 15mg subQ qw."	"CgĤ@Aib@ѷɶAҼ{iP_C
H֤U`g󸡳BjLΤWuCC`g`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1718C"	"? MOUNJAROixs2XC8XC (36XF46XF)BcC
? YݭnAC榸q`gΨC榸qp~ݧNáAibWL30XC (86XF)ǷŦsF21ѡC
? @fHhq`gKwikPenib̰30?C (86?F) ǷŤUsF 30ѡC
? ФŧNMOUNJAROCYwAФŨϥMOUNJAROC
? NMOUNJAROm]˲HקKӡC"	Tirzepatide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	1. }G @ιBk~UvAΩﵽĤG}fHfH}C: MOUNJAROi@kλPL}fvĪX֨ϥΡC 2. έDPL魫 (1) C?μW[ଡʤU?kAAιHHBl??(BMI) ? 30 kg/m2(έD)A  ? 27kg/m2 < 30 kg/m2 (L)Bܤֱw@魫@fA?pB?`B??feβĤG??fB?ʺίvIlΤߦޯefC (2) C?μW[ଡʤU?kAAΩ㦳צܭתʺίvIlgBq(BMI) ?30 kg/m2HAﵽίvIlY{סC ϥέ (1) MOUNJARO|bŦfvfHisC (2) MOUNJAROiΩĤ@}ffHC (3) MOUNJAROttirzepatideCĳPLttirzepatideī~Υɿ}`?-1 (GLP-1)Pľ֥ΡC (4) |TwMOUNJARO֥ΨLΩ魫ī~(]ABġBDBĩM󥻻s)wʩMġC		"MOUNJAROvq?5%}: ( MOUNJARO 5 mg, 10 mg, 15 mg vs Placebo %)
 12~18 vs 4 
m 12~17 vs 9
 5~11 vs 1
æR 5~9 vs 2
K 6~7 vs 1
Ƥ} 8~5 vs 3
h 6~5 vs 4"	ϥMOUNJARO{ƾڤHPĪYXͯʳByΨLέLण}GIChɿ}fη|MLaӭI (аѾ\{ɦҶq])CھڰʪʹެsAhtirzepatidei|LyICubqBL઺bIɡA~ibhϥMOUNJAROC	"There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition."	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7224069?cesid=75sLiblHicM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTirzepatide%26t%3Dname%26acs%3Dfalse%26acq%3DTirzepatide"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B01-50 j	Ts114.11.11		OI` 	0	OIs 20251124	IMOU51-a	IMOU51-b	IMOU51-c	114.11.11
۶O	A10BX16	rֵ 10 @J/0.6@	IMOU11	Mounjaro KwikPen 10mg/0.6mL		"TirzepatideGIPMGLP-1PiAOiħǦCA㦳C20ת?(C20 fatty diacid moiety)AiP?J?X??bICTirzepatideܩʪXìGIPMGLP- 1AY?饻?GIPMGLP-1йvC
TirzepatideH}̿?Wj?M?qخqcAíC@}@סC"	"1. ĳ_lqG@g@ 2.5 mg֤U`gC4 gANqW[ܨCg@ 5 mgC
2. YݧΪ}Aibϥηeqܤ4gAH 2.5 mgvW[qC
3. ̤jqGCg@ 15 mgC


1. Obesity, Or overweight with at least 1 weight-related complication: initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; may increase dose in 2.5mg increments after at least 4 weeks on the current dose to a maintenance dose of 5mg, 10mg, or 15mg qw; MAX, 15mg subQ qw.
2. Obesity - Obstructive sleep apnea (Moderate to Severe): initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; may increase dose in 2.5mg increments after at least 4 weeks on the current dose to a maintenance dosage of 10mg or 15mg qw; MAX, 15mg subQ qw.
3. Type 2 diabetes mellitus: initial, 2.5mg subQ qw for 4 weeks, then increase to 5mg subQ qw; if additional glycemic control is needed, increase dose in 2.5mg increments after at least 4 weeks on the current dose; MAX, 15mg subQ qw."	"CgĤ@Aib@ѷɶAҼ{iP_C
H֤U`g󸡳BjLΤWuCC`g`gC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1719C"	"? MOUNJAROixs2XC8XC (36XF46XF)BcC
? YݭnAC榸q`gΨC榸qp~ݧNáAibWL30XC (86XF)ǷŦsF21ѡC
? @fHhq`gKwikPenib̰30?C (86?F) ǷŤUsF 30ѡC
? ФŧNMOUNJAROCYwAФŨϥMOUNJAROC
? NMOUNJAROm]˲HקKӡC"	Tirzepatide	A10B	"Dخq} BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS"	0	1. }G @ιBk~UvAΩﵽĤG}fHfH}C: MOUNJAROi@kλPL}fvĪX֨ϥΡC 2. έDPL魫 (1) C?μW[ଡʤU?kAAιHHBl??(BMI) ? 30 kg/m2(έD)A  ? 27kg/m2 < 30 kg/m2 (L)Bܤֱw@魫@fA?pB?`B??feβĤG??fB?ʺίvIlΤߦޯefC (2) C?μW[ଡʤU?kAAΩ㦳צܭתʺίvIlgBq(BMI) ?30 kg/m2HAﵽίvIlY{סC ϥέ (1) MOUNJARO|bŦfvfHisC (2) MOUNJAROiΩĤ@}ffHC (3) MOUNJAROttirzepatideCĳPLttirzepatideī~Υɿ}`?-1 (GLP-1)Pľ֥ΡC (4) |TwMOUNJARO֥ΨLΩ魫ī~(]ABġBDBĩM󥻻s)wʩMġC		"MOUNJAROvq?5%}: ( MOUNJARO 5 mg, 10 mg, 15 mg vs Placebo %)
 12~18 vs 4 
m 12~17 vs 9
 5~11 vs 1
æR 5~9 vs 2
K 6~7 vs 1
Ƥ} 8~5 vs 3
h 6~5 vs 4"	ϥMOUNJARO{ƾڤHPĪYXͯʳByΨLέLण}GIChɿ}fη|MLaӭI (аѾ\{ɦҶq])CھڰʪʹެsAhtirzepatidei|LyICubqBL઺bIɡA~ibhϥMOUNJAROC	"There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition."	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/7224069?cesid=75sLiblHicM&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTirzepatide%26t%3Dname%26acs%3Dfalse%26acq%3DTirzepatide"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B01-51 j	Ts114.11.11		OI` 	0	OIs 20251124	IMOU11-a	IMOU11-b	IMOU11-c	114.11.11
KC01288209	M05BX04	˹wRw`g	IXGEV2	XGEVA 120mg/prefilled syringe(Denosumab)		XGEVA|PRANKLXARANKLO@عkӭM(|Ͱk@ΪӭM)ΦB\Psn､JթΥiʳJաCXGEVAiRANKLƨ䱵AYkӭMΨeXWRANKC~FoͰಾpAkӭMʦ]RANKLEӤɰDOoͰffܪDnC]C	ĳqC4g@WuBjLθ֤U`g120@JCɥRtPͯҡAHvιwCtgC	"ΩBeC֦kʰಾfwC
b}lϥXGEVAveABvJCtgCʴt@סAõݭnɥRtBκͯDCĻPtMLtĪ֥ήɥi|ϧCtIcơDKʴt@סD
b}lϥXGEVAveΨϥXGEVAvAwifˬdAñĨAfĹwIC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	 28JNxsC	Denosumab	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	AΩ~FwಾHfwAwoͰfƥC	LC	h/LOBCCQgߡC	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668905?cesid=8pqU2btVm48&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DDenosumab%26t%3Dname%26acs%3Dfalse%26acq%3DDenosumab"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.11.11	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.4._20241001.pdf"">OI` 5.5.4.</a>              "	OI` 5.5.4.	0	OIs 20251124	IXGEV2-a	IXGEV2-b	IXGEV2-c	114.11.11
۶O		Ddw D-cure / 10ml/bot/360w	LDCUR1	Ddw D-cure / 10ml/bot/360w		(~)ͯD@ξDnbPitlBtšAûPfBͪo|C~AͯD]ѻPgB٦ת`Ͳz\AùK̨tΩMӭMƵYAUո`骺\hͲz@ΡC			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1721C"	Ƿ25XCHUAקKӮgC	Cholecalciferol	0000	~iɥR~	0	iɥR					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiij	Ts114.11.11		OI` 	0	OIs 20251124	LDCUR1-a	LDCUR1-b	LDCUR1-c	114.11.11
۶O			LSUPE1	iiG / 8.2g / 25ml 		"(~)iɥR~AӫDī~CDnѨŲMJաAzLS޳NNѦpliġC

ް_iĿ@ۥBuȪW[Aiӳy\JսXW[AiӲͦ٦׳J"			пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1722C"	Ƿ25XCHUAקKӮgC		0000	~iɥR~	0	iɥR					аѦҾqPΪk		ѦҡuqΥΪkv	  	ixiiMϡj	Ts114.11.11		OI` 	0	OIs 20251124	LSUPE1-a	LSUPE1-b	LSUPE1-c	114.11.11
AC441611G0	C09AA03	QYմ	OZEST2	Lisnopril 10mg/tab		LisnoprilOpeptidyl dipeptidaseAަYഫï (ACE)ʤangiotensin Iഫangiotensin II (@ئަY` [peptide]) @ΡCAngiotensin II]PiǤWֽcaldosteroneCACE|Cangiotensin II@סAqӭC޼W@ΡAôaldosteronecC̤C|ɭP[W[C	"@Ѥ@A lvTC
?G
@ĳ}lq10mgAĺq20mg@Ѥ@; ̰q80mg/
?{ʤ߰I (CHF)G
iΤ@Ѥ@Zestril 2.5mg}lvC@릳ľq5~20mgA@Ѥ@C
?}fǯf
C龯q10 mg @Ѥ@QYݭnAiNqW[20 mg @Ѥ@
?ʤߦٱG
Zestrilbӯgoͪ24pɤ}lAΡAĤ@qfA5mgA24pɫ5mgA48pɫ10mgAᤧq10mg@Ѥ@CfHb}lvα᪺eTѥX{CY (120mmHgΧC)AhݵCqGfA2.5mgCYoͧC(YCε100mmHg)AiCѺq5mgAnɥiȮɭC2.5mgCYyʧC (Y<C90mmHgF1pɥHW)AZestrilC
ZestrilA6PAfHͤ߰IܯgɡA~AZestril 
"	ϥΧQfH}lϥZestrilɡAi|oͯgʧCFpfHwϥΧQhoͦ{HC]i|GM/Q\ܡCb}lϥZestrile2ѩ3ѶΧQC藍ఱΧQfHAZestril}lqq5mg}lAAվ㾯qCpnAQiϥΡC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30oCHUC	"
Lisinopril
10 mg"	C09A	"ޱiOƻï ACE INHIBITORS, PLAIN"	0	B{ʤ߰IܡBʤߦٱB}fǯfܡC	"?ZestrilB~󦨤ΨLަYഫï (ACE) LӪ̡C
?]ϥΦަYഫïӵo͹L/LӤΦީʤ~fv̡C
?ǩʩέoʦޤ~̡C
?hĤGMĤT 
?X֨ϥΥ~Χtaliskirenī~}fHεǥ\णfH (GFR < 60 ml/min/1.73 m2)"				"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668973?cesid=7iZW391k5f2&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DLisinopril%26t%3Dname%26acs%3Dfalse%26acq%3DLisinopril"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[1]_D3 [2]_D3 [ws]_w37-02 [E]_B4-04 j	Ts114.11.11		OI` 	0	OIs 20251124	OZEST2-a	OZEST2-b	OZEST2-c	114.11.11
AC61816255	M05BA08	ðH`gG5@J/100@	IACLS2	YungClasta 5mg/100mL(Zoledronic acid)		"Aclastaݩt᪺CQƦXADn@ΦbfCOkӭMAl@ΪC

"	"vgk貨Pg:C~榸R߿`5 mg`GA`ɶo֩15AHTw`tvġC
wgk貨Pg:C~榸R߿`5 mg`GA`ɶo֩15C
kʰ貨Pg:C~榸R߿`5 mgA`ɶo֩15C
TJʰ貨Pg:C~榸R߿`5 mgA`ɶo֩15C
Aclasta`ɶo֩15AHTw`tvġC
bR߿`AH10 mLͲzQR~Rߺ޽uC

ئNSf(Pagets disease of bone):C~榸R߿`5 mgA`ɶo֩15C


"	"AclastaTΩٻMvC35 mL/minHҹ㦳ʵǥ\णfwC
bAclasta`ᵹacetaminophenibuprofeniCʴgC
gkC饭1200mgtP800-1000IUͯDC

"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	"xs15-30 XC 
Y`gGwNáAb`eN÷G^_ǷšC}~˫AGb2-8XCūפUiO24p"	Zoledronic acid	M05B	vTfcqĪ DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	0	"vgk貨Pg
wgk貨Pg
kʰ貨Pg
TJʰ貨Pg
ئNSf(Pagets disease of bone)

"	"AclastaTΩUCfwG
? Ctg[ĵyP`Nƶ(5.2)]C ? AclastaTΩٻMv< 35 ml/minHҹ㦳ʵǥ\णfwA]o
ǯfwo͵ǰIܪI
? wzoledronic acidAclastaҧt󦨤LӡCLӤ]A֨C¯lMީʤ~AHΫD`uLөʤ/Jרҳi


"	"PAclastaʴxίgG٦׵h(17.1%)BoN(15.7%)Bh(12.4%)B`h(11.1%)Bkh(10.5%)BHŸ(9.8%)BYh(9.8%)ByPef(8.5%)B餣A(5.2%)έIh(3.3%)Ab뤩Aclasta3Ѥo͡CCoǯgjצܤסABjhb}X{3ѤYwѡAǥiݭn7-14Ѥ~wѡCoǯgoͲv|H۫AclastaĦӴ֡C

"	PL/|qLť	PL/|qLť	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668999?cesid=1Kvq5WfWRTN&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DZoledronic%2Bacid%26t%3Dname%26acs%3Dfalse%26acq%3DZoledronic%2Bacid"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[]_07-04 j	Ts114.11.11	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.5.3.2.2._20110101_000.pdf"">OI` 5.5.3.2.2.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.6.1._20250301.pdf"">OI` 5.6.1.</a>             "	"OI` 5.5.3.2.2.,5.6.1."	0	OIs 20251124	IACLS2-a	IACLS2-b	IACLS2-c	114.11.11
۶O	J07AL02	KͪyߤGQX̭]	IPV201	"(20PnC)Prevenar 20, Pneumococcal 20v Conjugate Vaccine"		6gHWൣBC֦~MHDʧḴءAwͪyߩҤް_IJʯefC	"HqG@q

ൣqG
1. ]WgƤp37g^B6gܥ15ӤൣG@4AC 0.5 mLC¦]A3A1q`bX2ӤɱءACܤֶj4gCĤ@Iɶ̦ibXͫ6gءF4l[ĳb1215ӤjءC
2. 7ܥ12Ӥjج̭]G@2AC 0.5 mLA⾯ܤֶj4gCëĳ~@ز3C
3. 12ܥ24Ӥjج̭]ൣG@2AC 0.5 mLA⾯ܤֶj8gC
4. 2ܥ5ج̭]ൣBe㱵عLͪ
yߵX̭]15Ӥjܥ5ൣBL׬O_eعLͪyߵX̭]5ܥ18ൣG@q]0.5 mL^C"	"1. Ϭ̭]AeaBGAGHM۹wRwåΤOn̡AweܦêզaBGC
2. w\G|౵YAfɰwCCʰw\Aq|౵YUw\CUw\ɡAp߽TO|쩵WC
3. sL߰wYG|౵YöɰwʰwYANAX٦ת`gwYswRwWC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1725C"	"1. N2-8JOsCiNC۵Lߥ]˨XߧYϥΡC
2. b8-25JūפUxsɡAiíw96pɡFη̭]b0-2JUxsɥiíw72pɡCboǮɶqɡAϥΧΥC"		J07A	ӵ̭߬] BACTERIAL VACCINES	0	AΩ6gHWൣBC֦~MHDʧḴءAHwͪyߦM1B3B4B5B6AB6BB7FB8B9VB10AB11AB12FB14B15BB18CB19AB19FB22FB23F33FҤް_IŧʯefC		`g짽BwBoNBwB֡BίvW[δֵC			аѦҾqPΪk		ѦҡuqΥΪkv	  	ixii[N]_B04-17 j	Ts114.11.11		OI` 	0	OIs 20251124	IPV201-a	IPV201-b	IPV201-c	114.11.11
KC00932244	H01AC01	Ӱ`g 12 @J (36IU)	ISAIZ	Saizen 12 mg(36IU) solution for injection		"SaizentH]u{覡ʪӭMsƦӱoդHͪEC191ӮĲզAıƧǡBզBĹСBqIBlqBPccyPͪʵһPHUcͪEۦPCSaizenѥ[JӭMgӸUͪE]ҦXC
SaizenO@ئPƤΧܲƾAȥiPiͪ]iզΥN¡CiPUتӭM]AٲӭMBxӭMBתղӭMBOڲӭMByӭMWM@ʱXA@άOgѤsomatomedins (IGF-1BIGF-2)FC
̾qPAϥSaizeniIGF-1BIGFBP-3BD୤ƯתջĤΥ̪oWɡBC夤BtqζuB[ƥXC"	"Hq
1. HͪEYcɥRk: }lvɡAĳCH 0.15~0.3mgCq֤U`gvC
2. vqi Insulinlike Growth Factor 1 (IGF-1)ȳvBվC
3. ̲׫ĳqܤֶWL 1mg/CѡC
4. @Өuݨϥγ̧CľqCpGϥΪ̬ѤH魫L̡AܸCqϥΡC
5. @ĳߤWΫe`gC

ൣq
1. @ĳߤWΫe`gA֤U`gC
2. ĵΫC֦~:
a.]ͩʥͪEcް_ͪ𺢡GCѥH 0.7~1.0 @J/m2 0.025~0.035@J/C
b.L Gonadol Dysgenesis (Turner syndrome)ҾɭPͪ𺢡GCѥH 1.4 mg/m2 0.045~0.05 mg/C
c.YPɨϥ non-androgenic anabolic steroidsAN|W[vĪGC
d.CKe]CʵŦIܾɭPͪ𺢡GCѥH 1.4 mg/m20.045~0.05mg/C
3. CX魫धͪwGCѵ 0.035mg/( 1mg/m2A۷ 0.1 IU/ 3 IU/m2)C
4. FzQHשΰ?wXɡAvC"	ߤWΫe`gA֤U`gC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1726C"	N2-8JץOsC~bϥΤwwʡAi 2-8XC U 28 ѡF䤤iFs 7 ѳ̰ 25XCC	Somatropin	H01A	eEP ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	0	UͪEcҾɭPͪ𺢡BLGONADOL DYSGENESIS (TURNER'S SYNDROME)ҾɭPͪ𺢡BCKe]CʵŦIܾɭPͪ𺢤ΦHͪEYcɥRkCCX魫(Small for Gestational Age ; SGA)O|̤ͪêC	"1. SomatropinΨξLӪ̡C
2. ?wgXൣiϥSomatropinPiͪC
3. SomatropinTΩ󦳬ʩؽF/Mʩʩζiʪ`l˩δ_oC
4. ]}ߤNBĤNBN~yhB~ˡBʩIlIܩξɭPoYefɡAϥSomatropinC
5. wCʵŦfൣbŦӮɡASomatropinġC
6. b`~FoͪAּƮרҷ|HͪEʥFxAveư~FiʡC}lSomatropin vɡAwsb~FʩʡABܸ~Fvݦb}lSomatropinveC"	`g|~BkoFGdGg~BwB`hB٦׵hMֽPı`C			"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668552?cesid=8DFk0MixfAR&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DSomatropin%26t%3Dname%26acs%3Dfalse%26acq%3DSomatropin"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[N]_B01-40 j	Ts114.11.19	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.1.1._20221101.pdf"">OI` 5.4.1.1.</a><a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=5.4.1.2._20170801_000.pdf"">OI` 5.4.1.2.</a>             "	"OI` 5.4.1.1.,5.4.1.2."	0	OIs 20251124	ISAIZ-A	ISAIZ-B	ISAIZ-C	114.11.19
BC28183457	R03AL11	ͺZƼQ160/7.2/5.0LJ	EBREZ	Breztri aerosphere 160/7.2/5.0 mcg/puff		"BREZTRI AEROSPHERE
BREZTRI AEROSPHERE t budesonideBglycopyrronium M formoterol fumaratedihydrateCHUӧO@?AA? BREZTRI AEROSPHERECoĪݩTؤPO (X?TJBxPĪAM?Ŀܩ ]2 ǤW@?)A COPD {?zǩMoШ㦳P@?C
Budesonide
Budesonide O?اܵo?TJA㦳jĿ}?ʩMLzq?ʡC
Glycopyrronium
Glycopyrronium O??ħܿrPAq`?٬xPĪAxPȫ M1?M5 ˩M?۪CbIlD?Ĳz@?AOzLƦ٪ M3 AP?XiC??MʪM龹xs?Aܧ@?㦳vʤΥifʡC{
e~餺s?AҰxP?QxPһo?ަY@?A@?㦳q̿ʡAi 12 ?ɥHWCoǵo{{ɬʤClJ glycopyrronium Უ??Xi@?ADnM?ʪ@?C
Formoterol Fumarate
Formoterol fumarate O?ا@?t?Ŀܩ ]2ǤW@? (]2 @?)ClJ formoterol fumarate bͤo@?AF?XiĪGC"	"C馭WαߤWU@AClJ2U覡ϥΡAgflJC
ФŶWLC⦸AClJUC

|TߥΩfHwʤġC"	"1. Ĥ@ϥΫeХ˶Ĳ~C˶AлyAªŤ4 ACeRnáCpGWL 7 ѥϥΧlJBlJAΦbCg@R~MAЦA׸˶lJAyAªŤ 2 ACeRnáC
2. qܾ (Sپƫܾ)A|ܳѾlilJơCilJƧYNΧɡAw|bϰFqܾwϰ 0 ɡAαqTUX 3 Ӥ (120 lJ)AHɶǡAYC
3. C馭WαߤWU@AgflJC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1727C"	"s25XCHUCmBAקKŤζC
F̨ήĪGAbϥΫe^_ܫǷšCϥΫeХRnáCЧsAקKൣC"	"Budesonide160 mcg, glycopyrrolate 9 mcg and formoterol fumarate 4.8 mcg"	R03A	"lJʵǤWE ADRENERGICS, INHALANTS"	0	AΩwlJʥֽTJPģ]2@ξX֪vBΪģ]2@ξPĿrPܾX֪vAӤΪܭ׺Cʪʪͯf (COPD) fHvC	BREZTRI T? budesonideBglycopyrronium Bformoterol ξLӪf?C	f|]y߷PVC	C	ĳ¨Űkϥ	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/6977481?cesid=6rbtKz4EbRe&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DBreztri%26t%3Dname%26acs%3Dfalse%26acq%3DBreztri"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixii[M]_M01-06j	Ts114.11.19		OI` 	0	OIs 20251124	EBREZ-a	EBREZ-b	EBREZ-c	114.11.19
KC010892B5	L01FD01	NMᴹ`g440@J	IOGIV	ĵƼfOGIVRI 440 mg/vial (Trastuzumab)		"Ogivri (trastuzumab) O?HƪIgG1 kappa AiܩʦaPH
W֥?]l2 J (HER2) ӭM~ϰHת˩MO۵XC
Trastuzumab YQΰ]է޳N󪺭ŰʪӭM (ܹZ_ӭM) isyӦCOgivri O?صLߡBզܲHBtGR߿`έᴹ꯻ (ᴹ)CCp~˪Ogivri ttrastuzumabBL-histidine HCl monohydrateBL-histidineBpolyethlene glycol 3350/macrogol 3350AHD-sorbitolCOgivri 440@JH20 @ɪA (BWFI SWFI) ws|ΦC@ɧt21 @Jtrastuzumab BpH Ȭ6 GC"	"1. Cg{G
a._lqG4 @J/AR߿` 90 C
b.򾯶qG2 @J//gAYfHeq@OΡAqi` 30 YiC
2. CTg@{G
a._lqG8 @J/AR߿` 90 C
b.򾯶qGP_lq 3 gA뤩 6 @J/AMCj 3 gƧ뤩 6 @J/CYfHeq@OΡA򾯶qiH 30 `YiC
3. vɶG
a.ಾʨBಾʭGGvX{efcƬC
b.Gv 1 ~AΪX{ef_o{HAHo̬ͪǡCĳvWL@~C
4. qվG
a.oͥѤް_ifʰĶgɡAfHi~ϥ OgivriAboqɶnpߦaʴfH]ݤʥզy֩Ҥް_ֵogC
b.oͻשΤ׿`ɡAC`tvFoͩIlx{ɤW㤧C{HɡA_`FoYΨͩR¯٩ʿ`ɡAϥΡC
c.oͤUC@pɡA_Ħܤ 4 PC
(1).߫ǮgXv(LVEF)MveۤﭰCTס16%F
(2).LVEFȧC󤽭q`dBMveۤﭰCTס10%F
(3).Yb 4-8 gALVEF_ܥ`dBMveۤﭰCTס15%ɡAiiHsϥΡF
(4).LVEFC (>8 g)Φ]ߦٯfܦӼȰϥζWL 3 HWɡAä[ΡC"	1.}lHerceptinveAHER2˴C 2.HerceptiniHR߱`覡ġC 3.YfHL@HerceptinAɶWL@gAĳ֪`g`qCYɶWL@gHWAhɧ֭s뤩_lqC	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1728C"	"1. }ʧN2-8JOsC
2. ts᷻GN2-8JiH 28 ѪwwC}᷻GN2-8Jis 24 pɡC"	Trastuzumab	L01F	ΧĪgX MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES	0	OgivriϥΩUCHER2Lת{HER2]amplificationBಾʨfHAG 1. (EBC) (1) g~NBƾk(NeγN)UkC (2) HdoxorubicinPcyclophosphamidevAAXpaclitaxeldocetaxelUkC (3) Pdocetaxelcarboplatin֥ΤUkC (4) NePƾk֥ΩMNᤧUkϥΩvߴ(]Ag)θ~F(|>2)C 2. ಾʨ(MBC) (1) WϥΩ󴿱L@(t)HWƾkಾʨFDfHAXϥanthracyclinetaxaneA_heƾǪvܤ֥]AanthracyclinetaxaneCϥΩXkѤX鶧ʤfHADfHAβXkC (2) Ppaclitaxeldocetaxel֥Ω󥼴LƾkಾʨC (3) Pڭ?֥ΩX鶧ʤಾʨ 3. ಾʭG(mGC) OgivriXcapecitabine (5-fluorouracil)cisplatinAΩ󥼴LƾǪvHER2Lת{ಾʭG(έGDXB)vCG (1) HER2Lת{˴kgåͥD޾֭(ΩG)AаѷӬ˴Mե椤AgAT(validation)ήį(performance)ԭzCtаѷӥ[{ɬs-ಾʭG]ԭzC (2) ϯøT{Ķ{󦳸HER2Jժ{(IHC2+/FISH+IHC3+)ڸsCHER2ڸsRGܡAHER2Jժ{C(IHC 0/FISH+: HR 0.92; IHC1+/FISH+: HR 1.24)ڸs`鴣ɤAϤAHER2Jժ{(IHC2+/FISH+: HR 0.75; IHC 3+/FISH+: HR 0.58)ڸs`鴣ɸC	 TrastuzumabBCHO ӭMJթΥĥξYLӪ̡C	oNBHŸBhBLOBmBߡBæRB`hB٦׵hB֯lC	D 		"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668426?cesid=2HCXXrbPM2o&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTrastuzumab%26t%3Dname%26acs%3Dfalse%26acq%3DTrastuzumab"">LexidrugľǸƮw</a>"		ѦҡuqΥΪkv	  	ixiij	Ts114.11.24	"<a href=""https://info.nhi.gov.tw/api/INAE3000/INAE3000S01/getPDF?DurgFileName=9.18._20250501.pdf"">OI` 9.18.</a>              "	OI` 9.18.	0	OIs 20251124	IOGIV-A	IOGIV-B	IOGIV-C	114.11.24
NC017831GA	G04BX06	(Ƹ)	OUROG2	Urogen 50mg/S.C.tab Ƹ(Phenazopyridine)		i߽ӭMͧ¾K@ΡC	HC100mgATIDApľq50mg TIDuCpYӵߩʤֵogPVɡAoPܥͯDiĵܵ߾֥ΡC	"1B~iiϥΡC]קKInɭPۦ^
2BAΥAG|eζŦC
3B֪`Nǥ\
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	H15-30CǷŤUxs	Phenazopyridine	G04B	c UROLOGICALS	0	H֪BǪBDBcʹ޾߽h	"YxAYǥ\णҥΥ~D
糧LӪ"	ߡBhBƤ}FYwBYhBoNFֽβܶFֽ_lFyBB}~ȵC	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668440?cesid=2347Op1SOVh&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DPhenazopyridine%26t%3Dname%26acs%3Dfalse%26acq%3DPhenazopyridine"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixii[ws]_w08-01 09[s]_340 09[®]_340 16[E]_A3-14 j	Ts110.6.16		OI` 	0	OIs 20251124	OUROG2-a	OUROG2-b	OUROG2-c	114.11.25
BC27657311	N02AB03	ڥwֶK 25LJ/p	EFE252	ĵOpiodur 25gg/hr/patch (Fentanyl)		FentanylO@~hADn@Φbu-~CDn@άhPRC良ϥιL~Īw̦ӨAfentanyļCĤhM@׬0.3-1.5 ng/mlAM@װ2 ng/mlɡAƧ@εoͤvWC̤p@ο@פεoͬrʪ@׷|Hۭ@ʪW[ӼW[C@ʲֺͤC]ӤHӦjtC  	"ĶvBϥΡC
~qHfwpPӲAbϥΫөwɵCfentanylܥ`tv۷25mcg/hAYCX0.6mgfentanylC
KΡB}ΥH覡}aA]i|}aKwC "	"1.]uɶϥεLkAqվABiɭPYΦMΥͩR𤣨AʩγNkhŨϥΥ~C
2.Fentanyl|y߸CA]߸LC߫ߤefwpߨϥΡC
3.FentanylDngѨxŦN¦DʥNªA]xŦefi|wưCxwƱw̦ӨADurogesic@qPAMfentanyl夤@׸AĪʤOǤܡCx\lfwϥΥ~A`NO_fentanylrxAnɭC~C"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ī~m 15 ~ 25 װBҡFpoܽιLAiAϥΡC	Fentanyl 	N02A	P OPIOIDS	0	ݭnϥ~sCʯkhMxTʯkhC   	wfentanylζKHKLӤfwATfentanylֶKC 	~PRߪ`g~ĪۦPƧ@ΡApIlBB٦׻w(]Aݳ٦)Bٰ}˹BʡB߸LCB(uȩ)CBߡBæRMwtC 	C  קKϥΰDvn	sͨiyIlAiϥΩŰk	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4669815?cesid=0kLVRFf5PqH&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DFENTANYL%26t%3Dname%26acs%3Dfalse%26acq%3DFENTANYL"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.15		OI` 	0	OIs 20251124	EFE252-a	EFE252-b	EFE252-c	114.12.15
AC61952100	N02AB03	"""PPCD""QmiଳtĽn5@J"	OOXYN2	ĵOxycodone I.R 5mg/cap		iݦ]ବO@د~mu ]sb۹ܩʡ^PiAbqU]iML~鵲XADnv@άhCpPҦ~PiAثeåq̤߳jqCb{ΤWAqվYHiFRhĪGǡAӤhĪGWhH}@зǡAY}]AIlMϯgtΧC	"ѤHζWL18 HG
լnC6pɪAΤ@AqMkhY{פίfwehĤݨDpC

vG
fwAݭnHiݦ]ପvɡAקK޵o_gAнwwխqC"	"ĤiZHοiAHKvTĮġC Ф@]A@լAtHq}AnJfAߧY]UC
}B ݥΤΤϥ
լ (OxyNorm) sbϥΪ̦}BݥΤΤϥΪIAiӾɭPĹLqM`C }߳BeAеUfwIAPɩwlܬO_ͦ欰MpC"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	xs30XCHUC	Oxycodone	N02A	P OPIOIDS	0	"1. ݭnkhgkhfwC 
2. ݭnkhCʤ׫DgkhfwABgL~ĪӵLkıkh̡C"	"oΩ㦳UCfgΪpfwG
-YIlC 
-ʩYޮݥʴεLϳ]ơC 
-wκæ·ʸzθzGDC
-iݦ]ହLӡ]LӤ^"	KBߡBݺΡBæRBhҡBYhBwtPhC	קKϥΰDvnϥ~hAsͨi|bXͫᤣ[YX{Ͳz̿ʩM~Ī_gԸsC	"קKϥΰDvnNiyRΩIl@ΡC
"	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668984?cesid=3ecfMHQNA1X&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DOxycodone%26t%3Dname%26acs%3Dfalse%26acq%3DOxycodone"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.15		0	0	OIs 20251124	OOXYN2-a	OOXYN2-b	OOXYN2-c	114.12.15
AC58548100	G04CA02	ZQbDf0.2@J	OHARN2	Tamlosin D 0.2mg/TAB		"Tamsulosin ܩʤvʦaPĲ᪺ \1Pg鵲XASOO \1A \1DȫADn@ΩPHVH@¶?D쪺٦ױi?AiPϱ???W[C\1B ȫ`?ޥ?٤WA]terazosin Pdoxazosin `
Ω󰪦v?C"	"q`AH1 1 A󶺫fAPTamsulosin Hydrochloride 0.2 mgCYĤΡA~W[0.4 mgC
C̤jϥξq0.4 mgC
ﰪ֪̪P
ѩ֪̦ɦǥ\CUΡAǥ\CU̥0.1 mg }lPAgLR?~Wq0.2 mgCP0.2 mg vӵLkoҹwĪGɡAФŦAWqAyĦLABmC
AήɡGЫɱw̤űNnɫrHαNn}AΡC(tamsulosin HCl wɥRwnAGi|ĪʺA)"	"(1)PϥΨL\1,Pgܾ@ˡAӮצbϥtamsulosin vAi|oͦCAɭPioͩ֡]u^AX{թʧCxɡ]YwBLO^AwӧUνUgCifw}lϥtamsulosin vAקKioͩ֡AɭP˪pC
(2)ϥΨC̤jϥξq(0.4 mg)ɡAקKioͩ־ɭP˪ΡC
(3)vYǥ\णw(ٻMv<10 mL/min)ApߡA]|ow̪{ɬsC
(4)@ǥbϥΩΥHeιLtamsulosin vw̦biդ٤NoͭiPgԸs(Intraoperative Floppy Iris SyndromeA²IFISA@YgԸsf)CiPgԸsi|W[NL{X֯gAwwƭnդ٤Nw̡AĳϥtamsulosinCiդ٤N1-2 gAϥtamsulosin O{UAbդ٤NeĮɶuPUqʡA|TߡC
bNeA?٤NvMζAӦҼ{wwƥդ٤Nw̬O_bϥΩΥHeιLtamsulosin vAHTONoͭiPgԸsɯĨAIC
(5)Tamsulosin DngCYP3A4 PCYP2D6 sxN¡AĤiPCYP3A4 jħ]pketoconazole)X֨ϥΡC
(6)ЯdNĤvëDf]kAӬOgkAGbPĦpLkoݪĪGɡAЦҼ{ĤNkLABmC
(7)oͯtwΡAGqưB@~B}񦳦MIʪ@~ɡA[`NC
(8)ħP}lɡAEfwLPAPɡA`NܤơAX{CUɡAĨqΤPABmC
"	пԸĮv	"Ƨ@νаѦҡuƧ@Ρv
pzoͺæƧ@νХߧYĪAÿԸHA|ĪԸ߱MuG1716B1717C"	ЫOsǷ(25JHU)ΤpıĲ줧BC	Tamsulosin	G04C	}@ΤjĪ DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0	eCΤjg(W)ҦHƧê	"tamsulosin ι糧ĥξLӪ̡C
թʧCfvw̡C
Yx\णw"	tw]߮YwBYhBݯv^BGַP]ߡBæRBfBKBGPBGhBBUgB]`ê^	קKϥ/SmҦw	קKϥ/SmҦw	"<a href=""https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668553?cesid=66t8doguZlD&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DTamsulosin%26t%3Dname%26acs%3Dfalse%26acq%3DTamsulosin"">LexidrugľǸƮw</a>"	  	ѦҡuqΥΪkv	  	ixiij	Ts114.12.19		OI` 	0	OIs 20251124	OHARN2-a	OHARN2-b	OHARN2-c	114.12.19
																																		
